﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Wachtlin, J
   Ringwald, A
   Maulhardt, T
   Pohl, K
   Wiedon, A
AF Wachtlin, Joachim
   Ringwald, Andreas
   Maulhardt, Tobias
   Pohl, Karin
   Wiedon, Annette
CA BRIDGE Investigators
TI Cooperation of German ophthalmologists in routine care of patients with
   neovascular age-related macular degeneration: results of the
   non-interventional BRIDGE study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor (VEGF); Germany; Neovascular
   age-related macular degeneration (nAMD); Non-interventional study;
   Physicians' networks; Ranibizumab
ID RANIBIZUMAB; THERAPY
AB In the non-interventional ophthalmological study 'BRIDGE' the routine care of patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab was observed in Germany. A patient regularly sees the general ophthalmologist (GO) for monitoring and, if needed, the injecting ophthalmologist (IO) for intravitreal injections (IVI). Thus, patients are routinely treated by two ophthalmologists in parallel and patient care depends on their collaboration. This cooperation was evaluated based on network questionnaires.
   'BRIDGE' was a multicenter, national, open-label, prospective, observational study, conducted between July 2010 and December 2012. The network questionnaire for GOs consisted of 51 questions, while the similar questionnaire for IOs consisted of 43 questions, addressing the type and details of the individual collaboration. The statistical analysis was purely descriptive.
   The network questionnaire for GOs was completed by 152 GOs, regularly cooperating with 2.5 +/- 1.1 IOs, while the questionnaire for IOs was completed by 43 IOs, regularly cooperating with 23.2 +/- 23.6 GOs. Generally, both GOs and IOs stated that they regularly exchange information regarding the patients' situation. Diagnostic standards were only established for 15 % of the GOs' collaborations and for 35 % of the IOs' collaborations. After initial treatment, both GOs and IOs agreed on the medical significance of regular monitoring visits performed by the GOs. Agreements on re-treatment criteria were only established in the case of 16 % of the GOs and 28 % of the IOs. Overall, both GOs and IOs were satisfied with the current situation, with regard to the medical treatment situation for patients and to the cooperation within the networks.
   The network questionnaires revealed well-established cooperation between IOs and GOs in Germany with an accepted division of responsibilities for the routine care of patients with nAMD. However, the cooperation between two ophthalmologists treating one patient harbors risks. Agreements on diagnostic and re-treatment criteria would help to improve network performance and outcomes.
C1 [Wachtlin, Joachim] Augenabt Sankt Gertrauden Krankenhaus, Paretzer Str 12, D-10713 Berlin, Germany.
   [Ringwald, Andreas] Augenklin Klinikum Dortmund, Beurhausstr 40, D-44137 Dortmund, Germany.
   [Maulhardt, Tobias] Augentagesklinik, Facharzt Augenheilkunde, Flemmingstr 8 Haus 9, D-09116 Chemnitz, Germany.
   [Pohl, Karin; Wiedon, Annette] Novartis Pharma GmbH, Roonstr 25, D-90429 Nurnberg, Germany.
C3 Novartis
RP Wachtlin, J (通讯作者)，Augenabt Sankt Gertrauden Krankenhaus, Paretzer Str 12, D-10713 Berlin, Germany.
EM joachim.wachtlin@sankt-gertrauden.de; andreas.ringwald@klinikumdo.de;
   tobias.maulhardt@gmx.de; karin.pohl@novartis.com;
   annette.wiedon@novartis.com
FU Novartis Pharma GmbH, Nuremberg, Germany
FX The authors would like to thank the investigators involved in the
   'BRIDGE' study for their contributions and efforts, and for filling in
   the network questionnaires. The NIS 'BRIDGE' was funded by Novartis
   Pharma GmbH, Nuremberg, Germany, and conducted by Kantar Health GmbH,
   Munich, Germany. Statistical analysis and medical writing services for
   the preparation of this manuscript were provided by Kantar Health GmbH,
   Munich, Germany. This support was funded by Novartis Pharma GmbH,
   Nuremberg, Germany.
CR Bornfeld N, 2009, KLIN MONATSBL AUGENH, V226, P388, DOI 10.1055/s-0028-1109432
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Heimann H, 2011, OPHTHALMOLOGE, V108, P575, DOI 10.1007/s00347-011-2383-0
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Milojcic C, 2014, OPHTHALMOLOGE, V111, P37, DOI 10.1007/s00347-013-2823-0
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Retinologische Gesellschaft, 2011, KLIN MONATSBL AUGENH, V228, P138
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wolfram C, 2012, WEISSBUCH SITUATION
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2016
VL 254
IS 8
BP 1529
EP 1536
DI 10.1007/s00417-015-3242-5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS3IB
UT WOS:000380675200011
PM 26678412
DA 2022-11-30
ER

PT J
AU Kamao, H
   Goto, K
   Mito, Y
   Miki, A
   Kiryu, J
AF Kamao, Hiroyuki
   Goto, Katsutoshi
   Mito, Yumi
   Miki, Atsushi
   Kiryu, Junichi
TI Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor
   Therapy in Patients with Neovascular Age-Related Macular Degeneration
   Smoking and Anti-VEGF Therapy in nAMD
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CIGARETTE-SMOKING; RISK-FACTORS; CHOROIDAL THICKNESS; BLOOD-FLOW;
   PREVALENCE; MACULOPATHY; POPULATION; RANIBIZUMAB; CHINESE
AB Purpose. To evaluate the effect of smoking on the outcome of antivascular endothelial growth factor (VEGF) therapy in patients with neovascular age-related macular degeneration (nAMD). Methods.. is retrospective case-control study included 64 eyes in 59 patients with treatment-naive nAMD. Smoking habits were obtained from hospital records and patient recall. The patients were divided into ever-smokers and never-smokers. The patients were treated with ranibizumab or aflibercept for at least 1 year. Outcome measures were best-corrected visual acuity (BCVA), central retinal thickness (CRT) at the fovea, subfoveal choroidal thickness (SCT), and number of injections received. Results.. ere were no statistically significant differences in BCVA, CRT, or SCT changes between ever-smokers and never-smokers. The number of injections received was significantly higher in ever-smokers with a history of heavy smokers (never-smokers vs. heavy smokers: 5.3 +/- 2.6/year vs. 7.3 +/- 2.5/year; P = 0.048 and mild smokers vs. heavy smokers: 5.2 +/- 2.5/year vs. 7.3 +/- 2.5/year; P = 0.043). There was no significant difference in the baseline CRT or presence of atrophic retinal pigment epithelium in the fellow eyes of patients with nAMD according to smoking status; however, the baseline CRT in eyes with nAMD was significantly thinner in ever-smokers than in never-smokers (P = 0.02). Conclusion. The anti-VEGF therapy was frequently required in nAMD patients with a history of heavy smoking. Heavy smoking could cause poor therapeutic response in nAMD patients.
C1 [Kamao, Hiroyuki; Goto, Katsutoshi; Mito, Yumi; Miki, Atsushi; Kiryu, Junichi] Kawasaki Med Sch, Dept Ophthalmol, 577 Matsushima, Kurashiki, Okayama 7010114, Japan.
C3 Kawasaki Medical School
RP Kamao, H (通讯作者)，Kawasaki Med Sch, Dept Ophthalmol, 577 Matsushima, Kurashiki, Okayama 7010114, Japan.
EM hironeri@med.kawasaki-m.ac.jp
OI Kamao, Hiroyuki/0000-0002-2194-7063
CR [Anonymous], 2014, HLTH CONSMOK 50 YE
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BURNS DM, 1991, CLIN CHEST MED, V12, P631
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   He J, 2001, ARCH INTERN MED, V161, P996, DOI 10.1001/archinte.161.7.996
   Iribarren C, 1999, NEW ENGL J MED, V340, P1773, DOI 10.1056/NEJM199906103402301
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   MORGADO PB, 1994, OPHTHALMOLOGY, V101, P1220
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   ROBINSON F, 1985, INVEST OPHTH VIS SCI, V26, P609
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Tamaki Y, 1999, OPHTHALMOLOGY, V106, P564, DOI 10.1016/S0161-6420(99)90117-3
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Ulas F, 2014, CURR EYE RES, V39, P504, DOI 10.3109/02713683.2013.850099
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
NR 35
TC 2
Z9 2
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2018
VL 2018
AR 2353428
DI 10.1155/2018/2353428
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HB6MY
UT WOS:000451185800001
PM 30538852
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Miere, A
   Sacconi, R
   Amoroso, F
   Capuano, V
   Jung, C
   Bandello, F
   Souied, EH
   Querques, G
AF Miere, Alexandra
   Sacconi, Riccardo
   Amoroso, Francesca
   Capuano, Vittorio
   Jung, Camille
   Bandello, Francesco
   Souied, Eric H.
   Querques, Giuseppe
TI SUB-RETINAL PIGMENT EPITHELIUM MULTILAMINAR HYPERREFLECTIVITY AT THE
   ONSET OF TYPE 3 MACULAR NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; onion sign; regressing drusen; type 3
   neovascularization; retinal angiomatous proliferation; optical coherence
   tomography
AB Purpose: To report the prevalence and treatment outcomes of eyes with sub-retinal pigment epithelium (sub-RPE) multilaminar hyperreflectivity at the onset/clinical detection of Type 3 macular neovascularization (MNV) secondary to exudative age-related macular degeneration. Methods: Retrospective analysis of consecutive patients diagnosed with Type 3 MNV secondary to age-related macular degeneration was performed. Eyes presenting with sub-RPE multilaminar hyperreflectivity on structural optical coherence tomography at the onset of Type 3 MNV were included in this study. An age-, sex-, and stage-matched control group was composed of eyes affected by Type 3 MNV without sub-RPE multilaminar hyperreflectivity. Prevalence and treatment outcomes after anti-vascular endothelial growth factor injections at 1-year follow-up were analyzed in both groups. Results: Nineteen treatment-naive eyes of 19 patients (8 men/11 women, mean age 83 +/- 8 years old) presenting with sub-RPE multilaminar hyperreflectivity before or at the onset/clinical detection of Type 3 MNV were included from a cohort of 162 eyes with treatment-naive Type 3 MNV. This accounts for an estimated prevalence of 11.7% (5.8-15.2, 95% confidence intervals). No significant differences were disclosed between cases studied and the control group (143 eyes of 143 patients) in age, sex, best-corrected visual acuity at baseline, and number of injections. Best-corrected visual acuity did not improve during the 1-year follow-up in patients showing sub-RPE multilaminar hyperreflectivity (P = 0.45), whereas best-corrected visual acuity significantly increased in the control group (P < 0.001). The presence of sub-RPE multilaminar hyperreflectivity in the context of Type 3 MNV was significantly associated with regressive calcific drusen (P < 0.001) and multiple Type 3 lesions/eye (P < 0.001). Conclusion: The detection of multilaminar hyperreflectivity at the onset/clinical detection of Type 3 MNV suggests that chronic exudation (i.e., the "onion-sign") in the sub-RPE space (i.e., focal sub-RPE neovascularization) may precede the onset/clinical detection of Type 3 MNV. Sub-retinal pigment epithelium multilaminar hyperreflectivity at the onset of Type 3 MNV may be an important predictor of poor visual outcome in these eyes.
C1 [Miere, Alexandra; Amoroso, Francesca; Capuano, Vittorio; Jung, Camille; Souied, Eric H.; Querques, Giuseppe] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Sacconi, Riccardo; Capuano, Vittorio; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM Giuseppe.querques@hotmail.it
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; bandello,
   francesco/0000-0003-3238-9682; Sacconi, Riccardo/0000-0003-2891-2012;
   Querques, Giuseppe/0000-0002-3292-9581
CR Chae B, 2019, BRIT J OPHTHALMOL, V103, P43, DOI 10.1136/bjophthalmol-2018-311850
   Corvi F, 2016, JAMA OPHTHALMOL, V134, DOI 10.1001/jamaophthalmol.2016.2687
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P2433, DOI 10.1097/IAE.0000000000000761
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P603, DOI 10.1097/IAE.0000000000000487
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 19
TC 8
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2021
VL 41
IS 1
BP 135
EP 143
DI 10.1097/IAE.0000000000002815
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PR6YJ
UT WOS:000607379100019
PM 32282662
DA 2022-11-30
ER

PT J
AU Leydolt, C
   Michels, S
   Prager, F
   Garhoefer, G
   Georgopoulos, M
   Polak, K
   Schmidt-Erfurth, U
AF Leydolt, Christina
   Michels, Stephan
   Prager, Franz
   Garhoefer, Gerhard
   Georgopoulos, Michael
   Polak, Kaija
   Schmidt-Erfurth, Ursula
TI Effect of intravitreal bevacizumab (Avastin (R)) in neovascular
   age-related macular degeneration using a treatment regimen based on
   optical coherence tomography: 6-and 12-month results
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE intravitreal bevacizumab; intravitreal injections; neovascular
   age-related macular degeneration; OCT
ID OCCULT CHOROIDAL NEOVASCULARIZATION; PIGMENT EPITHELIAL TEAR;
   PHOTODYNAMIC THERAPY; RANIBIZUMAB; INJECTION; TRIAMCINOLONE;
   VERTEPORFIN; SAFETY; TRIAL; EYE
AB Purpose:
   To study the effect of intravitreal bevacizumab therapy on visual and anatomical outcomes in patients with neovascular age-related macular degeneration (AMD) within a follow-up period of 6 and 12 months.
   Methods:
   A retrospective analysis of 102 eyes of 102 consecutive patients with neovascular AMD evaluated repeated intravitreal bevacizumab (1 or 2.5 mg) injections. Retreatment was performed following an optical coherence tomography (OCT)-based regimen. Ophthalmic examination included best-corrected visual acuity (BCVA), dilated fundus examination and OCT imaging. Data were analysed at baseline, 6 months (24 weeks) and 12 months (48 weeks) after treatment initiation.
   Results:
   BCVA remained stable at 6 months (mean: 0.00 +/- 0.41 logMAR; p = 0.95) and 12 months (mean: +0.02 +/- 0.43 logMAR; loss of similar to 1 letter; p = 0.70) after the first treatment. OCT retinal thickness decreased by a mean of -37.8 +/- 101.6 mu m (p < 0.05) compared to baseline at month 6 and -38.6 +/- 93.3 mu m (p < 0.05) at month 12. A mean of 2.6 +/- 1.2 injections were needed to obtain absence of fluid by OCT, and the time to recurrence was 23 +/- 11 weeks thereafter. There was no difference in BCVA and OCT outcomes between treatment-naive eyes and eyes that had undergone prior treatment.
   Conclusion:
   The 6- and 12-month follow-up of repeated intravitreal bevacizumab therapy in eyes with neovascular AMD demonstrated stabilization of vision and no safety concerns. An OCT-based retreatment strategy appears appropriate in the management of patients treated with intravitreal bevacizumab.
C1 [Michels, Stephan] Univ Zurich, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Leydolt, Christina; Prager, Franz; Garhoefer, Gerhard; Georgopoulos, Michael; Polak, Kaija; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 University of Zurich; Medical University of Vienna
RP Michels, S (通讯作者)，Univ Zurich, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM stephan.michels@usz.ch
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Drexler W, 2004, J BIOMED OPT, V9, P47, DOI 10.1117/1.1629679
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2006, BRIT J OPHTHALMOL, V90, P1333, DOI 10.1136/bjo.2006.102293
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Mulcahy MF, 2005, EXPERT OPIN BIOL TH, V5, P997, DOI 10.1517/14712598.5.7.997
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 47
TC 22
Z9 22
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2010
VL 88
IS 5
BP 594
EP 600
DI 10.1111/j.1755-3768.2008.01485.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 625MA
UT WOS:000279898200027
PM 19485959
OA Bronze
DA 2022-11-30
ER

PT J
AU Moeller, SM
   Parekh, N
   Tinker, L
   Ritenbaugh, C
   Blodi, B
   Wallace, RB
   Mares, JA
AF Moeller, Suzen M.
   Parekh, Niyati
   Tinker, Lesley
   Ritenbaugh, Cheryl
   Blodi, Barbara
   Wallace, Robert B.
   Mares, Julie A.
CA CAREDS Res Study Grp
TI Associations between intermediate age-related macular degeneration and
   lutein and zeaxanthin in the carotenoids in age-related eye disease
   study (CAREDS) - Ancillary study of the women's health initiative
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID 10-YEAR INCIDENCE; 5-YEAR INCIDENCE; VISIBLE-LIGHT; FATTY-ACIDS;
   MACULOPATHY; ANTIOXIDANT; PIGMENT; SUNLIGHT; PLASMA; RISK
AB Objective: To evaluate the relationship between dietary lutein plus zeaxanthin and intermediate age-related macular degeneration (AMD).
   Design: Women aged 50 to 79 years in Iowa, Wisconsin, and Oregon with intake of lutein plus zeaxanthin above the 78th (high) and below the 28th (low) percentiles at baseline in the Women's Health Initiative Observational Study were recruited 4 to 7 years later into the Carotenoids in Age-Related Eye Disease Study (CAREDS), when the presence of AMD was determined by fundus photographs. Logistic regression analyses examined the prevalence of AMD in 1787 CAREDS participants, after accounting for potential covariates.
   Results: The prevalence of intermediate AMD was not statistically different between the high and low lutein plus zeaxanthin intake recruitment groups after adjusting for age ( odds ratio, 0.96; 95% confidence interval, 0.75-1.23). Limiting analyses to women younger than 75 years with stable intake of lutein plus zeaxanthin, without a history of chronic diseases that are often associated with diet changes, substantially lowered odds ratios (0.57; 95% confidence interval, 0.34-0.95). Exploratory analyses of advanced AMD in 34 participants resulted in protective, but statistically nonsignificant, associations in the overall sample and in women younger than 75 years.
   Conclusion: Diets rich in lutein plus zeaxanthin may protect against intermediate AMD in healthy women younger than 75 years.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Wisconsin, Dept Nutr Sci, Madison, WI 53726 USA.
   Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   Univ Arizona, Dept Family & Community Med, Tucson, AZ USA.
   Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Fred
   Hutchinson Cancer Center; University of Arizona; University of Iowa
RP Mares, JA (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,1063 WARF Bldg, Madison, WI 53726 USA.
EM Jmarespe@wisc.edu
RI Parekh, Niyati/ABF-4933-2020
OI Parekh, Niyati/0000-0002-1334-0528; Ritenbaugh,
   Cheryl/0000-0002-3307-2727
FU NEI NIH HHS [EY13018] Funding Source: Medline; NIDDK NIH HHS [DK 07665]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY013018] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [T32DK007665] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   ALLAIN CC, 1974, CLIN CHEM, V20, P470
   Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BYERS T, 1987, AM J EPIDEMIOL, V125, P999, DOI 10.1093/oxfordjournals.aje.a114638
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Duncan DD, 2002, DEV OPHTHALMOL, V35, P76
   Feeney-Burns L, 1989, Prog Clin Biol Res, V314, P601
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gruszecki WI, 2004, OXIDAT STRESS DIS, V13, P151
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Landrum JT, 2004, OXIDAT STRESS DIS, V13, P445
   Langer RD, 2003, ANN EPIDEMIOL, V13, pS107, DOI 10.1016/S1047-2797(03)00047-4
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Mares-Perlman J.A., 1999, CRC MOD NUT, P181
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Vaicaitiene Ramute, 2003, Medicina (Kaunas), V39, P1231
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VU HTV, 2005, INVEST OPHTH VIS SCI, V46, P3304
   WAHLEFELD A., 1974, METHOD ENZYMAT AN, P1831
   WU ML, 1988, AM J EPIDEMIOL, V128, P1137
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
NR 48
TC 181
Z9 193
U1 0
U2 26
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2006
VL 124
IS 8
BP 1151
EP 1162
DI 10.1001/archopht.124.8.1151
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 073QQ
UT WOS:000239758100009
PM 16908818
OA Bronze
DA 2022-11-30
ER

PT J
AU Mukherjee, O
   De Silva, T
   Grisso, P
   Wiley, H
   Tiarnan, DLK
   Thavikulwat, TA
   Chew, EMILY
   Cukras, C
AF Mukherjee, Ouvick
   DE Silva, Tharindu
   Grisso, Peyton
   Wiley, Henry
   Tiarnan, D. L. Keenan
   Thavikulwat, T. Alisa
   Chew, Emily
   Cukras, Catherine
TI Retinal layer segmentation in optical coherence tomography (OCT) using a
   3D deep-convolutional regression network for patients with age-related
   macular degeneration
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID AUTOMATIC SEGMENTATION; SURFACE SEGMENTATION; FLUID SEGMENTATION;
   IMAGES; SEVERITY; AREDS
AB Introduction - Retinal layer segmentation in optical coherence tomography (OCT) images is an important approach for detecting and prognosing disease. Automating segmentation using robust machine learning techniques lead to computationally efficient solutions and significantly reduces the cost of labor-intensive labeling, which is traditionally performed by trained graders at a reading center, sometimes aided by semi-automated algorithms. Although several algorithms have been proposed since the revival of deep learning, eyes with severe pathological conditions continue to challenge fully automated segmentation approaches. There remains an opportunity to leverage the underlying spatial correlations between the retinal surfaces in the segmentation approach. Methods - Some of these proposed traditional methods can be expanded to utilize the three-dimensional spatial context governing the retinal image volumes by replacing the use of 2D filters with 3D filters. Towards this purpose, we propose a spatial-context, continuity and anatomical relationship preserving semantic segmentation algorithm, which utilizes the 3D spatial context from the image volumes with the use of 3D filters. We propose a 3D deep neural network capable of learning the surface positions of the layers in the retinal volumes. Results - We utilize a dataset of OCT images from patients with Age-related Macular Degeneration (AMD) to assess performance of our model and provide both qualitative (including segmentation maps and thickness maps) and quantitative (including error metric comparisons and volumetric comparisons) results, which demonstrate that our proposed method performs favorably even for eyes with pathological changes caused by severe retinal diseases. The Mean Absolute Error (MAE) and Root Mean Squared Error (RMSE) for patients with a wide range of AMD severity scores (0-11) were within 0.84 +/- 0.41 and 1.33 +/- 0.73 pixels, respectively, which are significantly better than some of the other state-of-the-art algorithms. Conclusion - The results demonstrate the utility of extracting features from the entire OCT volume by treating the volume as a correlated entity and show the benefit of utilizing 3D autoencoder based regression networks for smoothing the approximated retinal layers by inducing shape based regularization constraints.
C1 [Mukherjee, Ouvick; DE Silva, Tharindu; Grisso, Peyton; Cukras, Catherine] Unit Clin Invest Retinal Dis, 10 Ctr Dr,Bldg 10-CRC,Room 3-2531, Bethesda, MD 20892 USA.
   [Wiley, Henry; Tiarnan, D. L. Keenan; Thavikulwat, T. Alisa; Chew, Emily] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Cukras, C (通讯作者)，Unit Clin Invest Retinal Dis, 10 Ctr Dr,Bldg 10-CRC,Room 3-2531, Bethesda, MD 20892 USA.
EM cukrasc@nei.nih.gov
OI Keenan, Tiarnan/0000-0002-2253-1772; Mukherjee,
   Souvick/0000-0003-0748-8371
FU National Eye Institute [EY000509]
FX National Eye Institute (EY000509).
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   [Anonymous], ASS ELEVATED SERUM L, P6
   Asgari R., 2019, ARXIV191205404 CS EE
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Cicek Ozgun, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P424, DOI 10.1007/978-3-319-46723-8_49
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gopinath K., ARXIV180608859
   Hasani B, 2017, IEEE COMPUT SOC CONF, P2278, DOI 10.1109/CVPRW.2017.282
   He YF, 2021, MED IMAGE ANAL, V68, DOI 10.1016/j.media.2020.101856
   Heidelberg Engineering GmbH, 2016, SPECTR HRA OCT US MA
   Lang A, 2013, BIOMED OPT EXPRESS, V4, P1133, DOI 10.1364/BOE.4.001133
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Li MX, 2019, INT J OPHTHALMOL-CHI, V12, P1012, DOI 10.18240/ijo.2019.06.22
   Lou SL, 2020, IEEE ACCESS, V8, P53678, DOI 10.1109/ACCESS.2020.2981206
   Matovinovic IZ, 2019, INT SYMP IMAGE SIG, P49, DOI 10.1109/ISPA.2019.8868639
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mishra Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66355-5
   Montuoro A, 2017, BIOMED OPT EXPRESS, V8, P1874, DOI 10.1364/BOE.8.001874
   Pekala M, 2019, COMPUT BIOL MED, V114, DOI 10.1016/j.compbiomed.2019.103445
   Pham CH, 2017, I S BIOMED IMAGING, P197, DOI 10.1109/ISBI.2017.7950500
   Riegler G, 2017, PROC CVPR IEEE, P6620, DOI 10.1109/CVPR.2017.701
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Shah A, 2018, BIOMED OPT EXPRESS, V9, P4509, DOI 10.1364/BOE.9.004509
   Shah A, 2017, LECT NOTES COMPUT SC, V10553, P3, DOI 10.1007/978-3-319-67558-9_1
   Shengnan Liu, 2019, Machine Learning and Medical Engineering for Cardiovascular Health and Intravascular Imaging and Computer Assisted Stenting. First International Workshop, MLMECH 2019 and 8th Joint International Workshop, CVII-STENT 2019. Held in Conjunction with MICCAI 2019. Proceedings. Lecture Notes in Computer Science (LNCS 11794), P184, DOI 10.1007/978-3-030-33327-0_22
   Sonka M, 2016, MED IMAGE ANAL, V33, P165, DOI 10.1016/j.media.2016.06.001
   Stankiewicz A, 2016, METROL MEAS SYST, V23, P269, DOI 10.1515/mms-2016-0016
NR 32
TC 1
Z9 1
U1 0
U2 0
PU Optica Publishing Group
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD JUN 1
PY 2022
VL 13
IS 6
BP 3195
EP 3210
DI 10.1364/BOE.450193
PG 16
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 2A9YL
UT WOS:000809852000004
PM 35781941
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Fiess, A
   Elbaz, H
   Korb, CA
   Nickels, S
   Schulz, A
   Munzel, T
   Wild, PS
   Beutel, ME
   Schmidtmann, I
   Lackner, KJ
   Peto, T
   Pfeiffer, N
   Schuster, AK
AF Fiess, Achim
   Elbaz, Hisham
   Korb, Christina A.
   Nickels, Stefan
   Schulz, Andreas
   Muenzel, Thomas
   Wild, Philipp S.
   Beutel, Manfred E.
   Schmidtmann, Irene
   Lackner, Karl J.
   Peto, Tunde
   Pfeiffer, Norbert
   Schuster, Alexander K.
TI Low Birth Weight Is Linked to Age-Related Macular Degeneration: Results
   From the Population-Based Gutenberg Health Study (GHS)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE birth weight; age-related macular degeneration; age-related maculopathy;
   epidemiology; population-based study
ID CHOROIDAL THICKNESS; FORMER PRETERM; GESTATIONAL-AGE; PRIMATE FOVEA;
   CHILDREN; INFANTS; ATHEROSCLEROSIS; CLASSIFICATION; MACULOPATHY;
   RETINOPATHY
AB PURPOSE. This study analyzed whether low birth weight is linked to prevalence and incidence of age-related maculopathy (AMD) in adulthood.
   METHODS. The Gutenberg Health Study (GHS) is a population-based, observational cohort study in Germany. GHS participants at an age from 35 to 74 years were included. An ophthalmologic examination with fundus photography was carried out. Fundus photographs were graded according to the Rotterdam Grading Scheme for AMD at baseline and at the 5-year follow-up examination. Participants were divided into three different birth weight groups (low: <2500 g; normal: 2500-4000 g; and high: >4000 g). Poisson regression analysis with adjustment for several confounders was used to assess associations between birth weight and AMD prevalence (overall, early, late AMD) and 5-year cumulative incidence.
   RESULTS. Overall, 6492 participants were included (3538 female, aged 50.7 +/- 10.4 years). Prevalence of total AMD was highest in the low birth weight group (11.2%; 40/358) compared to the normal birth weight group (6.5%; 346/5328) and the high birth weight group (8.4%; 68/806). Low birth weight was associated with overall AMD prevalence (prevalence ratio [PR] = 1.54, P - 0.006), and in particular with early AMD prevalence (PR = 1.52; P = 0.01). No association was observed between low birth weight and cumulative 5-year incidence of AMD.
   CONCLUSION. Our analyses indicate that low birth weight may lead to higher prevalence of retinal diseases in later life, as we observed for AMD. Our results are limited due to missing data and loss to follow-up, but may be a first hint that AMD has one of its origins in early life.
C1 [Fiess, Achim; Elbaz, Hisham; Korb, Christina A.; Nickels, Stefan; Pfeiffer, Norbert; Schuster, Alexander K.] Johannes Gutenberg Univ Mainz, Dept Ophthalmol, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.
   [Elbaz, Hisham] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Schulz, Andreas; Wild, Philipp S.] Johannes Gutenberg Univ Mainz, Prevent Cardiol & Prevent Med Ctr Cardiol, Univ Med Ctr, Mainz, Germany.
   [Muenzel, Thomas] Johannes Gutenberg Univ Mainz, Ctr Cardiol Cardiol 1, Univ Med Ctr, Mainz, Germany.
   [Wild, Philipp S.] Johannes Gutenberg Univ Mainz, CTH, Univ Med Ctr, Mainz, Germany.
   [Wild, Philipp S.] German Ctr Cardiovasc Res DZHK, Partner Site Rhine Main, Mainz, Germany.
   [Beutel, Manfred E.] Johannes Gutenberg Univ Mainz, Dept Psychosomat Med & Psychotherapy, Univ Med Ctr, Mainz, Germany.
   [Schmidtmann, Irene] Johannes Gutenberg Univ Mainz, Inst Med Biostat Epidemiol & Informat, Div Biostat & Bioinformat, Univ Med Ctr, Mainz, Germany.
   [Lackner, Karl J.] Johannes Gutenberg Univ Mainz, Inst Clin Chem & Lab Med, Univ Med Ctr, Mainz, Germany.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res Biomed Res Ctr, London, England.
   [Peto, Tunde] UCL, Inst Ophthalmol, London, England.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 Johannes Gutenberg University of Mainz; Universite de Montreal; Johannes
   Gutenberg University of Mainz; Johannes Gutenberg University of Mainz;
   Johannes Gutenberg University of Mainz; German Centre for Cardiovascular
   Research; Johannes Gutenberg University of Mainz; Johannes Gutenberg
   University of Mainz; Johannes Gutenberg University of Mainz; University
   of London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London;
   Queens University Belfast
RP Fiess, A (通讯作者)，Johannes Gutenberg Univ Mainz, Dept Ophthalmol, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.
EM Achim.fiess@gmail.com
RI Munzel, Thomas/A-2912-2014; Pfeiffer, Norbert/AAO-7586-2020
OI Munzel, Thomas/0000-0001-5503-4150; Wild, Philipp/0000-0003-4413-9752
FU government of Rhineland-Palatinate ("Stiftung Rheinland-Pfalz fur
   Innovation") [AZ 961-386261/733]; research program "Wissen schafft
   Zukunft'' of the Johannes Gutenberg University Mainz; Boehringer
   Ingelheim; PHILIPS Medical Systems; Federal Ministry of Education and
   Research [BMBF 01EO1503]; Deutsche Ophthalmologische Gesellschaft;
   Berufsverband der Augenarzte Deutschlands e.V; research program "Center
   for Translational Vascular Biology (CTVB)'' of the Johannes Gutenberg
   University Mainz
FX Supported by the government of Rhineland-Palatinate ("Stiftung
   Rheinland-Pfalz fur Innovation,'' contract AZ 961-386261/733), the
   research programs "Wissen schafft Zukunft'' and "Center for
   Translational Vascular Biology (CTVB)'' of the Johannes Gutenberg
   University Mainz, and its contract with Boehringer Ingelheim and PHILIPS
   Medical Systems, including an unrestricted grant for the Gutenberg
   Health Study. Also supported by the Federal Ministry of Education and
   Research (BMBF 01EO1503, PSW); PSW is PI of the German Center for
   Cardiovascular Research (DZHK). AKS holds the professorship for
   ophthalmic healthcare research endowed by Stiftung Auge and financed by
   Deutsche Ophthalmologische Gesellschaft and Berufsverband der Augenarzte
   Deutschlands e.V.
CR Akerblom H, 2011, BRIT J OPHTHALMOL, V95, P799, DOI 10.1136/bjo.2010.184747
   Barker DJP, 2009, ANN HUM BIOL, V36, P445, DOI 10.1080/03014460902980295
   Barker DJP, 1997, NUTRITION, V13, P807, DOI 10.1016/S0899-9007(97)00193-7
   BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bowl W, 2016, INVEST OPHTH VIS SCI, V57, pOCT235, DOI 10.1167/iovs.15-18843
   Dammann O, 1996, PAEDIATR PERINAT EP, V10, P130, DOI 10.1111/j.1365-3016.1996.tb00037.x
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fiess A, 2019, JAMA OPHTHALMOL, V137, P507, DOI 10.1001/jamaophthalmol.2018.7121
   Fiess A, 2019, BRIT J OPHTHALMOL, V103, P99, DOI 10.1136/bjophthalmol-2017-311774
   Fiess A, 2017, GRAEF ARCH CLIN EXP, V255, P1433, DOI 10.1007/s00417-017-3662-5
   Fiess A, 2017, CORNEA, V36, P821, DOI 10.1097/ICO.0000000000001186
   Fiess A, 2016, INVEST OPHTH VIS SCI, V57, P6548, DOI 10.1167/iovs.16-20128
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hall NF, 2002, INVEST OPHTH VIS SCI, V43, P3641
   HENDRICKSON AE, 1984, OPHTHALMOLOGY, V91, P603
   Hohn R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120476
   Hughes MM, 2017, MATERN CHILD HLTH J, V21, P283, DOI 10.1007/s10995-016-2131-9
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Lampert T, 2013, BUNDESGESUNDHEITSBLA, V56, P131, DOI 10.1007/s00103-012-1583-3
   Li XQ, 2015, INVEST OPHTH VIS SCI, V56, P617, DOI 10.1167/iovs.14-15016
   Liew G, 2008, OPHTHAL EPIDEMIOL, V15, P56, DOI 10.1080/09286580701613769
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Molnar AEC, 2017, JAMA OPHTHALMOL, V135, P854, DOI 10.1001/jamaophthalmol.2017.2069
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nilsson M, 2016, INVEST OPHTH VIS SCI, V57, pOCT550, DOI 10.1167/iovs.15-18583
   Ojaimi E, 2005, AM J OPHTHALMOL, V140, P535
   Park KA, 2012, INVEST OPHTH VIS SCI, V53, P7201, DOI 10.1167/iovs.12-10599
   Provis JM, 1998, PROG NEUROBIOL, V54, P549, DOI 10.1016/S0301-0082(97)00079-8
   Sanderson M, 1998, AM J EPIDEMIOL, V147, P136
   Sayer AA, 1998, AGE AGEING, V27, P579, DOI 10.1093/ageing/27.5.579
   Sjostrand J, 2017, INVEST OPHTH VIS SCI, V58, P4948, DOI 10.1167/iovs.17-22333
   Springer AD, 1999, VISUAL NEUROSCI, V16, P629, DOI 10.1017/S0952523899164034
   Statistisches Bundesamt, 1972, BEV ERW BEV, V2
   Sun C, 2010, AM J OPHTHALMOL, V150, P909, DOI 10.1016/j.ajo.2010.06.028
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JY, 2012, RETINA-J RET VIT DIS, V32, P330, DOI 10.1097/IAE.0b013e318219e685
   Wild PS, 2012, BUNDESGESUNDHEITSBLA, V55, P824, DOI 10.1007/s00103-012-1502-7
   Yanni SE, 2012, BRIT J OPHTHALMOL, V96, P961, DOI 10.1136/bjophthalmol-2012-301612
   YUODELIS C, 1986, VISION RES, V26, P847, DOI 10.1016/0042-6989(86)90143-4
NR 43
TC 9
Z9 9
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2019
VL 60
IS 14
BP 4943
EP 4950
DI 10.1167/iovs.19-27964
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JS4YT
UT WOS:000500313300046
PM 31770434
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Peter, I
   Huggins, GS
   Ordovas, JM
   Haan, M
   Seddon, JM
AF Peter, Inga
   Huggins, Gordon S.
   Ordovas, Jose M.
   Haan, Mary
   Seddon, Johanna M.
TI Evaluation of New and Established Age-Related Macular Degeneration
   Susceptibility Genes in the Women's Health Initiative Sight Exam
   (WHI-SE) Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; CIGARETTE-SMOKING; DISEASE
   RISK; VITAMIN-C; MACULOPATHY; LOCI; PREVALENCE; VARIANT; POLYMORPHISM
AB PURPOSE: To assess whether established and newly reported genetic variants, independent of known lifestyle factors, are associated with the risk of age-related macular degeneration (AMD) among women participating in the Women's Health Initiative Sight Exam (WHI-SE) Genetic Ancillary Study.
   DESIGN: Multicenter case-control study.
   METHODS: One hundred and forty-six women with intermediate and late stages of AMD and 1269 subjects without AMD underwent ocular examinations and fundus photography to determine stage of AMD. Fourteen polymorphisms at or near 11 genes, including previously confirmed genes CFH, ARMS2/HTRA1, C2, C3, and CFI; recently reported AMD genes in the high-density lipoprotein cholesterol (HDL) pathway LIPC, ABCA1, CETP, and LPL; TIMP3/SYN3, a known ocular gene recently linked with AMD; and APOE, were assessed using logistic regression analysis.
   RESULTS: After adjustment for demographic, behavioral, and other genetic factors, a protective effect was detected among TT carriers compared with non-carriers for the HDL pathway gene, LIPC rs493258, for intermediate and late AMD (OR [95% confidence interval]: 0.3 [0.2-0.7], P = .003). Variants in CFH rs1410996, ARMS2/HTRA1 A69S, and C3 R102G were significantly associated with an increased risk of AMD. Individuals with the homozygous CFI rs10033900 TT genotype had a 2.9 [1.2-7.2]-fold increased risk, and those with the CFH Y402H GG genotype had a 2.2 [1.0-4.8]-fold higher risk of developing AMD compared with non-carriers. APOE4 carriers may have a reduced risk of intermediate/late AMD (OR = 0.5 [0.3-0.9], P = .015. Suggestive associations were seen between AMD and the HDL pathway genes CETP and LPL.
   CONCLUSION: In this unique national cohort of women, we found associations with established AMD-related genetic factors and the recently reported LIPC gene in the HDL pathway. These findings may help develop novel therapeutic targets to treat or delay the onset of the disease. (Am J Ophthalmol 2011;152:1005-1013. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Seddon, Johanna M.] Tufts Univ, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, Tufts Med Ctr,Sch Med, Boston, MA 02111 USA.
   [Peter, Inga] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.
   [Huggins, Gordon S.] Tufts Univ, Ctr Translat Genom, Mol Cardiol Res Inst, Sch Med, Boston, MA 02111 USA.
   [Ordovas, Jose M.] Tufts Univ, Nutr & Genom Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Haan, Mary] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA.
C3 Tufts Medical Center; Tufts University; Icahn School of Medicine at
   Mount Sinai; Tufts University; Tufts University; United States
   Department of Agriculture (USDA); University of California System;
   University of California San Francisco
RP Seddon, JM (通讯作者)，Tufts Univ, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, Tufts Med Ctr,Sch Med, 800 Washington St, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Haan, Mary N/Y-9354-2018; Ordovas, Jose/B-8727-2013
OI Haan, Mary N/0000-0001-9312-4501; Ordovas, Jose/0000-0002-7581-5680
FU Tufts University School of Medicine, Boston, Massachusetts; National
   Institutes of Health, Bethesda, Maryland [RO1-EY11309]; Massachusetts
   Lions Eye Research Fund, Inc, New Bedford, Massachusetts; Research to
   Prevent Blindness, Inc, New York, New York; Ophthalmic Epidemiology and
   Genetics Service, New England Eye Center, Tufts Medical Center, Tufts
   University School of Medicine, Boston, Massachusetts; National Heart
   Lung and Blood Institute, National Institutes of Health, Bethesda,
   Maryland; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023387] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011309] Funding
   Source: NIH RePORTER
FX AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF
   POTENTIAL CONFLICTS OF Interest and none were reported. Publication of
   this article was supported by the Russo Dual-Investigator Grant, Tufts
   University School of Medicine, Boston, Massachusetts; Grant RO1-EY11309
   from the National Institutes of Health, Bethesda, Maryland;
   Massachusetts Lions Eye Research Fund, Inc, New Bedford, Massachusetts;
   Research to Prevent Blindness, Inc, New York, New York; and the Macular
   Degeneration Research Fund of the Ophthalmic Epidemiology and Genetics
   Service, New England Eye Center, Tufts Medical Center, Tufts University
   School of Medicine, Boston, Massachusetts. WHI-SE was funded by
   Wyeth-Ayerst Laboratories, Inc, Collegeville, Pennsylvania; and WHI was
   funded by National Heart Lung and Blood Institute, National Institutes
   of Health, Bethesda, Maryland. Tufts Medical Center has filed a patent
   application for some materials related to this work. Involved in design
   and conduct of the study (I.P., M.H., J.M.S.); collection and
   interpretation of the data (I.P., G.S.H., J.M.O., M.H., J.M.S.); and
   preparation, review, or approval of the manuscript (I.P., G.S.H.,
   J.M.O., M.H., J.M.S.). This ancillary study was approved by the
   Institutional Review Board of Tufts University School of Medicine and
   Tufts Medical Center and the WHI ancillary study subcommittee.
CR Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7
   Aulchenko YS, 2009, NAT GENET, V41, P47, DOI 10.1038/ng.269
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ishida T, 2004, J BIOL CHEM, V279, P45085, DOI 10.1074/jbc.M406360200
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kooner JS, 2008, NAT GENET, V40, P149, DOI 10.1038/ng.2007.61
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Lewis SJ, 2004, INT J EPIDEMIOL, V33, P962, DOI 10.1093/ije/dyh214
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MAHLEY RW, 1984, J LIPID RES, V25, P1277
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Panza F, 2007, REJUV RES, V10, P441, DOI 10.1089/rej.2007.0537
   Peter I, 2010, AM J OPHTHALMOL, V150, P450, DOI 10.1016/j.ajo.2010.06.012
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   2001, ARCH OPHTHALMOL, V119, P1417
NR 45
TC 29
Z9 32
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2011
VL 152
IS 6
BP 1005
EP 1013
DI 10.1016/j.ajo.2011.05.016
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 857JN
UT WOS:000297714900015
PM 21906714
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Devyatkin, VA
   Redina, OE
   Kolosova, NG
   Muraleva, NA
AF Devyatkin, Vasiliy A.
   Redina, Olga E.
   Kolosova, Nataliya G.
   Muraleva, Natalia A.
TI Single-Nucleotide Polymorphisms Associated with the
   Senescence-Accelerated Phenotype of OXYS Rats: A Focus on Alzheimer's
   Disease-Like and Age-Related-Macular-Degeneration-Like Pathologies
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Age-related macular degeneration; aging; Alzheimer's disease;
   senescence-accelerated OXYS rats; SNP
ID AMD-LIKE RETINOPATHY; MICROSOMAL EPOXIDE HYDROLASE; ALPHA-B-CRYSTALLIN;
   CLASS-I PROTEINS; INTELLECTUAL DISABILITY; ANO10 MUTATIONS; LHX2;
   EXPRESSION; MITOCHONDRIA; HIPPOCAMPUS
AB Alzheimer's disease (AD) and age-related macular degeneration (AMD) are two complex incurable neurodegenerative disorders the common pathogenesis of which is actively discussed. There are overlapping risk factors and molecular mechanisms of the two diseases; at the same time, there are arguments in favor of the notion that susceptibility to each of these diseases is associated with a distinct genetic background. Here we identified single-nucleotide polymorphisms (SNPs) that are specific for senescence-accelerated OXYS rats, which simulate key characteristics of both sporadic AD and AMD. Transcriptomes of the hippocampus, prefrontal cortex, and retina (data of RNA-Seq) were analyzed. We detected SNPs in genes Rims2, AABR07072639.2, Lemd2, and AABR07045405.1, which thus can express significantly truncated proteins lacking functionally important domains. Additionally, 33 mutations in genes-which are related to various metabolic and signaling pathways-cause nonsynonymous amino acid substitutions presumably leading to disturbances in protein structure or functions. Some of the genes carrying these SNPs are associated with aging, neurodegenerative, and mental diseases. Thus, we revealed the SNPs can lead to abnormalities in protein structure or functions and affect the development of the senescence-accelerated phenotype of OXYS rats. Our data are consistent with the latest results of genome-wide association studies that highlight the importance of multiple pathways for the pathogenesis of AD and AMD. Identified SNPs can serve as promising research objects for further studies on the molecular mechanisms underlying this particular rat model as well as for the prediction of potential biomarkers of AD and AMD.
C1 [Devyatkin, Vasiliy A.; Redina, Olga E.; Kolosova, Nataliya G.; Muraleva, Natalia A.] Inst Cytol & Genet, 10 Lavrentyeva Ave, Novosibirsk 630090, Russia.
   [Devyatkin, Vasiliy A.; Redina, Olga E.] Novosibirsk State Univ, Novosibirsk, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; Novosibirsk State University
RP Muraleva, NA (通讯作者)，Inst Cytol & Genet, 10 Lavrentyeva Ave, Novosibirsk 630090, Russia.
EM myraleva@bionet.nsc.ru
RI Kolosova, Nataliya G/AAR-7409-2020; Devyatkin, Vasiliy/AAD-3990-2020
OI Kolosova, Nataliya G/0000-0003-2398-8544; Devyatkin,
   Vasiliy/0000-0002-3490-2059; Redina, Olga/0000-0003-0942-8460
FU Russian Science Foundation [19-15-00044]
FX The analysis of transcriptome data from OXYS rats was supported by the
   Russian Science Foundation [grant #19-15-00044]. The sponsor had no role
   in study design; in the collection, analysis and interpretation of data;
   in the writing of the report; and in the decision to submit the article
   for publication.
CR Abbasi AA, 2017, AM J MED GENET B, V174, P839, DOI 10.1002/ajmg.b.32602
   Abdelfatah N, 2019, JACC-BASIC TRANSL SC, V4, P204, DOI 10.1016/j.jacbts.2018.12.001
   Andrews SJ, 2017, GENES BRAIN BEHAV, V16, P472, DOI 10.1111/gbb.12368
   Ansoleaga B, 2015, NEUROBIOL AGING, V36, P68, DOI 10.1016/j.neurobiolaging.2014.08.004
   Augert A, 2013, FREE RADICAL BIO MED, V65, P969, DOI 10.1016/j.freeradbiomed.2013.08.177
   Augert A, 2009, EMBO REP, V10, P271, DOI 10.1038/embor.2008.255
   Balreira A, 2014, J NEUROL, V261, P2192, DOI 10.1007/s00415-014-7476-7
   Bernard D, 2014, BBA-REV CANCER, V1846, P40, DOI 10.1016/j.bbcan.2014.03.003
   Besson M, 2016, PSYCHOPHARMACOLOGY, V233, P3297, DOI 10.1007/s00213-016-4362-2
   Biscetti Leonardo, 2017, Front Biosci (Elite Ed), V9, P174
   Boone PM, 2016, MOL GENET GENOM MED, V4, P77, DOI 10.1002/mgg3.181
   Brown AJ, 2009, MOL ASPECTS MED, V30, P111, DOI 10.1016/j.mam.2009.02.005
   Cabrita I, 2017, FASEB J, V31, P2123, DOI 10.1096/fj.201600797RR
   Camacho F, 2001, FEBS LETT, V489, P159, DOI 10.1016/S0014-5793(00)02434-0
   Chamova T, 2012, J NEUROL, V259, P906, DOI 10.1007/s00415-011-6276-6
   Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008
   Cheng Christiana L, 2013, Mol Vis, V19, P955
   Chou SJ, 2019, BRAIN RES, V1705, P1, DOI 10.1016/j.brainres.2018.02.046
   Chou SJ, 2013, MOL CELL NEUROSCI, V56, P1, DOI 10.1016/j.mcn.2013.02.006
   Chou SJ, 2009, NAT NEUROSCI, V12, P1381, DOI 10.1038/nn.2427
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   de Melo J, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.159970
   de Melo J, 2016, SCI REP-UK, V6, DOI 10.1038/srep32757
   Demirci S, 2015, TURK J MED SCI, V45, P1115, DOI 10.3906/sag-1406-135
   Desbene C, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.008
   Drummond E, 2017, ACTA NEUROPATHOL, V133, P155, DOI 10.1007/s00401-016-1662-x
   Elmer BM, 2012, TRENDS NEUROSCI, V35, P660, DOI 10.1016/j.tins.2012.08.001
   Ermilov VV, 2016, ADV EXP MED BIOL, V854, P119, DOI 10.1007/978-3-319-17121-0_17
   FARIN FM, 1993, J TOXICOL ENV HEALTH, V40, P317, DOI 10.1080/15287399309531797
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Frost S, 2016, CURR ALZHEIMER RES, V13, P1259, DOI 10.2174/1567205013666160603003800
   Fukumoto K, 2009, MOL PSYCHIATR, V14, P1119, DOI 10.1038/mp.2009.60
   Garate M, 2008, EMBO REP, V9, P576, DOI 10.1038/embor.2008.48
   Gordon PJ, 2013, J NEUROSCI, V33, P12197, DOI 10.1523/JNEUROSCI.1494-13.2013
   Griveau A, 2018, AGING CELL, V17, DOI 10.1111/acel.12835
   Gulyaeva NV, 2017, BIOCHEMISTRY-MOSCOW+, V82, P1088, DOI 10.1134/S0006297917100029
   Hanna MC, 2009, NEUROGENETICS, V10, P217, DOI 10.1007/s10048-009-0172-6
   Hashimoto T, 2011, NEUROSCI LETT, V502, P10, DOI 10.1016/j.neulet.2011.07.008
   Hermsen R, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1594-1
   Horgusluoglu E, 2017, AM J MED GENET B, V174, P93, DOI 10.1002/ajmg.b.32429
   Horwitz T, 2019, MOL PSYCHIATR, V24, P378, DOI 10.1038/s41380-018-0055-z
   Hoseth EZ, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0102-1
   Hsu LCL, 2015, P NATL ACAD SCI USA, V112, P12199, DOI 10.1073/pnas.1507145112
   Huang XF, 2017, INVEST OPHTH VIS SCI, V58, P424, DOI 10.1167/iovs.16-20705
   Huang YL, 2012, J MOL NEUROSCI, V47, P470, DOI 10.1007/s12031-012-9729-1
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaeser PS, 2012, P NATL ACAD SCI USA, V109, P11830, DOI 10.1073/pnas.1209318109
   Kamiya A, 2008, ARCH GEN PSYCHIAT, V65, P996, DOI 10.1001/archpsyc.65.9.996
   Kinare V, 2018, J BIOSCIENCES, V43, P75, DOI 10.1007/s12038-018-9731-z
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Kolosova N. G., 2014, ADV GERONTOL, V4, P294, DOI DOI 10.1134/S2079057014040146
   Korbolina EE, 2016, BMC GENET, V17, DOI 10.1186/s12863-016-0461-7
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   Kozhevnikova OS, 2013, BIOGERONTOLOGY, V14, P753, DOI 10.1007/s10522-013-9439-2
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Kumar S, 2017, JAMA PSYCHIAT, V74, P1266, DOI 10.1001/jamapsychiatry.2017.3292
   Lazarczyk MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26199
   Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409
   Liu M, 2006, EUR J NEUROSCI, V23, P2027, DOI 10.1111/j.1460-9568.2006.04724.x
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Marbach F, 2019, AM J HUM GENET, V104, P749, DOI 10.1016/j.ajhg.2019.02.021
   Markovets AM, 2011, AGING-US, V3, P44
   Mayanagi T, 2008, J BIOL CHEM, V283, P31183, DOI 10.1074/jbc.M801606200
   Mochida GH, 2009, AM J HUM GENET, V85, P897, DOI 10.1016/j.ajhg.2009.10.027
   Mortreux J, 2018, EUR J HUM GENET, V26, P143, DOI 10.1038/s41431-017-0018-x
   Muraleva NA, 2017, EXP GERONTOL, V95, P26, DOI 10.1016/j.exger.2017.05.009
   Muraleva NA, 2014, CELL CYCLE, V13, P3499, DOI 10.4161/15384101.2014.958393
   Muraleva NA, 2012, INDIAN J MED RES, V135, P221
   Nanetti L, 2019, J NEUROL, V266, P378, DOI 10.1007/s00415-018-9141-z
   Obukhova L A, 2013, Adv Gerontol, V26, P229
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Paciotti S, 2014, J BIOL CHEM, V289, P9611, DOI 10.1074/jbc.M114.550509
   Patterson C, 2018, WORLD ALZHEIMER REPO
   Ravasi T, 2010, CELL, V140, P744, DOI 10.1016/j.cell.2010.01.044
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Roy A, 2013, J NEUROSCI, V33, P6877, DOI 10.1523/JNEUROSCI.4216-12.2013
   Rudnitskaya EA, 2019, EXP GERONTOL, V115, P32, DOI 10.1016/j.exger.2018.11.008
   Sakamoto S, 2014, PSYCHIAT RES, V216, P288, DOI 10.1016/j.psychres.2014.02.006
   Sanfor SD, 2012, J NEUROCHEM, V120, P974, DOI 10.1111/j.1471-4159.2012.07651.x
   Saprunova VB, 2012, BIOCHEMISTRY-MOSCOW+, V77, P648, DOI 10.1134/S0006297912060120
   Schaeffer EL, 2009, PSYCHOPHARMACOLOGY, V202, P37, DOI 10.1007/s00213-008-1351-0
   Seshadri S, 2010, JAMA-J AM MED ASSOC, V303, P1832, DOI 10.1001/jama.2010.574
   Starkey HDV, 2012, J MOL NEUROSCI, V48, P111, DOI 10.1007/s12031-012-9783-8
   Stefanova NA, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3984906
   Stefanova NA, 2019, J GERONTOL A-BIOL, V74, P33, DOI 10.1093/gerona/gly198
   Stefanova NA, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4480-9
   Stefanova NA, 2016, AGING-US, V8, P2713, DOI 10.18632/aging.101054
   Stefanova NA, 2015, ONCOTARGET, V6, P1396, DOI 10.18632/oncotarget.2751
   Stefanova NA, 2014, J ALZHEIMERS DIS, V38, P681, DOI 10.3233/JAD-131034
   Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810
   Subramanian L, 2011, P NATL ACAD SCI USA, V108, pE265, DOI 10.1073/pnas.1101109108
   Swiatek W, 2006, J BIOL CHEM, V281, P12233, DOI 10.1074/jbc.M510580200
   Tapia L, 2007, MOL PHARMACOL, V71, P769, DOI 10.1124/mol.106.030445
   Tapia O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116196
   Tarpey PS, 2007, NAT GENET, V39, P1127, DOI 10.1038/ng2100
   Telegina DV, 2015, CELL CYCLE, V14, P3544, DOI 10.1080/15384101.2015.1080399
   Tie JK, 2011, BLOOD, V117, P2967, DOI 10.1182/blood-2010-08-304303
   Tikhonova MA, 2014, PHARMACOL BIOCHEM BE, V120, P7, DOI 10.1016/j.pbb.2014.01.012
   Tyumentsev MA, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1083, DOI 10.1134/S0006297918090109
   Tyumentsev MA, 2018, J ALZHEIMERS DIS, V63, P1075, DOI 10.3233/JAD-180065
   Vaclavikova R, 2015, GENE, V571, P1, DOI 10.1016/j.gene.2015.07.071
   Vasiliou V, 2013, CHEM-BIOL INTERACT, V202, P22, DOI 10.1016/j.cbi.2012.12.018
   Vermeer S, 2010, AM J HUM GENET, V87, P813, DOI 10.1016/j.ajhg.2010.10.015
   Wang L, 2013, J BIOL CHEM, V288, P11887, DOI 10.1074/jbc.M112.425702
   Wang YJ, 2017, NAT CELL BIOL, V19, P808, DOI 10.1038/ncb3551
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Zoubovsky S, 2015, NEUROSCI RES, V98, P45, DOI 10.1016/j.neures.2015.02.002
NR 109
TC 7
Z9 7
U1 1
U2 5
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2020
VL 73
IS 3
BP 1167
EP 1183
DI 10.3233/JAD-190956
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA KJ8PZ
UT WOS:000512319400028
PM 31929160
DA 2022-11-30
ER

PT J
AU Losonczy, G
   Fekete, A
   Voko, Z
   Takacs, L
   Kaldi, I
   Ajzner, E
   Kasza, M
   Vajas, A
   Berta, A
   Balogh, I
AF Losonczy, Gergely
   Fekete, Agnes
   Voko, Zoltan
   Takacs, Lili
   Kaldi, Ildiko
   Ajzner, Eva
   Kasza, Marta
   Vajas, Attila
   Berta, Andras
   Balogh, Istvan
TI Analysis of complement factor H Y402H, LOC387715, HTRA1 polymorphisms
   and ApoE alleles with susceptibility to age-related macular degeneration
   in Hungarian patients
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration (AMD); apolipoprotein E (ApoE);
   case-control study; complement factor H (CFH); genetic risk factor;
   HTRA1; LOC387715
ID PROMOTER POLYMORPHISM; GEOGRAPHIC ATROPHY; SEVERITY SCALE; GENE VARIANT;
   ASSOCIATION; JAPANESE; PROTEIN; RISK; DISEASE; MACULOPATHY
AB Purpose:
   Recent studies strongly support the role of genetic factors in the aetiology of age-related macular degeneration (AMD). We investigated the frequency of Tyr402His polymorphism of the complement factor H (CFH) gene, Ser69Ala polymorphism at LOC387715, rs11200638 polymorphism of the HTRA1 gene and different apolipoprotein E (ApoE) alleles in Hungarian patients with AMD in order to determine the disease risk conferred by these factors.
   Methods:
   In a case-control study, we performed clinical and molecular genetic examination of 105 AMD patients (48 patients in the early and 57 in the late subgroup) and 95 unrelated healthy controls. Detailed patient histories were recorded with the use of a questionnaire focusing on known risk factors for AMD.
   Results:
   In the early AMD subgroup, homozygous CFH, LOC387715 or HTRA1 polymorphisms conferred a 4.9-fold (95% confidence interval [CI] 1.7-14.2), 7.4-fold (95% CI 2.1-26.2) or 10.1-fold (95% CI 2.5-40.8) risk of disease, respectively. In the late AMD subgroup, carriers of two CFH, LOC387715 or HTRA1 risk alleles were at 10.7-fold (95% CI 3.7-31.0), 11.3-fold (95% CI 3.2-40.4) or 13.5-fold (95% CI 3.3-55.4) greater disease risk, respectively. Two CFH and one LOC387715 risk alleles in combination conferred a 15.0-fold (95% CI 3.2-71.0) increase in risk, whereas two LOC387715 risk alleles combined with one CFH risk allele was associated with a 14.0-fold (95% CI 2.1-95.1) increased risk for late AMD. ApoE alleles neither increased disease risk nor proved to be protective.
   Conclusions:
   The CFH, LOC387715 and HTRA1 polymorphisms are strongly associated with the development of AMD in the Hungarian population. The association is particularly pronounced when homozygous risk alleles are present and in the late stages of the disease.
C1 [Fekete, Agnes; Balogh, Istvan] Univ Debrecen, Med & Hlth Sci Ctr, Dept Clin Biochem & Mol Pathol, H-4032 Debrecen, Hungary.
   [Losonczy, Gergely; Takacs, Lili; Kasza, Marta; Vajas, Attila; Berta, Andras] Univ Debrecen, Med & Hlth Sci Ctr, Dept Ophthalmol, H-4032 Debrecen, Hungary.
   [Voko, Zoltan] Univ Debrecen, Med & Hlth Sci Ctr, Dept Prevent Med, Div Biostat & Epidemiol, H-4032 Debrecen, Hungary.
   [Kaldi, Ildiko] Kenezy Gyula Cty Hosp, Dept Ophthalmol, Debrecen, Hungary.
   [Ajzner, Eva] Josa Andras Cty Hosp, Cent Lab, Nyiregyhaza, Hungary.
C3 University of Debrecen; University of Debrecen; University of Debrecen
RP Balogh, I (通讯作者)，Univ Debrecen, Med & Hlth Sci Ctr, Dept Clin Biochem & Mol Pathol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary.
EM balogh@med.unideb.hu
RI Vokó, Zoltán/H-1153-2017; Takács, Lili/L-6660-2014; Vokó,
   Zoltán/O-3747-2019; Vajas, Attila/AAA-3014-2021; Balogh,
   Istvan/N-2990-2019; Balogh, Istvan/A-4752-2013
OI Vokó, Zoltán/0000-0002-1004-1848; Takács, Lili/0000-0003-1641-0154;
   Vokó, Zoltán/0000-0002-1004-1848; Balogh, Istvan/0000-0003-3397-2829;
   Balogh, Istvan/0000-0003-3397-2829
FU University of Debrecen, Medical and Health Science Centre; Hungarian
   National Research Fund [K68616, F60643]; Hungarian Academy of Sciences
FX The first two authors (GL and AF) contributed equally to work. This work
   was supported by a Mecenatura Grant for the University of Debrecen,
   Medical and Health Science Centre, by the Hungarian National Research
   Fund (K68616 and F60643). IB was supported by a Bolyai Janos Fellowship
   from the Hungarian Academy of Sciences. This work was presented at the
   Association for Research in Vision and Ophthalmology Annual Meeting, 27
   April to 1 May, 2008, Fort Launderdale, FL, USA. The contribution of
   Erika Dzsudzsak is gratefully appreciated.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Asensio-Sánchez V.M., 2006, Arch Soc Esp Oftalmol, V81, P09
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaunt TR, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-428
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hoffmann MM, 2001, CLIN CHIM ACTA, V303, P41, DOI 10.1016/S0009-8981(00)00372-7
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Souied EH, 2005, MOL VIS, V11, P1135
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Utheim OA, 2008, ACTA OPHTHALMOL, V86, P401, DOI 10.1111/j.1600-0420.2007.01070.x
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 42
TC 14
Z9 15
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2011
VL 89
IS 3
BP 255
EP 262
DI 10.1111/j.1755-3768.2009.01687.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 751TR
UT WOS:000289641000016
PM 19845562
DA 2022-11-30
ER

PT J
AU Martin, DF
   Klein, M
   Haller, J
   Adamis, A
   Gragoudas, E
   Miller, J
   Blumenkrantz, M
   Goldberg, M
   Yannuzzi, L
   Henninger, D
   Wiegand, LB
   Chen, LS
   Drolet, DW
   Gill, SC
   Bill, J
   Tomkinson, B
   Bendele, RA
   O'Shaughnessy, D
   Guyer, DR
   Patel, S
AF Martin, DF
   Klein, M
   Haller, J
   Adamis, A
   Gragoudas, E
   Miller, J
   Blumenkrantz, M
   Goldberg, M
   Yannuzzi, L
   Henninger, D
   Wiegand, LB
   Chen, LS
   Drolet, DW
   Gill, SC
   Bill, J
   Tomkinson, B
   Bendele, RA
   O'Shaughnessy, D
   Guyer, DR
   Patel, S
CA Eyetech Study Grp
TI Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated
   aptamer (EYE001) for the treatment of exudative age-related macular
   degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE angiogenesis; age-related macular degeneration; pharmacologic
   intervention; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; INHIBITION; NEOVASCULARIZATION;
   PHARMACOKINETICS; RETINOPATHY; LETHALITY; NX1838; CELLS
AB Background: Recent studies have suggested that vascular endothelial growth factor (VEGF) is an important stimulus for the growth of new blood vessels in the eye. Anti-VEGF therapy is thus a potential treatment for exudative macular degeneration and diabetic retinopathy.
   Methods: Previously described animal models of vascular leakage and ocular neovascularization, including the Miles assay, the rat corneal angiogenesis model, and the mouse retinopathy of prematurity (ROP) model, were used to study this drug. After these studies, a phase IA single ascending dose study of intravitreal injections of the drug was performed in 15 patients with subfoveal choroidal neovascularization secondary to exudative age-related macular degeneration (AMD).
   Results: The Miles assay model showed almost complete attenuation of VEGF-mediated vascular leakage following addition of EYE001, and the corneal angiogenesis model also showed a significant reduction in neovascularization with EYE001. The ROP model showed inhibition of 80% of the retinal neovascularization compared with controls (P = 0.0001). The phase A safety study of patients with exudative AMD showed no significant safety issues related to the drug. Ophthalmic evaluation revealed that 80% of patients showed stable or improved vision 3 months after treatment and that 27% of eyes demonstrated a three-line or greater improvement in vision on the Early Treatment for Diabetic Retinopathy Study chart at this time.
   Conclusion: Anti-VEGF therapy is a promising new avenue for the treatment of neovascular diseases of the eye, including exudative macular degeneration and diabetic retinopathy. Preclinical data from studies with EYE001 support clinical evaluation of its efficacy in such diseases. This report is the first to describe administration of anti-VEGF therapy in humans for exudative macular degeneration and shows the safety of such therapy for single injections. Further clinical studies are necessary to determine the safety of multiple intravitreal injections of EYE001 and larger studies are needed to prove the efficacy of this novel, potentially therapeutic agent for neovascular AMD.
C1 Emory Univ, Sch Med, Atlanta, GA 30322 USA.
   Casey Eye Inst, Portland, OR USA.
   Wilmer Eye Inst, Baltimore, MD USA.
C3 Emory University; Johns Hopkins University; Johns Hopkins Medicine
RP Guyer, DR (通讯作者)，NYU, Sch Med, Dept Ophthalmol, 550 1st Ave, New York, NY 10016 USA.
EM drguyer@aol.com
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Afshari MA, 2001, INVEST OPHTH VIS SCI, V42, pS933
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Huang JZ, 2001, J PEDIATR SURG, V36, P357, DOI 10.1053/jpsu.2001.20716
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V109, P1219
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
NR 25
TC 283
Z9 313
U1 1
U2 26
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2002
VL 22
IS 2
BP 143
EP 152
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 543MU
UT WOS:000175106400002
PM 11927845
DA 2022-11-30
ER

PT J
AU el Matri, L
   Chebil, A
   Kort, F
   Bouraoui, R
   Baklouti, K
   Mghaieth, F
AF el Matri, Leila
   Chebil, Ahmed
   Kort, Fadra
   Bouraoui, Rym
   Baklouti, Karim
   Mghaieth, Fatma
TI Intravitreal injection of triamcinolone combined with bevacizumab for
   choroidal neovascularization associated with large retinal pigment
   epithelial detachment in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Bevacizumab; Triamcinolone acetonide; Pigment epithelium detachment
ID PHOTODYNAMIC THERAPY; VERTEPORFIN; ACETONIDE; PHOTOCOAGULATION;
   DEXAMETHASONE; AVASTIN
AB To discuss the effect and outcome of a combined intravitreal triamcinolone acetonide (IVTA) injection with intravitreal bevacizumab (IVB) in treating choroidal neovascularization (CNV) associated with large retinal pigment epithelial detachment (PED) in age-related macular degeneration (AMD).
   Prospective, consecutive, observational case series.
   Seven eyes (five patients) with CNV associated with large PED in AMD were treated by IVTA (4 mg/ 0.1 ml), followed by a IVB (1.25 mg/0.05 ml) 1 week later. Patients were evaluated for best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) at baseline, at 1 week and every 6 weeks. Fluorescein angiography (FA) and indocyanine green angiography (ICG) were performed at baseline and every 3 months afterwards. Indications for retreatment by combined injection were defined as persistent PED with subretinal and/or intraretinal fluid on OCT. Patients with flattening of the PED and activity leakage demonstrated by OCT underwent subsequent IVB.
   The mean duration of follow-up was 11 months (range 9-14 months). BCVA at baseline averaged 20/125, and 20/80 at the end of follow-up. FA showed no leakage from the lesion in four eyes at the end of follow-up, and three eyes showed a decrease in leakage. Average central foveal thickness was (CFT) 325.7 microns at baseline and 209.2 microns at the end. The average size of the PED was 2.34 disk diameters (range 1.33-3.25) at baseline, and the PED disappeared in four eyes, while it decreased in size at the end in the remaining three. The subretinal fluid disappeared in all patients at the end. The combined treatment (IVTA with IVB 1 week later) was repeated in four eyes, and the number of IVB after combined injection ranged from one to three. No RPE tear appeared during follow-up. Two eyes developed glaucoma controlled by topical medication. There were no other ocular or systemic complications
   Combined IVB and IVTA therapy seems to be an effective and safe procedure to treat CNV associated with large PED in AMD.
C1 [el Matri, Leila; Chebil, Ahmed; Kort, Fadra; Bouraoui, Rym; Baklouti, Karim; Mghaieth, Fatma] Hedi Rais Inst Ophthalmol, Dept Ophthalmol B, Tunis, Tunisia.
C3 Universite de Tunis-El-Manar; Institut Hedi Raies d'ophtalmologie de
   Tunis
RP el Matri, L (通讯作者)，Hedi Rais Inst Ophthalmol, Dept Ophthalmol B, Blvd 9 Avril 1006 Bab Saadoun, Tunis, Tunisia.
EM Leila.elmatri@rns.tn
CR Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hori Y, 1996, BRIT J PHARMACOL, V118, P1584, DOI 10.1111/j.1476-5381.1996.tb15578.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladas ID, 2007, OPHTHALMOLOGICA, V221, P313, DOI 10.1159/000104761
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Perretti M, 2000, MICROCIRCULATION, V7, P147, DOI 10.1038/sj.mn.7300108
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
NR 19
TC 13
Z9 13
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2010
VL 248
IS 6
BP 779
EP 784
DI 10.1007/s00417-010-1302-4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 587PT
UT WOS:000277005600002
PM 20169357
DA 2022-11-30
ER

PT J
AU Mathis, T
   Kodjikian, L
   Mauget-Faysse, M
   Feldman, A
AF Mathis, Thibaud
   Kodjikian, Laurent
   Mauget-Faysse, Martine
   Feldman, Audrey
TI Polypoidal Choroidal Vasculopathy Occurring in the Context of Large
   Colloid Drusen
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB The authors report, for the first time, an association between large colloid drusen (LCD) and choroidal neovascularization in a 58-year-old man. Multimodal imaging confirmed the diagnosis of LCD in both eyes and polypoidal choroidal vasculopathy in the left eye. The patient was treated with monthly intravitreal injections of aflibercept (Eylea; Regeneron, Tarrytown, NY). The authors hypothesize that these deposits are probably associated with retinal pigment epithelium dysfunction and could thus lead to delayed neovascularization and atrophy.
C1 [Mathis, Thibaud; Kodjikian, Laurent] Croix Rousse Univ Hosp, Hosp Civils Lyon, Dept Ophthalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
   [Mauget-Faysse, Martine] Rothschild Ophthalmol Fdn, Paris, France.
   [Feldman, Audrey] Clin HPEL, St Priest, France.
C3 CHU Lyon
RP Mathis, T (通讯作者)，Croix Rousse Univ Hosp, Hosp Civils Lyon, Dept Ophthalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
EM mathisthibaud@hotmail.fr
RI Mathis, Thibaud/R-3696-2016; Mathis, Thibaud/AAK-5745-2021
OI Mathis, Thibaud/0000-0002-1418-1872; 
CR De Bats Flore, 2013, ISRN Ophthalmol, V2013, P273085, DOI 10.1155/2013/273085
   Del Turco C, 2015, EUR J OPHTHALMOL, V25, P177, DOI 10.5301/ejo.5000526
   Guigui B, 2013, RETINA-J RET VIT DIS, V33, P1346, DOI 10.1097/IAE.0b013e318283127d
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Querques G, 2012, ACTA OPHTHALMOL, V90, pE327, DOI 10.1111/j.1755-3768.2011.02228.x
NR 6
TC 2
Z9 2
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD DEC
PY 2016
VL 47
IS 12
BP 1154
EP 1156
DI 10.3928/23258160-20161130-12
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3ID
UT WOS:000393104900012
PM 27977841
DA 2022-11-30
ER

PT J
AU Banevicius, M
   Gedvilaite, G
   Vilkeviciute, A
   Kriauciuniene, L
   Zemaitiene, R
   Liutkeviciene, R
AF Banevicius, Mantas
   Gedvilaite, Greta
   Vilkeviciute, Alvita
   Kriauciuniene, Loresa
   Zemaitiene, Reda
   Liutkeviciene, Rasa
TI Association of relative leukocyte telomere length and genetic variants
   in telomere-related genes (TERT, TERT-CLPTM1, TRF1, TNKS2, TRF2) with
   atrophic age-related macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Relative leukocyte telomere length; age-related macular degeneration;
   SNP
AB Background: In an experimental model, telomere shortening inhibits neovascularization. It is thus possible that telomere shortening might have a role in the pathogenesis of geographic atrophy in case of age-related macular degeneration (AMD). This is why we aimed to find any associated differences of telomere length and genetic variants in telomere-related genes (TERT, TERT-CLPTM1, TRF1, TNKS2, and TRF2) in patients with atrophic AMD compared to healthy controls.
   Methods: The study enrolled patients with atrophic AMD (n = 56) and healthy (n = 73) controls. Samples of DNA from peripheral blood leukocytes were extracted by DNA salting-out method. The genotyping of TERT rs2736098, rs401681 in TERT-CLPTM1 locus, TRF1 rs1545827, rs10107605, TNKS2 rs10509637, rs10509639, and TRF2 rs251796 and relative leukocyte telomere length (T/S) measurement were carried out using a real-time polymerase chain reaction method. The results were assessed using the statistical analysis method of "IBM SPSS Statistics 20.0".
   Results: We found statistically significantly higher T/S in atrophic AMD patients than in healthy controls (T/S, median (IQR): 1.638 (1.110) vs. 0.764 (0.801), p < .001). Also, statistically significant differences were found in TRF1 rs10107605 allele (A and C) distributions between the atrophic AMD and control groups (88.36% and 11.64% vs. 95.54% and 4.46%, respectively, p = .041), as well as between the short telomere and long telomere groups (86.92% and 13.08% vs. 96.09% and 3.91%, respectively, p = .008).
   Conclusions: Our research revealed the leukocyte telomere length having a role in atrophic AMD development, also the association between TRF1 rs10107605 and the telomere length.
C1 [Banevicius, Mantas; Vilkeviciute, Alvita; Kriauciuniene, Loresa; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Kaunas, Lithuania.
   [Gedvilaite, Greta; Kriauciuniene, Loresa; Zemaitiene, Reda; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Vilkeviciute, A (通讯作者)，LUHS Neurosci Inst, Eiveniu 2, Kaunas, Lithuania.
EM alvita.vilkeviciute@lsmuni.lt
OI Gedvilaite, Greta/0000-0001-7469-8825
CR Adnot S, 2015, PHARMACOL THERAPEUT, V153, P125, DOI 10.1016/j.pharmthera.2015.06.007
   BLASCO M, 2005, NAT REV GENET, V6
   Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   DOW C, 2016, CLIN OPHTHALMOL, V10
   Gardner M, 2014, EXP GERONTOL, V51, P15, DOI 10.1016/j.exger.2013.12.004
   Goglin SE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160748
   GRIFFITH J, 1999, CELL, V97
   HARLEY C, 1990, NATURE, V345
   Herrmann M, 2018, CLIN CHEM LAB MED, V56, P1210, DOI 10.1515/cclm-2017-0870
   Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062
   HUANG F, 2013, SCIENCE, V339
   Immonen I, 2013, ACTA OPHTHALMOL, V91, DOI 10.1111/j.1755-3768.2013.T077.x
   KLEIN R, 2007, OPHTHALMOLOGY, V114
   LEVY M, 1992, J MOL BIOL, V225
   LIU D, 2004, J BIOL CHEM, V279
   LIUTKEVICIENE R, 2010, MEDICINA-LITHUANIA, V46
   Liutkeviciene R, 2013, MED LITH, V49, P273
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   NANGIA V, 2011, RETINA-J RET VIT DIS, V31
   NILSSON P, 2013, TRANSL RES, V162
   PARK J, 2002, EXP MOL MED, V34
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   SALLO F, 2009, CURR EYE RES, V34
   Shekhidem HA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133233
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Wai Lin Kah, 2004, MedGenMed, V6, P19
   WENG X, 2015, EXP GERONTOL, V69
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yin J., 2012, PLOS ONE, V7
   YONG J, 2015, OPHTHALMOLOGY, V122
   YUAN X, 2017, ONCOTARGET, V8
   ZARBIN M, 2004, ARCH OPHTHALMOL-CHIC, V122
   Zhang R, 2015, ONCOTARGET, V6, P31360, DOI 10.18632/oncotarget.5153
   ZHOU M, 2018, FRONT PHYSIOL, V9
NR 38
TC 2
Z9 3
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD MAR 4
PY 2021
VL 42
IS 2
BP 189
EP 194
DI 10.1080/13816810.2021.1881976
EA FEB 2021
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA RA8NG
UT WOS:000616848000001
PM 33565341
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Chen, L
   Miller, JW
   Vavvas, D
   Kim, IK
AF Chen, Ling
   Miller, Joan W.
   Vavvas, Demetrios
   Kim, Ivana K.
TI ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY VERSUS COMBINATION
   TREATMENT WITH PHOTODYNAMIC THERAPY FOR SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION SECONDARY TO CAUSES OTHER THAN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; anti-VEGF; photodynamic therapy; non-AMD
ID INTRAVITREAL BEVACIZUMAB; PATHOLOGICAL MYOPIA; ANGIOID STREAKS;
   VERTEPORFIN
AB Purpose: To compare the visual outcomes and retreatment rates of monotherapy with intravitreal bevacizumab versus combination with photodynamic therapy for choroidal neovascularization secondary to causes other than age-related macular degeneration.
   Methods: Seventeen patients received intravitreal bevacizumab, and 6 patients underwent intravitreal bevacizumab combined with verteporfin photodynamic therapy within 3 days. Additional bevacizumab was administrated if there was persistent fluorescein leakage or subretinal fluid on optical coherence tomography.
   Results: The mean change in visual acuity was vision gain of 1.7 lines in the monotherapy group compared with 2.8 lines in the combination therapy group at 12-month follow-up (P = 0.45). At 12 months, 93% in the monotherapy group and 100% in the combination group lost <2 lines of vision (P = 1.0); 36% gained >3 lines of vision in the monotherapy compared with 60% in the combination therapy group (P = 0.60). The monotherapy group received a mean of 4.8 reinjections, while the combination group received 2.6 reinjections over 12 months (P = 0.11). Subgroup analysis of cases of choroidal neovascularization caused by pathologic myopia demonstrated a mean change in visual acuity of vision gain of +2.0 lines in the monotherapy group versus +2.3 lines in the combination therapy group (P = 0.82) and a mean of 7.2 reinjections versus 2 in monotherapy and combination group, respectively (P = 0.0498) at 12 months.
   Conclusion: The majority of patients had stabilization or improvement in vision in both treatment groups. Combination therapy with bevacizumab plus photodynamic therapy showed lower retreatment rates in patients with myopia. Randomized clinical trials are necessary to confirm these findings. RETINA 31:2078-2083, 2011
C1 [Chen, Ling; Miller, Joan W.; Vavvas, Demetrios; Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA.
   [Chen, Ling] Fudan Univ, Shanghai Med Sch, Dept Ophthalmol & Vis Sci, Eye & ENT Hosp, Shanghai 200433, Peoples R China.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Fudan University
RP Kim, IK (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM ivana_kim@meei.harvard.edu
RI Chen, Ling/AAM-1821-2021
OI Kim, Ivana/0000-0003-0310-6129; Vavvas, Demetrios/0000-0002-8622-6478;
   Miller, Joan/0000-0003-2046-3996
FU Research to Prevent Blindness; Pujiang Talent Fund [10PJ1401900]
FX Supported in part by Research to Prevent Blindness Physician-Scientist
   Award (I.K. Kim) and Pujiang Talent Fund (10PJ1401900, L. Chen).
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Arias L, 2006, GRAEF ARCH CLIN EXP, V244, P753, DOI 10.1007/s00417-005-0131-3
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Bottoni Ferdinando, 2001, International Ophthalmology, V24, P249, DOI 10.1023/A:1025488429802
   Brown J, 1996, OPHTHALMOLOGY, V103, P1100, DOI 10.1016/S0161-6420(96)30561-7
   Browning AC, 2005, OPHTHALMOLOGY, V112, P1227, DOI 10.1016/j.ophtha.2005.02.011
   Chan WM, 2009, BRIT J OPHTHALMOL, V93, P150, DOI 10.1136/bjo.2008.145797
   Chang LK, 2008, ARCH OPHTHALMOL-CHIC, V126, P941, DOI 10.1001/archopht.126.7.941
   GELISKEN O, 1988, AM J OPHTHALMOL, V105, P299, DOI 10.1016/0002-9394(88)90014-1
   Gharbiya M, 2009, AM J OPHTHALMOL, V147, P84, DOI 10.1016/j.ajo.2008.07.022
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hayashi K, 2009, AM J OPHTHALMOL, V148, P396, DOI 10.1016/j.ajo.2009.03.026
   Hayashi K, 2009, GRAEF ARCH CLIN EXP, V247, P609, DOI 10.1007/s00417-008-1021-2
   Heier JS, 2011, OPHTHALMOLOGY, V118, P111, DOI 10.1016/j.ophtha.2010.04.016
   Heimann H, 2005, GRAEF ARCH CLIN EXP, V243, P1115, DOI 10.1007/s00417-005-1193-y
   Ikuno Y, 2009, AM J OPHTHALMOL, V147, P94, DOI 10.1016/j.ajo.2008.07.017
   Jurklies B, 2006, OPHTHALMIC RES, V38, P209, DOI 10.1159/000093071
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Parodi MB, 2004, AM J OPHTHALMOL, V138, P263, DOI 10.1016/j.ajo.2004.03.029
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P899, DOI 10.1007/s00417-003-0734-5
   Yoon JU, 2010, RETINA-J RET VIT DIS, V30, P418, DOI 10.1097/IAE.0b013e3181bd2fe4
NR 25
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2011
VL 31
IS 10
BP 2078
EP 2083
DI 10.1097/IAE.0b013e3182109074
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 842AS
UT WOS:000296558500017
PM 21691258
DA 2022-11-30
ER

PT J
AU Sato, T
   Kishi, S
   Matsumoto, H
   Mukai, R
AF Sato, Taku
   Kishi, Shoji
   Matsumoto, Hidetaka
   Mukai, Ryo
TI Combined Photodynamic Therapy With Verteporfin and Intravitreal
   Bevacizumab for Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; SHORT-TERM SAFETY;
   MACULAR DEGENERATION; INJECTION; NEOVASCULARIZATION; EFFICACY;
   RANIBIZUMAB; COMBINATION; EXPRESSION
AB PURPOSE: To evaluate the efficacy of photodynamic therapy with verteporfin with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
   DESIGN: Retrospective case study.
   METHODS: This study included 29 treatment-naive patients with polypoidal choroidal vasculopathy followed up for 12 months after the first combined therapy. Patients received 1.25 mg intravitreal bevacizumab 1 week before photodynamic therapy with verteporfin. The main outcomes measures were visual acuity and the number of required retreatments.
   RESULTS: The mean best-corrected visual acuity (BCVA) level was 0.25 at baseline and 0.31, 0.39, 0.44, 0.44, and 0.45 at 1, 3, 6, 9, and 12 months after treatment, respectively. A significant (P<.01) improvement in the mean BCVA was observed at 3, 6, 9, and 12 months after combined therapy. At 12 months, the mean improvement in BCVA from baseline was 2.69 lines; the BCVA improved in 15 eyes (51.7%) by 3 lines or more, was stable in 13 eyes (44.8%), and decreased in 1 eye (3%) because of a massive subretinal hemorrhage 7 months after the first treatment. Eighteen eyes (62%) required 1 combined treatment during follow-up. Polypoidal lesions recurred in 6 eyes (21%). An abnormal branching vascular network persisted in all eyes. The mean number of treatments with combined therapy averaged 1.59. No complications, including endophthalmitis, uveitis, or ocular hypertension, developed.
   CONCLUSIONS: Combined treatment consisting of photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy seemed to be effective for improving visual acuity and reducing retreatment rates and complications. Further study is needed to determine the long-term clinical results. (Am J Ophthalmol 2010;149:947-954. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Sato, Taku; Kishi, Shoji; Matsumoto, Hidetaka; Mukai, Ryo] Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Sato, T (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3 Showamachi, Maebashi, Gunma 3718511, Japan.
EM takusato@showa.gunma-u.ac.jp
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 37
TC 60
Z9 67
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2010
VL 149
IS 6
BP 947
EP 954
DI 10.1016/j.ajo.2009.12.038
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 610SI
UT WOS:000278755400013
PM 20346441
DA 2022-11-30
ER

PT J
AU Hanhart, J
   Comaneshter, DS
   Freier-Dror, Y
   Vinker, S
AF Hanhart, Joel
   Comaneshter, Doron S.
   Freier-Dror, Yossi
   Vinker, Shlomo
TI Mortality associated with bevacizumab intravitreal injections in
   age-related macular degeneration patients after acute myocardial
   infarct: a retrospective population-based survival analysis
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular AMD; Anti-VEGF; Bevacizumab; Ischemic heart disease;
   Myocardial infarct; Safety; Mortality
ID ENDOTHELIAL GROWTH-FACTOR; ARTERIAL THROMBOEMBOLIC EVENTS; CHOROIDAL
   NEOVASCULARIZATION; SYSTEMIC SAFETY; PLASMA-LEVELS; RANIBIZUMAB; RISK;
   THERAPY; AVASTIN; STROKE
AB Intraocular injections of antivascular endothelial growth factor (VEGF) agents are currently the main therapy in age-related macular degeneration (AMD). The safety of bevacizumab, an anti-VEGF compound frequently delivered off label, is debated, particularly for high-group risks. We aim to analyze the mortality associated with intravitreal injections of bevacizumab for AMD in patients previously diagnosed with acute myocardial infarct (MI).
   In a national database, we identified bevacizumab-treated AMD patients with a diagnosis of MI prior to their first bevacizumab injection, delivered between September 2008 and October 2014 (n = 2100). We then generated sub-groups of patients treated within 3 months (n = 11), 6 months (n = 24), 12 months (n = 52), and 24 months (n = 124) after MI. Those patients were compared to age- and gender-matched members that had a MI at the same time and had never been exposed to anti-VEGF. Survival analysis was performed using propensity score-adjusted Cox regression.
   Bevacizumab-treated patients were slightly and insignificantly older than controls (mean age 83.25 vs 83.19 year, P = .75). Gender distribution was similar. In a Cox regression adjusted with propensity score, the following differences in mortality were found: within 3 months between MI and initiation of bevacizumab treatment, OR = 6.22 (95% C.I 1.08-35.97, P < .05); within 6 months, OR = 2.37 (95% C.I 0.93-6.02, P = .071); within 12 months, OR = 3.00 (95% C.I 1.44-6.28, P < .01); within 24 months after MI, OR = 2.24 (95% C.I 1.35-3.70, P < .01); and MI any time prior to first bevacizumab injection, OR = 1.71 (95% C.I 1.53-1.92, P < .001).
   We report increased mortality associated with the use of intravitreal bevacizumab in AMD patients after MI, compared to age- and gender-matched post-MI patients with no exposure to any anti-VEGF agent. Caution should be taken while offering bevacizumab to AMD patients after MI.
C1 [Hanhart, Joel] Shaare Zedek Med Ctr, Dept Ophthalmol, 12 Beyt St, IL-91031 Jerusalem, Israel.
   [Comaneshter, Doron S.; Vinker, Shlomo] Clalit Hlth Serv, Cent Headquarters, Tel Aviv, Israel.
   [Freier-Dror, Yossi] Mashav Appl Res, Jerusalem, Israel.
   [Vinker, Shlomo] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit
   Health Services; Tel Aviv University; Sackler Faculty of Medicine
RP Hanhart, J (通讯作者)，Shaare Zedek Med Ctr, Dept Ophthalmol, 12 Beyt St, IL-91031 Jerusalem, Israel.
EM hanhart@szmc.org.il
OI Hanhart, Joel/0000-0003-0952-3740
CR APA, 1994, DIAGNOSTIC STAT MANU
   Arevalo JF, 2015, RETINA
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bakbak B, 2013, J OCUL PHARMACOL TH, V29, P728, DOI 10.1089/jop.2013.0049
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Biswas P, 2011, OPHTHALMOLOGY, V118, P600, DOI 10.1016/j.ophtha.2010.10.027
   Boberg-Ans G, 2006, ACTA OPHTHALMOL SCAN, V84, P613, DOI 10.1111/j.1600-0420.2006.00719.x
   Brito IAS, 2015, CASE REP OPHTHALMOL, V2015, DOI 10.1155/2015/516921
   Bronnum-Hansen H, 2001, J CLIN EPIDEMIOL, V54, P1244, DOI 10.1016/S0895-4356(01)00405-X
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen XJ, 2013, INT C DIGIT MANUF, P1371, DOI 10.1109/ICDMA.2013.327
   COX DR, 1972, J R STAT SOC B, V34, P187
   Crafts TD, 2015, CYTOKINE, V71, P385, DOI 10.1016/j.cyto.2014.08.005
   Ellis Lee M, 2005, Nat Rev Drug Discov, VSuppl, pS8
   Etminan M, 2016, AM J OPHTHALMOL, V163, P53, DOI 10.1016/j.ajo.2015.11.030
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2009, INVEST OPHTH VIS SCI, V50, P4423
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   Gopinath B, 2016, MATURITAS, V84, P63, DOI 10.1016/j.maturitas.2015.11.001
   Gottlieb SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6
   Grinnon ST, 2012, CLIN TRIALS, V9, P322, DOI 10.1177/1740774512438980
   Hanhart J, 2014, EYE, V28, P646, DOI 10.1038/eye.2014.94
   Hanhart J, 2016, AM J OPHTHALMOL
   Hicks KA, 2015, CIRCULATION, V132, P302, DOI 10.1161/CIR.0000000000000156
   Hirai FE, 2008, AM J OPHTHALMOL, V145, P700, DOI 10.1016/j.ajo.2007.11.019
   Hojo Y, 2000, J AM COLL CARDIOL, V35, P968, DOI 10.1016/S0735-1097(99)00632-4
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Karaca C, 2013, JAMA OPHTHALMOL, V131, P1099, DOI 10.1001/jamaophthalmol.2013.400
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Liew G, 2007, OPHTHALMOLOGY, V114, P1793, DOI 10.1016/j.ophtha.2007.04.036
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mikacic I, 2016, DRUG SAF
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Monsuez JJ, 2010, INT J CARDIOL, V144, P3, DOI 10.1016/j.ijcard.2010.03.003
   Ng WY, 2015, AM J OPHTHALMOL, V159, P557, DOI 10.1016/j.ajo.2014.12.005
   Ogawa H, 2000, CARDIOLOGY, V93, P93, DOI 10.1159/000007008
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Rennert G, 2001, ISR MED ASSOC J, V3, P404
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Semeraro F, 2015, CURR DRUG METAB, V16, P572, DOI 10.2174/1389200216666151001120831
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 61
TC 21
Z9 24
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2018
VL 256
IS 4
BP 651
EP 663
DI 10.1007/s00417-018-3917-9
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ6HS
UT WOS:000427699300002
PM 29429131
DA 2022-11-30
ER

PT J
AU Rakoczy, EP
   Magno, AL
   Lai, CM
   Pierce, CM
   Degli-Esposti, MA
   Blumenkranz, MS
   Constable, IJ
AF Rakoczy, Elizabeth P.
   Magno, Aaron L.
   Lai, Chooi-May
   Pierce, Cora M.
   Degli-Esposti, Mariapia A.
   Blumenkranz, Mark S.
   Constable, Ian J.
TI Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene
   Therapy Trials for Exudative Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID IMMUNE-RESPONSE; RANIBIZUMAB; OUTCOMES; VECTORS; HORIZON; ANCHOR; MARINA
AB PURPOSE: To assess the safety and the 3-year results of combined phase 1 and 2a randomized controlled trials of rAAV.sFLT-1 gene therapy (GT) for wet age-related macular degeneration.
   DESIGN: Phase 1/2a clinical trial.
   METHODS: Patients were prospectively randomized into control (n = 13) and GT (n = 24) groups. GT patients received 1X10(11)vg rAAV.sFLT-1 and were seen every month for 1 year then as needed every 1 to 2 months. They were given retreatment anti-vascular endothelial growth factor injections according to predetermined criteria. At 12 months, GT patients were divided into 2 groups: HD-1 (n = 14), requiring < 2, and HD-2 (n = 10), requiring > 2 retreatments.
   RESULTS: Between 1 year and 3 years there were 3 adverse events (AEs) and 33 serious AEs reported. Of these, 15 occurred in the 13 control subjects and 21 in the 24 GT patients. Except for 1 case of transient choroiditis in a control patient, serious AEs were deemed to be unrelated to the study. Control patients received a median of 7.0 retreatments and lost a median of 7.0 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, HD-1 patients received a median of 2.5 retreatments and lost a median of 4.0 ETDRS letters, and HD-2 patients received a median of 11.0 retreatments and lost a median of 7.0 ETDRS letters over 3 years. Center point thickness fluctuated. Thirty-three percent of control subjects, 44% of HD-2 patients, and 5 1 To of HD-1 patients showed maintenance of baseline visual acuity. Four HD-1 patients (34%) maintained significant visual improvement at 3 years. None of these observations were statistically significant.
   CONCLUSIONS: Given the small number of patients, this study was unable to unequivocally confirm the existence of a biologic efficacy signal; however, it confirmed that rAAV.sFLT-1 gene delivery was well tolerated among the elderly. (Am J Ophthalmol 2019;204:113-123. (C) 2019 Published by Elsevier Inc.)
C1 [Rakoczy, Elizabeth P.; Magno, Aaron L.; Lai, Chooi-May; Pierce, Cora M.; Degli-Esposti, Mariapia A.; Constable, Ian J.] Lions Eye Inst, Nedlands, WA, Australia.
   [Constable, Ian J.] Sir Charles Gairdner Hosp, Nedlands, WA, Australia.
   [Rakoczy, Elizabeth P.; Lai, Chooi-May; Degli-Esposti, Mariapia A.; Constable, Ian J.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
   [Blumenkranz, Mark S.] Byers Eye Inst Stanford, Palo Alto, CA USA.
C3 Lions Eye Institute; University of Western Australia; University of
   Western Australia; University of Western Australia
RP Rakoczy, EP (通讯作者)，Univ Western Australia, Ctr Ophthalmol & Visual Sci, 2 Verdun St, Nedlands, WA 6009, Australia.
EM elizabeth.rakoczy@uwa.edu.au
OI Degli-Esposti, Mariapia/0000-0002-7808-5935; Magno,
   Aaron/0000-0001-6099-819X; constable, ian/0000-0002-2140-6478
FU NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL OF AUSTRALIA; Adverum
   Biotechnologies Inc.; RICHARD Pearce Bequest
FX WE THANK THE NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL OF AUSTRALIA,
   THE RICHARD Pearce Bequest, and Avalanche Biotechnologies (now Adverum
   Biotechnologies Inc.) for their financial support.
CR Amado D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000659
   Australian Institute of Health and Welfare, CANC AUSTR 2017
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Klimczak RR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007467
   Li QH, 2008, MOL VIS, V14, P1760
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mingozzi F, 2017, ANNU REV VIROL, V4, P511, DOI 10.1146/annurev-virology-101416-041936
   Miyamoto N, 2017, CLIN OPHTHALMOL, V11, DOI 10.2147/OPTH.S133332
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
NR 23
TC 27
Z9 29
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2019
VL 204
BP 113
EP 123
DI 10.1016/j.ajo.2019.03.006
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IN7KD
UT WOS:000478859400014
PM 30878487
DA 2022-11-30
ER

PT J
AU Cipriani, V
   Tierney, A
   Griffiths, JR
   Zuber, V
   Sergouniotis, PI
   Yates, JRW
   Moore, AT
   Bishop, PN
   Clark, SJ
   Unwin, RD
AF Cipriani, Valentina
   Tierney, Anna
   Griffiths, John R.
   Zuber, Verena
   Sergouniotis, Panagiotis, I
   Yates, John R. W.
   Moore, Anthony T.
   Bishop, Paul N.
   Clark, Simon J.
   Unwin, Richard D.
TI Beyond factor H: The impact of genetic-risk variants for age-related
   macular degeneration on circulating factor-H-like 1 and factor-H-related
   protein concentrations
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; BRUCHS MEMBRANE; RARE;
   CFH; DELETION; GWAS; COLOCALIZATION; POLYMORPHISM; ACTIVATION
AB Age-related macular degeneration (AMD) is a leading cause of vision loss; there is strong genetic susceptibility at the complement factor H (CFH) locus. This locus encodes a series of complement regulators: factor H (FH), a splice variant factor-H-like 1 (FHL-1), and five factorH-related proteins (FHR-1 to FHR-5), all involved in the regulation of complement factor C3b turnover. Little is known about how AMDassociated variants at this locus might influence FHL-1 and FHR protein concentrations. We have used a bespoke targeted mass-spectrometry assay to measure the circulating concentrations of all seven complement regulators and demonstrated elevated concentrations in 352 advanced AMD-affected individuals for all FHR proteins (FHR-1, p = 2.4 x 10(-10); FHR-2, p = 6.0 x 10(-10); FHR-3, p = 1.5 x 10(-5); FHR-4, p = 1.3 x 10(-3); FHR-5, p = 1.9 3 10(-4)) and FHL-1 (p = 4.9 3 10(-4)) when these individuals were compared to 252 controls, whereas no difference was seen for FH (p = 0.94). Genome-wide association analyses in controls revealed genome-wide-significant signals at the CFH locus for all five FHR proteins, and univariate Mendelian-randomization analyses strongly supported the association of FHR-1, FHR-2, FHR-4, and FHR-5 with AMD susceptibility. These findings provide a strong biochemical explanation for how genetically driven alterations in circulating FHR proteins could be major drivers of AMD and highlight the need for research into FHR protein modulation as a viable therapeutic avenue for AMD.
C1 [Cipriani, Valentina] Queen Mary Univ London, William Harvey Res Inst, London EC1M 6BQ, England.
   [Cipriani, Valentina; Yates, John R. W.; Moore, Anthony T.] UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
   [Cipriani, Valentina; Yates, John R. W.; Moore, Anthony T.] Moorfields Eye Hosp Natl Hlth Serv Fdn Trust, London EC1V 2PD, England.
   [Cipriani, Valentina] UCL, UCL Genet Inst, London WC1E 6BT, England.
   [Tierney, Anna; Griffiths, John R.] Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Div Cardiovasc Sci, Manchester M13 9NY, Lancs, England.
   [Zuber, Verena] Imperial Coll London, Dept Epidemiol & Biostat, London W2 1PG, England.
   [Sergouniotis, Panagiotis, I; Bishop, Paul N.] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Div Evolut & Genom Sci, Manchester M13 9PT, Lancs, England.
   [Sergouniotis, Panagiotis, I] Manchester Univ Natl Hlth Serv Fdn Trust, Manchester Ctr Genom Med, St Marys Hosp, Manchester M13 9WL, Lancs, England.
   [Yates, John R. W.] Univ Cambridge, Dept Med Genet, Cambridge CB2 0QQ, England.
   [Moore, Anthony T.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Bishop, Paul N.] Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England.
   [Clark, Simon J.] Univ Eye Clin, Eberhard Karls Univ Tubingen, Dept Ophthalmol, D-72076 Baden Baden, Germany.
   [Clark, Simon J.] Eberhard Karls Univ Tubingen, Inst Ophthalm Res, D-72076 Baden Baden, Germany.
   [Clark, Simon J.] Univ Manchester, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England.
   [Unwin, Richard D.] Univ Manchester, Fac Biol, Stoller Biomarker Discovery Ctr, Manchester M13 9NQ, Lancs, England.
   [Unwin, Richard D.] Univ Manchester, Fac Biol, Div Canc Sci, Fac Biol Med & Hlth, Manchester M13 9NQ, Lancs, England.
C3 University of London; Queen Mary University London; University of
   London; University College London; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of London; University College London; University of Manchester; Imperial
   College London; University of Manchester; University of Manchester;
   University of Cambridge; University of California System; University of
   California San Francisco; Manchester Royal Eye Hospital; University of
   Manchester; Eberhard Karls University of Tubingen; Eberhard Karls
   University of Tubingen; University of Manchester; University of
   Manchester; University of Manchester
RP Cipriani, V (通讯作者)，Queen Mary Univ London, William Harvey Res Inst, London EC1M 6BQ, England.; Cipriani, V (通讯作者)，UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.; Cipriani, V (通讯作者)，Moorfields Eye Hosp Natl Hlth Serv Fdn Trust, London EC1V 2PD, England.; Cipriani, V (通讯作者)，UCL, UCL Genet Inst, London WC1E 6BT, England.; Unwin, RD (通讯作者)，Univ Manchester, Fac Biol, Stoller Biomarker Discovery Ctr, Manchester M13 9NQ, Lancs, England.
EM v.cipriani@qmul.ac.uk; r.unwin@manchester.ac.uk
OI Clark, Simon/0000-0001-8394-8355; Tierney, Anna/0000-0002-8968-5717;
   Griffiths, John/0000-0001-8288-5380; Unwin, Richard/0000-0001-7955-9111;
   Zuber, Verena/0000-0001-9827-1877
FU Cambridge AMD Study (UK Medical Research Council) [G0000067]; Reading
   Centre, Moorfields Eye Hospital, London; Centre for Inherited Disease
   Research in Baltimore, MD [HHSN268201200008I]; Case Western Reserve
   University, Cleveland [EY022310]; University of Michigan, Department of
   Biostatistics [1x01HG006934-01]; Medical Research Council [MR/P025838/1,
   MR/M008959/1]; Helmut Ecker Foundation, Germany; MRC [MR/M008959/1]
   Funding Source: UKRI
FX We are grateful to all the subjects who kindly participated in this
   research. For the Cambridge AMD Study (UK Medical Research Council grant
   G0000067 to J.R.W.Y. and A.T.M.), we gratefully acknowledge help with
   patient recruitment from members of the Genetic Factors in AMD Study
   Group (P. Black, Z. Butt, V. Chong, C. Edelsten, A. Fitt, D.W. Flanagan,
   A. Glenn, S.P. Harding, C. Jakeman, C. Jones, R.J. Lamb, V. Moffatt,
   C.M. Moorman, R.J. Pushpanathan, E. Redmond, T. Rimmer, and D.A.
   Thurlby); we thank Jane Khan and Humma Shahid for carrying out the
   clinical evaluation and sampling of subjects and Tunde Peto and
   colleagues at the Reading Centre, Moorfields Eye Hospital, London, for
   grading the fundus photographs. We are grateful to Dr. Serena Sanna for
   the helpful discussion about causality and Mendelianrandomization
   analysis. We also thank the IAMDGC (for a full list of consortium
   members, please see the supplemental information) for providing the
   genotype data for the Cambridge AMD study samples and the consortium
   summary association statistics for the two-sample
   Mendelian-randomization analysis. The Cambridge samples were genotyped
   as part of the IAMDGC exomechip project supported by Centre for
   Inherited Disease Research in Baltimore, MD (contract number
   HHSN268201200008I) and funded by EY022310 (to J.L. Haines, Case Western
   Reserve University, Cleveland) and 1x01HG006934-01 (to G.R. Abecasis,
   University of Michigan, Department of Biostatistics). This work was
   funded by the Medical Research Council (MR/P025838/1) and facilitated by
   the Manchester National Institute for Health Research Biomedical
   Research Centre and the Greater Manchester Comprehensive Local Research
   Network. The Stoller Biomarker Discovery Centre was established with an
   award from the Medical Research Council (MR/M008959/1). S.J.C. is funded
   by the Helmut Ecker Foundation, Germany. The funding bodies had no role
   in the design of the study, in the collection, analysis, or
   interpretation of data, or in writing the manuscript.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bowden J, 2011, STAT MED, V30, P678, DOI 10.1002/sim.4138
   Burgess S, 2017, STAT METHODS MED RES, V26, P2333, DOI 10.1177/0962280215597579
   Burgess S, 2018, ANNU REV GENOM HUM G, V19, P303, DOI 10.1146/annurev-genom-083117-021731
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Cserhalmi M, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101341
   Davies NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k601
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Foley CN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20885-8
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hukku A, 2021, AM J HUM GENET, V108, P25, DOI 10.1016/j.ajhg.2020.11.012
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kubista KE, 2011, MOL VIS, V17, P2080
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Pino LK, 2020, MASS SPECTROM REV, V39, P229, DOI 10.1002/mas.21540
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005
   Walker VM, 2017, INT J EPIDEMIOL, V46, P2078, DOI 10.1093/ije/dyx207
   Wallace C, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008720
   Weinberger AWA, 2014, OPHTHALMIC RES, V51, P59, DOI 10.1159/000351624
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhang P, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600237
   Zheng J, 2020, NAT GENET, V52, P1122, DOI 10.1038/s41588-020-0682-6
NR 46
TC 17
Z9 17
U1 1
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD AUG 5
PY 2021
VL 108
IS 8
BP 1385
EP 1400
DI 10.1016/j.ajhg.2021.05.015
EA AUG 2021
PG 16
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA TW6OO
UT WOS:000682516900003
PM 34260948
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Chu, YK
   Lee, SC
   Byeon, SH
AF Chu, Young Kwang
   Lee, Sung Chul
   Byeon, Suk Ho
TI VEGF Rescues Cigarette Smoking-Induced Human RPE Cell Death by
   Increasing Autophagic Flux: Implications of the Role of Autophagy in
   Advanced Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE VEGF; cigarette smoke; AMD; autophagy; RPE cells
ID RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS; CHOROIDAL
   NEOVASCULARIZATION; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; RISK-FACTOR;
   ACTIVATION; ERK; MECHANISMS; SENESCENCE
AB PURPOSE. Cigarette smoking (CS) is the most consistent risk factor for advanced age-related macular degeneration (AMD). To verify the molecular basis for CS-induced RPE alterations, RPE cell survival levels after being exposed to CS in relation with VEGF expression and autophagic flux were evaluated.
   METHODS. Cigarette smoking extract (CSE) was added to ARPE-19 cells and hydrogen peroxide (HP) was used as a pure oxidant control. Cell survival was measured by flow cytometry with annexin V-fluorescein isothiocyanate. Cell survival analysis was performed after pretreatment with anti-VEGF or recombinant VEGF. The expression of VEGF-A, VEGF-R1/R2, and soluble VEGF-R1 was determined by semiquantitative RT-PCR. LC3B-I (microtubule-associated protein-1 inhibitors), LC3B-II, and phosphorylation of Akt or Erk were measured with Western blot. Autophagic flux was determined by increasing LC3B-II levels with inhibitors of lysosomal proteases.
   RESULTS. Incubation with 5% CSE for 16 hours induced approximately 30% cell death, which was similar to cell death levels when exposed to concentrations of 200 mu M HP. Pretreatment with anti-VEGF did not decrease cell survival under CSE, unlike the decrease in cell survival shown with HP. However, supplementation with VEGF rescued CSE-induced RPE cell death. Interestingly, CSE caused an increase in autophagic flux, which was augmented with VEGF pretreatment. Cigarette smoking extract also degraded the total amounts of Akt levels, and VEGF blunted CSE-induced phosphorylation of Erk.
   CONCLUSIONS. Cigarette smoking extract, similar to HP, affects cell viability and induces expression of VEGF and its receptors. Increased autophagic flux accelerated by treatment of exogenous VEGF may have a role in rescuing CSE-induced RPE cell death.
C1 [Chu, Young Kwang] Siloam Eye Hosp, Seoul, South Korea.
   [Chu, Young Kwang; Lee, Sung Chul; Byeon, Suk Ho] Yonsei Univ, Inst Vis Res, Dept Ophthalmol, Coll Med, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Byeon, SH (通讯作者)，Yonsei Univ, Inst Vis Res, Dept Ophthalmol, Coll Med, 134 Shinchon Dong, Seoul 120752, South Korea.
EM shbyeon@yuhs.ac
OI , Sung Chul/0000-0001-9438-2385; Byeon, suk ho/0000-0001-8101-0830
FU Converging Research Center Program through the Ministry of Science, ICT
   and Future Planning, Korea [2013K000365]; faculty research grant of
   Yonsei University College of Medicine [6-2009-0078]
FX Supported by the Converging Research Center Program through the Ministry
   of Science, ICT and Future Planning, Korea (2013K000365), and a faculty
   research grant of Yonsei University College of Medicine for 2009
   (6-2009-0078). The authors alone are responsible for the content and
   writing of the paper.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bernhard D, 2006, ARTERIOSCL THROM VAS, V26, P833, DOI 10.1161/01.ATV.0000205616.70614.e5
   Bernhard D, 2003, FASEB J, V17, P2302, DOI 10.1096/fj.03-0312fje
   Bolt AM, 2012, J APPL TOXICOL, V32, P465, DOI 10.1002/jat.1787
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cagnol S, 2013, ONCOGENE, V32, P564, DOI 10.1038/onc.2012.88
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Cao W, 2007, NUCL MED COMMUN, V28, P895, DOI 10.1097/MNM.0b013e3282f1ac9a
   Chheda LV, 2012, OPHTHALMOLOGY, V119, P333, DOI 10.1016/j.ophtha.2011.08.003
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Csordas A, 2011, CARDIOVASC RES, V92, P141, DOI 10.1093/cvr/cvr165
   Demidenko ZN, 2008, CELL CYCLE, V7, P3355, DOI 10.4161/cc.7.21.6919
   Edirisinghe I, 2010, ANTIOXID REDOX SIGN, V12, P1355, DOI 10.1089/ars.2009.2874
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359
   Han BS, 2007, J BIOCHEM MOL BIOL, V40, P196
   Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim SY, 2011, J BIOL CHEM, V286, P31932, DOI 10.1074/jbc.M111.267633
   Kode A, 2008, AM J PHYSIOL-LUNG C, V294, pL478, DOI 10.1152/ajplung.00361.2007
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Li HZ, 2007, J BIOL CHEM, V282, P4943, DOI 10.1074/jbc.M609494200
   Medici D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042913
   Messner B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.162
   Orrenius S, 2013, ANNU REV PHARMACOL, V53, P275, DOI 10.1146/annurev-pharmtox-011112-140210
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Son YO, 2011, TOXICOL APPL PHARM, V255, P287, DOI 10.1016/j.taap.2011.06.024
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
NR 34
TC 15
Z9 17
U1 1
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2013
VL 54
IS 12
BP 7329
EP 7337
DI 10.1167/iovs.13-12149
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265KH
UT WOS:000327949700021
PM 24084092
DA 2022-11-30
ER

PT J
AU Dimitrov, PN
   Guymer, RH
   Zele, AJ
   Anderson, AJ
   Vingrys, AJ
AF Dimitrov, Peter N.
   Guymer, Robyn H.
   Zele, Andrew J.
   Anderson, Andrew J.
   Vingrys, Algis J.
TI Measuring rod and cone dynamics in age-related maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID DARK-ADAPTATION; MACULAR DEGENERATION; PHOTORECEPTORS; MONITOR; VISION
AB PURPOSE. A cathode-ray-tube (CRT) monitor-based technique was used to isolate clinically significant components of dark adaptation. The utility of the technique in identifying adaptation abnormalities in eyes with age-related maculopathy (ARM) is described.
   METHODS. A CRT dark adaptometer was developed to assess cone and rod recovery after photopigment bleach. The following measures were obtained: cone recovery rate (R c; in decades per minute) and absolute threshold (Tf-c; log candelas per square meter), rod recovery rate (R-r; decades per minute), and rod-cone transition (rod-cone break [RCB], in minutes). These components were isolated by appropriately selecting stimulus size, stimulus location, pigment bleach, and test duration and by coupling the CRT with judiciously selected neutral-density (ND) filters. The protocol was developed by using 5 young observers and was tested on 27 subjects with ARM in the study eye and 22 age-matched control subjects.
   RESULTS. The parameters necessary for effective isolation of cone and early phase rod dark adaptation were a 2.6 ND filter (for a standard CRT monitor, 0.08-80 cd . m(-2) luminance output); a 4 degrees foveated, 200-ms, achromatic spot; similar to 30% pigment bleaching; and a 30-minute test duration. These settings returned obvious rod and cone recovery curves in control and ARM eyes that were compatible with conventional test methods and identified 93% of participants with ARM as having delayed dynamics in at least one of the parameters. Cone recovery dynamics were significantly slower in the ARM group when compared with age-matched control subjects (R-c, 0.99 +/- 0.35 vs. 2.63 +/- 0.61 decades . min(-1), P < 0.0001). Three of the 27 eyes with ARM did not achieve RCB during the allowed duration (30 minutes). The remaining eyes with ARM (n = 24) exhibited a significant delay in rod recovery (R-r, ARM, 0.16 +/- 0.03 vs. controls, 0.22 +/- 0.02 decades . min(-1), P < 0.0001) and the average time to RCB (+/- SD) in the ARM group was significantly longer than in the control subjects (19.12 +/- 5.17 minutes vs. 10.40 +/- 2.49 minutes, P < 0.0001).
   CONCLUSIONS. The CRT dark-adaptation technique described in this article is an effective test for identifying abnormalities in cone and rod recovery. Slowed cone and rod recovery and a delayed RCB were evident in the eyes with ARM. The test method is potentially useful for clinical intervention trials in which ARM progression is monitored.
C1 [Dimitrov, Peter N.; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Melbourne, Vic 3002, Australia.
   [Zele, Andrew J.] Queensland Univ Technol, Sch Optometry, Brisbane, Qld, Australia.
   [Zele, Andrew J.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
   [Anderson, Andrew J.; Vingrys, Algis J.] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3052, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Queensland
   University of Technology (QUT); Queensland University of Technology
   (QUT); University of Melbourne
RP Guymer, RH (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Zele, Andrew/0000-0003-0291-9929;
   Anderson, Andrew/0000-0001-7015-0061; Vingrys, Algis/0000-0001-5920-4604
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BEKESY GEORG v., 1947, ACTA OTO LARYNGOL [STOCKHOLM], V35, P411, DOI 10.3109/00016484709123756
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hecht S, 1937, J GEN PHYSIOL, V20, P831, DOI 10.1085/jgp.20.6.831
   Hecht S, 1935, J GEN PHYSIOL, V19, P321, DOI 10.1085/jgp.19.2.321
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   McFarland RA, 1939, AM J PHYSIOL, V127, P37, DOI 10.1152/ajplegacy.1939.127.1.37
   METHA AB, 1993, BEHAV RES METH INSTR, V25, P371, DOI 10.3758/BF03204528
   Motulsky H, 2003, PRISM 4 STAT GUIDE S, P122
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Pianta MJ, 2000, J PHYSIOL-LONDON, V528, P591, DOI 10.1111/j.1469-7793.2000.00591.x
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   RUSHTON WAH, 1972, VISION RES, V12, P1073, DOI 10.1016/0042-6989(72)90098-3
   Stirling RJ, 1996, INVEST OPHTH VIS SCI, V37, P1608
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
   TRAVIS D, 1991, COMPUTERS PEOPLE SER, P152
   TYLER CW, 1984, INVEST OPHTH VIS SCI, V25, P103
   WEST SK, 1988, INVEST OPHTH VIS SCI, V29, P73
   Zele AJ, 2005, J NEUROSCI METH, V141, P1, DOI 10.1016/j.jneumeth.2004.05.005
NR 33
TC 85
Z9 88
U1 0
U2 17
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2008
VL 49
IS 1
BP 55
EP 65
DI 10.1167/iovs.06-1048
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 256RJ
UT WOS:000252747000009
PM 18172075
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ulanczyk, Z
   Sobus, A
   Luczkowska, K
   Grabowicz, A
   Mozolewska-Piotrowska, K
   Safranow, K
   Kawa, MP
   Palucha, A
   Krawczyk, M
   Sikora, P
   Matczynska, E
   Machalinski, B
   Machalinska, A
AF Ulanczyk, Zofia
   Sobus, Anna
   Luczkowska, Karolina
   Grabowicz, Aleksandra
   Mozolewska-Piotrowska, Katarzyna
   Safranow, Krzysztof
   Kawa, Milosz Piotr
   Palucha, Andrzej
   Krawczyk, Mariusz
   Sikora, Piotr
   Matczynska, Ewa
   Machalinski, Boguslaw
   Machalinska, Anna
TI Associations of MicroRNAs, Angiogenesis-Regulating Factors and CFH Y402H
   Polymorphism-An Attempt to Search for Systemic Biomarkers in Age-Related
   Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE AMD; miRNA; CFH; growth factors; angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; PLASMA-LEVELS;
   TARGETING ANGIOGENESIS; INTRAVITREAL INJECTION; MIR-17-92 CLUSTER; VEGF
   THERAPY; GENE; EXPRESSION; ENDOSTATIN
AB Age-related macular degeneration (AMD) remains the leading cause of blindness in elderly people, but the pathophysiology of this disease is still largely unknown. We investigated the systemic expression of angiogenesis-regulating growth factors and selected miRNAs known to regulate angiogenesis in AMD patients. We also focused on possible correlations of their expression with the presence of CFH Y402H or ARMS A69S risk variants. A total of 354 AMD patients and 121 controls were enrolled in this study. The levels of angiogenesis-regulating factors were analyzed in plasma samples using Luminex technology. The expression of selected miRNAs was analyzed in peripheral blood plasma using real-time qPCR. The genetic analysis was performed with an Illumina NextSeq500 system. AMD was an independent factor associated with lower levels of angiogenin (beta = -0.29, p < 0.001), endostatin (beta = -0.18, p < 0.001), FGF-basic (beta = -0.18, p < 0.001), PlGF (beta = -0.24, p < 0.001), miRNA-21-3p (beta = -0.13, p = 0.01) and miRNA-155-5p (beta = -0.16, p = 0.002); and with higher levels of FGF-acidic (beta = 0.11, p = 0.03), miRNA-23a-3p (beta = 0.17, p < 0.001), miRNA-126-5p (beta = 0.13, p = 0.009), miRNA-16-5p (beta = 0.40, p < 0.001), miRNA-17-3p (beta = 0.13, p = 0.01), miRNA-17-5p (beta = 0.17, p < 0.001), miRNA-223-3p (beta = 0.15, p = 0.004), and miRNA-93 (beta = 0.11, p = 0.04). The expression of analyzed miRNA molecules significantly correlated with the levels of tested angiogenesis-regulating factors and clinical parameters in AMD patients, whereas such correlations were not observed in controls. We also found an association between the CFH Y402H polymorphism and miRNA profiles, whereby TT homozygotes showed evidently higher expression of miRNA-16-5p than CC homozygotes or TC heterozygotes (p = 0.0007). Our results suggest that the balance between systemic pro- and anti-angiogenic factors and miRNAs is vital in multifactorial AMD pathogenesis.
C1 [Ulanczyk, Zofia; Sobus, Anna; Luczkowska, Karolina; Kawa, Milosz Piotr; Machalinski, Boguslaw] Pomeranian Med Univ, Dept Gen Pathol, PL-70111 Szczecin, Poland.
   [Grabowicz, Aleksandra; Mozolewska-Piotrowska, Katarzyna; Machalinska, Anna] Pomeranian Med Univ, Dept Ophthalmol 1, PL-70111 Szczecin, Poland.
   [Safranow, Krzysztof] Pomeranian Med Univ, Dept Biochem & Med Chem, PL-70111 Szczecin, Poland.
   [Palucha, Andrzej; Krawczyk, Mariusz; Sikora, Piotr; Matczynska, Ewa] Genomed SA, PL-02971 Warsaw, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University
RP Machalinska, A (通讯作者)，Pomeranian Med Univ, Dept Ophthalmol 1, PL-70111 Szczecin, Poland.
EM z.litwinska@gmail.com; anna.sobus@pum.edu.pl;
   karolina.luczkowska@pum.edu.pl; aleksandra.grabowicz@pum.edu.pl;
   kmp@pum.edu.pl; chrissaf@mp.pl; kawamilosz@gmail.com;
   sekwencjonowanie@genomed.pl; ngs@genomed.pl; info@genomed.pl;
   ewamat@genomed.pl; machalin@pum.edu.pl; annam@pum.edu.pl
RI Safranow, Krzysztof/B-5127-2015
OI Safranow, Krzysztof/0000-0001-9415-2758; Ulanczyk,
   Zofia/0000-0003-0451-8723; Machalinski, Boguslaw/0000-0002-6013-0419
FU Polish National Science Center Grant [UMO-2013/09/B/NZ7/04031]; Polish
   National Centre for Research and Development
   [STRATEGMED1/234261/2NCBR/2014]; European Union funds from the European
   Union Regional Development Fund, Interreg Cooperation Program V A
   Mecklenburg-Western Pomerania/Brandenburg/Poland for 2014-2020:
   "Consolidating cross-border cooperation through exchange of knowledge
   and skills in the
FX This work was supported by Polish National Science Center Grant no.
   UMO-2013/09/B/NZ7/04031 (to AM), Polish National Centre for Research and
   Development (grant number: STRATEGMED1/234261/2NCBR/2014), European
   Union funds from the European Union Regional Development Fund, Interreg
   Cooperation Program V A Mecklenburg-Western Pomerania/Brandenburg/Poland
   for 2014-2020: "Consolidating cross-border cooperation through exchange
   of knowledge and skills in the field of modern diagnostic imaging
   methods in ophthalmology".
CR Abdollahi A, 2010, DRUG RESIST UPDATE, V13, P16, DOI 10.1016/j.drup.2009.12.001
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alexandrov PN, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00181
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Ardekani Ali M., 2010, Avicenna Journal of Medical Biotechnology, V2, P161
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bhise NS, 2011, EXPERT OPIN DRUG DEL, V8, P485, DOI 10.1517/17425247.2011.558082
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Bonyadi MHJ, 2016, CURR EYE RES, V41, P1519, DOI 10.3109/02713683.2016.1158274
   Boyle EA, 2014, BIOINFORMATICS, V30, P2670, DOI 10.1093/bioinformatics/btu353
   Cabral T., 2017, INT J RETINA VITREOU, V3, P31, DOI [10.1186/s40942-017-0084-9, DOI 10.1186/S40942-017-0084-9]
   Caporali A, 2011, VASC PHARMACOL, V55, P79, DOI 10.1016/j.vph.2011.06.006
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chamorro-Jorganes A, 2016, CIRC RES, V118, P38, DOI 10.1161/CIRCRESAHA.115.307408
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Dewerchin M, 2014, EXPERT OPIN THER TAR, V18, P1339, DOI 10.1517/14728222.2014.948420
   Dixelius J, 2003, CANCER LETT, V196, P1, DOI 10.1016/S0304-3835(03)00267-2
   Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909
   Ertekin S, 2014, MOL VIS, V20, P1057
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Fiedler J, 2016, CIRC RES, V118, P9, DOI 10.1161/CIRCRESAHA.115.307935
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Guduric-Fuchs J, 2012, J CELL BIOCHEM, V113, P2098, DOI 10.1002/jcb.24084
   He F, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160290
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Huo XC, 2015, CELL PHYSIOL BIOCHEM, V35, P1787, DOI 10.1159/000373990
   Ioanna Z, 2018, GRAEF ARCH CLIN EXP, V256, P325, DOI 10.1007/s00417-017-3846-z
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444
   Kawa M, 2014, J BIOCH PHARM RES, V2, P21
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Korc M, 2009, CURR CANCER DRUG TAR, V9, P639, DOI 10.2174/156800909789057006
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Landskroner-Eiger S, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006643
   Li D, 2016, CANCER LETT, V377, P164, DOI 10.1016/j.canlet.2016.04.036
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp100]
   Litwinska Z, 2017, LEUKEMIA LYMPHOMA, V58, P1297, DOI 10.1080/10428194.2016.1243676
   Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Martin M., 2011, EMBNET J, V17, P10, DOI [DOI 10.14806/EJ.17.1.200, 10.14806/ej.17.1.200]
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Miyake M, 2015, ONCOGENE, V34, P890, DOI 10.1038/onc.2014.2
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nunes DN, 2015, P NATL ACAD SCI USA, V112, P3770, DOI 10.1073/pnas.1500008112
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Ozaki H, 1996, OPHTHALMIC RES, V28, P356, DOI 10.1159/000267929
   Pechan P, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017335
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rusanova I, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7671850
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Senger DR, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005090
   Sheibani Nader, 2013, J Ophthalmic Vis Res, V8, P1
   Skeie JM, 2011, MOL VIS, V17, P576
   Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]
   Sun LL, 2018, J CELL MOL MED, V22, P4568, DOI 10.1111/jcmm.13700
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tatar O, 2006, EXP EYE RES, V83, P329, DOI 10.1016/j.exer.2005.12.017
   Testa Ugo, 2017, Non-Coding RNA, V3, P22, DOI 10.3390/ncrna3030022
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Vempati P, 2014, CYTOKINE GROWTH F R, V25, P1, DOI 10.1016/j.cytogfr.2013.11.002
   Wang L, 2016, J PHYSIOL BIOCHEM, V72, P583, DOI 10.1007/s13105-016-0496-2
   Wang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060895
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong CG, 2017, CURR EYE RES, V42, P237, DOI 10.1080/02713683.2016.1227448
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Ye PP, 2014, INT J MED SCI, V11, P17, DOI 10.7150/ijms.7329
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zhou MW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146993
   Zhou QB, 2016, MOL THER, V24, P1823, DOI 10.1038/mt.2016.108
NR 84
TC 11
Z9 11
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2019
VL 20
IS 22
AR 5750
DI 10.3390/ijms20225750
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JW0YW
UT WOS:000502786800232
PM 31731799
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wolf, J
   Schlecht, A
   Rosmus, DD
   Boneva, S
   Agostini, H
   Schlunck, G
   Wieghofer, P
   Lange, C
AF Wolf, Julian
   Schlecht, Anja
   Rosmus, Dennis-Dominik
   Boneva, Stefaniya
   Agostini, Hansjurgen
   Schlunck, Gunther
   Wieghofer, Peter
   Lange, Clemens
TI Comparative transcriptome analysis of human and murine choroidal
   neovascularization identifies fibroblast growth factor inducible-14 as
   phylogenetically conserved mediator of neovascular age-related macular
   degeneration
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE AMD; CNV; Human; Mouse; Transcriptomic; RNA-Seq; FN14; Laser-induced CNV
ID TWEAK MONOCLONAL-ANTIBODY; ANGIOGENESIS; EXPRESSION; GENE;
   PHARMACODYNAMICS; INVOLVEMENT; DEFICIENCY; INHIBITION; CYTOKINE; OXIDASE
AB Background: Visual outcome of patients with neovascular age-related macular degeneration has significantly improved during the last years following the introduction of anti-vascular endothelial growth factor (VEGF) therapy. However, about one third of patients show persistent exudation and decreasing visual acuity despite recurrent anti-VEGF treatment, which implies a role of other, still unknown proangiogenic mediators.Methods: The present study applied transcriptional profiling of human and mouse (C57BL/6J wildtype) choroidal neovascularization (CNV) membranes each with reference to healthy control tissue to identify yet unrecognized mediators of CNV formation. Key factors were further investigated by immunohistochemistry as well as by intravitreal inhibition experiments and multiplex protein assays in the laser-induced CNV mouse model.Findings: Transcriptional profiles of CNV membranes were characterized by enhanced activation of blood vessel development, cytoskeletal organization, and cytokine production, with angiogenesis and wound healing processes predominating in humans and activation of immune processes in mice. Besides several species-specific factors, 95 phylogenetically conserved CNV-associated genes were detected, among which fibroblast growth factor inducible-14 (FN14), a member of the tumor necrosis factor (TNF) receptor family, was identified as a key player of CNV formation. Blocking the pathway by intravitreal injection of a FN14 decoy receptor modulated the cytokine profile -most notably IL-6 -and led to a significant reduction of CNV size in vivo. Interpretation: This study characterizes the transcriptome of human and mouse CNV membranes in an unprejudiced manner and identifies FN14 as a phylogenetically conserved mediator of CNV formation and a promising new therapeutic target for neovascular AMD. Funding: This study was funded by the Helmut Ecker Foundation and the Volker Homann Foundation.
C1 [Wolf, Julian; Schlecht, Anja; Boneva, Stefaniya; Agostini, Hansjurgen; Schlunck, Gunther; Lange, Clemens] Univ Freiburg, Fac Med, Eye Ctr, Med Ctr, Freiburg, Germany.
   [Schlecht, Anja] Wuerzburg Univ, Inst Anat, Wurzburg, Germany.
   [Rosmus, Dennis-Dominik; Wieghofer, Peter] Univ Leipzig, Inst Anat, Leipzig, Germany.
   [Wieghofer, Peter] Univ Augsburg, Med Fac, Inst Theoret Med, Cellular Neuroanat, Augsburg, Germany.
   [Lange, Clemens] St Franziskus Hosp Muenster, Dept Ophthalmol, Ophtha Lab, Hohenzollernring 74, D-48145 Munster, Germany.
C3 University of Freiburg; University of Wurzburg; Leipzig University;
   University of Augsburg; St. Franziskus-Hospital
RP Lange, C (通讯作者)，St Franziskus Hosp Muenster, Dept Ophthalmol, Ophtha Lab, Hohenzollernring 74, D-48145 Munster, Germany.
EM clemens.lange@augen-franziskus.de
RI Wieghofer, Peter/AAV-9572-2020
OI Boneva, Stefaniya/0000-0002-9811-2160; Rosmus,
   Dennis-Dominik/0000-0002-4094-0334; Wolf, Julian/0000-0002-3470-9697
FU Helmut-Eckert foundation; Volker Homann foundation
FX The authors thank Lutz Hansen for surgical assistance, Gabriele Prinz
   and Sylvia Zeitler for excellent technical assistance. This study was
   supported by the Helmut-Eckert foundation and Volker Homann foundation.
CR Abdueva D, 2010, J MOL DIAGN, V12, P409, DOI 10.2353/jmoldx.2010.090155
   Abu El-Asrar AM, 2015, OPHTHALMIC RES, V53, P122, DOI 10.1159/000369300
   Afgan E, 2018, NUCLEIC ACIDS RES, V46, pW537, DOI 10.1093/nar/gky379
   Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Ameri H, 2014, INVEST OPHTH VIS SCI, V55, P801, DOI 10.1167/iovs.13-12812
   Andriessen EMMA, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.201911754
   Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Blair JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151615
   Boeck M, 2020, GLIA, V68, P1859, DOI 10.1002/glia.23810
   Boneva S, 2020, LAB INVEST, V100, P1345, DOI 10.1038/s41374-020-0446-z
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bucher F, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.20
   Buhler A, 2013, EXP EYE RES, V115, P73, DOI 10.1016/j.exer.2013.06.014
   Burkly LC, 2007, CYTOKINE, V40, P1, DOI 10.1016/j.cyto.2007.09.007
   Campbell S, 2006, J IMMUNOL, V176, P1889, DOI 10.4049/jimmunol.176.3.1889
   Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055
   Chan EC, 2013, INVEST OPHTH VIS SCI, V54, P7061, DOI 10.1167/iovs.13-12883
   Chen JC, 2010, J MED CHEM, V53, P4545, DOI [10.1021/jm100089e, 10.1021/jm100089c]
   Chen WS, 2017, INVEST OPHTH VIS SCI, V58, P9, DOI 10.1167/iovs.16-20009
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Fan Q, 2012, BIOCHEM BIOPH RES CO, V425, P703, DOI 10.1016/j.bbrc.2012.07.013
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grgic I, 2005, ARTERIOSCL THROM VAS, V25, P704, DOI 10.1161/01.ATV.0000156399.12787.5c
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Hara C, 2013, INVEST OPHTH VIS SCI, V54, P4321, DOI 10.1167/iovs.13-11611
   Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0
   Horiuchi K, 2003, MOL CELL BIOL, V23, P5614, DOI 10.1128/MCB.23.16.5614-5624.2003
   Hou Y, 2015, MOL MED REP, V12, P2360, DOI 10.3892/mmr.2015.3636
   Ishimaru Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15602-3
   Jia WZ, 2013, AM J PATHOL, V182, P1821, DOI 10.1016/j.ajpath.2013.01.017
   Kamata K, 2006, J IMMUNOL, V177, P6433, DOI 10.4049/jimmunol.177.9.6433
   Kasai A, 2011, YAKUGAKU ZASSHI, V131, P1201, DOI 10.1248/yakushi.131.1201
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lange C, 2016, EXP EYE RES, V147, P148, DOI 10.1016/j.exer.2016.05.007
   Lange CAK, 2018, EYE, V32, P1772, DOI 10.1038/s41433-018-0172-6
   Lee SJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209583
   Lejmi E, 2008, P NATL ACAD SCI USA, V105, P12491, DOI 10.1073/pnas.0804008105
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   McAnally D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202436
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Meulendijks D, 2016, CLIN CANCER RES, V22, P858, DOI 10.1158/1078-0432.CCR-15-1506
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Saas P, 2000, GLIA, V32, P102, DOI 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U
   Schlecht A, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.618598
   Schlecht A, 2020, AM J PATHOL, V190, P1632, DOI 10.1016/j.ajpath.2020.04.004
   Schurch NJ, 2016, RNA, V22, P839, DOI 10.1261/rna.053959.115
   Schwarzer P, 2020, AM J PATHOL, V190, P412, DOI 10.1016/j.ajpath.2019.10.011
   Stalin J, 2016, ONCOGENE, V35, P5489, DOI 10.1038/onc.2016.83
   Sun HY, 2020, INT OPHTHALMOL, V40, P269, DOI 10.1007/s10792-019-01158-w
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wada T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122723
   Wang B, 2006, J BIOL CHEM, V281, P6020, DOI 10.1074/jbc.M509134200
   Wang XM, 2013, NATURE, V499, P306, DOI 10.1038/nature12345
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Wieghofer P, 2021, EMBO J, V40, DOI 10.15252/embj.2020105123
   Winkles JA, 2008, NAT REV DRUG DISCOV, V7, P411, DOI 10.1038/nrd2488
   Wisniacki N, 2013, CLIN THER, V35, P1137, DOI 10.1016/j.clinthera.2013.06.008
   Wolf J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72864-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie B, 2008, FASEB J, V22, P2775, DOI 10.1096/fj.07-099283
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yao YL, 2019, CARBOHYD POLYM, V204, P111, DOI 10.1016/j.carbpol.2018.10.008
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098
NR 68
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD APR 1
PY 2022
VL 1868
IS 4
AR 166340
DI 10.1016/j.bbadis.2022.166340
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 0V1UJ
UT WOS:000788130100004
PM 35032596
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Figueras-Roca, M
   Parrado-Carrillo, A
   Nguyen, V
   Casaroli-Marano, RP
   Moll-Udina, A
   Gillies, MC
   Barthelmes, D
   Zarranz-Ventura, J
AF Figueras-Roca, Marc
   Parrado-Carrillo, Alba
   Nguyen, Vuong
   Casaroli-Marano, Ricardo P.
   Moll-Udina, Aina
   Gillies, Mark C.
   Barthelmes, Daniel
   Zarranz-Ventura, Javier
TI Treat-and-extend versus fixed bimonthly treatment regimens for
   treatment-naive neovascular age-related macular degeneration: real world
   data from the Fight Retinal Blindness registry
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age&#8211; related macular degeneration; Treat and extend;
   Fixed bimonthly; Electronic medical record; Benchmark standard; Naive
ID INTRAVITREAL THERAPY; 2-YEAR OUTCOMES; AFLIBERCEPT; RANIBIZUMAB;
   PREVALENCE; MANAGEMENT
AB Purpose To compare the outcomes of two different antivascular endothelial growth factor treatment regimens for treatment-naive eyes with neovascular age-related macular degeneration in routine clinical care at 12 and 24 months in Spain. Methods Observational study using the Fight Retinal Blindness (FRB) outcomes registry platform. Eyes were treated with fixed bimonthly (FB) aflibercept group at one center and a treat-and-extend (TAE) regimen using either aflibercept or ranibizumab at the other center. Results We included 192 eyes. Of these, 160 eyes (83%) completed 12 months (86 TAE and 74 FB) and 79 (41%) completed 24 months (46 for TAE and 33 for FB) of follow-up. No statistically significant differences (p > 0.05) were found regarding mean visual acuity (VA, logMAR letters) at baseline (12 month cohort TAE 59.6 vs FB 57.9; 24 month cohort TAE 61.7 vs FB 62.6), final mean VA (12 month cohort TAE 61.1 vs FB 63.0; 24 month cohort TAE 64.8 vs FB 66.4), and median number of injections (12 months TAE 7 vs FB 7; 24 months TAE 11 vs FB 12). However, the distribution of injection frequencies for the TAE group was larger, with 35% of TAE eyes receiving <= 6 injections at 12 months compared with only 19% of FB eyes (p = 0.024). Conclusion Similar VA results were observed with TAE and FB regimens, with no differences in the median number of injections. However, the TAE approach seemed to deliver a wider distribution of injection frequencies due to its individualized approach, which may help reduce the burden of injections in some eyes.
C1 [Figueras-Roca, Marc; Parrado-Carrillo, Alba; Casaroli-Marano, Ricardo P.; Moll-Udina, Aina; Zarranz-Ventura, Javier] Hosp Clin Barcelona, Inst Clin Oftalmol ICOF, C Sabino Arana 1, Barcelona 08028, Spain.
   [Figueras-Roca, Marc; Casaroli-Marano, Ricardo P.; Moll-Udina, Aina; Zarranz-Ventura, Javier] Biomed Res Inst August Pi & Sunyer IDIBAPS, Barcelona, Spain.
   [Nguyen, Vuong; Gillies, Mark C.; Barthelmes, Daniel] Univ Sydney, Save Sight Inst, Macular Res Grp, Sydney, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
   [Casaroli-Marano, Ricardo P.] Univ Barcelona, Sch Med, Dept Surg, Barcelona, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; University of
   Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Sydney;
   University of Zurich; University Zurich Hospital; University of
   Barcelona
RP Figueras-Roca, M (通讯作者)，Hosp Clin Barcelona, Inst Clin Oftalmol ICOF, C Sabino Arana 1, Barcelona 08028, Spain.; Figueras-Roca, M (通讯作者)，Biomed Res Inst August Pi & Sunyer IDIBAPS, Barcelona, Spain.
EM mafiguer@clinic.cat
RI Figueras-Roca, Marc/G-9095-2017; Zarranz-Ventura, Javier/AAB-5390-2021;
   Udina, Aina Moll/AAF-7319-2021
OI Figueras-Roca, Marc/0000-0002-0548-0539; Zarranz-Ventura,
   Javier/0000-0003-2338-8143; Udina, Aina Moll/0000-0003-4753-2111
CR Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mekjavic PJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1005-x
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Talks J, 2019, SURV OPHTHALMOL, VS0039-6257, P30337
   Vardarinos A, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0451-1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 27
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2021
VL 259
IS 6
BP 1463
EP 1470
DI 10.1007/s00417-020-05016-9
EA NOV 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SK9OI
UT WOS:000591118700001
PM 33219442
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Osthoff, M
   Dean, MM
   Baird, PN
   Richardson, AJ
   Daniell, M
   Guymer, RH
   Eisen, DP
AF Osthoff, Michael
   Dean, Melinda M.
   Baird, Paul N.
   Richardson, Andrea J.
   Daniell, Mark
   Guymer, Robyn H.
   Eisen, Damon P.
TI Association Study of Mannose-Binding Lectin Levels and Genetic Variants
   in Lectin Pathway Proteins with Susceptibility to Age-Related Macular
   Degeneration: A Case-Control Study
SO PLOS ONE
LA English
DT Article
ID ENVIRONMENT INTERACTION; H-FICOLIN; COMPLEMENT; RISK; INFECTION; CELLS;
   AMD; HAPLOTYPE; GENOTYPES; CANCER
AB Background
   In age-related macular degeneration (AMD) the complement system is thought to be activated by chronic oxidative damage with genetic variants identified in the alternative pathway as susceptibility factors. However, the involvement of the lectin pathway of complement, a key mediator of oxidative damage, is controversial. This study investigated whether mannose-binding lectin (MBL) levels and genetic variants in lectin pathway proteins, are associated with the predisposition to and severity of AMD.
   Methods
   MBL levels and single nucleotide polymorphisms (SNPs) in the MBL2 and the ficolin-2 (FCN2) gene were determined in 109 patients with AMD and 109 age-and sex-matched controls.
   Results
   MBL expression levels were equally distributed in both cases (early and late AMD) and controls (p>0.05). However, there was a trend towards higher median MBL levels in cases with late AMD compared to cases with early AMD (1.0 vs. 0.4 mu g/ml, p = 0.09) and MBL deficiency (<0.5 mu g/ml) was encountered less frequently in the late AMD group (35% vs 56%, p = 0.03). FCN2 and MBL2 allele frequencies were similarly distributed in early and late AMD cases compared with controls (p>0.05 for all analyses) as were MBL2 genotypes. Similarly, there was no significant difference in allele frequencies in any SNPs in either the MBL2 or FCN2 gene in cases with early vs. late AMD.
   Conclusions
   SNPs of lectin pathway proteins investigated in this study were not associated with AMD or AMD severity. However, MBL levels deserve further study in a larger cohort of early vs. late AMD patients to elucidate any real effect on AMD severity.
C1 [Osthoff, Michael; Eisen, Damon P.] Melbourne Hlth, Victorian Infect Dis Serv, Doherty Inst, Melbourne, Vic, Australia.
   [Osthoff, Michael; Eisen, Damon P.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia.
   [Osthoff, Michael] Univ Basel Hosp, Dept Infect Dis & Hosp Epidemiol, CH-4031 Basel, Switzerland.
   [Dean, Melinda M.] Australian Red Cross Blood Serv, Res & Dev, Kelvin Grove, Qld, Australia.
   [Baird, Paul N.; Richardson, Andrea J.; Daniell, Mark; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, East Melbourne, Vic, Australia.
C3 Royal Melbourne Hospital; University of Melbourne; University of Basel;
   Australian Red Cross Blood Service; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne
RP Osthoff, M (通讯作者)，Melbourne Hlth, Victorian Infect Dis Serv, Doherty Inst, Melbourne, Vic, Australia.
EM michael.osthoff@usb.ch
RI Daniell, Mark/AAS-1363-2020; eisen, damon/AAC-7433-2019
OI Daniell, Mark/0000-0001-9528-7005; Osthoff, Michael/0000-0001-5439-957X;
   Baird, Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356
CR Abou Ouf E, 2012, J INFECT DIS, V206, P562, DOI 10.1093/infdis/jis396
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Bernig T, 2007, CARCINOGENESIS, V28, P828, DOI 10.1093/carcin/bgl198
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Eisen DP, 2008, CLIN INFECT DIS, V47, P510, DOI 10.1086/590006
   Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garred P, 2006, GENES IMMUN, V7, P85, DOI 10.1038/sj.gene.6364283
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Heitzeneder S, 2012, CLIN IMMUNOL, V143, P22, DOI 10.1016/j.clim.2011.11.002
   Herpers BL, 2009, CLIN EXP IMMUNOL, V156, P488, DOI 10.1111/j.1365-2249.2009.03929.x
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kilpatrick DC, 2013, HUM IMMUNOL, V74, P867, DOI 10.1016/j.humimm.2013.04.011
   Kilpatrick DC, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/138797
   Kjaer TR, 2013, MOL IMMUNOL, V56, P413, DOI 10.1016/j.molimm.2013.05.007
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuraya M, 2005, IMMUNOBIOLOGY, V209, P689, DOI 10.1016/j.imbio.2004.11.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Minchinton RM, 2002, SCAND J IMMUNOL, V56, P630, DOI 10.1046/j.1365-3083.2002.01167.x
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Sallenbach S, 2011, PEDIAT ALLERG IMM-UK, V22, P424, DOI 10.1111/j.1399-3038.2010.01104.x
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zanetti KA, 2012, CANCER RES, V72, P1467, DOI 10.1158/0008-5472.CAN-11-3073
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 38
TC 7
Z9 7
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2015
VL 10
IS 7
AR e0134107
DI 10.1371/journal.pone.0134107
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN7NT
UT WOS:000358622000209
PM 26207622
OA Green Published, Green Submitted, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Mitsch, C
   Pemp, B
   Pollreisz, A
   Gleiss, A
   Karst, S
   Scholda, C
   Sacu, S
   Schmidt-Erfurth, U
AF Mitsch, Christoph
   Pemp, Berthold
   Pollreisz, Andreas
   Gleiss, Andreas
   Karst, Sonja
   Scholda, Christoph
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
TI Short-time effect of intravitreal injections on retinal vascular
   oxygenation and vessel diameter in patients with diabetic macular oedema
   or neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-VEGF; choroidal neovascularization; diabetic macular oedema;
   oximetry; retina
ID ANTI-VEGF TREATMENT; BLOOD-FLOW; INTRAOCULAR-PRESSURE; SATURATION;
   BEVACIZUMAB; RANIBIZUMAB; AUTOREGULATION; AFLIBERCEPT; RETINOPATHY;
   OXIMETRY
AB Purpose To investigate the short-time effect of intravitreal injections (IVI) of the vascular endothelial growth factor inhibitors ranibizumab and aflibercept on retinal arterial and venous oxygen saturation (SO2a and SO2v), arteriovenous oxygen saturation difference (AVD) and vessel diameter (VDa and VDv) in patients with diabetic macular oedema (DME) and patients with choroidal neovascularization (CNV) due to age-related macular degeneration. Methods Uncontrolled prospective observational study in 100 eyes. Retinal vessel oxygen saturation and diameters were assessed using a retinal oximeter before and minutes after IVI of ranibizumab or aflibercept. Results 40 eyes with CNV and 34 eyes with DME were included in the analysis. At baseline, SO2a and SO2v were significantly higher in DME (p = 0.043 and p = 0.009, respectively). After IVI, SO2a significantly decreased in CNV and DME eyes by 2.6% (p = 0.016) and 4.6% (p = 0.002) and SO2v decreased by 14.0% (p = 0.004) and 12.4% (p = 0.017), respectively. However, a significant increase in AVD was only found in CNV (15.7%, p = 0.001). VDa decreased significantly only in DME by 5.7% (p = 0.010). No medication-specific disease effect was found and vice versa. Conclusions The observed changes can be interpreted as signs of increased metabolic demand during the physiological stress after an IVI. The abnormal arterial constriction and the abolished increase in AVD seen only in eyes with DME indicate an impairment of vascular autoregulation and oxygen distribution and a reduced neuroretinal metabolism in the diabetic retina with a significant impact on inner retinal oxygen consumption shortly after IVI.
C1 [Mitsch, Christoph; Pemp, Berthold; Pollreisz, Andreas; Karst, Sonja; Scholda, Christoph; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Gleiss, Andreas] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Pemp, B (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM berthold.pemp@meduniwien.ac.at
RI Pollreisz, Andreas/AAJ-1538-2021
OI Pemp, Berthold/0000-0002-0569-0229; Mitsch,
   Christoph/0000-0002-5361-5418; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 2013, PROTOCOL ACQUISITION
   Bek T, 2008, GRAEF ARCH CLIN EXP, V246, P763, DOI 10.1007/s00417-008-0766-y
   Bek T, 2016, INVEST OPHTH VIS SCI, V57, P5429, DOI 10.1167/iovs.16-20305
   Bek T, 2013, PROG RETIN EYE RES, V36, P247, DOI 10.1016/j.preteyeres.2013.07.002
   Blair NP, 2017, INVEST OPHTH VIS SCI, V58, P5556, DOI 10.1167/iovs.17-21934
   Bracha P, 2018, SURV OPHTHALMOL, V63, P281, DOI 10.1016/j.survophthal.2017.08.008
   Consigli A, 2018, KLIN MONBL AUGENHE A, V063, P1664
   Corvi F, 2015, AM J OPHTHALMOL, V160, P45, DOI 10.1016/j.ajo.2015.04.019
   Coughlin BA, 2017, VISION RES, V139, P93, DOI 10.1016/j.visres.2017.03.013
   Czako C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28994-7
   Erdogan A, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-015-0066-x
   Fondi K, 2017, DIABETOLOGIA, V60, P1534, DOI 10.1007/s00125-017-4309-0
   Frederiksen CA, 2006, GRAEF ARCH CLIN EXP, V244, P1255, DOI 10.1007/s00417-006-0262-1
   Geirsdottir A, 2014, ACTA OPHTHALMOL, V92, P27, DOI 10.1111/aos.12294
   Geirsdottir A, 2012, INVEST OPHTH VIS SCI, V53, P5433, DOI 10.1167/iovs.12-9912
   GRUNWALD JE, 1992, INVEST OPHTH VIS SCI, V33, P356
   Hammer M, 2009, GRAEF ARCH CLIN EXP, V247, P1025, DOI 10.1007/s00417-009-1078-6
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Hardarson SH, 2012, BRIT J OPHTHALMOL, V96, P560, DOI 10.1136/bjophthalmol-2011-300640
   Hayreh SS, 2001, PROG RETIN EYE RES, V20, P595, DOI 10.1016/S1350-9462(01)00005-2
   He Z, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.55
   Jakobsen DB, 2019, ACTA OPHTHALMOL, V97, P525, DOI 10.1111/aos.13996
   Jorgensen CM, 2014, ACTA OPHTHALMOL, V92, P34, DOI 10.1111/aos.12283
   Khoobehi B, 2013, INVEST OPHTH VIS SCI, V54, P7103, DOI 10.1167/iovs.13-12723
   Klefter ON, 2015, ACTA OPHTHALMOL, V93, P697, DOI 10.1111/aos.12797
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Kurt MM, 2017, OPHTHALMOLOGICA, V238, P147, DOI 10.1159/000477180
   Li H, 2017, INVEST OPHTH VIS SCI, V58, P1, DOI 10.1167/iovs.16-20804
   Mandecka A, 2007, DIABETES CARE, V30, P3048, DOI 10.2337/dc07-0927
   Mursch-Edlmayr AS, 2019, ACTA OPHTHALMOL, V97, pE927, DOI 10.1111/aos.14098
   Nagel E, 2004, GRAEF ARCH CLIN EXP, V242, P13, DOI 10.1007/s00417-003-0663-3
   Nicholson BP, 2010, GRAEF ARCH CLIN EXP, V248, P915, DOI 10.1007/s00417-010-1315-z
   O'Connell RA, 2015, OPHTHAL PHYSL OPT, V35, P114, DOI 10.1111/opo.12170
   Palsson O, 2012, INVEST OPHTH VIS SCI, V53, P1729, DOI 10.1167/iovs.11-8621
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pemp B, 2008, CAN J OPHTHALMOL, V43, P295, DOI 10.3129/i08-049
   Pemp B, 2018, ACTA OPHTHALMOL, V96, pE804, DOI 10.1111/aos.13733
   Pemp B, 2009, DIABETES CARE, V32, P1536, DOI 10.2337/dc08-2130
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   RASSAM SMB, 1995, EXP PHYSIOL, V80, P53, DOI 10.1113/expphysiol.1995.sp003834
   RIVA CE, 1986, INVEST OPHTH VIS SCI, V27, P1706
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sheu SJ, 2015, ACTA OPHTHALMOL, V93, pE631, DOI 10.1111/aos.12745
   Soheilian M, 2012, RETINA-J RET VIT DIS, V32, P314, DOI 10.1097/IAE.0b013e31822f55de
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Tan BY, 2017, INVEST OPHTH VIS SCI, V58, P5532, DOI 10.1167/iovs.17-22412
   Tatlipinar S, 2012, CLIN EXP OPTOM, V95, P94, DOI 10.1111/j.1444-0938.2011.00662.x
   Tetikoglu M, 2018, CUTAN OCUL TOXICOL, V37, P84, DOI 10.1080/15569527.2017.1354217
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Traustason S, 2014, BRIT J OPHTHALMOL, V98, P1208, DOI 10.1136/bjophthalmol-2013-304580
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 55
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2020
VL 98
IS 3
BP E301
EP E308
DI 10.1111/aos.14276
EA OCT 2019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LH4QT
UT WOS:000492528100001
PM 31654481
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Yanagi, Y
   Ting, DSW
   Ng, WY
   Lee, SY
   Mathur, R
   Chan, CM
   Yeo, I
   Wong, TY
   Cheung, GCM
AF Yanagi, Yasuo
   Ting, Daniel S. W.
   Ng, Wei Yan
   Lee, Shu Yen
   Mathur, Ranjana
   Chan, Choi Mun
   Yeo, Ian
   Wong, Tien Yin
   Cheung, Gemmy Chui Ming
TI CHOROIDAL VASCULAR HYPERPERMEABILITY AS A PREDICTOR OF TREATMENT
   RESPONSE FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; choroidal vascular hyperpermeability;
   choroidal thickness; anti-VEGF treatment; photodynamic therapy
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; INTRAVITREAL RANIBIZUMAB; CLINICAL CHARACTERISTICS;
   THICKNESS; AFLIBERCEPT; EYES; EFFICACY; BEVACIZUMAB
AB Purpose: To investigate the influence of choroidal vascular hyperpermeability (CVH) and choroidal thickness on treatment outcomes in eyes with polypoidal choroidal vasculopathy (PCV) undergoing anti-vascular endothelial growth factor monotherapy or combination therapy of photodynamic therapy and anti-vascular endothelial growth factor injections.
   Methods: The authors performed a prospective, observational cohort study involving 72 eyes of 72 patients with polypoidal choroidal vasculopathy (mean age 68.6 years, 51% men) treated with either monotherapy (n = 41) or combination therapy (n = 31). Each eye was imaged with color fundus photography, fluorescent angiography, indocyanine green angiography, and spectral domain optical coherence tomography. Indocyanine green angiography images were used to evaluate CVH, and spectral domain optical coherence tomography was used to measure central choroidal thickness. Changes in visual acuity over 12 months, and number of anti-vascular endothelial growth factor injections were investigated.
   Results: Choroidal vascular hyperpermeability was present in 31 eyes (43.1%). Visual acuity change over 12 months was numerically better in the CVH group compared with the CVH (2) group (20.099 and 20.366 logarithm of the minimal angle of resolution unit in the CVH (2) and CVH (+) groups, respectively, multivariate P = 0.063) and significantly better in a matched pair analysis (P = 0.033). Furthermore, in the combination therapy group, the number of injection was significantly lower in the CVH (+) group compared with the CVH (2) group (4.68 vs. 2.58 injections/year in the CVH (2) and CVH (+) groups; P = 0.0044). There was no significant relationship between treatment response and choroidal thickening.
   Conclusion: The presence of CVH is associated with better visual outcome in eyes with polypoidal choroidal vasculopathy and lower injection number in combination therapy. Thus, CVH, but not choroidal thickness, should be further evaluated as a potential biomarker for selecting patients for combination therapy.
C1 [Yanagi, Yasuo; Ting, Daniel S. W.; Ng, Wei Yan; Lee, Shu Yen; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian; Wong, Tien Yin; Cheung, Gemmy Chui Ming] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Med Retina, Singapore, Singapore.
   [Yanagi, Yasuo; Lee, Shu Yen; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian; Wong, Tien Yin; Cheung, Gemmy Chui Ming] Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Program, 11 Third Hosp Ave, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Cheung, GCM (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020; Wong, Tien
   Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Yanagi, Yasuo/0000-0002-0362-7285
FU National Medical Research Council [NMRC/NIG/1003/2009]; BMRC
   [10/1/35/19/671]
FX Supported by National Medical Research Council Grant NMRC/NIG/1003/2009
   and BMRC Grant No. 10/1/35/19/671.
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Gupta P, 2017, RETINA
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lim FPM, 2016, BRIT J OPHTHALMOL, V100, P918, DOI 10.1136/bjophthalmol-2015-307055
   Lim JW, 2011, GRAEF ARCH CLIN EXP, V249, P969, DOI 10.1007/s00417-010-1581-9
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Mohamed YH, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2193518
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Tan KA, 2016, SURV OPHTHALMOL, V61, P566, DOI 10.1016/j.survophthal.2016.02.007
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 42
TC 29
Z9 30
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2018
VL 38
IS 8
BP 1509
EP 1517
DI 10.1097/IAE.0000000000001758
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VJ
UT WOS:000454002400019
PM 28704255
DA 2022-11-30
ER

PT J
AU Ren, C
   Liu, WM
   Yin, X
   Zhang, BY
   Lu, PR
AF Ren, Chi
   Liu, Weiming
   Yin, Xue
   Zhang, Bingyu
   Lu, Peirong
TI Renin-Angiotensin System Inhibitor Usage and Age-Related Macular
   Degeneration among Hypertensive Patients: Results from the National
   Health and Nutrition Examination Survey, 2005-2008
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; CONVERTING ENZYME; CHOROIDAL NEOVASCULARIZATION;
   VISUAL IMPAIRMENT; RISK-FACTORS; EYE DISEASE; INFLAMMATION; ASSOCIATION;
   MACULOPATHY; PROGRESSION
AB Purpose. To assess whether renin-angiotensin system inhibitor (RASI) utilization is associated with age-related macular degeneration (AMD) prevalence among hypertensive patients.Methods. A US population-based, cross-sectional study was conducted. 3,023 hypertensive participants aged 40 years and older with gradable retinal images and ascertained RASI usage in the National Health and Nutrition Examination Survey (NHANES), 2005-2008, were finally enrolled into the study. RASI usage was obtained by interview, and AMD was determined through retinal image assessment. We performed multivariable analyses to assess the relationship between utilization of RASIs and AMD prevalence. We also took drug treatment duration into account, in order to better understand the effects of RASIs.Results. Multivariable logistic regression analyses revealed that AMD prevalence had no significant association with RASI usage but was inversely correlated with RASI treatment duration (odds ratio (OR) = 0.87, 95% confidence interval (CI) = 0.78-0.98,p=0.02). Long-term usage (>5 years) of RASIs was significantly associated with not only reduced overall risk of AMD (OR = 0.23, 95% CI = 0.14-0.38,p<0.001) but also lower propensity to have early (OR = 0.23, 95% CI = 0.14-0.37,p<0.001) and late (OR = 0.25, 95% CI = 0.07-0.87,p=0.03) AMD. Furthermore, long-term RASI users were less prone to develop soft drusen (OR = 0.67, 95% CI = 0.45-0.99,p=0.04) and geographic atrophy (GA) (OR = 0.39, 95% CI = 0.22-0.71,p=0.003).Conclusions. Evidence supporting that RASI utilization could directly protect against AMD in hypertensive patients was still insufficient, but long-term RASI treatment seemed to be beneficial for both early and late AMD, implicating a promising therapeutic approach that RASIs might offer for AMD prevention and management.
C1 [Ren, Chi; Liu, Weiming; Yin, Xue; Zhang, Bingyu; Lu, Peirong] Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, 188 Shizi St, Suzhou 215006, Peoples R China.
C3 Soochow University - China
RP Lu, PR (通讯作者)，Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, 188 Shizi St, Suzhou 215006, Peoples R China.
EM cren1995@stu.suda.edu.cn; 20184032024@stu.suda.edu.cn;
   yinxuescu@suda.edu.cn; 20174032023@stu.suda.edu.cn;
   lupeirong@suda.edu.cn
OI Liu, Weiming/0000-0002-0625-9297; Ren, Chi/0000-0003-1686-8253
FU National Natural Science Foundation of China [81671641]; Natural Science
   Foundation of Jiangsu Province [BK20151208]; Jiangsu Provincial Medical
   Innovation Team [CXTDA2017039]; Soochow Scholar Project of Soochow
   University [R5122001]
FX This work was partly supported by the National Natural Science
   Foundation of China (NSFC No. 81671641), Natural Science Foundation of
   Jiangsu Province (No. BK20151208), Jiangsu Provincial Medical Innovation
   Team (No. CXTDA2017039), and the Soochow Scholar Project of Soochow
   University (No. R5122001).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Benigni A, 2010, EMBO MOL MED, V2, P247, DOI 10.1002/emmm.201000080
   Borghi C, 2017, NUTR METAB CARDIOVAS, V27, P115, DOI 10.1016/j.numecd.2016.07.013
   Centers for Disease Control and Prevention, NAT HLTH NUTR EX SUR
   Centers for Disease Control and Prevention, NHANES DIG GRAD PROT
   Chen P, 2006, EXP EYE RES, V83, P1041, DOI 10.1016/j.exer.2006.05.009
   Cipriani V, 2017, JAMA OPHTHALMOL, V135, P909, DOI 10.1001/jamaophthalmol.2017.2191
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hikichi T, 2001, AM J OPHTHALMOL, V132, P587, DOI 10.1016/S0002-9394(01)01139-4
   Katsi VK, 2015, J HYPERTENS, V33, P2382, DOI 10.1097/HJH.0000000000000766
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kurihara T, 2006, INVEST OPHTH VIS SCI, V47, P5545, DOI 10.1167/iovs.06-0478
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li H, 2013, MOL VIS, V19, P1107
   Maugeri A, 2019, ACTA OPHTHALMOL, V97, pE8, DOI 10.1111/aos.13849
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Suliburska J, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091284
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159, DOI 10.1136/bjo.80.2.159
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KHC, 2004, ACTA OPHTHALMOL SCAN, V82, P298, DOI 10.1111/j.1600-0420.2004.00265.x
   Zipf George, 2013, Vital Health Stat 1, P1
NR 38
TC 3
Z9 3
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUN 24
PY 2020
VL 2020
AR 4252031
DI 10.1155/2020/4252031
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MK9VT
UT WOS:000549127700001
PM 32676201
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Murray, CD
   Wood, D
   Allgar, V
   Walters, G
   Gale, RP
AF Murray, C. D.
   Wood, D.
   Allgar, V.
   Walters, G.
   Gale, R. P.
TI Short-term intraocular pressure trends following intravitreal
   ranibizumab injections for neovascular age-related macular
   degeneration-the role of oral acetazolamide in protecting glaucoma
   patients
SO EYE
LA English
DT Article
ID BEVACIZUMAB; HORIZON
AB Purpose To determine the effect of oral acetazolamide on lowering the peak and duration of intraocular pressure (IOP) rise in glaucoma and glaucoma suspect patients, following intravitreal injection of ranibizumab for neovascular age-related macular degeneration.
   Methods The study was an open-label, parallel, randomised, controlled trial (EudraCT Number: 2010-023037-35). Twenty-four glaucoma or glaucoma suspect patients received either 500 mg acetazolamide or no treatment 60-90 min before 0.5 mg ranibizumab. The primary outcome measure was the difference in IOP immediately after injection (T0) and 5, 10, and 30 min following injection. ANCOVA was used to compare groups, adjusting for baseline IOP. The study was powered to detect a 9-mm Hg difference at T0.
   Results The IOP at T0 was 2.3 mm Hg higher in the non-treated group (mean 44.5 mm Hg, range (19-86 mm Hg)) compared with the treated group (mean 42.2 mm Hg, range (25-58 mm Hg)), but was not statistically significant after adjusting for baseline IOP (P = 0.440). At 30 min, IOP was 4.9 mm Hg higher in the non-treated group mean 20.6 mm Hg, range (11-46 mm Hg)) compared with the treated group (mean 15.7 mm Hg, range (8-21 mm Hg)). This was statistically significant after adjusting for baseline IOP (P = 0.013).
   Conclusions Although the primary end points were not reached, 500 mg oral acetazolamide, 60-90 min before intravitreal injection, results in a statistically significant reduction in IOP at 3O min post injection. Prophylactic treatment may be considered as an option to minimise neuro-retinal rim damage in high-risk glaucoma patients who are most vulnerable to IOP spikes and undergoing repeated intravitreal injections of ranibizumab.
C1 [Murray, C. D.; Wood, D.; Allgar, V.; Walters, G.; Gale, R. P.] York Teaching Hosp NHS Fdn Trust, Acad Unit Ophthalmol, York YO31 8HE, N Yorkshire, England.
RP Murray, CD (通讯作者)，York Teaching Hosp NHS Fdn Trust, Acad Unit Ophthalmol, Wigginton Rd, York YO31 8HE, N Yorkshire, England.
EM matie@doctors.org.uk
OI Allgar, Victoria/0000-0002-5228-2623
FU Elsie May Sykes Trust Fund
FX York Teaching Hospital NHS Foundation Trust was the sponsor for the
   study and charitable funding was granted from the Elsie May Sykes Trust
   Fund.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Frenkel MPC, 2010, ARCH OPHTHALMOL-CHIC, V128, P1523, DOI 10.1001/archophthalmol.2010.297
   Frenkel REP, 2007, AM J OPHTHALMOL, V143, P1034, DOI 10.1016/j.ajo.2007.01.052
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kotliar K, 2007, ACTA OPHTHALMOL SCAN, V85, P777, DOI 10.1111/j.1600-0420.2007.00939.x
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Theoulakis PE, 2010, KLIN MONATSBL AUGENH, V227, P280, DOI 10.1055/s-0029-1245201
NR 14
TC 18
Z9 18
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2014
VL 28
IS 10
BP 1218
EP 1222
DI 10.1038/eye.2014.180
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR7PG
UT WOS:000343771100012
PM 25081290
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Bonyadi, M
   Mehdizadeh, F
   Bonyadi, MHJ
   Soheilian, M
   Javadzadeh, A
   Yaseri, M
AF Bonyadi, Mortaza
   Mehdizadeh, Faride
   Bonyadi, Mohammad Hossein Jabbarpoor
   Soheilian, Masoud
   Javadzadeh, Alireza
   Yaseri, Mehdi
TI Association of the DNA repair SMUG1 rs3087404 polymorphism and its
   interaction with high sensitivity C-reactive protein for age-related
   macular degeneration in Iranian patients
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration (AMD); c; -31A; G-SMUG1 gene;
   C-reactive protein; high sensitivity CRP; single nucleotide polymorphism
ID COMPLEMENT FACTOR-H; BASE EXCISION-REPAIR; CIGARETTE-SMOKING; OXIDATIVE
   STRESS; GENES; DAMAGE; RISK; GLYCOSYLASES; ENZYMES; FRAILTY
AB Background: Age-related macular degeneration (AMD) is a complex disease and recently the role of DNA repairing genes in its susceptibility has been studied. It has been hypothesized that polymorphism in DNA repair system genes reduce the capacity to repair DNA damages which may lead to a greater susceptibility to AMD. C-reactive protein (CRP) production is shown to enhance inflammatory processes by increasing oxidative stress and inducing DNA damage. We planned to evaluate the possible association of SMUG1 variants and their possible interaction with high sensitivity CRP levels in AMD.Materials and methods: We included 500 case-control samples consisting of 279 advanced type AMD patients and 221 genetically unrelated healthy controls enrolled for evaluation. Extracted-DNA samples were amplified to obtain fragments including the polymorphic region SMUG1 rs3087404. We calculated relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (S) to clarify possible interaction of different genotypes and CRP levels for AMD.Results: The distribution of the genotypes were not significantly different in the AMD patients compared to that of controls (p = 0.849). The allele frequency for SMUG1 was not different between study groups. No difference of SMUG1 polymorphism between case and control groups was evident in higher CRP levels (CRP>3mg/dl) compared with lower CRP levels. SMUG1/CRP synergy indices calculated as RERI = -0.12 and AP = -0.18 while S was not calculable.Conclusions: Our study showed that c.-31A/G-SMUG1 genotypes/alleles do not have any association with the occurrence or severity of advanced type AMD. There was no interaction of CRP levels and SMUG1 genotypes in AMD susceptibility.
C1 [Bonyadi, Mortaza; Mehdizadeh, Faride] Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Univ Av, Tabriz 5165639758, Iran.
   [Bonyadi, Mortaza] Univ Tabriz, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
   [Bonyadi, Mohammad Hossein Jabbarpoor; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Tehran, Iran.
   [Javadzadeh, Alireza] Tabriz Univ Med Sci, Dept Ophthalmol, Tabriz, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
C3 University of Tabriz; University of Tabriz; Shahid Beheshti University
   Medical Sciences; Tabriz University of Medical Science; Tehran
   University of Medical Sciences
RP Bonyadi, M (通讯作者)，Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Univ Av, Tabriz 5165639758, Iran.
EM jabbarpour@tabrizu.ac.ir
RI Yaseri, Mehdi/I-1645-2018; Soheilian, Masoud/AAW-4743-2020; Hossein,
   Jabbarpoor Bonyadi Mohammad/A-1886-2014; Javadzadeh, Alireza/L-6424-2017
OI Yaseri, Mehdi/0000-0002-4066-873X; Javadzadeh,
   Alireza/0000-0002-5151-6125; Soheilian, Masoud/0000-0001-7508-426X
FU Center of Excellence for Biodiversity, Faculty of Natural Sciences,
   University of Tabriz
FX The Center of Excellence for Biodiversity, Faculty of Natural Sciences,
   University of Tabriz funded this study.
CR An Q, 2005, EMBO J, V24, P2205, DOI 10.1038/sj.emboj.7600689
   Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P61, DOI 10.3109/13816810.2015.1126612
   Chu XK, 2014, AGE, V36, P1453, DOI 10.1007/s11357-014-9627-2
   Collerton J, 2012, MECH AGEING DEV, V133, P456, DOI 10.1016/j.mad.2012.05.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Frosina G, 2000, EUR J BIOCHEM, V267, P2135, DOI 10.1046/j.1432-1327.2000.01266.x
   Gabriel HE, 2006, AM J CLIN NUTR, V83, P835, DOI 10.1093/ajcn/83.4.835
   Gorgun E, 2010, INVEST OPHTH VIS SCI, V51, P4732, DOI 10.1167/iovs.09-4842
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hubbard RE, 2009, J CELL MOL MED, V13, P3103, DOI 10.1111/j.1582-4934.2009.00733.x
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Ladiges W, 2003, MECH AGEING DEV, V124, P27, DOI 10.1016/S0047-6374(02)00166-5
   Marian C, 2011, EUR J CLIN NUTR, V65, P683, DOI 10.1038/ejcn.2011.29
   Noren Hooten N, 2012, ARTERIOSCL THROM VAS, V32, P2776, DOI 10.1161/ATVBAHA.112.300276
   Pettersen HS, 2007, NUCLEIC ACIDS RES, V35, P3879, DOI 10.1093/nar/gkm372
   Sacca SC, 2009, MUTAT RES-FUND MOL M, V667, P98, DOI 10.1016/j.mrfmmm.2008.11.002
   Synowiec E, 2014, RETINA-J RET VIT DIS, V34, P38, DOI 10.1097/IAE.0b013e31829477d8
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Trzeciak AR, 2012, MUTAT RES-FUND MOL M, V736, P93, DOI 10.1016/j.mrfmmm.2012.01.002
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Wu IC, 2009, J AM GERIATR SOC, V57, P1666, DOI 10.1111/j.1532-5415.2009.02392.x
   Zou GY, 2008, AM J EPIDEMIOL, V168, P212, DOI 10.1093/aje/kwn104
NR 32
TC 3
Z9 4
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2017
VL 38
IS 5
BP 422
EP 427
DI 10.1080/13816810.2016.1251947
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA FN4HL
UT WOS:000415965700004
PM 28095127
DA 2022-11-30
ER

PT J
AU Kang, HM
   Kwon, HJ
   Yi, JH
   Lee, CS
   Lee, SC
AF Kang, Hae Min
   Kwon, Hee Jung
   Yi, Jeong Ho
   Lee, Christopher Seungkyu
   Lee, Sung Chul
TI Subfoveal Choroidal Thickness as a Potential Predictor of Visual Outcome
   and Treatment Response After Intravitreal Ranibizumab Injections for
   Typical Exudative Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; HIGHLY MYOPIC EYES; BLOOD-FLOW;
   CHORIOCAPILLARIS; VASCULOPATHY; DRUSEN; CIRCULATION; MACULOPATHY;
   SEVERITY; DISEASE
AB PURPOSE: To investigate the prognostic implication of subfoveal choroidal thickness on treatment outcome after intravitreal ranibizumab injections for typical exudative age-related macular degeneration (AMD).
   DESIGN: Retrospective study.
   METHODS: A total of 40 eyes of 37 patients who completed 6-month follow-up were analyzed. Patients' data were retrieved from medical records including best-corrected visual acuity (BCVA). Subfoveal choroidal thickness at baseline, 3 months, and 6 months was measured by enhanced depth imaging optical coherence tomography and adjusted for age and sex before statistical analysis. Treatment response was after 3 monthly intravitreal ranibizumab injections. Responders (responder group) were defined as a 100 mu m or more decrease or complete resolution of subretinal fluid, whereas nonresponders (nonresponder group) were defined as changes less than 100 mu m or more than 100 pm increase of subretinal fluid by optical coherence tomography.
   RESULTS: Mean age at diagnosis was 72.1 +/- 8.1 years, and 22 eyes (55.0%) were responders. The responder group had thicker subfoveal choroid (257.2 +/- 108.3 mu m) and smaller lesions (1.3 +/- 0.8 mu m) at baseline than the nonresponder group (167.1 +/- 62.4 mu m, P = .003; and 2.0 +/- 1.0 mu m, P = .008). The responder group showed significantly better BCVA and thicker subfoveal choroid than the nonresponder group at 3 months (P = .002 and P = .023) and 6 months (P = .004 and P = .031). Stepwise and binary regression analysis demonstrated that subfoveal choroidal thickness was significantly correlated with visual outcome (B = -0.002, P = .003) and treatment response (B = 8.136, P = .018).
   CONCLUSION: Subfoveal choroidal thickness may be a predictive factor for visual outcome and treatment response in typical exudative AMD after intravitreal ranibizumab injections. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Kang, Hae Min; Lee, Christopher Seungkyu; Lee, Sung Chul] Yonsei Univ, Dept Ophthalmol, Coll Med, Inst Vis Res, Seoul 120752, South Korea.
   [Kang, Hae Min] Int St Marys Hosp, Dept Ophthalmol, Inchon, South Korea.
   [Kwon, Hee Jung] CHA Univ, Bundang Cha Gen Hosp, Dept Ophthalmol, Gyunggi Do, South Korea.
   [Yi, Jeong Ho] Jeil Eye Clin, Gyunggi Do, South Korea.
C3 Yonsei University; Yonsei University Health System; Pochon Cha
   University
RP Lee, SC (通讯作者)，Yonsei Univ, Dept Ophthalmol, Coll Med, 134 Sinchon Dong, Seoul 120752, South Korea.
EM sunglee@yuhs.ac
OI , Sung Chul/0000-0001-9438-2385; Lee, Christopher/0000-0001-5054-9470
CR Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Flores-Moreno I, 2013, BRIT J OPHTHALMOL, V97, P1010, DOI 10.1136/bjophthalmol-2012-302836
   GRUNWALD JE, 1993, INVEST OPHTH VIS SCI, V34, P3609
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Ho M, 2013, OPHTHALMOLOGY, V120, P1909, DOI 10.1016/j.ophtha.2013.02.005
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Wang NK, 2012, AM J OPHTHALMOL, V153, P669, DOI 10.1016/j.ajo.2011.08.039
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 35
TC 74
Z9 79
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2014
VL 157
IS 5
BP 1013
EP 1021
DI 10.1016/j.ajo.2014.01.019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG1TU
UT WOS:000335199900012
PM 24487050
DA 2022-11-30
ER

PT J
AU Liang, IC
   Ko, WC
   Hsu, YJ
   Lin, YR
   Chang, YH
   Zong, XH
   Lai, PC
   Chang, DC
   Hung, CF
AF Liang, I-Chia
   Ko, Wen-Chin
   Hsu, Yu-Jou
   Lin, Yi-Ru
   Chang, Yun-Hsiang
   Zong, Xv-Hui
   Lai, Pei-Chen
   Chang, Der-Chen
   Hung, Chi-Feng
TI The Anti-Inflammatory Effect of Hydrogen Gas Inhalation and Its
   Influence on Laser-Induced Choroidal Neovascularization in a Mouse Model
   of Neovascular Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; hydrogen
   gas
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; RISK-FACTORS; EYE
   DISEASE; VISION LOSS; TNF-ALPHA; MACROPHAGE; ANGIOGENESIS; EXPRESSION;
   INTERLEUKIN-6
AB Background: Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly. Choroidal neovascularization (CNV) is the major pathologic feature of neovascular AMD. Oxidative damages and the ensuing chronic inflammation are representative of trigger events. Hydrogen gas (H-2) has been demonstrated as an antioxidant and plays a role in the regulation of oxidative stress and inflammation. This experiment aimed to investigate the influence of H-2 inhalation on a mouse model of CNV. Methods: Laser was used to induce CNV formation. C57BL/6J mice were divided into five groups: the control group; the laser-only group; and the 2 h, 5 h, and 2.5 h/2.5 h groups that received laser and H-2 inhalation (21% oxygen, 42% hydrogen, and 37% nitrogen mixture) for 2 h, 5 h, and 2.5 h twice every day, respectively. Results: The severity of CNV leakage on fluorescence angiography showed a significant decrease in the H-2 inhalation groups. The mRNA expression of hypoxia-inducible factor 1 alpha and its immediate downstream target vascular endothelial growth factor (VEGF) showed significant elevation after laser, and this elevation was suppressed in the H-2 inhalation groups in an inhalation period length-related manner. The mRNA expression of cytokines, including tumor necrosis factor alpha and interlukin-6, also represented similar results. Conclusion: H-2 inhalation could alleviate CNV leakage in a laser-induced mouse CNV model, and the potential mechanism might be related to the suppression of the inflammatory process and VEGF-driven CNV formation.
C1 [Liang, I-Chia; Chang, Yun-Hsiang] Triserv Gen Hosp, Natl Def Med Ctr, Dept Ophthalmol, Taipei 11490, Taiwan.
   [Liang, I-Chia] Fu Jen Catholic Univ, PhD Program Nutr & Food Sci, New Taipei 24205, Taiwan.
   [Ko, Wen-Chin; Hung, Chi-Feng] Fu Jen Catholic Univ, Sch Med, New Taipei 24205, Taiwan.
   [Ko, Wen-Chin] Cathay Gen Hosp, Dept Cardiovasc Ctr, Div Cardiac Electrophysiol, Taipei 10630, Taiwan.
   [Hsu, Yu-Jou; Hung, Chi-Feng] Fu Jen Catholic Univ, Grad Inst Biomed & Pharmaceut Sci, New Taipei 24205, Taiwan.
   [Lin, Yi-Ru] Cathay Gen Hosp, Dept Ophthalmol, Taipei 10630, Taiwan.
   [Zong, Xv-Hui] Fu Jen Catholic Univ, Coll Med, Tsung Cho Chang Lab, New Taipei 24205, Taiwan.
   [Lai, Pei-Chen] Natl Taiwan Univ, Inst Biochem & Mol Biol, Coll Med, Taipei 100233, Taiwan.
   [Chang, Der-Chen] Georgetown Univ, Dept Math & Stat, Washington, DC 20057 USA.
   [Chang, Der-Chen] Georgetown Univ, Dept Comp Sci, Washington, DC 20057 USA.
   [Hung, Chi-Feng] Kaohsiung Med Univ, Sch Pharm, Kaohsiung 80708, Taiwan.
C3 National Defense Medical Center; Tri-Service General Hospital; Fu Jen
   Catholic University; Fu Jen Catholic University; Cathay General
   Hospital; Fu Jen Catholic University; Cathay General Hospital; Fu Jen
   Catholic University; National Taiwan University; Georgetown University;
   Georgetown University; Kaohsiung Medical University
RP Hung, CF (通讯作者)，Fu Jen Catholic Univ, Sch Med, New Taipei 24205, Taiwan.; Hung, CF (通讯作者)，Fu Jen Catholic Univ, Grad Inst Biomed & Pharmaceut Sci, New Taipei 24205, Taiwan.; Hung, CF (通讯作者)，Kaohsiung Med Univ, Sch Pharm, Kaohsiung 80708, Taiwan.
EM yirulin83088@gmail.com; 054317@mail.fju.edu.tw; peggylai1116@gmail.com;
   chang@georgetown.edu
RI Hung, Chi-Feng/AAL-4977-2021
OI Hung, Chi-Feng/0000-0003-3478-5451; Liang, I Chia/0000-0001-9554-1114
FU Ministry of Science and Technology [MOST110-2320-B-030-004-MY3]; Cathay
   General Hospital [109-CGH-FJU-03]
FX This work was supported by research grants from Ministry of Science and
   Technology (MOST110-2320-B-030-004-MY3) and the Cathay General Hospital
   (109-CGH-FJU-03) in Taiwan.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Brijesh T, 2016, AM J OPHTHALMOL, V162, P200, DOI 10.1016/j.ajo.2015.11.002
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cui J, 2016, NEUROSCIENCE, V335, P232, DOI 10.1016/j.neuroscience.2016.08.021
   Cui W, 2014, INT J OPHTHALMOL-CHI, V7, P194, DOI 10.3980/j.issn.2222-3959.2014.02.02
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Ghasemi H, 2018, OCUL IMMUNOL INFLAMM, V26, P37, DOI 10.1080/09273948.2016.1277247
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Iwanishi H, 2016, LAB INVEST, V96, P641, DOI 10.1038/labinvest.2016.30
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koizumi K, 2003, INVEST OPHTH VIS SCI, V44, P2184, DOI 10.1167/iovs.02-0589
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0
   Li H, 2017, BIOCHEM PHARMACOL, V130, P83, DOI 10.1016/j.bcp.2017.02.003
   Ling C.N.Y., 2021, INVEST OPHTH VIS SCI, V45, P1863, DOI 10.1038/s41366-021-00829-y
   Long P, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1105-2
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Murray CJL, 2013, LANCET, V381, P628
   Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577
   Onami H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058580
   Outtz HH, 2011, BLOOD, V118, P3436, DOI 10.1182/blood-2010-12-327015
   Park JR, 2016, INVEST OPHTH VIS SCI, V57, pOCT331, DOI 10.1167/iovs.15-18946
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Roddy GW, 2021, CURR OPIN OPHTHALMOL, V32, P280, DOI 10.1097/ICU.0000000000000747
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sato Kota, 2018, Immunol Med, V41, P23, DOI 10.1080/09114300.2018.1451609
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   Wang RB, 2016, BRAIN RES, V1632, P82, DOI 10.1016/j.brainres.2015.12.015
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan WM, 2018, MED SCI MONITOR, V24, P3840, DOI 10.12659/MSM.907269
   Yang XR, 2021, AGING-US, V13, P19614, DOI 10.18632/aging.203374
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
NR 51
TC 4
Z9 4
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 21
AR 12049
DI 10.3390/ijms222112049
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WY1JS
UT WOS:000719041900001
PM 34769482
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Staurenghi, G
   Garweg, JG
   Gerendas, BS
   Macfadden, W
   Gekkiev, B
   Margaron, P
   Dunger-Baldauf, C
   Kolar, P
AF Staurenghi, Giovanni
   Garweg, Justus G.
   Gerendas, Bianca S.
   Macfadden, Wayne
   Gekkiev, Boris
   Margaron, Philippe
   Dunger-Baldauf, Cornelia
   Kolar, Petr
TI Functional versus functional and anatomical criteria-guided ranibizumab
   treatment in patients with neovascular age-related macular degeneration
   - results from the randomized, phase IIIb OCTAVE study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Best-corrected visual acuity; Neovascular age-related macular
   degeneration; Optical coherence tomography; Ranibizumab; Retreatment
   criteria
ID OPTICAL COHERENCE TOMOGRAPHY; 2.0 MG RANIBIZUMAB; QUALITY-OF-LIFE;
   INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; THERAPY; SAFETY;
   BEVACIZUMAB; MANAGEMENT
AB Background To evaluate the efficacy and safety of two individualized ranibizumab retreatment schemes in neovascular age-related macular degeneration. Methods Patients (N = 671) were randomized (1:1) to receive three initial monthly ranibizumab 0.5 mg injections, then retreatment guided by either best-corrected visual acuity (BCVA) loss (Group I) or BCVA loss and/or signs of disease activity on optical coherence tomography (OCT; Group II). The study was terminated prematurely and the decision to discontinue the study was made by the sponsor. Efficacy analyses were performed on patients who completed 12 months of the originally planned 24-month study. Safety analyses are presented for all safety analyzable patients. Results Of 671 randomized patients, 305 completed 12 months of the study. For the 12-month completers, baseline mean (standard deviation) BCVA and reading-center evaluated central subfield thickness (CSFT) were comparable [Group I: 60.9 (13.10) letters and 517.7(201.79) mu m; Group II: 60.2 (12.21) letters and 515.3 (198.37) mu m]. The change from baseline at Month 12 in BCVA was 6.7 (13.48) letters in Group I and 8.3 (13.53) letters in Group II and the change in CSFT was - 161.3 (163.48) mu m and - 175.3 (170.45) mu m, respectively. The mean number of ranibizumab injections was 8.2 in Group I and 8.4 in Group II. Conclusion Ranibizumab treatment resulted in visual and anatomic gains at 12 months for both retreatment strategies, with a trend in favor of OCT-guided vs BCVA loss guided retreatment. No new safety signals were seen.
C1 [Staurenghi, Giovanni] Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, GB Grassi 74, I-20157 Milan, Italy.
   [Garweg, Justus G.] Berner Augenklin Lindenhofspital, Bern, Switzerland.
   [Garweg, Justus G.] Univ Bern, Bern, Switzerland.
   [Gerendas, Bianca S.] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna Reading Ctr, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Macfadden, Wayne] Int Psychiat Serv, 1900 JFK Blvd,621, Philadelphia, PA 19103 USA.
   [Gekkiev, Boris; Margaron, Philippe; Dunger-Baldauf, Cornelia] Novartis Pharma AG, CH-4002 Basel, Switzerland.
   [Kolar, Petr] Slowak Med Univ, Antolska 11, Bratislava 85107, Slovakia.
   [Kolar, Petr] Univ Hosp Bratislava, Antolska 11, Bratislava 85107, Slovakia.
C3 University of Milan; Luigi Sacco Hospital; University of Bern; Medical
   University of Vienna; Novartis; Slovak Medical University Bratislava
RP Staurenghi, G (通讯作者)，Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, GB Grassi 74, I-20157 Milan, Italy.
EM giovanni.staurenghi@unimi.it
RI ; Staurenghi, Giovanni/K-4388-2017
OI Gerendas, Bianca S./0000-0001-8940-8130; Staurenghi,
   Giovanni/0000-0002-2299-5251; Kolar, Petr/0000-0003-3709-4648
FU Novartis Pharma AG, Basel, Switzerland
FX This study was funded by Novartis Pharma AG, Basel, Switzerland. The
   sponsor participated in the design and conduct of the study, in the
   interpretation of data, and in the preparation, review and final
   approval of this manuscript.
CR Agarwal A, 2016, MIDDLE EAST AFR J OP, V23, P27, DOI 10.4103/0974-9233.173133
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Group. RCoOAG, 2013, AG REL MAC DEG GUID
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P5405, DOI 10.1167/iovs.09-3505
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
NR 26
TC 5
Z9 5
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 9
PY 2020
VL 20
IS 1
AR 18
DI 10.1186/s12886-019-1251-6
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KL8ED
UT WOS:000513649400001
PM 31918685
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Solomon, SD
   Lindsley, K
   Vedula, SS
   Krzystolik, MG
   Hawkins, BS
AF Solomon, Sharon D.
   Lindsley, Kristina
   Vedula, Satyanarayana S.
   Krzystolik, Magdalena G.
   Hawkins, Barbara S.
TI Anti-vascular endothelial growth factor for neovascular age-related
   macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Angiogenesis Inhibitors [*therapeutic use]; Antibodies, Monoclonal
   [*therapeutic use]; Antibodies, Monoclonal, Humanized [*therapeutic
   use]; Aptamers, Nucleotide [*therapeutic use]; Choroidal
   Neovascularization; Intravitreal Injections; Macular Degeneration [*drug
   therapy]; Porphyrins [*therapeutic use]; Randomized Controlled Trials as
   Topic; Ranibizumab; Vascular Endothelial Growth Factor A [*antagonists
   &inhibitors]; Verteporfin; Visual Acuity [drug effects]; Aged; Humans;
   Middle Aged
ID VERTEPORFIN PHOTODYNAMIC THERAPY; VISION-RELATED FUNCTION; OPTICAL
   COHERENCE TOMOGRAPHY; BEVACIZUMAB AVASTIN THERAPY; RANDOMIZED
   CLINICAL-TRIAL; COST-UTILITY ANALYSIS; CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL BEVACIZUMAB; VISUAL-ACUITY; RANIBIZUMAB TREATMENT
AB Background
   Age-related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to AMD accounts for most cases of AMD-related severe vision loss. Intravitreous injection of anti-vascular endothelial growth factor (anti-VEGF) agents aims to block the growth of abnormal blood vessels in the eye to prevent vision loss and, in some instances, to improve vision.
   Objectives
   To investigate ocular and systemic effects of, and quality of life associated with, intravitreous injection of three anti-VEGF agents (pegaptanib, ranibizumab, and bevacizumab) versus no anti-VEGF treatment for patients with neovascular AMD
   To compare the relative effects of one of these anti-VEGF agents versus another when administered in comparable dosages and regimens
   Search methods
   To identify eligible studies for this review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Eyes and Vision Trials Register (searched January 31, 2018); MEDLINE Ovid (1946 to January 31, 2018); Embase Ovid (1947 to January 31, 2018); the Latin American and Caribbean Health Sciences Literature Database ( LILACS) 1982 to January 31, 2018); the International Standard Randomized Controlled Trials Number ( ISRCTN) Registry (www.isrctn.com/editAdvancedSearch - searched January 31, 2018); ClinicalTrials.gov (www.clinicaltrials.gov - searched November 28, 2018); and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en-searched January 31, 2018). We did not impose any date or language restrictions in electronic searches for trials.
   Selection criteria
   We included randomized controlled trials (RCTs) that evaluated pegaptanib, ranibizumab, or bevacizumab versus each other or versus a control treatment (e.g. sham treatment, photodynamic therapy), in which participants were followed for at least one year.
   Data collection and analysis
   Two review authors independently screened records, extracted data, and assessed risks of bias. We contacted trial authors for additional data. We compared outcomes using risk ratios (RRs) or mean differences (MDs). We used the standard methodological procedures expected by Cochrane.
   Main results
   We included 16 RCTs that had enrolled a total of 6347 participants with neovascular AMD (the number of participants per trial ranged from 23 to 1208) and identified one potentially relevant ongoing trial. Six trials compared anti-VEGF treatment (pegaptanib, ranibizumab, or bevacizumab) versus control, and 10 trials compared bevacizumab versus ranibizumab. Pharmaceutical companies conducted or sponsored four trials but funded none of the studies that evaluated bevacizumab. Researchers conducted these trials at various centers across five continents (North and South America, Europe, Asia, and Australia). The overall certainty of the evidence was moderate to high, and most trials had an overall low risk of bias. All but one trial had been registered prospectively.
   When compared with those who received control treatment, more participants who received intravitreous injection of any of the three anti-VEGF agents had gained 15 letters or more of visual acuity (risk ratio [RR] 4.19, 95% confidence interval [CI] 2.32 to 7.55; moderate-certainty evidence), had lost fewer than 15 letters of visual acuity (RR 1.40, 95% CI 1.27 to 1.55; high-certainty evidence), and showed mean improvement in visual acuity (mean difference 6.7 letters, 95% CI 4.4 to 9.0 in one pegaptanib trial; mean difference 17.8 letters, 95% CI 16.0 to 19.7 in three ranibizumab trials; moderate-certainty evidence) after one year of follow-up. Participants treated with anti-VEGF agents showed improvement in morphologic outcomes (e.g. size of CNV, central retinal thickness) compared with participants not treated with anti-VEGF agents (moderate-certainty evidence). No trial directly compared pegaptanib versus another anti-VEGF agent and followed participants for one year; however, when compared with control treatments, ranibizumab and bevacizumab each yielded larger improvements in visual acuity outcomes than pegaptanib.
   Visual acuity outcomes after bevacizumab and ranibizumab were similar when the same RCTs compared the same regimens with respect to gain of 15 or more letters of visual acuity (RR 0.95, 95% CI 0.81 to 1.12; high-certainty evidence) and loss of fewer than 15 letters of visual acuity (RR 1.00, 95% CI 0.98 to 1.02; high-certainty evidence); results showed similar mean improvement in visual acuity (mean difference [MD] -0.5 letters, 95% CI -1.5 to 0.5; high-certainty evidence) after one year of follow-up, despite the substantially lower cost of bevacizumab compared with ranibizumab. Reduction in central retinal thickness was less among bevacizumab-treated participants than among ranibizumab-treated participants after one year (MD -11.6 mu m, 95% CI -21.6 to -1.7; high-certainty evidence); however, this difference is within the range of measurement error, and we did not interpret it to be clinically meaningful.
   Ocular inflammation and increased intraocular pressure (TOP) after intravitreal injection were the most frequently reported serious ocular adverse events. Researchers reported endophthalmitis in less than 1% of anti-VEGF-treated participants and in no cases among control groups. The occurrence of serious systemic adverse events was comparable across anti-VEGF-treated groups and control groups; however, the numbers of events and trial participants may have been insufficient to show a meaningful difference between groups (evidence of low- to moderate-certainty). Investigators rarely measured and reported data on visual function, quality of life, or economic outcomes.
   Authors' conclusions
   Results of this review show the effectiveness of anti-VEGF agents (pegaptanib, ranibizumab, and bevacizumab) in terms of maintaining visual acuity; studies show that ranibizumab and bevacizumab improved visual acuity in some eyes that received these agents and were equally effective. Available information on the adverse effects of each medication does not suggest a higher incidence of potentially vision-threatening complications with intravitreous injection of anti-VEGF agents compared with control interventions; however, clinical trial sample sizes were not sufficient to estimate differences in rare safety outcomes. Future Cochrane Reviews should incorporate research evaluating variable dosing regimens of anti-VEGF agents, effects of long-term use, use of combination therapies (e.g. anti-VEGF treatment plus photodynamic therapy), and other methods of delivering these agents.
C1 [Solomon, Sharon D.; Hawkins, Barbara S.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 North Wolfe St,Maumenee 740, Baltimore, MD 21287 USA.
   [Lindsley, Kristina] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Vedula, Satyanarayana S.] Johns Hopkins Univ, Baltimore, MD USA.
   [Krzystolik, Magdalena G.] Mass Eye & Ear Infirm, Retina Serv, Dept Ophthalmol, Providence, RI USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health; Johns
   Hopkins University; Harvard University; Massachusetts Eye & Ear
   Infirmary
RP Solomon, SD (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 North Wolfe St,Maumenee 740, Baltimore, MD 21287 USA.
EM ssolomon1@jhmi.edu
FU Southern New England Retina Associates, Providence, RI, USA; Brown
   University, Providence, RI, USA; Johns Hopkins Medical Institutions,
   Johns Hopkins University, Baltimore, MD, USA; National Eye Institute,
   National Institutes of Health, Bethesda, MD, USA [1 U01 EY020522];
   Research to Prevent Blindness, New York, New York, USA; National
   Institute for Health Research (NIHR), UK; Department of Health through
   the National Institute for Health Research; NIHR, via Cochrane
   Infrastructure funding; NATIONAL EYE INSTITUTE [U01EY020522] Funding
   Source: NIH RePORTER
FX Internal sources; Southern New England Retina Associates, Providence,
   RI, USA.; Brown University, Providence, RI, USA.; Johns Hopkins Medical
   Institutions, Johns Hopkins University, Baltimore, MD, USA.; External
   sources; Cochrane Eyes and Vision US Project supported by Grant 1 U01
   EY020522, National Eye Institute, National Institutes of Health,
   Bethesda, MD, USA.; SDS and BSH received support during preparation of
   this review from an unrestricted grant to the Wilmer Eye Institute from
   Research to Prevent Blindness, New York, New York, USA.; National
   Institute for Health Research (NIHR), UK.; Richard Wormald,
   Co-ordinating Editor for Cochrane Eyes and Vision (CEV), acknowledges
   financial support for his CEV research sessions from the Department of
   Health through the award made by the National Institute for Health
   Research to Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology for a Specialist Biomedical Research Centre
   for Ophthalmology; This review update was supported by the NIHR, via
   Cochrane Infrastructure funding to the CEV UK Editorial base
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Abraham P, S 1 ANT 1
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1414
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alexander SG, 2006, INVESTIGATIVE OPHTHA, V47
   Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   [Anonymous], 2012, OPHTHALMOLOGY, V119, P1508
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Barbazetto I, 2010, RETINA-J RET VIT DIS, V30, P1376, DOI 10.1097/IAE.0b013e3181dcfb0b
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Benz MS, 2008, INVESTIGATIVE OPHTHA, V49
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   BERGER BB, 2015, INVESTIGATIVE OPHTHA, V56
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Blaha GR, 2015, RETINA-J RET VIT DIS, V35, P577, DOI 10.1097/IAE.0000000000000334
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bolz M, 2008, INVESTIGATIVE OPHTHA, V49
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brader HS, 2015, INVEST OPHTH VIS SCI, V56
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, S 2 ANT 2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2016, INVEST OPHTH VIS SCI, V57
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown DM, 2006, INVESTIGATIVE OPHTHA, V47
   Brown DM, 2008, RANIBIZUMAB LUCENTIS, P78
   Brown DM, 2007, INVESTIGATIVE OPHTHA, V48
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Centers for Medicare and Medicaid Services, A49034 ID CTR MED ME
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U., 2006, AM ACAD OPHTHALMOLOG, P116
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, BRIT J OPHTHALMOL, V96, P1351, DOI 10.1136/bjophthalmol-2011-301444
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chang TS, 2006, INVESTIGATIVE OPHTHA, V47
   Chang TS, 2006, RANIBIZUMAB LUCENTIS, P106
   Chang TS, 2007, INVESTIGATIVE OPHTHA, V48
   Chang TS, S 2 ANT 2
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christmas NJ, 2016, INVEST OPHTH VIS SCI, V57
   Christoforidis JB, 2005, INVEST OPHTH VIS SCI, V46
   Ciulla TA, 2007, INVESTIGATIVE OPHTHA, V48
   Cohen D., 2014, BMJ-BRIT MED J, V348, pg2006
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   D'Amico DJ, 2004, INVESTIGATIVE OPHTHA, V45
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Donahue SP, 2010, AM J OPHTHALMOL, V150, P287, DOI 10.1016/j.ajo.2010.04.006
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   DUGEL PU, 2016, INVESTIGATIVE OPHTHA, V57
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   EIBENBERGER K, 2015, INVESTIGATIVE OPHTHA, V56
   Enseleit F, 2017, OPHTHALMOLOGICA, V238, P205, DOI 10.1159/000478665
   Erdokur O, 2009, RETINA VITREUS, V17, P245
   Eyetech Pharmaceuticals Inc Pfizer Inc, PEG SOD INJ TREAT NE
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   FDA, NTR
   FDA, MAC PEG SOD INJ TREA
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Foss AJE, 2016, BRIT J OPHTHALMOL, V100, P1662, DOI 10.1136/bjophthalmol-2015-307595
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gallemore RP, 2016, INVEST OPHTHALMOL, V57, P4985
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   Gillies MC, 2017, CLIN EXP OPHTHALMOL, V45, P29
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gragoudas ES, 2004, INVESTIGATIVE OPHTHA, V45
   GRUNWALD JE, 2014, INVESTIGATIVE OPHTHA, V55
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Hatta Y, 2010, RETINA-J RET VIT DIS, V30, P495, DOI 10.1097/IAE.0b013e3181bcedbe
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2007, INVESTIGATIVE OPHTHA, V48
   Heier JS, 2006, INVESTIGATIVE OPHTHA, V47
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Heier JS, 2005, PROGR AM SOC RET SPE
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Ho A, 2006, RANIBIZUMAB NEOVASCU, P108
   Ho AC, 2008, RANIBIZUMAB LUCENTIS, P164
   Ho AC, 2008, INVESTIGATIVE OPHTHA, V49
   Holekamp NM, 2006, 2 YEAR FA OCT RESULT, P194
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   HUANG JY, 2014, INVESTIGATIVE OPHTHA, V55
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jackson TL, 2014, RETINA-J RET VIT DIS, V34, P568, DOI 10.1097/IAE.0b013e3182a487be
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2006, AM ACAD OPHTHALMOLOG, P195
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kokame GT., 2006, ANATOMIC OUTCOMES MA, P110
   Korobelnik JF, S 1 ANT 1
   Kralinger MT, 2014, INVEST OPHTH VIS SCI, V55
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krzystolik MG, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139
   Kuppermann BD, 2005, V I S I O N STUDY RE, P178
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Laganovska G, 2013, 1 IN HUMAN RESULTS R, P136
   Lai CM, 2017, MOL THER, V25, P315
   Lai CM, 2013, J GENE MED, V15, P319
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P., 2008, INVESTIGATIVE OPHTHA, V49
   Lanzetta P, S 1 ANT 1
   Larsen Michael, 2005, Ugeskr Laeger, V167, P3301
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   LI E, 2016, COCHRANE DB SYST REV
   Li J, 2013, INT J OPHTHALMOL-CHI, V6, P169, DOI 10.3980/j.issn.2222-3959.2013.02.12
   Li XX, 2017, J OCUL PHARMACOL TH, V33, P435, DOI 10.1089/jop.2016.0071
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Loewenstein A, S 1 ANT 1
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maguire Maureen G, 2012, LDI Issue Brief, V17, P1
   Marcus DM, 2008, INVESTIGATIVE OPHTHA, V49
   MARCUS DM, 2014, INVESTIGATIVE OPHTHA, V55
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matthe E, 2011, OPHTHALMOLOGE, V108, P337, DOI 10.1007/s00347-010-2300-y
   McDonald HR, 2006, ONE YEAR RESULTS ANC, P114
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Messori A, 2010, AM J OPHTHALMOL, V149, P867, DOI 10.1016/j.ajo.2009.12.039
   Michels M, 2008, INVESTIGATIVE OPHTHA, V49
   Michels SM, 2007, INVESTIGATIVE OPHTHA, V48
   Mieler W., 2005, INVESTIGATIVE OPHTHA, V46
   Mieler WF, 2006, INVESTIGATIVE OPHTHA, V47
   Mieler WF, S 1 ANT 1
   Miller JW, 2006, INVESTIGATIVE OPHTHA, V47
   Mills E, 2007, J CLIN EPIDEMIOL, V60, P456, DOI 10.1016/j.jclinepi.2006.09.001
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nordic Cochrane Centre The Cochrane Collaboration, 2014, REV MAN 5 REVMAN 5 V
   Nowak MS, 2012, MED SCI MONITOR, V18, pCR374, DOI 10.12659/MSM.882907
   NUNES RP, 2014, INVESTIGATIVE OPHTHA, V55
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Parodi MB, 2012, ARCH OPHTHALMOL-CHIC, V130, P934, DOI 10.1001/archophthalmol.2011.2617
   Patel M, QUALITY LIFE PATIENT
   Patel PJ, 2007, INVESTIGATIVE OPHTHA, V48
   PATEL PJ, 2015, INVESTIGATIVE OPHTHA, V56
   Patel PJ, 2011, INVEST OPHTH VIS SCI, V52, P3089, DOI 10.1167/iovs.10-6208
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Prager F, 2008, INVESTIGATIVE OPHTHA, V49
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rakic JM, 2005, NEW ENGL J MED, V352, P1720
   Rakoczy EP, 2016, INVEST OPHTH VIS SCI, V57
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Regillo CD, 2008, RANIBIZUMAB NEOVASCU, P166
   Regillo CD, VISION SPECIFIC QUAL
   Reichel E, 2008, RANIBIZUMAB LUCENTIS, P168
   Reichel E, 2006, SUBGROUP ANAL 2 YEAR, P194
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2007, INVESTIGATIVE OPHTHA, V48
   Rosenfeld PJ, 2008, INVESTIGATIVE OPHTHA, V49
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Sadda SR, 2007, INVESTIGATIVE OPHTHA, V48
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schauwvlieghe ASME, 2014, INVEST OPHTH VIS SCI, V55
   Schmid-Kubista KE, 2009, BRIT J OPHTHALMOL, V93, P914, DOI 10.1136/bjo.2008.144410
   Schmid-Kubista KE, 2011, CURR EYE RES, V36, P958, DOI 10.3109/02713683.2011.597536
   Schmid-Kubista KE, 2008, INVESTIGATIVE OPHTHA, V49
   Schmidt-Erfurth U, S 1 ANT 1
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Scholler A, 2014, WIEN KLIN WOCHENSCHR, V126, P355, DOI 10.1007/s00508-014-0539-z
   Schwartz SG, 2007, INVESTIGATIVE OPHTHA, V48
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sengul A, 2017, EYE, V31, P677, DOI 10.1038/eye.2016.305
   Shah N, 2016, OPHTHALMOLOGY, V123, P858, DOI 10.1016/j.ophtha.2015.11.030
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Singerman LI, 2006, 2 YEAR SYSTEMIC SAFE, P120
   SINGERMAN LJ, 2015, INVESTIGATIVE OPHTHA, V56
   Sjolie Anne Katrin, 2005, Ugeskr Laeger, V167, P3267
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Slakter JS, 2007, INVESTIGATIVE OPHTHA, V48
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Subramanian ML, 2010, AM J OPHTHALMOL, V149, P867, DOI 10.1016/j.ajo.2009.12.040
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Suner IJ, 2007, INVESTIGATIVE OPHTHA, V48
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Sutter FK, 2008, INVESTIGATIVE OPHTHA, V49
   Tano Y., 2008, INVESTIGATIVE OPHTHA, V49
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Tano Yasuo, 2008, Nippon Ganka Gakkai Zasshi, V112, P590
   Tielsch JA, 1994, PREVENT BLINDNESS
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Webster MK, 2007, INVESTIGATIVE OPHTHA, V48
   Webster MK, 2006, INVESTIGATIVE OPHTHA, V47
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Weinberg DV, 2013, OPHTHALMOLOGY, V120, P1278, DOI 10.1016/j.ophtha.2012.11.042
   Wells JA, 2018, OSLI RETINA, V49, P336, DOI 10.3928/23258160-20180501-07
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Win PH, 2008, INVESTIGATIVE OPHTHA, V49
   Wolf S, 2008, INVESTIGATIVE OPHTHA, V49
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   Yang YC, 2007, INVESTIGATIVE OPHTHA, V48
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yu EB, 2007, INVESTIGATIVE OPHTHA, V48
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zlateva G, 2006, INVESTIGATIVE OPHTHA, V47
NR 268
TC 107
Z9 111
U1 6
U2 41
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2019
IS 3
AR CD005139
DI 10.1002/14651858.CD005139.pub4
PG 164
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HR1ZM
UT WOS:000462935200042
PM 30834517
OA Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Cho, SC
   Ryoo, NK
   Ahn, J
   Woo, SJ
   Park, KH
AF Cho, Soo Chang
   Ryoo, Na-Kyung
   Ahn, Jeeyun
   Woo, Se Joon
   Park, Kyu Hyung
TI Association of Irregular Pigment Epithelial Detachment in Central Serous
   Chorioretinopathy with Genetic Variants Implicated in Age-related
   Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; POLYMORPHISMS; ANGIOGRAPHY; SPECTRUM; NEOVASCULARIZATION;
   SUSCEPTIBILITY; ADRENOMEDULLIN; DIAGNOSIS
AB We evaluated phenotype and genotype correlation of central serous chorioretinopathy (CSC) patients with or without irregular pigment epithelial detachment (PED) on optical coherence tomography (OCT). For CSC, a flat, irregular protrusion of retinal pigment epithelium (RPE) with hyper-reflective sub-RPE fluid on OCT was defined as an irregular PED. Participants were classified into 5 subgroups; (1) total CSC (n=280) (2) CSC with irregular PED (n=126) (3) CSC without irregular PED (n=154) (4) typical choroidal neovascularization (CNV) (n=203) and (5) polypoidal choroidal vasculopathy (PCV) (n=135). Ten known major AMD-associated single-nucleotide polymorphisms (SNPs) were analyzed. Age, sex adjusted logistic regression was performed for the association between subgroups. Association analysis between CSC without irregular PED and CNV revealed that significant difference for rs10490924 in ARMS2, rs10737680 in CFH, and marginally significant difference for rs800292 in CFH. Between CSC without irregular PED and PCV, rs10490924, rs10737680, and rs800292 were significantly different. In contrast, CSC with irregular PED and CNV revealed no SNP showing significant difference. Between CSC with irregular PED and PCV, only rs10490924 was significantly different. CSC with irregular PED and CSC without irregular PED revealed significant difference for rs800292, and marginal difference for rs10737680. These findings suggest CSC patients with irregular PED are genetically different from those without irregular PED and may have genetic and pathophysiologic overlap with AMD patients.
C1 [Cho, Soo Chang; Ryoo, Na-Kyung; Woo, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Seongnam, South Korea.
   [Cho, Soo Chang] Ewha Womans Univ, Dept Ophthalmol, Mokdong Hosp, Seoul, South Korea.
   [Ryoo, Na-Kyung] Vet Hlth Serv Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Ahn, Jeeyun] Seoul Natl Univ, Seoul Metropolitan Govt, Dept Ophthalmol, Coll Med,Boramae Med Ctr, Seoul, South Korea.
C3 Seoul National University (SNU); Ewha Womans University; Veterans Health
   Service Medical Center; Seoul National University (SNU); Seoul National
   University Hospital
RP Park, KH (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Seongnam, South Korea.
EM jiani4@snu.ac.kr
RI ; Woo, Se Joon/I-7357-2013
OI Ahn, Jeeyun/0000-0001-9017-1652; Woo, Se Joon/0000-0003-3692-7169
FU National Research Foundation of Korea (NRF) - Korea government (MSIP)
   [2017R1A2B2011436]
FX The authors thank Y.J. Kim, PhD, for his statistical advice about
   quality control of the data. This work was supported by the National
   Research Foundation of Korea (NRF) grant funded by the Korea government
   (MSIP)(No. 2017R1A2B2011436). The sponsor or funding organization had no
   role in the design or conduct of this research.
CR Ahn J., 2014, 64 ANN M AM SOC HUM
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Chen LJ, 2006, MOL VIS, V12, P1536
   Cheng CY., 2015, NAT COMMUN, V6
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Costanzo E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/134783
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   de Carlo TE, 2016, OSLI RETINA, V47, P128, DOI 10.3928/23258160-20160126-05
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Dorner GT, 2003, INVEST OPHTH VIS SCI, V44, P3947, DOI 10.1167/iovs.02-0855
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Hosoda Y, 2019, OPHTHALMOL RETINA, V3, P985, DOI 10.1016/j.oret.2019.05.025
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kim Hyung Chan, 2012, Korean J Ophthalmol, V26, P347, DOI 10.3341/kjo.2012.26.5.347
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Miki A, 2018, INVEST OPHTH VIS SCI, V59, P5542, DOI 10.1167/iovs.18-25497
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Moschos MM, 2016, RETINA-J RET VIT DIS, V36, P402, DOI 10.1097/IAE.0000000000000693
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Pio R, 2001, J BIOL CHEM, V276, P12292, DOI 10.1074/jbc.M007822200
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Quin G, 2013, CLIN EXP OPHTHALMOL, V41, P187, DOI 10.1111/j.1442-9071.2012.02847.x
   Schellevis RL, 2018, JAMA OPHTHALMOL, V136, P1128, DOI 10.1001/jamaophthalmol.2018.3190
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   Song IS, 2012, AM J OPHTHALMOL, V154, P366, DOI 10.1016/j.ajo.2012.02.031
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tittl MK, 1999, AM J OPHTHALMOL, V128, P63, DOI 10.1016/S0002-9394(99)00075-6
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   Udono-Fujimori R, 2003, REGUL PEPTIDES, V112, P95, DOI 10.1016/S0167-0115(03)00027-2
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Yannuzzi LA, 2010, AM J OPHTHALMOL, V149, P361, DOI 10.1016/j.ajo.2009.11.017
NR 42
TC 6
Z9 6
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 27
PY 2020
VL 10
IS 1
AR 1203
DI 10.1038/s41598-020-57747-8
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NA7KJ
UT WOS:000559995400003
PM 31988359
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gianniou, C
   Dirani, A
   Ferrini, W
   Marchionno, L
   Decugis, D
   Deli, A
   Ambresin, A
   Mantel, I
AF Gianniou, C.
   Dirani, A.
   Ferrini, W.
   Marchionno, L.
   Decugis, D.
   Deli, A.
   Ambresin, A.
   Mantel, I.
TI Two-year outcome of an observe-and-plan regimen for neovascular
   age-related macular degeneration: how to alleviate the clinical burden
   with maintained functional results
SO EYE
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB; DOSING REGIMEN; VERTEPORFIN; EFFICACY;
   THERAPY; SAFETY
AB Purpose The purpose of this study was to report the 2-year outcome of an individually tailored 'observe-and-plan' treatment regimen for neovascular age-related macular degeneration (nAMD), and to investigate its clinical value in terms of functional outcome. This regimen aimed to reduce the clinical burden (visits) by employing individually fixed injection intervals, based on the predictability of an individual's need for retreatment.
   Methods This prospective case series included 104 patients (115 eyes) with nAMD. Following three loading doses of ranibizumab, the disease recurrence interval was determined in monthly observation visits. Retreatment was applied in a series of three injections with individually fixed intervals (2 weeks shorter than the recurrence interval), combined with periodic adjustment of the intervals. The allowed injection intervals in treatment plans ranged from 1 to 3 months. If there was no recurrence at 3 months, the patient could change to monitoring alone.
   Results Mean visual acuity (VA) improved by 8.7, 9.7, and 9.2 letters at months 3, 12, and 24, respectively. The mean number of injections was 7.8 and 5.8 during years 1 and 2, respectively, whereas the mean number of ophthalmic examinations was 4.0 and 2.9, respectively. The mean treatment interval (after the loading doses) was 2.0 months during year 1, and 2.2 months during year 2.
   Conclusion The observe-and-plan regimen significantly improved and maintained VA over the course of 2 years. This favourable functional outcome was achieved with fewer clinic visits compared with other regimens. Therefore, this observe-and-plan regimen has the potential to alleviate the clinical burden of nAMD treatment.
C1 [Gianniou, C.; Dirani, A.; Ferrini, W.; Marchionno, L.; Decugis, D.; Deli, A.; Ambresin, A.; Mantel, I.] Univ Lausanne, Fdn Asile Aveugles, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, Dept Ophthalmol, 15 Ave France,Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerding H, 2014, KLIN MONATSBL AUGENH, V231, P427, DOI 10.1055/s-0034-1368241
   Gerding H, 2010, KLIN MONATSBL AUGENH, V227, P294, DOI 10.1055/s-0029-1245209
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Han DP, 2013, JAMA OPHTHALMOL, V131, P1124, DOI 10.1001/jamaophthalmol.2013.432
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Tschuor P, 2013, GRAEF ARCH CLIN EXP, V251, P2327, DOI 10.1007/s00417-013-2332-5
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
NR 28
TC 28
Z9 28
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2015
VL 29
IS 3
BP 342
EP 349
DI 10.1038/eye.2014.258
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD2CB
UT WOS:000350880300006
PM 25359289
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Too, LK
   Hunt, N
   Simunovic, MP
AF Too, Lay Khoon
   Hunt, Nicholas
   Simunovic, Matthew P.
TI The Role of Inflammation and Infection in Age-Related Neurodegenerative
   Diseases: Lessons From Bacterial Meningitis Applied to Alzheimer Disease
   and Age-Related Macular Degeneration
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE infection; neuroinflammation; neurodegenerative disease; Alzheimer
   disease; bacterial meningitis; age-related macular degeneration
ID CHLAMYDIA-PNEUMONIAE INFECTION; COGNITIVELY NORMAL INDIVIDUALS; CYTOKINE
   INTERFERON-GAMMA; SIMPLEX-VIRUS TYPE-1; COMPLEMENT-SYSTEM;
   CONTROLLED-TRIAL; RISK-FACTORS; ACTIVATION; BETA; NEUROINFLAMMATION
AB Age-related neurodegenerative diseases, such as Alzheimer disease (AD) and age-related macular degeneration (AMD), are multifactorial and have diverse genetic and environmental risk factors. Despite the complex nature of the diseases, there is long-standing, and growing, evidence linking microbial infection to the development of AD dementia, which we summarize in this article. Also, we highlight emerging research findings that support a role for parainfection in the pathophysiology of AMD, a disease of the neurosensory retina that has been shown to share risk factors and pathological features with AD. Acute neurological infections, such as Bacterial Meningitis (BM), trigger inflammatory events that permanently change how the brain functions, leading to lasting cognitive impairment. Neuroinflammation likewise is a known pathological event that occurs in the early stages of chronic age-related neurodegenerative diseases AD and AMD and might be triggered as a parainfectious event. To date, at least 16 microbial pathogens have been linked to the development of AD; on the other hand, investigation of a microbe-AMD relationship is in its infancy. This mini-review article provides a synthesis of existing evidence indicating a contribution of parainfection in the aetiology of AD and of emerging findings that support a similar process in AMD. Subsequently, it describes the major immunopathological mechanisms that are common to BM and AD/AMD. Together, this evidence leads to our proposal that both AD and AMD may have an infectious aetiology that operates through a dysregulated inflammatory response, leading to deleterious outcomes. Last, it draws fresh insights from the existing literature about potential therapeutic options for BM that might alleviate neurological disruption associated with infections, and which could, by extension, be explored in the context of AD and AMD.
C1 [Too, Lay Khoon; Hunt, Nicholas; Simunovic, Matthew P.] Univ Sydney, Save Sight Inst, Fac Med & Hlth, Sydney, NSW, Australia.
   [Too, Lay Khoon] Univ Sydney, Fac Med & Hlth, Discipline Pathol, Sydney, NSW, Australia.
   [Simunovic, Matthew P.] Sydney Eye Hosp, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney
RP Too, LK (通讯作者)，Univ Sydney, Save Sight Inst, Fac Med & Hlth, Sydney, NSW, Australia.; Too, LK (通讯作者)，Univ Sydney, Fac Med & Hlth, Discipline Pathol, Sydney, NSW, Australia.
EM laykhoon.too@sydney.edu.au
OI Simunovic, Matthew/0000-0003-0596-1356
CR Abbott A, 2005, NATURE, V437, P801, DOI 10.1038/437801a
   Afarid M, 2019, J RES MED SCI, V24, DOI 10.4103/jrms.JRMS_363_18
   Ahmed Niyaz, 2005, Ann Clin Microbiol Antimicrob, V4, P17, DOI 10.1186/1476-0711-4-17
   Ala TA, 2004, J ALZHEIMERS DIS, V6, P503
   Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Arjunan P, 2021, INT REV IMMUNOL, V40, P409, DOI 10.1080/08830185.2020.1845330
   Ashraf GM, 2019, MOL NEUROBIOL, V56, P4479, DOI 10.1007/s12035-018-1388-y
   Balin BJ, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00302
   Barichello T, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/371465
   Bewersdorf JP, 2018, CURR OPIN INFECT DIS, V31, P85, DOI 10.1097/QCO.0000000000000416
   Bonda DJ, 2010, NEUROPHARMACOLOGY, V59, P290, DOI 10.1016/j.neuropharm.2010.04.005
   Braun BJ, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-11
   Brouwer MC, 2010, CLIN MICROBIOL REV, V23, P467, DOI 10.1128/CMR.00070-09
   Browne TC, 2013, J IMMUNOL, V190, P2241, DOI 10.4049/jimmunol.1200947
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen T, 2015, J ORAL MICROBIOL, V7, DOI 10.3402/jom.v7.29008
   Chen XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103466
   Chetelat G, 2013, NEUROIMAGE-CLIN, V2, P356, DOI 10.1016/j.nicl.2013.02.006
   Coutinho LG, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-326
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR246, DOI 10.1093/hmg/ddx343
   Domingues C, 2017, CURR ALZHEIMER RES, V14, P870, DOI 10.2174/1567205014666170317113606
   Eikelenboom P, 2000, ALZ DIS ASSOC DIS, V14, pS54, DOI 10.1097/00002093-200000001-00009
   Fagan AM, 2009, EMBO MOL MED, V1, P371, DOI 10.1002/emmm.200900048
   Silva MVF, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0524-y
   Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2
   Fierz W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01314
   Fischer-Smith Tracy, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010239
   Floyd JL, 2020, OPHTHALMOL THER, V9, P499, DOI 10.1007/s40123-020-00278-2
   Fong IW, 2009, CURR CARDIOL REV, V5, P87, DOI 10.2174/157340309788166679
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Franceschi C, 2017, TRENDS ENDOCRIN MET, V28, P199, DOI 10.1016/j.tem.2016.09.005
   Fulop T, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00224
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geldhoff M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-358
   Haas P, 2009, EYE, V23, P2228, DOI 10.1038/eye.2008.422
   Hensley K, 2010, J ALZHEIMERS DIS, V21, P1, DOI 10.3233/JAD-2010-1414
   Hoffmann M, 2009, J ALZHEIMERS DIS, V16, P517, DOI 10.3233/JAD-2009-0985
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Itzhaki RF, 1997, LANCET, V349, P241, DOI 10.1016/S0140-6736(96)10149-5
   Itzhaki RF, 2020, NAT REV NEUROL, V16, P193, DOI 10.1038/s41582-020-0323-9
   Itzhaki RF, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00324
   Jevtic S, 2017, AGEING RES REV, V40, P84, DOI 10.1016/j.arr.2017.08.005
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kasanmoentalib ES, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1675-1
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Kenney Kimbra, 2018, Brain Inj, V32, P1276, DOI 10.1080/02699052.2018.1483530
   Khademi F, 2019, ARCH MED SCI, V15, P902, DOI 10.5114/aoms.2019.85509
   Khandhadia S, 2012, MOL VIS, V18, P29
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Koedel U, 2009, CURR TOP MICROBIOL, V336, P15, DOI 10.1007/978-3-642-00549-7_2
   Komaroff AL, 2020, JAMA-J AM MED ASSOC, V324, P239, DOI 10.1001/jama.2020.4085
   Kong XX, 2017, J NEUROSCI RES, V95, P1565, DOI 10.1002/jnr.24004
   Krance SH, 2021, MOL PSYCHIATR, V26, P5532, DOI 10.1038/s41380-019-0536-8
   Kutty RK, 2018, CYTOKINE, V104, P147, DOI 10.1016/j.cyto.2017.10.009
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Landreth GE, 2009, CURR TOP MICROBIOL, V336, P137, DOI 10.1007/978-3-642-00549-7_8
   Li N, 2010, ACTA BIOL HUNG, V61, P123, DOI 10.1556/ABiol.61.2010.2.1
   Liechti FD, 2015, FUTURE MICROBIOL, V10, P1195, DOI 10.2217/fmb.15.43
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Loeb MB, 2004, J AM GERIATR SOC, V52, P381, DOI 10.1111/j.1532-5415.2004.52109.x
   Mamik MK, 2017, BRAIN, V140, P2273, DOI 10.1093/brain/awx133
   McGeer PL, 2002, TRENDS MOL MED, V8, P519, DOI 10.1016/S1471-4914(02)02422-X
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006
   Miklossy J, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00046
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Moir RD, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00070
   Moir RD, 2018, ALZHEIMERS DEMENT, V14, P1602, DOI 10.1016/j.jalz.2018.06.3040
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Molloy DW, 2013, INT J GERIATR PSYCH, V28, P463, DOI 10.1002/gps.3846
   Mook-Kanamori B, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-71
   Mook-Kanamori BB, 2011, CLIN MICROBIOL REV, V24, P557, DOI 10.1128/CMR.00008-11
   Morris GP, 2018, ACTA NEUROPATHOL, V136, P663, DOI 10.1007/s00401-018-1918-8
   Nockher WA, 1999, J NEUROIMMUNOL, V101, P161, DOI 10.1016/S0165-5728(99)00141-1
   O'Bryant SE, 2010, J GERIATR PSYCH NEUR, V23, P49, DOI 10.1177/0891988709351832
   Oxford Alexandra E, 2020, Int J Alzheimers Dis, V2020, P5380346, DOI 10.1155/2020/5380346
   Pinter C, 2000, J NEUROVIROL, V6, pS42
   Pisa D, 2015, SCI REP-UK, V5, DOI 10.1038/srep15015
   Polfliet MMJ, 2001, J IMMUNOL, V167, P4644, DOI 10.4049/jimmunol.167.8.4644
   Prasad P L, 2005, Med J Armed Forces India, V61, P13, DOI 10.1016/S0377-1237(05)80110-8
   Price JL, 2009, NEUROBIOL AGING, V30, P1026, DOI 10.1016/j.neurobiolaging.2009.04.002
   Pritchard AB, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00336
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Sjogren M, 2001, NEUROSCI LETT, V314, P33, DOI 10.1016/S0304-3940(01)02285-6
   Sochocka M, 2019, MOL NEUROBIOL, V56, P1841, DOI 10.1007/s12035-018-1188-4
   Sochocka M, 2017, CURR NEUROPHARMACOL, V15, P996, DOI 10.2174/1570159X15666170313122937
   Soscia SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009505
   Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6
   Su F, 2016, NEUROSCI BULL, V32, P469, DOI 10.1007/s12264-016-0055-4
   Tabrah Frank L, 2011, Hawaii Med J, V70, P144
   Thiel A, 2014, STROKE, V45, P2825, DOI 10.1161/STROKEAHA.114.004285
   Thorsdottir S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00576
   Too LK, 2014, BRAIN BEHAV IMMUN, V40, P252, DOI 10.1016/j.bbi.2014.02.020
   Too LK, 2021, NEURAL REGEN RES, V16, P125, DOI 10.4103/1673-5374.286968
   Tooran NC, 2019, MICROB PATHOGENESIS, V137, DOI 10.1016/j.micpath.2019.103751
   Trempe CL, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00205
   Turgut Burak, 2010, J Clin Med Res, V2, P85, DOI 10.4021/jocmr2010.03.282w
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhang DF, 2016, NEUROPSYCHOPHARMACOL, V41, P1034, DOI 10.1038/npp.2015.232
NR 110
TC 5
Z9 5
U1 2
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD MAR 26
PY 2021
VL 15
AR 635486
DI 10.3389/fncel.2021.635486
PG 10
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA RJ9WM
UT WOS:000637957900001
PM 33867940
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Madhusudhana, KC
   Lee, AY
   Keane, PA
   Chakravarthy, U
   Johnston, RL
   Egan, CA
   Sim, D
   Zarranz-Ventura, J
   Tufail, A
   McKibbin, M
AF Madhusudhana, Krishnappa C.
   Lee, Aaron Y.
   Keane, Pearse A.
   Chakravarthy, Usha
   Johnston, Robert L.
   Egan, Catherine A.
   Sim, Dawn
   Zarranz-Ventura, Javier
   Tufail, Adnan
   McKibbin, Martin
CA UK AMD EMR Study Grp
TI UK Neovascular Age-Related Macular Degeneration Database. Report 6: time
   to retreatment after a pause in therapy. Outcomes from 92 976
   intravitreal ranibizumab injections
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEVACIZUMAB
AB Background/aims To study the time to retreatment in eyes with neovascular age-related macular degeneration (nAMD) that had been treatment-free for intervals of 3 months, 6 months, 9 months and 12 months during the maintenance phase of ranibizumab therapy within the UK National Health Service.
   Methods In this multicentre national nAMD database study, structured data were collected from 14 centres (involving 12 951 eyes receiving 92 976 ranibizumab injections). Patients were treated with three fixed, monthly injections in a loading phase of treatment, followed by a pro re nata retreatment regimen in a maintenance phase. Eyes with a treatment-free interval (TFI) of 3 months, 6 months, 9 months or 12 months in the maintenance phase were identified and the time to retreatment after these TFIs was determined.
   Results The time to retreatment for the 20th and 50th centiles was 0.58/2.54 months after a 3-month TFI, 2.07/9.62 months after a 6-month TFI, 3.69/15.84 months after a 9-month TFI and 5.90/22.49 months after a 12-month TFI. Following a TFI of 3 months, 6 months, 9 months and 12 months, 68%, 44%, 31% and 21% of eyes required retreatments after an additional 6 months of follow-up, respectively. Similarly, after 12 months of follow-up, 77%, 56%, 43% and 34% of these eyes required retreatment.
   Conclusions This study provides times to retreatment in eyes with nAMD that have been treatment-free for intervals of 3-12 months and demonstrates the likelihood of repeat therapy within the next year, even after a TFI of 12 months. These outcomes can help plan appropriate follow-up intervals for patients who have been treatment-free for intervals of up to 12 months.
C1 [Madhusudhana, Krishnappa C.] Hull & East Yorkshire Hosp NHS Trust, Med Retina Serv, Kingston Upon Hull, N Humberside, England.
   [Lee, Aaron Y.; Keane, Pearse A.; Egan, Catherine A.; Sim, Dawn; Zarranz-Ventura, Javier; Tufail, Adnan] UCL, Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Lee, Aaron Y.; Keane, Pearse A.; Egan, Catherine A.; Sim, Dawn; Zarranz-Ventura, Javier; Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Lee, Aaron Y.; Keane, Pearse A.; Egan, Catherine A.; Sim, Dawn; Zarranz-Ventura, Javier; Tufail, Adnan] Moorfields Eye Hosp NHS Fdn Trust, Med Retina Serv, London, England.
   [Lee, Aaron Y.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vasc & Vis Sci, Belfast, Antrim, North Ireland.
   [Johnston, Robert L.; Zarranz-Ventura, Javier] Gloucestershire Hosp NHS Fdn Trust, Cheltenham Gen Hosp, Med Retina Serv, Cheltenham, Glos, England.
   [McKibbin, Martin] Leeds Teaching Hosp NHS Trust, St Jamess Univ Hosp, Eye Clin, Leeds, W Yorkshire, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Washington; University of Washington
   Seattle; Queens University Belfast; Gloucestershire Hospitals NHS
   Foundation Trust; Cheltenham General Hospital; Saint James's University
   Hospital; University of Leeds
RP McKibbin, M (通讯作者)，St James Univ Hosp, Eye Clin, Beckett St, Leeds LS9 7TF, W Yorkshire, England.
EM Martin.McKibbin@nhs.net
RI Keane, Pearse/AAE-5709-2019; Zarranz-Ventura, Javier/AAB-5390-2021; Lee,
   Aaron/AAT-2839-2020
OI Keane, Pearse/0000-0002-9239-745X; Zarranz-Ventura,
   Javier/0000-0003-2338-8143; Bunce, Catey/0000-0002-0935-3713;
   Chakravarthy, Usha/0000-0002-2606-3734; Egan,
   Catherine/0000-0001-5593-1169; Tufail, Adnan/0000-0001-6131-7640; Lee,
   Aaron/0000-0002-7452-1648; McKibbin, Martin/0000-0003-4388-243X
FU Novartis Pharmaceuticals UK Limited, Frimley, UK; National Institute for
   Health Research [CS-2014-14-023, CL-2010-18-004] Funding Source:
   researchfish
FX Supported in part by an unrestricted grant from Novartis Pharmaceuticals
   UK Limited, Frimley, UK.
CR [Anonymous], 2013, AGE RELATED MACULAR
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 17
TC 15
Z9 15
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2016
VL 100
IS 12
BP 1617
EP 1622
DI 10.1136/bjophthalmol-2015-308077
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC7XD
UT WOS:000388353500006
PM 27030276
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Staurenghi, G
   Bandello, F
   Viola, F
   Varano, M
   Barbati, G
   Peruzzi, E
   Bassanini, S
   Biancotto, C
   Fenicia, V
   Furino, C
   Vadala, M
   Reibaldi, M
   Vujosevic, S
   Ricci, F
AF Staurenghi, Giovanni
   Bandello, Francesco
   Viola, Francesco
   Varano, Monica
   Barbati, Giulia
   Peruzzi, Elena
   Bassanini, Stefania
   Biancotto, Chiara
   Fenicia, Vito
   Furino, Claudio
   Vadala, Maria
   Reibaldi, Michele
   Vujosevic, Stela
   Ricci, Federico
CA EAGLE Study Investigators
TI Effectiveness of anti-vascular endothelial growth factors in neovascular
   age-related macular degeneration and variables associated with visual
   acuity outcomes: Results from the EAGLE study
SO PLOS ONE
LA English
DT Article
ID RANIBIZUMAB; MANAGEMENT; THERAPY; EYES
AB Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naive patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting.
   Study design EAGLE was a retrospective, 2-year, cohort observational, multicenter study conducted in Italy that analyzed secondary data of treatment-naive patients with nAMD. The primary endpoint evaluated the mean annualized number of anti-VEGF injections at Years 1 and 2. The main secondary endpoints analyzed the mean change in visual acuity (VA) from baseline and variables associated with visual outcomes at Years 1 and 2.
   Results Of the 752 patients enrolled, 745 (99.07%) received the first dose of anti-VEGF in 2016. Overall, 429 (57.05%) and 335 (44.5%) patients completed the 1- and 2-year follow-ups, respectively. At baseline, mean (standard deviation, SD) age was 75.6 (8.8) years and the mean (SD) VA was 53.43 (22.8) letters. The mean (SD) number of injections performed over the 2 years was 8.2 (4.1) resulting in a mean (SD) change in VA of 2.45 (19.36) (P = 0.0005) letters at Year 1 and -1.34 (20.85) (P = 0.3984) letters at Year 2. Linear regression models showed that age, baseline VA, number of injections, and early fluid resolution were the variables independently associated with visual outcomes at Years 1 and 2.
   Conclusions The EAGLE study analyzed the routine clinical practice management of patients with nAMD in Italy. The study suggested that visual outcomes in clinical practice may be improved with earlier diagnosis, higher number of injections, and accurate fluid resolution targeting during treatment induction.
C1 [Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Bandello, Francesco] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Milan, Italy.
   [Viola, Francesco] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.
   [Varano, Monica] IRCCS Fdn Bietti, Rome, Italy.
   [Barbati, Giulia] Univ Trieste, Dept Med Sci, Biostat Unit, Trieste, Italy.
   [Peruzzi, Elena; Bassanini, Stefania; Biancotto, Chiara] Novartis Farma SpA, Origgio, VA, Italy.
   [Fenicia, Vito] Univ Roma La Sapienza, S Andrea Hosp, Fac Med & Psychol, Ophthalmol Unit,NESMOS Dept, Rome, Italy.
   [Furino, Claudio] Azienda Osped Univ Policlin Consorziale Bari, Dept Med Sci Neurosci & Sense Organs, Eye Clin, Bari, Italy.
   [Vadala, Maria] Univ Palermo, Unit Ophthalmol, Biomed Neurosci & Adv Diagnost Dept, Palermo, Italy.
   [Reibaldi, Michele] Univ Torino, Dept Surg Sci, Turin, Italy.
   [Vujosevic, Stela] IRCCS MultiMed, Eye Clin, Milan, Italy.
   [Ricci, Federico] Tor Vergata Univ, Dept Expt Med, Viale Oxford, Rome, Italy.
C3 University of Milan; Luigi Sacco Hospital; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; IRCCS Ca Granda Ospedale
   Maggiore Policlinico; University of Milan; IRCCS - Fondazione "G.B.
   Bietti" per lo Studio e la Ricerca in Oftalmologia; University of
   Trieste; Novartis; Sapienza University Rome; Azienda Ospedaliera
   Sant'Andrea; University of Palermo; University of Turin; IRCCS
   Multimedica; University of Rome Tor Vergata
RP Staurenghi, G (通讯作者)，Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
EM giovanni.staurenghi@unimi.it
RI Barbati, Giulia/N-8418-2014; Staurenghi, Giovanni/K-4388-2017
OI Barbati, Giulia/0000-0001-8942-5686; Vujosevic,
   Stela/0000-0001-6773-9967; VADALA', Maria/0000-0002-2726-698X;
   Staurenghi, Giovanni/0000-0002-2299-5251; Varano,
   Monica/0000-0002-6530-1563
FU Novartis Farma S.p.A, Origgio, Italy
FX This study was funded by Novartis Farma S.p.A, Origgio, Italy. Elena
   Peruzzi (EP), Stefania Bassanini (SB) and Chiara Biancotto (CB) are
   employees of Novartis Farma S.p.A., Origgio, Italy. The funder provided
   support in the form of salaries for authors [CB,EP,SB]. The sponsor had
   a role in the study design, study conduction, data collection, data
   analysis, data interpretation and manuscript preparation. Additionally,
   Novartis Farma S.p.A was responsible for the conduct of the study and
   oversight of the collection and management of data. The specific roles
   of the authors employed by Novartis Farma are articulated in the 'author
   contributions' section.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Moshfeghi DM, 2016, OSLI RETINA, V47, P238, DOI 10.3928/23258160-20160229-06
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sagkriotis A, 2021, CONTEMP CLIN TRIALS, V104, DOI 10.1016/j.cct.2021.106364
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spooner KL, 2020, OPHTHALMOLOGY, V127, P1663, DOI 10.1016/j.ophtha.2020.06.019
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 29
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 1
PY 2021
VL 16
IS 9
AR e0256461
DI 10.1371/journal.pone.0256461
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WG6OB
UT WOS:000707112500028
PM 34469431
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sanabria, MR
   Alonso-Tarancon, AM
   Calles-Monar, PS
   Ibanez, P
   de Arriba, SG
   Alvarez, N
   Pinuel, JA
   Coco, RM
   Fernandez, I
AF Sanabria, Maria R.
   Alonso-Tarancon, Ana M.
   Calles-Monar, Paola S.
   Ibanez, Patricia
   Garcia de Arriba, Santiago
   Alvarez, Nuria
   Pinuel, Jesus A.
   Coco, Rosa M.
   Fernandez, Itziar
TI Silicone microbubbles after anti-vascular endothelial growth factor
   injections in patients with wet age-related macular degeneration:
   incidence, quantification and secondary optical coherence tomography
   artfacts
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; intravitreal injections; macular
   degenerations; OCT artfacts; silicone microbubbles; wet
ID OIL DROPLETS; INTRAVITREAL; BEVACIZUMAB
AB Purpose To report the incidence and quantity of silicone oil microbubbles and the relationship with the number of intravitreal anti-vascular endothelial growth factor (VEGF) injections and evaluate if microbubbles induce artefacts on optical coherence tomography (OCT) images.
   Methods Observational, descriptive, cross-sectional study. Patients with wet age-related macular degeneration were included who had been treated for 1 year minimally with anti-VEGF injections repackaged in the hospital pharmacy. Detection and quantification of silicone microbubbles by mydriatic biomicroscopic examination were conducted 1 month after the last injection. The numbers of microbubbles were quantified on a scale of 0-3: 0, none; 1 scarce (1-10 microbubbles); 2 moderate (10-30); or 3 numerous (>30). Shadowing on OCT images was classified as 0-3: 0, none; 1 obscuring some retinal layers; 2 obscuring all retinal layers; or 3 obscuring the retinal thickness.
   Results The study included 142 eyes of 98 patients (mean age, 82.4 years + 7.3; range, 65-97) treated with 2377 injections. Microbubbles were detected in 127 (89.4%) eyes, 62 (43.6%) with numerous microbubbles and 36 (25.4%) and 29 (20.4%), respectively, with scarce and moderate numbers. A positive correlation was found between the numbers of injections and intravitreal silicone (rho, 0.7). Optical coherence tomography (OCT) artefacts were detected in 11 eyes; the artefacts obscured all retinal layers in three eyes. No significant relationship could be established between the appearance of floaters and the microbubbles.
   Conclusion The presence and number of silicone microbubbles were correlated with the number of intravitreal injections. Microbubbles can produce OCT artefacts, which can hinder the treatment decision.
C1 [Sanabria, Maria R.; Alonso-Tarancon, Ana M.; Calles-Monar, Paola S.; Ibanez, Patricia; Garcia de Arriba, Santiago; Alvarez, Nuria; Pinuel, Jesus A.] Palencia Univ Hosp Complex, Palencia, Spain.
   [Sanabria, Maria R.; Coco, Rosa M.; Fernandez, Itziar] Univ Valladolid, Inst Appl Ophthalmobiol, Valladolid, Spain.
   [Coco, Rosa M.] Carlos III Hlth Inst, OFTARED Hlth Res Themat Network, Madrid, Spain.
   [Fernandez, Itziar] Univ Valladolid, Dept Stat, Valladolid, Spain.
C3 Universidad de Valladolid; Universidad de Valladolid
RP Sanabria, MR (通讯作者)，San Telmo Hosp, Palencia Univ Hosp Complex, Dept Ophthalmol, Palencia 34004, Spain.
EM msanabria@saludcastillayleon.es
RI Martin, Rosa Maria Coco/H-4511-2015
OI Martin, Rosa Maria Coco/0000-0002-1811-1417; Calles Monar, Paola
   Stefania/0000-0002-3749-3609; Sanabria, Maria Rosa/0000-0002-1818-9812
FU Castilla-Leon Regional Health Management [GRS/2109/A/19]
FX This research was supported by a grant from Castilla-Leon Regional
   Health Management GRS/2109/A/19.
CR Avery Robert L, 2019, Retin Cases Brief Rep, V13, P130, DOI 10.1097/ICB.0000000000000570
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Dias CD, 2020, EYE, V34, P2242, DOI 10.1038/s41433-020-0800-9
   Emerson GG., 2017, J VITREORETIN DIS, V1, P401, DOI [10.1177/2474126417735963, DOI 10.1177/2474126417735963]
   Fernandez-Avellaneda P, 2019, OPHTHALMOL RETINA, V3, P866, DOI 10.1016/j.oret.2019.05.024
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Gerhardt A, 2015, J PHARM SCI-US, V104, P1601, DOI 10.1002/jps.24387
   Kennelly KP, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0003-5
   Khurana RN, 2017, JAMA OPHTHALMOL, V135, P800, DOI 10.1001/jamaophthalmol.2017.1815
   Krayukhina E, 2015, J PHARM SCI-US, V104, P527, DOI 10.1002/jps.24184
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Melo GB, 2019, INT J RETIN VITR, V5, P34, DOI [10.1186/s40942-019-0184-9, DOI 10.1186/S40942-019-0184-9]
   Melo GB, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100862
   Melo GB, 2020, BRIT J OPHTHALMOL, V104, P291, DOI 10.1136/bjophthalmol-2019-313823
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Olea JL, 2020, EUR J OPHTHALMOL, V30, P774, DOI 10.1177/1120672118823133
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Sassalos TM, 2019, CLIN OPHTHALMOL, V13, P701, DOI 10.2147/OPTH.S169044
   Schargus M, 2020, CLIN OPHTHALMOL, V14, P897, DOI 10.2147/OPTH.S207978
   Scott IU, 2009, AM J OPHTHALMOL, V148, P725, DOI 10.1016/j.ajo.2009.06.004
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
NR 24
TC 1
Z9 1
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2021
VL 99
IS 7
BP E1051
EP E1055
DI 10.1111/aos.14743
EA JAN 2021
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WD6YR
UT WOS:000606001700001
PM 33421336
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Patra, S
   DaCosta, J
   Adewoyin, T
   Shona, O
   Pearce, E
   Chong, NV
AF Sivaprasad, S.
   Patra, S.
   DaCosta, J.
   Adewoyin, T.
   Shona, O.
   Pearce, E.
   Chong, N. V.
TI A Pilot Study on the Combination Treatment of Reduced-Fluence
   Photodynamic Therapy, Intravitreal Ranibizumab, Intravitreal
   Dexamethasone and Oral Minocycline for Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Verteporfin; Ranibizumab; Dexamethasone; Minocycline; Macular
   degeneration; Choroidal neovascularisation
ID CHOROIDAL NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE; OXIDATIVE STRESS;
   TRIPLE THERAPY; VERTEPORFIN; VEGF; PATHOGENESIS; EXPRESSION; INJECTION;
   PDT
AB Aim: To assess the safety and efficacy of the combined treatment of reduced-fluence verteporfin photodynamic therapy (PDT), intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD). Methods: Nineteen patients with subfoveal CNV secondary to AMD were recruited into the trial. All study eyes (n = 19) received a single cycle of reduced-fluence (25 mJ/cm(2)) PDT with verteporfin followed by an intravitreal injection of ranibizumab 0.3 mg/0.05 ml and dexamethasone 200 mu g at baseline. Oral minocycline 100 mg daily was started the following day and continued for 3 months. Patients were followed up monthly for 12 months. Repeat intravitreal ranibizumab was given if best-corrected visual acuity (BCVA) deteriorated by >5 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or central retinal thickness (CRT) on ocular coherence tomography increased >100 mu m. Results: Eighteen patients completed the 12-month study. Stable vision (loss of <= 15 ETDRS letters) was maintained in 89% eyes (16/18). The mean change in BCVA was -5.0 +/- 10.5 ETDRS letters. The mean number of ranibizumab injections was 3.4 (range 2-6). The mean reduction in the CRT was 66.3 mu m (+/-75). Conclusion: This open-label clinical trial has demonstrated the safety in terms of adverse effects and maintenance of stable vision of combination treatment with verteporfin, ranibizumab, dexamethasone and minocycline in exudative AMD. However, the outcomes with reduced-fluence PDT combination therapy does not differ significantly with outcomes of clinical trials on combination treatment with standard dose PDT and intravitreal ranibizumab in neovascular AMD. Copyright (C) 2011 S. Karger AG, Basel
C1 [Sivaprasad, S.] Kings Coll Hosp London, Laser & Retinal Res Unit, Dept Ophthalmol, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Laser & Retinal Res Unit, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Chong, Victor/Q-6565-2018; Sivaprasad, S./D-6876-2015
OI Chong, Victor/0000-0002-7693-522X; Sivaprasad, S./0000-0001-8952-0659
FU Novartis UK; Novartis; Allergan; Pfizer; Merck; Alcon; Bayer
FX Investigator-initiated research was funded by Novartis UK.; S.
   Sivaprasad has received research funds and travel grants, and is a
   consultant of Novartis, Allergan and Pfizer. N.V. Chong has received
   travel grants and research funds, and is a consultant of Novartis,
   Allergan, Pfizer, Merck, Alcon and Bayer.
CR Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   BAILEY CC, 2009, ARVO M APR 11, V50, P1905
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen FP, 2006, EUR J PHARMACOL, V536, P287, DOI 10.1016/j.ejphar.2006.03.011
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462, DOI 10.1177/112067210501500407
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Langevitz P, 2000, DRUG SAFETY, V22, P405, DOI 10.2165/00002018-200022050-00007
   Leung DW, 2007, INVEST OPHTH VIS SCI, V48, P412, DOI 10.1167/iovs.06-0522
   *LUC, EU106374001 LUC
   McConnell V, 2005, Ulster Med J, V74, P82
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062
   *NICE TECHN APPR G, 2008, 155 NICE TECHN APPR
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Pross C, 2002, J SURG RES, V102, P57, DOI 10.1006/jsre.2001.6220
   *RAN, 2008, CLIN GUID COMM CONT
   Rhee DJ, 2006, BRIT J OPHTHALMOL, V90, P999, DOI 10.1136/bjo.2006.090340
   Rosenfeld P, 2004, INVEST OPHTH VIS SCI, V45, pU904
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   SLAKTER JS, 2007, INVEST OPHTHALMOL VI, V48
   Song XZ, 2008, INT J MOL MED, V22, P9
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278
   Wu WS, 2006, J INVEST DERMATOL, V126, P1264, DOI 10.1038/sj.jid.5700274
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   2007, P NATL ACAD SCI US, V104, P967
NR 36
TC 10
Z9 13
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 4
BP 200
EP 206
DI 10.1159/000322363
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749YO
UT WOS:000289508200003
PM 21293163
DA 2022-11-30
ER

PT J
AU Cui, Z
   Zhou, W
   Chang, QX
   Zhang, TT
   Wang, H
   Meng, XD
   Liu, YY
   Yan, H
AF Cui, Zhuang
   Zhou, Wei
   Chang, Qinxue
   Zhang, Tiantian
   Wang, Hui
   Meng, Xiangda
   Liu, Yuanyuan
   Yan, Hua
TI Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular
   Degeneration, Diabetic Macular Edema, and Pathological Myopia:
   Population-Based Cohort Study and Markov Model
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE age-related macular degeneration (AMD); diabetic macular edema (DME);
   pathological myopia (PM); ranibizumab; conbercept; cost-effectiveness;
   Markov model
ID VISUAL-ACUITY OUTCOMES; REAL-WORLD OUTCOMES; CHOROIDAL
   NEOVASCULARIZATION; GLOBAL PREVALENCE; INTRAVITREAL RANIBIZUMAB; DISEASE
   BURDEN; AFLIBERCEPT; RETINOPATHY; SAFETY; EPIDEMIOLOGY
AB Background: With the advent of aging society of China, fundus diseases related to pathological neovascularization, including age-related macular degeneration (AMD), diabetic macular edema (DME), and pathological myopia (PM), have become an increasingly serious medical and health problems. As effective drugs of the treatment, conbercept and ranibizumab have been commonly used and covered by the national basic medical insurance in China. However, the pharmacoeconomic evaluation of conbercept vs. ranibizumab for DME and PM remains lacking. This study would assess the cost-effectiveness of conbercept and ranibizumab for the treatment of AMD, DME, and PM from the perspective of Chinese payers.Methods: A Markov chain model was constructed based on the visual conditions of the patient indicated by the number of letters in best corrected visual acuity (BCVA). We conducted models based on real-world scenario to calculate the cost per the quality-adjusted life-year (QALY) gained. A 1-year cycle length and a 10-year simulation treatment were applied and the number of injections of conbercept and ranibizumab was assumed to the average number within 10 years. Transition probabilities, costs, utility data, and other parameters were obtained from literature searches. A 3.5% discounting rate was applied for both the costs and utilities.Results: The incremental cost-effectiveness ratios (ICERs) were more favorable for conbercept than ranibizumab in treatment of AMD, DME, and PM, with associated ICER of 66,669 renminbi (RMB), -258,813 RMB, and -373,185 RMB per QALY gained. Compared with ranibizumab, the incremental effectiveness of conbercept in treatment of AMD, DME, and PM was -0.665 QALYs, 0.215 QALYs, and 0.029 QALYs, respectively. The sensitivity analysis showed the same findings, although the ICER is sensitive to the costs of this program.Conclusion: Under the current Chinese healthcare setting, conbercept is suitable and cost-effective in treatment of AMD, DME, and PM compared with ranibizumab.
C1 [Cui, Zhuang; Chang, Qinxue; Zhang, Tiantian; Wang, Hui] Tianjin Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Tianjin, Peoples R China.
   [Zhou, Wei; Meng, Xiangda; Liu, Yuanyuan; Yan, Hua] Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Yan, H (通讯作者)，Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
EM zyyyanhua@tmu.edu.cn
RI liu, yuanyuan/GWZ-5838-2022
OI Chang, Qinxue/0000-0002-1634-9691
FU National Natural Science Foundation of China [82020108007, 81830026];
   Beijing-Tianjin-Hebei Special Project [19JCZDJC64300(Z), 20JCZXJC00180]
FX This study was supported by the National Natural Science Foundation of
   China (Grant Numbers 82020108007 and 81830026) and the
   Beijing-Tianjin-Hebei Special Project (Grant Numbers 19JCZDJC64300(Z)
   and 20JCZXJC00180).
CR Aixia M., 2018, CHINA J PHARM EC, V13, P27, DOI [10.12010/j.issn.1673-5846.2018.09.005, DOI 10.12010/J.ISSN.1673-5846.2018.09.005]
   Alexander M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.11.20
   Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen J., 2017, J CHIN OPHTHALMOL OT, V7, P228, DOI [10.3969/j.issn.1674-9006.2017.04.013, DOI 10.3969/J.ISSN.1674-9006.2017.04.013]
   Chen R, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-1334
   Chen YX, 2019, RETINA-J RET VIT DIS, V39, P1985, DOI 10.1097/IAE.0000000000002292
   Cheng Y, 2021, INT J OPHTHALMOL-CHI, V14, P416, DOI 10.18240/ijo.2021.03.14
   Cheung GCM, 2018, CLIN EXP OPHTHALMOL, V46, P75, DOI 10.1111/ceo.12999
   Choi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201399
   Chua J, 2018, ASIA-PAC J OPHTHALMO, V7, P3, DOI 10.22608/APO.2017511
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Egan C, 2017, BRIT J OPHTHALMOL, V101, P75, DOI 10.1136/bjophthalmol-2016-309313
   El-Dahiyat F, 2020, VALUE HEALTH REG ISS, V22, P23, DOI 10.1016/j.vhri.2019.09.007
   Flood D, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003434
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Gao L, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019007
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Horowitz SA, 2020, INT MED CASE REP J, V13, P27, DOI 10.2147/IMCRJ.S191654
   Hykin P, 2021, HEALTH TECHNOL ASSES, V25, P1, DOI 10.3310/hta25380
   Ibrahim N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167123
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Li FJ, 2018, CURR EYE RES, V43, P218, DOI 10.1080/02713683.2017.1379542
   Li XX, 2019, GRAEF ARCH CLIN EXP, V257, P529, DOI 10.1007/s00417-018-04213-x
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lindner M, 2022, CLIN ORAL INVEST, V26, P505, DOI 10.1007/s00784-021-04028-x
   Liu K, 2022, BRIT J OPHTHALMOL, V106, P1436, DOI 10.1136/bjophthalmol-2020-318690
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Lotery AJ., 2012, EUR OPHTHALMIC REV, V6, P236, DOI [10.17925/EOR.2012.06.04.236, DOI 10.17925/EOR.2012.06.04.236]
   Mitchell P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233595
   Mitry D, 2012, GRAEF ARCH CLIN EXP, V250, P3, DOI 10.1007/s00417-011-1889-0
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Patrao NV, 2016, AM J OPHTHALMOL, V172, P51, DOI 10.1016/j.ajo.2016.09.002
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rathmann W, 2004, DIABETES CARE, V27, P2568, DOI 10.2337/diacare.27.10.2568
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2017, OPHTHALMOLOGICA, V237, P185, DOI 10.1159/000458539
   Sun Z., 2018, RECENT ADV OPHTHALMO, V38, P925, DOI [10.13389/j.cnki.rao.2018.0219, DOI 10.13389/J.CNKI.RAO.2018.0219]
   Tsai MJ, 2019, INT OPHTHALMOL, V39, P1511, DOI 10.1007/s10792-018-0970-7
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Varma R, 2014, JAMA OPHTHALMOL, V132, P1334, DOI 10.1001/jamaophthalmol.2014.2854
   Vos T, 2013, LANCET, V381, P628
   Wang BY, 2018, OBES RES CLIN PRACT, V12, P61, DOI 10.1016/j.orcp.2017.10.005
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu BH, 2019, INT J OPHTHALMOL-CHI, V12, P252, DOI 10.18240/ijo.2019.02.11
   Xu YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0554-8
   Xu YL, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2143082
   Xu YP, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1131-0
   Xuan J., 2019, PHARMACOECONOMICS ST
   Yan M, 2019, ACTA OPHTHALMOL, V97, pE813, DOI 10.1111/aos.13632
   Yang MC, 2017, JPN J OPHTHALMOL, V61, P159, DOI 10.1007/s10384-016-0496-3
   Yu JS, 2021, J MANAG CARE SPEC PH, V27, P743, DOI 10.18553/jmcp.2021.27.6.743
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhao JL, 2014, BIODRUGS, V28, P527, DOI 10.1007/s40259-014-0106-1
   Zhao M, 2015, VALUE HEALTH, V18, pA421, DOI 10.1016/j.jval.2015.09.558
   Ziemssen F, 2018, DIABETES THER, V9, P2271, DOI 10.1007/s13300-018-0513-2
NR 66
TC 1
Z9 1
U1 12
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD DEC 2
PY 2021
VL 8
AR 750132
DI 10.3389/fmed.2021.750132
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XP0NT
UT WOS:000730572300001
PM 34926500
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cui, BH
   Zhou, W
   Wang, WW
   Yang, H
   Dong, YL
   Liu, YY
   Yan, H
AF Cui, Bo-Hao
   Zhou, Wei
   Wang, Wen-Wen
   Yang, Hao
   Dong, Ya-Lan
   Liu, Yuan-Yuan
   Yan, Hua
TI Clinical efficacy of intravitreal corticoid as an adjunctive therapy to
   anti-VEGF treatment of neovascular age-related macular degeneration: a
   Meta-analysis
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; dexamethasone; triamcinolone;
   anti-vascular endothelial growth factor; Meta-analysis
ID ENDOTHELIAL GROWTH-FACTOR; COMBINATION THERAPY; RANIBIZUMAB;
   BEVACIZUMAB; DEXAMETHASONE; TRIAMCINOLONE; PERSISTENT; IMPLANT; EDEMA;
   GLUCOCORTICOIDS
AB AIM: To evaluate the efficacy and safety of intravitreal corticoid as an adjunctive therapy to anti- vascular endothelial growth factor (VEGF) treatment of neovascular age-related macular degeneration (nvAMD).
   METHODS: Four databases including PubMed, Embase, Cochrane Library, and the clinicaltrials.gov were comprehensively searched for studies comparing intravitreal corticoid plus anti-VEGF (IVC/IVA) vs anti-VEGF monotherapy (IVA) in patients with nvAMD. GRADE profiler was used to assess the quality of outcomes. Best-corrected visual acuity (BCVA), central macular thickness (CMT) and adverse events including the occurrence of severe elevation of intraocular pressure (IOP) and the progress of cataract were extracted from the eligible studies. Review Manager (RevMan) 5.3 was used to analyze the data.
   RESULTS: There was no statistic difference of mean change in BCVA at 6 and 12mo between IVC/IVA and IVA group [95% confidence interval (CI): -2.28 to 4.24, P=0.55; 95%CI: -3.01 to 8.70, P=0.34]. No statistic difference was found in the change of CMT between two groups at 6mo time point (95%CI: -17.98 to 16.42, P=0.93) while the CMT reduction in IVC/IVA group was significantly more obvious than IVA group at 12mo time point [ mean difference (MD)=-44.08, 95%CI: -80.52 to -7.63, P=0.02]. The risk of occurrence of severe elevation of IOP in the IVC/IVA group was higher than that in the IVA group (95%CI: 1.92 to 9.48; P=0.0004). Cataract progression risk was calculated no statistic difference between two groups (95%CI: 0.74 to 4.66; P=0.18).
   CONCLUSION: No visual or anatomical benefits are oberved in IVC/IVA group at 6mo. At 12mo, the CMT of the IVC/IVA group is significantly lower than that of the IVA group. Risk of severe elevation of IOP is significantly higher when treated by IVC/IVA.
C1 [Cui, Bo-Hao; Zhou, Wei; Liu, Yuan-Yuan; Yan, Hua] Tianjin Med Univ Gen Hosp, Dept Ophthalmol, Tianjin 300052, Peoples R China.
   [Wang, Wen-Wen] Tianjin Med Univ, Lab Mol Ophthalmol, Tianjin 300070, Peoples R China.
   [Yang, Hao] Tianjin Med Univ, Grad Sch, Tianjin 300070, Peoples R China.
   [Dong, Ya-Lan] Tianjin Med Univ Gen Hosp, Dept Obstet & Gynecol, Tianjin 300052, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University; Tianjin Medical University
RP Yan, H (通讯作者)，Tianjin Med Univ, Dept Ophthalmol, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.
EM zyyyanhua@tmu.edu.cn
RI liu, yuanyuan/GWZ-5838-2022
FU National Natural Science Foundation of China [81830026]; Youth Program
   of National Natural Science Foundation of China [81900883]; Science and
   Technology Support Project of Tianjin [18ZXDBSY00030]
FX Supported by the National Natural Science Foundation of China (No.
   81830026); Youth Program of National Natural Science Foundation of China
   (No.81900883); the Science and Technology Support Project of Tianjin
   (No.18ZXDBSY00030).
CR Ahmadieh H, 2011, RETINA-J RET VIT DIS, V31, P1819, DOI 10.1097/IAE.0b013e31820d58f2
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Broadhead GK, 2015, GRAEF ARCH CLIN EXP, V253, P979, DOI 10.1007/s00417-014-2891-0
   Chaudhary V, 2016, CAN J OPHTHALMOL, V51, P302, DOI 10.1016/j.jcjo.2016.04.020
   Croxtall JD, 2002, BRIT J PHARMACOL, V135, P511, DOI 10.1038/sj.bjp.0704474
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Dang YL, 2014, DRUG DES DEV THER, V8, P1441, DOI 10.2147/DDDT.S66611
   Dibas A, 2016, EUR J PHARMACOL, V787, P57, DOI 10.1016/j.ejphar.2016.06.018
   Flammer JR, 2011, MOL ENDOCRINOL, V25, P1075, DOI 10.1210/me.2011-0068
   Ganapathy PS, 2018, AM J OPHTHALMOL, V194, P63, DOI 10.1016/j.ajo.2018.07.003
   Giancipoli E, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5612342
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   He Y, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0779-1
   Iwami Hisashi, 2011, Osaka City Med J, V57, P49
   Kovacs KD, 2011, RETINA-J RET VIT DIS, V31, P446, DOI 10.1097/IAE.0b013e3181f6391f
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   Lam WC, 2015, CLIN OPHTHALMOL, V9, P1255, DOI 10.2147/OPTH.S80500
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maturi RK, 2018, JAMA OPHTHALMOL, V136, P29, DOI 10.1001/jamaophthalmol.2017.4914
   Maturi RK, 2015, RETINA-J RET VIT DIS, V35, P1604, DOI 10.1097/IAE.0000000000000533
   Mishra S K, 2018, Int J Retina Vitreous, V4, P13, DOI 10.1186/s40942-018-0114-2
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Motarjemizadeh Q, 2018, MIDDLE EAST AFR J OP, V25, P1, DOI 10.4103/meajo.MEAJO_292_16
   Nehme A, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-58
   Rajesh B, 2020, BRIT J OPHTHALMOL, V104, P39, DOI 10.1136/bjophthalmol-2019-313991
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rezar-Dreindl S, 2017, RETINA-J RET VIT DIS, V37, P962, DOI 10.1097/IAE.0000000000001264
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Singer MA, 2012, RETINA-J RET VIT DIS, V32, P1289, DOI 10.1097/IAE.0b013e318242b838
   Tamura H, 2005, INVEST OPHTH VIS SCI, V46, P1440, DOI 10.1167/iovs.04-0905
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 41
TC 0
Z9 0
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUL 18
PY 2021
VL 14
IS 7
BP 1092
EP 1099
DI 10.18240/ijo.2021.07.19
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XD0VC
UT WOS:000722428200019
PM 34282396
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tamura, H
   Akune, Y
   Hiratsuka, Y
   Kawasaki, R
   Kido, A
   Miyake, M
   Goto, R
   Yamada, M
AF Tamura, Hiroshi
   Akune, Yoko
   Hiratsuka, Yoshimune
   Kawasaki, Ryo
   Kido, Ai
   Miyake, Masahiro
   Goto, Rei
   Yamada, Masakazu
TI Real-world effectiveness of screening programs for age-related macular
   degeneration: amended Japanese specific health checkups and augmented
   screening programs with OCT or AI
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Clinical effectiveness;
   Cost-effectiveness analysis; Markov model; Screening
ID VISUAL IMPAIRMENT; COST-EFFECTIVENESS; 7-YEAR OUTCOMES; RANIBIZUMAB;
   PREVALENCE; BLINDNESS; EYE; POPULATION; SMOKING; HORIZON
AB Purpose To investigate the effectiveness of screening and subsequent intervention for age-related macular degeneration (AMD) in Japan. Study design Best-case-scenario analysis using a Markov model. Methods The clinical effectiveness and cost-effectiveness of screening for AMD were assessed by calculating the reduction proportion of blindness and the incremental cost-effectiveness ratio (ICER). The Markov model simulation began at screening at the age of 40 years and ended at screening at the age of 90 years. The first-eye and second-eye combined model assumed annual state-transition probabilities in the development and treatment of AMD. Data on prevalence, morbidity, transition probability, utility value, and treatment costs were obtained from previously published reports. Sensitivity analysis was performed to assess the influence of the parameters. Results In the base-case analysis, screening for AMD every 5 years, beginning at age 40 years and ending at age 74 years (reflecting the screening ages of the current Japanese legal "Specific Health Checkups") showed a decrease of 40.7% in the total number of blind patients. The screening program reduced the number of blind people more than did the additional AREDS/AREDS2 formula supplement intake. However, the ICER of screening versus no screening was yen 9,846,411/QALY, which was beyond what people were willing to pay (WTP) in Japan. Sensitivity analysis revealed that neither OCT nor AI improved the ICER, but the scenario in which the prevalence of smoking decreased by 30% improved the ICER ( yen 4,655,601/QALY) to the level under the WTP. Conclusions Ophthalmologic screening for AMD is highly effective in reducing blindness but is not cost-effective, as demonstrated by a Markov model based on real-world evidence from Japan.
C1 [Tamura, Hiroshi; Kido, Ai; Miyake, Masahiro] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
   [Tamura, Hiroshi] Kyoto Univ, Ctr Innovat Res & Educ Data Sci, Inst Liberal Arts & Sci, Kyoto, Japan.
   [Akune, Yoko] Keio Univ, Grad Sch Hlth Management, Tokyo, Japan.
   [Hiratsuka, Yoshimune] Juntendo Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Kawasaki, Ryo] Osaka Univ Hosp, Artificial Intelligence Ctr Med Res & Applicat, Suita, Osaka, Japan.
   [Goto, Rei] Keio Univ, Grad Sch Business Adm, Tokyo, Japan.
   [Yamada, Masakazu] Kyorin Univ, Sch Med, Dept Ophthalmol, Mitaka, Tokyo, Japan.
C3 Kyoto University; Kyoto University; Keio University; Juntendo
   University; Osaka University; Keio University; Kyorin University
RP Tamura, H (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.; Tamura, H (通讯作者)，Kyoto Univ, Ctr Innovat Res & Educ Data Sci, Inst Liberal Arts & Sci, Kyoto, Japan.
EM htamura@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732
FU Ministry of Health, Labor and Welfare, Japan [19FA1001]
FX This study was supported by a Grant (19FA1001) from the Ministry of
   Health, Labor and Welfare, Japan.
CR Bank of Japan, 2020, STAND FOR MARK
   Barendregt JJ, 1997, NEW ENGL J MED, V337, P1052, DOI 10.1056/NEJM199710093371506
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown GC, 2020, AM J OPHTHALMOL, V218, P225, DOI 10.1016/j.ajo.2020.05.029
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   Chandra S, 2021, EYE, V35, P409, DOI 10.1038/s41433-020-0851-y
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Cheung R, 2022, EYE, V36, P994, DOI 10.1038/s41433-021-01540-y
   Director-General for Statistics and Information Policy Ministry of Health Labour and Welfare Government of Japan, 2018, ABR LIF TABL JAP 201, P1
   e-Stat (Japanese Government Statistics), 2018, POPULATION ESTIMATES
   Elshout M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0514-3
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Hayashida K, 2010, HEALTH POLICY, V94, P84, DOI 10.1016/j.healthpol.2009.08.007
   Hiratsuka Y, 2021, J EPIDEMIOL, V31, P315, DOI 10.2188/jea.JE20200052
   Ho R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206690
   Holden BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1731, DOI 10.1001/archopht.126.12.1731
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Khalid S, 2018, J DIGIT IMAGING, V31, P464, DOI 10.1007/s10278-017-0038-7
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Ministry of Health Labour and Welfare., 5 NDB OP DAT 2021
   Ministry of Health Labour and Welfare., 2019, CONS RAT SPEC MED CH
   Morizane Y, 2019, JPN J OPHTHALMOL, V63, P26, DOI 10.1007/s10384-018-0623-4
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nakamura M, 2008, POINT GUIDANCE SMOKI
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Obata R, 2018, BRIT J OPHTHALMOL, V102, P1047, DOI 10.1136/bjophthalmol-2016-309980
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Research team on cost-effectiveness evaluation, 2019, GUID PREP COST EFF E
   Rim TH, 2017, BRIT J OPHTHALMOL, V101, P1367, DOI 10.1136/bjophthalmol-2016-309952
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Sasaki M, 2012, ARCH OPHTHALMOL-CHIC, V130, P254, DOI 10.1001/archopthalmol.2011.1368
   Shiroiwa T, 2010, HEALTH ECON, V19, P422, DOI 10.1002/hec.1481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Varma R, 2006, OPHTHALMOLOGY, V113, P1846, DOI 10.1016/j.ophtha.2006.04.028
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Wolff J, 2020, J MED INTERNET RES, V22, DOI 10.2196/16866
   Yanagi Y, 2011, JPN J OPHTHALMOL, V55, P35, DOI 10.1007/s10384-010-0893-y
   Yang JJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1474
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 59
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2022
VL 66
IS 1
BP 19
EP 32
DI 10.1007/s10384-021-00890-0
EA JAN 2022
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YF7XO
UT WOS:000739798800001
PM 34993676
DA 2022-11-30
ER

PT J
AU Souied, EH
   Devin, F
   Mauget-Faysse, M
   Kolar, P
   Wolf-Schnurrbusch, U
   Framme, C
   Gaucher, D
   Querques, G
   Stumpp, MT
   Wolf, S
AF Souied, Eric H.
   Devin, Francois
   Mauget-Faysse, Martine
   Kolar, Petr
   Wolf-Schnurrbusch, Ute
   Framme, Carsten
   Gaucher, David
   Querques, Giuseppe
   Stumpp, Michael T.
   Wolf, Sebastian
CA MP0112 Study Grp
TI Treatment of Exudative Age-Related Macular Degeneration with a Designed
   Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a
   Phase I/II Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; THERAPY; DARPINS; ANCHOR; EYE; EPIDEMIOLOGY
AB PURPOSE: To evaluate the safety, tolerability and bioactivity of ascending doses of MP0112, a designed ankyrin repeat protein (DARPin) that binds with high affinity to vascular endothelial growth factor-A (VEGF-A), in treatment-naive patients with exudative age-related macular degeneration (AMD).
   DESIGN: Phase I/II, open-label, multicenter, dose-escalation study.
   METHODS: Patients were to receive a single intravitreal injection of MP0112 at doses ranging from 0.04 to 3.6 mg and be monitored for 16 weeks for safety, efficacy, pharmacokinetics, and dose response.
   RESULTS: Altogether, 32 patients received a single injection of MP0112. The maximum tolerated dose was 1.0 mg because of a case of endophthalmitis in the 2.0 mg cohort. Drug-related adverse events were reported by 13 (41%) of 32 patients; they included ocular inflammation in 11 patients (7 mild, 4 moderate in severity). Visual acuity scores were stable or improved compared with baseline for >= 4 weeks following injection; both retinal thickness and fluorescein angiography leakage decreased in a dose-dependent manner. Rescue therapy was administered to 20 (91%) of 22 patients who received 0.04-0.4 mg MP0112 compared with 4 of 10 (40%) patients who received 1.0 or 2.0 mg. Of patients in the higher-dose cohorts who did not require rescue treatment, 83% (5/6) maintained reductions in central retinal thickness through week 16.
   CONCLUSIONS: A single injection of 1.0 or 2.0 mg MP0112 resulted in mean decreases in retinal thickness and leakage area despite ocular inflammation. larger-scale studies are warranted to confirm these observations. (C) 2014 The Authors. Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
C1 [Souied, Eric H.; Querques, Giuseppe] Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Devin, Francois] Ctr Ophtalmol Monticelli Paradis, Marseille, France.
   [Mauget-Faysse, Martine] Ctr Ophtalmolog Rabelais, Lyon, France.
   [Kolar, Petr] Masaryk Univ Brno, Univ Hosp Brno, Eye Clin, Brno, Czech Republic.
   [Wolf-Schnurrbusch, Ute] Univ Hosp Bern, Inselspital, Bern Photog Reading Ctr, CH-3010 Bern, Switzerland.
   [Framme, Carsten; Wolf, Sebastian] Univ Hosp Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
   [Gaucher, David] Univ Louis Pasteur, Hop Univ Strasbourg, Nouvel Hop Civil, Serv Ophtalmol, Strasbourg, France.
   [Stumpp, Michael T.] Mol Partners, Zurich, Switzerland.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Masaryk
   University Brno; University Hospital Brno; University of Bern;
   University Hospital of Bern; University of Bern; University Hospital of
   Bern; CHU Strasbourg; UDICE-French Research Universities; Universites de
   Strasbourg Etablissements Associes; Universite de Strasbourg
RP Wolf, S (通讯作者)，Univ Hosp Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
EM Sebastian.Wolf@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Querques,
   Giuseppe/0000-0002-3292-9581; Kolar, Petr/0000-0003-3709-4648
FU Allergan; Bayer; Novartis; Alcon; Molecular Partners; Heidelberg; Thea;
   Bausch Lomb; Heidelberg Engineering; Optos; Molecular Partners AG,
   Zurich, Switzerland
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST, and the following were reported. Dr
   Souied receives consulting fees or honoraria from Allergan, Bayer and
   Novartis and fees for participation in review activities from Allergan,
   Bayer and Novartis and holds board membership with Allergan, Bausch &
   Lomb, Bayer, and Novartis. Travel/accommodation/meeting expenses
   unrelated to activities listed - Allergan, Bayer, Novartis. Dr Devin
   holds board membership with Alcon, Allergan, Bayer, and Novartis;
   consults with Alcon, Allergan, Bayer, Novartis, Ophthotech, and Thea;
   receives payment for lectures, including service on speakers' bureaus,
   from Alcon, Allergan, Bayer, and Novartis; and receives payment for
   development of educational presentations from Alcon, Allergan, Bayer,
   and Novartis. Dr Mauget-Faysse receives consulting fees or honoraria,
   with fees going to the institution, from Molecular Partners and support
   for travel to meetings for the study of other purposes from Molecular
   Partners. Relevant financial activities outside the submitted work
   include board membership in Bayer and Novartis; payment for lectures,
   including service on speakers' bureaus, with fees going to the
   institution; from Bayer, Heidelberg, Novartis, and Thea;
   travel/accommodation/meeting expenses unrelated to activities listed,
   with fees going to the institution from Bayer, Heidelberg, Novartis, and
   Thea. Dr Kolar receives consulting honoraria from Molecular Partners.
   Relevant financial activities outside the submitted work include
   consultancy with Alcon, Bayer, and Novartis and payment for lectures,
   including service on speakers' bureaus, from Alcon, Bayer and Novartis.
   Dr Wolf-Schnurrbusch work under consideration for publication: payment
   for gradings to institution. Dr Framme holds board membership with
   Allergan, Bayer and Novartis, is a consultant for Bayer, and receives
   payment for lectures, including service on speakers' bureaus, from
   Bayer, Heidelberg and Novartis. Dr Gaucher holds board membership in
   Allergan, Bayer and Novartis and receives payment for development of
   educational presentations, with fees going to the institution, from
   Novartis; and receives travel/accommodation/meeting expenses unrelated
   to activities listed from Alcon, Bausch & Lomb, Bayer, and Novartis. Dr
   Querques receives consulting fees or honoraria from Molecular Partners;
   holds board membership in Alimera, Allergan and Bayer; and is a
   consultant to Alcon, Alimera, Allergan, Bayer, Bausch & Lomb, Molecular
   Partners, Novartis, and Ophthotech. Dr Stumpp holds employment, patents
   and stock/stock options in Molecular Partners. Dr Wolf has received a
   grant, with fee to the institution, from Molecular Partners; consulting
   fees or honoraria, with fees to the institution, from Molecular
   Partners; support for travel to meetings for the study of other purposes
   from Molecular Partners; is a board member of EURETINA; receives
   consultancy fees that go to the institution from Allergan, Bayer,
   Heidelberg Engineering, Novartis, and Optos; and receives fees for
   expert testimony, with fees going to the institution, from Bayer.
   Molecular Partners AG, Zurich, Switzerland, provided support for the
   study and participated in study design; conducted the study; and
   provided data collection, management and interpretation. The study is
   registered at ClinicalTrials.gov under the identifier: NCT01086761.
   Conception and design of study (E.S., M.S., S.W.); Analysis and
   interpretation of data (E.S., U.W., C.F., G.Q., M.S., S.W.); Preparation
   of manuscript (E.S.; , M.S., S.W.); Critical revision of manuscript
   (E.S., C.F., G.Q., M.S., S.W.); Final approval of manuscript (E.S.,
   F.D., M.M., P.K., U.W., C.F., DO., G.Q., M.S., S.W.); Data collection
   (U.W., C.F., S.W.); Provision of materials, patients, or resources
   (E.S., F.D., M.M., P.K., U.W., C.F., D.G., G.Q.). The authors thank
   Fiona Powell, Facilitate Ltd, Brighton, UK, for editorial assistance in
   the production of this manuscript.
CR Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Munch RC, 2011, MOL THER, V19, P686, DOI 10.1038/mt.2010.298
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seeger MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037845
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   Theurillat JP, 2010, MODERN PATHOL, V23, P1289, DOI 10.1038/modpathol.2010.103
   Zahnd C, 2010, CANCER RES, V70, P1595, DOI 10.1158/0008-5472.CAN-09-2724
NR 23
TC 61
Z9 65
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2014
VL 158
IS 4
BP 724
EP 732
DI 10.1016/j.ajo.2014.05.037
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ1PI
UT WOS:000342552900010
PM 24907435
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Sodhi, SK
   Pereira, A
   Oakley, JD
   Golding, J
   Trimboli, C
   Russakoff, DB
   Choudhry, N
AF Sodhi, Simrat K.
   Pereira, Austin
   Oakley, Jonathan D.
   Golding, John
   Trimboli, Carmelina
   Russakoff, Daniel B.
   Choudhry, Netan
TI Utilization of deep learning to quantify fluid volume of neovascular
   age-related macular degeneration patients based on swept-source OCT
   imaging: The ONTARIO study
SO PLOS ONE
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; PIGMENT EPITHELIAL DETACHMENT;
   CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; BIOMARKERS; RANIBIZUMAB
AB Purpose
   To evaluate the predictive ability of a deep learning-based algorithm to determine long-term best-corrected distance visual acuity (BCVA) outcomes in neovascular age-related macular degeneration (nARMD) patients using baseline swept-source optical coherence tomography (SS-OCT) and OCT-angiography (OCT-A) data.
   Methods
   In this phase IV, retrospective, proof of concept, single center study, SS-OCT data from 17 previously treated nARMD eyes was used to assess retinal layer thicknesses, as well as quantify intraretinal fluid (IRF), subretinal fluid (SRF), and serous pigment epithelium detachments (PEDs) using a novel deep learning-based, macular fluid segmentation algorithm. Baseline OCT and OCT-A morphological features and fluid measurements were correlated using the Pearson correlation coefficient (PCC) to changes in BCVA from baseline to week 52.
   Results
   Total retinal fluid (IRF, SRF and PED) volume at baseline had the strongest correlation to improvement in BCVA at month 12 (PCC = 0.652, p = 0.005). Fluid was subsequently subcategorized into IRF, SRF and PED, with PED volume having the next highest correlation (PCC = 0.648, p = 0.005) to BCVA improvement. Average total retinal thickness in isolation demonstrated poor correlation (PCC = 0.334, p = 0.189). When two features, mean choroidal neovascular membranes (CNVM) size and total fluid volume, were combined and correlated with visual outcomes, the highest correlation increased to PCC = 0.695 (p = 0.002).
   Conclusions
   In isolation, total fluid volume most closely correlates with change in BCVA values between baseline and week 52. In combination with complimentary information from OCT-A, an improvement in the linear correlation score was observed. Average total retinal thickness provided a lower correlation, and thus provides a lower predictive outcome than alternative metrics assessed. Clinically, a machine-learning approach to analyzing fluid metrics in combination with lesion size may provide an advantage in personalizing therapy and predicting BCVA outcomes at week 52.
C1 [Sodhi, Simrat K.] Univ Cambridge, Sch Clin Med, Cambridge, England.
   [Pereira, Austin; Choudhry, Netan] Univ Toronto, Dept Ophthalmol & Visual Sci, Toronto, ON, Canada.
   [Oakley, Jonathan D.; Russakoff, Daniel B.] Voxeleron LLC, San Francisco, CA USA.
   [Golding, John; Trimboli, Carmelina; Choudhry, Netan] Vitreous Retina Macula Specialists Toronto, Etobicoke, ON, Canada.
   [Choudhry, Netan] Cleveland Clin Canada, Toronto, ON, Canada.
C3 University of Cambridge; University of Toronto; Cleveland Clinic
   Foundation
RP Choudhry, N (通讯作者)，Univ Toronto, Dept Ophthalmol & Visual Sci, Toronto, ON, Canada.; Choudhry, N (通讯作者)，Vitreous Retina Macula Specialists Toronto, Etobicoke, ON, Canada.; Choudhry, N (通讯作者)，Cleveland Clin Canada, Toronto, ON, Canada.
EM netan.choudhry@vrmto.com
OI Oakley, Jonathan/0000-0003-2474-9609; Golding, John/0000-0003-0363-7325;
   Choudhry, Netan/0000-0002-1998-2257
FU National Center for Advancing Translational Sciences of the National
   Institutes of Health [R44TR001890]; Bayer Inc.
FX Research reported in this publication was supported by the National
   Center for Advancing Translational Sciences of the National Institutes
   of Health under Award Number R44TR001890. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. Voxeleron LLC.
   provided support in the form of a salary for authors JDO and DBR. This
   study was also supported by funding from Bayer Inc. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Badrinarayanan V, 2017, IEEE T PATTERN ANAL, V39, P2481, DOI 10.1109/TPAMI.2016.2644615
   Bressler NM, 2019, JAMA OPHTHALMOL, V137, P977, DOI 10.1001/jamaophthalmol.2019.1963
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Cheong KX, 2021, SURV OPHTHALMOL, V66, P68, DOI 10.1016/j.survophthal.2020.05.003
   Giavarina D, 2015, BIOCHEM MEDICA, V25, P141, DOI 10.11613/BM.2015.015
   Guo MY, 2019, ACTA OPHTHALMOL, V97, pE1, DOI 10.1111/aos.13825
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kishi Shoji, 2016, Taiwan J Ophthalmol, V6, P58, DOI 10.1016/j.tjo.2015.09.002
   Klimscha S, 2017, INVEST OPHTH VIS SCI, V58, P4039, DOI 10.1167/iovs.16-20201
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lains I, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100951
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liu XX, 2019, BIOMED OPT EXPRESS, V10, P1601, DOI 10.1364/BOE.10.001601
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Oakley JD, BIORXIV
   Oakley JD, 2014, INVEST OPHTH VIS SCI, V55
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Roberts PK, 2020, JAMA OPHTHALMOL, V138, P945, DOI 10.1001/jamaophthalmol.2020.2457
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Ronneberger O., 2015, LECT NOTES COMPUT S, P234, DOI [10.1007/978-3-319-24574-4_28, DOI 10.1007/978-3-319-24574-4_28]
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Sodhi SK, 2021, INT OPHTHALMOL, P1, DOI [10.1007/s10792-020-01545-8, DOI 10.1007/S10792-020-01545-8]
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Taibouni K, 2019, COMPUT BIOL MED, V114, DOI 10.1016/j.compbiomed.2019.103450
   Told R, 2021, CURR EYE RES, V46, P1002, DOI 10.1080/02713683.2020.1849734
   Tsuji S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57788-z
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 39
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 14
PY 2022
VL 17
IS 2
AR e0262111
DI 10.1371/journal.pone.0262111
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 0U9YZ
UT WOS:000788004500004
PM 35157713
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Corvi, F
   Souied, EH
   Falfoul, Y
   Georges, A
   Jung, C
   Querques, L
   Querques, G
AF Corvi, Federico
   Souied, Eric H.
   Falfoul, Yousra
   Georges, Anouk
   Jung, Camille
   Querques, Lea
   Querques, Giuseppe
TI Pilot evaluation of short-term changes in macular pigment and retinal
   sensitivity in different phenotypes of early age-related macular
   degeneration after carotenoid supplementation
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETICULAR PSEUDODRUSEN; OPTICAL-DENSITY; ADAPTIVE OPTICS; IN-VIVO;
   LUTEIN; ZEAXANTHIN; RISK; DRUSEN; EYES
AB Purpose To investigate the response of carotenoid supplementation in different phenotypes of early age-related macular degeneration (AMD) by measuring macular pigment optical density (MPOD) and retinal sensitivity.
   Methods Consecutive patients with only medium/large drusen and only reticular pseudodrusen (RPD) and age-matched and sex-matched controls were enrolled. At baseline, participants underwent a complete ophthalmological examination including measurement of best-corrected visual acuity (BCVA), MPOD and retinal sensitivity. Patients were put on vitamin supplementation (lutein 10 mg/day, zeaxanthin 2 mg/day) and 3 months later underwent a repeated ophthalmological examination.
   Results Twenty patients with medium/large drusen, 19 with RPD and 15 control subjects were included. At baseline, in controls, mean MPOD and BCVA were significantly higher compared with RPD (p=0.001 and p=0.01) but similar to medium/large drusen (p=0.9 and p=0.4). Mean retinal sensitivity was significantly higher in controls compared with RPD and medium/large drusen (for all p<0.0001). After 3 months of carotenoid supplementation the mean MPOD significantly increased in RPD (p=0.002), thus showing no more difference compared with controls (p=0.3); no significant changes were found in mean retinal sensitivity and BCVA (p=0.3 and p=0.7). Medium/large drusen did not show significant changes on MPOD, retinal sensitivity and BCVA (p=0.5, p=0.7 and p=0.7, respectively).
   Conclusions Patients with early AMD, especially RPD phenotype, show lower macular sensitivity and MPOD than controls. After supplementation, MPOD significantly increased in RPD. These results suggest different pathophysiology for RPD as compared with medium/large drusen and may open new ways to identifying further therapeutic targets in this phenotype of early AMD.
C1 [Corvi, Federico; Souied, Eric H.; Falfoul, Yousra; Georges, Anouk; Querques, Giuseppe] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
   [Corvi, Federico; Querques, Lea; Querques, Giuseppe] Univ Vita Salute, IRCCS, Osped San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Jung, Camille] Ctr Hosp Intercommunal Creteil, Ctr Rech Clin, Ctr Ressources Biol, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI Corvi, Federico/AAD-7691-2021
OI Corvi, Federico/0000-0002-2661-5500; Querques,
   Giuseppe/0000-0002-3292-9581; FALFOUL, YOUSRA/0000-0001-8922-2627; JUNG,
   Camille/0000-0001-8486-8939
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bartlett H, 2010, CLIN EXP OPTOM, V93, P300, DOI 10.1111/j.1444-0938.2010.00499.x
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Howells O, 2013, GRAEF ARCH CLIN EXP, V251, P871, DOI 10.1007/s00417-012-2127-0
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Prado-Cabrero A, 2016, EUR FOOD RES TECHNOL, V242, P599, DOI 10.1007/s00217-015-2569-9
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Sabour-Pickett S, 2014, RETINA-J RET VIT DIS, V34, P1757, DOI 10.1097/IAE.0000000000000174
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
NR 31
TC 9
Z9 9
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2017
VL 101
IS 6
BP 770
EP 773
DI 10.1136/bjophthalmol-2016-309115
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW2ZG
UT WOS:000402363900016
PM 27587715
DA 2022-11-30
ER

PT J
AU Chong, NHV
   Keonin, J
   Luthert, PJ
   Frennesson, CI
   Weingeist, DM
   Wolf, RL
   Mullins, RF
   Hageman, GS
AF Chong, NHV
   Keonin, J
   Luthert, PJ
   Frennesson, CI
   Weingeist, DM
   Wolf, RL
   Mullins, RF
   Hageman, GS
TI Decreased thickness and integrity of the macular elastic layer of
   Bruch's membrane correspond to the distribution of lesions associated
   with age-related macular degeneration
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; CLINICOPATHOLOGICAL CORRELATION; SUBRETINAL
   NEOVASCULARIZATION; LASER PHOTOCOAGULATION; OCULAR HISTOPLASMOSIS;
   MORPHOMETRIC-ANALYSIS; POSTMORTEM EYES; AGING CHANGES
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly. in its severest form, choroidal neovessels breach the macular Bruch's membrane, an extracellular matrix compartment comprised of elastin and collagen laminae, and grow into the retina. We sought to determine whether structural properties of the elastic lamina (EL) correspond to the region of the macula that is predilected. toward degeneration in AMD. Morphometric assessment of the macular and extramacular regions of 121 human donor eyes, with and without AMD, revealed a statistically significant difference in both the integrity (P < 0.0001) and thickness (P < 0.0001) of the EL between the macular and extramacular regions in donors of all ages. The EL was three to six times thinner and two to five times less abundant in the macula than in the periphery. The integrity of the macular EL was significantly lower in donors with early-stage AMD (P = 0.028), active choroidal neovascularization (P = 0.020), and disciform scars (P = 0.003), as compared to unaffected, age-matched controls. EL thickness was significantly lower only in individuals with disciform. scars (P = 0.008). The largest gaps in macular EL integrity were significantly larger in all categories of AMD (each P < 0.0001), as compared to controls. EL integrity, thickness, and gap length in donors with geographic atrophy did not differ from those of controls. These structural properties of the macular EL correspond spatially to the distribution of macular lesions associated with AMD and may help to explain why the macula is more susceptible to degenerative events that occur in this disease.
C1 Univ Iowa, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, Iowa City, IA 52240 USA.
   Kings Coll London, Dept Ophthalmol, London WC2R 2LS, England.
   Moorfields Eye Hosp, London, England.
   Linkoping Univ, Dept Neurosci & Locomot, Div Ophthalmol, Linkoping, Sweden.
   Kings Coll London, Dept Ophthalmol, London WC2R 2LS, England.
C3 University of Iowa; University of London; King's College London;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Linkoping University; University of London; King's
   College London
RP Hageman, GS (通讯作者)，Univ Iowa, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, 11190E PFP,200 Hawkins Dr, Iowa City, IA 52240 USA.
EM gregory-hageman@uiowa.edu
RI Chong, Victor/Q-6565-2018; Chong, Ngaihang V/A-5141-2009; Mullins,
   Robert F/I-6717-2013
OI Chong, Victor/0000-0002-7693-522X; Mullins, Robert/0000-0002-5006-0891;
   Luthert, Philip/0000-0001-7276-6898
FU NATIONAL EYE INSTITUTE [R01EY011515, R03EY014563] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000214, T32AG000214] Funding
   Source: NIH RePORTER; Intramural NIH HHS [Z01 AG000214] Funding Source:
   Medline; NEI NIH HHS [R01 EY011515, EY11515, R03 EY014563, EY014563]
   Funding Source: Medline; NIA NIH HHS [T32 AG000214] Funding Source:
   Medline
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bhagat N, 2002, AGE-RELATED MACULAR DEGENERATION, P67
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonnet M, 1973, Bull Mem Soc Fr Ophtalmol, V86, P353
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   DAVIDSON JM, 1992, ELASTIN REPAIR WOUND
   Dolan B J, 1996, Optom Clin, V5, P55
   ERKKILA H, 1983, ACTA OPHTHALMOL, V61, P589
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   GOLDBERG MF, 1976, INVEST OPHTH VISUAL, V15, P443
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   GUYMER R, 1988, BRUCHS MEMBRANE DRUS, P693
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HENDRICKSON AE, 1984, OPHTHALMOLOGY, V91, P603
   HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603
   Hogan M J, 1967, Trans Ophthalmol Soc U K, V87, P113
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   HOLLENBERG MJ, 1969, CAN J OPHTHALMOLOGY, V4, P296
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KAMEI M, 1997, TIMP 3 ACCUMULATION, P11
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lafaut BA, 2001, GRAEF ARCH CLIN EXP, V239, P5, DOI 10.1007/s004170000224
   LEE S, 2003, INVEST OPHTHALMOL VI, V44
   Lim JI, 1999, SURV OPHTHALMOL, V44, P95, DOI 10.1016/S0039-6257(99)00077-6
   Malthieu D, 1988, Bull Soc Ophtalmol Fr, V88, P645
   MARSHALL J, 1988, AGING BRUCHS MEMBRAN, P669
   Martyn CN, 1997, LANCET, V350, P953, DOI 10.1016/S0140-6736(96)10508-0
   MEREDITH TA, 1977, SURV OPHTHALMOL, V22, P189, DOI 10.1016/0039-6257(77)90055-8
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nackman GB, 1997, SURGERY, V122, P39, DOI 10.1016/S0039-6060(97)90262-2
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Norman P, 2002, CARDIOVASC RES, V55, P369, DOI 10.1016/S0008-6363(02)00444-3
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   OLK RJ, 1984, OPHTHALMOLOGY, V91, P1592
   PARKS WC, 1992, MATRIX, V12, P156, DOI 10.1016/S0934-8832(11)80057-0
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Phipps RP, 2000, P NATL ACAD SCI USA, V97, P6930, DOI 10.1073/pnas.97.13.6930
   POLLACK A, 1986, ARCH OPHTHALMOL-CHIC, V104, P1372, DOI 10.1001/archopht.1986.01050210126039
   QUAGLINO D, 1990, LAB INVEST, V63, P307
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RONCHETTI IP, 1991, J SUBMICR CYTOL PATH, V23, P439
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   RYAN SJ, 1989, RETINA
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shen WY, 2004, ARCH OPHTHALMOL-CHIC, V122, P353, DOI 10.1001/archopht.122.3.353
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   TARKKANEN A, 1967, ACTA OPHTHALMOL, V45, P694
   Tummalapalli CM, 1999, J CELL BIOCHEM, V75, P515, DOI 10.1002/(SICI)1097-4644(19991201)75:3<515::AID-JCB15>3.3.CO;2-3
   UITTO J, 1993, MOL GENETIC MED ASPE, P409
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wong SC, 2003, BRIT J OPHTHALMOL, V87, P796, DOI 10.1136/bjo.87.6.796
   WRAY SH, 1976, INVEST OPHTH VISUAL, V15, P128
   YAMAMOTO T, 1989, BRIT J OPHTHALMOL, V73, P162, DOI 10.1136/bjo.73.3.162
   YAMAMOTO T, 1989, JPN J OPHTHALMOL, V33, P327
   Yoshida T, 2002, OPHTHALMOLOGY, V109, P712, DOI 10.1016/S0161-6420(01)01007-7
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 86
TC 153
Z9 162
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JAN
PY 2005
VL 166
IS 1
BP 241
EP 251
DI 10.1016/S0002-9440(10)62248-1
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 883IN
UT WOS:000226004900022
PM 15632016
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Lim, JI
   Walonker, AF
   Levin, L
   Mahmoud, M
   Sadda, S
   Flaxel, CJ
   Humayun, M
   Dejuan, E
   Labree, L
AF Lim, Jennifer I.
   Walonker, A. Frances
   Levin, Lori
   Mahmoud, Mahmoud
   Sadda, Srinivas
   Flaxel, Christina J.
   Humayun, Mark
   Dejuan, Eugene
   Labree, Laurie
TI One-year results of a pilot study using oral 13-cis retinoic acid as a
   treatment for subfoveal predominantly occult choroidal
   neovascularization in patients with age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE accutane; age-related macular degeneration; predominantly occult
   choroidal neovascularization; 13-cis retinoic acid
ID PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE
   VITREORETINOPATHY; VERTEPORFIN THERAPY; VITAMIN-A; RECEPTOR; EXPRESSION;
   MEMBRANES; FAMILY
AB Purpose: To evaluate the safety and evidence of efficacy for oral 13-cis retinoic acid as a treatment for patients with subfoveal occult choroidal neovascularization (CNV) due to age-related macular degeneration (ARMID).
   Methods: Patients with active, subfoveal occult CNV with no prior treatment of the subfoveal component were eligible for inclusion. Patients received 40 mg of 13-cis retinoic acid twice daily for 5 months, stopped treatment for 2 months, and then resumed treatment for 5 months. Patients were observed monthly with Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA), clinical examination, fluorescein angiography, and laboratory testing.
   Results: Eleven patients, aged 64 to 88 years, were enrolled and followed for 1 year. Initial VA ranged from 55 (20/40) to 5 (20/400) ETDRS letters (median 48 letters). Mild drug-related side effects (dry skin, chapped lips) occurred in all 11 patients. Three patients experienced more severe side effects (muscle aches, mood swings) and did not resume treatment after the drug holiday. Moderate VA loss occurred in 36% at both 6 and 12 months.
   Conclusions: Oral 13-cis retinoic acid is too toxic to be useful in patients with ARMD. Oral 13-cis retinoic acid did not improve vision although it may have slowed visual acuity loss in patients with ARMD with occult subfoveal CNV.
C1 Univ So Calif, Doheny Retina Inst, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA 90033 USA.
   Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Southern California
RP Lim, JI (通讯作者)，1450 San Pablo St 3612, Los Angeles, CA 90033 USA.
EM jennifil@usc.edu
FU NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY03040] Funding Source: Medline
CR ARAIZ JJ, 1993, INVEST OPHTH VIS SCI, V34, P522
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BLANER WS, 1985, DIFFERENTIATION DIS, V113, P1
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0
   CAMPOCHIARO PA, 1991, INVEST OPHTH VIS SCI, V32, P65
   DOYLE JW, 1992, CURR EYE RES, V11, P753, DOI 10.3109/02713689209000749
   FEKRAT S, 1995, OPHTHALMOLOGY, V102, P412
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0
   SOMMER A, 1983, AM J OPHTHALMOL, V95, P349, DOI 10.1016/S0002-9394(14)78304-7
   UBELS JL, 1983, AM J OPHTHALMOL, V95, P353, DOI 10.1016/S0002-9394(14)78305-9
   Uchida H, 2005, EXP EYE RES, V80, P23, DOI 10.1016/j.exer.2004.08.004
   VERSTRAETEN T, 1992, INVEST OPHTH VIS SCI, V33, P2830
   Weninger W, 1998, J INVEST DERMATOL, V111, P907, DOI 10.1046/j.1523-1747.1998.00393.x
NR 16
TC 6
Z9 6
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2006
VL 26
IS 3
BP 314
EP 321
DI 10.1097/00006982-200603000-00010
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100QW
UT WOS:000241684700010
PM 16508432
DA 2022-11-30
ER

PT J
AU Lee, JS
   Li, PR
   Hou, CH
   Lin, KK
   Kuo, CF
   See, LC
AF Lee, Jiahn-Shing
   Li, Pei-Ru
   Hou, Chiun-Ho
   Lin, Ken-Kuo
   Kuo, Chang-Fu
   See, Lai-Chu
TI Effect of Blue Light-Filtering Intraocular Lenses on Age-Related Macular
   Degeneration: A Nationwide Cohort Study With 10-Year Follow-up
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PROPENSITY SCORE METHODS; CATARACT-SURGERY; TRANSMITTANCE; TAIWAN;
   DAMAGE; RISK
AB PURPOSE: To determine the incidence rate of age related macular degeneration (AMD) after cataract surgery and compare the relative incidence of AMD in pseudophakes with blue light-filtering intraocular lenses (BF-IOLs) and non-BF-IOLs. DESIGN: A nationwide cohort study conducted using the Taiwan National Health Insurance Research Database. METHODS: We enrolled 186,591 patients who underwent cataract surgery in both eyes between 2008 and 2013 and monitored them from the index date (the date of first cataract surgery) until AMD, death, loss to followup, or December 31, 2017, whichever occurred first. Propensity score matching (PSM) was used to balance the baseline characteristics between the BF-IOL and nonBF-IOL groups. RESULTS: BF-IOLs were implanted in 21,126 patients (11.3%) and non-BF-IOLs were implanted in 165,465 patients (88.7%). Patients in the BF-IOL group tended to be younger, with fewer men, different cataract surgery years, higher income, more nonmanual workers, more patients from urban and suburban areas, and fewer chronic diseases compared with the non-BF-IOL group. With a mean follow-up period of 6.1 years (range, 1-10 years) after cataract surgery, 12,533 and 1655 patients developed non-exudative AMD and exudative AMD, respectively. The incidence rate of non-exudative AMD and exudative AMD (per 1000 person-years) was 9.95 and 1.22 for the BF-IOL group and 11.13 and 1.44 for the non-BF-IOL group, respectively. After PSM, no statistical difference in the incidence rate of nonexudative AMD (hazards ratio, 0.95; 95% CI, 0.88-1.03) and exudative AMD (hazard ratio, 0.96; 95% CI, 0.77-1.18) was observed between the BF-IOL and non-BF-IOL groups. CONCLUSIONS: In Taiwan, the incidence rate of AMD after cataract surgery was 11.59 per 1000 person-years. The use of a BF-IOL for up to 10 years had no apparent advantage over a non-BF-IOL in the incidence of AMD. (Am J Ophthalmol 2021;234: 138-146. (c) 2021 Elsevier Inc. All rights reserved.)
C1 [Lee, Jiahn-Shing; Hou, Chiun-Ho; Lin, Ken-Kuo] Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan, Taiwan.
   [Lee, Jiahn-Shing; Hou, Chiun-Ho; Lin, Ken-Kuo] Chang Gung Univ, Taoyuan, Taiwan.
   [Li, Pei-Ru; See, Lai-Chu] Chang Gung Univ, Coll Med, Dept Publ Hlth, Taoyuan, Taiwan.
   [Kuo, Chang-Fu; See, Lai-Chu] Chang Gung Mem Hosp Linkou, Dept Internal Med, Div Rheumatol Allergy & Immunol, 5 Fu Shin St, Taoyuan 333, Taiwan.
   [See, Lai-Chu] Chang Gung Univ, Biostat Core Lab, Mol Med Res Ctr, Taoyuan, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung
   University; Chang Gung Memorial Hospital; Chang Gung University
RP Kuo, CF; See, LC (通讯作者)，Chang Gung Mem Hosp Linkou, Dept Internal Med, Div Rheumatol Allergy & Immunol, 5 Fu Shin St, Taoyuan 333, Taiwan.
EM zandis@gmail.com; lichu@mail.cgu.edu.tw
RI Kuo, Chang-Fu/Q-1714-2016
OI Kuo, Chang-Fu/0000-0002-9770-5730; Li, Pei-Ru/0000-0001-7744-0555; See,
   Lai-Chu/0000-0002-1379-8969
FU Chang Gung Memorial Hospital, Taiwan [CMRPG3K1821, BMRP300]
FX This study was supported by Chang Gung Memorial Hospital, Taiwan (grant
   number CMRPG3K1821, BMRP300) .
CR Achiron Asaf, 2021, Ophthalmology, V128, P410, DOI 10.1016/j.ophtha.2020.07.039
   Austin PC, 2014, STAT MED, V33, P1242, DOI 10.1002/sim.5984
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786
   Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Brookhart MA, 2013, CIRC-CARDIOVASC QUAL, V6, P604, DOI 10.1161/CIRCOUTCOMES.113.000359
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Downie LE, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011977.pub2
   Falkner-Radler CI, 2008, AM J OPHTHALMOL, V145, P499, DOI 10.1016/j.ajo.2007.10.021
   Hamel T, 2021, CLIN OPHTHALMOL, V15, P2287, DOI 10.2147/OPTH.S300461
   Hansun S, 2013, 2013 C NEW MED STUD, P1, DOI DOI 10.1109/CONMEDIA.2013.6708545
   Ho JD, 2018, ACTA OPHTHALMOL, V96, pe213, DOI 10.1111/aos.13511
   Hsieh CY, 2019, CLIN EPIDEMIOL, V11, P349, DOI 10.2147/CLEP.S196293
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Kara N, 2011, J CATARACT REFR SURG, V37, P2115, DOI 10.1016/j.jcrs.2011.06.024
   Lee BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018174
   Lee JS, 2016, INT J SURG, V36, P265, DOI 10.1016/j.ijsu.2016.11.011
   Li L., 2004, SURV RES METHOD APPL, V15, P5, DOI [10.7014/TCYCFFYYY.200404.0005, DOI 10.7014/TCYCFFYYY.200404.0005]
   Li X, 2017, EYE, V31, P258, DOI 10.1038/eye.2016.266
   Lu TH, 2000, INT J EPIDEMIOL, V29, P336, DOI 10.1093/ije/29.2.336
   Mainster M A, 1978, J Am Intraocul Implant Soc, V4, P84
   MAINSTER MA, 1978, AM J OPHTHALMOL, V85, P167, DOI 10.1016/S0002-9394(14)75943-4
   Mainster MA, 2011, OPHTHALMOLOGY, V118, P1, DOI 10.1016/j.ophtha.2010.11.016
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   McCaffrey DF, 2013, STAT MED, V32, P3388, DOI 10.1002/sim.5753
   Mester U, 2008, J CATARACT REFR SURG, V34, P608, DOI 10.1016/j.jcrs.2007.11.049
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   National Health Insurance Administration Ministry of Health and Welfare Taiwan, 2017 2018 NAT HLTH I
   Pipis A, 2015, EUR J OPHTHALMOL, V25, P128, DOI 10.5301/ejo.5000520
   Rim TH, 2017, SEMIN OPHTHALMOL, V32, P466, DOI 10.3109/08820538.2015.1119861
   Roisman Luiz, 2017, Curr Ophthalmol Rep, V5, P136, DOI 10.1007/s40135-017-0131-6
   Singh S, 2020, CLIN EXP OPHTHALMOL, V48, P125, DOI 10.1111/ceo.13653
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Stein JD, 2011, INVEST OPHTH VIS SCI, V52, P6842, DOI 10.1167/iovs.11-7179
   Tso M O, 1975, Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol, V79, pOP788
   Van Der Hoeve J, 1920, AM J OPHTHALMOL, V3, P178
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Zar JH, 2014, BIOSTAT ANAL
NR 41
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2022
VL 234
BP 138
EP 146
DI 10.1016/j.ajo.2021.08.002
EA NOV 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XI3TM
UT WOS:000726038400010
PM 34411525
DA 2022-11-30
ER

PT J
AU Gascon, P
   Ramtohul, P
   Delaporte, C
   Kerever, S
   Denis, D
   Comet, A
AF Gascon, Pierre
   Ramtohul, Prithvi
   Delaporte, Charles
   Kerever, Sebastien
   Denis, Daniele
   Comet, Alban
TI Aflibercept in real-life for the treatment of age-related macular
   degeneration using a treat and extend protocol: The Armada study
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Naive neovascular age-related macular degeneration; aflibercept; treat
   and extend regimen; "real-life" practice; Armada study
ID INTRAVITREAL AFLIBERCEPT; 2-YEAR OUTCOMES; RANIBIZUMAB; THERAPY; SAFETY;
   NEOVASCULARIZATION; PREVALENCE; EFFICACY; REGIMEN; TRIAL
AB Purpose: To report the visual and anatomic outcomes in treatment-naive neovascular age-related macular degeneration (nAMD) patients treated with aflibercept under a standardized Treat and Extend (T&E) protocol for up to 3 years of follow-up in "real-life" practice. Methods: This retrospective, observational, multicenter study included patients with treatment-naive nAMD and at least 12 months of follow-up. T&E regimen adjustment was initiated after loading phase. At each visit best-corrected visual acuity (BCVA) and optical coherence tomography parameters were performed. Results: One hundred and thirty-six eyes of 115patients had at least 1 year of follow-up with 114 and 82 eyes completing at least 2 and 3 years of follow-up, respectively (mean follow-up duration: 2.7 +/- 1.3 years). Mean age was 78.6 +/- 8.6 years old and 52% were women. Mean BCVA increased from 60.6 +/- 18.7 letters at diagnosis to 66.9 +/- 16.2 letters at 1 year (+6.3 letters, p = 0.003) and remained stable throughout the follow-up period (63.1 +/- 20.3 letters (+2.5, p = 0.1) and 64.0 +/- 20.1 letters (+3.4, p = 0.27) at 2 and 3 years, respectively). The mean central retinal thickness decreased significantly from 358.2 +/- 87.9 mu m at baseline to 302 +/- 71.7 mu m at 12 months and maintained stable after 36 months of follow-up (297.1 +/- 76 mu m, p < 0.0001). Mean number of injections was 6.6 +/- 2.2, 4.8 +/- 1.9, and 5.6 +/- 1.7 at 1, 2, and 3 years, respectively. Mean cumulative number of 16.4 +/- 5.6 injections after 3 years. Mean treatment interval was 6.8 +/- 2.5 weeks at 1 year. Eight-week and 12-week treatment interval were achieved in 59.5% and 19.1%, 65.8%, and 36.8% and 69.5% and 41.5% at 1, 2, and 3 years, respectively. Conclusions: Our study demonstrated that intravitreal injections of aflibercept initiated under a standardized T&E for patients with treatment-naive nAMD allow for significant visual improvement at 12 months, which was maintained over a 3-year follow-up period.
C1 [Gascon, Pierre; Ramtohul, Prithvi; Delaporte, Charles; Denis, Daniele; Comet, Alban] Aix Marseille Univ, Dept Ophthalmol, Hop Nord, F-13915 Marseille, France.
   [Gascon, Pierre] Aix Marseille Univ, Inst Neurosci Timone, Marseille, France.
   [Kerever, Sebastien] INSERM, ECSTRA Team Epidemiol & Biostat Sorbonne Paris Ci, UMR 1153, Paris, France.
   [Kerever, Sebastien] Univ Paris VII Denis Diderot, Paris, France.
C3 UDICE-French Research Universities; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; UDICE-French Research Universities;
   Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; UDICE-French
   Research Universities; Universite Paris Cite
RP Gascon, P (通讯作者)，Aix Marseille Univ, Dept Ophthalmol, Hop Nord, F-13915 Marseille, France.
EM pierre.gascon3@gmail.com
RI Kerever, Sébastien/S-1620-2019
OI Kerever, Sébastien/0000-0003-0764-4370; Gascon,
   Pierre/0000-0002-2012-8808; comet, alban/0000-0003-0003-6698
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   American Society of Retina Specialists, 2015 GLOB TRENDS RET
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Li JQ, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/1425707
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maruko I, 2020, OPHTHALMOL RETINA, V4, P767, DOI 10.1016/j.oret.2020.03.010
   Mekjavic PJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1005-x
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Toulouse E, 2018, ANAESTH CRIT CARE PA, V37, P607, DOI 10.1016/j.accpm.2018.10.013
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 38
TC 1
Z9 1
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 356
EP 363
AR 11206721211005703
DI 10.1177/11206721211005703
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000677799600001
PM 33779324
DA 2022-11-30
ER

PT J
AU Feigl, B
   Brown, B
   Lovie-Kitchin, J
   Swann, P
AF Feigl, Beatrix
   Brown, Brian
   Lovie-Kitchin, Jan
   Swann, Peter
TI The rod-mediated multifocal electroretinogram in aging and in early
   age-related maculopathy
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related maculopathy (ARM); aging; multifocal electroretinogram;
   rod-mediated multifocal ERG
ID DARK-ADAPTATION; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; RETINAL
   FUNCTION; BRUCHS MEMBRANE; A-WAVE; CONE; ERG; ABNORMALITIES; SENSITIVITY
AB Purpose: To measure function with the rod-mediated multifocal electroretinogram (mfERG) in younger and older subjects with normal vision and with early age-related maculopathy ( ARM). Methods: Thirty subjects were studied: 10 healthy subjects with a mean age of 31 years ( young group), 10 healthy subjects with a mean age of 71 years ( old group), and 10 early ARM subjects with a mean age of 71 years ( early ARM group). The influence of cataract was approximated by retesting five subjects of the young group through an 0.3 neutral density filter (ND filter group). We analyzed first-order N1P1-amplitude and P1-implicit time (P1-IT) mfERG responses and correlated them with funduscopic changes as defined by the Age-Related Eye Disease Study (AREDS) group. Results: Averaged concentric ring P1-ITs were significantly delayed in the old ( p = 0.02) and early ARM ( p < 0.001) compared with the young group and in the early ARM group compared with the old and ND group ( p <= 0.01). There were no significant differences in N1P1-amplitudes between groups, but there was a significant location effect for all groups with highest mean amplitudes for the most peripheral ring of hexagons ( p < 0.01). Significantly delayed overall P1-ITs ( p < 0.05) were correlated with progressive funduscopic changes. Conclusions: Aging and early ARM affects the rod-mediated mfERG, and there is good correlation with funduscopic changes. Although a lens effect cannot be excluded, a neuronal transmission alteration at the postreceptoral level is suggested.
C1 Queensland Univ Technol, Sch Optometry, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld 4059, Australia.
C3 Queensland University of Technology (QUT)
RP Feigl, B (通讯作者)，Queensland Univ Technol, Sch Optometry, Inst Hlth & Biomed Innovat, Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.
EM b.feigl@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Arai M, 1999, JPN J OPHTHALMOL, V43, P481, DOI 10.1016/S0021-5155(99)00119-7
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   Birch DG, 2002, ARCH OPHTHALMOL-CHIC, V120, P1045
   Bird AC, 2003, CLIN EXP OPHTHALMOL, V31, P461, DOI 10.1046/j.1442-9071.2003.00721.x
   Brown B, 1996, OPHTHAL PHYSL OPT, V16, P42
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Bui BV, 2003, EXP EYE RES, V77, P125, DOI 10.1016/S0014-4835(03)00132-5
   CAMPBELL CJ, 1969, RETINA MORPHOLOGY FU, P513
   Chan HL, 1998, OPHTHAL PHYSL OPT, V18, P335, DOI 10.1016/S0275-5408(98)00001-5
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHENG A, 1992, OPTOMETRY VISION SCI, V70, P89
   Cideciyan AV, 1996, VISION RES, V36, P2609, DOI 10.1016/0042-6989(95)00327-4
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Fortune B, 2002, J OPT SOC AM A, V19, P173, DOI 10.1364/JOSAA.19.000173
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gerth C, 2002, GRAEF ARCH CLIN EXP, V240, P202, DOI 10.1007/s00417-002-0442-6
   GONZALEZ P, 2004, 2002 ANN M ABSTR SEA
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hood DC, 1998, INVEST OPHTH VIS SCI, V39, P1152
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Jackson GR, 2006, VISION RES, V46, P1422, DOI 10.1016/j.visres.2005.09.003
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 2002, J OPT SOC AM A, V19, P185, DOI 10.1364/JOSAA.19.000185
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KEATING D, 1996, INVEST OPHTHALMOL  S, V37, P346
   Keating David, 2000, Documenta Ophthalmologica, V100, P77, DOI 10.1023/A:1002723501303
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LAMB T, 1981, VISION RES, V21
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   MACALUSO C, 1992, INVEST OPHTH VIS SCI, V33, P2798
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P181, DOI 10.1136/bjo.63.3.181
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   OWSLEY C, 1987, INVEST OPHTH VIS SCI, V26, P1165
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D., 1992, Ophthalmologe, V89, P363
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P413, DOI 10.1113/jphysiol.1975.sp010982
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   SCHEFRIN BE, 1992, J OPT SOC AM A, V9, P355, DOI 10.1364/JOSAA.9.000355
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Seiple W, 2003, INVEST OPHTH VIS SCI, V44, P1783, DOI 10.1167/iovs.02-0518
   Shimada Y, 2001, BRIT J OPHTHALMOL, V85, P414, DOI 10.1136/bjo.85.4.414
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Tam WK, 2004, EYE, V18, P691, DOI 10.1038/sj.eye.6701318
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Tzekov RT, 2004, GRAEF ARCH CLIN EXP, V242, P549, DOI 10.1007/s00417-004-0892-0
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wordehoff UV, 2004, DOC OPHTHALMOL, V108, P67, DOI 10.1023/B:DOOP.0000018394.84831.40
   Yoshii M, 2000, JPN J OPHTHALMOL, V44, P122, DOI 10.1016/S0021-5155(99)00189-6
   ZUCKERMAN J, 1973, INVEST OPHTH VIS SCI, V213, P213
NR 86
TC 24
Z9 25
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL-AUG
PY 2006
VL 31
IS 7-8
BP 635
EP 644
DI 10.1080/02713680600762739
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 069MR
UT WOS:000239452200009
PM 16877272
DA 2022-11-30
ER

PT J
AU You, QS
   Wang, J
   Guo, YK
   Flaxel, CJ
   Hwang, TS
   Huang, D
   Jia, YL
   Bailey, ST
AF You, Qi Sheng
   Wang, Jie
   Guo, Yukun
   Flaxel, Christina J.
   Hwang, Thomas S.
   Huang, David
   Jia, Yali
   Bailey, Steven T.
TI Detection of Reduced Retinal Vessel Density in Eyes with Geographic
   Atrophy Secondary to Age-Related Macular Degeneration Using
   Projection-Resolved Optical Coherence Tomography Angiography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTOCOAGULATION; RANIBIZUMAB; QUANTIFICATION
AB PURPOSE: To compare retinal vessel density in eyes with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to age-matched healthy eyes by using projection-resolved optical coherence tomography angiography (PR-OCTA).
   DESIGN: Prospective cross-sectional study.
   METHODS: Study participants underwent macular 3-X 3-mm OCTA scans with spectral domain OCTA. Reflectance-compensated retinal vessel densities were calculated on projection-resolved superficial vascular complex (SVC), intermediate capillary plexus (ICP), and deep capillary plexus (DCP). Quantitative analysis using normalized deviation compared the retinal vessel density in GA regions, 500-m GA rim regions, and non-GA regions to similar macular locations in control eyes.
   RESULTS: Ten eyes with GA and 10 control eyes were studied. Eyes with GA had significantly lower vessel density in the SVC (54.8 +/- 2.4% vs. 60.8 +/- 3.1%; P < 0.001), ICP (34.0 +/- 1.5% vs. 37.3 +/- 1.7%; P = 0.003) and DCP (24.4 +/- 2.3% vs. 28.0 +/- 2.3%; P < 0.001) than control eyes. Retinal vessel density within the GA region decreased significantly in SVC, ICP, and DCP. Retinal vessel density in the GA rim region decreased in SVC and ICP but not in DCP. The non-GA region did not significantly deviate from normal controls. Eyes with GA had significantly reduced photoreceptor layer thickness; but similar nerve fiber layer, ganglion cell complex, inner nuclear layer, and outer plexiform layer thickness.
   CONCLUSIONS: Eyes with GA have reduced retinal vessel density in SVC, ICP, and DCP compared to those in controls. Loss is greatest within regions of GA. Vessel density may be more sensitive than retinal layer thickness measurement in the detection of inner retinal change in eyes with GA. ((C) 2019 Elsevier Inc. All rights reserved.)
C1 [You, Qi Sheng; Guo, Yukun; Flaxel, Christina J.; Hwang, Thomas S.; Huang, David; Jia, Yali; Bailey, Steven T.] Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
   [Wang, Jie; Jia, Yali] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA.
C3 Oregon Health & Science University; Oregon Health & Science University
RP Bailey, ST (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM bailstev@ohsu.edu
RI You, Qisheng/AAG-7153-2020; Hwang, Thomas S./AAW-6618-2020; Hwang,
   Thomas/AAV-5146-2020; Guo, Yukun/AAB-6902-2020
OI You, Qisheng/0000-0003-0743-7320; Hwang, Thomas S./0000-0002-0535-4823;
   Guo, Yukun/0000-0002-6784-2355; Jia, Yali/0000-0002-2784-1905; Bailey,
   Steven/0000-0003-4949-1464
FU US National Institutes of Health [R01 EY024544, R01 EY027833, P30
   EY010572]; William and Mary Greve Special Scholar Award from Research to
   Prevent Blindness
FX Supported by US National Institutes of Health grants R01 EY024544, R01
   EY027833, and P30 EY010572; by an unrestricted departmental funding
   grant; and by a William and Mary Greve Special Scholar Award from
   Research to Prevent Blindness. The funding sources had no role in the
   design and conduct of the study; collection, management, analysis, and
   interpretation of the data; preparation, review, or approval of the
   manuscript; and decision to submit the manuscript for publication.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Budzynski E, 2008, INVEST OPHTH VIS SCI, V49, P380, DOI 10.1167/iovs.07-0065
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   FEKE GT, 1982, OPHTHALMOLOGY, V89, P757
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, P4485, DOI 10.1167/iovs.16-20080
   GRUNWALD JE, 1986, OPHTHALMOLOGY, V93, P590
   Guo YK, 2018, BIOMED OPT EXPRESS, V9, P4429, DOI 10.1364/BOE.9.004429
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hwang TS, 2018, JAMA OPHTHALMOL, V136, P929, DOI 10.1001/jamaophthalmol.2018.2257
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P367, DOI 10.1001/jamaophthalmol.2015.5658
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nesper PL, 2018, RETINA-J RET VIT DIS, V38, P1289, DOI 10.1097/IAE.0000000000001863
   Ramkumar HL, 2018, RETINA-J RET VIT DIS, V38, P2159, DOI 10.1097/IAE.0000000000001867
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wang J, 2017, BIOMED OPT EXPRESS, V8, P1536, DOI 10.1364/BOE.8.001536
   WILSON DJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P100, DOI 10.1001/archopht.1988.01060130106038
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zang PX, 2016, BIOMED OPT EXPRESS, V7, P2823, DOI 10.1364/BOE.7.002823
   Zhang GL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0080969, 10.1371/journal.pone.0063486, 10.1371/journal.pone.0059428, 10.1371/journal.pone.0064689, 10.1371/journal.pone.0059254]
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 35
TC 17
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2020
VL 209
BP 206
EP 212
DI 10.1016/j.ajo.2019.09.004
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC8NP
UT WOS:000507428600024
PM 31526797
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, JM
   Cho, HJ
   Kim, Y
   Jung, SH
   Lee, DW
   Kim, JW
AF Kim, Jae Min
   Cho, Han Joo
   Kim, Yeji
   Jung, Seoung Heon
   Lee, Dong Won
   Kim, Jong Woo
TI Responses of Types 1 and 2 Neovascularization in Age-Related Macular
   Degeneration to Anti-Vascular Endothelial Growth Factor Treatment:
   Optical Coherence Tomography Angiography Analysis
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; choroidal neovascularization; optical
   coherence tomography angiography; vascular endothelial growth factor
ID ANTI-VEGF THERAPY; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   AFLIBERCEPT
AB Purpose: To compare the responses of types 1 (sub-pigment epithelial) and 2 (subretinal) neovascularization in neovascular age-related macular degeneration (AMD) to anti-vascular endothelial growth factor (VEGF) treatment.Methods: Fifty-five treatment-naive neovascular AMD eyes (53 patients) were retrospectively included for analysis. All patients were treated with three loading injections of anti-VEGF agent, followed by further injections as required. The lesion size and vascular density of type 1 and 2 lesions before and after treatment for 12 months were analyzed using optical coherence tomography angiography (OCTA).Results: The mean lesion size of the type 1 neovascularization group (42 eyes) showed no significant change from 2.12 1.01 mm(2) at baseline to 2.08 +/- 0.91 mm(2) at 12 months (P = .682). However, the mean lesion size of type 2 neovascularization significantly decreased from 1.23 +/- 0.93 mm(2) at baseline to 0.79 +/- 0.61 mm(2) at 12 months (P = .022). The proportion of eyes with lesion sizes that decreased by more than 40% from baseline was also significantly higher for the type 2 compared to the type 1 neovascularization group (46.2% versus 11.9%, P = .007). Vascular density showed no significant changes for both groups after treatment and showed no association with the change in lesion size. There was no significant difference between the groups in terms of visual acuity improvement.Conclusion: OCTA analysis revealed different responses to anti-VEGF treatment depending on the location of neovascularization in neovascular AMD. Type 2 neovascularization was significantly regressed compared to type 1 neovascularization after anti-VEGF treatment. However, the changes in vascular density and visual outcome showed no significant differences between groups after 12 months of treatment.
C1 [Kim, Jae Min; Cho, Han Joo; Kim, Yeji; Jung, Seoung Heon; Lee, Dong Won; Kim, Jong Woo] Konyang Univ, Dept Ophthalmol, Kims Eye Hosp, Coll Med,Myung Gok Eye Res Inst, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156,4ga,Yeoungdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Dolz-Marco R, 2017, RETINA-J RET VIT DIS, V37, P222, DOI 10.1097/IAE.0000000000001279
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, OPHTHALMOLOGE, V108, P124, DOI 10.1007/s00347-010-2210-z
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lumbroso B, 2016, DEV OPHTHALMOL, V56, P77, DOI 10.1159/000442782
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   SHEU SJ, 1994, GRAEF ARCH CLIN EXP, V232, P695, DOI 10.1007/BF00171387
   Shrira A, 2019, AGING MENT HEALTH, V23, P752, DOI 10.1080/13607863.2018.1448970
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Terasaki H, 2015, RETINA-J RET VIT DIS, V35, P1007, DOI 10.1097/IAE.0000000000000428
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P717, DOI 10.1097/IAE.0b013e318203c1ef
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 30
TC 15
Z9 15
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD APR 3
PY 2019
VL 34
IS 3
BP 168
EP 176
DI 10.1080/08820538.2019.1620791
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IK4ML
UT WOS:000476560900008
PM 31132283
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Sadda, S
   Staurenghi, G
   Chew, EY
   Fleckenstein, M
   Holz, FG
AF Schmitz-Valckenberg, Steffen
   Sadda, Srinivas
   Staurenghi, Giovanni
   Chew, Emily Y.
   Fleckenstein, Monika
   Holz, Frank G.
CA CAM Grp
TI GEOGRAPHIC ATROPHY Semantic Considerations and Literature Review
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; geographic atrophy; retinal imaging;
   fundus grading; color fundus photography; spectral domain optical
   coherence tomography; confocal scanning laser ophthalmoscopy
ID AREOLAR CHOROIDAL DYSTROPHY; RETINAL-PIGMENT EPITHELIUM; MACULAR
   DEGENERATION; FUNDUS AUTOFLUORESCENCE; EYE DISEASE; PROGRESSION;
   SECONDARY; PATTERNS; OUTCOMES; ANCHOR
AB Purpose: There is a lack of agreement regarding the types of lesions and clinical conditions that should be included in the term "geographic atrophy." Varied and conflicting views prevail throughout the literature and are currently used by retinal experts and other health care professionals.
   Methods: We reviewed the nominal definition of the term "geographic atrophy" and conducted a search of the ophthalmologic literature focusing on preceding terminologies and the first citations of the term "geographic atrophy" secondary to age-related macular degeneration.
   Results: According to the nominal definition, the term "geography" stands for a detailed description of the surface features of a specific region, indicating its relative position. However, it does not necessarily imply that the borders of the region must be sharply demarcated or related to any anatomical structures. The term "geographical areas of atrophy" was initially cited in the 1960s in the ophthalmologic literature in the context of uveitic eye disease and shortly thereafter also for the description of variants of "senile macular degeneration." However, no direct explanation could be found in the literature as to why the terms "geographical" and "geographic" were chosen. Presumably the terms were used as the atrophic regions resembled the map of a continent or well-defined country borders on thematic geographical maps. With the evolution of the terminology, the commonly used adjunct "of the retinal pigment epithelium" was frequently omitted and solely the term "geographic atrophy" prevailed for the nonexudative late-stage of age-related macular degeneration itself. Along with the quantification of atrophic areas, based on different imaging modalities and the use of both manual and semiautomated approaches, various and inconsistent definitions for the minimal lesion diameter or size of atrophic lesions have also emerged.
   Conclusion: Reconsideration of the application of the term "geographic atrophy" in the context of age-related macular degeneration seems to be prudent given ongoing advances in multimodal retinal imaging technology with identification of various phenotypic characteristics, and the observation of atrophy development in eyes under antiangiogenic therapy.
C1 [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika; Holz, Frank G.] Univ Bonn, GRADE Reading Ctr, Dept Ophthalmol, Bonn, Germany.
   [Sadda, Srinivas] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
   [Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Eye Clin, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 University of Bonn; University of Southern California; University of
   Milan; Luigi Sacco Hospital; National Institutes of Health (NIH) - USA;
   NIH National Eye Institute (NEI)
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
RI Mitchell, Paul/P-1498-2014; Staurenghi, Giovanni/K-4388-2017
OI Fleckenstein, Monika/0000-0001-8321-8037; Staurenghi,
   Giovanni/0000-0002-2299-5251
FU Intramural NIH HHS [Z99 EY999999] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [ZIAEY000489] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1984, MED LETT DRUGS THER, V26, P69
   [Anonymous], 1984, Am J Ophthalmol, V98, P376
   [Anonymous], 1987, STEREOSCOPIC ATLAS M
   [Anonymous], 1986, MACULAR PHOTOCOAGULA, P14
   BAARSMA GS, 1976, DOC OPHTHALMOL, V40, P269, DOI 10.1007/BF00155041
   Behr C, 1920, MONATSBLATTER AUGENH, V65, P465
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   BRALEY AE, 1966, AM J OPHTHALMOL, V61, P1
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dimmer F, 1927, ATLAS PHOTOGRAPISCHE
   Dorland's Illustrated Medical Dictionary, 2011, DORL ILL MED DICT
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Duisdieker V, 2015, OPHTHALMOLOGICA, V234, P218, DOI 10.1159/000439358
   Duke-Elder S, 1966, SYSTEM OPHTHALMOLOGY, P603
   Duke-Elder S, 1967, SYSTEM OPHTHALMOLOGY, P638
   Falls HF, 1966, RETINAL DISEASES, P227
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   FRANCESCHETTI A, 1962, Doc Ophthalmol, V16, P81, DOI 10.1007/BF00146721
   FRANCOIS J, 1952, Ann Ocul (Paris), V185, P136
   Fuchs AE, 1943, ERKRANKUNGEN AUGEHIN, P112
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gass JD, 1970, STEREOSCOPIC ATLAS M
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GASS JDM, 1967, AM J OPHTHALMOL, V64, P612
   Grayson M, 1969, MANUAL DIS CORNEA
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Haab O, 1885, CENTRALBLAT AUGENHEI, V9, P384
   Harms C, 1904, MONATSBLATTER AUGENH, V42, P448
   Holland EJ, 2005, CORNEA, P1050
   Hollwich F, 1963, ERKRANKUNGSFORMEN NE, P683
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hughes AE, 1998, J MED GENET, V35, P770, DOI 10.1136/jmg.35.9.770
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Jonasson F, 2007, ACTA OPHTHALMOL SCAN, V85, P862, DOI 10.1111/j.1600-0420.2007.01002.x
   Junius P, 1926, SCHEIBENFORMIGE ENTA
   Kimura SJ, 1966, RET DIS S DIFF DIAGN
   Klausner E, 1910, ARCH DERMATOL SYPH-G, V103, P103, DOI 10.1007/BF01850560
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KLIEN BA, 1950, AM J OPHTHALMOL, V33, P371, DOI 10.1016/0002-9394(50)90335-7
   KLIEN BA, 1964, AM J OPHTHALMOL, V58, P927, DOI 10.1016/0002-9394(64)90001-7
   KORNZWEIG AL, 1959, AM J OPHTHALMOL, V48, P22, DOI 10.1016/0002-9394(59)90238-7
   KRAFFEL G, 1955, Klin Monbl Augenheilkd Augenarztl Fortbild, V127, P664
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Marchesani O, 1957, ATLAS AUGENHINTERGRU
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mosby's Dictionary of Medicine, 2013, MOSB DICT MED
   Nettleship E, 1884, T OPHTHAL SOC UK, V4, P165
   Prinz H, 1927, DENT COSMOS, VIXIX, P272
   Rezende RA, 2005, CORNEA, P330
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   RYAN SJ, 1980, A GRAEF ARCH KLIN EX, V215, P1, DOI 10.1007/BF00413392
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Santlus, 1854, J KINDERKRANKHEITEN, V23, P161
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Sautter H, 1959, BER DTSCH OPHTH GES, V63, P3
   Schieck F, 1930, KURZES HDB OPHTHALMO, P563
   Schlaegel TJ, 1969, ESSENTIALS UVEITIS
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Segen JC, 2006, CONCISE DICT MODERN
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   SORSBY A, 1953, BRIT J OPHTHALMOL, V37, P129, DOI 10.1136/bjo.37.3.129
   Steinbach P D, 1970, Klin Monbl Augenheilkd, V156, P710
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Sveinsson K., 1939, ACTA OPHTHALMOL, V17, P73
   THYGESON P, 1956, ARCH OPHTHALMOL-CHIC, V56, P375
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Varoni E, 2016, NEW ENGL J MED, V374, P670, DOI 10.1056/NEJMicm1502932
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wessing A, 1969, FLUORESCEIN ANGIOGRA
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 92
TC 43
Z9 43
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2016
VL 36
IS 12
BP 2250
EP 2264
DI 10.1097/IAE.0000000000001258
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED6DB
UT WOS:000388944100002
PM 27552292
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Virgili, G
   Michelessi, M
   Parodi, MB
   Bacherini, D
   Evans, JR
AF Virgili, Gianni
   Michelessi, Manuele
   Parodi, Maurizio B.
   Bacherini, Daniela
   Evans, Jennifer R.
TI Laser treatment of drusen to prevent progression to advanced age-related
   macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Laser Coagulation [methods]; Macular Degeneration [prevention &
   control]; Randomized Controlled Trials as Topic; Retinal Drusen
   [complications; surgery]; Humans
ID PIGMENT EPITHELIAL ABNORMALITIES; RETINAL VEIN OCCLUSION; CHOROIDAL
   NEOVASCULARIZATION; SOFT DRUSEN; PROPHYLACTIC TREATMENT; GRID
   PHOTOCOAGULATION; 810-NANOMETER LASER; CONTROLLED-TRIALS; MACULOPATHY;
   RISK
AB Background
   Drusen are amorphous yellowish deposits beneath the sensory retina. People with drusen, particularly large drusen, are at higher risk of developing age-related macular degeneration (AMD). The most common complication in AMD is choroidal neovascularisation (CNV), the growth of new blood vessels in the centre of the macula. The risk of CNV is higher among people who are already affected by CNV in one eye.
   It has been observed clinically that laser photocoagulation of drusen leads to their disappearance and may prevent the occurrence of advanced disease (CNV or geographic atrophy) associated with visual loss.
   Objectives
   To examine the effectiveness and adverse effects of laser photocoagulation of drusen in AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015, Issue 7), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to August 2015), EMBASE (January 1980 to August 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to August 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 3 August 2015.
   Selection criteria
   Randomised controlled trials (RCTs) of laser treatment of drusen in AMD in which laser treatment had been compared with no intervention or sham treatment. Two types of trials were included. Some trials studied one eye of each participant (unilateral studies); other studies recruited participants with bilateral drusen and randomised one eye to photocoagulation or control and the fellow eye to the other group.
   Data collection and analysis
   Two review authors independently selected studies and extracted data. We pooled data from unilateral and bilateral studies using a random-effects model. For the bilateral studies, we estimated the within-person correlation coefficient from one study and assumed it was valid for the others.
   Main results
   The update of this review found two additional studies, totaling 11 studies that randomised 2159 participants (3580 eyes) and followed them up to two years, of which six studies (1454 participants) included people with one eye randomised to treatment and one to control. Studies were conducted in Australia, Europe and North America.
   Overall, the risk of bias in the included studies was low, particularly for the larger studies and for the primary outcome development of CNV. Photocoagulation did not reduce the development of CNV at two years' follow-up (odds ratio (OR) 1.07, 95% confidence interval (CI) 0.79 to 1.46, 11 studies, 2159 participants (3580 eyes), high quality evidence). This estimate means that, given an overall occurrence of CNV of 8.3% in the control group, we estimated an absolute risk reduction by no more than 1.4% in the laser group, according to the lower CI limit. Only two studies investigated the effect on the development of geographic atrophy and could not show a difference, but estimates were imprecise (OR 1.30, 95% CI 0.38 to 4.51, two studies, 148 participants (148 eyes), low quality evidence).
   Among secondary outcomes, photocoagulation led to drusen reduction (OR 9.16, 95% CI 6.28 to 13.4, three studies, 570 participants (944 eyes), high quality evidence) but was not shown to limit loss of 3 or more lines of visual acuity (OR 0.99, 95% CI 0.81 to 1.22, nine studies, 2002 participants (2386 eyes), moderate quality evidence).
   In a subgroup analysis, no difference could be shown for conventional visible (eight studies) versus subthreshold invisible (four studies) photocoagulation for the primary outcomes (P value = 0.29). The effect in the subthreshold group did not suggest a relevant benefit (OR 1.27, 95% CI 0.82 to 1.98). No study used micropulse subthreshold photocoagulation.
   No other adverse effects (apart from development of CNV, geographic atrophy or visual loss) were reported.
   Authors' conclusions
   The trials included in this review confirm the clinical observation that laser photocoagulation of drusen leads to their disappearance. However, treatment does not result in a reduction in the risk of developing CNV, and was not shown to limit the occurrence of geographic atrophy or visual acuity loss.
   Ongoing studies are being conducted to assess whether the use of extremely short laser pulses (i.e. nanosecond laser treatment) cannot only lead to drusen regression but also prevent neovascular AMD.
C1 [Virgili, Gianni; Bacherini, Daniela] Univ Florence, Eye Clin, Dept Translat Surg & Med, Florence, Italy.
   [Michelessi, Manuele] Fdn GB Bietti Studio & Ric Oftalmolol IRCCS, Ophthalmol, Rome, Italy.
   [Michelessi, Manuele] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Parodi, Maurizio B.] Univ Vita Salute, Dept Ophthalmol, Osped San Raffaeale, Milan, Italy.
   [Evans, Jennifer R.] London Sch Hyg & Trop Med, ICEH, Cochrane Eyes & Vis Grp, London WC1, England.
C3 University of Florence; IRCCS - Fondazione "G.B. Bietti" per lo Studio e
   la Ricerca in Oftalmologia; Johns Hopkins University; Johns Hopkins
   Bloomberg School of Public Health; Vita-Salute San Raffaele University;
   University of London; London School of Hygiene & Tropical Medicine
RP Parodi, MB (通讯作者)，Univ Vita Salute, Dept Ophthalmol, Osped San Raffaeale, Milan, Italy.
EM maubp@yahoo.it
RI ; Virgili, Gianni/P-6607-2014; Evans, Jennifer/F-4672-2012
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961; Virgili,
   Gianni/0000-0002-9960-2989; Evans, Jennifer/0000-0002-6137-2030
FU National Institute of Health Research (NIHR), UK; Department of Health
   through National Institute for Health Research; NIHR; Italian Ministry
   of Health; Fondazione Roma, Italy; NATIONAL EYE INSTITUTE [U01EY020522]
   Funding Source: NIH RePORTER
FX External sources; National Institute of Health Research (NIHR), UK.;
   Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision
   Group (CEVG) acknowledges financial support for his CEVG research
   sessions from the Department of Health through the award made by the
   National Institute for Health Research to Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology for a Specialist
   Biomedical Research Centre for Ophthalmology.; The NIHR also funds the
   CEVG Editorial Base in London.; The views expressed in this publication
   are those of the authors and not necessarily those of the NIHR, NHS, or
   the Department of Health.; The contribution of the IRCCS Fondazione
   Bietti in this paper was supported by the Italian Ministry of Health and
   by Fondazione Roma, Italy.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Alexander J, 2004, INVESTIGATIVE OPHTHA, V45
   [Anonymous], 1998, Ophthalmology, V105, P1364
   [Anonymous], 1998, Ophthalmology, V105, P11
   [Anonymous], 2014, REV MAN REVMAN VERS
   Beaumont P, 2011, CLIN EXPT OPHTHAL S1, V39, P23
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler SB, 1995, INVESTIGATIVE OPHTHA, V36
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Chakravarthy Usha, 2005, Curr Opin Ophthalmol, V16, P179, DOI 10.1097/01.icu.0000163035.37957.c2
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Figueroa M, 2004, BRIT J OPHTHALMOL, V88, P792, DOI 10.1136/bjo.2003.033837
   Figueroa M, 2006, AM J OPHTHALMOL, V141, P863, DOI 10.1016/j.ajo.2005.11.049
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Fine SL, 2001, INVESTIGATIVE OPHTHA, V42
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Frennesson CI, 2009, ACTA OPHTHALMOL, V87, P720, DOI 10.1111/j.1755-3768.2008.01396.x
   Frennesson CI, 2003, ACTA OPHTHALMOL SCAN, V81, P449, DOI 10.1034/j.1600-0420.2003.00143.x
   Frennesson I C, 1996, Eur J Ophthalmol, V6, P307
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GRADEpro GDT, 2015, GRADEPRO GUID DEV TO
   Gross-Jendroska M, 1998, AM J OPHTHALMOL, V126, P77, DOI 10.1016/S0002-9394(98)00061-0
   Grunwald JE, 2004, INVESTIGATIVE OPHTHA, V45
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Guymer RH, 2001, BRIT J OPHTHALMOL, V85, P40, DOI 10.1136/bjo.85.1.40
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Ho AC, 1998, AM ACAD OPHTHALMOLOG, P127
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Huang YX, 2011, CHINESE MED J-PEKING, V124, P541, DOI 10.3760/cma.j.issn.0366-6999.2011.04.011
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kertes PJ, 2006, EVIDENCE BASED OPHTH, V7, P135
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Langan D, 2012, J CLIN EPIDEMIOL, V65, P511, DOI 10.1016/j.jclinepi.2011.10.009
   Lavinsky D, 2011, INVEST OPHTH VIS SCI, V52, P4314, DOI 10.1167/iovs.10-6828
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Little HL, 1995, AM ACAD OPHTHALMOLOG, P120
   Luttrull JK, 2012, CURR DIABETES REV, V8, P274, DOI 10.2174/157339912800840523
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Parodi MB, 2008, BRIT J OPHTHALMOL, V92, P1046, DOI 10.1136/bjo.2007.128025
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Parodi MB, 2006, OPHTHALMOLOGY, V113, P2237, DOI 10.1016/j.ophtha.2006.05.056
   Parodi MB, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006537, DOI 10.1002/14651858.CD006537]
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Regillo CD, 2003, EVIDENCE BASED EYE C, V4, P204
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Rosenbaltt BJ, 2001, INVESTIGATIVE OPHTHA, V42
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Sbarbaro JA, 2004, INVESTIGATIVE OPHTHA, V45
   Schtinemann HJ, 2011, COCHRANE HDB SYSTEMA
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   Sivagnanavel V, 2004, INVESTIGATIVE OPHTHA, V45
   Sivaprasad S, 2010, SURV OPHTHALMOL, V55, P516, DOI 10.1016/j.survophthal.2010.02.005
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   StataCorp, 2013, STATA STAT SOFTW REL
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Stoltz RA, 2004, INVESTIGATIVE OPHTHA, V45
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wetzig P C, 1994, Trans Am Ophthalmol Soc, V92, P299
   White IR, 2008, STAT MED, V27, P711, DOI 10.1002/sim.3008
   Ying GS, 2005, INVEST OPHTH VIS SCI, V46
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 93
TC 37
Z9 37
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2015
IS 10
AR CD006537
DI 10.1002/14651858.CD006537.pub3
PG 69
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CX9XO
UT WOS:000366060300021
PM 26493180
OA Green Accepted, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Joussen, AM
   Wong, D
   Walter, P
   Kirchhof, B
   Dreyhaupt, J
   Bauer, C
   Munzinger, J
   Unnebrink, K
   Freiberger, A
   Seibert-Grafe, M
   Victor, N
AF Joussen, A. M.
   Wong, D.
   Walter, P.
   Kirchhof, B.
   Dreyhaupt, J.
   Bauer, C.
   Munzinger, J.
   Unnebrink, K.
   Freiberger, A.
   Seibert-Grafe, M.
   Victor, N.
CA MARAN Study Grp
TI Surgical management of subfoveal choroidal neovascular membranes in
   age-related macular degeneration by macular relocation: experiences of
   an early-stopped randomised clinical trial (MARAN Study)
SO EYE
LA English
DT Article
DE age-related macular degeneration; macular relocation; randomised
   clinical trial
ID 360-DEGREE PERIPHERAL RETINECTOMY; QUALITY-OF-LIFE; PHOTODYNAMIC
   THERAPY; TRANSLOCATION SURGERY; RADIATION-THERAPY; VISUAL FUNCTION;
   PILOT-TRIAL; RANIBIZUMAB; VERTEPORFIN; ACUITY
AB Rationale The MARAN (Macular Relocation in Age-related Neovascular disease) trial was planned to assess the effectiveness of full macular relocation (MR) in patients with neovascular age-related macular degeneration (AMD).
   Design Randomised, prospective, controlled clinical trial.
   Methods Patients suffering from visual loss because of AMD were randomised to either surgery or a control group receiving standard treatment (observation or photodynamic therapy (PDT)). The primary end point was the change of visual acuity (VA) (ETDRS) 52 weeks after randomisation compared with initial VA, and secondary end points included reading performance, contrast sensitivity, stability of fixation, eye-specific quality of life, and the absolute number of letters read correctly at 52 weeks compared with initial examination.
   Results Owing to early determination, only 28 patients were included in the study. The study did not show a difference between the two groups with respect to the final visual result or any of the secondary outcomes measured. The study was limited by the low recruitment that was, at least in part, attributed to the inherent risks for those patients randomised to the surgical arm of the study as well as to the emerging new treatments for AMD.
   Conclusion The results of the MARAN trial failed to recruit a sufficient number of patients and a superiority of surgery over observation or PDT in patients with exudative AMD was not shown. There was a trend that the reading function was superior after surgery. In the light of the new pharmacological treatments, surgical options such as MR will be an option for only selected cases. Eye (2010) 24, 284-289; doi: 10.1038/eye.2009.107; published online 29 May 2009
C1 [Joussen, A. M.] Univ Dusseldorf, Dept Ophthalmol, D-402225 Dusseldorf, Germany.
   [Wong, D.] Royal Liverpool Univ Hosp, Dept Ophthalmol, Liverpool, Merseyside, England.
   [Walter, P.] Rhein Westfal TH Aachen, Dept Ophthalmol, Aachen, Germany.
   [Kirchhof, B.] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-5000 Cologne 41, Germany.
   [Dreyhaupt, J.; Bauer, C.; Munzinger, J.; Unnebrink, K.; Freiberger, A.; Victor, N.] Univ Heidelberg, IMBI, D-6900 Heidelberg, Germany.
   [Seibert-Grafe, M.] Johannes Gutenberg Univ Mainz, Koordinierungszentrum Klin Studien, D-6500 Mainz, Germany.
C3 Heinrich Heine University Dusseldorf; Royal Liverpool & Broadgreen
   University Hospitals NHS Trust; Royal Liverpool University Hospital;
   University of Liverpool; RWTH Aachen University; University of Cologne;
   Ruprecht Karls University Heidelberg; Johannes Gutenberg University of
   Mainz
RP Joussen, AM (通讯作者)，Univ Dusseldorf, Dept Ophthalmol, Moorenstr 5, D-402225 Dusseldorf, Germany.
EM Joussena@googlemail.com
RI Holle, Rolf/D-9333-2013; Joussen, Antonia/AAA-6901-2022; Wong, Sai Hung
   David/D-8482-2015; Walter, Peter/L-5982-2018
OI Holle, Rolf/0000-0001-5395-2695; Walter, Peter/0000-0001-8745-6593
FU Deutsche Forschungsgemeinschaft; Brunnenbusch Stein Stiftung; Glaser
   Stiftung; RetinoVit Stiftung Koln
FX This study was funded by the Deutsche Forschungsgemeinschaft, the
   Brunnenbusch Stein Stiftung, the Glaser Stiftung and the RetinoVit
   Stiftung Koln. Joussen AM, Wong D, Walter P, Kirchhof B were involved in
   the study design and writing of the paper. Dreyhaupt J, Bauer C,
   Munzinger J, Unnebrink K, Freiberger A, Seibert-Grafe M, and Victor N
   were involved in the statistical evaluation, monitoring and writing of
   the paper.
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Franke GH, 1998, Z MED PSYCHOL, P178
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Luke M, 2007, GRAEF ARCH CLIN EXP, V245, P1831, DOI 10.1007/s00417-007-0558-9
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   MANGIONE C, 2000, NATL EYE I 25 ITEM V, P1
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   Park CH, 2003, AM J OPHTHALMOL, V136, P830, DOI 10.1016/S0002-9394(03)00723-2
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Wong D, 2007, CLIN EXP OPHTHALMOL, V35, P167, DOI 10.1111/j.1442-9071.2006.01410.x
NR 21
TC 2
Z9 2
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD FEB
PY 2010
VL 24
IS 2
BP 284
EP 289
DI 10.1038/eye.2009.107
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 553WQ
UT WOS:000274397900012
PM 19478822
OA Bronze
DA 2022-11-30
ER

PT J
AU Ziskind, A
   Bardien, S
   van der Merwe, L
   Webster, AR
AF Ziskind, Ari
   Bardien, Soraya
   van der Merwe, Lize
   Webster, Andrew R.
TI The frequency of the H402 allele of CFH and its involvement with
   age-related maculopathy in an aged Black African Xhosa population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Y402H; CFH gene; Black African Xhosa population
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; ASSOCIATION; GENOME; EYE
AB The H402 allele of the CFH gene is an established risk factor for age-related maculopathy (ARMD) in Caucasians, accounting for approximately 60% of the genetic risk at the population level.(1) In general, the advanced forms of ARMD are rare in Black populations in Africa, as well as Black populations who have lived for generations in the United States or the West Indies, although there are reports that the earlier forms such as drusen may not be all that uncommon.(2-4) The aim of the present study was to estimate the frequency of the C allele of the CFH Y402H variant in an aged South African Black Xhosa population and to describe the evidence of ARMD found.
C1 [Ziskind, Ari] Univ Stellenbosch, Div Ophthalmol, Fac Hlth Sci, ZA-7505 Cape Town, South Africa.
   [Bardien, Soraya] Univ Stellenbosch, Fac Hlth Sci, Div Human Genet & Mol Biol, Cape Town, South Africa.
   [van der Merwe, Lize] MRC, Biostat Unit, Cape Town, South Africa.
   [Webster, Andrew R.] Moorfields Eye Hosp, London, England.
   [Webster, Andrew R.] UCL, Inst Ophthalmol, London, England.
C3 Stellenbosch University; Stellenbosch University; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Ziskind, A (通讯作者)，Univ Stellenbosch, Div Ophthalmol, Fac Hlth Sci, POB 19059, ZA-7505 Cape Town, South Africa.
EM az@sun.ac.za
RI Bardien, Soraya/AAJ-9003-2020; Bardien, Soraya/ABB-3313-2020; van der
   Merwe, Lize/D-3148-2012
OI Bardien, Soraya/0000-0002-3508-3438; van der Merwe,
   Lize/0000-0001-9705-8126
FU Division of Ophthalmology at the University of Stellenbosch
FX We thank the study participants for taking part in this study, Yandiswa
   Yako for technical assistance with the laboratory work and Vusi Majebe
   for assistance with the data collection. This research was supported by
   research funds from the Division of Ophthalmology at the University of
   Stellenbosch.
CR BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   CORFIELD VA, 1993, TRANSFUSION, V33, P119, DOI 10.1046/j.1537-2995.1993.33293158042.x
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   MAGNUSSON KP, 2006, PLOS MED, V3
   Stoneking M, 1996, CURR OPIN GENET DEV, V6, P731, DOI 10.1016/S0959-437X(96)80028-1
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
NR 11
TC 12
Z9 12
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2008
VL 29
IS 3
BP 117
EP 119
DI 10.1080/13816810802216472
PG 3
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 344DI
UT WOS:000258905600005
PM 18766990
DA 2022-11-30
ER

PT J
AU McKay, GJ
   Clarke, S
   Hughes, A
   McConnell, V
   Schultz, D
   Klein, M
   Silvestri, G
   Simpson, D
AF McKay, GJ
   Clarke, S
   Hughes, A
   McConnell, V
   Schultz, D
   Klein, M
   Silvestri, G
   Simpson, D
TI A novel diagnostic test detects a low frequency of the hemicentin
   Gln5345Arg variant among northern irish age related macular degeneration
   patients
SO MOLECULAR VISION
LA English
DT Article
ID SUSCEPTIBILITY LOCI; EXTENDED FAMILIES; GENOMEWIDE-SCAN; MACULOPATHY;
   ROTTERDAM; MUTATION; LINKAGE
AB Purpose: Age related macular degeneration (AMD) is a common cause of severe vision loss. Identification of genes involved in AMD will facilitate early detection and ultimately help to identify pathways for treatment for this disorder. The A16,263G mutation in the HEMICENTIN-1 gene produces a non-conservative substitution of arginine for glutamine at codon 5345 which has been implicated in familial AMD. The aim of this study is to develop a rapid diagnostic assay for the detection of this mutation and to evaluate its frequency in a sample of AMD patients.
   Methods: A primer probe set was designed from exon 104 of the HEMICENTIN-1 gene to differentiate between mutant and wild type alleles. A region spanning the mutation was amplified by PCR using a LightCycler (Roche Diagnostic). The mutation was then detected by melt curve analysis of the hybrid formed between the PCR product and a specific fluorescent probe. The frequency of the mutation within the Northern Ireland population was evaluated by assaying 508 affected AMD patients, 25 possibly affected and 163 controls.
   Results: This assay clearly discriminates between the A16,263G mutant and wild type HEMICENTIN-1 alleles. The wild type sequence has a single base mismatch with the probe which decreases the stability of the hybrid, resulting in a lower TM (TM=51.27 degreesC) than that observed for the perfectly matched mutant allele (TM=59.9 degreesC). The mutant allele was detected in only one of the 696 subjects, an affected AMD patient.
   Conclusions: We describe a rapid assay for the genotyping of the Gln5345Arg mutation using real-time fluorescence PCR to facilitate rapid processing of samples through combined amplification and detection steps. These characteristics are suitable for a clinical setting where high throughput diagnostic procedures are required. The frequency of this mutation within the Northern Ireland population has been estimated at 0.2%, concurring with previous findings that this mutation is a rare variant associated with AMD. A rapid diagnostic assay will facilitate a reliable and convenient evaluation of the frequency of the Gln5345Arg mutation and its association with AMD within other populations.
C1 Queens Univ Belfast, Dept Ophthalmol & Visual Sci, Belfast, Antrim, North Ireland.
   Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland.
   Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR USA.
C3 Queens University Belfast; Queens University Belfast; Oregon Health &
   Science University
RP Simpson, D (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland.
EM david.simpson@qub.ac.uk
RI McKay, Gareth/AAZ-2601-2020
OI McKay, Gareth/0000-0001-8197-6280; Silvestri,
   Giuliana/0000-0001-5662-5374
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Gorin MB, 1999, MOL VIS, V5, pU31
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MCKAY GJ, 2004, ARVO ANN M APR 25 29
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Sternberg P, 2004, AM J OPHTHALMOL, V137, P483, DOI 10.1016/j.ajo.2003.11.023
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   *US DEP HHS, 1998, NIH984288 PUBL
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   vanLeeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P955
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
NR 21
TC 8
Z9 9
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 24
PY 2004
VL 10
IS 82
BP 682
EP 687
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 859NT
UT WOS:000224275900001
PM 15467524
DA 2022-11-30
ER

PT J
AU Camelo, S
   Latil, M
   Veillet, S
   Dilda, PJ
   Lafont, R
AF Camelo, Serge
   Latil, Mathilde
   Veillet, Stanislas
   Dilda, Pierre J.
   Lafont, Rene
TI Beyond AREDS Formulations, What Is Next for Intermediate Age-Related
   Macular Degeneration (iAMD) Treatment? Potential Benefits of Antioxidant
   and Anti-inflammatory Apocarotenoids as Neuroprotectors
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID ENDOPLASMIC-RETICULUM STRESS; RETINAL-PIGMENT EPITHELIUM; FACTOR-H
   POLYMORPHISM; OXIDATIVE STRESS; PHOTORECEPTOR DEGENERATION;
   STRUCTURAL-CHANGES; DARK-ADAPTATION; ECONOMIC BURDEN; LUTEIN; ZEAXANTHIN
AB Age-related macular degeneration (AMD) is the commonest cause of severe visual loss and blindness in developed countries among individuals aged 60 and older. AMD slowly progresses from early AMD to intermediate AMD (iAMD) and ultimately late-stage AMD. Late AMD encompasses either neovascular AMD (nAMD) or geographic atrophy (GA). nAMD is defined by choroidal neovascularization (CNV) and hemorrhage in the subretinal space at the level of the macula. This induces a rapid visual impairment caused by the death of photoreceptor cells. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) antibodies is the standard treatment of nAMD but adds to the burden of patient care. GA is characterized by slowly expanding photoreceptor, and retinal pigment epithelium (RPE) degeneration patches progressively leading to blindness. There is currently no therapy to cure GA. Late AMD continues to be an unmet medical need representing a major health problem with millions of patients worldwide. Oxidative stress and inflammation are recognized as some of the main risk factors to developing late AMD. The antioxidant formulation AREDS (Age-Related Eye Disease Studies), contains beta-carotene, which has been replaced by lutein and zeaxanthin in AREDS2, are given to patients with iAMD but have a limited effect on the incidence of nAMD and GA. Thus, to avoid or slowdown the development of late stages of AMD (nAMD or GA), new therapies targeting iAMD are needed such as crocetin obtained through hydrolysis of crocin, an important component of saffron (Crocus sativus L.), and norbixin derived from bixin extracted from Bixa orellana seeds. We have shown that these apocarotenoids preserved more effectively RPE cells against apoptosis following blue light exposure in the presence of A2E than lutein and zeaxanthin. In this review, we will discuss the potential use of apocarotenoids to slowdown the progression of iAMD, to reduce the incidence of both forms of late AMD.
C1 [Camelo, Serge; Latil, Mathilde; Veillet, Stanislas; Dilda, Pierre J.; Lafont, Rene] Sorbonne Univ, Biophytis, BC9,4 Pl Jussieu, F-75005 Paris, France.
   [Lafont, Rene] Sorbonne Univ, CNRS, Inst Biol Paris Seine BIOSIPE, F-75005 Paris, France.
C3 UDICE-French Research Universities; Sorbonne Universite; Centre National
   de la Recherche Scientifique (CNRS); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite
RP Camelo, S (通讯作者)，Sorbonne Univ, Biophytis, BC9,4 Pl Jussieu, F-75005 Paris, France.
EM serge.camelo@biophytis.com; mathilde.latil@biophytis.com;
   stanislas.veillet@biophytis.com; pierre.dilda@biophytis.com;
   lafont.rene@wanadoo.fr
RI LAFONT, Rene/GYA-4891-2022
OI Camelo, Serge/0000-0001-8733-8503; Lafont, Rene/0000-0002-8044-540X;
   Dilda, Pierre/0000-0001-9916-8513; Latil, Mathilde/0000-0002-8424-017X
FU Biophytis
FX The contribution of Dr. L.N. Dinan (Biophytis) for critical reading of
   the manuscript and language improvement is acknowledged. We thank L.
   Guibout for his help with the presentation of the chemical structures.
   This work was financed by the Biophytis.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Arunkumar R, 2018, EYE, V32, P992, DOI 10.1038/s41433-018-0044-0
   Asai A, 2005, J AGR FOOD CHEM, V53, P7302, DOI 10.1021/jf0509355
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bernstein PS, 2012, INVEST OPHTH VIS SCI, V53, P6178, DOI 10.1167/iovs.12-10275
   Bianchi E, 2013, INT J MOL MED, V31, P232, DOI 10.3892/ijmm.2012.1164
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Broadhead GK, 2019, GRAEF ARCH CLIN EXP, V257, P31, DOI 10.1007/s00417-018-4163-x
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Corso L, 2016, PURINERG SIGNAL, V12, P161, DOI 10.1007/s11302-015-9490-3
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Di Marco S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070224
   Doumouchtsis Evangelos K., 2018, Journal of Dietary Supplements, V15, P471, DOI 10.1080/19390211.2017.1356417
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Fernandez-Albarral JA, 2020, NEURAL REGEN RES, V15, P1408, DOI 10.4103/1673-5374.274325
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fontaine V, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/j.1755-3768.2017.0F070
   Fontaine V., 2020, BIORXIV
   Fontaine V, 2020, AGING-US, V12, P6151, DOI 10.18632/aging.103014
   Fontaine V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167793
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Karimi P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082949
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Korobelnik JF, 2017, JAMA OPHTHALMOL, V135, P1259, DOI 10.1001/jamaophthalmol.2017.3398
   KOSNIK W, 1988, J GERONTOL, V43, pP63, DOI 10.1093/geronj/43.3.P63
   Kuppermann BD, 2021, RETINA-J RET VIT DIS, V41, P144, DOI 10.1097/IAE.0000000000002789
   La Torre G, 2013, EUR J EPIDEMIOL, V28, P445, DOI 10.1007/s10654-013-9798-7
   Laabich A, 2006, INVEST OPHTH VIS SCI, V47, P3156, DOI 10.1167/iovs.05-1621
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lautenschlager M, 2014, FITOTERAPIA, V92, P290, DOI 10.1016/j.fitote.2013.11.014
   Lech K, 2009, J MASS SPECTROM, V44, P1661, DOI 10.1002/jms.1631
   Li BX, 2018, ARCH BIOCHEM BIOPHYS, V649, P22, DOI 10.1016/j.abb.2018.05.003
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Madhavan J, 2018, PHARMACOGN MAG, V14, P268, DOI 10.4103/pm.pm_340_17
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   OH J, 2013, MEDIAT INFLAMM, V2013, DOI DOI 10.1155/2013/787042
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Roehrs M, 2017, FOOD RES INT, V100, P771, DOI 10.1016/j.foodres.2017.08.005
   Roehrs M, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/839095
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   Satyanarayana A, 2003, J FOOD SCI TECH MYS, V40, P131
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sepahi S, 2021, CURR NEUROPHARMACOL, V19, P392, DOI 10.2174/1570159X18666200507083346
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Tsuruma K, 2012, MOL NUTR FOOD RES, V56, P713, DOI 10.1002/mnfr.201100607
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2018, INVEST OPHTH VIS SCI, V59, P273, DOI 10.1167/iovs.17-22751
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
   Yanai R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196037
   Yorgun Mucella Arikan, 2017, Biochem Biophys Rep, V12, P245, DOI 10.1016/j.bbrep.2017.09.007
   Yu MZ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070842
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
NR 103
TC 7
Z9 8
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD DEC 8
PY 2020
VL 2020
AR 4984927
DI 10.1155/2020/4984927
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA PI6NU
UT WOS:000601206200001
PM 33520083
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sadda, SR
   Abdelfattah, NS
   Lei, JQ
   Shi, Y
   Marion, KM
   Morgenthien, E
   Gune, S
   Balasubramanian, S
AF Sadda, SriniVas R.
   Abdelfattah, Nizar Saleh
   Lei, Jianqin
   Shi, Yue
   Marion, Kenneth M.
   Morgenthien, Elizabeth
   Gune, Shamika
   Balasubramanian, Siva
TI Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy
   Development in the HARBOR Study for Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; GEOGRAPHIC-ATROPHY; RETICULAR PSEUDODRUSEN;
   CHOROIDAL THICKNESS; NATURAL-HISTORY; GROWTH; EYES; ASSOCIATION;
   BEVACIZUMAB; PROGRESSION
AB Purpose: To identify baseline risk factors for macular atrophy (MA) development in HARBOR via a longitudinal assessment of monthly spectral-domain (SD)-OCT scans. Previous analyses of MA in HARBOR examined data from color fundus photography (CFP) and fluorescein angiography (FA).
   Design: Retrospective, post hoc analysis of SD-OCT images from HARBOR (ClinicalTrial.gov identifier, NCT00891735), a phase 3, multicenter, prospective, randomized, double-blind, active treatment-controlled clinical trial.
   Participants: Patients (N = 1097) with subfoveal choroidal neovascularization secondary to neovascular age-related macular degeneration (nAMD) treated with intravitreal ranibizumab 0.5 mg monthly (n = 275), 0.5 mg pro re nata (PRN) after 3 loading doses (n = 275), 2.0 mg monthly (n = 274), or 2.0 mg PRN (n = 273).
   Methods: Evaluable SD-OCT macular cube scans from patients with 24 months of follow-up (N = 941) were examined monthly from baseline to month 24 by masked reading center-trained graders. Atrophy diagnosis criteria were consistent with those proposed by the Classification of Atrophy Meetings (CAM) group: hypertransmission of light into the choroid, loss of retinal pigment epithelium, and loss of outer retinal layers. Multivariable proportional hazards regression was performed for time to atrophy development.
   Main Outcome Measures: Risk factors for MA as determined by time to MA development over 24 months of treatment.
   Results: Baseline risk factors for MA were confirmed from prior analyses that used CFP and FA data: absence of subretinal fluid, presence of intraretinal cysts, presence of Type 3 neovascularization, and presence of atrophy in the fellow eye. This analysis of SD-OCT data identified new baseline risk factors for MA: higher central drusen volume, lower choroidal thickness, presence of nascent atrophy, presence of reticular pseudodrusen, and increased central foveal thickness. Ranibizumab treatment regimen and dose level were not found to be risk factors for MA development.
   Conclusions: In this analysis of a major nAMD trial using CAM atrophy criteria, new baseline risk factors for MA development were identified using an SD-OCT dataset. Risk factors for MA development identified by prior analyses were confirmed. Monthly treatment with ranibizumab 0.5 mg was not found to be a risk factor for MA development over 24 months. (C) 2020 by the American Academy of Ophthalmology.
C1 [Sadda, SriniVas R.; Abdelfattah, Nizar Saleh; Lei, Jianqin; Shi, Yue; Marion, Kenneth M.; Balasubramanian, Siva] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Sadda, SriniVas R.; Abdelfattah, Nizar Saleh] UCLA, Dept Ophthalmol, David Geffen Sch Med, Los Angeles, CA USA.
   [Lei, Jianqin] Xi An Jiao Tong Univ, Dept Ophthalmol, Affiliated Hosp 1, Xian, Peoples R China.
   [Morgenthien, Elizabeth; Gune, Shamika] Genentech Inc, San Francisco, CA 94080 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Xi'an Jiaotong
   University; Roche Holding; Genentech
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Abdelfattah, Nizar Saleh/H-6908-2019
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054
FU Genentech, Inc., South San Francisco, California
FX Supported by Genentech, Inc., South San Francisco, California. The
   sponsor funded third-party writing assistance and participated in the
   study design; data management, analysis, and interpretation; and
   preparation, review, and approval of the manuscript.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Domalpally A, 2018, OPHTHALMOL RETINA, V2, P1021, DOI 10.1016/j.oret.2018.04.009
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Ho CYD, 2018, CLIN EXP OPHTHALMOL, V46, P485, DOI 10.1111/ceo.13131
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   SADDA SR, 2018, INVEST OPHTH VIS SCI, V59
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   THULLIEZ M, 2019, IMAGING OPHTHALMOL R, V3, P478, DOI DOI 10.1016/j.oret.2019.01.024
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
NR 44
TC 20
Z9 20
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2020
VL 127
IS 10
BP 1360
EP 1370
DI 10.1016/j.ophtha.2020.03.031
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NT0HB
UT WOS:000572632200017
PM 32402555
OA hybrid
DA 2022-11-30
ER

PT J
AU Fujii, GY
   De Juan, E
   Pieramici, DJ
   Humayun, MS
   Phillips, S
   Reynolds, SM
   Melia, M
   Schachat, AP
AF Fujii, GY
   De Juan, E
   Pieramici, DJ
   Humayun, MS
   Phillips, S
   Reynolds, SM
   Melia, M
   Schachat, AP
TI Inferior limited macular translocation for subfoveal choroidal
   neovascularization secondary to age-related macular degeneration: 1-year
   visual outcome and recurrence report
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To report the 1-year visual outcomes and incidence of persistent and recurrent choroidal neovascularization (CNV) after limited macular translocation (LMT) for subfoveal CNV in patients with age related macular degeneration (ARMD).
   DESIGN: Interventional case series.
   METHODS: Retrospective review of 102 consecutive eyes of 101 patients that had the inferior limited macular translocation procedure for subfoveal choroidal neovascularization secondary to ARMD. The outcome measures were visual acuity at 12 months after surgery, change in visual acuity from baseline, the proportion of eyes with moderate (3 or more lines) or severe (6 or more lines) visual acuity loss, and cumulative incidence of persistent or recurrent CNV and its impact on visual acuity. Cumulative incidence was estimated using Kaplan-Meier survival analysis methods. Association between persistence and recurrence of CNV and the Snellen visual acuity recorded at each follow,up visit was evaluated using the Wilcoxon rank sum test.
   RESULTS: Eighty-six (84.3%) of 102 eyes completed the 1 year follow,up. By 12 months postoperatively, 35 (40.7%) of the 86 eyes achieved visual acuity of 20/100 or better while 34 (39.5%) of the 86 eyes experienced 2 or more Snellen lines of visual improvement. In the 52 eyes with effective translocation and complete laser photocoagulation of the CNV complex with sparing of the sensory fovea, the estimated incidence of recurrence was 34.6% at 12 months (95% confidence interval of 21%-48%). Sixty-five percent of the recurrences were subfoveal and caused a decrease in visual acuity. There was a trend toward worse median change in visual acuity in eyes with persistent or recurrent CNV.
   CONCLUSIONS: Limited macular translocation for the treatment of subfoveal CNV secondary to ARMD is associated with improvement in visual acuity in approximately 39.5% of eyes and enables complete laser photocoagulation of the neovascular complex with sparing of the sensory macula in approximately 60.4% of eyes that complete 1 year follow,up. Persistence and recurrence of CNV are common after LMT and are important causes of vision loss. Further studies are warranted to more prep cisely evaluate the risks and benefits of LMT in ARMD. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Univ So Calif, Keck Sch Med, Doheny Retina Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Doheny Eye Ctr, Los Angeles, CA 90033 USA.
   Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
C3 University of Southern California; Doheny Eye Institute; University of
   Southern California; Johns Hopkins University; Johns Hopkins Medicine
RP De Juan, E (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Retina Inst, 1450 San Pablo St,Room 3620, Los Angeles, CA 90033 USA.
CR de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
NR 8
TC 34
Z9 35
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2002
VL 134
IS 1
BP 69
EP 74
AR PII S0002-9394(02)01511-8
DI 10.1016/S0002-9394(02)01511-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 569QX
UT WOS:000176614600010
PM 12095810
DA 2022-11-30
ER

PT J
AU Finger, RP
   Dennis, N
   Freitas, R
   Quenechdu, A
   Clemens, A
   Karcher, H
   Souied, EH
AF Finger, Robert P.
   Dennis, Natalie
   Freitas, Rita
   Quenechdu, Arthur
   Clemens, Andreas
   Karcher, Helene
   Souied, Eric H.
TI Comparative Efficacy of Brolucizumab in the Treatment of Neovascular
   Age-Related Macular Degeneration: A Systematic Literature Review and
   Network Meta-Analysis
SO ADVANCES IN THERAPY
LA English
DT Review
DE Brolucizumab; Neovascular age-related macular degeneration; nAMD;
   Network meta-analysis; NMA; Anti-VEGF
ID RANIBIZUMAB; OUTCOMES; EXTEND
AB Introduction A systematic literature review (SLR) and network meta-analysis (NMA) were conducted to evaluate the comparative efficacy of brolucizumab relative to other anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) at 1 and 2 years, and overall safety and injection frequency of each treatment. Methods An SLR identifying randomized controlled trials (RCTs) published before June 2021 according to a pre-specified protocol was followed by a Bayesian NMA to compare brolucizumab (6 mg q12w/q8w) against sham and all relevant anti-VEGF regimens. Pooled mean injection frequency, serious adverse ocular events, and discontinuation rates were estimated for each treatment regimen. Results Nineteen RCTs were included in NMA base-case analysis. Brolucizumab (6 mg q12w/q8w) with loading-phase (LP) demonstrated superior best-corrected visual acuity (BCVA) gains to sham both at year 1 (mean difference 16.8 [95%CrI 13.3, 20.4]) and year 2 (mean difference 21.2 [95%CrI 17.4, 25.0]) and was comparable to other anti-VEGFs. Brolucizumab (6 mg q12w/q8w) also showed superior retinal thickness reduction to most comparators including ranibizumab (0.5 mg q4w; year 1 mean difference - 50.1 [95%CrI - 70.3, - 29.8]; year 2 mean difference - 49.5 [95%CrI - 70.8, - 28.6]), aflibercept (2 mg q8w; year 1 mean difference - 39.7 [95%CrI - 52.9, - 26.4]; year 2 mean difference - 35.0 [95%CrI - 49.1, - 21.4]), and faricimab (6 mg q16w/q8w; year 1 mean difference - 27.6 [95%CrI - 42.3, - 12.8]). Brolucizumab (6 mg q12w/q8w) showed similar rates of treatment discontinuation and serious and overall adverse events (both years). At year 2, pooled annualized injection frequency was lowest for brolucizumab (6 mg q12w/q8w) and highest for ranibizumab (0.5 mg q4w) at 5.7 and 11.5 injections annually, respectively. Conclusion Among all licensed anti-VEGF treatments, brolucizumab showed superior reduction in retinal thickness and comparable BCVA gains and discontinuation rates, despite having the lowest injection frequency. The current study provides the most up-to-date, robust comparison of treatments for nAMD.
C1 [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Dennis, Natalie] Amaris, Hlth Econ & Market Access, Paris, France.
   [Freitas, Rita] Novartis Farma Prod Farmaceut SA, Porto Salvo, Portugal.
   [Quenechdu, Arthur] Amaris, Hlth Econ & Market Access, Montreal, PQ, Canada.
   [Clemens, Andreas; Karcher, Helene] Novartis Pharma AG, Basel, Switzerland.
   [Clemens, Andreas] Univ Freiburg, Heart Ctr Freiburg Univ, Fac Med, Dept Cardiol & Angiol 1, Freiburg, Germany.
   [Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Biol Resources Ctr, GRC Macula, Clin Res Ctr, Creteil, France.
C3 University of Bonn; Novartis; Universitats Herzzentrum Freiburg;
   University of Freiburg; Universite Paris-Est-Creteil-Val-de-Marne
   (UPEC); CHI Creteil; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   CHI Creteil
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Bonn, Germany.
EM robert.finger@ukbonn.de
FU Novartis Pharma AG; Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL. This study
   was funded by Novartis Pharma AG. Novartis Pharma AG is also funding the
   journal's Rapid Service and Open Access Fees.
CR Airas L, 2020, MULT SCLER RELAT DIS, V40, DOI 10.1016/j.msard.2020.101980
   [Anonymous], VABYSMOTM FARICIMAB
   [Anonymous], GUID METH TECHN APPR
   Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12
   Carrasco J, 2021, OPHTHALMOL THER, V10, P397, DOI 10.1007/s40123-021-00350-5
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Dias, 2014, NICE DSU TECHNICAL S
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   European Medicines Agency Committee for medicinal products for human use (CHMP), 2021, DRAFT AGENDA M 2124
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Holz FG, 2021, OPHTHALMOLOGE, V118, P248, DOI 10.1007/s00347-021-01321-8
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khoramnia R, 2022, GRAEF ARCH CLIN EXP, V260, P1843, DOI 10.1007/s00417-021-05518-0
   Laws A, 2014, VALUE HEALTH, V17, P642, DOI 10.1016/j.jval.2014.06.001
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   National Institute for Health and Care Excellence, 2021, VIRT CAR RAM PER CAN
   National Institute for Health and Care Excellence (NICE), 2018, MACULAR DEGENERATION
   Novartis, 2022, BEOV GLOB US SAF INF
   Novartis, 2020, BEOV US PRESCR INF
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Sepahi S, 2018, AM J OPHTHALMOL, V190, P89, DOI 10.1016/j.ajo.2018.03.007
   Sharma A, 2021, EYE, V35, P1548, DOI 10.1038/s41433-020-01324-w
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   SINGER M, OPHTHALMOL RETINA, V2021
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Lu Y, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320953349
   Zhao XY, 2021, ACTA OPHTHALMOL, V99, pE1041, DOI 10.1111/aos.14756
   Ziemssen F, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-06362-w
NR 40
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD AUG
PY 2022
VL 39
IS 8
BP 3425
EP 3448
DI 10.1007/s12325-022-02193-3
EA JUN 2022
PG 24
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 3F1SH
UT WOS:000808403400001
PM 35678996
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Yang, SS
   Gao, ZY
   Qiu, HJ
   Zuo, CG
   Mi, L
   Xiao, H
   Liu, X
AF Yang, Shasha
   Gao, Zongyin
   Qiu, Haijiang
   Zuo, Chengguo
   Mi, Lan
   Xiao, Hui
   Liu, Xing
TI Low-Reflectivity Drusen With Overlying RPE Damage Revealed by
   Spectral-Domain OCT: Hint for the Development of Age-Related Macular
   Degeneration
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE drusen; age-related macular degeneration (AMD); optical coherence
   tomography; character; predictor
ID OPTICAL COHERENCE TOMOGRAPHY; SOFT DRUSEN; GEOGRAPHIC ATROPHY;
   PROGRESSION; PREVALENCE
AB Purpose: To observe the relationship between the characteristic changes in the drusen morphology revealed by the spectral-domain optical coherence tomography (SD-OCT) and the progression of age-related macular degeneration (AMD).
   Methods: A total of 380 drusen in 45 eyes in 35 patients with the intermediate drusen were longitudinally followed up every 6 months by SD-OCT for a period of 24 months. The drusen were divided into the dynamic group and stable group according to the following parameters: number, volume, concurrent retinal pigment epithelium (RPE)/ellipsoid zone (EZ) damage, and the development of advanced AMD. The morphological characteristics of the progressive or stable drusen were further analyzed. Odds ratios (ORs) and the risk for the drusen progression were calculated.
   Results: The level of interobserver and intraobserver agreement for each drusen tomographic morphological parameters ranged from 82.7 to 90%. At the end of an average follow-up of 15.92 +/- 6.99 months, six patients developed choroidal neovascularization and no patients developed geographic atrophy. Finally, 139 drusen changed and 241 drusen remained stable. The drusen with low reflectivity (p < 0.001; OR: 5.26; 95% CI: 2.24-12.36), non-homogeneity without a core (p < 0.001; OR: 4.31; 95% CI: 2.08-8.92), RPE damage (p < 0.001; OR: 28.12; 95% CI: 9.43-83.85), and the EZ damage (p < 0.001; OR: 14.01; 95% CI: 5.28-37.18) were significantly associated with active change; the drusen with low reflectivity (p = 0.01; OR: 2.95; 95% CI: 1.29-6.75) and decreased overlying RPE reflectivity (p < 0.001; OR: 21.67; 95% CI: 9.20-51.02) were the independent predictors for progression. The drusen with high reflectivity were significantly associated with stabilization (p = 0.03; OR: 0.17; 95% CI: 0.04-0.84).
   Conclusion: Spectral-domain optical coherence tomography is an optimized, accurate, and efficient method to follow-up the drusen. The intermediate non-exudative AMD prognosis of the patient was most strongly correlated with the drusen reflectivity and disruption of the overlying RPE layer. The drusen with low reflectivity and overlying RPE damage were more likely to progress and required frequent follow-up.
C1 [Yang, Shasha; Gao, Zongyin; Qiu, Haijiang] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Ophthalmol, Guangzhou, Peoples R China.
   [Zuo, Chengguo; Mi, Lan; Xiao, Hui; Liu, Xing] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
C3 South China University of Technology; Sun Yat Sen University
RP Liu, X (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
EM liuxing@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81970808]; Fundamental
   Research Funds of the State Key Laboratory of Ophthalmology; Sun Yat-sen
   University Clinical Research 5010 Program [2014016]; Guangzhou General
   Science and Technology Project of Medicine and Health [20161A011007];
   Science Foundation of Guangzhou First People's Hospital [M2019018]
FX This study was supported by the National Natural Science Foundation of
   China (Grant Number: 81970808), the Fundamental Research Funds of the
   State Key Laboratory of Ophthalmology and the Sun Yat-sen University
   Clinical Research 5010 Program (Grant Number: 2014016), the Guangzhou
   General Science and Technology Project of Medicine and Health (Grant
   Number: 20161A011007), and the Science Foundation of Guangzhou First
   People's Hospital (Grant Number: M2019018).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Chen L, 2021, OPHTHALMOL RETINA, V5, P1085, DOI 10.1016/j.oret.2021.01.012
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P1644, DOI 10.1097/IAE.0000000000002893
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Jaffe GJ., 2020, OPHTHALMOLOGY, V5, P855, DOI [10.1016/j.oret.2020.12.009, DOI 10.1016/J.ORET.2020.12.009]
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Scarinci F, 2015, JAMA OPHTHALMOL, V133, P1036, DOI 10.1001/jamaophthalmol.2015.2183
   Schlanitz F, 2019, BRIT J OPHTHALMOL, V103, P227, DOI 10.1136/bjophthalmol-2017-311782
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suh MH, 2009, AM J OPHTHALMOL, V147, P473, DOI 10.1016/j.ajo.2008.09.020
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Wu Z., 2021, OPHTHALMOLOGY, DOI [10.1016/j.oret.2021.03.008, DOI 10.1016/J.ORET.2021.03.008]
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
NR 47
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD OCT 26
PY 2021
VL 8
AR 706502
DI 10.3389/fmed.2021.706502
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA WV9RF
UT WOS:000717565700001
PM 34765613
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
TI Visual Prognosis in the Better-seeing Eyes of Patients with Unilateral
   Polypoidal Choroidal Vasculopathy
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID QUALITY-OF-LIFE; GROWTH-FACTOR THERAPY; MACULAR DEGENERATION;
   RISK-FACTORS; FELLOW EYE; RANIBIZUMAB; OUTCOMES; ACUITY; AFLIBERCEPT;
   DEPRESSION
AB PURPOSE The purpose of this study was to investigate the long-term changes in the visual acuity of the better-seeing eyes in patients with unilateral polypoidal choroidal vasculopathy. METHODS This retrospective, single-institution study was performed with 221 patients who were diagnosed as having unilateral polypoidal choroidal vasculopathy and who were treated with intravitreal anti-vascular endothelial growth factor. Only patients with an initially uninvolved eye best-corrected visual acuity (BCVA) of 20/40 or better and who were followed up for at least 24 months were included. The changes in the BCVAs of the initially involved and uninvolved eyes as well as the better-seeing eyes were measured. For patients with three or more lines of uninvolved eye visual deterioration, the cause for the visual deterioration was identified. RESULTS Patients were followed up for a mean of 43.1 +/- 11.8 months after diagnosis. During the follow-up period, three or more lines of deterioration in the BCVA were noted in 61 initially involved eyes (27.6%) and 11 uninvolved eyes (4.9%). The reasons for uninvolved eye visual deterioration were neovascularization (n = 8), retinal vein occlusion (n = 2), and posterior capsule opacification (n = 1). At diagnosis, the BCVA of the better-seeing eye was 0.05 +/- 0.08 (Snellen equivalents, 20/22). During the follow-up period, three or more lines of deterioration in the BCVA for the better-seeing eye were noted in eight patients (3.6%). CONCLUSIONS Visual acuity of the better-seeing eye over time remained stable in most patients who were initially diagnosed as having unilateral polypoidal choroidal vasculopathy. As a result, the visual prognosis of the better-seeing eye is highly favorable in this condition.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
EM kimoph@gmail.com
CR Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Chatziralli I, 2017, SEMIN OPHTHALMOL, V32, P772, DOI 10.1080/08820538.2016.1181192
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Elshout M, 2016, OPHTHALMOLOGY, V123, P2408, DOI 10.1016/j.ophtha.2016.07.015
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Jassim GA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008729.pub2
   Kim JH, 2019, RETINA-J RET VIT DIS, V39, P1672, DOI 10.1097/IAE.0000000000002239
   Kim JH, 2017, OPTOMETRY VISION SCI, V94, P556, DOI 10.1097/OPX.0000000000001066
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rasmussen A, 2017, EYE, V31, P978, DOI 10.1038/eye.2016.324
   Richards SH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002902.pub4
   Rovner BW, 2008, AM J GERIAT PSYCHIAT, V16, P454, DOI 10.1097/JGP.0b013e31816b7342
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stem MS, 2018, JAMA OPHTHALMOL, V136, P820, DOI 10.1001/jamaophthalmol.2018.1534
   Tateno Y, 2016, OPHTHALMIC GENET, V37, P177, DOI 10.3109/13816810.2015.1020557
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 33
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD SEP
PY 2019
VL 96
IS 9
BP 686
EP 694
DI 10.1097/OPX.0000000000001419
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IW5GE
UT WOS:000485005900009
PM 31479024
DA 2022-11-30
ER

PT J
AU Al-Holou, SN
   Tucker, WR
   Agron, E
   Clemons, TE
   Cukras, C
   Ferris, FL
   Chew, EY
AF Al-Holou, Shaza N.
   Tucker, William R.
   Agron, Elvira
   Clemons, Traci E.
   Cukras, Catherine
   Ferris, Frederick L., III
   Chew, Emily Y.
CA Age-Related Eye Dis Study 2 Res
TI The Association of Statin Use with Age-Related Macular Degeneration
   Progression The Age-Related Eye Disease Study 2 Report Number 9
SO OPHTHALMOLOGY
LA English
DT Article
ID COA REDUCTASE INHIBITORS; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE;
   BRUCHS MEMBRANE; LOWERING DRUGS; MEDICATION USE; UNITED-STATES; EYE
   DISEASE; RISK; MACULOPATHY
AB Purpose: To evaluate the association of statin use with progression of age-related macular degeneration (AMD).
   Design: Preplanned, prospective cohort study within a controlled clinical trial of oral supplementation for age-related eye diseases.
   Participants: Age-Related Eye Disease Study 2 (AREDS2) participants, aged 50 to 85 years.
   Methods: Factors, including age, gender, smoking status, aspirin use, and history of diabetes, hypertension, heart disease, angina, and stroke-all known to be associated with statin use-were included in a logistic regression model to estimate propensity scores for each participant. Age-adjusted proportional hazards regression models, with and without propensity score matching, were performed to evaluate the association of statin use with progression to late AMD. Analyses adjusting for the competing risk of death were also performed.
   Main Outcome Measures: Baseline and annual stereoscopic fundus photographs were assessed centrally by masked graders for the development of late AMD, either neovascular AMD or geographic atrophy (GA).
   Results: Of the 3791 participants (2462 with bilateral large drusen and 1329 with unilateral late AMD at baseline), 1659 (43.8%) were statin users. The overall analysis, with no matching of propensity scores and no adjustment for death as a competing risk, showed that statin use was not associated with progression to late AMD (hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.83-1.41; P = 0.56). When matched for propensity scores and adjusted for death as a competing risk, the result was not statistically significant (HR, 0.81; 95% CI, 0.55-1.20; P = 0.29). Furthermore, subgroup analyses of persons with or without late AMD at baseline and the various components of late AMD (neovascular AMD, central GA, or any GA) also showed no statistically significant association of statin use with progression to AMD.
   Conclusions: Statin use was not statistically significantly associated with progression to late AMD in the AREDS2 participants, and these findings are consistent with findings in the majority of previous studies. Statins have been demonstrated to reduce the risk of cardiovascular disease, but our data do not provide evidence of a beneficial effect on slowing AMD progression. (C) 2015 Published by Elsevier on behalf of the American Academy of Ophthalmology.
C1 [Al-Holou, Shaza N.; Agron, Elvira; Cukras, Catherine; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Tucker, William R.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Emmes Corporation
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Mitchell, Paul/P-1498-2014; SanGiovanni, John Paul/AAU-3895-2020
OI Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute/National Institutes of Health (NIH), Department
   of Health and Human Services, Bethesda Maryland [HHS-N-260-2005-0007-C,
   NO1-EY-5-0007]; NIH institute: Office of Dietary Supplements, National
   Center for Complementary and Alternative Medicine; NIH institute:
   National Institute on Aging; National Heart, Lung, and Blood Institute;
   NIH institute: National Institute of Neurological Disorders and Stroke;
   NIH; Pfizer Inc.; Doris Duke Charitable Foundation; Alexandria Real
   Estate Equities, Inc.; Mr. and Mrs. Joel S. Marcus; Howard Hughes
   Medical Institute; NATIONAL EYE INSTITUTE [ZIAEY000489] Funding Source:
   NIH RePORTER
FX Supported by intramural program funds and contracts from the National
   Eye Institute/National Institutes of Health (NIH), Department of Health
   and Human Services, Bethesda Maryland (contract HHS-N-260-2005-0007-C;
   ADB Contract NO1-EY-5-0007). Funds were generously contributed to these
   contracts by the following NIH institutes: Office of Dietary
   Supplements, National Center for Complementary and Alternative Medicine;
   National Institute on Aging; National Heart, Lung, and Blood Institute;
   and National Institute of Neurological Disorders and Stroke. The sponsor
   and funding organization participated in the design and conduct of the
   study; data collection, management, analysis, and interpretation; and
   the preparation, review, and approval of the manuscript. This research
   was made possible through the NIH Medical Research Scholars Program, a
   public-private partnership supported jointly by the NIH and generous
   contributions to the Foundation for the NIH from Pfizer Inc., The Doris
   Duke Charitable Foundation, The Alexandria Real Estate Equities, Inc.,
   Mr. and Mrs. Joel S. Marcus, and the Howard Hughes Medical Institute, as
   well as other private donors. For a complete list, please see the
   Foundation website at:
   http://fnih.org/work/education-training-0/medical-research-scholars-prog
   ram.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chodick G, 2010, ANN EPIDEMIOL, V20, P136, DOI 10.1016/j.annepidem.2009.10.007
   Coons JC, 2002, ANN PHARMACOTHER, V36, P326
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GRUNDY SM, 1988, NEW ENGL J MED, V319, P24
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Kohl M, PSHREG SAS R MACROPR
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   PEDERSEN TR, 1994, LANCET, V344, P1383
   Pignone M, 2000, BRIT MED J, V321, P983, DOI 10.1136/bmj.321.7267.983
   Sathasivam S, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2286
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Zanutto EL, 2006, J DATA SCI, P67, DOI DOI 10.6339/JDS.2006.04(1).233
NR 46
TC 19
Z9 20
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2015
VL 122
IS 12
BP 2490
EP 2496
DI 10.1016/j.ophtha.2015.08.028
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4EZ
UT WOS:000367057500028
PM 26435335
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Agron, E
   Mares, J
   Clemons, TE
   Swaroop, A
   Chew, EY
   Keenan, TDL
AF Agron, Elvira
   Mares, Julie
   Clemons, Traci E.
   Swaroop, Anand
   Chew, Emily Y.
   Keenan, Tiarnan D. L.
CA AREDS Res Grp
   AREDS2 Res Grp
TI Dietary Nutrient Intake and Progression to Late Age-Related Macular
   Degeneration in the Age-Related Eye Disease Studies 1 and 2
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; FISH INTAKE; LONG-CHAIN; EICOSAPENTAENOIC
   ACID; DOCOSAHEXAENOIC ACID; GENETIC RISK; B VITAMINS; HOMOCYSTEINE;
   ASSOCIATIONS; HEALTH
AB Purpose: To analyze associations between the dietary intake of multiple nutrients and risk of progression to late age-related macular degeneration (AMD), its subtypes, and large drusen.
   Design: Post hoc analysis of 2 controlled clinical trial cohorts: Age-Related Eye Disease Study (AREDS) and AREDS2.
   Participants: Eyes with no late AMD at baseline among AREDS participants (n = 4504) and AREDS2 participants (n = 3738) totaled 14 135 eyes. Mean age was 71.0 years (standard deviation, 6.7 years), and 56.5% of patients were women.
   Methods: Fundus photographs were collected at annual study visits and graded centrally for late AMD. Dietary intake of multiple nutrients was calculated from food frequency questionnaires.
   Main Outcome Measures: Progression to late AMD, geographic atrophy (GA), neovascular AMD, and (separate analyses) large drusen.
   Results: Over median follow-up of 10.2 years, of the 14 135 eyes, 32.7% progressed to late AMD. For 9 nutrients, intake quintiles 4 or 5 (vs. 1) were associated significantly (P <= 0.0005) with decreased risk of late AMD: vitamin A, vitamin B6, vitamin C, folate, beta-carotene, lutein and zeaxanthin, magnesium, copper, and alcohol. For 3 nutrients, quintiles 4 or 5 were associated significantly with increased risk: saturated fatty acid, monounsaturated fatty acid, and oleic acid. Similar results were observed for GA. Regarding neovascular AMD, 9 nutrients were associated nominally with decreased risk-vitamin A, vitamin B6, beta-carotene, lutein and zeaxanthin, magnesium, copper, docosahexaenoic acid, omega-3 fatty acid, and alcohol-and 3 nutrients were associated with increased risk-saturated fatty acid, monounsaturated fatty acid, and oleic acid. In separate analyses (n = 5399 eyes of 3164 AREDS participants), 12 nutrients were associated nominally with decreased risk of large drusen.
   Conclusions: Higher dietary intake of multiple nutrients, including minerals, vitamins, and carotenoids, is associated with decreased risk of progression to late AMD. These associations are stronger for GA than for neovascular AMD. The same nutrients also tend to show protective associations against large drusen development. Strong genetic interactions exist for some nutrient-genotype combinations, particularly omega-3 fatty acids and CFH. These data may justify further research into underlying mechanisms and randomized trials of supplementation. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Agron, Elvira; Chew, Emily Y.; Keenan, Tiarnan D. L.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD USA.
   [Mares, Julie] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI USA.
   [Clemons, Traci E.] Emmes Co LLC, Rockville, MD USA.
   [Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Wisconsin System; University of Wisconsin Madison;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Keenan, TDL (通讯作者)，NIH, Bldg 10,CRC,Room 10D45,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.; Chew, EY (通讯作者)，NIH, Bldg 10,CRC,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov; tiarnan.keenan@nih.gov
OI Agron, Elvira/0000-0002-2829-4042; Swaroop, Anand/0000-0002-1975-1141
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [NOI-EY-0-2127, HHS-N-260-2005-00007-C, ADB N01-EY-5-0007];
   National Institutes of Health institute: Office of Dietary Supplements;
   National Institutes of Health institute: National Center for
   Complementary and Alternative Medicine; National Institutes of Health
   institute: National Institute on Aging; National Institutes of Health
   institute: National Heart, Lung, and Blood Institute; National
   Institutes of Health institute: National Institute of Neurological
   Disorders and Stroke
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (intramural program funds and contracts: AREDS [grant
   no.: NOI-EY-0-2127] and AREDS2 [grant nos.: HHS-N-260-2005-00007-C and
   ADB N01-EY-5-0007]). Funds were contributed to these contracts by the
   following National Institutes of Health institutes: Office of Dietary
   Supplements; National Center for Complementary and Alternative Medicine;
   National Institute on Aging; National Heart, Lung, and Blood Institute;
   and National Institute of Neurological Disorders and Stroke. The sponsor
   and funding organization participated in the design and conduct of the
   study; data collection, management, analysis, and interpretation; and
   preparation, review, and approval of the manuscript.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2018, OPHTHALMOL RETINA, V2, P508, DOI 10.1016/j.oret.2017.10.001
   Christen WG, 2018, OPHTHAL EPIDEMIOL, V25, P79, DOI 10.1080/09286586.2017.1362009
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Corella D, 2012, BRIT J NUTR, V107, pS271, DOI 10.1017/S0007114512001651
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Drouin G, 2019, BIOCHIMIE, V159, P36, DOI 10.1016/j.biochi.2019.01.022
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gopinath B, 2018, J ACAD NUTR DIET, V118, P2311, DOI 10.1016/j.jand.2018.07.012
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   IOM, 2006, DIETARY REFERENCE IN, DOI [10.17226/11537, DOI 10.17226/11537]
   Kang JH, 2016, JAMA OPHTHALMOL, V134, P294, DOI 10.1001/jamaophthalmol.2015.5601
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Kipnis V, 2003, AM J EPIDEMIOL, V158, P14, DOI 10.1093/aje/kwg091
   Kleinbaum DG, 2012, STAT BIOL HEALTH, P201, DOI 10.1007/978-1-4419-6646-9_5
   Linseisen J, 2009, EUR J CLIN NUTR, V63, pS61, DOI 10.1038/ejcn.2009.75
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283
   O'Neil CE, 2012, NUTRIENTS, V4, P2097, DOI 10.3390/nu4122097
   Office of Dietary Supplements National Institutes of Health., 2011, NUTR REC DIET REF IN
   Office of Dietary Supplements National Institutes of Health, 2020, DIET SUPPL FACT SHEE
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Pinna A, 2018, ACTA OPHTHALMOL, V96, pE269, DOI 10.1111/aos.13343
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Rhee JJ, 2014, PUBLIC HEALTH NUTR, V17, P1054, DOI 10.1017/S1368980013001390
   RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
   Roh M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.20
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schwingshackl L, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-154
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2010, MOL VIS, V16, P2412
   Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tanaka K, 2011, MOL VIS, V17, P2751
   United States Department of Agriculture Agricultural Research Service, 2020, FOODDATA CENTRAL
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 80
TC 34
Z9 35
U1 9
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2021
VL 128
IS 3
BP 425
EP 442
DI 10.1016/j.ophtha.2020.08.018
EA FEB 2021
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QY6YQ
UT WOS:000630184400013
PM 32858063
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Elshout, M
   van der Reis, MI
   de Jong-Hesse, Y
   Webers, CA
   Schouten, JS
AF Elshout, Mari
   van der Reis, Margriet I.
   de Jong-Hesse, Yvonne
   Webers, Carroll A.
   Schouten, Jan S.
TI Distinguishing between Better and Worse Visual Acuity by Studying the
   Correlation with Quality of Life in Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VISION
AB Purpose: To determine whether there is a level of visual acuity (VA) in neovascular age-related macular degeneration (nAMD) above which the correlation of VA with disease-related quality of life (QoL) is significantly greater than below this level.
   Design: An observational, cross-sectional study.
   Participants: A total of 184 patients with nAMD aged at least 50 years were included in the study.
   Methods: In face-to-face interviews, we assessed QoL with the Macular Disease-Dependent Quality of Life (MacDQoL) questionnaire. We measured VA with standardized Radner reading charts. We used regression splines analysis with a single hinge point, with the MacDQoL score as the dependent variable and VA as the independent variable. The x-coordinate (VA) of the hinge point was varied and tested with each iteration. A second method of regression splines analysis was also performed, without a preset hinge point.
   Main Outcome Measures: The primary outcome measure is the cutoff point at or below which VA is associated with significantly less change in QoL than above this cutoff. The linear coefficients below and above the cutoff are defined as change in MacDQoL score per logarithm of the minimum angle of resolution (logMAR) unit of change in VA.
   Results: With Snellen equivalent VA 0.05 (1.3 logMAR) or worse, the linear coefficient was 0.15. With VA better than 0.05, the linear coefficient was 2.40 (P value of the difference: 0.009).
   Conclusions: When VA is above 0.05, there is a stronger and significant relation between VA and QoL. At or below this level, the relation between VA and QoL approaches zero. With better VA, a difference in VA implies a significant difference in QoL. With poorer VA, a difference in VA is unlikely to imply a difference in QoL. Therefore, in treating nAMD, the aim should be to keep Snellen VA above 0.05 to have an impact on QoL. If it is certain that the best-corrected VA below 0.05 is permanent, these findings imply there may be less, if any, benefit to continue further treatment. This is to be evaluated on a case-by-case basis. (C) 2016 by the American Academy of Ophthalmology.
C1 [Elshout, Mari; van der Reis, Margriet I.; Webers, Carroll A.; Schouten, Jan S.] Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
   [de Jong-Hesse, Yvonne] Vrije Univ Amsterdam Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER
RP Elshout, M (通讯作者)，Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM m.elshout@mumc.nl
RI Webers, Carroll A.B./D-1130-2010; Schouten, Johannes S.A.G./M-9376-2016
OI Schouten, Johannes S.A.G./0000-0001-6495-7758
FU Bayer; Novartis; Ophtec; Novartis Pharma; Bayer Healthcare; Alcon;
   Allergan; Santen; Sanofi
FX The author(s) have made the following disclosure(s): Y.deJ.-H.:
   Consultancy - Bayer; Grants/grants pending - Bayer, Novartis, and
   Ophtec; Payment for lectures including service on Speakers Bureaus -
   Novartis Pharma and Bayer Healthcare.; C.A.W.: Consultancy and payment
   for lectures including service on Speakers Bureaus - Alcon, Allergan,
   and Santen.; J.S.S.: Payment for development of educational
   presentations - Sanofi and Novartis.
CR Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   EBERT EM, 1986, ARCH OPHTHALMOL-CHIC, V104, P1009
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Maaijwee K J M, 2007, Ned Tijdschr Geneeskd, V151, P2494
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   Muggeo V.M.R., 2008, R NEWS, V8, P20, DOI DOI 10.1159/000323281
   NICE Appraisal Committee, 2008, RAN PEG TREATM AG RE
   Ophthalmologists Scientific Department Royal College of Ophthalmologists, 2013, AG MAC DEG GUID MAN
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Reeves BC, 2009, OPHTHALMOLOGY, V116, P2463, DOI 10.1016/j.ophtha.2009.10.031
   SMITH PL, 1979, AM STAT, V33, P57, DOI 10.2307/2683222
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 13
TC 10
Z9 10
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2016
VL 123
IS 11
BP 2408
EP 2412
DI 10.1016/j.ophtha.2016.07.015
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QK
UT WOS:000389509500026
PM 27568997
DA 2022-11-30
ER

PT J
AU Issa, PC
   Chong, NV
   Scholl, HPN
AF Issa, Peter Charbel
   Chong, N. Victor
   Scholl, Hendrik P. N.
TI The significance of the complement system for the pathogenesis of
   age-related macular degeneration - current evidence and translation into
   clinical application
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; Pathogenesis; Complement system;
   Genotype; Gene-environment interaction; Pharmacogenetics; Therapy
ID FACTOR-H POLYMORPHISM; PIGMENT EPITHELIAL-CELLS; FACTOR HY402H
   POLYMORPHISM; FAMILIAL AGGREGATION; CFH GENE; FACTOR-B; LOC387715
   GENOTYPES; GEOGRAPHIC ATROPHY; ALLOTYPIC VARIANT; BINDING-AFFINITY
AB Dysregulation of the complement system has been shown to play a major role in the pathogenesis of age-related macular degeneration (AMD).
   The current evidence from human studies derives from immunohistochemical and proteomic studies in donor eyes, genetic association studies, and studies of blood complement protein levels. These lines of evidence are corroborated by in vitro and animal studies.
   In AMD donor eyes, detection of complement proteins in drusen suggested local inflammatory processes involving the complement system. Moreover, higher levels of complement proteins in the Bruch's membrane/choroid complex could be detected in AMD donor eyes compared to controls. A large number of independent genetic studies have consistently confirmed the association of AMD with risk or protective variants in genes coding for complement proteins, including complement factor H (CFH), CFH-related proteins 1 and 3, factor B/C2, C3 and factor I. Another set of independent studies detected increased levels of complement activation products in plasma of AMD patients, suggesting that AMD may be a systemic disease and the macula a vulnerable anatomic site of minimal resistance to complement activation. Genotype-phenotype correlations, including the impact of genetic variants on disease progression, gene-environment and pharmacogenetic interactions, have been investigated. There is evidence that complement gene variants may be associated with the progression from early to late forms of AMD, whereas they do not appear to play a significant role when late atrophic AMD has already developed. There are indications for an interaction between genetic variants and supplementation and dietary factors. Also, there is some evidence that variants in the CFH gene influence treatment effects in patients with neovascular AMD.
   Such data suggest that the complement system may have a significant role for developing new prophylactic and therapeutic interventions in AMD. In fact, several compounds acting on the complement pathway are currently in clinical trials. Therapeutics that modulate the complement system need to balance inhibition with preservation of sufficient functional activity in order to maintain adequate immune responses and tissue homeostasis. Specifically, targeting the dysfunction appears more adequate than a global suppression of complement activation in chronic diseases such as AMD.
C1 [Scholl, Hendrik P. N.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Issa, Peter Charbel] Univ Oxford, Nuffield Lab Ophthalmol, Oxford OX2 6AW, England.
   [Chong, N. Victor] Univ Oxford, Oxford Eye Hosp, Oxford OX2 6AW, England.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Oxford;
   University of Oxford
RP Scholl, HPN (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, 748 Maumenee Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM hscholl1@jhmi.edu
RI Chong, Victor/Q-6565-2018; Issa, Peter Charbel/E-8935-2018; Issa, Peter
   Charbel/O-2580-2019; Issa, Peter Charbel/F-9603-2011
OI Chong, Victor/0000-0002-7693-522X; Issa, Peter
   Charbel/0000-0002-0351-6673; Issa, Peter Charbel/0000-0002-0351-6673; 
FU European Commission [237238]; National Neurovision Research Institute
   (NNRI) - Foundation Fighting Blindness (FFB) [NNCD-CL-0310.0049-JHU-WG];
   American Health Assistance Foundation (AHAF) [M2010042]
FX This work was supported by the European Commission, Seventh European
   Community Framework Program, Marie Curie Intra-European Fellowship
   (237238) to PCI; the Wynn-Gund Translational Research Acceleration
   Program Enhanced Research and Clinical Training Award, National
   Neurovision Research Institute (NNRI) - Foundation Fighting Blindness
   (FFB; NNCD-CL-0310.0049-JHU-WG) to HPNS; and the Macular Degeneration
   Research Award, American Health Assistance Foundation (AHAF; M2010042)
   to HPNS.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   HO L, 2010, ARCH OPHTHA IN PRESS
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Issa PC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012864
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kelly U, 2009, INVEST OPHTH VIS SCI, V50, P1540, DOI 10.1167/iovs.08-2782
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Luo L, 2008, VISION RES, V48, P494, DOI 10.1016/j.visres.2007.11.013
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McAvoy CE, 2005, EYE, V19, P985, DOI 10.1038/sj.eye.6701697
   Mollnes TE, 2006, MOL IMMUNOL, V43, P107, DOI 10.1016/j.molimm.2005.06.014
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schlingemann RO, 2009, PROG BRAIN RES, V175, P253, DOI 10.1016/S0079-6123(09)17517-9
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2007, MOL VIS, V13, P196
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Wagner E, 2010, NAT REV DRUG DISCOV, V9, P43, DOI 10.1038/nrd3011
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wasmuth S, 2009, INVEST OPHTH VIS SCI, V50, P5304, DOI 10.1167/iovs.08-3326
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
NR 116
TC 69
Z9 76
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2011
VL 249
IS 2
BP 163
EP 174
DI 10.1007/s00417-010-1568-6
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 723ML
UT WOS:000287510600002
PM 21127893
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Farwick, A
   Wellmann, J
   Stoll, M
   Pauleikhoff, D
   Hense, HW
AF Farwick, Astrid
   Wellmann, Juergen
   Stoll, Monika
   Pauleikhoff, Daniel
   Hense, Hans-Werner
TI Susceptibility Genes and Progression in Age-Related Maculopathy: A Study
   of Single Eyes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; FACTOR-B; DRUSEN; RISK;
   PATHOGENESIS; LOC387715; DISEASE; VARIANT; POLYMORPHISM
AB PURPOSE. The specific role of single-nucleotide polymorphisms (SNPs) in the progression of age-related maculopathy (AMD) is not clearly understood. The present study was conducted to investigated whether variants in three susceptibility genes are differentially associated with progression to early and late AMD.
   METHODS. The Munster Ageing and Retina Study (MARS) cohort includes 722 patients with different stages of AMD. Participants were reexamined after a median of 2.6 years. The association of SNPs in the CFH, ARMS2, and C3 genes with AMD progression was evaluated in 1435 single eyes by using multivariate logistic regression models with generalized estimating equations.
   RESULTS. CFH-rs1061170 was significantly related to the development of early (OR = 1.94, 95% confidence interval [CI], 1.3-3.0 for heterozygous, and OR = 2.9 [95% CI, 1.7-5.1] for homozygous allele carriers) but not to late AMD. In contrast, ARMS2-rs10490924 was associated only with progression to advanced disease (OR = 1.2 [0.7-2.1] and OR = 2.1 [1.1-3.9], respectively). The variant C3-rs2230199 showed no relation with AMD progression.
   CONCLUSIONS. The findings indicate that AMD progression is differentially affected by genotypic variants. Probably, aging processes of the human retina predispose to AMD onset in the presence of genetic variation in the complement system, which alters immunoregulatory and inflammatory responses. The specific functional role of ARMS2-rs10490924 remains as yet unknown, but it appears to mainly affect the progression to late AMD stages. (Invest Ophthalmol Vis Sci. 2010; 51: 731-736) DOI: 10.1167/iovs.09-3953
C1 [Farwick, Astrid; Wellmann, Juergen; Hense, Hans-Werner] Inst Epidemiol & Social Med, D-48129 Munster, Germany.
   [Farwick, Astrid; Stoll, Monika] Univ Munster, Leibniz Inst Arteriosclerosis Res, D-4400 Munster, Germany.
   [Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
C3 University of Munster; St. Franziskus-Hospital
RP Hense, HW (通讯作者)，Inst Epidemiol & Social Med, 3 Domagk Str, D-48129 Munster, Germany.
EM hense@uni-muenster.de
FU Deutsche Forschungsgemeinschaft [He 2293/5-1, He 2293/5-2, He 2293/5-3,
   We 1259/14-3]; University of Munster; Pro Retina Foundation
FX Supported in part by grants from Deutsche Forschungsgemeinschaft He
   2293/5-1,5-2,5-3 and We 1259/14-3; the Intramural IMF fund of the
   University of Munster; and the Pro Retina Foundation.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FARWICK A, EYE
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Glynn RJ, 2000, AM J EPIDEMIOL, V151, P965, DOI 10.1093/oxfordjournals.aje.a010140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Neuner B, 2007, ANN EPIDEMIOL, V17, P615, DOI 10.1016/j.annepidem.2007.03.005
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 45
TC 25
Z9 26
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2010
VL 51
IS 2
BP 731
EP 736
DI 10.1167/iovs.09-3953
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 545AS
UT WOS:000273704700016
PM 19797206
DA 2022-11-30
ER

PT J
AU Korb, CA
   Elbaz, H
   Schuster, AK
   Nickels, S
   Ponto, KA
   Schulz, A
   Wild, PS
   Munzel, T
   Beutel, ME
   Schmidtmann, I
   Lackner, KJ
   Peto, T
   Pfeiffer, N
AF Korb, Christina A.
   Elbaz, Hisham
   Schuster, Alexander K.
   Nickels, Stefan
   Ponto, Katharina A.
   Schulz, Andreas
   Wild, Philipp S.
   Muenzel, Thomas
   Beutel, Manfred E.
   Schmidtmann, Irene
   Lackner, Karl J.
   Peto, Tunde
   Pfeiffer, Norbert
TI Five-year cumulative incidence and progression of age-related macular
   degeneration: results from the German population-based Gutenberg Health
   Study (GHS)
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Cumulative incidence; Progression;
   Gutenberg Health Study
ID REFRACTIVE ERRORS; MACULOPATHY; RISK; PREVALENCE; CATARACT; DISEASE
AB Purpose Age-related macular degeneration (AMD) is a major cause of visual impairment and blindness. This study evaluates the incidence and progression of AMD in a large German cohort.
   Methods The Gutenberg Health Study (GHS) is a population-based, prospective, observational cohort study in Germany that includes 15,010 participants between 35 and 74 years of age. The baseline examination, including fundus photography, was conducted between 2007 and 2012, and the 5-year follow-up examination was performed between 2012 and 2017. AMD grading of fundus photographs was performed according to the Rotterdam Eye Study classification. The 5-year cumulative incidence and progression of AMD were calculated. Poisson regression analysis was conducted to investigate factors associated with the cumulative incidence and progression of AMD.
   Results Six-thousand-eight-hundred-eighty-eight participants (49.8%, n = 3427 female) were included in the analysis. AMD prevalence was 8.5% [95% CI: 7.9-9.2%] at baseline and 10.3% [95% CI: 9.6-11.1%] at follow-up. The cumulative 5-year-incidence was 2.0% [1.7-2.4%]. AMD progression within 5 years was seen in 18.1% [95% CI: 15.1-21.5%] of the participants. AMD incidence and AMD progression were associated with higher age, for each 10-year increase in age, the risk of AMD doubles (RR = 2.30), and the risk of progression of the disease is increased by 1.6. while AMD incidence also with pseudophakic status.
   Conclusions In summary, this population-based sample provides substantial epidemiologic data from a large German cohort, including data on progression and cumulative incidence of macular degeneration in younger age groups. AMD progression over 5 years is common in the German population, 18.1% of subjects with AMD showed progression in at least one eye in this time frame and is associated with higher age. Nevertheless, although usually defined to occur over the age of 50, in this cohort AMD occurred in 0.5% and AMD progression occurred in 5.4% of those already affected in the youngest age group before 50 years of age.
C1 [Korb, Christina A.; Elbaz, Hisham; Schuster, Alexander K.; Nickels, Stefan; Ponto, Katharina A.; Pfeiffer, Norbert] Johannes Gutenberg Univ Mainz, Dept Ophthalmol, Univ Med Ctr, Mainz, Germany.
   [Elbaz, Hisham] Otto von Guericke Univ, Dept Ophthalmol, Magdeburg, Germany.
   [Ponto, Katharina A.; Wild, Philipp S.] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis CTH, Univ Med Ctr, Mainz, Germany.
   [Schulz, Andreas; Wild, Philipp S.] Johannes Gutenberg Univ Mainz, Ctr Cardiol, Prevent Cardiol & Prevent Med, Univ Med Ctr, Mainz, Germany.
   [Wild, Philipp S.; Muenzel, Thomas; Lackner, Karl J.] German Ctr Cardiovasc Res DZHK, Partner Site Rhine Main, Mainz, Germany.
   [Muenzel, Thomas] Johannes Gutenberg Univ Mainz, Ctr Cardiol, Cardiol 1, Univ Med Ctr, Mainz, Germany.
   [Beutel, Manfred E.] Johannes Gutenberg Univ Mainz, Dept Psychosomat Med & Psychotherapy, Univ Med Ctr, Mainz, Germany.
   [Schmidtmann, Irene] Johannes Gutenberg Univ Mainz, Inst Med Biostat Epidemiol & Informat, Univ Med Ctr, Mainz, Germany.
   [Lackner, Karl J.] Johannes Gutenberg Univ Mainz, Inst Clin Chem & Lab Med, Univ Med Ctr, Mainz, Germany.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Peto, Tunde] UCL Inst Ophthalmol, London, England.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 Johannes Gutenberg University of Mainz; Otto von Guericke University;
   Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz; German Centre for Cardiovascular Research; Johannes Gutenberg
   University of Mainz; Johannes Gutenberg University of Mainz; Johannes
   Gutenberg University of Mainz; Johannes Gutenberg University of Mainz;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Queens University Belfast
RP Korb, CA (通讯作者)，Johannes Gutenberg Univ Mainz, Dept Ophthalmol, Univ Med Ctr, Mainz, Germany.
EM christina.korb@unimedizin-mainz.de; philipp.wild@unimedizin-mainz.de
OI Wild, Philipp/0000-0003-4413-9752
FU government of Rhineland-Palatinate ("Stiftung Rheinland-Pfalz fur
   Innovation") [AZ 961-386261/733]; Boehringer Ingelheim; PHILIPS Medical
   Systems; Novartis Pharma GmbH; Federal Ministry of Education and
   Research [BMBF 01EO1503]; Deutsche Ophthalmologische Gesellschaft;
   Berufsverband der Augenarzte Deutschlands e.V.; Bayer Vital; Novartis;
   Heidelberg Engineering; research program "Wissen schafft Zukunft" of the
   Johannes Gutenberg-University of Mainz; research program "Center for
   Translational Vascular Biology (CTVB)" of the Johannes
   Gutenberg-University of Mainz
FX The Gutenberg Health Study is funded through the government of
   Rhineland-Palatinate ("Stiftung Rheinland-Pfalz fur Innovation",
   contract AZ 961-386261/733), the research programs "Wissen schafft
   Zukunft" and "Center for Translational Vascular Biology (CTVB)" of the
   Johannes Gutenberg-University of Mainz, and its contracts with
   Boehringer Ingelheim and PHILIPS Medical Systems, including unrestricted
   grants for the Gutenberg Health Study. This analysis was supported by
   Novartis Pharma GmbH. Philipp S. Wild and Katharina A. Ponto are funded
   by the Federal Ministry of Education and Research (BMBF 01EO1503).
   Philipp S. Wild is the PI of the German Center for Cardiovascular
   Research (DZHK). Alexander K. Schuster holds the professorship for
   ophthalmic healthcare research donated by "Stiftung Auge" and financed
   by "Deutsche Ophthalmologische Gesellschaft" and "Berufsverband der
   Augenarzte Deutschlands e.V." He received research funding from Bayer
   Vital, Novartis and Heidelberg Engineering.
CR Armstrong Richard A, 2015, J Stem Cells, V10, P171
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Dillon J, 2004, EXP EYE RES, V79, P753, DOI 10.1016/j.exer.2004.06.025
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hohn R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120476
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Lampert T, 2013, BUNDESGESUNDHEITSBLA, V56, P131, DOI 10.1007/s00103-012-1583-3
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Li Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090897
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu YY, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7863987
   Farinha CVL, 2019, OPHTHALMIC RES, V61, P226, DOI 10.1159/000496393
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Schuster AK, 2018, OPHTHALMOLOGE, V115, P832, DOI 10.1007/s00347-018-0694-0
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Team RC, 2013, R LANG ENV STAT COMP
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wild PS, 2012, BUNDESGESUNDHEITSBLA, V55, P824, DOI 10.1007/s00103-012-1502-7
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 45
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2022
VL 260
IS 1
BP 55
EP 64
DI 10.1007/s00417-021-05312-y
EA AUG 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YI0WK
UT WOS:000687492200001
PM 34424371
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Skelly, A
   Carius, HJ
   Bezlyak, V
   Chen, FK
AF Skelly, Adrian
   Carius, Hans-Joachim
   Bezlyak, Vladimir
   Chen, Fred K.
TI Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of
   Neovascular Age-Related Macular Degeneration: A Retrospective Cohort
   Study in Australia
SO ADVANCES IN THERAPY
LA English
DT Article
DE Aflibercept; Anti-vascular endothelial growth factor; Dispensing
   pattern; Neovascular age-related macular degeneration; Ophthalmology;
   Ranibizumab; Vascular endothelial growth factor
ID ROUTINE CLINICAL-PRACTICE; VISUAL IMPAIRMENT
AB Introduction: Anti-vascular endothelial growth factor therapy is the standard of care for neovascular age-related macular degeneration (nAMD). The dosage of two licensed agents, ranibizumab and aflibercept, was established through clinical trials; however, it is unclear if either agent is administered as recommended in routine clinical practice. Using pharmacy claims data, we investigated if the dispensing patterns of ranibizumab differ from those of aflibercept 6 and 12 months after treatment initiation.
   Methods: Prescription data retrieved from the Australian IMSA (R) AUS LRx database were used to identify nAMD patients with one or more claims for ranibizumab or aflibercept between December 1, 2012, and March 31, 2015, with follow-up of at least 6 months. The number of ranibizumab and aflibercept units dispensed was adjusted for baseline patient Medication-Based Disease Burden Index (MBDBI) scores. No difference in the number of ranibizumab versus aflibercept units dispensed was concluded if the 95% confidence interval (CI) limits of the adjusted mean difference between the study cohorts were 1.00 unit or less.
   Results: Baseline patient MBDBI scores were similar for the ranibizumab (N = 1235) and aflibercept (N = 959) cohorts. The adjusted mean (standard deviation) number of units dispensed was 5.3 (1.3) versus 5.1 (1.4) at month 6 and 8.9 (2.2) versus 8.9 (2.3) at month 12. The 95% CI limits of the adjusted mean difference did not exceed 1.00 unit dispensed at either time point: 95% CI of 0.09 to 0.32 for an adjusted mean difference of 0.20 at month 6 and -0.23 to 0.30 for an adjusted mean difference of 0.04 at month 12. Mean (standard deviation) dispensing intervals were comparable for both cohorts: 35.3 (19.2) days versus 36.8 (20.0) days at month 6 (adjusted mean difference -1.59 days; 95% CI -2.51 to -0.67 days) and 41.2 (20.9) days versus 41.6 (20.4) days at month 12 (adjusted mean difference -0.40 days; 95% CI -1.70 to 0.91 days).
   Conclusions: Ranibizumab and aflibercept are dispensed in a similar manner by Australian pharmacies during the first year of treatment.
C1 [Skelly, Adrian; Bezlyak, Vladimir] Novartis Pharma AG, Basel, Switzerland.
   [Carius, Hans-Joachim] QuintilesIMS, Frankfurt, Germany.
   [Chen, Fred K.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Incorporating Lions Eye Inst, Perth, WA, Australia.
   [Chen, Fred K.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
C3 Novartis; IQVIA; Lions Eye Institute; University of Western Australia;
   Royal Perth Hospital; University of Western Australia
RP Skelly, A (通讯作者)，Novartis Pharma AG, Basel, Switzerland.
EM adrian.skelly@novartis.com
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930
FU Novartis Pharma AG
FX Novartis Pharma AG.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andrews EB, 2016, PHARMACOEPIDEM DR S, V25, P2, DOI 10.1002/pds.3891
   Australian Government Department of Health, 2016, EYLEA AFL CONS MED I
   Australian Government Department of Health, 2017, PHARM BEN SCHEM AFL
   Australian Government Department of Health, 2017, PHARM BEN SCHEM RAN
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Deloitte Access Economics, 2011, EYES FUT CLEAR OUTL
   Drug Utilisation Sub-committee, 2015, AG REL MAC DEG UT AN
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Galloway NR, 2006, COMMON EYE DIS THEIR, V3rd
   George J, 2006, ANN PHARMACOTHER, V40, P645, DOI 10.1345/aph.1G204
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Kiss S, 2014, INVEST OPHTH VIS SCI, V55
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lotery AJ, 2015, EYE, V29, P380, DOI 10.1038/eye.2014.308
   mivision, 2015, LUC LIST PBS DME RVO
   mivision, 2015, EYL APPR DIAB MAC ED
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Souied EH, 2016, OPHTHAL EPIDEMIOL, V23, P71, DOI 10.3109/09286586.2015.1090004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Therapeutic Goods Administration, 2017, LUC RAN CONS MED INF
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vandenbroucke JP, 2014, INT J SURG, V12, P1500, DOI 10.1016/j.ijsu.2014.07.014
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
NR 32
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD DEC
PY 2017
VL 34
IS 12
BP 2585
EP 2600
DI 10.1007/s12325-017-0624-6
PG 16
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FO4MN
UT WOS:000416818600004
PM 29164480
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Zhao, XY
   Xia, S
   Luo, MY
   Wang, EQ
   Chen, YX
AF Zhao, Xin-Yu
   Xia, Song
   Luo, Ming-Yue
   Wang, Er-Qian
   Chen, You-Xin
TI THE OCCURRENCE, CHARACTERISTICS, MANAGEMENT, AND PROGNOSIS OF RETINAL
   PIGMENT EPITHELIUM TEARS IN PATIENTS WITH POLYPOIDAL CHOROIDAL
   VASCULOPATHY A Retrospective Study of 397 Patients
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; retinal pigment epithelium tear;
   treatment; prognosis; pigment epithelial detachment
ID GROWTH-FACTOR THERAPY; ANTI-VEGF THERAPY; OPTICAL COHERENCE TOMOGRAPHY;
   MACULAR DEGENERATION; DETACHMENT; MECHANISM; CLASSIFICATION;
   PATHOGENESIS; PREDICTORS; INJECTION
AB Purpose: To investigate retinal pigment epithelium (RPE) tears in patients with polypoidal choroidal vasculopathy. Method: A retrospective review of polypoidal choroidal vasculopathy cases with confirmed RPE tears was conducted. Patients' comprehensive clinical data were collected and analyzed. The treatment strategy was a loading dose of one intravitreal antivascular endothelial growth factor injection, combined with additional injections if exudative activities or visual deterioration were detected. Results: Among 397 polypoidal choroidal vasculopathy patients, 33 patients with RPE tears (8.3%) were included. 42.4% of them happened spontaneously. Pigment epithelial detachment (PED) occurred more frequently in RPE tear patients and most of them had serous vascularized or hemorrhagic PED. The height and greatest linear diameter of PED, and the subfoveal choroidal thickness of these cases were significantly larger, whereas the central foveal thickness was significantly smaller. Most of the RPE tears occurred at the edge of the PED. After our treatment strategy, patients' best-corrected visual acuity improved significantly from 2.13 +/- 1.24 (median 20/52) to 1.32 +/- 1.31 (median 20/166). Large subretinal hemorrhage may increase the risk of the formation of subretinal fibrosis (P < 0.05). Conclusion: Retinal pigment epithelium tears in polypoidal choroidal vasculopathy are associated with high subRPE hydrostatic pressure, produced by a large PED or hemorrhage. After our intervention strategy, this condition may not necessarily result in poor prognosis.
C1 [Zhao, Xin-Yu; Xia, Song; Luo, Ming-Yue; Wang, Er-Qian; Chen, You-Xin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Xia, Song] Guizhou Prov Peoples Hosp, Dept Ophthalmol, Guiyang, Guizhou, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM 478252553@qq.com
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   BIRD AC, 1991, EYE, V5, P1
   Chalam KV, 2011, INDIAN J OPHTHALMOL, V59, P47, DOI 10.4103/0301-4738.73712
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2016, RETINA-J RET VIT DIS, V36, P1851, DOI 10.1097/IAE.0000000000001009
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Clemens CR, 2014, RETINA-J RET VIT DIS, V34, P24, DOI 10.1097/IAE.0b013e3182947811
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Durkin SR, 2016, GRAEF ARCH CLIN EXP, V254, P1, DOI 10.1007/s00417-015-2978-2
   Empeslidis T, 2014, OPEN OPHTHALMOL J, V8, P101, DOI 10.2174/1874364101408010101
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Mendis R, 2014, GRAEF ARCH CLIN EXP, V252, P1059, DOI 10.1007/s00417-013-2549-3
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Mouallem A, 2016, RETINA-J RET VIT DIS, V36, P2197, DOI 10.1097/IAE.0000000000001062
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Shin JY, 2015, GRAEF ARCH CLIN EXP, V253, P2151, DOI 10.1007/s00417-015-2977-3
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 35
TC 4
Z9 4
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2020
VL 40
IS 3
BP 477
EP 489
DI 10.1097/IAE.0000000000002389
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA1RI
UT WOS:000523731700011
PM 30475788
DA 2022-11-30
ER

PT J
AU Pirozzi, E
   Manganelli, C
   Piccardi, M
   Minnella, A
   Fadda, A
   Ziccardi, L
   Coccimiglio, F
   Falsini, B
AF Pirozzi, E
   Manganelli, C
   Piccardi, M
   Minnella, A
   Fadda, A
   Ziccardi, L
   Coccimiglio, F
   Falsini, B
TI Retinal function following transpupillary thermotherapy for occult
   choroidal neovascularization in age-related macular degeneration: a
   short-term study by focal electroretinography
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   electroretinogram; laser; transpupillary thermotherapy
ID HEAT-SHOCK PROTEINS; RETINITIS-PIGMENTOSA; FELLOW EYES; FLICKER;
   SENSITIVITY; MACULOPATHY; INFARCTION; APOPTOSIS; MELANOMA; DISEASE
AB Purpose: To assess short-term changes in macular function after transpupillary thermotherapy (TTT) in patients with occult subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), using focal electroretinography (FERG).
   Methods; Twenty-five patients with occult subfoveal CNV due to AMD were treated with TTT delivered using an infrared (810 nm) diode laser (spot size 3.0 mm, laser power 400-600 mW, duration 60 seconds). All patients were clinically evaluated before, 1 and 6 weeks after treatment. Snellen visual acuity (VA) was measured at each visit. Fluorescein angiography (FA) was performed at baseline and 6 weeks after TTT. Focal ERGs were recorded in all patients immediately before and 1 week after TTT in response to an 18-degree diameter, 41 Hz flickering spot (630 nm) centred on the fovea, presented on a steady background in Maxwellian view. A subgroup of 12 patients was also re-tested by FERG at 6-weeks post-TTT.
   Results: No significant changes in mean FERG amplitude and phase were observed across the different recording sessions before and after TTT. One week after TTT, four patients had significant (> 2 SD from baseline variability) increases in FERG amplitude and/or phase advances, one had a decrease in amplitude and four had phase delays, compared to baseline. The remaining 15 patients had stable FERGs. Six weeks after TTT, four patients had significant increases in FERG amplitude and/or phase advances, four had decreases in amplitude and/or phase delays, and four had stable FERGs, compared to baseline. Improvement in FERG parameters after TTT was always associated with an improvement in VA and a decrease in exudation. Patients with post-TTT FERG deterioration had stable or deteriorated clinical pictures. At either 1 or 6 weeks post-TTT, the FERG amplitude increase was inversely correlated (p < 0.05) with the baseline FERG amplitude and VA.
   Conclusions: Three major conclusions can be drawn: in a short-term follow-up, TTT was not found to be associated with significant changes in macular function; FERG improvement was associated with VA improvement, and the increase in FERG amplitude was greatest in patients with the worst baseline acuity.
C1 Univ Cattolica Sacro Cuore, Ist Oftalmol, I-00168 Rome, Italy.
   Higher Inst Hlth, Dept Technol & Hlth, Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Falsini, B (通讯作者)，Univ Cattolica Sacro Cuore, Ist Oftalmol, Lgo F Vito 1, I-00168 Rome, Italy.
EM MD0571@mclink.it
RI minnella, angelo maria/AAQ-6250-2020; Falsini, Benedetto/AAC-5907-2022;
   Falsini, Benedetto/V-1070-2019; Ziccardi, Lucia/AAQ-9066-2020; Fadda,
   Antonello/J-1560-2012; Piccardi, Marco/AAA-7849-2019
OI minnella, angelo maria/0000-0001-5896-5313; Falsini,
   Benedetto/0000-0002-1694-1062; Ziccardi, Lucia/0000-0002-5563-1243;
   Fadda, Antonello/0000-0001-7004-5245; Falsini,
   Benedetto/0000-0002-3569-4968; PICCARDI, Marco/0000-0002-9836-7534
CR AHUJA RM, 2001, SEMIN OPHTHALMOL, V16, P96
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   BAGOLINI B, 1988, DOC OPHTHALMOL, V70, P37, DOI 10.1007/BF00154734
   BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360
   Benner JD, 2002, AM J OPHTHALMOL, V134, P765, DOI 10.1016/S0002-9394(02)01694-X
   BIERSDORF WR, 1989, DOC OPHTHALMOL, V73, P313, DOI 10.1007/BF00154487
   BIRCH DG, 1988, DOC OPHTHALMOL, V69, P211, DOI 10.1007/BF00154401
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   BRINDLEY GS, 1965, J PHYSIOL-LONDON, V179, P518, DOI 10.1113/jphysiol.1965.sp007678
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P3337
   Desmettre T, 2001, INVEST OPHTH VIS SCI, V42, P2976
   FADDA A, 1989, COMPUT METH PROG BIO, V28, P45, DOI 10.1016/0169-2607(89)90180-6
   Fadda A, 1997, MED BIOL ENG COMPUT, V35, P441, DOI 10.1007/BF02534106
   FALSINI B, 1994, INVEST OPHTH VIS SCI, V35, P4282
   Falsini B, 1996, CURR EYE RES, V15, P638, DOI 10.3109/02713689609008904
   Falsini B, 2003, INVEST OPHTH VIS SCI, V44, P2133, DOI 10.1167/iovs.02-0716
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Gustavsson C, 2004, ACTA OPHTHALMOL SCAN, V82, P100, DOI 10.1111/j.1395-3907.2004.0189a.x
   JOHNSON RN, 2001, RETINA, V2, P875
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   Ming Y, 2004, INVEST OPHTH VIS SCI, V45, P1969, DOI 10.1167/iovs.03-1329
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   OVERGAARD J, 1987, INT J HYPERTHER, V3, P483, DOI 10.3109/02656738709140422
   Parisi V, 1998, Semin Ophthalmol, V13, P178, DOI 10.3109/08820539809056051
   Petrone S, 2000, INVEST OPHTH VIS SCI, V41, pS320
   PORCIATTI V, 1989, CLIN VISION SCI, V4, P323
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Salinas-Alaman A, 2003, ACTA OPHTHALMOL SCAN, V81, P197, DOI 10.1034/j.1600-0420.2003.t01-1-00025.x
   Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1379/1466-1268(1998)003<0228:HSPROS>2.3.CO;2
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   Scullica Luigi, 2001, Documenta Ophthalmologica, V102, P237, DOI 10.1023/A:1017562532731
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   SEIPLE WH, 1993, INVEST OPHTH VIS SCI, V34, P2638
   Shields C L, 1999, Curr Opin Ophthalmol, V10, P197
   Shields CL, 1996, OPHTHALMOLOGY, V103, P1642, DOI 10.1016/S0161-6420(96)30451-X
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Subramanian Manju L, 2003, Curr Opin Ophthalmol, V14, P155, DOI 10.1097/00055735-200306000-00008
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
NR 43
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD FEB
PY 2006
VL 84
IS 1
BP 27
EP 35
DI 10.1111/j.1600-0420.2005.00529.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 005VZ
UT WOS:000234854300004
PM 16445436
OA Bronze
DA 2022-11-30
ER

PT J
AU Ziemssen, F
   Sobolewska, B
AF Ziemssen, Focke
   Sobolewska, Bianka
TI Therapeutic Efficacy of Bevacizumab for Age-Related Macular Degeneration
   What are the Implications of CATT for Routine Management?
SO DRUGS & AGING
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; COST-EFFECTIVENESS; RANIBIZUMAB LUCENTIS;
   SPECTRAL-DOMAIN; VEGF-INHIBITORS; EXUDATIVE AMD; TIME-DOMAIN; SAFETY;
   PERSPECTIVE; THERAPIES
AB CATT (Comparison of Age-related macular degeneration [AMD] Treatment Trials) examined the efficacy of ranibizumab and bevacizumab for the treatment of neovascular AMD. This prospective, randomized, but unblinded trial revealed a significant improvement in vision with both treatments in terms of visual acuity; importantly, patients with juxtafoveal choroidal neo-vascularization (CNV) and retinal pigment epithelial detachments were not excluded from the study. Monthly treatment with the drugs resulted in similar increases in visual acuity, although angiograms indicated that ranibizumab was superior in terms of reducing retinal fluid and leakage.
   As the study also differentiated between a fixed regimen and an as-needed (pro re nata [PRN]) dosing regimen, a larger sample size and Bonferroni statistical correction were necessary. The equivalence of the PRN dosing of bevacizumab to the monthly treatment could not be confirmed. Almost all of the frequent deviations from the protocol (referring to retreatment criteria: 25.7-28.5%) resulted in under-treatment. Since this applied to both drugs equally, under-treatment alone could not explain the larger loss of visual acuity observed in the bevacizumab PRN arm. The PRN regimen was generally associated with a larger lesion size after 12 months compared with the fixed treatment regimens.
   The investigators accepted the drawbacks of an incomplete masking to allow co-payment by Medicare. As assessments of drug trials are often politically motivated, the higher demands of a non-inferiority trial compared with a superiority design must be emphasized. A comparison of the per-protocol and last-observation-carried-forward analysis has not yet been published; ongoing subgroup analysis might highlight the impact of different lesion characteristics. While CATT provided further evidence for the efficacy of bevacizumab treatment, differences in adverse events between the two treatments (e.g. a higher rate of serious adverse events with bevacizumab compared with ranibizumab) were reported; however, these still have to be analysed, with the larger sample sizes of previous ranibizumab studies needing to be taken into account. Preclinical studies imply some differences between the drugs in terms of their adverse event profiles. A possible increased risk of adverse events could not be ruled out by previous clinical case series and CATT because the sample sizes and the follow-up intervals were not adequate.
   The large discrepancy in the price of bevacizumab versus ranibizumab in the US means a cost-benefit analysis is warranted. A lack of quality-of-life data has prevented calculation of an appropriate bevacizumab price in the context of its performance in the ophthalmological setting.
   Thus, CATT suggests that a favourable visual acuity might be achieved by very frequent administration of bevacizumab in patients with neovascular AMD. Although there are certain safety caveats, increased focus on subgroup analyses and obtaining longer follow-up data are expected to yield additional information of clinical relevance.
C1 [Ziemssen, Focke; Sobolewska, Bianka] Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Ziemssen, F (通讯作者)，Univ Tubingen, Univ Eye Hosp, Ctr Ophthalmol, Schleichstr 12-15, D-72076 Tubingen, Germany.
EM focke.ziemssen@med.uni-tuebingen.de
RI , Ziemssen/B-9564-2009; Sobolewska, Bianka/A-8492-2015; Ziemssen,
   Focke/AAY-1686-2021
OI , Ziemssen/0000-0002-3873-0581; 
FU Alcon; Allergan; Bayer; Pfizer; Novartis
FX No sources of funding were used to assist in the preparation of this
   article. Focke Ziemssen has received speaker's fees or consultancy
   honoraria from Alcon, Allergan, Bayer, Pfizer and Novartis. Bianka
   Sobolewska has no conflicts of interest that are directly relevant to
   the content of this article.
CR Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Boron WF, 2006, PHYSIOLOGY, V21, P300, DOI 10.1152/physiol.00030.2006
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Deissler HL, 2011, BRIT J OPHTHALMOL, V95, P1151, DOI 10.1136/bjo.2010.192229
   Edwards M, 2009, PATIENT EDUC COUNS, V75, P37, DOI 10.1016/j.pec.2008.09.025
   Eriksson U, 2012, ACTA OPHTHALMOL, V90, P620, DOI 10.1111/j.1755-3768.2011.02112.x
   Ezzati M, 2008, PLOS MED, V5, P557, DOI 10.1371/journal.pmed.0050066
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fleming TR, 2011, ANN INTERN MED, V154, P113, DOI 10.7326/0003-4819-154-2-201101180-00010
   Goff SL, 2008, J GEN INTERN MED, V23, P236, DOI 10.1007/s11606-007-0470-3
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Gower EW, 2011, INVEST OPHTHALMOL VI, V52
   Hawkes N, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2794
   Hodge W, 2010, CAN J OPHTHALMOL, V45, P223, DOI 10.3129/i10-047
   Jampol LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1194, DOI 10.1001/archophthalmol.2009.180
   Johanson R, 2000, J PUBLIC HEALTH MED, V22, P439, DOI 10.1093/pubmed/22.3.439
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Kelly SP, 2011, EYE, V25, P710, DOI 10.1038/eye.2011.89
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   la Cour M, 2007, ACTA OPHTHALMOL SCAN, V85, P2, DOI 10.1111/j.1600-0420.2006.00869.x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lichter PR, 2008, ARCH OPHTHALMOL-CHIC, V126, P1593, DOI 10.1001/archopht.126.11.1593
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2010, NEW ENGL J MED, V363, P105, DOI 10.1056/NEJMp1001201
   Miller LE, 2011, CONTEMP CLIN TRIALS, V32, P240, DOI 10.1016/j.cct.2010.11.004
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Novack GD, 2007, OPHTHALMOLOGY, V114, P1037, DOI 10.1016/j.ophtha.2007.02.027
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Pauleikhoff D, 2011, GRAEF ARCH CLIN EXP, V249, P631, DOI 10.1007/s00417-011-1639-3
   Querques G, 2011, OPHTHALMIC RES, V46, P152, DOI 10.1159/000325027
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Shekelle P, 2010, J CLIN EPIDEMIOL, V63, P126, DOI 10.1016/j.jclinepi.2009.07.014
   Snapinn Steven M, 2000, Curr Control Trials Cardiovasc Med, V1, P19, DOI 10.1186/CVM-1-1-019
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Swindell JS, 2010, ANN FAM MED, V8, P260, DOI 10.1370/afm.1118
   Tarn DM, 2006, AM J MANAG CARE, V12, P657
   Tarn DM, 2009, J AM GERIATR SOC, V57, P462, DOI 10.1111/j.1532-5415.2008.02133.x
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   US Social Security Administration, 2007, PER LIF TABL
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zhao WL, 2012, PHARM STAT, V11, P39, DOI 10.1002/pst.493
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
   Ziemssen F, 2006, OPHTHALMOLOGE, V103, P484, DOI 10.1007/s00347-006-1354-3
   Ziemssen F, 2007, RETINA-J RET VIT DIS, V27, P1154, DOI 10.1097/IAE.0b013e3180ca7daf
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 62
TC 6
Z9 6
U1 0
U2 8
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2011
VL 28
IS 11
BP 853
EP 865
PG 13
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 860TK
UT WOS:000297970400002
PM 21970950
DA 2022-11-30
ER

PT J
AU Jiang, B
   Gao, L
   Dong, S
   Hou, QX
   Sun, MH
   Zhang, JJ
   Yu, HT
   Zhang, ZY
   Sun, DW
AF Jiang, Bo
   Gao, Lin
   Dong, Su
   Hou, Qingxue
   Sun, Minghao
   Zhang, Jingjie
   Yu, Haotian
   Zhang, Zhongyu
   Sun, Dawei
TI The Influence of COVID-19 on the Stability of Patients with Neovascular
   Age-Related Macular Degeneration with Different Treatment Regimens
SO ADVANCES IN THERAPY
LA English
DT Article
DE COVID-19; nAMD; PRN regimen; Stability; T&E regimen
ID INTRAVITREAL AFLIBERCEPT; CHOROIDAL THICKNESS; EXTEND THERAPY; EXIT
   STRATEGY; RANIBIZUMAB; OUTCOMES; EYES; MAINTENANCE; INJECTION
AB Introduction To explore the impact of coronavirus disease 2019 (COVID-19) on the stability of patients with neovascular age-related macular degeneration (nAMD) receiving the treat and extend (T&E) or the pro re nata (PRN) treatment regimen and to identify indicators that may predict the disease stability of nAMD. Methods This is a retrospective study of patients with nAMD treated at the Second Affiliated Hospital of Harbin Medical University whose treatment schedule was interrupted at least once between 1 February and 31 May 2020. The demographic and clinical characteristics, including the best corrected visual acuity (BCVA), optical coherence tomography (OCT) features, subfoveal choroidal thickness (SFCT), interval between the last injection and the beginning of the pandemic, and the number of anti-vascular endothelial growth factor (VEGF) injections, were analyzed. Results A total of 209 stable patients with nAMD (122 eyes received the T&E regimen; 87 eyes received the PRN regimen) were identified. Compared to those who received the PRN regimen, the patients who received the T&E regimen were more stable during the first visit after COVID-19 (53.3% vs. 33.3%, P = 0.004), the BCVA was significantly better (58.5 letters vs. 56 letters, P = 0.006), and the CRT fluctuated only slightly (15 mu m vs. 35 mu m, P = 0.001). Furthermore, a multivariate logistic regression analysis showed that stable patients with nAMD with type 1 choroidal neovascularization (CNV) (OR 2.493 [95% CI 1.179-5.272], compared with type 2 CNV; P = 0.017; OR 2.912 [95% CI 1.133-7.485], compared with retinal angiomatous proliferation; P = 0.026) or with pigment epithelial detachment (PED) were more likely to remain stable when treatment was interrupted (OR 0.392 [95% CI 0.181-0.852], compared with no PED; P = 0.018). Conclusion Compared to patients who received the PRN treatment regimen, stable patients with nAMD who received the T&E treatment regimen could better maintain stability when the treatments were suddenly interrupted by the COVID-19 pandemic. In addition, patients with type 1 CNV or patients with PED were more likely to remain stable. At present, the COVID-19 pandemic is becoming increasingly normalized, and the T&E regimen can become a more advanced treatment option for patients undergoing therapy.
C1 [Jiang, Bo; Gao, Lin; Dong, Su; Hou, Qingxue; Sun, Minghao; Zhang, Jingjie; Yu, Haotian; Zhang, Zhongyu; Sun, Dawei] Harbin Med Univ, Affiliated Hosp 2, Ophthalmol Dept, 246 Xuefu Rd, Harbin 150001, Heilongjiang, Peoples R China.
C3 Harbin Medical University
RP Sun, DW (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Ophthalmol Dept, 246 Xuefu Rd, Harbin 150001, Heilongjiang, Peoples R China.
EM sun.dawei@hotmail.com
RI Zhang, Jing/GWZ-7332-2022
FU National Natural Science Foundation of China [82171103]
FX Funding. This study was supported by the National Natural Science
   Foundation of China (No. 82171103). The journal's Rapid Service and Open
   Access fees were funded by the authors.
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   American Academy of Ophthalmology, 2020, REC URG NON PAT CAR
   Amoaku W, 2018, CLIN OPHTHALMOL, V12, P1731, DOI 10.2147/OPTH.S174560
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Chakravarthy U, 2020, EYE, V34, P2249, DOI 10.1038/s41433-020-0799-y
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Corazza P, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00226-z
   Daien V, 2021, BRIT J OPHTHALMOL, V105, P1475, DOI 10.1136/bjophthalmol-2020-317434
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Ishibashi K, 2021, THER ADV OPHTHALMOL, V13, DOI 10.1177/2515841420984586
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kaya F, 2017, J FR OPHTALMOL, V40, P832, DOI 10.1016/j.jfo.2017.04.014
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mack HG, 2021, CLIN EXP OPHTHALMOL, V49, P9, DOI 10.1111/ceo.13898
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Nguyen V, 2019, OPHTHALMOL RETINA, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2020, OPHTHALMOLOGY, V127, pE51, DOI 10.1016/j.ophtha.2020.04.029
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang KB, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.576275
   ZHANG X, 2018, BIOMED RES INT, V2018, DOI DOI 10.1155/2018/9640131
   Zhao XY, 2021, THER ADV CHRONIC DIS, V12, DOI 10.1177/20406223211026389
NR 44
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD APR
PY 2022
VL 39
IS 4
BP 1568
EP 1581
DI 10.1007/s12325-021-01993-3
EA NOV 2021
PG 14
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 0L4FP
UT WOS:000722120100001
PM 34817809
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Tang, DA
   Mitchell, P
   Liew, G
   Burlutsky, G
   Flood, VM
   Gopinath, B
AF Tang, Diana
   Mitchell, Paul
   Liew, Gerald
   Burlutsky, George
   Flood, Victoria M.
   Gopinath, Bamini
TI Telephone-Delivered Dietary Intervention in Patients with Age-Related
   Macular Degeneration: 3-Month Post-Intervention Findings of a Randomised
   Controlled Trial
SO NUTRIENTS
LA English
DT Article
DE age-related macular degeneration; education; nutrition; telehealth
ID MEDITERRANEAN DIET; EYE DISEASE; RISK; PROGRESSION; ADHERENCE;
   ASSOCIATION; CONSUMPTION; BEHAVIOR; ADULTS
AB There is an evidence-practice gap between the dietary recommendations for age-related macular degeneration (AMD) presented in the literature and those practiced by patients. This study reports on the 3-month post-intervention results of a randomised controlled trial (RCT) evaluating telephone-delivered counselling to improve dietary behaviours among AMD patients. A total of 155 AMD patients (57% female, aged 78 +/- 8 years; control: 78, intervention: 77), primarily residing in New South Wales, Australia, were recruited. Participants completed a baseline questionnaire and a short dietary questionnaire (SDQ-AMD). The intervention included an evidence-based nutrition resource and four monthly calls with a dietitian. Immediately post-intervention, intervention participants repeated the SDQ-AMD and completed a feedback form. At 3 months post-intervention, both study arms repeated the SDQ-AMD. Statistical analyses included t-tests and McNemar's test. Intervention participants reported satisfaction with the tailored phone calls, nutrition resource and nutrition education provided. At 3 months post-intervention, there was no statistically significant difference between study arms in the proportion of participants meeting the dietary goals nor in intake (mean servings +/- SE) of total vegetables (primary outcome) and other key food groups; however, there was a significantly higher intake of nuts (secondary outcome) (3.96 +/- 0.51 vs. 2.71 +/- 0.32; p = 0.04) among participants in the intervention versus control group. Within the intervention arm, there were also significant improvements in intakes of the following secondary outcomes: dark green leafy vegetables (0.99 +/- 0.17 vs. 1.71 +/- 0.22; p = 0.003) and legumes (0.69 +/- 0.10 vs. 1.12 +/- 0.16; p = 0.02) and intake of sweets and processed/prepared foods (8.31 +/- 0.76 vs. 6.54 +/- 0.58, p = 0.01). In summary, although there were few dietary differences between study arms at 3 months post-intervention, the intervention involving four monthly calls was acceptable and helpful to the participants. This type of intervention therefore has the potential to provide people with AMD the needed support for improving their nutrition knowledge and dietary practices, especially if continued over a longer period.
C1 [Tang, Diana; Mitchell, Paul; Liew, Gerald; Burlutsky, George; Gopinath, Bamini] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Camperdown, NSW 2006, Australia.
   [Tang, Diana; Mitchell, Paul; Liew, Gerald; Burlutsky, George; Gopinath, Bamini] Univ Sydney, Westmead Inst Med Res, Camperdown, NSW 2006, Australia.
   [Flood, Victoria M.] Univ Sydney, Fac Med & Hlth, Sydney Sch Hlth Sci, Camperdown, NSW 2006, Australia.
   [Flood, Victoria M.] Westmead Hosp, Western Sydney Local Hlth Dist, Westmead, NSW 2145, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; University of Sydney
RP Tang, DA (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Camperdown, NSW 2006, Australia.; Tang, DA (通讯作者)，Univ Sydney, Westmead Inst Med Res, Camperdown, NSW 2006, Australia.
EM diana.tang@sydney.edu.au; paul.mitchell@sydney.edu.au;
   gerald.liew@sydney.edu.au; george.burlutsky@sydney.edu.au;
   vicki.flood@sydney.edu.au; bamini.gopinath@sydney.edu.au
RI Flood, Victoria M/A-8732-2016; Liew, Gerald/AAB-6870-2022
OI Flood, Victoria M/0000-0001-5310-7221; Gopinath,
   Bamini/0000-0003-3573-359X; Tang, Diana/0000-0003-2007-9054
FU NHMRC [APP1150101]
FX This work is supported by NHMRC grant number APP1150101.
CR [Anonymous], 2013, AUSTR DIET GUID
   Australian Bureau of Statistics, 2014, AUSTR HLTH SURV NUTR
   Bandayrel K, 2011, J NUTR EDUC BEHAV, V43, P251, DOI 10.1016/j.jneb.2010.01.004
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   CAMPBELL MK, 1994, AM J PUBLIC HEALTH, V84, P783, DOI 10.2105/AJPH.84.5.783
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Darmadi-Blackberry I, 2004, ASIA PAC J CLIN NUTR, V13, P217
   Desroches S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008722.pub2
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Goldstein MG, 2004, AM J PREV MED, V27, P61, DOI 10.1016/j.amepre.2004.04.023
   Goode AD, 2012, AM J PREV MED, V42, P81, DOI 10.1016/j.amepre.2011.08.025
   Gopinath B, 2020, CLIN NUTR, V39, P580, DOI 10.1016/j.clnu.2019.03.009
   Gopinath B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122548
   Grains and Legumes Nutrition Council, 2013, LIFT LID LEG BEN CHO
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kelly JT, 2016, AM J CLIN NUTR, V104, P1693, DOI 10.3945/ajcn.116.136333
   Kim EK, 2018, EUR J CLIN NUTR, V72, P161, DOI 10.1038/ejcn.2017.152
   Lawrenson JG, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040823
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   National Institute for Health and Care Excellence (NICE), 2018, AG REL MAC DEG NIC G
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Pollard CM, 2008, PUBLIC HEALTH NUTR, V11, P314, DOI 10.1017/S1368980007000523
   Sahyoun NR, 2004, J AM DIET ASSOC, V104, P58, DOI 10.1016/j.jada.2003.10.013
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Stevens R, 2018, BRIT J VISUAL IMPA, V36, P110, DOI 10.1177/0264619617735144
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tang D, 2019, NUTRIENTS, V11, DOI 10.3390/nu11123031
   Tang D, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024774
   van den Berg N, 2012, MATURITAS, V73, P94, DOI 10.1016/j.maturitas.2012.06.010
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wosik J, 2020, J AM MED INFORM ASSN, V27, P957, DOI 10.1093/jamia/ocaa067
NR 42
TC 1
Z9 1
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2020
VL 12
IS 10
AR 3083
DI 10.3390/nu12103083
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nutrition & Dietetics
GA ON8RZ
UT WOS:000586962000001
PM 33050401
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Janik-Papis, K
   Zaras, M
   Krzyzanowska, A
   Wozniak, K
   Blasiak, J
   Szaflik, J
   Szaflik, JP
AF Janik-Papis, Katarzyna
   Zaras, Malgorzata
   Krzyzanowska, Anna
   Wozniak, Katarzyna
   Blasiak, Janusz
   Szaflik, Jerzy
   Szaflik, Jacek P.
TI Association between vascular endothelial growth factor gene
   polymorphisms and age-related macular degeneration in a Polish
   population
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE Age-related macular degeneration; AMD; Vascular endothelial growth
   factor; VEGF; Gene polymorphism
ID PROGRESS; DISEASE; VEGF
AB The pathogenesis of age-related macular degeneration (AMD) is thought to be determined by an array of environmental and genetic factors. The association of increased expression of vascular endothelial growth factor (VEGF) with AMD, especially the wet form of AMD, was reported in several studies. The VECF gene is highly polymorphic and some of its polymorphisms may affect its expression. In our work, we searched for an association between the -460C> (rs833061) and -634G>C (rs2010963) polymorphisms of the VEGF gene and the occurrence of AMD and its dry and wet forms. We have chosen these polymorphisms because they were shown to be significant in other studies and we previously showed their association with diabetic retinopathy. A total of 401 individuals were enrolled in this study: 136 controls, and 88 patients with dry and 177 with wet AMD. The polymorphisms were determined with DNA from peripheral blood lymphocytes by allele-specific and restriction fragment length polymorphism polymerase chain reaction. The significance of the polymorphisms was assessed by multiple logistic regression, producing odds ratios (ORs) and 95% confidence intervals (CIs). We observed a weak association (OR 2.90) between AMD occurrence and the C/T genotype of the -460C>T polymorphism. An association (OR 3.77) between the C/T genotype of the -460C>T polymorphism and the occurrence of dry AMD was observed. The T/T genotype considerably lowered the risk of dry AMD (OR 0.19). Dry AMD was associated with the C/C genotype of the -634G>C polymorphism (OR 3.68). Another weak association (OR 2.63) was found between the C/T genotype of the -460C>T polymorphism and the occurrence of wet AMD. The occurrence of AMD was correlated with the presence of the combined C/T-G/G genotype of both polymorphisms (OR 2.41), whereas the T/T-G/G and T/T-G/C genotypes exerted a protective effect against the disease (OR 0.22 and 0.48, respectively). The presence of the C/T-G/G and C/T-C/C combined genotypes increased the risk of dry AMD (OR 2.08 and 3.77, respectively), whereas the presence of the T/T-G/G and T/T-G/C genotypes decreased the risk (OR 0.15 and 0.28, respectively). In the wet form of AMD, the combined genotype C/T-G/G slightly favored the disease (OR 2.61) and the T/T-G/G genotype had a protective effect (OR 0.25). Analysis of haplotypes of both polymorphisms yielded similar results for AMD in general as well as for the dry and wet forms of the disease: the CG haplotype favored both forms of AMD, whereas the TG haplotype protected against both forms of AMD. The results obtained indicate that the -460C>T and -634G>C polymorphisms of the VEGF gene may be associated with the dry and wet forms of AMD in a Polish population. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Janik-Papis, Katarzyna; Krzyzanowska, Anna; Wozniak, Katarzyna; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90237 Lodz, Poland.
   [Zaras, Malgorzata; Szaflik, Jerzy; Szaflik, Jacek P.] Med Univ Warsaw, Dept Ophthalmol, PL-03710 Warsaw, Poland.
   [Zaras, Malgorzata; Szaflik, Jerzy; Szaflik, Jacek P.] Samodzielny Publ Szpital Okulisty, PL-03710 Warsaw, Poland.
C3 University of Lodz; Medical University of Warsaw
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, Banacha 12-16, PL-90237 Lodz, Poland.
EM januszb@biol.uni.lodz.pl
RI Janik-Superson, Katarzyna/ABA-2571-2021; Rocamora, Rodrigo/M-3917-2016;
   Wozniak, Katarzyna/R-9226-2018; Rocamora, Rodrigo/AAE-8052-2021
OI Janik-Superson, Katarzyna/0000-0001-9692-7238; Rocamora,
   Rodrigo/0000-0001-7345-4300; Wozniak, Katarzyna/0000-0001-6666-7973;
   Rocamora, Rodrigo/0000-0001-7345-4300; Blasiak,
   Janusz/0000-0001-9539-9584; Szaflik, Jerzy/0000-0002-7601-1326
FU Ministry of Science and Higher Education [402 071 32/2210]
FX This work was supported by the Ministry of Science and Higher Education,
   grant number 402 071 32/2210.
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Szaflik JP, 2008, GRAEF ARCH CLIN EXP, V246, P39, DOI 10.1007/s00417-007-0674-6
NR 14
TC 33
Z9 37
U1 1
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD DEC
PY 2009
VL 87
IS 3
BP 234
EP 238
DI 10.1016/j.yexmp.2009.09.005
PG 5
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 520OC
UT WOS:000271853800011
PM 19761764
DA 2022-11-30
ER

PT J
AU Kim, JG
   Kim, YC
   Kang, KT
AF Kim, Jae-Gon
   Kim, Yu Cheol
   Kang, Kyung Tae
TI Impact of Delayed Intravitreal Anti-Vascular Endothelial Growth Factor
   (VEGF) Therapy Due to the Coronavirus Disease Pandemic on the Prognosis
   of Patients with Neovascular Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; retina; neovascular AMD; intravitreal VEGF injection
ID VISUAL-ACUITY; RANIBIZUMAB
AB This study estimated the outcome of delayed intravitreal anti-vascular endothelial growth factor (VEGF) therapy due to the coronavirus (COVID-19) disease pandemic on the prognosis of patients with neovascular age-related macular degeneration (nAMD). This study retrospectively enrolled 57 nAMD patients whose intravitreal anti-VEGF injections were delayed for >2 weeks between February and June 2020. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and anatomical characteristics were evaluated before (baseline), on the day, and at 2, 4, and 6 months after the delayed injection, and risk factors were identified. The average injection interval before and after treatment delay was 3.05 +/- 1.45 and 2.41 +/- 1.46 months, respectively (p = 0.002). The CST at baseline and on the day of delayed injection was 227.82 +/- 62.46 and 267.26 +/- 77.74 mu m, respectively (p < 0.001). The average BCVA decreased from 0.29 +/- 0.29 logMAR (baseline) to 0.38 +/- 0.31 logMAR (6 months) (p = 0.001). The maximum subretinal fluid (SRF) height increased from 84.32 +/- 89.33 mu m (baseline) to 121.38 +/- 103.36 mu m (6 months) (p = 0.027). A higher baseline maximum SRF height was associated with less SRF height deterioration 6 months later (p < 0.001). Delayed intravitreal anti-VEGF therapy caused by the COVID-19 pandemic has worsened BCVA and residual SRF in nAMD patients after a temporary recovery. The baseline SRF reduce the degree of SRF height deterioration.
C1 [Kim, Jae-Gon; Kim, Yu Cheol; Kang, Kyung Tae] Keimyung Univ, Dongsan Hosp, Dept Ophthalmol, Sch Med, Daegu 42601, South Korea.
C3 Keimyung University
RP Kang, KT (通讯作者)，Keimyung Univ, Dongsan Hosp, Dept Ophthalmol, Sch Med, Daegu 42601, South Korea.
EM jgkim9418@naver.com; eyedr@dsmc.or.kr; kkt0604@dsmc.or.kr
OI Kang, Kyung Tae/0000-0001-9276-9607; Kim, Jae-Gon/0000-0003-2454-7724
FU Bisa Research Grant of Keimyung University
FX This research was supported by the Bisa Research Grant of Keimyung
   University in 2021.
CR Allegrini D, 2021, CLIN OPHTHALMOL, V15, P4073, DOI [10.2147/OPTH.S323058, 10.2147/OPTH.S3230582021]
   AlSaad MM, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01391-3
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Balaskas K, 2017, RETINA-J RET VIT DIS, V37, P1297, DOI 10.1097/IAE.0000000000001342
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Borrelli E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061265
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Elfalah M, 2021, CLIN OPHTHALMOL, V15, P661, DOI 10.2147/OPTH.S289068
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kang KT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44632-2
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Keenan TDL, 2021, ADV EXP MED BIOL, V1256, P1, DOI 10.1007/978-3-030-66014-7_1
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Martin DF, 2018, AM J OPHTHALMOL, V191, pXLI, DOI 10.1016/j.ajo.2017.12.019
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Naravane AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247161
   Parravano M, 2020, OPHTHALMOL THER, V9, P231, DOI 10.1007/s40123-020-00251-z
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Sekeroglu MA, 2022, EUR J OPHTHALMOL, V32, P1064, DOI 10.1177/11206721211010613
   Sevik MO, 2021, INT OPHTHALMOL, V41, P2951, DOI 10.1007/s10792-021-01854-6
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sridhar J, 2016, JAMA OPHTHALMOL, V134, P437, DOI 10.1001/jamaophthalmol.2016.0045
   Ung C, 2021, ADV EXP MED BIOL, V1256, P295, DOI 10.1007/978-3-030-66014-7_12
   Viola F, 2021, RETINA-J RET VIT DIS, V41, P701, DOI 10.1097/IAE.0000000000002941
   Wada I, 2019, GRAEF ARCH CLIN EXP, V257, P1411, DOI 10.1007/s00417-019-04361-8
   Yang KB, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.576275
   Yeter DY, 2021, J FR OPHTALMOL, V44, P299, DOI 10.1016/j.jfo.2021.02.001
NR 39
TC 0
Z9 0
U1 3
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2022
VL 11
IS 9
AR 2321
DI 10.3390/jcm11092321
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1E9WG
UT WOS:000794828500001
PM 35566445
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lotery, AJ
   Gibson, J
   Cree, AJ
   Downes, SM
   Harding, SP
   Rogers, CA
   Reeves, BC
   Ennis, S
   Chakravarthy, U
AF Lotery, Andrew J.
   Gibson, Jane
   Cree, Angela J.
   Downes, Susan M.
   Harding, Simon P.
   Rogers, Chris A.
   Reeves, Barnaby C.
   Ennis, Sarah
   Chakravarthy, Usha
CA Alternative Treatments Inhibit
TI Pharmacogenetic Associations with Vascular Endothelial Growth Factor
   Inhibition in Participants with Neovascular Age-related Macular
   Degeneration in the IVAN Study
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; VISUAL FUNCTION; RANIBIZUMAB; MUTATIONS; GENOTYPES;
   GENES; UK
AB Purpose: To determine if prespecified genetic polymorphisms influence responsiveness to vascular endothelial growth factor (VEGF) inhibition in neovascular age-related macular degeneration (nAMD). The objectives were to replicate 3 reported pharmacogenetic associations of response in nAMD and to test for novel associations.
   Design: Cohort study, combining information about patients' genotypes with information from a randomized controlled trial about responsiveness to anti-VEGF therapy for nAMD.
   Participants: Five hundred nine participants with nAMD, enrolled in the Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) trial.
   Methods: Participants were classified as responders or nonresponders to VEGF inhibition based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). We computed the change in TRT from baseline to the latest time point for which OCT data were available (3, 6, 9, or 12 months). Eyes with changes in TRT greater than or equal to the 75th percentile or more were classified as responders, and those with changes less than or equal to the 25th percentile or lower were classified as non-responders. Three previously reported associations of response to VEGF inhibition in nAMD involving single nucleotide polymorphisms (SNPs) at the CFH, FZD4, and HTRA1/ARMS2 loci were tested for replication. An additional 482 SNPs also were tested using a candidate gene approach. Associations were estimated as odds ratios (ORs) with confidence intervals (CIs).
   Main Outcome Measures: The primary outcome was evidence of a genetic association with response to VEGF inhibition as measured by change in TRT.
   Results: One hundred twenty-six participants were classified as responders and 128 were classified as nonresponders. The SNP rs10490924 in HTRA1/ARMS2 showed a borderline association with responsiveness after Bonferroni correction (OR, 1.53; CI, 0.99-2.36; P = 0.055, Bonferroni correction). None of the other 484 additional SNPs tested for association was significant after Bonferroni correction for multiple testing. The smallest corrected P value was 0.84 (P = 0.002, uncorrected) for rs9679290 in the EPAS1 (HIF2A) gene on chromosome 2. Four of the 10 most significant results were in this gene.
   Conclusions: We estimated pharmacogenetic associations using high-quality phenotype data from a randomized controlled clinical trial of nAMD. No significant association or replication of previous associations were observed. Further investigation of the EPAS1 (HIF2A) gene, however, may, be merited. (C) 2013 by the American Academy of Ophthalmology.
C1 [Lotery, Andrew J.; Cree, Angela J.] Univ Southampton, Fac Med, Clin Neurosci Res Grp, Southampton SO16 6YD, Hants, England.
   [Gibson, Jane; Ennis, Sarah] Univ Southampton, Fac Med, Southampton SO16 6YD, Hants, England.
   [Downes, Susan M.] Oxford Univ Hosp NHS Trust, Oxford Eye Hosp, Oxford, England.
   [Harding, Simon P.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L69 3BX, Merseyside, England.
   [Rogers, Chris A.; Reeves, Barnaby C.] Univ Bristol, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol, Avon, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis Sci, Belfast, Antrim, North Ireland.
C3 University of Southampton; University of Southampton; Oxford University
   Hospitals NHS Foundation Trust; University of Liverpool; University of
   Bristol; Queens University Belfast
RP Lotery, AJ (通讯作者)，Univ Southampton, Fac Med, Clin Neurosci Res Grp, Sir Henry Wellcome Labs,Univ Hosp Southampton, South Block,Mailpoint 806,Level D, Southampton SO16 6YD, Hants, England.
EM A.J.Lotery@soton.ac.uk
RI Gibson, Jane/I-1630-2012
OI Gibson, Jane/0000-0002-0973-8285; Reeves, Barnaby/0000-0002-5101-9487;
   Lotery, Andrew/0000-0001-5541-4305; Chakravarthy,
   Usha/0000-0002-2606-3734; Cree, Angela/0000-0002-1987-8900; Harding,
   Simon/0000-0003-4676-1158
FU Novartis; National Institute for Health Research (NIHR) Health
   Technology Assessment (HTA) program (National Institute for Health
   Research Evaluation, Trials and Studies Coordinating Centre, University
   of Southampton, Southampton, United Kingdom) [07/36/01]; Macular Society
   (Andover, Hampshire, United Kingdom); National Institute for Health
   Research [NF-SI-0507-10094] Funding Source: researchfish
FX The Queen's University of Belfast and the Belfast Trust, the University
   of Southampton, the University Hospital Southampton NHS Foundation
   Trust, and Oxford University Hospital have received payments from
   Novartis.; The IVAN trial was funded by the National Institute for
   Health Research (NIHR) Health Technology Assessment (HTA) program
   (National Institute for Health Research Evaluation, Trials and Studies
   Coordinating Centre, University of Southampton, Southampton, United
   Kingdom) (project no.: 07/36/01) and by the Macular Society (Andover,
   Hampshire, United Kingdom). The trial was designed, conducted, analyzed,
   and interpreted independent of the commercial funding sources. The
   writing committee had full access to the data and is responsible for
   submitting the publication. The views and opinions expressed are those
   of the authors and do not necessarily reflect those of the HTA program,
   the NIHR, the United Kingdom National Health Service, or the Department
   of Health.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ding K, 2005, INVEST OPHTH VIS SCI, V46, P1010, DOI 10.1167/iovs.04-0788
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Ennis S, 2010, EYE, V24, P328, DOI 10.1038/eye.2009.73
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grant SFA, 2007, EXPERT REV MOL DIAGN, V7, P371, DOI 10.1586/14737159.7.4.371
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Nakai K, 2009, FASEB J, V23, P2235, DOI 10.1096/fj.08-124321
   Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871
   Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72
NR 23
TC 50
Z9 54
U1 0
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2013
VL 120
IS 12
BP 2637
EP 2643
DI 10.1016/j.ophtha.2013.07.046
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 255OL
UT WOS:000327249600050
PM 24070809
DA 2022-11-30
ER

PT J
AU Sunness, JS
   Rubin, GS
   Broman, A
   Applegate, CA
   Bressler, NM
   Hawkins, BS
AF Sunness, Janet S.
   Rubin, Gary S.
   Broman, Aimee
   Applegate, Carol A.
   Bressler, Neil M.
   Hawkins, Barbara S.
TI Low luminance visual dysfunction as a predictor of subsequent visual
   acuity loss from geographic atrophy in age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID NATURAL-HISTORY; CLINICAL-TRIALS; RISK-FACTORS; ENLARGEMENT;
   MACULOPATHY; ADAPTATION
AB Objective: To show that low luminance visual dysfunction is predictive of subsequent visual acuity (VA) loss in eyes with geographic atrophy (GA) resulting from age-related macular degeneration (AMD).
   Design: Cohort study examining the prospective natural history study of GA from 1992 through 2000 at the Wilmer Eye Institute.
   Participants: Ninety-one participants with GA resulting from AMD without choroidal neovascularization in at least 1 eye who completed a 2-year study examination.
   Methods: Annual examinations included measurement of best-corrected VA, low luminance VA, Pelli-Robson contrast sensitivity, reading speed, examination, and fundus photography. The total GA area was quantified, as was the GA within a 10.2-mm(2) circle centered on the fovea.
   Main Outcome Measures: Visual acuity loss at 2 years and risk factors for visual loss.
   Results: Participants with baseline VA of 20/50 or more had a 40% 2-year rate of VA loss of 3 lines or more, compared with 13% for the participants with worse baseline acuities. The baseline low-luminance deficit (LLD) in VA was a strong predictor of subsequent VA loss for all levels of baseline VA. Within the good baseline VA group, the relative risk (RR) of 3-line loss for the worse LLD group compared with the better LLD group was 2.88 (95% confidence interval [CI], 1.13-7.35). The LLD is a stable and reproducible measure. Other significant visual function predictors of subsequent VA loss in eyes with good baseline VA included foveal dark-adapted sensitivity ;(RR, 4.20; 95% CI, 1.39-12.71) and reduced reading rate (RR, 2.43; 95% CI, 1.11-5.31). The rate of VA loss within the good acuity group was higher when the GA included 25% to 75% of the central 10.2 mm(2) than in eyes with GA including less than 25% or more than 75% of the central 10.2 mm(2). The following were not significant predictors of subsequent VA loss among these participants: age, gender, fellow eye diagnosis, fellow eye VA, baseline GA area, and GA enlargement rate.
   Conclusions: Visual function measures can predict the risk of future VA loss in subjects with GA and good baseline VA. They may allow identification of the highest risk group for VA loss, enabling more efficient design of clinical trials. They also may be appropriate surrogate measures of foveal health in short-term treatment trials.
C1 [Sunness, Janet S.; Applegate, Carol A.] Greater Baltimore Med Ctr, Richard E Hoover Rehabil Serv Low Vis & Blindness, Baltimore, MD 21204 USA.
   [Sunness, Janet S.; Broman, Aimee; Applegate, Carol A.; Bressler, Neil M.; Hawkins, Barbara S.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Rubin, Gary S.] UCL, Inst Ophthalmol, London, England.
C3 Greater Baltimore Medical Center; Johns Hopkins University; Johns
   Hopkins Medicine; University of London; University College London
RP Sunness, JS (通讯作者)，Greater Baltimore Med Ctr, Hoover Serv Low Vis & Blindness, 6569 N Charles St,PPW 305, Baltimore, MD 21204 USA.
EM jsunness@gbmc.org
OI Sunness, Janet/0000-0001-8823-0780
FU National Institutes of Health, Bethesda, Maryland [EY08552, EY14148];
   NATIONAL EYE INSTITUTE [R03EY014148, R01EY008552] Funding Source: NIH
   RePORTER
FX Supported by the National Institutes of Health, Bethesda, Maryland
   (grant nos.: EY08552 and EY14148).
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SLOAN LL, 1969, DOC OPHTHALMOL, V26, P384, DOI 10.1007/BF00943999
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
NR 18
TC 110
Z9 112
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2008
VL 115
IS 9
BP 1480
EP 1488
DI 10.1016/j.ophtha.2008.03.009
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 346LZ
UT WOS:000259071300007
PM 18486216
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Peng, YF
   Dharssi, S
   Chen, QY
   Keenan, TD
   Agron, E
   Wong, WT
   Chew, EY
   Lu, ZY
AF Peng, Yifan
   Dharssi, Shazia
   Chen, Qingyu
   Keenan, Tiarnan D.
   Agron, Elvira
   Wong, Wai T.
   Chew, Emily Y.
   Lu, Zhiyong
TI DeepSeeNet: A Deep Learning Model for Automated Classification of
   Patient-based Age-related Macular Degeneration Severity from Color
   Fundus Photographs
SO OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY; PREVALENCE; IMAGES; EDEMA; IDENTIFICATION;
   POPULATIONS; VALIDATION; ALGORITHM; AGREEMENT; GENETICS
AB Purpose: In assessing the severity of age-related macular degeneration (AMD), the Age-Related Eye Disease Study (AREDS) Simplified Severity Scale predicts the risk of progression to late AMD. However, its manual use requires the time-consuming participation of expert practitioners. Although several automated deep learning systems have been developed for classifying color fundus photographs (CFP) of individual eyes by AREDS severity score, none to date has used a patient-based scoring system that uses images from both eyes to assign a severity score.
   Design: DeepSeeNet, a deep learning model, was developed to classify patients automatically by the AREDS Simplified Severity Scale (score 0-5) using bilateral CFP.
   Participants: DeepSeeNet was trained on 58 402 and tested on 900 images from the longitudinal follow-up of 4549 participants from AREDS. Gold standard labels were obtained using reading center grades.
   Methods: DeepSeeNet simulates the human grading process by first detecting individual AMD risk factors (drusen size, pigmentary abnormalities) for each eye and then calculating a patient-based AMD severity score using the AREDS Simplified Severity Scale.
   Main Outcome Measures: Overall accuracy, specificity, sensitivity, Cohen's kappa, and area under the curve (AUC). The performance of DeepSeeNet was compared with that of retinal specialists.
   Results: DeepSeeNet performed better on patient-based classification (accuracy = 0.671; kappa = 0.558) than retinal specialists (accuracy = 0.599; kappa = 0.467) with high AUC in the detection of large drusen (0.94), pigmentary abnormalities (0.93), and late AMD (0.97). DeepSeeNet also outperformed retinal specialists in the detection of large drusen (accuracy 0.742 vs. 0.696; kappa 0.601 vs. 0.517) and pigmentary abnormalities (accuracy 0.890 vs. 0.813; kappa 0.723 vs. 0.535) but showed lower performance in the detection of late AMD (accuracy 0.967 vs. 0.973; kappa 0.663 vs. 0.754).
   Conclusions: By simulating the human grading process, DeepSeeNet demonstrated high accuracy with increased transparency in the automated assignment of individual patients to AMD risk categories based on the AREDS Simplified Severity Scale. These results highlight the potential of deep learning to assist and enhance clinical decision-making in patients with AMD, such as early AMD detection and risk prediction for developing late AMD. DeepSeeNet is publicly available on https://github. com/ncbi-nlp/DeepSeeNet. (C) 2018 by the American Academy of Ophthalmology
C1 [Peng, Yifan; Dharssi, Shazia; Chen, Qingyu; Lu, Zhiyong] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, 9000 Rockville Pike, Bethesda, MD 20894 USA.
   [Dharssi, Shazia; Keenan, Tiarnan D.; Agron, Elvira; Wong, Wai T.; Chew, Emily Y.] NEI, NIH, 9000 Rockville Pike, Bethesda, MD 20894 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Library of
   Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Lu, ZY (通讯作者)，NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, 9000 Rockville Pike, Bethesda, MD 20894 USA.; Chew, EY (通讯作者)，NEI, NIH, 9000 Rockville Pike, Bethesda, MD 20894 USA.
EM echew@nei.nih.gov; zhiyong.lu@nih.gov
RI Chen, Qingyu/Q-8343-2019; Peng, Yifan/M-1605-2016; Wong, Wai/B-6118-2017
OI Chen, Qingyu/0000-0002-6036-1516; Chew, Emily/0000-0003-0999-9802; Peng,
   Yifan/0000-0001-9309-8331; Wong, Wai/0000-0003-0681-4016
FU National Center for Biotechnology Information/National Library of
   Medicine/National Institutes of Health; National Eye Institute/National
   Institutes of Health, Department of Health and Human Services, Bethesda
   Maryland [HHS-N-260-2005-00007-C, NO1-EY-5-0007]; National Institutes of
   Health: Office of Dietary Supplements, National Center for Complementary
   and Alternative Medicine; National Institute on Aging; National Heart,
   Lung, and Blood Institute; National Institute of Neurological Disorders
   and Stroke; NATIONAL LIBRARY OF MEDICINE [ZIALM091813] Funding Source:
   NIH RePORTER
FX Supported by the intramural program funds and contracts from the
   National Center for Biotechnology Information/National Library of
   Medicine/National Institutes of Health, the National Eye
   Institute/National Institutes of Health, Department of Health and Human
   Services, Bethesda Maryland (Contract HHS-N-260-2005-00007-C; ADB
   contract NO1-EY-5-0007). Funds were generously contributed to these
   contracts by the following National Institutes of Health: Office of
   Dietary Supplements, National Center for Complementary and Alternative
   Medicine; National Institute on Aging; National Heart, Lung, and Blood
   Institute; and National Institute of Neurological Disorders and Stroke.
   The sponsor and funding organization participated in the design and
   conduct of the study; data collection, management, analysis and
   interpretation; and the preparation, review and approval of the
   manuscript.
CR Abadi M., 2016, TENSORFLOW LARGE SCA
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Banerjee I, 2017, ARXIV171106968
   Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Cerentini A, 2017, STUD HEALTH TECHNOL, V245, P318, DOI 10.3233/978-1-61499-830-3-318
   Ching T, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0387
   Choi JY, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0187338, 10.1371/journal.pone.0187336]
   Chollet F., 2015, KERAS
   COHEN J, 1968, PSYCHOL BULL, V70, P426, DOI 10.1037/h0026714
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Goodfellow I, 2016, ADAPT COMPUT MACH LE, P1
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kingma J., 2014, ARXIV
   Krause J, 2018, OPHTHALMOLOGY, V125, P1264, DOI 10.1016/j.ophtha.2018.01.034
   Lam C, 2018, INVEST OPHTH VIS SCI, V59, P590, DOI 10.1167/iovs.17-22721
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   LECUN Y, 1989, CONNECTIONISM IN PERSPECTIVE, P143
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lehman CD, 2015, JAMA INTERN MED, V175, P1828, DOI 10.1001/jamainternmed.2015.5231
   Marmor MF, 2011, ARCH OPHTHALMOL-CHIC, V129, P943, DOI 10.1001/archophthalmol.2011.160
   Matsuba S, 2019, INT OPHTHALMOL, V39, P1269, DOI 10.1007/s10792-018-0940-0
   Muhammad H, 2017, J GLAUCOMA, V26, P1086, DOI 10.1097/IJG.0000000000000765
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Raju M, 2017, STUD HEALTH TECHNOL, V245, P559, DOI 10.3233/978-1-61499-830-3-559
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Simonyan K., 2013, ARXIV PREPRINT ARXIV
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   Takahashi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179790
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   van der Maaten L, 2014, J MACH LEARN RES, V15, P3221
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Wang X, 2017, CVPR, P2097, DOI DOI 10.1109/CVPR.2017.369
   Wang XL, 2018, PROC CVPR IEEE, P7794, DOI 10.1109/CVPR.2018.00813
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 55
TC 117
Z9 120
U1 5
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2019
VL 126
IS 4
BP 565
EP 575
DI 10.1016/j.ophtha.2018.11.015
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HP9PK
UT WOS:000462025300024
PM 30471319
OA Green Accepted, Green Submitted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Liu, XQ
   Zhao, PQ
   Tang, SB
   Lu, F
   Hu, JB
   Lei, CT
   Yang, XA
   Lin, Y
   Ma, S
   Yang, JY
   Zhang, DD
   Shi, Y
   Li, T
   Chen, YY
   Fan, YC
   Yang, ZL
AF Liu, Xiaoqi
   Zhao, Peiquan
   Tang, Shibo
   Lu, Fang
   Hu, Jianbin
   Lei, Chuntao
   Yang, Xian
   Lin, Ying
   Ma, Shi
   Yang, Jiyun
   Zhang, Dingding
   Shi, Yi
   Li, Tao
   Chen, Yiye
   Fan, Yinchuan
   Yang, Zhenglin
TI ASSOCIATION STUDY OF COMPLEMENT FACTOR H, C2, CFB, AND C3 AND
   AGE-RELATED MACULAR DEGENERATION IN A HAN CHINESE POPULATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; association study; complement factor
   H, C2, CFB, C3
ID HTRA1 PROMOTER POLYMORPHISM; BODY-MASS INDEX; ENVIRONMENTAL
   ASSOCIATIONS; JAPANESE POPULATION; GENE POLYMORPHISMS; VARIANT
   INCREASES; NO ASSOCIATION; SUSCEPTIBILITY; SMOKING; Y402H
AB Purpose: Genes in the complement pathway, including complement factor H (CFH), C2/BF, and C3, have been reported to be associated with age-related macular degeneration (AMD). Genetic variants, single-nucleotide polymorphisms (SNPs), in these genes were geno-typed for a case-control association study in a mainland Han Chinese population.
   Methods: One hundred and fifty-eight patients with wet AMD, 80 patients with soft drusen, and 220 matched control subjects were recruited among Han Chinese in mainland China. Seven SNPs in CFH and two SNPs in C2, CFB', and C3 were genotyped using the ABI SNaPshot method. A deletion of 84,682 base pairs covering the CFHR1 and CFHR3 genes was detected by direct polymerase chain reaction and gel electrophoresis.
   Results: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet AMD in the cohort of this study. A haplotype containing these four SNPs (CATA) significantly increased protection of wet AMD with a P value of 0.0005 and an odds ratio of 0.29 (95% confidence interval: 0.15-0.60). Unlike in other populations, rs2274700 and rs1410996 did not show a significant association with AMD in the Chinese population of this study. None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and C3 showed a significant association with either wet AMD or drusen in the cohort of this study. The CFHR1 and CFHR3 deletion was not polymorphic in the Chinese population and was not associated with wet AMD or drusen.
   Conclusion: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population. This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD. RETINA 30:1177-1184, 2010
C1 [Liu, Xiaoqi; Lu, Fang; Lin, Ying; Ma, Shi; Yang, Jiyun; Zhang, Dingding; Shi, Yi; Yang, Zhenglin] Sichuan Acad Med Sci, Ctr Human Mol Biol & Genet, Chengdu, Sichuan, Peoples R China.
   [Liu, Xiaoqi; Lu, Fang; Hu, Jianbin; Lei, Chuntao; Lin, Ying; Ma, Shi; Yang, Jiyun; Zhang, Dingding; Shi, Yi; Fan, Yinchuan; Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
   [Liu, Xiaoqi; Lu, Fang; Lin, Ying; Ma, Shi; Yang, Jiyun; Shi, Yi; Yang, Zhenglin] Sichuan Acad Med Sci, Inst Lab Med, Chengdu, Sichuan, Peoples R China.
   [Zhao, Peiquan; Chen, Yiye] Shanghai Jiao Tong Univ, Dept Ophthalmol, Xinhua Hosp, Shanghai 200030, Peoples R China.
   [Hu, Jianbin; Lei, Chuntao; Fan, Yinchuan] Sichuan Acad Med Sci, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
   [Yang, Xian] Qingdao Univ, Dept Ophthalmol, Sch Med, Qingdao 266071, Peoples R China.
C3 Sichuan Provincial People's Hospital; Sichuan Provincial People's
   Hospital; Sichuan Provincial People's Hospital; Shanghai Jiao Tong
   University; Sichuan Provincial People's Hospital; Qingdao University
RP Yang, ZL (通讯作者)，Sichuan Acad Med Sci, Ctr Human Mol Biol & Genet, 32 1st Round Rd 2 W, Chengdu, Sichuan, Peoples R China.
EM zliny@yahoo.com
RI Chen, Yi-Chen/GVU-0551-2022; TANG, Shi/GXH-5719-2022; Yang,
   Jiyun/AAS-3937-2020
FU Department of Science and Technology of Sichuan Province [04JY029-045,
   05ZQ026-018, 08ZC0479]; Natural Science Foundation of China [30671182]
FX Supported by the Department of Science and Technology of Sichuan
   Province (04JY029-045, 05ZQ026-018, and 08ZC0479) and the Natural
   Science Foundation of China (30671182) (to Z.Y.).
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chang YC, 2007, DIABETES, V56, P2631, DOI 10.2337/db07-0421
   Chen LJ, 2006, MOL VIS, V12, P1536
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hughes JF, 2006, NAT GENET, V38, P853, DOI 10.1038/ng0806-853b
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Okamoto H, 2006, MOL VIS, V12, P156
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 42
TC 61
Z9 66
U1 1
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2010
VL 30
IS 8
BP 1177
EP 1184
DI 10.1097/IAE.0b013e3181cea676
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 647JF
UT WOS:000281614100005
PM 20523265
DA 2022-11-30
ER

PT J
AU Mcharg, S
   Booth, L
   Perveen, R
   Garcia, IR
   Brace, N
   Bayatti, N
   Sergouniotis, PI
   Phillips, AM
   Day, AJ
   Black, GCM
   Clark, SJ
   Dowsey, AW
   Unwin, RD
   Bishop, PN
AF Mcharg, Selina
   Booth, Laura
   Perveen, Rahat
   Garcia, Isabel Riba
   Brace, Nicole
   Bayatti, Nadhim
   Sergouniotis, Panagiotis, I
   Phillips, Alexander M.
   Day, Anthony J.
   Black, Graeme C. M.
   Clark, Simon J.
   Dowsey, Andrew W.
   Unwin, Richard D.
   Bishop, Paul N.
TI Mast cell infiltration of the choroid and protease release are early
   events in age-related macular degeneration associated with genetic risk
   at both chromosomes 1q32 and 10q26
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; proteomics; mast cells
ID FACTOR-H; BRUCHS MEMBRANE; HUMAN EYES; CHORIOCAPILLARIS; INFLAMMATION;
   TRYPTASE; COMPLEX
AB Age-related macular degeneration (AMD) is a leading cause of visual loss. It has a strong genetic basis, and common haplotypes on chromosome (Chr) 1 (CFH Y402H variant) and on Chr10 (near HTRA1/ARMS2) contribute the most risk. Little is known about the early molecular and cellular processes in AMD, and we hypothesized that analyzing submacular tissue from older donors with genetic risk but without clinical features of AMD would provide biological insights. Therefore, we used mass spectrometry-based quantitative proteomics to compare the proteins in human submacular stromal tissue punches from donors who were homozygous for high-risk alleles at either Chr1 or Chr10 with those from donors who had protective haplotypes at these loci, all without clinical features of AMD. Additional comparisons were made with tissue from donors who were homozygous for high-risk Chr1 alleles and had early AMD. The Chr1 and Chr10 risk groups shared common changes compared with the low-risk group, particularly increased levels of mast cell-specific proteases, including tryptase, chymase, and carboxypeptidase A3. Histological analyses of submacular tissue from donors with genetic risk of AMD but without clinical features of AMD and from donors with Chr1 risk and AMD demonstrated increased mast cells, particularly the tryptase-positive/chymase-negative cells variety, along with increased levels of denatured collagen compared with tissue from low-genetic risk donors. We conclude that increased mast cell infiltration of the inner choroid, degranulation, and subsequent extracellular matrix remodeling are early events in AMD pathogenesis and represent a unifying mechanistic link between Chr1- and Chr10-mediated AMD.
C1 [Mcharg, Selina; Booth, Laura; Brace, Nicole; Bayatti, Nadhim; Sergouniotis, Panagiotis, I; Black, Graeme C. M.; Bishop, Paul N.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Evolut Infect & Genom,Sch Biol Sci, Manchester M13 9PT, Lancs, England.
   [Perveen, Rahat; Sergouniotis, Panagiotis, I; Black, Graeme C. M.] Manchester Univ NHS Natl Hlth Serv Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Ctr Genom Med, St Marys Hosp, Manchester M13 9WL, Lancs, England.
   [Garcia, Isabel Riba; Unwin, Richard D.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Cardiovasc Sci,Sch Med Sci, Manchester M13 9NY, Lancs, England.
   [Sergouniotis, Panagiotis, I; Bishop, Paul N.] Manchester Univ NHS Natl Hlth Serv Fdn Trust, Manchester Royal Eye Hosp, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England.
   [Phillips, Alexander M.] Univ Liverpool, Dept Elect Engn & Elect, Liverpool L69 3GJ, Merseyside, England.
   [Day, Anthony J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Cell Matrix Biol & Regenerat Med,Sch Biol Sci, Manchester M13 9PT, Lancs, England.
   [Day, Anthony J.; Clark, Simon J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester M13 9PL, Lancs, England.
   [Day, Anthony J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Wellcome Ctr Cell Matrix Res,Sch Biol Sci, Manchester M13 9PT, Lancs, England.
   [Clark, Simon J.] Eberhard Karls Univ Tubingen, Univ Eye Clin, Dept Ophthalmol, D-72076 Tubingen, Germany.
   [Clark, Simon J.] Eberhard Karls Univ Tubingen, Inst Ophthalm Res, D-72076 Tubingen, Germany.
   [Dowsey, Andrew W.] Univ Bristol, Fac Hlth Sci, Dept Populat Hlth Sci, Bristol BS8 2BN, Avon, England.
   [Dowsey, Andrew W.] Univ Bristol, Fac Hlth Sci, Bristol Vet Sch, Bristol BS8 2BN, Avon, England.
   [Unwin, Richard D.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Stoller Biomarker Discovery Ctr, Manchester M13 9NQ, Lancs, England.
   [Unwin, Richard D.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Canc Sci,Sch Med Sci, Manchester M13 9NQ, Lancs, England.
C3 University of Manchester; University of Manchester; University of
   Manchester; Manchester Royal Eye Hospital; University of Manchester;
   University of Liverpool; University of Manchester; University of
   Manchester; University of Manchester; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Eberhard Karls University
   of Tubingen; Eberhard Karls University Hospital; University of Bristol;
   University of Bristol; University of Manchester; University of
   Manchester
RP Bishop, PN (通讯作者)，Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Evolut Infect & Genom,Sch Biol Sci, Manchester M13 9PT, Lancs, England.; Bishop, PN (通讯作者)，Manchester Univ NHS Natl Hlth Serv Fdn Trust, Manchester Royal Eye Hosp, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England.
EM paui.bishop@manchester.ac.uk
RI Day, Anthony/O-1658-2015
OI Day, Anthony/0000-0002-1415-3134; Phillips,
   Alexander/0000-0002-1637-4803; Brace, Nicole/0000-0002-6047-5193;
   Dowsey, Andrew/0000-0002-7404-9128
FU Fight for Sight UK [1517/18]; Macular Society (United Kingdom); Medical
   Research Council UK [MR/N028457/1]; Biotechnology and Biological
   Sciences Research Council (United Kingdom); Wellcome Trust (United
   Kingdom); University of Manchester Strategic Fund
FX This research was supported by Fight for Sight UK Grant 1517/18 and the
   Macular Society (United Kingdom). Development and application of the
   Bayesian models were funded by Medical Research Council UK Grant
   MR/N028457/1 (to A.W.D.). The Bioimaging Facility microscopes used in
   this study were purchased with grants from the Biotechnology and
   Biological Sciences Research Council (United Kingdom), the Wellcome
   Trust (United Kingdom), and the University of Manchester Strategic Fund.
   We thank Peter March and Roger Meadows for their help with the
   microscopy and Peter Walker at the University of Manchester Histology
   Core Facility for his support.
CR Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bousquet E, 2015, AM J PATHOL, V185, P2083, DOI 10.1016/j.ajpath.2015.04.002
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chen L, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.1.33
   Cipriani V, 2021, AM J HUM GENET, V108, P1385, DOI 10.1016/j.ajhg.2021.05.015
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Douaiher J, 2014, ADV IMMUNOL, V122, P211, DOI 10.1016/B978-0-12-800267-4.00006-7
   Komi DEA, 2020, ALLERGY, V75, P2818, DOI 10.1111/all.14413
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hadfield JD, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i02
   Hwang J, 2017, ACS NANO, V11, P9825, DOI 10.1021/acsnano.7b03150
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lubbers R, 2017, CLIN EXP IMMUNOL, V188, P183, DOI 10.1111/cei.12952
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   May CA, 1999, HISTOCHEM CELL BIOL, V112, P381, DOI 10.1007/s004180050420
   McHarg S, 2015, JOVE-J VIS EXP, DOI 10.3791/53382
   McLeod DS, 2017, INVEST OPHTH VIS SCI, V58, P5879, DOI 10.1167/iovs.17-22989
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Morris JS, 2008, BIOMETRICS, V64, P479, DOI 10.1111/j.1541-0420.2007.00895.x
   Mulfaul K, 2022, J PATHOL, V257, P29, DOI 10.1002/path.5867
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Ogura S, 2020, FASEB J, V34, P10117, DOI 10.1096/fj.202000807R
   Phillips A., 2022, STAT ANAL PROTEOMIC
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roszer T, 2013, TRENDS ENDOCRIN MET, V24, P460, DOI 10.1016/j.tem.2013.04.004
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Staden R, 2000, Methods Mol Biol, V132, P115
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Unwin RD, 2010, NAT PROTOC, V5, P1574, DOI 10.1038/nprot.2010.123
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Xu JS, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-018-0254-9
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 42
TC 2
Z9 2
U1 2
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 17
PY 2022
VL 119
IS 20
AR e2118510119
DI 10.1073/pnas.2118510119
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4N4QU
UT WOS:000854004800004
PM 35561216
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Zehetner, C
   Kralinger, MT
   Modi, YS
   Waltl, I
   Ulmer, H
   Kirchmair, R
   Bechrakis, NE
   Kieselbach, GF
AF Zehetner, Claus
   Kralinger, Martina T.
   Modi, Yasha S.
   Waltl, Inga
   Ulmer, Hanno
   Kirchmair, Rudolf
   Bechrakis, Nikolaos E.
   Kieselbach, Gerhard F.
TI Systemic levels of vascular endothelial growth factor before and after
   intravitreal injection of aflibercept or ranibizumab in patients with
   age-related macular degeneration: a randomised, prospective trial
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE Aflibercept; age-related macular degeneration; ranibizumab; vascular
   endothelial growth factor (VEGF)
ID NEONATAL FC-RECEPTOR; PLASMA-LEVELS; VEGF-TRAP; BEVACIZUMAB;
   PHARMACOKINETICS; ATHEROSCLEROSIS; POPULATION; ROTTERDAM; BLOCKADE;
   BINDING
AB PurposeTo evaluate the changes of vascular endothelial growth factor (VEGF) plasma levels after intravitreal injections of aflibercept or ranibizumab in patients with exudative age-related macular degeneration (AMD).
   MethodsThirty-eight patients with exudative AMD were included in this randomised, prospective study. Nineteen patients were randomised to treatment with intravitreal aflibercept (2.0mg) and 19 to intravitreal ranibizumab (0.5mg). The concentration of VEGF was measured by ELISA just before the injection, after 7days and 1month. Twenty-two age- and sex-matched healthy patients without chorioretinal diseases served as control.
   ResultsThe median baseline plasma VEGF concentration was 61.0pg/ml in the control group, 43.0pg/ml in the aflibercept group and 59.0pg/ml in the ranibizumab group (p=0.127). Seven days after intravitreal injection of aflibercept plasma levels were significantly reduced to values below the minimum detectable dose (MDD) in 17 of 19 patients (89.5%) resulting in a median VEGF concentration of <9pg/ml (p<0.001). The reduction persisted throughout 1month with values below the MDD in 5 of 19 patients (26.3%) and a median measurement of 17.0pg/ml (p<0.001). In patients treated with ranibizumab no significant effects could be observed with a baseline VEGF of 59.0pg/ml, 54.0pg/ml at 7days (p=0.776) and 58.5pg/ml at 4weeks of follow-up (p=0.670).
   ConclusionAfter intravitreal aflibercept injection, the systemic VEGF levels were significantly reduced throughout the observational period of 4weeks. No significant systemic effects of intravitreal ranibizumab on plasma VEGF were observed.
C1 [Zehetner, Claus; Kralinger, Martina T.; Waltl, Inga; Bechrakis, Nikolaos E.] Med Univ Innsbruck, Dept Ophthalmol, A-6020 Innsbruck, Austria.
   [Modi, Yasha S.] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA.
   [Ulmer, Hanno] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Econ, A-6020 Innsbruck, Austria.
   [Kirchmair, Rudolf] Med Univ Innsbruck, Dept Internal Med, A-6020 Innsbruck, Austria.
C3 Medical University of Innsbruck; Bascom Palmer Eye Institute; University
   of Miami; Medical University of Innsbruck; Medical University of
   Innsbruck
RP Zehetner, C (通讯作者)，Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
EM claus.zehetner@i-med.ac.at
RI Ulmer, Hanno/S-6615-2019
OI Ulmer, Hanno/0000-0001-5911-1002; Zehetner, Claus/0000-0003-1405-7457
CR Avery RL, 2014, BR J OPHTHALMOL
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kim H, 2009, MOL VIS, V15
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Krohne TU, 2014, OPHTHALMOLOGE, V111, P113, DOI 10.1007/s00347-013-2932-9
   Kubicka-Trzaska A, 2014, ACTA OPHTHALMOL
   Lu JF, 2008, CANCER CHEMOTH PHARM, V62, P779, DOI 10.1007/s00280-007-0664-8
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Powner MB, 2014, INVEST OPHTH VIS SCI, V55, P1607, DOI 10.1167/iovs.13-12574
   Proetzel G, 2014, METHODS, V65, P148, DOI 10.1016/j.ymeth.2013.07.005
   Renard C, 1997, BRIT J CLIN PHARMACO, V44, P135, DOI 10.1046/j.1365-2125.1997.00654.x
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang X, 2014, AM J OPHTHALMOL, V158
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Zachary I, 2000, ARTERIOSCL THROM VAS, V20, P1512, DOI 10.1161/01.ATV.20.6.1512
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang JS, 2010, CIRC RES, V107, P408, DOI 10.1161/CIRCRESAHA.109.210963
NR 29
TC 64
Z9 64
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2015
VL 93
IS 2
BP E154
EP E159
DI 10.1111/aos.12604
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CB8SC
UT WOS:000349900200011
PM 25488124
DA 2022-11-30
ER

PT J
AU Javadzadeh, A
   Ghorbanihaghjo, A
   Bahreini, E
   Rashtchizadeh, N
   Argani, H
   Alizadeh, S
AF Javadzadeh, Alireza
   Ghorbanihaghjo, Amir
   Bahreini, Elham
   Rashtchizadeh, Nadereh
   Argani, Hassan
   Alizadeh, Samira
TI SERUM PARAOXONASE PHENOTYPE DISTRIBUTION IN EXUDATIVE AGE-RELATED
   MACULAR DEGENERATION AND ITS RELATIONSHIP TO HOMOCYSTEINE AND OXIDIZED
   LOW-DENSITY LIPOPROTEIN
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE exudative age-related macular degeneration; paraoxonase; homocysteine;
   oxidized LDL
ID LIPID-PEROXIDATION; RISK-FACTORS; PLASMA HOMOCYSTEINE;
   ENDOTHELIAL-CELLS; VASCULAR-DISEASE; OXIDATIVE STRESS; MOLECULAR-BASIS;
   CORONARY; IDENTIFICATION; ASSOCIATION
AB Purpose: Disequilibrium between oxidative stress and antioxidant levels has been proposed as an important case of exudative age-related macular degeneration (AMD). The aim of the present study was to investigate homocysteine (Hcy) level and antioxidant paraoxonase 1 (PON1) activity within its phenotypes together with oxidized low-density lipoprotein (OX-LDL) levels in the patients with exudative AMD.
   Methods: Serum PON1 activity and plasma Hcy and OX-LDL levels were analyzed in 45 exudative AMD patients and compared with 45 healthy controls. Paraoxonase 1 activity was measured in serum using paraoxon and phenylacetate as substrates. The PON1 phenotype was determined using double-substrate method. Homocysteine and OX-LDL levels were determined by enzyme-linked immunosorbent assay method.
   Results: The distribution of PON1 phenotypes was significantly different between the patients with exudative AMD and control subjects (chi-square = 6.17, P = 0.01). AA phenotype with low activity was significantly more frequent in exudative AMD patients compared with healthy subjects (62.2% vs. 35.6%, respectively). Other phenotype frequencies in the patients compared with controls were as AB phenotype (intermediate activity) 28.9% versus 46.7% and BB phenotype (high activity) 8.9% versus 17.8%, respectively. Except in BB phenotype (P = 0.2), patients with AA and AB phenotypes had higher plasma Hcy levels in comparison to those of controls (P = 0.02 and P = 0.03, respectively). The mean OX-LDL levels, in all 3 phenotypes (P < 0.05), and OX-LDL/high-density lipoprotein ratio, in AA and AB phenotypes (P = 0.001, P = 0.1, respectively) but not in BB (P = 0.1), were significantly higher in the patients than controls. No significant differences in comparison of Hcy and OX-LDL levels between 3 PON1 phenotypes in both control (P = 0.6 for Hcy, P = 0.7 for OX-LDL) and patients (P = 0.8 for Hcy, P = 0.6 for OX-LDL) were found
   Conclusion: Increased plasma OX-LDL levels and ratios of OX-LDL/high-density lipoprotein, as biomarkers of lipoprotein oxidative stress, higher levels of Hcy, as oxidant agent, and more common low or intermediate PON1 activity in patients with exudative AMD, compared with controls, indicate that PON1 activity is insufficient to explain the increased oxidative stress observed in exudative AMD. RETINA 32: 658-666, 2012
C1 [Javadzadeh, Alireza; Ghorbanihaghjo, Amir; Bahreini, Elham; Alizadeh, Samira] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz 51664, Iran.
   [Rashtchizadeh, Nadereh; Argani, Hassan] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science
RP Ghorbanihaghjo, A (通讯作者)，Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz 51664, Iran.
EM ghorbaniamir@hotmail.com
RI Argani, Hassan/AAD-8372-2019; Rashtchizadeh, Nadereh/L-7691-2017;
   Bahreini, Elham/AAT-7055-2021; Javadzadeh, Alireza/L-6424-2017;
   Javadzadeh, Aliehsadat/J-9830-2017
OI Rashtchizadeh, Nadereh/0000-0003-2878-3847; Javadzadeh,
   Alireza/0000-0002-5151-6125; Alizadeh, Samira/0000-0001-6059-2181;
   Bahreini, Elham/0000-0001-6823-8638; ghorbanihaghjo,
   amir/0000-0001-6742-0526
CR ABBOTT CA, 1995, ARTERIOSCL THROM VAS, V15, P1812, DOI 10.1161/01.ATV.15.11.1812
   ADKINS S, 1993, AM J HUM GENET, V52, P598
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bleich S, 2004, AM J OPHTHALMOL, V138, P162, DOI 10.1016/j.ajo.2004.02.027
   BOK D, 1993, J CELL SCI, P189
   Bolann BJ, 2000, CLIN CHEM, V46, P1744
   Bostom AG, 1999, ANN INTERN MED, V131, P352, DOI 10.7326/0003-4819-131-5-199909070-00006
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035
   Ciaccio Marcello, 2008, Ther Clin Risk Manag, V4, P219
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   den Heijer T, 2003, BRAIN, V126, P170, DOI 10.1093/brain/awg006
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   ECKERSON HW, 1983, AM J HUM GENET, V35, P214
   Ferdinandusse S, 2001, J LIPID RES, V42, P1987
   Ferrari CKB, 2007, MATURITAS, V58, P327, DOI 10.1016/j.maturitas.2007.09.011
   Ferretti G, 2004, J CELL BIOCHEM, V92, P351, DOI 10.1002/jcb.20069
   FUJIMOTO WY, 1988, JPN CIRC J, V52, P604, DOI 10.1253/jcj.52.604
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73
   Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560
   Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957
   Jakubowski H, 2001, FEBS LETT, V491, P35, DOI 10.1016/S0014-5793(01)02143-3
   Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277
   Johnston N, 2006, AM J CARDIOL, V97, P640, DOI 10.1016/j.amjcard.2005.09.123
   Kazemi MBS, 2006, ANGIOLOGY, V57, P9, DOI 10.1177/000331970605700102
   Lynch SM, 2000, BBA-MOL CELL BIOL L, V1485, P11, DOI 10.1016/S1388-1981(00)00030-5
   MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nevin DN, 1996, ARTERIOSCL THROM VAS, V16, P1243, DOI 10.1161/01.ATV.16.10.1243
   Paolisso G, 1998, J AM GERIATR SOC, V46, P833, DOI 10.1111/j.1532-5415.1998.tb02716.x
   REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richter RJ, 1999, PHARMACOGENETICS, V9, P745, DOI 10.1097/01213011-199912000-00009
   Robertson KS, 2003, BBA-MOL BASIS DIS, V1639, P203, DOI 10.1016/j.bbadis.2003.09.008
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sprecher H, 1999, PROSTAG LEUKOTR ESS, V60, P317, DOI 10.1016/S0952-3278(99)80006-4
   Stein JH, 1998, ARCH INTERN MED, V158, P1301, DOI 10.1001/archinte.158.12.1301
   TRIBBLE DL, 1995, CURR OPIN LIPIDOL, V6, P196, DOI 10.1097/00041433-199508000-00003
   Vendrov AE, 2007, ARTERIOSCL THROM VAS, V27, P2714, DOI 10.1161/ATVBAHA.107.152629
   Vignini A, 2004, J CLIN ENDOCR METAB, V89, P4558, DOI 10.1210/jc.2004-0419
   Wassell J, 1997, BRIT J OPHTHALMOL, V81, P911, DOI 10.1136/bjo.81.10.911
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Winkler BS, 1999, MOL VIS, V5
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 61
TC 13
Z9 13
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2012
VL 32
IS 4
BP 658
EP 666
DI 10.1097/IAE.0b013e31822529b1
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 918ET
UT WOS:000302232800003
PM 22030834
DA 2022-11-30
ER

PT J
AU Costa, RA
   Jorge, R
   Calucci, D
   Melo, LAS
   Cardillo, JA
   Scott, IU
AF Costa, Rogerio A.
   Jorge, Rodrigo
   Calucci, Daniela
   Melo, Luiz A. S., Jr.
   Cardillo, Jose A.
   Scott, Ingrid U.
TI Intravitreal bevacizumab (Avastin) in combination with verteporfin
   photodynamic therapy for choroidal neovascularization associated with
   age-related macular degeneration (IBeVe Study)
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE angiogenesis; laser; neovascularization; choroid; pegaptanib;
   ranibizumab; vascular endotelhial growth factor (VEGF)
ID COHERENCE TOMOGRAPHY FINDINGS; TRIAMCINOLONE ACETONIDE; INJECTION;
   RANIBIZUMAB; OCCLUSION; SECONDARY; EDEMA; TRIAL; PDT
AB Background A novel alternative for combined treatment using verteporfin photodynamic therapy (PDT) has emerged as preliminary safety and efficacy data of the intravitreal use of the anti-angiogenic bevacizumab became available. In the current study we investigate the feasibility of intravitreal bevacizumab combined with verteporfin PDT for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Methods A single-centre, prospective, open-label study of 11 patients with documented CNV progression after PDT treatment who underwent combined PDT and intravitreal injection of 1.5 mg of bevacizumab was undertaken. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 2, 12 and 24. Clinical evidence of complications and changes in logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and in fluorescein leakage from CNV were evaluated.
   Results The mean (+/- SD) age of the 11 patients was 74 (+/- 5) years. Seven eyes had been treated with one previous PDT session and four eyes had two previous PDT sessions. The mean baseline logMAR ETDRS BCVA was 1.031 (Snellen equivalent, 20/200(-2)). At follow-up weeks 1, 2, 12 and 24, the mean logMAR ETDRS BCVA (Snellen equivalent) was 0.944 (20/160(-2)), 0.924 (20/160(-1)), 0.882 (20/160(+1)), and 0.933 (20/160(-2)), respectively. The change in BCVA from baseline was significant at each study follow-up interval (P <= 0.001); at 12 and 24 weeks, the mean change in BCVA from baseline was an improvement of 1.49 and of 0.98 ETDRS line, respectively. Fluorescein leakage from CNV was absent in all eyes at week 12. One additional treatment session was required in seven (63.6%) eyes at week 24 due to recurrent fluorescein leakage from CNV ("minimum" [< 50% of the leaking area noted at baseline], n = 4; and "moderate" [> 50% of the leaking area noted at baseline], n = 3). No progression of the neovascular lesion was observed at week 24. No safety issues were identified throughout the period of the study.
   Conclusions The overall changes in vision and fluorescein leakage from CNV throughout the study suggest that a possible synergistic effect may arise from the combination of intravitreal bevacizumab with verteporfin PDT for the treatment of neovascular AMD.
C1 Hosp Olhos Araraquara, UDAT Macular Imaging & Treatment Div, BR-1801310 Araraquara, SP, Brazil.
   Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Ophthalmol, Retina & Vitreous Sect, BR-14049 Ribeirao Preto, SP, Brazil.
   Penn State Univ, Coll Med, Dept Ophthalmol & Hlth Evaluat Sci, Hershey, PA USA.
C3 Universidade de Sao Paulo; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Penn State Health
RP Costa, RA (通讯作者)，Hosp Olhos Araraquara, UDAT Macular Imaging & Treatment Div, Rua Padre Duarte 989 Apto 172, BR-1801310 Araraquara, SP, Brazil.
EM roger.retina@globo.com
RI Jorge, Rodrigo/H-3930-2012; Jorge, Rodrigo/AAK-7615-2021; Costa, Rogerio
   A/E-6930-2013
OI Jorge, Rodrigo/0000-0002-2652-0720; Jorge, Rodrigo/0000-0002-2652-0720;
   Costa, Rogerio A/0000-0002-0800-2233; Cardillo, Jose
   Augusto/0000-0002-5791-3201; Scott, Ingrid/0000-0002-3908-7153
CR Aggermann T, 2006, OPHTHALMOLOGICA, V220, P131, DOI 10.1159/000090579
   Agrawal S, 2003, AM J OPHTHALMOL, V136, P539, DOI 10.1016/S0002-9394(03)00320-9
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Dal Canto AJ, 2005, OPHTHALMOLOGY, V112, P1092, DOI 10.1016/j.ophtha.2005.01.033
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GROSSWEINER LI, 1994, SCI PHOTOTHERAPY, P27
   Gupta OP, 2003, OPHTHALMOLOGY, V110, P443, DOI 10.1016/S0161-6420(02)01743-8
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Moshfeghi DM, 2002, AM J OPHTHALMOL, V134, P132, DOI 10.1016/S0002-9394(02)01426-5
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Paula JS, 2006, ACTA OPHTHALMOL SCAN, V84, P556, DOI 10.1111/j.1600-0420.2006.00721.x
   Quiram PA, 2006, AM J OPHTHALMOL, V141, P580, DOI 10.1016/j.ajo.2005.10.004
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saidel MA, 2005, AM J OPHTHALMOL, V140, P1141, DOI 10.1016/j.ajo.2005.06.058
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   VIOLA F, 2006, EYE             0224
   Yang CS, 2005, OPHTHALMOLOGICA, V219, P413, DOI 10.1159/000088388
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
NR 49
TC 46
Z9 49
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2007
VL 245
IS 9
BP 1273
EP 1280
DI 10.1007/s00417-007-0557-x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 201MG
UT WOS:000248835200004
PM 17333238
DA 2022-11-30
ER

PT J
AU Wachtlin, J
   Spital, G
   Schmitz-Valckenberg, S
   Liakopoulos, S
   Vogeler, J
   Muller, B
   Ziemssen, F
AF Wachtlin, Joachim
   Spital, Georg
   Schmitz-Valckenberg, Steffen
   Liakopoulos, Sandra
   Voegeler, Jessica
   Mueller, Bettina
   Ziemssen, Focke
CA Ocean Study Grp
TI Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes
   of Ranibizumab Treatment for Neovascular Age-Related Macular
   Degeneration in Germany
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; THERAPY
AB Background. To date, there are limited prospective real-world data on the impact of optical coherence tomography (OCT) diagnostics on treatment outcomes in neovascular age-related macular degeneration (nAMD). Therefore, the prospective, noninterventional OCEAN study () evaluated the use of OCT imaging and its impact on functional outcomes in Germany.Methods. The use of OCT imaging for treatment decisions was documented in nAMD patients receiving intravitreal ranibizumab injections at 347 study centres. Best-corrected visual acuity (BCVA) testing and treatment were performed according to routine clinical practice and documented over 24 months.Results. The majority of the 3,631 nAMD patients (59.6%) received a combination of OCT and fluorescein angiography imaging within the first 6 months. Over the remaining study course, this combination was used infrequently (range: 7.6% to 13.4%) and continually decreased over time; most patients received only OCT examinations (range: 48.9% to 52.5%; median: 3 within 12 months and 4 within 24 months). Subgroups according to the number of OCT examinations (<= 4, rarely OCT examined; 5-8, moderately OCT examined; >= 8, well monitored) were associated with different treatment frequencies and outcomes: Rarely OCT-examined patients had received a median of 4 injections (range: 1-19) at 24 months; well-monitored patients had received a median of 8 injections (range: 1-21) at 24 months. Rarely OCT-examined patients had a mean change of BCVA of -0.3 letters (+/- 26.1) at 24 months (n = 165); well-monitored patients showed a change of +2.0 letters (+/- 20.8) at 24 months (n = 249). Time-to-response was greater for rarely examined than well-monitored patients, while duration-of-response was similar.Conclusion. Low number of visits as well as high number of treatment decisions without the use of OCT may contribute to undertreatment and poorer functional outcomes in patients undergoing ranibizumab treatment for nAMD in Germany. One potential reason for this could be that OCT was not covered by insurance for all patients during the study.
C1 [Wachtlin, Joachim] Sankt Gertrauden Krankenhaus, Dept Ophthalmol, Berlin, Germany.
   [Wachtlin, Joachim] MHB Med Hsch Brandenburg, Neuruppin, Germany.
   [Spital, Georg] St Franziskus Hosp, Eye Ctr, Munster, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Liakopoulos, Sandra] Fac Med, Dept Ophthalmol, Cologne, Germany.
   [Liakopoulos, Sandra] Univ Hosp Cologne, Cologne, Germany.
   [Voegeler, Jessica; Mueller, Bettina] Novartis Pharma GmbH, Nurnberg, Germany.
   [Ziemssen, Focke] Eberhard Karls Univ Tuebingen, Ctr Ophthalmol, Tubingen, Germany.
C3 St. Franziskus-Hospital; University of Bonn; Utah System of Higher
   Education; University of Utah; University of Cologne; University of
   Cologne; Novartis; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital
RP Ziemssen, F (通讯作者)，Eberhard Karls Univ Tuebingen, Ctr Ophthalmol, Tubingen, Germany.
EM focke.ziemssen@med.uni-tuebingen.de
RI Ziemssen, Focke/AAY-1686-2021
OI Ziemssen, Focke/0000-0002-3873-0581
FU Novartis Pharma GmbH, Nuremberg, Germany
FX The authors would like to thank Susanne Faber (Project Management),
   Klaus Laschke (biostatistics), Catherine Mason (medical writing), and
   Daniela Mueller (medical writing), and all at Kantar, Munich, Germany,
   for assistance with the OCEAN study and this manuscript. This assistance
   was funded by the Novartis Pharma GmbH, Nuremberg, Germany. The OCEAN
   study and the preparation of this manuscript were funded by Novartis
   Pharma GmbH, Nuremberg, Germany.
CR Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Berufsverband Augenarzte Deutschla, 2017, OPHTHALMOLOGE, V114, P617, DOI 10.1007/s00347-017-0508-9
   Brinkmann CK, 2019, OPHTHALMOLOGE, V116, P753, DOI 10.1007/s00347-018-0805-y
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Deutsche Ophthalmologische Gesellschaft Retinologische Gesellschaft V, 2020, OPHTHALMOLOGE, DOI [10.1007/s00347-020-01117-2, DOI 10.1007/S00347-020-01117-2]
   Dubey S, 2019, INDIAN J OPHTHALMOL, V67, P1279, DOI 10.4103/ijo.IJO_1959_18
   Finger RP, 2017, KLIN MONATSBL AUGENH, V234, P1515, DOI 10.1055/s-0043-115392
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Guerrier M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062537
   Heimes B, 2016, OPHTHALMOLOGE, V113, P570, DOI 10.1007/s00347-016-0224-x
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mowatt G, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18690
   Ong SS, 2013, OPHTHALMOLOGY, V120, P2462, DOI 10.1016/j.ophtha.2013.05.019
   Patel Y, 2020, OPHTHALMOL RETINA, V4, P141, DOI 10.1016/j.oret.2019.09.006
   Pron G, 2014, Ont Health Technol Assess Ser, V14, P1
   Rosenfeld PJ, 2019, AM J OPHTHALMOL, V204, P26, DOI 10.1016/j.ajo.2019.02.036
   Sachs HG, 2016, KLIN MONATSBL AUGENH, V233, P958, DOI 10.1055/s-0041-107672
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Staurenghi G, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1251-6
   Vardarinos A, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0451-1
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Nguyen V, 2019, OPHTHALMOLOGY, V126, P64, DOI 10.1016/j.ophtha.2018.08.023
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Yang Y, 2017, OPHTHALMOL THER, V6, P175, DOI 10.1007/s40123-017-0091-9
   Ziemssen F, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0401-y
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 37
TC 4
Z9 4
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUL 17
PY 2020
VL 2020
AR 8024258
DI 10.1155/2020/8024258
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MV4LQ
UT WOS:000556331900002
PM 32724669
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schaumberg, DA
   Chasman, D
   Morrison, MA
   Adams, SM
   Guo, Q
   Hunter, DJ
   Hankinson, SE
   DeAngelis, MM
AF Schaumberg, Debra A.
   Chasman, Daniel
   Morrison, Margaux A.
   Adams, Scott M.
   Guo, Qun
   Hunter, David J.
   Hankinson, Susan E.
   DeAngelis, Margaret M.
TI Prospective Study of Common Variants in the Retinoic Acid
   Receptor-Related Orphan Receptor alpha Gene and Risk of Neovascular
   Age-Related Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; BEAVER DAM EYE; CIGARETTE-SMOKING; NUCLEAR RECEPTOR;
   ROR-ALPHA; ATTRIBUTABLE RISK; STAGGERER MOUSE; DIETARY-FAT; FACTOR-H;
   SUSCEPTIBILITY
AB Objectives: The retinoic acid receptor (RAR)-related orphan receptor alpha gene (RORA) is implicated as a candidate for age-related macular degeneration (AMD) through a previous microarray expression study, linkage data, biological plausibility, and 2 clinic-based cross-sectional studies. We aimed to determine if common variants in RORA predict future risk of neovascular AMD.
   Methods: We measured genotypes for 18 variants in intron 1 of the RORA gene among 164 cases who developed neovascular AMD and 485 age-and sex-matched controls in a prospective, nested, case-control study within the Nurses' Health Study and the Health Professionals Follow-up Study. We determined the incidence rate ratios and 95% confidence intervals (CI) for neovascular AMD for each variant and examined interactions with other AMD associated variants and modifiable risk factors.
   Results: We identified one single-nucleotide polymorphism (rs12900948) that was significantly associated with increased incidence of neovascular AMD. Participants with 1 and 2 copies of the G allele were 1.73 (CI, 1.32-2.27) and 2.99 (CI, 1.74-5.14) times more likely to develop neovascular AMD. Individuals homozygous for both the G allele of rs12900948 and ARMS2 A69S had a 40.8-fold increased risk of neovascularAMD(CI, 10.1-164; P=.017). Cigarette smokers who carried 2 copies of the G allele had a 9.89-fold risk of neovascular AMD but the interaction was not significant (P=.08). We identified a significant AMD-associated haplotype block containing the single-nucleotide polymorphisms rs730754, rs8034864, and rs12900948, with P values for ACA=1.16 X 10(-9), ACG=5.85 X 10(-12), and GAA=.0001 when compared with all other haplotypes.
   Conclusions: Common variants and haplotypes within the RORA gene appear to act synergistically with the ARMS2 A69S polymorphism to increase risk of neovascular AMD. These data add further evidence of a high level of complexity linking genetic and modifiable risk factors to AMD development and should help efforts at risk prediction.
C1 [Schaumberg, Debra A.; Chasman, Daniel] Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02215 USA.
   [Guo, Qun; Hunter, David J.; Hankinson, Susan E.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA.
   [Schaumberg, Debra A.; Morrison, Margaux A.; Adams, Scott M.; DeAngelis, Margaret M.] Massachusetts Eye & Ear Infirm, Ocular Mol Genet Inst, Boston, MA 02114 USA.
   [Schaumberg, Debra A.; Morrison, Margaux A.; Adams, Scott M.; DeAngelis, Margaret M.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   [Hunter, David J.] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
   [Schaumberg, Debra A.; Hunter, David J.; Hankinson, Susan E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Brigham & Women's Hospital; Harvard University; Massachusetts Eye & Ear
   Infirmary; Harvard University; Massachusetts Eye & Ear Infirmary;
   Harvard University; Harvard Medical School; Harvard University; Harvard
   T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan
   School of Public Health; Harvard University; Harvard T.H. Chan School of
   Public Health
RP Schaumberg, DA (通讯作者)，Brigham & Womens Hosp, Div Prevent Med, Dept Med, 900 Commonwealth Ave E,3rd Floor, Boston, MA 02215 USA.
EM dschaumberg@rics.bwh.harvard.edu
RI DeAngelis, e/J-7863-2015
FU National Institutes of Health [EY017362, EY013834, EY009611, EY014458,
   CA87969, CA49449, HL35464]; Lincy Fund; NATIONAL CANCER INSTITUTE
   [P01CA087969, R01CA049449, U01CA049449] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [P30EY014800, R01EY014458, R01EY013834,
   R01EY017362, R01EY009611] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health grants
   EY017362, EY013834, EY009611, EY014458, CA87969, CA49449, and HL35464,
   and the Lincy Fund.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   Armengol L, 2008, CYTOGENET GENOME RES, V123, P108, DOI 10.1159/000184698
   Besnard S, 2001, CIRC RES, V89, P1209, DOI 10.1161/hh2401.101755
   Besnard S, 2002, CIRC RES, V90, P820, DOI 10.1161/01.RES.0000014489.24705.71
   Boukhtouche F, 2006, J NEUROCHEM, V96, P1778, DOI 10.1111/j.1471-4159.2006.03708.x
   Boukhtouche F, 2004, ARTERIOSCL THROM VAS, V24, P637, DOI 10.1161/01.ATV.0000119355.56036.de
   BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174
   Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Fujieda H, 2009, J NEUROCHEM, V108, P91, DOI 10.1111/j.1471-4159.2008.05739.x
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Garcia-Lorda P, 2006, INT J OBESITY, V30, P468, DOI 10.1038/sj.ijo.0803182
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593
   Hubbard TJP, 2009, NUCLEIC ACIDS RES, V37, pD690, DOI 10.1093/nar/gkn828
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jetten Anton M., 2004, Current Drug Targets - Inflammation and Allergy, V3, P395, DOI 10.2174/1568010042634497
   Klar J, 2005, EUR J HUM GENET, V13, P928, DOI 10.1038/sj.ejhg.5201433
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Lau P, 2008, J BIOL CHEM, V283, P18411, DOI 10.1074/jbc.M710526200
   Maddox DM, 2008, J PHYSIOL-LONDON, V586, P4409, DOI 10.1113/jphysiol.2008.157289
   Margulies EH, 2008, NAT REV GENET, V9, P303, DOI 10.1038/nrg2185
   Migita H, 2004, FEBS LETT, V557, P269, DOI 10.1016/S0014-5793(03)01502-3
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Nielsen DM, 1999, GENET RES, V74, P271, DOI 10.1017/S0016672399004231
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P133
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Spiegelman D, 2007, CANCER CAUSE CONTROL, V18, P571, DOI 10.1007/s10552-006-0090-y
   Stapleton CM, 2005, AM J PHYSIOL-LUNG C, V289, pL144, DOI 10.1152/ajplung.00348.2004
   Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960
   Voyiaziakis E, 1998, J LIPID RES, V39, P313
   WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268
   Zhu Y, 2006, ONCOGENE, V25, P2901, DOI 10.1038/sj.onc.1209314
NR 49
TC 21
Z9 24
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2010
VL 128
IS 11
BP 1462
EP 1471
DI 10.1001/archophthalmol.2010.261
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 676RD
UT WOS:000283932600012
PM 21060049
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Kunimoto, D
   Yoon, YH
   Wykoff, CC
   Chang, A
   Khurana, RN
   Maturi, RK
   Agostini, H
   Souied, E
   Chow, DR
   Lotery, AJ
   Ohji, M
   Bandello, F
   Belfort, R
   Li, XY
   Jiao, J
   Le, G
   Schmidt, W
   Hashad, Y
AF Kunimoto, Derek
   Yoon, Young Hee
   Wykoff, Charles C.
   Chang, Andrew
   Khurana, Rahul N.
   Maturi, Raj K.
   Agostini, Hansjuergen
   Souied, Eric
   Chow, David R.
   Lotery, Andrew J.
   Ohji, Masahito
   Bandello, Francesco
   Belfort, Rubens, Jr.
   Li, Xiao-Yan
   Jiao, Jenny
   Le, Grace
   Schmidt, Werner
   Hashad, Yehia
CA CEDAR Study Grp
   SEQUOIA Study Grp
TI Efficacy and Safety of Abicipar in Neovascular Age-Related Macular
   Degeneration 52-Week Results of Phase 3 Randomized Controlled Study
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ANKYRIN REPEAT PROTEIN; DISEASE BURDEN;
   VISION LOSS; RANIBIZUMAB; PEGOL; AFLIBERCEPT; MORPHOLOGY; BLINDNESS;
   EXTEND
AB Purpose: To compare the efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) versus ranibizumab every 4 weeks in treatment-naive patients with neovascular age-related macular degeneration (AMD).
   Design: Two randomized, multicenter, double-masked, parallel-group, active-controlled, phase 3 clinical trials (CEDAR, SEQUOIA) with identical protocols were conducted. Data from both trials were pooled for analysis.
   Participants: Patients with active choroidal neovascularization secondary to AMD and best-corrected visual acuity (BCVA) of 24-73 Early Treatment Diabetic Retinopathy Study letters in the study eye were enrolled.
   Methods: Patients (n = 1888) were randomized in a 1:1:1 ratio to study eye treatment with abicipar 2 mg every 8 weeks after 3 initial doses at baseline and weeks 4 and 8 (Q8), abicipar 2 mg every 12 weeks after 3 initial doses at baseline and weeks 4 and 12 (Q12), or ranibizumab 0.5 mg every 4 weeks (Q4).
   Main Outcome Measures: The primary efficacy end point was proportion of patients with stable vision (defined as <15-letter loss in BCVA from baseline) in the study eye at week 52. Secondary end points included change from baseline in BCVA and central retinal thickness (CRT) at week 52. Safety measures included adverse events (AEs).
   Results: The proportion of patients with stable vision at week 52 was 93.2%, 91.3%, and 95.8% in the abicipar Q8, abicipar Q12, and ranibizumab Q4 groups, respectively, with both abicipar Q8 and Q12 noninferior to ranibizumab Q4. Week 52 mean change from baseline in BCVA was 7.5, 6.4, and 8.4 letters and in CRT was -144, -145, and -144 mu m in the abicipar Q8, abicipar Q12, and ranibizumab Q4 groups, respectively. Incidence of intraocular inflammation (IOI) AEs was 15.4%, 15.3%, and 0.3%, respectively. The IOI AEs were typically mild or moderate in severity and treated with topical corticosteroids; 62 of 192 patients (32.3%) received oral and/or injectable corticosteroids.
   Conclusions: Abicipar Q8 and Q12 were both noninferior to ranibizumab Q4 in the primary end point of stable vision at week 52. Intraocular inflammation was more frequent with abicipar. Quarterly and Q8 abicipar reduce nAMD disease and treatment burden compared with monthly treatment. (C) 2020 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.
C1 [Kunimoto, Derek] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Yoon, Young Hee] Univ Ulsan, Asan Med Ctr, Seoul, South Korea.
   [Wykoff, Charles C.] Retina Consultants Houston, Houston, TX USA.
   [Chang, Andrew] Sydney Retina Clin, Sydney, NSW, Australia.
   [Chang, Andrew] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Khurana, Rahul N.] Northern Calif Retina Vitreous Associates, Mountain View, CA USA.
   [Maturi, Raj K.] Midwest Eye Inst, Indianapolis, IN USA.
   [Maturi, Raj K.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Agostini, Hansjuergen] Univ Freiburg, Fac Med, Eye Ctr, Med Ctr, Freiburg, Germany.
   [Souied, Eric] Ctr Hosp Creteil, Serv Univ Ophthalmol, Creteil, France.
   [Chow, David R.] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada.
   [Chow, David R.] Toronto Retina Inst, N York, ON, Canada.
   [Lotery, Andrew J.] Univ Southampton, Southampton, Hants, England.
   [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Bandello, Francesco] Univ Vita Salute Sci Inst, Hosp San Raffaele, Milan, Italy.
   [Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Vis Inst, Sao Paulo, Brazil.
   [Li, Xiao-Yan; Jiao, Jenny; Le, Grace; Schmidt, Werner; Hashad, Yehia] Allergan Plc, Irvine, CA USA.
C3 University of Ulsan; University of Sydney; Indiana University System;
   Indiana University Bloomington; University of Freiburg; Assistance
   Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil; University of Toronto; University
   Toronto Affiliates; Saint Michaels Hospital Toronto; University of
   Southampton; Shiga University of Medical Science; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele; Universidade Federal
   de Sao Paulo (UNIFESP); AbbVie; Allergan
RP Kunimoto, D (通讯作者)，2152 S Vineyard,Suite 139 Bldg 12, Phoenix, AZ 85253 USA.
EM derek_kunimoto@yahoo.com
OI Khurana, Rahul/0000-0001-5198-1353; bandello,
   francesco/0000-0003-3238-9682
FU Allergan plc (Dublin, Ireland); Allergan plc
FX Sponsored by Allergan plc (Dublin, Ireland). The sponsor participated in
   the design of the study, data management, data analysis, interpretation
   of the data, and preparation, review, and approval of the manuscript.
   Evidence Scientific Solutions, Inc. (Philadelphia, PA) prepared a draft
   of the manuscript under the direction of the authors and provided
   editorial assistance, funded by Allergan plc. All authors met the
   International Committee of Medical Journal Editors authorship criteria.
   Neither honoraria nor payments were made for authorship. DARPin is a
   registered trademark of Molecular Partners (Zurich, Switzerland).
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan X, 2010, STAT BIOPHARM RES, V2, P329, DOI 10.1198/sbr.2009.0049
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
NR 33
TC 41
Z9 43
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2020
VL 127
IS 10
BP 1331
EP 1344
DI 10.1016/j.ophtha.2020.03.035
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NT0HB
UT WOS:000572632200015
PM 32471729
OA hybrid
DA 2022-11-30
ER

PT J
AU Dikmetas, O
   Kadayifcilar, S
   Eldem, B
AF Dikmetas, Ozlem
   Kadayifcilar, Sibel
   Eldem, Bora
TI The effect of CFH polymorphisms on the response to the treatment of
   age-related macular degeneration (AMD) with intravitreal ranibizumab
SO MOLECULAR VISION
LA English
DT Article
ID FACTOR HY402H POLYMORPHISM; GENETIC-FACTORS; SUBGROUP ANALYSIS; THERAPY;
   ASSOCIATION; PREVALENCE; ACTIVATION; Y402H; RISK
AB Purpose: The purpose of this study is to evaluate the effect of complement factor H (CFH) Y402H CC and TT polymorphisms on treatment response to intravitreal ranibizumab injection in patients with wet age-related macular degeneration (AMD).
   Methods: One hundred ninety-three patients with choroidal neovascularization (CNV) secondary to AMD who were monitored for at least 6 months of follow-up, and with at least three ranibizumab injections, were included in the study. At the final examination, an increase in visual acuity (VA) of five letters or more compared to the initial VA was regarded as a good response, and a decrease in VA of five letters or more compared to the initial VA was evaluated as a poor response. A genetic examination was performed with a PCR melting curve analysis. In the statistical evaluation, SPSS version 18 software was used.
   Results: The mean age of the patients was 71.01 (55-86) years, the mean follow-up was 13.34 (6-36) months, and the mean number of injections was 4.02 (3-15). There were 96 patients in the good response group (Group 1) and 97 patients in the poor response group (Group 2). The initial VA in Group 1 was 41.34 (10-64) letters, the initial central macular thickness (CMT) was 213.40 (126-494) mu m, and the initial lesion width was 3760 (1430-6430) mu m. The initial VA in Group 2 was 52.89 (26-82) letters, the initial CMT was 257.60 (115-882) mu m, and the initial lesion width was 4460 (1000-7650) mu m. There was no statistically significant difference between the two groups in terms of the initial VA and CMT (p=0.094, p=0.083). However, there was a statistically significant difference between the groups in the width of the initial lesion (p=0.003). In Group 1, 15 CC, 30 TT, and 51 TC alleles were found, and in Group 2, 49 CC, two TT, and 46 TC alleles were found, and the distribution was significantly different between the two groups (p=0.012). The change in the distribution of genotypes was not associated with either the lesion size or VA (p=0.841). Fibrosis developed in 12 patients who were all poor responders.
   Conclusions: CFH Y402H CC accompanied a poor response, and TT accompanied a good response in this series of patients with AMD undergoing ranibizumab therapy.
C1 [Dikmetas, Ozlem; Kadayifcilar, Sibel; Eldem, Bora] Hacettepe Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
C3 Hacettepe University
RP Kadayifcilar, S (通讯作者)，Hacettepe Univ, Dept Ophthalmol, Ankara, Turkey.
EM sibelkadayifcilar@yahoo.com
RI dikmetas, ozlem/W-1603-2017
OI Dikmetas, Ozlem/0000-0001-5670-2384
FU Novartis
FX The authors acknowledge Ergun Karaagaoglu from the Department of
   Biostatistics for his invaluable assistance with the statistical
   evaluation of this study. Financial support was received from Novartis
   for genetic analysis. The study was presented as poster at 4th World
   Congress on Controversies in Ophthalmology (COPHy), 4-7 April 2013, in
   Budapest, Hungary.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2011, AM J OPHTHALMOL, V152, P153, DOI 10.1016/j.ajo.2011.02.016
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Lommatzsch A, 2010, OPHTHALMOLOGE, V107, P1115, DOI 10.1007/s00347-010-2143-6
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mello E, 2012, CLIN CHEM LAB MED, V50, P1031, DOI 10.1515/cclm-2011-0859
   Micieli JA, 2011, CAN J OPHTHALMOL, V46, P549, DOI 10.1016/j.jcjo.2011.09.022
   Ngai LY, 2011, EYE, V25, P784, DOI 10.1038/eye.2011.56
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Schwartz SG, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/252549
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Souied EH, 2005, MOL VIS, V11, P1135
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Teper SJ, 2010, MOL VIS, V16, P2598
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 28
TC 18
Z9 20
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 20
PY 2013
VL 19
BP 2571
EP 2578
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AB5HX
UT WOS:000331820600001
PM 24367156
DA 2022-11-30
ER

PT J
AU Cukras, C
   Agron, E
   Klein, ML
   Ferris, FL
   Chew, EY
   Gensler, G
   Wong, WT
AF Cukras, Catherine
   Agron, Elvira
   Klein, Michael L.
   Ferris, Frederick L., III
   Chew, Emily Y.
   Gensler, Gary
   Wong, Wai T.
CA Age Related Eye Dis Study Res Grp
TI Natural History of Drusenoid Pigment Epithelial Detachment in
   Age-Related Macular Degeneration: Age-Related Eye Disease Study Report
   No. 28
SO OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; CLASSIFICATION; MACULOPATHY
AB Objective: To describe the natural history of eyes with drusenoid pigment epithelial detachments (DPEDs) associated with age-related macular degeneration (AMD).
   Design: Multicenter, clinic-based, prospective cohort study.
   Participants: Among 4757 participants enrolled in the Age-Related Eye Disease Study (AREDS), 255 were identified as having DPED in at least 1 eye and having 5 or more years of follow-up after the initial detection of the DPED.
   Methods: Baseline and annual fundus photographs were evaluated for the evolution of the fundus features and the development of advanced AMD in the forms of central geographic atrophy (CGA) or neovascular (NV) AMD. Kaplan-Meier analyses of progression to advanced AMD and of moderate vision loss (>= 15 letters compared with baseline) were performed.
   Main Outcome Measures: Rate of progression to advanced AMD and change in visual acuity from baseline (in terms of mean letters lost and proportion losing >= 15 letters).
   Results: A total of 311 eyes (from 255 participants) with DPED were followed for a median follow-up time of 8 years subsequent to the initial detection of a DPED. Of the 282 eyes that did not have advanced AMD at baseline, advanced AMD developed within 5 years in 119 eyes (42%) (19% progressing to CGA and 23% progressing to NV-AMD). In the remaining eyes that did not develop advanced AMD (n = 163), progressive fundus changes, typified by the development of calcified drusen and pigmentary changes, were detected. Visual decline was prominent among study eyes, with approximately 40% of all eyes decreasing in visual acuity by >= 15 letters at 5 years follow-up. Mean visual acuity decreased from 76 letters (similar to 20/30) at baseline to 61 letters (similar to 20/60) at 5 years. Five-year decreases in mean visual acuity averaged 26 letters for eyes progressing to advanced AMD and 8 letters for non-progressing eyes.
   Conclusions: The natural history of eyes containing DPED is characterized by a high rate of progression to both CGA and NV-AMD. Among eyes not progressing to advanced AMD, progressive development of pigmentary changes and calcified drusen were observed. Decline of visual acuity is a common outcome, with or without progression to advanced forms of AMD.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2010; 117: 489-499 (C) 2010 by the American Academy of Ophthalmology.
C1 [Wong, Wai T.] NEI, Off Sci Director, NIH, Bethesda, MD 20892 USA.
   [Cukras, Catherine; Agron, Elvira; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   [Klein, Michael L.] Legacy Good Samaritan Hosp & Med Ctr, Devers Eye Inst, Portland, OR USA.
   [Gensler, Gary] EMMES Corp, AREDS Coordinating Ctr, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Devers Eye Institute; Emmes Corporation
RP Wong, WT (通讯作者)，NEI, Off Sci Director, NIH, 7 Mem Dr,Bldg 7,Room 217, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020; Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute Intramural Research Program; NATIONAL EYE
   INSTITUTE [ZIAEY000485, ZIEEY000487, ZIAEY000489] Funding Source: NIH
   RePORTER
FX Supported by funding from the National Eye Institute Intramural Research
   Program.
CR *AG REL EYE DIS ST, 1990, CONTROL CLIN TRIALS, V20, P573
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
NR 16
TC 103
Z9 108
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2010
VL 117
IS 3
BP 489
EP 499
DI 10.1016/j.ophtha.2009.12.002
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 563BQ
UT WOS:000275101000013
PM 20079925
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Iyengar, SK
   Song, DH
   Klein, BEK
   Klein, R
   Schick, JH
   Humphrey, J
   Millard, C
   Liptak, R
   Russo, K
   Jun, G
   Lee, KE
   Fijal, B
   Elston, RC
AF Iyengar, SK
   Song, DH
   Klein, BEK
   Klein, R
   Schick, JH
   Humphrey, J
   Millard, C
   Liptak, R
   Russo, K
   Jun, G
   Lee, KE
   Fijal, B
   Elston, RC
TI Dissection of genomewide-scan data in extended families reveals a major
   locus and oligogenic susceptibility for age-related macular degeneration
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID BEAVER-DAM-EYE; STARGARDT-DISEASE GENE; VISUAL IMPAIRMENT; MALATTIA
   LEVENTINESE; QUANTITATIVE TRAIT; 10-YEAR INCIDENCE; 5-YEAR INCIDENCE;
   COMPLEX TRAITS; GRADING SYSTEM; VISION LOSS
AB To examine the genetic basis of age-related macular degeneration (ARMD), a degenerative disease of the retinal pigment epithelium and neurosensory retina, we conducted a genomewide scan in 34 extended families ( 297 individuals, 349 sib pairs) ascertained through index cases with neovascular disease or geographic atrophy. Family and medical history was obtained from index cases and family members. Fundus photographs were taken of all participating family members, and these were graded for severity by use of a quantitative scale. Model-free linkage analysis was performed, and tests of heterogeneity and epistasis were conducted. We have evidence of a major locus on chromosome 15q (GATA50C03 multipoint P = 1.98 x 10(-7); empirical P less than or equal to 1.0 x 10(-5); single-point P = 3.6 x 10(-7)). This locus was present as a weak linkage signal in our previous genome scan for ARMD, in the Beaver Dam Eye Study sample (D15S659, multipoint P = .047), but is otherwise novel. In this genome scan, we observed a total of 13 regions on 11 chromosomes (1q31, 2p21, 4p16, 5q34, 9p24, 9q31, 10q26, 12q13, 12q23, 15q21, 16p12, 18p11, and 20q13), with a nominal multipoint significance level of P less than or equal to .01 or LOD greater than or equal to 1.18. Family-by-family analysis of the data, performed using model-free linkage methods, suggests that there is evidence of heterogeneity in these families. For example, a single family ( family 460) individually shows linkage evidence at 8 loci, at the level of P < .0001. We conducted tests for heterogeneity, which suggest that ARMD susceptibility loci on chromosomes 9p24, 10q26, and 15q21 are not present in all families. We tested for mutations in linked families and examined SNPs in two candidate genes, hemicentin-1 and EFEMP1, in subsamples (145 and 189 sib pairs, respectively) of the data. Mutations were not observed in any of the 11 exons of EFEMP1 nor in exon 104 of hemicentin-1. The SNP analysis for hemicentin-1 on 1q31 suggests that variants within or in very close proximity to this gene cause ARMD pathogenesis. In summary, we have evidence for a major ARMD locus on 15q21, which, coupled with numerous other loci segregating in these families, suggests complex oligogenic patterns of inheritance for ARMD.
C1 Case Western Reserve Univ, Metrohlth Med Ctr, Dept Epidemiol & Biostat, Cleveland, OH 44109 USA.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Case Western Reserve University; MetroHealth System; University of
   Wisconsin System; University of Wisconsin Madison
RP Iyengar, SK (通讯作者)，Case Western Reserve Univ, Metrohlth Med Ctr, Dept Epidemiol & Biostat, Rammelkamp Bldg,R215,2500 Metrohlth Dr, Cleveland, OH 44109 USA.
RI /S-1190-2019
OI /0000-0001-7488-250X; Jun, Gyungah/0000-0002-3230-8697
FU NCRR NIH HHS [RR03655, P41 RR003655] Funding Source: Medline; NEI NIH
   HHS [U10-EY06594, U10 EY006594, EY10605] Funding Source: Medline; NHLBI
   NIH HHS [HL07567, T32 HL007567] Funding Source: Medline; NIGMS NIH HHS
   [R01 GM028356, R37 GM028356, GM28356] Funding Source: Medline; NATIONAL
   CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY010605, U10EY006594] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [R01GM028356, R37GM028356] Funding Source: NIH RePORTER
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Balatsoukas D D, 1995, J R Coll Surg Edinb, V40, P49
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Cordell HJ, 2001, ANN HUM GENET, V65, P491, DOI 10.1017/S0003480001008831
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   DeBlack Susan Sanders, 2003, Optometry, V74, P99
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Elston RC, 2000, GENET EPIDEMIOL, V19, P1, DOI 10.1002/1098-2272(200007)19:1<1::AID-GEPI1>3.0.CO;2-E
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fulker DW, 1999, AM J HUM GENET, V64, P259, DOI 10.1086/302193
   Gensler G, 2002, J NUTR, V132, P697
   Gorin MB, 2001, ARCH OPHTHALMOL-CHIC, V119, P752, DOI 10.1001/archopht.119.5.752
   Guymer RH, 2002, CLIN EXP OPHTHALMOL, V30, P419, DOI 10.1046/j.1442-9071.2002.00572.x
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hunt DWC, 2003, IDRUGS, V6, P464
   Jacques PF, 1999, INT J VITAM NUTR RES, V69, P198, DOI 10.1024/0300-9831.69.3.198
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keverline MR, 1998, OPHTHALMIC GENET, V19, P19, DOI 10.1076/opge.19.1.19.2176
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1995, PB95273827
   Klein R, 1991, PB91149823
   KLEIN R, 1991, PB91184267AS
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mittra Robert A, 2003, Minn Med, V86, P40
   Olson JM, 1999, AM J HUM GENET, V64, P1464, DOI 10.1086/302360
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   SCHMIDT S, 2003, ASS RES VIS OPHTH M
   SCHULTZ DW, 2003, ASS RES VIS OPHTH M
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 2003, ASS RES VIS OPHTH M
   Shete S, 2003, HUM HERED, V55, P79, DOI 10.1159/000072312
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Tiwari HK, 1997, ANN HUM GENET, V61, P253, DOI 10.1017/S0003480097006167
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P2203, DOI 10.1016/S0161-6420(00)00459-0
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   Vogel BE, 2001, DEVELOPMENT, V128, P883
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WILSON AF, 1993, GENET EPIDEMIOL, V10, P593, DOI 10.1002/gepi.1370100644
   WILSON AF, 1991, AM J HUM GENET, V48, P862
   Wiltshire S, 2002, AM J HUM GENET, V71, P1175, DOI 10.1086/342976
   Yoshida A, 2000, JPN J OPHTHALMOL, V44, P290, DOI 10.1016/S0021-5155(99)00227-0
NR 74
TC 133
Z9 141
U1 0
U2 8
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JAN
PY 2004
VL 74
IS 1
BP 20
EP 39
DI 10.1086/380912
PG 20
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 759DR
UT WOS:000187723500003
PM 14691731
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Sim, PY
   Gajree, S
   Dhillon, B
   Borooah, S
AF Sim, Peng Yong
   Gajree, Sonul
   Dhillon, Baljean
   Borooah, Shyamanga
TI Investigation of time to first presentation and extrahospital factors in
   the treatment of neovascular age-related macular degeneration: a
   retrospective cross-sectional study
SO BMJ OPEN
LA English
DT Article
ID RISK-FACTORS; VISUAL OUTCOMES; RANIBIZUMAB; AWARENESS; KNOWLEDGE; EYE;
   ATTITUDES; DELAY; VERTEPORFIN; AUSTRALIA
AB Objectives To assess the time from symptom onset to treatment for neovascular age-related macular degeneration (nvAMD) and to measure the awareness of AMD in Southeast Scotland.
   Design Retrospective cross-sectional study.
   Setting Secondary care, Southeast of Scotland.
   Methods Patients treated with intravitreal therapy (IVT) for nvAMD in Southeast Scotland between 2013 and 2015 were identified using a treatment register. Notes were retrospectively reviewed. We measured time from: (A) symptom onset to first presentation at primary care, (B) referral to ophthalmic clinic appointment and (C) ophthalmic clinic appointment to first IVT treatment. To investigate AMD awareness, we performed a cluster random sample survey of patients visiting non-AMD ophthalmic clinics using a previously validated 12-item questionnaire.
   Results 195 patients (mean age 78 years) were included in the study. The mean delays between the different stages-A, B and C-were 54.2 (95% CI +/- 13), 28.2 (95% CI +/- 4.0) and 31.5 (95% CI +/- 3.6) days, respectively. There was an additional mean delay of 7.5 (95% CI +/- 1.6) days when patients were indirectly referred by optometrists via general practitioners (P<0.05). 140 patients (mean age 78) participated in the awareness survey; 62.1% reported being 'aware' of AMD but only 37.3% described AMD symptoms correctly.
   Conclusions There was a significant delay at every step of the nvAMD care pathway. The causes for this were multifactorial and included delays in first presentation to a healthcare provider, referral from primary care and initiation of secondary care treatment. Our data are likely to underestimate prehospital delays as a large number of cases are likely to have undefined symptoms and onset. We also identified suboptimal awareness of AMD which could account for a substantial delay in presentation from symptom onset. These findings highlight the need to address AMD awareness and the need for urgent treatment to prevent avoidable vision loss resulting from nvAMD.
C1 [Sim, Peng Yong; Dhillon, Baljean] Univ Edinburgh, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland.
   [Gajree, Sonul] Gartnavel Royal Hosp, Ophthalmol Dept, Glasgow, Lanark, Scotland.
   [Dhillon, Baljean] Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Borooah, Shyamanga] Moorfields Eye Hosp, London, England.
   [Borooah, Shyamanga] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.
C3 University of Edinburgh; Gartnavel Royal Hospital; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of Edinburgh
RP Sim, PY (通讯作者)，Univ Edinburgh, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland.
EM pengyong91@gmail.com
RI Borooah, Shyamanga/AAM-6581-2021
OI Sim, Peng Yong/0000-0001-5500-2634
FU Wellcome Trust Scottish Translational Medicine and Therapeutics
   Initiative (STMTI) scheme [R42141]
FX SB was sponsored by the Wellcome Trust Scottish Translational Medicine
   and Therapeutics Initiative (STMTI) scheme (grant no: R42141) during the
   course of this research.
CR Aitken E, 2013, TRANSPL P, V45, P2176, DOI 10.1016/j.transproceed.2012.12.031
   Alliance International AMD, 2005, AW AG REL MAC DEG AS
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cameron JR, 2009, EYE, V23, P1134, DOI 10.1038/eye.2008.196
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Chevreaud O, 2016, EUR J OPHTHALMOL, V26, P44, DOI 10.5301/ejo.5000649
   Chew J, 2013, INVEST OPHTH VIS SCI, V54
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   GARRAWAY WM, 1987, JAMA-J AM MED ASSOC, V258, P214, DOI 10.1001/jama.258.2.214
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heraghty J, 2012, AM J PUBLIC HEALTH, V102, P1655, DOI 10.2105/AJPH.2012.300657
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Islam FMA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133043
   Kim YS, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-2
   Lau JTF, 2002, BRIT J OPHTHALMOL, V86, P1080, DOI 10.1136/bjo.86.10.1080
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780
   Low L, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007290
   Macular Society, 2016, STRAT 2016 2020
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Muniraju R, 2013, INVEST OPHTH VIS SCI, V54
   National Statistics, 2012, SCOTT IND MULT DEPR
   Niksic M, 2016, BRIT J CANCER, V115, P876, DOI 10.1038/bjc.2016.246
   Optegra Eye Health Care, 2015, VIS BRIT REP INS NAT
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Royal National Institute of Blind People, 2013, DONT LOS SIGHT DONT
   Sanjay S, 2009, CLIN EXP OPHTHALMOL, V37, P795, DOI 10.1111/j.1442-9071.2009.02153.x
   Saw SM, 2003, BRIT J OPHTHALMOL, V87, P446, DOI 10.1136/bjo.87.4.446
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Takahashi H, 2015, RETINA-J RET VIT DIS, V35, P1331, DOI 10.1097/IAE.0000000000000513
   Thapa R, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0175-z
   The Royal College of Ophthalmologists, 2007, COMM CONT AMD SERV G
   Thompson C, 2007, OPHTHAL PHYSL OPT, V27, P389, DOI 10.1111/j.1475-1313.2007.00483.x
   Thornton J, 2007, J PUBLIC HEALTH-UK, V29, P142, DOI 10.1093/pubmed/fdm019
   Uhr JH, 2016, JAMA OPHTHALMOL, V134, P424, DOI 10.1001/jamaophthalmol.2015.6212
   Winther C, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/285463
   WORDEN JK, 1990, PREV MED, V19, P254, DOI 10.1016/0091-7435(90)90026-G
   World Health Organization [webpage on the Internet], 2017, PRIOR EYE DIS
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
   Zhang CX, 2017, CHINESE MED J-PEKING, V130, P155, DOI 10.4103/0366-6999.197994
NR 49
TC 10
Z9 10
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD DEC
PY 2017
VL 7
IS 12
AR e017771
DI 10.1136/bmjopen-2017-017771
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FU4MH
UT WOS:000423826700076
PM 29229653
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tvenning, AO
   Hanssen, SR
   Austeng, D
   Morken, TS
AF Tvenning, Arnt-Ole
   Hanssen, Stian Rikstad
   Austeng, Dordi
   Morken, Tora Sund
TI Deep learning identify retinal nerve fibre and choroid layers as markers
   of age-related macular degeneration in the classification of macular
   spectral-domain optical coherence tomography volumes
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; convolutional neural network; deep
   learning; explainable artificial intelligence; spectral-domain optical
   coherence tomography; visualization
ID THICKNESS; DISEASES
AB PurposeDeep learning models excel in classifying medical image data but give little insight into the areas identified as pathology. Visualization of a deep learning model's point of interest (POI) may reveal unexpected areas associated with diseases such as age-related macular degeneration (AMD). In this study, a deep learning model coined OptiNet was trained to identify AMD in spectral-domain optical coherence tomography (SD-OCT) macular scans and the anatomical distribution of POIs was studied.
   MethodsThe deep learning model OptiNet was trained and validated on two data sets. Data set no. 1 consisted of 269 AMD cases and 115 controls with one scan per person. Data set no. 2 consisted of 337 scans from 40 AMD cases (62 eyes) and 46 from both eyes of 23 controls. POIs were visualized by calculating feature dependencies across the layer hierarchy in the deep learning architecture.
   ResultsThe retinal nerve fibre and choroid layers were identified as POIs in 82 and 70% of cases classified as AMD by OptiNet respectively. Retinal pigment epithelium (98%) and drusen (97%) were the areas applied most frequently. OptiNet obtained area under the receiver operator curves of >= 99.7%.
   ConclusionPOIs applied by the deep learning model OptiNet indicates alterations in the SD-OCT imaging regions that correspond to the retinal nerve fibre and choroid layers. If this finding represents a tissue change in macular tissue with AMD remains to be investigated, and future studies should investigate the role of the neuroretina and choroid in AMD development.
C1 [Tvenning, Arnt-Ole; Austeng, Dordi; Morken, Tora Sund] Trondheim Reg & Univ Hosp, St Olav Hosp, Dept Ophthalmol, N-7006 Trondheim, Norway.
   [Hanssen, Stian Rikstad] Norwegian Univ Sci & Technol NTNU, Dept Comp Sci, Trondheim, Norway.
   [Austeng, Dordi; Morken, Tora Sund] NTNU, Dept Neuromed & Movement Sci, Trondheim, Norway.
C3 Norwegian University of Science & Technology (NTNU); Norwegian
   University of Science & Technology (NTNU); Norwegian University of
   Science & Technology (NTNU)
RP Tvenning, AO (通讯作者)，Trondheim Reg & Univ Hosp, St Olav Hosp, Dept Ophthalmol, N-7006 Trondheim, Norway.
EM arnt-ole.tvenning@stolay.no
OI Austeng, Dordi/0000-0001-9782-576X
FU Dam Foundation [2016/FO80635]
FX The project has been made possible by the Dam Foundation (2016/FO80635
   to A-O. Tvenning). Professor Keith Downing is acknowledged for his
   invaluable and constructive suggestions during this research work. The
   authors report no conflicts of interest.
CR Apostolopoulos S., 2016, ARXIV PREPRINT ARXIV
   Bany M., 2021, SN COMPUT SCI, V2, P47
   Budenz DL, 2007, OPHTHALMOLOGY, V114, P1046, DOI 10.1016/j.ophtha.2006.08.046
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Cho J., 2015, ARXIV PREPRINT ARXIV
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V191, P23, DOI 10.1016/j.ajo.2018.03.038
   Dou Q, 2017, IEEE T BIO-MED ENG, V64, P1558, DOI 10.1109/TBME.2016.2613502
   Farinha C, 2021, GRAEF ARCH CLIN EXP, V259, P2545, DOI 10.1007/s00417-021-05140-0
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Glorot X, 2010, P 13 INT C ART INT S, P249, DOI DOI 10.1177/1753193409103364.
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   Ho CYD, 2018, CLIN EXP OPHTHALMOL, V46, P485, DOI 10.1111/ceo.13131
   Ioffe S., 2015, PR MACH LEARN RES, P448, DOI DOI 10.1007/S13398-014-0173-7.2
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kermany Daniel, 2018, Mendeley Data, V3, DOI 10.17632/RSCBJBR9SJ.3
   Kingma J., 2014, ARXIV
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   LeCun Y, 1998, LECT NOTES COMPUT SC, V1524, P9, DOI 10.1007/3-540-49430-8_2
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lu W, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.41
   Mopuri KR, 2019, IEEE T IMAGE PROCESS, V28, P2116, DOI 10.1109/TIP.2018.2881920
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Nair V., 2010, P 27 INT C MACHINE L, P1
   Perdomo O, 2019, COMPUT METH PROG BIO, V178, P181, DOI 10.1016/j.cmpb.2019.06.016
   Rivera JC, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0943-1
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Santos AM, 2018, BIOMED ENG ONLINE, V17, DOI 10.1186/s12938-018-0592-3
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Scherer D, 2010, LECT NOTES COMPUT SC, V6354, P92, DOI 10.1007/978-3-642-15825-4_10
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tran D, 2018, PROC CVPR IEEE, P6450, DOI 10.1109/CVPR.2018.00675
   Tvenning AO, 2020, ACTA OPHTHALMOL, V98, P701, DOI 10.1111/aos.14423
   Venhuizen F., 2015, P SPIE MED IM ORL US, P9414
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zeiler MD, 2014, LECT NOTES COMPUT SC, V8689, P818, DOI 10.1007/978-3-319-10590-1_53
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 39
TC 0
Z9 0
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2022
VL 100
IS 8
BP 937
EP 945
DI 10.1111/aos.15126
EA MAR 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6D4SX
UT WOS:000762573400001
PM 35233918
DA 2022-11-30
ER

PT J
AU Pietraszkiewicz, A
   van Asten, F
   Kwong, A
   Ratnapriya, R
   Abecasis, G
   Swaroop, A
   Chew, EY
AF Pietraszkiewicz, Alexandra
   van Asten, Freekje
   Kwong, Alan
   Ratnapriya, Rinki
   Abecasis, Goncalo
   Swaroop, Anand
   Chew, Emily Y.
TI Association of Rare Predicted Loss-of-Function Variants in Cellular
   Pathways with Sub-Phenotypes in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; HIGH-RISK; EYE DISEASE; GENETIC-VARIANTS; CODING
   VARIANT; SUSCEPTIBILITY; PREVALENCE; COMMON; DEPOSITS; CONFERS
AB Purpose: To investigate the association of rare predicted loss-of-function (pLoF) variants within age-related macular degeneration (AMD) risk loci and AMD sub-phenotypes.
   Design: Case-control study.
   Participants: Participants of AREDS, AREDS2, and Michigan Genomics Initiative.
   Methods: Whole genome sequencing data were analyzed for rare pLoF variants (frequency <0.1%) in the regions of previously identified 52 independent risk variants known to be associated with AMD. Frequency of the rare pLoF variants in cases with intermediate or advanced AMD was compared with controls. Variants were assigned to the complement, extracellular matrix (ECM), lipid, cell survival, immune system, metabolism, or unknown/other pathway. Associations of rare pLoF variant pathways with AMD sub-phenotypes were analyzed using logistic and linear regression, and Cox proportional hazards models.
   Main Outcome Measures: Differences in rare pLoF variant pathway burden and association of rare pLoF variant pathways with sub-phenotypes within the population with AMD were evaluated.
   Results: Rare pLoF variants were found in 298 of 1689 cases (17.6%) and 237 of 1518 controls (15.6%) (odds ratio [OR], 1.11; 95% confidence interval [CI], 0.91-1.36; P = 0.310). An enrichment of rare pLoF variants in the complement pathway in cases versus controls (OR, 2.94; 95% CI, 1.49-5.79; P = 0.002) was observed. Within cases, associations between all rare pLoF variants and choroidal neovascularization (CNV) (OR, 1.34; 95% CI, 1.04-1.73; P = 0.023), calcified drusen (OR, 1.33; 95% CI, 1.04-1.72; P = 0.025), higher scores on the AREDS Extended AMD Severity Scale (Standardized Coefficient Beta (beta) = 0.346 [0.086-0.605], P = 0.009), and progression to advanced disease (hazard ratio, 1.25; 95% CI, 1.01-1.55; P = 0.042) were observed. At the pathway level, there were associations between the complement pathway and geographic atrophy (GA) (OR, 2.17; 95% CI, 1.12-4.24; P = 0.023), the complement pathway and calcified drusen (OR, 3.75; 95% CI, 1.79-7.86; P < 0.001), and the ECM pathway and more severe levels in the AREDS Extended AMD Severity Scale (beta = 0.62; 95% CI, 0.04-1.20; P = 0.035).
   Conclusions: Rare pLoF variants are associated with disease progression. Variants in the complement pathway modify the clinical course of AMD and increase the risk of developing specific subphenotypes. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Pietraszkiewicz, Alexandra; van Asten, Freekje; Ratnapriya, Rinki; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [van Asten, Freekje; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10 CRC,Room 3-2531,10 Ctr Dr, Bethesda, MD 20892 USA.
   [Kwong, Alan; Abecasis, Goncalo] Univ Michigan, Biostat & Ctr Stat Genet, Ann Arbor, MI 48109 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); University of Michigan System; University of Michigan
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10 CRC,Room 3-2531,10 Ctr Dr, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI van Asten, Freekje/P-6028-2015
OI van Asten, Freekje/0000-0002-8141-4234; Swaroop,
   Anand/0000-0002-1975-1141; Pietraszkiewicz,
   Alexandra/0000-0002-9982-6261; Ratnapriya, Rinki/0000-0002-0469-4631
FU Intramural Research Program of the National Eye Institute [EY000474,
   EY000546, NOI-EY-02127]; NATIONAL EYE INSTITUTE [ZIAEY000489,
   ZIAEY000546] Funding Source: NIH RePORTER
FX Supported by the Intramural Research Program of the National Eye
   Institute (EY000474 and EY000546 to A.S., and AREDS Contract
   NOI-EY-02127 to E.Y.C.). The funding organization had no role in the
   design or conduct of this research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179
   Browning SR, 2007, AM J HUM GENET, V81, P1084, DOI 10.1086/521987
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   den Hollander AI, 2016, INVEST OPHTH VIS SCI, V57, P1378, DOI 10.1167/iovs.15-18167
   Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Jun G, 2015, GENOME RES, V25, P918, DOI 10.1101/gr.176552.114
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Milacic Marija, 2012, Cancers (Basel), V4, P1180, DOI 10.3390/cancers4041180
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Parsons LS, 2001, P 26 ANN SAS US GROU
   Rashkin S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006811
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang CL, 2014, NAT GENET, V46, P409, DOI 10.1038/ng.2924
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 48
TC 7
Z9 7
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2018
VL 125
IS 3
BP 398
EP 406
DI 10.1016/j.ophtha.2017.10.027
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW5SE
UT WOS:000425377300018
PM 29224928
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Scott, IU
   Feuer, WJ
   Jacko, JA
AF Scott, IU
   Feuer, WJ
   Jacko, JA
TI Impact of graphical user interface screen features on computer task
   accuracy and speed in a cohort of patients with age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; INTRAOCULAR-LENS IMPLANTATION; INITIAL GLAUCOMA
   TREATMENT; CATARACT-SURGERY; VISUAL FUNCTION; CONTRAST SENSITIVITY;
   UTILITY VALUES; CLINICAL-TRIAL; VISION; OUTCOMES
AB PURPOSE: To investigate the impact of graphical user interface screen features on computer task performance in patients with age,related macular degeneration (AMD).
   DESIGN: Interventional case series.
   METHODS: Eighteen patients with visual impairment due to AMD were recruited from the Bascom Palmer Eye Institute Low Vision Clinic. Each patient underwent evaluation of visual acuity using the Early Treatment Diabetic Retinopathy Study protocol, contrast sensitivity using a Pelli-Robson chart, binocular simultaneous visual field using the Esterman program on an automated perimeter, and color vision using Farnsworth D- 15. Each subject then completed computer icon identification tasks while the following screen features of the graphical user interface were varied: size of icons displayed, icon set size (number of icons displayed), and background color. Each patient performed all 125 computer tasks with each of five icon sizes (9.2 mm, 14.6 mm, 23.2 mm, 36.8 mm, 58.3 mm), each of five icon set sizes (2, 3, 4, 5, 6), and each of five different background colors (black, white, red, green, blue) in a randomly ordered fashion. Relationships between computer task performance (accuracy and speed) and graphical user interface screen features were studied.
   RESULTS: Icon size and icon set size are significantly associated with computer task accuracy (P <.001), whereas background color is not a significant predictor of task accuracy (P =.63). The impact of icon size on accuracy is nonlinear, with the data indicating that no additional improvement in accuracy is associated with increasing the icon size beyond 23.2 mm. The impact of icon set size on accuracy is linear, with a smaller icon set size significantly associated with greater computer accuracy. A larger icon size is significantly associated with a shorter time to task completion (P =.001); this relationship is largely linearly related to icon size. There was no significant impact of background color (P = .11) or set size (P =.37) on time to task completion.
   CONCLUSIONS: Modifications of graphical user interface design may permit improved computer task performance among patients with visual impairment due to AMD.
C1 Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33101 USA.
   Georgia Inst Technol, Dept Ind & Syst Engn, Atlanta, GA 30332 USA.
C3 Bascom Palmer Eye Institute; University of Miami; University System of
   Georgia; Georgia Institute of Technology
RP Scott, IU (通讯作者)，Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, POB 016880, Miami, FL 33101 USA.
OI Scott, Ingrid/0000-0002-3908-7153
CR APPLEGATE WB, 1987, JAMA-J AM MED ASSOC, V257, P1064
   Balcer LJ, 2000, MULT SCLER J, V6, P382, DOI 10.1191/135245800701566359
   BERNTHPETERSEN P, 1981, ACTA OPHTHALMOL, V59, P198
   Birch J., 1979, CONGENITAL ACQUIRED, P83
   BRENNER MH, 1993, ARCH OPHTHALMOL-CHIC, V111, P680, DOI 10.1001/archopht.1993.01090050114040
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 1998, INT OPHTHALMOL, V22, P307, DOI 10.1023/A:1006311910304
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2002, BRIT J OPHTHALMOL, V86, P8, DOI 10.1136/bjo.86.1.8
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   Courtright P, 1998, Ophthalmic Epidemiol, V5, P13, DOI 10.1076/opep.5.1.13.1498
   DAMIANO AM, 1995, MED CARE, V33, P120
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   *EARL TREATM DIAB, 1980, MAN OP, P1
   ELLIOTT DB, 1990, EYE, V4, P712, DOI 10.1038/eye.1990.100
   ESTERMAN B, 1982, OPHTHALMOLOGY, V89, P1226
   Esterman B., 1985, DOC OPHTHALMOL P SER, V42, P333
   Farnsworth D., 1947, FARNSWORTH DICHOTOMO, P1
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Frost A, 2001, EYE, V15, P739, DOI 10.1038/eye.2001.241
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   Jacko J. A., 1999, Human-Computer Interaction: Ergonomics and User Interfaces. Proceedings of HCI International '99 (8th International Conference on Human-Computer Interaction), P975
   Jacko JA, 2000, INT J HUM-COMPUT INT, V12, P135, DOI 10.1207/S15327590IJHC1201_6
   Jacko JA, 2000, INT J HUM-COMPUT INT, V12, P151, DOI 10.1207/S15327590IJHC1201_7
   JACKO JA, 1999, VISUAL PROFILES CRIT, P330
   Janz NK, 2001, OPHTHALMOLOGY, V108, P887, DOI 10.1016/S0161-6420(00)00624-2
   Javitt J, 2000, J CATARACT REFR SURG, V26, P1356, DOI 10.1016/S0886-3350(00)00636-2
   Javitt JC, 2000, OPHTHALMOLOGY, V107, P2040, DOI 10.1016/S0161-6420(00)00368-7
   Kupersmith MJ, 2001, J NEURO-OPHTHALMOL, V21, P266, DOI 10.1097/00041327-200112000-00008
   LEGRO MW, 1991, OPHTHALMIC SURG LAS, V22, P431
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Lundstrom M, 2001, J CATARACT REFR SURG, V27, P1553, DOI 10.1016/S0886-3350(01)00984-1
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   MANGIONE CM, 1992, MED CARE, V30, P111
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P205
   MILLS RP, 1986, OPHTHALMOLOGY, V93, P371
   Mills RP, 2001, J GLAUCOMA, V10, P192, DOI 10.1097/00061198-200106000-00008
   Odberg T, 2001, ACTA OPHTHALMOL SCAN, V79, P116, DOI 10.1034/j.1600-0420.2001.079002116.x
   PARRISH RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P777
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   ROSS JE, 1984, BRIT J OPHTHALMOL, V68, P821, DOI 10.1136/bjo.68.11.821
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Scott IU, 1998, OPHTHALMOLOGY, V105, P795, DOI 10.1016/S0161-6420(98)95017-5
   Scott IU, 2001, AM J OPHTHALMOL, V131, P515, DOI 10.1016/S0002-9394(00)00820-5
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   SEARS A, 1998, P 42 ANN M HUM FACT
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P195
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
NR 54
TC 21
Z9 23
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2002
VL 134
IS 6
BP 857
EP 862
AR PII S0002-9394(02)01795-6
DI 10.1016/S0002-9394(02)01795-6
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624BA
UT WOS:000179738600009
PM 12470754
DA 2022-11-30
ER

PT J
AU Perrone, V
   Dovizio, M
   Veronesi, C
   Citraro, R
   De Francesco, A
   Dell'Orco, S
   Di Manno, G
   Paciello, A
   Resta, AM
   Quarta, F
   Ferrante, N
   Ritrovato, D
   Degli Esposti, L
AF Perrone, Valentina
   Dovizio, Melania
   Veronesi, Chiara
   Citraro, Rita
   De Francesco, Adele
   Dell'Orco, Stefania
   Di Manno, Gianluca
   Paciello, Arrigo
   Resta, Anna Maria
   Quarta, Fabrizio
   Ferrante, Nicola
   Ritrovato, Daniela
   Degli Esposti, Luca
TI Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors
   and Health Care Costs among Patients with Wet Age-Related Macular
   Degeneration and Other Ocular Diseases in Italy
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; real-world evidence;
   pharmaco-utilization; health care costs
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIENCES; PREVALENCE
AB This Italian retrospective study aimed to analyze the pharmaco-utilization of anti-VEGF drugs and health care costs among patients with wet age-related macular degeneration (wAMD) or other ocular diseases. A retrospective analysis was performed on administrative databases of Italian entities covering approximately six million individuals. Across January 2010-December 2017, patients aged >= 50 years with a prescription of intravitreal anti-VEGFs were included as "wAMD" patients [by wAMD hospitalization or intravitreal injections] or as "other ocular diseases" patients [by hospitalization for other ocular disorders or intravitreal injections, with concomitant diabetes diagnosis or dexamethasone treatment]. The date of first matching of inclusion criteria was index-date. wAMD-cohort. Overall, 3879 patients were included; at index-date, 82.2% were treated with Ranibizumab, 15.8% with Aflibercept, and 2% with Pegaptanib. During the follow-up, the mean/annual anti-VEGF prescription [3.6 (first-year)-0.8 (third-year)] and the total expenditure [5799.84 euro (first-year)-3212.84 euro (third-year)] decreased. Other ocular diseases-cohort. Overall, 2646 patients were enclosed; 85.9% were treated with Ranibizumab, 13.5% with Aflibercept, and 0.6% with Pegaptanib. During the follow-up, the mean/annual anti-VEGF prescription [3.3 (first-year)-0.5 (third-year)] and the total cost [7196.83 euro (first-year)-5162.68 euro (third-year)] decreased. This observational study highlighted a decline in anti-VEGF prescriptions over time in both cohorts, suggesting a trend of under-treatment that could worsen the patients' clinical outcomes and increase health care resource consumption.
C1 [Perrone, Valentina; Dovizio, Melania; Veronesi, Chiara; Degli Esposti, Luca] CliCon Srl, Soc Benefit Hlth Econ & Outcomes Res, Bologna, Italy.
   [Citraro, Rita; De Francesco, Adele] Univ Magna Grecia Catanzaro, Unita Operat Farmacol Clin & Farmacovigilanza, Azienda Osped Univ Mater Domini, Catanzaro, Italy.
   [Dell'Orco, Stefania; Di Manno, Gianluca] Azienda Sanit Locale ASL Roma 6, Albano Laziale, Rome, Italy.
   [Paciello, Arrigo] Agenzia Tutela Salute ATS Bergamo, Bergamo, Italy.
   [Resta, Anna Maria] Struttura Complessa Farmacia Terr Area Vasta 1, Fano, Italy.
   [Quarta, Fabrizio] Azienda Sanit Locale ASL Lecce, UO Epidemiol & Stat, Lecce, Italy.
   [Ferrante, Nicola; Ritrovato, Daniela] Novartis Farma SpA, Varese, Italy.
C3 Clicon S.r.l; Magna Graecia University of Catanzaro; Novartis
RP Perrone, V (通讯作者)，CliCon Srl, Soc Benefit Hlth Econ & Outcomes Res, Bologna, Italy.
EM valentina.perrone@clicon.it; melania.dovizio@clicon.it;
   chiara.veronesi@clicon.it; valentina.perrone@clicon.it;
   citraro@unicz.it; defrancescoad@gmail.com; gianluca.dimanno@aslroma6.it;
   arrigo.paciello@ats-bg.it; anna.resta@sanita.marche.it; uose@ausl.le.it;
   nicola.ferrante@novartis.com; daniela.ritrovato@novartis.com;
   luca.degliesposti@clicon.it
OI Citraro, Rita/0000-0001-6746-6751; Veronesi, Chiara/0000-0003-2852-2022
FU Novartis Farma S.p.a., Origgio, Varese, Italy
FX FundingThis study was sponsored by Novartis Farma S.p.a., Origgio,
   Varese, Italy.
CR Albrecht M, 2018, GLOB REG HEALTH TECH, DOI 10.1177/2284240318793905
   Barzey V., 2015, P 15 ESASO RET AC 20
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cornel Stefan, 2015, Rom J Ophthalmol, V59, P235
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Marciano I., 2017, P 38 C IT PHARM SOC
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Rohowetz LJ, 2019, J MED ETHICS, V45, P668, DOI 10.1136/medethics-2018-105286
   Scalzo A. L., 2009, Health Systems in Transition (European Observatory on Health Systems and Policies), V11
   Scondotto G, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7582763
   Staurenghi G, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256461
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
NR 21
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD MAR
PY 2022
VL 19
IS 5
AR 2548
DI 10.3390/ijerph19052548
PG 12
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA ZZ6FS
UT WOS:000773362800001
PM 35270241
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jorstad, OK
   Faber, RT
   Moe, MC
AF Jorstad, Oystein Kalsnes
   Faber, Rowan Thomas
   Moe, Morten Carstens
TI Two-year functional and anatomical results after converting treatment
   resistant eyes with exudative age-related macular degeneration to
   aflibercept in accordance with a treat and extend protocol
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; age-related macular degeneration; exudative age-related
   macular degeneration; treatment resistance
ID RANIBIZUMAB; BEVACIZUMAB
AB PurposeTo study the effects of converting to aflibercept in accordance with a treat and extend (T&E) strategy in eyes with treatment resistant exudative age-related macular degeneration (AMD).
   MethodsTwo-year prospective study of eyes with exudative AMD and persistent macular fluid despite monthly treatment with ranibizumab or bevacizumab. Eyes were converted to 2.0mg aflibercept in accordance with a T&E protocol.
   ResultsFifty eyes from 47 patients were included. At baseline, the mean central retinal thickness (CRT) was 273m and mean best-corrected visual acuity (BCVA) 0.25 logarithm of the minimal angle of resolution (logMAR). The mean number of aflibercept injections the first year was 9.2. After 1year, there was a reduction in mean CRT to 228m (p<0.001); 22 eyes (44%) had a dry macula; and the mean BCVA was 0.24 logMAR (p=0.531). The mean number of aflibercept injections the second year was 8.0 (p=0.013 compared to first year). After 2years, 24 eyes (48%) received treatment more frequently than every eighth week. The mean CRT was 225m (p<0.001 compared to baseline); 31 eyes (62%) had a dry macula; and mean BCVA was 0.32 logMAR (p=0.005 compared to baseline). Five eyes did not complete 2years of aflibercept treatment after failing to improve.
   ConclusionA majority of eyes showed improved anatomic outcomes. There was a small decrease in mean BCVA after the second year of treatment. About half of the eyes required treatment more frequently than the recommended aflibercept label of an 8-week interval.
C1 [Jorstad, Oystein Kalsnes] Oslo Univ Hosp, Dept Ophthalmol, Postboks 4950 Nydalen, N-0424 Oslo, Norway.
   Univ Oslo, Oslo, Norway.
C3 University of Oslo; University of Oslo
RP Jorstad, OK (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Postboks 4950 Nydalen, N-0424 Oslo, Norway.
EM OEYJOE@ous-hf.no
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jorstad OK, 2015, ACTA OPHTHALMOL, V93, pE510, DOI 10.1111/aos.12681
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Patel Avni V, 2015, Int Ophthalmol Clin, V55, P103, DOI 10.1097/IIO.0000000000000080
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
NR 13
TC 19
Z9 19
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2017
VL 95
IS 5
BP 460
EP 463
DI 10.1111/aos.13480
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA4BJ
UT WOS:000405388500022
PM 28556485
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Nguyen, QD
   Shah, SM
   Browning, DJ
   Hudson, H
   Sonkin, P
   Hariprasad, SM
   Kaiser, P
   Slakter, JS
   Haller, J
   Do, DV
   Mieler, WF
   Chu, K
   Yang, K
   Ingerman, A
   Vitti, RL
   Berliner, AJ
   Cedarbaum, JM
   Campochiaro, PA
AF Nguyen, Quan Dong
   Shah, Syed Mahmood
   Browning, David J.
   Hudson, Henry
   Sonkin, Peter
   Hariprasad, Seenu M.
   Kaiser, Peter
   Slakter, Jason S.
   Haller, Julia
   Do, Diana V.
   Mieler, William F.
   Chu, Karen
   Yang, Ke
   Ingerman, Avner
   Vitti, Robert L.
   Berliner, Alyson J.
   Cedarbaum, Jesse M.
   Campochiaro, Peter A.
TI A Phase I Study of Intravitreal Vascular Endothelial Growth Factor
   Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; VEGF; RANIBIZUMAB
AB Purpose: To determine the safety, tolerability, maximum tolerated dose, and bioactivity of an intravitreal injection of vascular endothelial growth factor (VEGF) Trap-Eye, a fusion protein of binding domains from human VEGF receptors 1 and 2 with human immunoglobulin-G Fc that binds VEGF family members, in patients with neovascular age-related macular degeneration (AMD).
   Design: Dose-escalation, multicenter, interventional clinical trial.
   Participants: Twenty-one patients (13 female, 8 male) with neovascular AMD (NVAMD) and lesions <= 12 disc areas in size and >= 50% active choroidal neovascularization (CNV) with best-corrected visual acuity (BCVA) : <= 20/40 received a single intraocular injection of 0.05 mg (n = 3), 0.15 mg (n = 3), 0.5 mg (n = 3), 1 mg (n = 6), 2 mg (n = 3), or 4 mg (n = 3) of VEGF Trap-Eye.
   Methods: Safety assessments included eye examinations, vital signs, and laboratory tests. Measures of bioactivity included changes from baseline in BCVA, optical coherence tomography (OCT), and fluorescein angiography. The primary end point was 6 weeks and patients were followed up for 12 weeks.
   Main Outcome Measure: Safety assessments.
   Results: There were no serious adverse events and no identifiable intraocular inflammation. The mean decrease in excess foveal thickness for all patients was 104.5 mu m at 6 weeks, and the mean increase in visual acuity was 4.43 letters. In the 2 highest dose groups combined (2 and 4 mg), the mean increase in BCVA was 13.5 letters, with 3 of 6 patients demonstrating improvement of >= 3 lines and 3 patients requiring no adjunctive treatment of any type for 12 weeks. Some showed elimination of fluorescein leakage and reduction in area of CNV.
   Conclusions: Intravitreal injection of up to 4 mg of VEGF Trap-Eye in patients with NVAMD was well tolerated with no evidence of ocular inflammation. Although the number of patients in each cohort was small, there was evidence of bioactivity, because several patients, especially those receiving 2 or 4 mg of VEGF Trap-Eye, showed substantial improvement in BCVA associated with reductions in foveal thickness. Phase III trials to investigate the efficacy of intraocular VEGF Trap-Eye in patients with NVAMD are under way.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009;116:2141-2148 (C) 2009 by the American Academy of Ophthalmology.
C1 [Nguyen, Quan Dong; Shah, Syed Mahmood; Haller, Julia; Do, Diana V.; Campochiaro, Peter A.] Johns Hopkins Wilmer Eye Inst, Baltimore, MD USA.
   [Browning, David J.] Charlotte Eye Ear Nose & Throat Associates, Charlotte, NC USA.
   [Hudson, Henry] Retina Ctr PC, Tucson, AZ USA.
   [Sonkin, Peter] Retina Vitreous Associates PC, Nashville, TN USA.
   [Hariprasad, Seenu M.; Mieler, William F.] Univ Chicago, Chicago, IL 60637 USA.
   [Kaiser, Peter] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
   [Slakter, Jason S.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Chu, Karen; Yang, Ke; Ingerman, Avner; Vitti, Robert L.; Berliner, Alyson J.; Cedarbaum, Jesse M.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Chicago;
   Cleveland Clinic Foundation; Vitreous Retina Macula Consultants of New
   York; Regeneron
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI Shah, Syed/K-2672-2018
OI Kaiser, Peter/0000-0001-5126-045X
FU National Eye Institute [EY 13552]; Regeneron; NATIONAL EYE INSTITUTE
   [K23EY013552] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): QDN is a recipient
   of a K23 Career Development Award (EY 13552) from the National Eye
   Institute. PAC is the George S. and Dolores Dore Eccles Professor of
   Ophthalmology and Neuroscience. QDN is on the Steering Committee for the
   phase 3 studies of VEGF Trap-Eye for NVAMD. PAC is on the Safety and
   Data Monitoring Board for the Regeneron Phase 3 trial of VEGF Trap-Eye
   for NVAMD. but was not during the time frame of this study. QDN and the
   Johns Hopkins University have received research funding from Regeneron
   to support the studies of VEGF Trap-Eye in retinal vascular diseases.
   KC. KY. AI, RV, and JC were employees of Regeneron during the conduct of
   the study, which has a commercial interest in VEGF Trap-Eye. JSS
   received research grant support and travel reimbursement from Regeneron.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carratala J, 2001, CLIN MICROBIOL INFEC, V7, P83, DOI 10.1046/j.1469-0691.2001.00062.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Nguyen QD, 2008, AM J OPHTHALMOL, V145, P257, DOI 10.1016/j.ajo.2007.09.025
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   ZIMMER E, 2006, INVEST OPHTHALMOL VI, V47
NR 13
TC 75
Z9 82
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2009
VL 116
IS 11
BP 2141
EP 2148
DI 10.1016/j.ophtha.2009.04.030
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 512ZQ
UT WOS:000271291600015
PM 19700196
DA 2022-11-30
ER

PT J
AU Leal, S
   Silva, R
   Figueira, J
   Cachulo, ML
   Pires, I
   de Abreu, JRF
   Cunha-Vaz, JG
AF Leal, Sergio
   Silva, Rufino
   Figueira, Joao
   Luz Cachulo, M.
   Pires, Isabel
   Faria de Abreu, Jose Rui
   Cunha-Vaz, Jose Guilherme
TI PHOTODYNAMIC THERAPY WITH VERTEPORFIN IN POLYPOIDAL CHOROIDAL
   VASCULOPATHY Results After 3 Years of Follow-Up
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; photodynamic therapy; verteporfin
ID INDOCYANINE-GREEN VIDEOANGIOGRAPHY; INTRAVITREAL BEVACIZUMAB; MACULAR
   DEGENERATION; NEOVASCULARIZATION
AB Purpose: The purpose of this study was to evaluate the efficacy of verteporfin photodynamic therapy on the treatment of polypoidal choroidal vasculopathy.
   Methods: A prospective, nonrandomized institutional study was conducted involving 42 eyes of 38 patients with newly diagnosed symptomatic polypoidal choroidal vasculopathy treated exclusively with photodynamic therapy. Twenty-seven eyes completed 3 years of follow-up. Subjects were observed every 3 months with evaluation of best-corrected visual acuity (BCVA), retinography, and fluorescein and indocyanine green angiography. Treatment was given whenever the patient exhibited subfoveal exudation on fluorescein angiography.
   Results: Mean BCVA was 0.91 +/- 0.33 logarithm of the minimum angle of resolution on the initial visit and 0.93 +/- 0.39 on the 36-month visit. Patients were submitted to an average of 3.19 treatment sessions. On the final evaluation at 36 months, 14.8% of the treated eyes improved their BCVA by at least 0.3 logarithm of the minimum angle of resolution, 74.1% had no significant loss of BCVA, and 25.9% lost >0.3 logarithm of the minimum angle of resolution. Recurrences were frequent (59.3% of the eyes at 3 years of follow-up), responded well to retreatment, and were not associated with additional BCVA loss.
   Conclusion: Photodynamic therapy remains a good option for management of polypoidal choroidal vasculopathy. After 3 years, approximately three fourths of the treated eyes had no significant loss of vision, and 14.8% showed significant improvement in visual acuity. RETINA 30: 1197-1205, 2010
C1 [Leal, Sergio; Silva, Rufino; Figueira, Joao; Luz Cachulo, M.; Pires, Isabel; Faria de Abreu, Jose Rui; Cunha-Vaz, Jose Guilherme] Univ Hosp Coimbra, Dept Ophthalmol, P-3004567 Coimbra, Portugal.
   [Leal, Sergio; Silva, Rufino; Figueira, Joao; Luz Cachulo, M.; Pires, Isabel; Faria de Abreu, Jose Rui; Cunha-Vaz, Jose Guilherme] AIBILI Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Cunha-Vaz, Jose Guilherme] Univ Coimbra, Ctr Ophthalmol, Inst Biomed Res Light & Image, Fac Med, Coimbra, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra
RP Leal, S (通讯作者)，Univ Hosp Coimbra, Dept Ophthalmol, P-3004567 Coimbra, Portugal.
EM sergiosilvaleal@gmail.com
RI Silva, Rufino M/J-2817-2012
OI Silva, Rufino M/0000-0001-8676-0833; Pires, Isabel/0000-0002-5764-0178;
   Cunha-Vaz, Jose/0000-0002-0947-9850; Figueira, Joao
   P/0000-0002-3511-1515; Cachulo, Maria Luz/0000-0002-0900-4548
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   HUSSAIN N, 2005, INDIAN OPHTHALMOL, V52, P529
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 19
TC 47
Z9 55
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2010
VL 30
IS 8
BP 1197
EP 1205
DI 10.1097/IAE.0b013e3181d37486
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 647JF
UT WOS:000281614100008
PM 20827139
DA 2022-11-30
ER

PT J
AU Visser, MS
   Amarakoon, S
   Missotten, T
   Timman, R
   Busschbach, JJ
AF Visser, Martijn S.
   Amarakoon, Sankha
   Missotten, Tom
   Timman, Reinier
   Busschbach, Jan J.
TI SF-6D utility values for the better- and worse-seeing eye for health
   states based on the Snellen equivalent in patients with age-related
   macular degeneration
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; VISION-RELATED FUNCTION;
   RANDOMIZED CLINICAL-TRIAL; RANIBIZUMAB TREATMENT; EQ-5D; RESPONSIVENESS;
   POPULATION; ACUITY
AB Objective
   Economic evaluations in wet age-related macular degeneration (ARMD) is hampered as often utility values for solely one eye are used, mostly the better-seeing eye (BSE). Moreover, frequently chosen methods rely on patient values and/or disease specific measures, while economic evaluations prefer generic quality of life (QoL) measures based on societal preferences. The generic QoL utility instrument EQ-5D has shown to be insensitive for differences in visual acuity. The aim of this study was therefore to provide societal utility values, using the generic SF-6D, for health states acknowledging both BSE and worse-seeing eye (WSE).
   Methods
   SF-6D utility values of 191 ARMD patients (>= 65 years) with 153 follow-up measures at 1 year were used to fill health states defined by the combination of BSE and WSE using Snellen equivalents; no visual loss (>= 20/40), mild-moderate (<20/40 -> 20/200) and severe (<= 20/200).
   Results
   QoL utilities were estimated for the SF-6D, ranging from 0.740 for ARMD patients without visual loss to 0.684 for patients with a combination of mild-moderate visual loss in their BSE and severe visual loss in their WSE.
   Conclusion
   Societal utility values are provided for ARMD patients using the generic QoL instrument SF-6D for visual acuity health states based on both BSE and WSE. The range of the values is smaller than previous elicited utilities with the disease-specific VisQoL. Besides, the utility values are placed on a more realistic position on the utility scale, and SF-6D utility values avoid the problem associated with the interpretation of disease-specific utility values.
C1 [Visser, Martijn S.; Amarakoon, Sankha; Missotten, Tom] Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
   [Visser, Martijn S.; Timman, Reinier; Busschbach, Jan J.] Erasmus MC, Dept Psychiat, Sect Med Psychol & Psychotherapy, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC
RP Visser, MS (通讯作者)，Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
EM m.s.visser@erasmusmc.nl
RI Busschbach, Jan/P-1584-2019
OI Busschbach, Jan/0000-0002-8602-0381
FU Foundation for scientific research of the Rotterdam Eye Hospital
   (SWOO-Flieringa); Stichting voor Ooglijders Rotterdam; Theia foundation
   [2010157]; CZ foundation [AFVV09-168]
FX This work was financially supported by the Foundation for scientific
   research of the Rotterdam Eye Hospital (SWOO-Flieringa); the Stichting
   voor Ooglijders Rotterdam; the Theia foundation (grant number: 2010157)
   and the CZ foundation (grant number: AFVV09-168). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Bozzani FM, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-43
   Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8
   Brazier J, 2004, HEALTH ECON, V13, P873, DOI 10.1002/hec.866
   Brazier J, 2012, EUR J HEALTH ECON, V13, P575, DOI 10.1007/s10198-011-0352-9
   Brazier J, 2010, HEALTH ECON, V19, P125, DOI 10.1002/hec.1580
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Drummond MF, 2015, METHODS FOR THE ECON
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Finger RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081042
   Fryback DG, 1997, MED DECIS MAKING, V17, P276, DOI 10.1177/0272989X9701700303
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090
   Luo N, 2005, MED CARE, V43, P1078, DOI 10.1097/01.mlr.0000182493.57090.c1
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Miskala PH, 2004, AM J OPHTHALMOL, V137, P961, DOI 10.1016/j.ajo.2003.11.018
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Richardson J, 2012, OPHTHAL EPIDEMIOL, V19, P172, DOI 10.3109/09286586.2012.674613
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Stolk EA, 2003, QUAL LIFE RES, V12, P363, DOI 10.1023/A:1023453405252
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   Visser MS, 2016, HIGH INJECTION FREQU
   Ware Jr JE, 1993, SF 36 HEALTH SURVEY
   1991, OPHTHALMOLOGY S, V98, P741, DOI DOI 10.1001/ARCHOPHT.125.7.945
NR 30
TC 3
Z9 3
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 22
PY 2017
VL 12
IS 2
AR e0169816
DI 10.1371/journal.pone.0169816
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Science & Technology - Other Topics
GA EL5SK
UT WOS:000394680900003
PM 28225799
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Duan, QC
   Gao, YR
   Cao, XX
   Wang, SL
   Xu, MM
   Jones, OD
   Xu, XH
AF Duan, Qinchun
   Gao, Yuru
   Cao, Xixi
   Wang, Shulin
   Xu, Meng Meng
   Jones, Odell D.
   Xu, Xuehong
TI Mosaic loss of chromosome Y in peripheral blood cells is associated with
   age-related macular degeneration in men
SO CELL AND BIOSCIENCE
LA English
DT Article
DE Age-related macular degeneration (AMD); Mosaic loss of Y chromosome
   (mLOY); Hematopoietic stem cells (hSC); Monocyte-macrophage
   differentiation system; Mitosis; meiosis
ID MACROPHAGES; DISEASE
AB Background Age-related macular degeneration (AMD) is the leading cause of severe vision loss in patients over 55 years old in the industrialized world. In the past 20 years, approximately 288 million patents have been affected by this disease. Despite this high prevalence, the molecular mechanism for AMD remains unclear, and there remains no effective treatment for this disease. The mosaic loss of Y chromosome (mLOY) has been identified as a common phenomenon in multiple age-related disease (i.e., oncogenesis and cardiovascular disease) has recently been identified by genome-wide analysis to be linked to AMD as well. As the Y chromosome mainly possesses three genomic functions, sister chromatin cohesion, cell cycle mitosis, and apoptotic signaling, here we characterize the Y chromosome euchromatic genes and non-chromosome AMD genes in relevance to cellular proliferation and apoptotic signaling of leukocytes. Results Using STRING, a publically available database of all protein-protein interaction, Grassmann et al. found the genes on the Y chromosome is mainly believed to take part in three major cellular genomic functions- sister chromatin cohesion, cell cycle mitosis, and apoptotic signaling. Based on data from the Ensembl Genome database, we focus on our discussion on coding genes found in the euchromatins but not the PAR1 and PAR2 regions of the Y chromosomes. All 14 known euchromatic genes on the Y chromosome short arm and all 31 known euchromatic genes on the Y chromosome long arm (Yq) are directly or indirectly involved in the cell cycle (meiosis and mitosis) and proliferation. We sorted non-Y chromosome AMD associated genes into these three categories to identify signaling pathways that may compound with cellular dysregulation due to mLOY. Of the genes associated with AMD, complement pathway genes such as C2, C9 and CFH/ARMD4 are associated with proliferation, receptor-mediated endocytosis genes such as APOE, DAB2 and others associated with apoptotic signaling. Because nucleated cells found in peripheral circulation are mainly composed of leukocytes with reduced expression of CD99, a protein essential for leukocytes adhesion, translocation, and function, mLOY in these cells likely affect retinal degeneration through altered immunological surveillance. In fact, there is precedence that circulating macrophage can stabilize and modify the cardiac rhythm and contractility post ischemic damage. Therefore, the most likely mechanism through which peripheral mLOY affects AMD development in men is through the role affected leukocytes play in retinal proliferation and apoptosis. Conclusions mLOY in peripheral blood is newly discovered in AMD by Grassmann et al. as it is a common phenomenon in oncogenesis and cardiac dysfunction. Here the recent data conclude the possible mechanism for the newly identified link between mLOY and AMD, and provide support that mLOY in circulating macrophage-monocyte of affected male patients promotes AMD by targeting the retina and causing macular degeneration.
C1 [Duan, Qinchun; Gao, Yuru; Cao, Xixi; Wang, Shulin] Shaanxi Normal Univ, Coll Life Sci, Lab Cell Biol Genet & Dev Biol, West Changan 620, Xian 710119, Peoples R China.
   [Duan, Qinchun; Gao, Yuru; Cao, Xixi; Wang, Shulin; Xu, Xuehong] Univ Hosp Med Ctr, West Changan 620, Xian 710119, Peoples R China.
   [Xu, Meng Meng] Columbia Univ, Morgan Stanley Childrens Hosp, Dept Pediat, 3959 Broadway, New York, NY 10032 USA.
   [Jones, Odell D.] Univ Penn, Sch Med, ULAR, Philadelphia, PA 19144 USA.
   [Xu, Xuehong] Shaanxi Normal Univ, Univ Hosp Med Ctr, Coll Life Sci, Xian 710062, Peoples R China.
C3 Shaanxi Normal University; Columbia University; NewYork-Presbyterian
   Hospital; Morgan Stanley Children's Hospital; University of
   Pennsylvania; Shaanxi Normal University
RP Xu, MM (通讯作者)，Columbia Univ, Morgan Stanley Childrens Hosp, Dept Pediat, 3959 Broadway, New York, NY 10032 USA.; Xu, XH (通讯作者)，Shaanxi Normal Univ, Univ Hosp Med Ctr, Coll Life Sci, Xian 710062, Peoples R China.
EM mex9002@nyp.org; xhx0708@snnu.edu.cn
FU National Natural Science Foundation of China [31771377, 31571273,
   31371256]; Foreign Distinguished Scientist Program [MS2014SXSF038];
   National Department of Education Central Universities Research Fund
   [GK201301001, 201701005, GERP-17-45]; US Maryland Stem Cell Research
   Fund [2009MSCRFE008300]; Outstanding Doctoral Thesis Fund [X2014YB02,
   X2015YB05]; Medical Scientist Training Program (MSPT) NIH
FX This work was supported by the National Natural Science Foundation of
   China (#31771377/31571273/31371256), the Foreign Distinguished Scientist
   Program (#MS2014SXSF038), the National Department of Education Central
   Universities Research Fund (#GK201301001/201701005/GERP-17-45), US
   Maryland Stem Cell Research Fund (2009MSCRFE008300), and the Outstanding
   Doctoral Thesis Fund (#X2014YB02/X2015YB05). The partial collection of
   references for this article is supported by the Medical Scientist
   Training Program (MSPT) NIH to MMX.
CR Aurora AB, 2014, J CLIN INVEST, V124, P1382, DOI 10.1172/JCI72181
   Charchar FJ, 2012, LANCET, V379, P915, DOI 10.1016/S0140-6736(11)61453-0
   Dumanski JP, 2021, CELL MOL LIFE SCI, V78, P4019, DOI 10.1007/s00018-021-03822-w
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Forsberg LA, 2019, EUR J HUM GENET, V27, P17, DOI 10.1038/s41431-018-0261-9
   Forsberg LA, 2017, NAT REV GENET, V18, P128, DOI 10.1038/nrg.2016.145
   Grassmann F, 2020, HUM GENET, V139, P401, DOI 10.1007/s00439-019-02029-1
   Grassmann F, 2019, EUR J HUM GENET, V27, P36, DOI 10.1038/s41431-018-0238-8
   Hulsmans M, 2017, CELL, V169, P510, DOI 10.1016/j.cell.2017.03.050
   Mattisson J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94588-5
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Vogt PH, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00551-2
   Wright DJ, 2017, NAT GENET, V49, P674, DOI 10.1038/ng.3821
NR 13
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045-3701
J9 CELL BIOSCI
JI Cell Biosci.
PD MAY 31
PY 2022
VL 12
IS 1
AR 73
DI 10.1186/s13578-022-00811-9
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 1S4TD
UT WOS:000804043700007
PM 35642040
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Banister, K
   Cook, JA
   Scotland, G
   Azuara-Blanco, A
   Goulao, B
   Heimann, H
   Hernandez, R
   Hogg, R
   Kennedy, C
   Sivaprasad, S
   Ramsay, C
   Chakravarthy, U
AF Banister, Katie
   Cook, Jonathan A.
   Scotland, Graham
   Azuara-Blanco, Augusto
   Goulao, Beatriz
   Heimann, Heinrich
   Hernandez, Rodolfo
   Hogg, Ruth
   Kennedy, Charlotte
   Sivaprasad, Sobha
   Ramsay, Craig
   Chakravarthy, Usha
CA EDNA Study Grp
TI Non-invasive testing for early detection of neovascular macular
   degeneration in unaffected second eyes of older adults: EDNA diagnostic
   accuracy study
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; QUALITY-OF-LIFE; EVALUATING FLUORESCEIN
   ANGIOGRAMS; STATE UTILITY VALUES; CHOROIDAL NEOVASCULARIZATION;
   COST-EFFECTIVENESS; REGRESSION-ANALYSIS; PREDICTION MODEL; SEVERITY
   SCALE; CLINICAL-TRIAL
AB Background: Neovascular age-related macular degeneration is a leading cause of sight loss, and early detection and treatment is important. For patients with neovascular age-related macular degeneration in one eye, it is usual practice to monitor the unaffected eye. The test used to diagnose neovascular age-related macular degeneration, fundus fluorescein angiography, is an invasive test. Non-invasive tests are available, but their diagnostic accuracy is unclear. Objectives: The primary objective was to determine the diagnostic monitoring performance of tests for neovascular age-related macular degeneration in the second eye of patients with unilateral neovascular age-related macular degeneration. The secondary objectives were the cost-effectiveness of tests and to identify predictive factors of developing neovascular age-related macular degeneration. Design: This was a multicentre, prospective, cohort, comparative diagnostic accuracy study in a monitoring setting for up to 3 years. A Cox regression risk prediction model and a Markov microsimulation model comparing cost-effectiveness of the index tests over 25 years were used. Setting: This took place in hospital eye services. Participants: Participants were adults (aged 50-95 years) with newly diagnosed (within the previous 6 weeks) neovascular age-related macular degeneration in one eye and an unaffected second (study) eye who were attending for treatment injections in the first eye and who had a study eye baseline visual acuity of >= 68 Early Treatment Diabetic Retinopathy Study letters. Interventions: The index tests were Amsler chart (completed by participants), fundus clinical examination, optical coherence tomography, self-reported vision assessment (completed by participants) and visual acuity. The reference standard was fundus fluorescein angiography.
C1 [Banister, Katie; Scotland, Graham; Goulao, Beatriz; Ramsay, Craig] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland.
   [Cook, Jonathan A.] Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed, Oxford, England.
   [Scotland, Graham; Hernandez, Rodolfo; Kennedy, Charlotte] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland.
   [Azuara-Blanco, Augusto; Hogg, Ruth; Chakravarthy, Usha] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Heimann, Heinrich] Liverpool Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England.
   [Sivaprasad, Sobha] Moorfields Eye Hosp NHS Fdn Trust, Moorfields Biomed Res Ctr, Natl Inst Hlth Res, London, England.
C3 University of Aberdeen; University of Oxford; University of Aberdeen;
   Queens University Belfast; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Ramsay, Craig/AAD-8249-2021; Cook, Jonathan/D-3648-2015
OI Ramsay, Craig/0000-0003-4043-7349; Cook, Jonathan/0000-0002-4156-6989;
   Azuara-Blanco, Augusto/0000-0002-4805-9322; Kennedy,
   Charlotte/0000-0002-1974-6318; Banister, Kathryn
   Ruth/0000-0002-2189-3755; Hernandez, Rodolfo/0000-0003-2619-8230;
   Goulao, Beatriz/0000-0003-1490-7183; Sivaprasad,
   Sobha/0000-0001-8952-0659; Hogg, Ruth/0000-0001-9413-2669
FU National Institute for Health Research (NIHR) Health Technology
   Assessment programme [8]
FX This project was funded by the National Institute for Health Research
   (NIHR) Health Technology Assessment programme and will be published in
   full in Health Technology Assessment; Vol. 26, No. 8. See the NIHR
   Journals Library website for further project information.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Azuara-Blanco A, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20080
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1136/bmj.h5527, 10.1373/clinchem.2015.246280, 10.1148/radiol.2015151516]
   Briggs ADM, 2016, POPUL HEALTH METR, V14, DOI 10.1186/s12963-016-0085-1
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Burns A., 2019, UNIT COSTS HLTH SOCI
   Butt T, 2017, APPL HEALTH ECON HEA, V15, P23, DOI 10.1007/s40258-016-0275-9
   Butt T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006535
   Butt T, 2015, BRIT J OPHTHALMOL, V99, P540, DOI 10.1136/bjophthalmol-2014-305802
   Butt T, 2013, OPTOMETRY VISION SCI, V90, P855, DOI 10.1097/OPX.0b013e3182962318
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2019, OPHTHALMOL RETINA, V3, P920, DOI 10.1016/j.oret.2019.06.012
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Claxton L, 2017, PHARMACOECONOMICS, V35, P237, DOI 10.1007/s40273-016-0459-z
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   COX DR, 1957, J AM STAT ASSOC, V52, P543, DOI 10.2307/2281704
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Department of Health and Social Care (DHSC), 2010, ACHIEVING WORLD CLAS
   Dixon P, 2016, QUAL LIFE RES, V25, P935, DOI 10.1007/s11136-015-1145-x
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Evans RN, 2020, OPHTHALMOLOGY, V127, P1191, DOI 10.1016/j.ophtha.2020.03.020
   Feigl B, 2011, CURR MED RES OPIN, V27, P1745, DOI 10.1185/03007995.2011.603301
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Friberg TR, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.02.048
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Healthcare Quality Improvement Partnership, 2018, OPTH NAT EL AG REL M
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Hodgson R, 2017, ADV THER, V34, P2360, DOI 10.1007/s12325-017-0620-x
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Information Services Division Scotland, OUTP SPEC COSTS 2018
   ISD Scotland, 2019, SCOTT HLTH SERV COST
   ISRCTN Registry, 2019, OBS STUD FOLL PAT NE, DOI [10.1186/ISRCTN76889861, DOI 10.1186/ISRCTN76889861]
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Joint Formulary Committee, 2020, BRIT NATL FORMULARY
   Kappen Teus H, 2018, Diagn Progn Res, V2, P11, DOI 10.1186/s41512-018-0033-6
   Karnon J, 2008, HEALTH TECHNOL ASSES, V12, P2
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Lamin A, 2020, OPHTHALMIC RES, V63, P375, DOI 10.1159/000505628
   Lamin A, 2019, EYE, V33, P910, DOI 10.1038/s41433-019-0338-x
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Medical Advisory Secretariat, 2009, Ont Health Technol Assess Ser, V9, P1
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698
   Mowatt G, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18690
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR
   National Institute for Health and Care Excellence (NICE), 2018, AGE RELATED MACULAR
   National Institute for Health and Care Excellence (NICE), 2012, RAN PEG TREATM AG RE
   National Institute for Health and Care Excellence (NICE), 2014, AFL SOL INJ TREAT WE
   Newcombe RG, 1998, STAT MED, V17, P2635, DOI 10.1002/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.3.CO;2-3
   NHS England, 2020, NAT SCHED NHS COSTS
   Obuchowski NA, 1998, STAT MED, V17, P1495, DOI 10.1002/(SICI)1097-0258(19980715)17:13<1495::AID-SIM863>3.0.CO;2-I
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Parikh R, 2019, JAMA OPHTHALMOL, V137, P914, DOI 10.1001/jamaophthalmol.2019.1947
   Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8
   PEPE MS, 1994, COMMUN STAT SIMULAT, V23, P939, DOI 10.1080/03610919408813210
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Pi-Sunyer FX, 1998, OBES RES, V6, p51S
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Roberts PK, 2017, BRIT J OPHTHALMOL, V101, P1361, DOI 10.1136/bjophthalmol-2016-310004
   Rochon J, 1998, STAT MED, V17, P1643, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1643::AID-SIM869>3.0.CO;2-3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists, 2014, CONS OPHTH GUID JOB
   Sangroongruangsri S, 2018, EXPERT REV CLIN PHAR, V11, P903, DOI 10.1080/17512433.2018.1507735
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sivaprasad S, 2021, OPHTHALMOLOGY, V128, P1736, DOI 10.1016/j.ophtha.2021.07.025
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P40, DOI 10.1001/archophthalmol.2010.328
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sternberg MR, 2001, STAT MED, V20, P1529, DOI 10.1002/sim.688
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   The College of Optometrists The Royal College of Ophthalmologists, 2013, COMM BETT EYE CAR
   The Royal College of Ophthalmologists, 2013, AGE RELATED MACULAR
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Calster B, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1466-7
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zayit-Soudry S, 2007, RETINA-J RET VIT DIS, V27, P798, DOI 10.1097/IAE.0b013e31802c50a3
   Zhou X. H., 2002, STAT METHODS DIAGNOS, DOI [10.1002/9780470317082, DOI 10.1002/9780470317082]
NR 128
TC 1
Z9 1
U1 3
U2 4
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD JAN
PY 2022
VL 26
IS 8
DI 10.3310/VLFL1739
PG 176
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA YU9RU
UT WOS:000752373300001
PM 35119357
OA Green Published
DA 2022-11-30
ER

PT J
AU Tarakcioglu, HN
   Ozkaya, A
   Kemer, B
   Taskapili, M
AF Tarakcioglu, H. N.
   Ozkaya, A.
   Kemer, B.
   Taskapili, M.
TI Multimodal imaging based biomarkers predictive of early and late
   response to anti-VEGFs during the first year of treatment for
   neovascular age-related macular degeneration
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Fluorescein angiography;
   Optical coherence tomography; Ranibizumab
ID INTRAVITREAL RANIBIZUMAB; CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY;
   AFLIBERCEPT; VERTEPORFIN; INJECTION; OUTCOMES; EYES
AB Purpose. - To evaluate baseline predictive markers of early and late anatomical response to anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with neovascular age related macular degeneration (nAMD).
   Methods. - The records of the nAMD patients who underwent intravitreal ranibizumab or aflibercept treatment, received the 3 monthly loading doses, and completed a follow-up period of 12 months were included retrospectively. The anatomical treatment response at month 3 (early) and between month 3 and 12 (late) was classified as good, intermediate or poor. Baseline demographic, fluorescein angiography, and optical coherence tomography findings were compared among the three groups.
   Results. - One hundred and ten eyes (74.3%) showed good, 18 (12.2%) showed intermediate and 20 (13.5%) showed poor anatomical response at month 3, and 114 eyes (77.0%) showed good, 27 (18.2%) showed intermediate and 7 (4.7%) showed poor anatomical response between month 3 and month 12. Of the evaluated parameters, drug type (better in aflibercept), showed a statistically significant difference in regards to anatomical outcomes at both the early and late periods (P = 0.02 and P = 0.03). The greatest linear dimension of choroidal neovascularization (CNV) and presence of peaked pigment epithelial detachment (PED) were important factors for early anatomical anti-VEGF treatment response.
   Conclusion. - Larger CNV and the presence of a peaked PED appeared to be associated with a good early response, and the drug type seemed to be associated with both early and late poor anatomical response of anti-VEGF treatment in nAMD patients. Aflibercept appears to be more effective than ranibizumab in regards to the percentage of patients with better anatomical response in both the early and late treatment periods. (C) 2018 Elsevier Masson SAS. All rights reserved.
C1 [Tarakcioglu, H. N.; Ozkaya, A.; Kemer, B.; Taskapili, M.] Beyoglu Eye Training & Res Hosp, TR-34421 Istanbul, Turkey.
C3 Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research Hospital
RP Ozkaya, A (通讯作者)，Beyoglu Eye Training & Res Hosp, TR-34421 Istanbul, Turkey.
EM abdozkaya@gmail.com
RI tarakçıoğlu, hatice nur/ABB-5178-2020
OI tarakçıoğlu, hatice nur/0000-0002-8611-4353
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chauvaud D, 2002, J FR OPHTALMOL, V25, P756
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Donati G, 2007, J FR OPHTALMOL, V30, P837, DOI 10.1016/S0181-5512(07)92619-4
   Donati G, 2002, J FR OPHTALMOL, V25, P740
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Kapran Z, 2013, OSLI RETINA, V44, P471, DOI 10.3928/23258160-20130909-09
   Kawashima Y, 2017, AM J OPHTHALMOL, V181, P61, DOI 10.1016/j.ajo.2017.06.015
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Kolb S, 2012, KLIN MONATSBL AUGENH, V229, P343, DOI 10.1055/s-0031-1299250
   Leveziel N, 2009, J FR OPHTALMOL, V32, P440, DOI 10.1016/j.jfo.2009.04.009
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Ozkaya A, 2014, J FR OPHTALMOL, V37, P280, DOI 10.1016/j.jfo.2013.08.006
   Ozkaya A, 2013, ISRN OPTHALMOL, V28, P895
   Pichi F, 2018, INT OPHTHALMOL, V38, P975, DOI 10.1007/s10792-017-0547-x
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   TORNAMBE PE, 1992, RETINA-J RET VIT DIS, V12, P305, DOI 10.1097/00006982-199212040-00003
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
NR 24
TC 2
Z9 2
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD JAN
PY 2019
VL 42
IS 1
BP 22
EP 31
DI 10.1016/j.jfo.2018.06.005
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HH4BN
UT WOS:000455665200010
PM 30578008
DA 2022-11-30
ER

PT J
AU Carrasco, J
   Daien, V
   Eldem, BM
   Spoorendonk, JA
   Yoon, J
AF Carrasco, Joao
   Daien, Vincent
   Eldem, Bora M.
   Spoorendonk, Jelle A.
   Yoon, Jisu
TI 2-Year Real-World Outcomes with Intravitreal Aflibercept in Neovascular
   Age-Related Macular Degeneration: Literature Review and Meta-analysis of
   Patient-Relevant Outcomes
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Age-related macular degeneration; Intravitreal aflibercept; Patient
   outcomes; Real-world outcomes; Treatment burden
ID RANIBIZUMAB; EFFICACY
AB Background The 96 weeks' assessment from the VIEW studies provided insights into the long-term efficacy of intravitreal aflibercept (IVT-AFL) in neovascular age-related macular degeneration (nAMD) and demonstrated that it was possible to maintain long-term outcomes while moving from a fixed bimonthly regimen in Year 1 to a variable dosing regimen in Year 2. The aim of this analysis was to perform a literature review and meta-analysis assessing the use of IVT-AFL and real-world outcomes in treatment-naive patients with nAMD treated with IVT-AFL for 2 years, as per label. Methods A literature review and meta-analysis were performed to provide an overview of the baseline characteristics of the population, the 2-year outcomes, the associated treatment burden, and safety. Results Eleven publications providing data from patients with nAMD who had treatment initiated with IVT-AFL between 2012 and 2016 were identified. The mean baseline age of patients was 78.62 years, with a baseline best-corrected visual acuity (BCVA) of 57.73 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Patients reported a mean BCVA at 2 years of 62.55 ETDRS letters, with 47.39% of patients having a BCVA >= 70 ETDRS letters. Mean gain in BCVA versus baseline was + 4.49 ETDRS letters for the combined population (+ 5.91 letters for patients treated with a treat-and-extend regimen). Over the 2 years of the study, patients received an average of 12.34 injections, with a reduction in injections in Year 2 versus Year 1. The qualitative assessment of the safety data suggested that no new safety signals were identified. Conclusion Patients treated with IVT-AFL reported significant gains in visual acuity versus baseline after 2 years. The evidence identified indicates that the visual gains achieved during the first year of treatment are maintained through the second year and that these were achieved with a reduction in the mean number of IVT-AFL injections administered in Year 2 of treatment.
C1 [Carrasco, Joao] Bayer Consumer Care AG, Pharmaceut, Peter Merian Str 84, CH-4052 Basel, Switzerland.
   [Daien, Vincent] Gui Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Eldem, Bora M.] Hacettepe Univ, Fac Med, Ophthalmol Dept, Ankara, Turkey.
   [Spoorendonk, Jelle A.] OPEN Hlth Co, Pharmerit Int, Rotterdam, Netherlands.
   [Yoon, Jisu] OPEN Hlth Co, Pharmerit Int, Berlin, Germany.
C3 Bayer AG; Universite de Montpellier; CHU de Montpellier; University of
   Sydney; Hacettepe University
RP Carrasco, J (通讯作者)，Bayer Consumer Care AG, Pharmaceut, Peter Merian Str 84, CH-4052 Basel, Switzerland.
EM joao.carrasco@bayer.com
OI Carrasco, Joao/0000-0001-7084-2674
FU Bayer Consumer Care AG, Basel, Switzerland; Bayer Consumer Care AG
FX This research was funded by Bayer Consumer Care AG, Basel, Switzerland.
   Bayer Consumer Care AG is also responsible for funding the journal's
   Rapid Service and Open Access Fees.
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buuren S., 2011, J STAT SOFTW, V45, P1, DOI DOI 10.18637/JSS.V045.I03
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Centre for Reviews and Dissemination, 2006, SYSTEMATIC REV CRDS
   Chatziralli I, 2018, EYE, V32, P1523, DOI 10.1038/s41433-018-0114-3
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   European Medicines Agency, AFL SUMM PROD CHAR
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2021, ACTA OPHTHALMOL, V99, P604, DOI 10.1111/aos.14698
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P567, DOI 10.1089/jop.2017.0031
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Mekjavic PJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1005-x
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sedgwick P, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4419
   Shamsher E, 2019, ACTA OPHTHALMOL, V97, DOI 10.1111/j.1755-3768.2019.5445
   Siempis Thomas, 2019, Oman J Ophthalmol, V12, P99, DOI 10.4103/ojo.OJO_24_2018
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   TURNER R, 2013, J CLIN EPIDEMIOL, V8
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
NR 41
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD SEP
PY 2021
VL 10
IS 3
BP 397
EP 411
DI 10.1007/s40123-021-00350-5
EA JUN 2021
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TR1YM
UT WOS:000656761400001
PM 34075564
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Fasler, K
   Moraes, G
   Wagner, S
   Kortuem, KU
   Chopra, R
   Faes, L
   Preston, G
   Pontikos, N
   Fu, DJ
   Patel, P
   Tufail, A
   Lee, AY
   Balaskas, K
   Keane, PA
AF Fasler, Katrin
   Moraes, Gabriella
   Wagner, Siegfried
   Kortuem, Karsten U.
   Chopra, Reena
   Faes, Livia
   Preston, Gabriella
   Pontikos, Nikolas
   Fu, Dun Jack
   Patel, Praveen
   Tufail, Adnan
   Lee, Aaron Y.
   Balaskas, Konstantinos
   Keane, Pearse A.
TI One- and two-year visual outcomes from the Moorfields age-related
   macular degeneration database: a retrospective cohort study and an open
   science resource
SO BMJ OPEN
LA English
DT Article
ID EXTEND INTRAVITREAL THERAPY; GROWTH-FACTOR THERAPY; ACUITY OUTCOMES;
   NEOVASCULAR AMD; RANIBIZUMAB; AFLIBERCEPT; TREAT
AB Objectives To analyse treatment outcomes and share clinical data from a large, single-centre, well-curated database (8174 eyes/6664 patients with 120 756 single entries) of patients with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (VEGF). By making our depersonalised raw data openly available, we aim to stimulate further research in AMD, as wet as set a precedent for future work in this area.
   Setting Retrospective, comparative, non-randomised electronic medical record (EMR) database cohort study of the UK Moorfields AMD database with data extracted between 2008 and 2018.
   Participants Including one eye per patient, 3357 eyes/patients (61% female). Extraction criteria were ranibizumab or aflibercept injection, entry of 'AMD' in the diagnosis field of the EMR and a minimum of 1 year of follow-up. Exclusion criteria were unknown date of first injection and treatment outside of routine clinical care at Moorfields before the first recorded injection in the database.
   Main outcome measures Primary outcome measure was change in VA at 1 and 2 years from baseline as measured in Early Treatment Diabetic Retinopathy Study letters. Secondary outcomes were the number of injections and predictive factors for VA gain.
   Results Mean VA gain at 1 year and 2 years were +5.5 (95% CI 5.0 to 6.0) and +4.9 (95% CI 4.2 to 5.6) letters, respectively. Fifty-four per cent of eyes gained >= 5 letters at 2 years, 63% had stable VA (-14 letters), 44% of eyes maintained good VA (70 letters). Patients received a mean of 7.7 (95% CI 7.6 to 7.8) injections during year 1 and 13.0 (95% CI 12.8 to 13.2) injections over 2 years. Younger age, lower baseline VA and more injections were associated with higher VA gain at 2 years.
   Conclusion This study benchmarks high quality EMR study results of real life AMD treatment and promotes open science in clinical AMD research by making the underlying data publicly available.
C1 [Fasler, Katrin; Moraes, Gabriella; Wagner, Siegfried; Kortuem, Karsten U.; Chopra, Reena; Faes, Livia; Preston, Gabriella; Pontikos, Nikolas; Fu, Dun Jack; Patel, Praveen; Tufail, Adnan; Balaskas, Konstantinos; Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Fasler, Katrin] Univ Spital Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Kortuem, Karsten U.] Klinikum Univ Munchen, Augenklin, Munich, Germany.
   [Faes, Livia] Luzerner Kantonsspital Zentrumsspital, Augenklin, Luzern, Switzerland.
   [Lee, Aaron Y.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Balaskas, Konstantinos] Univ Manchester, Sch Biol Sci, Manchester, Lancs, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Zurich; University Zurich Hospital;
   University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Munich; University of Washington; University of Washington
   Seattle; University of Manchester
RP Keane, PA (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
EM pearse.keane1@nhs.net
RI Balaskas, Konstantinos/ABD-5979-2020; Pontikos, Nikolas/U-3642-2018
OI Balaskas, Konstantinos/0000-0002-7690-6277; Pontikos,
   Nikolas/0000-0003-1782-4711; Lee, Aaron/0000-0002-7452-1648; Keane,
   Pearse/0000-0002-9239-745X; Tufail, Adnan/0000-0001-6131-7640
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of
   Ophthalmology; Alfred Vogt Stipendium; Schweizerischer Fonds zur
   Verhutung und Bekampfung der Blindheit; NATIONAL EYE INSTITUTE
   [K23EY029246] Funding Source: NIH RePORTER
FX The research supported by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology. The views expressed
   are those of the author(s) and not necessarily those of the NHS, the
   NIHR or the Department of Health. Dr. Fasler has received fellowship
   support from Alfred Vogt Stipendium and Schweizerischer Fonds zur
   Verhutung und Bekampfung der Blindheit.
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   COHEN D, 2015, BMJ-BRIT MED J, V350, DOI [DOI 10.1136/BMJ.H1654, DOI 10.1136/bmj.h1654]
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Denaxas S, 2017, BIODATA MIN, V10, DOI 10.1186/s13040-017-0151-7
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Hambleton D, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5013
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Kilkenny MF, 2018, HEALTH INF MANAG J, V47, P103, DOI 10.1177/1833358318774357
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Ozturk M, 2018, CLIN EXP OPHTHALMOL, V46, P407, DOI 10.1111/ceo.13085
   Packer M, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k510
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
NR 33
TC 21
Z9 21
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD JUN
PY 2019
VL 9
IS 6
AR e027441
DI 10.1136/bmjopen-2018-027441
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ND7XT
UT WOS:000562117100122
PM 31230012
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Cheng, CK
   Peng, CH
   Chang, CK
   Hu, CC
   Chen, LJ
AF Cheng, Cheng-Kuo
   Peng, Chi-Hsien
   Chang, Chun-Kai
   Hu, Chao-Chien
   Chen, Lee-Jen
TI ONE-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR
   POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; Avastin; polypoidal choroidal vasculopathy; age-related
   macular degeneration; vascular endothelial growth factor; intravitreal;
   Taiwan; Chinese
ID OPTICAL COHERENCE TOMOGRAPHY; EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL
   GROWTH-FACTOR; PHOTODYNAMIC THERAPY; INDOCYANINE GREEN; LASER
   PHOTOCOAGULATION; NEOVASCULAR MEMBRANES; MACULAR DEGENERATION;
   RANIBIZUMAB; VERTEPORFIN
AB Purpose: To report on 1-year visual, anatomical, and angiographic responses with intravitreal bevacizumab for the treatment of polypoidal choroidal vasculopathy.
   Methods: Patients with macula-involved, symptomatic polypoidal choroidal vasculopathy with initial best-corrected visual acuity of 20/400 or better and a minimal follow-up period of 12 months were retrospectively enrolled. Eyes were treated with intravitreal bevacizumab (2.5 mg) at baseline and monitored monthly for best-corrected visual acuity and central retinal thickness (by optical coherence tomography). Indocyanine green angiography was evaluated on a 6-month basis. Eyes were retreated on an "as-needed'' basis according to visual and anatomical changes.
   Results: A total of 35 eyes of 33 patients were treated with a mean of 3.3 (range, 1-8) times of injection. Best-corrected visual acuity significantly improved from a mean logarithm of the minimum angle of resolution of 0.79 +/- 0.42 at baseline (Snellen equivalent, 20/123) to 0.69 +/- 0.47 (20/94), 0.66 +/- 0.45 (20/87), 0.67 +/- 0.44 (20/87), 0.67 +/- 0.48 (20/87), and 0.67 +/- 0.51 (20/87) at 1, 3, 6, 9, and 12 months, respectively (P = 0.002, 0.0003, 0.0008, 0.017, and 0.02, respectively; paired Student's t-test). Central retinal thickness also significantly improved from a mean of 297 +/- 94 mu m at baseline to 215 +/- 58 mu m, 214 +/- 59 mu m, 218 +/- 79 mu m, 213 +/- 75 mu m, and 221 +/- 61 mu m at 1, 3, 6, 9, and 12 months, respectively (all P < 0.0001, paired Student's t-test). Indocyanine green angiography showed 3 of 32 eyes (9.4%) and 5 of 31 eyes (16.1%) with completely resolved polyps and 11 of 32 eyes (34.4%) and 10 of 31 eyes (32.3%) with reduced polyps at 6 and 12 months, respectively. No systemic complication or severe local complication, such as endophthalmitis, was found.
   Conclusion: Intravitreal bevacizumab therapy has a favorable outcome in improving visual acuity and macular exudative changes in patients with polypoidal choroidal vasculopathy. It can also moderately reduce polypoidal lesions on indocyanine green angiography. RETINA 31:846-856, 2011
C1 [Cheng, Cheng-Kuo; Peng, Chi-Hsien; Chang, Chun-Kai; Hu, Chao-Chien] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei 11120, Taiwan.
   [Cheng, Cheng-Kuo; Peng, Chi-Hsien; Hu, Chao-Chien] Fu Jen Catholic Univ, Dept Ophthalmol, Coll Med, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Natl Taiwan Univ, Dept Ophthalmol, Coll Med, Taipei 10764, Taiwan.
   [Peng, Chi-Hsien] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
C3 Shin Kong Wu Ho Su Memorial Hospital; Fu Jen Catholic University;
   National Taiwan University; National Yang Ming Chiao Tung University;
   Mackay Memorial Hospital
RP Cheng, CK (通讯作者)，Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, 95 Wen Chang Rd, Taipei 11120, Taiwan.
EM ckcheng.md@yahoo.com.tw
FU Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan [SKH-8302-96-DR-23,
   SKH-8302-97-DR-26, SKH-8302-98-DR-27, SKH-8302-99-DR-32]
FX Supported by the Shin Kong Wu Ho-Su Memorial Hospital
   (SKH-8302-96-DR-23, SKH-8302-97-DR-26, SKH-8302-98-DR-27, and
   SKH-8302-99-DR-32), Taipei, Taiwan.
CR Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2009, RETINA-J RET VIT DIS, V29, P306, DOI 10.1097/IAE.0b013e3181909404
   CHO M, 2009, AM J OPHTHALMOL, V70
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coma MC, 2007, OPHTHALMOLOGY, V114, P1574, DOI 10.1016/j.ophtha.2006.11.028
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Hernandez-Rojas ML, 2007, RETINA-J RET VIT DIS, V27, P707
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Karacorlu SA, 2006, RETINA-J RET VIT DIS, V26, P752, DOI 10.1097/01.iae.0000231382.83491.c1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Peng CH, 2009, EYE, V23, P2126, DOI 10.1038/eye.2008.401
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Shah AR, 2009, BRIT J OPHTHALMOL, V93, P1027, DOI 10.1136/bjo.2008.149674
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wu L, 2009, JPN J OPHTHALMOL, V53, P125, DOI 10.1007/s10384-008-0622-y
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
NR 46
TC 47
Z9 48
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2011
VL 31
IS 5
BP 846
EP 856
DI 10.1097/IAE.0b013e3181f84fdf
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 755LV
UT WOS:000289933600005
PM 21317837
DA 2022-11-30
ER

PT J
AU Ouyang, YL
   Heussen, FM
   Hariri, A
   Keane, PA
   Sadda, SR
AF Ouyang, Yanling
   Heussen, Florian M.
   Hariri, Amirhossein
   Keane, Pearse A.
   Sadda, SriniVas R.
TI Optical Coherence Tomography-Based Observation of the Natural History of
   Drusenoid Lesion in Eyes with Dry Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; CHOROIDAL THICKNESS; GRADING SYSTEM;
   CLASSIFICATION; MACULOPATHY
AB Purpose: To use spectral domain optical coherence tomography (SD-OCT) to investigate risk factors predictive for the development of atrophy of drusenoid lesions (DLs) (drusen and drusenoid pigment epithelium detachment) in eyes with non-neovascular age-related macular degeneration (NNVAMD).
   Design: Cohort study.
   Participants: Forty-one eyes from 29 patients with NNVAMD.
   Methods: Patients with NNVAMD who underwent registered SD-OCT imaging over a minimum period of 6 months were reviewed. Drusenoid lesions that were accompanied by new atrophy onset at 6 months or last follow-up (FUL) were further analyzed. Detailed lesion change was described throughout the study period. Odds ratios (ORs) and risk for new local atrophy onset were calculated. Main Outcome Measures: Drusenoid lesion features and longitudinal changes in features, including maximum lesion height, lesion diameter, lesion internal reflectivity, and presence and extent of overlying intra-retinal hyperreflective foci (HRF). Subfoveal choroidal thickness (SFCT) and choroidal thickness (CT) were measured below each lesion.
   Results: A total of 543 individual DLs were identified at baseline, and 28 lesions developed during follow-up. The mean follow-up time was 21.3 +/- 8.6 months (range, 6-44 months). Some 3.2% of DLs (18/571) progressed to atrophy within 18.3 +/- 9.5 months (range, 5-28 months) of the initial visit. Drusenoid lesions with heterogeneous internal reflectivity were significantly associated with new atrophy onset at 6 months (OR, 5.614; 95% confidence interval [CI], 1.277-24.673) and new atrophy onset at FUL (OR, 7.005; 95% CI, 2.300-21.337). Lesions with the presence of HRF were significant predictors of new atrophy onset at 6 months (OR, 30.161; 95% CI, 4.766-190.860) and FUL (OR, 11.211; 95% CI, 2.513-50.019). Lesions with a baseline maximum height >80 mu m or CT <= 135 mu m showed a positive association with the new atrophy onset at FUL (OR, 7.886; 95% CI, 2.105-29.538 and OR, 3.796; 95% CI, 1.154-12.481, respectively).
   Conclusions: The presence of HRF overlying DLs, a heterogeneous internal reflectivity of these lesions, was found consistently to be predictive of local atrophy onset in the ensuing months. These findings provide further insight into the natural history of anatomic change occurring in patients with NNVAMD. (C) 2013 by the American Academy of Ophthalmology.
C1 [Ouyang, Yanling; Heussen, Florian M.; Hariri, Amirhossein; Sadda, SriniVas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Ouyang, Yanling; Heussen, Florian M.] Charite Univ Med Berlin, Dept Ophthalmol, Berlin, Germany.
   [Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Keane, Pearse A.] UCL Inst Ophthalmol, London, England.
C3 Doheny Eye Institute; University of Southern California; Free University
   of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of London; University College
   London
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
RI Mitchell, Paul/P-1498-2014; Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X; Heussen, Florian
   Moritz/0000-0003-0536-9870
FU Carl Zeiss Meditec; Optos; Optovue, Inc.; National Eye Institute [R01
   EY014375]; Research to Prevent Blindness; Department of Health's NIHR
   Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital;
   UCL Institute of Ophthalmology; Deutsche Forschungsgemeinschaft (DFG)
   [He 6094/1-1]; Academy of Medical Sciences (AMS) [AMS-SGCL6-Keane]
   Funding Source: researchfish; National Institute for Health Research
   [CL-2010-18-004] Funding Source: researchfish; NATIONAL EYE INSTITUTE
   [R21EY015914, R01EY014375] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): Dr. Sadda is an
   inventor of Doheny intellectual property related to OCT that has been
   licensed by Topcon Medical Systems, has served as a consultant for Carl
   Zeiss Meditec and Optos, and receives research support from Carl Zeiss
   Meditec, Optos, and Optovue, Inc.; This research has been supported in
   part by National Eye Institute Grant R01 EY014375, Research to Prevent
   Blindness, the Department of Health's NIHR Biomedical Research Centre
   for Ophthalmology at Moorfields Eye Hospital and the UCL Institute of
   Ophthalmology, and the Deutsche Forschungsgemeinschaft (DFG Grant He
   6094/1-1). Dr. Keane has received a proportion of his funding from the
   Department of Health's NIHR Biomedical Research Centre for Ophthalmology
   at Moorfields Eye Hospital and UCL Institute of Ophthalmology. The views
   expressed in the publication are those of the authors and not
   necessarily those of the Department of Health.
CR BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Ouyang YL, 2011, INVEST OPHTH VIS SCI, V52, P7019, DOI 10.1167/iovs.11-8046
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   THOMPSON JR, 1993, BRIT J OPHTHALMOL, V77, P115, DOI 10.1136/bjo.77.2.115
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 19
TC 108
Z9 112
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2013
VL 120
IS 12
BP 2656
EP 2665
DI 10.1016/j.ophtha.2013.05.029
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 255OL
UT WOS:000327249600052
PM 23830761
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Liew, G
   Joachim, N
   Mitchell, P
   Burlutsky, G
   Wang, JJ
AF Liew, Gerald
   Joachim, Nichole
   Mitchell, Paul
   Burlutsky, George
   Wang, Jie Jin
TI Validating the AREDS Simplified Severity Scale of Age-Related Macular
   Degeneration with 5-and 10-Year Incident Data in a Population-Based
   Sample
SO OPHTHALMOLOGY
LA English
DT Article
ID EYE DISEASE; INTERNATIONAL CLASSIFICATION; 5-YEAR INCIDENCE;
   MACULOPATHY; SYSTEM
AB Purpose: Most classification systems for age-related macular degeneration (AMD) were developed from patients in clinical trials. We aimed to validate the Age-Related Eye Diseases Study (AREDS) simplified severity scale of AMD classification using 5- and 10-year incident late AMD data from the population-based Blue Mountains Eye Study (BMES) cohort.
   Design: Comparative study of population-based cohort and clinical trial.
   Participants: Blue Mountains Eye Study participants 40 to 97 years of age at baseline (n = 2134) and AREDS participants 55 to 80 years of age (n = 3640).
   Methods: In the BMES, AMD lesions were graded from stereoscopic color photographs and were classified according to the AREDS simplified severity scale. The AREDS simplified scale calculates a risk score based on the number of early AMD risk factors (large drusen and pigment abnormalities) in both eyes that can range from 0 to 4.
   Main Outcome Measures: Five-and 10-year incident late AMD (presence of geographic atrophy or choroidal neovascularization).
   Results: The AREDS simplified scale performed similarly when applied to both the BMES population-based participants and the AREDS clinical trial-based participants in predicting 5-and 10-year incidence of late AMD. For scores 0 to 4, the 5-year incidence rates for the BMES compared with the AREDS were 0.2% versus 0.4%, 3.1% versus 3.1%, 12.1% versus 11.8%, 13.5% versus 25.9%, and 47.1% versus 47.3%, respectively. The corresponding 10-year incidence rates for the BMES compared with the AREDS were 0.7% versus 1.5%, 7.3% versus 8.4%, 36.6% versus 27.6%, 20.0% versus 52.7%, and 75.0% versus 71.4%, respectively.
   Conclusions: The AREDS simplified severity scale classified late AMD risk levels similarly when applied to population-based and clinical trial samples. These results support the robustness of the AREDS simplified severity scale. (C) 2016 by the American Academy of Ophthalmology.
C1 [Liew, Gerald; Joachim, Nichole; Mitchell, Paul; Burlutsky, George; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst Med Res, Westmead Hosp, Ctr Vision Res,Dept Ophthalmol, Sydney, NSW, Australia.
C3 University of Sydney
RP Liew, G (通讯作者)，Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Westmead, NSW 2145, Australia.
EM gerald.liew@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022; wang, jie/GRS-0942-2022; Mitchell,
   Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
FU National Health and Medical Research Council, Canberra, Australia
   [974159, 211069, 457349]
FX The Blue Mountains Eye Study was supported by the National Health and
   Medical Research Council, Canberra, Australia (grant nos.: 974159,
   211069, and 457349). The sponsors or funding organizations had no role
   in the design or conduct of this research.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 14
TC 17
Z9 17
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2016
VL 123
IS 9
BP 1874
EP 1878
DI 10.1016/j.ophtha.2016.05.043
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QE
UT WOS:000389508500016
PM 27378016
DA 2022-11-30
ER

PT J
AU Bressler, NM
AF Bressler, NM
CA Treatment Age Related Macular Dege
TI Verteporfin therapy for subfoveal choroidal neovascularization in
   age-related macular degeneration - Three-year results of an open-label
   extension of 2 randomized clinical trials - TAP report No. 5
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY
AB Objective: To report vision and safety outcomes from an extension of a 2-year investigation evaluating verteporfin photodynamic therapy in patients with age-related macular degeneration with subfoveal choroidal neovascularization (CNV).
   Design and Setting: Open-label extension of selected patients from 2 multicenter, double-masked, placebo-controlled, randomized clinical trials, the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation, at 22 ophthalmology practices in Europe and North America.
   Participants: Patients enrolled in the TAP Investigation and followed up for at least 24 months in whom verteporfin therapy to CNV might reduce the risk of further vision loss.
   Methods: Before receiving verteporfin therapy in the extension, eligible patients signed a written informed consent form accompanied by an oral consent process approved by local institutional review boards. Methods were similar to those described for 1- and 2-year results, with follow-up examinations beyond 2 years continuing at 3-month intervals with a few exceptions, including that extension patients with fluorescein leakage from CNV were to receive open-label verteporfin therapy irrespective of their original treatment assignment.
   Results: Of 402 patients in the verteporfin group, 351 (87.3%) completed the month 24 examination; 320 (91.2%) of these enrolled in the extension study. The enrolled participants included 124 (78.0%) of the 159 verteporfin-treated patients with lesions composed of predominantly classic CNV at baseline, of whom 105 (84.7%) completed the month 36 examination. Verteporfin-treated patients with this lesion composition at baseline who participated in the extension study, with or without a month 36 examination, appeared more likely to have a younger age, better level of visual acuity, absence of fluorescein leakage from classic CNV, or no progression of classic CNV beyond the baseline boundaries of the lesion at the month 24 examination compared with those who did not enrolled in the extension. For the 105 patients with a predominantly classic baseline lesion composition who completed the month 36 examination, an average of 1.3 treatments were given from the month 24 examination up to, but not including, the month 36 examination. A letter score loss in the study eye of at least 15 from baseline for these patients occurred in 39 (37.5%) at the month 24 examination compared with 44 (41.9%) of these patients at the month 36 examination. Visual acuity changed little from the month 24 examination (mean, - 1.9 lines) to the month 36 examination (mean, - 2.0 lines) for these eyes. Verteporfin-treated patients had little change in the mean visual acuity lost and few or no additional instances of infusion-related back pain or photosensitivity reactions from month 24 to month 36. Two patients originally assigned to placebo had acute severe vision decrease within 7 days after verteporfin treatment during the extension. One patient originally assigned to verteporfin had acute severe vision decrease after verteporfin treatment of the fellow eye during the extension.
   Conclusions: Vision outcomes for verteporfin-treated patients with predominantly classic lesions at baseline remained relatively stable from month 24 to month 36, although only approximately one third of the verteporfin-treated patients originally enrolled with this lesion composition had a month 36 examination. From these results, the TAP Study Group identified no safety concerns to preclude repeating photodynamic therapy with verteporfin. Additional treatment was judged likely to reduce the risk of further vision loss. Caution appears warranted in the absence of comparison with an untreated group during the extension and since not all patients in the TAP Investigation participated in the TAP Extension.
C1 Novartis Ophthalm, Duluth, GA 30097 USA.
C3 Novartis
RP Bressler, NM (通讯作者)，Novartis Ophthalm, 11460 Johns Creek Pkwy, Duluth, GA 30097 USA.
EM mmboffice@jhmi.edu
OI Mones, Jordi/0000-0003-3685-2160
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
NR 3
TC 145
Z9 156
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2002
VL 120
IS 10
BP 1307
EP 1314
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 603LG
UT WOS:000178560500006
PM 12365909
DA 2022-11-30
ER

PT J
AU Faatz, H
   Farecki, ML
   Rothaus, K
   Gunnemann, F
   Gutfleisch, M
   Lommatzsch, A
   Pauleikhoff, D
AF Faatz, Henrik
   Farecki, Marie-Louise
   Rothaus, Kai
   Gunnemann, Frederic
   Gutfleisch, Matthias
   Lommatzsch, Albrecht
   Pauleikhoff, Daniel
TI Optical coherence tomography angiography of types 1 and 2 choroidal
   neovascularization in age-related macular degeneration during anti-VEGF
   therapy: evaluation of a new quantitative method
SO EYE
LA English
DT Article
ID OCT ANGIOGRAPHY; RANIBIZUMAB; VERTEPORFIN; AMD; CNV
AB Purpose The aim of this pilot study was to test whether mathematical parameters of the vascular morphology of choroidal neovascularization (CNV) can be used as biomarkers and to investigate how these parameters change during anti-vascular endothelial growth factor (VEGF) therapy.
   Methods Treatment-naive CNV in exudative age-related macular degeneration (AMD) was diagnosed in 28 patients. OCT-angiography (OCT-A) (Avanti/FA Optovue) performed before and after anti-VEGF therapy. The OCT-A data sets were exported to an external image processing program and vessel skeletonization was accomplished by means of edge detection. Based on this technique the total vessel length, the number of segments and the fractal dimension (FD) of the CNV were calculated before and after therapy. The results were compared with other clinical parameters such as VA and central retinal thickness (RT).
   Results The total vessel length of the CNV was significantly reduced by anti-VEGF-therapy (mean value 652 pixels vs. 397 pixels; p < 0.0001), as well as the number of individual vessel segments of the CNV (mean value 117 vs. 76; p < 0.0001). The FD of the CNV also decreased significant reduction during therapy (mean 1.23 vs. 1.16, p < 0.0001). The changes in these parameters during treatment corresponded with an increase in VA and a reduction in RT.
   Conclusion This pilot study demonstrates that the vascular pattern of CNV in AMD can be visualized and described using mathematical parameters of OCT-A. The changes during therapy correlate significantly with established "activity" parameters of CNV, so changes in these parameters (especially FD) may represent additional CNV "activity" biomarkers.
C1 [Faatz, Henrik; Farecki, Marie-Louise; Rothaus, Kai; Gunnemann, Frederic; Gutfleisch, Matthias; Lommatzsch, Albrecht; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Lommatzsch, Albrecht; Pauleikhoff, Daniel] Univ Essen Duisburg, Dept Ophthalmol, Duisburg, Germany.
C3 St. Franziskus-Hospital; University of Duisburg Essen
RP Faatz, H (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
EM henrik.faatz@augen-franziskus.de
OI Rothaus, Kai/0000-0002-4288-8795; Gutfleisch,
   Matthias/0000-0002-2001-5838; Faatz, Henrik/0000-0002-5363-0052
CR al Sharaa M, 2017, NATO SCI PEACE SEC, V138, P1, DOI 10.3233/978-1-61499-802-0-1
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Faatz H, 2017, KLIN MONATSBL AUGENH, V234, P1125, DOI 10.1055/s-0043-118346
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lindner M, 2016, INVEST OPHTH VIS SCI, V57, P6342, DOI 10.1167/iovs.16-19741
   Lopez AM, 2000, COMPUT VIS IMAGE UND, V77, P111, DOI 10.1006/cviu.1999.0812
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Matthe E, 2011, OPHTHALMOLOGE, V108, P237, DOI 10.1007/s00347-010-2282-9
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Rothaus K, 2005, LECT NOTES COMPUT SC, V3687, P502
   Souedan V, 2018, INT OPHTHALMOL, V38, P1051, DOI 10.1007/s10792-017-0559-6
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
NR 20
TC 21
Z9 23
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2019
VL 33
IS 9
BP 1466
EP 1471
DI 10.1038/s41433-019-0429-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IX6FN
UT WOS:000485778400015
PM 30971814
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Ecker, SM
   Pfahler, SM
   Hines, JC
   Lovelace, AS
   Glaser, BM
AF Ecker, Stephanie M.
   Pfahler, Scott M.
   Hines, Joshua C.
   Lovelace, Ann S.
   Glaser, Bert M.
TI Sequential in-office vitreous aspirates demonstrate vitreous matrix
   metalloproteinase 9 levels correlate with the amount of subretinal fluid
   in eyes with wet age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID MATRIX METALLOPROTEINASES; EXPRESSION; BIOMARKERS; INHIBITORS; PROTEIN;
   EXTENT
AB Purpose: To evaluate levels of 37 native pathway proteins of the vitreous proteome from a subset of wet age-related macular degeneration (AMD) patients with and without subretinal fluid (SRF).
   Methods: A total of 62 consecutive samples were aspirated from 12 patients with AMD, six who had SRF at baseline, and six who did not have SRF at any point during the study. Vitreous levels of the 37 native pathway proteins were analyzed in these patients using reverse phase protein microarray technology. At each visit, at which the 62 samples were taken, SRF and central retinal thickness were measured. These values were then compared to the relative intensity level of the 37 proteins screened.
   Results: In the subset of AMD patients with SRF, the average matrix metalloproteinase 9 (MMP-9), interleukin (IL)-12, Abelson murine leukemia viral oncogene homolog 1 (cABL) Thr735, heme oxygenase-1, Musashi, platelet-derived growth factor receptor beta Tyr751 (PDGFR beta), IL-8, and BCL-2 associated death promoter (BAD) Ser112 levels in the vitreous were found to be significantly different with a 21%-82% increase in expression compared to those without SRF (p<0.0001). Within the SRF group, there was a positive correlation between the vitreous MMP-9 levels and the SRF level. MMP-9 levels in the vitreous proteome varied with the level of SRF but not retinal edema. Compared to patients without SRF, the patients with initial SRF had persistent or progressive disease.
   Conclusions: This is the first prospective case series sequentially monitoring the vitreous proteome in patients with wet AMD. The results suggest that MMP-9 is a proteomic biomarker of SRF accumulation, separate from macular edema.
C1 [Ecker, Stephanie M.; Pfahler, Scott M.; Hines, Joshua C.; Lovelace, Ann S.; Glaser, Bert M.] Natl Retina Inst, Dept Ocular Prote, Towson, MD 21204 USA.
   [Ecker, Stephanie M.; Hines, Joshua C.; Glaser, Bert M.] Ocular Prote LLC, Towson, MD USA.
RP Ecker, SM (通讯作者)，Natl Retina Inst, Dept Ocular Prote, 901 Dulaney Valley Rd,Suite 200, Towson, MD 21204 USA.
EM secker@ocularproteomics.com
FU National Institutes of Health/ National Eye Institute "Small Business
   Innovation Research Grant Program" [1R43EY021082-01]; NIH/NEI R21 Grant
   [1 R21 EY018942-01A1]; NIH/NEI SBIR Phase I Grant [1R 43EY02182-01];
   HHS/IRS Qualified Therapeutic Discovery Program Grant
   [09QTDP27-20181471]; NATIONAL EYE INSTITUTE [R21EY018942, R43EY021082]
   Funding Source: NIH RePORTER
FX This study was funded in part by The National Institutes of Health/
   National Eye Institute "Small Business Innovation Research Grant
   Program" Grant Number 1R43EY021082-01. The authors would like to thank
   Richard Thompson and his staff at the Johns Hopkins Biostatistics Center
   for assisting with the statistical analysis of this work. Financial
   Support: NIH/NEI R21 Grant: 1 R21 EY018942-01A1 NIH/NEI SBIR Phase I
   Grant: 1R 43EY02182-01 HHS/IRS Qualified Therapeutic Discovery Program
   Grant: 09QTDP27-20181471 The grantee organizations had no role in the
   design or conduct of this research. Conflict of Interest: Stephanie
   Ecker, Joshua Hines, and Bert Glaser are employees of Ocular Proteomics
   LLC. Bert Glaser is the owner and serves as the chief scientific
   officer.
CR Boja ES, 2011, KOREAN J LAB MED, V31, P61, DOI 10.3343/kjlm.2011.31.2.61
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Davuluri G, 2009, ARCH OPHTHALMOL-CHIC, V127, P613, DOI 10.1001/archophthalmol.2009.88
   Espina V, 2003, PROTEOMICS, V3, P2091, DOI 10.1002/pmic.200300592
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hoffman S, 2006, RETINA, V26, P453
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Pfahler SM, 2009, RETINA-J RET VIT DIS, V29, P1032, DOI 10.1097/IAE.0b013e3181a2c1eb
   Plantner JJ, 1998, CURR EYE RES, V17, P132, DOI 10.1076/ceyr.17.2.132.5610
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Symeonidis C, 2007, RETINA-J RET VIT DIS, V27, P1279, DOI 10.1097/IAE.0b013e3180592c00
   Symeonidis C, 2007, GRAEF ARCH CLIN EXP, V245, P560, DOI 10.1007/s00417-006-0386-3
NR 15
TC 21
Z9 23
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUN 20
PY 2012
VL 18
IS 169-73
BP 1658
EP 1667
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 962OW
UT WOS:000305555700003
PM 22773904
DA 2022-11-30
ER

PT J
AU Zhao, XY
   Zhang, XY
   Lv, B
   Meng, LH
   Zhang, CF
   Liu, Y
   Lv, CF
   Xie, GT
   Chen, YX
AF Zhao, Xinyu
   Zhang, Xiaoyue
   Lv, Bin
   Meng, Lihui
   Zhang, Chengfen
   Liu, Yang
   Lv, Chuanfeng
   Xie, Guotong
   Chen, Youxin
TI Optical coherence tomography-based short-term effect prediction of
   anti-vascular endothelial growth factor treatment in neovascular
   age-related macular degeneration using sensitive structure guided
   network
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Anti-vascular endothelial
   growth factor; Deep learning; Treatment prediction
ID VISUAL-ACUITY; ASSOCIATION
AB Purpose To predict short-term anti-vascular endothelial growth factor (anti-VEGF) treatment responder/non-responder for neovascular age-related macular degeneration (nAMD) patients based on optical coherence tomography (OCT) images.
   Methods A total of 4944 OCT scans from 206 patients with nAMD were involved to develop and evaluate a responder/non-responder prediction method for the short-term effect of anti-VEGF therapy. A deep learning architecture named sensitive structure guided network (SSG-Net) was proposed to make the prediction leveraging a sensitive structure guidance module trained from pre- and post-treatment images. To verify its clinical efficiency, other 2 deep learning methods and 4 experienced ophthalmologists were involved to evaluate the performance of the developed model.
   Results For the testing dataset, SSG-Net could predict the response by an accuracy of 84.6% and an area under the receiver curve (AUC) of 0.83, with a sensitivity of 0.692 and specificity of 1. In contrast, the 2 compared deep learning methods achieved an accuracy of 65.4% with a sensitivity of 0.461 and specificity of 0.846, and an accuracy of 73.1% with a sensitivity of 0.692 and specificity of 0.846, respectively. The predicted accuracy for 4 experienced ophthalmologists was 53.8 to 76.9%, with sensitivity of 0.538 to 0.923 and specificity of 0.385 to 0.846, respectively.
   Conclusion Our proposed SSG-Net shows effective prediction on the short-term efficacy of anti-VEGF treatment for nAMD patients. This technique could potentially help clinicians explain the necessity of anti-VEGF treatment to the potential responder and avoid unnecessary treatment for the non-responder.
C1 [Zhao, Xinyu; Meng, Lihui; Chen, Youxin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Zhao, Xinyu; Meng, Lihui; Chen, Youxin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
   [Zhang, Xiaoyue; Lv, Bin; Zhang, Chengfen; Liu, Yang; Lv, Chuanfeng; Xie, Guotong] Ping Healthcare Technol, Beijing, Peoples R China.
   [Xie, Guotong] Ping Hlth & Technol Co Ltd, Shanghai, Peoples R China.
   [Xie, Guotong] Ping Int Smart City Technol Co Ltd, Shenzhen, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.; Chen, YX (通讯作者)，Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.; Xie, GT (通讯作者)，Ping Healthcare Technol, Beijing, Peoples R China.; Xie, GT (通讯作者)，Ping Hlth & Technol Co Ltd, Shanghai, Peoples R China.; Xie, GT (通讯作者)，Ping Int Smart City Technol Co Ltd, Shenzhen, Peoples R China.
EM xieguotong@pingan.com.cn; 478252553@qq.com
RI meng, li/GVT-2063-2022
OI Chen, Youxin/0000-0002-7231-5058
CR Arichika S, 2010, RETINA-J RET VIT DIS, V30, P503, DOI 10.1097/IAE.0b013e3181bd2d65
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Hodgson N, 2016, MOL PHARMACEUT, V13, P2877, DOI 10.1021/acs.molpharmaceut.5b00775
   Hu J, 2018, PROC CVPR IEEE, P7132, DOI [10.1109/TPAMI.2019.2913372, 10.1109/CVPR.2018.00745]
   Hu ZP, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-01815-8
   Hwang HS, 2017, INVEST OPHTH VIS SCI, V58, P5958, DOI 10.1167/iovs.17-22725
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kawczynski MG, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.51
   Keane PA, 2014, OPHTHALMOLOGY, V121, P2489, DOI 10.1016/j.ophtha.2014.07.054
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Lee J, 2016, OPHTHALMOLOGY, V123, P2368, DOI 10.1016/j.ophtha.2016.07.010
   Liu TYA, 2020, BRIT J OPHTHALMOL, V104, P1629, DOI 10.1136/bjophthalmol-2020-316300
   Liu YT, 2020, BRIT J OPHTHALMOL, V104, P1735, DOI 10.1136/bjophthalmol-2019-315338
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Rasti R, 2020, BIOMED OPT EXPRESS, V11, P1139, DOI 10.1364/BOE.379150
   Rim TH, 2021, BRIT J OPHTHALMOL, V105, P1133, DOI 10.1136/bjophthalmol-2020-316984
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schreur V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206482
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Vujosevic S, 2017, ACTA OPHTHALMOL, V95, P464, DOI 10.1111/aos.13294
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   ZHOU B, 2016, PROC CVPR IEEE
NR 29
TC 2
Z9 2
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2021
VL 259
IS 11
BP 3261
EP 3269
DI 10.1007/s00417-021-05247-4
EA JUN 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WI6ZZ
UT WOS:000658679800002
PM 34097114
DA 2022-11-30
ER

PT J
AU Mursch-Edlmayr, AS
   Luft, N
   Podkowinski, D
   Ring, M
   Schmetterer, L
   Bolz, M
AF Mursch-Edlmayr, Anna Sophie
   Luft, Nikolaus
   Podkowinski, Dominika
   Ring, Michael
   Schmetterer, Leopold
   Bolz, Matthias
TI Short-term effect on the ocular circulation induced by unilateral
   intravitreal injection of aflibercept in age-related maculopathy
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; age-related macular degeneration; anti-VEGF; laser speckle
   flowgraphy; ocular perfusion
ID CHOROIDAL BLOOD-FLOW; LASER SPECKLE FLOWGRAPHY; RETROBULBAR
   HEMODYNAMICS; MACULAR DEGENERATION; BEVACIZUMAB; RANIBIZUMAB; PRESSURE;
   EYES
AB Purpose Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the standard treatment for neovascular age-related macular degeneration (AMD). As VEGF is a physiological key player for regulating retinal vascular tone, questions have been raised whether the application of anti-VEGF could induce alterations in ocular perfusion. Methods The study included 20 eyes from 20 Caucasian patients with unilateral neovascular AMD and 20 fellow eyes. All eyes were treated with standard intravitreal injection of aflibercept (IVA). Measurements of blood flow at the optic nerve head (ONH) and the choroid were performed with laser speckle flowgraphy (LSFG). The intraocular pressure (IOP), systolic and diastolic blood pressure, heart rate, mean arterial pressure (MAP) and ocular perfusion pressure (OPP) were analysed. Measurements were performed at baseline and repeated immediately after the injection and 30 and 45 min later. Results Mean time between injection of aflibercept and first follow-up was 8:56 +/- 4:25 min. The injection led to significant rise in IOP. In the injected eyes, mean blur rate (MBR, i.e. a relative measure of perfusion and the main outcome parameter of LSFG) within the major vessels of the ONH as well as at the entire ONH region decreased significantly (p < 0.001). No change in MBR was observed in the fellow eye. Choroidal blood flow was maintained stable in both eyes. Conclusion Intravitreal injection of aflibercept (IVA) led to a short-term reduction in perfusion only in the treated eye. This was independent from IOP, indicating a direct pharmacological effect. No changes in choroidal perfusion were observed during the first 45 min after the injection.
C1 [Mursch-Edlmayr, Anna Sophie; Podkowinski, Dominika; Ring, Michael; Bolz, Matthias] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Ophthalmol, Linz, Austria.
   [Luft, Nikolaus] Ludwig Maximilians Univ Munchen, Univ Eye Hosp, Munich, Germany.
   [Schmetterer, Leopold] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Schmetterer, Leopold] Nanyang Technol Univ, Lee Kong Chian Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Schmetterer, Leopold] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
C3 Johannes Kepler University Linz; Kepler University Hospital; University
   of Munich; National University of Singapore; Singapore National Eye
   Center; Nanyang Technological University & National Institute of
   Education (NIE) Singapore; Nanyang Technological University; National
   University of Singapore; Medical University of Vienna; Medical
   University of Vienna
RP Bolz, M (通讯作者)，Kepler Univ Hosp, Dept Ophthalmol, Krankenhausstr 9, A-4020 Linz, Austria.
EM matthias.bolz@kepleruniklinikum.at
RI Bolz, Matthias/HCI-0622-2022
OI Reisinger, Anna Sophie/0000-0003-2218-5897; Schmetterer,
   Leopold/0000-0002-7189-1707
CR Aizawa N, 2011, CLIN OPHTHALMOL, V5, P1171, DOI 10.2147/OPTH.S22093
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Enaida Hiroshi, 2010, Ophthalmic Surg Lasers Imaging, V41 Online, pe1, DOI 10.3928/15428877-20101124-11
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gok M, 2018, INT OPHTHALMOL, V38, P713, DOI 10.1007/s10792-017-0522-6
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Lemos-Reis R, 2014, CLIN OPHTHALMOL, V8, P1383, DOI 10.2147/OPTH.S64721
   Longo A, 2004, INVEST OPHTH VIS SCI, V45, P546, DOI 10.1167/iovs.03-0757
   Luft N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168190
   McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Movaffaghy A, 2002, KLIN MONATSBL AUGENH, V219, P299, DOI 10.1055/s-2002-30665
   Nagasato D, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0211-7
   Nitta F, 2014, CLIN OPHTHALMOL, V8, P1119, DOI 10.2147/OPTH.S62022
   Okamoto M, 2015, OSLI RETINA, V46, P25, DOI 10.3928/23258160-20150101-04
   Okuno T., 2000, J OPHTHALMOL, V46, P170
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P1752
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Schmidl D, 2016, INVEST OPHTH VIS SCI, V57, P5705, DOI 10.1167/iovs.16-20225
   Schmidl D, 2012, INVEST OPHTH VIS SCI, V53, P4337, DOI 10.1167/iovs.11-9055
   Selid PD, 2014, OSLI RETINA, V45, P275, DOI 10.3928/23258160-20140709-03
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Simader C, 2009, INVEST OPHTH VIS SCI, V50, P372, DOI 10.1167/iovs.07-1614
   Sivertsen MS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20525-8
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Sugimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1543, DOI 10.1007/s00417-017-3692-z
   Sugiyama T, 2010, ACTA OPHTHALMOL, V88, P723, DOI 10.1111/j.1755-3768.2009.01586.x
   Tetikoglu M, 2018, CUTAN OCUL TOXICOL, V37, P84, DOI 10.1080/15569527.2017.1354217
   Toklu Y, 2011, ACTA OPHTHALMOL, V89, pE41, DOI 10.1111/j.1755-3768.2010.02075.x
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
NR 31
TC 3
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2019
VL 97
IS 6
BP E927
EP E932
DI 10.1111/aos.14098
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IP7VT
UT WOS:000480256800028
PM 30916896
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Zhao, XY
   Meng, LH
   Chen, YX
AF Zhao, Xinyu
   Meng, Lihui
   Chen, Youxin
TI Comparative efficacy and safety of different regimens of ranibizumab for
   neovascular age-related macular degeneration: a network meta-analysis of
   randomised controlled trials
SO BMJ OPEN
LA English
DT Article
DE ophthalmology; medical ophthalmology; medical retina
AB Objective
   To give a comprehensive efficacy and safety ranking of different therapeutic regimens of ranibizumab for neovascular age-related macular degeneration (nAMD).
   Design
   A systematic review and network meta-analysis.
   Methods
   The PubMed, Embase, Cochrane Central Register of Controlled Trials, and other clinical trial registries were searched up to 1 October 2019 to identify related randomised controlled trials (RCT) of different regimens of ranibizumab for nAMD. The primary efficacy outcome was the changes of best-corrected visual acuity (BCVA) at 1 year, the primary safety outcome was the incidence of severe ocular adverse events. Secondary outcomes such as changes of central retinal thickness (CRT) were evaluated. We estimated the standardised mean difference (SMD), ORs, 95% CIs, the surface under the cumulative ranking curves and the mean ranks for each outcome using network meta-analyses with random effects by Stata 14.0.
   Results
   We identified 26 RCTs involving 10 821 patients with nAMD randomly assigned to 21 different therapeutic regimens of ranibizumab or sham treatment. Ranibizumab 0.5 mg (treat and extend, T&E) is most effective in terms of changes of BCVA (letters, SMD=21.41, 95% CI 19.86 to 22.95) and three or more lines of BCVA improvement (OR=2.83, 95% CI 1.27 to 4.38). However, it could not significantly reduce retreatment times compared with monthly injection (SMD=-0.94, 95% CI -2.26 to 0.39). Ranibizumab 0.5 mg (3+pro re nata)+non-steroidal anti-inflammatory drugs (NSAIDs) is most effective in reducing CRT and port delivery system of ranibizumab (100 mg/mL) could reduce the number of retreatment most significantly. All regimes have no more risk of severe ocular complications (including vitreous haemorrhage, rhegmatogenous retinal detachment, endophthalmitis, retinal tear and retinal pigment epithelium tear) or cardiocerebral vascular complications.
   Conclusions
   Ranibizumab 0.5 mg (T&E) is most effective in improving the visual outcome. The administration of topical NSAIDs could achieve additional efficacy in CRT reduction and visual improvement. Both interventions had acceptable risks of adverse events.
C1 [Zhao, Xinyu; Meng, Lihui; Chen, Youxin] Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing, Peoples R China.
   [Zhao, Xinyu; Meng, Lihui; Chen, Youxin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing, Peoples R China.; Chen, YX (通讯作者)，Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
EM chenyx@pumch.cn
RI meng, li/GVT-2063-2022
OI Chen, Youxin/0000-0002-7231-5058
CR Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1073, DOI 10.2147/OPTH.S13969
   Cipriani A, 2013, ANN INTERN MED, V159, P130, DOI 10.7326/0003-4819-159-2-201307160-00008
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Danyliv A, 2017, ADV THER, V34, P611, DOI 10.1007/s12325-017-0484-0
   Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Gallemore RP, 2017, CLIN OPHTHALMOL, V11, P223, DOI 10.2147/OPTH.S119510
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hatz K, 2015, OPHTHALMOLOGICA, V233, P66, DOI 10.1159/000367603
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins JPT, 2012, RES SYNTH METHODS, V3, P98, DOI 10.1002/jrsm.1044
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Ohji M, 2020, ADV THER, V37, P2184, DOI 10.1007/s12325-020-01298-x
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russo A, 2018, CLIN OPHTHALMOL, V12, P587, DOI 10.2147/OPTH.S159672
   Salanti G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099682
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Semeraro F, 2015, RETINA-J RET VIT DIS, V35, P1547, DOI 10.1097/IAE.0000000000000525
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Weingessel B, 2016, WIEN KLIN WOCHENSCHR, V128, P560, DOI 10.1007/s00508-015-0772-0
   White IR, 2012, RES SYNTH METHODS, V3, P111, DOI 10.1002/jrsm.1045
   Williams PD, 2012, CLIN OPHTHALMOL, V6, P1519, DOI 10.2147/OPTH.S31010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zhao XY, 2020, RETINA-J RET VIT DIS, V40, P477, DOI 10.1097/IAE.0000000000002389
NR 59
TC 1
Z9 1
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD FEB
PY 2021
VL 11
IS 2
AR e040906
DI 10.1136/bmjopen-2020-040906
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QR6XH
UT WOS:000625358900013
PM 33550238
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU El-Mollayess, GM
   Mahfoud, Z
   Schakal, AR
   Salti, HI
   Jaafar, D
   Bashshur, ZF
AF El-Mollayess, Georges M.
   Mahfoud, Ziyad
   Schakal, Alexandre R.
   Salti, Haytham I.
   Jaafar, Dalida
   Bashshur, Ziad F.
TI Fixed-Interval Versus OCT-Guided Variable Dosing of Intravitreal
   Bevacizumab in the Management of Neovascular Age-Related Macular
   Degeneration: A 12-Month Randomized Prospective Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; THERAPY; REGIMEN; AVASTIN(R); INJECTION; SAFETY
AB PURPOSE: To compare the efficacy of as-needed or variable dosing of intravitreal bevacizumab to continuous fixed-interval dosing in the management of neovascular age-related macular degeneration (AMD).
   DESIGN: Prospective, open-label, randomized clinical study.
   METHODS: One hundred twenty eyes of 120 patients with treatment-naive subfoveal neovascular AMD participated in this study at the American University of Beirut and Hotel Dieu de France Retina Clinics. Eyes were randomized (1:1) to fixed-interval dosing (every 4 to 6 weeks) or variable dosing with intravitreal bevacizumab (1.25 mg/0.05 mL). Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) using optical coherence tomography (OCT) were measured at baseline and at each follow-up visit. Presence or recurrence of fluid on OCT was the main indicator for retreatment in variable dosing. Main outcome measure was improvement in BCVA and CRT at 12 months.
   RESULTS: Compared to baseline, variable dosing had a mean improvement in BCVA of 11.0 letters after 12 months vs 9.2 letters for fixed-interval dosing (P = .81). Similarly, CRT decreased after 12 months by 80.7 mu m for variable dosing vs 100.5 mu m for fixed-interval dosing (P = .37). The average number of injections over 12 months was higher for fixed-interval dosing than variable dosing (9.5 vs 3.8 injections, P < .001).
   CONCLUSIONS: Fixed-interval and variable dosing regimens of intravitreal bevacizumab improved visual acuity and anatomic outcomes after 12 months in eyes with neovascular AMD. However, variable dosing had a reduced treatment burden. Larger trials are needed to confirm these results. (Am J Ophthalmol 2012;153:481-489. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [El-Mollayess, Georges M.; Salti, Haytham I.; Jaafar, Dalida; Bashshur, Ziad F.] Amer Univ Beirut, Med Ctr, Dept Ophthalmol, Beirut, Lebanon.
   [Mahfoud, Ziyad] Weill Cornell Med Coll, Dept Publ Hlth, Doha, Qatar.
   [Schakal, Alexandre R.] St Josephs Univ, Hotel Dieu France, Beirut, Lebanon.
C3 American University of Beirut; Weill Cornell Medical College Qatar;
   Saint Joseph University Beirut
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 11-0236-B11, Beirut, Lebanon.
EM zb00@aub.edu.lb
OI Mahfoud, Ziyad/0000-0003-4098-6401
FU DEPARTMENT OF OPHTHALMOLOGY AND UNIVERSITY RESEARCH Board of American
   University of Beirut Medical Center, Beirut, Lebanon
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY THE DEPARTMENT OF
   OPHTHALMOLOGY AND UNIVERSITY RESEARCH Board of American University of
   Beirut Medical Center, Beirut, Lebanon. The authors indicate no
   financial interest in any product discussed in this study. Involved in
   design of study (Z.F.B., Z.M.); conduct of study (Z.F.B., G.M.E.,
   A.R.S., H.I.S.); data collection (G.M.E., D.J.); management, analysis,
   and interpretation of the data (Z.F.B., Z.M.); and preparation (Z.F.B.,
   Z.M., G.M.E.), review (Z.F.B., Z.M., G.M.E., A.R.S., H.I.S., D.J.), and
   approval of the manuscript (Z.F.B., Z.M., G.M.E., A.R.S., HIS., D.J.).
   This study was approved prospectively by the institutional review board
   at the American University of Beirut Medical Center and was in adherence
   to the tenets of the Declaration of Helsinki. All patients signed a
   study consent form in which the procedure and treatment options were
   explained thoroughly. Patients were also reminded of the off-label use
   of intravitreal bevacizumab.
CR Abdollahi A, 2005, DRUG RESIST UPDATE, V8, P59, DOI 10.1016/j.drup.2005.03.001
   [Anonymous], 2010, CATT LUC AV TRIAL MA, P31
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shah AR, 2009, BRIT J OPHTHALMOL, V93, P1027, DOI 10.1136/bjo.2008.149674
   Ton NC, 2004, CURR PHARM DESIGN, V10, P51
   van Kempen LCL, 2006, EUR J CELL BIOL, V85, P61, DOI 10.1016/j.ejcb.2005.10.003
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 24
TC 18
Z9 19
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2012
VL 153
IS 3
BP 481
EP 489
DI 10.1016/j.ajo.2011.08.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907CB
UT WOS:000301394300013
PM 22014603
DA 2022-11-30
ER

PT J
AU Augustin, AJ
   D'Amico, DJ
   Mieler, WF
   Schneebaum, C
   Beasley, C
AF Augustin, AJ
   D'Amico, DJ
   Mieler, WF
   Schneebaum, C
   Beasley, C
TI Safety of posterior juxtascleral depot administration of the angiostatic
   cortisene anecortave acetate for treatment of subfoveal choroidal
   neovascularization in patients with age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL GANCICLOVIR; STEROIDS
AB Background: Anecortave acetate is a synthetic derivative of cortisol, but very specific and irreversible chemical modifications to the cortisol structure have resulted in the creation of a potent inhibitor of blood vessel growth with no evidence non-clinically or clinically of glucocorticoid receptor-mediated bioactivity. The clinical safety of Anecortave Acetate administered as a posterior juxtascleral depot every 6 months for up to 4 years is reviewed in this manuscript. Methods: Clinical safety and efficacy of the novel angiostatic agent Anecortave Acetate for Depot Suspension was evaluated in patients with subfoveal exudative age- related macular degeneration (AMD) in a masked, randomized, dose-duration clinical trial completed in June 2003. This safety and efficacy study enrolled and treated 128 patients at 18 clinical sites in the US and EU. This was the first clinical trial of Anecortave Acetate for Depot Suspension administered as a posterior juxtascleral depot. Assessments of clinical safety were made with general physical examinations including electrocardiograms and hematology/ serum chemistry/urinalysis, detailed ophthalmic evaluations with fluorescein/ indocyanine green angiography and assessments of best-corrected log-MAR visual acuity. All safety reports have been reviewed periodically by an Independent Safety Committee responsible for overseeing these activities. Results: No clinically relevant safety issues related to either Anecortave Acetate for Depot Suspension or the administration procedure have been identified by an Independent Safety Committee. The most frequent safety issues reported were cataractous changes, decreased visual acuity, ptosis, ocular pain, abnormal vision and subconjunctival hemorrhage, but the majority of these were assessed as unrelated to treatment. Conclusions: Anecortave Acetate for Depot Suspension ( 3, 15 and 30 mg) is clinically safe following administration and re-administration at 6-month intervals as a posterior juxtascleral depot using a specially designed curved cannula.
C1 Stadt Klinikum Karlsruhe, Eye Clin, D-76133 Karlsruhe, Germany.
C3 Municipal Hospital Karlsruhe
RP Augustin, AJ (通讯作者)，Stadt Klinikum Karlsruhe, Eye Clin, Moltkestr 90, D-76133 Karlsruhe, Germany.
EM 106020.560@compuserve.com
OI Augustin, Prof. Dr. Albert J./0000-0003-1591-0536
CR BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348
   HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
NR 10
TC 26
Z9 30
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2005
VL 243
IS 1
BP 9
EP 12
DI 10.1007/s00417-004-0961-4
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 889TT
UT WOS:000226466200003
PM 15290154
DA 2022-11-30
ER

PT J
AU Oner, A
   Gonen, ZB
   Sevim, DG
   Kahraman, NS
   Unlu, M
AF Oner, Ayse
   Gonen, Zeynep Burcin
   Sevim, Duygu Gulmez
   Kahraman, Neslihan Smim
   Unlu, Metin
TI Suprachoroidal Adipose Tissue-Derived Mesenchymal Stem Cell Implantation
   in Patients with Dry-Type Age-Related Macular Degeneration and
   Stargardt's Macular Dystrophy: 6-Month Follow-Up Results of a Phase 2
   Study
SO CELLULAR REPROGRAMMING
LA English
DT Article
DE adipose tissue derived mesenchymal stem cell; dry type age-related
   macular degeneration; Stargardt's macular dystrophy; suprachoroidal
   implantation
AB This prospective clinical case series aimed to investigate the safety and efficacy of suprachoroidal adipose tissue-derived mesenchymal stem cell (ADMSC) implantation in patients with dry-type age-related macular degeneration (AMD) and Stargardt's macular dystrophy (SMD). This study included four patients with advanced-stage dry-type AMD and four patients with SMD who underwent suprachoroidal implantation of ADMSCs. The best-corrected visual acuity (BCVA) in the study was 20/200. The worse eye of the patient was operated on. Patients were evaluated on the first day, first week, and first, third, and sixth months postopera-tively. BCVA, anterior segment and fundus examination, color photography, fundus autofluorescence, optical coherence tomography, and visual field examination were carried out at each visit. Fundus fluorescein angiography and multifocal electroretinography (mf-ERG) recordings were performed at the end of the first, third, and sixth months and anytime if necessary during the follow-up. All eight patients completed the sixth month follow-up. None of them had any systemic or ocular complications. All of the eight patients experienced visual acuity improvement, visual field improvement, and improvement in mf-ERG recordings. Stem cell treatment with suprachoroidal implantation of ADMSCs seems to be safe and effective in the treatment of dry-type AMD and SMD.
C1 [Oner, Ayse] Erciyes Univ, Dept Ophthalmol, Fac Med, TR-38039 Kayseri, Turkey.
   [Gonen, Zeynep Burcin] Erciyes Univ, Genome & Stem Cell Ctr GENKOK, Kayseri, Turkey.
   [Gonen, Zeynep Burcin] Erciyes Univ, Dept Oral & Maxillofacial Surg, Fac Dent, Kayseri, Turkey.
   [Sevim, Duygu Gulmez; Kahraman, Neslihan Smim] Erciyes Univ, Dept Ophthalmol, Kayseri, Turkey.
   [Unlu, Metin] Erciyes Univ, Dept Ophthalmol, Fac Med, Kayseri, Turkey.
C3 Erciyes University; Erciyes University; Erciyes University; Erciyes
   University; Erciyes University
RP Oner, A (通讯作者)，Erciyes Univ, Dept Ophthalmol, Fac Med, TR-38039 Kayseri, Turkey.
EM aoner@erciyes.edu.tr
RI Gonen, Zeynep Burcin/A-8330-2017; Sevim, Duygu Gülmez/AAB-7286-2019
OI Sevim, Duygu Gülmez/0000-0002-1413-2528
FU Scientific Research Support Division of Erciyes University
FX This study is funded by The Scientific Research Support Division of
   Erciyes University.
CR Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cotrim CC, 2017, CLIN OPHTHALMOL, V11, P931, DOI 10.2147/OPTH.S133502
   Fujinami K, 2015, OPHTHALMOLOGY, V122, P326, DOI 10.1016/j.ophtha.2014.08.012
   Fujinami K, 2013, AM J OPHTHALMOL, V155, P1075, DOI 10.1016/j.ajo.2013.01.018
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Jones MK, 2017, PROG RETIN EYE RES, V58, P1, DOI 10.1016/j.preteyeres.2017.01.004
   Khan M., 2014, ISRN OPHTHALMOL, V2014
   Kumar A, 2017, INT J OPHTHALMOL-CHI, V10, P1552, DOI 10.18240/ijo.2017.10.12
   Limoli PG, 2016, ONCOTARGET, V7, P46913, DOI 10.18632/oncotarget.10442
   Limoli PG, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000355
   Oner A., 2017, STEM CELL RES OPEN L, V1, P1
   Oner A, 2018, TURK OFTALMOL DERG, V48, P33, DOI 10.4274/tjo.89972
   Oner A, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0432-y
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Siqueira RC, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0020-6
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 20
TC 21
Z9 22
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4971
EI 2152-4998
J9 CELL REPROGRAM
JI Cell. Reprogramm.
PD DEC
PY 2018
VL 20
IS 6
BP 329
EP 336
DI 10.1089/cell.2018.0045
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
GA HS4ZV
UT WOS:000463880500001
PM 31251672
DA 2022-11-30
ER

PT J
AU Xu, XR
   Hang, L
   Huang, BL
   Wei, YH
   Zheng, SZ
   Li, W
AF Xu, Xinrong
   Hang, Li
   Huang, Binglin
   Wei, Yuanhua
   Zheng, Shizhong
   Li, Wei
TI Efficacy of Ethanol Extract of Fructus lycii and Its Constituents
   Lutein/Zeaxanthin in Protecting Retinal Pigment Epithelium Cells against
   Oxidative Stress: In Vivo and In Vitro Models of Age-Related Macular
   Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MATRIX METALLOPROTEINASES; ZEAXANTHIN; LUTEIN; PATHOGENESIS; INJURY;
   DIET
AB Age-related macular degeneration (AMD) is a major cause of blindness worldwide. Oxidative stress plays a large role in the pathogenesis of AMD. The present study was to evaluate the effects of Fructus lycii ethanol extract on AMD in mice and to investigate whether combination of lutein and zeaxanthin, two carotenoid pigments in Fructus lycii, could protect human retinal pigment epithelial ARPE-19 cells treated with hydrogen peroxide (H2O2) in vitro. We found that severe sediment beneath retinal pigment epithelium and thickened Bruch membrane occurred in AMD mice. However, Fructus lycii ethanol extract improved the histopathologic changes and decreased the thickness of Bruch membrane. Furthermore, the gene and protein expression of cathepsin B and cystatin C was upregulated inAMD mice but was eliminated by Fructus lycii ethanol extract. Investigations in vitro showed that ARPE-19 cell proliferation was suppressed by H2O2. However, lutein/zeaxanthin not only stimulated cell proliferation but also abrogated the enhanced expression of MMP-2 and TIMP-1 in H2O2-treated ARPE-19 cells. These data collectively suggested that Fructus lycii ethanol extract and its active components lutein/zeaxanthin had protective effects on AMD in vivo and in vitro, providing novel insights into the beneficial role of Fructus lycii for AMD therapy.
C1 [Xu, Xinrong; Hang, Li] Nanjing Univ Tradit Chinese Med, Affiliated Hosp, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
   [Huang, Binglin] Nanjing Univ Tradit Chinese Med, Clin Med Coll 1, Dept Ophthalmol & Otorhinolaryngol, Nanjing 210046, Jiangsu, Peoples R China.
   [Huang, Binglin] Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, Dept Ophthalmol, Nanchang 330006, Peoples R China.
   [Wei, Yuanhua] Jiangsu Prov Hosp Tradit Chinese Med, Dept Clin Lab, Nanjing 210029, Jiangsu, Peoples R China.
   [Zheng, Shizhong; Li, Wei] Nanjing Univ Tradit Chinese Med, Collage Pharm, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Jiangxi University of Traditional Chinese Medicine; Nanjing
   University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Xu, XR (通讯作者)，Nanjing Univ Tradit Chinese Med, Affiliated Hosp, Dept Ophthalmol, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM xinrong_xu@yahoo.com.cn
FU Jiangsu Provincial Natural Science Foundation [BK2008494]; Jiangsu
   Provincial Program of Leading Talents of Traditional Chinese Medicine
   [LJ200911]
FX This work was supported by the Jiangsu Provincial Natural Science
   Foundation (BK2008494) and the Jiangsu Provincial Program of Leading
   Talents of Traditional Chinese Medicine (LJ200911). The authors are
   grateful to Professor Shuhua Ding (Nanjing University of Chinese
   Medicine) for the assistance in design and conduction of the studies.
CR Alizadeh P, 2006, EXP EYE RES, V83, P679, DOI 10.1016/j.exer.2006.03.009
   Catanuto P, 2009, EXP EYE RES, V88, P99, DOI 10.1016/j.exer.2008.10.013
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Colquitt J. L., 2008, HLTH TECHNOLOGY ASSE, V12
   Dhoot DS, 2012, EXPERT OPIN BIOL TH, V12, P371, DOI 10.1517/14712598.2012.660523
   Elliot S, 2006, INVEST OPHTH VIS SCI, V47, P1696, DOI 10.1167/iovs.05-1258
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Flaxel C, 2007, RETINA-J RET VIT DIS, V27, P629, DOI 10.1097/01.iae.0000249561.02567.fd
   Fu YM, 2008, MOL PHARMACOL, V73, P399, DOI 10.1124/mol.107.039818
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lee GH, 2008, J FOOD SCI, V73, pC500, DOI 10.1111/j.1750-3841.2008.00851.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mares JA, 2006, AM J CLIN NUTR, V83, P733, DOI 10.1093/ajcn/83.4.733
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Nakajima Y, 2009, CURR EYE RES, V34, P311, DOI 10.1080/02713680902745408
   Obermajer N, 2008, CONNECT TISSUE RES, V49, P193, DOI 10.1080/03008200802143158
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Paraoan L, 2010, VISION RES, V50, P737, DOI 10.1016/j.visres.2009.10.022
   Pitlick JM, 2012, ANN PHARMACOTHER, V46, P290, DOI 10.1345/aph.1Q471
   Pons M, 2010, AM J PATHOL, V177, P1198, DOI 10.2353/ajpath.2010.091108
   Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753
   Sugino IK, 2003, MOL NEUROBIOL, V28, P177, DOI 10.1385/MN:28:2:177
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Vray B, 2002, CELL MOL LIFE SCI, V59, P1503, DOI 10.1007/s00018-002-8525-4
   Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P1901
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
NR 31
TC 17
Z9 18
U1 1
U2 15
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 862806
DI 10.1155/2013/862806
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 222TJ
UT WOS:000324754200001
PM 24163760
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lestable, L
   Gabrielle, PH
   Bron, AM
   Nguyen, P
   Creuzot-Garcher, C
AF Lestable, L.
   Gabrielle, P. H.
   Bron, A. M.
   Nguyen, P.
   Creuzot-Garcher, C.
TI Twelve-month outcomes of intra-vitreal anti-VEGF agents for
   treatment-naive neovascular age-related macular degeneration eyes:
   French data from the fight for retinal blindness!
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Neovascular age-related macular degeneration; Anti-VEGF therapy; Retina
ID VISUAL-ACUITY; RANIBIZUMAB; BEVACIZUMAB; AFLIBERCEPT; THERAPY
AB Introduction. - To describe the one-year functional outcomes of treatment-naive neovascular age-related macular degeneration (nAMD) treated with anti-VEGF agents at the Dijon University Hospital Ophthalmology Department.
   Methods. - Real-life interventional study including all treatment-naive nAMD patients from January 2016 to December 2018 in the Ophthalmology Department of Dijon University Hospital. Data were retrospectively collected from the Fight Retinal Blindness! (FRB!) registry. At baseline, medical history, visual acuity (VA), type of lesion and activity on angiography and optical coherence tomography (OCT), and treatment were recorded. On follow-up, VA, lesion activity and treatment were recorded.
   Results Three-hundred twenty eyes of 259 patients were included, of which 65.6% were female and with a mean age of 80.1 +/- 11.1 years. Mean VA (standard deviation, SD) at baseline was 53.2 ETDRS letters (25.3). All patients received anti-VEGF injections, of which 164 eyes (51.2%), 152 eyes (47.5%) and 4 eyes (1.2%) were treated with aflibercept, ranibizumab and bevacizumab, respectively. A total of 198 eyes of 169 patients completed the 12-month follow-up, with a median (first quartile, third quartile) of 12 visits (10, 13). At one year (n=198), the overall mean VA gain [95% CI] was +3.3 ETDRS letters [0.7, 5.9] and 173 (87.4%) of the treated eyes did not lose 15 or more letters. We found no statistically significant difference in mean VA gain between aflibercept and ranibizumab.
   Conclusion. - This real-world study confirmed the efficacy of anti-VEGF agents in nAMD and the feasibility of analyzing data in an international registry. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Lestable, L.; Gabrielle, P. H.; Bron, A. M.; Creuzot-Garcher, C.] CHU Dijon, Serv Ophtalmol, Dijon, France.
   [Bron, A. M.; Creuzot-Garcher, C.] Univ Bourgogne Franche Comte, UMR1324, CSGA, Eye & Nutr Res Grp,CNRS 6265INRA, 14 Rue Paul Gaffarel, F-21079 Dijon, France.
   [Nguyen, P.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
C3 CHU Dijon Bourgogne; Institut Agro; AgroSup Dijon; Centre National de la
   Recherche Scientifique (CNRS); Universite de Bourgogne; University of
   Sydney
RP Lestable, L (通讯作者)，CHU Dijon, Serv Ophtalmol, Dijon, France.
EM lolita.lestable@gmail.com
RI GABRIELLE, Pierre-Henry/Y-4971-2018
OI GABRIELLE, Pierre-Henry/0000-0002-9688-4845
CR Augsburger M, 2019, GRAEFES ARCH CLIN EX
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Daien V, 2018, AM J OPHTHALMOL, V190, P50, DOI 10.1016/j.ajo.2018.03.012
   Galles MC, 2014, RETINA, V34, P188
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P573
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Traynor K, 2012, AM J HEALTH-SYST PH, V69, P6, DOI 10.2146/news120001
   Westborg I, 2017, RETINA-J RET VIT DIS, V37, P2035, DOI 10.1097/IAE.0000000000001431
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 25
TC 5
Z9 5
U1 1
U2 2
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD OCT
PY 2020
VL 43
IS 8
BP 761
EP 769
DI 10.1016/j.jfo.2019.11.016
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NV5RZ
UT WOS:000574379800022
PM 32622633
OA Green Published
DA 2022-11-30
ER

PT J
AU Kashani, AH
   Lebkowski, JS
   Rahhal, FM
   Avery, RL
   Salehi-Had, H
   Chen, S
   Chan, LM
   Palejwala, N
   Ingram, A
   Dang, W
   Lin, CM
   Mitra, D
   Pennington, BO
   Hinman, C
   Faynus, MA
   Bailey, JK
   Mohan, S
   Rao, N
   Johnson, LV
   Clegg, DO
   Hinton, DR
   Humayun, MS
AF Kashani, Amir H.
   Lebkowski, Jane S.
   Rahhal, Firas M.
   Avery, Robert L.
   Salehi-Had, Hani
   Chen, Sanford
   Chan, Clement
   Palejwala, Neal
   Ingram, April
   Dang, Wei
   Lin, Chih-Min
   Mitra, Debbie
   Pennington, Britney O.
   Hinman, Cassidy
   Faynus, Mohamed A.
   Bailey, Jeffrey K.
   Mohan, Sukriti
   Rao, Narsing
   Johnson, Lincoln, V
   Clegg, Dennis O.
   Hinton, David R.
   Humayun, Mark S.
TI One-Year Follow-Up in a Phase 1/2a Clinical Trial of an Allogeneic RPE
   Cell Bioengineered Implant for Advanced Dry Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE implant; RPE cells; clinical trial; geographic atrophy
ID RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC ATROPHY; TRANSLOCATION;
   TRANSPLANTATION
AB Purpose: To report 1-year follow-up of a phase 1/2a clinical trial testing a composite subretinal implant having polarized human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells on an ultrathin parylene substrate in subjects with advanced non-neovascular age-related macular degeneration (NNAMD)
   Methods: The phase 1/2a clinical trial included 16 subjects in two cohorts. The main endpoint was safety assessed at 365 days using ophthalmic and systemic exams. Pseudophakic subjects with geographic atrophy (GA) and severe vision loss were eligible. Low-dose tacrolimus immunosuppression was utilized for 68 days in the periimplantation period. The implant was delivered to the worst seeing eye with a custom subretinal insertion device in an outpatient setting. A data safety monitoring committee reviewed all results.
   Results: The treated eyes of all subjectswere legally blindwith a baseline best-corrected visual acuity (BCVA) of <= 20/200. Therewere no unexpected serious adverse events. Four subjects in cohort 1 had serious ocular adverse events, including retinal hemorrhage, edema, focal retinal detachment, or RPE detachment, which was mitigated in cohort 2 using improved hemostasis during surgery. Although this study was not powered to assess efficacy, treated eyes from four subjects showed an increased BCVA of >5 letters (6-13 letters). A larger proportion of treated eyes experienced a >5-letter gain when compared with the untreated eye (27% vs. 7%; P = not significant) and a larger proportion of nonimplanted eyes demonstrated a >5-letter loss (47% vs. 33%; P = not significant).
   Conclusions: Outpatient delivery of the implant can be performed routinely. At 1 year, the implant is safe and well tolerated in subjects with advanced dry AMD.
   Translational Relevance: This work describes the first clinical trial, to our knowledge, of a novel implant for advanced dry AMD.
C1 [Kashani, Amir H.] Johns Hopkins Univ, Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   [Lebkowski, Jane S.; Ingram, April; Pennington, Britney O.; Hinman, Cassidy; Faynus, Mohamed A.; Bailey, Jeffrey K.; Johnson, Lincoln, V] Regenerat Patch Technol, Menlo Pk, CA USA.
   [Rahhal, Firas M.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Avery, Robert L.] Calif Retina Consultants, Santa Barbara, CA USA.
   [Salehi-Had, Hani] Atlantis Eye Care, Huntington Beach, CA USA.
   [Chen, Sanford] Orange Cty Retina Med Grp, Santa Ana, CA USA.
   [Chan, Clement] Southern Calif Desert Retina Consultants, Palm Desert, CA USA.
   [Palejwala, Neal] Retinal Res Inst LLC, Retinal Consultants Arizona, Phoenix, AZ USA.
   [Dang, Wei; Lin, Chih-Min] City Hope Natl Med Ctr, Beckman Res Inst, Ctr Biomed & Genet, Duarte, CA USA.
   [Mitra, Debbie; Mohan, Sukriti; Hinton, David R.; Humayun, Mark S.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, USC Ginsburg Inst Biomed Therapeut, 1450 San Pablo St, Los Angeles, CA 90033 USA.
   [Mitra, Debbie; Mohan, Sukriti; Hinton, David R.; Humayun, Mark S.] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, 1450 San Pablo St, Los Angeles, CA 90033 USA.
   [Pennington, Britney O.; Hinman, Cassidy; Faynus, Mohamed A.; Bailey, Jeffrey K.; Johnson, Lincoln, V; Clegg, Dennis O.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Stem Cell Biol & Engn, Santa Barbara, CA 93106 USA.
   [Rao, Narsing; Hinton, David R.] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Humayun, Mark S.] Univ Southern Calif, Dept Biomed Engn, Los Angeles, CA 90033 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Retina Vitreous
   Associates Medical Group; City of Hope; Beckman Research Institute of
   City of Hope; University of Southern California; University of Southern
   California; University of California System; University of California
   Santa Barbara; University of Southern California; University of Southern
   California
RP Humayun, MS (通讯作者)，Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, USC Ginsburg Inst Biomed Therapeut, 1450 San Pablo St, Los Angeles, CA 90033 USA.; Humayun, MS (通讯作者)，Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, 1450 San Pablo St, Los Angeles, CA 90033 USA.; Kashani, AH (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM akashan1@jhmi.edu; humayun@usc.edu
FU California Institute for Regenerative Medicine; Regenerative Patch
   Technologies LLC; Research to Prevent Blindness; National Center for
   Advancing Translational Science of the National Institutes of Health
FX Supported by the California Institute for Regenerative Medicine;
   Regenerative Patch Technologies LLC; gifts from the Lori Mars
   Foundation, William K. Bowes Foundation, Vermont Community Foundation,
   Breaux Foundation, Dennis and Michele Slivinski, and Wilcox Family
   Foundation; unrestricted departmental support to the University of
   Southern California Roski Eye Institute from Research to Prevent
   Blindness; and the National Center for Advancing Translational Science
   of the National Institutes of Health.
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Benner JD, 2002, ARCH OPHTHALMOL-CHIC, V120, P586, DOI 10.1001/archopht.120.5.586
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kashani AH, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17681
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lo DM, 2017, CURR EYE RES, V42, P98, DOI 10.3109/02713683.2016.1146776
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
NR 22
TC 11
Z9 11
U1 3
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD DEC
PY 2021
VL 10
IS 10
SI SI
AR 13
DI 10.1167/tvst.10.10.13
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YH3JF
UT WOS:000743065700004
PM 34613357
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ma, HW
   Yang, F
   Ding, XQ
AF Ma, Hongwei
   Yang, Fan
   Xi-Qin Ding
TI Deficiency of thyroid hormone receptor protects retinal pigment
   epithelium and photoreceptors from cell death in a mouse model of
   age-related macular degeneration
SO CELL DEATH & DISEASE
LA English
DT Article
ID CONE OPSIN EXPRESSION; SODIUM IODATE; BETA; MECHANISMS; TISSUE; RNA;
   DYSFUNCTION; MATURATION; STRATEGY; STRESS
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly. Progressive dystrophy of the retinal pigment epithelium (RPE) and photoreceptors is the characteristic of dry AMD, and oxidative stress/damage plays a central role in the pathogenic lesion of the disease. Thyroid hormone (TH) regulates cell growth, differentiation, and metabolism, and regulates development/function of photoreceptors and RPE in the retina. Population-/patient-based studies suggest an association of high free-serum TH levels with increased risk of AMD. We recently showed that suppressing TH signaling by antithyroid treatment reduces cell damage/death of the RPE and photoreceptors in an oxidative-stress/sodium iodate (NaIO3)-induced mouse model of AMD. This work investigated the effects of TH receptor (THR) deficiency on cell damage/death of the RPE and photoreceptors and the contribution of the receptor subtypes. Treatment with NaIO3 induced RPE and photoreceptor cell death/necroptosis, destruction, and oxidative damage. The phenotypes were significantly diminished in Thr alpha 1(-)(/)(-), Thrb(-)(/)(-), and Thrb2(-)(/)(-) mice, compared with that in the wild-type (C57BL/6 J) mice. The involvement of the receptor subtypes varies in the RPE and retina. Deletion of Thr alpha 1 or Thrb protected RPE, rods, and cones, whereas deletion of Thrb2 protected RPE and cones but not rods. Gene-expression analysis showed that deletion of Thr alpha 1 or Thrb abolished/suppressed the NaIO3-induced upregulation of the genes involved in cellular oxidative-stress responses, necroptosis/apoptosis signaling, and inflammatory responses. In addition, THR antagonist effectively protected ARPE-19 cells and hRPE cells from NaIO3-induced cell death. This work demonstrates the involvement of THR signaling in cell damage/death of the RPE and photoreceptors after oxidative-stress challenge and the receptor-subtype contribution. Findings from this work support a role of THR signaling in the pathogenesis of AMD and the strategy of suppressing THR signaling locally in the retina for protection of the RPE/retina in dry AMD.
C1 [Ma, Hongwei; Yang, Fan; Xi-Qin Ding] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center
RP Ding, XQ (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
EM xi-qin-ding@ouhsc.edu
FU BrightFocus Foundation [M2018107]; Oklahoma Center for the Advancement
   of Science and Technology; Presbyterian Health Foundation; NEI
   [P30EY021725]
FX This work was supported by the BrightFocus Foundation grant M2018107,
   the Oklahoma Center for the Advancement of Science and Technology, the
   Presbyterian Health Foundation, and the NEI grant P30EY021725. We thank
   Dr. Douglas Forrest for providing Thrb<SUP>-/-</SUP> and
   Thrb2<SUP>-/-</SUP> mouse lines. We thank Dr. Goldis Malek for providing
   hRPE cell line. We thank the Imaging Core Facility and the Histology
   Core Facility of the Department of Cell Biology at the University of
   Oklahoma Health Sciences Center for technical assistance.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Applebury ML, 2007, DEV DYNAM, V236, P1203, DOI 10.1002/dvdy.21155
   Bassett JHD, 2009, J MOL ENDOCRINOL, V42, P269, DOI 10.1677/JME-08-0142
   Brent GA, 2012, J CLIN INVEST, V122, P3035, DOI 10.1172/JCI60047
   Ceresini G, 2009, J AM GERIATR SOC, V57, P89, DOI 10.1111/j.1532-5415.2008.02080.x
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Chatziralli Irini, 2017, Biomed Hub, V2, P1, DOI 10.1159/000454706
   Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Cordas EA, 2012, ENDOCRINOLOGY, V153, P1548, DOI 10.1210/en.2011-1834
   Cruz-Guilloty F, 2011, NATURE, V478, P42, DOI 10.1038/478042a
   Duncan KG, 1999, OPHTHALMIC RES, V31, P399, DOI 10.1159/000055564
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Flamant F, 2006, PHARMACOL REV, V58, P705, DOI 10.1124/pr.58.4.3
   Forrest D, 2002, CURR OPIN NEUROBIOL, V12, P49, DOI 10.1016/S0959-4388(02)00289-1
   Forrest D, 1996, NAT GENET, V13, P354, DOI 10.1038/ng0796-354
   Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Glaschke A, 2011, J NEUROSCI, V31, P4844, DOI 10.1523/JNEUROSCI.6181-10.2011
   Golozoubova V, 2004, MOL ENDOCRINOL, V18, P384, DOI 10.1210/me.2003-0267
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Grover GJ, 2003, P NATL ACAD SCI USA, V100, P10067, DOI 10.1073/pnas.1633737100
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hashimoto K, 2001, P NATL ACAD SCI USA, V98, P3998, DOI 10.1073/pnas.051454698
   HOSODA L, 1993, ACTA OPHTHALMOL, V71, P616
   Hwang JY, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.200436
   Johnson RL, 2011, J BIOMOL SCREEN, V16, P618, DOI 10.1177/1087057111402199
   Jones I, 2007, MOL ENDOCRINOL, V21, P1108, DOI 10.1210/me.2007-0037
   Kalmijn S, 2000, CLIN ENDOCRINOL, V53, P733, DOI 10.1046/j.1365-2265.2000.01146.x
   Kindblom JM, 2001, J ENDOCRINOL, V171, P15, DOI 10.1677/joe.0.1710015
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Krieger TG, 2019, P NATL ACAD SCI USA, V116, P22754, DOI 10.1073/pnas.1908762116
   Lin SY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050902
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Ma HW, 2017, FASEB J, V31, P3425, DOI 10.1096/fj.201601166RR
   Ma HW, 2015, J BIOL CHEM, V290, P20880, DOI 10.1074/jbc.M115.641159
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   Ma HW, 2013, HUM MOL GENET, V22, P3906, DOI 10.1093/hmg/ddt245
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Minakhina S, 2020, THYROID, V30, P1193, DOI 10.1089/thy.2019.0763
   Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829
   Ng L, 2010, J NEUROSCI, V30, P3347, DOI 10.1523/JNEUROSCI.5267-09.2010
   Ng L, 2009, NEUROREPORT, V20, P627, DOI 10.1097/WNR.0b013e32832a2c63
   Pool FM, 2020, NPJ AGING MECH DIS, V6, DOI 10.1038/s41514-019-0039-5
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103
   Stempel AJ, 2014, MOL VIS, V20, P1366
   Trimarchi JM, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-101
   Volkov LI, 2020, P NATL ACAD SCI USA, V117, P15262, DOI 10.1073/pnas.1920086117
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455
   Xu JH, 2013, J NEUROSCI, V33, P14939, DOI 10.1523/JNEUROSCI.0909-13.2013
   Xu JH, 2012, INVEST OPHTH VIS SCI, V53, P1117, DOI 10.1167/iovs.11-8168
   Yang F, 2018, FASEB J, V32, P6316, DOI 10.1096/fj.201800484RR
   Yang F, 2016, FASEB J, V30, P4313, DOI 10.1096/fj.201600715R
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 60
TC 1
Z9 1
U1 1
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR 21
PY 2022
VL 13
IS 3
AR 255
DI 10.1038/s41419-022-04691-2
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA ZW8XH
UT WOS:000771488800002
PM 35314673
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kaur, I
   Hussain, A
   Hussain, N
   Das, T
   Pathangay, A
   Mathai, A
   Hussain, A
   Nutheti, R
   Nirmalan, PK
   Chakrabarti, S
AF Kaur, Inderjeet
   Hussain, Avid
   Hussain, Nazimul
   Das, Taraprasad
   Pathangay, Avinash
   Mathai, Annie
   Hussain, Anjli
   Nutheti, Rishita
   Nirmalan, Praveen K.
   Chakrabarti, Subhabrata
TI Analysis of CFH, TLR4, and APOE polymorphism in India suggests the
   Tyr402His variant of CFH to be a global marker for age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; APOLIPOPROTEIN-E GENE; SUSCEPTIBILITY LOCI;
   EPSILON-4 ALLELE; LINKAGE ANALYSIS; GENOMEWIDE SCAN; RISK-FACTORS; EYE
   DISEASE; ASSOCIATION; POPULATION
AB PURPOSE. To screen polymorphisms in complement factor-H ( CFH), toll-like receptor 4 ( TLR4), and APOE genes as potential risk factors for age-related macular degeneration ( AMD) in Indian patients.
   METHODS. One hundred patients with AMD and 120 normal control subjects were screened for the polymorphisms by restriction digestion and resequencing. Five intragenic SNPs in CFH were screened to generate haplotype data in cases and controls. The data were analyzed in conjunction with data from other populations based on genotype and haplotype frequencies, and odds ratios were computed to estimate the risk of AMD in the different genotypes.
   RESULTS. Significant association was noted with the CFH variant ( Tyr402His) among AMD cases ( P = 1.19 x 10(-7)). Individuals homozygous for the mutant genotype CC had a significantly higher risk ( P < 0.0001) of AMD ( OR = 11.52; 95% CI 5.05 - 26.28) than those carrying a single copy of the C allele ( OR = 1.51; 95% CI 0.82 - 2.80), after adjusting for age, gender, and diabetes. Linkage disequilibrium and haplotype analysis at the CFH locus indicated the C-G-T-C-A-G to be a risk haplotype ( P = 0.0003). No significant differences were observed in the genotype frequencies of APOE polymorphisms among patients and control subjects ( P = 0.76). The carriers of epsilon 4 allele had a reduced risk ( P = 0.03) of AMD ( OR = 0.42, 95% CI 0.19 - 0.91). TLR4 did not exhibit any association with AMD.
   CONCLUSIONS. The CFH polymorphism Tyr402His appears indicative of AMD pathogenesis. Diabetes, age, and gender in the presence of the homozygous "CC" genotype in CFH carry an increased risk of AMD. Hence this polymorphism could be used as a potential marker for predictive testing across continents.
C1 LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Kallam Anji Reddy Mol Genet Lab, Hyderabad, Andhra Pradesh, India.
   LV Prasad Eye Inst, Smt Kanuri Santhamma Retina Vitreous Ctr, Hyderabad, Andhra Pradesh, India.
   LV Prasad Eye Inst, Int Ctr Advancement Rural Eye Care, Hyderabad, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; L. V. Prasad Eye
   Institute
RP Chakrabarti, S (通讯作者)，LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Kallam Anji Reddy Mol Genet Lab, Rd 2,Banjara Hills, Hyderabad, Andhra Pradesh, India.
EM subho@lvpei.org
RI Kaur, Inderjeet/ABD-1833-2021; Chakrabarti, Subhabrata/F-2468-2015;
   Hussain, Nazimul/Q-7563-2019
OI Chakrabarti, Subhabrata/0000-0003-3717-4963; Hussain,
   Nazimul/0000-0001-6920-5168; Nirmalan, Praveen/0000-0003-0655-8104
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   *AG REL EYE DIS ST, 2005, OPHTHALMOLOGY, V11, P532
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2005, EUR J HUM GENET, V13, P793, DOI 10.1038/sj.ejhg.5201431
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   KAUNISTO RMV, 2000, DIABETES CARE, V23, P1672
   Kenealy SJ, 2004, MOL VIS, V10, P57
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 2003, DEV OPHTHALMOL, V37, P155
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lorenz E, 2001, BIOTECHNIQUES, V31, P22, DOI 10.2144/01311bm01
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Okamoto H, 2006, MOL VIS, V12, P156
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sambrook J., 1989, MOL CLONING LAB MANU, P17
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 48
TC 66
Z9 72
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2006
VL 47
IS 9
BP 3729
EP 3735
DI 10.1167/iovs.05-1430
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 077SP
UT WOS:000240050700006
PM 16936080
DA 2022-11-30
ER

PT J
AU Lee, SH
   Lee, SJ
   Shin, YI
   Lim, HB
   Kim, JY
   Han, YS
   Nam, KY
AF Lee, Seung Ha
   Lee, Sang Joon
   Shin, Yong Il
   Lim, Hyung Bin
   Kim, Jung Yeul
   Han, Yong Seop
   Nam, Ki Yup
TI The effect of initial intravitreal tissue plasminogen activator and gas
   injection on vision improvement in patients with submacular haemorrhage
   associated with age-related macular degeneration
SO EYE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PNEUMATIC DISPLACEMENT; SUBRETINAL
   HEMORRHAGE; NATURAL-HISTORY; VITREOUS HEMORRHAGE; MANAGEMENT; SECONDARY;
   RANIBIZUMAB
AB Purpose To compare visual improvements between initial intravitreal t-PA with gas injection before anti-vascular endothelial growth factor (VEGF) and anti-VEGF injection monotherapy for submacular haemorrhage (SMH) associated with age-related macular degeneration (AMD). Methods We retrospectively reviewed medical records of naive patients treated with intravitreal t-PA with gas injection before anti-VEGF (Group 1) or only with intravitreal anti-VEGF injection (Group 2) for SMH [disc area (DA) >= 2] associated with AMD from two institutions. Both groups received 3 monthly loads of anti-VEGF injections followed by injections as needed for AMD treatment. Changes in best-corrected visual acuity (BCVA, logMAR) between the initial visit and after 6 months of treatment were compared between two groups. Results A total of 82 patients were enroled. Of these, 32 patients and 50 patients were grouped in Groups 1 and 2, respectively. The mean change in BCVA over 6 months for Group 1 was -0.52 +/- 0.88, which was significantly larger (p = 0.044) than the mean change for Group 2 (-0.15 +/- 0.58). We compared visual improvements between the two groups based on the following SMH size categories: <= 5, >5, and <= 15, and >15 DA. When the SMH size was <= 5, or >5 and <= 15 DA, the mean change in BCVA was larger for Group 1 than for Group 2, but this difference was not significant. When SMH size was >15 DA, Group 1 patients exhibited a mean visual improvement of -0.79 +/- 0.80, which was significantly greater (p = 0.029) than that of Group 2 (-0.06 +/- 0.67). Conclusions Patients that were primarily treated for SMH associated with AMD using t-PA and gas injection (followed by anti-VEGF injection) exhibited better visual improvement than those treated with anti-VEGF monotherapy, especially in patients exhibiting larger SMH sizes (>15 DA) at the initial visit.
C1 [Lee, Seung Ha; Lee, Sang Joon] Kosin Univ, Coll Med, Dept Ophthalmol, Busan, South Korea.
   [Shin, Yong Il] Rhees Eye Hosp, Daejeon, South Korea.
   [Lim, Hyung Bin; Kim, Jung Yeul] Chungnam Natl Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
   [Han, Yong Seop] Gyeongsang Natl Univ, Coll Med, Dept Ophthalmol, Jinju, South Korea.
   [Nam, Ki Yup] Chungnam Natl Univ, Sejong Hosp, Dept Ophthalmol, Sejong, South Korea.
C3 Chungnam National University; Gyeongsang National University; Chungnam
   National University
RP Nam, KY (通讯作者)，Chungnam Natl Univ, Sejong Hosp, Dept Ophthalmol, Sejong, South Korea.
EM oksnam1231@daum.net
OI Nam, Ki Yup/0000-0002-3602-8422; Kim, Jung yeul/0000-0003-3679-1310
FU Chungnam National University Sejong Hospital Research Fund
FX This work was supported by Chungnam National University Sejong Hospital
   Research Fund, 2020.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Cho HJ, 2015, RETINA-J RET VIT DIS, V35, P205, DOI 10.1097/IAE.0000000000000295
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Fujikawa M, 2013, RETINA-J RET VIT DIS, V33, P1908, DOI 10.1097/IAE.0b013e318287d99d
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   Johnson M W, 2000, Curr Opin Ophthalmol, V11, P201, DOI 10.1097/00055735-200006000-00009
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kokame GT, 2000, AM J OPHTHALMOL, V129, P546, DOI 10.1016/S0002-9394(99)00474-2
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   Wu TT, 2005, J OCUL PHARMACOL TH, V21, P62, DOI 10.1089/jop.2005.21.62
NR 29
TC 2
Z9 2
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2021
VL 35
IS 11
BP 3064
EP 3070
DI 10.1038/s41433-020-01383-z
EA JAN 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WJ3DG
UT WOS:000606372900002
PM 33423044
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Tano, Y
   Ohji, M
AF Tano, Yasuo
   Ohji, Masahito
CA EXTEND-I Study Grp
TI Long-term efficacy and safety of ranibizumab administered pro re nata in
   Japanese patients with neovascular age-related macular degeneration in
   the EXTEND-I study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; best-corrected visual acuity score;
   efficacy; individualized flexible interval regimen; Japanese patients;
   PRN; ranibizumab; safety; subfoveal choroidal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN; PREVALENCE; THERAPY
AB Purpose:
   To evaluate the long-term efficacy and safety of ranibizumab administered pro re nata (PRN) in Japanese patients with choroidal neovascularization secondary to age-related macular degeneration during the extension phase of the EXTEND-I study.
   Methods:
   EXTEND-I, an open-label, multicenter, Phase I/II study comprised: a single-injection (Group A); a multiple-injection (Groups A and B; the latter consisted of patients who did not participate in the single-injection phase); and an extension phase. In the extension phase, a PRN regimen of ranibizumab (0.3 or 0.5 mg) guided by monthly best-corrected visual acuity (BCVA) score and other ophthalmic examinations was employed. The efficacy variables included the mean BCVA change from Month 12 to the last visit in Group B. Safety was assessed in all patients.
   Results:
   In the extension phase, efficacy was assessed only in Group B patients. The number of ranibizumab injections per year in the 0.3 and 0.5 mg Group B patients was 4.19 and 4.27, respectively. The mean BCVA change (SD) from Month 12 to the last visit was -3.6 (14.82) letters for 0.3 mg (n = 28) and -2.2 (7.92) letters for 0.5 mg groups (n = 33) in Group B. Conjunctival haemorrhage and nasopharyngitis were the most commonly reported adverse events. Of the 13 serious adverse events reported, cerebral infarction (two incidences) was suspected to be study-drug related.
   Conclusions:
   Pro re nata regimen of ranibizumab guided by monthly BCVA and other ophthalmic examinations appears effective in sustaining the BCVA gained with 12 monthly injections while reducing the number of injections during the extension phase. Ranibizumab was well tolerated during the extension phase.
C1 [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Shiga 5202192, Japan.
   [Tano, Yasuo] Osaka Univ, Sch Med, Dept Ophthalmol, Osaka, Japan.
C3 Shiga University of Medical Science; Osaka University
RP Ohji, M (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowa Cho, Shiga 5202192, Japan.
EM ohji@belle.shiga-med.ac.jp
FU Novartis Pharma
FX The authors acknowledge principal investigators for multiple-injection
   phase, Dr Yuichiro Ogura (Nagoya City University Hospital), Dr Nagahisa
   Yoshimura (Kyoto University Hospital) and Dr Shinobu Takeuchi and Dr
   Fumihiko Yagi (Toho University Ohashi Medical Center), latter principle
   investigator, Dr Nobuyuki Ohguro (Osaka University Medical School) and
   Dr Takashi Tokoro (Tokyo Medical and Dental University) for their
   contribution to the study protocol and clinical study report. The
   authors acknowledge medical writing assistance from Ajithkumar
   Vasudevan, PhD, and Aditi Gandhe, PhD, Novartis Healthcare Pvt Ltd. This
   study was funded by Novartis Pharma.
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
NR 13
TC 20
Z9 24
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2011
VL 89
IS 3
BP 208
EP 217
DI 10.1111/j.1755-3768.2010.02065.x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 751TR
UT WOS:000289641000003
PM 21232078
OA Bronze
DA 2022-11-30
ER

PT J
AU Parmeggiani, F
   Costagliola, C
   Gernmati, D
   D'Angelo, S
   Perri, P
   Scapoli, GL
   Catozzi, L
   Federici, F
   Sebastiani, A
   Incorvaia, C
AF Parmeggiani, Francesco
   Costagliola, Ciro
   Gernmati, Donato
   D'Angelo, Sergio
   Perri, Paolo
   Scapoli, Gian Luigi
   Catozzi, Linda
   Federici, Federica
   Sebastiani, Adolfo
   Incorvaia, Carlo
TI Predictive role of coagulation-balance gene polymorphisms in the
   efficacy of photodynamic therapy with verteporfin for classic choroidal
   neovascularization secondary to age-related macular degeneration
SO PHARMACOGENETICS AND GENOMICS
LA English
DT Article
DE blood coagulation factors; choroidal neovascularization; genetic
   markers; low vision; macular degeneration; pharmacogenetics;
   photodynamic therapy; single nucleotide polymorphisms
ID FACTOR-XIII; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; OXIDANT STRESS;
   LESION SIZE; DISEASE; HOMOCYSTEINE; ACTIVATION; RISK;
   HYPERHOMOCYSTEINEMIA
AB Objectives Age-related macular degeneration (AMD) represents the leading cause of blindness in Western populations. The majority of severe vision loss occurs in the exudative form of AMD, characterized by the development of choroidal neovascularization (CNV) beneath the fovea. Photodynamic therapy with verteporfin (PDT-V) represents one of the most largely employed modality that maybe achieves the subfoveal CNV inactivation in AMD patients. Although several ocular factors have been hitherto investigated as predictors, these researches have weakly contributed to PDT-V optimization. As PDT-V benefit is determined by CNV photothrombosis, we have retrospectively studied several coagulation-balance gene polymorphisms as predictors of PDT-V efficacy.
   Methods Ninety Caucasian patients with neovascular AMD were subdivided in responder and nonresponder, on the basis of CNV responsiveness to PDT-V application. Six gene polymorphisms, that is factor V G1691A, prothrombin G20210A, factor XIII-A G185T, methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, and methionine synthase reductase A66G, were genotyped in the entire cohort.
   Results Logistic regression models showed that PDT-V responders were more prevalent within patients with prothrombin G20210A mutation [odds ratio (OR)=5.6, 95% confidence interval (Cl) (1.2, 27.2), P=0.03], and within methylenetetrahydrofolate reductase 677T carriers [OR = 6.9, 95% Cl (2.7,18.1), P < 0.001]. Conversely, PDT-V nonresponders were overrepresented in carriers for factor XIII-A 185T [OR=0.13, 95% Cl (0.05, 0.36), P < 0.001].
   Conclusion These results provide evidences for the presence of pharmacogenetic relationship between peculiar coagulation-balance gene polymorphisms and different levels of PDT-V effectiveness in patients with AMD-related CNV. Pharmacogenetics and Genomics 17:1039-1046 (c) 2007 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 Univ Ferrara, Dept Ophthalmol, I-44100 Ferrara, Italy.
   Univ Ferrara, Ctr Study Hemostasis & Thrombosis, Dept Hematol, I-44100 Ferrara, Italy.
   Univ Molise, Dept Hlth Sci, Campobasso, Italy.
C3 University of Ferrara; University of Ferrara; University of Molise
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Dipartimento Discipline Med Chirurg Comun & Compo, Sez Clin Oculist, Corso Giovecca 203, I-44100 Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Costagliola, Ciro/G-5707-2012; Gemmati, Donato/E-5107-2010; Perri,
   Paolo/L-3047-2015
OI Costagliola, Ciro/0000-0001-8477-6188; Perri, Paolo/0000-0003-4652-9842;
   Gemmati, Donato/0000-0001-6213-6120; Federici,
   Federica/0000-0002-6628-3803
CR Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Ariens RAS, 2002, BLOOD, V100, P743, DOI 10.1182/blood.V100.3.743
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Austin RC, 2004, CELL DEATH DIFFER, V11, pS56, DOI 10.1038/sj.cdd.4401451
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Bernardi F, 2002, PATHOPHYSIOL HAEMO T, V32, P335, DOI 10.1159/000076692
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Castoldi E, 2004, CURR OPIN HEMATOL, V11, P176, DOI 10.1097/01.moh.0000130315.41033.32
   Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Coppola A, 2000, SEMIN THROMB HEMOST, V26, P243, DOI 10.1055/s-2000-8469
   Danckwardt S, 2006, ACTA HAEMATOL-BASEL, V115, P192, DOI 10.1159/000090934
   Dardik R, 2003, ARTERIOSCL THROM VAS, V23, P1472, DOI 10.1161/01.ATV.0000081636.25235.C6
   Framme C, 2006, GRAEF ARCH CLIN EXP, V244, P773, DOI 10.1007/s00417-005-0221-2
   Gemmati D, 2004, CANCER EPIDEM BIOMAR, V13, P787
   Gemmati D, 2001, HAEMOSTASIS, V31, P99
   Gemmati D, 2001, AM J HEMATOL, V67, P183, DOI 10.1002/ajh.1104
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holven KB, 2007, J THROMB HAEMOST, V5, P193, DOI 10.1111/j.1538-7836.2006.02275.x
   Holven KB, 2003, J NUTR, V133, P3588, DOI 10.1093/jn/133.11.3588
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kanani PM, 1999, CIRCULATION, V100, P1161, DOI 10.1161/01.CIR.100.11.1161
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Parmeggiani F, 2006, OPHTHALMOLOGY, V113, P157
   Postea O, 2006, ARTERIOSCL THROM VAS, V26, P508, DOI 10.1161/01.ATV.0000201039.21705.dc
   Rongioletti M, 2005, PLATELETS, V16, P185, DOI 10.1080/09537100400020187
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai K, 2003, J PHARMACOL SCI, V91, P182
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schwahn B, 2001, Am J Pharmacogenomics, V1, P189, DOI 10.2165/00129785-200101030-00004
   Shemirani AH, 2006, BBA-PROTEINS PROTEOM, V1764, P1420, DOI 10.1016/j.bbapap.2006.06.007
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2
   Weiss N, 2005, CURR DRUG METAB, V6, P27, DOI 10.2174/1389200052997357
   Wickens J, 2006, DRUG SAFETY, V29, P189, DOI 10.2165/00002018-200629030-00003
   Yang N, 2006, EYE, V20, P523, DOI 10.1038/sj.eye.6701991
   Ye Z, 2006, LANCET, V367, P651, DOI 10.1016/S0140-6736(06)68263-9
   Zuluaga MF, 2007, INVEST OPHTH VIS SCI, V48, P1767, DOI 10.1167/iovs.06-1224
   2005, RETINA, V25, P119
NR 54
TC 34
Z9 35
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1744-6872
J9 PHARMACOGENET GENOM
JI Pharmacogenet. Genomics
PD DEC
PY 2007
VL 17
IS 12
BP 1039
EP 1046
DI 10.1097/FPC.0b013e3282f12a4e
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
   & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
   & Pharmacy
GA 236AK
UT WOS:000251275200004
PM 18004208
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Zhao, JL
   Li, XX
   Tang, SB
   Xu, GZ
   Xu, X
   Zhang, F
   Zhang, MX
   Shamsazar, J
   Pilz, S
   Nieweg, A
AF Zhao, Jialiang
   Li, Xiaoxin
   Tang, Shibo
   Xu, Gezhi
   Xu, Xun
   Zhang, Feng
   Zhang, Meixia
   Shamsazar, Jila
   Pilz, Stefan
   Nieweg, Annette
TI EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate
   Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal
   Choroidal Neovascularization Secondary to Age-Related Macular
   Degeneration
SO BIODRUGS
LA English
DT Article
ID VISUAL IMPAIRMENT; CLINICAL-RESEARCH; VERTEPORFIN; EYE; PREVALENCE;
   THERAPY; ANCHOR; ACUITY
AB Purpose To evaluate the efficacy and safety of monthly ranibizumab 0.5 mg in Chinese patients with subfoveal choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD).
   Methods A 12-month open-label single-arm multicenter phase III study that included treatment-na < ve (study eye) patients with primary/recurrent subfoveal CNV secondary to AMD. Patients (N = 114) aged >= 50 years with best-corrected visual acuity (BCVA) of 73-24 letters were treated with monthly ranibizumab for 12 months. Main outcomes were mean BCVA change from baseline to month 4 (primary endpoint) and over time to month 12, effects of ranibizumab treatment on retinal structure (months 4 and 12), and safety.
   Results Ranibizumab led to significant improvements in mean BCVA +/- standard error (SE) at both months 4 and 12 versus baseline (+9.5 +/- 1.10 letters, 95 % confidence interval [CI] 7.3-11.7, and +12.7 +/- 1.14 letters, 95 % CI 10.4-14.9, respectively, both P < 0.0001). Ranibizumab prevented loss of vision (>= 0 letters BCVA gain) in 91.2 % of patients. Mean central retinal thickness +/- SE reduced from baseline to month 12 (-119.9 +/- 12.97 mu m, 95 % CI -145.59 to -94.20, P < 0.0001). No new safety findings were reported in this study.
   Conclusion Ranibizumab administered monthly over 12 months was effective in improving BCVA and was well-tolerated in Chinese nAMD patients.
C1 [Zhao, Jialiang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
   [Li, Xiaoxin] Peking Univ, Peoples Hosp, Ctr Eye, Beijing 100871, Peoples R China.
   [Tang, Shibo] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
   [Xu, Gezhi] Fudan Univ, Eyes & ENT Hosp, Shanghai 200433, Peoples R China.
   [Xu, Xun] Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China.
   [Zhang, Feng] Beijing Tongren Hosp, Beijing, Peoples R China.
   [Zhang, Meixia] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Shamsazar, Jila; Pilz, Stefan; Nieweg, Annette] Novartis Pharma AG, Basel, Switzerland.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Peking University; Sun Yat Sen
   University; Fudan University; Shanghai Jiao Tong University; Capital
   Medical University; Sichuan University; Novartis
RP Zhao, JL (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China.
EM zhjialiang@163.com
RI TANG, Shi/GXH-5719-2022; Zhang, meixia/AAH-6247-2019
FU Novartis Pharma AG, Switzerland
FX Novartis Pharma AG, Switzerland sponsored the study and was involved in
   the study conception and design, protocol writing, study drug provision,
   study coordination, data collection, data analysis, and interpretation.
   At all stages, the authors have had control over the content of this
   manuscript, for which they have given final approval and take full
   responsibility. Novartis Pharma AG enforces a 'no ghost-writing' policy.
   As funding sponsors, they have had the opportunity to review the
   manuscript but do not have authority to change any aspect of the
   manuscript. All authors (Jialiang Zhao, Xiaoxin Li, Shibo Tang, Gezhi
   Xu, Xun Xu, Feng Zhang, Meixia Zhang, Jila Shamsazar, Stefan Pilz, and
   Annette Nieweg) contributed to the conception, design, and conduct of
   the study, data collection, analysis, and interpretation; critical
   revision and final approval of the article.
CR Arevalo JF, 2009, RETINAL ANGIOGRAPHY, P253
   Barbazetto IA, 2008, EXPERT REV OPHTHALMO, V3, P365, DOI 10.1586/17469899.3.4.365
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   Ferris FL, 1996, OPHTHALMOLOGY, V103, P181, DOI 10.1016/S0161-6420(96)30742-2
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Kwon OW, 2012, GRAEF ARCH CLIN EXP, V250, P1467, DOI 10.1007/s00417-012-1970-3
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 24
TC 10
Z9 11
U1 0
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-8804
EI 1179-190X
J9 BIODRUGS
JI Biodrugs
PD DEC
PY 2014
VL 28
IS 6
BP 527
EP 536
DI 10.1007/s40259-014-0106-1
PG 10
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA AW0OX
UT WOS:000345993600005
PM 25012926
DA 2022-11-30
ER

PT J
AU Khurana, RN
   Rahimy, E
   Joseph, WA
   Saroj, N
   Gibson, A
   Vitti, R
   Berliner, AJ
   Chu, KR
   Cheng, YC
   Boyer, DS
AF Khurana, Rahul N.
   Rahimy, Ehsan
   Joseph, W. Anthony
   Saroj, Namrata
   Gibson, Andrea
   Vitti, Robert
   Berliner, Alyson J.
   Chu, Karen
   Cheng, Yenchieh
   Boyer, David S.
TI Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal
   Aflibercept and Ranibizumab in Neovascular Age-Related Macular
   Degeneration: Post Hoc Analysis of VIEW Trials
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR
AB PURPOSE: To evaluate outcomes and disease characteristics in eyes with neovascular age-related macular degeneration that received intravitreal aflibercept injection (IAI) and ranibizumab every 12 weeks or longer (>= q12 weeks) or less than every 12 weeks (< q12 weeks) during year 2 of VIEW studies.
   DESIGN: Post hoc analysis of randomized clinical trial data.
   METHODS: In year 1, eyes received ranibizumab q4 weeks (Rq4), IAI 2 mg q4 weeks (2q4), or IAI 2 mg q8 weeks after 3 monthly injections (2q8). In year 2, eyes received pro re nata treatment, with mandatory treatment at least q12 weeks.
   RESULTS: At week 96, 218 (42.5%), 284 (53.9%), and 245 (47.9%) eyes treated with Rq4, 2q4, and 2q8, respectively, received treatment at >= q12-week intervals and 295 (57.5%), 243 (46.1%), and 266 (52.1%) eyes at < 12q-week intervals during the second year. Baseline occult-type choroidal neovascularization (CNV) (P = .0156) and retinal fluid (P < .0001) and leakage (P < .0001) at week 52 were associated with < q12-week dosing. Mean best-corrected visual acuity gains from baseline with Rq4, 2q4, and 2q8 at >= q12-week interval were 8.7, 9.9, and 9.7 letters at week 52 and 8.5, 8.8, and 9.2 letters at week 96, respectively. The corresponding gains with < q12-week dosing were 10.3, 9.7, and 8.9 letters at week 52 and 9.1, 7.7, and 8.1 letters at week 96.
   CONCLUSIONS: Baseline CNV type other than occult and absence of retinal fluid and leakage at week 52 were significantly associated with >= q12-week dosing. Vision improvements at week 52 following a year of fixed dosing with ranibizumab and IAI were maintained at week 96 in eyes that received treatment >= q12 weeks and < q12 weeks. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Khurana, Rahul N.] Northern Calif Retina Vitreous Associates, Mountain View, CA USA.
   [Rahimy, Ehsan] Palo Alto Med Fdn, Palo Alto, CA USA.
   [Joseph, W. Anthony] Ophthalm Consultants Boston, Boston, MA USA.
   [Saroj, Namrata; Gibson, Andrea; Vitti, Robert; Berliner, Alyson J.; Chu, Karen; Cheng, Yenchieh] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, 9001 Wilshire Blvd,Ste 301, Beverly Hills, CA 90211 USA.
C3 Palo Alto Medical Foundation Research Institute; Ophthalmic Consultants
   of Boston; Regeneron; Retina Vitreous Associates Medical Group
RP Boyer, DS (通讯作者)，Retina Vitreous Associates Med Grp, 9001 Wilshire Blvd,Ste 301, Beverly Hills, CA 90211 USA.
EM vitdoc@aol.com
OI Khurana, Rahul/0000-0001-5198-1353; Rahimy, Ehsan/0000-0001-8446-7078
FU REGENERON PHARMACEUTICALS, INC., TARRYTOWN, New York, USA; Bayer
   HealthCare, Berlin, Germany
FX THE VIEW 1 AND VIEW 2 TRIALS WERE FUNDED BY REGENERON PHARMACEUTICALS,
   INC., TARRYTOWN, New York, USA and Bayer HealthCare, Berlin, Germany.
   The sponsors participated in the design and conduct of the trial,
   analysis of the data, and preparation of the manuscript.
CR [Anonymous], ASRS PAT SURV 2016
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Ohji M, 2017, EUR SOC RET SPEC EUR
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Yancopoulos GD, 2010, CELL, V143, P13, DOI 10.1016/j.cell.2010.09.028
NR 14
TC 22
Z9 24
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2019
VL 200
BP 161
EP 168
DI 10.1016/j.ajo.2019.01.005
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HT5TG
UT WOS:000464625600018
PM 30664844
OA Bronze
DA 2022-11-30
ER

PT J
AU Choudhury, F
   Varma, R
   Klein, R
   Gauderman, WJ
   Azen, SP
   McKean-Cowdin, R
AF Choudhury, Farzana
   Varma, Rohit
   Klein, Ronald
   Gauderman, W. James
   Azen, Stanley P.
   McKean-Cowdin, Roberta
CA Los Angeles Latino Eye Study Grp
TI Age-Related Macular Degeneration and Quality of Life in Latinos The Los
   Angeles Latino Eye Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; DIABETIC-RETINOPATHY; RISK-FACTORS;
   PSYCHOMETRIC PROPERTIES; CARDIOVASCULAR-DISEASE; CONTRAST SENSITIVITY;
   4-YEAR INCIDENCE; FIELD LOSS; MACULOPATHY; ACUITY
AB IMPORTANCE This study found evidence of a threshold effect in which the presence of bilateral soft drusen and depigmentation of retinal pigment epithelium was associated with substantially low health-related quality of life (HRQoL) in adult Latinos from the United States.
   OBJECTIVE To assess the association of general and vision-specific HRQoL with age-related macular degeneration (AMD), overall and by bilaterality and severity, in adult Latinos.
   DESIGN, SETTING, AND PARTICIPANTS This cross-sectional, population-based study included 4876 participants from the general urban community in 6 US Census tracts in La Puente, California. The data for these analyses were collected as part of a population-based study of ocular diseases in adult Latinos in the Los Angeles Latino Eye Study from February 1, 2000, through May 31, 2003. The analysis was performed from November 2010 to February 2011. Additional analyses were performed in June 2014.
   MAIN OUTCOMES AND MEASURES Mean-adjusted HRQoL scores and effect sizes.
   RESULTS Of the 4876 participants included in the analysis, 4402 (90.3%) had no AMD, and 474 (9.7%) had any AMD, with 453 having early (9.3%) and 21 (0.4%) having late stages of the disease. The mean (SD) age of the cohort was 54.8 (10.7) years. Of the 4876 participants, 2001 (41.0%) were male and 2875 (59.0%) were female. In this cohort of Latinos, participants with AMD had lower vision-specific HRQoL scores. General HRQoL was assessed by the Medical Outcomes Study 12-Item Short-Form Health Survey and self-reported vision-related HRQoL by the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25). Composite NEI-VFQ-25 scores were 59.5 (95% CI, 50.8-68.1) for those with late-stage AMD and 79.4 (95% CI, 72.5-86.1) for those with early-stage AMD, compared with participants without AMD 80.7 (95% CI, 73.9-82.4); P < .001. Several lesions of early AMD were associated with lower NEI-VFQ-25 composite scores and 8 to 10 individual scales. Large effect sizes and lower mean scores were observed for those with late AMD lesions, overall and specifically for geographic atrophy and neovascular AMD, compared with those without AMD. With the use of concatenated bilateral severity levels for AMD, decreases in the NEI-VFQ-25 composite and individual scale scores were observed at the transition from a unilateral to bilateral severity level of 40, which corresponds to having bilateral soft drusen (>125 mu m in diameter with drusen area >= 196 350 mu m(2)) and depigmentation of retinal pigment epithelium (slope of -19.17 for the NEI-VFQ-25 composite score). Measures of general health, as assessed by the Medical Outcomes Study 12-Item Short-Form Health Survey, were not affected in this cohort.
   CONCLUSIONS AND RELEVANCE In this study of adult Latinos, early AMD lesions are associated with lower self-reported, vision-specific HRQoL but not general HRQoL. Severity and bilaterality of AMD are associated with measurably lower HRQoL scores, with the largest difference in scores occurring for individuals with both eyes affected. A concatenated approach to incorporate bilateral severity might be more useful and provide better insight into the association of AMD and HRQoL.
C1 [Choudhury, Farzana; Varma, Rohit] Univ Southern Calif, Keck Sch Med, USC Eye Inst, Dept Ophthalmol, 1450 San Pablo St,Ste 4900, Los Angeles, CA 90033 USA.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   [Gauderman, W. James; Azen, Stanley P.; McKean-Cowdin, Roberta] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
C3 University of Southern California; University of Wisconsin System;
   University of Wisconsin Madison; University of Southern California
RP Varma, R (通讯作者)，Univ Southern Calif, Keck Sch Med, USC Eye Inst, Dept Ophthalmol, 1450 San Pablo St,Ste 4900, Los Angeles, CA 90033 USA.
FU National Eye Institute [EY-11753, EY-03040]; National Center on Minority
   Health and Health Disparities, National Institutes of Health; Research
   to Prevent Blindness; NATIONAL EYE INSTITUTE [P30EY003040, U10EY011753]
   Funding Source: NIH RePORTER
FX This work was supported by grants EY-11753 and EY-03040 from the
   National Eye Institute and the National Center on Minority Health and
   Health Disparities, National Institutes of Health and an unrestricted
   grant from Research to Prevent Blindness (Dr Varma).
CR Aamodt K, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.252302
   Abelev BI, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.022301
   Bradley C, 2001, LANCET, V357, P7, DOI 10.1016/S0140-6736(00)03562-5
   Broman AT, 2001, INVEST OPHTH VIS SCI, V42, P606
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Covert D, 2007, SURV OPHTHALMOL, V52, pS20, DOI 10.1016/j.survophthal.2006.10.014
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Du K, 2011, ENVIRON SCI TECHNOL, V45, P658, DOI 10.1021/es101904q
   Ennis S.R., 2010, HISPANIC POPULATION
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1989, OPHTHALMOLOGY, V96, P1501
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Lim JI, 2008, AGE RELATED MACULAR
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Liutkeviciene R, 2014, MEDICINA-LITHUANIA, V50, P281, DOI 10.1016/j.medici.2014.10.008
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mazhar K, 2011, OPHTHALMOLOGY, V118, P649, DOI 10.1016/j.ophtha.2010.08.003
   McKean-Cowdin R, 2008, OPHTHALMOLOGY, V115, P941, DOI 10.1016/j.ophtha.2007.08.037
   McKean-Cowdin R, 2007, AM J OPHTHALMOL, V143, P1013, DOI 10.1016/j.ajo.2007.02.022
   McKean-Cowdin R, 2010, OPHTHALMOLOGY, V117, P1900, DOI 10.1016/j.ophtha.2010.01.059
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Owsley C, 2015, CURR EYE RES, V41, P1
   Patino CM, 2011, OPHTHALMOLOGY, V118, P1310, DOI 10.1016/j.ophtha.2010.12.018
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Varma R, 2010, AM J OPHTHALMOL, V149, P3
   Varma R, 2010, INVEST OPHTH VIS SCI, V51, P6095, DOI 10.1167/iovs.10-5627
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 44
TC 11
Z9 11
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2016
VL 134
IS 6
BP 683
EP 690
DI 10.1001/jamaophthalmol.2016.0794
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR0KL
UT WOS:000379596300014
PM 27124819
OA Bronze
DA 2022-11-30
ER

PT J
AU Bandello, F
   Augustin, A
   Sahel, JA
   Benhaddi, H
   Negrini, C
   Hieke, K
   Berdeaux, GH
AF Bandello, Francesco
   Augustin, Albert
   Sahel, Jose-Alain
   Benhaddi, Hicham
   Negrini, Cristina
   Hieke, Klaus
   Berdeaux, Gilles H.
CA MICMAC Study Grp
TI Association between visual acuity and medical and non-medical costs in
   patients with wet age-related macular degeneration in France, Germany
   and Italy
SO DRUGS & AGING
LA English
DT Article
ID QUALITY-OF-LIFE; RISK-FACTORS; IMPAIRMENT; BLINDNESS; DISEASE;
   PROGRESSION; MACULOPATHY; PREVALENCE; VISION; BURDEN
AB Introduction: Exudative ('wet') age-related macular degeneration (ARMD) is the major cause of blindness in Western developed countries. Treatments aimed at preserving vision are already available and new compounds are under development. Micro-economics information will be pivotal to justifying forthcoming investment.
   Objective: This study sought to investigate the costs of exudative ARMD in patients who were actively treated at ophthalmology referral centres in three European countries: France, Germany and Italy.
   Method: This cross-sectional observational study was conducted in France, Germany and Italy in 2004. The following data were collected: ARMD description, visual acuity (VA), and the medical and non-medical resources used for ARMD in the preceding year. The economic perspective was that of society. ANOVA for cost variables estimated the impact of ARMD per eye, adjusted for sex and age. Both hospital and ambulatory eye centres were included. Patients with exudative ARMD were stratified into four levels of severity using VA thresholds of 20/200 for the worst eye (WE) and 20/40 for the best eye (BE). The main outcome measure was medical and non-medical costs.
   Results: 360 patients were included (females 60%; mean age 77 years; mean interval since diagnosis 2.3 years). The two groups with the greatest difference in severity of VA loss consisted of BE >= 20/40, WE >= 20/200 (27.2% of patients) and BE <20/40, WE <20/200 (25.5% of patients). Total cost was two-thirds medical and one-third non-medical. Total costs increased with ARMD severity and were 1.1-2 times greater for severe disease compared with less severe disease. Average medical costs (2004 values) in France were (sic)3714, compared with (sic)1810 in Germany and (sic)2020 in Italy, and showed slight increases with ARMD severity. Non-medical costs were significantly higher for patients with severe disease and highest in Germany.
   Conclusion: The impact of ARMD on costs was considerable and a positive correlation was found between total costs and ARMD severity. Differences among countries were partly explained by differences in customary care delivery.
C1 [Berdeaux, Gilles H.] Alcon France, F-92563 Rueil Malmaison, France.
   [Bandello, Francesco] Univ Udine, I-33100 Udine, Italy.
   [Augustin, Albert] Augenklin, Karlsruhe, Germany.
   [Sahel, Jose-Alain] Hop XV XX, Paris, France.
   [Benhaddi, Hicham] Aremis Consultants, Neuilly Sur Seine, France.
   [Negrini, Cristina] PBE Consulting, Verona, Italy.
   [Hieke, Klaus] Neos Hlth, Basel, Switzerland.
   [Berdeaux, Gilles H.] Conservatoire Natl Arts & Metiers, Paris, France.
C3 Novartis; Alcon; University of Udine; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; CHNO des Quinze-Vingts; UDICE-French
   Research Universities; Sorbonne Universite; heSam Universite;
   Conservatoire National Arts & Metiers (CNAM)
RP Berdeaux, GH (通讯作者)，Alcon France, 4 Rue Henri Sainte Claire Deville, F-92563 Rueil Malmaison, France.
EM gilles.berdeaux@alconlabs.com
RI Sahel, Jose-Alain/F-3172-2017; bandello, francesco/AAH-2405-2019
OI Sahel, Jose-Alain/0000-0002-4831-1153; bandello,
   francesco/0000-0003-3238-9682; Varano, Monica/0000-0002-6530-1563;
   Augustin, Prof. Dr. Albert J./0000-0003-1591-0536; Boscia,
   Francesco/0000-0002-5478-060X
CR *ADELF, 1997, DEONT BONN PRAT EP R
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   AUQUIER P, 2004, FRENCH GUIDELINES EC, P1
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brezin Antoine Pierre, 2005, Health Qual Life Outcomes, V3, P27, DOI 10.1186/1477-7525-3-27
   Brezin AP, 2005, ARCH OPHTHALMOL-CHIC, V123, P1117, DOI 10.1001/archopht.123.8.1117
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   *CTR EYE RES AUSTR, IMP AG REL MAC DEG D
   DeBlack Susan Sanders, 2003, Optometry, V74, P99
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   GARATTINI L, 1995, PHARMACOECONOMICS, V7, P1, DOI 10.2165/00019053-199507010-00001
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREINER RA, 2001, SEMIN OPHTHALMOL, V6, P218
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Korobelnik JF, 2006, INVEST OPHTH VIS SCI, V47, P4270, DOI 10.1167/iovs.05-1467
   Lafuma A, 2006, PHARMACOECONOMICS, V24, P193, DOI 10.2165/00019053-200624020-00007
   Lafuma Antoine, 2006, Eur J Health Econ, V7, P158, DOI 10.1007/s10198-006-0346-1
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nuijten M. J. C., 2001, EUR J HEALTH ECON, V2, P162, DOI [10.1007/s10198-001-0079-0, DOI 10.1007/S10198-001-0079-0]
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Schoffski O, 2000, MED KLIN, V95, P52
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soubrane G, 2002, PRESSE MED, V31, P1282
   Souetre E, 1999, BRIT J PSYCHIAT, V174, P51, DOI 10.1192/bjp.174.1.51
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   *TRANSP COMM, 2003, VERT VIS 15MG
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   *UCANSS, 2003, NOM GEN ACT PROF
NR 46
TC 13
Z9 13
U1 0
U2 5
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2008
VL 25
IS 3
BP 255
EP 268
DI 10.2165/00002512-200825030-00007
PG 14
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 283UG
UT WOS:000254661400007
PM 18331076
DA 2022-11-30
ER

PT J
AU Sagar, P
   Sodhi, PS
   Roy, S
   Takkar, B
   Azad, SV
AF Sagar, Pradeep
   Sodhi, Preetkanwar Singh
   Roy, Sangeeta
   Takkar, Brijesh
   Azad, Shorya Vardhan
TI Pachychoroid neovasculopathy: A comparative review on pathology,
   clinical features, and therapy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Pachychoroid; pachychoroid neovasculopathy; choroidal neovascular
   membrane
ID OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL
   SEROUS CHORIORETINOPATHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   VERTEPORFIN PHOTODYNAMIC THERAPY; ENDOTHELIAL GROWTH-FACTOR;
   DOUBLE-LAYER SIGN; MACULAR DEGENERATION; INTRAVITREAL INJECTION;
   SWEPT-SOURCE
AB There have been major changes in our understanding of choroidal diseases in the last decade owing to multiple retinal and choroidal imaging related advances. A major conceptual pivot is establishment of pachychoroid and its spectrum of clinical disorders: pachychoroid pigment epitheliopathy, central serous chorioretinopathy, pachychoroid neovasculopathy, polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization, peripapillary pachychoroid syndrome, and focal choroidal excavation. However, considerable overlaps in manifestations and therapeutics of these disorders make differentiation amongst them difficult. This review is focused on pathogenesis and clinical aspects of pachychoroid neovasculopathy (PNV). Since PNV was defined as a separate entity around 5 years ago, there have been numerous contrasting observations surrounding it. We review and summarize these studies, and also compare PNV with other disorders of the pachychoroid spectrum in detail. There are important differences between etiologies of neovascular age related macular degeneration and PNV. Yet the current treatment strategies for PNV have been extrapolated from the trials for the former. Future research needs to validate this assumption with long-term results.
C1 [Sagar, Pradeep] Sankara Eye Hosp, Dept Vitreo Retina, Shivamogga, India.
   [Sodhi, Preetkanwar Singh] Sodhi Eye Hosp, Dept Vitreo Retina, Patiala, Punjab, India.
   [Roy, Sangeeta] Susrut Eye Fdn & Res Ctr, Dept Vitreo Retina, Kolkata, West Bengal, India.
   [Takkar, Brijesh] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Banjara Hills, Hyderabad 500034, Telangana, India.
   [Azad, Shorya Vardhan] All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, New Delhi, India.
   [Takkar, Brijesh] Publ Hlth & Econ Res Ctr IHOPE, Indian Hlth Outcomes, Hyderabad, Telangana, India.
C3 L. V. Prasad Eye Institute; All India Institute of Medical Sciences
   (AIIMS) New Delhi; Dr. Rajendra Prasad Centre for Ophthalmic Sciences
RP Takkar, B (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Banjara Hills, Hyderabad 500034, Telangana, India.
EM britak.aiims@gmail.com
OI Takkar, Brijesh/0000-0001-5779-7645
FU Hyderabad Eye Research Foundation; DBT Wellcome Trust India Alliance
   Clinical Research Training Programme Fellowship [IA/CRC/19/1/610010]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The work
   of Dr BT is supported by a) Hyderabad Eye Research Foundation and b) the
   DBT Wellcome Trust India Alliance Clinical Research Training Programme
   Fellowship [grant number IA/CRC/19/1/610010] awarded to Dr Raja
   Narayanan and collaborators.
CR Agarwal A, 2016, MIDDLE EAST AFR J OP, V23, P27, DOI 10.4103/0974-9233.173133
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Ahn J., 2014, OPHTHALMOLOGY, V121
   Akkaya S, 2018, INT OPHTHALMOL, V38, P2239, DOI 10.1007/s10792-017-0666-4
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Arf S, 2020, JPN J OPHTHALMOL, V64, P257, DOI 10.1007/s10384-020-00730-7
   Attanasio Marcella, 2022, Retin Cases Brief Rep, V16, P300, DOI 10.1097/ICB.0000000000000962
   Azar G, 2017, ACTA OPHTHALMOL, V95, P421, DOI 10.1111/aos.13221
   Azuma K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212055
   Bayraktar Serife, 2019, Med Hypothesis Discov Innov Ophthalmol, V8, P44
   Cao XS, 2014, RETINA-J RET VIT DIS, V34, P1554, DOI 10.1097/IAE.0000000000000122
   Cao XS, 2014, OPHTHALMOLOGICA, V231, P221, DOI 10.1159/000357114
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Chan WM, 2003, AM J OPHTHALMOL, V136, P836, DOI 10.1016/S0002-9394(03)00462-8
   Chen ZY, 2019, GRAEF ARCH CLIN EXP, V257, P2111, DOI 10.1007/s00417-019-04374-3
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chhablani J, 2015, RETINA-J RET VIT DIS, V35, P2489, DOI 10.1097/IAE.0000000000000655
   Cho HJ, 2019, J OCUL PHARMACOL TH, V35, P174, DOI 10.1089/jop.2018.0107
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Cooper BA, 2000, AM J OPHTHALMOL, V130, P187, DOI 10.1016/S0002-9394(00)00395-0
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P957, DOI 10.1097/IAE.0000000000001655
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gajdzik-Gajdecka U, 2012, MED SCI MONITOR, V18, pCR51, DOI 10.12659/MSM.882455
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Gass, 1987, STEREOSCOPIC ATLAS M, P12
   Ghadiali Quraish, 2016, Retin Cases Brief Rep, V10, P293, DOI 10.1097/ICB.0000000000000301
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gupta MP, 2016, CLIN OPHTHALMOL, V10, P1275, DOI 10.2147/OPTH.S105080
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   HO AC, 1995, OPHTHALMOLOGY, V102, P782, DOI 10.1016/S0161-6420(95)30968-2
   Hosoda Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0712-z
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ibrahim AM, 2018, SEMIN OPHTHALMOL, V33, P664, DOI 10.1080/08820538.2017.1416410
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Iovino C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020595
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Karacorlu M, 2018, GRAEF ARCH CLIN EXP, V256, P2319, DOI 10.1007/s00417-018-4144-0
   Kim H, 2015, RETINA-J RET VIT DIS, V35, P481, DOI 10.1097/IAE.0000000000000354
   Kitajima Y, 2020, GRAEF ARCH CLIN EXP, V258, P1279, DOI 10.1007/s00417-020-04661-4
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Konstantinidis L, 2010, EUR J OPHTHALMOL, V20, P955, DOI 10.1177/112067211002000524
   Kovacs KD, 2020, OSLI RETINA, V51, P54, DOI 10.3928/23258160-20191211-08
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Lai TYY, 2018, RETINA-J RET VIT DIS, V38, P1464, DOI 10.1097/IAE.0000000000001744
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee JH, 2016, RETINA-J RET VIT DIS, V36, P889, DOI 10.1097/IAE.0000000000000809
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Liu BQ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0791-5
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsumoto H, 2020, JPN J OPHTHALMOL, V64, P203, DOI 10.1007/s10384-020-00722-7
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Mudvari SS, 2007, RETINA-J RET VIT DIS, V27, P1168, DOI 10.1097/IAE.0b013e318156db8a
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   PRUNTE C, 1995, INT OPHTHALMOL, V19, P77, DOI 10.1007/BF00133176
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy R, 2019, INDIAN J OPHTHALMOL, V67, P1678, DOI 10.4103/ijo.IJO_1481_18
   Sacconi R, 2019, EYE, V33, P1809, DOI 10.1038/s41433-019-0511-2
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schworm B, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65370-w
   Schworm B, 2020, GRAEF ARCH CLIN EXP, V258, P1013, DOI 10.1007/s00417-020-04623-w
   Semeraro F, 2019, CLIN OPHTHALMOL, V13, P2341, DOI 10.2147/OPTH.S220845
   Shah RC, 2019, INDIAN J OPHTHALMOL, V67, P696, DOI 10.4103/ijo.IJO_1263_18
   Sheth J, 2018, INDIAN J OPHTHALMOL, V66, P1796, DOI 10.4103/ijo.IJO_377_18
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P5103, DOI 10.1167/iovs.08-2127
   St Martin JM, 2013, OPTOMETRY VISION SCI, V90, pE293, DOI 10.1097/OPX.0000000000000079
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Terao N, 2018, INVEST OPHTH VIS SCI, V59, P5924, DOI 10.1167/iovs.18-25517
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   VONWINNING CHOM, 1982, OPHTHALMOLOGICA, V185, P7, DOI 10.1159/000309216
   Vukojevic N, 2001, COLLEGIUM ANTROPOL, V25, P83
   Waldstein SM, 2015, EYE, V29, P409, DOI 10.1038/eye.2014.319
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yang LH, 2013, INVEST OPHTH VIS SCI, V54, P4659, DOI 10.1167/iovs.12-10991
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yeo JH, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7217906
   Yin HF, 2016, SCI REP-UK, V6, DOI 10.1038/srep31880
   Zhao M, 2016, INT J OPHTHALMOL-CHI, V9, P561, DOI 10.18240/ijo.2016.04.14
NR 107
TC 1
Z9 1
U1 1
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2022
VL 32
IS 2
BP 767
EP 780
AR 11206721211036290
DI 10.1177/11206721211036290
EA JUL 2021
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZU0VX
UT WOS:000679693900001
PM 34325545
DA 2022-11-30
ER

PT J
AU Chan, WM
   Lai, TYY
   Tano, Y
   Liu, DTL
   Li, KKW
   Lam, DSC
AF Chan, WM
   Lai, TYY
   Tano, Y
   Liu, DTL
   Li, KKW
   Lam, DSC
TI Photodynamic therapy in macular diseases of Asian populations: When East
   meets West
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Asian population; central serous chorioretinopathy; choroidal
   neovascularization; photodynamic therapy; polypoidal choroidal
   vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   RANDOMIZED CLINICAL-TRIAL; INDOCYANINE GREEN ANGIOGRAPHY; PROSPECTIVE
   CASE SERIES; PATHOLOGICAL MYOPIA; NEOVASCULARIZATION SECONDARY;
   FOLLOW-UP; INTRAVITREAL TRIAMCINOLONE; LASER PHOTOCOAGULATION
AB Purpose: We reviewed the indications, safety, and efficacy of photodynamic therapy with verteporfin in various macular diseases and vasculopathies, which are common in Asian populations. and compared the outcomes of photodynamic therapy in Asian patients with the outcomes in Caucasian patients.
   Methods: Relevant clinical and laboratory original articles, case reports, and review articles that have been published in the literature between January 1999 and October 2004 were searched in Medline. The potential differences in the response to photodynamic therapy between Asian and Caucasian patients were evaluated. Articles in foreign languages with English abstracts were included.
   Results: Macular diseases commonly seen in Asian populations. including choroidal neovascularization (CNV) of age-related macular degeneration, secondary to pathologic myopia or from an idiopathic cause, and choroidal vasculopathies such as central serous chorioretinopathy and polypoidal choroidal vasculopathy were included in the review The results were tabulated and the differences with Caucasian populations were compared and highlighted.
   Conclusions: Photodynamic therapy has been found to be an effective and noninvasive treatment for various subfoveal CNV and choroidal vasculopathies of the macula. Diverse behavior in different ethnic groups is observed.
C1 Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp 3 F, Kowloon, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
   Osaka Univ, Sch Med, Dept Ophthalmol, Osaka, Japan.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Osaka University
RP Chan, WM (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp 3 F, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cwm6373@netvigator.com
RI Lai, Timothy Y Y/AAC-2120-2020; Lam, Dennis/AAL-1211-2020; Li,
   Kenneth/M-4140-2017
OI Lai, Timothy Y Y/0000-0002-7832-6428; Li, Kenneth/0000-0001-9440-8063
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Canakis C, 2003, AM J OPHTHALMOL, V136, P750, DOI 10.1016/S0002-9394(03)00397-0
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2003, OPHTHALMOLOGY, V110, P2395, DOI 10.1016/S0161-6420(03)00788-7
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cohen SY, 2003, AM J OPHTHALMOL, V136, P371, DOI 10.1016/S0002-9394(03)00201-0
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Flower RW, 1999, RETINA-J RET VIT DIS, V19, P365
   Gass JDM, 1967, AM J OPHTHALMOL, V63, P587
   Granville DJ, 2001, HISTOL HISTOPATHOL, V16, P309, DOI 10.14670/HH-16.309
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   HALL LS, 1999, RETINA VITREOUS MACU, P206
   HO AC, 1995, OPHTHALMOLOGY, V102, P782, DOI 10.1016/S0161-6420(95)30968-2
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Joseph DP, 2003, RETINA-J RET VIT DIS, V23, P463, DOI 10.1097/00006982-200308000-00003
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lam DSC, 2005, EYE, V19, P834, DOI 10.1038/sj.eye.6701681
   Lam DSC, 2004, BRIT J OPHTHALMOL, V88, P1315, DOI 10.1136/bjo.2004.041624
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Levine R, 1984, OPHTHALMOLOGY, V91, P1544
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Lindblom B, 1998, OPHTHALMOLOGY, V105, P1816, DOI 10.1016/S0161-6420(98)91021-1
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   MAZIERE JC, 1991, J PHOTOCH PHOTOBIO B, V8, P351, DOI 10.1016/1011-1344(91)80111-T
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Ohno-Matsui Kyoko, 2004, Curr Opin Ophthalmol, V15, P197, DOI 10.1097/01.icu.0000120709.35941.e9
   Oshima Y, 1998, RETINA-J RET VIT DIS, V18, P109, DOI 10.1097/00006982-199818020-00003
   Parodi MB, 2003, RETINA-J RET VIT DIS, V23, P235, DOI 10.1097/00006982-200304000-00016
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   RICHTER AM, 1990, J PHOTOCH PHOTOBIO B, V5, P231, DOI 10.1016/1011-1344(90)80008-L
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Rogers AH, 2003, OPHTHALMOLOGY, V110, P1315, DOI 10.1016/S0161-6420(03)00466-4
   Ruiz-Moreno JM, 2002, EUR J OPHTHALMOL, V12, P117, DOI 10.1177/112067210201200207
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Secretan M, 1997, Eur J Ophthalmol, V7, P307
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Shuler MF, 2001, CURR OPIN OPHTHALMOL, V12, P202, DOI 10.1097/00055735-200106000-00010
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2002, AM J OPHTHALMOL, V134, P645, DOI 10.1016/S0002-9394(02)01883-4
   Torrón Fernández-Blanco C, 2003, Arch Soc Esp Oftalmol, V78, P471
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   UYAMA M, 1991, Nippon Ganka Gakkai Zasshi, V95, P1145
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Wachtlin J, 2004, OPHTHALMOLOGE, V101, P489, DOI 10.1007/s00347-004-0993-5
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 71
TC 36
Z9 41
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR-APR
PY 2006
VL 50
IS 2
BP 161
EP 169
DI 10.1007/s10384-005-0259-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 033HD
UT WOS:000236836800015
PM 16604394
DA 2022-11-30
ER

PT J
AU Korb, CA
   Kottler, UB
   Wolfram, C
   Hoehn, R
   Schulz, A
   Zwiener, I
   Wild, PS
   Pfeiffer, N
   Mirshahi, A
AF Korb, Christina A.
   Kottler, Ulrike B.
   Wolfram, Christian
   Hoehn, Rene
   Schulz, Andreas
   Zwiener, Isabella
   Wild, Philipp S.
   Pfeiffer, Norbert
   Mirshahi, Alireza
TI Prevalence of age-related macular degeneration in a large European
   cohort: Results from the population-based Gutenberg Health Study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Age-related maculopathy; Epidemiology;
   Prevalence; Population-based study
ID BEAVER DAM EYE; SKIN SUN SENSITIVITY; BLUE MOUNTAINS EYE; RISK-FACTORS;
   10-YEAR INCIDENCE; POOLED FINDINGS; GRADING SYSTEM; 3 CONTINENTS; IRIS
   COLOR; MACULOPATHY
AB The aim of this study was to describe the sex- and age-specific prevalence of age-related macular degeneration (AMD) and its correlation with urban or rural residence in a large and relatively young European cohort.
   We evaluated fundus photographs from participants in the Gutenberg Health Study (GHS), a population-based, prospective, observational, single-centre study in the Rhineland-Palatine region in midwestern Germany. The participants were 35-74 years of age at enrolment. The fundus images were classified as described in the Rotterdam Study and were graded independently by two experienced ophthalmologists (CK and UBK) based on the presence of hard and soft drusen, retinal pigmentary abnormalities, and signs of atrophic or neovascular age-related macular generation (AMD).
   Photographs from 4,340 participants were available for grading. Small, hard drusen (< 63 mu m, stages 0b and 0c) were present in 37.4 % of participants (95 % confidence interval [CI], stage 0b, 31.6 % [30.3-33.7]; stage 0c, 5.8 % [5.1-6.5]). Early AMD (soft drusen, pigmentary abnormalities, stages 1-3) was present in 3.8 % of individuals in the youngest age group (35-44 years) (95 % CI, stage 1a, 0.4 % [0.3-0.5 %]; stage 1b, 3.2 % [2.9-3.5 %]; stage 2a, 0.1 % [0.1-0.2 %]; stage 2b, 0 % [0-0.0 %]; stage 3, 0.1 % [0.1-0.2 %]), whereas late AMD (stages 4a and 4b) did not appear in the youngest age group. In all age groups, signs of early AMD were detected in 11.9 % of individuals (stage 1a, 2.1 % [1.7-2.6]; stage 1b, 8.0 % [7.2-8.8]; stage 2a, 1.0 % [0.7-1.3]; stage 2b, 0.5 % [0.3-0.7]; stage 3, 0.3 % [0.2-0.6]). Late AMD (geographic atrophy or neovascular AMD) was found in 0.2 % of individuals (stage 4a, 0.1 % [0.0-0.2]; stage 4b, 0.1 % [0.0-0.2]). AMD increased significantly with age (odds ratio [OR], 1.09; 95 % CI, 1.08-1.10). Sex, iris colour, and residence (rural vs. urban) were not associated with different rates of AMD.
   In this study, the prevalence of AMD increased dramatically with age; however, although AMD is usually thought to occur after age 50, signs of early AMD were found in 3.8 % of individuals in the youngest age group (younger than 45 years). This population-based sample is the first to provide substantial epidemiologic data from a large German cohort, including data on macular degeneration in younger age groups and incidence data after recall.
C1 [Korb, Christina A.; Kottler, Ulrike B.; Wolfram, Christian; Hoehn, Rene; Pfeiffer, Norbert; Mirshahi, Alireza] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, D-55131 Mainz, Germany.
   [Zwiener, Isabella] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat, D-55131 Mainz, Germany.
   [Schulz, Andreas; Wild, Philipp S.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 2, D-55131 Mainz, Germany.
   [Wild, Philipp S.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Ctr Thrombosis & Hemostasis, D-55131 Mainz, Germany.
   [Wild, Philipp S.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, German Ctr Cardiovasc Res DZHK, D-55131 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg
   University of Mainz; German Centre for Cardiovascular Research; Johannes
   Gutenberg University of Mainz
RP Korb, CA (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Langenbeckstr 1, D-55131 Mainz, Germany.
EM christina.korb@unimedizin-mainz.de
RI Pfeiffer, Norbert/AAO-7586-2020; Wild, Philipp S./M-2106-2019
OI Wild, Philipp/0000-0003-4413-9752; Hohn, Rene/0000-0003-2870-1469
FU government of Rhineland-Palatine ("Stiftung Rheinland Pfalz fur
   Innovation") [AZ 961-386261/733]; University Medical Center Mainz,
   Germany; Boehringer Ingelheim, Germany; PHILIPS Medical Systems;
   Novartis
FX The Gutenberg Health Study is funded through the government of
   Rhineland-Palatine ("Stiftung Rheinland Pfalz fur Innovation", contract
   number AZ 961-386261/733); the research programs "Wissen schafft
   Zukunft" and "Schwerpunkt Vaskulaere Praevention" of the University
   Medical Center Mainz, Germany, and its contract with Boehringer
   Ingelheim, Germany; and PHILIPS Medical Systems, including an
   unrestricted grant for the Gutenberg Health Study. The Department of
   Ophthalmology received a grant from Novartis.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Heijl A, 2005, ACTA OPHTHALMOL SCAN, V83, P278, DOI 10.1111/j.1600-0420.2005.00500.x
   Hoehn R, 2013, OPHTHALMOLOGY, V120, P961, DOI 10.1016/j.ophtha.2012.10.031
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krumpaszky H. G., 1996, Ophthalmologica, V210, P1
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mirshahi A, 2013, OPHTHALMOLOGE, V110, P210, DOI 10.1007/s00347-012-2666-0
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stang A, 1999, EPIDEMIOLOGY, V10, P181, DOI 10.1097/00001648-199903000-00017
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P53
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wild PS, 2012, BUNDESGESUNDHEITSBLA, V55, P824, DOI 10.1007/s00103-012-1502-7
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 42
TC 50
Z9 50
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2014
VL 252
IS 9
BP 1403
EP 1411
DI 10.1007/s00417-014-2591-9
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO9WA
UT WOS:000341709000007
PM 24566902
DA 2022-11-30
ER

PT J
AU Angermann, R
   Franchi, A
   Stockl, V
   Rettenwander, J
   Rettenwander, T
   Goldin, D
   Stattin, M
   Kralinger, MT
   Zehetner, C
AF Angermann, Reinhard
   Franchi, Alexander
   Stoeckl, Victoria
   Rettenwander, Julia
   Rettenwander, Tanja
   Goldin, David
   Stattin, Martin
   Kralinger, Martina T.
   Zehetner, Claus
TI Intravitreal Aflibercept Therapy and Treatment Outcomes of Eyes with
   Neovascular Age-Related Macular Degeneration in a Real-Life Setting: A
   Five-Year Follow-Up Investigation
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Anti-VEGF; Compliance; Macular degeneration; Nonpersistence; Vision loss
ID RANIBIZUMAB; ADHERENCE
AB Introduction We aimed to evaluate visual and anatomical outcomes among eyes with neovascular age-related macular degeneration (nAMD) that were persistent to intravitreal aflibercept therapy compared to those that were nonpersistent to therapy. Methods We audited 648 treatment-naive eyes of 559 patients regarding visual acuity (VA) given as the logarithm of the minimum angle of resolution (logMAR) and anatomic outcomes at baseline and at each subsequent follow-up visit for up to 5 years. Nonpersistence was defined as a visit-free interval of > 6 months. Results Among the enrolled eyes, 405 were persistent to the therapy and 243 (37%) were nonpersistent, of which 161 (66%) eyes returned for further therapy after a gap of clinical care. In the nonpersistent group, we observed a decline from 0.58 +/- 0.35 to 0.92 +/- 0.57 logMAR (p = 0.01) after 60 months. Compared with the persistent group, the nonpersistent group had worse visual outcomes at their 33-month (p = 0.03), 42-month (p = 0.01), 51-month (p = 0.001) and 60-month (p = 0.01) visits. Additionally, 5/405 (1.2%) eyes in the persistent group and 8/161 (5.0%) eyes in the nonpersistent group developed an end-stage disease with a subfoveal fibrosis during the observational period (p = 0.013). Conclusion We found that eyes with nAMD that were nonpersistent to intravitreal aflibercept therapy experienced statistically significantly worse VA compared to eyes persistent to therapy within 3 years. Moreover, eyes in the nonpersistent group had a four-fold higher risk of developing a fovea-involving fibrosis. Considering the potential irreversible deterioration with respect to best-corrected VA within nAMD, strategies need to be developed for patients at risk of nonpersistence to therapy.
C1 [Angermann, Reinhard; Franchi, Alexander; Stoeckl, Victoria; Rettenwander, Julia; Rettenwander, Tanja; Goldin, David; Kralinger, Martina T.; Zehetner, Claus] Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
   [Angermann, Reinhard] Paracelsus Med Univ Salzburg, Dept Ophthalmol, Salzburg, Austria.
   [Stattin, Martin] Vienna Healthcare Grp, Dept Ophthalmol, Clin Landstr, Vienna, Austria.
   [Stattin, Martin] Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.
C3 Medical University of Innsbruck; Paracelsus Private Medical University
RP Zehetner, C (通讯作者)，Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
EM claus.zehetner@i-med.ac.at
OI Goldin, David/0000-0002-9942-9100; Zehetner, Claus/0000-0003-1405-7457
CR Angermann R, 2019, GRAEF ARCH CLIN EXP, V257, P2119, DOI 10.1007/s00417-019-04414-y
   Averitt AJ, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0277-8
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Downer SR, 2005, MED J AUSTRALIA, V183, P366, DOI 10.5694/j.1326-5377.2005.tb07085.x
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Okada M, 2021, JAMA OPHTHALMOL, V139, P769, DOI 10.1001/jamaophthalmol.2021.1660
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Perepelkina T, 2021, SEMIN OPHTHALMOL, V36, P304, DOI 10.1080/08820538.2021.1896756
   Rauchegger T, 2020, KLIN MONATSBL AUGENH, V237, P789, DOI 10.1055/a-1008-9357
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1318, DOI 10.1097/IAE.0000000000003023
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sekeroglu MA, 2022, EUR J OPHTHALMOL, V32, P1064, DOI 10.1177/11206721211010613
   Soares RR, 2020, OPHTHALMOL RETINA, V4, P134, DOI 10.1016/j.oret.2019.07.010
   Starr MR, 2019, AM J OPHTHALMOL, V208, P206, DOI 10.1016/j.ajo.2019.03.021
   Stattin M, 2021, OPHTHALMOL THER, V10, P935, DOI 10.1007/s40123-021-00381-y
   Teo KYC, 2021, EYE, V35, P2793, DOI 10.1038/s41433-020-01315-x
   Wang XX, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0635-7
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
   Yeter DY, 2021, J FR OPHTALMOL, V44, P299, DOI 10.1016/j.jfo.2021.02.001
   Yoshida I, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/5308597
NR 27
TC 0
Z9 0
U1 2
U2 4
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD APR
PY 2022
VL 11
IS 2
BP 559
EP 571
DI 10.1007/s40123-022-00452-8
EA JAN 2022
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZU8LH
UT WOS:000744396200001
PM 35048330
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schroeder, M
   Westborg, I
   Fluur, C
   Olsen, R
   Lovestam-Adrian, M
AF Schroeder, Marion
   Westborg, Inger
   Fluur, Caroline
   Olsen, Rasmus
   Lovestam-Adrian, Monica
TI Exploration of real-world outcomes and treatment patterns in patients
   treated with anti-vascular endothelial growth factors for neovascular
   age-related macular degeneration in Sweden
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-vascular endothelial growth factor; neovascular age-related macular
   degeneration; real world; Swedish macula register
ID RANIBIZUMAB; EXTEND; AFLIBERCEPT; THERAPY; REGIMENS; EFFICACY; VISION;
   SAFETY
AB Purpose To analyse and compare the number and interval of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (nAMD), as well as the visual development in patients followed up for one to three years in clinical practice and during different index periods. Methods This observational study included treatment-naive eyes with nAMD from the Swedish Macula Register that started treatment between 2007 and 2017, stratified by different index periods (2007-2010, 2011-2013, 2014-2015 and 2016-2017) and by follow-up cohorts for each index period of one, two or three years (cohorts 1-3). Their intravitreal anti-VEGF treatment was assessed by number of injections, injection intervals, visual acuity (VA) and near VA change. Results From the earliest index period 2007-2010 to the latest 2016-2017, the number of injections increased for the comparable follow-up time; 6.2 +/- 1.4 versus 8.3 +/- 2.0 injections after 1 year of treatment, 4.8 +/- 1.6 versus 6.7 +/- 2.4 during year 2. The last injection interval was 73 +/- 34 days after 1, 71 +/- 33 after 2 and 67 +/- 32 after 3 years of follow-up for the index period 2014-2015. For the same period, the percentage of eyes with at least two consecutive 12-16 weeks of injection interval over 1-, 2- and 3-year follow-up increased from 5.2%, 15.0%, to 17.5% respectively. Baseline VA for eyes indexed 2016-2017 increased and presented with 62.1 +/- 13.4 letters compared with 57.7 +/- 13.5 letters in 2007-2010; p < 0.0001. Conclusions From the earliest to the latest index periods, the number of injections increased for the comparable follow-up time. Accordingly, baseline VA and near VA and their outcomes improved continuously.
C1 [Schroeder, Marion; Lovestam-Adrian, Monica] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Div Ophthalmol, Lund, Sweden.
   [Westborg, Inger] Uppsala Univ, Dept Neurosci Ophthalmol, Uppsala, Sweden.
   [Fluur, Caroline] Novartis Sverige AB, Kista, Sweden.
   [Olsen, Rasmus] Novartis Healthcare AS, Copenhagen, Denmark.
C3 Lund University; Skane University Hospital; Uppsala University; Novartis
RP Schroeder, M (通讯作者)，Lund Univ, Dept Ophthalmol, SE-22185 Lund, Sweden.
EM marion.schroeder@med.lu.se
CR Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Kiss S, 2020, OPHTHALMOLOGY, V127, P1179, DOI 10.1016/j.ophtha.2020.02.027
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Svenska Makula Registret, 2018, RSRAPP 2018
   Svenska Makula Registret, 2019, RSRAPP 2019
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   Textskalor Syntr?ningsavdelning Tomtebodaskolan., 1977, TEXTSK UT TOMT STAND
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 21
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2022
VL 100
IS 4
BP E928
EP E935
DI 10.1111/aos.15025
EA SEP 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1A9ZF
UT WOS:000697253400001
PM 34543528
OA Green Published
DA 2022-11-30
ER

PT J
AU Roald, AB
   Aass, HCD
   Moe, MC
AF Roald, Anca B.
   Aass, Hans C. D.
   Moe, Morten C.
TI Recovery of plasma vascular endothelial growth factor concentrations
   during aflibercept loading phase and after the transition to bimonthly
   treatment for neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL INJECTION; RANIBIZUMAB; BEVACIZUMAB; SERUM
AB Aims To provide data on plasma vascular endothelial growth factor (VEGF) concentration during three consecutive monthly intravitreal aflibercept injections and after transition to bimonthly treatment in patients with neovascular age-related macular degeneration (nAMD).
   Methods Sixteen consecutive treatment-naive Caucasian patients with nAMD were included in the study. The treatment consisted of one intravitreal aflibercept (2 mg) injection every 28 days for three consecutive months followed by a fourth injection 8 weeks later. VEGF plasma concentrations were measured with Luminex on day 0 (baseline, prior to first injection); days 1, 6 and 27 (prior to second injection); day 55 (prior to third injection) and days 97 and 111 (after third injection).
   Results Baseline plasma VEGF concentration was 59.6 +/- 13.3 pg/mL. Aflibercept decreased plasma VEGF concentration to 32.5 +/- 3 pg/mL on day 1 (p<0.0001) and 34.7 +/- 6.3 pg/mL on day 6 (p<0.0001). On day 27, the VEGF plasma level increased to 50.6 +/- 6.5 pg/mL (p=0.009) and on day 55 to 52.8 +/- 8.8 pg/mL (p=0.027). There was no statistically significant difference between mean plasma VEGF concentrations on days 27 and 55 (p=0.139). Plasma VEGF concentration recovered completely 6 weeks after the third injection, reaching 57.9 +/- 9.6 pg/mL on day 97 (p=0.600) and 59.5 +/- 11.6 pg/mL on day 111 (p=0.987).
   Conclusions Intravitreal aflibercept decreases plasma VEGF concentration mostly in the first week after treatment. Despite repeated monthly intravitreal injections, there was a monthly increase in plasma VEGF values to near baseline levels, with complete recovery 6 weeks after the third injection.
C1 [Roald, Anca B.; Moe, Morten C.] Oslo Univ Hosp, Dept Ophthalmol, N-0450 Oslo, Norway.
   [Aass, Hans C. D.] Oslo Univ Hosp, Dept Med Biochem, N-0450 Oslo, Norway.
   [Moe, Morten C.] Univ Oslo, Fac Med, Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo
RP Roald, AB (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Kirkeveien 166, N-0450 Oslo, Norway.
EM uxranc@ous-hf.no
FU Department of Ophthalmology, Oslo University Hospital, Norway
FX The study was funded by the Department of Ophthalmology, Oslo University
   Hospital, Norway.
CR Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Davidovic SP, 2012, EUR J OPHTHALMOL, V22, P792, DOI 10.5301/ejo.5000118
   Enders P, 2015, RETINA-J RET VIT DIS, V35, P454, DOI 10.1097/IAE.0000000000000320
   Gounant V, 2009, REV MAL RESPIR, V26, P221, DOI 10.1016/S0761-8425(09)71598-0
   Qi WX, 2014, CLIN DRUG INVEST, V34, P231, DOI 10.1007/s40261-014-0174-5
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart Michael W., 2011, Inflammation & Allergy Drug Targets, V10, P497
   Trichonas G, 2013, OPHTHALMOL THER, V2, P89, DOI 10.1007/s40123-013-0015-2
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 13
TC 3
Z9 3
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2015
VL 99
IS 12
BP 1610
EP 1613
DI 10.1136/bjophthalmol-2015-306781
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW8YJ
UT WOS:000365285100006
PM 25966740
DA 2022-11-30
ER

PT J
AU Wakabayashi, T
   Gomi, F
   Sawa, M
   Tsujikawa, M
   Nishida, K
AF Wakabayashi, Taku
   Gomi, Fumi
   Sawa, Miki
   Tsujikawa, Motokazu
   Nishida, Kohji
TI Intravitreal bevacizumab for exudative branching vascular networks in
   polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CYSTOID MACULAR EDEMA; PHOTODYNAMIC THERAPY; INDOCYANINE GREEN; CLINICAL
   CHARACTERISTICS; JAPANESE PATIENTS; FOLLOW-UP; DEGENERATION;
   ANGIOGRAPHY; VERTEPORFIN
AB Aims To assess the long-term efficacy of intravitreal bevacizumab for recurrent leakage owing to the residual branching vascular networks in polypoidal choroidal vasculopathy after photodynamic therapy.
   Methods Forty-five eyes with exudative branching vascular networks were treated with intravitreal bevacizumab and followed for at least 24 months. Original polypoidal lesions had been treated successfully with previous photodynamic therapy in all eyes. The best-corrected visual acuity and retinal morphological changes were assessed retrospectively.
   Results Exudative branching vascular networks were characterised as occult choroidal neovascularisation (38 eyes) or classic choroidal neovascularisation (7 eyes) on fluorescein angiography. Intravitreal bevacizumab maintained or improved vision in 38 eyes (84%) over 12 months and in 36 eyes (80%) over 24 months, although the mean visual acuity at 12 and 24 months did not differ significantly compared with baseline. Complete resolution of macular fluid was achieved continuously in 26 eyes (58%) during 24 months. Sixteen eyes (36%) responded once to treatment but became unresponsive to additional injections for recurrent exudation. Three eyes (7%) were refractory to treatment throughout follow-up. Cystoid macular oedema eventually developed in 10 eyes and was a poor prognostic sign for visual outcome.
   Conclusion Intravitreal bevacizumab improved the retinal morphology and maintained vision over 1 year in most eyes with recurrent fluid owing to persistent abnormal vascular networks in polypoidal choroidal vasculopathy. The therapeutic response, however, may decrease during the second year.
C1 [Wakabayashi, Taku; Gomi, Fumi; Sawa, Miki; Tsujikawa, Motokazu; Nishida, Kohji] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Dept Ophthalmol, Grad Sch Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Nishida, Kohji/0000-0001-9069-3610; Gomi, Fumi/0000-0003-0807-8817
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kiernan DF, 2009, AM J OPHTHALMOL, V147, P267, DOI 10.1016/j.ajo.2008.08.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SOUBRANE G, 1988, J FR OPHTALMOL, V11, P711
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 25
TC 26
Z9 27
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2012
VL 96
IS 3
BP 394
EP 399
DI 10.1136/bjo.2011.204123
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 896XO
UT WOS:000300604900019
PM 21719568
DA 2022-11-30
ER

PT J
AU Imamura, Y
   Engelbert, M
   Iida, T
   Freund, KB
   Yannuzzi, LA
AF Imamura, Yutaka
   Engelbert, Michael
   Iida, Tomohiro
   Freund, K. Bailey
   Yannuzzi, Lawrence A.
TI Polypoidal Choroidal Vasculopathy: A Review
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; antivasogenic treatment; fluorescein
   angiography; genetics; indocyanine green angiography; optical coherence
   tomography; pathogenesis; photodynamic therapy; polypoidal choroidal
   vasculopathy
ID INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY;
   INTRAVITREAL BEVACIZUMAB INJECTION; PIGMENT EPITHELIAL DETACHMENT;
   PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; JAPANESE PATIENTS; LASER
   PHOTOCOAGULATION; GENE POLYMORPHISMS; FEATURES
AB More than a quarter century has passed since the original description of polypoidal choroidal vasculopathy (PCV) in 1982 as a peculiar hemorrhagic disorder involving the macula characterized by recurrent subretinal pigment epithelial bleeding. lit the ensuing years, numerous reports have described the expanded clinical spectrum of this entity PCV is the principal vascular composition of patients of pigmented races experiencing neovascular maculopathies, particularly African Americans and Asians. This form of neovascularization is now known to occur in white patients with or without concomitant drusen, and the site of involvement has extended from the peripapillary area to the peripheral fundus Indocyanine green angiography has made detection of these abnormal vascular changes more reliable and definitive. More precise diagnosis has also led to a better understanding of specific clinical features that distinguish PCV from more typical proliferations of abnormal choroidal vessels We review the nature of PCV, including its genetic basis, demographic features, histopathology, clinical manifestations, natural course, response to treatments, and the histopathological and genetic bases:We emphasize Ill tilt ophthalmic imaging of these vessels. in particular fluorescein and Indocyanine green angiography and optical coherence tomography. (Surv Ophthalmol 55:501-515, 2010. (c) 2010 Elsevier Inc All rights reserved.)
C1 [Imamura, Yutaka; Engelbert, Michael; Freund, K. Bailey; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Imamura, Yutaka; Engelbert, Michael; Freund, K. Bailey; Yannuzzi, Lawrence A.] Manhattan Eye Ear & Throat Hosp, LuEster T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Iida, Tomohiro] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Fukushima Medical University
RP Yannuzzi, LA (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY USA.
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation Inc at LuEsther T Mertz Retinal Research Center;
   Manhattan Eye, Ear, and Throat Hospital, New York, New York; Komeisha
   Ganslukkan Kenkyu Zaidan; Mishima Sauchi-kinen Gankakenkyu Kokusarkouryu
   Kikin; Takeda Kagaku Shinkou Zaidan
FX Publication of this article was supported in part by the Macula
   Foundation Inc at LuEsther T Mertz Retinal Research Center. Manhattan
   Eye, Ear, and Throat Hospital, New York, New York Dr Imamura was funded
   by grants from Komeisha Ganslukkan Kenkyu Zaidan. Mishima Sauchi-kinen
   Gankakenkyu Kokusarkouryu Kikin, and Takeda Kagaku Shinkou Zaidan The
   authors reported no proprietary or commercial interest in any product
   mentioned or concept discussed in this article. The authors would like
   to thank Dr Hidetoshi Yamashita for his contribution towards the
   preparation of materials in this article
CR ABE S, 2010, OPHTHAL SURG LAS IM, DOI DOI 10.3928/15428877-20100215-761
   Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   AKAZA E, 2008, RETINA, V28, P712
   Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Escano MFT, 2000, JPN J OPHTHALMOL, V44, P313, DOI 10.1016/S0021-5155(99)00224-5
   Fine Howard F, 2008, Retin Cases Brief Rep, V2, P15, DOI 10.1097/ICB.0b013e318159e7e9
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Giovannini A, 1999, DOC OPHTHALMOL, V97, P367, DOI 10.1023/A:1002102630242
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Iida T, 2002, RETINA-J RET VIT DIS, V22, P455, DOI 10.1097/00006982-200208000-00010
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   KITAMURA T, 1995, JPN J CLIN OPHTHAL, V49, P208
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   KUSASHIGE Y, 2008, AM J OPHTHALMOL, V146, P513
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   LEE S, 2008, APPL PHYS LETT, V92, pNIL94
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Li HT, 2004, RETINA-J RET VIT DIS, V24, P629, DOI 10.1097/00006982-200408000-00026
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   NAKAJIMA M, 2004, IPIT OPHTLIAMOL, V48, P249
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   OSHMIA Y, 2007, BR J OPHTHALMOL, V91, P193
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Phillips WB, 1996, OPHTHALMIC SURG LAS, V27, P467
   Prakash M, 2006, AM J OPHTHALMOL, V142, P1079, DOI 10.1016/j.ajo.2006.06.059
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SILVA RM, 2005, CRADLES ATCH CHIT, V243, P973
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   TATEIWA H, 2002, OPLITHALINOL, V240, P354
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2008, CLIN EXP OPHTHALMOL, V36, P817, DOI 10.1111/j.1442-9071.2009.01907.x
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   UYAMA M, 1991, ACTA SOC OPHTHALMOL, V95, P1145
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yodoi Yuko, 2008, International Ophthalmology, V28, P297, DOI 10.1007/s10792-007-9129-7
   Yodoi Y, 2007, AM J OPHTHALMOL, V143, P984, DOI 10.1016/j.ajo.2007.01.026
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 118
TC 200
Z9 215
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD NOV-DEC
PY 2010
VL 55
IS 6
BP 501
EP 515
DI 10.1016/j.survophthal.2010.03.004
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 673WG
UT WOS:000283694300001
PM 20850857
DA 2022-11-30
ER

PT J
AU Bakri, SJ
   Kaiser, PK
AF Bakri, SJ
   Kaiser, PK
TI Anecortave acetate
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE anecortave acetate; angiogenesis; angiostatic; choroidal
   neovascularisation; cortisene; juxtascleral; inacular degeneration;
   periocular
ID AGE-RELATED MACULOPATHY; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   ANGIOSTATIC STEROIDS; VERTEPORFIN; PREVALENCE; CAM
AB This manuscript reviews the pharmacotherapeutics of the novel, angiostatic cortisene, anecortave acetate suspension, for the treatment of age-related macular degeneration. The chemistry; pharmacokinetics and pharmacodynamics of anecortave acetate are discussed, and the results of the multi-centre, randomised, controlled clinical trials for the treatment of subfoveal choroidal neovascularisation in age-related macular degeneration summarised. It also discusses ongoing clinical trials involving anecortave acetate for dry and wet age-related macular degeneration.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   BERKOW JW, 1984, AM J OPHTHALMOL, V97, P143, DOI 10.1016/S0002-9394(14)76083-0
   BINGAMAN DP, 2004, INVEST OPHTH VIS SCI, V45, pE1850
   BLEI F, 1993, J CELL PHYSIOL, V155, P568, DOI 10.1002/jcp.1041550315
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   Casey R, 1997, AM J OPHTHALMOL, V124, P521, DOI 10.1016/S0002-9394(14)70868-2
   Cebulla CM, 2005, INVEST OPHTH VIS SCI, V46, pE1106
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P1126, DOI 10.1016/S0161-6420(13)30905-1
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   MCNATT LG, 1992, J STEROID BIOCHEM, V42, P687, DOI 10.1016/0960-0760(92)90109-V
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   YANG R, 2005, INVEST OPHTH VIS SCI, V46, pE4177
   YANG R, 2004, INVEST OPHTH VIS SCI, V45, pE1914
NR 29
TC 6
Z9 6
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD FEB
PY 2006
VL 15
IS 2
BP 163
EP 169
DI 10.1517/13543784.15.2.163
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 013SQ
UT WOS:000235430100008
PM 16433595
DA 2022-11-30
ER

PT J
AU Angermann, R
   Franchi, A
   Frede, K
   Stockl, V
   Palme, C
   Kralinger, M
   Zehetner, C
AF Angermann, Reinhard
   Franchi, Alexander
   Frede, Katharina
   Stockl, Victoria
   Palme, Christoph
   Kralinger, Martina
   Zehetner, Claus
TI Long-term persistence with aflibercept therapy among treatment-naive
   patients with exudative age-related macular degeneration in a universal
   health care system: a retrospective study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Adherence; Long-term effect of compliance; Loss to follow-up;
   Persistence; Aflibercept; Age-related macular degeneration
ID GROWTH-FACTOR THERAPY; RANIBIZUMAB; ADHERENCE; INJECTION
AB Background This study aimed to analyse the persistence rates of treatment-naive patients with neovascular age-related macular degeneration (nAMD) who received intravitreal aflibercept therapy in a universal health care system. Methods In this single-centre retrospective cohort study, we audited data of 918 treatment-naive patients who received exclusively intravitreal aflibercept therapy for nAMD between September 2015 and May 2021. The primary outcome measures were the rates of treatment nonpersistence (gap in ophthalmological care > 6 months) and long-term nonpersistence (> 12 months). Results The rates of nonpersistence and long-term nonpersistence were 12.3% and 3.4% after one year; 22.4% and 9.5% after two years; and 38.3% and 19.3% after five years, respectively. Logistic regression analysis revealed that older age (p = 0.045), male sex (p = 0.039), requirement for caretakers or ambulance (p = 0.001), and low visual acuity of the study eye (p = 0.010) or fellow eye (p = 0.029) were independent risk factors for long-term nonpersistence. Patients aged > 80 and > 85 years (p = 0.013 and p = 0.022, respectively) had more than twice the risk for being nonpersistent to therapy within two years of follow-up compared with younger patients. Male patients (p = 0.033), patients requiring a caretaker (p = 0.038), and patients living > 60 km from the clinic (p = 0.029) had a 2 x higher risk of being persistently nonpersistent to therapy. Conclusions Patients with nAMD who were treated with aflibercept had lower nonpersistence rates than those reported in current literature. Multiple independent risk factors were correlated with long-term nonpersistence, early nonpersistence, or complete loss to follow-up. Considering the possible consequences of reduced compliance, further strategies are urgently needed for patients at risk of nonpersistence to therapy.
C1 [Angermann, Reinhard; Franchi, Alexander; Frede, Katharina; Stockl, Victoria; Palme, Christoph; Kralinger, Martina; Zehetner, Claus] Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
   [Angermann, Reinhard] Landesklinikum Mistelbach Ganserndorf, Dept Ophthalmol, Lichtensteinstr 67, A-2130 Mistelbach, Austria.
C3 Medical University of Innsbruck
RP Zehetner, C (通讯作者)，Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
EM claus.zehetner@i-med.ac.at
CR Angermann R, 2022, KLIN MONATSBL AUGENH, DOI 10.1055/a-1830-0505
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Brady CJ, 2020, TELEMED E-HEALTH, V26, P565, DOI 10.1089/tmj.2020.0011
   Downer SR, 2005, MED J AUSTRALIA, V183, P366, DOI 10.5694/j.1326-5377.2005.tb07085.x
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Elam AR, 2013, SURV OPHTHALMOL, V58, P348, DOI 10.1016/j.survophthal.2012.07.005
   Heimes B, 2016, OPHTHALMOLOGE, V113, P925, DOI 10.1007/s00347-016-0275-z
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Okada M, 2021, JAMA OPHTHALMOL, V139, P769, DOI 10.1001/jamaophthalmol.2021.1660
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Perepelkina T, 2021, SEMIN OPHTHALMOL, V36, P304, DOI 10.1080/08820538.2021.1896756
   Piccirillo JF, 2008, CRIT REV ONCOL HEMAT, V67, P124, DOI 10.1016/j.critrevonc.2008.01.013
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Starr MR, 2019, AM J OPHTHALMOL, V208, P206, DOI 10.1016/j.ajo.2019.03.021
   Stattin M, 2021, OPHTHALMOL THER, V10, P935, DOI 10.1007/s40123-021-00381-y
   Stone LG, 2021, GRAEF ARCH CLIN EXP, V259, P1773, DOI 10.1007/s00417-021-05174-4
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 26
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 19
PY 2022
VL 22
IS 1
AR 372
DI 10.1186/s12886-022-02593-7
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4P6CK
UT WOS:000855480600001
PM 36123657
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Sahoo, NK
   Mehta, MC
   Rani, PK
   Khanna, RC
   Raman, R
   Bhattacharya, J
   Das, AV
   Murthy, GVS
   Narayanan, R
AF Sahoo, Niroj K.
   Mehta, Mehul C.
   Rani, Padmaja K.
   Khanna, Rohit C.
   Raman, Rajiv
   Bhattacharya, Jayanta
   Das, Anthony, V
   Murthy, Gudlavalleti V. S.
   Narayanan, Raja
TI Impact of age-related macular degeneration on diabetic retinopathy: An
   electronic health record based big data analysis from a tertiary eye
   centre in South India
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; AMD; diabetic retinopathy; DR
ID MACULOPATHY
AB Purpose: To determine whether the presence of age-related macular degeneration (AMD) decreases the risk of diabetic retinopathy. Methods: This was a retrospective, case-cohort study performed in patients with a systemic diagnosis of diabetes at a tertiary health care center from May 2011 to April 2020. A total of 43,153 patients (1,024 AMD patients and 42,129 non-AMD patients) were included in the analysis. A total of 1,024 age and diabetes mellitus (DM) duration-matched controls were chosen from the non-AMD group for risk factor analysis. The severity of diabetic retinopathy was compared between the patients with AMD and the patients without AMD. Results: Out of the enrolled 43,153 diabetic patients, 26,906 were males and 16,247 were females. A total of 1,024 patients had AMD and 42,129 had no AMD. The mean age of the cohort was 58.60 +/- 0.09 years. The overall prevalence of DR was noted to be 22.8% (9,825 out of 43,153 eyes). A significantly lower prevalence of diabetic retinopathy (DR) (23% in non-AMD, 11.4% in AMD, OR = -0.43, P < 0.001), non-proliferative diabetic retinopathy (NPDR) (12% in non-AMD, 8.2% in AMD, OR = -0.66, P < 0.001), and proliferative diabetic retinopathy (PDR) (11% in non-AMD, 3.2% in AMD, OR = -0.27, P < 0.001) was seen in the AMD patients. No significant difference was seen between the dry and wet AMD. On multivariate logistic regression analysis, the lower age, absence of AMD, and male gender were associated with a higher risk of PDR. Conclusion: The presence of AMD was noted to statistically reduce the risk of DR. Our results may be useful in the field of resource allocation and awareness of DR.
C1 [Sahoo, Niroj K.] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Indian Hlth Outcomes Publ Hlth & Econ Res IHOPE C, Vijayawada, Andhra Pradesh, India.
   [Rani, Padmaja K.; Khanna, Rohit C.; Das, Anthony, V; Narayanan, Raja] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Indian Hlth Outcomes Publ Hlth & Econ Res IHOPE C, Hyderabad, Telangana, India.
   [Murthy, Gudlavalleti V. S.] Publ Hlth Fdn India, Indian Inst Publ Hlth Hyderabad, Indian Hlth Outcomes Publ Hlth & Econ Res IHOPE C, Hyderabad, Telangana, India.
   [Raman, Rajiv] Sankara Nethralaya, Indian Hlth Outcomes Publ Hlth & Econ Res IHOPE C, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
   [Mehta, Mehul C.] LV Prasad Eye Inst, Dept Vitreoretina, Vijayawada, Andhra Pradesh, India.
   [Bhattacharya, Jayanta] Stanford Univ, Indian Hlth Outcomes Publ Hlth & Econ Res IHOPE C, Dept Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; Public Health
   Foundation of India; L. V. Prasad Eye Institute; Stanford University
RP Narayanan, R (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Banjara Hills, Hyderabad 34, Telangana, India.
EM narayanan@lvpei.org
RI Das, Anthony Vipin/R-9027-2019; Sahoo, Niroj/AHD-3511-2022; Sahoo,
   Niroj/AHD-3438-2022
OI Das, Anthony Vipin/0000-0001-9692-2621; 
FU The DBT Wellcome Trust India Alliance Clinical Research Centre Grant
   [IA/CRC/19/1/610010]
FX The DBT Wellcome Trust India Alliance Clinical Research Centre Grant
   [grant number IA/CRC/19/1/610010].
CR Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   International Diabetes Federation, 2019, IDF DIABETES ATLAS, V9th
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Kutty VR, 2018, INT J NONCOMMUN DIS, V3, P67
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Lima-Gomez V, 2001, Gac Med Mex, V137, P413
   Liu Y, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016280
   Magliah Sultan F, 2018, J Family Med Prim Care, V7, P975, DOI 10.4103/jfmpc.jfmpc_85_18
   Mohan V, 2018, J DIABETOL, V9, P73, DOI 10.4103/jod.jod_35_17
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Rewbury R, 2016, EYE, V30, P1568, DOI 10.1038/eye.2016.187
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   Tan NYQ, 2018, OPHTHALMOL RETINA, V2, P574, DOI 10.1016/j.oret.2017.09.019
   Thomas RL, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107840
   Wang W, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.29
NR 19
TC 1
Z9 1
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD NOV
PY 2021
VL 69
IS 11
BP 3184
EP +
DI 10.4103/ijo.IJO_1175_21
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YY0RM
UT WOS:000754501000048
PM 34708768
OA gold, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Kelkar, AS
   Kelkar, J
   Bolisetty, M
   Kelkar, SB
AF Kelkar, Aditya S.
   Kelkar, Jai
   Bolisetty, Mounika
   Kelkar, Shreekant B.
TI Visual outcomes, safety profile and morphometric response of optical
   coherence tomography biomarkers to ranibizumab biosimilar treatment in
   neovascular age-related macular degeneration: Real-world evidence
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF; biosimilars; optical
   coherence tomography; Razumab
ID INTRAVITREAL BEVACIZUMAB AVASTIN; PIGMENT EPITHELIAL DETACHMENT;
   ANTI-VEGF; EFFICACY; THERAPY
AB Purpose: The aim of this study was to evaluate the safety, efficacy, and morphological response of intravitreal ranibizumab biosimilar (Razumab) in neovascular age-related macular degeneration (n-AMD) up to 12 weeks. Methods: Retrospective analysis of 20 eyes of n-AMD receiving 4 weekly intravitreal Razumab. Main outcome measures were mean change in best-corrected visual acuity (BCVA), intraretinal-fluid (IRF), subretinal-fluid (SRF), central-subfield thickness (CSFT), maximum central-retinal thickness (CRT), and dimensions of pigment epithelial detachment (PED) from baseline to weeks 4, 8 and 12. Results: Improvement in BCVA was seen at all visits, although not significantly (4 weeks: P = 0.18; 8 weeks: P = 0.4; 12 weeks: P = 0. 06). At 12 weeks, 90% of eyes either maintained or had an improvement in BCVA, with 40% of them showing an improvement of >= 3-lines and only 5% of them losing >= 3-lines of visual acuity. The median PED height and PED width reduced by 20.5 mu m (P = 0.03) and 557.5 mu m (P = 0.14), respectively, along with a mean reduction of 57.26 mu min CSFT (P < 0.001) and 44.15 mu m in CRT (P = 0.004), respectively, at 12 weeks. On qualitative analysis, resolution of SRF and IRF was observed in 45% and 25% of eyes ' at 12 weeks. There were no serious ocular or systemic side effects identified. Conclusion: In real-world scenario, Razumab is an efficacious and economical anti-vascular endothelial growth factor (anti-VEGF) agent for optimal management of n-AMD. The therapeutic outcomes demonstrated reasonable stabilization and improvement in visual acuity, favorable anatomical outcomes pertaining to OCT-biomarkers with an acceptable safety profile.
C1 [Kelkar, Aditya S.; Kelkar, Jai; Bolisetty, Mounika; Kelkar, Shreekant B.] Natl Inst Ophthalmol, 1187-30,Off Ghole Rd,Near Phule Museum, Pune 411005, Maharashtra, India.
RP Kelkar, AS (通讯作者)，Natl Inst Ophthalmol, 1187-30,Off Ghole Rd,Near Phule Museum, Pune 411005, Maharashtra, India.
EM adityapune4@gmail.com
CR Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Campa C, 2016, CURR DRUG TARGETS, V17, P328, DOI 10.2174/1573399811666150615151324
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Jain N, 2017, ASIA-PAC J OPHTHALMO, V6, P488, DOI 10.22608/APO.2017125
   Jain P, 2017, INDIAN J OPHTHALMOL, V65, P596, DOI 10.4103/ijo.IJO_992_16
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Lai TYY, 2018, RETINA-J RET VIT DIS, V38, P1464, DOI 10.1097/IAE.0000000000001744
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Mansour SE, 2020, CLIN OPHTHALMOL, V14, P653, DOI 10.2147/OPTH.S236637
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma A, 2019, INDIAN J OPHTHALMOL, V67, P1384, DOI 10.4103/ijo.IJO_430_19
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Sharma S., 2018, INT J OPHTHALMOL EYE, V6, P368
   Sharma S, 2020, OPHTHALMOL THER, V9, P625, DOI 10.1007/s40123-020-00277-3
   Sharma S, 2020, OPHTHALMOL THER, V9, P103, DOI 10.1007/s40123-019-00228-7
   Sharma S, 2019, OPHTHALMOLOGICA, V241, P24, DOI 10.1159/000488602
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yang JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1244-5
   Yorston David, 2014, Community Eye Health, V27, P44
   Zhang Yi, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V37, P165
NR 32
TC 0
Z9 0
U1 2
U2 4
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUN
PY 2021
VL 69
IS 6
BP 1469
EP 1474
DI 10.4103/ijo.IJO_2977_20
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2LT
UT WOS:000658809500024
PM 34011722
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bonyadi, MHJ
   Yaseri, M
   Soheilian, M
AF Jabbarpoor Bonyadi, Mohammad Hossein
   Yaseri, Mehdi
   Soheilian, Masoud
TI Association of combined complement factor H Y402H and ARMS2/LOC387715
   A69S polymorphisms with age-related macular degeneration: an updated
   meta-analysis
SO OPHTHALMIC GENETICS
LA English
DT Review
DE Meta-analysis; CFH Y402H; ARMS2; LOC387715 A69S; age-related macular
   degeneration (AMD); synergistic effect
ID GENE POLYMORPHISMS; SUSCEPTIBILITY; ARMS2; LOC387715; CFH; MACULOPATHY;
   ALLELES; VARIANT
AB Background: Complement factor H (CFH) Y402 H (rs1061170) and age-related maculopathy susceptibility2 (ARMS2)/LOC387715 A69 S (rs10490924) polymorphisms shown to have significant association with AMD. In this meta-analysis, we updated and pooled the results of available association studies between combined ARMS2/LOC387715A69 S-CFHY402 H genotypes and AMD to estimate the synergistic effects. Methods: Heterogeneity of studies was evaluated using Cochran Q-test and I-square index. To modify the heterogeneity in the variables we used random effects model. Meta-analysis was performed using STATA. To estimate the additive or supra-additive effects we calculated RERI (relative excess risk due to interaction), AP (attributable proportion due to interaction), S (synergy index) and V (multiplicative index). Results: We included 12 studies with 4668 AMD patients and 4936 control subjects. Considering the GGTT genotypes as reference line, the pooled AMD odds ratios for stratified combined genotypes was 2.13 (95% CI 1.64-2.78) for GGnonTT, 2.17 (95% CI 1.63-2.89) for nonGGTT and 7.23 (95% CI 4.95-10.55) for nonGGnonTT. Pooled synergy analysis revealed RERI = 3.90 (95% CI 0.58-10.03), AP = .53 (95% CI 0.09-0.69), S = 2.57 (95% CI 1.27-5.22) and V = 1.47 (95% CI 1.21-1.80). Conclusion: This updated analysis showed a strong synergistic and positive multiplicative effect of these two genes indicating that there is common pathway of ARMS2/LOC387715 A69 S and CFH Y402 H in AMD pathogenesis which may be complement system pathway.
C1 [Jabbarpoor Bonyadi, Mohammad Hossein; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Tehran University of
   Medical Sciences
RP Bonyadi, MHJ (通讯作者)，Ophthalm Res Ctr, Pasdaran Ave,Boustan 9th St, Tehran, Iran.
EM mhbonyadi@yahoo.com
RI Yaseri, Mehdi/I-1645-2018
OI Yaseri, Mehdi/0000-0002-4066-873X
CR Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   Ayub H, 2019, ANN HUM GENET, V83, P285, DOI 10.1111/ahg.12311
   Bonyadi MHJ, 2017, OPHTHALMIC GENET, V38, P308, DOI 10.1080/13816810.2016.1237664
   Bonyadi MHJ, 2016, CURR EYE RES, V41, P1519, DOI 10.3109/02713683.2016.1158274
   Bonyadi M, 2018, OPHTHALMIC GENET, V39, P189, DOI 10.1080/13816810.2017.1393829
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chirco KR, 2018, EYE, V32, P1740, DOI 10.1038/s41433-018-0170-8
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Franke L, 2006, AM J HUM GENET, V78, P1011, DOI 10.1086/504300
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Losonczy G, 2011, ACTA OPHTHALMOL, V89, P255, DOI 10.1111/j.1755-3768.2009.01687.x
   Maugeri A, 2019, ACTA OPHTHALMOL, V97, pE8, DOI 10.1111/aos.13849
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Nazari Khanamiri Hossein, 2014, J Ophthalmic Vis Res, V9, P181
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tong Y, 2010, MOL VIS, V16, P1958
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Xu YL, 2008, MOL VIS, V14, P1373
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Zeng FX, 2013, GRAEF ARCH CLIN EXP, V251, P2539, DOI 10.1007/s00417-013-2442-0
NR 35
TC 1
Z9 1
U1 1
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD JUL 3
PY 2020
VL 41
IS 4
BP 301
EP 307
DI 10.1080/13816810.2020.1765396
EA MAY 2020
PG 7
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA MM4XT
UT WOS:000534887100001
PM 32406777
DA 2022-11-30
ER

PT J
AU Mekjavic, PJ
   Kraut, A
   Urbancic, M
   Lenassi, E
   Hawlina, M
AF Mekjavic, Polona Jaki
   Kraut, Aleksandra
   Urbancic, Mojca
   Lenassi, Eva
   Hawlina, Marko
TI Efficacy of 12-month treatment of neovascular age-related macular
   degeneration with intravitreal bevacizumab based on individually
   determined injection strategies after three consecutive monthly
   injections
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; Avastin (R); bevacizumab;
   choroidal neovascularization; intravitreal injections; loading dose
   treatment strategy; vascular endothelial growth factor
ID OCCULT CHOROIDAL NEOVASCULARIZATION; RETINA STUDY-GROUP; RANIBIZUMAB
   LUCENTIS; AVASTIN THERAPY; SECONDARY; 6-MONTH; SAFETY; GUIDELINES;
   REGIMEN
AB Purpose: To report the results of intravitreal treatment with bevacizumab in neovascular age-related macular degeneration (AMD) after a loading dose (LD) of three monthly injections followed by an optical coherence tomography (OCT)-guided strategy, based on best-corrected visual acuity (VA) and number of injections required over 1 year.
   Methods: A series of consecutive cases of 149 eyes of 147 patients received three or more intravitreal injections of bevacizumab (1.25 mg) for neovascular AMD over a 1-year period. The patients underwent ophthalmological examinations: measurement of the VA, fluorescein angiography, dilated fundus examination at baseline; VA, OCT and dilated fundus examination at monthly follow-up visits. Repeated injections were given each month for the first 3 months (LD); thereafter, injections were only administered if leakage or macular oedema were present.
   Results: Mean baseline VA was 51 +/- 14 letters, which improved to 58 +/- 15 letters (p < 0.0001; n = 149) at first evaluation (15 +/- 2 weeks), 59 +/- 15 letters (p < 0.0001; n = 143) at second evaluation (25 +/- 2 weeks) and 57 +/- 16 letters (p < 0.0001; n = 132) at third evaluation (51 +/- 3 weeks). The baseline mean central retinal thickness (344.6 mu m) and total macular volume (8.6 mm(3)) decreased at first evaluation, to 219.0 mu m (p < 0.0001) and 7.2 mm(3) (p < 0.0001), respectively. The mean number of injections per patient treated for 1 year was 5.1 (range 3-9). No systemic side-effects were noted.
   Conclusion: Treatment of neovascular AMD with intravitreal bevacizumab administered in LD of three monthly injections and followed by an OCT-guided strategy provides functional and anatomical improvements for up to 1 year.
C1 [Mekjavic, Polona Jaki; Kraut, Aleksandra; Urbancic, Mojca; Lenassi, Eva; Hawlina, Marko] Univ Med Ctr Ljubljana, Eye Clin, SI-1000 Ljubljana, Slovenia.
C3 University Medical Centre Ljubljana
RP Mekjavic, PJ (通讯作者)，Univ Med Ctr Ljubljana, Eye Clin, Grabloviceva 46, SI-1000 Ljubljana, Slovenia.
EM polona.jaki@guest.arnes.si
RI Urbancic, Mojca/ABA-4408-2020; Hawlina, Marko/AAZ-8084-2020
OI Urbancic, Mojca/0000-0001-8007-834X; Jaki Mekjavic,
   Polona/0000-0003-1949-4525
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 32
TC 18
Z9 18
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2011
VL 89
IS 7
BP 647
EP 653
DI 10.1111/j.1755-3768.2009.01740.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 838ZB
UT WOS:000296332000025
PM 19860774
OA Bronze
DA 2022-11-30
ER

PT J
AU Parravano, M
   Tedeschi, M
   Manca, D
   Costanzo, E
   Di Renzo, A
   Giorno, P
   Barbano, L
   Ziccardi, L
   Varano, M
   Parisi, V
AF Parravano, Mariacristina
   Tedeschi, Massimiliano
   Manca, Daniela
   Costanzo, Eliana
   Di Renzo, Antonio
   Giorno, Paola
   Barbano, Lucilla
   Ziccardi, Lucia
   Varano, Monica
   Parisi, Vincenzo
TI Effects of Macuprev (R) Supplementation in Age-Related Macular
   Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6
   Months of Follow-Up
SO ADVANCES IN THERAPY
LA English
DT Article
DE Carotenoid and antioxidant supplementation; Intermediate age-related
   macular degeneration; mfERG; OCT; Ophthalmology
ID RETINAL FUNCTION; MULTIFOCAL ELECTRORETINOGRAM; RETICULAR PSEUDODRUSEN;
   CHOROIDAL THICKNESS; EYES; CAROTENOIDS; PIGMENT; MACULOPATHY;
   PREVALENCE; ZEAXANTHIN
AB Background To evaluate the effects of Macuprev (R) supplementation on macular function and structure in intermediate age-related macular degeneration (AMD) along 6 months of follow-up. Methods In this double-blind, monocentric, randomized, and prospective study, 30 patients with intermediate AMD were enrolled and randomly divided into two age-similar groups: 15 patients (AMD-M group; mean age 68.50 +/- 8.79 years) received 6-month oral daily supplementation with Macuprev (R) (Farmaplus Italia s.r.l., Italy, two tablets/day on an empty stomach, before meals; contained in total lutein 20 mg, zeaxanthin 4 mg, N-acetylcysteine 140 mg, bromelain 2500GDU 80 mg, vitamin D-3 800 IU, vitamin B-12 18 mg, alpha-lipoic acid 140 mg, rutin 157 mg, vitamin C 160 mg, zinc oxide 16 mg, Vaccinium myrtillus 36% anthocyanosides 90 mg, Ganoderma lucidum 600 mg) and 15 patients (AMD-P group; mean age 70.14 +/- 9.87) received two tablets of placebo daily on an empty stomach, before meals. A total of 28 eyes, 14 from each AMD group, completed the study. Multifocal electroretinogram (mfERG) and spectral domain-optical coherence tomography (SD-OCT) were assessed at baseline and after 6 months. Results At 6-month follow-up, AMD-M eyes showed a significant increase of mfERG response amplitude density (RAD) recorded from the central macular areas (ring 1, 0-2.5 degrees; ring 2, 2.5-5 degrees), whereas non-significant changes of retinal and choroidal SD-OCT parameters were found when values were compared to baseline. Non-significant correlations between functional and structural changes were found. In AMD-P eyes, non-significant differences for each mfERG and SD-OCT parameters were observed at 6 months. Conclusions In intermediate AMD, Macuprev (R) supplementation increases the function of the macular pre-ganglionic elements, with no associated retinal and choroidal ultra-structural changes. Funding Research for this study was financially supported by the Italian Ministry of Health and Fondazione Roma. Article processing charges were funded by Farmaplus Italia s.r.l., Italy.
C1 [Parravano, Mariacristina; Tedeschi, Massimiliano; Manca, Daniela; Costanzo, Eliana; Di Renzo, Antonio; Giorno, Paola; Barbano, Lucilla; Ziccardi, Lucia; Varano, Monica; Parisi, Vincenzo] IRCCS Fdn Bietti, Rome, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia
RP Ziccardi, L (通讯作者)，IRCCS Fdn Bietti, Rome, Italy.
EM luxzic@hotmail.com
RI Barbano, Lucilla/AAL-6652-2020; Parisi, Vincenzo/J-6137-2018; Di Renzo,
   Antonio/AAB-4899-2020; Ziccardi, Lucia/AAQ-9066-2020; Costanzo,
   Eliana/AAA-7690-2020; Varano, Monica/K-8573-2016
OI Barbano, Lucilla/0000-0001-5120-8635; Ziccardi,
   Lucia/0000-0002-5563-1243; di renzo, antonio/0000-0002-6541-5333;
   Varano, Monica/0000-0002-6530-1563
FU Italian Ministry of Health; Farmaplus Italia s.r.l., Italy; Fondazione
   Roma
FX Research for this study was financially supported by the Italian
   Ministry of Health and Fondazione Roma. Article processing charges were
   funded by Farmaplus Italia s.r.l., Italy.
CR Berrow EJ, 2016, DOC OPHTHALMOL, V132, P123, DOI 10.1007/s10633-016-9532-3
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Carver KA, 2016, INVEST OPHTH VIS SCI, V57, P360, DOI 10.1167/iovs.15-17117
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Novaes LCD, 2016, BIOTECHNOL PROGR, V32, P5, DOI 10.1002/btpr.2190
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keenan TD, 2019, RETINA, DOI 10.1097/IAE.0000000000002434
   Kim YS, 2018, BIOCHEM BIOPH RES CO, V503, P1307, DOI 10.1016/j.bbrc.2018.07.041
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Moschos MM, 2018, SEMIN OPHTHALMOL, V33, P461, DOI 10.1080/08820538.2017.1301496
   Moschos MM, 2017, EYE VISION, V4, DOI 10.1186/s40662-017-0088-4
   Nakayama M, 2011, MOL VIS, V17, P1784
   Obana A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139257
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Parisi V, 2012, INVEST OPHTH VIS SCI, V53, P6973, DOI 10.1167/iovs.12-10256
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Wilde C, 2016, EUR J OPHTHALMOL, V26, P128, DOI 10.5301/ejo.5000661
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yang SS, 2016, DOC OPHTHALMOL, V132, P17, DOI 10.1007/s10633-016-9523-4
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
NR 43
TC 10
Z9 10
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD SEP
PY 2019
VL 36
IS 9
BP 2493
EP 2505
DI 10.1007/s12325-019-01016-2
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IR4PE
UT WOS:000481415900025
PM 31243641
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Feltgen, N
   Bertelmann, T
   Bretag, M
   Pfeiffer, S
   Hilgers, R
   Callizo, J
   Goldammer, L
   Bemme, S
   Hoerauf, H
AF Feltgen, Nicolas
   Bertelmann, Thomas
   Bretag, Mirko
   Pfeiffer, Sebastian
   Hilgers, Reinhard
   Callizo, Josep
   Goldammer, Lena
   Bemme, Sebastian
   Hoerauf, Hans
TI Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen
   in eyes with neovascular age-related macular degeneration: results from
   the RABIMO trial
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; AMD; Ranibizumab; Treatment schedule;
   PRN; Optical coherence tomography
ID AFLIBERCEPT; VERTEPORFIN; CATT
AB Purpose To evaluate prospectively the efficacy and safety of a fixed bimonthly ranibizumab treatment regimen (RABIMO) in eyes with neovascular age-related macular degeneration (nAMD) and to compare these results with a pro re nata (PRN) treatment scheme.
   Methods This was a 12-month, phase IV, single center, randomised, non-inferiority study. Following three initial monthly injections, patients were randomised to receive either ranibizumab bimonthly (RABIMO group) or ranibizumab PRN (PRN group) (n = 20 each). Main outcome measures were best-corrected visual acuity (BCVA), central retinal thickness (CRT), number of injections, and adverse events (AEs).
   Results BCVA [median (interquartile range, IQR)] increased significantly in both groups after 12 months [RABIMO group +8.5 (14); PRN group +6.5 (16) ETDRS letters] when compared to baseline (p < 0.0001; p = 0.0085). At month 12, the RABIMO treatment regimen was non-inferior to the PRN scheme (Delta BCVA = 3.5 ETDRS letters; p < 0.0001). CRT was significantly reduced in both groups after the 12-month study period (p < 0.0001 each), with no significant difference between groups (p = 0.6772). Number of overall injections [median (IQR)] was 8 (0) in the RABIMO versus 4 (5) in the PRN group (p = 0.0037). Three patients in the RABIMO group received one additional unscheduled injection. We observed no significant differences between groups in the number of patients with reported SAEs/AEs (RABIMO group n = 6/15; PRN group n = 7/13) (p = 0.7357/p = 0.4902).
   Conclusions We found no evidence of significant functional or anatomical differences between the RABIMO and PRN treatment regimens. However, the RABIMO group's number of injections was twice as high as the PRN group's (protocol-driven). In light of potential side effects, the fixed bimonthly treatment regimen might not be advisable for routine clinical care, but it might be a worthwhile treatment option if monthly monitoring is not possible. Eudra-CT number: 2009-017324-11.
C1 [Feltgen, Nicolas; Bertelmann, Thomas; Callizo, Josep; Bemme, Sebastian; Hoerauf, Hans] Univ Med Ctr, Dept Ophthalmol, Robert Koch Str 40, D-37075 Gottingen, Germany.
   [Bretag, Mirko] Carl Thiem Klinikum gGmbH, Dept Ophthalmol, Cottbus, Germany.
   [Pfeiffer, Sebastian] Georg August Univ, Inst Clin Res GmbH, Gottingen, Germany.
   [Hilgers, Reinhard] Georg August Univ, Inst Med Stat, Gottingen, Germany.
   [Goldammer, Lena] Eye Ctr Celle, Celle, Germany.
C3 University of Gottingen; University of Gottingen; University of
   Gottingen
RP Feltgen, N (通讯作者)，Univ Med Ctr, Dept Ophthalmol, Robert Koch Str 40, D-37075 Gottingen, Germany.
EM nicolas.feltgen@med.uni-goettingen.de
OI Feltgen, Nicolas/0000-0002-6857-3003
FU Novartis Pharma GmbH, Germany
FX The study was funded by Novartis Pharma GmbH, Germany and is registered
   with Eudra-CT number: 2009-017324-11. The sponsor or funding
   organization did not participate in the design of the study, data
   management, data analysis and interpretation, or preparation, review
   and, approval of the manuscript.
CR [Anonymous], 2011, KLIN MONATSBL AUGENH, V228, P138, DOI 10.1055/s-0029-1246016
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2014, OPHTHALMOLOGICA, V231, P80, DOI 10.1159/000356401
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Garcia-Layana A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/412903
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada T, 2014, GRAEF ARCH CLIN EXP, V252, P1545, DOI 10.1007/s00417-014-2612-8
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Taban M, 2009, OPHTHALMOLOGY, V116, P964, DOI 10.1016/j.ophtha.2008.12.033
   Warwick AN, 2016, INT J OPHTHALMOL-CHI, V9, P1156, DOI 10.18240/ijo.2016.08.12
   Yazdi MH, 2015, EXPERT OPIN BIOL TH, V15, P1349, DOI 10.1517/14712598.2015.1057565
NR 30
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2017
VL 255
IS 5
BP 923
EP 934
DI 10.1007/s00417-017-3589-x
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV0ND
UT WOS:000401436500008
PM 28102456
DA 2022-11-30
ER

PT J
AU Parekh, N
   Voland, RP
   Moeller, SM
   Blodi, BA
   Ritenbaugh, C
   Chappell, RJ
   Wallace, RB
   Mares, JA
AF Parekh, Niyati
   Voland, Rickie P.
   Moeller, Suzen M.
   Blodi, Barbara A.
   Ritenbaugh, Cheryl
   Chappell, Richard J.
   Wallace, Robert B.
   Mares, Julie A.
CA CAREDS Res Study Grp
TI Association Between Dietary Fat Intake and Age-Related Macular
   Degeneration in the Carotenoids in Age-Related Eye Disease Study
   (CAREDS) An Ancillary Study of the Women's Health Initiative
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID 3RD NATIONAL-HEALTH; FISH CONSUMPTION; BLOOD-PRESSURE; ACID INTAKE;
   RISK; MACULOPATHY; ANTIOXIDANTS; ZEAXANTHIN; MORTALITY; LUTEIN
AB Objective: To evaluate the relationships between the amount and type of dietary fat and intermediate age-related macular degeneration (AMD).
   Design: Women aged 50 to 79 years with high and low lutein intake from 3 sites of the Women's Health Initiative Observational Study were recruited into the Carotenoids in Age-Related Eye Disease Study. Fat intake from 1994 through 1998 was estimated using food frequency questionnaires, and AMD was assessed photographically from 2001 through 2004.
   Results: Intakes of omega-6 and omega-3 polyunsaturated fatty acids, which were highly correlated (r=0.8), were associated with approximately 2-fold higher prevalence of intermediate AMD in high vs low quintiles. However, monounsaturated fatty acid intake was associated with lower prevalence. Age interactions were often observed. In women younger than 75 years (n=1325), total fat and saturated fatty acid intakes were associated with increased prevalence of AMD (multivariate adjusted odds ratios [95% confidence interval] for intermediate AMD, 1.7 [1.0-2.7] for quintile 5 vs quintile 1 for total fat [P=.10 for trend] and 1.6 [0.7-3.6] for saturated fatty acids [P=.23 for trend]). The associations were reversed in older women.
   Conclusions: These results support a growing body of evidence suggesting that diets high in several types of fat may contribute to the risk of intermediate AMD and that diets high in monounsaturated fatty acids may be protective.
C1 [Voland, Rickie P.; Blodi, Barbara A.; Mares, Julie A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Chappell, Richard J.] Univ Wisconsin, Dept Stat & Biostat, Madison, WI 53726 USA.
   [Parekh, Niyati] NYU, Dept Nutr Food Studies & Publ Hlth, New York, NY USA.
   [Moeller, Suzen M.] Amer Med Assoc, Dept Prevent & Healthy Lifestyles, Chicago, IL 60610 USA.
   [Ritenbaugh, Cheryl] Univ Arizona, Dept Family & Community Med, Tucson, AZ USA.
   [Wallace, Robert B.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; New
   York University; American Medical Association; University of Arizona;
   University of Iowa
RP Mares, JA (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Room 1063,610 N Walnut St, Madison, WI 53726 USA.
EM jmarespe@wisc.edu
RI Parekh, Niyati/ABF-4933-2020
OI Parekh, Niyati/0000-0002-1334-0528; Snodderly,
   Donald/0000-0002-3428-609X; Ritenbaugh, Cheryl/0000-0002-3307-2727
FU NEI NIH HHS [U10 EY013018-01, U10 EY013018-05, EY13018, U10 EY013018-04,
   U10 EY013018-03, U10 EY013018, U10 EY013018-02, R01 EY016886] Funding
   Source: Medline; NIDDK NIH HHS [T32 DK007665] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [U10EY013018, R01EY016886] Funding Source: NIH
   RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   BAZAN NG, 1990, UPSALA J MED SCI, P97
   BERMAN ER, 1991, BIOCH EYE
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   De Lorgeril Michel, 2007, Subcell Biochem, V42, P283
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Diau GY, 2003, INVEST OPHTH VIS SCI, V44, P4559, DOI 10.1167/iovs.03-0478
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN DS, 2002, VISION PROBLEMS US P
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Kris-Etherton PM, 1999, AM J CLIN NUTR, V70, p504S, DOI 10.1093/ajcn/70.3.504s
   Kris-Etherton PM, 1999, J NUTR, V129, P2280
   Larsson SC, 2004, AM J CLIN NUTR, V79, P935
   MARES JA, 2008, DIET SUPPLEMENTS PRE
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, J AM COLL NUTR, V14, P349
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Nicklas TA, 2004, NUTR REV, V62, P132, DOI [10.1301/nr.2004.apr.132-141, 10.1301/nr.2004.apr.132&ndash;141]
   Ouchi M, 2002, OPHTHALMOLOGICA, V216, P363, DOI 10.1159/000066178
   Owen RW, 2000, EUR J CANCER, V36, P1235, DOI 10.1016/S0959-8049(00)00103-9
   Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Willett WC, 2007, J CARDIOVASC MED, V8, pS42, DOI 10.2459/01.JCM.0000289275.72556.13
   *WOM HLTH IN STUD, 1998, CONTROL CLIN TRIALS, V61, P109
NR 56
TC 58
Z9 59
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2009
VL 127
IS 11
BP 1483
EP 1493
DI 10.1001/archophthalmol.2009.130
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 516ZY
UT WOS:000271583700010
PM 19901214
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Ahn, JK
   Moon, HJ
AF Ahn, Jae Kyoun
   Moon, Hyung Jin
TI Changes in Aqueous Vascular Endothelial Growth Factor and Pigment
   Epithelium-derived Factor after Ranibizumab Alone or Combined with
   Verteporfin for Exudative Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; PHOTODYNAMIC THERAPY; FACTOR
   VEGF; EXPRESSION; PEDF; EYE; ANGIOGENESIS; MEMBRANES
AB PURPOSE: To investigate changes in aqueous vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) after ranibizumab (Lucentis; Genentech Inc, South San Francisco, California, USA) monotherapy or combined with photodynamic therapy (PDT).
   DESIGN: Prospective, interventional, case-control study.
   METHODS: We recruited 34 patients with CNV secondary to AMD and 10 controls. Baseline examinations, including visual acuity (VA), central macular thickness (CMT), fluorescein angiography, and indocyanine angiography, were performed, and the measurements of VA and CMT were repeated 1 month after treatments. Seventeen of 34 patients received a single intravitreal injection of 0.5 mg ranibizumab, and the remaining 17 patients underwent combined PDT on the same day. Aqueous samples were collected at the time of injection and 1 month after treatment and were measured by enzyme,linked immunosorbent assay. Main outcomes measures were the changes in VA and CMT and the changes in VEGF and PEDF levels.
   RESULTS: Demographic features, lesion characteristics, and mean changes in VA and CMT were similar between the two groups. Aqueous VEGF and PEDF levels were reduced significantly 1 month after treatment in all patients. The reduction levels of VEGF and PEDF were similar between the two groups. There was a positive correlation between the reduction levels of aqueous VEGF and the reduction levels of aqueous PEDF. The reduction levels of VEGF and PEDF were correlated positively with the decrease in CMT, but were not positively correlated with the improvements in VA.
   CONCLUSIONS: Ranibizumab therapy for CNV secondary to AMD is associated with reduced levels of aqueous VEGF and PEDF regardless of combined therapy with PDT. The reduction levels of VEGF and PEDF are correlated with anatomic improvements in the macula. (Am J Ophthalmol 2009;148:718-724. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Ahn, Jae Kyoun; Moon, Hyung Jin] Chonnam Natl Univ, Sch Med, Dept Ophthalmol, Kwangju 501757, South Korea.
C3 Chonnam National University
RP Ahn, JK (通讯作者)，Chonnam Natl Univ, Sch Med, Dept Ophthalmol, 8 Hakdong, Kwangju 501757, South Korea.
EM jkahn@jnu.ac.kr
FU THE RESEARCH INSTITUTE OF MEDICAL SCIENCES, CHONNAM National University;
   Institutional Review Board (IRB)/Ethics Committee approval was obtained
   from the Chonnam National University Clinical Research Institute
   [1-2008-09-119]
FX THIS STUDY WAS SUPPORTED BY A RESEARCH GRANT FROM THE RESEARCH INSTITUTE
   OF MEDICAL SCIENCES, CHONNAM National University (2009-CURIMS-DR005),
   Guangju, Republic of Korea. The authors indicate no financial conflict
   of interest. Involved in design and conduct Of study (J.K.A.);
   collection of data (J.K.A., H-J-M); interpretation of data (J.K.A.);
   statistical analysis of data (J.K.A., H.J.M.); and preparation, review,
   or approval of the manuscript (J.K.A., H.J.M.). Institutional Review
   Board (IRB)/Ethics Committee approval was obtained from the Chonnam
   National University Clinical Research Institute (IRB no. 1-2008-09-119).
   The study protocol was in accordance with the provisions of the
   Declaration of Helsinki.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 23
TC 19
Z9 24
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2009
VL 148
IS 5
BP 718
EP 724
DI 10.1016/j.ajo.2009.06.012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 518DA
UT WOS:000271669300013
PM 19674731
DA 2022-11-30
ER

PT J
AU Pan, CW
   Cheung, CY
   Aung, T
   Cheung, CM
   Zheng, YF
   Wu, RY
   Mitchell, P
   Lavanya, R
   Baskaran, M
   Wang, JJ
   Wong, TY
   Saw, SM
AF Pan, Chen-Wei
   Cheung, Carol Y.
   Aung, Tin
   Cheung, Chiu-Ming
   Zheng, Ying-Feng
   Wu, Ren-Yi
   Mitchell, Paul
   Lavanya, Raghavan
   Baskaran, Mani
   Wang, Jie Jin
   Wong, Tien Yin
   Saw, Seang-Mei
TI Differential Associations of Myopia with Major Age-related Eye Diseases
   The Singapore Indian Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; REFRACTIVE ERRORS; RISK-FACTORS; AXIAL LENGTH;
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; ADULT-POPULATION;
   PREVALENCE; MACULOPATHY; CLASSIFICATION
AB Purpose: To determine the associations of myopia and axial length (AL) with major age-related eye diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), age-related cataract, and primary open-angle glaucoma (POAG).
   Design: Population-based, cross-sectional study.
   Participants: A total of 3400 Indians (75.6% response rate) aged 40 to 84 years in Singapore.
   Methods: Refractive error was determined by subjective refraction, and AL was determined by noncontact partial coherence laser interferometry. Age-related macular degeneration and DR were defined from retinal photographs according to the Wisconsin Age-Related Maculopathy Grading System and Airlie House classification system, respectively. Age-related cataract was diagnosed clinically using the Lens Opacity Classification System (LOCS) III system. Glaucoma was defined according to International Society for Geographical and Epidemiological Ophthalmology criteria.
   Main Outcome Measures: Age-related macular degeneration, DR, age-related cataract, and POAG.
   Results: Myopic eyes (spherical equivalent [SE] <-0.5 diopter [D]) were less likely to have AMD (early plus late AMD) (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.25-0.79) or DR (OR, 0.68; 95% CI, 0.46-0.98) compared with emmetropic eyes; each millimeter increase in AL was associated with a lower prevalence of AMD (OR, 0.76; 95% CI, 0.65-0.89) and DR (OR, 0.73; 95% CI, 0.63-0.86). Myopic eyes were more likely to have nuclear (OR, 1.57; 95% CI, 1.13-2.20) and posterior subcapsular (OR, 1.73; 95% CI, 1.10-2.72) cataract, but not cortical cataract (P = 0.64); each millimeter increase in AL was associated with a higher prevalence of posterior subcapsular cataract (PSC) (OR, 1.29; 95% CI, 1.07-1.55), but not nuclear (P = 0.77) or cortical (P = 0.39) cataract. Eyes with high myopia (SE <-6.0 D) were more likely to have POAG (OR, 5.90; 95% CI, 2.68-12.97); each millimeter increase in AL was associated with a higher prevalence of POAG (OR, 1.43; 95% CI, 1.13-1.80).
   Conclusions: Myopic eyes are less likely to have AMD and DR but more likely to have nuclear cataract, PSC, and POAG. The associations of myopia with AMD, DR, and POAG are mostly explained by longer AL. However, the association between myopia and nuclear cataract is explained by lens refraction rather than AL.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:284-291 (C) 2013 by the American Academy of Ophthalmology.
C1 [Pan, Chen-Wei; Wong, Tien Yin; Saw, Seang-Mei] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117597, Singapore.
   [Cheung, Carol Y.; Aung, Tin; Cheung, Chiu-Ming; Zheng, Ying-Feng; Wu, Ren-Yi; Lavanya, Raghavan; Baskaran, Mani; Wong, Tien Yin; Saw, Seang-Mei] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Carol Y.; Aung, Tin; Cheung, Chiu-Ming; Baskaran, Mani; Wang, Jie Jin; Wong, Tien Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore 117597, Singapore.
   [Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wong, Tien Yin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 National University of Singapore; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   University of Sydney; Centre for Eye Research Australia; University of
   Melbourne
RP Saw, SM (通讯作者)，Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 16 Med Dr,MD 3, Singapore 117597, Singapore.
EM ephssm@nus.edu.sg
RI Pan, Chen-Wei/L-7174-2019; Cheung, Carol Y./G-7895-2016; Zheng,
   Yingfeng/CAE-9225-2022; Mani, Baskaran/GWZ-8299-2022; Pan,
   Chen-Wei/E-6205-2015; wang, jie/GRS-0942-2022; Wong, Tien
   Yin/AAC-9724-2020; Cheung, Carol/AAF-1101-2020; Wang, Jie
   Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; Zheng,
   Yingfeng/AAE-2983-2022
OI Zheng, Yingfeng/0000-0002-0914-7864; Wong, Tien Yin/0000-0002-8448-1264;
   Cheung, Carol/0000-0002-9672-1819; Wang, Jie Jin/0000-0001-9491-4898;
   Pan, Chen-Wei/0000-0003-3362-4613; Cheung, Carol/0000-0003-0869-859X;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU Biomedical Research Council [08/1/35/19/550]; National Medical Research
   Council, Singapore [STaR/0003/2008]
FX Funded by Biomedical Research Council 08/1/35/19/550 and National
   Medical Research Council STaR/0003/2008, Singapore.
CR Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   CAHANE M, 1992, OPHTHALMIC RES, V24, P280, DOI 10.1159/000267179
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Ciulla TA, 2002, ACTA OPHTHALMOL SCAN, V80, P468, DOI 10.1034/j.1600-0420.2002.800503.x
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   GLYNN RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P381, DOI 10.1001/archopht.1992.01080150079033
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 1997, GRAEF ARCH CLIN EXP, V235, P627, DOI 10.1007/BF00946938
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Kifley A, 2007, AM J OPHTHALMOL, V143, P1024, DOI 10.1016/j.ajo.2007.01.034
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P76, DOI 10.1001/archopht.122.1.76
   Klein R, 2003, OPHTHALMOLOGY, V110, P2118, DOI 10.1016/S0161-6420(03)00863-7
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KOHNER EM, 1995, DIABETES, V44, P603, DOI 10.2337/diabetes.44.6.603
   Krishnaiah S, 2009, CLIN OPHTHALMOL, V3, P17
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Leske MC, 2002, OPHTHALMOLOGY, V109, P1303, DOI 10.1016/S0161-6420(02)01094-1
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Lim LS, 2011, INVEST OPHTH VIS SCI, V52, P669, DOI 10.1167/iovs.10-6184
   Lim LS, 2010, OPHTHALMOLOGY, V117, P524, DOI 10.1016/j.ophtha.2009.07.044
   Lim R, 1999, INVEST OPHTH VIS SCI, V40, P3021
   Lorenzi M, 2001, DIABETOLOGIA, V44, P791, DOI 10.1007/s001250100544
   Luo HD, 2006, INVEST OPHTH VIS SCI, V47, P2773, DOI 10.1167/iovs.05-1380
   Marcus MW, 2011, OPHTHALMOLOGY, V118, P1989, DOI 10.1016/j.ophtha.2011.03.012
   McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4
   McKay R, 2000, BRIT J OPHTHALMOL, V84, P865, DOI 10.1136/bjo.84.8.865
   Mitchell P, 1999, OPHTHALMOLOGY, V106, P2010, DOI 10.1016/S0161-6420(99)90416-5
   MOSS SE, 1989, INVEST OPHTH VIS SCI, V30, P823
   MOSS SE, 1994, OPHTHALMOLOGY, V101, P77
   Mukesh BN, 2006, ARCH OPHTHALMOL-CHIC, V124, P79, DOI 10.1001/archopht.124.1.79
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Perera SA, 2010, ARCH OPHTHALMOL-CHIC, V128, P900, DOI 10.1001/archophthalmol.2010.125
   Quigley M, 1999, ARCH OPHTHALMOL-CHIC, V117, P84
   Quigley M, 2010, OPHTHALMOLOGY, V117, P2040, DOI 10.1016/j.ophtha.2010.05.003
   Saw SM, 2008, OPHTHALMOLOGY, V115, P1713, DOI 10.1016/j.ophtha.2008.03.016
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Wensor M, 1999, ARCH OPHTHALMOL-CHIC, V117, P658
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
   Wong TY, 2003, OPHTHALMOLOGY, V110, P211, DOI 10.1016/S0161-6420(02)01260-5
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P1449
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   Wong TY, 2003, INVEST OPHTH VIS SCI, V44, P1479, DOI 10.1167/iovs.02-0526
   Wu SY, 1999, INVEST OPHTH VIS SCI, V40, P2179
NR 50
TC 96
Z9 99
U1 0
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2013
VL 120
IS 2
BP 284
EP 291
DI 10.1016/j.ophtha.2012.07.065
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 085WX
UT WOS:000314646100011
PM 23084122
DA 2022-11-30
ER

PT J
AU Feigl, B
   Brown, B
   Lovie-Kitchin, J
   Swann, P
AF Feigl, B
   Brown, B
   Lovie-Kitchin, J
   Swann, P
TI Monitoring retinal function in early age-related maculopathy: visual
   performance after 1 year
SO EYE
LA English
DT Article
DE multifocal electroretinogram; early age-related maculopathy;
   cone-mediated function; rod-mediated function; mfERG; monitoring
ID ROD SYSTEM FUNCTION; MULTIFOCAL ELECTRORETINOGRAM; LOCAL CONE;
   SENSITIVITY; DELAYS; VULNERABILITY; DEGENERATION; DYSFUNCTION;
   ADAPTATION; TOPOGRAPHY
AB Purpose To monitor visual performance in early age-related maculopathy (ARM).
   Methods We measured monocular visual function - high-contrast visual acuity (HC-VA), central visual fields (mean sensitivity, MS), colour vision (desaturated Panel D-15), Pelli-Robson (P-R), and cone- and rod-mediated multifocal electroretinograms (mfERG) in 13 ARM subjects and 13 age-matched control subjects with normal fundi at baseline and after 1 year. All had visual acuity of 6/12 or better. The mfERG data were compared to templates derived from the control group at baseline. We analysed the mfERG results by averaging the central and peripheral fields and the superior and inferior fields (CP and SI methods) and by calculating the local responses.
   Results The mean rod-mediated responses were significantly delayed in the ARM group for the CP (P = 0.04) and the SI methods (P = 0.03) at baseline compared to the control group. This did not change significantly after 1 year, whereas the mean cone- mediated responses were within the normal range at both times. Although the local analysis revealed lower amplitudes for the cone- and rod-mediated responses at baseline this was not found after 1 year and only the local rod-mediated latencies were delayed at both times (P < 0.01). HC-VA, desaturated Panel D-15 and P-R were significantly worse in the ARM group (P <= 0.01) at baseline but did not show further significant deterioration. Progressive fundus changes were found in only two subjects (18%).
   Conclusion Although there was significant impairment of retinal function in early ARM at baseline no further deterioration was evident after 1 year.
C1 Queensland Univ Technol, Sch Optometry, Ctr Hlth Res, Kelvin Grove, Qld 4059, Australia.
   Graz Univ, Dept Ophthalmol, A-8010 Graz, Austria.
C3 Queensland University of Technology (QUT); University of Graz
RP Feigl, B (通讯作者)，Queensland Univ Technol, Sch Optometry, Ctr Hlth Res, Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.
EM b.feigi@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   Chan HL, 1998, OPHTHAL PHYSL OPT, V18, P335, DOI 10.1016/S0275-5408(98)00001-5
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   *COMM VIS, 1981, 41 COMM VIS, P57
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P323, DOI 10.1111/j.1475-1313.1990.tb00877.x
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   FEIGL B, 2004, EYE             0730
   FEIGL B, IN PRESS CURR EYE RE
   Fortune B, 1999, INVEST OPHTH VIS SCI, V40, P2638
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Han Y, 2004, INVEST OPHTH VIS SCI, V45, P948, DOI 10.1167/iovs.03-1101
   Holopigian K, 2002, INVEST OPHTH VIS SCI, V43, P2364
   Holopigian K, 2001, INVEST OPHTH VIS SCI, V42, P779
   Hood DC, 1998, INVEST OPHTH VIS SCI, V39, P1152
   Hood DC, 1998, VISION RES, V38, P163, DOI 10.1016/S0042-6989(97)00143-0
   HOOD DC, 1997, NONINVASIVE ASSESSME, V11, P33
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   LANTHONY P, 1978, DOC OPHTHALMOL, V46, P185
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Liu CD, 1999, J NEUROSCI, V19, P4778
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Mohand-Said S, 2001, PROG RETIN EYE RES, V20, P451, DOI 10.1016/S1350-9462(01)00006-4
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Seiple W, 2003, INVEST OPHTH VIS SCI, V44, P1783, DOI 10.1167/iovs.02-0518
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
NR 47
TC 33
Z9 33
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2005
VL 19
IS 11
BP 1169
EP 1177
DI 10.1038/sj.eye.6701711
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982EZ
UT WOS:000233142000006
PM 15389263
OA Bronze
DA 2022-11-30
ER

PT J
AU Lee, WK
   Park, YH
   Lee, PY
AF Lee, Won Ki
   Park, Young Hoon
   Lee, Phil Young
TI Neovascularization associated with large retinal pigment epithelial
   detachment in elderly Korean patients: Subdivision according to
   indocyanine green angiographic features
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularization; indocyanine green angiography; polypoidal
   choroidal vasculopathy; retinal angiomatous proliferation; retinal
   pigment epithelial detachment
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; MACULAR DEGENERATION; ANASTOMOSES;
   DRUSEN
AB Purpose: In Korean patients, to subdivide the neovascular forms of age-related macular degeneration (AMD) associated with large retinal pigment epithelial detachment (PED), according to the indocyanine green angiographic features.
   Methods: Indocyanine green angiograms (ICGA) of 67 elderly patients (72 eyes) who presented with a PED of at least 1 disc diameter were evaluated retrospectively.
   Results: Polypoidal choroidal vasculopathy (PCV) and typical choroidal neovascularization (CNV)-associated PEDs were identified in 18 eyes (25%) and 19 eyes (26%), respectively. In ten eyes (13.9%), the exact type of neovascularization, whether PCV or CNV, could not be determined. Pure serous PEDs were identified in seven eyes (10%). The remaining 18 eyes (25%) were classified as having retinal angiomatous proliferation (R A P) -associated PED based upon the angiographic findings of vascular connections between the retinal vasculature and the neovascular complex.
   Conclusions: Three subset groups of PCV, CNV, and RAP were present with similar frequency in neovascularized AMD with a large PED in these Korean patients. In particular, RAP, previously thought to be rare in Asian patients, was found to be present with considerable frequency.
C1 Catholic Univ Korea, Dept Ophthalmol, Kangnam St Marys Hosp, Seoul 137701, South Korea.
   Catholic Univ Korea, Dept Ophthalmol, Uijeongbu St Marys Hosp, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University Korea Hospital;
   Catholic University of Korea
RP Lee, WK (通讯作者)，Catholic Univ Korea, Dept Ophthalmol, Kangnam St Marys Hosp, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
CR BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YANNUZZI LA, 1992, RETINA, V12, P192
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 19
TC 3
Z9 5
U1 0
U2 1
PU SPRINGER TOKYO
PI TOKYO
PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY-JUN
PY 2007
VL 51
IS 3
BP 216
EP 223
DI 10.1007/s10384-006-0430-1
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 177UX
UT WOS:000247179100009
PM 17554485
DA 2022-11-30
ER

PT J
AU Hong, Y
   Makita, S
   Yamanari, M
   Miura, M
   Kim, S
   Yatagai, T
   Yasuno, Y
AF Hong, Youngjoo
   Makita, Shuichi
   Yamanari, Masahiro
   Miura, Masahiro
   Kim, Soohyun
   Yatagai, Toyohiko
   Yasuno, Yoshiaki
TI Three-dimensional visualization of choroidal vessels by using standard
   and ultra-high resolution scattering optical coherence angiography
SO OPTICS EXPRESS
LA English
DT Article
ID RETINAL BLOOD-FLOW; HIGH-SPEED; DOPPLER TOMOGRAPHY; HUMAN SKIN;
   FREQUENCY; NM; IMAGES
AB Scattering optical coherence angiography (S-OCA) is a non-invasive imaging method that is based on the high-speed standard 800nm band spectral-domain optical coherence tomography (SD-OCT) and the ultra-high-resolution SD-OCT which has the axial resolution of 6.1 mu m and 2.9 mu m in tissue, respectively. In this paper, we have demonstrated the use of this method for in vivo human retinal imaging. A three-dimensional view of the choroidal vasculature was obtained by segmenting the choroidal vessels; this was done using intensity threshold based binarization at each depth plane relative to the retinal pigment epithelium. A vascular projection image was obtained by integrating the segmented choroidal vasculature. In order to assess the feasibility of the proposed method, we compared these images with those obtained using existing invasive methods such as fluorescein angiography and indocyanine green angiography. Clinically worthful images are obtained from the application of S-OCA to the age-related macular degeneration and polypoidal choroidal vasculopathy. (c) 2007 Optical Society of America.
C1 Univ Tsukuba, Computat Opt Grp, Tsukuba, Ibaraki 3058573, Japan.
   Computat Opt & Opthalmol Grp, Tsukuba, Ibaraki 3058573, Japan.
   Korea Adv Inst Sci & Technol, Dept Engn Mech, Taejon 305701, South Korea.
   Tokyo Med Univ, Dept Ophthalmol, Tokyo, Japan.
C3 University of Tsukuba; Korea Advanced Institute of Science & Technology
   (KAIST); Tokyo Medical University
RP Hong, Y (通讯作者)，Univ Tsukuba, Computat Opt Grp, Tsukuba, Ibaraki 3058573, Japan.
EM hongyoungjoo@kaist.ac.kr; yasuno@optlab2.bk.tsukuba.ac.jp
RI Makita, Shuichi/G-3806-2011; Yasuno, Yoshiaki/F-2586-2011; Yamanari,
   Masahiro/B-3147-2010; KIM, SOOHYUN/C-1888-2011
OI Makita, Shuichi/0000-0002-6614-3640; Yasuno,
   Yoshiaki/0000-0003-1645-7948; Yamanari, Masahiro/0000-0001-9873-2151; 
CR American National Standards Institute, 2000, Z1361 ANSI LAS I AM
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   FERCHER AF, 1995, OPT COMMUN, V117, P43, DOI 10.1016/0030-4018(95)00119-S
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Hausler G, 1998, J BIOMED OPT, V3, P21, DOI 10.1117/1.429899
   HAMMER M, 1995, PHYS MED BIOL, V40, P963, DOI 10.1088/0031-9155/40/6/001
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Hori Y, 2006, OPT EXPRESS, V14, P1862, DOI 10.1364/OE.14.001862
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Lee ECW, 2006, OPT EXPRESS, V14, P4403, DOI 10.1364/OE.14.004403
   Leitgeb RA, 2004, OPT EXPRESS, V12, P2156, DOI 10.1364/OPEX.12.002156
   Leitgeb RA, 2003, OPT LETT, V28, P2201, DOI 10.1364/OL.28.002201
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480
   PATEL V, 1992, BMJ-BRIT MED J, V305, P678, DOI 10.1136/bmj.305.6855.678
   Povazay B, 2003, OPT EXPRESS, V11, P1980, DOI 10.1364/OE.11.001980
   Rainer L, 2002, PROC SPIE, V4619, P16, DOI 10.1117/12.470477
   Roggan A, 1999, J BIOMED OPT, V4, P36, DOI 10.1117/1.429919
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
   Yazdanfar S, 2003, ARCH OPHTHALMOL-CHIC, V121, P235
   Zhao YH, 2000, OPT LETT, V25, P114, DOI 10.1364/OL.25.000114
NR 28
TC 46
Z9 48
U1 0
U2 4
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD JUN 11
PY 2007
VL 15
IS 12
BP 7538
EP 7550
DI 10.1364/OE.15.007538
PG 13
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 194QU
UT WOS:000248359700053
PM 19547079
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bogunovic, H
   Mares, V
   Reiter, GS
   Schmidt-Erfurth, U
AF Bogunovic, Hrvoje
   Mares, Virginia
   Reiter, Gregor S.
   Schmidt-Erfurth, Ursula
TI Predicting treat-and-extend outcomes and treatment intervals in
   neovascular age-related macular degeneration from retinal optical
   coherence tomography using artificial intelligence
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE neovascular age related macular degeneration; optical coherence
   tomography; anti-VEGF (vascular endothelial growth factor); image
   analysis; retina; machine learning; AI
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF AGENTS; HYPERREFLECTIVE FOCI;
   FACTOR THERAPY; RANIBIZUMAB; FLUID; QUANTIFICATION; DISEASES; REGIMEN;
   IMPACT
AB PurposeTo predict visual outcomes and treatment needs in a treat & extend (T&E) regimen in neovascular age-related macular degeneration (nAMD) using a machine learning model based on quantitative optical coherence tomography (OCT) imaging biomarkers. Materials and methodsStudy eyes of 270 treatment-naive subjects, randomized to receiving ranibizumab therapy in the T&E arm of a randomized clinical trial were considered. OCT volume scans were processed at baseline and at the first follow-up visit 4 weeks later. Automated image segmentation was performed, where intraretinal (IRF), subretinal (SRF) fluid, pigment epithelial detachment (PED), hyperreflective foci, and the photoreceptor layer were delineated using a convolutional neural network (CNN). A set of respective quantitative imaging biomarkers were computed across an Early Treatment Diabetic Retinopathy Study (ETDRS) grid to describe the retinal pathomorphology spatially and its change after the first injection. Lastly, using the computed set of OCT features and available clinical and demographic information, predictive models of outcomes and retreatment intervals were built using machine learning and their performance evaluated with a 10-fold cross-validation. ResultsData of 228 evaluable patients were included, as some had missing scans or were lost to follow-up. Of those patients, 55% reached and maintained long (8, 10, 12 weeks) and another 45% stayed at short (4, 6 weeks) treatment intervals. This provides further evidence for a high disease activity in a major proportion of patients. The model predicted the extendable treatment interval group with an AUROC of 0.71, and the visual outcome with an AUROC of up to 0.87 when utilizing both, clinical and imaging features. The volume of SRF and the volume of IRF, remaining at the first follow-up visit, were found to be the most important predictive markers for treatment intervals and visual outcomes, respectively, supporting the important role of quantitative fluid parameters on OCT. ConclusionThe proposed Artificial intelligence (AI) methodology was able to predict visual outcomes and retreatment intervals of a T&E regimen from a single injection. The result of this study is an urgently needed step toward AI-supported management of patients with active and progressive nAMD.
C1 [Bogunovic, Hrvoje; Reiter, Gregor S.; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Lab Ophthalm Image Anal, Vienna, Austria.
   [Mares, Virginia] Univ Fed Minas Gerais, Dept Ophthalmol, Belo Horizonte, Brazil.
C3 Medical University of Vienna; Universidade Federal de Minas Gerais
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Lab Ophthalm Image Anal, Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Reiter, Gregor/0000-0001-7661-4015
FU FWF Austrian Science Fund [FG 9-N]; Austrian Federal Ministry for
   Digital and Economic Affairs; National Foundation for Research,
   Technology and Development; Novartis
FX This study was financially supported by the FWF Austrian Science Fund
   (grant number FG 9-N), the Austrian Federal Ministry for Digital and
   Economic Affairs, and the National Foundation for Research, Technology
   and Development. The TREND study was funded and conducted by Novartis.
   The funding organizations were not involved in the study design,
   collection, analysis, interpretation of data, the writing of this
   article or the decision to submit it for publication.
CR Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Ehlers JP, 2021, OPHTHALMOL RETINA, V5, P1204, DOI 10.1016/j.oret.2021.02.012
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Gallardo M, 2021, OPHTHALMOL RETINA, V5, P604, DOI 10.1016/j.oret.2021.05.002
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Grechenig C, 2021, RETINA-J RET VIT DIS, V41, P2221, DOI 10.1097/IAE.0000000000003180
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Hsia Y, 2020, GRAEF ARCH CLIN EXP, V258, P273, DOI 10.1007/s00417-019-04546-1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Khanani AM, 2022, JAMA OPHTHALMOL, V140, P20, DOI 10.1001/jamaophthalmol.2021.4585
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2020, OPHTHALMOLOGY, V127, pS135, DOI 10.1016/j.ophtha.2020.01.029
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Michl M, 2022, BRIT J OPHTHALMOL, V106, P113, DOI 10.1136/bjophthalmol-2020-317416
   Nguyen V, 2021, CLIN EXP OPHTHALMOL, V49, P652, DOI 10.1111/ceo.13949
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Orlando JI, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62329-9
   Pfau M, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.7.30
   Proust-Lima C, 2017, J STAT SOFTW, V78, P1, DOI 10.18637/jss.v078.i02
   Riedl S, 2020, RETINA-J RET VIT DIS, V40, P2148, DOI 10.1097/IAE.0000000000002717
   Romo-Bucheli D, 2020, IEEE J BIOMED HEALTH, V24, P3456, DOI 10.1109/JBHI.2020.3000136
   Rosenfeld PJ, 2019, AM J OPHTHALMOL, V204, P26, DOI 10.1016/j.ajo.2019.02.036
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Schlegl T., 2018, PREPRINT
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2022, EYE, DOI 10.1038/s41433-022-02077-4
   Schmidt-Erfurth U, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100972
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Viola P, 2021, DRUG TODAY, V57, P689, DOI 10.1358/dot.2021.57.11.3331006
   Zhang L, 2014, INVEST OPHTH VIS SCI, V55, P2329, DOI 10.1167/iovs.13-13048
NR 52
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD AUG 9
PY 2022
VL 9
AR 958469
DI 10.3389/fmed.2022.958469
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 3Y5US
UT WOS:000843790900001
PM 36017006
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Saito, M
   Iida, T
   Kano, M
AF Saito, Masaaki
   Iida, Tomohiro
   Kano, Mariko
TI COMBINED INTRAVITREAL RANIBIZUMAB AND PHOTODYNAMIC THERAPY FOR
   POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; ranibizumab; photodynamic therapy;
   vascular endothelial growth factor; age-related macular degeneration;
   retinal pigment epithelial detachment; optical coherence tomography;
   retinal pigment epithelium; indocyanine green angiography; bevacizumab
ID MACULAR DEGENERATION; NEOVASCULAR MEMBRANES; ANGIOGRAPHIC FINDINGS;
   JAPANESE PATIENTS; VERTEPORFIN; BEVACIZUMAB; EXPRESSION; LUCENTIS;
   EFFICACY; VEGF
AB Purpose: To clarify the efficacy of combined therapy with intravitreal ranibizumab injections and photodynamic therapy in patients with symptomatic polypoidal choroidal vasculopathy.
   Methods: We retrospectively reviewed 28 naive eyes of 28 patients (17 men, 11 women; mean age, 73.4 years; range, 55-85 years) with 20/40 or less baseline visual acuity treated with 3 consecutive monthly intravitreal injections of ranibizumab (0.5 mg/0.05 mL) and photodynamic therapy and followed-up for at least 12 months. Photodynamic therapy was administered 1 day or 2 days after the initial injection of ranibizumab.
   Results: The mean best-corrected visual acuity levels significantly (P < 0.0001) improved from 0.33 at baseline to 0.61 at 12 months. The mean improvement in best-corrected visual acuity 12 months from baseline was 2.65 lines. The best-corrected visual acuity at 12 months improved in 15 eyes (53.6%) by >= 3 lines and was stable (defined as a loss of <3 lines of vision) in 13 eyes (46.4%). The central retinal thickness significantly (P < 0.0001) decreased from 366 mu m to 151 mu m at 12 months. The mean numbers of photodynamic therapy treatments and injections during 12 months including the treatments during the initial regimen were 1.1 and 3.7, respectively. No complications developed.
   Conclusion: Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy maintained or improved visual acuity and reduced the exudation without adverse events. RETINA 32:1272-1279, 2012
C1 [Saito, Masaaki; Iida, Tomohiro; Kano, Mariko] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan.
C3 Fukushima Medical University
RP Saito, M (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM smasaaki@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kohno RI, 2010, AM J OPHTHALMOL, V150, P223, DOI 10.1016/j.ajo.2010.03.016
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Saito M, 2010, AM J OPHTHALMOL, V149, P472, DOI 10.1016/j.ajo.2009.09.016
   Saito M, 2008, AM J OPHTHALMOL, V146, P935, DOI 10.1016/j.ajo.2008.06.033
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 39
TC 17
Z9 19
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2012
VL 32
IS 7
BP 1272
EP 1279
DI 10.1097/IAE.0b013e318236e624
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 965QK
UT WOS:000305782100007
PM 22547209
DA 2022-11-30
ER

PT J
AU Lo, KJ
   Chang, JY
   Chang, HY
   Chiou, SH
   Hwang, DK
   Chen, SJ
AF Lo, Kang-Jung
   Chang, Jin-Yu
   Chang, Hsin-Yi
   Chiou, Shih-Hwa
   Hwang, De-Kuang
   Chen, Shih-Jen
TI Three-Year Outcomes of Patients with Neovascular Age-Related Macular
   Degeneration Treated with Aflibercept under the National Health
   Insurance Program in Taiwan
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; OPTICAL COHERENCE TOMOGRAPHY;
   INTRAVITREAL RANIBIZUMAB; ANCHOR
AB Purpose. To observe and analyze the long-term outcomes of patients with neovascular age-related macular degeneration (nAMD) treated with aflibercept monotherapy under the National Health Insurance (NHI) program in Taiwan. Methods. This retrospective observational study was conducted at Taipei Veterans General Hospital. Patients with naive nAMD who were treated with aflibercept and followed for more than 3 years were reviewed. The better eye was enrolled if both eyes were affected. Visual acuity (VA) and central macular thickness (CMT) were recorded for 3 years. The lost-to-follow-up rate, number of injections, and predictive factors for visual outcomes were analyzed. Results. Ninety-nine eyes in 99 patients were followed up for 3 years. The mean age at onset of nAMD was 82.8 +/- 9.26 years, and 65% of the patients were male. Compared with initial visual acuity, 5 (5.1%) of our patients improved their vision for 3 or more lines after 3 years of follow-up, 11 (11.1%) of our patients improved for 1 to 3 lines, 62 (62.6%) patients remained their vision with 1 line or less changes, 15 (15.2%) patients lost their vision for 1 to 3 lines, and 6 (6%) patients lost their vision for 3 or more lines. The CMT was 359 +/- 180 mu m before treatment and 259 +/- 98 after 3 years (p<0.001). The mean number of injections was 4.63 +/- 1.91 in the first year, 2.13 +/- 2.2 in the second year, and 1.42 +/- 1.79 in the third year. Multivariate analysis showed that final VA was significantly associated with VA at year 1, the presence of retinal pigment epithelial detachment at year 1, and receiving more than four injections in the first year. Final CMT was only significantly associated with CMT at year 1. Conclusion. After 3 years of treatment under the NHI program in Taiwan, 21.2% of the patients with nAMD still had a visual decline despite good anatomical outcomes. More aggressive treatment or other strategies should be used for patients who may have a poor prognosis.
C1 [Lo, Kang-Jung; Chang, Jin-Yu; Chiou, Shih-Hwa; Hwang, De-Kuang; Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chang, Hsin-Yi] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chiou, Shih-Hwa] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan.
   [Chiou, Shih-Hwa] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan.
   [Hwang, De-Kuang; Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Dept Ophthalmol, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; Shin Kong Wu Ho Su Memorial Hospital;
   National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University
RP Hwang, DK (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.; Hwang, DK (通讯作者)，Natl Yang Ming Univ, Sch Med, Dept Ophthalmol, Taipei, Taiwan.
EM kan42731@gmail.com; ailblis929@gmail.com; d4351019@gmail.com;
   shchiou@vghtpe.gov.tw; m95gbk@gmail.com; sjchen96@gmail.com
RI Hwang, DK De-Kuang/J-3931-2016
OI Hwang, DK De-Kuang/0000-0001-6346-8485; Chen,
   Shih-Jen/0000-0001-9798-1578; Chang, Hsin-Yi/0000-0002-6998-4226; Lo,
   Kang-jung/0000-0002-7008-6829
CR Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Chou YB, 2019, J CHIN MED ASSOC, V82, P659, DOI 10.1097/JCMA.0000000000000138
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garweg JG, 2018, GRAEF ARCH CLIN EXP, V256, P823, DOI 10.1007/s00417-018-3907-y
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
NR 29
TC 4
Z9 4
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD FEB 22
PY 2020
VL 2020
AR 4538135
DI 10.1155/2020/4538135
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KS9IO
UT WOS:000518621900001
PM 32148945
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sayed, KM
   Naito, T
   Nagasawa, T
   Katome, T
   Mitamura, Y
AF Sayed, Khulood Mohammed
   Naito, Takeshi
   Nagasawa, Toshihiko
   Katome, Takashi
   Mitamura, Yoshinori
TI Early visual impacts of optical coherence tomographic parameters in
   patients with age-related macular degeneration following the first
   versus repeated ranibizumab injection
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; optical coherence tomography;
   Ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   PHOTODYNAMIC THERAPY; FLUORESCEIN ANGIOGRAPHY; MICROPERIMETRY;
   MEMBRANES; ACUITY; EYE; FAB
AB The aim of this study is to evaluate the early visual impacts of various optical coherence tomographic (OCT) parameters after the first versus repeated intravitreal ranibizumab injection in patients with exudative age-related macular degeneration (AMD).
   A retrospective comparative case series study was conducted on 20 eyes of 18 consecutive patients who received intravitreal ranibizumab injection for exudative AMD either for the first time (group 1; n = 8) with no prior anti-vascular endothelial growth factor (anti-VEGF) injection in the same or fellow eye, or for repeated times during the course of monthly injected ranibizumab (group 2; n = 12 eyes). The following baseline and 1 month post-injection data was collected for both groups and compared: best-corrected visual acuity (BCVA), qualitative and quantitative OCT parameters including: foveal thickness, foveal volume (central 1-mm circle), retinal volume at 3- and 5-mm central circles, retinal pigment epithelium (RPE) elevation, type of fluid collections, and type of AMD lesion. The size of the fluid and fibrovascular lesion (FVL) areas were measured using manual delineation and automatic calculation of the device. We made correlations between the post-injection visual acuity (VA) and each of post-injection OCT parameters in both groups and these were the main outcome measures.
   In group 1, there was a strong correlation between post-injection logarithm of minimum angle of resolution (logMAR) BCVA and each of the following: FVL size, foveal thickness, retinal volume at 3- and 5-mm central circles, RPE elevation, the size of the fluid area, and age of the patient (r > 0.70, p < 0.05), whereas in group 2; logMAR BCVA was strongly correlated only with foveal volume (r = 0.74, p = 0.01). Multivariate analysis showed that post-injection FVL size (r (2) = 0.69) and foveal volume (r (2) = 0.55) were the most important factors for VA 1 month following the initial and repeated ranibizumab injection, respectively.
   The size of FVL and foveal volume showed a significant correlation with VA in AMD patients shortly after the first and repeated ranibizumab injection, respectively. Further studies with larger sample sizes are needed in order to support these results.
C1 [Sayed, Khulood Mohammed; Naito, Takeshi; Nagasawa, Toshihiko; Katome, Takashi; Mitamura, Yoshinori] Univ Tokushima, Dept Ophthalmol & Visual Neurosci, Inst Hlth Biosci, Grad Sch, Tokushima 7708503, Japan.
   [Sayed, Khulood Mohammed] Sohag Univ, Dept Ophthalmol, Sohag Fac Med, Sohag 82524, Egypt.
C3 Tokushima University; Egyptian Knowledge Bank (EKB); Sohag University
RP Naito, T (通讯作者)，Univ Tokushima, Dept Ophthalmol & Visual Neurosci, Inst Hlth Biosci, Grad Sch, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
EM naito@clin.med.tokushima-u.ac.jp
CR Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P84, DOI 10.1136/bjo.2007.124016
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
NR 30
TC 4
Z9 5
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2011
VL 249
IS 10
BP 1449
EP 1458
DI 10.1007/s00417-011-1672-2
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 823NL
UT WOS:000295129000003
PM 21494878
DA 2022-11-30
ER

PT J
AU Moja, L
   Lucenteforte, E
   Kwag, KH
   Bertele, V
   Campomori, A
   Chakravarthy, U
   D'Amico, R
   Dickersin, K
   Kodjikian, L
   Lindsley, K
   Loke, Y
   Maguire, M
   Martin, DF
   Mugelli, A
   Muhlbauer, B
   Puntmann, I
   Reeves, B
   Rogers, C
   Schmucker, C
   Subramanian, ML
   Virgili, G
AF Moja, Lorenzo
   Lucenteforte, Ersilia
   Kwag, Koren H.
   Bertele, Vittorio
   Campomori, Annalisa
   Chakravarthy, Usha
   D'Amico, Roberto
   Dickersin, Kay
   Kodjikian, Laurent
   Lindsley, Kristina
   Loke, Yoon
   Maguire, Maureen
   Martin, Daniel F.
   Mugelli, Alessandro
   Muehlbauer, Bernd
   Puentmann, Isabel
   Reeves, Barnaby
   Rogers, Chris
   Schmucker, Christine
   Subramanian, Manju L.
   Virgili, Gianni
TI Systemic safety of bevacizumab versus ranibizumab for neovascular
   age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF AGENTS; INTRAVITREAL BEVACIZUMAB;
   ADVERSE EVENTS; RISK; PREVALENCE; MORTALITY; GRADE; PHARMACOKINETICS;
   METAANALYSES
AB Background
   Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin (R)) and ranibizumab (Lucentis (R)) are targeted biological drugs (a monoclonal antibody) that inhibit vascular endothelial growth factor, an angiogenic cytokine that promotes vascular leakage and growth, thereby preventing its pathological angiogenesis. Ranibizumab is approved for intravitreal use to treat neovascular AMD, while bevacizumab is approved for intravenous use as a cancer therapy. However, due to the biological similarity of the two drugs, bevacizumab is widely used off-label to treat neovascular AMD.
   Objectives
   To assess the systemic safety of intravitreal bevacizumab (brand name Avastin (R); Genentech/Roche) compared with intravitreal ranibizumab (brand name Lucentis (R); Novartis/Genentech) in people with neovascular AMD. Primary outcomes were death and All serious systemic adverse events (All SSAEs), the latter as a composite outcome in accordance with the International Conference on Harmonisation Good Clinical Practice. Secondary outcomes examined specific SSAEs: fatal and non-fatal myocardial infarctions, strokes, arteriothrombotic events, serious infections, and events grouped in some Medical Dictionary for Regulatory Activities System Organ Classes (MedDRA SOC). We assessed the safety at the longest available follow-up to a maximum of two years.
   Search methods
   We searched CENTRAL, MEDLINE, EMBASE and other online databases up to 27 March 2014. We also searched abstracts and clinical study presentations at meetings, trial registries, and contacted authors of included studies when we had questions.
   Selection criteria
   Randomised controlled trials (RCTs) directly comparing intravitreal bevacizumab (1.25 mg) and ranibizumab (0.5 mg) in people with neovascular AMD, regardless of publication status, drug dose, treatment regimen, or follow-up length, and whether the SSAEs of interest were reported in the trial report.
   Data collection and analysis
   Two authors independently selected studies and assessed the risk of bias for each study. Three authors independently extracted data.
   We conducted random-effects meta-analyses for the primary and secondary outcomes. We planned a pre-specified analysis to explore deaths and All SSAEs at the one-year follow-up.
   Main results
   We included data from nine studies (3665 participants), including six published (2745 participants) and three unpublished (920 participants) RCTs, none supported by industry. Three studies excluded participants at high cardiovascular risk, increasing clinical heterogeneity among studies. The studies were well designed, and we did not downgrade the quality of the evidence for any of the outcomes due to risk of bias. Although the estimated effects of bevacizumab and ranibizumab on our outcomes were similar, we downgraded the quality of the evidence due to imprecision.
   At the maximum follow-up (one or two years), the estimated risk ratio (RR) of death with bevacizumab compared with ranibizumab was 1.10 (95% confidence interval (CI) 0.78 to 1.57, P value = 0.59; eight studies, 3338 participants; moderate quality evidence). Based on the event rates in the studies, this gives a risk of death with ranibizumab of 3.4% and with bevacizumab of 3.7% (95% CI 2.7% to 5.3%).
   For All SSAEs, the estimated RR was 1.08 (95% CI 0.90 to 1.31, P value = 0.41; nine studies, 3665 participants; low quality evidence). Based on the event rates in the studies, this gives a risk of SSAEs of 22.2% with ranibizumab and with bevacizumab of 24% (95% CI 20% to 29.1%).
   For the secondary outcomes, we could not detect any difference between bevacizumab and ranibizumab, with the exception of gastrointestinal disorders MedDRA SOC where there was a higher risk with bevacizumab (RR 1.82; 95% CI 1.04 to 3.19, P value = 0.04; six studies, 3190 participants).
   Pre-specified analyses of deaths and All SSAEs at one-year follow-up did not substantially alter the findings of our review.
   Fixed-effect analysis for deaths did not substantially alter the findings of our review, but fixed-effect analysis of All SSAEs showed an increased risk for bevacizumab (RR 1.12; 95% CI 1.00 to 1.26, P value = 0.04; nine studies, 3665 participants): the meta-analysis was dominated by a single study (weight = 46.9%).
   The available evidence was sensitive to the exclusion of CATT or unpublished results. For All SSAEs, the exclusion of CATT moved the overall estimate towards no difference (RR 1.01; 95% CI 0.82 to 1.25, P value = 0.92), while the exclusion of LUCAS yielded a larger RR, with more SSAEs in the bevacizumab group, largely driven by CATT (RR 1.19; 95% CI 1.06 to 1.34, P value = 0.004). The exclusion of all unpublished studies produced a RR of 1.12 for death (95% CI 0.78 to 1.62, P value = 0.53) and a RR of 1.21 for SSAEs (95% CI 1.06 to 1.37, P value = 0.004), indicating a higher risk of SSAEs in those assigned to bevacizumab than ranibizumab.
   Authors' conclusions
   This systematic review of non-industry sponsored RCTs could not determine a difference between intravitreal bevacizumab and ranibizumab for deaths, All SSAEs, or specific subsets of SSAEs in the first two years of treatment, with the exception of gastrointestinal disorders. The current evidence is imprecise and might vary across levels of patient risks, but overall suggests that if a difference exists, it is likely to be small. Health policies for the utilisation of ranibizumab instead of bevacizumab as a routine intervention for neovascular AMD for reasons of systemic safety are not sustained by evidence. The main results and quality of evidence should be verified once all trials are fully published.
C1 [Moja, Lorenzo] Univ Milan, IRCCS Galeazzi Orthopaed Inst, Dept Biomed Sci Hlth, I-20133 Milan, Italy.
   [Lucenteforte, Ersilia] Univ Florence, Dept Neurosci Psychol Drug Res & Childrens Hlth, Florence, Italy.
   [Kwag, Koren H.] IRCCS Galeazzi Orthopaed Inst, Clin Epidemiol Unit, Milan, Italy.
   [Bertele, Vittorio] IRCCS Mario Negri Inst Pharmacol Res, Lab Regulatory Policies, Milan, Italy.
   [Campomori, Annalisa] Trento Gen Hosp, Hosp Pharm, Hlth Trust Autonomous Prov Trento, Trento, Italy.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast, Antrim, North Ireland.
   [D'Amico, Roberto] Univ Modena & Reggio Emilia, Dept Diagnost Clin & Publ Hlth Med, Italian Cochrane Ctr, Modena, Italy.
   [Dickersin, Kay] Johns Hopkins Univ, Ctr Clin Trials, Baltimore, MD USA.
   [Dickersin, Kay] Johns Hopkins Univ, US Cochrane Ctr, Baltimore, MD USA.
   [Kodjikian, Laurent] Hop Croix Rousse, Dept Ophthalmol, F-69317 Lyon, France.
   [Lindsley, Kristina] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Loke, Yoon] Univ E Anglia, Sch Med, Norwich NR4 7TJ, Norfolk, England.
   [Maguire, Maureen] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Mugelli, Alessandro] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Florence, Italy.
   [Muehlbauer, Bernd; Puentmann, Isabel] Klinikum Bremen Mitte gGmbH, Dept Pharmacol, Bremen, Germany.
   [Reeves, Barnaby; Rogers, Chris] Univ Bristol, Sch Clin Sci, Bristol, Avon, England.
   [Schmucker, Christine] Univ Med Ctr Freiburg, Inst Med Biometry & Med Informat, German Cochrane Ctr, Freiburg, Germany.
   [Subramanian, Manju L.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Virgili, Gianni] Univ Florence, Eye Clin, Dept Translat Surg & Med, Florence, Italy.
C3 IRCCS Istituto Ortopedico Galeazzi; University of Milan; University of
   Florence; IRCCS Istituto Ortopedico Galeazzi; Istituto di Ricerche
   Farmacologiche Mario Negri IRCCS; Queens University Belfast; Universita
   di Modena e Reggio Emilia; Johns Hopkins University; Johns Hopkins
   University; CHU Lyon; Johns Hopkins University; Johns Hopkins Bloomberg
   School of Public Health; University of East Anglia; University of
   Pennsylvania; Cleveland Clinic Foundation; University of Florence;
   Klinikum Bremen-Mitte; University of Bristol; University of Freiburg;
   Boston University; University of Florence
RP Moja, L (通讯作者)，Univ Milan, IRCCS Galeazzi Orthopaed Inst, Dept Biomed Sci Hlth, Via Pascal 36, I-20133 Milan, Italy.
EM lorenzo.moja@unimi.it
RI Bertele, Vittorio/AAA-6461-2020; Lucenteforte, Ersilia/AAB-9055-2019;
   Moja, Pasquale Lorenzo/CAH-0318-2022; D'Amico, Roberto/I-8106-2014;
   Virgili, Gianni/P-6607-2014
OI Bertele, Vittorio/0000-0002-0032-7033; Lucenteforte,
   Ersilia/0000-0001-5608-5902; Moja, Pasquale Lorenzo/0000-0001-6680-6507;
   D'Amico, Roberto/0000-0002-3211-6687; Reeves,
   Barnaby/0000-0002-5101-9487; Chakravarthy, Usha/0000-0002-2606-3734;
   Schmucker, Christine/0000-0002-1188-3158; Virgili,
   Gianni/0000-0002-9960-2989
FU Emilia Romagna Regional Health Service, Italy; Emilia Romagna Regional
   Health Service; Italian Ministry of Health, Italy; Italian Ministry of
   Health [GR-2011-02348048]; National Institutes of Health, USA; National
   Eye Institute, National Institutes of Health, Department of Health and
   Human Services, United States [U10-EY017823]; National Eye Institute,
   National Institutes of Health [1 (U01-EY020522)]; National Institute for
   Health Research (NIHR), UK; National Institute for Health Research to
   Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of
   Ophthalmology for a Specialist Biomedical Research Centre for
   Ophthalmology; NIHR; NATIONAL EYE INSTITUTE [U01EY020522, U10EY017823]
   Funding Source: NIH RePORTER
FX External sources; Emilia Romagna Regional Health Service, Italy.; This
   systematic review has been funded by the Emilia Romagna Regional Health
   Service to the Italian Cochrane Centre. The funding source had no role
   in the development of the systematic review or the writing of this
   manuscript.; Italian Ministry of Health, Italy.; Lorenzo Moja is a
   recipient of a Research Early Career Award from the Italian Ministry of
   Health on "Improving appropriateness and transparency of processes to
   develop guidelines on controversial clinical areas: evidence, values and
   context preferences to help mitigate disputes and enhance the
   applicability of recommendations to practice" (GR-2011-02348048).;
   National Institutes of Health, USA.; Dr. Maguire's effort in
   contributing to the design and reporting of this review was supported by
   a grant (U10-EY017823) from the National Eye Institute, National
   Institutes of Health, Department of Health and Human Services, United
   States.; Kay Dickersin's contribution was supported by Grant 1
   (U01-EY020522) from the National Eye Institute, National Institutes of
   Health.; National Institute for Health Research (NIHR), UK.; Richard
   Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision Group
   (CEVG) acknowledges financial support for his CEVG research sessions
   from the Department of Health through the award made by the National
   Institute for Health Research to Moorfields Eye Hospital NHS Foundation
   Trust and UCL Institute of Ophthalmology for a Specialist Biomedical
   Research Centre for Ophthalmology.; The NIHR also funds the CEVG
   Editorial Base in London.; The views expressed in this publication are
   those of the authors and not necessarily those of the NIHR, NHS, or the
   Department of Health.
CR Akl EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057132
   Avery RL, 2014, BRIT J OPHTHALMOLOGY
   Bassler D, 2013, STAT METHODS MED RES, V22, P159, DOI 10.1177/0962280211432211
   Berg K., 2013, AAO ANN M 2013 SUBSP
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Bosco JLF, 2010, J CLIN EPIDEMIOL, V63, P64, DOI 10.1016/j.jclinepi.2009.03.001
   Braithwaite T, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007325.pub3
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Cancer Therapy Evaluation Program, 2003, CANC THER EV PROGR C
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Cortes J, 2012, ANN ONCOL, V23, P1130, DOI 10.1093/annonc/mdr432
   Cruess AF, 2014, OPHTHALMOLOGICA, V231, P75, DOI 10.1159/000355569
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Esarey J, QUANTITATIVE METHODS
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   French DD, 2011, RETINA-J RET VIT DIS, V31, P1036, DOI 10.1097/IAE.0b013e31821dc66f
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Hapani S, 2009, LANCET ONCOL, V10, P559, DOI 10.1016/S1470-2045(09)70112-3
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Horsley W, BEVACIZUMAB AVASTIN
   Ioannidis JPA, 2005, JAMA-J AM MED ASSOC, V294, P218, DOI 10.1001/jama.294.2.218
   Ioannidis JPA, 2005, J CLIN EPIDEMIOL, V58, P543, DOI 10.1016/j.jclinepi.2004.10.019
   Ioannidis JPA, 1997, J CLIN EPIDEMIOL, V50, P1089, DOI 10.1016/S0895-4356(97)00149-2
   Kasenda B, 2014, JAMA-J AM MED ASSOC, V311, P1045, DOI 10.1001/jama.2014.1361
   Kim H, 2009, MOL VIS, V15
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Manzoli L, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3058
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nordic Cochrane Centre, 2014, COCHR COLL REV MAN R
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Ranpura V, 2011, JAMA-J AM MED ASSOC, V305, P487, DOI 10.1001/jama.2011.51
   ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052
   Saif MW, 2006, EXPERT OPIN DRUG SAF, V5, P553, DOI 10.1517/14740338.5.4.553
   Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643
   Schauwvlieghe ASME, 2014, INVEST OPHTH VIS SCI, V55
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Singh JA, 2009, CAN MED ASSOC J, V181, P787, DOI 10.1503/cmaj.091391
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stergiou PK, 2011, ACTA OPHTHALMOL, V89, P218, DOI 10.1111/j.1755-3768.2009.01669.x
   Sterne JAC, 2011, COCHRANE HDB SYSTEMA
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Thulliez M, 2014, JAMA OPTHALMOLO 0724
   Tobias A, 1999, STATA TECH B, V8, P1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu SH, 2010, J AM SOC NEPHROL, V21, P1381, DOI 10.1681/ASN.2010020167
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
NR 66
TC 156
Z9 158
U1 1
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2014
IS 9
AR CD011230
DI 10.1002/14651858.CD011230.pub2
PG 90
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AY5YT
UT WOS:000347645800078
PM 25220133
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Mantel, I
   Dirani, A
   Zola, M
   Parvin, P
   De Massougnes, S
   Bergin, C
AF Mantel, Irmela
   Dirani, Ali
   Zola, Marta
   Parvin, Parmis
   De Massougnes, Sophie
   Bergin, Ciara
TI MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Risk Factor
   Evaluation for Individualized Treatment Need of Ranibizumab or
   Aflibercept According to an Observe-and-Plan Regimen
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE atrophy; retinal pigment epithelium; intravitreal injection; anti-VEGF;
   vascular endothelial growth factor; neovascular age-related macular
   degeneration; ranibizumab; aflibercept
ID PIGMENT EPITHELIAL ATROPHY; GEOGRAPHIC-ATROPHY; RETICULAR PSEUDODRUSEN;
   CHOROIDAL THICKNESS; FELLOW-EYES; VEGF; ASSOCIATION; PROGRESSION;
   OUTCOMES; THERAPY
AB Purpose: To investigate factors associated with macular atrophy (MA) incidence in neovascular age-related macular degeneration treated with either ranibizumab or aflibercept in an Observe-and-Plan variable dosing regimen.
   Methods: Information was obtained from two identical prospective treatment protocols using ranibizumab or aflibercept in a variable dosing regimen termed "Observe and Plan." Eyes without MA at baseline were included. New atrophy at the final 2-year visit was investigated with univariate and multivariate analysis to identify associated risk factors, focusing on treatment factors.
   Results: De novo MA developed in 63 (42%) of 149 eyes/patients (mean age 79.0 years), in 70 eyes treated using aflibercept and 79 eyes using ranibizumab. The univariate analysis showed multiple associations of MA with baseline factors, of which the following were confirmed as independent risk factors after multivariate stepwise logistic regression: lower number of anti-vascular endothelial growth factors injections (P = 0.011), depigmentation (P = 0.0004), reticular pseudodrusen (P = 0.0005), lower baseline visual acuity (P = 0.0006), and retinal angiomatous proliferation (P = 0.001). The drug type showed no significant association with MA incidence (P = 0.21).
   Conclusion: Within the variable dosing regimen, MA incidence was higher when fewer injections were required. More injections, if required by disease activity, did not increase the risk for MA.
C1 [Mantel, Irmela; Dirani, Ali; Zola, Marta; Parvin, Parmis; De Massougnes, Sophie; Bergin, Ciara] Univ Lausanne, Dept Ophthalmol, Jules Gonin Eye Hosp, 15 Ave France,CP 5143, CH-1000 Lausanne 2, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Lausanne, Dept Ophthalmol, Jules Gonin Eye Hosp, 15 Ave France,CP 5143, CH-1000 Lausanne 2, Switzerland.
EM irmela.mantel@fa2.ch
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 32
TC 15
Z9 15
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2019
VL 39
IS 5
BP 906
EP 917
DI 10.1097/IAE.0000000000002054
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4VP
UT WOS:000480749600022
PM 29370035
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Keane, PA
   Liakopoulos, S
   Chang, KT
   Heussen, FM
   Ongchin, SC
   Walsh, AC
   Sadda, SR
AF Keane, P. A.
   Liakopoulos, S.
   Chang, K. T.
   Heussen, F. M.
   Ongchin, S. C.
   Walsh, A. C.
   Sadda, S. R.
TI Comparison of the optical coherence tomographic features of choroidal
   neovascular membranes in pathological myopia versus age-related macular
   degeneration, using quantitative subanalysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; PHOTODYNAMIC THERAPY; LACQUER CRACKS;
   RANIBIZUMAB; VERTEPORFIN
AB Aim: To compare the retinal morphological characteristics of eyes with choroidal neovascularisation (CNV) secondary to pathological myopia versus eyes with CNV secondary to age-related macular degeneration (AMD), using quantitative optical coherence tomography (OCT) subanalysis.
   Methods: Twenty-one eyes of 21 patients newly diagnosed as having CNV secondary to pathological myopia, and 43 consecutive cases of eyes with newly diagnosed subfoveal CNV secondary to AMD were retrospectively collected. In all patients, StratusOCT images and fluorescein angiograms (FA) were available for analysis. StratusOCT images were analysed using custom software (termed "OCTOR''), which allowed calculation of the thickness/volume of the neurosensory retina, subretinal fluid (SRF), subretinal tissue (SRT) and pigment epithelial detachments (PEDs). FA images were used to calculate CNV leakage area and CNV lesion size for each eye.
   Results: The total volume of neurosensory retina in the pathological myopia group was significantly less than in the AMD group (7.10 (SD 0.50) mm(3) vs 7.76 (0.93) mm(3), p = 0.004). The total volume of SRF in the pathological myopia group was less than in the AMD group, but the difference was not statistically significant (0.33 (1.38) mm(3) vs 0.55 (0.82) mm(3), p = 0.434). The total volume of SRT in the pathological myopia group was less than in the AMD group, but the difference was not statistically significant (0.16 (0.15) mm(3) vs 0.36 (0.60) mm(3), p = 0.144). The total volume of PED in the pathological myopia group was markedly less than in the AMD group (0.01 (0.03) mm(3) vs 1.09 (1.89) mm(3), p<0.001). On FA, the total leakage of CNV in the AMD group was significantly greater than in the pathological myopia group (4.17 (3.29) DAs vs 0.53 (0.58) DAs, p<0.001).
   Conclusions: CNV lesions in pathological myopia were associated with considerably less retinal oedema, SRF and SRT compared with CNV associated with AMD. PEDs were almost negligible in myopic lesions compared with AMD. These findings are consistent with previous clinical and angiographic descriptions of myopic CNV as relatively small lesions with modest exudation.
C1 [Keane, P. A.; Chang, K. T.; Sadda, S. R.] Univ So Calif, Keck Sch Med, Doheny Image Reading Ctr, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Liakopoulos, S.; Heussen, F. M.] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-5000 Cologne 41, Germany.
C3 Doheny Eye Institute; University of Southern California; University of
   Cologne
RP Sadda, SR (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Image Reading Ctr, Doheny Eye Inst, 1450 San Pablo St,DEI 3623, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
RI Keane, Pearse/AAE-5709-2019; Keane, Pearse A/H-1860-2011
OI Keane, Pearse/0000-0002-9239-745X; Heussen, Florian
   Moritz/0000-0003-0536-9870
FU NEI NIH HHS [R21 EY015914, R21 EY015914-03, R21 EY015914-04, R01
   EY014375, P30 EY003040, EY03040] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R21EY015914, P30EY003040, R01EY014375] Funding Source: NIH
   RePORTER
CR Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   AVETISOV ES, 1977, ANN OPHTHALMOL, V9, P1261
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Chan WM, 2007, OPHTHALMOLOGY, V114, P2190, DOI 10.1016/j.ophtha.2007.03.043
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   CURTIN BJ, 1971, AM J OPHTHALMOL, V71, P42, DOI 10.1016/0002-9394(71)91092-0
   CURTIN BJ, 1985, MYOPIAS BASIC SCI CL, P237
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass JD., 1997, STEREOSCOPIC ATLAS M, V1
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923
   Hee MR, 2005, AM J OPHTHALMOL, V139, P154, DOI 10.1016/j.ajo.2004.08.066
   Hernandez-Rojas ML, 2007, RETINA-J RET VIT DIS, V27, P707
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KEANE PA, INVEST OPHTHALMOL VI
   KLEIN RM, 1988, AM J OPHTHALMOL, V106, P282, DOI 10.1016/0002-9394(88)90362-5
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   NOBLE KG, 1982, OPHTHALMOLOGY, V89, P1099
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011
   Tano Y, 2002, AM J OPHTHALMOL, V134, P645, DOI 10.1016/S0002-9394(02)01883-4
   Toth CA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1425, DOI 10.1001/archopht.1997.01100160595012
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
NR 30
TC 34
Z9 37
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2008
VL 92
IS 8
BP 1081
EP 1085
DI 10.1136/bjo.2008.138891
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 329RR
UT WOS:000257888800018
PM 18586903
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Khanani, AM
   Brown, DM
   Jaffe, GJ
   Wykoff, CC
   Adiguzel, E
   Wong, R
   Meng, XY
   Heier, JS
AF Khanani, Arshad M.
   Brown, David M.
   Jaffe, Glenn J.
   Wykoff, Charles C.
   Adiguzel, Eser
   Wong, Randall
   Meng, Xiangyi
   Heier, Jeffrey S.
CA MERLIN Investigators
TI MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of
   Brolucizumab in Participants with Neovascular Age-Related Macular
   Degeneration and Persistent Retinal Fluid
SO OPHTHALMOLOGY
LA English
DT Article
ID TREAT-AND-EXTEND; RANIBIZUMAB; AFLIBERCEPT
AB Purpose: To assess the 52-week efficacy and safety of brolucizumab 6 mg administered every 4 weeks compared with aflibercept 2 mg dosed every 4 weeks in eyes with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid.
   Design: Multicenter, randomized, double-masked phase 3a study.
   Participants: Participants with recalcitrant nAMD (persistent residual retinal fluid despite previous frequent anti-vascular endothelial growth factor treatment).
   Methods: Eyes were randomized (2:1) to intravitreal brolucizumab 6 mg or aflibercept 2 mg every 4 weeks up to and including week 100.
   Main Outcome Measures: The primary end point was analysis of noninferiority in mean best-corrected visual acuity (BCVA) change from baseline to week 52 (margin, 4 letters). Other key end points included change in central subfield thickness (CST) from baseline to week 52, fluid-free status (no intraretinal fluid and no subretinal fluid), and safety.
   Results: At week 52, brolucizumab was noninferior to aflibercept in BCVA change from baseline (least squares mean difference, -0.6 Early Treatment Diabetic Retinopathy Study letters; 95% confidence interval [CI], -2.1 to 0.9; P < 0.001). A total of 4.8% and 1.7% of participants reported a 15-letter or more BCVA loss from baseline at week 52 in the brolucizumab and aflibercept groups, respectively. In eyes treated with brolucizumab compared with those treated with aflibercept, the CST was reduced significantly (P < 0.001), and a significantly greater proportion of eyes were fluid free at week 52 (40.4% brolucizumab vs. 19.0% aflibercept; 95% CI, 13.9-29.0; P < 0.001). Incidence of intraocular inflammation (IOI), including retinal vasculitis and retinal vascular occlusion, were 9.3% (0.8% and 2.0%) for brolucizumab versus 4.5% (0% and 0%) for aflibercept, respectively.
   Conclusions: Visual acuity outcomes in previously treated participants with nAMD and persistent retinal fluid receiving brolucizumab 6 mg dosed every 4 weeks were noninferior to aflibercept 2 mg dosed every 4 weeks, with superior anatomic outcomes. However, incidences of IOI, including retinal vasculitis and retinal vascular occlusion, also were higher, leading to study termination. (c) 2022 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology
C1 [Khanani, Arshad M.] Siena Eye Associates, Reno, NV USA.
   [Khanani, Arshad M.] Univ Nevada, Sch Med, Reno, NV 89557 USA.
   [Brown, David M.; Wykoff, Charles C.] Retina Consultants Texas, Retina Consultants Amer, Houston, TX USA.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX 77030 USA.
   [Adiguzel, Eser; Wong, Randall; Meng, Xiangyi] Novartis Pharmaceut, E Hanover, NJ USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Reno;
   Duke University; The Methodist Hospital System; The Methodist Hospital -
   Houston; Novartis; Ophthalmic Consultants of Boston
RP Brown, DM (通讯作者)，Retina Consultants Texas, Retina Consultants Amer, 4460 Bissonnet,Suite 200, Bellaire, TX 77401 USA.
EM dmbmd@retinaconsultantstexas.com
OI Heier, Jeffrey/0000-0003-4625-3145; Khanani, Arshad/0000-0001-8928-5599;
   Wykoff, Charles/0000-0001-7756-5091
FU Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
FX Supported by Novartis Pharmaceuticals Corporation, East Hanover, New
   Jersey.
CR American Academy of Ophthalmology, 2019, AGE RELATED MACULAR
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Eter N, 2021, GRAEF ARCH CLIN EXP, V259, P2213, DOI 10.1007/s00417-021-05073-8
   Genentech Inc, 2006, LUCENTIS PRESCRIBING
   Gill CR, 2020, OPHTHALMOL THER, V9, P725, DOI 10.1007/s40123-020-00288-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Jackson TL, 2020, JAMA OPHTHALMOL, V138, P835, DOI 10.1001/jamaophthalmol.2020.2309
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Kaiser PK, 2021, RETINA-J RET VIT DIS, V41, P1579, DOI 10.1097/IAE.0000000000003194
   Khanani AM, 2022, JAMA OPHTHALMOL, V140, P20, DOI 10.1001/jamaophthalmol.2021.4585
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Novartis AG, 2021, NOVARTIS REPORTS ONE
   Novartis Europharm Limited Beovu, 2020, SUMMARY PRODUCT CHAR
   Novartis Pharmaceuticals Corporation, 2019, BEOVU PRESCRIBING IN
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Regeneron Pharmaceuticals Inc, 2011, EYLEA PRESCR INF
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Thomas CN, 2022, BRIT J PHARMACOL, V179, P1908, DOI 10.1111/bph.15459
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Tufail A, 2020, BRIT J OPHTHALMOL, V104, P672, DOI 10.1136/bjophthalmol-2018-313682
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
NR 32
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2022
VL 129
IS 9
BP 974
EP 985
DI 10.1016/j.ophtha.2022.04.028
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3V2KG
UT WOS:000841489000031
PM 35537533
DA 2022-11-30
ER

PT J
AU Pham, TQ
   Rochtchina, E
   Mitchell, P
   Smith, W
   Wang, JJ
AF Pham, Thuan Quoc
   Rochtchina, Elena
   Mitchell, Paul
   Smith, Wayne
   Wang, Jie Jin
TI Sunlight-Related Factors and the 10-Year Incidence of Age-Related
   Maculopathy
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Sunlight; age-related maculopathy; age-related macular degeneration;
   incidence; Blue Mountains Eye Study
ID BLUE MOUNTAINS EYE; SENILE MACULAR DEGENERATION; SKIN SUN SENSITIVITY;
   RISK-FACTORS; IRIS PIGMENTATION; 5-YEAR INCIDENCE; GRADING SYSTEM;
   VISUAL-ACUITY; HAIR COLOR; PREVALENCE
AB Purpose: To examine the associations among iris, skin, or hair color, and skin sun sensitivity and the 10-year incidence of age-related maculopathy (ARM). Methods: The Blue Mountains Eye Study (BMES) recruited 3654 participants aged 49+ years at baseline (1992-1994, 82.4% participation rate). Re-examinations of 2335 participants (75.1% of survivors) were done after 5 years (1997-1999) and 1952 (76.5% of survivors) after 10 years (2002-2004). Retinal photographs were graded using the Wisconsin ARM Grading System and incident ARM confirmed using the side-by-side grading method. Iris, skin, and hair color, and sun-related skin damage were assessed and skin sun-sensitivity questions were asked at baseline. Ten-year ARM incidence was calculated using Kaplan Meier methods and discrete logistic models were used to assess associations after adjusting for age, sex, and smoking. Results: After adjustment, no significant associations were found between iris or hair color and either late- or early-incident ARM. Compared to persons with fair skin, those with very fair skin had an increased risk of developing geographic atrophy (multivariate adjusted risk ratio, RR = 7.6; 95% confidence interval, CI = 3.0-19.6). In contrast, compared to persons with average skin sun sensitivity, persons who reported that their skin would usually burn and tan with difficulty had a reduced risk of neovascular ARM (RR = 0.2, 95% CI = 0.0-0.7). Sun-related skin damage was not associated with late or early ARM. Conclusions: In this older cohort, we did not find a consistent pattern of association between sunlight-related factors and ARM incidence, except that persons with very fair skin might have an increased risk of geographic atrophy, consistent with our 5-year incidence data. The protective association between skin sensitivity to sun damage and neovascular ARM could have be the result of confounding by sun-avoidance behavior among persons sensitive to sunburn.
C1 [Pham, Thuan Quoc; Rochtchina, Elena; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   [Pham, Thuan Quoc; Rochtchina, Elena; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Smith, Wayne] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Newcastle
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wml.usyd.edu.au
RI wang, jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014; Mitchell,
   Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869
   GIBSON JM, 1986, T OPHTHAL SOC UK, V105, P463
   HOLMAN CDJ, 1984, BRIT J DERMATOL, V110, P129, DOI 10.1111/j.1365-2133.1984.tb07458.x
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   HOWELL WL, 1982, INVEST OPHTH VIS SCI, V22, P139
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1991, PB14923AS, P85
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MITCHELL P, 2001, OPHTHALMOLOGY
   SANDBERG MA, 1994, INVEST OPHTH VIS SCI, V35, P2734
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P53
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, CLIN EXP OPHTHALMOL, V31, P317, DOI 10.1046/j.1442-9071.2003.00659.x
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 26
TC 13
Z9 14
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2009
VL 16
IS 2
BP 136
EP 141
DI 10.1080/09286580701299395
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 435DN
UT WOS:000265324000010
PM 19353402
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Fleckenstein, M
   Zouache, MA
   Pfau, M
   Pappas, C
   Hageman, JL
   Agron, E
   Malley, C
   Keenan, TDL
   Chew, EY
   Hageman, GS
AF Schmitz-Valckenberg, Steffen
   Fleckenstein, Monika
   Zouache, Moussa A.
   Pfau, Maximilian
   Pappas, Christian
   Hageman, Jill L.
   Agron, Elvira
   Malley, Claire
   Keenan, Tiarnan D. L.
   Chew, Emily Y.
   Hageman, Gregory S.
TI Progression of Age-Related Macular Degeneration Among Individuals
   Homozygous for Risk Alleles on Chromosome 1 (CFH-CFHR5) or Chromosome 10
   (ARMS2/HTRA1) or Both
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY
   SECONDARY; EYE DISEASE; AREDS; POLYMORPHISM; ASSOCIATION; GENOTYPE;
   GENETICS; FEATURES
AB IMPORTANCE Age-related macular degeneration (AMD) is a common cause of irreversible vision loss among individuals older than 50 years. Although considerable advances have been made in our understanding of AMD genetics, the differential effects of major associated loci on disease manifestation and progression may not be well characterized.
   OBJECTIVE To elucidate the specific associations of the 2 most common genetic risk loci for AMD, the CFH-CFHP5 locus on chromosome 1q32 (Chr1) and the ARMS2/HTRA1 locus on chromosome 10q26 (Chr10)-independent of one another and in combination-with time to conversion to late-stage disease and to visual acuity loss.
   DESIGN, SETTING. AND PARTICIPANTS This case series study included 502 individuals who were homozygous for risk variants at both Chr1 and Chr10 (termed Chr1&10-risk) or at either Chr1 (Chr1-risk) or Chr10 (Chr10-risk) and who had enrolled in Genetic and Molecular Studies of Eye Diseases at the Sharon Eccles Steele Center for Translational Medicine between September 2009 and March 2020. Multimodal imaging data were reviewed for AMD staging, including grading of incomplete and complete retinal pigment epithelium and outer retinal atrophy.
   MAIN OUTCOMES AND MEASURES Hazard ratios and survival times for conversion to any late-stage AMD, atrophic or neovascular, and associated vision loss of 2 or more lines.
   RESULTS In total, 317 participants in the Chr1-risk group (median [IQR] age at first visit, 75.6 [69.5-81.7] years; 193 women [60.9%]), 93 participants in the Chr10-risk group (median [IQR] age at first visit, 77.5 [72.2-84.2] years; 62 women [66.7%]), and 92 participants in the Chr1&10-risk group (median [IQR] age at first visit, 71.7 [68.0-76.3] years; 62 women [67.4%]) were included in the analyses. After adjusting for age and AMD grade at first visit, compared with 257 participants in the Chr1-risk group, 56 participants in the Chr1&10-risk group (factor of 3.3 [95% CI, 1.6-6.8]; P < .001) and 58 participants in the Chr10-risk group (factor of 2.6 [95% CI, 1.3-5.2]; P = .007) were more likely to convert to a late-stage phenotype during follow-up. This difference was mostly associated with conversion to macular neovascularization, which occurred earlier in participants with Chr1&10-risk and Chr10-risk. Eyes in the Chr1&10-risk group (median [IQR] survival, 5.7 [2.1-11.1] years) were 2.1 (95% CI, 1.1-3.9; P = .03) times as likely and eyes in the Chr10-risk group (median [IQR] survival, 6.3 [2.7-11.3] years) were 1.8 (95% CI, 1.0-3.1; P = .05) times as likely to experience a visual acuity loss of 2 or more lines compared with eyes of the Chr1-risk group (median [IQR] survival, 9.4 [4.1-* (asterisk indicates event rate did not reach 75%)] years).
   CONCLUSIONS AND RELEVANCE These findings suggest differential associations of the 2 major AMD-related risk loci with structural and functional disease progression and suggest distinct underlying biological mechanisms associated with these 2 loci. These genotype-phenotype associations may warrant consideration when designing and interpreting AMD research studies and clinical trials.
C1 [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika; Zouache, Moussa A.; Pappas, Christian; Hageman, Jill L.; Hageman, Gregory S.] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Sharon Eccles Steele Ctr Translat Med, 65 N Mario Capecchi Dr, Salt Lake City, UT 84312 USA.
   [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Utah Retinal Reading UREAD Ctr, Salt Lake City, UT USA.
   [Schmitz-Valckenberg, Steffen] Univ Bonn, GRADE Reading Ctr, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Pfau, Maximilian; Agron, Elvira; Malley, Claire; Keenan, Tiarnan D. L.; Chew, Emily Y.] Natl Inst Hlth, Div Epidemiol & Clin Applicat, Natl Eye Inst, Bethesda, MD USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; University of Bonn; University of
   Bonn; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Schmitz-Valckenberg, S; Hageman, GS (通讯作者)，Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Sharon Eccles Steele Ctr Translat Med, 65 N Mario Capecchi Dr, Salt Lake City, UT 84312 USA.
EM steffen.valckenberg@utah.edu; gregory.hageman@hsc.utah.edu
OI Pfau, Maximilian/0000-0001-9761-9640
FU Voyant Biotherapeutics; Research to Prevent Blindness, New York, New
   York; National Institutes of Health Core Grant [EY014800]; German
   Research Foundation [PF950/1-1]; National Eye Institute of the National
   Institutes of Health [R24EY017404]
FX This work was supported by charitable donations to the Sharon Eccles
   Steele Center for Translational Medicine to Dr G. Hageman; research
   funding from Voyant Biotherapeutics to Dr G. Hageman; an unrestricted
   grant from Research to Prevent Blindness, New York, New York, to the
   Department of Ophthalmology, University of Utah; a National Institutes
   of Health Core Grant (EY014800) to the Department of Ophthalmology &
   Visual Sciences, University of Utah; German Research Foundation grant
   PF950/1-1 to Dr Pfau; and the National Eye Institute of the National
   Institutes of Health under award R24EY017404 to Dr G. Hageman.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Biarnes M, 2020, OPHTHALMOL RETINA, V4, P1129, DOI 10.1016/j.oret.2020.04.014
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Grassmann F, 2019, JAMA OPHTHALMOL, V137, P867, DOI 10.1001/jamaophthalmol.2019.1318
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heesterbeek TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43144-3
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2021, OPHTHALMOL RETINA, V5, P855, DOI 10.1016/j.oret.2020.12.009
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Pappas CM, 2021, HUM GENOMICS, V15, DOI 10.1186/s40246-021-00359-8
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Ripatti S, 2000, BIOMETRICS, V56, P1016, DOI 10.1111/j.0006-341X.2000.01016.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakata LM, 2009, CLIN EXP OPHTHALMOL, V37, P90, DOI 10.1111/j.1442-9071.2009.02015.x
   Schmitz-Valckenberg S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100893
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Team RC, 2013, R LANG ENV STAT COMP
   Therneau T.M., 2000, MODELLING SURVIVAL D
   Therneau TM, 2003, J COMPUT GRAPH STAT, V12, P156, DOI 10.1198/1061860031365
   Williams BL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103617118
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zouache MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78059-x
NR 47
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2022
VL 140
IS 3
BP 252
EP 260
DI 10.1001/jamaophthalmol.2021.6072
EA FEB 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZV2WK
UT WOS:000750998800004
PM 35113155
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Wickremasinghe, SS
   Janakan, V
   Sandhu, SS
   Amirul-Islam, FM
   Abedi, F
   Guymer, RH
AF Wickremasinghe, Sanjeewa S.
   Janakan, Vyshnavi
   Sandhu, Sukhpal S.
   Amirul-Islam, Fakir M.
   Abedi, Farshad
   Guymer, Robyn H.
TI IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE
   TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration (AMD); antivascular endothelial growth
   factor (anti-VEGF); choroidal neovascularisation (CNV); intraretinal
   fluid (IRF); optical coherence tomography (OCT); ranibizumab; subretinal
   fluid (SRF)
ID ANTI-VEGF THERAPY; SUBGROUP ANALYSIS; RANIBIZUMAB; AFLIBERCEPT;
   BEVACIZUMAB
AB Purpose: Assess the correlation between optical coherence tomography findings and change in vision for patients receiving "treat and extend" protocol ranibizumab for neovascular age-related macular degeneration.
   Methods: Optical coherence tomography analysis and best-corrected visual acuity (BCVA) change: mild = 5 to 9 letters, moderate = 10 to 14 letters, and severe >= 15 letters.
   Results: A total of 103 eyes (99 patients, 63% female, 65-91 years) followed for 20.8 +/- 4.9 months. By 12 months, there were 1.38 +/- 0.59 instances of intraretinal fluid (IRF)/subretinal fluid recurrence on optical coherence tomography and 1.25 +/- 1.00 instances of BCVA loss (>= 5 letters) per patient. When BCVA was lost, IRF/subretinal fluid was present in 37.3% of cases. Occurrences of severe BCVA loss were less likely to recover vision than when BCVA loss was mild (5.9% vs. 75.6%, P = 0.001). New occurrence of IRF (33.9%) or subretinal fluid (29.6%) was more likely to lead to BCVA loss, compared with dry (16.6%) or persistent IRF (11.9%) or persistent subretinal fluid (14%, P < 0.001). With persistent fluid, any new loss of vision had a lower chance of recovery than when fluid was new in onset (64.3% vs. 85.3%, P = 0.04).
   Conclusion: During ranibizumab treatment, vision can decrease without signs of fluid. When fluid is present, IRF is associated with poorer vision. New occurrence of any fluid on optical coherence tomography is likely to lead to vision loss, but small amounts of persistent fluid can be tolerated without compromising vision.
C1 [Wickremasinghe, Sanjeewa S.; Janakan, Vyshnavi; Sandhu, Sukhpal S.; Amirul-Islam, Fakir M.; Abedi, Farshad; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Amirul-Islam, Fakir M.] Swinburne Univ Technol, FHAD, Dept Stat Data Sci & Epidemiol, Hawthorn, Vic 3122, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Swinburne University of Technology
RP Wickremasinghe, SS (通讯作者)，Royal Victorian Eye & Ear Hosp, FRANZCO Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM sanj.wickremasinghe@eyeandear.org.au
RI Islam, Fakir M Amirul/P-6665-2015
OI Islam, Fakir M Amirul/0000-0003-3897-3302; Guymer,
   Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) [590205]
FX Supported by National Health and Medical Research Council (NHMRC)
   project grant 590205, (RHG). The Centre for Eye Research Australia
   (CERA) receives Operational Infrastructure Support from the Victorian
   Government.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1552, DOI 10.1136/bjo.2010.194670
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liakopoulos S, 2013, OSLI RETINA, V44, pS11, DOI 10.3928/23258160-20131101-03
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 23
TC 41
Z9 42
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2016
VL 36
IS 7
BP 1331
EP 1339
DI 10.1097/IAE.0000000000000902
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP6GK
UT WOS:000378595100032
PM 26655608
DA 2022-11-30
ER

PT J
AU Gabrielle, PH
   Maitrias, S
   Nguyen, V
   Arnold, JJ
   Squirrell, D
   Arnould, L
   Sanchez-Monroy, J
   Viola, F
   O'Toole, L
   Barthelmes, D
   Creuzot-Garcher, C
   Gillies, M
AF Gabrielle, Pierre-Henry
   Maitrias, Samuel
   Nguyen, Vuong
   Arnold, Jennifer J.
   Squirrell, David
   Arnould, Louis
   Sanchez-Monroy, Jorge
   Viola, Francesco
   O'Toole, Louise
   Barthelmes, Daniel
   Creuzot-Garcher, Catherine
   Gillies, Mark
CA Fight Retinal Blindness Study Grp
TI Incidence, risk factors and outcomes of submacular haemorrhage with loss
   of vision in neovascular age-related macular degeneration in daily
   clinical practice: data from the FRB! registry
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE AMD; database study; incidence; macular haemorrhage; neovascular
   age-related macular degeneration; real-world study; risk factors;
   submacular haemorrhage; VEGF inhibitors
ID TISSUE-PLASMINOGEN ACTIVATOR; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL
   RANIBIZUMAB; PNEUMATIC DISPLACEMENT; SUBRETINAL HEMORRHAGE; INJECTION;
   VITRECTOMY; MANAGEMENT; BEVACIZUMAB
AB Purpose The main purpose of the study was to report the estimated incidence, cumulative rate, risk factors and outcomes of submacular haemorrhage (SMH) with loss of vision in neovascular age-related macular degeneration (nAMD) receiving intravitreal injections (IVT) of vascular endothelial growth factor (VEGF) inhibitor in routine clinical practice. Methods Retrospective analysis of treatment-naive eyes receiving IVTs of VEGF inhibitors (ranibizumab, aflibercept or bevacizumab) for nAMD from 1 January 2010 to 31 December 2020 that were tracked the Fight Retinal Blindness! registry. Estimated incidence, cumulative rate and hazard ratios (HR) of SMH with loss of vision during treatment were measured using the Poisson regression, Kaplan-Meier survival curves and Cox proportional hazard models. Results We identified 7642 eyes (6425 patients) with a total of 135 095 IVT over a 10-year period. One hundred five eyes developed SMH with loss of vision with a rate of 1 per 1283 injections (0.08% 95% confidence interval [95% CI] [0.06; 0.09]). The estimated incidence [95% CI] was 4.6 [3.8; 5.7] SMH with loss of vision per year per 1000 treated patients during the study. The cumulative [95% CI] rate of SMH per patient did not increase significantly with each successive injection (p = 0.947). SMH cases had a mean VA drop of around 6 lines at diagnosis, which then improved moderately to a 4-line loss at 1 year. Conclusions Submacular haemorrhage (SMH) with loss of vision is an uncommon complication that can occur at any time in eyes treated for nAMD in routine clinical practice, with only limited recovery of vision 1 year later.
C1 [Gabrielle, Pierre-Henry; Maitrias, Samuel; Creuzot-Garcher, Catherine] Dijon Univ Hosp, Dept Ophthalmol, Dijon, France.
   [Gabrielle, Pierre-Henry; Nguyen, Vuong; Arnould, Louis; Barthelmes, Daniel; Gillies, Mark] Univ Sydney, Sydney Med Sch, Save Sight Inst, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialist, Sydney, NSW, Australia.
   [Squirrell, David] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand.
   [Sanchez-Monroy, Jorge] Miguel Servet Univ Hosp, Dept Ophthalmol, Zaragoza, Spain.
   [Viola, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.
   [Viola, Francesco] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [O'Toole, Louise] Mater Private Hosp, Dept Ophthalmol, Dublin, Ireland.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 CHU Dijon Bourgogne; University of Sydney; University of Auckland;
   Miguel Servet University Hospital; IRCCS Ca Granda Ospedale Maggiore
   Policlinico; University of Milan; Mater Private Hospital; University of
   Zurich; University Zurich Hospital
RP Gabrielle, PH (通讯作者)，Dijon Univ, Ophthalmol Dept, 14 Rue Gaffarel, F-21000 Dijon, France.
EM phgabrielle@gmail.com
RI GABRIELLE, Pierre-Henry/Y-4971-2018
OI GABRIELLE, Pierre-Henry/0000-0002-9688-4845; SANCHEZ-MONROY,
   JORGE/0000-0001-5743-1520
FU La Fondation de France research fellowship programme; Royal Australian
   NZ College of Ophthalmologists Eye Foundation; National Health and
   Medical Research Council, Australia (NHMRC); Macular Disease Foundation,
   Australia; Novartis; Bayer
FX Gabrielle P-H is supported by an educational grant from La Fondation de
   France research fellowship programme. The FRB registry project was
   supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), a grant from the National
   Health and Medical Research Council, Australia (NHMRC 2010-2012) and a
   grant from the Macular Disease Foundation, Australia. Funding was also
   provided by Novartis and Bayer. These supporting organizations had no
   role in the design or conduct of the research.
CR Al-Hity A, 2019, EYE, V33, P486, DOI 10.1038/s41433-018-0239-4
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bhandari S, 2020, OPHTHALMOLOGY, V127, P369, DOI 10.1016/j.ophtha.2019.10.006
   Corvi F, 2022, AM J OPHTHALMOL, V234, P108, DOI 10.1016/j.ajo.2021.08.006
   Dong LM, 2003, OPHTHAL EPIDEMIOL, V10, P149, DOI 10.1076/opep.10.3.149.15080
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Kapran Z, 2013, OSLI RETINA, V44, P471, DOI 10.3928/23258160-20130909-09
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Kunavisarut P, 2018, ASIA-PAC J OPHTHALMO, V7, P109, DOI 10.22608/APO.2017389
   Lestable L, 2020, J FR OPHTALMOL, V43, P761, DOI 10.1016/j.jfo.2019.11.016
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Matsunaga DR., 2020, OPH RETINA, V5, P342
   Moon SW, 2013, J OCUL PHARMACOL TH, V29, P556, DOI 10.1089/jop.2012.0148
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Tognetto D, 2011, CLIN OPHTHALMOL, V5, P459, DOI 10.2147/OPTH.S15864
NR 25
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2022
VL 100
IS 8
BP E1569
EP E1578
DI 10.1111/aos.15137
EA MAR 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6D4SX
UT WOS:000772224100001
PM 35322568
OA Green Published
DA 2022-11-30
ER

PT J
AU Li, YM
   Liang, LN
   Snellingen, T
   Xu, K
   Gao, Y
   Zhang, FM
   Guo, CW
   Zuo, T
   Liang, FM
   Yao, XP
   Yang, XY
AF Li, Yamin
   Liang, Lina
   Snellingen, Torkel
   Xu, Kai
   Gao, Yun
   Zhang, Fengmei
   Guo, Chengwei
   Zuo, Tao
   Liang, Fengming
   Yao, Xiaoping
   Yang, Xueyan
TI Mingjing granule, a traditional Chinese medicine in the treatment of
   neovascular age-related macular degeneration: study protocol for a
   randomized controlled trial
SO TRIALS
LA English
DT Article
DE nAMD; Mingjing granule; Randomized controlled trial
ID MARROW-DERIVED CELLS; CHOROIDAL NEOVASCULARIZATION; BURDEN; RANIBIZUMAB;
   PREVALENCE; EXTRACT; INJURY; MG
AB BackgroundNeovascular age-related macular degeneration (nAMD) is the most common cause of irreversible vision loss and blindness among the older people aged 50 and over. Although anti-vascular endothelial growth factor (anti-VEGF) therapies have resulted in improving patient outcomes, there are limitations associated with these treatments. In China, traditional Chinese medicine (TCM) has been used to treat eye diseases for more than 2000years. Previous studies have shown that TCM may be beneficial for nAMD patients. However, explicit evidence has not been obtained. The purpose of the present trial is to examine the efficacy and safety of the Mingjing granule, a compound Chinese herbal medicine, for nAMD patients.Methods/designThis is a double-blind, placebo-controlled, randomized trial of Mingjing granule as an add-on to intravitreous ranibizumab for nAMD. One hundred eighty nAMD patients from six hospitals in China will be enrolled according to the inclusion and exclusion criteria and randomly allocated into two groups, 90 in each. All participants will receive a 24-week treatment and then be followed up for another 24weeks. The primary outcome is the mean change of best-corrected visual acuity at week 24 and 48 as compared to the baseline. The secondary outcomes include mean change in central retinal thickness, area of retinal hemorrhage and exudation, and TCM syndrome score, mean number of intravitreal ranibizumab injection, and total cost of the treatment. Indexes of safety include blood regular test, urine regular test, liver function test, renal function test, and electrocardiogram from baseline to weeks 24 and 48. Qualitative control and some standard operating processes will be formed throughout the trial. Any ocular or systemic adverse events will be treated suitably, and related data will be recorded accurately and completely in the case report form.DiscussionBased on previous empirical and animal laboratory studies, this study will address the question of whether Mingjing granule could contribute to improving efficacy, safety, and efficiency with need for fewer intravitreal injections of anti-VEGF, improving compliance and visual outcomes in the management of persons with nAMD.Trial registrationChinese Clinical Trial Registry (http://www.chictr.org.cn), ChiCTR2000035990. Registered on 21 August 2020.
C1 [Li, Yamin; Liang, Lina; Xu, Kai; Gao, Yun] China Acad Chinese Med Sci, Eye Hosp, 33 Lugu Rd, Beijing 100040, Peoples R China.
   [Snellingen, Torkel] Aurora Eye Res Fdn, St Olavsgate 4, N-3126 Tonsberg, Norway.
   [Zhang, Fengmei] Henan Univ Chinese Med, Affiliated Hosp 2, Henan Prov Hosp Tradit Chinese Med, Zhengzhou 450002, Peoples R China.
   [Guo, Chengwei] Shandong Univ Tradit Chinese Med, Shandong Prov Hosp Tradit Chinese Med, Affiliated Hosp, Jinan 250011, Peoples R China.
   [Zuo, Tao] Liaoning Univ Tradit Chinese Med, Affiliated Hosp 2, Shenyang 110034, Peoples R China.
   [Liang, Fengming] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin 300110, Peoples R China.
   [Yao, Xiaoping] Shenzhen Tradit Chinese Med Hosp, Shenzhen 518033, Peoples R China.
   [Yang, Xueyan] Foshan Hosp Tradit Chinese Med, Foshan 528500, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Eye Hospital, CACMS; Henan
   University of Traditional Chinese Medicine; Shandong University of
   Traditional Chinese Medicine; Liaoning University of Traditional Chinese
   Medicine; Tianjin University of Traditional Chinese Medicine
RP Liang, LN (通讯作者)，China Acad Chinese Med Sci, Eye Hosp, 33 Lugu Rd, Beijing 100040, Peoples R China.
EM lianglina163@163.com
FU China Academy of Chinese Medical Sciences; Central Public-interest
   Scientific Institution Basal Research Fund [ZZ13-024-8]; State
   Administration of Traditional Chinese Medicine of the People's Republic
   of China: Project of Building Evidence Based Practice Capacity for TCM
   [2019XZZX-YK002, 2019XZZX-YK004, 2019XZZX-YK005, 2019XZZX-YK008,
   2019XZZX-YK009, 2019XZZX-YK012]; National Natural Science Foundation of
   China [81973912]
FX This study is supported by China Academy of Chinese Medical Sciences and
   is funded by the Central Public-interest Scientific Institution Basal
   Research Fund (No.ZZ13-024-8), the State Administration of Traditional
   Chinese Medicine of the People's Republic of China: Project of Building
   Evidence Based Practice Capacity for TCM (2019XZZX-YK002,
   2019XZZX-YK004, 2019XZZX-YK005, 2019XZZX-YK008, 2019XZZX-YK009,
   2019XZZX-YK012), and the National Natural Science Foundation of China
   (No. 81973912). These funding bodies do not play any role in the study
   design, data collection, statistical analysis, interpretation of data,
   or preparation of the manuscript.
CR Budzinskaya M V, 2017, Vestn Oftalmol, V133, P103, DOI 10.17116/oftalma20171334103-108
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Elshout M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0514-3
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Feng, 2005, CHINA J CHINESE OPHT, V15, P6, DOI [10.13444/j.cnki.zgzyykzz.001935, DOI 10.13444/J.CNKI.ZGZYYKZZ.001935]
   Feng, 2009, RECENT ADV OPHTHALMO, V29, P881, DOI [10.13389/j.cnki.rao.2009.12.001, DOI 10.13389/J.CNKI.RAO.2009.12.001]
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Han JY, 2008, PHARMACOL THERAPEUT, V117, P280, DOI 10.1016/j.pharmthera.2007.09.008
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hou HY, 2006, CURR EYE RES, V31, P1051, DOI 10.1080/02713680601100459
   Hu XY, 2018, MOL MED REP, V17, P3599, DOI 10.3892/mmr.2017.8310
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   [江伟 Jiang Wei], 2013, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V28, P2572
   Jin M, 2018, CURR MOL MED, V18, P622, DOI 10.2174/1566524019666190107155311
   Julious SA, 2004, STAT MED, V23, P1921, DOI 10.1002/sim.1783
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li Xue-Jing, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P896
   [梁丽娜 Liang Lina], 2013, [中华眼底病杂志, Chinese Journal of Ocular Fundus Diseases], V29, P52
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Saxena N, 2016, OPHTHAL EPIDEMIOL, V23, P232, DOI 10.1080/09286586.2016.1193617
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Shahzad M, 2016, CURR DRUG TARGETS, V17, P1331, DOI 10.2174/1389450116666150907104742
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Sun J, 2016, SCI REP-UK, V6, DOI 10.1038/srep34328
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V320, P372, DOI 10.1016/j.bbrc.2004.05.177
   Tang, 2008, CHINA J CHINESE OPHT, V18, P92, DOI [10.13444/j.cnki.zgzyykzz.002311, DOI 10.13444/J.CNKI.ZGZYYKZZ.002311]
   Tang, 2008, CHINA J CHINESE OPHT, V18, P322, DOI [10.13444/j.cnki.zgzyykzz.002279, DOI 10.13444/J.CNKI.ZGZYYKZZ.002279]
   Wang, 2014, RECENT ADV OPHTHALMO, V34, P155, DOI [10.13389/j.cnki.rao.2014.02.014, DOI 10.13389/J.CNKI.RAO.2014.02.014]
   Wang, 2009, CHINA J CHINESE OPHT, V19, P340, DOI [10.13444/j.cnki.zgzyykzz.002560, DOI 10.13444/J.CNKI.ZGZYYKZZ.002560]
   [王慧娟 Wang Huijuan], 2010, [中医杂志, Journal of Traditional Chinese Medicine], V51, P316
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   [詹文捷 Zhan Wenjie], 2012, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V23, P526
   Zhang L., 2009, LIAONING J TRADIT CH, V36, P2038, DOI [10.13192/j.ljtcm.2009.12.27.yuj.061, DOI 10.13192/J.LJTCM.2009.12.27.YUJ.061]
   Zhang YB, 2012, VALUE HEALTH, V15, pA251, DOI 10.1016/j.jval.2012.03.1353
   Zhang ZX, 2011, CURR EYE RES, V36, P838, DOI 10.3109/02713683.2011.593107
   Zhou SK., 2014, CHINA J CHINESE OPHT, V24, P5, DOI [10.13444/j.cnki.zgzyykzz.003223, DOI 10.13444/J.CNKI.ZGZYYKZZ.003223]
NR 46
TC 3
Z9 4
U1 8
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JAN 19
PY 2021
VL 22
IS 1
AR 69
DI 10.1186/s13063-021-05025-x
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA PY4RL
UT WOS:000612033100006
PM 33468208
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Inoue, M
   Arakawa, A
   Yamane, S
   Kadonosono, K
AF Inoue, Maiko
   Arakawa, Akira
   Yamane, Shin
   Kadonosono, Kazuaki
TI SHORT-TERM EFFICACY OF INTRAVITREAL AFLIBERCEPT IN TREATMENT-NAIVE
   PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; CLINICOPATHOLOGICAL CORRELATION;
   FOLLOW-UP; RANIBIZUMAB; BEVACIZUMAB; VERTEPORFIN; PENETRATION
AB Purpose: To evaluate the functional and morphologic outcomes of patients with polypoidal choroidal vasculopathy who underwent intravitreal aflibercept treatment.
   Methods: We prospectively studied all the treatment-naive patients with polypoidal choroidal vasculopathy who were scheduled to undergo intravitreal aflibercept between February 2013 and July 2013. The best-corrected visual acuity was compared before treatment and at 6 months after the initial treatment. Changes in the central foveal thickness, choroidal thickness, presence/absence of subretinal fluid, fibrin, pigment epithelial detachment, and subretinal hemorrhage were also evaluated. The regression of the polyps was assessed using indocyanine green angiography.
   Results: A total of 16 patients were included in this study. A significantly better best-corrected visual acuity at 6 months was seen, compared with that at baseline (P = 0.041). The mean central foveal thickness significantly decreased from 417 +/- 127 mu m to 187 +/- 50 mu m (P < 0.001). The mean choroidal thickness also significantly decreased from 250 +/- 63 mu m to 217 +/- 64 mu m (P = 0.011). Overall, a complete resolution was obtained in 93.3% (14/15) of the cases with subretinal fluid, 75.0% (3/4) of the cases with fibrin, and 88.9% (8/9) of the cases with subretinal hemorrhage. Fifty-six percent (5/9) of the cases with pigment epithelial detachment obtained a complete improvement, whereas 33.3%(3/9) exhibited a partial decrease. The rate of polyp regression was 75.0% (12/16).
   Conclusion: Intravitreal aflibercept was well tolerated and had improved the vision of treatment-naive patients with polypoidal choroidal vasculopathy when it was evaluated at short-term follow-up examinations. Intravitreal aflibercept might be associated with a high possibility of achieving involution of polyps and reducing exudative findings.
C1 [Inoue, Maiko; Arakawa, Akira; Yamane, Shin; Kadonosono, Kazuaki] Yokohama City Univ, Dept Ophthalmol, Med Ctr, Yokohama, Kanagawa 232, Japan.
C3 Yokohama City University
RP Inoue, M (通讯作者)，Dept Ophthalmol, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2012, AM J OPHTHALMOL
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Koh A, 2012, RETINA
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee WK, 2012, AM J OPHTHALMOL
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 34
TC 41
Z9 41
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2014
VL 34
IS 11
BP 2178
EP 2184
DI 10.1097/IAE.0000000000000229
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0DK
UT WOS:000344607100010
PM 25046397
DA 2022-11-30
ER

PT J
AU Fenwick, EK
   Lee, EPX
   Man, REK
   Ho, KC
   Najjar, RP
   Milea, D
   Teo, KYC
   Tan, ACS
   Lee, SY
   San Yeo, IY
   Tan, GSW
   Mathur, R
   Wong, TY
   Cheung, CMG
   Lamoureux, EL
AF Fenwick, Eva K.
   Lee, Ester P. X.
   Man, Ryan E. K.
   Ho, Kam Chun
   Najjar, Raymond P.
   Milea, Dan
   Teo, Kelvin Y. C.
   Tan, Anna C. S.
   Lee, Shu Yen
   San Yeo, Ian Yew
   Tan, Gavin S. W.
   Mathur, Ranjana
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
   Lamoureux, Ecosse L.
TI Identifying the content for an item bank and computerized adaptive
   testing system to measure the impact of age-related macular degeneration
   on health-related quality of life
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Quality of life; Item bank;
   Computerized adaptive testing; Qualitative
ID ANTI-VEGF TREATMENT; LIVED EXPERIENCE; CANDIDATES; BURDEN
AB Purpose We are developing an age-related macular degeneration (AMD) health-related quality of life (HRQoL) item bank, applicable to Western and Asian populations. We report primarily on content generation and refinement, but also compare the HRQoL issues reported in our study with Western studies and current AMD-HRQoL questionnaires. Methods In this cross-sectional, qualitative study of AMD patients attending the Singapore National Eye Centre (May-December 2019), items/domains were generated from: (1) AMD-specific questionnaires; (2) published articles; (3) focus groups/semi-structured interviews with AMD patients (n = 27); and (4) written feedback from retinal experts. Following thematic analysis, items were systematically refined to a minimally representative set and pre-tested using cognitive interviews with 16 AMD patients. Results Of the 27 patients (mean +/- standard deviation age 67.9 +/- 7.0; 59.2% male), 18 (66.7%), two (7.4%), and seven (25.9%) had no, early-intermediate, and late/advanced AMD (better eye), respectively. Whilst some HRQoL issues, e.g. activity limitation, mobility, lighting, and concerns were similarly reported by Western patients and covered by other questionnaires, others like anxiety about intravitreal injections, work tasks, and financial dependency were novel. Overall, 462 items within seven independent HRQoL domains were identified: Activity limitation, Lighting, Mobility, Emotional, Concerns, AMD management, and Work. Following item refinement, items were reduced to 219, with 31 items undergoing amendment. Conclusion Our 7-domain, 219-item AMD-specific HRQoL instrument will undergo psychometric testing and calibration for computerized adaptive testing. The future instrument will enable users to precisely, rapidly, and comprehensively quantify the HRQoL impact of AMD and associated treatments, with item coverage relevant across several populations.
C1 [Fenwick, Eva K.; Lee, Ester P. X.; Man, Ryan E. K.; Ho, Kam Chun; Najjar, Raymond P.; Milea, Dan; Teo, Kelvin Y. C.; Tan, Anna C. S.; Lee, Shu Yen; San Yeo, Ian Yew; Tan, Gavin S. W.; Mathur, Ranjana; Wong, Tien Yin; Cheung, Chui Ming Gemmy; Lamoureux, Ecosse L.] Singapore Eye Res Inst, Singapore Natl Eye Ctr, 20 Coll Rd,Level 6, Singapore 169856, Singapore.
   [Fenwick, Eva K.; Man, Ryan E. K.; Najjar, Raymond P.; Teo, Kelvin Y. C.; Tan, Anna C. S.; Lee, Shu Yen; San Yeo, Ian Yew; Tan, Gavin S. W.; Mathur, Ranjana; Wong, Tien Yin; Lamoureux, Ecosse L.] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Ho, Kam Chun] UNSW Sydney, Sydney, NSW, Australia.
   [Lamoureux, Ecosse L.] Univ Melbourne, Parkville, Vic, Australia.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; University of New South Wales Sydney;
   University of Melbourne
RP Lamoureux, EL (通讯作者)，Singapore Eye Res Inst, Singapore Natl Eye Ctr, 20 Coll Rd,Level 6, Singapore 169856, Singapore.; Lamoureux, EL (通讯作者)，Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.; Lamoureux, EL (通讯作者)，Univ Melbourne, Parkville, Vic, Australia.
EM ecosse.lamoureux@duke-nus.edu.sg
RI Ho, Kam Chun/AAX-9509-2021; Najjar, Raymond P./J-4979-2019; Wong, Tien
   Yin/AAC-9724-2020
OI Ho, Kam Chun/0000-0001-9029-4329; Najjar, Raymond
   P./0000-0002-3770-2300; Wong, Tien Yin/0000-0002-8448-1264; Man,
   Ryan/0000-0001-5028-605X
FU National Medical Research Council Open Fund Large Collaborative Grant
   [NMRC/OFLCG/004a/2018]; NMRC Senior-Clinician Scientist Awards
   [NMRC/CSASI/0009/2016]; NMRC Transition Award [MOH-TA19may-0002]
FX This study was funded by a National Medical Research Council Open Fund
   Large Collaborative Grant (NMRC/OFLCG/004a/2018). Professor Lamoureux is
   supported by the NMRC Senior-Clinician Scientist Awards
   (#NMRC/CSASI/0009/2016) and Dr. Man is supported by the NMRC Transition
   Award (#MOH-TA19may-0002). The funding organizations had no role in the
   design or conduct of this research or preparation of this manuscript.
CR [Anonymous], 2004, QUALITATIVE RES THEO, DOI DOI 10.1093/OXFORDHB/9780199811755.013.015
   Awang H, 2018, J INT MED RES, V46, P175, DOI 10.1177/0300060517710857
   Baumhauer JF, 2016, CLIN ORTHOP RELAT R, V474, P1375, DOI 10.1007/s11999-016-4813-4
   Bedford O, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00100
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Bian W, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018756
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Burton AE, 2015, J HEALTH PSYCHOL, V20, P1285, DOI 10.1177/1359105313511134
   Cella D, 2007, QUAL LIFE RES, V16, P133, DOI 10.1007/s11136-007-9204-6
   DeWalt DA, 2007, MED CARE, V45, pS12, DOI 10.1097/01.mlr.0000254567.79743.e2
   Fenwick EK, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.3
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Fenwick EK, 2013, QUAL LIFE RES, V22, P1851, DOI 10.1007/s11136-012-0307-3
   Fenwick EK, 2012, QUAL LIFE RES, V21, P1771, DOI 10.1007/s11136-012-0110-1
   Finger RP, 2012, OPHTHALMOLOGY, V119, P2351, DOI 10.1016/j.ophtha.2012.05.031
   Gibbons RD, 2008, PSYCHIAT SERV, V59, P361, DOI 10.1176/ps.2008.59.4.361
   Haley SM, 2009, QUAL LIFE RES, V18, P461, DOI 10.1007/s11136-009-9463-5
   Henriksen K., 2013, INT J OPHTHALMIC PRA, V1, P68, DOI [10.12968/ijop.2010.1.2.68, DOI 10.12968/ijop.2010.1.2.68, DOI 10.12968/IJOP.2010.1.2.68]
   JOBE JB, 1989, AM J PUBLIC HEALTH, V79, P1053, DOI 10.2105/AJPH.79.8.1053
   Khadka J, 2015, J GLAUCOMA, V24, P12, DOI 10.1097/IJG.0b013e318287ac11
   Khadka J, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-80
   Khadka J, 2012, INVEST OPHTH VIS SCI, V53, P1276, DOI 10.1167/iovs.12-9541
   Kimel M, 2016, INVEST OPHTH VIS SCI, V57, P6298, DOI 10.1167/iovs.16-20361
   Lane J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209218
   Lee Hsien Loong, 2019, NATL DAY RALLY SPEEC
   Lee MC, 2018, GERONTOL GERIATR MED, V4, DOI 10.1177/2333721418778195
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Mitchell J., 2004, QUAL LIFE RES, V13, p1163 1175
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Pondorfer SG, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.1.5
   Rice P., 1999, QUALITATIVE RES METH
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Sivaprasad S, 2019, OPHTHALMOL THER, V8, P115, DOI 10.1007/s40123-019-0160-3
   Taylor DJ, 2018, OPHTHAL PHYSL OPT, V38, P98, DOI 10.1111/opo.12419
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Vaughn S., 1996, FOCUS GROUP INTERVIE
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
NR 44
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD APR
PY 2022
VL 31
IS 4
BP 1237
EP 1246
DI 10.1007/s11136-021-02989-w
EA SEP 2021
PG 10
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 0A4WL
UT WOS:000698994900001
PM 34562188
DA 2022-11-30
ER

PT J
AU Ferrara, D
   Waheed, NK
   Duker, JS
AF Ferrara, Daniela
   Waheed, Nadia K.
   Duker, Jay S.
TI Investigating the choriocapillaris and choroidal vasculature with new
   optical coherence tomography technologies
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Optical coherence tomography; En face; Optical coherence tomography
   angiography; Choriocapillaris; Choroid
ID CENTRAL SEROUS CHORIORETINOPATHY; SWEPT-SOURCE OCT; INDOCYANINE GREEN
   VIDEOANGIOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE
   PATTERNS; GEOGRAPHIC ATROPHY SECONDARY; GROWTH-FACTOR THERAPY;
   COMPLEMENT FACTOR-H; DOME-SHAPED MACULA; HIGH-FAT DIET
AB The body of knowledge of in vivo investigation of the choroid has been markedly enhanced by recent technological advances in optical coherence tomography (OCT). New insights elucidating the morphological features of the choriocapillaris and choroidal vasculature, in both physiological and pathological conditions, indicate that the choroid plays a pivotal role in many posterior segment diseases. In this article, a review of the histological characteristics of the choroid, which must be considered for the proper interpretation of in vivo imaging, is followed by a comprehensive discussion of fundamental principles of the current state-of-the-art in OCT, including cross-sectional OCT, en face OCT, and OCT angiography using both spectral domain OCT and swept source OCT technologies. A detailed review of the tomographic features of the choroid in the normal eye is followed by relevant findings in prevalent chorioretinal diseases, focusing on major causes of vision loss such as typical early and advanced age related macular degeneration, polypoidal choroidal vasculopathy, central serous chorioretinopathy, pachychoroid spectrum disorders, diabetic choroidopathy, and myopia. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ferrara, Daniela; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, New England Med Ctr, Sch Med, 260 Tremont St,10th Floor, Boston, MA 02111 USA.
C3 Tufts Medical Center; Tufts University
RP Ferrara, D (通讯作者)，800 Washington St,Box 450, Boston, MA 02111 USA.
EM daniela@ferrara.md
FU NIH [R01-EY011289-27, R01-EY013178-12, R01-EY018184-05, R44EY022864-01,
   R01-CA075289-16, R01-NS057476-05, R44-EY022864-01]; AFOSR
   [FA9550-10-1-0551, FA9550-10-1-0063]; Massachusetts Lions Club; German
   Science Foundation DFG [DFG-GSC80-SAOT]; NATIONAL CANCER INSTITUTE
   [R01CA075289] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY013178, R44EY022864, R01EY018184] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057476]
   Funding Source: NIH RePORTER
FX We acknowledge support from NIH (R01-EY011289-27, R01-EY013178-12,
   R01-EY018184-05, R44EY022864-01, R01-CA075289-16, R01-NS057476-05,
   R44-EY022864-01); AFOSR (FA9550-10-1-0551 and FA9550-10-1-0063);
   Massachusetts Lions Club; German Science Foundation DFG
   (DFG-GSC80-SAOT). The funding organizations had no role in the design or
   conduct of this research.
CR A Sohrab Mahsa, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P69
   Adatia FA, 2015, SURV OPHTHALMOL, V60, P204, DOI 10.1016/j.survophthal.2014.10.002
   Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   Adhi M, 2014, AM J OPHTHALMOL, V157, P1272, DOI 10.1016/j.ajo.2014.02.034
   Adhi M, 2013, CAN J OPHTHALMOL, V48, P535, DOI 10.1016/j.jcjo.2013.05.010
   Adhi M, 2013, OSLI RETINA, V44, pS40, DOI 10.3928/23258160-20131101-08
   Adhi M, 2013, JAMA OPHTHALMOL, V131, P1267, DOI 10.1001/jamaophthalmol.2013.4321
   Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Agawa T, 2011, GRAEF ARCH CLIN EXP, V249, P1485, DOI 10.1007/s00417-011-1708-7
   Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Benavente-Perez A, 2010, OPTOMETRY VISION SCI, V87, P867, DOI 10.1097/OPX.0b013e3181f3eced
   BERGMANSON JPG, 1977, EXP EYE RES, V24, P225, DOI 10.1016/0014-4835(77)90160-9
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bonini Filho M.A., 2015, JAMA OPHTHALMOL
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Brandl C, 2014, INT OPHTHALMOL, V34, P7, DOI 10.1007/s10792-013-9774-y
   Braun RD, 1997, AM J PHYSIOL-HEART C, V272, pH1444, DOI 10.1152/ajpheart.1997.272.3.H1444
   BRON AJ, 1997, WOLFFS ANATOMY EYE O, P736
   Brown JS, 2009, INVEST OPHTH VIS SCI, V50, P5, DOI 10.1167/iovs.08-1779
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Caillaux V, 2013, AM J OPHTHALMOL, V156, P958, DOI 10.1016/j.ajo.2013.06.032
   Carrai P, 2015, INT OPHTHALMOL, V35, P167, DOI 10.1007/s10792-014-0034-6
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Chassine T, 2015, EUR J OPHTHALMOL, V25, P280, DOI 10.5301/ejo.5000571
   Chen Q, 2015, OPT EXPRESS, V23, P8974, DOI 10.1364/OE.23.008974
   Chinn SR, 1997, OPT LETT, V22, P340, DOI 10.1364/OL.22.000340
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Choma M., 2003, OPT EXPRESS, V49, P4679
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cicinelli MV, 2015, INT OPHTHALMOL, V35, P897, DOI 10.1007/s10792-015-0118-y
   Copete S, 2014, BRIT J OPHTHALMOL, V98, P334, DOI 10.1136/bjophthalmol-2013-303904
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Coscas F, 2011, EUR J OPHTHALMOL, V21, P331, DOI 10.5301/EJO.2010.2803
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Danesh H, 2014, COMPUT MATH METHOD M, V2014, DOI 10.1155/2014/479268
   Dansingani K, 2015, RETINA
   Dansingani KK, 2015, AM J OPHTHALMOL
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Duan L, 2013, OPT EXPRESS, V21, P15787, DOI 10.1364/OE.21.015787
   El Matri Leila, 2012, Ophthalmic Surg Lasers Imaging, V43, pS38, DOI 10.3928/15428877-20121001-02
   Ellabban AA, 2012, AM J OPHTHALMOL, V153, P1133, DOI 10.1016/j.ajo.2011.12.013
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Esmaeelpour M, 2011, INVEST OPHTH VIS SCI, V52, P5311, DOI 10.1167/iovs.10-6875
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FEENEY L, 1961, AM J OPHTHALMOL, V51, P1057
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Fingler J, 2007, OPT EXPRESS, V15, P12636, DOI 10.1364/OE.15.012636
   Fixler D, 2011, LASER SURG MED, V43, P339, DOI 10.1002/lsm.21047
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Flores-Moreno I, 2015, BRIT J OPHTHALMOL, V99, P1260, DOI 10.1136/bjophthalmol-2014-306422
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FRIEDMAN E, 1970, ARCH OPHTHALMOL-CHIC, V83, P95, DOI 10.1001/archopht.1970.00990030097018
   FRIEDMAN E, 1972, ARCH OPHTHALMOL-CHIC, V87, P70, DOI 10.1001/archopht.1972.01000020072015
   FRIEDMAN E, 1964, INVEST OPHTH VISUAL, V3, P539
   FRYCZKOWSKI AW, 1989, INT OPHTHALMOL, V13, P269, DOI 10.1007/BF02280087
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   Fujimoto J, 2008, BIOL MED PHYS BIOMED, P1, DOI 10.1007/978-3-540-77550-8_1
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Gaucher D, 2008, AM J OPHTHALMOL, V145, P909, DOI 10.1016/j.ajo.2008.01.012
   Gerendas BS, 2014, AM J OPHTHALMOL, V158, P1039, DOI 10.1016/j.ajo.2014.08.001
   Gohil R, 2015, EYE, V29, P593, DOI 10.1038/eye.2014.311
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamzah F, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-145
   Hayreh S S, 1962, Br J Ophthalmol, V46, P212, DOI 10.1136/bjo.46.4.212
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hayreh SS, 2001, PROG RETIN EYE RES, V20, P563, DOI 10.1016/S1350-9462(01)00004-0
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Ho J, 2011, OPHTHALMOLOGY, V118, P2001, DOI 10.1016/j.ophtha.2011.02.049
   Ho M, 2013, OPHTHALMOLOGY, V120, P1909, DOI 10.1016/j.ophtha.2013.02.005
   HOGAN M J, 1961, Trans Pac Coast Otoophthalmol Soc Annu Meet, V42, P61
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P1722, DOI 10.1167/iovs.12-10578
   Huang YP, 2015, BIOMED OPT EXPRESS, V6, P1195, DOI 10.1364/BOE.6.001195
   Ida H, 2004, INVEST OPHTH VIS SCI, V45, P2348, DOI 10.1167/iovs.03-1337
   Iida T, 2002, ARCH OPHTHALMOL-CHIC, V120, P37
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Ikuno Y, 2013, CLIN OPHTHALMOL, V7, P889, DOI 10.2147/OPTH.S44138
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kajic V, 2013, BIOMED OPT EXPRESS, V4, P134, DOI 10.1364/BOE.4.000134
   Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   KIEL JW, 1995, INVEST OPHTH VIS SCI, V36, P579
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim JT, 2013, INVEST OPHTH VIS SCI, V54, P3378, DOI 10.1167/iovs.12-11503
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Knight OJ, 2009, OPHTHALMOLOGY, V116, P1271, DOI 10.1016/j.ophtha.2008.12.032
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kuehlewein L, 2015, INVEST OPHTH VIS SCI, V56, P3984, DOI 10.1167/iovs.15-16510
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lam CSY, 2004, OPTOMETRY VISION SCI, V81, P317, DOI 10.1097/01.opx.0000134905.98403.18
   Lee CS, 2014, OPHTHALMOLOGY, V121, P1029, DOI 10.1016/j.ophtha.2013.11.043
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Lehmann M, 2013, BRIT J OPHTHALMOL, V97, P1181, DOI 10.1136/bjophthalmol-2012-302974
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Levinson RD, 2006, AM J OPHTHALMOL, V141, P185, DOI 10.1016/j.ajo.2005.08.025
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Lim FPM, 2014, EYE, V28, P1088, DOI 10.1038/eye.2014.78
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Lutjen-Drecoll E, 2006, EXP EYE RES, V82, P357, DOI 10.1016/j.exer.2005.09.015
   Lutty G, 1999, MOL VIS, V5
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Manjunath V, 2010, RETINA-J RET VIT DIS, V30, P1320, DOI 10.1097/IAE.0b013e3181e798b1
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Matsuo Y, 2013, INVEST OPHTH VIS SCI, V54, P7630, DOI 10.1167/iovs.13-13135
   McCourt Emily A, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS28, DOI 10.3928/15428877-20101031-14
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Michalewska Z, 2015, RETINA-J RET VIT DIS, V35, P244, DOI 10.1097/IAE.0000000000000281
   Motaghiannezam R, 2012, INVEST OPHTH VIS SCI, V53, P2337, DOI 10.1167/iovs.11-7823
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mutti DO, 2007, INVEST OPHTH VIS SCI, V48, P2510, DOI 10.1167/iovs.06-0562
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Nishide T, 2013, GRAEF ARCH CLIN EXP, V251, P2415, DOI 10.1007/s00417-013-2419-z
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   OLSEN S, 1989, MEDICINE, V68, P173, DOI 10.1097/00005792-198905000-00005
   OLSEN TS, 1986, ULTRASTRUCT PATHOL, V10, P1
   OLVER JM, 1989, EYE, V3, P588, DOI 10.1038/eye.1989.92
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Ooto S, 2015, CURR EYE RES, V40, P213, DOI 10.3109/02713683.2014.952828
   Ooto S, 2011, INVEST OPHTH VIS SCI, V52, P8769, DOI 10.1167/iovs.11-8388
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, INVEST OPHTH VIS SCI, V55, P5252, DOI 10.1167/iovs.14-14959
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Park KA, 2014, AM J OPHTHALMOL, V158, P716, DOI 10.1016/j.ajo.2014.07.008
   Patel SR, 2012, INVEST OPHTH VIS SCI, V53, P4433, DOI 10.1167/iovs.12-9872
   Pearce W, 2015, CURR OPIN OPHTHALMOL, V26, P233, DOI 10.1097/ICU.0000000000000143
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   PICCOLINO FC, 1995, EYE, V9, P324, DOI 10.1038/eye.1995.63
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pitcher JD, 2015, BRIT J OPHTHALMOL, V99, P848, DOI 10.1136/bjophthalmol-2014-306018
   Polak K, 2007, ARCH OPHTHALMOL-CHIC, V125, P494, DOI 10.1001/archopht.125.4.494
   Polska E, 2007, INVEST OPHTH VIS SCI, V48, P3768, DOI 10.1167/iovs.07-0307
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rayess N, 2015, AM J OPHTHALMOL, V159, P85, DOI 10.1016/j.ajo.2014.09.033
   Razavi S, 2014, AM J OPHTHALMOL, V157, P852, DOI 10.1016/j.ajo.2013.12.029
   Read SA, 2010, INVEST OPHTH VIS SCI, V51, P6262, DOI 10.1167/iovs.10-5457
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P2338
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P1752
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosa RH, 1996, ARCH OPHTHALMOL-CHIC, V114, P480, DOI 10.1001/archopht.1996.01100130476025
   Ruiz-Medrano J, 2014, INVEST OPHTH VIS SCI, V55, P3532, DOI 10.1167/iovs.14-13868
   RUSKELL GL, 1971, EXP EYE RES, V12, P166, DOI 10.1016/0014-4835(71)90085-6
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sanchez-Cano A, 2014, AM J OPHTHALMOL, V158, P574, DOI 10.1016/j.ajo.2014.05.035
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Saw SM, 2005, OPHTHAL PHYSL OPT, V25, P381, DOI 10.1111/j.1475-1313.2005.00298.x
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmidt-Erfurth U., 2015, PROG RETIN EYE RES, V22
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schroedl F, 2008, INVEST OPHTH VIS SCI, V49, P5222, DOI 10.1167/iovs.08-1721
   Shen L., 2015, OPHTHALMOLOGY
   Shin JW, 2012, OPHTHALMOLOGY, V119, P1017, DOI 10.1016/j.ophtha.2011.10.029
   Shinojima A, 2014, RETINA-J RET VIT DIS, V34, P1407, DOI 10.1097/IAE.0000000000000108
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Sogawa K, 2012, AM J OPHTHALMOL, V153, P1129, DOI 10.1016/j.ajo.2011.11.005
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3979, DOI 10.1167/iovs.14-14188
   Spaide R.F., 2015, RETINA
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide R, 2010, ESSENT OPHTHALMOL, P169, DOI 10.1007/978-3-540-85540-8_15
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P5103, DOI 10.1167/iovs.08-2127
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tan BB, 2012, J GLAUCOMA, V21, P266, DOI 10.1097/IJG.0b013e3182071cdd
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Tan CSH, 2015, BRIT J OPHTHALMOL, V99, P354, DOI 10.1136/bjophthalmol-2014-305331
   Tanabe H, 2012, RETINA-J RET VIT DIS, V32, P134, DOI 10.1097/IAE.0b013e318217ff87
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tian J, 2013, BIOMED OPT EXPRESS, V4, P397, DOI 10.1364/BOE.4.000397
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Wajer SD, 2000, MICROVASC RES, V60, P281, DOI 10.1006/mvre.2000.2270
   Wang JW, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0110-3
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   WOLTER JR, 1960, ARCH OPHTHALMOL-CHIC, V64, P150
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yamashita T, 2012, INVEST OPHTH VIS SCI, V53, P1102, DOI 10.1167/iovs.11-8836
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yannuzzi LA, 1982, MAC SOC M MIAM FLOR
   Yannuzzi LA, 2010, AM J OPHTHALMOL, V149, P361, DOI 10.1016/j.ajo.2009.11.017
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
   Yi J, 2014, BIOMED OPT EXPRESS, V5, P3603, DOI 10.1364/BOE.5.003603
   Yiu G, 2014, AM J OPHTHALMOL, V158, P745, DOI 10.1016/j.ajo.2014.06.006
   ZHANG HR, 1994, PROG RETIN EYE RES, V13, P243, DOI 10.1016/1350-9462(94)90012-4
   Zhang L, 2015, INVEST OPHTH VIS SCI, V56, P3202, DOI 10.1167/iovs.14-15669
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
   Zhang QQ, 2015, J INNOV OPT HEAL SCI, V8, DOI 10.1142/S1793545815500121
   Zhang QQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.6.066008
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 286
TC 169
Z9 178
U1 2
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2016
VL 52
BP 130
EP 155
DI 10.1016/j.preteyeres.2015.10.002
PG 26
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL7JP
UT WOS:000375817300007
PM 26478514
DA 2022-11-30
ER

PT J
AU Hudson, HL
   Lane, SS
   Heier, JS
   Stulting, RD
   Singerman, L
   Lichter, PR
   Sternberg, P
   Chang, DF
AF Hudson, Henry L.
   Lane, Stephen S.
   Heier, Jeffrey S.
   Stulting, R. Doyle
   Singerman, Lawrence
   Lichter, Paul R.
   Sternberg, Paul
   Chang, David F.
CA IMT 002 Study Grp
TI Implantable miniature telescope for the treatment of visual acuity loss
   resulting from end-stage age-related macular degeneration: 1-year
   results
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; CATARACT-SURGERY; FUNCTION QUESTIONNAIRE; IMPACT;
   MACULOPATHY; LENS; PHACOEMULSIFICATION
AB Purpose: To evaluate the safety and efficacy of an implantable visual prosthetic device (IMT; VisionCare Ophthalmic Technologies, Saratoga, CA) in patients with bilateral, end-stage age-related macular degeneration (AMD).
   Design: Prospective, open-label, multicenter clinical trial with fellow eye controls.
   Participants: A total of 217 patients (mean age, 76 years) with AMD and moderate to profound bilateral central visual acuity loss (20/80-20/800) resulting from bilateral untreatable geographic atrophy, disciform scars, or both were enrolled.
   Methods: A visual prosthetic device (implantable telescope), designed to enlarge retinal images of the central visual field, was implanted monocularly in the capsular bag after lens extraction. Fellow eyes were not implanted to provide peripheral vision and served as controls. Study patients participated in 6 visual rehabilitation visits after surgery.
   Main Outcome Measures: Best-corrected distance visual acuity (BCDVA) and best-corrected near visual acuity (BCNVA), quality-of-life scores from the National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) and the Activities of Daily Life scale, endothelial cell density (ECD), and incidence of complications and adverse events.
   Results: At 1 year, 67% of implanted eyes achieved a 3-line or more improvement in BCDVA versus 13% of fellow eye controls (P < 0.0001). Fifty-three percent of implanted eyes achieved a 3-line or more improvement in both BCDVA and BCNVA versus 10% of fellow eyes (P<0.0001). Mean BCDVA and BCNVA improved 3.5 lines and 3.2 lines, respectively, in implanted eyes versus 0.8 lines and 1.8 lines, respectively, in fellow eyes (P<0.0001). Change in visual acuity was not related to lesion type. Mean NEI VFQ-25 scores improved by more than 7 points from baseline (P < 0.01) on 7 of 8 relevant subscales. Eleven eyes did not receive the device because of an aborted procedure. Endothelial cell density was reduced by 20% at 3 months and 25% at 1 year. The decrease in ECD was correlated with postsurgical edema (P < 0.0001), and there was no evidence that endothelial cell loss is accelerated by ongoing endothelial trauma after implantation.
   Conclusions: This implantable visual prosthesis can improve visual acuity and quality of life in patients with moderate to profound visual impairment caused by bilateral, end-stage AMD. (c) 2006 by the American Academy of Ophthalmology.
C1 Retina Ctr, Tucson, AZ USA.
   Associated Eye Care, Stillwater, MN USA.
   Ophthalm Consultants Boston, Boston, MA USA.
   Emory Univ, Ctr Eye, Atlanta, GA 30322 USA.
   Retina Associates Cleveland, Beachwood, OH USA.
   Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA.
   Vanderbilt Univ, Inst Eye, Nashville, TN USA.
   Altos Eye Phys, Los Altos, CA USA.
C3 Ophthalmic Consultants of Boston; Emory University; Retina Associates of
   Cleveland, Inc.; University of Michigan System; University of Michigan;
   Vanderbilt University
RP Hudson, HL (通讯作者)，6585 N Oracle Rd,Suite A, Tucson, AZ 85704 USA.
RI Bittner, Ava/AAK-8778-2021
OI Bittner, Ava/0000-0002-9498-2230; Lichter, Paul/0000-0001-8394-4813
CR ADAMS E, 2003, VA TECHNOLOGY ASSESS
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Beltrame G, 2002, J CATARACT REFR SURG, V28, P118, DOI 10.1016/S0886-3350(01)00983-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bourne RRA, 2004, OPHTHALMOLOGY, V111, P679, DOI 10.1016/j.ophtha.2003.07.015
   Bourne WM, 1997, INVEST OPHTH VIS SCI, V38, P779
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   CHENG H, 1986, ARCH OPHTHALMOL-CHIC, V104, P1170
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Globe DR, 2004, OPHTHALMOLOGY, V111, P1141, DOI 10.1016/j.ophtha.2004.02.003
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hinds A, 2003, BRIT J OPHTHALMOL, V87, P1391, DOI 10.1136/bjo.87.11.1391
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   KOZIOL JE, 1994, OPHTHALMIC SURG LAS, V25, P675
   Krummenauer F, 2005, EUR J OPHTHALMOL, V15, P74, DOI 10.1177/112067210501500112
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Martin David C, 2004, Prev Chronic Dis, V1, pA05
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Oshika T, 2004, J CATARACT REFR SURG, V30, P357, DOI 10.1016/S0886-3350(03)00615-1
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   *SST, 2004, OPHTHALMOLOGY, V11, P1981
   Sunness JS, 1999, MOL VIS, V5
   Tranos PG, 2004, CURR EYE RES, V29, P41, DOI 10.1080/02713680490513191
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
NR 45
TC 66
Z9 69
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2006
VL 113
IS 11
BP 1987
EP 2001
DI 10.1016/j.ophtha.2006.07.010
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 101CS
UT WOS:000241717100013
PM 16989902
DA 2022-11-30
ER

PT J
AU van Asten, F
   Michels, CTJ
   Hoyng, CB
   van der Wilt, GJ
   Klevering, BJ
   Rovers, MM
   Grutters, JPC
AF van Asten, Freekje
   Michels, Charlotte T. J.
   Hoyng, Carel B.
   van der Wilt, Gert Jan
   Klevering, B. Jeroen
   Rovers, Maroeska M.
   Grutters, Janneke P. C.
TI The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for
   the treatment of age-related macular degeneration-A cost-effectiveness
   analysis from a societal perspective
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL-ACUITY; INTRAVITREAL RANIBIZUMAB;
   CLINICAL-TRIAL; MODEL; EFFICACY; OUTCOMES; EYE; UK
AB Background
   The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues. Bevacizumab is an effective, safe and inexpensive treatment option for neovascular age-related macular degeneration (AMD), albeit unregistered for the disease. Therefore, in some countries ophthalmologists use the equally effective but expensive drugs ranibizumab and aflibercept. We describe the economic consequences of this dilemma surrounding AMD treatment from a societal perspective.
   Methods
   We modelled cost-effectiveness of treatment with ranibizumab (as-needed), aflibercept (bimonthly) and bevacizumab (as-needed). Effectiveness was estimated by systematic review and meta-analysis. The drug with the most favourable cost-effectiveness profile compared to bevacizumab was used for threshold analyses. First, we determined how much we overspend per injection. Second, we calculated the required effectiveness to justify the current price and the reasonable price for a drug leading to optimal vision. Finally, we estimated how much Europe overspends if bevacizumab is not first choice.
   Results
   Bevacizumab treatment costs (sic)27,087 per year, about (sic)4,000 less than aflibercept and 6,000 less than ranibizumab. With similar effectiveness for all drugs as shown by meta analysis, bevacizumab was the most cost-effective. Aflibercept was chosen for threshold analyses. Aflibercept costs 943 per injection, but we determined that the maximum price to be cost-effective is (sic)533. Alternatively, at its current price, aflibercept should yield about twice the visual gain. Even when optimal vision can be achieved, the maximum price for any treatment is 37,453 per year. Most importantly, Europe overspends 335 million yearly on AMD treatment when choosing aflibercept over bevacizumab.
   Conclusion
   Bevacizumab is the most cost-effective treatment for AMD, yet is not the standard of care across Europe. The registered drugs ranibizumab and aflibercept lead to large overspending without additional health benefits. Health authorities should consider taking steps to implement bevacizumab into clinical practice as first choice.
C1 [van Asten, Freekje; Hoyng, Carel B.; Klevering, B. Jeroen] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Michels, Charlotte T. J.; van der Wilt, Gert Jan; Rovers, Maroeska M.; Grutters, Janneke P. C.] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP van Asten, F (通讯作者)，Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
EM Freekje.vanAsten@radboudumc.nl
RI Grutters, Janneke PC/G-1499-2013; van der Wilt, G.J./H-8120-2014;
   Rovers, Maroeska/F-2969-2014
OI Grutters, Janneke PC/0000-0002-2579-1561; van der Wilt,
   G.J./0000-0002-5856-762X; Rovers, Maroeska/0000-0002-3095-170X
FU Radboud Institute for Health Sciences [016.096.309]
FX This study was made possible by a grant awarded to the research project
   "Toward personalized medicine in patients with age-related macular
   degeneration" by the Radboud Institute for Health Sciences (grant
   016.096.309) (FvA). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 2015, KOST PRAKT
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Briggs AH, 2012, VALUE HEALTH, V15, P835, DOI 10.1016/j.jval.2012.04.014
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Centraal Bureau voor de Statistiek (CBS), 2013, IND PRIC
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Claxton K, 2008, BMJ-BRIT MED J, V336, P251, DOI [10.1136/bmj.39434.500185.25, DOI 10.1136/BRNI.39434.500185.25]
   Claxton K, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19140
   Claxton K, 2015, HEALTH ECON, V24, P1, DOI 10.1002/hec.3130
   Cohen D, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1654
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Drummond MF, 2005, METHODS EC EVALUATIO
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Eurostat, 2015, POP 1 JAN
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Husereau D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-80
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Koch KR, 2012, GRAEF ARCH CLIN EXP, V250, P201, DOI 10.1007/s00417-011-1792-8
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mullard A, 2012, NAT REV DRUG DISCOV, V11, P426, DOI 10.1038/nrd3749
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE
   National Institute for Health and Care Excellence (NICE), 2013, AFL SOL INJ TREAT WE
   Office of Inspector General, 2012, OEI031000360 DEP HLT
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Vottonen P, 2016, ACTA OPHTHALMOL, V94, P652, DOI 10.1111/aos.13185
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 42
TC 43
Z9 43
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 17
PY 2018
VL 13
IS 5
AR e0197670
DI 10.1371/journal.pone.0197670
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GG0DP
UT WOS:000432348900086
PM 29772018
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lane, J
   Rohan, EMF
   Sabeti, F
   Essex, RW
   Maddess, T
   Dawel, A
   Robbins, RA
   Barnes, N
   He, XM
   McKone, E
AF Lane, Jo
   Rohan, Emilie M. F.
   Sabeti, Faran
   Essex, Rohan W.
   Maddess, Ted
   Dawel, Amy
   Robbins, Rachel A.
   Barnes, Nick
   He, Xuming
   McKone, Elinor
TI Impacts of impaired face perception on social interactions and quality
   of life in age-related macular degeneration: A qualitative study and new
   community resources
SO PLOS ONE
LA English
DT Article
ID VISUAL FUNCTION; LOW-VISION; DEVELOPMENTAL PROSOPAGNOSIA; INDIVIDUALIZED
   MEASURE; IMAGE-ENHANCEMENT; RECOGNITION; REHABILITATION; PERFORMANCE;
   ADJUSTMENT; EXPERIENCE
AB Aims
   Previous studies and community information about everyday difficulties in age-related macular degeneration (AMD) have focussed on domains such as reading and driving. Here, we provide the first in-depth examination of how impaired face perception impacts social interactions and quality of life in AMD. We also develop a Faces and Social Life in AMD brochure and information sheet, plus accompanying conversation starter, aimed at AMD patients and those who interact with them (family, friends, nursing home staff).
   Method
   Semi-structured face-to-face interviews were conducted with 21 AMD patients covering the full range from mild vision loss to legally blind. Thematic analysis was used to explore the range of patient experiences.
   Results
   Patients reported faces appeared blurred and/or distorted. They described recurrent failures to recognise others' identity, facial expressions and emotional states, plus failures of alternative non-face strategies (e.g., hairstyle, voice). They reported failures to follow social nuances (e.g., to pick up that someone was joking), and feelings of missing out ('I can't join in'). Concern about offending others (e.g., by unintentionally ignoring them) was common, as were concerns of appearing fraudulent ('Other people don't understand'). Many reported social disengagement. Many reported specifically face-perception-related reductions in social life, confidence, and quality of life. All effects were observed even with only mild vision loss. Patients endorsed the value of our Faces and Social Life in AMD Information Sheet, developed from the interview results, and supported future technological assistance (digital image enhancement).
   Conclusion
   Poor face perception in AMD is an important domain contributing to impaired social interactions and quality of life. This domain should be directly assessed in quantitative quality of life measures, and in resources designed to improve community understanding. The identity-related social difficulties mirror those in prosopagnosia, of cortical rather than retinal origin, implying findings may generalise to all low-vision disorders.
C1 [Lane, Jo; Dawel, Amy; McKone, Elinor] Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.
   [Lane, Jo; Dawel, Amy; McKone, Elinor] Australian Natl Univ, ARC Ctr Excellence Cognit & Its Disorders, Canberra, ACT, Australia.
   [Rohan, Emilie M. F.; Sabeti, Faran; Maddess, Ted] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia.
   [Sabeti, Faran] Univ Canberra, Discpline Optometry & Vis Sci, Bruce, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Canberra, ACT, Australia.
   [Robbins, Rachel A.] Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.
   [Barnes, Nick] Australian Natl Univ, Res Sch Engn, Canberra, ACT, Australia.
   [Barnes, Nick] CSIRO, Data61, Canberra, ACT, Australia.
   [He, Xuming] ShanghaiTech Univ, Sch Informat Sci & Technol, Shanghai, Peoples R China.
C3 Australian National University; Australian National University;
   Australian National University; John Curtin School of Medical Research;
   University of Canberra; Australian National University; Australian
   National University; Australian National University; Commonwealth
   Scientific & Industrial Research Organisation (CSIRO); ShanghaiTech
   University
RP McKone, E (通讯作者)，Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.; McKone, E (通讯作者)，Australian Natl Univ, ARC Ctr Excellence Cognit & Its Disorders, Canberra, ACT, Australia.
EM elinor.mckone@anu.edu.au
RI Sabeti, Faran/AAR-1767-2021; Barnes, Nick/Y-2744-2018; Dawel,
   Amy/AAY-2083-2020; Maddess, Teddy L/A-3200-2008; Robbins, Rachel
   A/A-5542-2008
OI Barnes, Nick/0000-0002-9343-9535; Dawel, Amy/0000-0001-6668-3121;
   Maddess, Teddy L/0000-0003-4591-3658; Essex, Rohan/0000-0001-5323-0334;
   Robbins, Rachel/0000-0001-9363-4528; McKone, Elinor/0000-0003-1655-4297;
   Lane, Jo/0000-0002-2518-1050; SABETI, Faran/0000-0001-9187-7569
FU Australian Research Council [CE110001021, DP150100684]; National Health
   and Medical Research Council [1063458]; Rebecca Cooper Medical
   Foundation Grant
FX This research was supported by Australian Research Council grants
   CE110001021 (www.ccd.edu.au; EM, JL, AD) and DP150100684 (EM), National
   Health and Medical Research Council Project Grant 1063458
   (https://www.nhmrc.gov.au/TM, ER and FS), Rebecca Cooper Medical
   Foundation Grant (FS). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Asper Lisa, 2000, Clin Exp Optom, V83, P49
   Bach AM, 2016, GLOB QUALIT NURS RES, V3, DOI 10.1177/2333393616651351
   Barbour RS, 2001, BMJ-BRIT MED J, V322, P1115, DOI 10.1136/bmj.322.7294.1115
   Barteselli G, 2014, EYE, V28, P1231, DOI 10.1038/eye.2014.189
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   Bowles DC, 2009, COGN NEUROPSYCHOL, V26, P423, DOI 10.1080/02643290903343149
   Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Burton AM, 1999, PSYCHOL SCI, V10, P243, DOI 10.1111/1467-9280.00144
   Cimarolli VR, 2012, CLIN REHABIL, V26, P748, DOI 10.1177/0269215511429162
   Crabb DP, 2013, OPHTHALMOLOGY, V120, P1120, DOI 10.1016/j.ophtha.2012.11.043
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Dalrymple KA, 2014, J PSYCHOSOM RES, V77, P144, DOI 10.1016/j.jpsychores.2014.06.001
   Davis JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028800
   Dawel A., J EXP PSYCHOL APPL
   Dawel A, PERSONAL DISORD
   de Ridder D, 2008, LANCET, V372, P246, DOI 10.1016/S0140-6736(08)61078-8
   Duchaine B, 2007, COGN NEUROPSYCHOL, V24, P419, DOI 10.1080/02643290701380491
   Ehrlich JR, 2017, AM J OPHTHALMOL, V176, P26, DOI 10.1016/j.ajo.2016.12.021
   Evans BJW, 2007, OPHTHAL PHYSL OPT, V27, P417, DOI 10.1111/j.1475-1313.2007.00488.x
   FERRIS FL, 1993, AM J OPHTHALMOL, V116, P735
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Fusch PI, 2015, QUAL REP, V20, P1408
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Hammarberg K, 2016, HUM REPROD, V31, P498, DOI 10.1093/humrep/dev334
   Heerey EA, 2015, CURR DIR PSYCHOL SCI, V24, P285, DOI 10.1177/0963721415570731
   Heraghty J, 2012, AM J PUBLIC HEALTH, V102, P1655, DOI 10.2105/AJPH.2012.300657
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Irons J, 2014, J VISION, V14, DOI 10.1167/14.2.12
   Irons JL, 2017, VISION RES, V137, P61, DOI 10.1016/j.visres.2017.06.002
   Johnson AP, 2017, INVEST OPHTH VIS SCI, V58, P2520, DOI 10.1167/iovs.16-21349
   Khadka J, 2013, OPTOMETRY VISION SCI, V90, P720, DOI 10.1097/OPX.0000000000000001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lowe JB, 2000, OPTOMETRY VISION SCI, V77, P260, DOI 10.1097/00006324-200005000-00013
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Marakis TP, 2017, QUAL LIFE RES, V26, P183, DOI 10.1007/s11136-016-1407-2
   Marmor DJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P117, DOI 10.1001/archophthalmol.2009.366
   Marty MA, 2011, PRINCIPLES PRACTICE, P152
   Mason M., 2010, FORUM QUALITATIVE SO, V11, DOI 10.17169/fqs-11.3.1428
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   Murray E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20089-7
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Pachana NA, 2007, INT PSYCHOGERIATR, V19, P103, DOI 10.1017/S1041610206003504
   Palermo R, 2017, Q J EXP PSYCHOL, V70, P218, DOI 10.1080/17470218.2016.1161058
   PELI E, 1994, J OPT SOC AM A, V11, P1929, DOI 10.1364/JOSAA.11.001929
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   Sheldon S, 2014, OPTOMETRY VISION SCI, V91, P1000, DOI 10.1097/OPX.0000000000000314
   Sinha P, 1996, NATURE, V384, P404, DOI 10.1038/384404a0
   Stanford P, 2009, BRIT J VISUAL IMPA, V27, P129, DOI 10.1177/0264619609102216
   Taylor DJ, 2018, OPHTHAL PHYSL OPT, V38, P98, DOI 10.1111/opo.12419
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   van Rheede JJ, 2015, INVEST OPHTH VIS SCI, V56, P4802, DOI 10.1167/iovs.14-16311
   Villegas EA, 2008, INVEST OPHTH VIS SCI, V49, P4688, DOI 10.1167/iovs.08-2316
   Wang SW, 2008, CLIN REHABIL, V22, P816, DOI 10.1177/0269215508091435
   Whelan E, 2007, SOCIOL HEALTH ILL, V29, P957, DOI 10.1111/j.1467-9566.2007.01024.x
   Wilson Amanda, 2008, Vis Impair Res, V10, P23, DOI 10.1080/13882350802053731
   Wong EYH, 2004, J VISUAL IMPAIR BLIN, V98, P629, DOI 10.1177/0145482X0409801007
   World Health Organization, 2015, INT STAT CLASS DIS R
   Yardley L, 2008, J PSYCHOSOM RES, V65, P445, DOI 10.1016/j.jpsychores.2008.03.013
NR 66
TC 23
Z9 23
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2018
VL 13
IS 12
AR e0209218
DI 10.1371/journal.pone.0209218
PG 31
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Science & Technology - Other Topics
GA HG0IO
UT WOS:000454627200034
PM 30596660
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Frennesson, C
   Nilsson, UL
   Peebo, BB
   Nilsson, SEG
AF Frennesson, Christina
   Nilsson, Ulla L.
   Peebo, Beatrice B.
   Nilsson, Sven E. G.
TI Significant improvements in near vision, reading speed, central visual
   field and related quality of life after ranibizumab treatment of wet
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE best-corrected visual acuity; near vision; quality of life; ranibizumab
   treatment; reading speed; visual field; wet AMD
ID VERTEPORFIN PHOTODYNAMIC THERAPY
AB Purpose:
   To investigate the effects on near visual acuity, reading speed, central visual field and related quality of life of ranibizumab treatment of wet age-related macular degeneration (AMD).
   Methods:
   The study was a prospective, non-comparative consecutive case series, followed for 3 months and investigator-driven. Thirty eyes of 30 patients with wet AMD were included, mean age 75 years (range 69-95 years). In addition to a full ophthalmological examination - including best-corrected visual acuity (BCVA; Early Treatment Diabetic Research Study chart), fundus biomicroscopy, fundus photography, fluorescein angiography, indocyanine green angiography (occult cases) and ocular coherence tomography - near visual acuity, reading speed, central visual field and quality of life for related activities were also investigated at baseline and at 3 months after ranibizumab treatment.
   Results:
   Mean BCVA increased from 62 +/- 11 to 66 +/- 14 letters at 3 months (7%; p = 0.018). Near vision improved from 9 +/- 5 to 6 +/- 3 points (33%; p = 0.0006) and reading speed increased from 59 +/- 40 to 85 +/- 50 words/min (44%; p < 0.0001). The mean deviation from normal of the visual field improved from -9 +/- 7 to -6 +/- 5 dB (33%; p < 0.0001). Quality of life improved for distance activities from 54 +/- 28 to 63 +/- 28 points (17%; p < 0.0001) but significantly (p = 0.024) more for near activities, from 49 +/- 26 to 63 +/- 26 points (29%; p < 0.0001). Reading newspaper text in the group in which the better eye was treated showed the highest increase in quality of life score of all: 116%.
   Conclusion:
   The increase in BCVA after ranibizumab treatment is well established. The present study also showed significant improvements in other important visual qualities, such as near visual acuity, reading speed, central visual field and several activities influencing quality of life. The improvement was greater for near activities than for distance activities. Therefore, the beneficial effects of ranibizumab treatment shown here are more extensive than those reported previously.
C1 [Frennesson, Christina; Nilsson, Ulla L.; Peebo, Beatrice B.; Nilsson, Sven E. G.] Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
C3 Linkoping University
RP Frennesson, C (通讯作者)，Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
EM christina.frennesson@lio.se
FU Crown Princess Margareta's Foundation; Linkoping University Hospital;
   Ostergotland's Foundation; Pfizer AB; Novartis A/S Denmark; Novartis
   Sweden AB; Alcon Sweden
FX The present study was supported by grants from Crown Princess
   Margareta's Foundation for the Visually Handicapped, from the Linkoping
   University Hospital Research Fund (ALF) and from Ostergotland's
   Foundation for the Visually Handicapped. Lena Hagdahl, Karin Hilmo and
   Karin Strid-Moller, registered nurses accredited for BCVA tests, fundus
   photography, angiography and optical coherence tomography examinations
   in international clinical trials, are acknowledged gratefully for their
   excellent assistance. C.F. is an advisory board member of Novartis
   Sweden AB and received fees from Novartis Sweden AB for lecturing.
   S.E.N. received fees from Novartis Sweden AB and Pfizer AB for lecturing
   and a travel grant from Novartis A/S Denmark. B.B.P is a consultant to
   Pfizer AB and received fees for lecturing from Novartis Sweden AB and
   Alcon Sweden. The present study was investigator-driven and received no
   financial or other support from Novartis Sweden AB.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HEIER JS, 2007, INVEST OPHTHALMOL VI, V48
   Kloos P, 2008, KLIN MONATSBL AUGENH, V225, P385, DOI 10.1055/s-2008-1027252
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Stefansson E, 2006, ACTA OPHTHALMOL SCAN, V84, P449, DOI 10.1111/j.1600-0420.2006.00725.x
   Swamy BN, 2009, ACTA OPHTHALMOL, V87, P335, DOI 10.1111/j.1755-3768.2008.01203.x
   Trauzettel-Klosinski S., 2003, VIS IMPAIR RES, V5, P83, DOI [10.1076/vimr.5.2.83.26264, DOI 10.1076/VIMR.5.2.83.26264]
NR 16
TC 33
Z9 33
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2010
VL 88
IS 4
BP 420
EP 425
DI 10.1111/j.1755-3768.2009.01576.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 603BD
UT WOS:000278182000007
PM 19678811
OA Bronze
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Ohtsuka, H
   Higuchi, M
   Matsushita, T
   Ariga, H
   Kosaka, S
   Matsushita, R
   Takami, K
AF Hikichi, Taiichi
   Ohtsuka, Hideo
   Higuchi, Makoto
   Matsushita, Takuro
   Ariga, Hiroko
   Kosaka, Shoko
   Matsushita, Reiko
   Takami, Kimitaka
TI FACTORS PREDICTIVE OF VISUAL ACUITY OUTCOMES 1 YEAR AFTER PHOTODYNAMIC
   THERAPY IN JAPANESE PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE photodynamic therapy; polypoidal choroidal vasculopathy
ID PIGMENT EPITHELIAL DETACHMENTS; MACULAR DEGENERATION; INTRAVITREAL
   BEVACIZUMAB; VERTEPORFIN; RANIBIZUMAB
AB Purpose: The purpose of this study was to determine the factors predictive of visual acuity (VA) outcomes 1 year after photodynamic therapy (PDT) for polypoidal choroidal vasculopathy.
   Methods: We prospectively studied 220 eyes of 210 Japanese patients with polypoidal choroidal vasculopathy treated with primary application of PDT. A stepwise logistic regression model was used to estimate the independent factors predictive of better VA and improvement of VA 1 year after the primary PDT.
   Results: Visual acuities at the various follow-up evaluations improved significantly compared with baseline (P = 0.001 for all comparisons). The VA improved and decreased more than 0.3 logarithm of minimum angle of resolution unit 1 year after the primary PDT in 55 (25%) and 21 (10%) eyes, respectively. Stepwise logistic regression analysis showed that younger age, smaller greatest linear dimension, better baseline VA, and less baseline hemorrhage were significant and independent factors predictive of better VA 1 year after PDT, and younger age, smaller greatest linear dimension, better baseline VA, less hemorrhaging, and the presence of a serous macular detachment at baseline were significant and independent factors predictive of VA improvement.
   Conclusion: Photodynamic therapy stabilized eyes anatomically and functionally. Clinical characteristics at baseline were predictors of favorable VA outcomes after PDT. These findings may help establish the strategy of treatment for polypoidal choroidal vasculopathy. RETINA 31:857-865, 2011
C1 [Hikichi, Taiichi] Ohtsuka Eye Hosp, Kita Ku, Sapporo, Hokkaido 0010016, Japan.
RP Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Kita Ku, Kita 16,Nishi 4, Sapporo, Hokkaido 0010016, Japan.
EM taiichi-hikichi@hokkaido.med.or.jp
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 34
TC 21
Z9 23
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2011
VL 31
IS 5
BP 857
EP 865
DI 10.1097/IAE.0b013e3181fecda9
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 755LV
UT WOS:000289933600006
PM 21124252
DA 2022-11-30
ER

PT J
AU Pham, TQ
   Cugati, S
   Rochtchina, E
   Mitchell, P
   Maloof, A
   Wang, JJ
AF Pham, T. Q.
   Cugati, S.
   Rochtchina, E.
   Mitchell, P.
   Maloof, A.
   Wang, J. J.
TI Age-related maculopathy and cataract surgery outcomes: visual acuity and
   health-related quality of life
SO EYE
LA English
DT Article
DE surgical outcomes; cataract surgery; age-related maculopathy; VF-14;
   health related quality of life; SF-12
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; POPULATION-CROSS-SECTIONS; MACULAR
   DEGENERATION; CLINICAL-OUTCOMES; POSTOPERATIVE OUTCOMES; AUCKLAND
   CATARACT; PREVALENCE; IMPAIRMENT; PREDICTORS
AB Purpose To assess visual acuity (VA) and health-related quality of life (HRQoL) outcomes in patients with and without age-related maculopathy (ARM) after cataract surgery.
   Methods Patients aged 60+ years who had undergone cataract surgery at the Westmead Hospital during 2001-2003 were re-examined 1-3 years after surgery. Tests included VA and assessment of visual- and HRQoL using standardised questionnaires (VF-14, SF-12). Preoperative comorbidity data were collected from medical records. Poor surgical outcomes (VA < 6/12; no VA improvement; lowest quintile of VF-14, SF-12 scores) were compared in patients with and without ARM, adjusting for age, sex, preoperative systemic comorbidities, ocular comorbidities and surgical or postoperative complications.
   Results Of 622 surviving patients, 454 (73%) were followed up for a mean period of 2.8 years. Similar proportions with VA >= 6/12 were observed in patients with (80.2%) and without (88.8%) pre-existing ARM. Preoperative early ARM was only associated with slightly lower mean VF-14 scores (87.64 with vs 92.58 without ARM, P = 0.01). Increasing age and preoperative ocular comorbidities were associated with all poor outcomes measured. Low SF-12 scores were associated with preoperative systemic comorbidities.
   Conclusion Our study documents favourable cataract surgical outcomes 1-3 years after cataract surgery in patients with preoperative ARM.
C1 Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol,Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   Westmead Hosp, Dept Ophthalmol, Westmead, NSW 2145, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol,Westmead Millennium Inst, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; Cugati, Sudha/ABB-1331-2021; wang,
   jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
CR Alonso J, 1997, OPHTHALMOLOGY, V104, P799, DOI 10.1016/S0161-6420(97)30230-9
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   BATTERBURY M, 1991, Eye (London), V5, P369
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Keeffe JE, 1996, AUST NZ J OPHTHALMOL, V24, P313, DOI 10.1111/j.1442-9071.1996.tb01601.x
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Lundstrom M, 1999, BRIT J OPHTHALMOL, V83, P1272, DOI 10.1136/bjo.83.11.1272
   McCarty CA, 1999, BRIT J OPHTHALMOL, V83, P62, DOI 10.1136/bjo.83.1.62
   Murphy C, 2002, J CATARACT REFR SURG, V28, P62, DOI 10.1016/S0886-3350(01)01027-6
   Pham TQ, 2005, CLIN EXP OPHTHALMOL, V33, P360, DOI 10.1111/j.1442-9071.2005.01031.x
   Pham TQ, 2004, CLIN EXP OPHTHALMOL, V32, P383, DOI 10.1111/j.1442-9071.2004.00842.x
   Riley AF, 2002, BRIT J OPHTHALMOL, V86, P185, DOI 10.1136/bjo.86.2.185
   SCHEIN OD, 1994, OPHTHALMOLOGY, V101, P1142
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   Tan AG, 2004, CLIN EXP OPHTHALMOL, V32, P284, DOI 10.1111/j.1442-9071.2004.00817.x
   Thompson AM, 2004, BRIT J OPHTHALMOL, V88, P1042, DOI 10.1136/bjo.2003.032581
   TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1312, DOI 10.1001/archopht.1995.01100100100038
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   Westcott MC, 2000, BRIT J OPHTHALMOL, V84, P1380, DOI 10.1136/bjo.84.12.1380
NR 31
TC 17
Z9 20
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD MAR
PY 2007
VL 21
IS 3
BP 324
EP 330
DI 10.1038/sj.eye.6702171
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 141US
UT WOS:000244604900004
PM 16284600
OA Bronze
DA 2022-11-30
ER

PT J
AU Ueno, C
   Gomi, F
   Sawa, M
   Nishida, K
AF Ueno, Chikako
   Gomi, Fumi
   Sawa, Miki
   Nishida, Kohji
TI CORRELATION OF INDOCYANINE GREEN ANGIOGRAPHY AND OPTICAL COHERENCE
   TOMOGRAPHY FINDINGS AFTER INTRAVITREAL RANIBIZUMAB FOR POLYPOIDAL
   CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE indocyanine green angiography; optical coherence tomography; polypoidal
   choroidal vasculopathy; ranibizumab
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; CLINICAL CHARACTERISTICS;
   FEATURES; BEVACIZUMAB; EFFICACY
AB Purpose: To evaluate findings in eyes with polypoidal choroidal vasculopathy on indocyanine green angiography (ICGA) and optical coherence tomography (OCT) over 3 months after ranibizumab treatment.
   Method: Fifty-one eyes from 51 patients with treatment-naive polypoidal choroidal vasculopathy received intravitreal ranibizumab injections. We evaluated changes in polypoidal lesions on ICGA and OCT and their correlation over 3 months. Ranibizumab was injected again based on the presence of residual fluid on OCT.
   Results: Indocyanine green angiography detected 75 polypoidal lesions. All corresponding OCT lesions showed baseline protrusion of the retinal pigment epithelium. At 3 months, 26 lesions (35%) resolved on ICGA: retinal pigment epithelium protrusion on OCT resolved in 10 lesions (38%), 10 lesions (38%) decreased in height, and 6 lesions (24%) remained unchanged. Forty-nine lesions persisted on ICGA, retinal pigment epithelium protrusion resolved in 2 lesions (4%), decreased in 4 lesions (8%), were stable in 36 lesions (73%), and increased in 7 lesions (15%). Three lesions newly developed. Six eyes (12%) had resolved lesions, and 33 eyes (67%) had persistent lesions on ICGA and OCT. Residual exudative changes were associated with persistent lesions on OCT.
   Conclusion: Indocyanine green angiography and OCT baseline findings of polypoidal lesions in polypoidal choroidal vasculopathy were well correlated; however, a discrepancy was seen during treatment. Polypoidal lesions persisted more often on OCT, although ICGA and OCT showed the efficacy of ranibizumab for some polypoidal lesions.
   RETINA 32: 2006-2013, 2012
C1 [Ueno, Chikako; Gomi, Fumi; Sawa, Miki; Nishida, Kohji] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Dept Ophthalmol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Nishida, Kohji/0000-0001-9069-3610; Gomi, Fumi/0000-0003-0807-8817
FU Japan Society for the Promotion of Science, Tokyo, Japan
FX Supported in part by the Japan Society for the Promotion of Science,
   Tokyo, Japan.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lantry LE, 2007, CURR OPIN MOL THER, V9, P592
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 18
Z9 18
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2012
VL 32
IS 10
BP 2006
EP 2013
DI 10.1097/IAE.0b013e31825c1c31
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 029TZ
UT WOS:000310520400003
PM 22772392
DA 2022-11-30
ER

PT J
AU Kim, SJ
   Yu, HG
AF Kim, Sang Jin
   Yu, Hyeong Gon
TI EFFICACY OF COMBINED PHOTODYNAMIC THERAPY AND INTRAVITREAL BEVACIZUMAB
   INJECTION VERSUS PHOTODYNAMIC THERAPY ALONE IN POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; photodynamic therapy; polypoidal choroidal vasculopathy;
   verteporfin
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; VERTEPORFIN; RANIBIZUMAB; NEOVASCULARIZATION; EXPRESSION;
   OUTCOMES; AVASTIN; VEGF
AB Purpose: To compare the efficacy of combined photodynamic therapy (PDT) and optical coherence tomography-guided intravitreal bevacizumab injection versus PDT alone for the treatment of polypoidal choroidal vasculopathy.
   Methods: The medical records of 39 patients with symptomatic polypoidal choroidal vasculopathy who received combination therapy with PDT and intravitreal bevacizumab injections or PDT monotherapy were retrospectively reviewed. Best-corrected visual acuity, number of treatments, and optical coherence tomography and angiographic findings were compared between the two patient groups.
   Results: In the PDT monotherapy group (n = 19), the mean number of PDTs was 1.89, whereas in the combined therapy group (n = 20), mean 1.30 times of PDT and 2.90 times of intravitreal bevacizumab injection were performed during the 12 months of follow-up. The number of PDTs was significantly different between the 2 groups (P = 0.032). At 12 months, the mean improvement in best-corrected visual acuity was 3.0 lines in the combined group and 1.6 lines in the PDT monotherapy group. At 12 months, improved vision by >= 3 lines was achieved in 55.0% in the combined therapy group and 36.8% in the PDT monotherapy group.
   Conclusion: Combined PDT and bevacizumab therapy effectively treated polypoidal choroidal vasculopathy with fewer PDTs compared with PDT alone during the 1 year of follow-up. Combined treatment appeared to result in better visual acuity, but a larger scale study is required to draw a definite conclusion. RETINA 31: 1827-1834, 2011
C1 [Kim, Sang Jin; Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
   [Yu, Hyeong Gon] Seoul Natl Univ, Med Res Ctr, Sensory Organ Res Inst, Seoul 110744, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU)
RP Yu, HG (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, 101 Daehang Ro, Seoul 110744, South Korea.
EM hgonyu@snu.ac.kr
RI Yu, Hyeong Gon/J-2772-2012
OI Yu, Hyeong Gon/0000-0002-1795-202X
FU Ministry of Health & Welfare, SouthKorea [A080588]
FX Supported by a grant from the Korea Healthcare Technology R&D Project
   (A080588), Ministry of Health & Welfare, SouthKorea.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TY, 2010, INVEST OPHTH VIS SCI, V51
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   LIM JY, 2010, ACTA OPHTHALMOL 0316
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moon JW, 2010, CURR EYE RES, V35, P314, DOI 10.3109/02713680903548962
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 22
Z9 28
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2011
VL 31
IS 9
BP 1827
EP 1834
DI 10.1097/IAE.0b013e318214d01e
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 825YR
UT WOS:000295318800013
PM 21734621
DA 2022-11-30
ER

PT J
AU Daien, V
   Nguyen, V
   Essex, RW
   Guymer, R
   Arnold, JJ
   Munk, M
   Ceklic, L
   Gillies, MC
   Barthelmes, D
AF Daien, Vincent
   Nguyen, Vuong
   Essex, Rohan W.
   Guymer, Robin
   Arnold, Jennifer J.
   Munk, Marion
   Ceklic, Lala
   Gillies, Mark C.
   Barthelmes, Daniel
CA Fight Retinal Blindness Investigat
TI Prevalence and characteristics of macular atrophy in eyes with
   neovascular age-related macular degeneration. A study from a long-term
   observational dataset: the Fight Retinal Blindness! project
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retina; neovascularisation; vision
ID GEOGRAPHIC ATROPHY; RANIBIZUMAB; GROWTH; PROGRESSION; EPIDEMIOLOGY;
   OUTCOMES; RISK
AB Background
   To assess the prevalence and characteristics associated with macular atrophy (MA) in eyes with neovascular age-related macular degeneration (nAMD) treated with vascular endothelial growth factor (VEGF) inhibitors.
   Methods
   This was a retrospective, cross-sectional study of nAMD eyes that commenced anti-VEGF between January 2006 and August 2016. MA (absent/extrafoveal/subfoveal) was graded by treating practitioners based on multimodal imaging from April 2016. The prevalence of MA over time and risk factors of MA were assessed.
   Results
   The prevalence of MA in a cohort of 1689 eyes was 9.9% (22/222) in eyes within 1 year of starting treatment, 41.5% (71/171) after 5 years and 48.4% (30/62) after 9 years of treatment. Risk factors for subfoveal MA included the proportion of visits at which the lesion was graded as inactive ((adjusted OR (AOR) 3.72 for the highest vs lowest the quartile of frequency of inactive gradings (95% CI 2.33 to 6.07)), age (AOR 1.05 per year (95% CI 1.02 to 1.07)), baseline visual acuity (AOR 3.9 for <= 35 letters vs >= 70 letters (95% CI 2.4 to 6.4)) and the number of injections received (AOR 1.20 every 10 injections (95% CI 1.08 to 1.33)). Similar associations were observed with extrafoveal MA.
   Conclusions
   The risk of MA appeared to drop in eyes that had not developed it within 5 years. Low choroidal neovascularisation activity was by far the strongest predictor. We could not determine whether the increased prevalence of MA with time was due to anti-VEGF treatment or the natural history of the condition.
C1 [Daien, Vincent] Gui De Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] INSERM, U1061, Montpellier, France.
   [Daien, Vincent; Nguyen, Vuong; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2000, Australia.
   [Essex, Rohan W.] Canberra Hosp, Dept Ophthalmol, Garran, ACT, Australia.
   [Guymer, Robin] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Arnold, Jennifer J.] Marsen Eye Specialists, Sydney, NSW, Australia.
   [Munk, Marion; Ceklic, Lala] Univ Hosp Bern, Bern Photog Reading Ctr, Dept Ophthalmol, Bern, Switzerland.
   [Barthelmes, Daniel] Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 Universite de Montpellier; CHU de Montpellier; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite de Montpellier;
   University of Sydney; Australian National University; Canberra Hospital;
   Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Bern; University Hospital of Bern; University of Zurich;
   University Zurich Hospital
RP Nguyen, V (通讯作者)，Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2000, Australia.
EM phuc.nguyen@sydney.edu.au
RI Daien, Vincent/Z-5516-2019
OI Daien, Vincent/0000-0001-5675-0861; Essex, Rohan/0000-0001-5323-0334;
   Fraser-Bell, Samantha/0000-0001-5646-9359; Nguyen,
   Vuong/0000-0001-9070-9803
FU Royal Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia (NHMRC); Macular Disease
   Foundation, Australia; NHMRC; Walter and Gertud Siegenthaler Foundation
   Zurich, Switzerland; Swiss National Foundation; Novartis; Bayer
FX Supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), a grant from the National
   Health and Medical Research Council, Australia (NHMRC 2010-2012) and a
   grant from the Macular Disease Foundation, Australia. MCG is a Sydney
   Medical Foundation Fellow and is supported by an NHMRC practitioner
   fellowship. DB was supported by the Walter and Gertud Siegenthaler
   Foundation Zurich, Switzerland and the Swiss National Foundation.
   Funding was also provided by Novartis and Bayer.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   R Core Team, 2019, R LANG ENV STAT COMP
   Razavi H, 2015, CLIN EXP OPHTHALMOL, V43, P707, DOI 10.1111/ceo.12658
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zuur AF, 2010, METHODS ECOL EVOL, V1, P3, DOI 10.1111/j.2041-210X.2009.00001.x
NR 32
TC 6
Z9 6
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2020
VL 104
IS 8
BP 1064
EP 1069
DI 10.1136/bjophthalmol-2019-315055
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PK2OA
UT WOS:000602289600007
PM 31843790
DA 2022-11-30
ER

PT J
AU Solecki, L
   Loganadane, P
   Gauthier, AS
   Simonin, M
   Puyraveau, M
   Delbosc, B
   Saleh, M
AF Solecki, Lauriana
   Loganadane, Prisca
   Gauthier, Anne-Sophie
   Simonin, Manon
   Puyraveau, Marc
   Delbosc, Bernard
   Saleh, Maher
TI Predictive factors for exudation of quiescent choroidal neovessels
   detected by OCT angiography in the fellow eyes of eyes treated for a
   neovascular age-related macular degeneration
SO EYE
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; TYPE-1 NEOVASCULARIZATION; PREVALENCE;
   SECONDARY
AB Background To identify predictive factors for exudation for quiescent choroidal neovessels (qCNV) in the fellow eyes of eyes treated for a neovascular age-related macular degeneration (AMD). Methods Prospective observational study. One hundred and forty-four contralateral eyes of 144 patients treated for wet AMD were analysed. At a baseline visit, multimodal imaging including dye angiographies and optical coherence tomography angiography (OCT-A) was performed in order to detect qCNV. Patients were followed up for 12 months with a monthly assessment. The manifestation of any type of exudation (either intra- or subretinal fluid or hyperreflective subretinal material) was monitored. Results The prevalence of qCNV in the treatment-naive eyes was 15.9% with an incidence over a 12-month period of 2.8%. In total, 40.7% of the overall neovessels remained stable with no sign of exudation, while 59.3% presented some fluid during the follow-up. A statistically significant relationship was established for the following variables preceding the exudation: increase in central macular thickness (OR = 116; 95% CI [4.74; 50530] p = 0.038), increase in pigment epithelial detachment height (OR = 1.76; 95% CI [1.17; 3.18] p = 0.021) and width (OR = 1.53; 95% CI [1.12; 2.62] p = 0.042), increase in neovessels' surface on OCT-A (OR = 6.32; 95% CI [1.62; 51.0] p = 0.033), emergence of a branching pattern (OR = 7.50; 95% CI[1.37; 61.5] p = 0.032) and appearance of a hypointense halo surrounding the lesion (OR = 10.00; 95% CI [1.41; 206] p = 0.048). Conclusions The risk of exudation in the treatment-naive fellow eyes of eyes treated for neovascular AMD was notably increased in the presence of qCNV. The biomarkers identified will help to detect their activation in order to ensure prompt antiangiogenic therapy.
C1 [Solecki, Lauriana; Loganadane, Prisca; Gauthier, Anne-Sophie; Simonin, Manon; Delbosc, Bernard; Saleh, Maher] Besancon Univ Hosp, Dept Ophthalmol, Besancon, France.
   [Puyraveau, Marc] Besancon Univ Hosp, Ctr Clin Methodol, Besancon, France.
C3 CHU Besancon; CHU Besancon
RP Saleh, M (通讯作者)，Besancon Univ Hosp, Dept Ophthalmol, Besancon, France.
EM drmahersaleh@gmail.com
FU Francomtoise Association for Research in Ophthalmology (AFCRO, Besancon,
   France)
FX This work was funded by the Francomtoise Association for Research in
   Ophthalmology (AFCRO, Besancon, France). The authors declare their
   independence in reporting the data.
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   CHOPRA R, 2018, INVEST OPHTH VIS SCI, V59
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Nehemy MB, 2015, OSLI RETINA, V46, P1056, DOI 10.3928/23258160-20151027-13
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Roisman Luiz, 2017, Curr Ophthalmol Rep, V5, P136, DOI 10.1007/s40135-017-0131-6
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
NR 27
TC 4
Z9 4
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2021
VL 35
IS 2
BP 644
EP 650
DI 10.1038/s41433-020-0936-7
EA MAY 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PX7VQ
UT WOS:000532116400012
PM 32398845
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Elwes, F
   Borooah, S
   Aspinall, P
   Sim, PY
   Loo, CY
   Armbrecht, AM
   Dhillon, B
   Cackett, P
AF Elwes, Flora
   Borooah, Shyamanga
   Aspinall, Peter
   Sim, Peng Yong
   Loo, Cheng Yi
   Armbrecht, Ana-Maria
   Dhillon, Baljean
   Cackett, Peter
TI Clinical outcomes of switching to aflibercept using a pro re nata
   treatment regimen in patients with neovascular age-related macular
   degeneration who incompletely responded to ranibizumab
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Ranibizumab; Aflibercept; Anti-VEGF
ID INTRAVITREAL AFLIBERCEPT; DOSING REGIMEN; BEVACIZUMAB; EFFICACY
AB Background: To assess the effect of switching patients previously incompletely treated with ranibizumab (RBZ) to aflibercept (AFL) using a pro re nata (PRN) treatment strategy in neovascular age-related macular degeneration (nvAMD).
   Methods: A retrospective case series was conducted on patients who had persistent or recurrent intra-and/or sub-retinal fluid treated initially with RBZ and subsequently switched to AFL. The main outcome measures were best corrected visual acuity (BCVA) and central retinal thickness (CRT) measured at different stages of the study. Friedman analysis of variance and Wilcoxon test were used to examine differences in BCVA and CRT.
   Results: Two hundred and seven eyes from 182 patients were included. BCVA and CRT improved significantly initially following 3 RBZ injections with a mean gain of 3.7 letters (p < 0.001) and a mean loss of 69 mu m (p < 0.001) respectively. Following PRN RBZ therapy and immediately prior to switching to AFL (mean 129 weeks), there was a mean loss of 6.7 letters (p < 0.001) BCVA and a mean gain of 24 mu m (p < 0.001) CRT. AFL loading resulted in a mean improvement of 0.7 letters (p = 0.28) BCVA and 55 mu m (p < 0.001) CRT. At final follow-up following AFL PRN therapy (mean 85 weeks), there was a mean loss of 8.9 letters (p < 0.001) BCVA and a mean gain of 12 mu m (p < 0.05) CRT.
   Conclusion: AFL loading resulted in a significant anatomical improvement but no significant change in visual acuity. However, the benefits of switching were gradually lost over time with AFL PRN dosing despite an increased injection rate when compared with RBZ PRN treatment.
C1 [Elwes, Flora] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
   [Borooah, Shyamanga; Armbrecht, Ana-Maria; Dhillon, Baljean; Cackett, Peter] Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Aspinall, Peter] Heriot Watt Univ, Hlth & Environm Grp, Edinburgh, Midlothian, Scotland.
   [Borooah, Shyamanga; Aspinall, Peter; Sim, Peng Yong; Loo, Cheng Yi; Dhillon, Baljean; Cackett, Peter] Univ Edinburgh, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland.
C3 Royal Infirmary of Edinburgh; University of Edinburgh; Heriot Watt
   University; University of Edinburgh
RP Borooah, S (通讯作者)，Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.; Borooah, S (通讯作者)，Univ Edinburgh, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland.
EM shyamanga@aol.com
RI Borooah, Shyamanga/AAM-6581-2021
OI Sim, Peng Yong/0000-0001-5500-2634
FU Wellcome Trust STMTI scheme [R42141]
FX SB was supported by a Wellcome Trust STMTI scheme (grant number R42141)
   during the writing of this article. FE, PA, PS, CL, AA, BD and PC
   certify that no funding was received.
CR Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Davidson MH, 2006, AM J MANAG CARE, V12, pS405
   Doguizi S, 2015, INT J OPHTHALMOL-CHI, V8, P846, DOI 10.3980/j.issn.2222-3959.2015.04.37
   Eghoj MS, 2011, BR J OPHTHALMOL, V96
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Homer N, 2015, EYE, V29, P1152, DOI 10.1038/eye.2015.87
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin K, 2004, BRIT J CLIN PHARMACO, V57, P86, DOI 10.1046/j.1365-2125.2003.01953.x
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Slean Geraldine R, 2016, Int J Retina Vitreous, V2, P2, DOI 10.1186/s40942-016-0028-9
   Sophie R, 2012, BIOL THER, V2, P1
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Waizel M, 2016, EUR J OPHTHALMOL, V26, P469, DOI 10.5301/ejo.5000781
   Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
NR 30
TC 2
Z9 2
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 30
PY 2018
VL 18
AR 20
DI 10.1186/s12886-018-0688-3
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FU2IZ
UT WOS:000423674600002
PM 29378528
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kelkar, A
   Webers, C
   Shetty, R
   Kelkar, J
   Labhsetwar, N
   Pandit, A
   Malode, M
   Tidke, S
AF Kelkar, Aditya
   Webers, Caroll
   Shetty, Rohit
   Kelkar, Jai
   Labhsetwar, Nikhil
   Pandit, Abhishek
   Malode, Madhulika
   Tidke, Sayali
TI Factors affecting compliance to intravitreal anti-vascular endothelial
   growth factor therapy in Indian patients with retinal vein occlusion,
   age-related macular degeneration, and diabetic macular edema
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Follow-up; intravitreal injection; patient compliance
ID DISEASES; RANIBIZUMAB; MANAGEMENT
AB Purpose: To evaluate the rate of compliance and the reasons for loss to follow-up in Indian patients with diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) being treated with anti-vascular endothelial growth factor (VEGF) therapy. Methods: This was a retrospective single-center study. Patients with DME, AMD, or RVO were eligible if they initiated anti-VEGF therapy between January 2013 and December 2017. Patients' data were obtained from hospital electronic records, including the number of injections received, visits, details of follow-up, missed appointments, and reasons for loss to follow-up (>365 days). Results: A total of 648 patients were eligible for the study, of which 334 (51.54%) patients were lost to follow-up. Overall, 343 (64.96%) were males and the overall mean (SD) age was 66.40 (7.44) years. A total of 376 (58.0%) patients had a history of diabetes and 364 (56.2%) patients had a history of hypertension. Further, 127 (38.0), 112 (33.5), and 95 (28.4) had DME, AMD, and RVO, respectively and were lost to follow-up. The most commonly reported reason for loss to follow-up was "non-affordability" (n = 120; 41.1%) followed by "no improvement in vision" (n = 83; 28.4%). "No improvement in vision" (42.2%) and "non-affordability" (37.5%) were higher among patients with DME. No association was found in gender-and treatment-wise distribution of reasons for loss to follow-up. Conclusion: The results showed that around half of the patients with DME, AMD, and RVO were lost to follow-up to intravitreal anti-VEGF therapy, and the most common factors were "non-affordability" and "no improvement in vision."
C1 [Kelkar, Aditya; Kelkar, Jai; Labhsetwar, Nikhil; Pandit, Abhishek; Tidke, Sayali] Natl Inst Ophthalmol, Pune, Maharashtra, India.
   [Webers, Caroll] Maastricht Univ, Dept Ophthalmol, Med Ctr, Maastricht, Netherlands.
   [Shetty, Rohit] Narayana Nethralaya, Bengaluru, Karnataka, India.
   [Malode, Madhulika] Sqarona Med Commun LLP, Navi Mumbai, Maharashtra, India.
C3 Maastricht University
RP Kelkar, A (通讯作者)，Natl Inst Ophthalmol NIO, Ghole Rd,Near Mahatma Phule Museum,Shivajinagar, Pune 411005, Maharashtra, India.
EM adityapune4@gmail.com
OI Hattar, Mariana/0000-0003-1995-6793
CR Amoaku W, 2018, CLIN OPHTHALMOL, V12, P1731, DOI 10.2147/OPTH.S174560
   Boeid A, 2019, RETINAL PHYS, V16, P18
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Eichenbaum DA, 2018, OSLI RETINA, V49, pE191, DOI 10.3928/23258160-20181101-17
   Fiebai B, 2017, OPEN OPHTHALMOL J, V11, P315, DOI 10.2174/1874364101711010315
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Gao XX, 2019, OPHTHALMOL RETINA, V3, P230, DOI 10.1016/j.oret.2018.11.002
   Kwong TQ, 2014, BRIT J CLIN PHARMACO, V78, P699, DOI 10.1111/bcp.12371
   Pham B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022031
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Schwarzer P, 2019, OPHTHALMOLOGICA, V241, P220, DOI 10.1159/000495623
   Tah V, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/627674
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
NR 15
TC 11
Z9 11
U1 0
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD OCT
PY 2020
VL 68
IS 10
BP 2143
EP 2147
AR PMID 32971626
DI 10.4103/ijo.IJO_1866_19
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NZ5NI
UT WOS:000577150200021
PM 32971626
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Sugiyama, A
   Tanabe, N
   Kikushima, W
   Kume, A
   Iijima, H
AF Sakurada, Yoichi
   Sugiyama, Atsushi
   Tanabe, Naohiko
   Kikushima, Wataru
   Kume, Atsuki
   Iijima, Hiroyuki
TI CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH
   AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal thickness polypoidal choroidal vasculopathy; photodynamic
   therapy; aflibercept; ranibizumab
ID INTRAVITREAL RANIBIZUMAB; MACULAR DEGENERATION; FOLLOW-UP; BEVACIZUMAB;
   INJECTIONS; EFFICACY; VEGF
AB Purpose: To investigate factors associated with visual improvement and retreatment 12 months after a combination therapy of intravitreal injection of ranibizumab or aflibercept followed by photodynamic therapy for polypoidal choroidal vasculopathy.
   Methods: Changes in the best-corrected visual acuity and the subfoveal thickness of the retina and choroid were studied in 56 consecutive eyes with polypoidal choroidal vasculopathy treated initially with a combination therapy of either intravitreal ranibizumab injection (n = 23) or intravitreal aflibercept injection (n = 33) followed by photodynamic therapy. Factors associated with visual improvement and retreatment were investigated.
   Results: Best-corrected visual acuity significantly improved with significant reduction in central macular thickness and subfoveal choroidal thickness at all points irrespective of treatment modalities (P < 0.001). Better best-corrected visual acuity and improvement of best-corrected visual acuity at 12 months were associated with baseline greater subfoveal choroidal thickness (P = 0.028 and P = 0.028) and baseline smaller greatest linear dimension (P = 0.0077 and P = 0.0077). Retreatment during 12-month follow-up was associated with baseline lesser subfoveal choroidal thickness (P = 0.036).
   Conclusion: Irrespective of treatment modalities, the visual outcome at 12 months is favorable in eyes with polypoidal choroidal vasculopathy treated by photodynamic therapy combined with intravitreal ranibizumab or aflibercept. Baseline greater subfoveal choroidal thickness was associated with a better visual outcome and with reduction in the need for retreatment.
C1 [Sakurada, Yoichi; Sugiyama, Atsushi; Tanabe, Naohiko; Kikushima, Wataru; Kume, Atsuki; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Yamanashi, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Mukai R, 2010, OPHTHALMOLOGICA, V224, P267, DOI 10.1159/000287348
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 27
TC 16
Z9 18
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2017
VL 37
IS 10
BP 1866
EP 1872
DI 10.1097/IAE.0000000000001427
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI1GH
UT WOS:000411680300018
PM 28002268
DA 2022-11-30
ER

PT J
AU Faes, L
   Bodmer, NS
   Bachmann, LM
   Thiel, MA
   Schmid, MK
AF Faes, L.
   Bodmer, N. S.
   Bachmann, L. M.
   Thiel, M. A.
   Schmid, M. K.
TI Diagnostic accuracy of the Amsler grid and the preferential hyperacuity
   perimetry in the screening of patients with age-related macular
   degeneration: systematic review and meta-analysis
SO EYE
LA English
DT Review
ID SHAPE-DISCRIMINATION; MONITORING-SYSTEM; VISUAL OUTCOMES; M-CHARTS;
   RANIBIZUMAB; METAMORPHOPSIA; BEVACIZUMAB; TOOL; PHP; TRIAL
AB Objective To clarify the screening potential of the Amsler grid and preferential hyperacuity perimetry (PHP) in detecting or ruling out wet age-related macular degeneration (AMD).
   Evidence acquisition Medline, Scopus and Web of Science (by citation of reference) were searched. Checking of reference lists of review articles and of included articles complemented electronic searches. Papers were selected, assessed, and extracted in duplicate.
   Evidence synthesis Systematic review and meta-analysis. Twelve included studies enrolled 903 patients and allowed constructing 27 two-by-two tables. Twelve tables reported on the Amsler grid and its modifications, twelve tables reported on the PHP, one table assessed the MCPT and two tables assessed the M-charts. All but two studies had a case-control design. The pooled sensitivity of studies assessing the Amsler grid was 0.78 (95% confidence intervals; 0.64-0.87), and the pooled specificity was 0.97 (95% confidence intervals; 0.91-0.99). The corresponding positive and negative likelihood ratios were 23.1 (95% confidence intervals; 8.4-64.0) and 0.23 (95% confidence intervals; 0.14-0.39), respectively. The pooled sensitivity of studies assessing the PHP was 0.85 (95% confidence intervals; 0.80-0.89), and specificity was 0.87 (95% confidence intervals; 0.82-0.91). The corresponding positive and negative likelihood ratios were 6.7 (95% confidence intervals; 4.6-9.8) and 0.17 (95% confidence intervals; 0.13-0.23). No pooling was possible for MCPT and M-charts.
   Conclusion Results from small preliminary studies show promising test performance characteristics both for the Amsler grid and PHP to rule out wet AMD in the screening setting. To what extent these findings can be transferred to a real clinic practice still needs to be established.
C1 [Faes, L.; Bodmer, N. S.; Bachmann, L. M.] Medignition Inc, Res Consultants, Zug, Switzerland.
   [Thiel, M. A.; Schmid, M. K.] Cantonal Hosp Lucerne, Eye Clin, CH-6000 Luzern, Switzerland.
C3 Lucerne Cantonal Hospital
RP Schmid, MK (通讯作者)，Cantonal Hosp Lucerne, Eye Clin, Spitalstr,Luzern 16, CH-6000 Luzern, Switzerland.
EM info@medignition.ch
OI , Lucas/0000-0002-9868-154X
CR Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   AMSLER M, 1947, OPHTHALMOLOGICA, V114, P248, DOI 10.1159/000300476
   Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535
   Bachmann LM, 2005, INT J EPIDEMIOL, V34, P953, DOI 10.1093/ije/dyi105
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chhetri AP, 2010, P 1 ACM INT HLTH INF, P502, DOI DOI 10.1145/1882992.1883072
   Chou R, 2009, ANN INTERN MED, V1511, pW11
   Chou R, 2009, ANN INTERN MED, V151, P44, DOI 10.7326/0003-4819-151-1-200907070-00008
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Harbord RM, 2008, J CLIN EPIDEMIOL, V61, P1095, DOI 10.1016/j.jclinepi.2007.09.013
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Kampmeier J, 2006, KLIN MONATSBL AUGENH, V223, P752, DOI 10.1055/s-2006-926880
   Klatt C, 2006, OPHTHALMOLOGE, V103, P945, DOI 10.1007/s00347-006-1381-0
   Lai YH, 2011, RETINA-J RET VIT DIS, V31, P1620, DOI 10.1097/IAE.0b013e31820d3ed1
   Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew R, 2012, EYE, V26, P389, DOI 10.1038/eye.2011.326
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Nowomiejska K, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-13
   Robison CD, 2011, BRIT J OPHTHALMOL, V95, P1419, DOI 10.1136/bjo.2010.194886
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zwinderman AH, 2008, STAT MED, V27, P687, DOI 10.1002/sim.2992
NR 33
TC 49
Z9 49
U1 0
U2 23
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2014
VL 28
IS 7
BP 788
EP 796
DI 10.1038/eye.2014.104
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL5LT
UT WOS:000339175900004
PM 24788016
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Yuzawa, M
   Mori, R
   Kawamura, A
AF Yuzawa, M
   Mori, R
   Kawamura, A
TI The origins of polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; CLINICOPATHOLOGICAL CORRELATION; MACULAR
   DEGENERATION; IPCV
AB Background/aim: There are two theories on the pathogenesis of polypoidal choroidal vasculopathy (PCV): variants in choroidal neovascularisation (CNV) and inner choroidal vessel abnormalities. On indocyanine green angiography (IGA) with a video camera system, PCV has a characteristic appearance, but inadequate image quality has made detailed interpretation difficult. This study aims to improve imaging, using confocal scanning laser ophthalmoscopy (SLO), to elucidate the pathogenesis of PCV.
   Methods: High speed IGA with confocal SLO of 45 eyes (44 patients) showed typical PCV findings of a branching vascular network and polypoidal lesions.
   Results: Vessels comprising branching networks began to fill simultaneously with the surrounding choroidal arteries in 38 eyes. Small numbers of vessels filling within a branching network, in the arterial and arteriovenous phases of IGA, showed focal dilatation, constriction, and tortuousity. Vessel abnormalities, corresponding to polypoidal lesions, existed within a network in eight eyes and included loops similar in calibre to network vessels, and numerous microaneurysmal dilatations of small vessels. Vessel pulsation was seen in 24 eyes.
   Conclusion: PCV is caused by inner choroidal vessel abnormalities, not CNV.
C1 Nihon Univ, Surugadai Hosp, Chiyoda Ku, Tokyo, Japan.
C3 Nihon University
RP Yuzawa, M (通讯作者)，Nihon Univ, Surugadai Hosp, Chiyoda Ku, 1-8-13 Surugadai, Tokyo, Japan.
EM yuzawam@med.nihon-u.ac.jp
CR BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Shiraki K, 2001, JPN J OPHTHALMOL, V45, P368, DOI 10.1016/S0021-5155(01)00362-8
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   WOON WH, 1992, BRIT J OPHTHALMOL, V76, P470, DOI 10.1136/bjo.76.8.470
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 25
TC 147
Z9 163
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2005
VL 89
IS 5
BP 602
EP 607
DI 10.1136/bjo.2004.049296
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 917GN
UT WOS:000228444600023
PM 15834093
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Colijn, JM
   den Hollander, AI
   Demirkan, A
   Cougnard-Gregoire, A
   Verzijden, T
   Kersten, E
   Meester-Smoor, MA
   Merle, BMJ
   Papageorgiou, G
   Ahmad, S
   Mulder, MT
   Costa, MA
   Benlian, P
   Bertelsen, G
   Bron, AM
   Claes, B
   Creuzot-Garcher, C
   Erke, MG
   Fauser, S
   Foster, PJ
   Hammond, CJ
   Hense, HW
   Hoyng, CB
   Khawaja, AP
   Korobelnik, JF
   Piermarocchi, S
   Segato, T
   Silva, R
   Souied, EH
   Williams, KM
   van Duijn, CM
   Delcourt, C
   Klaver, CCW
   Acar, N
   Altay, L
   Anastosopoulos, E
   Azuara-Blanco, A
   Berendschot, T
   Bergen, A
   Binquet, C
   Bird, A
   Bobak, M
   Larsen, MB
   Boon, C
   Bourne, R
   Bretillon, L
   Broe, R
   Bron, A
   Buitendijk, G
   Cachulo, ML
   Capuano, V
   Carriere, I
   Chakravarthy, U
   Chan, M
   Chang, P
   Colijn, J
   Cree, A
   Cumberland, P
   Cunha-Vaz, J
   Daien, V
   De Jong, E
   Deak, G
   Delyfer, MN
   den Hollander, A
   Dietzel, M
   Faria, P
   Farinha, C
   Finger, R
   Fletcher, A
   Foster, P
   Founti, P
   Gorgels, T
   Grauslund, J
   Grus, F
   Hammond, C
   Heesterbeek, T
   Hermann, M
   Hoehn, R
   Hogg, R
   Holz, F
   Hoyng, C
   Jansonius, N
   Janssen, S
   de Jong, E
   Khawaja, A
   Klaver, C
   Lamparter, J
   Le Goff, M
   Lehtimaki, T
   Leung, I
   Lotery, A
   Mauschitz, M
   Meester, M
   Merle, B
   Westrup, VMZ
   Midena, E
   Miotto, S
   Mirshahi, A
   Mohan-Said, S
   Mueller, M
   Muldrew, A
   Murta, J
   Nickels, S
   Nunes, S
   Owen, C
   Peto, T
   Pfeiffer, N
   Prokofyeva, E
   Rahi, J
   Raitakari, O
   Rauscher, F
   Ribeiro, L
   Rougier, MB
   Rudnicka, A
   Sahel, J
   Salonikiou, A
   Sanchez, C
   Schick, T
   Schmitz-Valckenberg, S
   Schuster, A
   Schweitzer, C
   Shehata, J
   Silvestri, G
   Simader, C
   Souied, E
   Speckauskas, M
   Springelkamp, H
   Tapp, R
   Topouzis, F
   van Leeuwen, E
   Verhoeven, V
   Vingerling, H
   Von Hanno, T
   Williams, K
   Wolfram, C
   Yip, J
   Zerbib, J
   Ajana, S
   Arango-Gonzalez, B
   Arndt, V
   Bhatia, V
   Bhattacharya, SS
   Biarnes, M
   Borrell, A
   Buhren, S
   Calado, SM
   Dammeier, S
   de Jong, EK
   De la Cerda, B
   Diaz-Corrales, FJ
   Diether, S
   Emri, E
   Endermann, T
   Ferraro, LL
   Garcia, M
   Heesterbeek, TJ
   Honisch, S
   Kilger, E
   Langen, H
   Lengyel, I
   Luthert, P
   Maugeais, C
   Meester-Smoor, M
   Inserm, BMJM
   Mones, J
   Nogoceke, E
   Pool, FM
   Rodriguez, E
   Ueffing, M
   Bartz-Schmidt, KUU
   van Leeuwen, EM
   Zumbansen, M
AF Colijn, Johanna M.
   den Hollander, Anneke, I
   Demirkan, Ayse
   Cougnard-Gregoire, Audrey
   Verzijden, Timo
   Kersten, Eveline
   Meester-Smoor, Magda A.
   Merle, Benedicte M. J.
   Papageorgiou, Grigorios
   Ahmad, Shahzad
   Mulder, Monique T.
   Costa, Miguel Angelo
   Benlian, Pascale
   Bertelsen, Geir
   Bron, Alain M.
   Claes, Birte
   Creuzot-Garcher, Catherine
   Erke, Maja Gran
   Fauser, Sascha
   Foster, Paul J.
   Hammond, Christopher J.
   Hense, Hans-Werner
   Hoyng, Carel B.
   Khawaja, Anthony P.
   Korobelnik, Jean-Francois
   Piermarocchi, Stefano
   Segato, Tatiana
   Silva, Rufino
   Souied, Eric H.
   Williams, Katie M.
   van Duijn, Cornelia M.
   Delcourt, Cecile
   Klaver, Caroline C. W.
   Acar, Niyazi
   Altay, Lebriz
   Anastosopoulos, Eleftherios
   Azuara-Blanco, Augusto
   Berendschot, Tos
   Bergen, Arthur
   Binquet, Christine
   Bird, Alan
   Bobak, Martin
   Larsen, Morten Bogelund
   Boon, Camiel
   Bourne, Rupert
   Bretillon, Lionel
   Broe, Rebecca
   Bron, Alain
   Buitendijk, Gabrielle
   Cachulo, Maria Luz
   Capuano, Vittorio
   Carriere, Isabelle
   Chakravarthy, Usha
   Chan, Michelle
   Chang, Petrus
   Colijn, Johanna
   Cree, Angela
   Cumberland, Phillippa
   Cunha-Vaz, Jose
   Daien, Vincent
   De Jong, Eiko
   Deak, Gabor
   Delyfer, Marie-Noelle
   den Hollander, Anneke
   Dietzel, Martha
   Faria, Pedro
   Farinha, Claudia
   Finger, Robert
   Fletcher, Astrid
   Foster, Paul
   Founti, Panayiota
   Gorgels, Theo
   Grauslund, Jakob
   Grus, Franz
   Hammond, Christopher
   Heesterbeek, Thomas
   Hermann, Manuel
   Hoehn, Rene
   Hogg, Ruth
   Holz, Frank
   Hoyng, Carel
   Jansonius, Nomdo
   Janssen, Sarah
   de Jonga, Eiko
   Khawaja, Anthony
   Klaver, Caroline
   Lamparter, Julia
   Le Goff, Melanie
   Lehtimaki, Terho
   Leung, Irene
   Lotery, Andrew
   Mauschitz, Matthias
   Meester, Magda
   Merle, Benedicte
   Westrup, Verena Meyer Zu
   Midena, Edoardo
   Miotto, Stefania
   Mirshahi, Alireza
   Mohan-Said, Sadek
   Mueller, Michael
   Muldrew, Alyson
   Murta, Joaquim
   Nickels, Stefan
   Nunes, Sandrina
   Owen, Christopher
   Peto, Tunde
   Pfeiffer, Norbert
   Prokofyeva, Elena
   Rahi, Jugnoo
   Raitakari, Olli
   Rauscher, Franziska
   Ribeiro, Luisa
   Rougier, Marie-Benedicte
   Rudnicka, Alicja
   Sahel, Jose
   Salonikiou, Aggeliki
   Sanchez, Clarisa
   Schick, Tina
   Schmitz-Valckenberg, Steffen
   Schuster, Alexander
   Schweitzer, Cedric
   Shehata, Jasmin
   Silvestri, Giuliana
   Simader, Christian
   Souied, Eric
   Speckauskas, Martynas
   Springelkamp, Henriet
   Tapp, Robyn
   Topouzis, Fotis
   van Leeuwen, Elisa
   Verhoeven, Virginie
   Vingerling, Hans
   Von Hanno, Therese
   Williams, Katie
   Wolfram, Christian
   Yip, Jennifer
   Zerbib, Jennyfer
   Ajana, Soufiane
   Arango-Gonzalez, Blanca
   Arndt, Verena
   Bhatia, Vaibhav
   Bhattacharya, Shomi S.
   Biarnes, Marc
   Borrell, Anna
   Buehren, Sebastian
   Calado, Sofia M.
   Dammeier, Sascha
   de Jong, Eiko K.
   De la Cerda, Berta
   Diaz-Corrales, Francisco J.
   Diether, Sigrid
   Emri, Eszter
   Endermann, Tanja
   Ferraro, Lucia L.
   Garcia, Miriam
   Heesterbeek, Thomas J.
   Honisch, Sabina
   Kilger, Ellen
   Langen, Hanno
   Lengyel, Imre
   Luthert, Phil
   Maugeais, Cyrille
   Meester-Smoor, Magda
   Inserm, Benedicte M. J. Merle
   Mones, Jordi
   Nogoceke, Everson
   Pool, Frances M.
   Rodriguez, Eduardo
   Ueffing, Marius
   Bartz-Schmidt, Karl U. Ulrich
   van Leeuwen, Elisabeth M.
   Zumbansen, Markus
CA European Eye Epidemiology Consorti
   EYE-RISK Consortium
TI Increased High-Density Lipoprotein Levels Associated with Age-Related
   Macular Degeneration Evidence from the EYE-RISK and European Eye
   Epidemiology Consortia
SO OPHTHALMOLOGY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HEPATIC LIPASE; STATIN USE; CHOLESTEROL;
   PLASMA; MACULOPATHY; DRUSEN; PROGRESSION; ACTIVATION; PROTEINS
AB Purpose: Genetic and epidemiologic studies have shown that lipid genes and high-density lipoproteins (HDLs) are implicated in age-related macular degeneration (AMD). We studied circulating lipid levels in relationship to AMD in a large European dataset.
   Design: Pooled analysis of cross-sectional data.
   Participants: Individuals (N = 30 953) aged 50 years or older participating in the European Eye Epidemiology (E3) consortium and 1530 individuals from the Rotterdam Study with lipid subfraction data.
   Methods: AMD features were graded on fundus photographs using the Rotterdam classification. Routine blood lipid measurements, genetics, medication, and potential confounders were extracted from the E3 database. In a subgroup of the Rotterdam Study, lipid subfractions were identified by the Nightingale biomarker platform. Random-intercepts mixed-effects models incorporating confounders and study site as a random effect were used to estimate associations.
   Main Outcome Measures: AMD features and stage; lipid measurements.
   Results: HDL was associated with an increased risk of AMD (odds ratio [OR], 1.21 per 1-mmol/l increase; 95% confidence interval [CI], 1.14-1.29), whereas triglycerides were associated with a decreased risk (OR, 0.94 per 1-mmol/l increase; 95% CI, 0.91-0.97). Both were associated with drusen size. Higher HDL raised the odds of larger drusen, whereas higher triglycerides decreases the odds. LDL cholesterol reached statistical significance only in the association with early AMD (P = 0.045). Regarding lipid subfractions, the concentration of extra-large HDL particles showed the most prominent association with AMD (OR, 1.24; 95% CI, 1.10-1.40). The cholesteryl ester transfer protein risk variant (rs17231506) for AMD was in line with increased HDL levels (P = 7.7 x 10(-7)), but lipase C risk variants (rs2043085, rs2070895) were associated in an opposite way (P = 1.0 x 10(-6) and P = 1.6 x 10(-4)).
   Conclusions: Our study suggested that HDL cholesterol is associated with increased risk of AMD and that triglycerides are negatively associated. Both show the strongest association with early AMD and drusen. Extra-large HDL subfractions seem to be drivers in the relationship with AMD, and variants in lipid genes play a more ambiguous role in this association. Whether systemic lipids directly influence AMD or represent lipid metabolism in the retina remains to be answered. (C) 2018 by the American Academy of Ophthalmology
C1 [Colijn, Johanna M.; Verzijden, Timo; Meester-Smoor, Magda A.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Colijn, Johanna M.; Demirkan, Ayse; Verzijden, Timo; Meester-Smoor, Magda A.; Ahmad, Shahzad; van Duijn, Cornelia M.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [den Hollander, Anneke, I; Kersten, Eveline; Hoyng, Carel B.; Klaver, Caroline C. W.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Cougnard-Gregoire, Audrey; Merle, Benedicte M. J.; Korobelnik, Jean-Francois; Delcourt, Cecile] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, UMR 1219, Bordeaux, France.
   [Papageorgiou, Grigorios] Erasmus MC, Dept Biostat, Rotterdam, Netherlands.
   [Mulder, Monique T.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Costa, Miguel Angelo; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Benlian, Pascale] Univ Lille, UMR 8199 EGID, CHU Lille, Lille, France.
   [Bertelsen, Geir] Arctic Univ Norway, Dept Community Med, UiT, Tromso, Norway.
   [Bertelsen, Geir] Univ Hosp North Norway, Dept Ophthalmol, Tromso, Norway.
   [Bron, Alain M.; Creuzot-Garcher, Catherine] Univ Hosp, Dept Ophthalmol, Eye & Nutr Res Grp, Dijon, France.
   [Claes, Birte; Hense, Hans-Werner] Univ Munster, Inst Epidemiol & Social Med, Munster, Germany.
   [Erke, Maja Gran] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Fauser, Sascha] Hoffmann La Roche AG, Basel, Switzerland.
   [Foster, Paul J.; Khawaja, Anthony P.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Foster, Paul J.; Khawaja, Anthony P.; Chan, Michelle; Foster, Paul; Rahi, Jugnoo; Yip, Jennifer] UCL Inst Ophthalmol, London, England.
   [Foster, Paul J.] UCL Inst Ophthalmol, Integrat Epidemiol, London, England.
   [Hammond, Christopher J.; Williams, Katie M.] Kings Coll London, St Thomas Hosp, Sch Life Course Sci, Sect Acad Ophthalmol, London, England.
   [Hammond, Christopher J.; Williams, Katie M.] Kings Coll London, St Thomas Hosp, Dept Twin Res & Genet Epidemiol, London, England.
   [Khawaja, Anthony P.] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Sch Clin Med, Cambridge, England.
   [Korobelnik, Jean-Francois] Ctr Hosp Univ Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Piermarocchi, Stefano; Segato, Tatiana] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Silva, Rufino] Ctr Hospitalar & Univ Coimbra Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res, Coimbra, Portugal.
   [Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Papageorgiou, Grigorios] Erasmus MC, Dept Cardiothorac Surg, Rotterdam, Netherlands.
   [Acar, Niyazi; Bretillon, Lionel] Inra Univ Burgundy, Dijon, France.
   [Fauser, Sascha; Altay, Lebriz; Hermann, Manuel] Univ Eye Hosp, Cologne, Germany.
   [Anastosopoulos, Eleftherios; Founti, Panayiota; Salonikiou, Aggeliki; Topouzis, Fotis] Univ Thessaloniki, Thessaloniki, Greece.
   [Azuara-Blanco, Augusto; Chakravarthy, Usha; Chang, Petrus; Hogg, Ruth; Muldrew, Alyson; Peto, Tunde; Silvestri, Giuliana] Queens Univ, Belfast, Antrim, North Ireland.
   [Berendschot, Tos; Dammeier, Sascha] Univ Eye Clin Maastricht, Maastricht, Netherlands.
   [Berendschot, Tos; Larsen, Morten Bogelund] Univ Maastricht, Maastricht, Netherlands.
   [Bergen, Arthur; Janssen, Sarah] Netherlands Inst Neurosci KNAW, Amsterdam, Netherlands.
   [Bertelsen, Geir; Erke, Maja Gran; Von Hanno, Therese; Ferraro, Lucia L.] Univ Tromso, Tromso, Norway.
   [Creuzot-Garcher, Catherine; Binquet, Christine; Bron, Alain] Univ Hosp Dijon, Dijon, France.
   [Bird, Alan; Hammond, Christopher; Leung, Irene] Moorfields Eye Hosp, London, England.
   [Bobak, Martin; Speckauskas, Martynas] Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
   [Larsen, Morten Bogelund; Broe, Rebecca; Grauslund, Jakob] Univ Southern Denmark, Odense, Denmark.
   [Larsen, Morten Bogelund; Chang, Petrus] Odense Univ Hosp, Odense, Denmark.
   [Boon, Camiel] Leiden Univ, Med Ctr, Leiden, Netherlands.
   [Bourne, Rupert; Meester, Magda] Univ Ruskin, Cambridge, England.
   [Verzijden, Timo; Buitendijk, Gabrielle; Colijn, Johanna; Jansonius, Nomdo; Klaver, Caroline; Meester, Magda; Springelkamp, Henriet; Verhoeven, Virginie; Vingerling, Hans] Erasmus MC, Rotterdam, Netherlands.
   [Silva, Rufino; Cachulo, Maria Luz; Faria, Pedro; Farinha, Claudia; Murta, Joaquim; Nunes, Sandrina; Ribeiro, Luisa] AIBILI CHUC, Coimbra, Portugal.
   [Capuano, Vittorio; Souied, Eric; Zerbib, Jennyfer] Univ Hosp Creteil, Creteil, France.
   [Carriere, Isabelle; Daien, Vincent; Mauschitz, Matthias] INSERM, U1061, Montpellier, France.
   [Chang, Petrus; Finger, Robert; Holz, Frank; Mauschitz, Matthias; Schmitz-Valckenberg, Steffen] Univ Bonn, Bonn, Germany.
   [Colijn, Johanna; van Leeuwen, Elisa] Erasmus MC, Netherlands, Rotterdam, Netherlands.
   [Cougnard-Gregoire, Audrey] Bordeaux Populat Hlth Res Ctr UMR1219, UMR121, Bordeaux, France.
   [Cree, Angela; Lotery, Andrew] Univ Southampton, Southampton, Hants, England.
   [Cumberland, Phillippa] UCL Inst Child Hlth, London, England.
   [Cunha-Vaz, Jose] CHUC, AIBILI, Coimbra, Portugal.
   [De Jong, Eiko; den Hollander, Anneke; Heesterbeek, Thomas; Hoyng, Carel; de Jonga, Eiko; Khawaja, Anthony; Sanchez, Clarisa] Radboud Univ Nijmegen, Nijmegen, Netherlands.
   [Deak, Gabor; Shehata, Jasmin; Simader, Christian] Med Univ Vienna, Vienna, Austria.
   [Korobelnik, Jean-Francois; Delcourt, Cecile; Delyfer, Marie-Noelle; Le Goff, Melanie] Bordeaux Populat Hlth Res Ctr, UMR1219, Bordeaux, France.
   [Hense, Hans-Werner; Dietzel, Martha; Westrup, Verena Meyer Zu] Univ Munster, Munster, Germany.
   [Fletcher, Astrid] London Sch Hyg & Trop Med, London, England.
   [Gorgels, Theo] Netherlands Inst Neurosci, KNAW, Amsterdam, Netherlands.
   [Grus, Franz; Lamparter, Julia] Univ Med Ctr Mainz, Mainz, Germany.
   [Hoehn, Rene; Nickels, Stefan; Pfeiffer, Norbert; Schuster, Alexander; Wolfram, Christian] Univ Med Ctr, Mainz, Germany.
   [Khawaja, Anthony] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, UCL Inst Opht, London, England.
   [Lehtimaki, Terho] Univ Tampere, Fimlab Labs, Tampere, Finland.
   [Merle, Benedicte; Schweitzer, Cedric] Bordeaux Populat Hlth Res Ctr UMR1219, Bordeaux, France.
   [Piermarocchi, Stefano; Segato, Tatiana; Midena, Edoardo; Miotto, Stefania] Univ Padua, Padua, Italy.
   [Mirshahi, Alireza] Dardenne Eye Hosp, Bonn, Germany.
   [Mohan-Said, Sadek; Sahel, Jose] Inst Vis, Paris, France.
   [Mueller, Michael; Tapp, Robyn] Pirkanmaa Hosp Dist, Tampere, Finland.
   [Owen, Christopher; Rudnicka, Alicja] Univ London, London, England.
   [Prokofyeva, Elena] Sci Inst Publ Hlth WIV ISP, Brussels, Belgium.
   [Raitakari, Olli] Univ Turku, Turku Univ Hosp, Turku, Finland.
   [Rauscher, Franziska] Leipzig Univ Hosp, Leipzig, Germany.
   [Rougier, Marie-Benedicte] Bordeaux Populat Hlth Res Ctr, Bordeaux, France.
   [Schick, Tina] Univ Hosp Cologne, Cologne, Germany.
   [Williams, Katie] Kings Coll London, London, England.
   [Cougnard-Gregoire, Audrey; Kersten, Eveline; Arango-Gonzalez, Blanca; Diaz-Corrales, Francisco J.; Heesterbeek, Thomas J.; Rodriguez, Eduardo; Ueffing, Marius] Eberhard Karls Univ Tuebingen, Univ Clin Tuebingen, Ctr Ophthalmol, Inst Ophthalm Res, Tubingen, Germany.
   [Arango-Gonzalez, Blanca; Emri, Eszter] AYOXXA Biosyst GmbH, Assay Dev, Cologne, Germany.
   [den Hollander, Anneke, I; Arndt, Verena; Bhatia, Vaibhav; Buehren, Sebastian; de Jong, Eiko K.] Andalusian Mol Biol & Regenerat Med Ctr CABIMER, Dept Regenerat & Cell Therapy, Seville, Spain.
   [Bhattacharya, Shomi S.; Biarnes, Marc; Endermann, Tanja; Inserm, Benedicte M. J. Merle; Pool, Frances M.] Barcelona Macula Fdn, Barcelona, Spain.
   [Borrell, Anna] AYOXXA Biosyst GmbH, Business Dev, Cologne, Germany.
   [Calado, Sofia M.; Bartz-Schmidt, Karl U. Ulrich; van Leeuwen, Elisabeth M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Calado, Sofia M.; Maugeais, Cyrille; van Leeuwen, Elisabeth M.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Colijn, Johanna M.; Ajana, Soufiane; De la Cerda, Berta; Meester-Smoor, Magda] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, Bordeaux, France.
   [Hoyng, Carel B.; Delcourt, Cecile; Garcia, Miriam; Honisch, Sabina] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Delcourt, Cecile] Radboud Univ Nijmegen Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
   [Diether, Sigrid; Langen, Hanno] Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Kilger, Ellen] Radboud Univ Nijmegen Med Ctr, Erasmus Med Ctr, Dept Epidemiol, Nijmegen, Netherlands.
   [Kilger, Ellen] Erasmus MC, Dept Ophthalmol, Nijmegen, Netherlands.
   [Kilger, Ellen] Dept Ophthalmol, Nijmegen, Netherlands.
   [Klaver, Caroline C. W.; Luthert, Phil; Mones, Jordi] Roche Innovat Ctr Basel, Hoffmann Roche Ltd, Basel, Switzerland.
   [Lengyel, Imre] UCL, Inst Ophthalmol, London, England.
   [Maugeais, Cyrille] Dept Epidemiol Erasmus Med Ctr, Rotterdam, Netherlands.
   [Nogoceke, Everson] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Peto, Tunde] UCL Inst Ophthalmol, Ocular Biol, London, England.
   [Ueffing, Marius] Univ Med Ctr Tubingen, Dept Ophthalmol, Tubingen, Germany.
   [Bartz-Schmidt, Karl U. Ulrich] Erasmus MC, Dept & Ophthalmol, Rotterdam, Netherlands.
   [Verzijden, Timo; Zumbansen, Markus] AYOXXA Biosyst GmbH, Res & Dev, Cologne, Germany.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Radboud University Nijmegen; Institut National de la Sante
   et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite de Bordeaux; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Universidade de
   Coimbra; Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Universite de Lille - ISITE; CHU
   Lille; Universite de Lille; UiT The Arctic University of Tromso; UiT The
   Arctic University of Tromso; University Hospital of North Norway; CHU
   Dijon Bourgogne; Institut Agro; AgroSup Dijon; Universite de Bourgogne;
   University of Munster; University of Oslo; University of Cologne; Roche
   Holding; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of London; University College
   London; University of London; University College London; Guy's & St
   Thomas' NHS Foundation Trust; University of London; King's College
   London; Guy's & St Thomas' NHS Foundation Trust; University of London;
   King's College London; University of Cambridge; CHU Bordeaux; University
   of Padua; Universidade de Coimbra; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Erasmus University
   Rotterdam; Erasmus MC; INRAE; Universite de Bourgogne; University of
   Cologne; Aristotle University of Thessaloniki; Queens University
   Belfast; Maastricht University; Maastricht University Medical Centre
   (MUMC); Maastricht University; Royal Netherlands Academy of Arts &
   Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); UiT The
   Arctic University of Tromso; CHU Dijon Bourgogne; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Lithuanian University of Health Sciences; University of Southern
   Denmark; University of Southern Denmark; Odense University Hospital;
   Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC;
   Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Montpellier; University of
   Bonn; Erasmus University Rotterdam; Erasmus MC; University of
   Southampton; University of London; University College London;
   Universidade de Coimbra; Radboud University Nijmegen; Medical University
   of Vienna; University of Munster; University of London; London School of
   Hygiene & Tropical Medicine; Royal Netherlands Academy of Arts &
   Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Johannes
   Gutenberg University of Mainz; Johannes Gutenberg University of Mainz;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Tampere University; University of Padua;
   UDICE-French Research Universities; Sorbonne Universite; Pirkanmaa
   Hospital District; University of London; University of Turku; Leipzig
   University; University of Cologne; University of London; King's College
   London; Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Consejo Superior de Investigaciones Cientificas (CSIC);
   Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro
   Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; Radboud
   University Nijmegen; Radboud University Nijmegen; Queens University
   Belfast; Erasmus University Rotterdam; Erasmus MC; Radboud University
   Nijmegen; Erasmus University Rotterdam; Erasmus MC; Roche Holding;
   University of London; University College London; Queens University
   Belfast; University of London; University College London; Eberhard Karls
   University of Tubingen; Eberhard Karls University Hospital; Erasmus
   University Rotterdam; Erasmus MC
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI DAIEN, Vincent/Z-5516-2019; Midena, Edoardo/AAB-6010-2020; Silva, Rufino
   M/J-2817-2012; Kersten, Eveline/P-8173-2015; Pfeiffer,
   Norbert/AAO-7586-2020; Hogg, Ruth E./ABC-9602-2020; Grauslund,
   Jakob/J-1031-2014; Ahmad, Shahzad/AAY-7240-2020; Binquet,
   Christine/E-8953-2018; Delyfer, Marie-Noelle/T-3304-2019; Emri,
   Eszter/ABE-9363-2020; Calado, Sofia M./K-2202-2016; Rauscher,
   Franziska/AAV-8222-2021; Merle, Benedicte MJ/F-1247-2015; Delcourt,
   Cecile/I-2627-2013; Lehtimäki, Terho/AAD-1094-2022; Lengyel,
   Imre/B-5217-2009; mones, jordi/CAJ-2963-2022; Bron, Alain/AAP-8010-2020;
   SCHWEITZER, CEDRIC/AAY-2787-2020; COUGNARD-GREGOIRE, Audrey/T-4443-2019;
   Foster, Paul/V-7288-2019; Bertelsen, Geir/ABB-9865-2021;
   Arango-Gonzalez, Blanca/AAR-7427-2021; Merle, Benedicte
   MJ/AAQ-5021-2021; De la cerda, Berta/L-7039-2014; Berendschot, Tos
   TJM/M-8509-2016; Ajana, Soufiane/AAH-5181-2021; KOROBELNIK,
   Jean-Francois/A-5448-2016; Carrière, Isabelle/W-8728-2019; Raitakari,
   Olli/AAQ-7389-2021; Farinha, Claudia/R-1392-2017; Murta,
   Joaquim/V-5494-2017; Boon, CJF/P-7534-2014; Diaz-Corrales, Francisco
   J./L-7559-2014
OI DAIEN, Vincent/0000-0001-5675-0861; Silva, Rufino M/0000-0001-8676-0833;
   Hogg, Ruth E./0000-0001-9413-2669; Grauslund, Jakob/0000-0001-5019-0736;
   Binquet, Christine/0000-0002-9417-5754; Calado, Sofia
   M./0000-0001-5509-4145; Rauscher, Franziska/0000-0003-0183-0340; Merle,
   Benedicte MJ/0000-0003-1332-0954; Delcourt, Cecile/0000-0002-2099-0481;
   Lehtimäki, Terho/0000-0002-2555-4427; Lengyel, Imre/0000-0001-7467-2174;
   mones, jordi/0000-0003-3685-2160; Bron, Alain/0000-0002-7265-931X;
   COUGNARD-GREGOIRE, Audrey/0000-0002-1494-5764; Foster,
   Paul/0000-0002-4755-177X; Arango-Gonzalez, Blanca/0000-0002-9045-182X;
   Merle, Benedicte MJ/0000-0003-1332-0954; De la cerda,
   Berta/0000-0001-5603-6473; Berendschot, Tos TJM/0000-0002-8101-939X; Van
   Duijn, Cornelia/0000-0002-2374-9204; Farinha,
   Claudia/0000-0003-4596-0913; Murta, Joaquim/0000-0001-8926-5176; Lotery,
   Andrew/0000-0001-5541-4305; Boon, CJF/0000-0002-6737-7932; Khawaja,
   Anthony/0000-0001-6802-8585; Biarnes, Marc/0000-0003-2584-4894; Ribeiro,
   Maria Luisa/0000-0002-5801-8487; Hammond,
   Christopher/0000-0002-3227-2620; Cunha-Vaz, Jose/0000-0002-0947-9850;
   Rahi, Jugnoo/0000-0002-5718-9209; Cree, Angela/0000-0002-1987-8900;
   Demirkan, Ayse/0000-0002-7546-0867; Bretillon,
   Lionel/0000-0002-6957-100X; Topouzis, Fotis/0000-0002-8966-537X; Ahmad,
   Shahzad/0000-0002-8658-3790; Schweitzer, Cedric/0000-0002-2162-9479;
   Owen, Christopher/0000-0003-1135-5977; Bergen,
   Arthur/0000-0002-6333-9576; Diaz-Corrales, Francisco
   J./0000-0002-5752-0205; Williams, Katie M/0000-0003-4596-3938;
   Azuara-Blanco, Augusto/0000-0002-4805-9322; Bobak,
   Martin/0000-0002-2633-6851
FU European Union's Horizon 2020 research and innovation programme
   [634479]; Laboratoires Thea (Clermont-Ferrand, France); Fondation Voir
   et Entendre (Paris, France); Caisse Nationale de Solidarite pour
   l'Autonomie (Paris, France); AIBILI - Novartis Pharma AG; Medical
   Research Council [MC_PC_13048, G1000143]; Cancer Research UK
   [C864/A14136]; Research into Ageing [262]; Moorfields Eye Charity
   fellowship; Richard Desmond Charitable Trust; Department for Health
   through National Institute for Health Research; Landelijke Stiching voor
   Blinden en Slechtzienden; Stichting Blindenhulp, Stichting A. F. Deutman
   Oogheelkunde Researchfonds; Netherlands Organization for Scientific
   Research (Vidi Innovational Research Award) [016.096.309]; European
   Research Council under the European Union's Seventh Framework Programme
   (FP/2007-2013) [310644 MACULA]; Inter-regional grant (Programme
   Hospitalier de Recherche Clinique [PHRC]); Regional Council of Burgundy;
   CNRS; Universite de Bourgogne, Regional Council of Burgundy France (PARI
   Agrale 1); FEDER (European Funding for Regional Economic Development);
   French Government grant [ANR-11-LABX-0021-01-LipSTIC Labex]; Institut
   National de la Sante et de la Recherche Medicale (Inserm), Paris,
   France; Fondation de France; Fondation pour la Recherche Medicale,
   Paris; Region Languedoc-Roussillon, Montpellier, France; Rhones Poulenc;
   Horiba ABX Montpellier; Research Institute for Diseases in the Elderly
   (RIDE); Ministry of Education, Culture and Science; Ministry for Health,
   Welfare and Sports, the European Commission (DG XII); Municipality of
   Rotterdam; Oogfonds; Landelijke Stichting voor Blinden en Slechtzienden;
   Novartis Foundation; Netherlands Organisation of Scientific Research
   (Nederlandse Organisatie voor Wetenschappelijk Onderzoek [NWO])
   Investments [175.010.2005.011, 911-03-012]; Genetic Laboratory of the
   Department of Internal Medicine, Erasmus Medical Center; Research
   Institute for Diseases in the Elderly [014-93-015]; Netherlands Genomics
   Initiative/Netherlands Organisation for Scientific Research/Netherlands
   Consortium for Healthy Aging [050-060-810]; MaculaFonds; INRA;
   Department of Epidemiology of Ageing, Paris; Association Retina-France,
   Toulouse; Essilor; Specia; Centre de Recherche et d'Information
   Nutritionnelle, Paris; Erasmus Medical Center and Erasmus University,
   Rotterdam; Netherlands Organization for the Health Research and
   Development (ZonMw); MaculaFonds [2015-36]; MRC [MR/K023721/1] Funding
   Source: UKRI
FX Supported by the European Union's Horizon 2020 research and innovation
   programme (grant no.: 634479).; The Alienor-3C study received financial
   support from Laboratoires Thea (Clermont-Ferrand, France), Fondation
   Voir et Entendre (Paris, France) and Caisse Nationale de Solidarite pour
   l'Autonomie (Paris, France). Laboratoires Thea participated in the
   design of the study, but no sponsor participated in the collection,
   management, statistical analysis and interpretation of the data, nor in
   the preparation, review or approval of the present manuscript. The
   genome-wide association study genotype data for the Alienor-3C study are
   managed by the RID-AGE (Risk factors and molecular determinants of
   aging-related diseases) group of University of Lille, Institut Pasteur
   de Lille, and INSERM U1167 (Lille, France). We thank Benjamin
   Grenier-Boley, Celine Bellenguez, Jean-Charles Lambert and Philippe
   Amouyel for the creation and analysis of the imputed data. The Coimbra
   Eye Study is an Investigator Initiated Study sponsored by AIBILI that
   was financially supported by Novartis Pharma AG. The funding
   organization played no role in the design or conduct of this research.;
   EPIC-Norfolk infrastructure and core functions are supported by grants
   from the Medical Research Council (G1000143) and Cancer Research UK
   (C864/A14136). The clinic for the third health examination was funded by
   Research into Ageing (262). Genotyping was funded by the Medical
   Research Council (MC_PC_13048). Mr Khawaja is supported by a Moorfields
   Eye Charity fellowship. Professor Foster has received additional support
   from the Richard Desmond Charitable Trust (via Fight for Sight) and we
   were also supported by the Department for Health through the award made
   by the National Institute for Health Research to Moorfields Eye Hospital
   and the UCL Institute of Ophthalmology for a specialist Biomedical
   Research Centre for Ophthalmology.; EUGENDA was funded by grants from
   the Oogfonds, MaculaFonds, Landelijke Stiching voor Blinden en
   Slechtzienden, Stichting Blindenhulp, Stichting A. F. Deutman
   Oogheelkunde Researchfonds, the Netherlands Organization for Scientific
   Research (Vidi Innovational Research Award 016.096.309), and the
   European Research Council under the European Union's Seventh Framework
   Programme (FP/2007-2013) (ERC Grant Agreement n. 310644 MACULA).;
   MONRACHET Funding was provided by an Inter-regional grant (Programme
   Hospitalier de Recherche Clinique [PHRC]) and the Regional Council of
   Burgundy. This study was also funded by INRA, CNRS, Universite de
   Bourgogne, Regional Council of Burgundy France (PARI Agrale 1), FEDER
   (European Funding for Regional Economic Development) and French
   Government grant managed by the French National Research Agency (ANR) as
   part of the "Investissements d'Avenir" program (reference
   ANR-11-LABX-0021-01-LipSTIC Labex). The funding organizations had no
   role in the design or conduct of this research.; The POLA study was
   supported by the Institut National de la Sante et de la Recherche
   Medicale (Inserm), Paris, France; by grants from the Fondation de
   France, Department of Epidemiology of Ageing, Paris, the Fondation pour
   la Recherche Medicale, Paris, the Region Languedoc-Roussillon,
   Montpellier, France and the Association Retina-France, Toulouse; and by
   financial support from Rhones Poulenc, Essilor, Specia and Horiba ABX
   Montpellier, and the Centre de Recherche et d'Information
   Nutritionnelle, Paris. The sponsors and funding organizations played no
   role in the design or conduct of this research.; The Rotterdam Study is
   funded by Erasmus Medical Center and Erasmus University, Rotterdam,
   Netherlands Organization for the Health Research and Development
   (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the
   Ministry of Education, Culture and Science, the Ministry for Health,
   Welfare and Sports, the European Commission (DG XII), and the
   Municipality of Rotterdam. Additionally, the ophthalmic research within
   the Rotterdam Study was supported by the following foundations:
   Oogfonds, Landelijke Stichting voor Blinden en Slechtzienden, Novartis
   Foundation and MaculaFonds that contributed through UitZicht (grants
   2015-36). The funding organizations had no role in the design or conduct
   of this research and provided unrestricted grants.; The generation and
   management of genome-wide association study genotype data for the
   Rotterdam Study (RS I, RS II, RS III) was executed by the Human
   Genotyping Facility of the Genetic Laboratory of the Department of
   Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The
   genome-wide association study datasets are supported by the Netherlands
   Organisation of Scientific Research (Nederlandse Organisatie voor
   Wetenschappelijk Onderzoek [NWO]) Investments (nr. 175.010.2005.011,
   911-03-012), the Genetic Laboratory of the Department of Internal
   Medicine, Erasmus Medical Center, the Research Institute for Diseases in
   the Elderly (014-93-015); and the Netherlands Genomics
   Initiative/Netherlands Organisation for Scientific Research/Netherlands
   Consortium for Healthy Aging (project no.: 050-060-810).
CR Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bindu GH, 2011, CHOLESTEROL, DOI 10.1155/2011/274629
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Brunzell JD, 2012, BBA-MOL CELL BIOL L, V1821, P365, DOI 10.1016/j.bbalip.2011.09.008
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   CHEN CH, 1982, BIOCHEM BIOPH RES CO, V107, P1091, DOI 10.1016/0006-291X(82)90633-7
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Delcourt C, 2016, EUR J EPIDEMIOL, V31, P197, DOI 10.1007/s10654-015-0098-2
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Eren Esin, 2012, Open Biochem J, V6, P78, DOI 10.2174/1874091X01206010078
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   FRIEDEWA WT, 1972, CLIN CHEM, V18, P499, DOI [DOI 10.1093/clinchem/18.6.499, 10.1093/clinchem/18.6.499]
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   GLOMSET JA, 1962, BIOCHIM BIOPHYS ACTA, V65, P128, DOI 10.1016/0006-3002(62)90156-7
   Gordon SM, 2010, J PROTEOME RES, V9, P5239, DOI 10.1021/pr100520x
   Green PS, 2008, CIRCULATION, V118, P1259, DOI 10.1161/CIRCULATIONAHA.108.770669
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hasham SN, 2006, CLIN CHIM ACTA, V372, P179, DOI 10.1016/j.cca.2006.04.020
   Heagerty PJ, 2000, STAT SCI, V15, P1
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kettunen J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11122
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Kujala UM, 2013, CIRCULATION, V127, P340, DOI 10.1161/CIRCULATIONAHA.112.105551
   Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neale Benjamin M, 2010, Proc Natl Acad Sci U S A, V107, P7395, DOI 10.1073/pnas.0912019107
   NEUMAN MP, 1991, ATHEROSCLEROSIS, V91, pS11, DOI 10.1016/0021-9150(91)90202-E
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Pinheiro J, 2019, NLME LINEAR NONLINEA, DOI DOI 10.1016/S0006-3207(01)00201-4
   Rezaee F, 2006, PROTEOMICS, V6, P721, DOI 10.1002/pmic.200500191
   ROSENFELD SI, 1983, J CLIN INVEST, V71, P795, DOI 10.1172/JCI110833
   Semba RD, 2014, JAMA OPHTHALMOL, V132, P464, DOI 10.1001/jamaophthalmol.2013.7664
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shao BH, 2018, EXPERT REV PROTEOMIC, V15, P31, DOI 10.1080/14789450.2018.1402680
   Skerka C, 1997, J BIOL CHEM, V272, P5627, DOI 10.1074/jbc.272.9.5627
   Soininen P, 2009, ANALYST, V134, P1781, DOI 10.1039/b910205a
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Watanabe J, 2012, ARTHRITIS RHEUM-US, V64, P1828, DOI 10.1002/art.34363
   Wurtz P, 2016, J AM COLL CARDIOL, V67, P1200, DOI 10.1016/j.jacc.2015.12.060
   Wurtz P, 2015, CIRCULATION, V131, P774, DOI 10.1161/CIRCULATIONAHA.114.013116
   Wurtz P, 2012, DIABETES, V61, P1372, DOI 10.2337/db11-1355
   Yang K, 2014, RETINA-J RET VIT DIS, V34, P1539, DOI 10.1097/IAE.0000000000000118
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 73
TC 59
Z9 61
U1 2
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2019
VL 126
IS 3
BP 393
EP 406
DI 10.1016/j.ophtha.2018.09.045
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HM5GZ
UT WOS:000459505400021
PM 30315903
OA Green Published, Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Hallak, JA
   de Sisternes, L
   Osborne, A
   Yaspan, B
   Rubin, DL
   Leng, T
AF Hallak, Joelle A.
   de Sisternes, Luis
   Osborne, Aaron
   Yaspan, Brian
   Rubin, Daniel L.
   Leng, Theodore
TI Imaging, Genetic, and Demographic Factors Associated With Conversion to
   Neovascular Age-Related Macular Degeneration: Secondary Analysis of a
   Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID PROGRESSION; PREDICTION; DISEASE
AB IMPORTANCE Risk factors associated with the development of neovascular age-related macular degeneration (AMD) have been identified. However, population size and methods to integrate imaging, genetic, and demographic factors associated with conversion to neovascular AMD are limited, specifically when treatment is administered in 1 eye.
   OBJECTIVE To determine the imaging, genetic, and demographic factors associated with conversion from nonneovascular to neovascular AMD in fellow eyes.
   DESIGN, SETTING, AND PARTICIPANTS This post hoc secondary analysis of the 24-month phase 3 multicenter, double-masked, active treatment-controlled HARBOR trial included 686 fellow eyes with nonneovascular AMD at baseline. Imaging features describing the presence, number, extent, density, and relative reflectivity of drusen were automatically extracted from spectral-domain optical coherence tomography scans. Genetic analysis included 34 single-nucleotide polymorphisms. Least absolute shrinkage and selection operator regression was performed to narrow imaging features. Survival analysis and Cox proportional hazards regression were performed to determine the association of the selected imaging features and genetic and demographic factors with conversion to neovascular AMD. Data were collected from November 2016 through October 2017 and analyzed from October 2017 through October 2018.
   EXPOSURE Nonneovascular AMD in the fellow eye.
   MAIN OUTCOMES AND MEASURES Features associated with conversion to neovascular AMD. Hazard ratios (HRs) and their 95% CIs were calculated.
   RESULTS Among the 686 fellow eyes included in the analysis (406 [59.2%] women; mean [SD] age, 78.12 [8.28] years), 154 (22.4%) converted to neovascular AMD. Female sex was significantly associated with conversion to neovascular AMD (HR,1.57; 95% CI, 1.11-2.20; P=.009). After controlling for demographic and treatment effects, drusen area within 3 mm of the fovea (HR, 1.45; 95% CI, 1.24-1.69; HR for 1-SD increase, 1.36 [95% CI, 1.20-1.54]) and mean drusen reflectivity (HR, 3.97; 95% CI, 1.11-14.18; HR for 1-SD increase, 1.32 [95% CI, 1.02-1.71]) were significantly associated with conversion to neovascular AMD. In addition, 1 genetic variant (rs61941274) was found to be associated with conversion to neovascular AMD.
   CONCLUSIONS AND RELEVANCE Two imaging features (total en face area of drusen restricted to a circular area 3 mm from the fovea and mean drusen reflectivity) and 1 genetic variant (ACAD10 locus) were associated with conversion to neovascular AMD. Drusen characteristics may be associated with conversion to neovascular AMD despite treatment in 1 eye.
C1 [Hallak, Joelle A.] Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St,Ste 2186C, Chicago, IL 60612 USA.
   [de Sisternes, Luis] Carl Zeiss Meditec Inc, Dublin, CA USA.
   [Osborne, Aaron; Yaspan, Brian] Genentech Inc, San Francisco, CA 94080 USA.
   [Rubin, Daniel L.] Stanford Univ, Sch Med, Dept Biomed Data Sci Radiol & Med Biomed Informat, Stanford, CA 94305 USA.
   [Leng, Theodore] Stanford Sch Med, Byers Eye Inst Stanford, Palo Alto, CA USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Carl Zeiss AG; Roche Holding;
   Genentech; Stanford University; Stanford University
RP Hallak, JA (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St,Ste 2186C, Chicago, IL 60612 USA.
EM joelle@uic.edu
RI Leng, Theodore/AAQ-7459-2020
FU Genentech/Roche
FX This study was supported by Genentech/Roche.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cascella R, 2017, ONCOTARGET, V9, P7812, DOI [10.18632/oncotarget.23241, DOI 10.18632/ONCOTARGET.23241]
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cohen RA, 2006, P 31 SAS US GROUP
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Sisternes Luis, 2017, Transl Vis Sci Technol, V6, P12, DOI 10.1167/tvst.6.1.12
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Lujan BJZL., 2012, 2012 JOINT M AM AC O
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sardell RJ, 2016, MOL VIS, V22, P1062
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Shin KU, 2017, OPHTHALMIC RES, V57, P32, DOI 10.1159/000449168
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Talks SJ, 2017, ASIA-PAC J OPHTHALMO, V6, P498, DOI 10.22608/APO.2017305
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 29
TC 16
Z9 16
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2019
VL 137
IS 7
BP 738
EP 744
DI 10.1001/jamaophthalmol.2019.0868
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IR5XZ
UT WOS:000481513900003
PM 31021381
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Almeida, DRP
   Zhang, L
   Chin, EK
   Mullins, RF
   Kucukevcilioglu, M
   Critser, DB
   Sonka, M
   Stone, EM
   Folk, JC
   Abramoff, MD
   Russell, SR
AF Almeida, David R. P.
   Zhang, Li
   Chin, Eric K.
   Mullins, Robert F.
   Kucukevcilioglu, Murat
   Critser, D. Brice
   Sonka, Milan
   Stone, Edwin M.
   Folk, James C.
   Abramoff, Michael D.
   Russell, Stephen R.
TI Comparison of Retinal and Choriocapillaris Thicknesses Following Sitting
   to Supine Transition in Healthy Individuals and Patients With
   Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; CHOROIDAL THICKNESS; VISUAL-FIELD; BLOOD-FLOW;
   MORPHOMETRIC-ANALYSIS; BRUCHS MEMBRANE; EYES; POSTURE
AB IMPORTANCE The effects of position on retinal and choroidal structure are absent from the literature yet may provide insights into disease states such as age-related macular degeneration (AMD).
   OBJECTIVE To evaluate the effect of postural change on retinal and choroidal structures in healthy volunteers and patients with non-neovascular AMD.
   DESIGN, SETTING, AND PARTICIPANTS Prospective observational case series at an academic tertiary care retina service from September 2013 to April 2014 involving 4 unaffected volunteers (8 eyes) and 7 patients (8 eyes) with intermediate AMD. Healthy volunteers selected for the study had no evidence of ocular disease. Patients with AMD were required to have at least 10 intermediate-sized drusen.
   EXPOSURES Spectral-domain optical coherence tomography with enhanced depth imaging in upright (sitting) and supine positions. Stable imaging was achieved using a rotating adjustable mechanical arm that we constructed to allow the optical coherence tomography transducer to rotate 90 degrees. The Iowa Reference Algorithms were used to quantify choroid and choriocapillaris thicknesses.
   MAIN OUTCOMES AND MEASURES Changes in sitting and supine position central macular thickness (in micrometers), total macular volume (in cubic millimeters), choroidal thickness (in micrometers), and choriocapillaris-equivalent thickness (CCET, in micrometers).
   RESULTS Choriocapillaris-equivalent thickness was thinner in healthy participants (9.89 mu m; range, 7.15-12.5 mu m) compared with patients with intermediate AMD (16.73 mu m; range, 10.31-27.38 mu m) (P = .02); there was no difference in overall choroidal thickness between the 2 groups (P = .38). There was a 15% CCET reduction among healthy participants when transitioning from a sitting (9.89 mu m) to supine (8.4 mu m; range, 6.92-10.7 mu m) position (P = .02) vs a CCET reduction of 11.1% from sitting (16.73 mu m) to supine (14.88 mu m; range, 8.76-20.8 mu m) positioning (P = .10) in patients with intermediate AMD.
   CONCLUSIONS AND RELEVANCE Intermediate AMD appears to be associated with an increase in CCET and with a lack of positional responses that are observed in the CCET of normal eyes. Our results suggest that although outer portions of the choroid do not appear to be responsive to modest positional or hydrostatic pressure, the choriocapillaris capacity is, and this is measurable in vivo. Whether this physiologic deviation that occurs in AMD is related to atrophy, inflammation, or changes in autoregulatory factors or growth factors remains to be determined.
C1 [Almeida, David R. P.; Chin, Eric K.; Critser, D. Brice; Stone, Edwin M.; Folk, James C.; Abramoff, Michael D.; Russell, Stephen R.] Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Vitreoretinal Serv, Iowa City, IA 52240 USA.
   [Zhang, Li; Mullins, Robert F.; Kucukevcilioglu, Murat; Sonka, Milan; Stone, Edwin M.; Abramoff, Michael D.; Russell, Stephen R.] Univ Iowa, Stephen A Wynn Inst Vis Res, Iowa City, IA USA.
   [Abramoff, Michael D.] Iowa Inst Biomed Imaging, Iowa City, IA USA.
   [Abramoff, Michael D.] Vet Affairs Med Ctr, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care
   System
RP Almeida, DRP (通讯作者)，Univ Iowa Hosp & Clin, Dept Ophthalmol, 200 Hawkins Dr,PFP Room 11196-D, Iowa City, IA 52240 USA.
EM dalmeida@evolation-medical.com
RI Abramoff, Michael D/A-5836-2009; Mullins, Robert F/I-6717-2013;
   Kucukevcilioglu, Murat/AAH-3033-2021
OI Abramoff, Michael D/0000-0002-3490-0037; Folk,
   James/0000-0002-6271-2906; Russell, Stephen/0000-0003-3776-1367; Stone,
   Edwin M./0000-0003-3343-4414; Mullins, Robert/0000-0002-5006-0891
FU National Institutes of Health; Arnold and Mabel Beckman Initiative for
   Macular Research; American Diabetes Association; University of Iowa;
   NATIONAL EYE INSTITUTE [R01EY019112, R01EY018853] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [R01EB004640] Funding Source: NIH RePORTER
FX Dr Sonka has received grants from the National Institutes of Health. Dr
   Abramoff has received grants from the National Institutes of Health and
   the Arnold and Mabel Beckman Initiative for Macular Research, as well as
   other support from the American Diabetes Association and the University
   of Iowa.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Chen JC, 1984, INVEST OPHTHALMOL  S, V30, P153
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FRIEDMAN E, 1965, BIBL ANAT, P129
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Hwang JC, 2012, INVEST OPHTH VIS SCI, V53, P3020, DOI 10.1167/iovs.11-8552
   Jylhava J, 2009, CLIN EXP IMMUNOL, V155, P53, DOI 10.1111/j.1365-2249.2008.03752.x
   Kaeser P, 2005, BRIT J OPHTHALMOL, V89, P1302, DOI 10.1136/bjo.2005.067884
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Longo A, 2004, INVEST OPHTH VIS SCI, V45, P546, DOI 10.1167/iovs.03-0757
   Manjunath V, 2010, RETINA-J RET VIT DIS, V30, P1320, DOI 10.1097/IAE.0b013e3181e798b1
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nicolela MT, 1996, AM J OPHTHALMOL, V121, P502, DOI 10.1016/S0002-9394(14)75424-8
   Prager SG, 2014, CHANGES MACULAR PERF
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sarks SH, 1979, ACTA 23 CONCILIUM OP, VI, P228
   Sato EA, 2006, GRAEF ARCH CLIN EXP, V244, P795, DOI 10.1007/s00417-005-0177-2
   SAVIN E, 1995, EUR J APPL PHYSIOL O, V71, P161, DOI 10.1007/BF00854974
   SAYEGH FN, 1983, ANGIOLOGY, V34, P176, DOI 10.1177/000331978303400303
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Told R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060424
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Xu J, 2013, OPHTHALMOLOGY, V120, P2023, DOI 10.1016/j.ophtha.2013.03.009
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
NR 36
TC 26
Z9 27
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2015
VL 133
IS 3
BP 297
EP 303
DI 10.1001/jamaophthalmol.2014.5168
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD6UE
UT WOS:000351224200011
PM 25521616
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Campochiaro, PA
   Marcus, DM
   Awh, CC
   Regillo, C
   Adamis, AP
   Bantseev, V
   Chiang, YW
   Ehrlich, JS
   Erickson, S
   Hanley, WD
   Horvath, J
   Maass, KF
   Singh, N
   Tang, F
   Barteselli, G
AF Campochiaro, Peter A.
   Marcus, Dennis M.
   Awh, Carl C.
   Regillo, Carl
   Adamis, Anthony P.
   Bantseev, Vladimir
   Chiang, Yawen
   Ehrlich, Jason S.
   Erickson, Signe
   Hanley, William D.
   Horvath, Joshua
   Maass, Katie F.
   Singh, Natasha
   Tang, Fan
   Barteselli, Giulio
TI The Port Delivery System with Ranibizumab for Neovascular Age-Related
   Macular Degeneration Results from the Randomized Phase 2 Ladder Clinical
   Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; AFLIBERCEPT; OUTCOMES
AB Purpose: To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration (nAMD) treatment.
   Design: Phase 2, multicenter, randomized, active treatmentecontrolled clinical trial.
   Participants: Patients diagnosed with nAMD within 9 months who had received 2 or more prior antievascular endothelial growth factor intravitreal injections and were responsive to treatment.
   Methods: Patients were randomized 3:3:3:2 to receive the PDS filled with ranibizumab 10 mg/ml, 40 mg/ml, 100 mg/ml, or monthly intravitreal ranibizumab 0.5-mg injections.
   Main Outcome Measures: Time to first implant refill assessed when the last enrolled patient completed the month 9 visit (primary efficacy end point), improvement in best-corrected visual acuity (BCVA) and central foveal thickness (CFT), and safety.
   Results: The primary analysis population was 220 patients, with 58, 62, 59, and 41 patients in the PDS 10-mg/ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively. Median time to first implant refill was 8.7, 13.0, and 15.0 months in the PDS 10-mg/ml, PDS 40-mg/ml, and PDS 100-mg/ml arms, respectively. At month 9, the adjusted mean BCVA change from baseline was -3.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letters,. 0.5 ETDRS letters, thorn5.0 ETDRS letters, and +3.9 ETDRS letters in the PDS 10-mg/ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively. At month 9, the adjusted mean CFT change from baseline was similar in the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg arms. The optimized PDS implant insertion and refill procedures were generally well tolerated. After surgical procedure optimization, postoperative vitreous hemorrhage rate was 4.5% (7/157; 1 event classified as serious). There was no evidence of implant clogging.
   Conclusions: In the phase 2 Ladder trial, the PDS was generally well tolerated and demonstrated a dose response across multiple end points in patients with nAMD. The PDS 100-mg/ml arm showed visual and anatomic outcomes comparable with monthly intravitreal ranibizumab 0.5-mg injections but with a reduced total number of ranibizumab treatments. The PDS has the potential to reduce treatment burden in nAMD while maintaining vision. (C) 2019 by the American Academy of Ophthalmology.
C1 [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Marcus, Dennis M.] Southeast Retina Ctr, Augusta, GA USA.
   [Awh, Carl C.] Tennessee Retina, Nashville, TN USA.
   [Regillo, Carl] Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA USA.
   [Adamis, Anthony P.; Bantseev, Vladimir; Chiang, Yawen; Ehrlich, Jason S.; Erickson, Signe; Hanley, William D.; Horvath, Joshua; Maass, Katie F.; Singh, Natasha; Tang, Fan; Barteselli, Giulio] Genentech Inc, San Francisco, CA 94080 USA.
   [Ehrlich, Jason S.] Kodiak Sci Inc, Palo Alto, CA USA.
   [Hanley, William D.] Seattle Genet, Washington, DC USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Jefferson University;
   Roche Holding; Genentech
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 North Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
OI Maass, Katie/0000-0002-0493-2863
FU Genentech, Inc.
FX Third-party writing assistance (manuscript draft preparation and
   revision per author direction) was provided by Betsy C. Taylor, PhD,
   CMPP, of Envision Pharma Group and funded by Genentech, Inc.
CR American Academy of Ophthalmology Retina/ Vitreous Panel, 2015, AGE RELATED MACULAR
   Bantseev V, 2019, RETINA
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   International Conference on Harmonisation of Technical Re-quirements for Registration of Pharmaceuticals for Human Use, ICH HARM TRIP GUID G
   Lowe J, 2018, J IMMUNOL METHODS, V461, P44, DOI 10.1016/j.jim.2018.05.007
   Lowenstein A, PORT DELIVERY UNPUB
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ozturk M, 2018, CLIN EXP OPHTHALMOL, V46, P407, DOI 10.1111/ceo.13085
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   STERNBERG G, 2013, INVEST OPHTHALMOL VI, V54
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   World Medical Association, 2018, WMA DECL HELS ETH PR
   Yun S, 2016, DEV OPHTHALMOL, V55, P84, DOI 10.1159/000434692
NR 25
TC 140
Z9 142
U1 3
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2019
VL 126
IS 8
BP 1141
EP 1154
DI 10.1016/j.ophtha.2019.03.036
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IJ3ZZ
UT WOS:000475845500024
PM 30946888
OA hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Knobbe, CA
   Stojanoska, M
AF Knobbe, Chris A.
   Stojanoska, Marija
TI The 'Displacing Foods of Modern Commerce' Are the Primary and Proximate
   Cause of Age-Related Macular Degeneration: A Unifying Singular
   Hypothesis
SO MEDICAL HYPOTHESES
LA English
DT Article
ID FATTY-ACIDS; CARDIOVASCULAR-DISEASE; DIETARY-FAT; FRAMINGHAM EYE;
   RISK-FACTORS; VISUAL IMPAIRMENT; SATURATED FAT; UNITED-STATES;
   TRANS-FATTY; FISH INTAKE
AB Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss and blindness, in developed nations. AMD is anticipated to affect 196 million people worldwide, by 2020. However, the etiology of this disease remains unknown. Aging, genetic, and environmental influences have generally been implicated as major etiologic factors. We sought to examine the hypothesis that consumption of the 'displacing foods of modern commerce,' which equate to processed, nutrient-deficient and potentially toxic foods, may be the primary and,proximate cause of AMD. To evaluate this hypothesis, we ran correlative AMD prevalence data against well-known proxy markers of processed food consumption, namely, sugar and vegetable oils, in 25 nations. In twenty-one nations, published studies provided AMD prevalence data and in four Pacific Island nations, practicing ophthalmologists in the regions completed retrospective chart analyses to estimate AMD prevalence in their respective regions. To estimate AMD prevalence historically, an extensive review of published papers and ophthalmic literature was completed. This review indicates that, between the years 1851 and 1930, AMD was a medical rarity worldwide, which then rose modestly in prevalence in the 1930s in the U.S. and U.K, finally elevating to epidemic proportions by 1975 in the U.S. Numerous developed nations have followed suit in recent decades. Simultaneously, between approximately 1880 and 2009, processed, nutrient-deficient foods gradually supplanted and displaced whole, unprocessed, nutrient-dense foods in developed nations, such that by 2009, 63 percent of the American diet was made up of nutrient-deficient foods in the form of refined white flour, added sugars, vegetable oils, and artificially created trans fats. The correlative data in 25 nations shows that increasing sugar and polyunsaturated vegetable oil consumption is invariably associated with new onset or rising prevalence of AMD, generally within about 30-40 years of the beginning of increasing consumption of these proxy marker processed food components. The correlative data also demonstrates that, when consumption of sugar is moderate, but "harmful vegetable oil" consumption remains extremely low or absent, the prevalence of AMD remains rare. This study supports the hypothesis that the 'displacing foods of modern commerce,' which equate to processed, nutrient-deficient, and potentially toxic foods, are the primary and proximate cause of AMD. This study also supports the conclusion that macular degeneration is entirely preventable, through ancestral dietary strategy and avoidance of processed foods. Finally, this research has implications for patients with existing early and intermediate stages of AMD.
C1 [Knobbe, Chris A.] Univ Texas Southwestern Med Ctr Dallas, Dept Ophthalmol, 5323 Harry Hines Blvd,MC 9057, Dallas, TX 75390 USA.
   [Stojanoska, Marija] Mite Bogoevski 2-21, Skopje 1000, Macedonia.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas
RP Knobbe, CA (通讯作者)，POB 3365, Boulder, CO 80307 USA.
EM cknobbe@me.com
RI Knobbe-Thomsen, Christiane B/D-3116-2019
CR Adegbehingbe BO, 2007, AUST J RURAL HEALTH, V15, P269, DOI 10.1111/j.1440-1584.2007.00906.x
   Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Albert Daniel M, 1996, HIST OPHTHALMOLOGY, P195
   Albert Daniel M, 1996, HIST OPHTHALMOLOGY, P76
   Allison DB, 1999, J AM DIET ASSOC, V99, P166, DOI 10.1016/S0002-8223(99)00041-3
   Ames BN, 2006, P NATL ACAD SCI USA, V103, P17589, DOI 10.1073/pnas.0608757103
   [Anonymous], 2008, BULLETIN, V33
   Astrup A, 2011, AM J CLIN NUTR, V93, P684, DOI 10.3945/ajcn.110.004622
   BAGHURST KI, 1988, MED J AUSTRALIA, V149, P12, DOI 10.5694/j.1326-5377.1988.tb120476.x
   Basu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057873
   Benjamin Rones, 1938, AM J OPHTHALMOL, V21, P239
   Blasbalg TL, 2011, AM J CLIN NUTR, V93, P950, DOI 10.3945/ajcn.110.006643
   Brenchley R, 2012, NATURE, V491, P705, DOI 10.1038/nature11650
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Campbell GM, 2007, HANDB POWD TECHNOL, V12, P383, DOI 10.1016/S0167-3785(07)12010-8
   Carol Carter Nancy, 2008, J SAN DIEGO HIST, V54, P138
   Carrera-Bastos P, 2011, RES REP CLIN CARDIOL, V2, P15, DOI 10.2147/RRCC.S16919
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Choe E, 2006, COMPR REV FOOD SCI F, V5, P169, DOI 10.1111/j.1541-4337.2006.00009.x
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cordain L, 2005, AM J CLIN NUTR, V81, P341, DOI 10.1093/ajcn.81.2.341
   Cordain L., 2007, EVOLUTION HUMAN DIET, P363
   De Jong PTVM, 2015, HIST OPHTHAL INT, V1, P139
   DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duke-Elder W. Stewart, 1927, RECENT ADV OPHTHALMO
   Duke-Elder WS, 1940, TXB OPHTHALMOLOGY, VIII, P2372
   Egan ICM, 1994, PRINCIPLES PRACTICE, P1273
   Egan KM, 1994, PRINCIPLES PRACTICE, P1266
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Faeh D, 2005, DIABETES, V54, P1907, DOI 10.2337/diabetes.54.7.1907
   Ford ES, 2013, AM J CLIN NUTR, V97, P848, DOI 10.3945/ajcn.112.052662
   Foster Cathy, 1993, Ethnicity and Disease, V3, P404
   Fuchs Ernest, 1892, TXB OPHTHALMOLOGY, P315
   Gaskin PS, 2008, PUBLIC HEALTH NUTR, V11, P41, DOI 10.1017/S1368980007000195
   Gaskin PS, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/242875
   Greyt W. de, 1996, Fett/Lipid, V98, P30, DOI 10.1002/lipi.19960980109
   GRIGG D, 1993, GEOFORUM, V24, P277, DOI 10.1016/0016-7185(93)90021-9
   Guyenet S., 2012, 2606 US DIET WILL BE
   Haab O., 1895, ATLAS GRUNDRISS OPHT
   Haab O., 1885, ZENTRALBL PRAKT AUGE, V9, P383
   Hamm H, 2013, EDIBLE OIL PROCESSIN
   He Ka, 2006, J Cardiometab Syndr, V1, P351, DOI 10.1111/j.1559-4564.2006.05702.x
   Hirschberg Julius, 1914, HIST OPHTHALMOLOGY, V10
   HOSHINO M, 1984, JPN J OPHTHALMOL, V28, P89
   Hutchinson J., 1874, R LOND OPHTHALMIC HO, V8, P231
   Ichikawa H., 1981, JPN J OPHTHALMOL, V35, P9
   Jacobs DR, 2003, AM J CLIN NUTR, V78, p508S, DOI 10.1093/ajcn/78.3.508S
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Keeler CR, 2003, BRIEF HIST OPHTHALMO, V4, P138
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Kostik V., 2013, Journal of Hygienic Engineering and Design, V4, P112
   Kreidberg Marjorie, 1975, FOOD FRONTIER MINNES, P39
   MANN I, 1969, AM J OPHTHALMOL, V67, P358, DOI 10.1016/0002-9394(69)92045-5
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   May Charles H, 1930, MANUAL DIS EYE, P188
   McCann JC, 2009, AM J CLIN NUTR, V90, P889, DOI 10.3945/ajcn.2009.27930
   Micha R, 2010, LIPIDS, V45, P893, DOI 10.1007/s11745-010-3393-4
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Ngai LY, 2011, EYE, V25, P784, DOI 10.1038/eye.2011.56
   Nieto FJ, 1999, AM J PUBLIC HEALTH, V89, P292, DOI 10.2105/AJPH.89.3.292
   Nixey Catherine, TRANS FATS HYDROGENA
   Nixon HC, 1930, J POLIT ECON, V38, P73, DOI 10.1086/254082
   Nwosu SNN, 2011, NIGER J CLIN PRACT, V14, P327, DOI 10.4103/1119-3077.86778
   O'Keefe JH, 2004, MAYO CLIN PROC, V79, P101, DOI 10.4065/79.1.101
   OKeefe S, 1994, J FOOD LIPIDS, V1, P165, DOI [10.1111/ j.1745-4522.1994.tb00244.x, DOI 10.1111/J.1745-4522.1994.TB00244.X]
   Ouchi M, 2002, OPHTHALMOLOGICA, V216, P363, DOI 10.1159/000066178
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Popkin BM, 2016, LANCET DIABETES ENDO, V4, P174, DOI 10.1016/S2213-8587(15)00419-2
   Popkin BM, 2004, INT J OBESITY, V28, pS2, DOI [10.1038/sj.ijo.0802804, 10.1038/sj.ijo.0802557]
   Price Weston A., 1939, NUTR PHYS DEGENERATI
   Ramke J, 2007, CLIN EXP OPHTHALMOL, V35, P627, DOI 10.1111/j.1442-9071.2007.01556.x
   Rees A, 2014, EYE, V28, P832, DOI 10.1038/eye.2014.103
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rylander R, 1996, J Cardiovasc Risk, V3, P4, DOI 10.1097/00043798-199602000-00002
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schisgall O., 1981, EYES TOMORROW EVOLUT, P63
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Semma M, 2002, J HEALTH SCI, V48, P7, DOI 10.1248/jhs.48.7
   Sharma S, 2008, J HUM NUTR DIET, V21, P150, DOI 10.1111/j.1365-277X.2008.00858.x
   Siri-Tarino PW, 2010, AM J CLIN NUTR, V91, P535, DOI 10.3945/ajcn.2009.27725
   Slavin JL, 2001, CRIT REV BIOTECHNOL, V21, P49, DOI 10.1080/20013891081683
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   U.S. Department of Agriculture U.S. Department of Health and Human Services, 2010, DIET GUID AM 2010
   US Food and Drug Administration, FIN DET REG PART HYD
   Van Bol L, 2014, Rev Med Brux, V35, P265
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Worsley D, 2015, NEW ZEAL MED J, V128, P44
   Yang QH, 2014, JAMA INTERN MED, V174, P516, DOI 10.1001/jamainternmed.2013.13563
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 107
TC 3
Z9 3
U1 0
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2017
VL 109
BP 184
EP 198
DI 10.1016/j.mehy.2017.10.010
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Research & Experimental Medicine
GA FQ2XL
UT WOS:000418221200041
PM 29150284
DA 2022-11-30
ER

PT J
AU Dasch, B
   Fuhs, A
   Behrens, T
   Meister, A
   Wellmann, J
   Fobker, M
   Pauleikhoff, D
   Hense, HW
AF Dasch, B
   Fuhs, A
   Behrens, T
   Meister, A
   Wellmann, J
   Fobker, M
   Pauleikhoff, D
   Hense, HW
TI Inflammatory markers in age-related maculopathy - Cross-sectional
   analysis from the Muenster Aging and Retina Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
AB Objective: To evaluate recent reports indicating that plasma levels of fibrinogen and high-sensitivity C-reactive protein (CRP) are associated with age-related maculopathy (ARM).
   Methods: From the baseline examinations of the Muenster Aging and Retina Study, a cohort of 1060 subjects aged 59 to 82 years was assembled. Of these, 873 persons (82%) with bilateral gradable fundus photographs and complete data on fibrinogen, CRP, and potential confounders were included in a cross-sectional analysis. The main outcome measure was the association among fibrinogen, CRP, and ARM as assessed by multivariate logistic regression analysis.
   Results: Fibrinogen and CRP levels were higher among participants with early and late ARM than among those without ARM. The crude odds ratios for ARM between the highest vs the lowest quartile were 1.90 (95% confidence interval [CI], 1.29-2.80) for fibrinogen and 1.43 (95% CI, 0.972.10) for CRP. After adjustment for cardiovascular risk factors, these odds ratios were 1.37 for fibrinogen (95% CI, 0.91-2.06) and 1.12 (95% CI, 0.73-1.73) for CRP.
   Conclusions: After adjustment for cardiovascular risk factors, we found no statistically significant association between fibrogen, CRP, and ARM. Therefore, our results do not indicate a role of systemic inflammation in ARM beyond what is already present owing to concurrent cardiovascular disease.
C1 Univ Munster, Inst Epidemiol & Social Med, D-48149 Munster, Germany.
   Univ Munster, Clin Chem, Munster, Germany.
   Univ Munster, Lab Med, Munster, Germany.
   St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
C3 University of Munster; University of Munster; University of Munster; St.
   Franziskus-Hospital
RP Hense, HW (通讯作者)，Univ Munster, Inst Epidemiol & Social Med, Domagkstr 3, D-48149 Munster, Germany.
EM hense@uni-muenster.de
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bergmann K E, 1999, Gesundheitswesen, V61 Spec No, pS115
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Imhof A, 2003, CLIN CHEM, V49, P669, DOI 10.1373/49.4.669
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Junge B, 1999, Gesundheitswesen, V61 Spec No, pS121
   KATZ J, 1994, INVEST OPHTH VIS SCI, V35, P2461
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1999, AGE RELATED MACULAR, V31, P55
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kostis JB, 2004, EUR J CARDIOV PREV R, V11, P9, DOI 10.1097/01.hjr.0000114968.39211.01
   Li JJ, 2004, MED HYPOTHESES, V62, P499, DOI 10.1016/j.mehy.2003.12.014
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C
   Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   THAMM M, 1999, GESUNDHEITSWESEN, V61, pS909
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 45
TC 46
Z9 48
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2005
VL 123
IS 11
BP 1501
EP 1506
DI 10.1001/archopht.123.11.1501
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 981BM
UT WOS:000233062100002
PM 16286611
OA Bronze
DA 2022-11-30
ER

PT J
AU Lores-Motta, L
   Riaz, M
   Grunin, M
   Corominas, J
   van Asten, F
   Pauper, M
   Leenders, M
   Richardson, AJ
   Muether, P
   Cree, AJ
   Griffiths, HL
   Pham, C
   Belanger, MC
   Meester-Smoor, MA
   Ali, M
   Heid, IM
   Fritsche, LG
   Chakravarthy, U
   Gale, R
   McKibbin, M
   Inglehearn, CF
   Schlingemann, RO
   Omar, A
   Chen, J
   Koenekoop, RK
   Fauser, S
   Guymer, RH
   Hoyng, CB
   de Jong, EK
   Lotery, AJ
   Mitchell, P
   den Hollander, AI
   Baird, PN
   Chowers, I
AF Lores-Motta, Laura
   Riaz, Moeen
   Grunin, Michelle
   Corominas, Jordi
   van Asten, Freekje
   Pauper, Marc
   Leenders, Mathieu
   Richardson, Andrea J.
   Muether, Philipp
   Cree, Angela J.
   Griffiths, Helen L.
   Pham, Connie
   Belanger, Marie-Claude
   Meester-Smoor, Magda A.
   Ali, Manir
   Heid, Iris M.
   Fritsche, Lars G.
   Chakravarthy, Usha
   Gale, Richard
   McKibbin, Martin
   Inglehearn, Chris F.
   Schlingemann, Reinier O.
   Omar, Amer
   Chen, John
   Koenekoop, Robert K.
   Fauser, Sascha
   Guymer, Robyn H.
   Hoyng, Carel B.
   de Jong, Eiko K.
   Lotery, Andrew J.
   Mitchell, Paul
   den Hollander, Anneke I.
   Baird, Paul N.
   Chowers, Itay
TI Association of Genetic Variants With Response to Anti-Vascular
   Endothelial Growth Factor Therapy in Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; INTRAVITREAL RANIBIZUMAB TREATMENT; TOLL-LIKE
   RECEPTORS; SUBGROUP ANALYSIS; NEOVASCULAR AMD; POLYMORPHISMS; VEGF;
   BEVACIZUMAB; PREDICTORS; RARE
AB IMPORTANCE Visual acuity (VA) outcomes differ considerably among patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) drugs. Identification of pharmacogenetic associations may help clinicians understand the mechanisms underlyingthis variability as well as pave the way for personalized treatment in nAMD.
   OBJECTIVE To identify genetic factors associated with variability in the response to anti-VEGF therapy for patients with nAMD.
   DESIGN, SETTING, AND PARTICIPANTS In this multicenter genome-wide association study, 678 patients with nAMD with genome-wide genotyping data were included in the discovery phase; 1380 additional patients with nAMD were genotyped for selected common variants in the replication phase. All participants received 3 monthly injections of bevacizumab or ranibizumab. Clinical data were evaluated for inclusion/exclusion criteria from October 2014 to October 2015, followed by data analysis from October 2015 to February 2016. For replication cohort genotyping, clinical data collection and analysis (including meta-analysis) was performed from March 2016 to April 2017.
   MAIN OUTCOMES AND MEASURES Change in VA after the loading dose of 3 monthly anti-VEGF injections compared with baseline.
   RESULTS Of the 2058 included patients, 1210 (58.8%) were women, and the mean (SD) age across all cohorts was 78 (7.4) years. Patients included in the discovery cohort and most of the patients in the replication cohorts were of European descent. The mean (SD) baseline VA was 51.3 (20.3) Early Treatment Diabetic Retinopathy Study (ETDRS) score letters, and the mean (SD) change in VA after the loading dose of 3 monthly injections was a gain of 5.1(13.9) ETDRS score letters (ie, 1-line gain). Genome-wide single-variant analyses of common variants revealed 5 independent loci that reached a P value less than 10 x 10(-5). After replication and meta-analysis of the lead variants, rs12138564 located in the CCT3 gene remained nominally associated with a better treatment outcome (ETDRS letter gain, 1.7; beta, 0.034; SE, 0.008; P = 1.38 x 10(-5)). Genome-wide gene-based optimal unified sequence kernel association test of rare variants showed genome-wide significant associations for the C10orf88 (P = 4.22 x 10(-7)) and UNC9.381(P = 6.09 x 10(-7)) genes, in both cases leading to a worse treatment outcome. Patients carrying rare variants in the C10orf88 and UNC93B1genes lost a mean (SD) VA of 30.6 (17.4) ETDRS score letters (ie, loss of 6.09 lines) and 26.5 (13.8) ETDRS score letters (ie, loss of 5.29 lines), respectively, after 3 months of anti-VEGF treatment.
   CONCLUSIONS AND RELEVANCE We propose that there is a limited contribution of common genetic variants to variability in nAMD treatment response. Our results suggest that rare protein-altering variants in the C10orf88 and UNC93B1genes are associated with a worse response to anti VEGF therapy in patients with nAMD, but these results require further validation in other cohorts.
C1 [Lores-Motta, Laura; Corominas, Jordi; Pauper, Marc; Leenders, Mathieu; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
   [Riaz, Moeen; Richardson, Andrea J.; Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg Ophthalmol, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Riaz, Moeen] Monash Univ, Sch Publ Hlth & Prevent Med, Publ Hlth Genom, Melbourne, Vic, Australia.
   [Grunin, Michelle; Chowers, Itay] Hebrew Univ Jerusalem, Hadassah Med Ctr, Hadassah Med Sch, Dept Ophthalmol, Jerusalem, Israel.
   [Corominas, Jordi; Pauper, Marc; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behaviour, Dept Human Genet, Nijmegen, Netherlands.
   [van Asten, Freekje] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [van Asten, Freekje] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Muether, Philipp; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Cree, Angela J.; Griffiths, Helen L.; Lotery, Andrew J.] Univ Southampton, Clin & Expt Sci, Fac Med, Southampton, England.
   [Pham, Connie; Belanger, Marie-Claude] McGill Univ, Ctr Hlth, Dept Ophthalmol, Montreal, PQ, Canada.
   [Meester-Smoor, Magda A.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Ali, Manir; Inglehearn, Chris F.] Univ Leeds, Leeds Inst Mol Med, Sect Ophthalmol & Neurosci, Leeds, W Yorkshire, England.
   [Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Fritsche, Lars G.] Norwegian Univ Sci & Technol, Trondheim, Norway.
   [Chakravarthy, Usha] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Gale, Richard] York Hosp, York, N Yorkshire, England.
   [McKibbin, Martin; Inglehearn, Chris F.] St James Univ Hosp, Eye Clin, Leeds, W Yorkshire, England.
   [Schlingemann, Reinier O.] Acad Med Ctr, Ocular Angiogenesis Grp, Dept Ophthalmol, Amsterdam, Netherlands.
   [Schlingemann, Reinier O.] Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [Omar, Amer] Montreal Retina Inst, Westmtunt, PQ, Canada.
   [Chen, John; Koenekoop, Robert K.] McGill Univ, Ctr Hlth, Dept Pediat Surg, Montreal, PQ, Canada.
   [Chen, John; Koenekoop, Robert K.] McGill Univ, Ctr Hlth, Dept Human Genet, Montreal, PQ, Canada.
   [Chen, John; Koenekoop, Robert K.] McGill Univ, Ctr Hlth, Dept Ophthalmol, Montreal, PQ, Canada.
   [Fauser, Sascha] Hoffmann La Roche AG, Roche Pharma Res & Early Dev, Basel, Switzerland.
   [Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   [Mitchell, Paul] Univ Sydney, Westmead Millennium Inst Med Res, Sydney, NSW, Australia.
C3 Philips; Radboud University Nijmegen; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne; Monash
   University; Hebrew University of Jerusalem; Hadassah University Medical
   Center; Radboud University Nijmegen; National Institutes of Health (NIH)
   - USA; NIH National Eye Institute (NEI); National Institutes of Health
   (NIH) - USA; NIH National Eye Institute (NEI); University of Cologne;
   University of Southampton; McGill University; Erasmus University
   Rotterdam; Erasmus MC; University of Leeds; University of Regensburg;
   Norwegian University of Science & Technology (NTNU); Queens University
   Belfast; Saint James's University Hospital; University of Amsterdam;
   Academic Medical Center Amsterdam; Royal Netherlands Academy of Arts &
   Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); McGill
   University; McGill University; McGill University; Roche Holding;
   University of Sydney; University of Sydney
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM anneke.denhollander@radboundumc.nl
RI Pauper, Marc/B-6342-2018; Koenekoop, Robert/AAT-6676-2021; Hollander,
   Anneke den/N-4911-2014; Grunin, Michelle/O-6044-2019; Fritsche, Lars
   G/AAF-9387-2019; Pauper, Marc/AGZ-0438-2022; Inglehearn,
   Chris/GYD-9783-2022; Omar, Amer/M-5342-2019; Ali, Manir/ABE-5251-2020
OI Pauper, Marc/0000-0001-6274-9891; Grunin, Michelle/0000-0002-3155-2858;
   Fritsche, Lars G/0000-0002-2110-1690; Pauper, Marc/0000-0001-6274-9891;
   Omar, Amer/0000-0003-1520-392X; Ali, Manir/0000-0003-3204-3788; Baird,
   Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356; Lotery,
   Andrew/0000-0001-5541-4305; Lores-Motta, Laura/0000-0002-2423-9126;
   Cree, Angela/0000-0002-1987-8900
FU CIHR Funding Source: Medline; NHLBI NIH HHS [HHSN268201200008I] Funding
   Source: Medline; Department of Health [07/36/01] Funding Source: Medline
CR Ahn J, 2010, HUM MOL GENET, V19, P2739, DOI 10.1093/hmg/ddq155
   Bakbak B, 2016, CURR EYE RES, V41, P862, DOI 10.3109/02713683.2015.1067325
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brinkmann MM, 2007, J CELL BIOL, V177, P265, DOI 10.1083/jcb.200612056
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang W, 2013, MOL VIS, V19, P702
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hagstrom SA, 2014, OPHTHALMOLOGY, V121
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Harris KG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141383
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Holz FG, 2017, OPHTHALMIC RES, V58, P49, DOI 10.1159/000449001
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726
   Koch KR, 2012, GRAEF ARCH CLIN EXP, V250, P201, DOI 10.1007/s00417-011-1792-8
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Lazzeri S, 2016, PHARMACOGENOMICS, V17, P27, DOI 10.2217/pgs.15.153
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007
   Lores-Motta L, 2016, PHARMACOGENET GENOM, V26, P20, DOI 10.1097/FPC.0000000000000180
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   Medina FM, 2015, OPHTHALMIC RES, V54, P169, DOI 10.1159/000439172
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Riaz M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37924
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Stewart EA, 2015, EXP EYE RES, V138, P114, DOI 10.1016/j.exer.2015.06.012
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wagner AH, 2013, EXP EYE RES, V111, P105, DOI 10.1016/j.exer.2013.03.004
   Wang VM, 2012, MOL VIS, V18, P2578
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 63
TC 19
Z9 19
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2018
VL 136
IS 8
BP 875
EP 884
DI 10.1001/jamaophthalmol.2018.2019
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP8TE
UT WOS:000441186300009
PM 29852030
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Hollo, G
   Naghizadeh, F
AF Hollo, Gabor
   Naghizadeh, Farzaneh
TI Influence of a New Software Version of the RTVue-100 Optical Coherence
   Tomograph on Ganglion Cell Complex Segmentation in Various Forms of
   Age-Related Macular Degeneration
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE glaucoma; RTVue Fourier-domain optical coherence tomography; age-related
   macular degeneration; macular thickness; ganglion cell complex
ID NERVE-FIBER LAYER; DETECT GLAUCOMA; VISUAL-ACUITY; HIGH MYOPIA;
   THICKNESS; EYES
AB Purpose:Previously, we have shown that age-related macular degeneration (AMD) influences glaucoma classification with the ganglion cell complex (GCC) parameters of the RTVue-100 optical coherence tomograph (RTVue-OCT) in nonglaucomatous eyes. Now, we reevaluated the influence of AMD on GCC image segmentation and classification for glaucoma on the same eyes, using a new version of the software.Methods:GCC images of nonglaucomatous eyes [30 healthy, 19 with early/intermediate AMD, 16 with subfoveal choroidal neovascularization (CNV), and 19 after intravitreal antiangiogenic treatment of CNV, CNV-anti-VEGF] were reanalyzed with software versions 6.3 (the currently available version) and 6.12 (a version not yet commercially released).Results:Global loss volume (GLV) was significantly reduced with version 6.12 in all groups (P0.0416). Segmentation errors were seen in 2 versus 0 of the normal eyes (P=0.500), 8 versus 0 of the early/intermediate AMD eyes (P=0.0312), 16 versus 6 of the CNV eyes (P=0.0080), and 18 versus 3 of the CNV-anti-VEGF eyes (P=0.0004) with software versions 6.3 and 6.12, respectively. For focal loss volume the distribution of the classification results differed significantly between the software versions in the CNV and CNV-anti-VEGF groups (P=0.0312 and 0.0160, respectively). For both groups more eyes were classified as within normal limits, and less as outside normal limits with software version 6.12 than with version 6.3.Conclusions:For nonglaucomatous AMD eyes the frequency of GCC segmentation errors was significantly reduced, GLV was significantly lower (more normal), and the classification for glaucoma was more correct with software version 6.12 than with version 6.3.
C1 [Hollo, Gabor; Naghizadeh, Farzaneh] Semmelweis Univ, Dept Ophthalmol, H-1089 Budapest, Hungary.
C3 Semmelweis University
RP Hollo, G (通讯作者)，Semmelweis Univ, Dept Ophthalmol, Maria U 39, H-1089 Budapest, Hungary.
EM hg@szem1.sote.hu
CR Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   American Academy of Ophthalmology Retina Panel, 2008, AG REL MAC DEG PREF
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Choi YJ, 2013, INVEST OPHTH VIS SCI, V54, P2296, DOI 10.1167/iovs.12-10530
   Garas A, 2011, EYE, V25, P57, DOI 10.1038/eye.2010.139
   Garas A, 2013, J GLAUCOMA, V22, P195, DOI 10.1097/IJG.0b013e31824083e6
   Garas A, 2010, OPHTHALMOLOGY, V117, P738, DOI 10.1016/j.ophtha.2009.08.039
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim NR, 2011, BRIT J OPHTHALMOL, V95, P1115, DOI 10.1136/bjo.2010.182493
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Mori S, 2010, J GLAUCOMA, V19, P528, DOI 10.1097/IJG.0b013e3181ca7acf
   Naghizadeh F, 2014, J GLAUCOMA, V23, P195, DOI 10.1097/IJG.0b013e31826a9707
   Nakatani Y, 2011, J GLAUCOMA, V20, P252, DOI 10.1097/IJG.0b013e3181e079ed
   Nouri-Mahdavi K, 2013, AM J OPHTHALMOL, V156, P1297, DOI 10.1016/j.ajo.2013.08.001
   Optovue Inc, 2011, US MAN US ONL OUTS U
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Seong M, 2010, INVEST OPHTH VIS SCI, V51, P1446, DOI 10.1167/iovs.09-4258
   Sung KR, 2012, OPHTHALMOLOGY, V119, P308, DOI 10.1016/j.ophtha.2011.08.022
   Sung MS, 2013, J GLAUCOMA
   Tan O, 2009, OPHTHALMOLOGY, V116, P2305, DOI 10.1016/j.ophtha.2009.05.025
   Toth M, 2005, BRIT J OPHTHALMOL, V89, P1139, DOI 10.1136/bjo.2005.070011
NR 23
TC 10
Z9 10
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD MAR
PY 2015
VL 24
IS 3
BP 245
EP 250
DI 10.1097/IJG.0000000000000092
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE0BS
UT WOS:000351468400014
PM 25055214
DA 2022-11-30
ER

PT J
AU Sanjay, S
   Chin, YC
   Teo, HT
   Ong, SX
   Toh, SHF
   Khong, MH
   Yeo, ACH
   Eong, KGA
AF Sanjay, Srinivasan
   Chin, You Chuen
   Teo, Hui Ting
   Ong, Shu Xuan
   Toh, Serene Hui Fang
   Khong, Ming Hui
   Yeo, Anna C. H.
   Eong, Kah-Guan Au
TI A Follow-Up Survey on the Knowledge of Age-Related Macular Degeneration
   and its Risk Factors among Singapore Residents after 5 Years of
   Nation-Wide Awareness Campaigns
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; awareness; singapore
ID EYE DISEASES; POPULATION; COMMUNITY; BLINDNESS
AB Purpose: To re-evaluate the awareness of age-related macular degeneration (AMD) and knowledge of its risk factors among Singapore residents after 5 years of awareness campaigns.
   Methods: Cross-sectional, questionnaire-based telephone survey (modified from the AMD Alliance International Global Report), conducted in Singapore in 2011. Participants were randomly selected using the Global Yellow Pages Singapore residential listings 2009/2010. Awareness of AMD and its risk factors was assessed among participants.
   Results: Of 1773 Singapore residents contacted over the telephone, 559 participated (31.5% response rate). The mean age of participants was 43.1 years (range 21-85 years). A total of 157 participants (28.1%) were familiar with AMD. Among these, the number who correctly identified the risk factors were: smoking, n = 132 (84.1%); ageing, n = 123 (78.3%); lack of vitamins/nutrients, n = 121 (77.1%); genetics, n = 101 (64.3%); unprotected light exposure, n = 100 (63.7%) and; sex, n = 62 (39.5%). Participants aged >450 years (prevalence rate ratio, PRR 2.23, confidence interval, CI, 1.31-3.81) or who had undergone an eye test within the previous year (PRR 2.61, 95% CI 1.79-3.82) were more familiar with AMD, while females (PRR 0.68, 95% CI 0.47-0.98) were less familiar.
   Conclusion: Self-reported awareness of AMD among Singapore residents increased four-fold from 7.3% in 2006 to 28.1% in 2011 following 5 years of awareness campaigns. Participants who were >450 years or had undergone an eye test within the previous year were more aware of AMD while female participants were less aware of AMD.
C1 [Sanjay, Srinivasan; Eong, Kah-Guan Au] Khoo Teck Puat Hosp, Dept Ophthalmol & Visual Sci, Singapore 768828, Singapore.
   [Sanjay, Srinivasan; Chin, You Chuen] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore.
   [Teo, Hui Ting; Ong, Shu Xuan; Toh, Serene Hui Fang; Khong, Ming Hui; Yeo, Anna C. H.] Singapore Polytech, Dept Optometry, Singapore, Singapore.
   [Eong, Kah-Guan Au] Mt Elizabeth Med Ctr, Singapore Int Eye Cataract Retina Ctr, Singapore, Singapore.
   [Eong, Kah-Guan Au] Farrer Pk Med Ctr, Singapore, Singapore.
C3 National University of Singapore; Singapore Polytechnic; Mount Elizabeth
   Medical Centre
RP Sanjay, S (通讯作者)，Khoo Teck Puat Hosp, Dept Ophthalmol & Visual Sci, 90 Yishun Cent, Singapore 768828, Singapore.
EM sanjay_s@alexandrahealth.sg
RI Sanjay, Srinivasan/L-4107-2019
OI Sanjay, Srinivasan/0000-0001-9756-1207
CR Allen M, 1996, ABNF J, V7, P72
   Attebo K, 1997, AUST NZ J OPHTHALMOL, V25, P283, DOI 10.1111/j.1442-9071.1997.tb01516.x
   Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955
   CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   GARRAWAY WM, 1987, JAMA-J AM MED ASSOC, V258, P214, DOI 10.1001/jama.258.2.214
   Huang OS, 2013, OPHTHAL EPIDEMIOL, V20, P52, DOI 10.3109/09286586.2012.751429
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Lau JTF, 2002, BRIT J OPHTHALMOL, V86, P1080, DOI 10.1136/bjo.86.10.1080
   Noertjojo K, 2006, CAN J OPHTHALMOL, V41, P617, DOI 10.1016/S0008-4182(06)80035-9
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenthal Bruce, 2003, Optometry, V74, P16
   Sanjay S, 2009, EYE, V23, P486, DOI 10.1038/eye.2008.81
   Sanjay S, 2009, CLIN EXP OPHTHALMOL, V37, P795, DOI 10.1111/j.1442-9071.2009.02153.x
   The Royal College of Ophthalmologists, 2017, NAT EL AG REL MAC DA
   Woo JH, 2008, SINGAP MED J, V49, P850
   WORDEN JK, 1990, PREV MED, V19, P254, DOI 10.1016/0091-7435(90)90026-G
NR 18
TC 7
Z9 7
U1 0
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD AUG
PY 2014
VL 21
IS 4
BP 230
EP 236
DI 10.3109/09286586.2014.929708
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM4EV
UT WOS:000339806800005
PM 24983763
DA 2022-11-30
ER

PT J
AU Inoue, M
   Yamane, S
   Taoka, R
   Arakawa, A
   Kadonosono, K
AF Inoue, Maiko
   Yamane, Shin
   Taoka, Rina
   Arakawa, Akira
   Kadonosono, Kazuaki
TI AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY As Needed Versus Fixed
   Interval Dosing
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; aflibercept; intravitreal injection;
   polypoidal choroidal vasculopathy; branching vascular network; fixed
   dosing; pro re nata
ID MACULAR DEGENERATION; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB INJECTIONS;
   THERAPY; VERTEPORFIN; EFFICACY
AB Purpose: To evaluate the functional and morphologic outcomes of patients with polypoidal choroidal vasculopathy undergoing intravitreal aflibercept (IVA) treatment using every 2-month injections compared with a pro re nata (PRN) regimen after 3 initial monthly doses.
   Methods: The authors prospectively studied all the treatment-naive patients with polypoidal choroidal vasculopathy who were scheduled to undergo IVA using every 2-month injections or PRN after induction treatment between March 2013 and October 2013. All patients who had a follow-up period of 1 year or longer were included in the study. The best-corrected visual acuity in the 2 groups was compared before treatment and at 4 months, 6 months, and 12 months after the initial treatment. The regression of the polyps was also assessed using indocyanine-green angiography at baseline and 12 months.
   Results: Forty-two eyes were assessed at the 12-month follow-up examination. Twenty-five eyes were treated with IVA injections every 2-month after 3 initial monthly doses, and 17 eyes were treated using PRN after loading doses. The mean number of administered IVA was 7.0 in the every 2-month group and 5.0 +/- 2.9 in the PRN group, with significant difference between the 2 groups (P < 0.01). Both groups showed significant improvement of the mean logarithm of the minimum angle of resolution values for best-corrected visual acuity at 12 months, as compared with baseline values (P < 0.01 in every 8-week group and P = 0.03 in PRN group, respectively). No significant difference in the improvement of best-corrected visual acuity between the 2 groups was observed at baseline or at 4 months, 6 months, and 12 months after treatment (P > 0.05, respectively) although there was a trend toward better results in the every 8-week group. The rate of polyp regression was 48.0% (12/25) in the every 8-week group and 52.9% (9/17) in the PRN group, with no significant difference between the 2 groups (P = 0.50).
   Conclusion: Among the 2 treatment modalities, IVA was well tolerated and improved the visual outcomes in patients with polypoidal choroidal vasculopathy as evaluated at 1-year follow-up examinations. However, there was a trend toward better vision improvement with fixed treatment every 2 months.
C1 [Inoue, Maiko; Yamane, Shin; Taoka, Rina; Arakawa, Akira; Kadonosono, Kazuaki] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa, Japan.
C3 Yokohama City University
RP Inoue, M (通讯作者)，4-57 Urafune Cho,Minami Ku, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 21
TC 24
Z9 24
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2016
VL 36
IS 8
BP 1527
EP 1534
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS7MI
UT WOS:000380967200031
PM 26710307
DA 2022-11-30
ER

PT J
AU Browning, AC
   Amoaku, WM
   Dua, HS
AF Browning, AC
   Amoaku, WM
   Dua, HS
TI Treatment of age-related macular degeneration
SO JOURNAL OF THE ROYAL SOCIETY OF MEDICINE
LA English
DT Review
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; PHOTODYNAMIC THERAPY;
   TRANSLOCATION; MACULOPATHY; PREVALENCE
C1 Univ Nottingham Hosp, Queens Med Ctr, Div Ophthalmol & Visual Sci, Eye Ear Nose & Throat Ctr, Nottingham NG7 2UH, England.
C3 University of Nottingham
RP Amoaku, WM (通讯作者)，Univ Nottingham Hosp, Queens Med Ctr, Div Ophthalmol & Visual Sci, Eye Ear Nose & Throat Ctr, Nottingham NG7 2UH, England.
EM WMA@nottingham.ac.uk
OI Amoaku, Winfried/0000-0001-5028-7984
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Ciulla TA, 2003, ACTA OPHTHALMOL SCAN, V81, P103, DOI 10.1034/j.1600-0420.2003.00071.x
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V104, P1109
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MEADS C, 2002, CLIN EFFECTIVENESS C
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P7, DOI 10.1016/S0008-4182(01)80060-0
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 27
TC 6
Z9 8
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0141-0768
EI 1758-1095
J9 J ROY SOC MED
JI J. R. Soc. Med.
PD APR
PY 2004
VL 97
IS 4
BP 166
EP 169
DI 10.1258/jrsm.97.4.166
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 810JS
UT WOS:000220701200003
PM 15056736
OA Green Published
DA 2022-11-30
ER

PT J
AU Zhong, YY
   Wang, K
   Jiang, L
   Wang, JM
   Zhang, XB
   Xu, JW
   Yao, K
AF Zhong, Yueyang
   Wang, Kai
   Jiang, Li
   Wang, Jiaming
   Zhang, Xiaobo
   Xu, Jingwei
   Yao, Ke
TI Dietary fatty acid intake, plasma fatty acid levels, and the risk of
   age-related macular degeneration (AMD): a dose-response meta-analysis of
   prospective cohort studies
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Dietary fatty acid; Plasma fatty acid; Docosahexaenoic acid;
   Eicosatetraenoic acid; Age-related macular degeneration; Dose-response
   meta-analysis
ID DOCOSAHEXAENOIC ACID; EYE DISEASE; EICOSAPENTAENOIC ACID; OXIDATIVE
   STRESS; TREND ESTIMATION; OMEGA-3-FATTY-ACIDS; BIOMARKERS; HEALTH; FISH;
   PHOTORECEPTORS
AB Purpose Previous population studies on the associations between dietary fatty acids (FAs), plasma FAs levels, and the risk of age-related macular degeneration (AMD) have yielded inconclusive results. Herein, we conducted a dose-response meta-analysis to quantitatively evaluate the associations between specific type of dietary FAs, plasma FAs on early and advanced AMD risk.
   Methods PubMed, Web of Science, and EMBASE were systematically searched for observational cohort studies published through May 2020. For highest versus lowest comparison and dose-response analyses, the relative risk (RR) estimates with a 95% confidence interval (CI) were analyzed using random effects model.
   Results 11 studies with 167,581 participants were included in the meta-analysis. During the follow-up periods (ranging from 3 to 28 years), 6,318 cases of AMD were recorded. Dietary intake of docosahexaenoic acid (DHA) and eicosatetraenoic acid (EPA) combined (per 1 g/day increment) were found to be negatively associated with early AMD (RR: 0.67, 95% CI [0.51, 0.88]). Each 1 g/day increment of DHA (RR: 0.50, 95% CI [0.32, 0.78]) and EPA (RR: 0.40, 95% CI [0.18, 0.87]) was associated with a 50% and 60% reduction of early AMD risk, respectively. Plasma DHA (RR: 0.72, 95% CI [0.55, 0.95]) and EPA (RR: 0.57, 95% CI [0.40, 0.81]) indicated significant negative relationship with advanced AMD.
   Conclusion Increasing dietary intake of omega-3 polyunsaturated fatty acids (PUFAs), specifically DHA and EPA, were associated with a reduced risk of early subtype of AMD, while other types of FAs did not present significant results. Further research is warranted to explore the potential association between dietary FA, plasma FA levels, and advanced subtype of AMD.
C1 [Zhong, Yueyang; Wang, Kai; Zhang, Xiaobo; Xu, Jingwei; Yao, Ke] Zhejiang Univ, Eye Ctr, Affiliated Hosp 2, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
   [Jiang, Li; Wang, Jiaming] Zhejiang Univ, Sch Publ Hlth, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Yao, K (通讯作者)，Zhejiang Univ, Eye Ctr, Affiliated Hosp 2, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM xlren@zju.edu.cn
RI Yao, Ke/AAM-6866-2021; Xu, Jing-Wei/AGK-4569-2022; Zhong,
   Yueyang/GQI-2317-2022
OI Xu, Jing-Wei/0000-0002-5146-2251; Yao, Ke/0000-0002-6764-7365
CR Albert CM, 2002, NEW ENGL J MED, V346, P1113, DOI 10.1056/NEJMoa012918
   Amrhein V, 2019, NATURE, V567, P305, DOI 10.1038/d41586-019-00857-9
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Baylin A, 2006, CURR OPIN LIPIDOL, V17, P22, DOI 10.1097/01.mol.0000199814.46720.83
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12
   Calder PC, 2003, LIPIDS, V38, P343, DOI 10.1007/s11745-003-1068-y
   Calder PC, 2010, NUTRIENTS, V2, P355, DOI 10.3390/nu2030355
   Chew EY, 2017, JAMA-J AM MED ASSOC, V317, P2226, DOI 10.1001/jama.2017.1926
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Denke Margo A, 2006, Curr Atheroscler Rep, V8, P466, DOI 10.1007/s11883-006-0021-0
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Eckel R. H., 2014, Circulation, V129, pS76, DOI [10.1016/j.jacc.2013.11.003, 10.1161/01.cir.0000437740.48606.d1]
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elmadfa I, 2009, ANN NUTR METAB, V55, P56, DOI 10.1159/000228996
   Ferrucci L, 2006, J CLIN ENDOCR METAB, V91, P439, DOI 10.1210/jc.2005-1303
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hooper L, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002137.pub2, 10.1002/14651858.CD011834]
   Jackson D, 2012, STAT MED, V31, P3805, DOI 10.1002/sim.5453
   Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200
   Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Murota SI, 2000, ANN NY ACAD SCI, V902, P208
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Rotstein NP, 1996, J NEUROCHEM, V66, P1851
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Rucker G, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-79
   Sacca SC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060668
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sasaki M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.23
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Serra-Majem L, 2012, BRIT J NUTR, V107, pS64, DOI 10.1017/S000711451200147X
   Simon MV, 2016, J NEUROCHEM, V136, P931, DOI 10.1111/jnc.13487
   SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sun Q, 2007, AM J CLIN NUTR, V86, P74, DOI 10.1093/ajcn/86.1.74
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thesing CS, 2018, PSYCHONEUROENDOCRINO, V97, P206, DOI 10.1016/j.psyneuen.2018.07.002
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   von Schacky C, 2011, PROSTAG OTH LIPID M, V96, P94, DOI 10.1016/j.prostaglandins.2011.06.008
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2017, AM J CLIN NUTR, V105, P1483, DOI 10.3945/ajcn.116.143453
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
NR 71
TC 5
Z9 6
U1 2
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD SEP
PY 2021
VL 60
IS 6
BP 3013
EP 3027
DI 10.1007/s00394-020-02445-4
EA JAN 2021
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA TY4OR
UT WOS:000608928000002
PM 33469697
DA 2022-11-30
ER

PT J
AU Lindblad, AS
   Clemons, TE
AF Lindblad, AS
   Clemons, TE
CA Age Related Eye Dis Study Res Grp
TI Responsiveness of the National Eye Institute Visual Function
   Questionnaire to progression to advanced age-related macular
   degeneration, vision loss, and lens opacity - AREDS report No. 14
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; MACULOPATHY; INSTRUMENTS; INDEX; VF-14
AB Objective: To describe the ability of the National Eye Institute Visual Function Questionnaire (NEI-VFQ) to detect meaningful change over time (responsiveness) to the primary Age-Related Eye Disease Study outcomes.
   Methods: The 25-item NEI-VFQ plus appendix was administered at 2 visits at 1- to 4-year intervals to 4119 participants in the Age-Related Eye Disease Study. Events evaluated were progression to advanced age-related macular degeneration (AMD), visual acuity (VA) loss of at least 15 letters, and lens opacity progression. Responsiveness was measured by the t statistic, effect size (ES), responsiveness statistic, and area under the receiver operating characteristic curve. Variance components were used to estimate the contributions of events to variability of the NEI-VFQ score.
   Results: Overall NEI-VFQ score was responsive to AMD progression (t = 14.0; P <.001; ES=0.81) and VA (t=16.2; P <.001; ES=0.74). Mean changes ranged from 11 to 25 points for the subscales of general vision, near and distance activities, social functioning, mental health, role difficulties, dependency, and driving. The NEI-VFQ was unresponsive to lens opacity progression, although when the event occurred in the eye with the best vision at the first administration, the lens opacity ES was moderate for the color vision (ES=0.62) and driving subscales (ES=0.66). Progression to advanced AMD and VA loss contributed significantly to the variation in the mean difference in overall VFQ score.
   Conclusions: Changes in the NEI-VFQ overall and subscale scores of 10 points or more are associated with clinically significant changes in vision and AMD. This finding may assist the design of interventional studies of AMD and VA loss that include the NEI-VFQ as an outcome measure.
C1 EMMES Corp, AREDS Coordinating Ctr, Rockville, MD 20850 USA.
C3 Emmes Corporation
RP Lindblad, AS (通讯作者)，EMMES Corp, AREDS Coordinating Ctr, 401 N Washington St,Suite 700, Rockville, MD 20850 USA.
EM aredspub@emmes.com
FU NATIONAL EYE INSTITUTE [Z01EY000394] Funding Source: NIH RePORTER
CR Boisjoly H, 2002, AM J OPHTHALMOL, V134, P166, DOI 10.1016/S0002-9394(02)01529-5
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513
   LYDICK E, 1993, QUAL LIFE RES, V2, P221, DOI 10.1007/BF00435226
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   Stratford PW, 1996, PHYS THER, V76, P1109, DOI 10.1093/ptj/76.10.1109
NR 22
TC 82
Z9 84
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2005
VL 123
IS 9
BP 1207
EP 1214
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 961CS
UT WOS:000231640100005
PM 16157800
DA 2022-11-30
ER

PT J
AU Cui, J
   Sun, D
   Lu, H
   Dai, R
   Xing, L
   Dong, H
   Wang, L
   Wei, D
   Jiang, B
   Jiao, Y
   Jablonski, MM
   Charles, S
   Gu, W
   Chen, H
AF Cui, J.
   Sun, D.
   Lu, H.
   Dai, R.
   Xing, L.
   Dong, H.
   Wang, L.
   Wei, D.
   Jiang, B.
   Jiao, Y.
   Jablonski, M. M.
   Charles, S.
   Gu, W.
   Chen, H.
TI Comparison of effectiveness and safety between conbercept and
   ranibizumab for treatment of neovascular age-related macular
   degeneration. A retrospective case-controlled non-inferiority multiple
   center study
SO EYE
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; EXTEND PROTOCOL; OUTCOMES; EYE; BEVACIZUMAB;
   PREVALENCE; INJECTION; THERAPY
AB Purpose To compare the efficacy and safety of conbercept and ranibizumab when administered according to a treat-and-extend (TREX) protocol for the treatment of neovascular age-related macular degeneration (AMD) in China.
   Patients and methods Between May 2014 and May 2015, 180 patients were treated in a 1 : 1 ratio using conbercept or ranibizumab from four hospitals. Patients received either conbercept 0.5 mg or ranibizumab 0.5 mg intravitreal injections. Follow-up time was 1 year and treated based on a TREX approach. Main outcomes and measures include best-corrected visual acuity (BCVA), using Early Treatment Diabetic Retinopathy Study (ETDRS); number of injections; central retinal thickness (CRT); and leakage of choroidal neovascularization before and after the treatment was analyzed by fluorescein fundus angiography and indocyanine green angiography.
   Results The 1-year visit was completed by 168 (93.3%) of patients. Mean BCVA was equivalent between two cohorts, and were improved by 12.7 +/- 7.770 and 12.3 +/- 7.269 letters in the conbercept and ranibizumab cohorts, respectively (P=0.624). There was no significant difference in measured CRT, with a mean decrease of 191.5 mu m for conbercept and 187.8 mu m for ranibizumab (P=0.773). There was a statistically significant difference (P=0.001) between the drugs regarding the number of treatments: 7.4 for conbercept and 8.7 for ranibizumab. The difference in the distribution of injection intervals was statistically significant between two groups (P=0.011). During the study, there were no cases of endophthalmitis or intraocular inflammation.
   Conclusion Both drugs had equivalent effects in visual and anatomic gains at 1 year when administered. In the conbercept group, longer treatment intervals were achieved with more patients.
C1 [Cui, J.; Lu, H.; Dong, H.; Wang, L.; Wei, D.; Chen, H.] First Hosp Qiqihaer City, Ctr Integrat Res, 30 Gongyuan Rd, Qiqihar 161005, Heilongjiang, Peoples R China.
   [Cui, J.; Jiao, Y.; Gu, W.] Univ Tennessee, Hlth Sci Ctr, Dept Orthoped Surg, Memphis, TN 38163 USA.
   [Cui, J.; Jiao, Y.; Gu, W.] Univ Tennessee, Hlth Sci Ctr, BME Campbell Clin, Memphis, TN 38163 USA.
   [Sun, D.; Jiang, B.] Harbin Med Univ, Dept Ophthalmol, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China.
   [Dai, R.] Beijing Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Xing, L.] Qiqihar Med Univ, Dept Ophthalmol, Affiliated Hosp 3, Qiqihar, Heilongjiang, Peoples R China.
   [Jablonski, M. M.; Charles, S.] Univ Tennessee, Dept Ophthalmol, Hlth Sci Ctr, Memphis, TN 38163 USA.
   [Charles, S.] Charles Retina Inst, Germantown, TN USA.
   [Gu, W.] Vet Affairs Med Ctr, Res Serv, Memphis, TN USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center; Harbin Medical University; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College
   Hospital; Qiqihar Medical University; University of Tennessee System;
   University of Tennessee Health Science Center; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center
RP Chen, H (通讯作者)，First Hosp Qiqihaer City, Ctr Integrat Res, 30 Gongyuan Rd, Qiqihar 161005, Heilongjiang, Peoples R China.; Gu, W (通讯作者)，Univ Tennessee, Hlth Sci Ctr, Dept Orthoped Surg, BME, 956 Court Ave, Memphis, TN 38163 USA.
EM wgu@uthsc.edu; qsdyyych@163.com
FU First Hospital of Qiqihar City, Heilongjiang province, PR China;
   National Natural Science Foundation of China, PR China [81372996];
   Research to Prevent Blindness (New York, NY); U.S. Department of
   Veterans Affairs, TN [I01 BX000671]; Veterans Administration Medical
   Center in Memphis, TN; Veterans Affairs [I01BX000671] Funding Source:
   NIH RePORTER
FX This work was partially supported by funding from The First Hospital of
   Qiqihar City, Heilongjiang province, PR China; the National Natural
   Science Foundation of China (Project 81372996 to YJ), PR China; an
   unrestricted grant from Research to Prevent Blindness (New York, NY); a
   merit grant (I01 BX000671 to WG) from the U.S. Department of Veterans
   Affairs and the Veterans Administration Medical Center in Memphis, TN.
   The funding organizations had no role in the design or conduct of this
   research.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   [Anonymous], 2015, AM SOC RETINAL SPECI
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chaikitmongkol V, 2013, JAMA OPHTHALMOL, V131, P260, DOI 10.1001/jamaophthalmol.2013.1733
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lu Hang, 2015, Zhonghua Yan Ke Za Zhi, V51, P818
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell EP, 2013, CLIN COLORECTAL CANC, V12, P73, DOI 10.1016/j.clcc.2012.08.001
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Souied E, 2001, J FR OPHTALMOL, V24, P875
   Vedula SS, 2008, COCHRANE DB SYST REV, V16
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
NR 25
TC 27
Z9 33
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2018
VL 32
IS 2
BP 391
EP 399
DI 10.1038/eye.2017.187
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FV5VK
UT WOS:000424650300033
PM 28937147
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Giocanti-Auregan, A
   Garcia-Layana, A
   Peto, T
   Gentile, B
   Chi, GC
   Mirt, M
   Kosmas, CE
   Lambert, J
   Lanar, S
   Lewis, HB
   Holekamp, NM
AF Giocanti-Auregan, Audrey
   Garcia-Layana, Alfredo
   Peto, Tunde
   Gentile, Brittany
   Chi, Gloria C.
   Mirt, Mirela
   Kosmas, Charlotte E.
   Lambert, Jeremy
   Lanar, Sally
   Lewis, Hannah B.
   Holekamp, Nancy M.
TI Drivers of and Barriers to Adherence to Neovascular Age-Related Macular
   Degeneration and Diabetic Macular Edema Treatment Management Plans: A
   Multi-National Qualitative Study
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE qualitative interviews; treatment experience; adherence; neovascular
   age-related macular degeneration; diabetic macular edema
ID GROWTH-FACTOR THERAPY; RANIBIZUMAB TREATMENT; DISEASE BURDEN;
   EXPERIENCES; RETINOPATHY; INJECTIONS; SATURATION; CARE
AB Purpose: Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) patients treated with intravitreally injected anti-vascular endothelial growth factor (anti-VEGF) monotherapies achieve lower vision improvements compared with patients in clinical trials. This qualitative research study aimed to better understand the real-world anti-VEGF treatment experience from nAMD and DME patients', caregivers', and retina specialists' perspectives. Methods: One-time, semi-structured, individual interviews were conducted with adult patients with nAMD or DME treated with antiVEGF injections for >= 12 months, their caregivers, and experienced retina specialists. Interview transcripts were analyzed qualitatively using a thematic analysis approach. Results: A total of 49 nAMD and 46 DME patients, 47 nAMD and 33 DME caregivers, and 62 retina specialists were interviewed in the USA, Canada, France, Germany, Italy and Spain. Most (79%) patients and caregivers reported disruptions to their routine on the day before, the day of, or the day after anti-VEGF injection. Seven nAMD patients (14%) and 14 DME patients (30%) reported having missed an injection visit. The most frequently reported driver for adherence for patients was the doctor-patient relationship (n=66, 70%), whereas for caregivers, it was the ease of booking an appointment (n=25, 32%). Retina specialists reported patient education on the treatment (n=28, 45%) as the most important driver. Treatment barriers could be grouped into four categories: tolerability, clinical factors, logistical parameters and human factors. The most frequently reported barrier to adherence for patients and caregivers was related to side effects (pain/discomfort/irritation: n=63, 67% of patients; n=52, 66% of caregivers), whereas for retina specialists it was logistical parameters (travel logistics: n=44, 71%). Conclusion: This study highlights the importance of the doctor-patient relationship and patient education as key drivers, and treatment tolerability and logistics as key barriers to treatment adherence. Improved doctor-patient relationship/communication and patient education together with new therapies offering convenience, long-acting effectiveness, and better tolerability may improve treatment adherence.
C1 [Giocanti-Auregan, Audrey] Avicenne Hosp, Ophthalmol Dept, 125 Rue Stalingrad, F-93009 Bobigny, France.
   [Garcia-Layana, Alfredo] Univ Navarra, Clin Univ Navarra, Pamplona 31009, Spain.
   [Peto, Tunde] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Gentile, Brittany; Chi, Gloria C.] Genentech Inc, San Francisco, CA USA.
   [Mirt, Mirela] F Hoffmann La Roche, Basel, Switzerland.
   [Kosmas, Charlotte E.; Lewis, Hannah B.] ICON Plc, Patient Centred Outcomes, Reading, Berks, England.
   [Lambert, Jeremy; Lanar, Sally] ICON Plc, Patient Centred Outcomes, Lyon, France.
   [Holekamp, Nancy M.] Pepose Vis Inst, Chesterfield, MO USA.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Avicenne - APHP; University of Navarra; Queens University Belfast; Roche
   Holding; Genentech; Roche Holding; ICON plc; ICON plc
RP Giocanti-Auregan, A (通讯作者)，Avicenne Hosp, Ophthalmol Dept, 125 Rue Stalingrad, F-93009 Bobigny, France.
EM audrey.giocanti@aphp.fr
OI Lambert, Jeremy/0000-0002-7164-1492
FU F. Hoffmann-La Roche Ltd., Basel, Switzerland
FX F. Hoffmann-La Roche Ltd., Basel, Switzerland, provided financial
   support for the study, which was conducted by ICON plc, and participated
   in the review and approval of the manuscript. Funding was provided by F.
   Hoffmann-La Roche Ltd. for third-party writing assistance, which was
   provided by Andrea de Palma BSc, MSc, of ICON plc, and Sandra Boswell
   PhD, and Anne Nunn, PhD, CMPP, of Envision Pharma Group.
CR Bian W, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018756
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Burton AE, 2013, BRIT J VISUAL IMPA, V31, P178, DOI 10.1177/0264619613490517
   Cavan D, 2017, DIABETES RES CLIN PR, V129, P16, DOI 10.1016/j.diabres.2017.03.023
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Dervenis N, 2017, ADV THER, V34, P1270, DOI 10.1007/s12325-017-0548-1
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Gohil R, 2016, PATIENT PREFER ADHER, V10, P949, DOI 10.2147/PPA.S105536
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gomi F, 2021, J CLIN MED, V10, DOI 10.3390/jcm10143106
   Granstrom T, 2018, NORD J NURS RES, V38, P11, DOI [10.1177/2057158517709409, DOI 10.1177/2057158517709409]
   Hartnett ME, 2005, ARCH OPHTHALMOL-CHIC, V123, P387, DOI 10.1001/archopht.123.3.387
   Hennink MM, 2017, QUAL HEALTH RES, V27, P591, DOI 10.1177/1049732316665344
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Jelin E, 2018, ACTA OPHTHALMOL, V96, P804, DOI 10.1111/aos.13847
   Joffe H, 2004, RES METHODS CLIN HLT, DOI DOI 10.4135/9781849209793
   Kerr C, 2010, EXPERT REV PHARM OUT, V10, P269, DOI [10.1586/erp.10.30, 10.1586/ERP.10.30]
   MacKinnon JR, 2002, OXFORD TXB ENDOCRINO, P1764
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Muller S, 2017, GRAEF ARCH CLIN EXP, V255, P2237, DOI 10.1007/s00417-017-3739-1
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Okada M, 2021, JAMA OPHTHALMOL, V139, P769, DOI 10.1001/jamaophthalmol.2021.1660
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Peters CM, 2012, INVEST OPHTHALMOL VI, V53, P5449
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Sobolewska B, 2021, CLIN OPHTHALMOL, V15, P4317, DOI 10.2147/OPTH.S325763
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   VERBI Software, 2019, MAXQDA 2020
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
   Wolf A, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910362
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 39
TC 1
Z9 1
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2022
VL 16
BP 587
EP 604
DI 10.2147/PPA.S347713
PG 18
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZO3GZ
UT WOS:000765618000001
PM 35264847
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Holekamp, N
   Wykoff, CC
   Schmitz-Valckenberg, S
   Mones, J
   Souied, EH
   Lin, H
   Rabena, MD
   Cantrell, RA
   Henry, EC
   Tang, F
   Swaminathan, B
   Martin, J
   Ferrara, D
   Staurenghi, G
AF Holekamp, Nancy
   Wykoff, Charles C.
   Schmitz-Valckenberg, Steffen
   Mones, Jordi
   Souied, Eric H.
   Lin, Hugh
   Rabena, Melvin D.
   Cantrell, Ronald A.
   Henry, Erin C.
   Tang, Fan
   Swaminathan, Balakumar
   Martin, Jillian
   Ferrara, Daniela
   Staurenghi, Giovanni
TI Natural History of Geographic Atrophy Secondary to Age-Related Macular
   Degeneration Results from the Prospective Proxima A and B Clinical
   Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY LOSS; EYE DISEASE; PROGRESSION; ENLARGEMENT; AREA
AB Purpose: To better characterize visual function decline and geographic atrophy (GA) progression secondary to age-related macular degeneration (AMD).
   Design: Proxima A (NCT02479386)/Proxima B (NCT02399072) were global, prospective, noninterventional, observational clinical trials.
   Participants: Eligible patients were aged >= 50 years.
   Patients in Proxima A had bilateral GA without choroidal neovascularization (CNV) in either eye (N = 295). Patients in Proxima B had GA without CNV in the study eye and CNV +/- GA in the fellow eye (fellow eye CNV cohort, n = 168) or GA without CNV in the study eye, no CNV/GA in the fellow eye (fellow eye intermediate AMD cohort, n = 32).
   Methods: Changes in visual function and imaging/anatomic parameters were evaluated over time using a mixed model for repeated measurement accounting for key baseline characteristics.
   Main Outcome Measures: Prespecified end points included change in GA area from baseline, best-corrected visual acuity (BCVA) score assessed by Early Treatment Diabetic Retinopathy Study (ETDRS), and visual acuity under low-luminance (LLVA).
   Results: At 24 months, adjusted mean (standard error) change in GA lesion area from baseline was 3.87 (0.15) mm(2) in participants with bilateral GA (Proxima A), 3.55 (0.16) mm(2) in the fellow eye CNV cohort (Proxima B), and 2.96 (0.25) mm(2) in the fellow eye intermediate AMD cohort (Proxima B). Progression of GA was greater in patients with baseline nonsubfoveal (vs. subfoveal) GA lesions and tended to increase as baseline low-luminance deficit increased (all patients). Conversion to GA or CNV in the fellow eye occurred in 30% and 6.7% of participants, respectively, in the Proxima B intermediate AMD cohort at month 12. Adjusted mean (standard error) changes in BCVA and LLVA (ETDRS letters) in the study eye from baseline to 24 months were -13.88 (1.40) and -7.64 (1.20) in Proxima A, -9.49 (1.29) and -7.57 (1.26) in Proxima B fellow eye CNV cohort, and -11.48 (3.39) and -8.37 (3.02) in Proxima B fellow eye intermediate AMD cohort, respectively.
   Conclusions: The prospective Proxima A and B studies highlight the severe functional impact of GA and the rapid rate of GA lesion progression over a 2-year period, including in patients with unilateral GA at baseline. (C) 2019 by the American Academy of Ophthalmology.
C1 [Holekamp, Nancy] Pepose Vis Inst, Chesterfield, MO USA.
   [Holekamp, Nancy] Washington Univ, Sch Med, St Louis, MO USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Blanton Eye Inst, Retina Consultants Houston, Houston, TX 77030 USA.
   [Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Bonn, GRADE Reading Ctr, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Mones, Jordi] Inst Macula, Barcelona, Spain.
   [Mones, Jordi] Barcelona Macula Fdn, Barcelona, Spain.
   [Souied, Eric H.] Ctr Hosp Intercommunal, Creteil, France.
   [Souied, Eric H.] Univ Paris Est, Paris, France.
   [Lin, Hugh; Rabena, Melvin D.; Cantrell, Ronald A.; Henry, Erin C.; Tang, Fan; Martin, Jillian; Ferrara, Daniela] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
   [Swaminathan, Balakumar] Hoffmann La Roche Ltd, Mississauga, ON, Canada.
   [Staurenghi, Giovanni] Univ Milan, Dept Biomed & Clin Sci, Eye Clin, Luigi Sacco Sacco Hosp, Milan, Italy.
C3 Washington University (WUSTL); The Methodist Hospital System; The
   Methodist Hospital - Houston; University of Bonn; University of Bonn;
   Utah System of Higher Education; University of Utah; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Roche Holding;
   Genentech; University of Milan; Luigi Sacco Hospital
RP Lin, H (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM lin.hugh@gene.com
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160
FU F. Hoffmann-La Roche, Ltd., Basel, Switzerland; Genentech, Inc.; F.
   Hoffmann-La Roche Ltd.
FX F. Hoffmann-La Roche, Ltd., Basel, Switzerland, provided financial
   support for the study and participated in the study design; conduct of
   the studies; collection, management, analysis, and interpretation of the
   data; preparation, review, and approval of the manuscript; and decision
   to submit the manuscript for publication. Funding was provided by
   Genentech, Inc. and F. Hoffmann-La Roche Ltd. for third-party writing
   assistance, which was provided by Emily Bailey, MRes, and Joanne
   Vaughan, BSc, CMPP, of Envision Pharma Group.
CR Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   CHAKRAVARTHY U, 2017, INVEST OPHTHALMOL VI, V58
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Domalpally A, 2018, OPHTHALMOL RETINA, V2, P1021, DOI 10.1016/j.oret.2018.04.009
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   PIERAMICI DJ, 2018, INVEST OPHTH VIS SCI, V59
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   World Medical Association, WMA DECL HELS ETH PR
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 31
TC 26
Z9 26
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2020
VL 127
IS 6
BP 769
EP 783
DI 10.1016/j.ophtha.2019.12.009
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MR8XV
UT WOS:000553874500012
PM 32081489
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Smailhodzic, D
   Muether, PS
   Chen, J
   Kwestro, A
   Zhang, AY
   Omar, A
   Van de Ven, JPH
   Keunen, JEE
   Kirchhof, B
   Hoyng, CB
   Klevering, BJ
   Koenekoop, RK
   Fauser, S
   den Hollander, AI
AF Smailhodzic, Dzenita
   Muether, Philipp S.
   Chen, John
   Kwestro, Angela
   Zhang, Alice Yang
   Omar, Amer
   Van de Ven, Johannes P. H.
   Keunen, Jan E. E.
   Kirchhof, Bernd
   Hoyng, Carel B.
   Klevering, B. Jeroen
   Koenekoop, Robert K.
   Fauser, Sascha
   den Hollander, Anneke I.
TI Cumulative Effect of Risk Alleles in CFH, ARMS2, and VEGFA on the
   Response to Ranibizumab Treatment in Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULAR
   MEMBRANES; INTRAVITREAL RANIBIZUMAB; MACULOPATHY; ASSOCIATION;
   POLYMORPHISM; THERAPY; PHARMACOGENETICS; BEVACIZUMAB
AB Purpose: Intravitreal ranibizumab injections currently are the standard treatment for neovascular age-related macular degeneration (AMD). However, a broad range of response rates have been observed, the reasons for which are poorly understood. This pharmacogenetic study evaluated the impact of high-risk alleles in CFH, ARMS2, VEGFA, vascular endothelial growth factor (VEGF) receptor KDR, and genes involved in angiogenesis (LRP5, FZD4) on the response to ranibizumab treatment and on the age of treatment onset. In contrast to previous studies, the data were stratified according to the number of high-risk alleles to enable the study of the combined effects of these genotypes on the treatment response.
   Design: Case series study.
   Participants: A cohort of 420 eyes of 397 neovascular AMD patients.
   Methods: The change in visual acuity (VA) between baseline and after 3 ranibizumab injections was calculated. Genotyping of single nucleotide polymorphisms in the CFH, ARMS2, VEGFA, KDR, LPR5, and FZD4 genes was performed. Associations were assessed using linear mixed models.
   Main Outcome Measures: The VA change after 3 ranibizumab injections and the age of neovascular disease onset.
   Results: After ranibizumab treatment, AMD patients without risk alleles in the CFH and ARMS2 genes (4.8%) demonstrated a mean VA improvement of 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, whereas no VA improvement was observed in AMD patients with 4 CFH and ARMS2 risk alleles (6.9%; P = 0.014). Patients with 4 high-risk alleles in CFH and ARMS2 were 5.2 years younger than patients with 1 or 2 risk alleles, respectively (63.5%; P<0.0001). The mean age at which the first ranibizumab treatment was carried out among AMD patients with all 6 risk alleles in CFH, ARMS2, and VEGFA was 65.9 years (2%) versus 75.3 years in patients with 0 or 1 high-risk allele (8.8%; P = 0.001). After ranibizumab treatment, patients with 6 high-risk alleles demonstrated a mean VA loss of 10 ETDRS letters (P<0.0001).
   Conclusions: This study evaluated the largest pharmacogenetic AMD cohort reported to date. A cumulative effect of high-risk alleles in CFH, ARMS2, and VEGFA seems to be associated with a younger age of onset in combination with poor response rates to ranibizumab treatment.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:2304-2311 (C) 2012 by the American Academy of Ophthalmology.
C1 [Smailhodzic, Dzenita; Kwestro, Angela; Van de Ven, Johannes P. H.; Keunen, Jan E. E.; Hoyng, Carel B.; Klevering, B. Jeroen; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands.
   [Muether, Philipp S.; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Dept Ophthalmol, D-50931 Cologne, Germany.
   [Chen, John; Zhang, Alice Yang; Omar, Amer; Koenekoop, Robert K.] McGill Univ, Dept Ophthalmol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 EX Nijmegen, Netherlands.
C3 Radboud University Nijmegen; University of Cologne; McGill University;
   Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM A.denHollander@ohk.umcn.nl
RI Omar, Amer/M-5342-2019; Zhang, Alice Yang/Y-8148-2018; Keunen,
   J.E.E./H-8061-2014; Hollander, Anneke den/N-4911-2014; Hoyng,
   C.B./H-8050-2014; Koenekoop, Robert/AAT-6676-2021; Klevering,
   B.J./L-4434-2015
OI Omar, Amer/0000-0003-1520-392X; Zhang, Alice Yang/0000-0001-5194-5256; 
FU Netherlands Organization for Scientific Research, The Hague, the
   Netherlands [016.096.309]; MD Fonds, Utrecht, the Netherlands; Oogfonds,
   Utrecht, the Netherlands; Landelijke Stichting voor Blinden en
   Slechtzienden, Utrecht, the Netherlands; Algemene Nederlandse Vereniging
   ter Voorkoming van Blindheid, Doorn, the Netherlands; Stichting A.F.
   Deutman Oogheelkunde Researchfonds, Nijmegen, the Netherlands; Stichting
   Nederlands Oogheelkundig Onderzoek, Rotterdam, the Netherlands;
   Stichting Blindenhulp, Den Haag, the Netherlands; Gelderse
   Blindenstichting, Velp, the Netherlands; Nijmeegse Oogonderzoek
   Stichting, Nijmegen, the Netherlands; Foundation Fighting Blindness
   Canada, Toronto, Canada; Koeln Fortune Program/Faculty of Medicine,
   University of Cologne, Cologne, Germany
FX Supported by the Netherlands Organization for Scientific Research, The
   Hague, the Netherlands (grant no. 016.096.309); the MD Fonds, Utrecht,
   the Netherlands; Oogfonds, Utrecht, the Netherlands; Landelijke
   Stichting voor Blinden en Slechtzienden, Utrecht, the Netherlands;
   Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Doorn, the
   Netherlands; Stichting A.F. Deutman Oogheelkunde Researchfonds,
   Nijmegen, the Netherlands; Stichting Nederlands Oogheelkundig Onderzoek,
   Rotterdam, the Netherlands; Stichting Blindenhulp, Den Haag, the
   Netherlands; the Gelderse Blindenstichting, Velp, the Netherlands;
   Nijmeegse Oogonderzoek Stichting, Nijmegen, the Netherlands; the
   Foundation Fighting Blindness Canada, Toronto, Canada; and by the Koeln
   Fortune Program/Faculty of Medicine, University of Cologne, Cologne,
   Germany.
CR Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chan IS, 2011, ANNU REV GENOM HUM G, V12, P217, DOI 10.1146/annurev-genom-082410-101446
   Dugel Pravin U, 2006, Int Ophthalmol Clin, V46, P131, DOI 10.1097/01.iio.0000212142.15794.30
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Ma Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/pr.110.003533
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Shahbazi M, 2002, J AM SOC NEPHROL, V13, P260, DOI 10.1681/ASN.V131260
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Teper SJ, 2010, MOL VIS, V16, P2598
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 37
TC 83
Z9 89
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2012
VL 119
IS 11
BP 2304
EP 2311
DI 10.1016/j.ophtha.2012.05.040
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030OH
UT WOS:000310579500017
PM 22840423
DA 2022-11-30
ER

PT J
AU Aranaz, M
   Costas-Rodriguez, M
   Lobo, L
   Gonzalez-Iglesias, H
   Vanhaecke, F
   Pereiro, R
AF Aranaz, Marta
   Costas-Rodriguez, Marta
   Lobo, Lara
   Gonzalez-Iglesias, Hector
   Vanhaecke, Frank
   Pereiro, Rosario
TI Pilot study of homeostatic alterations of mineral elements in serum of
   patients with age-related macular degeneration via elemental and
   isotopic analysis using ICP-mass spectrometry
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Age-related macular degeneration; Blood serum; Elemental determinations;
   Isotopic composition; Sector-field ICP-MS; Multi-collector ICP-MS
ID BLOOD-SERUM; CU; COPPER; HEALTHY; DISEASE; ZINC; DIAGNOSIS; TISSUES
AB Age-related macular degeneration (AMD), the main cause of irreversible blindness in people over 60 years of age, is an eye disease that evolves with loss of central vision. Although AMD manifests itself in the eye, blood is continuously flowing through the macular region, such that potential alterations in this region could be reflected in the composition of whole blood or plasma/serum. Therefore, the potential clinical relevance of analysis of serum samples was assessed because of the low degree of invasiveness of blood sampling. 40 initial samples (20 from controls and 20 from patients with the dry form of AMD) have been analysed in this work to investigate the possible occurrence of homeostatic alterations of essential mineral elements caused by the disease. Both major (Na, Mg, P and K) and trace (Fe, Cu and Zn) essential mineral elements were determined in blood serum using single-collector ICP-mass spectrometry. Also, the isotopic composition of Cu (an element proposed to be directly involved in the onset of AMD) was determined using multi-collector ICP-mass spectrometry. Unexpected light Cu isotopic compositions in three individuals assumed as controls, resulted in a re-evaluation of their clinical information and a later exclusion due to pathologies initially not accounted for. In this pilot study, a significant alteration in the delta Cu-65 value has been found between the two final cohorts (AMD patients: n = 20; controls n = 17), with lower delta Cu-66 values (i.e. an enrichment in the light Cu-63 isotope) in the case of AMD. Also, higher serum concentrations of the elements P and Zn were established in AMD at a systemic level. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Aranaz, Marta; Lobo, Lara; Pereiro, Rosario] Univ Oviedo, Dept Phys & Analyt Chem, Avda Julian Claveria 8, E-33006 Oviedo, Spain.
   [Costas-Rodriguez, Marta; Vanhaecke, Frank] Univ Ghent, Dept Chem, A&MS Res Unit, Campus Sterre,Krijgslaan 281-S12, B-9000 Ghent, Belgium.
   [Gonzalez-Iglesias, Hector] Inst Oftalmol Fernandez Vega, Avda Fernandez Vega 34, Oviedo 33012, Spain.
   [Gonzalez-Iglesias, Hector; Pereiro, Rosario] Univ Oviedo, Inst Univ Fernandez Vega, Fdn Invest Oftalmol, Oviedo, Spain.
C3 University of Oviedo; Ghent University; University of Oviedo
RP Lobo, L (通讯作者)，Univ Oviedo, Dept Phys & Analyt Chem, Avda Julian Claveria 8, E-33006 Oviedo, Spain.
EM lobolara@uniovi.es
RI Rodriguez, Marta Costas/K-3862-2012; Gonzalez-Iglesias,
   Hector/K-2447-2014; Pereiro, Rosario/D-2485-2014; Gonzalez-Iglesias,
   Hector/AAB-5993-2019; Vanhaecke, Frank/AAO-4582-2020; Lobo Revilla,
   Lara/O-6592-2014
OI Rodriguez, Marta Costas/0000-0002-8159-9961; Gonzalez-Iglesias,
   Hector/0000-0001-5251-0967; Pereiro, Rosario/0000-0002-5936-7726;
   Vanhaecke, Frank/0000-0002-1884-3853; Aranaz, Marta/0000-0002-4184-474X;
   Lobo Revilla, Lara/0000-0001-5342-223X
FU Agencia Estatal de Investigation, Spain [CTQ2016-79015-R];
   FWO-Vlaanderen; FEDER; Catedra Rafael del Pino
FX This work was supported by project CTQ2016-79015-R(Agencia Estatal de
   Investigation, Spain) and FEDER. Marta Costas Rodriguez acknowledges
   FWO-Vlaanderen for the postdoctoral grant. The lnstituto Oftalmologico
   Fernandez - Vega and Fundacion de Investigacion Oftalmologica
   acknowledge support from "Catedra Rafael del Pino".
CR Abduljabbar TN, 2019, TALANTA, V204, P663, DOI 10.1016/j.talanta.2019.05.098
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Albarede F, 2011, METALLOMICS, V3, P926, DOI 10.1039/c1mt00025j
   [Anonymous], [No title captured]
   Aramendia M, 2013, J ANAL ATOM SPECTROM, V28, P675, DOI 10.1039/c3ja30349g
   Balter V, 2015, P NATL ACAD SCI USA, V112, P982, DOI 10.1073/pnas.1415151112
   Cao B, 2019, J TRACE ELEM MED BIO, V51, P79, DOI 10.1016/j.jtemb.2018.10.009
   CAROLI S, 1994, CRIT REV ANAL CHEM, V24, P363, DOI 10.1080/10408349408048824
   Costas-Rodriguez M, 2015, METALLOMICS, V7, P491, DOI 10.1039/c4mt00319e
   Das A, 2019, FUTURE GENER COMP SY, V93, P486, DOI 10.1016/j.future.2018.10.050
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P5702, DOI 10.1167/iovs.14-14774
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Krachler M, 1999, BIOL TRACE ELEM RES, V68, P121, DOI 10.1007/BF02784401
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lauwens S, 2018, TALANTA, V189, P332, DOI 10.1016/j.talanta.2018.07.011
   Lauwens S, 2018, ANAL CHIM ACTA, V1025, P69, DOI 10.1016/j.aca.2018.05.025
   Lauwens S, 2016, SCI REP-UK, V6, DOI 10.1038/srep30683
   Lobo L, 2017, TALANTA, V165, P92, DOI 10.1016/j.talanta.2016.12.007
   Majewska U, 2016, SPECTROCHIM ACTA B, V122, P56, DOI 10.1016/j.sab.2016.05.001
   Pohl Hana R, 2013, Met Ions Life Sci, V13, P29, DOI 10.1007/978-94-007-7500-8_2
   Saiki M, 2007, J TRACE ELEM MED BIO, V21, P70, DOI 10.1016/j.jtemb.2007.09.022
   Sarwar S, 2017, PROSTATE CANCER, V2017, DOI 10.1155/2017/5687212
   Telouk P, 2015, METALLOMICS, V7, P299, DOI 10.1039/c4mt00269e
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
NR 30
TC 9
Z9 9
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 0731-7085
EI 1873-264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD JAN 1
PY 2020
VL 177
AR 112857
DI 10.1016/j.jpba.2019.112857
PG 7
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA JK9HA
UT WOS:000495148000043
PM 31557587
DA 2022-11-30
ER

PT J
AU Schuman, SG
   Koreishi, AF
   Farsiu, S
   Jung, SH
   Izatt, JA
   Toth, CA
AF Schuman, Stefanie G.
   Koreishi, Anjum F.
   Farsiu, Sina
   Jung, Sin-ho
   Izatt, Joseph A.
   Toth, Cynthia A.
TI Photoreceptor Layer Thinning over Drusen in Eyes with Age-Related
   Macular Degeneration Imaged In Vivo with Spectral-Domain Optical
   Coherence Tomography
SO OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; FOLLOW-UP; MACULOPATHY; PATHOGENESIS; ABNORMALITIES;
   LIPIDS
AB Purpose: Detect changes in the neurosensory retina using spectral-domain optical coherence tomography (SD OCT) imaging over drusen in age-related macular degeneration (AMD). Quantitative imaging biomarkers may aid in defining risk of disease progression.
   Design: Cross-sectional, case-control study evaluating SD OCT testing in AMD.
   Participants and Controls: Seventeen eyes of 12 subjects with nonneovascular AMD and drusen and 17 eyes of 10 age-matched control subjects.
   Methods: Spectral-domain OCT imaging across the fovea in the study eye with multiple 10- to 12-mm scans of 1000 A scans each.
   Main Outcome Measures: In summed SD OCT scans, the height of individual retinal layers either over drusen or at corresponding locations in the control eye and qualitative changes in retinal layers over drusen. Secondary measures included photoreceptor layer (PRL) area, inner retinal area, and retinal pigment epithelium (RPE)/drusen area.
   Results: The PRL was thinned over 97% of drusen, average PRL thickness was reduced by 27.5% over drusen compared with over a similar location in controls, and the finding of a difference was valid and significant (P = 0.004). Photoreceptor outer segments were absent over at least 1 druse in 47% of eyes. Despite thinning of the PRL, inner retinal thickness remained unchanged. We observed 2 types of hyperreflective abnormalities in the neurosensory retina over drusen. Distinct hyperreflective speckled patterns occurred over drusen in 41% of AMD eyes and never in control eyes. A prominent hyperreflective haze was present in the photoreceptor nuclear layer over drusen in 67% of AMD eyes and more subtly in the photoreceptor nuclear layer in 18% of control eyes (no drusen).
   Conclusions: With SD OCT as used in this study, we can easily detect and measure changes in PRL over drusen. Decreased PRL thickness over drusen suggests a degenerative process, with cell loss leading to decreased visual function. The hyperreflective foci overlying drusen are likely to represent progression of disease RPE cell migration into the retina and possible photoreceptor degeneration or glial scar formation. A longitudinal study using SD OCT to examine and measure the neurosensory retina over drusen will resolve the timeline of degenerative changes relative to druse formation.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009; 116:488-496 (C) 2009 by the American Academy of Ophthalmology.
C1 [Toth, Cynthia A.] Duke Univ, Ctr Eye, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Jung, Sin-ho] Duke Univ, Dept Biostat & Bioinformat, Med Ctr, Durham, NC 27710 USA.
   [Izatt, Joseph A.; Toth, Cynthia A.] Duke Univ, Pratt Sch Engn, Dept Biomed Engn, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Toth, CA (通讯作者)，Duke Univ, Ctr Eye, Med Ctr, Dept Ophthalmol, DUMC 3802, Durham, NC 27710 USA.
EM cynthia.toth@duke.edu
RI Izatt, Joseph/C-9067-2014; Toth, Cynthia/L-5534-2019; toth, cynthia
   a/F-5614-2011
OI Izatt, Joseph/0000-0003-1993-2249; Toth, Cynthia/0000-0002-2324-0854;
   Farsiu, Sina/0000-0003-4872-2902
FU Bioptuen, Inc.; Research Triangle Park, North Carolina; Duke University,
   Durham, North Carolina; North Carolina Biotechnology Center, Research
   Triangle Park, North Carolina [2007-CFG-8005]; National Institutes of
   Health, Bethesda, Maryland [R21 EY017393, 1 UL1 RR024128-01]; NATIONAL
   CENTER FOR RESEARCH RESOURCES [UL1RR024128] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R21EY017393] Funding Source: NIH
   RePORTER
FX Supported in part by Bioptuen. Inc., Research Triangle Park, North
   Carolina; Duke University, Durham, North Carolina: and The North
   Carolina Biotechnology Center, Research Triangle Park, North Carolina
   (Collaborative Funding Grant no.: 2007-CFG-8005) the National Institutes
   of Health, Bethesda. Maryland (grant nos.: R21 EY017393 and 1 UL1
   RR024128-01 [S.-h.J.]).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   *AM NAT STAND SAF, 2000, Z13612000 ANSI
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Caicedo A, 2005, J COMP NEUROL, V483, P263, DOI 10.1002/cne.20413
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Green W R, 1999, Mol Vis, V5, P27
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kampmeier J, 2006, KLIN MONATSBL AUGENH, V223, P752, DOI 10.1055/s-2006-926880
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 33
TC 193
Z9 197
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2009
VL 116
IS 3
BP 488
EP 496
DI 10.1016/j.ophtha.2008.10.006
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 416KQ
UT WOS:000264005400020
PM 19167082
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Lores-Motta, L
   van Beek, AE
   Willems, E
   Zandstra, J
   van Mierlo, G
   Einhaus, A
   Mary, JL
   Stucki, C
   Bakker, B
   Hoyng, CB
   Fauser, S
   Clark, SJ
   de Jonge, MI
   Nogoceke, E
   Koertvely, E
   Jongerius, I
   Kuijpers, TW
   den Hollander, AI
AF Lores-Motta, Laura
   van Beek, Anna E.
   Willems, Esther
   Zandstra, Judith
   van Mierlo, Gerard
   Einhaus, Alfred
   Mary, Jean-Luc
   Stucki, Corinne
   Bakker, Bjorn
   Hoyng, Carel B.
   Fauser, Sascha
   Clark, Simon J.
   de Jonge, Marien, I
   Nogoceke, Everson
   Koertvely, Elod
   Jongerius, Ilse
   Kuijpers, Taco W.
   den Hollander, Anneke, I
TI Common haplotypes at the CFH locus and low-frequency variants in CFHR2
   and CFHR5 associate with systemic FHR concentrations and age-related
   macular degeneration
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; ENDOTHELIAL-CELLS;
   BINDING-AFFINITY; PLASMA-LEVELS; RISK; RARE; PROTEINS; GENES;
   POLYMORPHISM
AB Age-related macular degeneration (AMD) is the principal cause of blindness in the elderly population. A strong effect on AMD risk has been reported for genetic variants at the CFH locus, encompassing complement factor H (CFH) and the complement-factor-H-related (CFHR) genes, but the underlying mechanisms are not fully understood. We aimed to dissect the role of factor H (FH) and FH-related (FHR) proteins in AMD in a cohort of 202 controls and 216 individuals with AMD. We detected elevated systemic levels of FHR-1 (p = 1.84 3 10(-6)), FHR-2 (p = 1.47 3 10(-4)), FHR-3 (p = 1.05 3 10(-5)) and FHR-4A (p = 1.22 3 10(-2)) in AMD, whereas FH concentrations remained unchanged. Common AMD genetic variants and haplotypes at the CFH locus strongly associated with FHR protein concentrations (e.g., FH p.Tyr402His and FHR-2 concentrations, p = 3.68 310(-17)), whereas the association with FH concentrations was limited. Furthermore, in an International AMD Genomics Consortium cohort of 17,596 controls and 15,894 individuals with AMD, we found that low-frequency and rare protein-altering CFHR2 and CFHR5 variants associated with AMD independently of all previously reported genome-wide association study (GWAS) signals (p = 5.03 x 10(-3) and p = 2.81 x 10(-6), respectively). Low-frequency variants in CFHR2 and CFHR5 led to reduced or absent FHR-2 and FHR-5 concentrations (e.g., p.Cys72Tyr in CFHR2 and FHR-2, p = 2.46 3 10(-16)). Finally, we showed localization of FHR-2 and FHR-5 in the choriocapillaris and in drusen. Our study identifies FHR proteins as key proteins in the AMD disease mechanism. Consequently, therapies that modulate FHR proteins might be effective for treating or preventing progression of AMD. Such therapies could target specific individuals with AMD on the basis of their genotypes at the CFH locus.
C1 [Lores-Motta, Laura; Bakker, Bjorn; Hoyng, Carel B.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands.
   [Lores-Motta, Laura; Einhaus, Alfred; Mary, Jean-Luc; Stucki, Corinne; Fauser, Sascha; Nogoceke, Everson; Koertvely, Elod] F Hoffmann Roche Ltd, Roche Pharma Res & Early Dev, Roche Innovat Ctr Basel, CH-4070 Basel, Switzerland.
   [van Beek, Anna E.; Zandstra, Judith; van Mierlo, Gerard; Jongerius, Ilse] Univ Amsterdam, Amsterdam Univ, Med Ctr, Dept Immunopathol,Sanquin Res & Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands.
   [van Beek, Anna E.; Zandstra, Judith; Jongerius, Ilse; Kuijpers, Taco W.] Univ Amsterdam, Emma Childrens Hosp, Dept Pediat Immunol Rheumatol & Infect Dis, Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [van Beek, Anna E.] Swiss Trop & Publ Hlth Inst, Dept Med Parasitol & Infect Biol, CH-4051 Basel, Switzerland.
   [van Beek, Anna E.] Univ Basel, CH-4051 Basel, Switzerland.
   [Willems, Esther; de Jonge, Marien, I] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Med Ctr, Lab Med Immunol,Dept Lab Med, NL-6525 GA Nijmegen, Netherlands.
   [Willems, Esther; de Jonge, Marien, I] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, NL-6525 GA Nijmegen, Netherlands.
   [Willems, Esther] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Translat Metab Lab,Dept Lab Med, NL-6525 GA Nijmegen, Netherlands.
   [Clark, Simon J.] Univ Tubingen, Dept Ophthalmol, Univ Eye Clin, D-72076 Tubingen, Germany.
   [Clark, Simon J.] Eberhard Karls Univ Tubingen, Inst Ophthalm Res, D-72076 Tubingen, Germany.
   [Clark, Simon J.] Univ Manchester, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester M13 9PL, Lancs, England.
   [Kuijpers, Taco W.] Univ Amsterdam, Amsterdam Univ, Dept Blood Cell Res, Sanquin Res & Landsteiner Lab,Med Ctr, NL-1066 CX Amsterdam, Netherlands.
   [den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, NL-6525 GA Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Roche Holding; University of Amsterdam;
   Emma Children's Hospital; University of Amsterdam; University of Basel;
   Swiss Tropical & Public Health Institute; University of Basel; Radboud
   University Nijmegen; Radboud University Nijmegen; Radboud University
   Nijmegen; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; University of Manchester; University of
   Amsterdam; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands.; den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, NL-6525 GA Nijmegen, Netherlands.
EM Anneke.denHollander@radboudumc.nl
RI Bakker, Bjorn/E-2842-2016; de Jonge, Marien I./P-5869-2015
OI de Jonge, Marien I./0000-0003-2812-5895; Willems,
   Esther/0000-0002-7993-9613; Clark, Simon/0000-0001-8394-8355
FU Roche Postdoctoral Fellowship Programme (RPF) [480]; European Union's
   Seventh Framework program under EC-GA (EUCLIDS) [279185]; European Union
   Horizon 2020 research and innovation program under EC-GA [668303];
   Oogfonds; MaculaFonds; Landelijke Stichting voor Blinden en
   Slechtzienden; Stichting Blindenhulp; Stichting A.F. Deutman
   Oogheelkunde Researchfonds; Dutch Research Council [016.096.309];
   European Research Council under the European Union's Seventh Framework
   Programme (FP/2007-2013) (ERC grant) [310644]; Center for Inherited
   Disease Research [HHSN268201200008I]; Case Western Reserve University,
   Cleveland [EY022310]; University of Michigan, Department of
   Biostatistics [1x01HG006934-01]
FX This study was funded by the Roche Postdoctoral Fellowship Programme
   (RPF-ID 480). The study was partially supported by the European Union's
   Seventh Framework program under EC-GA no. 279185 (EUCLIDS) and by the
   European Union Horizon 2020 research and innovation program under EC-GA
   no. 668303 (PERFORM). The EUGENDA cohort was funded by grants from the
   Oogfonds, MaculaFonds, Landelijke Stichting voor Blinden en
   Slechtzienden, Stichting Blindenhulp, Stichting A.F. Deutman
   Oogheelkunde Researchfonds, the Dutch Research Council (Vidi
   Innovational Research Award 016.096.309), and the European Research
   Council under the European Union's Seventh Framework Programme
   (FP/2007-2013) (ERC grant agreement no. 310644 MACULA). The EUGENDA
   samples were genotyped as part of the IAMDGC exome chip project
   supported by the Center for Inherited Disease Research (contract number
   HHSN268201200008I) and funded by EY022310 (to Jonathan L. Haines, Case
   Western Reserve University, Cleveland) and 1x01HG006934-01 (to Goncalo
   R. Abecasis, University of Michigan, Department of Biostatistics). We
   would like to acknowledge the contribution of the International AMD
   Genomics Consortium (IAMDGC) for providing genotypes at the CFH locus
   from the IAMDGC dataset, and we thank Iris Heid and Thomas Winkler for
   aiding in the data extraction. We thank Tessel Galesloot for her
   critical revision of the manuscript.
CR Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x
   Alic L, 2020, P NATL ACAD SCI USA, V117, P9942, DOI 10.1073/pnas.1913970117
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Cantsilieris S, 2018, P NATL ACAD SCI USA, V115, pE4433, DOI 10.1073/pnas.1717600115
   Cipriani V, 2021, AM J HUM GENET, V108, P1385, DOI 10.1016/j.ajhg.2021.05.015
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cserhalmi M, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101341
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   FONTAINE M, 1989, BIOCHEM J, V258, P927, DOI 10.1042/bj2580927
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kubista KE, 2011, MOL VIS, V17, P2080
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811
   Lee S, 2012, BIOSTATISTICS, V13, P762, DOI 10.1093/biostatistics/kxs014
   Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Pouw RB, 2019, BLOOD ADV, V3, P621, DOI 10.1182/bloodadvances.2018025692
   Pouw RB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00729
   Pouw RB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152164
   R Core Team, 2022, R LANG ENV STAT COMP
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Rentzsch P, 2019, NUCLEIC ACIDS RES, V47, pD886, DOI 10.1093/nar/gky1016
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Sanchez-Corral P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01607
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Silva AS, 2012, MOL VIS, V18, P2288
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   SKERKA C, 1992, J IMMUNOL, V148, P3313
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Strunz T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24219-z
   TIMMANN C, 1991, J IMMUNOL, V146, P1265
   Turner S., 2017, QQMAN Q Q MANHATTAN
   van Beek AE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01328
   Wei T., 2021, R PACKAGE CORRPLOT V
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 62
TC 20
Z9 20
U1 1
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD AUG 5
PY 2021
VL 108
IS 8
BP 1367
EP 1384
DI 10.1016/j.ajhg.2021.06.002
EA AUG 2021
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA TW6OO
UT WOS:000682516900002
PM 34260947
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wolf, A
   Kampik, A
AF Wolf, Armin
   Kampik, Anselm
TI Efficacy of treatment with ranibizumab in patients with wet age-related
   macular degeneration in routine clinical care: data from the COMPASS
   health services research
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Intravitreal injections;
   Non-interventional study; Ranibizumab; Visual acuity; Neovascular
   age-related macular degeneration
ID MACULOPATHY; BLINDNESS; GERMANY
AB Background To assess healthcare processes during treatment of neovascular age-related macular degeneration (AMD) in patients under real-life conditions and evaluate efficacy of monthly visual acuity (VA) assessment in a pro re nata treatment regime.
   Methods A multicentre, prospective, non-interventional study based in Germany included neovascular AMD patients treated with intravitreal ranibizumab. Patients completed a 3-month loading phase with monthly intravitreal injections of 0.5 mg ranibizumab, followed by a 12-month maintenance phase during which investigators documented VA, additional injections, metamorphopsias, routine ophthalmological examinations and adverse events at monthly follow-up visits. Efficacy analysis included change from baseline in best-corrected VA (BCVA) based on descriptive statistics.
   Results A total of 2,232 patients were enrolled throughout Germany and 1,729 patients (mean age 77.8 years, 63.2 % women) comprised the efficacy population with a complete set of data. In the clinical setting recorded in our study, only a minority of patients underwent optical coherence tomography during the maintenance phase (71 of 1,729 patients). Patients received a mean total of 4.5 injections; three injections during upload phase and 1.5 additional injections during maintenance phase. Over half of the patients (51.4 %) did not receive additional injections. Mean decimal BCVA increased during the upload phase, (from LogMAR mean of 0.201 at baseline to 0.219 at Month 4) but displayed a decline over time (0.192 at Month 15).
   Conclusion Ranibizumab treatment in a real-life setting demonstrated efficacy in neovascular AMD patients, as shown by initial gains in BCVA. However, maintenance and improvement of these gains during the maintenance phase in a clinical routine setting remained below those expected compared with MARINA, ANCHOR and CATT trials, most likely due to a low number of retreatments, and the high number of patients with a poor response in regard to improvements of VA who were not investigated in these studies.
   Trial registration number This phase IV non-interventional health services research study was conducted under the Novartis internal registration code, CRFB002ADE10.
C1 [Wolf, Armin; Kampik, Anselm] LMU, Klinikum Univ Munchen, Augenklin, D-80336 Munich, Germany.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Munich
RP Wolf, A (通讯作者)，LMU, Klinikum Univ Munchen, Augenklin, Campus Innenstadt,Mathildenstr 8, D-80336 Munich, Germany.
EM armin.wolf@med.uni-muenchen.de
FU Novartis Pharma GmbH, Germany
FX Financial support for medical editorial assistance was provided by
   Novartis Pharma GmbH, Germany. We thank Birgit Eschweiler, PhD, Medical
   Writing Services, Lage, Germany, and Fishawack Communications, Abingdon,
   UK, for medical editorial assistance with this manuscript. The authors
   wish to thank the Institute of Empirical Health Economics (IeFG),
   Burscheid, Germany, for planning and conducting statistical analysis of
   this study. Further thanks are extended to the investigators who
   participated in the COMPASS study. Research was funded by Novartis
   Pharma GmbH, Germany.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BROWN D, 2009, STAND, V9, P20
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kirchhof B, 2000, DT ARZTEBL, V97, P1458
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Pauleikhoff D, 2009, OPHTHALMOLOGE, V106, P242, DOI 10.1007/s00347-008-1797-9
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wolf A, 2013, OPHTHALMOLOGE, V110, P740, DOI 10.1007/s00347-012-2717-6
NR 14
TC 68
Z9 71
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2014
VL 252
IS 4
BP 647
EP 655
DI 10.1007/s00417-013-2562-6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG8HN
UT WOS:000335659500013
PM 24424409
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Book, M
   Ziegler, M
   Rothaus, K
   Faatz, H
   Gunnemann, ML
   Gutfleisch, M
   Spital, G
   Lommatzsch, AP
   Pauleikhoff, D
AF Book, Marius
   Ziegler, Martin
   Rothaus, Kai
   Faatz, Henrik
   Gunnemann, Marie-Louise
   Gutfleisch, Matthias
   Spital, Georg
   Lommatzsch, Albrecht Peter
   Pauleikhoff, Daniel
TI Analysis of the Vascular Morphology of the Fibrotic Choroidal
   Neovascularization in Neovascular Age-Related Macular Degeneration Using
   Optical Coherence Tomography Angiography
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE AMD; CNV; fibrosis; OCTA; morphology
ID SUBRETINAL HYPERREFLECTIVE MATERIAL; TYPE-1 NEOVASCULARIZATION; THERAPY
AB Purpose Choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD) undergoing anti-VEGF therapy transforms into a fibrotic lesion. This fibrovascular transformation is associated with a great variety of functional and morphological effects. The aim of this study was to investigate the vascular morphology of fibrotic CNV, to compare it with its surrounding tissue and to identify phenotypes using optical coherence tomography angiography (OCTA).
   Methods In 18 eyes with fibrotic CNV in nAMD spectral domain OCT (SD-OCT) and OCTA were performed. The automated segmentation lines were manually adjusted. A slab from 60 mu m beneath Bruch's membrane to the inner edge of the subretinal hyperreflective material was applied. Quantitative analysis of the vascular morphology was performed using skeletonized OCTA images.
   Results Compared to the perilesional rim, the number of segments per area was significantly lower (234.75 +/- 25.68 vs. 255.30 +/- 20.34 1/mm(2), p = 0.0003) within the fibrovascular lesion. Two phenotypes could be identified within the lesion. The phenotypic traits of cluster 1 were few, long and thick vascular segments; Cluster 2 was characterized by many, short and thin vascular segments (number of segments per area: 219.4 +/- 18.8 vs. 258.8 +/- 13.2 1/mm(2), p = 0.00009, segment length: 49.6 +/- 2.7 vs. 45.0 +/- 1.3 mu m, p = 0.0002, vascular caliber: 26.6 +/- 1.2 vs. 23.5 +/- 1.8 mu m, p = 0.003). The clusters did not differ significantly regarding visual acuity (0.52 +/- 0.44 vs. 0.54 +/- 0.18 logMAR, p = 0.25), differentiability of subretinal (OR = 3.43, CI = [0.30, 39.64], p = 0.6) and intraretinal fluid (OR = 5.34, CI = [0.48, 89.85], p = 0.14). Less normalized ellipsoid zone (EZ) loss could be observed in cluster 1 (131.0 +/- 161.3 vs. 892.4 +/- 955.6 1/m, p = 0.006).
   Conclusion In this study the vascular morphology of fibrotic CNV was analyzed using OCTA. Differences between the lesion and a perilesional rim could be detected. Two phenotypes within the fibrovascular lesion were identified. These morphological clusters could indicate different patterns of fibrovascular transformation of the CNV under long-term anti-VEGF therapy and be useful identifying possible predictive biomarkers in future studies.
C1 [Book, Marius; Ziegler, Martin; Rothaus, Kai; Faatz, Henrik; Gunnemann, Marie-Louise; Gutfleisch, Matthias; Spital, Georg; Lommatzsch, Albrecht Peter; Pauleikhoff, Daniel] Augenzentrum St Franziskus Hosp, Retinol, Hohenzollemring 74, D-48145 Munster, Germany.
   [Lommatzsch, Albrecht Peter; Pauleikhoff, Daniel] Univ Klinikum Essen, Klin Augenheilkunde, Essen, Germany.
   [Lommatzsch, Albrecht Peter; Pauleikhoff, Daniel] Univ Klinikum Essen, Achim Wessing Inst Ophthalmol Diagnost, Essen, Germany.
C3 University of Duisburg Essen; University of Duisburg Essen
RP Book, M (通讯作者)，Augenzentrum St Franziskus Hosp, Retinol, Hohenzollemring 74, D-48145 Munster, Germany.
EM marius.book@augen-franziskus.de
OI Book, Marius/0000-0002-5178-8673; Gutfleisch,
   Matthias/0000-0002-2001-5838; Rothaus, Kai/0000-0002-4288-8795
FU Novartis Pharma GmbH, Nuremberg, Germany
FX This study was funded by Novartis Pharma GmbH, Nuremberg, Germany.
CR Babiuch AS, 2020, RETINA-J RET VIT DIS, V40, P672, DOI 10.1097/IAE.0000000000002443
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Faatz H, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000369
   Faatz H, 2019, EYE, V33, P1466, DOI 10.1038/s41433-019-0429-8
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Lira Rodrigo Pessoa Cavalcanti, 2007, Arq. Bras. Oftalmol., V70, P615, DOI 10.1590/S0004-27492007000400011
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Park YG, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/637316
   Pauleikhoff D, 2019, GRAEF ARCH CLIN EXP, V257, P1381, DOI 10.1007/s00417-019-04323-0
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schneider EW, 2018, CURR OPIN OPHTHALMOL, V29, P217, DOI 10.1097/ICU.0000000000000469
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Uchida A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218889
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
NR 23
TC 1
Z9 1
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD NOV
PY 2020
VL 237
IS 11
BP 1312
EP 1319
DI 10.1055/a-1214-6521
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OS5JX
UT WOS:000590201200009
PM 32869243
DA 2022-11-30
ER

PT J
AU Backman, H
   Williams, R
AF Backman, H
   Williams, R
TI Living with age-related macular degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID VISUAL FUNCTION; EYE
C1 Pierrefonds Med Ctr, Montreal, PQ H8Z 1W5, Canada.
   Low Vis Self Help Assoc, Pointe Claire, PQ H9R 5P5, Canada.
RP Backman, H (通讯作者)，Pierrefonds Med Ctr, 12774 Goulin Blvd W, Montreal, PQ H8Z 1W5, Canada.
EM liseback@hotmail.com
CR Alexander L J, 1993, J Am Optom Assoc, V64, P822
   Ambrecht A, 2000, BRIT J OPHTHALMOL, V84, P1343
   BACKMAN HA, 1996, OPTOMETRISTE, V18, P23
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Valbuena M, 1999, INVEST OPHTH VIS SCI, V40, P280
NR 10
TC 3
Z9 3
U1 0
U2 1
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD MAY
PY 2002
VL 96
IS 5
BP 345
EP 348
DI 10.1177/0145482X0209600506
PG 4
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 555JT
UT WOS:000175791500006
DA 2022-11-30
ER

PT J
AU Rezende, FA
   Lapalme, E
   Qian, CX
   Smith, LE
   Sangiovanni, JP
   Sapieha, P
AF Rezende, Flavio A.
   Lapalme, Eric
   Qian, Cynthia X.
   Smith, Lois E.
   Sangiovanni, John Paul
   Sapieha, Przemyslaw
TI Omega-3 Supplementation Combined With Anti-Vascular Endothelial Growth
   Factor Lowers Vitreal Levels of Vascular Endothelial Growth Factor in
   Wet Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; DOCOSAHEXAENOIC ACID; PLASMA-LEVELS;
   RANIBIZUMAB; BEVACIZUMAB; BURDEN; HEALTH; RISK; VEGF
AB PURPOSE: To determine the influence of omega-3 supplementation on vitreous vascular endothelial growth factor A (VEGF-A) levels in patients with exudative age-related macular degeneration (wet AMD) receiving intravitreal anti-VEGF treatment.
   DESIGN: Prospective, randomized, open-label, single-center, clinical trial, consecutive interventional case series.
   METHODS: The study included 3 cohorts with wet AMD and a control group with epiretinal membrane or macular hole. Twenty wet AMD patients being treated with anti-VEGF were randomized to daily supplementation of antioxidants, zinc, and carotenoids with omega-3 fatty acids (docosahexaenoic acid and eicosapentaenoic acid; group 1, n = 10) or without omega-3 fatty acids (group 2, n = 10). They were compared with an anti-VEGF treatment-nave wet AMD group (group 3, n = 10) and an epiretinal membrane or macular hole group (group 4, n = 10). Primary outcome was vitreal VEGF-A levels (at the time of anti-VEGF injection). Secondary outcomes were plasma VEGF-A and central foveal thickness. Patients with new submacular hemorrhage or any other treatment within 3 months were excluded. Final analyses included 9, 6, 7, and 8 patients in groups 1 through 4, respectively.
   RESULTS: Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 +/- 61.89 pg/mL) when compared with group 2 (626.09 +/- 279.27 pg/mL; P = .036) and group 3 (735.48 +/- 216.43 pg/mL; P = .013), but similar levels to group 4(235.81 +/- 33.99 pg/mL; P = .215). All groups showed similar values for plasma VEGF-A and central foveal thickness measurements.
   CONCLUSIONS: This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients. (C) 2014 The Authors. Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY-NC-SA license (http://creativecommons.or/licenses/by-nc-sa/3.0/).)
C1 [Rezende, Flavio A.; Lapalme, Eric; Qian, Cynthia X.; Sapieha, Przemyslaw] Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Dept Ophthalmol, Montreal, PQ, Canada.
   [Smith, Lois E.] Harvard Univ, Sch Med, Dept Ophthalmol, Childrens Hosp Boston, Boston, MA USA.
   [Sangiovanni, John Paul] NEI, Clin Trials Branch, NIH, Bethesda, MD 20892 USA.
C3 Universite de Montreal; Harvard University; Boston Children's Hospital;
   Harvard Medical School; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Rezende, FA (通讯作者)，Maisonneuve Rosemont Hosp, Dept Ophthalmol, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.
EM frezendef@hotmail.com
RI SanGiovanni, John Paul/AAU-3895-2020
OI Rezende, Flavio/0000-0001-7764-6713; Sapieha,
   Przemyslaw/0000-0002-9171-2825; SanGiovanni, John
   Paul/0000-0001-7199-7053
FU Novartis; Lachine, Quebec, Canada; Alcon Canada; Bausch &. Lomb,
   Montreal, Quebec, Canada; Allergan, Markham, Ontario, Canada; Bayer,
   Toronto, Ontario, Canada; Gerson Lehman Group; Department of
   Ophthalmology, University of Montreal; Department of Ophthalmology,
   Maisonneuve-Rosemont Hospital; Fond de Recherche en Ophtalmologie,
   University of Montreal; Foundation Fighting Blindness Canada; Canadian
   Institutes of Health Research [324573]; Retina Foundation of Canada;
   Insight Instruments, Stuart, Florida, USA; Synergetics, Inc.; O'Fallon,
   Missouri, USA; Novartis Canada, Montreal, Quebec, Canada; National
   Institutes of Health, Bethesda, Maryland [EY022275, EY017017, P01
   HD18655]; Research to Prevent Blindness, New York, New York, USA; Lowy
   Medical Foundation; European Commission (LEHS) [305485]; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
   [P30HD018655] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY017017, R01EY022275] Funding Source: NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and the following were reported. Dr
   Rezende has received consultation fees from Novartis, Lachine, Quebec,
   Canada, Alcon Canada, Bausch &. Lomb, Montreal, Quebec, Canada,
   Allergan, Markham, Ontario, Canada, and Bayer, Toronto, Ontario, Canada,
   none of which are related to the current study. Przemyslaw Sapieha holds
   a Canada Research Chair and has received consultation fees from Gerson
   Lehman Group not related to the current research. Supported by the
   Department of Ophthalmology, University of Montreal; Department of
   Ophthalmology, Maisonneuve-Rosemont Hospital; Fond de Recherche en
   Ophtalmologie, University of Montreal; Foundation Fighting Blindness
   Canada; Grant 324573 from the Canadian Institutes of Health Research;
   Retina Foundation of Canada; Insight Instruments, Stuart, Florida, USA;
   Synergetics, Inc., O'Fallon, Missouri, USA; Novartis Canada, Montreal,
   Quebec, Canada; Grants EY022275, EY017017, and P01 HD18655 from the
   National Institutes of Health, Bethesda, Maryland; a Senior Investigator
   Award from Research to Prevent Blindness, New York, New York, USA; the
   Lowy Medical Foundation; and FP7 project 305485 of the European
   Commission (LEHS). The sponsors or funding organizations had no role in
   the design or conduct of this research. Involved in Design and conduct
   of study (F.A.R., P.S.); Collection of data (F.A.R., E.L., C.X.Q.);
   Management of data (F.A.R., E.L., P.S.); Analysis and interpretation of
   data (F.A.R., E.L., L.S., J.P.S., P.S.); Preparation of manuscript
   (F.A.R., E.L., P.S.); and Review and approval of manuscript (F.A.R.,
   L.S., J.P.S., P.S.). The authors thank Karsten Gronert, School of
   Optometry, University of California, Berkeley, California, USA, for
   carrying out lipidomic assay on patient vitreous (data was not
   included).
CR Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Calder PC, 2009, BIOFACTORS, V35, P266, DOI 10.1002/biof.42
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Feldberg W, 1938, J PHYSIOL-LONDON, V94, P232, DOI 10.1113/jphysiol.1938.sp003676
   Fetterman JW, 2009, AM J HEALTH-SYST PH, V66, P1169, DOI 10.2146/ajhp080411
   FORTIN PR, 1995, J CLIN EPIDEMIOL, V48, P1379, DOI 10.1016/0895-4356(95)00028-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holub BJ, 2009, PROSTAG LEUKOTR ESS, V81, P199, DOI 10.1016/j.plefa.2009.05.016
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rezende FA, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-58
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053155
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sonoda S, 2014, RETINA-J RET VIT DIS, V34, P741, DOI 10.1097/IAE.0b013e3182a48917
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   von Euler US, 1936, J PHYSIOL-LONDON, V88, P213, DOI 10.1113/jphysiol.1936.sp003433
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang GD, 2013, P NATL ACAD SCI USA, V110, P6530, DOI 10.1073/pnas.1304321110
   Zhang YW, 2002, PROSTAG LEUKOTR ESS, V67, P253, DOI 10.1054/plef.2002.0427
   Zhang YW, 1999, PROSTAG LEUKOTR ESS, V61, P33, DOI 10.1054/plef.1999.0070
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 40
TC 20
Z9 20
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2014
VL 158
IS 5
BP 1071
EP 1078
DI 10.1016/j.ajo.2014.07.036
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR7TT
UT WOS:000343783400028
PM 25089351
OA Green Accepted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Trinh, M
   Kalloniatis, M
   Nivison-Smith, L
AF Trinh, Matt
   Kalloniatis, Michael
   Nivison-Smith, Lisa
TI Should clinical automated perimetry be considered for routine functional
   assessment of early/intermediate age-related macular degeneration (AMD)?
   A systematic review of current literature
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Review
DE age-related macular degeneration; automated perimetry; photopic; visual
   fields
ID FREQUENCY-DOUBLING TECHNOLOGY; OPTICAL COHERENCE TOMOGRAPHY; MEDIATED
   MULTIFOCAL ELECTRORETINOGRAM; VISUAL-FIELD SENSITIVITY; QUALITY-OF-LIFE;
   FLICKER PERIMETRY; DARK-ADAPTATION; EYE DISEASE; CONTRAST SENSITIVITY;
   OCULAR HYPERTENSION
AB Purpose There is growing interest in functional testing for early/intermediate age-related macular degeneration (iAMD). However, systematic evaluation of existing clinical functional tests is lacking. This systematic review examines evidence for using clinical automated perimetry in routine assessment of early/iAMD. Recent findings PubMed, Web of Science Core Collection, and Embase were searched from inception to October 2020 to answer, is there evidence of visual field defects in early/iAMD, and if so, are early/iAMD visual field defects linked to real-world patient outcomes? Articles using clinical automated perimetry (commercially accessible and non-modified devices/protocols) were included. Microperimetry was excluded as this has yet to be incorporated into clinical guidelines. The primary outcome was global visual field indices including mean deviation (MD), pattern standard deviation (PSD), mean sensitivity (MS) and frequency of defects. The secondary outcome was any real-world patient outcome including quality of life and/or activities of daily living indices. Twenty-six studies were eligible for inclusion and all studies were observational. There was consistent evidence of worsened MD, PSD, MS and frequency of defects for early/iAMD compared to normal eyes under photopic, low-photopic and scotopic conditions. Meta-analysis of studies using standard automated perimetry (SAP) under photopic conditions revealed worsened MD (-1.52dB [-2.27, -0.78 dB]) and MS (-1.47dB [-2, -0.94 dB]) in early/iAMD compared to normal eyes, representing large statistical effect sizes but non-clinically meaningful reductions. There was insufficient data for meta-analyses regarding other clinical automated perimetry protocols. Only one study assessed a real-world patient outcome (on-road driving performance), with no significant link to visual field outcomes in early/iAMD. Significant reduction of global visual field indices is present in early/iAMD, but not clinically meaningful using SAP under photopic conditions. Translational relevance of visual field outcomes to patient outcomes in early/iAMD remains unclear. Thus, SAP under photopic conditions is unlikely to be useful for routine assessment of early/iAMD.
C1 [Trinh, Matt; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
   [Trinh, Matt; Kalloniatis, Michael; Nivison-Smith, Lisa] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Nivison-Smith, L (通讯作者)，Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
EM L.nivison-smith@unsw.edu.au
RI Trinh, Matt/AAV-1249-2021
OI Nivison-Smith, Lisa/0000-0001-6677-1949; Trinh,
   Matt/0000-0002-6184-0666; Kalloniatis, Michael/0000-0002-5264-4639
FU NHMRC [1174385]
FX NHMRC grant, Grant/Award Number: 1174385
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Acton JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039944
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Aguila M., 1954, Optica Acta, V1, P59
   American Academy of Ophthalmology, PRIM OP ANGL GLAUC P
   Anderson AJ, 2011, OPTOMETRY VISION SCI, V88, P806, DOI 10.1097/OPX.0b013e31821861bd
   Artes PH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1528, DOI 10.1001/archophthalmol.2010.292
   ATCHISON DA, 1990, OPTOMETRY VISION SCI, V67, P179, DOI 10.1097/00006324-199003000-00006
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Bedell HE, 2009, OPTOMETRY VISION SCI, V86, P485, DOI 10.1097/OPX.0b013e31819fa6e2
   Bero LA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000075
   Bharathi R., 2013, INT J RES HLTH SCI, V1, P251
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borenstein M., 2009, INTRO META ANAL, DOI [10.1002/9780470743386.ch13, DOI 10.1002/9780470743386.CH13]
   Bosworth C F, 2000, Semin Ophthalmol, V15, P172, DOI 10.3109/08820530009037869
   Bramer WM, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0644-y
   BRENTON RS, 1986, OPHTHALMOLOGICA, V193, P56, DOI 10.1159/000309679
   Brown A, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00176
   Carta A, 1998, CURR EYE RES, V17, P506, DOI 10.1076/ceyr.17.5.506.5191
   CASSON EJ, 1993, J OPT SOC AM A, V10, P1792, DOI 10.1364/JOSAA.10.001792
   Casson R, 2001, BRIT J OPHTHALMOL, V85, P360, DOI 10.1136/bjo.85.3.360
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Chauhan BC, 1999, INVEST OPHTH VIS SCI, V40, P648
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Choi AJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48026-2
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Commision Internationale de L'Eclairage, 1989, 0811989 CIE
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01467-0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Davson H., 1990, DAVSONS PHYSL EYE
   Denniss J, 2018, INVEST OPHTH VIS SCI, V59, P4590, DOI 10.1167/iovs.18-24861
   Dudzinski Andrzej, 2003, Klin Oczna, V105, P283
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   European Glaucoma Society, 2020, EUR GLAUC SOC TERM G
   Fairfield CJ, 2017, WORLD J GASTROENTERO, V23, P7198, DOI 10.3748/wjg.v23.i39.7198
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Fragiotta S., 2017, INT J RETINA VITR, V3, DOI 10.1186/s40942-017-0061-3
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Guyatt GH., 2002, USERSGUIDES MEDICAL
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   HEIJL A, 1987, ARCH OPHTHALMOL-CHIC, V105, P1544
   Herse, 2005, INT C SER, V1282, P568
   Herse P, 2005, VISION RES, V45, P461, DOI 10.1016/j.visres.2004.09.008
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HOOD DC, 1990, VISION RES, V30, P51, DOI 10.1016/0042-6989(90)90127-7
   Hristova EG., 2014, J BIOMED CLIN RES, V7, P148
   Hu RR, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002618
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703
   JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6
   Jampel HD, 2011, OPHTHALMOLOGY, V118, P986, DOI 10.1016/j.ophtha.2011.03.019
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   KALLONIATIS M, 1993, OPHTHAL PHYSL OPT, V13, P155, DOI 10.1111/j.1475-1313.1993.tb00445.x
   KALLONIATIS M, 1993, OPHTHAL PHYSL OPT, V13, P56, DOI 10.1111/j.1475-1313.1993.tb00427.x
   Katrak Persis, 2004, BMC Med Res Methodol, V4, P22, DOI 10.1186/1471-2288-4-22
   Keefe Richard S E, 2013, Innov Clin Neurosci, V10, p4S
   Klein B E, 1996, Ophthalmic Epidemiol, V3, P47, DOI 10.3109/09286589609071600
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, HUM FACTORS, V33, P521, DOI 10.1177/001872089103300504
   Kundi M, 2006, ENVIRON HEALTH PERSP, V114, P969, DOI 10.1289/ehp.8297
   Ladewig M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1557, DOI 10.1001/archopht.121.11.1557
   Lamparter J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057663
   Lamparter J, 2012, INVEST OPHTH VIS SCI, V53, P7553, DOI 10.1167/iovs.12-10892
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Landers J, 2007, BRIT J OPHTHALMOL, V91, P1285, DOI 10.1136/bjo.2007.114926
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Leske MC, 1999, OPHTHALMOLOGY, V106, P2144, DOI 10.1016/S0161-6420(99)90497-9
   LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Lundh A, 2018, INTENS CARE MED, V44, P1603, DOI 10.1007/s00134-018-5293-7
   Luu CD, 2013, INVEST OPHTH VIS SCI, V54, P3560, DOI 10.1167/iovs.12-10465
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Malik R, 2012, CLIN EXP OPHTHALMOL, V40, P369, DOI 10.1111/j.1442-9071.2012.02770.x
   Mandrioli D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162198
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   McKendrick Allison M, 2005, Clin Exp Optom, V88, P73
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299
   Monsalve B, 2017, EYE, V31, P443, DOI 10.1038/eye.2016.251
   Montesano G, 2019, OPHTHALMOLOGY, V126, P242, DOI 10.1016/j.ophtha.2018.08.010
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Nittala MG, 2019, OSLI RETINA, V50, pE236, DOI 10.3928/23258160-20190905-15
   Ogino K, 2014, JPN J OPHTHALMOL, V58, P155, DOI 10.1007/s10384-013-0295-z
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pan F, 2006, J VISION, V6, P1159, DOI 10.1167/6.11.2
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   PFAU M, 2020, PROG RETIN EYE RES, V3
   Phipps JA, 1999, AUST NZ J OPHTHALMOL, V27, P265, DOI 10.1046/j.1440-1606.1999.00193.x
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Phu J, 2017, CLIN EXP OPTOM, V100, P313, DOI 10.1111/cxo.12551
   Piccardi M, 2009, OPHTHALMIC RES, V41, P194, DOI 10.1159/000217723
   PONDORFER S, 2020, INVEST OPHTHALMOL VI, V61
   Pondorfer SG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231748
   Pondorfer SG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51769-7
   Pow DV, 2007, EXP EYE RES, V84, P850, DOI 10.1016/j.exer.2007.01.005
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Racette L, 2008, INVEST OPHTH VIS SCI, V49, P954, DOI 10.1167/iovs.07-0493
   Reznicek L, 2015, CURR EYE RES, V40, P683, DOI 10.3109/02713683.2014.957324
   Robin A, 2011, INDIAN J OPHTHALMOL, V59, pS93, DOI 10.4103/0301-4738.73693
   Rodriguez JD, 2018, CLIN OPHTHALMOL, V12, P1325, DOI 10.2147/OPTH.S165658
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Roh M, 2019, BRIT J OPHTHALMOL, V103, P1769, DOI 10.1136/bjophthalmol-2018-313316
   Rudnicka AR, 2012, OPHTHAL PHYSL OPT, V32, P174, DOI 10.1111/j.1475-1313.2012.00901.x
   Rutjes AWS, 2006, CAN MED ASSOC J, V174, DOI 10.1503/cmaj.050090
   RUTTER M, 1994, J CONSULT CLIN PSYCH, V62, P928, DOI 10.1037/0022-006X.62.5.928
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sample PA, 2000, INVEST OPHTH VIS SCI, V41, P1783
   Sample PA, 2011, OPTOMETRY VISION SCI, V88, P4, DOI 10.1097/OPX.0b013e3181fc3735
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Sassmannshausen M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.19
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Schiavo Julie H., 2019, Medical Reference Services Quarterly, V38, P171, DOI 10.1080/02763869.2019.1588072
   Schiefer U, 2005, OPHTHALMOLOGE, V102, P627, DOI 10.1007/s00347-005-1189-3
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schunemann HJ, 2020, J CLIN EPIDEMIOL, V122, P129, DOI 10.1016/j.jclinepi.2019.12.020
   Schunemann HJ, 2019, J CLIN EPIDEMIOL, V111, P69, DOI 10.1016/j.jclinepi.2019.02.003
   Schwartz Gail F, 2005, Curr Opin Ophthalmol, V16, P114, DOI 10.1097/01.icu.0000156139.05323.26
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Sinko K, 2008, CLEFT PALATE-CRAN J, V45, P87, DOI 10.1597/06-118.1
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spry PGD, 2001, INVEST OPHTH VIS SCI, V42, P1404
   Stavrou EP, 2005, ACTA OPHTHALMOL SCAN, V83, P574, DOI 10.1111/j.1600-0420.2005.00527.x
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sterne JAC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000076
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1
   Sun H, 2006, OPTOMETRY VISION SCI, V83, P455, DOI 10.1097/01.opx.0000225103.18087.5d
   Swanson WH, 2011, INVEST OPHTH VIS SCI, V52, P764, DOI 10.1167/iovs.10-6158
   Tan NYQ, 2018, OPHTHALMOLOGY, V125, P15, DOI 10.1016/j.ophtha.2017.08.002
   Tan RS, 2019, INVEST OPHTH VIS SCI, V60, P1511, DOI 10.1167/iovs.18-26385
   Tarita-Nistor L, 2006, CAN J OPHTHALMOL, V41, P327, DOI 10.1139/I06-029
   Thi HCT, 2012, OPTOMETRY VISION SCI, V89, P419, DOI 10.1097/OPX.0b013e31824c3a21
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Trinh M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.2
   Ugurlu SK, 2017, EYE, V31, P395, DOI 10.1038/eye.2016.219
   Urata CN, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.17
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wall M, 1998, ARCH OPHTHALMOL-CHIC, V116, P53, DOI 10.1001/archopht.116.1.53
   Wall M, 2013, INVEST OPHTH VIS SCI, V54, P1345, DOI 10.1167/iovs.12-10299
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   Wang Z, 2015, CLIN EPIDEMIOL, V7, P243, DOI 10.2147/CLEP.S78879
   Wareham KJ, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1146-9
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wells GSB., 2013, NEWCASTLE OTTAWA SCA
   Wesselink C, 2017, OPHTHAL PHYSL OPT, V37, P594, DOI 10.1111/opo.12401
   White AJR, 2002, INVEST OPHTH VIS SCI, V43, P3590
   WHITTLE P, 1969, VISION RES, V9, P1095, DOI 10.1016/0042-6989(69)90050-9
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2018, INVEST OPHTH VIS SCI, V59, P273, DOI 10.1167/iovs.17-22751
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood J, 2008, ORGAN RES METHODS, V11, P79, DOI 10.1177/1094428106296638
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Yanagisawa M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203258
   Yoon MK, 2012, MIDDLE EAST AFR J OP, V19, P211, DOI 10.4103/0974-9233.95254
   ZEISS Medical Technology | ZEISS International, HUMPHR FDT TECHN DAT
   Zeppieri M, 2008, OPTOMETRY VISION SCI, V85, P318, DOI 10.1097/OPX.0b013e31816be9fd
   Zhuang XH, 2015, INVEST OPHTH VIS SCI, V56, P2901, DOI 10.1167/iovs.14-16067
   Zult T, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09255-7
NR 208
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JAN
PY 2022
VL 42
IS 1
BP 161
EP 177
DI 10.1111/opo.12919
EA NOV 2021
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XM1AM
UT WOS:000723241200001
PM 34843120
OA Green Published
DA 2022-11-30
ER

PT J
AU Baulig, C
   Krummenauer, F
   Geis, B
   Tulka, S
   Knippschild, S
AF Baulig, Christine
   Krummenauer, Frank
   Geis, Berit
   Tulka, Sabrina
   Knippschild, Stephanie
TI Reporting quality of randomised controlled trial abstracts on
   age-related macular degeneration health care: a cross-sectional
   quantification of the adherence to CONSORT abstract reporting
   recommendations
SO BMJ OPEN
LA English
DT Article
ID SHOWED SUBOPTIMAL IMPROVEMENT; LEADING JOURNALS; EXTENSION
AB Objective To assess the reporting quality of randomised controlled trial (RCT) abstracts on age-related macular degeneration (AMD) healthcare, to evaluate the adherence to the Consolidated Standards of Reporting Trials (CONSORT) statement's recommendations on minimum abstract information and to identify journal characteristics associated with abstract reporting quality.
   Design Cross-sectional evaluation of RCT abstracts on AMD healthcare.
   Methods A PubMed search was implemented to identify RCT abstracts on AMD healthcare published in the English language between January 2004 and December 2013. Data extraction was performed by two parallel readers independently by means of a documentation format in accordance with the 16 items of the CONSORT checklist for abstracts. The total number of criteria fulfilled by an abstract was derived as primary endpoint of the investigation; incidence rate ratios (IRRs) with unadjusted 95% CI were estimated by means of multiple Poisson regression to identify journal and article characteristics (publication year, multicentre design, structured abstract recommendations, effective sample size, effective abstract word counts and journal impact factor) possibly associated with the total number of fulfilled items.
   Study characteristics 136 of 673 identified abstracts (published in 36 different journals) fulfilled all eligibility criteria.
   Results The median number of fulfilled items was 7 (95% CI 7 to 8). No abstract reported all 16 recommended items; the maximum total number was 14, the minimum 3 of 16 items. Multivariate analysis only demonstrated the abstracts' word counts as being significantly associated with a better reporting of abstracts (Poisson regression-based IRR 1.002, 95% CI 1.001 to 1.003).
   Conclusions Reporting quality of RCT abstracts on AMD investigations showed a considerable potential for improvement to meet the CONSORT abstract reporting recommendations. Furthermore, word counts of abstracts were identified as significantly associated with the overall abstract reporting quality.
C1 [Baulig, Christine; Krummenauer, Frank; Geis, Berit; Tulka, Sabrina; Knippschild, Stephanie] Witten Herdecke Univ, Fac Hlth, Inst Med Biometry & Epidemiol, D-58448 Witten, Germany.
RP Baulig, C (通讯作者)，Witten Herdecke Univ, Fac Hlth, Inst Med Biometry & Epidemiol, D-58448 Witten, Germany.
EM Christine.Baulig@uni-wh.de
RI Baulig, Christine/L-3550-2019; Prof. Dr. Baulig, Christine/HDN-2311-2022
FU Internal Research Foundation Initiative of the Witten / Herdecke
   University's Faculty of Health [IFF 2016-001]
FX This work was supported by the Internal Research Foundation Initiative
   of the Witten / Herdecke University's Faculty of Health, comprising a
   1-year research position for SK (grant number IFF 2016-001).
CR [Anonymous], 2006, PLOS MED, V3, P563, DOI 10.1371/journal.pmed.0030252
   Baulig C, 2018, OPHTHALMOLOGE, V115, P40, DOI 10.1007/s00347-017-0446-6
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   Berwanger O, 2009, J CLIN EPIDEMIOL, V62, P387, DOI 10.1016/j.jclinepi.2008.05.013
   Bigna JJR, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0243-y
   Blair DA, 2014, J MED LIBR ASSOC, V102, P110, DOI 10.3163/1536-5050.102.2.010
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Can OS, 2011, EUR J ANAESTH, V28, P485, DOI 10.1097/EJA.0b013e32833fb96f
   Chen YL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011926
   Chhapola V, 2016, J CLIN EPIDEMIOL, V71, P11, DOI 10.1016/j.jclinepi.2015.10.013
   Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507
   Faggion CM, 2012, J PERIODONTOL, V83, P1251, DOI 10.1902/jop.2012.110609
   Ghimire S, 2014, J CLIN EPIDEMIOL, V67, P658, DOI 10.1016/j.jclinepi.2013.10.012
   Ghimire S, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-77
   Glasziou P, 2014, LANCET, V383, P267, DOI 10.1016/S0140-6736(13)62228-X
   Hopewell S, 2008, PLOS MED, V5, P48, DOI 10.1371/journal.pmed.0050020
   Hua F, 2016, EUR J ORTHODONT, V38, P584, DOI 10.1093/ejo/cjv094
   Kiriakou J, 2014, J EVID-BASED DENT PR, V14, P9, DOI 10.1016/j.jebdp.2013.10.018
   Knobloch K, 2011, ANN SURG, V254, P546, DOI 10.1097/SLA.0b013e31822ad829
   Mbuagbaw L, 2014, CONTEMP CLIN TRIALS, V38, P245, DOI 10.1016/j.cct.2014.05.012
   Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2
   Moher David, 2010, J Clin Epidemiol, V63, pe1, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]
   Samaan Z, 2013, J MULTIDISCIP HEALTH, V6, P169, DOI 10.2147/JMDH.S43952
   Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI [10.1016/j.jclinepi.2010.02.005, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18, 10.4103/0976-500X.72352]
   Seehra J, 2013, J EVID-BASED DENT PR, V13, P1, DOI 10.1016/j.jebdp.2012.11.001
   Stolberg HO, 2004, AM J ROENTGENOL, V183, P1539, DOI 10.2214/ajr.183.6.01831539
   Wang L, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-75
NR 27
TC 14
Z9 14
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD MAY
PY 2018
VL 8
IS 5
AR e021912
DI 10.1136/bmjopen-2018-021912
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ7KZ
UT WOS:000435567200179
PM 29789352
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nie, Q
   Gong, XD
   Gong, LL
   Zhang, L
   Tang, XC
   Wang, L
   Liu, FY
   Fu, JL
   Xiang, JW
   Xiao, Y
   Luo, ZW
   Qi, RL
   Chen, ZG
   Liu, YF
   Sun, Q
   Qing, WJ
   Yang, L
   Xie, J
   Zou, M
   Gan, YW
   Chen, HM
   Li, DWC
AF Nie, Qian
   Gong, Xiaodong
   Gong, Lili
   Zhang, Lan
   Tang, Xiangcheng
   Wang, Ling
   Liu, Fangyuan
   Fu, Jia-ling
   Xiang, Jia-Wen
   Xiao, Yuan
   Luo, Zhongwen
   Qi, Ruili
   Chen, Zhigang
   Liu, Yunfei
   Sun, Qian
   Qing, Wenjie
   Yang, Lan
   Xie, Jie
   Zou, Ming
   Gan, Yuwen
   Chen, Huimin
   Li, David Wan-Cheng
TI Sodium Iodate-Induced Mouse Model of Age-Related Macular Degeneration
   Displayed Altered Expression Patterns of Sumoylation Enzymes E1, E2 and
   E3
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Age-related macular degeneration; oxidative stress; sumoylation enzymes;
   E1; E2; E3
ID SUMO MODIFICATION; OXIDATIVE DAMAGE; MECHANISMS; UBIQUITIN; RESPONSES;
   PATHWAY; DISEASE
AB Purpose: Protein sumoylation is a highly dynamic and reversible post-translational modification, involving covalently conjugation of the small ubiquitin-like modifier (SUMO) to the lysine residue of the target protein. Similar to ubiquitination, sumoylation is catalyzed by E1, E2 and several E3 ligases. However, sumoylation usually does not cause protein degradation but alter the target function through diverse mechanisms. Increasing evidences have shown that sumoylation plays pivotal roles in the pathogenesis of human diseases, including neuron degeneration, cancer and heart disease, etc. We and others have shown that sumoylation is critically implicated in mouse eye development. However, the expression of sumoylation machinery has not been characterized in normal and pathogenic retina. Worldwide, age-related macular degeneration (AMD) is the leading cause of irreversible blindness in aged person. In the present study, we investigated the expression of the major sumoylation enzymes in normal mice and sodium iodate-induced AMD mouse model.
   Methods: Four-week-old C57BL/6J mice were used in our experiment. A sterile 1% NaIO3 solution was freshly prepared in PBS from solid NaIO3. Experimental mice were injected with 70 mg/kg NaIO3, and similar volumes of PBS as control. Eyes were enucleated and immersion in FAA fixation overnight and processed for eye cross-sections. After fixation, cross sections eyes were dehydrated, embedded in paraffin, and 6 mm transverse sections were cut using the rotary microtome. Then paraffin sections were stained with hematoxylin and eosin (H&E), and mouse retinal thickness was observed to assess the histopathologic changes.
   Results: Significantly declined RNA levels of E1, E2 and E3 ligase PIAS1 in NaIO3-injected mouse RPE one day-post treatment. Consistently, the protein level of PIAS1 was also decreased at this time point. At the late stage of treatment (three days post-injection), significantly reduced expression of El enzyme SAE1/UBA2 was detected in NaIO3-injected mouse retinas. In the contrary, dramatically increased E3 ligase RanBP2 was found in the injected-retinas.
   Conclusion: Together, our results demonstrated for the first time the dynamic expression of sumoylation pathway enzymes during the progression of retina degeneration induced by oxidative stress. Dynamic expression of E1, E2 and E3 enzymes were found during the time course of RPE and retina degeneration, which revealed the potential regulatory roles of sumoylation in AMD pathogenesis.
C1 [Nie, Qian; Gong, Xiaodong; Gong, Lili; Zhang, Lan; Tang, Xiangcheng; Wang, Ling; Liu, Fangyuan; Fu, Jia-ling; Xiang, Jia-Wen; Xiao, Yuan; Luo, Zhongwen; Qi, Ruili; Chen, Zhigang; Liu, Yunfei; Sun, Qian; Qing, Wenjie; Yang, Lan; Xie, Jie; Zou, Ming; Gan, Yuwen; Chen, Huimin; Li, David Wan-Cheng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 7 Jinsui Rd,Res Bldg,Room 602-5, Guangzhou 510230, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Li, DWC (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 7 Jinsui Rd,Res Bldg,Room 602-5, Guangzhou 510230, Guangdong, Peoples R China.
EM liwancheng@gzzoc.com
RI LIU, Fangyuan/GRX-8688-2022; Li, David/AAN-9205-2021
OI Gong, Lili/0000-0002-3129-3868
FU National Natural Science Foundation of China [81570824, 81770910,
   81500707, 81500738, 81700821]; Fundamental Research Funds of the State
   Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
   Yat-sen University
FX This study was supported in part by the Grants from the National Natural
   Science Foundation of China (Grant Number Grant Number #81570824,
   #81770910, #81500707, #81500738, #81700821), the Fundamental Research
   Funds of the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic
   Center, Sun Yat-sen University. We thank all members of David W. Li's
   Laboratory in the State Key Laboratory of Ophthalmology in Zhongshan
   Ophthalmic Center of Sun Yat-sen University.
CR Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   Cubenas-Potts C, 2013, DEV CELL, V24, P1, DOI 10.1016/j.devcel.2012.11.020
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dorval V, 2007, BBA-MOL CELL RES, V1773, P694, DOI 10.1016/j.bbamcr.2007.03.017
   Ferreira PA, 1997, P NATL ACAD SCI USA, V94, P1556, DOI 10.1073/pnas.94.4.1556
   Flotho A, 2013, ANNU REV BIOCHEM, V82, P357, DOI 10.1146/annurev-biochem-061909-093311
   Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657
   Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011
   Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604
   Gong LL, 2018, P NATL ACAD SCI USA, V115, pE3987, DOI 10.1073/pnas.1715237115
   Gong LL, 2014, P NATL ACAD SCI USA, V111, P5574, DOI 10.1073/pnas.1315034111
   Henley JM, 2014, PHYSIOL REV, V94, P1249, DOI 10.1152/physrev.00008.2014
   Jackson SP, 2013, MOL CELL, V49, P795, DOI 10.1016/j.molcel.2013.01.017
   Kho C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8229
   Kho C, 2011, NATURE, V477, P601, DOI 10.1038/nature10407
   Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100
   Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593
   Nie Q, 2018, CURR MOL MED
   Onishi A, 2009, NEURON, V61, P234, DOI 10.1016/j.neuron.2008.12.006
   Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503
   Snider NT, 2014, NAT REV MOL CELL BIO, V15, P163, DOI 10.1038/nrm3753
   Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194
   Terada K, 2010, DEV BIOL, V347, P180, DOI 10.1016/j.ydbio.2010.08.023
   Yan Q, 2010, P NATL ACAD SCI USA, V107, P21034, DOI 10.1073/pnas.1007866107
   Zhao Y, 2014, TRENDS CELL BIOL, V24, P426, DOI 10.1016/j.tcb.2014.01.005
NR 26
TC 4
Z9 4
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2018
VL 18
IS 8
BP 550
EP 555
DI 10.2174/1566524019666190112101147
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA HJ4QZ
UT WOS:000457159900007
PM 30636606
DA 2022-11-30
ER

PT J
AU Chew, EY
   Clemons, TE
   Agron, E
   Sperduto, RD
   SanGiovanni, JP
   Kurinij, N
   Davis, MD
AF Chew, Emily Y.
   Clemons, Traci E.
   Agron, Elvira
   Sperduto, Robert D.
   SanGiovanni, John Paul
   Kurinij, Natalie
   Davis, Matthew D.
CA Age-Related Eye Dis Study Res Grp
TI Long-Term Effects of Vitamins C and E, beta-Carotene, and Zinc on
   Age-related Macular Degeneration AREDS Report No. 35
SO OPHTHALMOLOGY
LA English
DT Article
AB Objective: To describe the long-term effects (10 years) of the Age-Related Eye Disease Study (AREDS) formulation of high-dose antioxidants and zinc supplement on progression of age-related macular degeneration (AMD).
   Design: Multicenter, randomized, controlled, clinical trial followed by an epidemiologic follow-up study.
   Participants: We enrolled 4757 participants with varying severity of AMD in the clinical trial; 3549 surviving participants consented to the follow-up study.
   Methods: Participants were randomly assigned to antioxidants C, E, and beta-carotene and/or zinc versus placebo during the clinical trial. For participants with intermediate or advanced AMD in 1 eye, the AREDS formulation delayed the progression to advanced AMD. Participants were then enrolled in a follow-up study. Eye examinations were conducted with annual fundus photographs and best-corrected visual acuity assessments. Medical histories and mortality were obtained for safety monitoring. Repeated measures logistic regression was used in the primary analyses.
   Main Outcome Measures: Photographic assessment of progression to, or history of treatment for, advanced AMD (neovascular [NV] or central geographic atrophy [CGA]), and moderate visual acuity loss from baseline (>= 15 letters).
   Results: Comparison of the participants originally assigned to placebo in AREDS categories 3 and 4 at baseline with those originally assigned to AREDS formulation at 10 years demonstrated a significant (P<0.001) odds reduction in the risk of developing advanced AMD or the development of NV AMD (odds ratio [OR], 0.66, 95% confidence interval [CI], 0.53-0.83 and OR, 0.60; 95% CI, 0.47-0.78, respectively). No significant reduction (P = 0.93) was seen for the CGA (OR, 1.02; 95% CI, 0.71-1.45). A significant reduction (P = 0.002) for the development of moderate vision loss was seen (OR 0.71; 95% CI, 0.57-0.88). No adverse effects were associated with the AREDS formulation. Mortality was reduced in participants assigned to zinc, especially death from circulatory diseases.
   Conclusions: Five years after the clinical trial ended, the beneficial effects of the AREDS formulation persisted for development of NV AMD but not for CGA. These results are consistent with the original recommendations that persons with intermediate or advanced AMD in 1 eye should consider taking the AREDS formulation. (C) 2013 by the American Academy of Ophthalmology.
C1 [Chew, Emily Y.; Agron, Elvira; SanGiovanni, John Paul] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.; Sperduto, Robert D.] EMMES Corp, Rockville, MD USA.
   [Kurinij, Natalie] NEI, Div Extramural Res, NIH, Bethesda, MD 20892 USA.
   [Davis, Matthew D.] Univ Wisconsin, Madison, WI USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); University of Wisconsin System; University
   of Wisconsin Madison
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda, MD [NOI-EY-0-2127]; NATIONAL EYE
   INSTITUTE [ZIEEY000487, ZIAEY000489, N01EY002127] Funding Source: NIH
   RePORTER
FX Supported by the intramural program funds and contracts AREDS (Contract
   NOI-EY-0-2127) from the National Eye Institute/National Institutes of
   Health, Department of Health and Human Services, Bethesda, MD.
CR [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cook NR, 2000, ARCH INTERN MED, V160, P921, DOI 10.1001/archinte.160.7.921
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Nathan DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1707, DOI 10.1001/archopht.126.12.1707
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
NR 8
TC 143
Z9 149
U1 0
U2 75
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2013
VL 120
IS 8
BP 1604
EP +
DI 10.1016/j.ophtha.2013.01.021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196LW
UT WOS:000322778000022
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, YY
   Chou, P
   Huang, YF
   Chien, HJ
   Wu, YC
   Lee, CC
   Huang, LY
   Chen, HH
AF Chen, Yu-Yen
   Chou, Pesus
   Huang, Yu-Fang
   Chien, Hung-Jen
   Wu, Yu-Chieh
   Lee, Chia-Chi
   Huang, Li-Ying
   Chen, Hsin-Hua
TI Repeated intravitreal injections of antivascular endothelial growth
   factor in patients with neovascular age-related macular degeneration may
   increase the risk of ischemic optic neuropathy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Intravitreal injection; Antivascular endothelial growth factor;
   Neovascular age-related macular degeneration; Ischemic optic neuropathy;
   Cohort study; Risk factor; National Health Insurance Research Database
ID BEVACIZUMAB
AB Background: Previous case reports have demonstrated the occurrence of ischemic optic neuropathy (ION) following intravitreal injections of antivascular endothelial growth factor (anti-VEGF). However, no previous studies have investigated the impact of injection numbers on the risk of ION. The aim of our study was to investigate whether repeated intravitreal injections of anti-VEGF would increase the risk of subsequent ION in patients with neovascular age-related macular degeneration (AMD).
   Methods: A population-based, retrospective cohort study using the Taiwan National Health Insurance Research Database was conducted from 2007 to 2013. Neovascular AMD patients receiving intravitreal injections of anti-VEGF during the study period were enrolled in the study cohort. Enrollees were divided into three groups according to the categorized levels of injection number (first level: < 10 times, second level: 10-15 times, and third level: > 15 times). Kaplan-Meier curves were generated to compare the cumulative hazard of subsequent ION among the three groups. Cox regression analyses were used to estimate crude and adjusted hazard ratios (HRs) for ION development with respect to the different levels of injection numbers. The confounders included for adjustment were age, sex, and comorbidities (diabetes, hypertension, hyperlipidemia, ischemic heart disease, and glaucoma).
   Results: In total, the study cohort included 77,210 patients. Of these, 26,520, 38,010, and 12,680 were in the first-, second-, and third-level groups, respectively. The Kaplan-Meier method revealed that the cumulative hazards of ION were significantly higher in those who had a higher injection number. After adjusting for confounders, the adjusted HRs for ION in the second- and third-level groups were 1.91 (95% confidence interval [CI], 1.32-2.76) and 2.20 (95% CI, 1.42-3.43), respectively, compared with those in the first-level group.
   Conclusions: Among patients with neovascular AMD, those who receive a higher number of anti-VEGF injections have a significantly higher risk of developing ION compared with individuals who receive a lower number of injections.
C1 [Chen, Yu-Yen; Huang, Yu-Fang; Chien, Hung-Jen; Wu, Yu-Chieh; Lee, Chia-Chi] Taichung Vet Gen Hosp, Dept Ophthalmol, 1650 Taiwan Blvd Sect 4, Taichung 40705, Taiwan.
   [Chen, Yu-Yen; Chou, Pesus; Chen, Hsin-Hua] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Chen, Yu-Yen; Chou, Pesus; Chen, Hsin-Hua] Natl Yang Ming Univ, Community Med Res Ctr, Taipei, Taiwan.
   [Chen, Yu-Yen; Chou, Pesus; Chen, Hsin-Hua] Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.
   [Huang, Li-Ying] Fu Jen Catholic Univ, Sch Med, Coll Med, New Taipei, Taiwan.
   [Huang, Li-Ying] Fu Jen Catholic Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, New Taipei, Taiwan.
   [Huang, Li-Ying] Fu Jen Catholic Univ Hosp, Dept Med Educ, New Taipei, Taiwan.
   [Chen, Hsin-Hua] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan.
   [Chen, Hsin-Hua] Taichung Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Taichung, Taiwan.
   [Chen, Hsin-Hua] Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan.
   [Chen, Hsin-Hua] Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan.
C3 Taichung Veterans General Hospital; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; National Yang Ming
   Chiao Tung University; Fu Jen Catholic University; Fu Jen Catholic
   University; Fu Jen Catholic University Hospital; Fu Jen Catholic
   University; Fu Jen Catholic University Hospital; Taichung Veterans
   General Hospital; Taichung Veterans General Hospital; National Chung
   Hsing University; National Chung Hsing University
RP Chen, YY (通讯作者)，Taichung Vet Gen Hosp, Dept Ophthalmol, 1650 Taiwan Blvd Sect 4, Taichung 40705, Taiwan.; Chen, YY (通讯作者)，Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
EM yuyenchen.phd@gmail.com
OI Chen, Yu-Yen/0000-0003-0891-3819
CR Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Biousse V, 2015, NEW ENGL J MED, V372, P2428, DOI 10.1056/NEJMra1413352
   BURDE RM, 1993, AM J OPHTHALMOL, V116, P759, DOI 10.1016/S0002-9394(14)73478-6
   Chang YS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25864-0
   Chang YS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003174
   Choudhari NS, 2010, INDIAN J OPHTHALMOL, V58, P437, DOI 10.4103/0301-4738.67070
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ganssauge M, 2009, GRAEF ARCH CLIN EXP, V247, P1707, DOI 10.1007/s00417-009-1184-5
   Hayreh SS, 2008, OPHTHALMOLOGY, V115, P1818, DOI 10.1016/j.ophtha.2008.03.032
   Hayreh SS, 2013, GRAEF ARCH CLIN EXP, V251, P1873, DOI 10.1007/s00417-013-2399-z
   HAYREH SS, 1994, AM J OPHTHALMOL, V118, P766, DOI 10.1016/S0002-9394(14)72557-7
   HAYREH SS, 1980, ARCH OPHTHALMOL-CHIC, V98, P1410, DOI 10.1001/archopht.1980.01020040262010
   Hayreh SS, 2001, PROG RETIN EYE RES, V20, P595, DOI 10.1016/S1350-9462(01)00005-2
   Hosseini H, 2009, J NEURO-OPHTHALMOL, V29, P160, DOI 10.1097/WNO.0b013e3181a58fd1
   Huang JY, 2010, JPN J OPHTHALMOL, V54, P252, DOI 10.1007/s10384-009-0790-4
   Hurmeric V, 2014, INDIAN J OPHTHALMOL, V62, DOI 10.4103/0301-4738.111135
   Iglicki M, 2019, ACTA DIABETOL, V56, P1141, DOI 10.1007/s00592-019-01357-y
   Iglicki M, 2018, ACTA DIABETOL, V55, P541, DOI 10.1007/s00592-018-1117-z
   Iglicki M, 2019, RETINA-J RET VIT DIS, V39, P44, DOI 10.1097/IAE.0000000000002196
   Jacobson DM, 1997, ARCH OPHTHALMOL-CHIC, V115, P1403, DOI 10.1001/archopht.1997.01100160573008
   Kim Kyoung Nam, 2015, Korean J Ophthalmol, V29, P209, DOI 10.3341/kjo.2015.29.3.209
   Kuriyan AE, 2013, CLIN OPHTHALMOL, V7, P1233, DOI 10.2147/OPTH.S45372
   McCulley TJ, 2003, AM J OPHTHALMOL, V136, P1171, DOI 10.1016/S0002-9394(03)00676-7
   Mello P, 2019, OPHTHALMOLOGICA, V241, P9, DOI 10.1159/000492132
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nicoletti JN, 2008, NEUROSCIENCE, V151, P232, DOI 10.1016/j.neuroscience.2007.09.083
   Park HYL, 2014, AM J PATHOL, V184, P1752, DOI 10.1016/j.ajpath.2014.02.016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Vedula SS, 2008, COCHRANE DB SYST REV, V2
   ZUR D, 2019, ACTA DIABETOL, DOI DOI 10.1111/AOS.14230
   Zur D, 2019, OPHTHALMIC RES, V62, P231, DOI 10.1159/000499540
NR 33
TC 3
Z9 4
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 30
PY 2019
VL 19
IS 1
AR 268
DI 10.1186/s12886-019-1284-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KH4HO
UT WOS:000510605500002
PM 31888553
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Craig, A
   Kifley, A
   Liew, G
   Bloffwitch, J
   Vu, KV
   Joachim, N
   Cummins, R
   Heraghty, J
   Broady, T
   Hayes, A
   Mitchell, P
AF Gopinath, Bamini
   Craig, Ashley
   Kifley, Annette
   Liew, Gerald
   Bloffwitch, Jaye
   Vu, Kim Van
   Joachim, Nichole
   Cummins, Rob
   Heraghty, Julie
   Broady, Timothy
   Hayes, Alison
   Mitchell, Paul
TI Implementing a multi-modal support service model for the family
   caregivers of persons with age-related macular degeneration: a study
   protocol for a randomised controlled trial
SO BMJ OPEN
LA English
DT Article
ID COGNITIVE-BEHAVIORAL THERAPY; OLDER-ADULTS; INTERVENTIONS; DEPRESSION;
   SEVERITY; PEOPLE
AB Introduction Age-related macular degeneration (AMD) is a leading cause of blindness and low vision among older adults. Previous research shows a high prevalence of distress and disruption to the lifestyle of family caregivers of persons with late AMD. This supports existing evidence that caregivers are 'hidden patients' at risk of poor health outcomes. There is ample scope for improving the support available to caregivers, and further research should be undertaken into developing services that are tailored to the requirements of family caregivers of persons with AMD. This study aims to implement and evaluate an innovative, multi-modal support service programme that aims to empower family caregivers by improving their coping strategies, enhancing hopeful feelings such as self-efficacy and helping them make the most of available sources of social and financial support.
   Methods and analysis A randomised controlled trial consisting of 360 caregiver-patient pairs (180 in each of the intervention and wait-list control groups). The intervention group will receive the following: (1) maildelivered cognitive behavioural therapy designed to improve psychological adjustment and adaptive coping skills; (2) telephone-delivered group counselling sessions allowing caregivers to explore the impacts of caring and share their experiences; and (3) education on available community services/resources, financial benefits and respite services. The cognitive behavioural therapy embedded in this programme is the best evaluated and widely used psychosocial intervention. The primary outcome is a reduction in caregiver burden. Secondary outcomes include improvements in caregiver mental wellbeing, quality of life, fatigue and self-efficacy. Economic analysis will inform whether this intervention is costeffective and if it is feasible to roll out this service on a larger scale.
   Ethics and dissemination The study was approved by the University of Sydney human research ethics committee. Study findings will be disseminated via presentations at national/international conferences and peer-reviewed journal articles.
C1 [Gopinath, Bamini; Kifley, Annette; Liew, Gerald; Bloffwitch, Jaye; Vu, Kim Van; Joachim, Nichole; Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   [Gopinath, Bamini; Kifley, Annette; Liew, Gerald; Bloffwitch, Jaye; Vu, Kim Van; Joachim, Nichole; Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Gopinath, Bamini; Craig, Ashley; Kifley, Annette; Vu, Kim Van] Univ Sydney, Kolling Inst Med Res, Sydney Med Sch, John Walsh Ctr Rehabil Res, Sydney, NSW, Australia.
   [Cummins, Rob; Heraghty, Julie] Macular Dis Fdn Australia, Sydney, NSW, Australia.
   [Broady, Timothy] Carers NSW, Sydney, NSW, Australia.
   [Hayes, Alison] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; Kolling Institute of Medical
   Research; University of Sydney
RP Gopinath, B (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.; Gopinath, B (通讯作者)，Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.; Gopinath, B (通讯作者)，Univ Sydney, Kolling Inst Med Res, Sydney Med Sch, John Walsh Ctr Rehabil Res, Sydney, NSW, Australia.
EM bamini.gopinath@sydney.edu.au
RI Gopinath, Bamini/K-4286-2019; Liew, Gerald/AAB-6870-2022; Broady,
   Timothy/J-7362-2017
OI Gopinath, Bamini/0000-0003-3573-359X; Broady,
   Timothy/0000-0002-4341-1868; Craig, Ashley/0000-0001-7647-7604
FU Australian National Health and Medical Research Council Partnership
   Project Grant [APP1115729]; Macular Disease Foundation Australia
FX The study is supported by an Australian National Health and Medical
   Research Council Partnership Project Grant (APP1115729) and the Macular
   Disease Foundation Australia.
CR ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Bambara JK, 2009, INVEST OPHTH VIS SCI, V50, P1585, DOI 10.1167/iovs.08-2744
   Brenes GA, 2015, JAMA PSYCHIAT, V72, P1012, DOI 10.1001/jamapsychiatry.2015.1154
   Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003
   Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586
   Craig A, 1998, AUST NZ J PSYCHIAT, V32, P112, DOI 10.1046/j.1440-1614.1998.00376.x
   Craig AR, 1997, ARCH PHYS MED REHAB, V78, P33, DOI 10.1016/S0003-9993(97)90006-X
   Economics DA, 2015, EC VAL INF CAR AUSTR
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gopinath B, 2015, AGING MENT HEALTH, V19, P1
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Horrell L, 2014, BRIT J PSYCHIAT, V204, P224, DOI 10.1192/bjp.bp.112.121855
   Hu C, 2015, J AM MED INFORM ASS, V22
   Kavanagh D, 2009, DRUG ALCOHOL REV, V28, P73, DOI 10.1111/j.1465-3362.2008.00011.x
   KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mains JA, 2003, J CLIN PSYCHOL, V59, P237, DOI 10.1002/jclp.10145
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin-Carrasco M, 2010, AGING MENT HEALTH, V14, P705, DOI 10.1080/13607860903586094
   Norman R, 2013, APPL HEALTH ECON HEA, V11, P287, DOI 10.1007/s40258-013-0035-z
   ORGUL S, 1994, OPHTHALMOLOGICA, V208, P142, DOI 10.1159/000310471
   Pinquart M, 2006, INT PSYCHOGERIATR, V18, P577, DOI 10.1017/S1041610206003462
   Reinhard C.S., 2008, PATIENT SAFETY QUALI, P341
   Schwarzer R., 1995, MEASURES HLTH PSYCHO, P35
   Sorensen S, 2002, GERONTOLOGIST, V42, P356, DOI 10.1093/geront/42.3.356
   VARMA R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1068, DOI 10.1001/archopht.1994.01090200074026
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   Westaway L, 2011, INSIGHT RES PRACTICE, V4, P29
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Williams K, 2009, FAMILY MATTERS, P38
   ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649
NR 35
TC 6
Z9 6
U1 0
U2 16
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD AUG
PY 2017
VL 7
IS 8
AR e018204
DI 10.1136/bmjopen-2017-018204
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA FI2UT
UT WOS:000411802700280
PM 28780563
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ying, GS
   Maguire, MG
   Daniel, E
   Grunwald, JE
   Ahmed, O
   Martin, DF
AF Ying, Gui-shuang
   Maguire, Maureen G.
   Daniel, Ebenezer
   Grunwald, Juan E.
   Ahmed, Osama
   Martin, Daniel F.
CA Comparison Age-Related Macular
TI Association between Antiplatelet or Anticoagulant Drugs and Retinal or
   Subretinal Hemorrhage in the Comparison of Age-Related Macular
   Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID MASSIVE INTRAOCULAR HEMORRHAGE; ASPIRIN; THERAPY; RISK
AB Purpose: To evaluate the association between use of antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in participants with neovascular age-related macular degeneration (AMD) in the Comparison of AMD Treatments Trials (CATT).
   Design: Cohort study within CATT.
   Participants: Participants in CATT with untreated active neovascular AMD (n = 1185).
   Methods: Participants were interviewed for use of antiplatelet or anticoagulant drugs. Trained readers evaluated photographs for the presence and size of retinal or subretinal hemorrhage at baseline and years 1 and 2. Associations between use of antiplatelet or anticoagulant drugs and hemorrhage were evaluated among all participants and by baseline hypertension status using multivariate logistic regression models.
   Main Outcome Measures: Odds ratio for association with antiplatelet or anticoagulant use.
   Results: Among 1165 participants with gradable photographs, 724 (62.1%) had retinal or subretinal hemorrhage at baseline; 84.4% of hemorrhages were 1 disc area (DA) or less, 8.1% were 1 to 2 DA, and 7.5% were more than 2 DA. At baseline, 608 participants (52.2%) used antiplatelet or anticoagulant drugs, including 514 participants (44.1%) using antiplatelets only, 77 (6.6%) using anticoagulants only, and 17 (1.5%) using both. Hemorrhage was present in 64.5% of antiplatelet or anticoagulant users and in 59.6% of nonusers (P = 0.09; adjusted odds ratio [OR], 1.18; 95% confidence interval, 0.91-1.51; P = 0.21). Neither presence nor size of baseline hemorrhage was associated with the type, dose, or duration of antiplatelet or anticoagulant use. Forty-four of 1078 participants (4.08%) had retinal or subretinal hemorrhage detected on 1- or 2-year photographs; these hemorrhages were not associated with antiplatelet or anticoagulant use at baseline (P = 0.28) or during follow-up (P = 0.64). Among participants with hypertension (n = 807), antiplatelet or anticoagulant use was associated with a higher rate of hemorrhage at baseline (66.8% vs. 56.4%; adjusted OR, 1.48; P = 0.01), but not size of retinal or subretinal hemorrhage (P = 0.41).
   Conclusions: Most retinal or subretinal hemorrhages in eyes enrolled in CATT were less than 1 DA. Among all CATT participants, antiplatelet or anticoagulant use was not associated significantly with hemorrhage, but it was associated significantly with hemorrhage in participants with hypertension. (C) 2016 by the American Academy of Ophthalmology.
C1 [Ying, Gui-shuang; Maguire, Maureen G.; Daniel, Ebenezer; Grunwald, Juan E.] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Ahmed, Osama] Univ Penn, Wharton Sch, Program Life Sci & Management, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Cleveland Clinic Foundation
RP Ying, GS (通讯作者)，Univ Penn, Perelman Sch Med, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM gsying@mail.med.upenn.edu
RI Ahmed, Osama/AAD-8330-2020
OI Ahmed, Osama/0000-0003-1492-9868
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828,
   R21EY023689]; NATIONAL EYE INSTITUTE [R21EY023689] Funding Source: NIH
   RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (cooperative agreement nos.: U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, and R21EY023689).
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   [Anonymous], 1991, Ophthalmology, V98, P757
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Brown JS, 2011, RETINA-J RET VIT DIS, V31, P1983, DOI 10.1097/IAE.0b013e31821800cd
   CHEW EY, 1995, ARCH OPHTHALMOL-CHIC, V113, P52, DOI 10.1001/archopht.1995.01100010054020
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hylek Elaine M, 2003, Semin Vasc Med, V3, P271
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   Knox FA, 2002, EYE, V16, P669, DOI 10.1038/sj.eye.6700109
   Kuhli-Hattenbach C, 2012, OPHTHALMOLOGE, V109, P665, DOI 10.1007/s00347-012-2567-2
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Olson JM, 2013, OPHTHAL SURG LAS IM, V44, P455, DOI 10.3928/23258160-20130909-06
   Palareti G, 2009, THROMB HAEMOSTASIS, V102, P268, DOI 10.1160/TH08-11-0730
   Schulman S, 2003, NEW ENGL J MED, V349, P675, DOI 10.1056/NEJMcp025373
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   United States Department of Health and Human Services. Administration on Aging Administration for Community Living, 2013, ADM AG ADM COMM LIV, V2013, P15
   United States Government, DIS COND INJ AFF SEN
NR 23
TC 27
Z9 27
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2016
VL 123
IS 2
BP 352
EP 360
DI 10.1016/j.ophtha.2015.09.046
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB2TK
UT WOS:000368362200028
PM 26545320
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Young, SL
   Anderson, MJ
   Borooah, S
   Armbrecht, AM
   Cackett, PD
AF Young, Su Ling
   Anderson, Martin J.
   Borooah, Shyamanga
   Armbrecht, Ana-Maria
   Cackett, Peter D.
TI Ten-year mortality and long-term visual acuity outcomes in patients with
   exudative age-related macular degeneration treated with intravitreal
   anti-vascular endothelial growth factor injections
SO AGE AND AGEING
LA English
DT Article
DE age-related macular degeneration (AMD); anti-vascular endothelial growth
   factor (VEGF); mortality; blind registration; visual outcomes; older
   people
ID RANIBIZUMAB; RISK; BLINDNESS; DISEASE
AB Purpose There are limited real-world data on long-term mortality and visual outcomes in patients treated with anti-vascular endothelial growth factor (VEGF) for exudative age-related macular degeneration (exudative AMD). We assessed 10-year mortality and clinical outcomes in exudative AMD patients treated with intravitreal therapy (IVT) anti-VEGF injections on a pro-re-nata (PRN) regime following a standard loading regime. Methods Retrospective cohort study of the first 216 exudative AMD patients receiving IVT anti-VEGF for exudative AMD at a public tertiary referral hospital in Scotland. Main outcome measures were mortality, cause of death and best-corrected visual acuity (BCVA). Results A total of 216 patients were included. Mean age at presentation was 79.1 years [standard deviation (SD) 6.9]. Mean follow-up duration was 6.6 years (SD 3.2) during which there was a mean 24.3 Early Treatment Diabetic Retinopathy Study (ETDRS) letter loss in BCVA (P < 0.0001). Patients received a mean of 2.2 (SD 1.8) injections per year of follow-up. Overall, 52.6% (113/216) died during the period studied. Observed annual mortality incidence risk was 6.5% (SD 3.1) and was found to be significantly lower (P = 0.0064) than the expected annual death incidence risk (9.6%, SD 1.5) based on age and sex standardised Scottish mortality risk. The most common causes of death were malignancies (21.3%) and infection (20.0%). Conclusions This study highlights the relatively good long-term prognosis in vision and mortality in exudative AMD treated with a PRN regime in the real world. Although the majority lost vision, the rate of decline was significantly slower than that which would have been experienced in the pre-anti-VEGF era and reassuringly standardised mortality risk was lower than the national average.
C1 [Young, Su Ling; Anderson, Martin J.; Armbrecht, Ana-Maria; Cackett, Peter D.] NHS Lothian, Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Borooah, Shyamanga] Univ Calif San Diego, Shiley Eye Inst, Dept Retina & Vitreous, San Diego, CA 92103 USA.
   [Borooah, Shyamanga] Univ Edinburgh, Ctr Clin Brain Sci, Sch Clin Sci, Edinburgh, Midlothian, Scotland.
C3 University of California System; University of California San Diego;
   University of Edinburgh
RP Young, SL (通讯作者)，Princess Alexandra Eye Pavil, 45 Chalmers St, Edinburgh EH3 9HA, Midlothian, Scotland.
EM drsuyoung@gmail.com
OI Young, Su Ling/0000-0003-2992-5990
FU Foundation Fighting Blindness career development award
FX S.B. is supported by a Foundation Fighting Blindness career development
   award.
CR Blind RNIft, 2020, CRIT CERT RNIB
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Chong EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137322
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Elwes F, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0688-3
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Government S, 2019, LIF EXP SCOTL
   Government S, 2020, LIF EXP SCOTL
   Government S, 2020, SCOTT IND MULT DEPR
   Gu DA, 2013, J APPL GERONTOL, V32, P876, DOI 10.1177/0733464812438634
   Hanhart J, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0586-0
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Karpa MJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1347, DOI 10.1001/archophthalmol.2009.240
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Leyland AH, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-172
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   Naing N N, 2000, Malays J Med Sci, V7, P10
   Papudesu C, 2018, OPHTHALMOLOGY, V125, P512, DOI 10.1016/j.ophtha.2017.10.028
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scotland NRo, MID 2020 POP EST SCO
   Seaman R, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2358-1
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   UK Of NS, 2020, REG LEAD CAUS DEATH
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 38
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-0729
EI 1468-2834
J9 AGE AGEING
JI Age Ageing
PD JAN 6
PY 2022
VL 51
IS 1
AR afab262
DI 10.1093/ageing/afab262
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 0D8QB
UT WOS:000776252000007
PM 34977924
DA 2022-11-30
ER

PT J
AU Forshaw, TRJ
   Parpounas, AK
   Sorensen, TL
AF Forshaw, Thomas Richard Johansen
   Parpounas, Alexandra Kalia
   Sorensen, Torben Lykke
TI Correlation of macular sensitivity measures and visual acuity to
   vision-related quality of life in patients with age-related macular
   degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Early treatment diabetic retinopathy
   study; Macular sensitivity; Microperimetry; Visual acuity;
   Vision-related quality of life; Visual function questionnaire 39
ID TREATMENT DIABETIC-RETINOPATHY; FUNDUS AUTOFLUORESCENCE; FIXATION
   STABILITY; MICROPERIMETRY; SNELLEN; MODE
AB BackgroundVisual acuity is commonly used as a functional outcome measure in patients with age-related macular degeneration (AMD), despite having a weak correlation with self-perceived visual quality of life. Microperimetry is a useful method of detecting loss of macular function. We wanted to investigate the relationship between these two objective visual outcome measures and subjective vision-related quality of life, finding out which objective measure is more patient-relevant.MethodsFifty-one consecutive patients with AMD were recruited to the study. Participants were required to complete the Visual Function Questionnaire 39, the Early Treatment Diabetic Retinopathy Study visual acuity examination and a microperimetry assessment using the Micro Perimeter 3. One patient withdrew consent and seven patients dropped out due to cooperation difficulties under microperimetry. Forty-three patients with AMD were included in the study: twenty-eight patients with late AMD (exudative AMD) and fifteen patients with early (non-exudative) AMD. The right eye was included as standard, as was the eye with the best-corrected visual acuity.ResultsThere was a higher correlation between vision-related quality of life and macular sensitivity (r=0.458; p=0.014) than between vision-related quality of life and visual acuity (r=0.446; p=0.018) in patients with late AMD. There was a positive correlation between vision-related quality of life and macular sensitivity in patients with early AMD (r=0.542; p=0.037) while the correlation between vision-related quality of life and visual acuity in these patients was not statistically significant. Composite score (r=0.469; p=0.012) correlated highest with the nasal outer macular sub-region and near-distance activities score (r=0.652; p<0.001) correlated highest with the nasal inner macular sub-region in patients with late AMD. Correlations between composite score and macular sub-regions in patients with early AMD were not significant, but near-distance activities score correlated with the nasal outer macular sub-region in these patients (r=0.469; p=0.012).ConclusionsMacular sensitivity as measured using microperimetry correlates with vision-related quality of life in early AMD and in late AMD, showing it to be a patient-relevant outcome measure. Furthermore, the nasal sub-regions of the macula appear to be preferred retinal loci in patients with AMD.(338 words)
C1 [Forshaw, Thomas Richard Johansen; Parpounas, Alexandra Kalia; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Forshaw, Thomas Richard Johansen; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Forshaw, TRJ (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.; Forshaw, TRJ (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
EM forshawthomas@yahoo.co.uk
RI Forshaw, Thomas Richard Johansen/AGF-9674-2022
OI Forshaw, Thomas Richard Johansen/0000-0003-0667-6514
FU Danish Eye Research Foundation; Synoptik Foundation; Fight for Sight
   Denmark; Jascha Fund
FX This study was supported by the Danish Eye Research Foundation, Synoptik
   Foundation, Fight for Sight Denmark, and the Jascha Fund. The funding
   bodies had no influence on: the design of the study; the collection,
   analysis and interpretation of the data; the preparation of the
   manuscript; or the decision to publish.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Boynton PM, 2004, BMJ-BRIT MED J, V328, P1433, DOI 10.1136/bmj.328.7453.1433
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Crossland M, 2012, OPTOMETRY REP, V2
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Forshaw TRJ, 2020, ACTA OPHTHALMOL, V98, P693, DOI 10.1111/aos.14430
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Gundy CM, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-35
   Han RFC, 2017, CLIN EXP OPHTHALMOL, V45, P489, DOI 10.1111/ceo.12907
   Hays RD, 2009, VALUE HEALTH, V12, P1035, DOI 10.1111/j.1524-4733.2009.00566.x
   Houtkoop-Steenstra H., 2000, INTERACTION STANDARD, DOI [10.1017/CBO9780511489457, DOI 10.1017/CBO9780511489457]
   Kafieh R, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/259123
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kaltenegger K, 2019, GRAEF ARCH CLIN EXP, V257, P1499, DOI 10.1007/s00417-019-04328-9
   Kim MS, 2016, J KOR OPHTHALMOL SOC, V57, P1087, DOI 10.3341/jkos.2016.57.7.1087
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Laishram M, 2017, J CLIN DIAGN RES, V11, pNC08, DOI 10.7860/JCDR/2017/25799.10213
   Ma YY, 2015, J CATARACT REFR SURG, V41, P1248, DOI 10.1016/j.jcrs.2014.09.046
   McColl E., 2005, ASSESSING QUALITY LI
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena E, 2011, SAUDI J OPHTHALMOL, V25, P131, DOI 10.1016/j.sjopt.2011.01.010
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Nagpal M, 2018, INDIAN J OPHTHALMOL, V66, P1790, DOI 10.4103/ijo.IJO_866_18
   Okada K, 2006, EYE, V20, P805, DOI 10.1038/sj.eye.6702014
   Osterberg G, 1935, Acta Ophthalmol., V13, P11
   Pedersen KB, 2016, GRAEF ARCH CLIN EXP, V254, P1897, DOI 10.1007/s00417-016-3323-0
   Pedersen KB, 2010, RETINA-J RET VIT DIS, V30, P1025, DOI 10.1097/IAE.0b013e3181cafc8f
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Raasch TW, 2004, BRIT J OPHTHALMOL, V88, P443, DOI 10.1136/bjo.2003.034827
   Barboni MTS, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.25
   Schechter S., 1996, P SECT SURV METH RES
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Shamir RR, 2016, INT J OPHTHALMOL-CHI, V9, P119, DOI 10.18240/ijo.2016.01.20
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Sorensen MS, 2011, DAN MED BULL, V58
   Sugawara T, 2011, JPN J OPHTHALMOL, V55, P643, DOI 10.1007/s10384-011-0080-9
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Vujosevic S, 2011, INVEST OPHTH VIS SCI, V52, P442, DOI 10.1167/iovs.10-5588
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
   Willis GB, 1999, COGNITIVE INTERVIEWI
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
NR 49
TC 4
Z9 4
U1 1
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAR 23
PY 2021
VL 21
IS 1
AR 149
DI 10.1186/s12886-021-01901-x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RF3YM
UT WOS:000634777000004
PM 33757447
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Donicova, E
   Ramm, L
   Augsten, R
   Hammer, M
AF Donicova, Emilia
   Ramm, L.
   Augsten, R.
   Hammer, M.
TI The flicker response of venous oxygen saturation is significantly
   reduced in the early and late stages of age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; retinal vessels; blood flow regulation; oxygen saturation; Retinal
   Vessel Analyzer; flicker response
ID BLOOD-PRESSURE
AB Background Retinal oxygen saturation (SO2) during flicker light stimulation was measured non-invasively in humans with age-related macular degeneration (AMD). Furthermore, the differences between early and late stages of AMD were evaluated. Methods In 60 eyes of 45 AMD patients (74 +/- 8.3 years) and 23 eyes of 23 healthy controls (73.4 +/- 7.4 years), the SO2 of arterioles and venules was measured with the oximetry module of the Retinal Vessel Analyzer. Arterial SO2, venous SO2 and arteriovenous SO2 difference at baseline and with the flicker were assessed and compared with controls. From the difference between the arteriovenous SO2 under flicker stimulation and at baseline, the parameter delta av. Diff was calculated. Subgroup analyses of non-exudative (dry) AMD, exudative (wet) AMD and their end stages, geographic atrophy (GA) and disciform scar (DS) were performed. Results In comparison with healthy subjects (mean - 4.90, CI [- 6.32, - 3.43]), the parameter delta av. Diff was significantly reduced in all AMD patients (mean - 2.20, CI - 3.15, -1.23, p = 0.003), dry AMD (mean - 1.97, CI - 3.31, -0.63, p = 0.013) and wet AMD (mean - 2.35, CI - 3.50, - 1.19, p = 0.025). The comparison between wet and dry AMD revealed no significant results (p = 1). The comparison between AMD subgroups and healthy controls (median (IQR) - 4.29 (- 8.32; - 2.42) %) showed significant differences in non-neovascular (early dry AMD) (median (IQR) - 2.43 (- 4.59; - 0.74) %, p = 0.038), GA (median (IQR) 0.10 (- 4.02; 3.15) %, p = 0.019) and DS (median (IQR) - 1.67 (- 3.52; - 0.12) %, p = 0.03). A nearly significant reduction was observed in exudative (early wet) AMD (median (IQR) - 2.71 (- 5.84; - 0.2) %, p = 0.055). Minimal, not statistically significant differences of delta av. Diff were found between AMD subgroups. None of the baseline parameters was significantly different between patients and healthy controls, even after flicker light stimulation. Conclusions Non-invasive retinal oximetry with flicker light stimulation seems to be a suitable method to study the pathogenetic mechanisms of AMD. The mathematically derived parameter delta av. Diff appears to be more sensitive than arteriovenous SO2 difference. Results suggest that the regulation of retinal oxygen supply, oxygen consumption or both is impaired in AMD.
C1 [Donicova, Emilia; Augsten, R.; Hammer, M.] Univ Hosp Jena, Dept Ophthalmol Expt Ophthalmol, Klinikum 1, D-07747 Jena, Germany.
   [Donicova, Emilia] Hannover Med Sch, Dept Ophthalmol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
   [Ramm, L.] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Ophthalmol, Fetscherstr 74, D-01307 Dresden, Germany.
C3 Friedrich Schiller University of Jena; Hannover Medical School;
   Technische Universitat Dresden; Carl Gustav Carus University Hospital
RP Donicova, E (通讯作者)，Univ Hosp Jena, Dept Ophthalmol Expt Ophthalmol, Klinikum 1, D-07747 Jena, Germany.; Donicova, E (通讯作者)，Hannover Med Sch, Dept Ophthalmol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM emilia.donicova@gmail.com
CR Beach JM, 1999, J APPL PHYSIOL, V86, P748, DOI 10.1152/jappl.1999.86.2.748
   Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Geirsdottir A, 2014, ACTA OPHTHALMOL, V92, P27, DOI 10.1111/aos.12294
   Gopinath B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04697-3
   Hammer M, 2011, INVEST OPHTH VIS SCI, V52, P274, DOI 10.1167/iovs.10-5537
   Hammer M, 2009, GRAEF ARCH CLIN EXP, V247, P1025, DOI 10.1007/s00417-009-1078-6
   Hammer M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976032
   Katsi VK, 2015, J HYPERTENS, V33, P2382, DOI 10.1097/HJH.0000000000000766
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Lanzl IM, 2011, ACTA OPHTHALMOL, V89, P472, DOI 10.1111/j.1755-3768.2009.01718.x
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nagel E, 2004, INVEST OPHTH VIS SCI, V45, P1486, DOI 10.1167/iovs.03-0667
   Riva CE, 2005, PROG RETIN EYE RES, V24, P183, DOI 10.1016/j.preteyeres.2004.07.002
   Sato E, 2006, EYE, V20, P697, DOI 10.1038/sj.eye.6701951
   Xin XL, 2018, RETINA-J RET VIT DIS, V38, P497, DOI 10.1097/IAE.0000000000001741
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 18
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2020
VL 258
IS 1
BP 31
EP 37
DI 10.1007/s00417-019-04533-6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KI9XF
UT WOS:000511711500006
PM 31781881
DA 2022-11-30
ER

PT J
AU Chaudhary, V
   Holz, FG
   Wolf, S
   Midena, E
   Souied, EH
   Allmeier, H
   Lambrou, G
   Machewitz, T
   Mitchell, P
AF Chaudhary, Varun
   Holz, Frank G.
   Wolf, Sebastian
   Midena, Edoardo
   Souied, Eric H.
   Allmeier, Helmut
   Lambrou, George
   Machewitz, Tobias
   Mitchell, Paul
CA ARIES Study Investigators
TI Association Between Visual Acuity and Fluid Compartments with
   Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related
   Macular Degeneration: An ARIES Post Hoc Analysis
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Aflibercept; Intraretinal Fluid; Neovascular Age-Related Macular
   Degeneration; Subretinal Fluid; Treat-and-Extend; Visual Acuity
ID THERAPY; RANIBIZUMAB; MORPHOLOGY; RELEVANT; EFFICACY; REGIMEN; SAFETY
AB Introduction: Recently, there has been growing interest in exploring the relationship between visual acuity and fluid localization in different retinal compartments. This post hoc analysis of the ARIES study explores the relationship between the presence of intraretinal fluid (IRF) and subretinal fluid (SRF), both at baseline and throughout treatment, and best-corrected visual acuity (BCVA) in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) in a treat-and-extend regimen.
   Methods: ARIES (NCT02581891) was a multicenter, randomized, phase 3b/4 study comparing the efficacy of two IVT-AFL treat-and-extend regimens over 2 years in patients with treatment-naive nAMD. This post hoc analysis explores the relationship between the presence of SRF/IRF and absolute BCVA (letter score) at baseline and fixed visits.
   Results: In 210 patients (treat-and-extend treatment arms combined), SRF presence at baseline was associated at every time point with a numerically higher mean BCVA than if absent, with 10 more letters at week 104. IRF presence at baseline was associated at all but one time point with a numerically lower mean BCVA than if absent (week 104, 8-letter difference). Baseline SRF+IRF was associated with lower BCVA (week 104, 7-letter difference) than if only SRF was present, but higher BCVA (week 104, 8-letter difference) than if only IRF was present. Absence of SRF+IRF was not associated with better BCVA at any time point during the study.
   Conclusion: In ARIES, in patients with nAMD treated with IVT-AFL, the presence of SRF was associated with better visual acuity, whereas IRF was associated with poorer visual acuity. The findings of this post hoc analysis suggest that differentiating IRF from SRF may offer better prognostic value in guiding treatment-extension decisions than the use of combined or "any" IRF and SRF. Prospective trials are needed to validate these results and determine their clinical relevance.
C1 [Chaudhary, Varun] Hamilton & Hamilton Hlth Sci, Hamilton Reg Eye Inst, St Josephs Healthcare, 2757 King St East Room 2500, Hamilton, ON L8G 5E4, Canada.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Wolf, Sebastian] Univ Bern, Reading Ctr, Inselspital, Bern, Switzerland.
   [Wolf, Sebastian] Univ Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Midena, Edoardo] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Souied, Eric H.] Hop Intercommunal Creteil, Dept Ophtalmol, Creteil, France.
   [Allmeier, Helmut; Lambrou, George] Bayer Consumer Care AG, Basel, Switzerland.
   [Machewitz, Tobias] Bayer AG, Berlin, Germany.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Chaudhary, Varun] McMaster Univ, Dept Surg, Div Ophthalmol, Hamilton, ON, Canada.
   [Chaudhary, Varun] McMaster Univ, Dept Hlth Res Methods Evidence & Impact HEI, Hamilton, ON, Canada.
C3 University of Bonn; University of Bern; University of Bern; University
   of Padua; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Bayer AG; Bayer AG; University of Sydney; Westmead Institute for Medical
   Research; McMaster University; McMaster University
RP Chaudhary, V (通讯作者)，Hamilton & Hamilton Hlth Sci, Hamilton Reg Eye Inst, St Josephs Healthcare, 2757 King St East Room 2500, Hamilton, ON L8G 5E4, Canada.
EM vchaudh@mcmaster.ca
RI Chaudhary, Varun/AAQ-2371-2021
OI Chaudhary, Varun/0000-0002-9988-4146
FU Bayer AG, Leverkusen, Germany; Bayer Consumer Care AG, Basel,
   Switzerland
FX The ARIES study was sponsored by Bayer AG, Leverkusen, Germany. Bayer
   Consumer Care AG, Basel, Switzerland funded the post hoc analysis and is
   also responsible for funding the journal's Rapid Service Fees.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Chaudhary V, 2022, RETINA-J RET VIT DIS, V42, P589, DOI 10.1097/IAE.0000000000003283
   FARROKHYAR F, 2022, EYE LOND
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holekamp NM, 2022, AM J OPHTHALMOL, V233, P8, DOI 10.1016/j.ajo.2021.06.029
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kaiser PK, 2021, RETINA-J RET VIT DIS, V41, P1579, DOI 10.1097/IAE.0000000000003194
   Kodjikian L, 2021, EYE, V35, P2119, DOI 10.1038/s41433-021-01487-0
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P1911, DOI 10.1097/IAE.0000000000003128
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Riedl S, 2020, RETINA-J RET VIT DIS, V40, P2148, DOI 10.1097/IAE.0000000000002717
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Siedlecki J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64901-9
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
NR 26
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD JUN
PY 2022
VL 11
IS 3
BP 1119
EP 1130
DI 10.1007/s40123-022-00491-1
EA MAR 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1I2EU
UT WOS:000770520800001
PM 35303285
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nakashizuka, H
   Mitsumata, M
   Okisaka, S
   Shimada, H
   Kawamura, A
   Mori, R
   Yuzawa, M
AF Nakashizuka, Hiroyuki
   Mitsumata, Masako
   Okisaka, Shigekuni
   Shimada, Hiroyuki
   Kawamura, Akiyuki
   Mori, Ryusaburo
   Yuzawa, Mitsuko
TI Clinicopathologic Findings in Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; RETINAL
   NEOVASCULARIZATION; PIGMENT EPITHELIUM; FEATURES; TRANSLOCATION;
   MEMBRANES; CELLS
AB PURPOSE. To elucidate the pathogenic mechanism of polypoidal choroidal vasculopathy (PCV) based on histopathologic findings.
   METHODS. Specimens obtained by surgical excision of PCV from five eyes of five patients (mean age, 75.6 +/- 3.1 years) were studied histopathologically. Immunohistochemical studies were also performed to identify CD34, vascular endothelial growth factor (VEGF), CD68, alpha-smooth muscle actin (alpha-SMA) and hypoxia-inducible factor (HIF)-1 alpha.
   RESULTS. Hyalinization of choroidal vessels and massive exudation of fibrin and blood plasma were observed in all the specimens of PCV lesions. Some blood vessels were located above the RPE in two of the five eyes. Immunohistochemically, CD68-positive cells were detected around the hyalinized vessels. There were no alpha-SMA-positive cells in the vessels of PCV. CD34 staining showed endothelial discontinuity. Vascular endothelial cells within the PCV specimens were negative for VEGF. HIF-1 alpha positive inflammatory cells were located in the stroma of specimens.
   CONCLUSIONS. Hyalinization of choroidal vessels, like arteriosclerosis, is characteristic of PCV. (Invest Ophthalmol Vis Sci. 2008;49:4729-4737) DOI:10.1167/iovs.08-2134
C1 [Nakashizuka, Hiroyuki] Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol,Chiyoda Ku, Tokyo 1018309, Japan.
   [Mitsumata, Masako] Nihon Univ, Sch Med, Div Pathol, Dept Pathol & Microbiol, Tokyo 1018309, Japan.
   [Okisaka, Shigekuni] Lab Ophthalm Pathol Educ, Tokyo, Japan.
C3 Nihon University; Nihon University
RP Nakashizuka, H (通讯作者)，Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol,Chiyoda Ku, 1-8-13 Surugadai, Tokyo 1018309, Japan.
EM shizuk@med.nihon-u.ac.jp
FU Research Committee on Chorioretinal Degenerations and Optic Atrophy;
   Ministry of Health and Welfare of Japan
FX Supported in part by Research Committee on Chorioretinal Degenerations
   and Optic Atrophy, The Ministry of Health and Welfare of Japan, and by a
   Grant-in-Aid for Scientific Research, The Ministry of Education,
   Culture, Sports, Science and Technology of Japan.
CR FICHTE C, 1978, American Journal of Ophthalmology, V85, P509
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hogan MJ, 1962, OPHTHALMIC PATHOLOGY, P64
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   LEE WR, 1987, EYE, V1, P296, DOI 10.1038/eye.1987.48
   LEISHMAN R, 1957, Br J Ophthalmol, V41, P641, DOI 10.1136/bjo.41.11.641
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   MANSCHOT WA, 1984, GRAEF ARCH CLIN EXP, V222, P63, DOI 10.1007/BF02150633
   MANSCHOT WA, 1985, T OPHTHAL SOC UK, V104, P880
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   OTSUJI T, 2006, J JPN OPHTHALMOL SOC, V110, P454
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   THOMAS JW, 1993, RETINA-J RET VIT DIS, V13, P93, DOI 10.1097/00006982-199313020-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 40
TC 167
Z9 187
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2008
VL 49
IS 11
BP 4729
EP 4737
DI 10.1167/iovs.08-2134
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366RX
UT WOS:000260502200006
PM 18586873
DA 2022-11-30
ER

PT J
AU Tepelus, TC
   Hariri, AH
   Al-Sheikh, M
   Sadda, SR
AF Tepelus, Tudor C.
   Hariri, Amir H.
   Al-Sheikh, Mayss
   Sadda, SriniVas R.
TI Correlation Between Mesopic Retinal Sensitivity and Optical Coherence
   Tomographic Metrics of the Outer Retina in Patients With Non-Atrophic
   Dry Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID VISUAL-ACUITY; GEOGRAPHIC ATROPHY; AMD PATIENTS; MICROPERIMETRY; DRUSEN;
   MACULOPATHY; THICKNESS; LAYER; EYES
AB BACKGROUND AND OBJECTIVE: To determine the correlation between mesopic retinal sensitivity and optical coherence tomographic metrics of the outer retina in patients with intermediate age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Participants with nonatrophic dry AMD underwent mesopic MP-3 microperimetry (Nidek, Padova, Italy) and both Nidek and Cirrus (Carl Zeiss Meditec, Dublin, CA) spectral-domain optical coherence tomography (SD-OCT). The volume of the outer retinal layers was measured on the Nidek SD-OCT scans using the automatic segmentation algorithm of Navis-EX software. In addition, drusen area and volume within a 5-mm circle centered on the fovea were determined using the Cirrus Advanced RPE Analysis Tool. The mean retinal sensitivity at 8 degrees and 10 degrees of fixation (5-mm and 6-mm circles) was calculated for every eye. The correlation between retinal sensitivity and patient age, outer retinal layer volume, drusen area, and drusen volume was assessed.
   RESULTS: Thirty-seven eyes from 25 patients with nonatrophic dry AMD were included in the study. The mean age of the patients was 76 years +/- 9 years. The mean sensitivity across the whole tested retinal area was 24.9 dB +/- 2.4 dB, with a sensitivity of 25.1 dB +/- 2.4 dB within the central 5-mm circle. Drusen area within the central 5-mm circle was 0.7 mm(2) +/- 0.89 mm(2) with a drusen volume of 0.03 mm(3)+/- 0.04 mm(3). Retinal pigment epithelium and photoreceptor outer segment (RPE + OS) volume was 1.96 mm(3) +/- 0.1 mm(3), and outer nuclear layer (ONL) volume was 1.91 mm(3) +/- 0.17 mm(3). There was a significant correlation between RPE + OS volume and retinal sensitivity, as well as between patients' age and retinal sensitivity. There was no significant correlation between drusen area or volume and retinal sensitivity, nor between ONL volume and retinal sensitivity.
   CONCLUSION: In eyes with nonatrophic AMD, retinal sensitivity is correlated with the RPE + OS volume, but not the ONL volume or the area or volume of drusen.
C1 [Tepelus, Tudor C.; Hariri, Amir H.; Al-Sheikh, Mayss; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Tepelus, Tudor C.; Hariri, Amir H.; Al-Sheikh, Mayss; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St,DVRC 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
FU Allergan; Carl Zeiss Meditec; Genentech; Optos
FX Dr. Sadda is a co-inventor of Doheny intellectual property related to
   optical coherence tomography that has been licensed by Topcon Medical
   Systems and is a member of the scientific advisory board for Heidelberg
   Engineering. He receives research support from and serves as a
   consultant for Allergan, Carl Zeiss Meditec, Genentech, and Optos and
   has served as a consultant for Alcon, Novartis, and Roche. The remaining
   authors report no relevant financial disclosures.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Hanout M, 2015, CURR OPIN OPHTHALMOL, V26, P149, DOI 10.1097/ICU.0000000000000153
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   NEBBIOSO M, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/671529
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Tran BK, 2015, KLIN MONATSBL AUGENH, V232, P529, DOI 10.1055/s-0035-1545779
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Villanova L, 2013, J BIOL REG HOMEOS AG, V27, P497
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
NR 24
TC 8
Z9 8
U1 0
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD APR
PY 2017
VL 48
IS 4
BP 312
EP 318
DI 10.3928/23258160-20170329-05
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EW4LN
UT WOS:000402473100007
PM 28419396
DA 2022-11-30
ER

PT J
AU Simonelli, F
   Zarrilli, F
   Mazzeo, S
   Verde, V
   Romano, N
   Savoia, M
   Testa, F
   Vitale, DF
   Rinaldi, M
   Sacchetti, L
AF Simonelli, F
   Zarrilli, F
   Mazzeo, S
   Verde, V
   Romano, N
   Savoia, M
   Testa, F
   Vitale, DF
   Rinaldi, M
   Sacchetti, L
TI Serum oxidative and antioxidant parameters in a group of Italian
   patients with age-related maculopathy
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE age-related maculopathy; oxidative status; vitamins; total plasma
   antioxidant capacity; reactive oxygen metabolites; Ox-LDL
   immunoglobulins
ID MACULAR DEGENERATION; BETA-CAROTENE; ALPHA-TOCOPHEROL; ZEAXANTHIN;
   LUTEIN; DIET
AB Objectives: The purpose of this study was to measure the oxidative and antioxidant biochemical parameters in the serum of Italian patients with age-related maculopathy (ARM) and in a similar age control group from the same area, in order to determine the weight of oxidative status as risk factor in the early stage of macular degeneration onwards. Design and methods : Forty-eight ARM patients (19 early and 29 late form) and 46 normal subjects, similar for age, sex and life-style, were studied. A series of serum and/or plasma antioxidants (vitamins C, E, A, total and individual carotenoids, zinc, total plasma antioxidant capacity-TRAP) and oxidative parameters (reactive oxygen metabolites-ROM, oxidized-low-density lipoprotein anti bodies-anti-Ox-LDL) were evaluated in both groups, also with regard to age and disease stage. Results,: Levels of vitamins C, E, total carotenoids and beta-cryptoxanthine were lower in late ARM than in early ARM (p<0.05). Of the serum carotenoids investigated, only lycopene was lower in the two ARM forms than in controls (p<0.05). The main biochemical parameters, TRAP, zinc, anti-Ox-LDL and ROM were similar in the two groups. Conclusions: A deficit of antioxidants (vitamins C, E and carotenoids) seems to be associated with ARM in Italian patients, particularly the advanced form, it is also Suggested that in ARM patients macular susceptibility to oxidative damage is not related with age. (C) 2002 Elsevier Science B.V All rights reserved.
C1 Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy.
   Univ Naples Federico II, CEINGE, I-80131 Naples, Italy.
   Univ Naples 2, Fac Med & Chirurg, Dipartimento Clin Oculist, Naples, Italy.
   Fdn Salvatore Maugeri, Ist IRCCS, Benevento, Italy.
C3 University of Naples Federico II; CEINGE Biotecnologie Avanzate;
   University of Naples Federico II; Universita della Campania Vanvitelli;
   Istituti Clinici Scientifici Maugeri IRCCS
RP Sacchetti, L (通讯作者)，Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.
RI Testa, Francesco/J-3185-2012; Simonelli, Francesca/AHE-7571-2022;
   Zarrilli, Federica/F-4501-2012
OI Simonelli, Francesca/0000-0001-8520-6769; Zarrilli,
   Federica/0000-0003-1614-6816; Testa, Francesco/0000-0002-1482-1577;
   Savoia, Marcella/0000-0003-2283-093X
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   Belisario M. A., 1993, Bollettino Societa Italiana Biologia Sperimentale, V69, P641
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407
   Sauer CG, 2001, BRIT J OPHTHALMOL, V85, P969, DOI 10.1136/bjo.85.8.969
   SCHRIJVER F, 1991, NUTR STATUS ASSESSME, P315
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   SOWELL AL, 1994, CLIN CHEM, V40, P411
   SOWELL AL, 1988, J CHROMATOGR-BIOMED, V431, P424, DOI 10.1016/S0378-4347(00)83113-8
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   VUILLEUMIER JP, 1983, INT J VITAM NUTR RES, V53, P265
NR 17
TC 37
Z9 39
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD JUN
PY 2002
VL 320
IS 1-2
BP 111
EP 115
AR PII S0009-8981(02)00056-6
DI 10.1016/S0009-8981(02)00056-6
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 561HA
UT WOS:000176133100016
PM 11983208
DA 2022-11-30
ER

PT J
AU Dhirachaikulpanich, D
   Lagger, C
   Chatsirisupachai, K
   de Magalhaes, JP
   Paraoan, L
AF Dhirachaikulpanich, Dhanach
   Lagger, Cyril
   Chatsirisupachai, Kasit
   de Magalhaes, Joao Pedro
   Paraoan, Luminita
TI Intercellular communication analysis of the human retinal pigment
   epithelial and choroidal cells predicts pathways associated with aging,
   cellular senescence and age-related macular degeneration
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE RPE; choroid; aging; senescence; VEGF; BMP; tenascin; AMD
ID GENOME-WIDE ASSOCIATION; GENE-EXPRESSION; CYSTATIN C; TENASCIN-X; VEGF;
   EYE; CHORIOCAPILLARIS; SECRETION; DISEASE; RECEPTORS
AB The retinal pigment epithelium (RPE) and the choroid are ocular tissues with fundamental roles in supporting neuroretinal function. The pathogenesis of age-related macular degeneration (AMD), a leading cause of irreversible blindness for which aging is the highest risk factor is closely linked with progressive impairment of various functions of these tissues. Cellular senescence, marked by cell cycle arrest and secretion of proinflammatory factors, is known to be associated with aging and has been proposed as a potential driver of AMD. Here, we investigated the role played by intercellular communication in the RPE/choroid within the context of aging, senescence and AMD. We inferred cell-cell interactions in the RPE/choroid by applying CellChat and scDiffCom on a publicly available scRNA-seq dataset from three human donors with and without AMD. We identified age-regulated ligand and receptor genes by using limma on a separate publicly available bulk microarray dataset providing RPE/choroid samples at multiple time points. Cellular senescence was investigated by assigning a score to each cell and each sample of these scRNA-seq and microarray datasets, respectively, based on the expression of key signature genes determined by a previous senescence meta-analysis. We identified VEGF-, BMP-and tenascin-mediated pathways supporting some of the strongest cell-cell interactions between RPE cells, fibroblasts and choroidal endothelial cells and as strong intercellular communication pathways related to both aging and senescence. Their signaling strength was enhanced between subpopulations of cells having high senescence scores. Predominant ligands of these pathways were upregulated with age whereas predominant receptors were downregulated. Globally, we also observed that cells from AMD samples presented slightly bigger senescence scores than normal cells and that the senescence score positively correlated with age in bulk samples (R = 0.26, value of p < 0.01). Hence, our analysis provides novel information on RPE/choroid intercellular communication that gives insights into the connection between aging, senescence and AMD.
C1 [Dhirachaikulpanich, Dhanach; Paraoan, Luminita] Univ Liverpool, Inst Life Course & Med Sci, Ocular Mol Biol & Mech Dis Grp, Liverpool, England.
   [Dhirachaikulpanich, Dhanach] Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok, Thailand.
   [Lagger, Cyril; Chatsirisupachai, Kasit; de Magalhaes, Joao Pedro] Univ Liverpool, Inst Life Course & Med Sci, Integrat Genom Ageing Grp, Liverpool, England.
C3 University of Liverpool; Mahidol University; University of Liverpool
RP Paraoan, L (通讯作者)，Univ Liverpool, Inst Life Course & Med Sci, Ocular Mol Biol & Mech Dis Grp, Liverpool, England.; de Magalhaes, JP (通讯作者)，Univ Liverpool, Inst Life Course & Med Sci, Integrat Genom Ageing Grp, Liverpool, England.
EM jp@senescence.info; Luminita.Paraoan@edgehill.ac.uk
FU Liverpool-Mahidol Partnership Scholarship; Human Frontier Science
   Program;  [LT000741/2019-C]
FX DD and KC were recipients of a Liverpool-Mahidol Partnership
   Scholarship. CL is grateful for the funding provided by the Human
   Frontier Science Program (fellowship LT000741/2019-C).
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Albacete-Albacete L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.671485
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Armingol E, 2021, NAT REV GENET, V22, P71, DOI 10.1038/s41576-020-00292-x
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Basisty N, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000599
   Bermond K, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.35
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Borcherding N, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01625-6
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Boulton M.E., 2013, AGE RELATED MACULAR, P45
   Butler JM, 2021, J CELL MOL MED, V25, P5572, DOI 10.1111/jcmm.16569
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Cao DF, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.34
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Chatsirisupachai K, 2019, AGING CELL, V18, DOI 10.1111/acel.13041
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Choi YE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228693
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Corridoni D, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1003-4
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dhirachaikulpanich D, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00808
   Dimitrov D., 2021, COMP RESOURCES METHO, DOI 10.1101/2021.05.21.445160
   Dimitrov Daniel, 2022, Nat Commun, V13, P3224, DOI 10.1038/s41467-022-30755-0
   El-Nimri NW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78802-4
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096
   Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Harman AM, 1997, INVEST OPHTH VIS SCI, V38, P2016
   He L, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-021-00754-7
   Hocking JC, 2007, INT J DEV BIOL, V51, P161, DOI 10.1387/ijdb.062185jh
   Hu C, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf0787
   Ibrahim AS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072293
   Ikuta T, 2000, GENES CELLS, V5, P913, DOI 10.1046/j.1365-2443.2000.00376.x
   Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kobayashi Y, 2016, MOL VIS, V22, P436
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kritsilis M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102937
   Lagger C., 2021, BIORXIV, V8, P456238, DOI [10.1101/2021.08.13.456238, DOI 10.1101/2021.08.13.456238]
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Mao JR, 2002, NAT GENET, V30, P421, DOI 10.1038/ng850
   Marneros AG, 2016, EMBO MOL MED, V8, P208, DOI 10.15252/emmm.201505613
   Martinez-Cue C, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00016
   Matsumoto KI, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.609752
   Miller WL, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.612497
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moreno P, 2021, NAT METHODS, V18, P327, DOI 10.1038/s41592-021-01102-w
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Papatheodorou I, 2020, NUCLEIC ACIDS RES, V48, pD77, DOI 10.1093/nar/gkz947
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Paraoan L, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100859
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Pouw AE, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030687
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reinhard J, 2017, FRONT INTEGR NEUROSC, V11, DOI 10.3389/fnint.2017.00030
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Saptarshi N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413457
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Sharif U, 2019, J CELL MOL MED, V23, P405, DOI 10.1111/jcmm.13944
   Sieber C, 2009, CYTOKINE GROWTH F R, V20, P343, DOI 10.1016/j.cytogfr.2009.10.007
   Solursh M, 1996, BIOCHEM BIOPH RES CO, V218, P438, DOI 10.1006/bbrc.1996.0078
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tajiri K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.624703
   Voigt AP, 2022, HUM MOL GENET, V31, P2406, DOI 10.1093/hmg/ddac043
   Voigt AP, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100934
   Voigt AP, 2020, MICROVASC RES, V131, DOI 10.1016/j.mvr.2020.104031
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang AC, 2021, NATURE, V595, P565, DOI 10.1038/s41586-021-03710-0
   Yang PR, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115542
   Yao HP, 2019, FASEB J, V33, P3212, DOI 10.1096/fj.201800858RR
NR 92
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD NOV 3
PY 2022
VL 14
AR 1016293
DI 10.3389/fnagi.2022.1016293
PG 15
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 6I6WE
UT WOS:000886274100001
PM 36408112
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Invernizzi, A
   Nguyen, V
   Arnold, J
   Young, S
   Barthelmes, D
   Gillies, MC
AF Invernizzi, Alessandro
   Nguyen, Vuong
   Arnold, Jennifer
   Young, Stephanie
   Barthelmes, Daniel
   Gillies, Mark C.
TI Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular
   Endothelial Growth Factor Therapy for Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF THERAPIES; RANIBIZUMAB; BEVACIZUMAB
AB Purpose: To investigate when retinal pigment epithelium (RPE) tears occur and their associated treatment patterns and long-term visual outcomes in patients with neovascular age-related macular degeneration (nAMD) during antievascular endothelial growth factor (VEGF) treatment.
   Design: Case-control analysis from a prospectively designed observational database.
   Participants: Treatment-naive eyes enrolled in the Fight Retina Blindness! observational study that commenced anti-VEGF treatment for nAMD between January 2006 and January 2017 were identified. Cases were defined as eyes in which an RPE tear developed during treatment. Three control eyes per case were matched for age, baseline visual acuity (VA), lesion size, treatment duration before tearing, and duration of follow-up.
   Methods: Cases were classified as having early or late tears using a segmented regression model. Baseline characteristics were compared between the 2 groups. Comparisons of VA and injections received between tear eyes and control eyes were performed at baseline, before and immediately after the tear, and then 12 and 24 months later. Visual acuity also was compared among different visits within each group.
   Main Outcome Measures: Visual acuity, time to tear, and injections received.
   Results: Fifty-five cases and 165 matched control eyes were included. The segmented regression estimated a breakpoint for the time to tear at 182 days. We therefore defined eyes as having early tears if they tore before the breakpoint (38/55 eyes [69%]), and as late tears if they tore afterward (17/55 eyes [31%]). Baseline VA was significantly lower in early compared with late tears (53.6 vs. 63.4 letters; P = 0.009). Visual acuity had improved in early tears before the tear (+5.6 letters from baseline; P = 0.01), decreased immediately after the tear (-8.3 letters; P = 0.002), then recovered with no difference compared with control eyes 12 and 24 months later (P > 0.05 for both). Late tear eyes had significantly lower VA than control eyes before tearing (55.5 vs. 66.9 letters; P < 0.001). Visual acuity did not decrease significantly after the tear, but continued to decline compared with control eyes at all end points. Both early and late tear eyes received more injections than control eyes after tearing.
   Conclusions: Retinal pigment epithelium tears act differently depending on when they occur. Long-term visual outcomes in eyes affected by RPE tearing may be related more to the patient's response to therapy than to the tear itself. (C) 2017 by the American Academy of Ophthalmology
C1 [Invernizzi, Alessandro] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
   [Invernizzi, Alessandro; Nguyen, Vuong; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Arnold, Jennifer] Marsden Eye Specialists, Parramatta, Australia.
   [Young, Stephanie] Gladesville Retina, Gladesville, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Milan; Luigi Sacco Hospital; University of Sydney;
   University of Zurich; University Zurich Hospital
RP Invernizzi, A (通讯作者)，Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
EM alessandro.invernizzi@gmail.com
OI Nguyen, Vuong/0000-0001-9070-9803
FU Alcon; Allergan; Bayer; Novartis; Macular Disease Foundation Australia
FX The author(s) have made the following disclosure(s): A. I.: Financial
   support Alcon, Allergan; J.A.: Financial support - Bayer, Novartis,
   Allergan; D.B.: Financial support - Bayer, Novartis; Inventor of the
   software used to collect the data for this analysis; M.C.G.: Consultant
   - Ophthea; Financial support - Bayer, Novartis, Allergan; Inventor of
   the software used to collect the data for this analysis; The Fight
   Retinal Blindness! project is supported by a grant from the Macular
   Disease Foundation Australia and unrestricted educational grants from
   Bayer and Novartis.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   [Anonymous], 2021, R LANGUAGE ENV STAT
   Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Barkmeier AJ, 2011, SEMIN OPHTHALMOL, V26, P94, DOI 10.3109/08820538.2011.571055
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2016, RETINA-J RET VIT DIS, V36, P1851, DOI 10.1097/IAE.0000000000001009
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Clemens CR, 2017, ACTA OPHTHALMOL
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Durkin SR, 2016, GRAEF ARCH CLIN EXP, V254, P1, DOI 10.1007/s00417-015-2978-2
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muggeo V.M.R., 2008, R NEWS, V8, P20, DOI DOI 10.1159/000323281
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zahid S, 2016, RETIN CASES BRIEF RE
NR 27
TC 13
Z9 14
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2018
VL 125
IS 2
BP 237
EP 244
DI 10.1016/j.ophtha.2017.08.039
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT0FN
UT WOS:000422797600023
PM 28993010
DA 2022-11-30
ER

PT J
AU Evereklioglu, C
   Doganay, S
   Er, H
   Cekmen, M
   Ozerol, E
   Otlu, B
AF Evereklioglu, C
   Doganay, S
   Er, H
   Cekmen, M
   Ozerol, E
   Otlu, B
TI Serum leptin concentrations are decreased and correlated with disease
   severity in age-related macular degeneration: a preliminary study
SO EYE
LA English
DT Article
DE age-related macular degeneration; chronicity; ELISA; leptin; serum
ID PLASMA LEPTIN; DIETARY-FAT; RISK-FACTORS; BODY-FAT; MACULOPATHY;
   PROTEIN; GENE
AB Background Age-related maculopathy (ARM) or degeneration (ARMD) is the leading cause of irreversible blindness in developed countries. Despite several studies on the morphology of ARMD, the aetiology is unknown and factor(s) contributing to the pathogenesis remain to be characterised. More recent studies have demonstrated that cholesterol esters and lipids are present within Bruch's membrane deposits and drusen, and dietary fat intake is associated with ARMD. The product of Ob gene, leptin, is a recently discovered peptide participating in human metabolism. There is a direct relationship between serum leptin and diet, and lipoprotein metabolism, but the role of leptin in the course of ARMD has not previously been investigated.
   Purpose This cross-sectional case-control study investigated whether serum leptin level was associated with ARMD as a new possible risk factor and to assess its relationship with disease severity.
   Methods A total of 32 patients with ARM or ARMD (17 men, 15 women) and 20 age- and sex-matched healthy control subjects without ARMD (11 men, nine women) from a similar ethnic background were enrolled in this multicentre study. Body mass index (BMI) (weight (kg)/height (m(2))) was calculated for each group. The presence of maculopathy was assessed on the basis of colour fundus photographs using an international classification system. Patients were classified as early-ARM (n = 16) or late-ARMD (n = 16) using clinical examination and grading of photographs. Serum leptin levels were measured by an enzyme-linked immunosorbent assay kit. The Mann-Whitney U test or chi(2) test was used for statistics as indicated, and P<0.05 was considered to be significant.
   Results The age, sex ratio, and BMI between groups were comparable. Patients with maculopathy had significantly (P<0.001) lower leptin levels (mean +/- SD, 6.01 +/- 2.55 ng/ ml) than control subjects (13.21+/- 2.27 ng/ml). In addition, late-ARMD patients had significantly lower leptin levels (3.81 +/- 0.58 ng/ ml) than early-ARM patients (8.21 +/- 1.68 ng/ml, P<0.001) or control subjects (P<0.001).
   Conclusion Leptin seems to be a possible newly associated factor in the course of ARM and may be involved in the lipid composition of the macular lesions, especially in late-ARMD.
C1 Erciyes Univ, Dept Ophthalmol, Fac Med, Kayseri, Turkey.
   Inonu Univ, Fac Med, Turgut Ozal Med Ctr, Malatya, Turkey.
   Gaziantep Univ, Dept Biochem, Fac Med, Res Hosp, Gaziantep, Turkey.
C3 Erciyes University; Inonu University; Gaziantep University
RP Evereklioglu, C (通讯作者)，Sivas Cad Cebeci Apt A Block 175-15, TR-38020 Kayseri, Turkey.
EM evereklioglu@hotmail.com
RI cekmen, mustafa baki/G-6122-2011; OTLU, BARIS/ABI-5532-2020;
   Evereklioğlu, Cem/A-5370-2018
OI OTLU, BARIS/0000-0002-6220-0521; Evereklioğlu, Cem/0000-0001-7889-4532
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Arnalich F, 1999, J INFECT DIS, V180, P908, DOI 10.1086/314963
   Auwerx J, 1998, LANCET, V351, P737, DOI 10.1016/S0140-6736(97)06348-4
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bornstein SR, 1998, J INFECT DIS, V178, P887, DOI 10.1086/515349
   CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   EVEREKLIOGLU C, 2002, IN PRESS DOC OPHTHAL
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   HANNAN WJ, 1995, INT J EAT DISORDER, V18, P91, DOI 10.1002/1098-108X(199507)18:1&lt;91::AID-EAT2260180110&gt;3.0.CO;2-M
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Landt M, 2000, CLIN CHEM, V46, P854
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Noske UM, 1998, OPHTHALMOLOGE, V95, P814, DOI 10.1007/s003470050358
   Ostlund RE, 1996, J CLIN ENDOCR METAB, V81, P3909, DOI 10.1210/jc.81.11.3909
   Sackett Catherine Stewart, 2002, Insight, V27, P5
   Segal KR, 1996, DIABETES, V45, P988, DOI 10.2337/diabetes.45.7.988
   Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Thong FSL, 2000, J APPL PHYSIOL, V88, P2037, DOI 10.1152/jappl.2000.88.6.2037
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Winkler BS, 1999, MOL VIS, V5
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
NR 33
TC 11
Z9 11
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2003
VL 17
IS 3
BP 350
EP 355
DI 10.1038/sj.eye.6700345
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 682RQ
UT WOS:000183106400010
PM 12724698
OA Bronze
DA 2022-11-30
ER

PT J
AU Fourgeux, C
   Dugas, B
   Richard, F
   Bjorkhem, I
   Acar, N
   Bron, AM
   Korobelnik, JF
   Leveziel, N
   Zerbib, J
   Puche, N
   Creuzot-Garcher, CP
   Souied, E
   Bretillon, L
AF Fourgeux, Cynthia
   Dugas, Brice
   Richard, Florence
   Bjorkhem, Ingemar
   Acar, Niyazi
   Bron, Alain M.
   Korobelnik, Jean-Francois
   Leveziel, Nicolas
   Zerbib, Jennyfer
   Puche, Nathalie
   Creuzot-Garcher, Catherine P.
   Souied, Eric
   Bretillon, Lionel
TI Single Nucleotide Polymorphism in the Cholesterol-24S-Hydroxylase
   (CYP46A1) Gene and Its Association with CFH and LOC387715 Gene
   Polymorphisms in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOLESTEROL 24S-HYDROXYLASE GENE; COMPLEMENT FACTOR-H;
   ALZHEIMERS-DISEASE; INTRON-2 POLYMORPHISM; CHINESE POPULATION;
   VERTEBRATE RETINA; T/C POLYMORPHISM; GRADING SYSTEM; PLASMA-LEVELS;
   LIVER VOLUME
AB PURPOSE. We investigated the association of single nucleotide polymorphism (SNP) in the cholesterol-24S-hydroxylase (CYP46A1) gene, according to CFH and LOC387715 SNPs, with age-related macular degeneration (AMD).
   METHODS. We enrolled 1388 AMD patients with neovascular AMD or geographic atrophy and 487 unrelated control subjects. SNPs were genotyped in the CYP46A1 (rs754203), LOC387715 (rs10490924), and CFH (rs1061170) genes. Plasma 24S-hydroxycholesterol, the metabolic product of CYP46A1, was quantified by gas chromatography-mass spectrometry using an authentic deuterated internal standard in subgroups of patients and controls. The chi(2) test was used to compare categoric allelic and genotype distributions between cases and controls. The odds ratio (OR) with a 95% confidence interval (95% CI) was calculated for AMD risk, and adjusted for age and gender. Significance levels were set at P < 0.05.
   RESULTS. The rs754203 SNP in the CYP46A1 gene was not associated with AMD (crude OR = 1.2, 95% CI = 0.9-1.4, P = 0.2). The crude OR for risk of AMD was 2.9 (95% CI = 2.4-3.4, P < 0.0001) according to the number of rs10490924 T alleles in the LOC387715 gene, and 2.0 (95% CI = 1.7-2.3, P < 0.0001) according to the number of rs1061170 C alleles in the CFH gene. After adjustment for age and gender, an OR of 2.2 (95% CI = 1.1-4.1, P = 0.04) was obtained for AMD cases with the C allele in the CYP46A1 gene, and carrying no risk alleles in the CFH and LOC387715 genes.
   CONCLUSIONS. The rs754203 C allele in the CYP46A1 gene may confer a higher risk for exudative AMD in patients who carry no risk alleles in the CFH and LOC387715 genes. Additional studies with larger sample sizes are needed in AMD subjects at no risk in CFH and LOC387715. (Invest Ophthalmol Vis Sci. 2012;53:7026-7033) DOI:10.1167/iovs.12-9652
C1 [Bretillon, Lionel] INRA, CSGA, Eye & Nutr Res Grp, Res Ctr,UMR1324, F-21065 Dijon, France.
   [Fourgeux, Cynthia; Acar, Niyazi; Bron, Alain M.; Creuzot-Garcher, Catherine P.; Bretillon, Lionel] CNRS, UMR6265, Ctr Sci Gout & Alimentat, Eye & Nutr Res Grp, Dijon, France.
   [Fourgeux, Cynthia; Acar, Niyazi; Bron, Alain M.; Creuzot-Garcher, Catherine P.; Bretillon, Lionel] Univ Bourgogne, Ctr Sci Gout & Alimentat, Eye & Nutr Res Grp, Dijon, France.
   [Dugas, Brice; Bron, Alain M.; Creuzot-Garcher, Catherine P.] CHU Dijon, Serv Ophtalmol, Dijon, France.
   [Richard, Florence] Inst Pasteur, F-59019 Lille, France.
   [Bjorkhem, Ingemar] Karolinska Univ, Huddinge Hosp, Dept Lab Med, Div Clin Chem, Stockholm, Sweden.
   [Korobelnik, Jean-Francois] Univ Bordeaux Segalen, Serv Ophtalmol, CHU Bordeaux, Bordeaux, France.
   [Leveziel, Nicolas; Zerbib, Jennyfer; Puche, Nathalie; Souied, Eric] Univ Hosp, Dept Ophthalmol, Creteil, France.
C3 INRAE; Institut Agro; AgroSup Dijon; Centre National de la Recherche
   Scientifique (CNRS); Universite de Bourgogne; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Institut Agro; AgroSup Dijon; Universite de Bourgogne; Institut
   Agro; AgroSup Dijon; Centre National de la Recherche Scientifique
   (CNRS); Universite de Bourgogne; CHU Dijon Bourgogne; Le Reseau
   International des Instituts Pasteur (RIIP); Universite de Lille - ISITE;
   Institut Pasteur Lille; Karolinska Institutet; Karolinska University
   Hospital; CHU Bordeaux; UDICE-French Research Universities; Universite
   de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP
RP Bretillon, L (通讯作者)，INRA, CSGA, Eye & Nutr Res Grp, Res Ctr,UMR1324, 17 Rue Sully,BP 86510, F-21065 Dijon, France.
EM lionel.bretillon@dijon.inra.fr
RI Bron, Alain/AAP-8010-2020; KOROBELNIK, Jean-Francois/A-5448-2016
OI Bron, Alain/0000-0002-7265-931X; Bjorkhem, Ingemar/0000-0001-6087-9190;
   Bretillon, Lionel/0000-0002-6957-100X; Bjorkhem,
   Ingemar/0000-0002-0575-9425; Nicolas, Leveziel/0000-0001-8533-9457
FU Programme Hospitalier de Recherche Clinique (Direction de la Recherche
   Clinique, University Hospital, Dijon, France); Fournier/Solvay/Abbott
   Laboratory (Daix, France)
FX Supported by Programme Hospitalier de Recherche Clinique (Direction de
   la Recherche Clinique, University Hospital, Dijon, France) and
   Fournier/Solvay/Abbott Laboratory (Daix, France). The authors alone are
   responsible for the content and writing of the paper.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjorkhem I, 2006, J INTERN MED, V260, P493, DOI 10.1111/j.1365-2796.2006.01725.x
   Bjorkhem I, 1998, J LIPID RES, V39, P1594
   Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178
   Borroni B, 2004, NEUROBIOL AGING, V25, P747, DOI 10.1016/j.neurobiolaging.2003.08.004
   Bretillon L, 2000, NEUROSCI LETT, V293, P87, DOI 10.1016/S0304-3940(00)01466-X
   Bretillon L, 2000, J LIPID RES, V41, P840
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Carroll MD, 2005, JAMA-J AM MED ASSOC, V294, P1773, DOI 10.1001/jama.294.14.1773
   Chalmers KA, 2004, NEUROREPORT, V15, P95, DOI 10.1097/00001756-200401190-00019
   Combarros O, 2004, DEMENT GERIATR COGN, V18, P257, DOI 10.1159/000080025
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410
   del Pozo VF, 2006, DEMENT GERIATR COGN, V21, P81, DOI 10.1159/000090215
   Desai P, 2002, NEUROSCI LETT, V328, P9, DOI 10.1016/S0304-3940(02)00443-3
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fourgeux C, 2011, CHEM PHYS LIPIDS, V164, P496, DOI 10.1016/j.chemphyslip.2011.04.006
   Fourgeux C, 2009, INVEST OPHTH VIS SCI, V50, P5712, DOI 10.1167/iovs.09-3655
   Fu BY, 2009, INT J GERIATR PSYCH, V24, P921, DOI 10.1002/gps.2196
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Halford RW, 2009, P NATL ACAD SCI USA, V106, P3502, DOI 10.1073/pnas.0813349106
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Helisalmi S, 2006, J NEUROL NEUROSUR PS, V77, P421, DOI 10.1136/jnnp.2005.071928
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hudry E, 2010, MOL THER, V18, P44, DOI 10.1038/mt.2009.175
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Ingelsson M, 2004, NEUROSCI LETT, V367, P228, DOI 10.1016/j.neulet.2004.06.011
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johansson A, 2004, HUM GENET, V114, P581, DOI 10.1007/s00439-004-1107-9
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Juhasz A, 2005, NEUROCHEM RES, V30, P943, DOI 10.1007/s11064-005-5979-4
   Kabbara A, 2004, NEUROSCI LETT, V363, P139, DOI 10.1016/j.neulet.2004.03.066
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kolsch H, 2002, MOL PSYCHIATR, V7, P899, DOI 10.1038/sj.mp.4001109
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Leoni V, 2009, SCAND J CLIN LAB INV, V69, P22, DOI 10.1080/00365510802651858
   Li Y, 2006, DEMENT GERIATR COGN, V22, P399, DOI 10.1159/000095723
   Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799
   Ma SL, 2006, INT PSYCHOGERIATR, V18, P37, DOI 10.1017/S1041610205003108
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Papassotiropoulos A, 2003, ARCH NEUROL-CHICAGO, V60, P29, DOI 10.1001/archneur.60.1.29
   Papassotiropoulos A, 2005, J CLIN PSYCHIAT, V66, P940, DOI 10.4088/JCP.v66n0720
   Ramirez DMO, 2008, J COMP NEUROL, V507, P1676, DOI 10.1002/cne.21605
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seet RCS, 2011, FREE RADICAL BIO MED, V50, P1787, DOI 10.1016/j.freeradbiomed.2011.03.019
   Shafaati M, 2009, BIOCHEM BIOPH RES CO, V378, P689, DOI 10.1016/j.bbrc.2008.11.103
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Tedde A, 2006, NEUROBIOL AGING, V27, DOI 10.1016/j.neurobiolaging.2005.03.029
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1002/hep.1840210515
   Vega GL, 2004, CURR ALZHEIMER RES, V1, P71, DOI 10.2174/1567205043480546
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang BB, 2004, NEUROSCI LETT, V369, P104, DOI 10.1016/j.neulet.2004.07.020
   Wang GF, 2012, EXP EYE RES, V94, P187, DOI 10.1016/j.exer.2011.11.005
   Weger M, 2007, MOL VIS, V13, P1274
   WYNNE HA, 1989, HEPATOLOGY, V9, P297, DOI 10.1002/hep.1840090222
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 94
TC 12
Z9 12
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2012
VL 53
IS 11
BP 7026
EP 7033
DI 10.1167/iovs.12-9652
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030SH
UT WOS:000310589900040
PM 22977134
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Diadori, A
   Zalaffi, A
   Bocci, V
AF Borrelli, Emma
   Diadori, Angelica
   Zalaffi, Alessandro
   Bocci, Velio
TI Effects of major ozonated autohemotherapy in the treatment of dry age
   related macular degeneration: a randomized controlled clinical study
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OXIDATIVE STRESS; ATHEROSCLEROTIC ISCHEMIA; OZONE THERAPY; LOWER-LIMBS;
   BLOOD; MODEL
AB AIM: To evaluate the effect of systemic ozonated major autohaemotherapy (O-3-AHT) in patients affected by dry age related macular degeneration (AMD).
   METHODS: This study was a randomized, controlled clinical study. One hundred and forty patients with the diagnosis of AMD in both eyes, with the study eye presenting dry AMD and soft drusen, were randomly assigned in a 1:1 ratio to either receive 27 major ozonated autohemotherapy treatments during 12-month period, or a standardized multi-vitamin therapy. Primary outcome was the change in best corrected visual acuity (mean logMar change) between the baseline and 6 and 12 months, end point of the study. In addition, to investigate the safety of prolonged ozonated autohaemotherapy, we measured the routine haematochemical parameters and biochemical oxidative stress values at baseline and after 12 months treatment time.
   RESULTS: The mean baseline best corrected visual acuity in study eyes was 0.36 in the treatment group and 0.38 in the control group (difference not statistically significant). At the primary endpoint, 6 months post-baseline, the mean logMAR change in the treated group improved by 0.1 and the values of the control group at the same time impaired by 0.2 respect to the baseline. Four percent and twenty-five percent of eyes in the group treated with O-3-AHT gained 1 or more lines after 6 and 12 months respectively compared to 0% in the eyes which received no treatment (P<0.05 at 12 months). None of the treated patients experienced a loss in visual acuity in their study eye at 6 and 12 months, compared to 16% and 40 % of patients in the control group who lost 2 lines or more at 6 months and 12 months respectively (P <0.05 treated vs control group)). Major ozonated autohemotherapy was shown to be safe and well-tolerated by the patients. Moreover, the haematochemical parameters showed a decrease in the Reactive Oxygen Metabolites (300 +/- 10.1 UCARR at 12 months compared to a baseline value of 380 +/- 10.4 UCARR, P<0.05) and an increase in Biological Antioxidant Potential plasma values (2100 +/- 34.8 micromoles/ C vitamin after 12 months compared to the baseline value of 1610 +/- 36.2, P<0.05) in the treated patients when compared to the control group. This data suggests that major ozonated autohaemotherapy may exert a role in reducing oxidative stress by endogenously stimulating the production of antioxidant molecules.
   CONCLUSION: The results of this study suggests that major ozonated autohaemotherapy could be a safe and effective therapeutic option for high-risk patients with dry AMD, and that a series of such treatments could improve the natural course of AMD. DOI:10.3980/j.issn.2222-3959.2012.06.11
C1 [Borrelli, Emma] Univ Siena, Dept Surg & Bioengn, Policlin Le Scotte, I-53100 Siena, Italy.
   [Diadori, Angelica] Terr Hlth Unit 7, Siena, Italy.
   [Zalaffi, Alessandro] Univ Siena, Policlin Le Scotte, Dept Ophthalmol & Neurol Sci, I-53100 Siena, Italy.
   [Bocci, Velio] Univ Siena, Dept Physiol, I-53100 Siena, Italy.
C3 University of Siena; University of Siena; University of Siena
RP Borrelli, E (通讯作者)，Univ Hosp Le Scotte, Dept Surg & Bioengn, Postgrad Course Oxygen Ozone Therapy, Viale Bracci 16, I-53100 Siena, Italy.
EM ebita1y2007@libero.it
RI Borrelli, Emma/AAE-7013-2019; Borrelli, Emma/AAJ-8172-2021; Borrelli,
   Emma/P-1018-2017
OI Borrelli, Emma/0000-0002-4991-0289; Borrelli, Emma/0000-0002-4991-0289;
   bocci, velio/0000-0002-2153-6248
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTALMOL, V119, P1439
   Bocci V, 2007, BRIT J BIOMED SCI, V64, P44, DOI 10.1080/09674845.2007.11732755
   Bocci V, BR J BIOMED, V56, P270
   BOCCI V, 2002, OXYGEN OZONE THERAPY, P1
   Bocci VA, 2006, ARCH MED RES, V37, P425, DOI 10.1016/j.arcmed.2005.08.006
   Bocci V, 2011, AM J CARDIOVASC DRUG, V11, P73, DOI 10.2165/11539890-000000000-00000
   Bocci V, 2006, J BIOCHEM MOL TOXIC, V20, P133, DOI 10.1002/jbt.20124
   Bocci V, 2012, FREE RADICAL RES, V46, P1068, DOI 10.3109/10715762.2012.693609
   Bocci V, 2009, MED RES REV, V29, P646, DOI 10.1002/med.20150
   CAGLAYAN S, 1994, P SOC PHOTO-OPT INS, V2100, P183
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Giunta R, 2001, ANN HEMATOL, V80, P745, DOI 10.1007/s002770100377
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036
   Kakita H, 2006, PEDIATR RES, V60, P675, DOI 10.1203/01.pdr.0000245911.79943.8a
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Kuno Noriyuki, 2011, Curr Mol Pharmacol, V4, P196
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Neymotin A, 2011, FREE RADICAL BIO MED, V51, P88, DOI 10.1016/j.freeradbiomed.2011.03.027
   Querques G, 2011, CLIN OPHTHALMOL, V5, P593, DOI 10.2147/OPTH.S10161
   SANSEVERINO ER, 1990, PANMINERVA MED, V32, P77
   Tylicki L, 2003, INT J ARTIF ORGANS, V26, P297, DOI 10.1177/039139880302600404
   Tylicki L, 2001, INT J ARTIF ORGANS, V24, P79, DOI 10.1177/039139880102400204
   Vassalle C, 2006, CLIN CHEM LAB MED, V44, P1372, DOI 10.1515/CCLM.2006.243
   WEHRLI F, 1954, ARS MED, V10, P44
   WOLFF HH, 1974, ERFAHR HK, V23, P181
   YAGI K, 1984, METHOD ENZYMOL, V105, P328
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
NR 30
TC 23
Z9 29
U1 0
U2 9
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2012
VL 5
IS 6
BP 708
EP 713
DI 10.3980/j.issn.2222-3959.2012.06.11
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 059ZW
UT WOS:000312745400011
PM 23275905
DA 2022-11-30
ER

PT J
AU Vitale, S
   Clemons, TE
   Agron, E
   Ferris, FL
   Domalpally, A
   Danis, RP
   Chew, EY
AF Vitale, Susan
   Clemons, Traci E.
   Agron, Elvira
   Ferris, Frederick L., III
   Domalpally, Amitha
   Danis, Ronald P.
   Chew, Emily Y.
CA Age-Related Eye Dis Study 2 AREDS2
TI Evaluating the Validity of the Age-Related Eye Disease Study Grading
   Scale for Age-Related Macular Degeneration AREDS2 Report 10
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SEVERITY SCALE; CLINICAL-TRIAL; UNITED-STATES; PREVALENCE; MODEL
AB ` IMPORTANCE To test potential treatments for age-related macular degeneration (AMD), clinical trials need standardized outcome measures that are valid for predicting AMD progression in different study populations.
   OBJECTIVE To evaluate the validity of the Age-Related Eye Disease Study (AREDS) detailed and simple AMD severity scales by comparing rates of development of late AMD (neovascular AMD and/ or central geographic atrophy) between AREDS and AREDS2 participants.
   DESIGN, SETTING, AND PARTICIPANTS Both AREDS (1992-2001) and AREDS2 (2006-2012) enrolled patients from academic and community-based retinal practices across the United States. In AREDS (n = 4519), participants with varying severity of AMD-from no AMD to late AMD in 1 eye-were enrolled. In AREDS2 (n = 4203), participants with bilateral large drusen or large drusen in the study eye and late AMD in the fellow eye were enrolled.
   MAIN OUTCOMES AND MEASURES Five-year incidence of late AMD, assessed by annual masked centralized fundus photograph grading.
   RESULTS In AREDS, the mean (SD) age of the patients was 69.3 (5.7) years, and 2519 (55.7%) were female. In AREDS2, the mean (SD) age of the patients was 73.1 (7.7) years, and 2388 (56.8%) were female. The 5-year rates of late AMD did not differ between AREDS2 and AREDS participants within nearly all baseline AMD detailed severity scale levels: levels 1 to 3: 2.4% vs 0.5%(difference, 1.9%; 95% CI, -0.2% to 4.0%; P<.001); level 4: 6.5% vs 4.9% (difference, 1.6%; 95% CI, -1.7% to 4.8%; P=.34); level 5: 8.0% vs 5.6%(difference, 2.4%; 95% CI, -1.2% to 5.9%; P=.22); level 6: 12.8% vs 13.7%(difference, -0.9%; 95% CI, -4.8% to 3.1%; P=.66); level 7: 26.2% vs 27.8%(difference, -1.5%; 95% CI, -6.6% to 3.5%; P=.54); and level 8: 46.4% vs 44.7%(difference, 1.7%; 95% CI, -7.5% to 10.9%; P=.72). Within simple scale levels, AREDS2 and AREDS 5-year rates did not differ significantly except for level 1 (9.4% vs 3.1%, P=.02; level 2: 12.8% vs 11.8%, P=.65; level 3: 26.3% vs 25.9%, P=.90; and level 4: 45.6% vs 47.3%, P=.57).
   CONCLUSIONS AND RELEVANCE The AREDS detailed and simple AMD severity scales were useful measures for assessing the risk of developing late AMD in the AREDS2 population; these data suggest that they should be useful tools for clinical trials of AMD treatments.
C1 [Vitale, Susan; Agron, Elvira; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr,Room 10D45, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Domalpally, Amitha; Danis, Ronald P.] Univ Wisconsin, Fundus Photog Reading Ctr, Madison, WI 53706 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; University of Wisconsin System; University of
   Wisconsin Madison
RP Vitale, S (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr,Room 10D45, Bethesda, MD 20892 USA.
EM sev@nei.nih.gov
RI Mitchell, Paul/P-1498-2014
OI Domalpally, Amitha/0000-0002-8145-9619; vitale,
   susan/0000-0002-5972-6848; Ferris, Frederick/0000-0002-4933-0639
FU ABD from National Eye Institute (NEI), National Institutes of Health
   (NIH), Department of Health and Human Services, Bethesda, Maryland
   [N01-EY-5-00007]; Research to Prevent Blindness; intramural program
   funds;  [HHS-N-260-2005-00007-C]; NATIONAL EYE INSTITUTE [ZIAEY000489]
   Funding Source: NIH RePORTER
FX This study was supported by the intramural program funds and contract
   HHS-N-260-2005-00007-C and ABD contract N01-EY-5-00007 from the National
   Eye Institute (NEI), National Institutes of Health (NIH), Department of
   Health and Human Services, Bethesda, Maryland (design and conduct of the
   study; collection, management, analysis, and interpretation of the data;
   and preparation, review, or approval of the manuscript; and decision to
   submit the manuscript for publication), and in part by an unrestricted
   grant from Research to Prevent Blindness to the Department of
   Ophthalmology and Visual Sciences, University of Wisconsin, Madison (Drs
   Domalpally and Danis) (collection, management, analysis, and
   interpretation of the data).
CR Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605
   Armitage P, 1994, STAT METHODS MED RES
   Brown GC, 2011, EVIDENCE BASED OPHTH, V12, P160
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   McCarthy LC, 2012, AM J OPHTHALMOL, V154, P568, DOI 10.1016/j.ajo.2012.03.021
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
NR 15
TC 19
Z9 22
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2016
VL 134
IS 9
BP 1041
EP 1047
DI 10.1001/jamaophthalmol.2016.2383
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW9NY
UT WOS:000383988800021
PM 27442263
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Wang, ZY
   Li, MY
   Yao, YO
   Hu, J
   Tang, JY
   Tang, R
   Piao, ZY
   Qu, JF
AF Wang, Zongyi
   Li, Mengyang
   Yao, Yuou
   Hu, Jie
   Tang, Jiyang
   Tang, Ran
   Piao, Zhenyu
   Qu, Jinfeng
TI Short-Term Results of Switch from Conbercept to Bevacizumab or
   Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF THERAPY; INTRAVITREAL AFLIBERCEPT; TACHYPHYLAXIS; INJECTION;
   EFFICACY; OUTCOMES; SAFETY
AB Purpose. To study the short-term anatomical and functional outcomes in patients with neovascular age-related macular degeneration (nAMD) who were previously treated with conbercept and switched to ranibizumab or bevacizumab due to persistent activity.Methods. This retrospective single-arm study included nAMD patients who were followed up for at least three months after switching from at least 3 monthly intravitreal conbercept injections to bevacizumab or ranibizumab for persistent choroidal neovascularization (CNV) activity. The demographic data, treatments, best-corrected visual acuity (BCVA), central macular thickness (CMT), and the height of pigmented epithelial detachment (PED) before and after switching were recorded and analyzed.Results. A total of 64 eyes of 64 patients were included with a mean follow-up of 9.6 +/- 3.0 months. The average number of injections of conbercept was 3.6 +/- 0.8 (range, 3-5) before switching. 18 eyes were switched to bevacizumab, and the other 46 eyes were switched to ranibizumab. After switching, mean BCVA slowly improved from 0.73 +/- 0.48 to 0.64 +/- 0.41 (p=0.0132) at one month after the last intravitreal injection of ranibizumab or bevacizumab during the mean follow-up of 4.4 +/- 2.0 months. One month after switching, the mean CMT decreased significantly from 294.9 +/- 121.8 mu m to 230.9 +/- 107.0 mu m (p<0.0001) and kept stable during the follow-up. There was a significant reduction of maximum PED height (mPEDH) at the first month after switching (from 384.3 +/- 340.3 mu m to 287.2 +/- 245.2 mu m,p=0.0018) and kept stable during the follow-up. The mean PED height at foveal center (cPEDH) showed a regression over time after switching (from 169.3 +/- 230.6 mu m to 130.5 +/- 180.2 mu m,p=0.0227) and also kept stable during the follow-up. The proportion of patients with IRF was slightly increased but not statistically significant before switching. After switching, this proportion decreased significantly from 96.9% to 81.3% at one month after the first intravitreal injection of ranibizumab or bevacizumab (p=0.0086). The proportion of patients with SRF did not change significantly before and after switching. The mean decrease of mPEDH and cPEDH at the last follow-up after switching was significantly larger in the IVR subgroup than in the IVB subgroup (p=0.023and 0.010).Conclusion. Our results indicate that switching from intravitreal conbercept injections to bevacizumab or ranibizumab can lead to significant improvement of CMT, PED, and IRF and slight improvement of BCVA in a short period of time for persistent nAMD patients.
C1 [Wang, Zongyi; Li, Mengyang; Yao, Yuou; Hu, Jie; Tang, Jiyang; Tang, Ran; Piao, Zhenyu; Qu, Jinfeng] Peking Univ, Beijing Key Lab Diag & Therapy Retinal & Choroid, Coll Optometry,Hlth Sci Ctr, Dept Ophthalmol,Peoples Hosp,Eye Dis & Optometry, Beijing 100044, Peoples R China.
C3 Peking University
RP Qu, JF (通讯作者)，Peking Univ, Beijing Key Lab Diag & Therapy Retinal & Choroid, Coll Optometry,Hlth Sci Ctr, Dept Ophthalmol,Peoples Hosp,Eye Dis & Optometry, Beijing 100044, Peoples R China.
EM wangzongyi929@bjmu.edu.cn; lmy_shsmu@126.com; 13651177854@139.com;
   383342038@qq.com; karentownecn@yahoo.co.uk; tangran.hi@163.com;
   pzhy8@sina.com; qujinfeng_pkuph@126.com
OI Qu, Jinfeng/0000-0001-6875-8393; Wang, Zongyi/0000-0003-3173-0711
FU Capital Clinical Diagnosis and Treatment Technology Research and
   Demonstration Application Project of China [Z191100006619029]
FX This work was financially supported by the Capital Clinical Diagnosis
   and Treatment Technology Research and Demonstration Application Project
   of China (Grant: Z191100006619029).
CR Aghdam KA, 2016, EUR J OPHTHALMOL, V26, P473, DOI 10.5301/ejo.5000757
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Azuma K, 2018, CLIN OPHTHALMOL, V12, P1589, DOI 10.2147/OPTH.S172115
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Despreaux R, 2016, GRAEF ARCH CLIN EXP, V254, P639, DOI 10.1007/s00417-015-3084-1
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Elwes F, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0688-3
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   Gao L, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019007
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Jin GM, 2019, CLIN EXP OPHTHALMOL, V47, P1019, DOI 10.1111/ceo.13580
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Li X, 2019, RETINA-J RET VIT DIS, V39, P1353, DOI 10.1097/IAE.0000000000002152
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Major JC, 2015, CAN J OPHTHALMOL, V50, P373, DOI 10.1016/j.jcjo.2014.12.012
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Narayan DS, 2015, INDIAN J OPHTHALMOL, V63, P832, DOI 10.4103/0301-4738.171964
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Nudleman E, 2016, CLIN OPHTHALMOL, V10, P1053, DOI 10.2147/OPTH.S109894
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Saari JM, 2014, OPEN OPHTHALMOL J, V8, P95, DOI 10.2174/1874364101408010095
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   TYAGI P, 2018, BMC OPHTHALMOLOGY, V18, DOI DOI 10.1186/S12886-018-0824-02-S2.0-85048855906
   Van Lancker L, 2017, EUR J OPHTHALMOL, V27, P342, DOI 10.5301/ejo.5000861
   Waizel M, 2016, EUR J OPHTHALMOL, V26, P469, DOI 10.5301/ejo.5000781
   Wang F, 2013, GRAEF ARCH CLIN EXP, V251, P2131, DOI 10.1007/s00417-013-2392-6
   Wu BH, 2019, INT J OPHTHALMOL-CHI, V12, P252, DOI 10.18240/ijo.2019.02.11
   Zambrowski G. R., 2016, INT J RETINA VITREOU, V2, P1, DOI [10.1186/s40942-016-0028-92-s2.0-85041216406, DOI 10.1186/S40942-016-0028-92-S2.0-85041216406]
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 41
TC 0
Z9 1
U1 1
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD SEP 7
PY 2020
VL 2020
AR 9340356
DI 10.1155/2020/9340356
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NV5EX
UT WOS:000574345800001
PM 33005448
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Arevalo, JF
   Sanchez, JG
   Wu, L
   Berrocal, MH
   Alezzandrini, AA
   Restrepo, N
   Maia, M
   Farah, ME
   Brito, M
   Diaz-Llopis, M
   Rodriguez, FJ
   Reategui, G
   Iturralde-Iraola, J
   Udaondo-Mirete, P
AF Fernando Arevalo, J.
   Sanchez, Juan G.
   Wu, Lihteh
   Berrocal, Maria H.
   Alezzandrini, Arturo A.
   Restrepo, Natalia
   Maia, Mauricio
   Farah, Michel E.
   Brito, Miguel
   Diaz-Llopis, Manuel
   Rodriguez, Francisco J.
   Reategui, Guillermo
   Iturralde-Iraola, Juan
   Udaondo-Mirete, Patricia
CA Pan-Amer Collaborative Retina Stud
TI Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in
   Age-Related Macular Degeneration at Twenty-four Months: The Pan-American
   Collaborative Retina Study
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AVASTIN TREATMENT; INJECTION; SECONDARY;
   ANTIBODY; TEAR
AB Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2.5 mg) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Design: Retrospective, multicenter, interventional, comparative case series.
   Participants: We reviewed the clinical records of 180 consecutive patients (207 eyes) with subfoveal CNV secondary to AMD at 9 centers from 8 countries.
   Methods: Patients were treated with at least 1 injection of IVB 1.25 mg (124 eyes [59.9%]) or 2.5 mg (83 eyes [40.1%]). Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and 1-, 3-, 6-, 12-, and 24-month visits.
   Main Outcome Measures: Changes in BCVA and OCT.
   Results: The mean age of our patients was 74.3 +/- 7.5 years. The mean number of IVB injections per eye was 5.1 (range, 1- 24 injections). In the 1.25 mg group, baseline BCVA improved from 20/235 (logarithm of the minimum angle of resolution [logMAR] 1.07) to 20/172 (logMAR 0.92) at 24 months (P<0.0001). Similar BCVA changes were observed in the 2.5 mg group. At baseline, the mean central macular thickness (CMT) by OCT in the 1.25 mg group was 308.4 +/- 127.52 mu m, which was reduced to 269.35 +/- 97.92 mu m, 262.1 +/- 94.81 mu m, 264.03 +/- 97.06 mu m, 245.91 +/- 89.52 mu m, and 249.27 +/- 89.14 mu m at 1, 3, 6, 12, and 24 months, respectively (P<0.0001). Similar changes were observed in the 2.5 mg group. In the 2.5 mg group, systemic complications included 2 new cases (2.6%) of arterial hypertension, 1 case (1.3%) of stroke, and 1 case (1.3%) of death.
   Conclusions: Primary IVB at a dose of 1.25 or 2.5 mg seems to provide stability or improvement in BCVA, OCT, and FA in subfoveal CNV secondary to AMD at 24 months. Our results show no significant difference regarding BCVA with IVB at doses of 1.25 or 2.5 mg.
C1 [Fernando Arevalo, J.] Clin Oftalmolog, Ctr Caracas, Retina & Vitreous Serv, Caracas 1010, Venezuela.
   [Sanchez, Juan G.; Restrepo, Natalia] Inst Nacl Invest Oftalmol, Medellin, Colombia.
   [Wu, Lihteh] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
   [Alezzandrini, Arturo A.] Univ Buenos Aires, Fac Med, OFTALMOS, Buenos Aires, DF, Argentina.
   [Maia, Mauricio; Farah, Michel E.] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Brito, Miguel; Iturralde-Iraola, Juan] Inst Docente Especialidades Oftalmol, Maracaibo, Venezuela.
   [Diaz-Llopis, Manuel; Udaondo-Mirete, Patricia] Gen Univ Valencia, Consorcio Hosp, Valencia, Spain.
   [Rodriguez, Francisco J.] Univ Rosario, Fdn Oftalmol Nacl, Bogota, Colombia.
   [Reategui, Guillermo] Inst Nacl Oftalmol, Lima, Peru.
C3 University of Puerto Rico; University of Buenos Aires; Universidade
   Federal de Sao Paulo (UNIFESP); Universidad del Rosario
RP Arevalo, JF (通讯作者)，Clin Oftalmolog, Ctr Caracas, Retina & Vitreous Serv, Edif Ctr Caracas PH 1,Av Panteon, Caracas 1010, Venezuela.
EM arevalojf2020@gmail.com
RI Fromow-Guerra, J. Jans/A-3346-2015; Farah, Michel Eid E/F-3285-2012;
   Maia, Mauricio/I-5892-2015; Maia, Mauricio/Z-1042-2019
OI Fromow-Guerra, J. Jans/0000-0001-5335-1275; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Maia,
   Mauricio/0000-0002-7034-8091; Arevalo Suarez, Fernando
   Antonio/0000-0002-4114-5949; Udaondo, Patricia/0000-0002-5241-0066
FU Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
   Venezuela
FX Supported in part by the Arevalo-Coutinho Foundation for Research in
   Ophthalmology, Caracas, Venezuela.
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MODARRES M, 2009, RETINA, V3, P319
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 35
TC 32
Z9 35
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2010
VL 117
IS 10
BP 1974
EP U155
DI 10.1016/j.ophtha.2010.01.056
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 656VV
UT WOS:000282370100017
PM 20569989
OA Green Published
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Tomany, SC
   Moss, SE
AF Klein, R
   Klein, BEK
   Tomany, SC
   Moss, SE
TI Ten-year incidence of age-related maculopathy and smoking and drinking -
   The Beaver Dam Eye Study
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE alcohol drinking; incidence; macular degeneration; population; risk
   factors; smoking
ID SENILE MACULAR DEGENERATION; ALCOHOL-CONSUMPTION; CIGARETTE-SMOKING;
   RISK-FACTORS; 5-YEAR INCIDENCE; VISUAL-ACUITY; PREVALENCE; PATHOGENESIS;
   POPULATION; WISCONSIN
AB The authors examined associations between smoking and alcohol consumption and the long-term incidence of age-related maculopathy (ARM) in people in, the Beaver Dam Eye Study who were aged 43-86 years (n = 3,684) in 1988-1990 and examined over a 10-year period. ARM status was determined by grading stereoscopic color fundus photographs. After controlling for age, sex, and other factors, the authors found that people who had smoked more were more likely to develop large (greater than or equal to250 mum in diameter) soft drusen (risk ratio (FIR) per 10 back-years smoked = 1.08, 95% confidence interval (CI): 1.02, 1.14) and pigmentary abnormalities (RR = 1.09, 95% CI: 1.04, 1.14) and to have progression of early ARM (RR = 1.05, 95% CI: 1.00, 1.10) than people Who had smoked less. Smoking was not associated with the incidence of late ARM. People who reported being heavy drinkers at baseline were more likely to, develop late ARM (RR = 6.94, 95% CI: 1.85, 26.1) than people who reported never having been heavy drinkers. Smoking appears to have a modest, positive association With early but not late signs of ARM, and heavy drinking appears to be related to an increased risk of late ARM, although the exposure and outcome were infrequent, and the effect is based on few exposed cases.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 610 N Walnut St,460 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], [No title captured]
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   FRIEDMAN E, 1970, ARCH OPHTHALMOL-CHIC, V83, P95, DOI 10.1001/archopht.1970.00990030097018
   Greenland S, 2000, AM J EPIDEMIOL, V151, P531
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   LIEBER CS, 1979, CANCER RES, V39, P2863
   Lieber CS, 2000, CRIT REV CL LAB SCI, V37, P551, DOI 10.1080/10408360091174312
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009
   RIKANS LE, 1990, ALCOHOL CLIN EXP RES, V14, P872, DOI 10.1111/j.1530-0277.1990.tb01830.x
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   ROSENBLUM ER, 1989, FREE RADICAL BIO MED, V7, P569, DOI 10.1016/0891-5849(89)90034-8
   SAS, 1999, SAS STAT US GUID VER
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1999, INVEST OPHTH VIS SCI, V40, pS568
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   TIELSCH JM, 1994, VISION PROBLEMS US, P6
   *US DHEW, 1971, HSM PUBL
   *USDA, 1990, PRIM NUTR DAT SET US
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 60
TC 113
Z9 123
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD OCT 1
PY 2002
VL 156
IS 7
BP 589
EP 598
DI 10.1093/aje/kwf092
PG 10
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 600FU
UT WOS:000178380600001
PM 12244027
DA 2022-11-30
ER

PT J
AU Mukai, R
   Matsumoto, H
   Miyakubo, T
   Akiyama, H
AF Mukai, Ryo
   Matsumoto, Hidetaka
   Miyakubo, Tomoko
   Akiyama, Hideo
TI REDUCED VASCULAR DENSITY IN THE CHOROID AFTER TREATMENT WITH
   PHOTODYNAMIC THERAPY COMBINED WITH AFLIBERCEPT IN PATIENTS WITH
   POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE antivascular endothelial growth factor; optical coherence tomography;
   photodynamic therapy; polypoidal choroidal vasculopathy
AB Purpose: To investigate changes of vascular density in the choroid of patients with polypoidal choroidal vasculopathy treated with photodynamic therapy (PDT) combined with intravitreal aflibercept. Methods: This study examined 12 eyes of 12 patients, who were diagnosed as polypoidal choroidal vasculopathy. All patents underwent optical coherence tomography before and at 3 months after PDT combined with intravitreal aflibercept treatment. Using en face optical coherence tomography images, we analyzed vascular density of the area outside the polypoidal choroidal vasculopathy lesion and within the PDT exposure area at the level of the choriocapillaris and middle layer of the choroid. In the outer layer of the choroid, the thickest vessel was selected in the area exposed to PDT, with the diameter of the vessel analyzed. Results: The vascular density in the choriocapillaris and middle layer of the choroid significantly decreased from 0.54 +/- 0.09 before treatment to 0.44 +/- 0.07 after PDT treatment in the choriocapillaris and from 0.53 +/- 0.10 to 0.47 +/- 0.08 in the middle layer of the choroid, respectively. There was also a significant reduction in the diameter of the largest vessel from 309 +/- 85 mu m at baseline to 220 +/- 52 mu m. Conclusion: Photodynamic therapy may cause occlusion of the choriocapillaris and middle vessels in the choroid, as well as stenosis of the large vessels.
C1 [Mukai, Ryo; Matsumoto, Hidetaka; Miyakubo, Tomoko; Akiyama, Hideo] Gunma Univ, Dept Ophthalmol, Grad Sch Med, 3-35-15 Showa Cho, Maebashi, Gumma 3718511, Japan.
C3 Gunma University
RP Mukai, R (通讯作者)，Gunma Univ, Dept Ophthalmol, Grad Sch Med, 3-35-15 Showa Cho, Maebashi, Gumma 3718511, Japan.
EM rmukai@gunma-u.ac.jp
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Hatta Y, 2010, RETINA-J RET VIT DIS, V30, P495, DOI 10.1097/IAE.0b013e3181bcedbe
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Mukai R, 2010, OPHTHALMOLOGICA, V224, P267, DOI 10.1159/000287348
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 21
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2021
VL 41
IS 1
BP 156
EP 161
DI 10.1097/IAE.0000000000002793
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PR6YJ
UT WOS:000607379100021
PM 32251239
DA 2022-11-30
ER

PT J
AU Lotery, A
   Xu, X
   Zlatava, G
   Loftus, J
AF Lotery, Andrew
   Xu, Xiao
   Zlatava, Gergana
   Loftus, Jane
TI Burden of illness, visual impairment and health resource utilisation of
   patients with neovascular age-related macular degeneration: results from
   the UK cohort of a five-country cross-sectional study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; FUNCTION QUESTIONNAIRE; VISION; DEPRESSION; IMPACT;
   SELF
AB Background/aims: Quantitative data regarding the impact of neovascular age-related macular degeneration (NV-AMD) on individuals and society is a prerequisite for rational decision-making processes when evaluating alternative treatments for the disease.
   Methods: 75 bilateral NV-AMD ( patients) and 91 elderly non-AMD ( controls) subjects forming the UK cohort of an international cross-sectional, observational study were independently analysed. Subjects completed a telephone survey including the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), the EuroQol (EQ-5D), the Hospital Anxiety and Depression Scale ( HADS), history of falls and health resource utilisation.
   Results: Patients with NV-AMD reported substantially worse vision-related functioning and overall well-being, including higher depression scores, than controls after adjusting for age, gender and co-morbidities ( adjusted mean scores: NEI-VFQ-25 overall 52.7 vs 90.7, p < 0.0001; EQ-5D 0.67 vs 0.77, p = 0.0273; HADS depression 6.8 vs 4.0, p = 0.0026). Significantly more patients reported a need for assistance with daily activities compared with controls (25.3% vs 6.6%, p = 0.003). Total annual healthcare utilisation costs were more than sevenfold higher for patients with AMD compared with controls (3,823.89 pound vs 517.05 pound, respectively; p < 0.0001)
   Conclusions: Patients with NV-AMD show a significant decline in quality of life and increased need for daily living assistance compared to a control population without AMD. With the availability of effective new therapies there is a need for improved early access to treatment.
C1 Univ Southampton, Southampton Gen Hosp, Southampton Eye Unit, Southampton SO16 6YD, Hants, England.
   Covance Market Access Serv, Gaithersburg, MD USA.
   Pfizer Inc, New York, NY USA.
   Pfizer Ltd, Sandwich, Kent, England.
C3 University of Southampton; Covance; Pfizer; Pfizer
RP Lotery, A (通讯作者)，Univ Southampton, Southampton Gen Hosp, Southampton Eye Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   CURTIS L, 2004, UNITS COSTS HLTH SOC
   Eichenbaum JW, 1999, ARCH GERONTOL GERIAT, V28, P191, DOI 10.1016/S0167-4943(99)00009-6
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Harwood RH, 2001, AGE AGEING, V30, P13, DOI 10.1093/ageing/30.suppl_4.13
   Hawkins BS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1616, DOI 10.1001/archopht.122.11.1616
   Haywood KL, 2005, QUAL LIFE RES, V14, P1651, DOI 10.1007/s11136-005-1743-0
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KNUR KK, 2004, ANN M ASS RES VIS OP
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   *MATTS JACK GROUP, 2003, EP AG REL MAC DEG
   MEADS C, 2003, HLTH TECHNOL ASSESS, V7
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Rovner BW, 2006, OPHTHALMOLOGY, V113, P1743, DOI 10.1016/j.ophtha.2006.05.033
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   SOUBRANE G, IN PRESS ARCH OPHTHA
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 28
TC 91
Z9 91
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2007
VL 91
IS 10
BP 1303
EP 1307
DI 10.1136/bjo.2007.116939
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214AH
UT WOS:000249707900018
PM 17504847
OA Green Published
DA 2022-11-30
ER

PT J
AU Jager, RD
   Mieler, WF
   Miller, JW
AF Jager, Rama D.
   Mieler, William F.
   Miller, Joan W.
TI Medical progress: Age-related macular degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Review
ID COMPLEMENT FACTOR-H; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   TISSUE-PLASMINOGEN ACTIVATOR; THICK SUBMACULAR HEMORRHAGE; 5-YEAR
   INCIDENCE; VISUAL IMPAIRMENT; CIGARETTE-SMOKING; VITAMIN-E; JAPANESE
   POPULATION; GEOGRAPHIC ATROPHY
C1 [Jager, Rama D.; Mieler, William F.] Univ Chicago, Sect Ophthalmol & Visual Sci, Dept Surg, Chicago, IL 60637 USA.
   [Miller, Joan W.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
C3 University of Chicago; Harvard University; Harvard Medical School
RP Jager, RD (通讯作者)，Univ Retina & Macula Assoc, 6320 W 159th St,Suite A, Oak Forest, IL 60452 USA.
EM rjager@uretina.com
OI Miller, Joan/0000-0003-2046-3996
CR ALGVERE PV, IN PRESS ACTA OPHTHA
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2006, AGE RELATED MACULAR
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chew EY, 2005, ARCH OPHTHALMOL-CHIC, V123, P395, DOI 10.1001/archopht.123.3.395
   Colenbrander August, 2007, International Ophthalmology Clinics, V47, P139, DOI 10.1097/IIO.0b013e31802bd939
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dowling J, 2005, EXPERT REV MED DEVIC, V2, P73, DOI 10.1586/17434440.2.1.73
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   GASS JD, 1967, AM J OPHTHALMOL, V63
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas E S, 2004, PHOTODYNAMIC THERAPY
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P1126, DOI 10.1016/S0161-6420(13)30905-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   National Eye Institute, AG REL EYE DIS STUD
   Okamoto H, 2006, MOL VIS, V12, P156
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, ARCH OPHTHALMOL-CHIC, V122, P426
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 99
TC 1099
Z9 1152
U1 5
U2 116
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 12
PY 2008
VL 358
IS 24
BP 2606
EP 2617
DI 10.1056/NEJMra0801537
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 311IJ
UT WOS:000256593600008
PM 18550876
DA 2022-11-30
ER

PT J
AU Iwama, D
   Tsujikawa, A
   Sasahara, M
   Hirami, Y
   Tamura, H
   Yoshimura, N
AF Iwama, Daisuke
   Tsujikawa, Akitaka
   Sasahara, Manabu
   Hirami, Yasuhiko
   Tamura, Hiroshi
   Yoshimura, Nagahisa
TI Polypoidal choroidal vasculopathy with drusen
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; drusen; polypoidal choroidal
   vasculopathy
ID AGE-RELATED MACULOPATHY; PIGMENT EPITHELIAL DETACHMENTS; MACULAR
   DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; PHOTODYNAMIC THERAPY;
   CLINICAL CHARACTERISTICS; JAPANESE PATIENTS; VERTEPORFIN; POPULATION;
   PREVALENCE
AB Purpose: To study the prevalence and clinical features of drusen in eyes with polypoidal choroidal vasculopathy (PCV).
   Methods: Retrospectively, we reviewed the records of 98 consecutive patients with PCV (102 eyes). Drusen were examined in the inner macula, which was defined as an area within 1500 mu m of the center of the fovea. Eyes that had at least one intermediate or large (>= 63 mu m) soft druse within the inner macula were defined as having drusen.
   Results: In these 102 eyes with PCV, 23 (23%) showed soft drusen in the inner macula. In such cases, the fellow eyes, those without a PCV lesion, sometimes also showed soft drusen in the inner macula (11 eyes); 34 (33%) of the eyes with PCV had soft drusen in the inner macula of at least one eye. Comparison of the group of eyes with PCV and drusen in one or both eyes with the group with PCV and no drusen in either eye revealed no significant difference in patient characteristics or in ocular manifestations.
   Conclusions: Drusen are not an unusual feature of PCV, at least in Japanese patients, and, when present, they appear to have only a minor effect, if any, on the clinical course.
C1 [Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BONNET M, 1976, ARCH OPHTALMOL-PARIS, V36, P465
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 30
TC 21
Z9 22
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD APR
PY 2008
VL 52
IS 2
BP 116
EP 121
DI 10.1007/s10384-007-0503-9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 331AY
UT WOS:000257986300006
PM 18626734
DA 2022-11-30
ER

PT J
AU Algvere, PV
   Marshall, J
   Seregard, S
AF Algvere, PV
   Marshall, J
   Seregard, S
TI Age-related maculopathy and the impact of blue light hazard
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Review
DE age-related maculopathy; short-wavelength radiation; blue light hazard;
   lipofuscin; free radicals; aphakia; retinal damage; 'yellow' intraocular
   lens (IOL); antioxidants
ID PIGMENT EPITHELIAL-CELLS; MITOCHONDRIAL-DNA DAMAGE; C-REACTIVE PROTEIN;
   HUMAN RPE CELLS; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   GEOGRAPHIC ATROPHY; INDUCED APOPTOSIS; OXIDATIVE STRESS;
   INTRAOCULAR-LENS
AB The pathogenesis of age-related maculopathy (ARM), the most common cause of visual loss after the age of 60 years, is indeed a complicated scenario that involves a variety of hereditary and environmental factors. The pathological cellular and molecular events underlying retinal photochemical light damage, including photoreceptor apoptosis, have been analysed in experimental animal models. Studies of age-related alterations of the retina and photoreceptors, the accumulation of lipofuscin in retinal pigment epithelium (RPE) cells, and the formation of drusen have greatly contributed to our knowledge. A new concept of an inflammatory response to drusen has emerged, suggesting immunogenic and systemic reactions in Bruch's membrane and the subretinal space. Oxidative stress and free radical damage also impact on the photoreceptors and RPE cells in the ageing eye. Based on the photoelectric effect, a fundamental concept in quantum physics, the consequences of high-energy irradiation have been analysed in animal models and cell culture. Short-wavelength radiation (rhodopsin spectrum), and the blue light hazard (excitation peak 440 nm), have been shown to have a major impact on photoreceptor and RPE function, inducing photochemical damage and apoptotic cell death. Following cataract surgery, there is a dramatic change in ocular transmittance. In aphakic or pseudophakic eyes (with clear intraocular lenses), high-energy (blue) and ultraviolet-A radiation strikes the retina. Epidemiological data indicate a significantly increased 5-year incidence of late ARM in non-phakic eyes compared with phakic eyes. In recent years, putative prophylactic measures against ARM have emerged. The implantation of 'yellow' intraocular lenses (IOLs) that absorb high-energy blue radiation is, from a theoretical point of view, the most rational approach, and, from a practical point of view, is easy to accomplish. With increasing age, RPE cells accumulate lipofuscin (chromophore A2E). It is noteworthy that the yellow IOL not only protects A2E-laden human RPE cells from blue light (peak 430 nm) damage, but also alleviates the detrimental effects of green (peak 550 nm) and white light. A prophylactic treatment using antioxidants is aimed at counteracting oxidative stress and free radical cellular damage. The Age-Related Eye Disease Study (AREDS), a randomized clinical trial, showed a significantly lower incidence of late ARM in a cohort of patients with drusen maculopathy treated with high doses of antioxidants than in a placebo group. In recent years, considerable progress in retinal research has been achieved, creating a platform for the search for new prophylactic and therapeutic measures to alleviate or prevent photoreceptor and RPE degeneration in ARM.
C1 St Eriks Eye Hosp, Karolinska Inst, SE-11282 Stockholm, Sweden.
   St Thomas Hosp, Rayne Inst, London, England.
C3 Karolinska Institutet; Guy's & St Thomas' NHS Foundation Trust;
   University of London; King's College London
RP Algvere, PV (通讯作者)，St Eriks Eye Hosp, Karolinska Inst, Polhemsgatan 50, SE-11282 Stockholm, Sweden.
EM peep.algvere@sankterik.se
CR Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENSON H, 1991, U PHYS, P820
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Berg AO, 2003, ANN INTERN MED, V139, P51, DOI 10.7326/0003-4819-139-1-200307010-00013
   Bermann M, 2001, EXP EYE RES, V72, P191
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bjelakovic G, 2004, LANCET, V364, P1219, DOI 10.1016/S0140-6736(04)17138-9
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chew EY, 2005, ARCH OPHTHALMOL-CHIC, V123, P395, DOI 10.1001/archopht.123.3.395
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   CICERONE CM, 1976, SCIENCE, V194, P1183, DOI 10.1126/science.996550
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Csaky K, 2004, ARCH OPHTHALMOL-CHIC, V122, P650, DOI 10.1001/archopht.122.4.650
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V37, P1236
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   DICK JSB, 2001, RETINA, V2, P987
   EDWARDS AO, 2005, COMPLEMENT FACTOR H, V308, P421
   ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grimm C, 2000, INVEST OPHTH VIS SCI, V41, P3984
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 2004, AGE-RELATED MACULAR DEGENERATION, P31
   Iseli HP, 2002, EXP EYE RES, V75, P407, DOI 10.1006/exer.2002.2032
   JACKSON G, 2005, OPHTHALMOLOGY TIMES
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Jarrard DF, 2005, ARCH OPHTHALMOL-CHIC, V123, P102, DOI 10.1001/archopht.123.1.102
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   KUWABARA T, 1976, INVEST OPHTH VISUAL, V15, P407
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Laube T, 2004, OPHTHALMOLOGY, V111, P880, DOI 10.1016/j.ophtha.2003.08.031
   Leitzmann MF, 2003, J NATL CANCER I, V95, P1004, DOI 10.1093/jnci/95.13.1004
   Li WY, 1999, MECH AGEING DEV, V110, P137, DOI 10.1016/S0047-6374(99)00047-0
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Mainster MA, 2003, BRIT J OPHTHALMOL, V87, P1523, DOI 10.1136/bjo.87.12.1523
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   MARSHALL J, 1985, OPHTHAL PHYSL OPT, V5, P241, DOI 10.1111/j.1475-1313.1985.tb00666.x
   Mellerio J., 1994, PRINCIPLES PRACTICE, V1, P1326
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Nilsson SE, 2004, ACTA OPHTHALMOL SCAN, V82, P123, DOI 10.1111/j.1600-0420.2004.00248.x
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   NILSSON SEG, 1990, LASERS LIGHT OPHTHAL, V3, P1
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5
   OSTEEN WK, 1974, INVEST OPHTH VISUAL, V13, P334
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pawlak A, 2002, ARCH BIOCHEM BIOPHYS, V403, P59, DOI 10.1016/S0003-9861(02)00260-6
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   RAPP LM, 1992, INVEST OPHTH VIS SCI, V33, P3367
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Rozanowska M, 2004, INVEST OPHTH VIS SCI, V45, P1052, DOI 10.1167/iovs.03-0277
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   SPERLING HG, 1980, VISION RES, V20, P1117, DOI 10.1016/0042-6989(80)90049-8
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Terman A, 2004, ANN NY ACAD SCI, V1019, P70, DOI 10.1196/annals.1297.015
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Wolffsohn JS, 2000, OPTOMETRY VISION SCI, V77, P73, DOI 10.1097/00006324-200002000-00011
   Wu JM, 2002, INVEST OPHTH VIS SCI, V43, P3349
   Wu JM, 1999, EYE, V13, P577, DOI 10.1038/eye.1999.142
NR 133
TC 247
Z9 279
U1 8
U2 92
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD FEB
PY 2006
VL 84
IS 1
BP 4
EP 15
DI 10.1111/j.1600-0420.2005.00627.x
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 005VZ
UT WOS:000234854300001
PM 16445433
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Higuchi, M
   Matsushita, T
   Kosaka, S
   Matsushita, R
   Takami, K
   Ohtsuka, H
AF Hikichi, Taiichi
   Higuchi, Makoto
   Matsushita, Takuro
   Kosaka, Shoko
   Matsushita, Reiko
   Takami, Kimitaka
   Ohtsuka, Hideo
TI FACTORS PREDICTIVE OF OUTCOMES 1 YEAR AFTER 3 MONTHLY RANIBIZUMAB
   INJECTIONS AND AS-NEEDED REINJECTIONS FOR POLYPOIDAL CHOROIDAL
   VASCULOPATHY IN JAPANESE PATIENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; predictive factor; ranibizumab
ID PIGMENT EPITHELIAL DETACHMENTS; MACULAR DEGENERATION; INTRAVITREAL
   RANIBIZUMAB; PHOTODYNAMIC THERAPY; BLACK-WOMEN; ASSOCIATION; FEATURES
AB Purpose: To determine baseline factors predictive of outcomes 1 year after 3 monthly intravitreal ranibizumab injections followed by as-needed injections for polypoidal choroidal vasculopathy.
   Methods: A nonrandomized prospective 1-year trial collected data from 144 Japanese patients (144 eyes) with symptomatic polypoidal choroidal vasculopathy who received one 0.5-mg intravitreal ranibizumab injection monthly for 3 months followed by as-needed retreatments. Statistical analysis evaluated baseline independent factors predictive of better visual acuity and the need for fewer injections 1 year after the first injection.
   Results: After the initial 3 monthly injections, a mean +/- standard deviation of 1.2 +/- 1.1 as-needed injections was administered. The mean visual acuity improved significantly (P, 0.01) from 20/80 to 20/50. Better visual acuity and no history of photodynamic therapy or clusters of grape-like polypoidal lesions were significant independent baseline factors predictive of better visual acuity 1 year after the first injection. No factors were significantly associated with a need for fewer ranibizumab reinjections during follow-up.
   Conclusion: The baseline clinical characteristics predicted favorable visual acuity outcomes. These findings might be useful to explaining the prognosis of ranibizumab treatment to the patients with polypoidal choroidal vasculopathy.
C1 [Hikichi, Taiichi; Higuchi, Makoto; Matsushita, Takuro; Kosaka, Shoko; Matsushita, Reiko; Takami, Kimitaka; Ohtsuka, Hideo] Ohtsuka Eye Hosp, Sapporo, Hokkaido 0010016, Japan.
RP Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Kita Ku, Kita 16 Nishi 4, Sapporo, Hokkaido 0010016, Japan.
EM taiichi-hikichi@hokkaido.med.or.jp
FU Novartis Pharma Japan; Bayer, Japan; Santen; Alcon Japan
FX Dr. Hikichi received lecture fees from Novartis Pharma Japan, Bayer,
   Japan, Santen, and Alcon Japan. The other authors declare no conflicts
   of interest.
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Ogino Tetsuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P498
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Romano MR, 2010, CLIN OPHTHALMOL, V4, P1237, DOI 10.2147/OPTH.S12577
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 32
TC 14
Z9 14
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1949
EP 1958
DI 10.1097/IAE.0b013e31828bcafa
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500027
PM 23612049
DA 2022-11-30
ER

PT J
AU Lee, JH
   Lee, WK
AF Lee, Jae Hyung
   Lee, Won Ki
TI HALF-DOSE PHOTODYNAMIC THERAPY COMBINED WITH BEVACIZUMAB FOR POLYPOIDAL
   CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; photodynamic therapy; polypoidal choroidal vasculopathy
ID FOLLOW-UP; INTRAVITREAL RANIBIZUMAB; VERTEPORFIN; THICKNESS
AB Purpose:To evaluate the efficacy of half-dose photodynamic therapy (PDT) combined with intravitreal bevacizumab (IVB) for polypoidal choroidal vasculopathy.Methods:For this retrospective comparative study, data from 57 patients (63 eyes) with at least 12 months of follow-up were reviewed. Full-dose or half-dose PDT combined with a single IVB treatment was performed according to the time period. From 3 months after the initial combination treatment, retreatment was performed mainly using anti-vascular endothelial growth factor injections on an as-needed basis.Results:Consecutively, 33 eyes were treated with full-dose PDT/IVB and 30 eyes with half-dose PDT/IVB. At Month 3, half-dose PDT/IVB induced negligible damage to the physiologic choroid but was inferior to full-dose PDT/IVB in achieving complete polyp closure (43.3% vs. 72.7%, P = 0.018) and improving mean best-corrected visual acuity (20/66 vs. 20/43, P = 0.020). At Month 12, the half-dose group achieved comparable visual improvement (20/51 vs. 20/40, P = 0.254) but required more additional injections (a mean of 2.80 vs. 1.03, P = 0.004).Conclusion:Despite inferior efficacy in inducing polyp closure, half-dose PDT/IVB followed by additional injections showed promising visual outcomes while avoiding damage to the physiologic choroid. Further long-term study is needed to evaluate the efficacy of half-dose PDT plus anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
C1 [Lee, Jae Hyung; Lee, Won Ki] Catholic Univ Korea, Dept Ophthalmol, Seoul St Marys Hosp, Coll Med, Seoul 137701, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Dept Ophthalmol, Seoul St Marys Hosp, Coll Med, 222 Banpo Daero, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
FU Novartis; Bayer; Allergan; Alcon; Santen
FX W. K. Lee has served on advisory boards for Novartis, Bayer, Allergan,
   Alcon, and Santen and has received consultancy fees from these
   companies. He has received payments for lectures from Novartis, Bayer,
   Allergan, and Alcon. J. H. Lee has no financial or conflicting interests
   to disclose.
CR Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   KUSASHIGE Y, 2008, AM J OPHTHALMOL, V146, P513
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 21
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2015
VL 35
IS 8
BP 1561
EP 1568
DI 10.1097/IAE.0000000000000498
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP4HX
UT WOS:000359843700009
PM 25768248
DA 2022-11-30
ER

PT J
AU Wu, MX
   Guo, YN
   Ma, YR
   Zheng, Z
   Wang, Q
   Zhou, XY
AF Wu, Mingxing
   Guo, Yunan
   Ma, Yanran
   Zheng, Zheng
   Wang, Qian
   Zhou, Xiyuan
TI Association of Two Polymorphisms, rs1061170 and rs1410996, in Complement
   Factor H with Age-Related Macular Degeneration in an Asian Population: A
   Meta-Analysis
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Complement factor H polymorphism;
   Meta-analysis
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; C-REACTIVE PROTEIN; CHINESE
   POPULATION; JAPANESE POPULATION; GENE POLYMORPHISMS; Y402H POLYMORPHISM;
   VARIANT INCREASES; CFH GENE; RISK; SUSCEPTIBILITY
AB Background: With the increasing number of studies indicating that two single-nucleotide polymorphisms (SNPs), rs1061170 and rs1410996, in complement factor H (CFH) might be associated with the susceptibility to age-related macular degeneration (AMD), the exact association still remains uncertain. Thus, we conducted a meta-analysis to systematically summarize and clarify the association between the two SNPs and the AMD risk particularly in an Asian population. Methods: A systematic search of studies on the association of two SNPs with the susceptibility to AMD was conducted in PubMed, Embase and Web of Science. Summary odds ratios (ORs) and 95% confidence intervals (CIs) of allele contrast and genotype contrast were estimated using the random or fixed effects model. The Q statistic test was used to identify heterogeneity, and the funnel plot was adopted to evaluate publication bias. A total of 19 case-control studies on rs1061170 and 8 studies on rs1410996 were included. Results: Clearly a significantly increased trend of AMD was observed with the rs1061170 (T vs. C: OR = 1.91, 95% CI = 1.71-2.13, p(H) = 0.029; TC vs. CC: OR = 2.11, 95% CI = 1.30-3.42, p(H) = 0.792; TT vs. CC: OR = 3.90, 95% CI = 2.45-6.22, p(H) = 0.774). Similarly, the rs1410996 polymorphism also showed a rising AMD tendency (T vs. C: OR = 1.48, 95% CI = 1.17-1.87, p(H) < 0.001; TC vs. CC: OR = 1.52, 95% CI = 1.13-2.04, p(H) = 0.002; TT vs. CC: OR = 2.10, 95% CI = 1.27-3.49, p(H) < 0.001). What is more, subgroup analysis revealed that both polymorphisms indicated a high risk of nAMD (neovascular AMD) in Asian populations. Conclusions: This meta-analysis suggested that CFH rs1061170 and rs1410996 polymorphisms were associated with AMD risk, both of which demonstrated a higher susceptibility to AMD, especially to nAMD. However, the results of rs1410996 should be interpreted with caution due to the limited sample and heterogeneity. Large-scale and well-designed studies are needed to validate our findings. (C) 2016 S. Karger AG, Basel
C1 [Wu, Mingxing; Guo, Yunan; Ma, Yanran; Zheng, Zheng; Wang, Qian; Zhou, Xiyuan] Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Chongqing 400010, Peoples R China.
C3 Chongqing Medical University
RP Zhou, XY (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Chongqing 400010, Peoples R China.
EM zhouxiyuan2002@aliyun.com
FU National Natural Science Foundation of China [81170858]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81170858).
CR Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   DerSimonian R, 1986, STAT MED, V21, P1539
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gao Y, 2010, RETINA-J RET VIT DIS, V30, P443, DOI 10.1097/IAE.0b013e3181c2e086
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim YH, 2013, OPHTHALMIC GENET, V34, P151, DOI 10.3109/13816810.2012.749287
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Ma YH, 2014, FOOD SCI TECHNOL RES, V20, P1, DOI 10.3136/fstr.20.1
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Okamoto H, 2006, MOL VIS, V12, P156
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wang D, 2015, OPHTHALMIC GENET
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
NR 37
TC 12
Z9 13
U1 0
U2 13
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 55
IS 3
BP 135
EP 144
DI 10.1159/000442257
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DD1IF
UT WOS:000369673800004
PM 26727378
DA 2022-11-30
ER

PT J
AU Feigl, B
   Brown, B
   Lovie-Kitchin, J
   Swann, P
AF Feigl, B
   Brown, B
   Lovie-Kitchin, J
   Swann, P
TI Cone-mediated multifocal electroretinogram in early age-related
   maculopathy and its relationships with subjective macular function tests
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related maculpathy; early ARM; mfERG; multifocal electroretinogram
ID ROD SYSTEM FUNCTION; RETINAL FUNCTION; LOCAL CONE; ERG; EYES;
   ABNORMALITIES; DESIGN; DRUSEN; FIELD; RISK
AB Purpose. To investigate the multifocal electroretinogram (rnfERG) and subjective function in early age-related maculopathy (ARM).
   Methods. Seventeen Subjects with early ARM with visual acuity (VA) of 6/12 or better and 20 age-matched control subjects were examined. We assessed mfERGs. high and low contrast distance VA, near VA, low luminance VA, contrast sensitivity, saturated and desaturated Panel D-15 and visual fields (mean sensitivity). The mfERG responses were analysed by comparing central-overall (method 1) and superior-inferior (method 2) ratios.
   Results. The mfERG did not discriminate between the groups whereas colour vision (tritan deficiency),, contrast sensitivity, and high contrast and low contrast VA showed significantly reduced responses for the early ARM group compared with the control group (p less than or equal to 0.01). The mfERG first-order kernel responses correlated significantly with the desaturated D-15 in both methods (r = -0.5, p less than or equal to 0.05). Fundus grading was not correlated with the mfERG measures.
   Conclusions. Although the mfERG correlated significantly with the desaturated D-15 in early ARM, suggesting it operates at a sensitive level, it failed to discriminate between tile control and ARM -roups. In our sample, the subjective function measures were more sensitive than the mfERG measures.
C1 Queensland Univ Technol, Ctr Hlth Res, Sch Optometry, Brisbane, Qld 4059, Australia.
   Graz Univ, Dept Ophthalmol, Graz, Austria.
C3 Queensland University of Technology (QUT); University of Graz
RP Feigl, B (通讯作者)，Queensland Univ Technol, Ctr Hlth Res, Sch Optometry, Victoria Pk Rd,Kelvin Grove, Brisbane, Qld 4059, Australia.
EM b.feigi@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373
CR Adams AJ, 1982, DOC OPHTHALMOL P SER
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Albrecht Johannes, 2002, J Vis, V2, P543, DOI 10.1167/2.8.2
   BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bearse MA, 1996, J OPT SOC AM A, V13, P634
   BEARSE MA, 1994, VISION SCI ITS APPL, P358
   BOWMAN KJ, 1984, DOCUMENTA OPHTHAL P, V39, P363
   BRENTON RS, 1986, INVEST OPHTH VIS SCI, V27, P799
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   Chan HHL, 2000, BRIT J OPHTHALMOL, V84, P1147, DOI 10.1136/bjo.84.10.1147
   Chappelow AV, 2000, ARCH OPHTHALMOL-CHIC, V118, P1211
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DUBOISPOULSEN A, 1973, B SOC OPHTHALMOL FR, V73, P861
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P323, DOI 10.1111/j.1475-1313.1990.tb00877.x
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   FEIGL B, 1984, EYE             0730
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Greenstein VC, 2000, INVEST OPHTH VIS SCI, V41, P3643
   HaegerstromPortnoy G, 1997, INVEST OPHTH VIS SCI, V38, P207
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Heinemann-Vernaleken Bernhild, 2000, Documenta Ophthalmologica, V101, P247, DOI 10.1023/A:1002898112128
   Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071
   Holopigian K, 2002, INVEST OPHTH VIS SCI, V43, P2364
   Holopigian K, 2001, INVEST OPHTH VIS SCI, V42, P779
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hood DC, 1997, VISUAL NEUROSCI, V14, P533, DOI 10.1017/S0952523800012190
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   JURKLIES B, 2000, IOVS, V41
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KATZ J, 1986, ARCH OPHTHALMOL-CHIC, V104, P65
   Keating D, 2002, VISION RES, V42, P2959, DOI 10.1016/S0042-6989(02)00359-0
   KLEIN R, 1991, OPHTHALMOLOGY, V131, P167
   KONDO M, 1995, INVEST OPHTH VIS SCI, V36, P2146
   Kretschmann U, 1998, BRIT J OPHTHALMOL, V82, P267, DOI 10.1136/bjo.82.3.267
   Kretschmann Ulf, 2000, Documenta Ophthalmologica, V100, P99, DOI 10.1023/A:1002775518141
   LANTHONY P, 1978, DOC OPHTHALMOL, V46, P185
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Lovie-Kitchin JE, 2000, OPTOMETRY VISION SCI, V77, P412, DOI 10.1097/00006324-200008000-00008
   Marmor MF, 2002, GRAEF ARCH CLIN EXP, V240, P241, DOI 10.1007/s00417-002-0438-2
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   MARTINSON G, 2000, THESIS U CALIFORNIA
   MARTINSON G, 1999, IOVS, V40
   MARTINSON G, 2000, IOVS, V42
   Meigen T, 2002, OPHTHALMOLOGE, V99, P713, DOI 10.1007/s00347-002-0630-0
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Mohand-Said S, 2001, PROG RETIN EYE RES, V20, P451, DOI 10.1016/S1350-9462(01)00006-4
   Nabeshima T, 2002, JPN J OPHTHALMOL, V46, P261, DOI 10.1016/S0021-5155(02)00475-6
   *NAT RES COUNC COM, 1981, PROC TEST COL VIS RE, P57
   ODEL J, 1999, INVEST OPHTH VIS SCI, V41, P513
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PALMOWSKI A, 2001, TECHNICAL DIGEST SER, P32
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Palmowski AM, 1999, OPHTHALMOLOGE, V96, P166, DOI 10.1007/s003470050389
   Palmowski AM, 1997, INVEST OPHTH VIS SCI, V38, P2586
   Parks Stuart, 1996, Documenta Ophthalmologica, V92, P281, DOI 10.1007/BF02584082
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Piao CH, 2000, INVEST OPHTH VIS SCI, V41, P513
   Poloschek CM, 2002, J VISION, V2, DOI 10.1167/2.8.5
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Seeliger M, 1998, AM J OPHTHALMOL, V125, P214, DOI 10.1016/S0002-9394(99)80094-4
   Seiple W, 2003, INVEST OPHTH VIS SCI, V44, P1783, DOI 10.1167/iovs.02-0518
   Seiple W, 2002, VISION RES, V42, P257, DOI 10.1016/S0042-6989(01)00276-0
   Shimada Y, 2001, BRIT J OPHTHALMOL, V85, P414, DOI 10.1136/bjo.85.4.414
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   SUTTER E, 1999, TECHNICAL DIGEST SER, P52
   SUTTER E, 1998, TECHNICAL DIGEST SER, V1, P20
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Sutter EE, 2001, VISION RES, V41, P1241, DOI 10.1016/S0042-6989(01)00078-5
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGRYS AJ, 1992, OPHTHAL PHYSL OPT, V12, P38, DOI 10.1016/0275-5408(92)90009-L
   VINGRYS AJ, 1988, INVEST OPHTH VIS SCI, V29, P50
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 83
TC 35
Z9 37
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD OCT-NOV
PY 2004
VL 29
IS 4-5
BP 327
EP 336
DI 10.1080/02713680490516198
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 888KW
UT WOS:000226373900015
PM 15590480
DA 2022-11-30
ER

PT J
AU Vottonen, P
AF Vottonen, Pasi
TI Anti-vascular endothelial growth factors treatment of wet age-related
   macular degeneration: from neurophysiology to cost-effectiveness
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-EVOKED-POTENTIALS; INTRAVITREAL
   AFLIBERCEPT INJECTION; EVALUATING FLUORESCEIN ANGIOGRAMS; VISION-RELATED
   FUNCTION; ANTI-VEGF TREATMENT; 2.0 MG RANIBIZUMAB; WORSE-SEEING EYE;
   FACE RECOGNITION; PHOTODYNAMIC THERAPY
AB Wet age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in the Western world, causing suffering to the individual and high social and healthcare costs to society. During the last decade, anti-vascular endothelial growth factors (anti-VEGF) have become the first choice treatments for this previously devastating condition. Currently, there are three intravitreally injected anti-VEGF medications available: bevacizumab, ranibizumab and aflibercept. Clinical trials have shown that these three anti-VEGF medications exert similar effects on visual acuity and possess similar safety profiles, although aflibercept requires less frequent injections. In fact, the required frequency of repeated injections represents a major burden on ophthalmology clinics.
   Visual evoked potential (VEP) recording offers a non-invasive tool to investigate the function of the visual pathway. The aims of this study were to determine (1) how the VEP changes after bevacizumab injections, (2) if VEP is useful as a diagnostic or monitoring tool for wet AMD, (3) if the binocular face detection task improve after anti-VEGF injections, and (4) which anti-VEGF medication and injection protocol may be considered as most cost-effective.
   The publication I was a pilot study of six wet AMD-patients treated with anti-VEGF injections, where VEP revealed that its latency had shortened and amplitude increased after the treatment. The subsequent publications II and III were non-randomized cohort studies. A total of 16 patients with unilateral wet AMD and six healthy control subjects were included. The patients received three bevacizumab injections every 4-6 weeks. VEPs were performed before the first injection and 4-6 weeks after the last injection with a similar time interval used for the non-treated controls.
   In publication II, significant changes (p < 0.05) were found in the following parameters in the treated eyes: logMAR visual acuity decreased on average by 0.18 +/- 0.32 units, optical coherence tomography (OCT) retinal thickness decreased by 170 +/- 200 lm and VEP amplitude increased by 1.0 +/- 1.4 lV. There was a significant correlation between the relative changes of VEP amplitude and retinal thickness r = -0.630 (p < 0.05), and between visual acuity (logMAR) and retinal thickness r = 0.576 (p < 0.05). These results seem to indicate that the application of VEP does not confer any additional benefits in the diagnosis or monitoring of wet AMD.
   In publication III, face pictures elicited well-defined event-related components in occipital and parieto-occipital cortical areas at baseline and after treatment. The face-specific N170 component was pronounced in all subjects with longer peak latency in patients than in controls (p = 0.032). However patients did not experience any significant improvement in face-specific electrical potentials after the anti-VEGF treatment. In publication IV, the cost-effectiveness of the three anti-VEGF injections and two injection protocols (i.e. regular monthly and pro re nata) for wet AMD were compared. A two-eye Markov transition model was developed for this analysis and a sensitivity analysis of estimated model parameters was performed. Regular monthly injections of bevacizumab were superior in comparison to the other options, a result reinforced by the sensitivity analyses. National Library of Medicine Classification: W 74, WW 103, WW 166, WW 270
   Medical Subject Headings: Wet Macular degeneration/drug therapy; Neurophysiology; Drug Costs; Treatment Outcome
C1 [Vottonen, Pasi] Univ Eastern Finland, Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
C3 Kuopio University Hospital; University of Eastern Finland
RP Vottonen, P (通讯作者)，Kuopio Univ Hosp, Dept Ophthalmol, POB 1777, Kuopio 70211, Finland.
EM pasi.vottonen@kuh.fi
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548
   Adatia FA, 2015, SURV OPHTHALMOL, V60, P204, DOI 10.1016/j.survophthal.2014.10.002
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anastasopoulos E, 2006, AM J OPHTHALMOL, V142, P1081, DOI 10.1016/j.ajo.2006.06.058
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Arnold JJ, 2007, BMJ CLIN EVID, V2007
   Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Bajwa A, 2015, INT OPHTHALMOL, V35, P733, DOI 10.1007/s10792-015-0087-1
   Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   Barnes CS, 2011, OPTOMETRY VISION SCI, V88, P188, DOI 10.1097/OPX.0b013e318205a17c
   Baseler HA, 2011, OPTOMETRY VISION SCI, V88, P1255, DOI 10.1097/OPX.0b013e3182282f13
   Baseler HA, 2011, NAT NEUROSCI, V14, P649, DOI 10.1038/nn.2793
   BASS SJ, 1985, INVEST OPHTH VIS SCI, V26, P1071
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Begg D, 1997, ECONOMICS, P2
   BEGLEITER H, 1995, ELECTROEN CLIN NEURO, V94, P41, DOI 10.1016/0013-4694(94)00240-L
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Bentin S, 2006, J COGNITIVE NEUROSCI, V18, P1406, DOI 10.1162/jocn.2006.18.8.1406
   Bindemann M, 2008, PSYCHOPHYSIOLOGY, V45, P535, DOI 10.1111/j.1469-8986.2008.00663.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brar VS, 2010, MOL VIS, V16, P1848
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003
   Briggs A H, 1999, Health Technol Assess, V3, P1
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Burnat K, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/307929
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Butt T, 2014, APPL HEALTH ECON HEA, V12, P289, DOI 10.1007/s40258-014-0090-0
   Butt T, 2013, OPTOMETRY VISION SCI, V90, P855, DOI 10.1097/OPX.0b013e3182962318
   Calder AJ, 2005, NAT REV NEUROSCI, V6, P641, DOI 10.1038/nrn1724
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Canadian Agency for Drugs and Technologies in Health, 2014, LONG TERM US RAN TRE
   Castillo MM, 2014, EYE, V28, P1399, DOI 10.1038/eye.2014.214
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiappa Keith H., 1997, P95
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Creel D., 1995, WEBVISION ORG RETINA
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De Moraes Carlos Gustavo, 2013, J Glaucoma, V22 Suppl 5, pS2, DOI 10.1097/IJG.0b013e3182934978
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Dekowska M, 2008, ACTA NEUROBIOL EXP, V68, P229
   Di Russo F, 2002, HUM BRAIN MAPP, V15, P95, DOI 10.1002/hbm.10010
   Diaz RI, 2015, SURV OPHTHALMOL, V60, P279, DOI 10.1016/j.survophthal.2015.02.005
   Dilks DD, 2014, OPTOMETRY VISION SCI, V91, pE199, DOI 10.1097/OPX.0000000000000325
   Dilks DD, 2009, J NEUROSCI, V29, P2768, DOI 10.1523/JNEUROSCI.5258-08.2009
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Dolan P, 2008, ECON J, V118, P215, DOI 10.1111/j.1468-0297.2007.02110.x
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Drummond MF, 2005, METHODS EC EVALUATIO
   Ekman P, 1976, PICTURES FACIAL AFFE
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   EMMERSONHANOVER R, 1994, ELECTROEN CLIN NEURO, V92, P93, DOI 10.1016/0168-5597(94)90049-3
   Fairhall SL, 2007, CEREB CORTEX, V17, P2400, DOI 10.1093/cercor/bhl148
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Folgar FA, 2014, OPHTHALMOLOGY, V121, P1956, DOI 10.1016/j.ophtha.2014.04.020
   FOLK JC, 1984, ARCH OPHTHALMOL-CHIC, V102, P1299
   France T D, 1984, Trans Am Ophthalmol Soc, V82, P383
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   de Mendonca RHF, 2007, DOC OPHTHALMOL, V115, P117, DOI 10.1007/s10633-007-9060-2
   GASS JD, 1982, ARCH OPHTHALMOL-CHIC, V100, P769
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Gonzalez EG, 2011, INVEST OPHTH VIS SCI, V52, P4208, DOI 10.1167/iovs.10-7026
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hannula DE, 2005, NAT REV NEUROSCI, V6, P247, DOI 10.1038/nrn1630
   Hanso L, 2010, PSYCHOLOGY, V1, P199, DOI DOI 10.4236/PSYCH.2010.13027
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hasler PW, 2015, ACTA OPHTHALMOL, V93, P122, DOI 10.1111/aos.12589
   Hatz K, 2015, OPHTHALMOLOGICA, V233, P66, DOI 10.1159/000367603
   Haxby JV, 2000, TRENDS COGN SCI, V4, P223, DOI 10.1016/S1364-6613(00)01482-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heron-Delaney M, 2011, PHILOS T R SOC B, V366, P1753, DOI 10.1098/rstb.2010.0371
   Hirneiss C, 2014, CLIN OPHTHALMOL, V8, P1703, DOI 10.2147/OPTH.S64200
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hodge W, 2010, CAN J OPHTHALMOL, V45, P223, DOI 10.3129/i10-047
   Holder GE, 2001, PROG RETIN EYE RES, V20, P531, DOI 10.1016/S1350-9462(00)00030-6
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hood DC, 2003, J NEURO-OPHTHALMOL, V23, P279, DOI 10.1097/00041327-200312000-00010
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hunter A, 2013, CLIN OPHTHALMOL, V7, P2085, DOI 10.2147/OPTH.S49552
   Iarossi G, 2003, INVEST OPHTH VIS SCI, V44, P866, DOI 10.1167/iovs.01-1256
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JASPER H H, 1958, Res Publ Assoc Res Nerv Ment Dis, V36, P316
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jiang S, 2014, J CLIN PHARM THER, V39, P234, DOI 10.1111/jcpt.12146
   JOHNSON LN, 1987, GRAEF ARCH CLIN EXP, V225, P123, DOI 10.1007/BF02160343
   Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kaarniranta K, 2016, 2016 LAST UPDATE KAY
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaas JH, 2015, VISUAL NEUROSCI, V32, DOI 10.1017/S0952523815000152
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kalloniatis M., 1995, WEBVISION ORG RETINA
   Kanwisher N, 1997, J NEUROSCI, V17, P4302
   Kapiainen S, 2014, TERVEYDEN JA SOSIAAL
   Karlica D, 2010, ACTA CLIN CROAT, V49, P251
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATO M, 1991, DOC OPHTHALMOL, V76, P341, DOI 10.1007/BF00142672
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kedar S, 2011, INDIAN J OPHTHALMOL, V59, P103, DOI 10.4103/0301-4738.77013
   Kimura M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00267
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kinnunen Kati, 2012, Front Biosci (Elite Ed), V4, P2546
   Kinnunen K, 2012, ANN MED, V44, P1, DOI 10.3109/07853890.2010.532150
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Ko KF, 2010, SINGAP MED J, V51, P716
   Kolb H., 1995, WEBVISION ORG RETINA
   Kourlaba G, 2015, VALUE HEALTH, V18, pA421, DOI 10.1016/j.jval.2015.09.557
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   LaBar KS, 2003, CEREB CORTEX, V13, P1023, DOI 10.1093/cercor/13.10.1023
   Lampela Hanna, 2005, Duodecim, V121, P170
   Landa G, 2007, EUR J OPHTHALMOL, V17, P615, DOI 10.1177/112067210701700421
   Langwinska-Wosko E, 2015, DOC OPHTHALMOL, V130, P103, DOI 10.1007/s10633-015-9479-9
   Le Grand R, 2001, NATURE, V410, P890, DOI 10.1038/35073749
   Le Grand R, 2003, NAT NEUROSCI, V6, P1108, DOI 10.1038/nn1121
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Little AC, 2011, PHILOS T R SOC B, V366, P1638, DOI 10.1098/rstb.2010.0404
   LIU Y, 2009, ADV OPHTHALMOL, V119, P163, DOI DOI 10.1007/S10633-009-9189-2
   Lotery A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6887
   Macky TA, 2012, J OCUL PHARMACOL TH, V28, P159, DOI 10.1089/jop.2011.0141
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Major JC, 2014, RETINA-J RET VIT DIS, V34, P48, DOI 10.1097/IAE.0b013e3182965743
   Makela M, 2007, MENETELMIEN ARVIOINT, P34
   MARCUS M, 1983, ANN OPHTHALMOL, V15, P235
   MARMOR MF, 2011, ADV OPHTHALMOL, V122, P1, DOI DOI 10.1007/S10633-011-9259-0
   Martikainen J, 2006, DOSIS, V22, P289
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martins Rosa A, 2013, BIOMED RES INT, V2013
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Melcher D, 2015, VISUAL NEUROSCI, V32, DOI 10.1017/S095252381500019X
   Ministry of Social Affairs and Health, 2015, 2015 LAST UPD TERV P
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Mnatsakanian EV, 2004, CLIN NEUROPHYSIOL, V115, P880, DOI 10.1016/j.clinph.2003.11.027
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mondloch CJ, 2013, DEVELOPMENTAL SCI, V16, P728, DOI 10.1111/desc.12065
   Morgan JIW, 2016, OPHTHAL PHYSL OPT, V36, P218, DOI 10.1111/opo.12289
   Moscovitch M, 1997, J COGNITIVE NEUROSCI, V9, P555, DOI 10.1162/jocn.1997.9.5.555
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Anton ZAM, 2015, VALUE HEALTH, V18, pA880, DOI 10.1016/j.jval.2015.09.067
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Neumann MF, 2008, BRAIN RES, V1239, P181, DOI 10.1016/j.brainres.2008.08.039
   Nyrke T, 2006, KLIININEN NEUROFYSIO, P272
   Odom JV, 2016, DOC OPHTHALMOL, V133, P1, DOI 10.1007/s10633-016-9553-y
   Odom JV, 2010, DOC OPHTHALMOL, V120, P111, DOI 10.1007/s10633-009-9195-4
   Ojamo M, 2016, POWER POINT PRESENTA
   Ojamo M, 2015, NAKOVAMMAREKISTERIN
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Oster SF, 2003, BRIT J OPHTHALMOL, V87, P639, DOI 10.1136/bjo.87.5.639
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Pai SA, 2007, AM J OPHTHALMOL, V143, P601, DOI 10.1016/j.ajo.2006.12.037
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Peirce JW, 2015, J VISION, V15, DOI 10.1167/15.7.5
   Phillips JS, 2012, JOVE-J VIS EXP, DOI 10.3791/4125
   Prasad Sashank, 2014, Continuum (Minneap Minn), V20, P1023, DOI 10.1212/01.CON.0000453305.65851.1c
   Nguyen QD, 2012, J OCUL PHARMACOL TH, V28, P581, DOI 10.1089/jop.2011.0261
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rasanen P, 2006, INT J TECHNOL ASSESS, V22, P235, DOI 10.1017/S0266462306051051
   Rasanen P, 2013, SUOM LAAKARIL, V68, P1255
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rossion B, 2014, TRENDS COGN SCI, V18, P310, DOI 10.1016/j.tics.2014.02.013
   Rouvas A, 2011, RETINA-J RET VIT DIS, V31, P871, DOI 10.1097/IAE.0b013e3182003ca8
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Sabeti F, 2013, DOC OPHTHALMOL, V126, P125, DOI 10.1007/s10633-012-9366-6
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schweinberger SR, 2004, NEUROREPORT, V15, P1501, DOI 10.1097/01.wnr.0000131675.00319.42
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shamir RR, 2016, INT J OPHTHALMOL-CHI, V9, P119, DOI 10.18240/ijo.2016.01.20
   SHERMAN J, 1986, INVEST OPHTH VIS SCI, V27, P214
   Shimada Y, 1997, ACTA OPHTHALMOL SCAN, V75, P277
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Simcock P, 2014, EYE, V28, P1161, DOI 10.1038/eye.2014.153
   Singh A, 2012, ACTA OPHTHALMOL, V90, P476, DOI 10.1111/j.1755-3768.2010.02051.x
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Sintonen H., 2013, SUOMEN LAAKARII, V68, P1261
   Sintonen H, 2006, TERVEYSTALOUSTIEDE H, P27
   Slotnick SD, 1999, CLIN NEUROPHYSIOL, V110, P1793, DOI 10.1016/S1388-2457(99)00135-2
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Stingl K, 2010, KLIN MONATSBL AUGENH, V227, P940, DOI 10.1055/s-0029-1245830
   Sunness JS, 1999, MOL VIS, V5
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   Tarita-Nistor L, 2006, VISION RES, V46, P2487, DOI 10.1016/j.visres.2006.01.035
   Tempelaar S, 2015, VALUE HEALTH, V18, pA420, DOI 10.1016/j.jval.2015.09.554
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   TOWLE VL, 1995, ELECTROEN CLIN NEURO, V94, P221, DOI 10.1016/0013-4694(95)98474-M
   Trobe JD, 1996, AM J OPHTHALMOL, V121, P547, DOI 10.1016/S0002-9394(14)75429-7
   Tsao DY, 2008, ANNU REV NEUROSCI, V31, P411, DOI 10.1146/annurev.neuro.30.051606.094238
   Tuulonen A, 2009, ACTA OPHTHALMOL, V87, P820, DOI 10.1111/j.1755-3768.2009.01532.x
   Vakalis N, 2015, SCI REP-UK, V5, DOI 10.1038/srep08627
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
   Valimaki Juha, 2012, Duodecim, V128, P1140
   Vottonen P, 2015, ACTA OPHTHALMOL, V93, P621, DOI 10.1111/aos.12774
   Vottonen P, 2013, CLIN OPHTHALMOL, V7, P437, DOI 10.2147/OPTH.S40427
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wandell BA, 2007, NEURON, V56, P366, DOI 10.1016/j.neuron.2007.10.012
   Wang HB, 2016, MOL VIS, V22, P189
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wilhelm H, 2015, DTSCH ARZTEBL INT, V112, P616, DOI 10.3238/arztebl.2015.0616
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
   Wolff BE, 2010, DOC OPHTHALMOL, V121, P189, DOI 10.1007/s10633-010-9245-y
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu L, 1999, Curr Opin Ophthalmol, V10, P217, DOI 10.1097/00055735-199906000-00011
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
   Xerri C, 2012, NEUROSCIENTIST, V18, P133, DOI 10.1177/1073858410397894
   Yadav NK, 2012, DOC OPHTHALMOL, V124, P177, DOI 10.1007/s10633-012-9319-0
   Yanagi Y, 2011, JPN J OPHTHALMOL, V55, P35, DOI 10.1007/s10384-010-0893-y
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Young B, 2012, CURR OPIN OPHTHALMOL, V23, P497, DOI 10.1097/ICU.0b013e328359045e
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Zayit-Soudry S, 2007, RETINA-J RET VIT DIS, V27, P798, DOI 10.1097/IAE.0b013e31802c50a3
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 303
TC 2
Z9 2
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2018
VL 96
SU A109
SI SI
BP 1
EP 46
PG 46
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FX0JD
UT WOS:000425728400001
PM 29468838
OA Bronze
DA 2022-11-30
ER

PT J
AU Azuma, K
   Obata, R
   Nomura, Y
   Tan, X
   Takahashi, H
   Yanagi, Y
AF Azuma, Keiko
   Obata, Ryo
   Nomura, Yoko
   Tan, Xue
   Takahashi, Hidenori
   Yanagi, Yasuo
TI ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL
   VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH
   INTRAVITREAL AFLIBERCEPT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; ranibizumab; aflibercept; anti-VEGF
   drug; polypoidal lesion; branching vascular network vessels
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; ANTI-VEGF
   TREATMENT; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; CLINICAL
   CHARACTERISTICS; FOLLOW-UP; BEVACIZUMAB; VERTEPORFIN; INJECTION
AB Purpose: The aim of this study was to study the angiopathic findings of ranibizumabresistant polypoidal choroidal vasculopathy after switching to a treat-and-extend regimen with intravitreal aflibercept.
   Methods: The authors retrospectively reviewed 17 eyes of 17 Japanese patients with polypoidal choroidal vasculopathy (10 men and 7 women, age: 73.8 +/- 7.4 years) who were treated with intravitreal aflibercept (2 mg/0.05 mL) injections from February 2013 to August 2014 at Tokyo University Hospital. All patients had switched to aflibercept because their polypoidal choroidal vasculopathy had been refractory to ranibizumab.
   Results: The mean logMAR best-corrected visual acuity at baseline and after 12 months of therapy was 0.30 +/- 0.29 (Snellen equivalent: 20/40) and 0.17 +/- 0.26 (20/30) (paired t-test P, 0.001). Visual acuity remained stable in 5 cases (29%), deteriorated in 3 (18%), and improved in 9 (53%). Branching vascular networks persisted in all 17 eyes but shrank in 15 (88%). The mean lesion diameter was 3329 +/- 1261 mm at baseline and 3180 +/- 1247 mm after 12 months (P = 0.0002).
   Conclusion: A treat-and-extend regimen with intravitreal aflibercept for ranibizumabresistant patients resulted in branching vascular network shrinkage over a 1-year period.
C1 [Azuma, Keiko; Obata, Ryo; Nomura, Yoko; Tan, Xue; Takahashi, Hidenori; Yanagi, Yasuo] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Azuma, Keiko; Obata, Ryo; Nomura, Yoko; Tan, Xue; Takahashi, Hidenori; Yanagi, Yasuo] Univ Tokyo, Fac Med, Tokyo, Japan.
   [Takahashi, Hidenori] Jichi Med Univ, Dept Ophthalmol, Shimotsuke, Tochigi, Japan.
   [Yanagi, Yasuo] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Singapore, Singapore.
   [Yanagi, Yasuo] Duke NUS Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
C3 University of Tokyo; University of Tokyo; Jichi Medical University;
   Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center
RP Yanagi, Y (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 113-8655, Tokyo 1138655, Japan.; Yanagi, Y (通讯作者)，Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 113-8655, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020; Takahashi,
   Hidenori/H-2945-2019
OI Takahashi, Hidenori/0000-0001-5331-4730; Yanagi,
   Yasuo/0000-0002-0362-7285
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [24791837]
FX Supported in part by a Grant-in-Aid for Scientific Research (B), number
   24791837, from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan. The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. No additional external funding was received for this study.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Fan NW, 2014, J CHIN MED ASSOC, V77, P101, DOI 10.1016/j.jcma.2013.10.012
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rush RB, 2014, AM J OPHTHALMOL, V158, P337, DOI 10.1016/j.ajo.2014.05.007
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 55
TC 10
Z9 11
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2016
VL 36
IS 11
BP 2158
EP 2165
DI 10.1097/IAE.0000000000001047
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB1AY
UT WOS:000387079800023
PM 27258669
DA 2022-11-30
ER

PT J
AU Singh, SR
   Goyal, P
   Parameswarappa, DC
   Goud, A
   Chhablani, J
AF Singh, Sumit Randhir
   Goyal, Prakhar
   Parameswarappa, Deepika C.
   Goud, Abhilash
   Chhablani, Jay
TI Angiographic features of polypoidal choroidal vasculopathy using
   indocyanine green angiography and optical coherence tomography
   angiography: A comparative study
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; optical coherence tomography
   angiography; indocyanine green angiography; branching vascular network;
   polyp
ID VERTEPORFIN PHOTODYNAMIC THERAPY; RANIBIZUMAB; COMBINATION; DIAGNOSIS;
   EFFICACY; EVEREST; SAFETY
AB Background: To compare the vascular lesion size using optical coherence tomography angiography and indocyanine green angiography in eyes with polypoidal choroidal vasculopathy. Methods: Treatment-naive cases (46 eyes of 44 patients) with polypoidal choroidal vasculopathy were retrospectively analyzed. The comparison of mean area of branching vascular network and polyp detection rate was done between indocyanine green angiography and optical coherence tomography angiography and correlated with various optical coherence tomography features. Results: The mean age of the study patients was 62.33 +/- 10.74 years. The mean branching vascular network size was 7.47 +/- 5.74 and 7.51 +/- 5.69 mm(2) in indocyanine green angiography and optical coherence tomography angiography, respectively, with an excellent correlation (r = 0.997). Optical coherence tomography angiography overestimated (mean +/- SD: 0.28 +/- 0.19 mm(2)) and underestimated branching vascular network area (0.36 +/- 0.33 mm(2)) in 23 eyes each as compared to indocyanine green angiography. However, the difference in branching vascular network size was not statistically significant (p = 0.53). Indocyanine green angiography and optical coherence tomography angiography could identify polyps in 43 of 46 (93.48%) and 32 of 46 (69.57%) patients, respectively. Conclusion: Branching vascular network size measurements with indocyanine green angiography and optical coherence tomography angiography were comparable and showed significant correlation, albeit the polyp identification rate was lower with optical coherence tomography angiography. Optical coherence tomography angiography may serve as a useful substitute to indocyanine green angiography in measurements of branching vascular network for photodynamic therapy and follow-up of polypoidal choroidal vasculopathy eyes.
C1 [Singh, Sumit Randhir; Goyal, Prakhar; Parameswarappa, Deepika C.; Goud, Abhilash; Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad 500034, India.
   [Singh, Sumit Randhir] LV Prasad Eye Inst, Retina & Uveitis Dept, Visakhapatnam, Andhra Pradesh, India.
   [Goyal, Prakhar; Parameswarappa, Deepika C.] LV Prasad Eye Inst, Acad Eye Care Educ, Hyderabad, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; L. V. Prasad Eye
   Institute
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad 500034, India.
EM jay.chhablani@gmail.com
OI Chhablani, Jay/0000-0003-1772-3558
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Choi W, 2017, RETINA-J RET VIT DIS, V37, P11, DOI 10.1097/IAE.0000000000001250
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Peiretti E, 2019, RETINA-J RET VIT DIS, V39, P1693, DOI 10.1097/IAE.0000000000002234
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 28
TC 1
Z9 1
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2020
VL 30
IS 5
BP 1076
EP 1081
DI 10.1177/1120672119850075
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OB6JS
UT WOS:000578575700056
PM 31113262
DA 2022-11-30
ER

PT J
AU Koh, A
   Lai, TYY
   Takahashi, K
   Wong, TY
   Chen, LJ
   Ruamviboonsuk, P
   Tan, CS
   Feller, C
   Margaron, P
   Lim, TH
   Lee, WK
AF Koh, Adrian
   Lai, Timothy Y. Y.
   Takahashi, Kanji
   Wong, Tien Y.
   Chen, Lee-Jen
   Ruamviboonsuk, Paisan
   Tan, Colin S.
   Feller, Chrystel
   Margaron, Philippe
   Lim, Tock H.
   Lee, Won Ki
CA EVEREST II study grp
TI Efficacy and Safety of Ranibizumab With or Without Verteporfin
   Photodynamic Therapy for Polypoidal Choroidal Vasculopathy A Randomized
   Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION; EVEREST;
   COMBINATION; DIAGNOSIS; FEATURES
AB IMPORTANCE Polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative age-related macular degeneration among Asian individuals. To our knowledge, there are no large randomized clinical trials to evaluate intravitreal ranibizumab, with and without verteporfin photodynamic therapy (vPDT), for the treatment of PCV.
   OBJECTIVE To compare the efficacy and safety of combination therapy of ranibizumab and vPDT with ranibizumab monotherapy in PCV.
   DESIGN, SETTING, AND PARTICIPANTS A double-masked, multicenter randomized clinical trial of 322 Asian participants with symptomatic macular PCV confirmed by the Central Reading Center using indocyanine green angiography was conducted between August 7, 2013, and March 2, 2017.
   INTERVENTIONS Participants were randomized 1: 1 to ranibizumab, 0.5 mg, and vPDT (n = 168; combination therapy group) or ranibizumab, 0.5 mg, and sham PDT (n = 154; monotherapy group). All participants received 3 consecutive monthly ranibizumab injections, followed by a pro re nata regimen. Participants also received vPDT/sham PDT on day 1, followed by a pro re nata regimen based on the presence of active polypoidal lesions.
   MAIN OUTCOMES AND MEASURES Step 1 assessed whether combination therapy was noninferior (5-letter margin) to monotherapy for change in best-corrected visual acuity from baseline and superior in complete polyp regression. If noninferiority was established, step 2 assessed whether combination therapy was superior to monotherapy measured by best-corrected visual acuity change at month 12.
   RESULTS Baseline demographics of the 322 participants were comparable between the treatment groups. Mean (SD) age of the patients was 68.1 (8.8) years, and overall, 69.9% of the patients were men. At baseline, the overall mean best-corrected visual acuity and mean central subfield thickness were 61.1 letters and 413.3 mu m, respectively. At 12 months, mean improvement from baseline was 8.3 letters with combination therapy vs 5.1 letters with monotherapy (mean difference, 3.2 letters; 95% CI, 0.4-6.1), indicating that combination therapymet the predefined criterion for noninferiority as well as being superior to monotherapy (P = .01). Combination therapy was also superior to monotherapy in achieving complete polyp regression at month 12 (69.3% vs 34.7%; P < .001). Over 12 months, the combination therapy group received a median of 4.0 ranibizumab injections compared with 7.0 in the monotherapy group. Vitreous hemorrhage was the only ocular serious adverse event (combination therapy group, 1 [0.6%]; monotherapy group, 3 [2.0%]).
   CONCLUSIONS AND RELEVANCE After 12 months, combination therapy of ranibizumab plus vPDT was not only noninferior but also superior to ranibizumab monotherapy in best-corrected visual acuity and superior in complete polyp regression while requiring fewer injections. Combination therapy should be considered for eyes with PCV.
C1 [Koh, Adrian] Eye & Retina Surg, Camden Med Ctr, Singapore, Singapore.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Takahashi, Kanji] Kansai Med Univ, Hirakata Hosp, Dept Ophthalmol, Osaka, Japan.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore Natl Eye Ctr, Duke NUS Med Sch, Singapore, Singapore.
   [Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Tan, Colin S.; Lim, Tock H.] Natl Healthcare Grp, Eye Inst, Singapore, Singapore.
   [Tan, Colin S.; Lim, Tock H.] Natl Healthcare Grp, Tan Tock Seng Hosp, Eye Inst, Singapore, Singapore.
   [Feller, Chrystel; Margaron, Philippe] Novartis Pharma AG, Basel, Switzerland.
   [Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Chinese University of Hong Kong; Kansai Medical University; National
   University of Singapore; Singapore National Eye Center; Mackay Memorial
   Hospital; Rajavithi Hospital; Tan Tock Seng Hospital; Novartis; Catholic
   University of Korea; Seoul St. Mary's Hospital
RP Koh, A (通讯作者)，Eye & Retina Surg, 13-03 Camden Med Ctr,1 Orchard Blvd, Singapore 248649, Singapore.
EM ak@ers.clinic
RI Lai, Timothy Y Y/AAC-2120-2020; Tan, Colin S/K-8972-2012; Wong, Tien
   Yin/AAC-9724-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428; Tan, Colin S/0000-0003-3088-5690;
   Wong, Tien Yin/0000-0002-8448-1264
FU Novartis Pharma AG
FX This study was funded and managed by Novartis Pharma AG.
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Iida T., 2016, AS PAC VITR RET SOC
   Iida T, 2007, BRIT J OPHTHALMOL, V91, P1103, DOI 10.1136/bjo.2007.116160
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Li X, 2016, AM AC OPHTH OCT 17
   Lim Ji Won, 2010, Korean J Ophthalmol, V24, P155, DOI 10.3341/kjo.2010.24.3.155
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Saito Masaaki, 2009, Nippon Ganka Gakkai Zasshi, V113, P792
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 32
TC 184
Z9 192
U1 6
U2 22
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2017
VL 135
IS 11
BP 1206
EP 1213
DI 10.1001/jamaophthalmol.2017.4030
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM2ER
UT WOS:000414798100015
PM 28983556
OA Green Published, Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Matuskova, V
   Balcar, VJ
   Khan, NA
   Bonczek, O
   Ewerlingova, L
   Zeman, T
   Kolar, P
   Vyslouzilova, D
   Vlkova, E
   Sery, O
AF Matuskova, Veronika
   Balcar, Vladimir J.
   Khan, Naim A.
   Bonczek, Ondrej
   Ewerlingova, Laura
   Zeman, Tomas
   Kolar, Petr
   Vyslouzilova, Daniela
   Vlkova, Eva
   Sery, Omar
TI CD36 gene is associated with intraocular pressure elevation after
   intravitreal application of anti-VEGF agents in patients with
   age-related macular degeneration: Implications for the safety of the
   therapy
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Glaucoma; polymorphism; receptor; Schlemm's canal; thrombospondin
ID LIPID TASTE PERCEPTION; ALZHEIMERS-DISEASE; BUD CELLS; THROMBOSPONDIN-1;
   OBESE; LYMPHANGIOGENESIS; POLYMORPHISM; BEVACIZUMAB; MECHANISMS; ROLES
AB Background: The wet form of age-related macular degeneration (AMD) is characterized by pathological vascularization of the outer retinal layers. The condition responds to treatment with antibodies against vascular endothelial growth factor (VEGF), but the patients receiving such anti-VEGF therapy sometimes show undesirable acute short-term increases in the intraocular pressure (IOP). The cause of this adverse effect is unknown, and here, we are testing a hypothesis that it is related to CD36 gene polymorphisms.
   Materials and Methods: A group of 134 patients with AMD were given three therapeutic doses of anti-VEGF antibody (ranibizumab) at monthly intervals. Their IOP was measured immediately before and 30 min after each injection. Patients' DNA was analyzed, and the changes in IOP were matched against seven polymorphisms of the CD36 gene.
   Results: Three polymorphisms were found to be associated with increases in IOP: rs1049673 (p = 0.006), rs3211931 (p = 0.01), and rs1761667 (p = 0.043) at the time of the third injection only. Pronounced elevations (IOP > 25 mmHg) were associated with rs1049673 polymorphism: GC genotype (p < 0.01) and CC genotype (p < 0.05); both increasing the risk 2.6-fold, the presence of C-allele conferring a 1.5-fold greater risk and with rs3211931 polymorphism: AG genotype (p < 0.01) and GG genotype (p < 0.05); increasing the risk 2.6-fold (AG) and 2.7-fold (GG).
   Conclusions: CD36 receptor may be involved in mediating the effects of VEGF on IOP. The findings will help to identify the patients at risk of acutely elevated IOP following the anti-VEGF therapy.
C1 [Matuskova, Veronika; Kolar, Petr; Vyslouzilova, Daniela; Vlkova, Eva] Masaryk Univ, Univ Hosp Brno, Dept Ophthalmol, Brno, Czech Republic.
   [Matuskova, Veronika; Kolar, Petr; Vyslouzilova, Daniela; Vlkova, Eva] Masaryk Univ, Med Fac, Brno, Czech Republic.
   [Balcar, Vladimir J.] Univ Sydney, Sydney Med Sch, Sch Med Sci, Bosch Inst, Sydney, NSW, Australia.
   [Balcar, Vladimir J.] Univ Sydney, Sydney Med Sch, Sch Med Sci, Discipline Anat & Histol, Sydney, NSW, Australia.
   [Khan, Naim A.] Univ Bourgogne, Agrosup, UMR INSERM U866, Physiol Nutr & Toxicol, Dijon, France.
   [Bonczek, Ondrej; Ewerlingova, Laura; Zeman, Tomas; Sery, Omar] Masaryk Univ, Fac Sci, Dept Biochem, Lab Neurobiol & Mol Psychiat, Kotlarska 2, CS-61137 Brno, Czech Republic.
   [Sery, Omar] Acad Sci Czech Republ, Inst Anim Physiol & Genet, Brno, Czech Republic.
C3 Masaryk University Brno; University Hospital Brno; Masaryk University
   Brno; University of Sydney; University of Sydney; Institut Agro; AgroSup
   Dijon; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Bourgogne; Masaryk University Brno; Czech
   Academy of Sciences; Institute of Animal Physiology & Genetics of the
   Czech Academy of Sciences
RP Sery, O (通讯作者)，Masaryk Univ, Fac Sci, Dept Biochem, Lab Neurobiol & Mol Psychiat, Kotlarska 2, CS-61137 Brno, Czech Republic.
EM omarsery@sci.muni.cz
RI Bonczek, Ondrej/GRR-6377-2022; Matuskova, Veronika/ABE-1154-2020; Zeman,
   Tomáš/AAX-6235-2021; Bonczek, Ondřej/ABE-9844-2020; Bonczek,
   Ondrej/AAH-3415-2020; Matuskova, Veronika/AAD-7189-2021
OI Bonczek, Ondrej/0000-0003-0745-3136; Bonczek,
   Ondřej/0000-0003-0745-3136; Matuskova, Veronika/0000-0002-3308-463X;
   Khan, Naim Akhtar/0000-0002-8930-9332; Kolar, Petr/0000-0003-3709-4648
FU Agency for Healthcare Research, Czech Republic (AZV CR) [16-31207A];
   Ministry of Health of the Czech Republic-conceptual development of
   research organization (FNBr) [65269705]
FX This work has been supported by Agency for Healthcare Research, Czech
   Republic (AZV CR)-Grant Project No. 16-31207A and by Ministry of Health
   of the Czech Republic-conceptual development of research organization
   (FNBr, 65269705).
CR Abdoul-Azize S, 2014, BIOCHIMIE, V96, P8, DOI 10.1016/j.biochi.2013.06.005
   Andrijevic-Derk B, 2008, ACTA CLIN CROAT, V47, P175
   Aspelund A, 2014, J CLIN INVEST, V124, P3975, DOI 10.1172/JCI75395
   Chatterjee A, 2014, J OCUL PHARMACOL TH, V30, P447, DOI 10.1089/jop.2014.0013
   Chu LY, 2013, BLOOD, V122, P1822, DOI 10.1182/blood-2013-01-482315
   Cursiefen C, 2011, J EXP MED, V208, P1083, DOI 10.1084/jem.20092277
   Daoudi H, 2015, NUTRIENTS, V7, P9096, DOI 10.3390/nu7115455
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Freund KB, 2015, OPHTHALMOLOGY, V122, P1802, DOI 10.1016/j.ophtha.2015.04.018
   Frost S, 2016, CURR ALZHEIMER RES, V13, P1259, DOI 10.2174/1567205013666160603003800
   Gilbertson TA, 2014, PROG LIPID RES, V53, P82, DOI 10.1016/j.plipres.2013.11.001
   Goel M, 2010, OPEN OPHTHALMOL J, V4, P52, DOI 10.2174/1874364101004010052
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Housset M, 2015, J OCUL PHARMACOL TH, V31, P406, DOI 10.1089/jop.2015.0023
   Janssen Sarah F, 2013, J Clin Bioinforma, V3, P21, DOI 10.1186/2043-9113-3-21
   Karpinich NO, 2014, J CLIN INVEST, V124, P3701, DOI 10.1172/JCI77507
   Kiddee W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137833
   Love-Gregory L, 2011, CURR OPIN CLIN NUTR, V14, P527, DOI 10.1097/MCO.0b013e32834bbac9
   McMonnies CW, 2017, CLIN EXP OPTOM, V100, P203, DOI 10.1111/cxo.12497
   Mrizak I, 2015, BRIT J NUTR, V113, P1330, DOI 10.1017/S0007114515000343
   Mwaikambo B. R., 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P255, DOI 10.2174/187153008786848330
   Mwaikambo BR, 2008, CORNEA, V27, P1037, DOI 10.1097/ICO.0b013e31817780b6
   Ozdener MH, 2014, GASTROENTEROLOGY, V146, P995, DOI 10.1053/j.gastro.2014.01.006
   Popescu V, 2015, J Med Life, V8, P8
   Rac ME, 2012, KARDIOL POL, V70, P918
   Resovi A, 2014, MATRIX BIOL, V37, P83, DOI 10.1016/j.matbio.2014.01.012
   Sayed A, 2015, INT J OBESITY, V39, P920, DOI 10.1038/ijo.2015.20
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schollhorn L, 2015, J OCUL PHARMACOL TH, V31, P376, DOI 10.1089/jop.2015.0020
   Sery O, 2017, BIOCHIMIE, V135, P46, DOI 10.1016/j.biochi.2017.01.009
   Sery O, 2013, FOLIA NEUROPATHOL, V51, P1, DOI 10.5114/fn.2013.34190
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stintzing Sebastian, 2014, F1000Prime Rep, V6, P108, DOI 10.12703/P6-108
   Sundaresan S, 2015, J NUTR, V145, P2195, DOI 10.3945/jn.115.215483
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
NR 36
TC 9
Z9 9
U1 1
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2018
VL 39
IS 1
BP 4
EP 10
DI 10.1080/13816810.2017.1326508
PG 7
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA GA7MM
UT WOS:000428520500002
PM 28557591
DA 2022-11-30
ER

PT J
AU Mahmood, S
   Roberts, SA
   Aslam, TM
   Parkes, J
   Barugh, K
   Bishop, PN
AF Mahmood, Sajjad
   Roberts, Stephen A.
   Aslam, Tariq M.
   Parkes, Jeremy
   Barugh, Kate
   Bishop, Paul N.
CA GMAN Study Grp
TI Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals
   for Neovascular Age-Related Macular Degeneration 92-Week Results of the
   GMAN Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB; PHARMACOKINETICS; INJECTION;
   REPEATABILITY; AFLIBERCEPT; AVASTIN; SAFETY
AB Purpose: To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) in patients with neovascular age-related macular degeneration (nAMD) using 2 different treatment regimens in which patients were assessed clinically at up to 12-week intervals.
   Design: Randomized, controlled, noninferiority trial.
   Participants: A total of 331 patients with nAMD.
   Methods: Patients were treated with 1.25 mg intravitreal bevacizumab and followed up to 92 weeks. They were randomized into 2 arms. All patients received 3 loading doses 4 weeks apart and thereafter were assessed every 12 weeks until the end of the study. One arm received a routine treatment at each 12-week assessment, and the other arm was treated at these assessments on an as-needed basis. After the loading doses, patients in either arm who showed signs of disease activity had an additional assessment after 6 weeks and at that visit had top-up treatments on an as-needed basis.
   Main Outcome Measures: Mean best-corrected visual acuity (BCVA) at 92 weeks.
   Results: At 92 weeks, patients who had treatments every 12 weeks had superior BCVA to those treated on an as-needed basis every 12 weeks (P = 0.008), with the regular treatment arm gaining a mean BCVA of 5.5 letters and the as-needed treatment arm gaining 0.6 letters. The regular treatment arm of the study showed significantly improved outcomes with respect to 5-, 10-, and 15-letter changes in BCVA from baseline compared with the as-needed treatment arm, as well as superior reading speed. In patients who completed the study, up to but not including week 92, the mean number of treatments was 10.8 for the regular treatment arm and 9.1 for the as-needed treatment arm.
   Conclusions: A treatment regimen with regular bevacizumab injections every 12 weeks after loading doses supplemented with as-needed top-up treatments produced a stable improvement in BCVA from baseline. The improvement in BCVA was broadly similar to that obtained in other studies using anti-vascular endothelial growth factor drugs with more frequent assessments and treatments. (C) 2015 by the American Academy of Ophthalmology.
C1 [Mahmood, Sajjad; Aslam, Tariq M.; Parkes, Jeremy; Barugh, Kate; Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Roberts, Stephen A.] Univ Manchester, Inst Populat Hlth, Ctr Biostat, Manchester M13 9PL, Lancs, England.
   [Mahmood, Sajjad; Aslam, Tariq M.; Bishop, Paul N.] Univ Manchester, Ctr Ophthalmol & Vis Sci, Manchester M13 9PL, Lancs, England.
   [Mahmood, Sajjad; Aslam, Tariq M.; Bishop, Paul N.] Univ Manchester, CADET, Inst Human Dev, Manchester M13 9PL, Lancs, England.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester; University of Manchester; University of Manchester
RP Bishop, PN (通讯作者)，Univ Manchester, Ctr Ophthalmol & Vis Sci, AV Hill Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.
EM Paul.Bishop@manchester.ac.uk
RI Mahmood, Sajjad/AAK-7645-2021; Aslam, Tariq/A-8532-2016
OI Bishop, Paul/0000-0001-7937-7932; Aslam, Tariq/0000-0002-9739-7280
FU Novartis; Bayer; Manchester Biomedical Research Centre; Greater
   Manchester Primary Care Trusts, National Health Service, England
FX The author(s) have made the following disclosure(s): S.M.: Advisory
   boards of and financial support - Novartis and Bayer. T.M.A: Advisory
   boards of and financial support - Novartis and Bayer.; Supported by
   Greater Manchester Primary Care Trusts, National Health Service,
   England, and Manchester Biomedical Research Centre.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Aslam T, 2014, GRAEF ARCH CLIN EXP, V252, P201, DOI 10.1007/s00417-013-2421-5
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Elliott DB, 1996, BRIT J OPHTHALMOL, V80, P799, DOI 10.1136/bjo.80.9.799
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Entezari M, 2014, INDIAN J OPHTHALMOL, V62, P468, DOI 10.4103/0301-4738.111192
   Goldberg RA, 2013, OPHTHALMOLOGY, V120, P1448, DOI 10.1016/j.ophtha.2012.12.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   IVAN Study Investigators, 2014, BMJ OPEN, V4
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
NR 29
TC 7
Z9 7
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2015
VL 122
IS 7
BP 1348
EP 1355
DI 10.1016/j.ophtha.2015.03.017
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL0HI
UT WOS:000356621700017
PM 25892016
OA hybrid
DA 2022-11-30
ER

PT J
AU Fujita, A
   Kataoka, K
   Takeuchi, J
   Nakano, Y
   Horiguchi, E
   Kaneko, H
   Ito, Y
   Terasaki, H
AF Fujita, Ai
   Kataoka, Keiko
   Takeuchi, Jun
   Nakano, Yuyako
   Horiguchi, Etsuyo
   Kaneko, Hiroki
   Ito, Yasuki
   Terasaki, Hiroko
TI DIAGNOSTIC CHARACTERISTICS OF POLYPOIDAL CHOROIDAL VASCULOPATHY BASED ON
   B-SCAN SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND ITS
   INTERRATER AGREEMENT COMPARED WITH INDOCYANINE GREEN ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy; OCT
   angiography; diagnostic characteristics
AB Purpose: To examine the characteristics of polypoidal choroidal vasculopathy using B-scan optical coherence tomography angiography (OCTA), and determine the diagnostic criteria of polypoidal choroidal vasculopathy based on OCTA.
   Methods: This retrospective case series included patients diagnosed with treatment-naive polypoidal choroidal vasculopathy who underwent indocyanine green angiography (ICGA) and swept-source OCTA at baseline. We compared the characteristics of the polyps detected using B-scan OCTA and ICGA. Then, the diagnostic concordance of each polypoidal lesion between ICGA and OCTA was evaluated.
   Results: Among 54 eyes of 52 patients, all 54 eyes showed flow signals indicating polyps on both ICGA and B-scan OCTA. All polyps on B-scan OCTA were detected as round/ring-like flow signals inside pigment epithelial detachments, incomplete round/ring-like flow signals overlaid with round/ring-like OCT structures inside pigment epithelial detachments, or flow signals adjacent to a pigment epithelial detachment notch. Using B-scan OCTA, 94.7% of the polypoidal lesions were detected by an independent evaluator with an overall accuracy of 92.6% for counting the polypoidal lesions per eye relative to ICGA and a Kappa value of 0.82.
   Conclusion: Polyp detection on B-scan OCTA demonstrates high accuracy and is comparable to that obtained on ICGA. B-scan OCTA could replace ICGA for the diagnosis of polypoidal choroidal vasculopathy.
C1 [Kataoka, Keiko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Kataoka, K (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM kkeiko@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022
OI Kaneko, Hiroki/0000-0003-0731-6465
FU Japan Society for the Promotion of Science KAKENHI [18K169533]
FX From the Supported by the Japan Society for the Promotion of Science
   KAKENHI, grant number 18K169533 (K.K.). The sweptsource optical
   coherence tomography device used in this study was loaned by Carl Zeiss
   Meditec.
CR Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   de Carlo TE, 2018, OPHTHALMOLOGICA, V239, P103, DOI 10.1159/000481540
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Shoji T, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.31
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Wang M, 2016, INVEST OPHTHALMOL VI, V57, P32
NR 36
TC 16
Z9 17
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2020
VL 40
IS 12
BP 2296
EP 2303
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI4NW
UT WOS:000618957100006
PM 31971919
DA 2022-11-30
ER

PT J
AU Say, EAT
   Jani, PD
   Appenzeller, MF
   Houghton, OM
AF Say, Emil Anthony T.
   Jani, Pooja D.
   Appenzeller, Matthew F.
   Houghton, Odette M.
TI Focal Choroidal Excavation Associated With Polypoidal Choroidal
   Vasculopathy
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SPECTRUM
AB A 48-year-old woman presented with blurred vision in her right eye for 6 weeks. Visual acuity was 20/300 and 20/25 in the right and left eyes, respectively. Fundus examination showed subretinal hemorrhage in the superonasal macula in the right eye, whereas the left eye was normal. Fluorescein angiography showed blocked fluorescence from hemorrhage and a round distinct hypofluorescent spot along the inferotemporal arcade. Indocyanine green angiography revealed hyperfluorescent tubular and aneurysmal dilatations consistent with polypoidal choroidal vasculopathy in the superior macula. Spectral-domain optical coherence tomography showed retinal pigment epithelial irregularities and detachment. Scans through the round area of hypofluorescence revealed a conforming focal choroidal excavation and thinning of the underlying choriocapillaries. Because the pathogenesis of focal choroidal excavation is currently unclear, the authors propose the possibility of an acquired etiology related to loss of choriocapillaries from perfusion abnormalities as evidenced here.
C1 [Say, Emil Anthony T.; Jani, Pooja D.; Houghton, Odette M.] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC USA.
   [Appenzeller, Matthew F.] Alamance Eye Ctr, Burlington, NC USA.
C3 University of North Carolina; University of North Carolina Chapel Hill
RP Houghton, OM (通讯作者)，5151 Bioinformat Bldg,CB 7040, Chapel Hill, NC 27599 USA.
EM odetteh@med.unc.edu
FU Research to Prevent Blindness
FX Supported by an unrestricted grant from Research to Prevent Blindness.
CR Abe Sachi, 2010, Retin Cases Brief Rep, V4, P373, DOI 10.1097/ICB.0b013e3181babe7e
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Katome T, 2012, CASE REP OPHTHALM, V3, P96, DOI 10.1159/000337880
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Wakabayashi Y, 2010, ACTA OPHTHALMOL, V88, pe87, DOI 10.1111/j.1755-3768.2010.01895.x
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 8
TC 20
Z9 21
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JUL-AUG
PY 2013
VL 44
IS 4
BP 409
EP 411
DI 10.3928/23258160-20130715-12
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 219UB
UT WOS:000324534900018
PM 23883536
DA 2022-11-30
ER

PT J
AU Bhutto, IA
   Kim, SY
   McLeod, DS
   Merges, C
   Fukai, N
   Olsen, BR
   Lutty, GA
AF Bhutto, IA
   Kim, SY
   McLeod, DS
   Merges, C
   Fukai, N
   Olsen, BR
   Lutty, GA
TI Localization of collagen XVIII and the endostatin portion of collagen
   XVIII in aged human control eyes and eyes with age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; CELL-GROWTH;
   TUMOR-GROWTH; HUMAN RETINA; ENDOGENOUS INHIBITOR; HEPARAN-SULFATE;
   ANGIOGENESIS; EXPRESSION; CANCER
AB Purpose. Endostatin, a C-terminal fragment of Collagen XVIII (coll XVIII) formed by proteolysis, specifically inhibits endothelial cell migration and proliferation in vitro and potently inhibits angiogenesis and tumor growth in vivo. The purpose of this study was to examine the immunolocalization of endostatin and colt XVIII in the retina and choroid of human donor tissue sections from aged control donor eyes and to determine whether the localization or relative levels are changed in age-related macular degeneration (AMD).
   Methods. Ocular tissues were obtained from six aged control donors (age range, 75-86 years-, mean age, 80.5 years) without evidence or history of chorioretinal disease and from nine donors with AMD (age range, 74-105 years; mean age, 88.6 years). Tissues were cryopreserved, and streptavidin alkaline phosphatase immunohistochemistry was performed with goat anti-human and mouse anti-human endostatin antibodies and rabbit anti-mouse Coll XVIII. Blood vessels were identified with mouse anti-human CD-34 antibody in adjacent sections. Pigment in RPE and choroidal melanocytes was bleached. Three independent observers scored the immunohistochemical reaction product.
   Results. In aged control eyes, Coll XVIII and endostatin (the endostatin portion of Coll XVIII) immunoreactivity was observed in large retinal blood vessels and in capillaries in some individuals, but the internal limiting membrane (ILM) had the most intense retinal immunostaining. There was no significant difference in immunoreactivity to both antibodies in retinal blood vessels in aged control eyes. In the choroid, endostatin and coll XVIII were localized to blood vessels, Bruch's membrane, and RPE basal lamina. AMD retina and choroid had a similar pattern and intensity of coil XVIII immunostaining, as observed in control eyes but reaction product was more diffuse in the choroid. Endostatin immunoreactivity was significantly higher in ILM (P=0.037) in AMD retina and significantly lower in the choriocapillaris, Bruch's membrane, and RPE basal lamina of AMD choroids (P<0.05) and completely negative in some areas of AMD choroids.
   Conclusions. These data suggest that reduced levels of the endostatin portion of coll XVIII in Bruch's membrane, RPE basal lamina, intercapillary septa, and choriocapillaris in eyes with AMD may be permissive for choroidal neovascularization.
C1 Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Harvard University;
   Harvard Medical School
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dept Ophthalmol, 170 Woods Res Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu
FU NEI NIH HHS [EY01765] Funding Source: Medline; NIAMS NIH HHS [AR36820]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND
   MUSCULOSKELETAL AND SKIN DISEASES [R37AR036820, R01AR036820] Funding
   Source: NIH RePORTER
CR Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   Aiello LP, 2000, NAT MED, V6, P379, DOI 10.1038/74633
   Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126
   Boulton M, 1998, BRIT J OPHTHALMOL, V82, P561, DOI 10.1136/bjo.82.5.561
   BREM S, 1976, CANCER RES, V36, P2807
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chang Z, 1999, AM J PATHOL, V155, P71, DOI 10.1016/S0002-9440(10)65101-2
   CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988
   Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187
   Feldman AL, 2000, CANCER RES, V60, P1503
   Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   GLASER BM, 1985, ARCH OPHTHALMOL-CHIC, V103, P1870
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   HANNEKEN A, 1989, J CELL PHYSIOL, V138, P115, DOI 10.1002/jcp.1041380116
   JACOBSON B, 1984, ARCH OPHTHALMOL-CHIC, V102, P1543
   JACOBSON B, 1985, EXP EYE RES, V41, P581, DOI 10.1016/0014-4835(85)90031-4
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   Lin HC, 2001, INVEST OPHTH VIS SCI, V42, P2517
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   LUTTY GA, 1983, INVEST OPHTH VIS SCI, V24, P52
   LUTTY GA, 1985, J CELL SCI, V76, P53
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180
   Mathews MK, 1997, INVEST OPHTH VIS SCI, V38, P2729
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   PAGE C, 1992, AM J PATHOL, V141, P673
   Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644
   Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605
   Ramchandran R, 2002, CRIT REV EUKAR GENE, V12, P175, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.20
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9
   Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249
   Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597
   Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051
   Standker L, 1997, FEBS LETT, V420, P129, DOI 10.1016/S0014-5793(97)01503-2
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Wen W, 1999, CANCER RES, V59, P6052
   WILLIAMS GA, 1984, AM J OPHTHALMOL, V97, P366, DOI 10.1016/0002-9394(84)90637-8
   Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97
NR 58
TC 84
Z9 105
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2004
VL 45
IS 5
BP 1544
EP 1552
DI 10.1167/iovs.03-0862
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 816BF
UT WOS:000221084700037
PM 15111613
DA 2022-11-30
ER

PT J
AU Malek, G
   Li, CM
   Guidry, C
   Medeiros, NE
   Curcio, CA
AF Malek, G
   Li, CM
   Guidry, C
   Medeiros, NE
   Curcio, CA
TI Apolipoprotein B in cholesterol-containing drusen and basal deposits of
   human eyes with age-related maculopathy
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID BEAVER DAM EYE; TRIGLYCERIDE-RICH LIPOPROTEINS;
   AMERICAN-HEART-ASSOCIATION; TO-RETENTION HYPOTHESIS; MACULAR
   DEGENERATION; BRUCHS MEMBRANE; RISK-FACTORS; ATHEROSCLEROTIC PLAQUES;
   CARDIOVASCULAR-DISEASE; PIGMENT-EPITHELIUM
AB Lipids accumulate in Bruch's membrane (BrM), a specialized vascular intima of the eye, and in extracellular lesions associated with aging and age-related maculopathy (ARM). We tested the hypothesis that ARM and atherosclerotic cardiovascular disease share molecules and mechanisms pertaining to extracellular lipid accumulation by localizing cholesterol and apolipoprotein B (apo B) in BrM, basal deposits, and drusen. Human donor eyes were preserved < 4 hours postmortem and cryosectioned. Sections were stained with traditional lipid stains and filipin for esterified and unesterifted cholesterol or probed with antibodies to apo B, apo E, and apo C-III. Normal adult retinal pigment epithelium (RPE) was subjected to RT-PCR and Western blot analysis for apolipoprotein mRNA and protein. Esterified and unesterified cholesterol was present in all drusen and basal deposits of ARM and normal eyes. Both apo B and apo E but not apo C-III were found in BrM, drusen, and basal deposits. Fewer macular drusen were stained by traditional lipid stains and apolipoprotein antibodies than peripheral drusen. RPE contained apo B and apo E mRNA and protein. Finding cholesterol and apo B in sub-RPE deposits links ARM with important molecules and mechanisms in atherosclerosis initiation and progression. The combination of apo B mRNA and protein in RPE raises the possibility that intraocular assembly of apo B-containing lipoproteins is a pathway involved in forming cholesterol-enriched lesions in ARM.
C1 Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Retina Specialists N Alabama, Huntsville, AL USA.
   Univ Alabama Birmingham, Vis Sci Training Program, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, 700 S 18th St,Rm H020, Birmingham, AL 35294 USA.
EM curcio@uab.edu
OI Malek, Goldis/0000-0003-0026-2388
FU NEI NIH HHS [R01 EY013258, EY 13258, EY 06109, T32 EY007033,
   T32-EY07033, R01 EY006109] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY013258, T32EY007033] Funding Source: NIH RePORTER
CR ADAMS C, 1975, LIPID BIOCH TECHNIQU, P100
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Buraczynska M, 2002, INVEST OPHTH VIS SCI, V43, P603
   CALL TW, 1990, EXP EYE RES, V51, P451, DOI 10.1016/0014-4835(90)90158-Q
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chan L, 2000, RECENT PROG HORM RES, V55, P93
   Chang CCY, 2000, J BIOL CHEM, V275, P28083
   CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622
   Chung BH, 2000, J LIPID RES, V41, P285
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013
   Eckhart L, 2000, BIOCHEM BIOPH RES CO, V271, P726, DOI 10.1006/bbrc.2000.2716
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200
   Giambernardi TA, 1998, BIOTECHNIQUES, V25, P564, DOI 10.2144/98254bm03
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   *GROUP A REDSR, 2000, 3 GROUP A REDSR, V107, P2224
   GUYTON JR, 1994, ARTERIOSCLER THROMB, V14, P1305, DOI 10.1161/01.ATV.14.8.1305
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HAVEL RJ, 2001, METABOLIC MOL BASIS, P2707
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Kruth HS, 1997, CURR OPIN LIPIDOL, V8, P246, DOI 10.1097/00041433-199710000-00002
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   LIN WL, 1992, INVEST OPHTH VIS SCI, V33, P2072
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mamballikalathil I, 2000, INVEST OPHTH VIS SCI, V41, P529
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519
   Oorni K, 2000, J LIPID RES, V41, P1703
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmidt S, 2000, MOL VIS, V6, P287
   Segrest JP, 2001, J LIPID RES, V42, P1346
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804
   SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462
   STARY HC, 1992, CIRCULATION, V85, P391, DOI 10.1161/01.CIR.85.1.391
   Tabas I, 1999, ANNU REV NUTR, V19, P123, DOI 10.1146/annurev.nutr.19.1.123
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012
   Wistow G, 2002, MOL VIS, V8, P205
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Yao ZM, 1997, J LIPID RES, V38, P1937
NR 74
TC 201
Z9 205
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD FEB
PY 2003
VL 162
IS 2
BP 413
EP 425
DI 10.1016/S0002-9440(10)63836-9
PG 13
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 638NL
UT WOS:000180577100007
PM 12547700
OA Green Published
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Mengelkamp, J
   Brandl, C
   Harsch, S
   Zimmermann, ME
   Linkohr, B
   Peters, A
   Heid, IM
   Palm, C
   Weber, BHF
AF Grassmann, Felix
   Mengelkamp, Judith
   Brandl, Caroline
   Harsch, Sebastian
   Zimmermann, Martina E.
   Linkohr, Birgit
   Peters, Annette
   Heid, Iris M.
   Palm, Christoph
   Weber, Bernhard H. F.
TI A Deep Learning Algorithm for Prediction of Age-Related Eye Disease
   Study Severity Scale for Age-Related Macular Degeneration from Color
   Fundus Photography
SO OPHTHALMOLOGY
LA English
DT Article
ID PROGRESSION; CLASSIFICATION; AMD; ASSOCIATION; MACULOPATHY; GENETICS;
   HEALTH
AB Purpose: Age-related macular degeneration (AMD) is a common threat to vision. While classification of disease stages is critical to understanding disease risk and progression, several systems based on color fundus photographs are known. Most of these require in-depth and time-consuming analysis of fundus images. Herein, we present an automated computer-based classification algorithm.
   Design: Algorithm development for AMD classification based on a large collection of color fundus images. Validation is performed on a cross-sectional, population-based study.
   Participants: We included 120 656 manually graded color fundus images from 3654 Age-Related Eye Disease Study (AREDS) participants. AREDS participants were >55 years of age, and non-AMD sight-threatening diseases were excluded at recruitment. In addition, performance of our algorithm was evaluated in 5555 fundus images from the population-based Kooperative Gesundheitsforschung in der Region Augsburg (KORA; Cooperative Health Research in the Region of Augsburg) study.
   Methods: We defined 13 classes (9 AREDS steps, 3 late AMD stages, and 1 for ungradable images) and trained several convolution deep learning architectures. An ensemble of network architectures improved prediction accuracy. An independent dataset was used to evaluate the performance of our algorithm in a population-based study.
   Main Outcome Measures: kappa Statistics and accuracy to evaluate the concordance between predicted and expert human grader classification.
   Results: A network ensemble of 6 different neural net architectures predicted the 13 classes in the AREDS test set with a quadratic weighted kappa of 92% (95% confidence interval, 89%-92%) and an overall accuracy of 63.3%. In the independent KORA dataset, images wrongly classified as AMD were mainly the result of a macular reflex observed in young individuals. By restricting the KORA analysis to individuals >55 years of age and prior exclusion of other retinopathies, the weighted and unweighted kappa increased to 50% and 63%, respectively. Importantly, the algorithm detected 84.2% of all fundus images with definite signs of early or late AMD. Overall, 94.3% of healthy fundus images were classified correctly.
   Conclusions: Our deep learning algoritm revealed a weighted kappa outperforming human graders in the AREDS study and is suitable to classify AMD fundus images in other datasets using individuals >55 years of age. (C) 2018 by the American Academy of Ophthalmology.
C1 [Grassmann, Felix; Mengelkamp, Judith; Brandl, Caroline; Harsch, Sebastian; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Mengelkamp, Judith; Palm, Christoph] Ostbayer Tech Hsch Regensburg OTH Regensburg, Regensburg Med Image Comp, Regensburg, Germany.
   [Brandl, Caroline; Zimmermann, Martina E.; Heid, Iris M.] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Brandl, Caroline] Univ Regensburg, Inst Epidemiol, Dept Genet Epidemiol, Regensburg, Germany.
   [Linkohr, Birgit; Peters, Annette] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol II, Neuherberg, Germany.
   [Palm, Christoph] OTH Regensburg, RCBE, Regensburg, Germany.
   [Palm, Christoph] Regensburg Univ, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg; Helmholtz Association; Helmholtz-Center Munich - German
   Research Center for Environmental Health; University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.; Palm, C (通讯作者)，Ostbayer Tech Hsch Regensburg, Regensburg Med Image Comp, Univ Str 31, D-93053 Regensburg, Germany.
EM christoph.palm@oth-regensburg.de; bweb@klinik.uni-regensburg.de
RI Zimmermann, Martina/AAL-2990-2021; Palm, Christoph/AAI-7959-2020;
   Peters, Annette/A-6117-2011; Palm, Christoph/F-4943-2014
OI Zimmermann, Martina/0000-0002-6916-4404; Peters,
   Annette/0000-0001-6645-0985; Palm, Christoph/0000-0001-9468-2871;
   Linkohr, Birgit/0000-0002-3387-5685; Brandl,
   Caroline/0000-0001-8223-6137; Grassmann, Felix/0000-0003-1390-7528
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [N01-EY0-2127]; German Federal Ministry of Education and
   Research [BMBF 01ER1206, 01ER1507]; Institutional Budget for Research
   and Teaching from the Freestate of Bavaria; German Research Foundation
   [WE 1259/19-2]
FX Funding support for Age-Related Eye Disease Study was provided by the
   National Eye Institute, National Institutes of Health, Bethesda,
   Maryland (grant no.: N01-EY0-2127). The work was funded in part by
   grants from the German Federal Ministry of Education and Research (grant
   nos.: BMBF 01ER1206 [I.M.H] and 01ER1507 [I.M.H. and B.H.F.W]); by the
   Institutional Budget for Research and Teaching from the Freestate of
   Bavaria and the German Research Foundation (grant no.: WE 1259/19-2
   [B.H.F.W.]).
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Aiello S, FDN OPEN ACCESS STAT
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Castelvecchi D, 2016, NATURE, V537, P20, DOI 10.1038/538020a
   Chen T, 2015, ARXIV1512
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Ciresan D, 2012, PROC CVPR IEEE, P3642, DOI 10.1109/CVPR.2012.6248110
   COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Graham B, 2015, KAGGLE DIABETIC RETI
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   He K, 2016, COMPUTING RES REPOSI
   Ho TK, 1998, IEEE T PATTERN ANAL, V20, P832, DOI 10.1109/34.709601
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klikauer T, 2016, TRIPLEC-COMMUN CAPIT, V14, P260
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Powers DMW., 2011, INT J MACH LEARN TEC, V2, P37
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Stark K, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0122-0
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Szegedy C, 2015, COMPUTING RES REPOSI
   Szegedy C., 2015, IEEE C COMP VIS PATT, P1, DOI DOI 10.1109/CVPR.2015.7298594
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Verma L, 2003, ACTA OPHTHALMOL SCAN, V81, P373, DOI 10.1034/j.1600-0420.2003.00004.x
   Wintergerst MWM, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.10
NR 41
TC 209
Z9 214
U1 3
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2018
VL 125
IS 9
BP 1410
EP 1420
DI 10.1016/j.ophtha.2018.02.037
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR1IE
UT WOS:000442285800029
PM 29653860
OA hybrid, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Coleman, AL
   Yu, F
   Ensrud, KE
   Stone, KL
   Cauley, JA
   Pedula, KL
   Hochberg, MC
   Mangione, CM
AF Coleman, Anne L.
   Yu, Fei
   Ensrud, Kristine E.
   Stone, Katie L.
   Cauley, Jane A.
   Pedula, Kathryn L.
   Hochberg, Marc C.
   Mangione, Carol M.
TI Impact of Age-Related Macular Degeneration on Vision-Specific Quality of
   Life: Follow-up from the 10-Year and 15-Year Visits of The Study of
   Osteoporotic Fractures
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-FUNCTION-QUESTIONNAIRE; BEAVER DAM EYE; UNITED-STATES; CHOROIDAL
   NEOVASCULARIZATION; RESOURCE UTILIZATION; RISK-FACTORS; NEI-VFQ;
   MACULOPATHY; PREVALENCE; HEALTH
AB PURPOSE: To assess vision-specific quality of life (QOL), based on abbreviated surveys derived from the National Eye Institute Visual Function Questionnaire (NEI-VFQ), in a cohort of United States women who participated in the Study of Osteoporotic Fractures.
   DESIGN: Prospective, observational cohort study.
   METHODS: Age-related macular degeneration (AMD) status, based on a 3-level classification (no AMD, early AMD, late AMD), and vision-specific QOL, based on abbreviated NEI-VFQ surveys, were calculated for 1674 women enrolled in the Study of Osteoporotic Fractures at 4 centers within the United States who had gradable fundus photographs at both the 10-year and 15-year follow-up visits. The associations among 5-year changes in NEI-VFQ composite scores, change in AMD status, and distance visual acuity were examined.
   RESULTS: Compared with study participants without AMD at both visits, study participants with late AMD at both visits and those who progressed from early AMD to late AMD demonstrated the greatest declines in adjusted NEI-VFQ composite scores, up to a mean decrease of 16.2 from a scale of 100. Visual acuity declines also were most prominent for patients with late AMD at both visits and for those who progressed from early AMD to late AMD. Change in visual acuity was found to correlate significantly with change in vision-specific QOL.
   CONCLUSIONS: The abbreviated NEI-VFQ surveys provide reliable assessments of vision-specific QOL in AMD patients. The decline in vision-specific QOL associated with the progression of AMD is clinically meaningful. (Am J Ophthalmol 2010;150:683-691. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Coleman, Anne L.; Yu, Fei] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Coleman, Anne L.; Yu, Fei] Univ Calif Los Angeles, Dept Ophthalmol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Coleman, Anne L.] Univ Calif Los Angeles, Dept Epidemiol, Sch Publ Hlth, Los Angeles, CA 90095 USA.
   [Yu, Fei] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
   [Ensrud, Kristine E.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA.
   [Ensrud, Kristine E.] VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
   [Stone, Katie L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   [Pedula, Kathryn L.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
   [Hochberg, Marc C.] Univ Maryland, Dept Med, Baltimore, MD 21201 USA.
   [Hochberg, Marc C.] Univ Maryland, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA.
   [Mangione, Carol M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California System; University of California Los Angeles; University of
   Minnesota System; University of Minnesota Twin Cities; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA
   Health Care System; University of California System; University of
   California San Francisco; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Kaiser Permanente;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Coleman, AL (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM colemana@ucla.edu
OI Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036
FU NATIONAL EYE INSTITUTE, National Institutes of Health, Bethesda,
   Maryland [EY013626-03]; Research to Prevent Blindness, Inc, New York,
   New York; National Institutes of Health, Bethesda, Maryland [AR35582,
   AR35583, AR35584, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, 2
   R01 AG027574-22A1]; NATIONAL EYE INSTITUTE [U10EY013626] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND
   SKIN DISEASES [R01AR035583, R01AR035584, R01AR035582] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005407, R01AG027574,
   R01AG027576, R01AG005394] Funding Source: NIH RePORTER
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY RESEARCH GRANT EY013626-03
   FROM THE NATIONAL EYE INSTITUTE, National Institutes of Health,
   Bethesda, Maryland; an unrestricted grant from Research to Prevent
   Blindness, Inc, New York, New York, to the Jules Stein Eye Institute and
   the Center for Eye Epidemiology, Jules Stein Eye Institute, University
   of California, Los Angeles. The Study of Osteoporotic Fractures (SOP) is
   supported by Public Health Service Research Grants AR35582, AR35583,
   AR35584, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, and 2 R01
   AG027574-22A1 from the National Institutes of Health, Bethesda,
   Maryland. The authors indicate no financial conflict of interest.
   Involved in Design and conduct of study (A.L.C., K.E.E., K.L.S., J.A.C.,
   M.C.H., C.M.M.); Collection and management of data (A.L.C., K.E.E.,
   K.L.S., J.A.C., M.C.H., C.M.M.); Analysis of data (F.Y.); Interpretation
   of data (A.L.C., F.Y., K.E.E., K.L.S., J.A.C., K.L.P., M.C.H., C.M.M.);
   Preparation of manuscript (A.L.C.); and Review and approval of
   manuscript (A.L.C., F.Y., K.E.E., K.L.S., J.A.C., K.L.P., M.C.H.,
   C.M.M.). Institutional Review Board approvals were obtained from the
   University of California, Los Angeles; the University of California, San
   Francisco; the University of Maryland; the University of Minnesota;
   Kaiser Permanente Center for Health Research, Portland, Oregon; and the
   University of Pittsburgh before the study.
CR Afifi AA, 2007, ANNU REV PUBL HEALTH, V28, P95, DOI 10.1146/annurev.publhealth.28.082206.094100
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Kodjebacheva G, 2010, AM J OPHTHALMOL, V149, P330, DOI 10.1016/j.ajo.2009.09.008
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Luke M, 2007, GRAEF ARCH CLIN EXP, V245, P1831, DOI 10.1007/s00417-007-0558-9
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   *NAT EYE I, NIH PUBL
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
NR 39
TC 36
Z9 42
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2010
VL 150
IS 5
BP 683
EP 691
DI 10.1016/j.ajo.2010.05.030
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 679RA
UT WOS:000284177300016
PM 20691423
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Siedlecki, J
   Fischer, C
   Schworm, B
   Kreutzer, TC
   Luft, N
   Kortuem, KU
   Schumann, RG
   Wolf, A
   Priglinger, SG
AF Siedlecki, Jakob
   Fischer, Cheryl
   Schworm, Benedikt
   Kreutzer, Thomas C.
   Luft, Nikolaus
   Kortuem, Karsten U.
   Schumann, Ricarda G.
   Wolf, Armin
   Priglinger, Siegfried G.
TI Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular
   Atrophy in Neovascular Age-related Macular Degeneration under Treat &
   Extend Anti-Vascular Endothelial Growth Factor Inhibitors
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PIGMENT EPITHELIAL ATROPHY; GEOGRAPHIC ATROPHY; VISUAL-ACUITY;
   FOLLOW-UP; VEGF; MORPHOLOGY; THERAPY
AB Sub-retinal fluid (SRF) has been discussed as a protective factor against macular atrophy in eyes with neovascular age-related macular degeneration (nAMD).To gauge the impact of SRF on macular atrophy, a database of 310 nAMD eyes was screened for eyes manifesting an SRF-only phenotype under treat & extend anti-VEGF treatment, defined as nAMD expressing CNV exudation beyond the three monthly anti-VEGF loading doses by SRF only without any signs of exudative intra-retinal fluid (IRF) for >= 3 years. Incidence of macular atrophy and treatment responses were evaluated on multimodal imaging, including optical coherence tomography (OCT), blue autofluorescence (BAF) and near-infrared (NIR) confocal scanning laser ophthalmoscopy and fluorescence and indocyanine green angiography (FAG/ICGA). In total, 27 eyes (8.7%) of 26 patients with a mean follow-up of 4.2 +/- 0.9 (3-5) years met the inclusion criteria. Mean age was 72 +/- 6 (range: 61-86) years. The SRF only phenotype was seen from baseline in 14 eyes (52%), and in 13 eyes (48%) after a mean 1.0 +/- 1.3 (1-3) injections. In years 1 to 5, mean 7.5, 5.9, 6.1, 6.1 and 7.0 anti-VEGF injections were given (p=0.33). Cumulative macular atrophy incidence was 11.5% at year 1, 15.4% throughout years 2 to 4, and 22.4% at year 5. In conclusion, eyes manifesting activity by SRF only in treat & extend anti-VEGF regimen for nAMD seem to exhibit rather low rates of macular atrophy during long-term follow-up. SRF might be an indicator of a more benign form of nAMD.
C1 [Siedlecki, Jakob; Fischer, Cheryl; Schworm, Benedikt; Kreutzer, Thomas C.; Luft, Nikolaus; Kortuem, Karsten U.; Schumann, Ricarda G.; Wolf, Armin; Priglinger, Siegfried G.] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany.
C3 University of Munich
RP Siedlecki, J (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany.
EM jakob.siedlecki@med.uni-muenchen.de
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2018, AM J OPHTHALMOL, V192, P84, DOI 10.1016/j.ajo.2018.05.008
   Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Dhrami-Gavazi E, 2015, INT J RETINA VITREOU, V1, P1
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hodgson N, 2016, MOL PHARMACEUT, V13, P2877, DOI 10.1021/acs.molpharmaceut.5b00775
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Li A, 2018, OPHTHALMOL RETINA, V2, P550, DOI 10.1016/j.oret.2017.10.010
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roh M, 2019, BRIT J OPHTHALMOL, V103, P1769, DOI 10.1136/bjophthalmol-2018-313316
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Siedlecki J, 2017, GRAEF ARCH CLIN EXP, V255, P963, DOI 10.1007/s00417-017-3595-z
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Wightman AJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.3
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 35
TC 11
Z9 12
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 15
PY 2020
VL 10
IS 1
AR 8036
DI 10.1038/s41598-020-64901-9
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ND9FI
UT WOS:000562205900011
PM 32415240
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lechner, J
   Chen, M
   Hogg, RE
   Toth, L
   Silvestri, G
   Chakravarthy, U
   Xu, HP
AF Lechner, Judith
   Chen, Mei
   Hogg, Ruth E.
   Toth, Levente
   Silvestri, Giuliana
   Chakravarthy, Usha
   Xu, Heping
TI Peripheral blood mononuclear cells from neovascular age-related macular
   degeneration patients produce higher levels of chemokines CCL2 (MCP-1)
   and CXCL8 (IL-8)
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularisation;
   Fibrosis; Cytokines; Chemokines; IL-8; CCL2
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; PIGMENT EPITHELIAL-CELLS;
   NF-KAPPA-B; CHOROIDAL NEOVASCULARIZATION; PULMONARY-FIBROSIS;
   ENDOTHELIAL-CELLS; AQUEOUS-HUMOR; RISK-FACTORS; INFLAMMATION; EXPRESSION
AB Background: Infiltrating immune cells including monocytes/macrophages have been implicated in the pathogenesis of neovascular age-related macular degeneration (nAMD). The aim of this study was to investigate the cytokine and chemokine expression and secretion profile of peripheral blood mononuclear cells (PBMCs) from nAMD patients and the relationship between the cytokine/chemokine expression profile and clinical phenotype of nAMD, including macular fibrosis, macular atrophy or the responsiveness to anti-VEGF therapy.
   Methods: One hundred sixty-one nAMD patients and 43 controls were enrolled in this study. nAMD patients were divided into subgroups based on the presence/absence of (1) macular atrophy, (2) macular fibrosis and (3) responsiveness to anti-VEGF therapy; 25-30 ml of peripheral blood were obtained from all participants and 5 ml were used for serum collection, and the remaining were used for PBMC isolation using density gradient centrifugation. Intracellular cytokine expressions by PBMCs following phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulation were examined using flow cytometry. Cytokine productions in lipopolysaccharides (LPS)-or 1% oxygen -treated PBMC were measured using cytometric bead array (CBA) assay. In addition, cytokine and chemokine levels in the serum were also measured by CBA assay.
   Results: PBMCs from nAMD patients secreted higher levels of IL-8, CCL2 and VEGF, especially following LPS and 1% oxygen stimulation, than those from controls. 60 similar to 80% of IL-8 producing cells were CD11b(+)CD3(-)monocytes. The percentage of CD11b(+) CD3-IL-8(+) was significantly increased in nAMD patients compared to controls. PBMCs from nAMD patients without macular fibrosis produced the highest levels of IL-8 and CCL2, whilst PBMCs from nAMD patients with macular atrophy produced highest levels of VEGF. In addition, PBMCs from patients who partially responded to anti-VEGF produced higher levels of IL-8 compared to the cells from complete responders. Interestingly, serum level of CCL2 was not increased in nAMD patients although there was a trend of increased IL-8 in nAMD patients.
   Conclusions: PBMCs, in particular monocytes, may contribute to CNV development in nAMD through secreting elevated levels of IL-8, CCL2 and VEGF after they are recruited to the macula. Apart from VEGF, IL-8 and CCL2 may be additional targets for nAMD management.
C1 [Lechner, Judith; Chen, Mei; Hogg, Ruth E.; Toth, Levente; Silvestri, Giuliana; Chakravarthy, Usha; Xu, Heping] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Xu, Heping] Queens Univ Belfast, Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP Xu, HP (通讯作者)，Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.; Xu, HP (通讯作者)，Queens Univ Belfast, Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020; Xu, Heping/A-4430-2008; Lechner,
   Judith/GQH-8616-2022
OI Hogg, Ruth E./0000-0001-9413-2669; Xu, Heping/0000-0003-4000-931X;
   Silvestri, Giuliana/0000-0001-5662-5374; Chakravarthy,
   Usha/0000-0002-2606-3734
FU Dunhill Medical Trust [R188/0211]; Guide Dogs for the Blind Association
   UK [2008-5a]
FX The study was funded by the Dunhill Medical Trust (R188/0211) and Guide
   Dogs for the Blind Association UK (2008-5a).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambreen F, 2015, MOL VIS, V21, P985
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baran J, 2001, CLIN DIAGN LAB IMMUN, V8, P303, DOI 10.1128/CDLI.8.2.303-313.2001
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Capelli A, 2005, EUR RESPIR J, V25, P701, DOI 10.1183/09031936.05.00082604
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Furuse S, 2003, J RHEUMATOL, V30, P1524
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Henkels KM, 2011, FEBS LETT, V585, P159, DOI 10.1016/j.febslet.2010.11.031
   Hintermann E, 2010, J AUTOIMMUN, V35, P424, DOI 10.1016/j.jaut.2010.09.003
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200
   Miao H, 2012, MOL VIS, V18, P574
   Mizukami Y, 2006, NAT MED, V12, P253, DOI 10.1038/nm0206-253c
   Okuma T, 2004, J PATHOL, V204, P594, DOI 10.1002/path.1667
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Robbie SJ, 2016, NEUROBIOL AGING, V40, P110, DOI 10.1016/j.neurobiolaging.2015.12.019
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Tager AM, 2004, AM J RESP CELL MOL, V31, P395, DOI 10.1165/rcmb.2004-0175OC
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Vielhauer V, 2001, J AM SOC NEPHROL, V12, P1173, DOI 10.1681/ASN.V1261173
   Yamamoto T, 2003, J INVEST DERMATOL, V121, P510, DOI 10.1046/j.1523-1747.2003.12408.x
   Yoshida A, 1998, INVEST OPHTH VIS SCI, V39, P1097
   Yoshida A, 2001, BRIT J OPHTHALMOL, V85, P872, DOI 10.1136/bjo.85.7.872
   Zimmermann HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021381
NR 52
TC 37
Z9 37
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD FEB 23
PY 2017
VL 14
AR 42
DI 10.1186/s12974-017-0820-y
PG 12
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA EP1NC
UT WOS:000397150600002
PM 28231837
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Houston, SK
   Rayess, N
   Cohen, MN
   Ho, AC
   Regillo, CD
AF Houston, Samuel K., III
   Rayess, Nadim
   Cohen, Michael N.
   Ho, Allen C.
   Regillo, Carl D.
TI INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED
   MACULAR DEGENERATION (VINTREX)
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID POSTERIOR VITREOUS DETACHMENT; OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB
   TREATMENT; ADHESION; REGIMEN
AB Purpose:
   To determine the influence of vitreomacular adhesion (VMA) on treatment outcomes in patients with neovascular age-related macular degeneration who were treated with anti-vascular endothelial growth factor agents using a treat and extend treatment regimen.
   Methods:
   A retrospective consecutive case series of 204 eyes from 181 patients with a minimum of 1 year of follow-up at Wills Eye Hospital Retina Service. Vitreomacular interface characteristics were determined by spectral domain optical coherence tomography. One hundred and fifty-three eyes (75%) had no signs of VMA (non-VMA), and 51 (25%) had VMA.
   Results:
   Baseline mean visual acuity was 20/133 with a mean central retinal thickness of 350.5 mu m in the non-VMA group and was 20/145 with 371.8 mu m in the VMA group. Mean visual acuity in the non-VMA group was 20/83 and 20/64 at Years 1 and 2, respectively (P < 0.01 to baseline). Mean visual acuity in the VMA group was 20/81 and 20/85 at Years 1 and 2, respectively (P < 0.01 to baseline). The central retinal thickness was 289.71 mu m and 267 mu m at Years 1 and 2, respectively (P < 0.01 to baseline) in the non-VMA group and was 305.3 mu m and 289.24 mu m (P < 0.01 to baseline) in the VMA group. The mean total number of injections at Year 1 for non-VMA was 7.4 compared with 8.4 in VMA (P = 0.001) and 5.5 versus 6.7 for the 2 groups in Year 2 (P = 0.027). The mean longest extension at Year 1 was 11.8 weeks compared with 10.1 week (P = 0.005) and for Year 2 was 14.1 weeks compared with 12 weeks (P = 0.041).
   Conclusion:
   The vitreomacular interface seems to have a significant influence on anti-vascular endothelial growth factor treatment intervals but not visual acuity or exudative control outcomes. Eyes with VMA on spectral domain optical coherence tomography at baseline may require more intensive treatment with decreased ability to extend treatment intervals.
C1 Mid Atlantic Retina, Philadelphia, PA USA.
   [Regillo, Carl D.] Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Regillo, CD (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM cregillo@aol.com
OI Ho, Allen/0000-0003-3921-608X
FU Regeneron; Genentech
FX Supported by grant from Regeneron and Genentech (A.C.H., C.D.R., and
   S.K.H.).
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   STEFANSSON E, 1990, INVEST OPHTH VIS SCI, V31, P284
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
NR 30
TC 20
Z9 20
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2015
VL 35
IS 9
BP 1757
EP 1764
DI 10.1097/IAE.0000000000000663
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR2YK
UT WOS:000361196600007
PM 26110596
DA 2022-11-30
ER

PT J
AU Hou, J
   Tao, Y
   Li, XX
   Zhao, MW
AF Hou, Jing
   Tao, Yong
   Li, Xiao-xin
   Zhao, Ming-wei
TI Clinical characteristics of polypoidal choroidal vasculopathy in Chinese
   patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Exudative age-related macular
   degeneration; Choroidal neovascularization; Chinese
ID MACULAR DEGENERATION
AB To describe the clinical characteristics of polypoidal choroidal vasculopathy (PCV) in a large number of Chinese patients.
   This study enrolled 204 consecutive patients (246 eyes) in our department who were diagnosed as having polypoidal choroidal vasculopathy PCV. Patients underwent ophthalmologic examinations including best-corrected visual acuity (BCVA) testing, ophthalmoscopy, fundus photography, fluorescein angiography, indocyanine green angiography, and optic coherence tomography.
   Mean patient age was 66.1 years and 60.3% were men. Of the cases, 79.4% were unilateral and 51.2% of BCVA was less than 35 letters. In 171 eyes (69.5%), polypoidal lesions were located in the macula area. Among them, polypoidal lesions were located in the foveal area in 29 eyes (11.8%), in the parafoveal area in 50 eyes (20.3%), and in the extrafoveal area in 88 eyes (35.8%), in both the foveal and parafoveal area in three eyes (1.2%), and in both the parafoveal and extrafoveal area in one eye (0.4%). In 37 eyes (15.0%), PCV lesions were under the temporal retinal vascular arcade; in 11 eyes (4.5%), PCV lesions were found peripapillary. PCV lesion formation was single in 88 eyes (35.8%), cluster in 145 eyes (59.0%), string in two eyes (0.8%), and branch in two eyes (0.8%). In nine eyes (3.6%), the formation of PCV lesions showed both single and cluster shape in the same eye. There were 54.5% with drusen, 44.7% with serous PED, 20.7% with hemorrhagic PED, and 39.0% with neuroretinal detachment.
   The majority of Chinese PCV patients were male, unilateral, and showed macular polyps. Drusen, serous PED, hemorrhagic PED, and neuroretinal detachment on OCT were commonly seen.
C1 [Hou, Jing; Tao, Yong; Li, Xiao-xin; Zhao, Ming-wei] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100044, Peoples R China.
   [Hou, Jing; Tao, Yong; Li, Xiao-xin; Zhao, Ming-wei] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
C3 Peking University
RP Li, XX (通讯作者)，Peking Univ, Dept Ophthalmol, Peoples Hosp, 11 Xizhimen S St, Beijing 100044, Peoples R China.
EM drxiaoxinli@gmail.com
OI Tao, Yong/0000-0003-1443-2667
FU Major State Basic Research Development Program of China [2005CB724307];
   National Natural Science Foundation of China [30901639]; Beijing Novel
   Program [2009B04]; Special Funds for Central Health research projects,
   China [B2009B041]; Epidemiological Survey and Consultation Network
   Construction of Polypoidal Choroidal Vasculopathy in the Beijing Region
FX This study was supported by the Major State Basic Research Development
   Program of China (No:2005CB724307), the National Natural Science
   Foundation of China (No:30901639), the Beijing Novel Program
   (No:2009B04), Special Funds for Central Health research projects
   (No.B2009B041; China:MWZ) and the Epidemiological Survey and
   Consultation Network Construction of Polypoidal Choroidal Vasculopathy
   in the Beijing Region.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Hwang De-Kuang, 2007, J Chin Med Assoc, V70, P84
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Squirrell DM, 2009, CLIN EXP OPHTHALMOL, V37, P368, DOI 10.1111/j.1442-9071.2009.02044.x
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   YAMAOKA S, 2009, INT J OPHTHALMOLOGY, V224, P147
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yeung Ling, 2004, Chang Gung Med J, V27, P366
   Yi C, 2001, Yan Ke Xue Bao, V17, P126
NR 22
TC 23
Z9 31
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2011
VL 249
IS 7
BP 975
EP 979
DI 10.1007/s00417-010-1575-7
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 784NG
UT WOS:000292163400004
PM 21153654
DA 2022-11-30
ER

PT J
AU Biggs, RM
   Makou, E
   Lauder, S
   Herbert, AP
   Barlow, PN
   Katti, SK
AF Biggs, Robyn M.
   Makou, Elisavet
   Lauder, Scott
   Herbert, Andrew P.
   Barlow, Paul N.
   Katti, Suresh K.
TI A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103)
   for the Treatment of Age-Related Macular Degeneration Shows Similar In
   Vitro Functional Activity to Native CFH
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; complement factor H; recombinant
   protein therapy; GEM103; alternative pathway
ID SIALIC-ACID; ACTIVATION; RARE; C3B; ATTACHMENT; VARIANTS; HOST
AB Purpose GEM103 is a recombinantly produced full-length version of the human complement factor H (CFH) under clinical investigation for treatment of age-related macular degeneration (AMD) in individuals carrying an AMD risk-associated genetic variant of CFH. This study aimed to investigate the complement pathway-related functions of GEM103 in comparison with those of native human CFH. Methods Key biological activities of GEM103 and human serum-derived CFH (sdCFH) were compared using four independent functional assays. Assays of C3b binding and C3 convertase decay-accelerating activity (DAA) were performed by surface plasmon resonance (SPR). Cofactor activity (CA) was measured using 8-anilinonaphthalene-1-sulfonic acid as a fluorescent probe of C3b integrity. The abilities of GEM103 and sdCFH to protect sheep erythrocytes from hemolysis by CFH-depleted normal human serum were assessed colorimetrically. Results In multiple SPR-based assays of C3b binding and DAA, the performance of GEM103 was consistently comparable to that of sdCFH across a range of matching concentrations. The EC50 +/- SD in the fluorescence-based fluid-phase CA assay was 0.21 +/- 0.06 mu M for GEM103 compared to 0.20 +/- 0.09 mu M for sdCFH. In hemolysis assays, the EC50 value of 0.33 +/- 0.16 mu M for GEM103 versus 0.46 +/- 0.06 mu M for sdCFH were not significantly different (p = 0.81). Conclusions GEM103, a recombinant CFH developed by Gemini Therapeutics, shows activity profiles comparable to sdCFH in all complement-related assays employed in this study, suggesting that GEM103 is equivalent to the native glycoprotein in terms of its in vitro functional activity. These results support further study of GEM103 as a potential therapy for AMD.
C1 [Biggs, Robyn M.; Lauder, Scott; Katti, Suresh K.] Gemini Therapeut Inc, 300 One Kendall Sq, Cambridge, MA 02139 USA.
   [Makou, Elisavet; Herbert, Andrew P.; Barlow, Paul N.] Univ Edinburgh, Sch Chem, Edinburgh, Midlothian, Scotland.
   [Barlow, Paul N.] Univ Edinburgh, Sch Biol Sci, Edinburgh, Midlothian, Scotland.
C3 University of Edinburgh; University of Edinburgh
RP Katti, SK (通讯作者)，Gemini Therapeut Inc, 300 One Kendall Sq, Cambridge, MA 02139 USA.
EM suresh@geminitherapeutics.com
FU Gemini Therapeutics
FX This study was funded by Gemini Therapeutics, Inc.
CR BASEMAN JB, 1982, INFECT IMMUN, V38, P389, DOI 10.1128/IAI.38.1.389-391.1982
   Biggs R., 2021, 13 INT C COMPL THER
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Cipriani V, 2021, AM J HUM GENET, V108, P1385, DOI 10.1016/j.ajhg.2021.05.015
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Herbert AP, 2015, J IMMUNOL, V195, P4986, DOI 10.4049/jimmunol.1501388
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   ISENMAN DE, 1983, J BIOL CHEM, V258, P4238
   Kerr H, 2017, J BIOL CHEM, V292, P13345, DOI 10.1074/jbc.M117.795088
   Khanani Arshad M, 2022, Ophthalmol Sci, V2, P100154, DOI 10.1016/j.xops.2022.100154
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Lachmann PJ, 2018, FASEB J, V32, P123, DOI 10.1096/fj.201700734
   Losse J, 2010, J IMMUNOL, V184, P912, DOI 10.4049/jimmunol.0901702
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Mulfaul K, 2022, J PATHOL, V257, P29, DOI 10.1002/path.5867
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Pangburn MK, 2008, VACCINE, V26, pI15, DOI 10.1016/j.vaccine.2008.11.023
   Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schmidt CQ, 2013, J IMMUNOL, V190, P5712, DOI 10.4049/jimmunol.1203548
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WHALEY K, 1976, SCIENCE, V193, P1011, DOI 10.1126/science.948757
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
NR 35
TC 1
Z9 1
U1 2
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL 3
PY 2022
VL 47
IS 7
BP 1087
EP 1093
DI 10.1080/02713683.2022.2053725
EA APR 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2T6WG
UT WOS:000777911500001
PM 35282732
OA Green Submitted, hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Ohji, M
   Takahashi, K
   Okada, AA
   Kobayashi, M
   Matsuda, Y
   Terano, Y
AF Ohji, Masahito
   Takahashi, Kanji
   Okada, Annabelle A.
   Kobayashi, Masato
   Matsuda, Yoshimi
   Terano, Yasuhiro
CA ALTAIR Investigators
TI Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend
   Regimens in Exudative Age-Related Macular Degeneration: 52-and 96-Week
   Findings from ALTAIR A Randomized Controlled Trial
SO ADVANCES IN THERAPY
LA English
DT Article
DE Aflibercept; Anti-vascular endothelial growth factor agents; Exudative
   age-related macular degeneration; Ophthalmology; Treat-and-extend
ID ENDOTHELIAL GROWTH-FACTOR; CLINICAL-PRACTICE; FACTOR THERAPY;
   RANIBIZUMAB; SUPPRESSION; INJECTION; OUTCOMES
AB Purpose To evaluate efficacy and safety of intravitreal injections of aflibercept (IVT-AFL) treat-and-extend (T&E) dosing regimens in treatment-naive patients with exudative age-related macular degeneration (AMD). Methods Adults aged at least 50 years old with exudative AMD and best-corrected visual acuity (BCVA) of 73-25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters were included. Patients received three monthly doses of IVT-AFL 2 mg. At week 16, patients were randomized 1:1 to IVT-AFL T&E with either 2- or 4-week adjustments. The primary endpoint was mean change in BCVA from baseline to week 52. Outcomes were assessed at weeks 52 and 96. Results Baseline characteristics were comparable between the groups (n = 123 each). Over 52 weeks, mean number of injections was 7.2 and 6.9 and mean last injection interval was 10.7 and 11.8 weeks, for the 2- and 4-week groups, respectively. From baseline, mean change in BCVA was + 9.0 and + 8.4 letters (week 52) and + 7.6 and + 6.1 letters (week 96); mean change in central retinal thickness was - 134.4 mu m and - 126.1 mu m (week 52) and - 130.5 mu m and - 125.3 mu m (week 96). Last injection interval before week 52 was at least 12 weeks in 42.3% and 49.6% of patients and 56.9% and 60.2% before week 96. Over 96 weeks, mean number of injections was 10.4 (both groups). The safety profile of IVT-AFL was consistent with previous reports. Conclusions IVT-AFL administered using two different T&E regimens for treatment-naive exudative AMD improved functional and anatomic outcomes at week 52 and outcomes were maintained to week 96. Outcomes were similar between the 2- and 4-week groups.
C1 [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowa Cho, Otsu, Shiga, Japan.
   [Takahashi, Kanji] Kansai Med Univ, Sch Med, Dept Ophthalmol, Hirakata, Osaka, Japan.
   [Okada, Annabelle A.] Kyorin Univ, Sch Med, Dept Ophthalmol, Mitaka, Tokyo, Japan.
   [Kobayashi, Masato] Bayer Yakuhin Ltd, Chiyoda Ku, Marunouchi 1 Chome, Tokyo, Japan.
   [Matsuda, Yoshimi; Terano, Yasuhiro] Bayer Yakuhin Ltd, Kita Ku, Umeda 2 Chome, Osaka, Japan.
C3 Shiga University of Medical Science; Kansai Medical University; Kyorin
   University; Bayer AG; Bayer AG
RP Ohji, M (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowa Cho, Otsu, Shiga, Japan.
EM eye.ohji@gmail.com
FU Bayer
FX Funding for the study, medical writing and editorial assistance for this
   manuscript, and funding for the Rapid Service Fee and Open Access Fee
   was provided by Bayer. In conjunction with the ALTAIR steering
   committee, Bayer participated in the design of the study; analysis and
   interpretation of the data; preparation, review, and approval of the
   manuscript; and decision to submit the manuscript for publication.
   Additionally, Bayer was responsible for the conduct of the study and
   oversight of the collection and management of data.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Do DV, 2017, INVEST OPHTH VIS SCI, V58
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Koh A, 2017, ASIA-PAC J OPHTHALMO, V6, P296, DOI 10.22608/APO.2016125
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Rezaei KA, 2016, GLOBAL TRENDS RETINA
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   WHO, 2019, PREV BLINDN VIS IMP
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Yamada M, 2010, OPHTHAL EPIDEMIOL, V17, P50, DOI 10.3109/09286580903450346
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 27
TC 83
Z9 85
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD MAR
PY 2020
VL 37
IS 3
BP 1173
EP 1187
DI 10.1007/s12325-020-01236-x
EA FEB 2020
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KR4UT
UT WOS:000515820000001
PM 32016788
OA Green Published, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Bressler, SB
   Pieramici, D
   Koester, JM
   Bressler, NM
AF Bressler, SB
   Pieramici, D
   Koester, JM
   Bressler, NM
CA TAP Study Grp
TI Natural history of minimally classic subfoveal choroidal neovascular
   lesions in the treatment of age-related macular degeneration with
   photodynamic therapy (TAP) investigation - Outcomes potentially relevant
   to Management - TAP report no. 6
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN THERAPY; GUIDELINES
AB Objective: To determine if there is a rationale for monitoring patients with age-related macular degeneration who have a minimally classic subfoveal choroidal neovascular lesion and do not receive treatment at initial examination.
   Methods: Participants assigned to placebo who had a minimally classic lesion composition at baseline were identified from the TAP Investigation. Fluorescein angiograms at baseline and follow-up examinations from these participants were reviewed by photograph reading center graders to determine if any follow-up angiograms had converted from a minimally classic lesion composition to a predominantly classic lesion composition.
   Main Outcome Measures: Proportion of minimally classic lesions at baseline that converted to a predominantly classic lesion composition, time of this conversion, and visual acuity and lesion size at the time of conversion.
   Results: Of the 207 patients assigned to placebo in the TAP Investigation, 98 were judged to have a minimally classic lesion at baseline in the study eye when the fluorescein angiograms were reviewed in 2001. Of these 98 patients, 39 (40%) had lesions that converted to a predominantly classic lesion composition, including 21 by the month 3 examination. At the time of conversion, 32 (82%) lesions were no greater than 9 disc areas, including 20 (51%) with visual acuity of 20/200 or better.
   Conclusions: These data would suggest that patients with minimally classic lesions, in whom no therapy is recommended initially, should be monitored so that potential conversion to a predominantly classic lesion can be identified promptly and verteporfin therapy considered.
C1 Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Retinal Vasc Ctr, Baltimore, MD 21218 USA.
   Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21218 USA.
   Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
   Novartis AG, Duluth, GA USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins Medicine; Novartis
RP Bressler, SB (通讯作者)，Novartis Ophthalm Med Affairs, 1 Hlth Plaza,Bldg 118, E Hanover, NJ 07936 USA.
EM nmboffice@jhmi.edu
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 2003, 2003 ANN M ABSTR PRO
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TAP and VIP Study Group, 2002, RETINA, V22, P6
NR 9
TC 22
Z9 23
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2004
VL 122
IS 3
BP 325
EP 329
DI 10.1001/archopht.122.3.325
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 801CY
UT WOS:000220075200002
PM 15006843
OA Bronze
DA 2022-11-30
ER

PT J
AU Liew, G
   Wang, JJ
   Klein, R
   Duncan, BB
   Brancati, F
   Yeh, HC
   Wong, TY
AF Liew, Gerald
   Wang, Jie Jin
   Klein, Ronald
   Duncan, Bruce B.
   Brancati, Frederick
   Yeh, Hsin-Chieh
   Wong, Tien Y.
TI The relationship between birthweight and early age-related maculopathy:
   The atherosclerosis risk in communities study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; MACULAR DEGENERATION; FETAL-GROWTH; SIZE;
   ADULTHOOD; CHILDHOOD; EXPOSURES; RETINA
AB Purpose: Birthweight is a marker of fetal growth, and has been linked to future risk of chronic diseases in adults. We examined the association between birthweight and age-related maculopathy (ARM). Methods: We studied 9730 adults from the population-based Atherosclerosis Risk in Communities study, of whom 4744 reported their exact birthweight and an additional 4986 provided categorical birthweight data (low, medium or high). We graded retinal photographs for presence of ARM using a modification of the Wisconsin ARM Grading System. Results: Early ARM was present in 479 (4.9%) adults. Among persons with exact birthweight data, there was no association between birthweight and early ARM (OR 1.1, 95% CI 0.9-1.3, for each kg increase in birthweight). However, in Whites, greater birthweight was associated with an increased risk of early ARM (OR 1.2, 95% CI 1.0-1.4, for each kilogram increase in birthweight), after adjustment for age, sex, smoking, blood pressure and education level. In analyses including additional participants who provided categorical birthweight data, the pattern of associations were similar but not statistically significant. We did not have sufficient numbers to examine associations for late ARM (n = 12) or in African-Americans separately. Conclusions: We found no association between birthweight and risk of early ARM in the whole population. Among the white participants, higher birthweight was associated with a slight increased risk of early ARM. These findings, if confirmed in other studies, suggest that fetal growth may be important in ARM development in white persons.
C1 [Wang, Jie Jin; Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Liew, Gerald; Wang, Jie Jin] Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res,Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Duncan, Bruce B.] Univ Fed Rio Grande do Sul, Sch Med, Grad Studies Program Epidemiol, Porto Alegre, RS, Brazil.
   [Brancati, Frederick; Yeh, Hsin-Chieh] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Med, Baltimore, MD USA.
   [Yeh, Hsin-Chieh] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Sydney; Westmead Institute for Medical Research; University of
   Wisconsin System; University of Wisconsin Madison; Universidade Federal
   do Rio Grande do Sul; Johns Hopkins University; Johns Hopkins Bloomberg
   School of Public Health; Johns Hopkins University; Johns Hopkins
   Bloomberg School of Public Health; National University of Singapore;
   Singapore National Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Liew, Gerald/AAB-6870-2022; Duncan, Bruce
   B/L-4140-2016; wang, jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Duncan, Bruce B/0000-0002-7491-2630;
   Wang, Jie Jin/0000-0001-9491-4898; Klein, Ronald/0000-0002-4428-6237
FU NHLBI NIH HHS [R21-HL077166, N01-HC-55016, N01-HC-55022, N01-HC-55021,
   N01-HC-55020, N01-HC-55019, N01-HC-55018, N01-HC-55015] Funding Source:
   Medline; NIDDK NIH HHS [K24DK62222] Funding Source: Medline; DIVISION OF
   EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055020, N01HC055019,
   N01HC055016, N01HC055018, N01HC055021, N01HC055015, N01HC055022] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R21HL077166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK062222] Funding Source:
   NIH RePORTER
CR Allen DS, 2002, AM J EPIDEMIOL, V155, P379, DOI 10.1093/aje/155.4.379
   Barker DJP, 2005, NEW ENGL J MED, V353, P1802, DOI 10.1056/NEJMoa044160
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Gunnell D, 2002, INT J EPIDEMIOL, V31, P390, DOI 10.1093/ije/31.2.390
   Hall NF, 2002, INVEST OPHTH VIS SCI, V43, P3641
   Ingelfinger JR, 2007, NEW ENGL J MED, V356, P2093, DOI 10.1056/NEJMe078071
   Jackson R, 1996, J CLIN EPIDEMIOL, V49, P1441, DOI 10.1016/0895-4356(95)00047-X
   Kajantie E, 2005, INT J EPIDEMIOL, V34, P655, DOI 10.1093/ije/dyi048
   Kemp M, 2000, J EPIDEMIOL COMMUN H, V54, P639, DOI 10.1136/jech.54.8.639
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Loeliger M, 2005, INVEST OPHTH VIS SCI, V46, P3300, DOI 10.1167/iovs.04-1357
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2
   Okasha M, 2003, BREAST CANCER RES TR, V78, P223, DOI 10.1023/A:1022988918755
   Sanderson M, 1998, AM J EPIDEMIOL, V147, P136
   Sayer AA, 1998, AGE AGEING, V27, P579, DOI 10.1093/ageing/27.5.579
   Tilling K, 2004, EPIDEMIOLOGY, V15, P557, DOI 10.1097/01.ede.0000135172.67293.60
   White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Yliharsila H, 2003, HYPERTENSION, V41, P446, DOI 10.1161/01.HYP.0000055780.21222.96
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 25
TC 7
Z9 7
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD JAN-FEB
PY 2008
VL 15
IS 1
BP 56
EP 61
DI 10.1080/09286580701613769
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 268MN
UT WOS:000253584000009
PM 18300090
DA 2022-11-30
ER

PT J
AU Hallam, D
   Collin, J
   Bojic, S
   Chichagova, V
   Buskin, A
   Xu, YB
   Lafage, L
   Otten, EG
   Anyfantis, G
   Mellough, C
   Przyborski, S
   Alharthi, S
   Korolchuk, V
   Lotery, A
   Saretzki, G
   McKibbin, M
   Armstrong, L
   Steel, D
   Kavanagh, D
   Lako, M
AF Hallam, Dean
   Collin, Joseph
   Bojic, Sanja
   Chichagova, Valeria
   Buskin, Adriana
   Xu, Yaobo
   Lafage, Lucia
   Otten, Elsje. G.
   Anyfantis, George
   Mellough, Carla
   Przyborski, Stefan
   Alharthi, Sameer
   Korolchuk, Viktor
   Lotery, Andrew
   Saretzki, Gabriele
   McKibbin, Martin
   Armstrong, Lyle
   Steel, David
   Kavanagh, David
   Lako, Majlinda
TI An Induced Pluripotent Stem Cell Patient Specific Model of Complement
   Factor H (Y402H) Polymorphism Displays Characteristic Features of
   Age-Related Macular Degeneration and Indicates a Beneficial Role for UV
   Light Exposure
SO STEM CELLS
LA English
DT Article
DE Age-related macular degeneration; Complement factor H; Induced
   pluripotent stem cell; Retinal pigment epithelium
ID BRUCHS MEMBRANE IMPLICATIONS; GENOME-WIDE ASSOCIATION; OXIDATIVE STRESS;
   HUMAN RETINA; DISEASE; RISK; EYE; IDENTIFICATION; MITOCHONDRIA;
   RANIBIZUMAB
AB Age-related macular degeneration (AMD) is the most common cause of blindness, accounting for 8.7% of all blindness globally. Vision loss is caused ultimately by apoptosis of the retinal pigment epithelium (RPE) and overlying photoreceptors. Treatments are evolving for the wet form of the disease; however, these do not exist for the dry form. Complement factor H polymorphism in exon 9 (Y402H) has shown a strong association with susceptibility to AMD resulting in complement activation, recruitment of phagocytes, RPE damage, and visual decline. We have derived and characterized induced pluripotent stem cell (iPSC) lines from two subjects without AMD and low-risk genotype and two patients with advanced AMD and high-risk genotype and generated RPE cells that show local secretion of several proteins involved in the complement pathway including factor H, factor I, and factor H-like protein 1. The iPSC RPE cells derived from high-risk patients mimic several key features of AMD including increased inflammation and cellular stress, accumulation of lipid droplets, impaired autophagy, and deposition of "drusen"-like deposits. The low- and high-risk RPE cells respond differently to intermittent exposure to UV light, which leads to an improvement in cellular and functional phenotype only in the high-risk AMD-RPE cells. Taken together, our data indicate that the patient specific iPSC model provides a robust platform for understanding the role of complement activation in AMD, evaluating new therapies based on complement modulation and drug testing.
C1 [Hallam, Dean; Collin, Joseph; Bojic, Sanja; Chichagova, Valeria; Buskin, Adriana; Xu, Yaobo; Lafage, Lucia; Anyfantis, George; Mellough, Carla; Armstrong, Lyle; Steel, David; Kavanagh, David; Lako, Majlinda] Newcastle Univ, Inst Med Genet, Int Ctr Life, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Otten, Elsje. G.; Korolchuk, Viktor; Saretzki, Gabriele] Newcastle Univ, Inst Cell & Mol Biosci, Campus Ageing & Vital, Newcastle Upon Tyne, Tyne & Wear, England.
   [Otten, Elsje. G.; Korolchuk, Viktor; Saretzki, Gabriele] Newcastle Univ, Inst Ageing, Newcastle Upon Tyne, Tyne & Wear, England.
   [Przyborski, Stefan] Univ Durham, Dept Biosci, Durham, England.
   [Alharthi, Sameer] King Abdulaziz Univ, Princess Al Jawhara Al Brahim Ctr Excellence Res, Jeddah, Saudi Arabia.
   [Lotery, Andrew] Univ Southampton, Clin & Expt Sci, Fac Med, Southampton, Hants, England.
   [McKibbin, Martin] Leeds Teaching Hosp NHS, Leeds, W Yorkshire, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK; Durham University; King Abdulaziz University;
   University of Southampton; Leeds General Infirmary
RP Lako, M (通讯作者)，Newcastle Univ, Inst Med Genet, Int Ctr Life, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM majlinda.lako@ncl.ac.uk
RI Saretzki, Gabriele Christine/I-7175-2019; Buskin, Adriana/GLS-0912-2022;
   Buskin, Adriana/GLU-3363-2022; Steel, David/I-8053-2015
OI Saretzki, Gabriele Christine/0000-0003-2100-8223; Mellough,
   Carla/0000-0003-3685-6516; Lotery, Andrew/0000-0001-5541-4305;
   Chichagova, Valeria/0000-0002-7289-3640; armstrong,
   lyle/0000-0002-7234-9362; Al-Harthi, Sameer/0000-0003-4293-3215; Otten,
   Elsje/0000-0002-8716-3560; Steel, David/0000-0001-8734-3089; Korolchuk,
   Viktor/0000-0002-4071-592X; Anyfantis, George/0000-0001-5647-3841; lako,
   majlinda/0000-0003-1327-8573; Bojic, Sanja/0000-0001-6853-3143; Lafage,
   Lucia/0000-0002-8105-5083; Buskin, Adriana/0000-0001-6216-6186
FU Macular Society U.K.; European Research Council [614620]; Biotechnology
   and Biological Sciences Research Council [BB/I020209/1]; IMI2; Bayer AG;
   Biotechnology and Biological Sciences Research Council [1368759,
   BB/E012841/1] Funding Source: researchfish; National Institute for
   Health Research [NF-SI-0515-10020] Funding Source: researchfish;
   Rosetrees Trust [M124-F1] Funding Source: researchfish; National Centre
   for the Replacement [NC/C016106/1] Funding Source: researchfish; Fight
   for Sight [1870] Funding Source: researchfish; BBSRC [BB/J007803/1,
   BB/E012841/1, BB/I020209/1] Funding Source: UKRI
FX We thank Tracey Davey and Dr. Kathryn White at Newcastle University
   Electron Microscopy Research Services for sample preparation and
   assistance with transmission electron microscopy image processing,
   Newcastle University core genomics and flow cytometry core facility for
   help with flow cytometric analysis, Dr. Angela Pyle for carrying out
   mitochondrial deletion analysis and RNA-seq analysis, and Dr. Heli
   Skottman for help with Trans-epithelial resistance analysis. This work
   was supported by the Macular Society U.K., FP7 Ideas, European Research
   Council (grant no. 614620), Biotechnology and Biological Sciences
   Research Council (grant no. BB/I020209/1), IMI2 funded EbiSC project,
   and Bayer AG.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anders S, 2014, BIOINFORMATICS
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 2013, PLOS ONE
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chong EW, 2015, RETINA-J RET VIT DIS, V35, P989, DOI 10.1097/IAE.0000000000000417
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crump F., SOC URGENTLY CALLS M
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kanemura H, 2013, SCI REP-UK, V3, DOI 10.1038/srep02334
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Lee HC, 2000, BIOCHEM J, V348, P425, DOI 10.1042/0264-6021:3480425
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Mathis T, 2016, AGING CELL
   Miller JD, 2013, CELL STEM CELL, V13, P691, DOI 10.1016/j.stem.2013.11.006
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Nowak JZ, 2010, PHARMACOL REP, V62, P113, DOI 10.1016/S1734-1140(10)71232-9
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Saini J.S., 2017, CELL STEM CELL
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schang AL, 2013, NEUROENDOCRINOLOGY, V97, P115, DOI 10.1159/000337661
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Stojkovic M, 2004, STEM CELLS, V22, P790, DOI 10.1634/stemcells.22-5-790
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang Shu-Zhen, 2014, J Ophthalmic Vis Res, V9, P83
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Yan RT, 2013, INVEST OPHTH VIS SCI, V54, P4766, DOI 10.1167/iovs.13-11936
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x
NR 61
TC 44
Z9 45
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD NOV
PY 2017
VL 35
IS 11
BP 2305
EP 2320
DI 10.1002/stem.2708
PG 16
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA FL0TS
UT WOS:000413924300009
PM 28913923
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Shao, Y
   Yu, HT
   Yang, Y
   Li, M
   Hang, L
   Xu, XR
AF Shao, Yan
   Yu, Haitao
   Yang, Yan
   Li, Min
   Hang, Li
   Xu, Xinrong
TI A Solid Dispersion of Quercetin Shows Enhanced Nrf2 Activation and
   Protective Effects against Oxidative Injury in a Mouse Model of Dry
   Age-Related Macular Degeneration
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID PHOSPHOLIPID COMPLEX; STRESS; BIOAVAILABILITY; DISSOLUTION; NARINGENIN
AB Age-related macular degeneration (AMD) represents a major reason for blindness in the elderly population. Oxidative stress is a predominant factor in the pathology of AMD. We previously evaluated the effects of phospholipid complex of quercetin (Q-PC) on oxidative injury in ARPE-19 cells, but the underlying mechanisms are not fully understood. Herein, the solid dispersion of quercetin-PC (Q-SD) was prepared with solubility being 235.54 mu g/mL in water and 2.3x10(4) mu g/mL in chloroform, which were significantly higher than that of quercetin (QT) and Q-PC. Q-SD also exhibited a considerably higher dissolution rate than QT and Q-PC. Additionally, Q-SD had Cmax of 4.143 mu g/mL and AUC of 12.015 mu g center dot h/mL in rats, suggesting better bioavailability than QT and Q-PC. Then, a mouse model of dry AMD (Nrf2 wild-type (WT) and Nrf2 knockout (KO)) was established for evaluating the effects of Q-SD in vivo. Q-SD more potently reduced retinal pigment epithelium sediments and Bruch's membrane thickness than QT and Q-PC at 200 mg/kg in Nrf2 WT mice and did not work in Nrf2 KO mice at the same dosage. Additionally, Q-SD significantly decreased ROS and MDA contents and restored SOD, GSH-PX, and CAT activities of serum and retinal tissues in Nrf2 WT mice, but not in Nrf2 KO mice. Furthermore, Q-SD more potently increased Nrf2 mRNA expression and stimulated its nuclear translocation in retinal tissues of Nrf2 WT mice. Q-SD significantly increased the expression of Nrf2 target genes HO-1, HQO-1, and GCL of retinal tissues in Nrf2 WT mice, not in Nrf2 KO mice. Altogether, Q-SD had improved physicochemical and pharmacokinetic properties compared to QT and Q-PC and exhibited more potent protective effects on retina oxidative injury in vivo. These effects were associated with activation of Nrf2 signaling and upregulation of antioxidant enzymes.
C1 [Shao, Yan; Hang, Li; Xu, Xinrong] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
   [Yu, Haitao] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Jiangsu, Peoples R China.
   [Yang, Yan] Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Ophthalmol, Nanjing 210017, Jiangsu, Peoples R China.
   [Li, Min] Nanjing Univ Chinese Med, Affiliated Hosp, Liyang Branch, Dept Ophthalmol, Liyang 213300, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Nanjing University of
   Chinese Medicine
RP Xu, XR (通讯作者)，Nanjing Univ Chinese Med, Affiliated Hosp, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
EM xinrong_xu@aliyun.com
RI Xu, Xinrong/AAX-3118-2021
OI xu, xinrong/0000-0003-2047-7298
FU Jiangsu Provincial Key Research and Development Program [BE2018757]
FX The work was supported by the Jiangsu Provincial Key Research and
   Development Program (Grant No. BE2018757).
CR Alia M, 2006, TOXICOL APPL PHARM, V212, P110, DOI 10.1016/j.taap.2005.07.014
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cai X, 2013, CURR MED CHEM, V20, P2572, DOI 10.2174/09298673113209990120
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gonzales GB, 2017, P NUTR SOC, V76, P175, DOI 10.1017/S0029665116002858
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Huang YB, 2014, ACTA PHARM SIN B, V4, P18, DOI 10.1016/j.apsb.2013.11.001
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Khan AW, 2015, DRUG DEV IND PHARM, V41, P772, DOI 10.3109/03639045.2014.902466
   Lee GH, 2008, J FOOD SCI, V73, pC500, DOI 10.1111/j.1750-3841.2008.00851.x
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Maiti K, 2006, J PHARM PHARMACOL, V58, P1227, DOI 10.1211/jpp.58.9.0009
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Pershing S, 2019, AM J OPHTHALMOL, V207, P385, DOI 10.1016/j.ajo.2019.05.011
   Russo M, 2012, BIOCHEM PHARMACOL, V83, P6, DOI 10.1016/j.bcp.2011.08.010
   Shinde VR, 2008, J PHARM PHARMACOL, V60, P1121, DOI 10.1211/jpp.60.9.0002
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037
   Singh Devendra, 2012, Curr Drug Discov Technol, V9, P17
   Singh S, 2010, FREE RADICAL RES, V44, P1267, DOI 10.3109/10715762.2010.507670
   Wang HZ, 2015, DRUG DEV IND PHARM, V41, P1693, DOI 10.3109/03639045.2014.991402
   Xu XR, 2016, EUR J PHARMACOL, V770, P1, DOI 10.1016/j.ejphar.2015.11.050
   Xu XR, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4378461
   Xu XR, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/862806
   Yang L, 2015, EUR J PHARM SCI, V78, P103, DOI 10.1016/j.ejps.2015.07.007
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 29
TC 27
Z9 29
U1 4
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD NOV 7
PY 2019
VL 2019
AR 1479571
DI 10.1155/2019/1479571
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA JP9PQ
UT WOS:000498589400001
PM 31781321
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Boxell, EM
   Amoaku, WM
   Bradley, C
AF Boxell, Emily M.
   Amoaku, Winfried M.
   Bradley, Clare
TI Healthcare experiences of patients with age-related macular
   degeneration: have things improved? Cross-sectional survey responses of
   Macular Society members in 2013 compared with 1999
SO BMJ OPEN
LA English
DT Article
ID RANIBIZUMAB; VERTEPORFIN; PREVALENCE; GENDER
AB Objective: To investigate healthcare experiences of patients with age-related macular degeneration (AMD) and determine whether a previous survey and Royal College of Ophthalmologists (RCOphth) management guidelines brought improvements.
   Design: Cross-sectional survey of Macular Society members in 2013 compared with previous 1999 survey.
   Setting: UK Postal Questionnaires.
   Participants: 1169 respondents in 2013 (1187 in 1999).
   Intervention: Publication of 1999 survey results (2002), and RCOphth AMD guidelines (2009).
   Main outcome measures: Respondents answered questions about experiences at diagnosis. Five questions were replicated from the 1999 survey for direct comparison in the 2013 survey which included additional questions based on 2009 RCOphth recommendations for information and support provision for patients with AMD.
   Results: Most 2013 survey respondents were given the name of their macular condition (91%), felt the healthcare professional was interested in them (71%) and were satisfied overall with the diagnostic consultation (76%). These outcomes show significant improvement since 1999. Within the 2013 sample, multivariable analyses showed gradual trends of improvement over time in: provision of written information, Macular Society information and receiving appropriate help, support and advice at diagnosis. Only overall satisfaction with the diagnostic consultation (but not the other nine areas of information and support provision studied) significantly improved in the time after publication of the RCOphth 2009 guidelines. There were no significant improvements associated with the publication of the 1999 survey results. Low information and support provision remained, for example, 44% of respondents diagnosed after the RCOphth 2009 guidelines reported not receiving information on what to do if vision deteriorated. Lack of such information at diagnosis was significantly associated with registration as sight impaired p< 0.01). Reports of general practitioner (GP) knowledge of AMD remained low: 39% reported their GP was 'not at all well informed'. The 2013 respondents reported lower levels of help and support from GPs than 1999 respondents (p< 0.001).
   Conclusions: Patients diagnosed with AMD after 1999 (vs before 1999) reported better experiences at diagnostic consultation. However, information and support provision at diagnosis, and satisfaction with GPs remained low.
C1 [Boxell, Emily M.; Bradley, Clare] Univ London, Royal Holloway, Hlth Psychol Res Unit, Egham, Surrey, England.
   [Boxell, Emily M.] Univ London, Royal Holloway, Dept Psychol, Egham, Surrey, England.
   [Amoaku, Winfried M.] Univ Nottingham, Univ Hosp, B Floor Eye & ENT Ctr, DCN,QMC,Ophthalmol, Nottingham, England.
   [Bradley, Clare] Univ London, Hlth Psychol Res Ltd, Royal Holloway, Egham, Surrey, England.
C3 University of London; Royal Holloway University London; University of
   London; Royal Holloway University London; Nottingham University Hospital
   NHS Trust; University of Nottingham; University of London; Royal
   Holloway University London
RP Bradley, C (通讯作者)，Univ London, Royal Holloway, Hlth Psychol Res Unit, Egham, Surrey, England.; Bradley, C (通讯作者)，Univ London, Hlth Psychol Res Ltd, Royal Holloway, Egham, Surrey, England.
EM c.bradley@rhul.ac.uk
OI Boxell, Emily/0000-0002-6499-525X; Bradley, Clare/0000-0002-4079-0364;
   Amoaku, Winfried/0000-0001-5028-7984
FU Macular Society; Alcon Laboratories
FX EB is supported by a PhD studentship funded by the Macular Society to CB
   via Royal Holloway, University of London. The Macular Society reviewed
   and commented on the 2013 survey resulting in the addition of one item
   to be reported elsewhere. They were responsible for printing and posting
   the surveys. The MDSQ 1999 was funded by the Macular Disease Society
   (now the Macular Society) and Alcon Laboratories.
CR Amoaku WMK, 2008, EYE, V22, P864, DOI 10.1038/eye.2008.1
   [Anonymous], 2008, RAN PEG TREATM AG RE
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Burton AE, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003306
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cox TM, 2014, BRIT J OPHTHALMOL, V98, P1236, DOI 10.1136/bjophthalmol-2014-304920
   Croker JE, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002762
   Douglas G, 2010, OPHTHAL PHYSL OPT, V30, P748, DOI 10.1111/j.1475-1313.2010.00784.x
   Elliott MN, 2012, HEALTH SERV RES, V47, P1482, DOI 10.1111/j.1475-6773.2012.01389.x
   Grysman A, 2016, MEM COGNITION, V44, P856, DOI 10.3758/s13421-016-0610-2
   Heje HN, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-178
   Ipsos MORI, 2016, GP PAT SURV NAT SUMM
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   National Institute for Health and Care Excellence, 2013, AFL SOL INJ TREAT WE
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists, 2000, AG REL MAC DEG GUID
   Royal College of Ophthalmologists, 2009, AG REL MAC DEG GUID
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Thi PLN, 2002, SOC SCI MED, V54, P493
   Voutilainen A, 2015, J RES NURS, V20, P698, DOI 10.1177/1744987115619209
NR 27
TC 4
Z9 4
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD FEB
PY 2017
VL 7
IS 2
AR e012790
DI 10.1136/bmjopen-2016-012790
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA EQ2BD
UT WOS:000397872400039
PM 28196945
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Say, EAT
   Melamud, A
   Esserman, DA
   Povsic, TJ
   Chavala, SH
AF Say, Emil Anthony T.
   Melamud, Alex
   Esserman, Denise Ann
   Povsic, Thomas J.
   Chavala, Sai H.
TI Comparative Analysis of Circulating Endothelial Progenitor Cells in
   Age-Related Macular Degeneration Patients Using Automated Rare Cell
   Analysis (ARCA) and Fluorescence Activated Cell Sorting (FACS)
SO PLOS ONE
LA English
DT Article
ID TUMOR-CELLS; POPULATIONS; CANCER
AB Background: Patients with age-related macular degeneration (ARMD) begin with non-neovascular (NNV) phenotypes usually associated with good vision. Approximately 20% of NNV-ARMD patients will convert to vision debilitating neovascular (NV) ARMD, but precise timing of this event is unknown. Developing a clinical test predicting impending conversion to NV-ARMD is necessary to prevent vision loss. Endothelial progenitor cells (EPCs), defined as CD34(+)VEGR2(+) using traditional fluorescence activated cell sorting (FACS), are rare cell populations known to be elevated in patients with NV-ARMD compared to NNV-ARMD. FACS has high inter-observer variability and subjectivity when measuring rare cell populations precluding development into a diagnostic test. We hypothesized that automated rare cell analysis (ARCA), a validated and FDA-approved technology for reproducible rare cell identification, can enumerate EPCs in ARMD patients more reliably. This pilot study serves as the first step in developing methods for reproducibly predicting ARMD phenotype conversion.
   Methods: We obtained peripheral venous blood samples in 23 subjects with NNV-ARMD or treatment naive NV-ARMD. Strict criteria were used to exclude subjects with known angiogenic diseases to minimize confounding results. Blood samples were analyzed in masked fashion in two separate laboratories. EPCs were independently enumerated using ARCA and FACS within 24 hours of blood sample collection, and p < 0.2 was considered indicative of a trend for this proof of concept study, while statistical significance was established at 0.05.
   Results: We measured levels of CD34(+)VEGFR2(+) EPCs suggestive of a trend with higher values in patients with NV compared to NNV-ARMD (p = 0.17) using ARCA. Interestingly, CD34(+)VEGR2(+) EPC analysis using FACS did not produce similar results (p = 0.94).
   Conclusions: CD34(+)VEGR2(+) may have predictive value for EPC enumeration in future ARCA studies. EPC measurements in a small sample size were suggestive of a trend in ARMD using ARCA but not FACS. ARCA could be a helpful tool for developing a predictive test for ARMD phenotype conversion.
C1 [Say, Emil Anthony T.; Chavala, Sai H.] Univ N Carolina Hosp, Kittner Eye Ctr, Chapel Hill, NC 27515 USA.
   [Melamud, Alex] Retina Grp Washington, Washington, DC USA.
   [Esserman, Denise Ann] Univ N Carolina, Dept Med, Div Gen Med & Clin Epidemiol & Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Povsic, Thomas J.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
   [Povsic, Thomas J.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
C3 University North Carolina Hospital; University of North Carolina;
   University of North Carolina Chapel Hill; Duke University; Duke
   University
RP Chavala, SH (通讯作者)，Univ N Carolina Hosp, Kittner Eye Ctr, Chapel Hill, NC 27515 USA.
EM schavala@med.unc.edu
FU Adler Foundation; Hope for Vision Career Development Award; Research to
   Prevent Blindness
FX SHC would like to acknowledge the Adler Foundation, Hope for Vision
   Career Development Award, and Research to Prevent Blindness for
   unrestricted grant support. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Brunner S, 2009, INVEST OPHTH VIS SCI, V50, P392, DOI 10.1167/iovs.08-1748
   Damani S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003451
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur H, 2002, RETINA-J RET VIT DIS, V22, P44, DOI 10.1097/00006982-200202000-00008
   Kraan J, 2011, CYTOM PART B-CLIN CY, V80B, P112, DOI 10.1002/cyto.b.20573
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Machalinska A, 2010, ARCH OPHTHALMOL-CHIC, V128, P1311, DOI 10.1001/archophthalmol.2010.221
   Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744
   Riethdorf S, 2007, CLIN CANCER RES, V13, P920, DOI 10.1158/1078-0432.CCR-06-1695
   Scholtens TM, 2012, CYTOM PART A, V81A, P138, DOI 10.1002/cyto.a.22002
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shaffer DR, 2007, CLIN CANCER RES, V13, P2023, DOI 10.1158/1078-0432.CCR-06-2701
   Strijbos MH, 2009, BLOOD CELL MOL DIS, V43, P63, DOI 10.1016/j.bcmd.2009.02.007
   Thill M, 2008, INVEST OPHTH VIS SCI, V49, P2696, DOI 10.1167/iovs.07-0955
   Van Craenenbroeck EMF, 2008, J IMMUNOL METHODS, V332, P31, DOI 10.1016/j.jim.2007.12.006
NR 17
TC 4
Z9 4
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 24
PY 2013
VL 8
IS 1
AR e55079
DI 10.1371/journal.pone.0055079
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 077JK
UT WOS:000314023600150
PM 23359346
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Wang, X
   Yu, CF
   Yang, JS
   Liu, YZ
   Xu, YL
   Li, WS
AF Wang, Xue
   Yu, Chaofeng
   Yang, Jiasong
   Liu, Yuzhen
   Xu, Yali
   Li, Wensheng
TI Comparison of Efficacy and Safety between Conbercept and Ranibizumab in
   Neovascular Age-Related Macular Degeneration: A Meta-Analysis of
   Randomized Controlled Trials
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Conbercept; Ranibizumab; Age-related macular degeneration; Vascular
   endothelial growth factor; Meta-analysis
ID INFLAMMATION; DISEASES; TARGET
AB Background: Conbercept, as a novel vascular endothelial growth factor (VEGF) inhibitor, was approved for the treatment of neovascular age-related macular degeneration (nAMD) in China. Objective: This study aimed to compare the efficacy and safety between conbercept and ranibizumab in patients with nAMD.
   Methods: Several databases (PubMed, Web of Science, China National Knowledge Infrastructure, and WANFANG) were searched for the results of studies describing conbercept and ranibizumab for the treatment of nAMD. Sixteen randomized controlled trials including 1,224 eyes met our search criteria and were assessed.
   Results: Conbercept and ranibizumab had comparable effects on improving visual acuity at 3 months (standardized mean difference [SMD]: -0.19; 95% confidence interval [CI]: -0.46 to 0.08; p = 0.17) and 6-12 months (SMD: -0.01; 95% CI: -0.20 to 0.18; p = 0.90). At 3 months and 6-12 months, the differences in the change of central macular thickness in conbercept and ranibizumab groups were 1.06 mu m (95% CI: -3.52 to 5.64; p = 0.65) and -0.12 mu m (95% CI: -9.26 to 9.02; p = 0.98). In the short term, there was no significant difference between the 2 groups with respect to ocular adverse events (odds ratio [OR]: 0.86; 95% CI: 0.46-1.61; p = 0.63). No significant differences were observed in the recovery rate of choroidal neovascularization leakage between conbercept and ranibizumab at both 3 months (OR: 1.49; 95% CI: 0.83-2.68; p = 0.18) and 6-12 months (OR: 0.66; 95% CI: 0.18-2.43; p = 0.53). There were significant differences between conbercept and ranibizumab in terms of decreasing intraocular pressure (weighted mean difference [WMD]: -1.74; 95% CI: -2.28 to -1.20; p < 0.00001), the plasma VEGF level (WMD: -21.49; 95% CI: -26.28 to -16.70; p < 0.00001), and the C-reactive protein level (WMD: -1.16; 95% CI: -1.45 to -0.87; p < 0.00001) in the short term.
   Conclusion: Conbercept was similar to ranibizumab in terms of efficacy and safety for the treatment of nAMD in China. Further studies with longer term observation are needed to support this conclusion.
   (c) 2021 The Author(s).Published by S. Karger AG, Basel
C1 [Wang, Xue; Yu, Chaofeng; Yang, Jiasong; Liu, Yuzhen; Xu, Yali; Li, Wensheng] Cent South Univ, Aier Sch Ophthalmol, Changsha, Peoples R China.
   [Li, Wensheng] Shanghai Aier Eye Hosp, Shanghai, Peoples R China.
C3 Central South University
RP Li, WS (通讯作者)，Cent South Univ, Aier Sch Ophthalmol, Changsha, Peoples R China.; Li, WS (通讯作者)，Shanghai Aier Eye Hosp, Shanghai, Peoples R China.
EM drlws@qq.com
FU Natural Science Foundation of Hunan Province [2020JJ4143]
FX This work was supported by the Natural Science Foundation of Hunan
   Province (No. 2020JJ4143 [W.L.]).
CR Bai F, 2020, CHIN J GERONTOL, V40, P826
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Bertaud S, 2019, REV MED INTERNE, V40, P445, DOI 10.1016/j.revmed.2018.12.001
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Chen YT, 2018, J OCUL PHARMACOL TH, V34, P235, DOI 10.1089/jop.2017.0097
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Havens SJ, 2016, DEV OPHTHALMOL, V55, P196, DOI 10.1159/000431196
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Hozo S.P., 2005, BMC MED RES METHODOL, V5, DOI DOI 10.1186/1471-2288-5-13
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin EZ, 2017, RETINA-J RET VIT DIS, V37, P971, DOI 10.1097/IAE.0000000000001274
   Jin J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0812-4
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lei JP, 2018, CHIN J URBAN RURAL I
   Liang XD., 2019, J GUANGDONG MED COLL, V37, P207
   Liu GH, 2018, J CLIN MED, V72, P98
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   [刘瑞 Liu Rui], 2015, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V35, P104
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Lv P., 2016, J COMMUNITY MED, V14, P30
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Rodrigues Gustavo B, 2016, Int J Retina Vitreous, V2, P26
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shen ZX, 2017, CHIN J PRACT OPHTHAL, V6, P563
   Shibuya M, 2015, ENDOCR METAB IMMUNE, V15, P135, DOI 10.2174/1871530315666150316121956
   Shu BJ, 2018, J CLIN MED PRACT, V17, P93
   Tong T, 2019, CHIN MOD MED, V26, P163
   Wang LP, 2018, DRUG DES DEV THER, V12, P3625, DOI 10.2147/DDDT.S176021
   Wang NF., 2017, CHIN HLTH CARE NUTR, V27, P192
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wei YL., 2018, PROG MOD BIOMED, V18, P1515
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Xu Y, 2019, PUBLIC MED FORUM MAG, V25, P3613
   Xue BQ, 2019, J N PHARM, V3
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhang LL., 2017, J CHANGZHI MED COLL, V3, P209
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
   Zhang YJ., 2018, CHIN J HOSP PHARM, V38, P412, DOI DOI 10.13286/j.cnki.chinhosppharmacyj.2018.04.14
   Zhao M, 2015, VALUE HEALTH, V18, pA421, DOI 10.1016/j.jval.2015.09.558
   Zheng MW., 2017, J MATH MED, V30, P228
NR 52
TC 0
Z9 0
U1 2
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD APR
PY 2022
VL 65
IS 2
BP 140
EP 151
DI 10.1159/000519815
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1H2TD
UT WOS:000796398000003
PM 34583363
OA hybrid
DA 2022-11-30
ER

PT J
AU Llorente-Gonzalez, S
   Hernandez, M
   Gonzalez-Zamora, J
   Bilbao-Malave, V
   Fernandez-Robredo, P
   Saenz-de-Viteri, M
   Barrio-Barrio, J
   Rodriguez-Cid, MJ
   Donate, J
   Ascaso, FJ
   Gomez-Ramirez, AM
   Araiz, J
   Armada, F
   Ruiz-Moreno, O
   Recalde, S
   Garcia-Layana, A
AF Llorente-Gonzalez, Sara
   Hernandez, Maria
   Gonzalez-Zamora, Jorge
   Bilbao-Malave, Valentina
   Fernandez-Robredo, Patricia
   Saenz-de-Viteri, Manuel
   Barrio-Barrio, Jesus
   Rodriguez-Cid, Maria Jose
   Donate, Juan
   Ascaso, Francisco J.
   Gomez-Ramirez, Ana M.
   Araiz, Javier
   Armada, Felix
   Ruiz-Moreno, Oscar
   Recalde, Sergio
   Garcia-Layana, Alfredo
CA Spanish AMD Grp
TI The role of retinal fluid location in atrophy and fibrosis evolution of
   patients with neovascular age-related macular degeneration long-term
   treated in real world
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE macular atrophy; retinal fluid location; subretinal fibrosis; nAMD
ID VISUAL-ACUITY; PREDICTORS; OUTCOMES; AMD
AB Purpose To assess the effect of clinical factors on the development and progression of atrophy and fibrosis in patients with neovascular age-related macular degeneration (nAMD) receiving long-term treatment in the real world.
   Methods An ambispective 36-month multicentre study, involving 359 nAMD patients from 17 Spanish hospitals treated according to the Spanish Vitreoretinal Society guidelines, was designed. The influence of demographic and clinical factors, including the presence and location of retinal fluid, on best-corrected visual acuity (BCVA) and progression to atrophy and/or fibrosis were analysed.
   Results After 36 months of follow-up and an average of 13.8 anti-VEGF intravitreal injections, the average BCVA gain was +1.5 letters, and atrophy and/or fibrosis were present in 54.8% of nAMD patients (OR = 8.54, 95% CI = 5.85-12.47, compared to baseline). Atrophy was associated with basal intraretinal fluid (IRF) (OR = 1.87, 95% CI = 1.09-3.20), whereas basal subretinal fluid (SRF) was associated with a lower rate of atrophy (OR = 0.40, 95% CI = 0.23-0.71) and its progression (OR = 0.44, 95% CI = 0.26-0.75), leading to a slow progression rate (OR = 0.34, 95% CI = 0.14-0.83). Fibrosis development and progression were related to IRF at any visit (p < 0.001). In contrast, 36-month SRF was related to a lower rate of fibrosis (OR = 0.49, 95% CI = 0.29-0.81) and its progression (OR = 0.50, 95% CI = 0.31-0.81).
   Conclusion Atrophy and/or fibrosis were present in 1 of 2 nAMD patients treated for 3 years. Both, especially fibrosis, lead to vision loss. Subretinal fluid (SRF) was associated with good visual outcomes and lower rates of atrophy and fibrosis, whereas IRF yields worse visual results and a higher risk of atrophy and especially fibrosis in routine clinical practice.
C1 [Llorente-Gonzalez, Sara; Bilbao-Malave, Valentina] Clin Univ Navarra, Dept Ophthalmol, Madrid, Spain.
   [Llorente-Gonzalez, Sara; Hernandez, Maria; Fernandez-Robredo, Patricia; Saenz-de-Viteri, Manuel; Recalde, Sergio; Garcia-Layana, Alfredo] Clin Univ Navarra, Dept Ophthalmol, Retinal Pathol & New Therapies Grp, Expt Ophthalmol Lab, Pamplona, Spain.
   [Llorente-Gonzalez, Sara; Hernandez, Maria; Fernandez-Robredo, Patricia; Saenz-de-Viteri, Manuel; Barrio-Barrio, Jesus; Donate, Juan; Araiz, Javier; Recalde, Sergio; Garcia-Layana, Alfredo] Clin Univ Navarra, Hlth Inst Carlos III, Dept Ophthalmol, Themat Network Cooperat Hlth Res Eye Dis Oftared, Pamplona, Spain.
   [Hernandez, Maria; Fernandez-Robredo, Patricia; Barrio-Barrio, Jesus; Recalde, Sergio; Garcia-Layana, Alfredo] IdiSNA, Navarra Inst Hlth Res, Pamplona, Spain.
   [Gonzalez-Zamora, Jorge; Bilbao-Malave, Valentina; Saenz-de-Viteri, Manuel; Barrio-Barrio, Jesus] Clin Univ Navarra, Dept Ophthalmol, Pamplona, Spain.
   [Rodriguez-Cid, Maria Jose] Complexo Hosp Univ Santiago, Santiago De Compostela, Spain.
   [Donate, Juan] Hosp Clin San Carlos, Madrid, Spain.
   [Ascaso, Francisco J.] Hosp Clin Univ Lozano Blesa, Dept Ophthalmol, Zaragoza, Spain.
   [Ascaso, Francisco J.] Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza, Spain.
   [Gomez-Ramirez, Ana M.] Hosp Gen Univ Reina Sofia Murcia, Murcia, Spain.
   [Araiz, Javier] Hosp San Eloy, Bilbao, Spain.
   [Armada, Felix] Hosp Univ La Paz, Madrid, Spain.
   [Ruiz-Moreno, Oscar] IIS Aragon, Hosp Univ Miguel Servet, Zaragoza, Spain.
   [Ruiz-Moreno, Oscar] Grp Invest & Innovac Miguel Servet Oftalmol GIMSO, Zaragoza, Spain.
C3 University of Navarra; University of Navarra; University of Navarra;
   University of Navarra; Complexo Hospitalario Universitario de Santiago
   de Compostela; Hospital Clinico San Carlos; Lozano Blesa University
   Clinical Hospital; Hospital Universitario La Paz; Miguel Servet
   University Hospital
RP Fernandez-Robredo, P (通讯作者)，Expt Ophthalmol Lab, Irunlarrea 1,Los Castanos Bldg, Pamplona 31008, Navarra, Spain.
EM pfrobredo@unav.es
RI Marín Méndez, Juan Jesús/AGA-7380-2022; Barrio-Barrio,
   Jesus/AAW-5511-2021
OI Marín Méndez, Juan Jesús/0000-0002-7746-6365; Barrio-Barrio,
   Jesus/0000-0002-0654-0249; DONATE, JUAN/0000-0002-9944-6736; Gonzalez
   Zamora, Jorge/0000-0002-2826-6842; LLORENTE GONZALEZ,
   SARA/0000-0001-8815-4757; Saenz-de-Viteri, Manuel/0000-0002-9375-4535
CR Arias-Barquet L, 2016, PROTOCOLO DIAGNOSTIC, P5
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bilbao-Malave V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236071
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Galvez MIL, 2020, ACTA OPHTHALMOL, V98, pE820, DOI 10.1111/aos.14399
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Ruiz Moreno J., 2012, TRATAMIENTO DEGENERA
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Saenz-de-Viteri M, 2021, ACTA OPHTHALMOL, V99, P861, DOI 10.1111/aos.14786
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Stone RA, 2001, INVEST OPHTH VIS SCI, V42, P557
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 28
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2022
VL 100
IS 2
BP E521
EP E531
DI 10.1111/aos.14905
EA JUN 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YX9MP
UT WOS:000657637600001
PM 34085771
OA Green Published
DA 2022-11-30
ER

PT J
AU Lazzeri, S
   Ripandelli, G
   Sartini, MS
   Parravano, M
   Varano, M
   Nardi, M
   Di Desidero, T
   Orlandi, P
   Bocci, G
AF Lazzeri, Stefano
   Ripandelli, Guido
   Sartini, Maria Sole
   Parravano, Mariacristina
   Varano, Monica
   Nardi, Marco
   Di Desidero, Teresa
   Orlandi, Paola
   Bocci, Guido
TI Aflibercept administration in neovascular age-related macular
   degeneration refractory to previous anti-vascular endothelial growth
   factor drugs: a critical review and new possible approaches to move
   forward
SO ANGIOGENESIS
LA English
DT Review
DE Aflibercept; Resistant wet AMD; Recurrent exudative AMD; Intravitreal
   injections; Anti-VEGF drug
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ANTI-VEGF THERAPY; PIGMENT EPITHELIAL
   DETACHMENTS; INTRAVITREAL AFLIBERCEPT; 2.0 MG; CLINICAL CHARACTERISTICS;
   ANATOMICAL OUTCOMES; LESION SIZE; RANIBIZUMAB; BEVACIZUMAB
AB The recent introduction of anti-VEGF drugs has widely changed the prognosis of exudative age-related macular degeneration (AMD), even if a variable percentage of patients showed an insufficient response. Aflibercept is a new anti-VEGF drug approved by FDA for the treatment of exudative AMD with a wider binding capacity than either bevacizumab or ranibizumab. Therefore, the purposes were as follows: (i) to report anatomical and functional outcomes of switching from bevacizumab/ranibizumab to aflibercept previously described in the scientific literature, (ii) to hypothesize the possible pathophysiological mechanisms of the resistance and tachyphylaxis to anti-VEGF drugs, and (iii) to suggest possible clinical actions to increase the chances of success for such difficult cases.
   We reviewed the available scientific literature in Medline, Cochrane database, Current Contents, PubMed, and cross-referencing from identified articles, regarding the treatment of exudative AMD patients refractory to bevacizumab and/or ranibizumab and switched to aflibercept monotherapy. We included in this review all the cases in which the diagnosis of refractory or resistant exudative AMD was properly made, and the results of at least one aflibercept injection were described.
   We reported the outcomes of 21 papers for a total of 1066 eyes affected by exudative AMD resistant to previous anti-VEGF drug injections and switched to aflibercept. Enrolled reports were divided into two groups: 5 prospective reports and 16 retrospective reports. All the reported papers conclude their analysis, stating that switching from bevacizumab/ranibizumab to aflibercept injections can improve outcomes successfully in refractory neovascular AMD patients.
   Analysis of the papers reported in this review demonstrates that switching from bevacizumab/ranibizumab to aflibercept injections can improve outcomes successfully in refractory neovascular AMD patients. The mechanism for these effects is not yet completely understood.
C1 [Lazzeri, Stefano; Sartini, Maria Sole; Nardi, Marco] Univ Pisa, Univ Ophthalmol, Dept Surg Med & Mol Pathol & Crit Area, Operat Unit, I-56126 Pisa, Italy.
   [Lazzeri, Stefano; Ripandelli, Guido; Parravano, Mariacristina; Varano, Monica] IRCCS, Bietti Fdn, Rome, Italy.
   [Di Desidero, Teresa; Orlandi, Paola; Bocci, Guido] Univ Pisa, Scuola Med, Dept Clin & Expt Med, Div Pharmacol, I-56126 Pisa, Italy.
C3 University of Pisa; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia; University of Pisa
RP Bocci, G (通讯作者)，Univ Pisa, Scuola Med, Dept Clin & Expt Med, Div Pharmacol, Via Roma 55, I-56126 Pisa, Italy.
EM guido.bocci@med.unipi.it
RI Bocci, Guido/AAC-7515-2022
OI Di Desidero, Teresa/0000-0002-5487-071X; Varano,
   Monica/0000-0002-6530-1563
CR Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Broadhead GK, 2015, RETINA
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chaikitmongkol V, 2013, JAMA OPHTHALMOL, V131, P260, DOI 10.1001/jamaophthalmol.2013.1733
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Chong V, 2012, OPHTHALMOLOGICA, V227, P2, DOI 10.1159/000337152
   Dias JRD, 2015, OSLI RETINA, V46, P91, DOI 10.3928/23258160-20150101-17
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Eadie JA, 2014, OSLI RETINA, V45, P394, DOI 10.3928/23258160-20140909-03
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fassnacht-Riederle H, 2014, GRAEFES ARCH CLIN EX
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujii A, 2014, CLIN OPHTHALMOL, V8, P1199, DOI 10.2147/OPTH.S65810
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Griffin DR, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/497178
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hahn P, 2014, CLIN OPHTHALMOL, V8, P2129, DOI 10.2147/OPTH.S73265
   Hall LB, 2014, J OCUL PHARM THER
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2013, GRAEFES ARCH CLIN EX
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Hoffman B.B., 2001, GOODMAN GILMANS PHAR, P115
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kawashima Y, 2014, GRAEFES ARCH CLIN EX, V2014
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P1239, DOI 10.2217/pgs.13.100
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Leveziel N, 2013, ASS RES VIS OPHTH AR
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Michalewski J, 2014, CAN J OPHTHALMOL, V49, P431, DOI 10.1016/j.jcjo.2014.07.012
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park UC, 2014, MOL VIS, V20, P1680
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Rusu IM, 2014, RETINA-J RET VIT DIS, V34, P2161, DOI 10.1097/IAE.0000000000000264
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Wykoff CC, 2014, BR J OPHTHALMOL
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yonekawa Y, 2013, CAN J OPHTHALMOL, V48, pE59, DOI 10.1016/j.jcjo.2012.12.015
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
NR 85
TC 25
Z9 30
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD OCT
PY 2015
VL 18
IS 4
BP 397
EP 432
DI 10.1007/s10456-015-9483-4
PG 36
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA CT3CF
UT WOS:000362683200003
PM 26346237
DA 2022-11-30
ER

PT J
AU Thomas, DS
   Warwick, A
   Olvera-Barrios, A
   Egan, C
   Schwartz, R
   Patra, S
   Eleftheriadis, H
   Khawaja, A
   Lotery, A
   Muller, PL
   Hamilton, R
   Preston, E
   Taylor, P
   Tufail, A
AF Thomas, Darren S.
   Warwick, Alasdair
   Olvera-Barrios, Abraham
   Egan, Catherine
   Schwartz, Roy
   Patra, Sudeshna
   Eleftheriadis, Haralabos
   Khawaja, Anthony
   Lotery, Andrew
   Muller, Philipp L.
   Hamilton, Robin
   Preston, Ella
   Taylor, Paul
   Tufail, Adnan
CA UK EMR Users Grp
TI Estimating excess visual loss from neovascular age-related macular
   degeneration in the UK during the COVID-19 pandemic: a retrospective
   clinical audit and simulation model
SO BMJ OPEN
LA English
DT Article
DE COVID-19; public health; ophthalmology
ID RANIBIZUMAB
AB Objectives To report the reduction in new neovascular age-related macular degeneration (nAMD) referrals during the COVID-19 pandemic and estimate the impact of delayed treatment on visual outcomes at 1 year. Design Retrospective clinical audit and simulation model. Setting Multiple UK National Health Service (NHS) ophthalmology centres. Participants Data on the reduction in new nAMD referrals were obtained from four NHS Trusts comparing April 2020 with April 2019. To estimate the potential impact on 1-year visual outcomes, a stratified bootstrap simulation model was developed drawing on an electronic medical records dataset of 20 825 nAMD eyes from 27 NHS Trusts. Main outcome measures Simulated mean visual acuity and proportions of eyes with vision <= 6/60, <= 6/24 and >= 6/12 at 1 year under four hypothetical scenarios: 0-month, 3-month, 6-month and 9-month treatment delays. Estimated additional number of eyes with vision <= 6/60 at 1 year nationally. Results The number of nAMD referrals dropped on average by 72% (range 65%-87%). Simulated 1-year visual outcomes for 1000 nAMD eyes with a 3-month treatment delay suggested an increase in the proportion of eyes with vision <= 6/60 from 15.5% (13.2%-17.9%) to 23.3% (20.7%-25.9%), and a decrease in the proportion of eyes with vision >= 6/12 (driving vision) from 35.1% (32.1%-38.1%) to 26.4% (23.8%-29.2%). Outcomes worsened incrementally with longer modelled delays. Assuming nAMD referrals are reduced to this level for 1 month nationally, these simulated results suggest an additional 186-365 eyes with vision <= 6/60 at 1 year. Conclusions We report a large decrease in nAMD referrals during the COVID-19 lockdown and provide an important public health message regarding the risk of delayed treatment. As a conservative estimate, a treatment delay of 3 months could lead to a >50% relative increase in the number of eyes with vision <= 6/60 and 25% relative decrease in the number of eyes with driving vision at 1 year.
C1 [Thomas, Darren S.; Taylor, Paul] UCL, Inst Hlth Informat, London, England.
   [Warwick, Alasdair] UCL, Inst Cardiovasc Sci, London, England.
   [Warwick, Alasdair; Olvera-Barrios, Abraham; Egan, Catherine; Schwartz, Roy; Khawaja, Anthony; Muller, Philipp L.; Hamilton, Robin; Preston, Ella; Tufail, Adnan] Moorfields Eye Hosp NHS Fdn Trust, Moorfields Eye Hosp, London, England.
   [Olvera-Barrios, Abraham; Egan, Catherine; Schwartz, Roy; Khawaja, Anthony; Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Patra, Sudeshna] Barts Hlth NHS Trust, Ophthalmol, London, England.
   [Eleftheriadis, Haralabos] Kings Coll Hosp NHS Fdn Trust, Ophthalmol, London, England.
   [Lotery, Andrew] Univ Southampton, Fac Med Clin & Expt Sci, Southampton, Hants, England.
   [Lotery, Andrew] Univ Hosp Southampton NHS Fdn Trust, Southampton Eye Unit, Southampton, Hants, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; Barts Health NHS Trust; King's
   College Hospital NHS Foundation Trust; University of Southampton;
   University of Southampton; University Hospital Southampton NHS
   Foundation Trust
RP Tufail, A (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, Moorfields Eye Hosp, London, England.; Tufail, A (通讯作者)，UCL, Inst Ophthalmol, London, England.
EM Adnan.tufail@nhs.net
RI Olvera-Barrios, Abraham/AAG-1197-2020; Olvera-Barrios,
   Abraham/GQH-4711-2022
OI Olvera-Barrios, Abraham/0000-0002-3305-4465; Olvera-Barrios,
   Abraham/0000-0002-3305-4465; Talks, James/0000-0001-6126-6476; Tufail,
   Adnan/0000-0001-6131-7640; Khawaja, Anthony/0000-0001-6802-8585
FU Department of Health's NIHR Biomedical Research Centre for Ophthalmology
   at Moorfields Eye Hospital; UCL Institute of Ophthalmology; UCL Wellcome
   Trust PhD Programme for Clinicians [220558/Z/20/Z]; German Research
   Foundation [MU4279/2--1]; Novartis Pharmaceutical
FX AT, CE and RS received a proportion of their funding from the Department
   of Health's NIHR Biomedical Research Centre for Ophthalmology at
   Moorfields Eye Hospital and UCL Institute of Ophthalmology. AW is
   supported by the UCL Wellcome Trust PhD Programme for Clinicians
   (220558/Z/20/Z). PLM is supported by the German Research Foundation
   (grant #MU4279/2--1). Data collection was funded by a grant from
   Novartis Pharmaceutical.
CR [Anonymous], 2021, R LANGUAGE ENV STAT
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Chen FK, 2014, ASIA-PAC J OPHTHALMO, V3, P277, DOI 10.1097/APO.0000000000000007
   European Centre for Disease Prevention and Control, 2020, ASSESSMENT UPDATE, DOI DOI 10.1002/AU.30219
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Lai AG, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-043828
   Lanzetta P, 2018, ACTA OPHTHALMOL, V96, pE911, DOI 10.1111/aos.13751
   NHS Digital, HOSP OUTP ACT 2018 1
   Ophthalmologists RCo, PROTECTING PATIENTS
   Ophthalmologists RCo, MED RET MAN PLANS CO
   Ophthalmologists. RCo0, REOP RED OPHTH SERV
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Prime Minister's Office DS, 2020, PM STAT COR
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tufail A, 2020, BRIT J OPHTHALMOL, V104, P672, DOI 10.1136/bjophthalmol-2018-313682
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   UK DoHaSC, 2017, CERT VIS IMP EXPL NO
   West, 2020, HEALTH SERV J
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD APR
PY 2022
VL 12
IS 4
AR e057269
DI 10.1136/bmjopen-2021-057269
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0O9KM
UT WOS:000783842400012
PM 35428639
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Taylor, J
   Scott, LJ
   Rogers, CA
   Muldrew, A
   O'Reilly, D
   Wordsworth, S
   Mills, N
   Hogg, R
   Violato, M
   Harding, SP
   Peto, T
   Townsend, D
   Chakravarthy, U
   Reeves, BC
AF Taylor, J.
   Scott, L. J.
   Rogers, C. A.
   Muldrew, A.
   O'Reilly, D.
   Wordsworth, S.
   Mills, N.
   Hogg, R.
   Violato, M.
   Harding, S. P.
   Peto, T.
   Townsend, D.
   Chakravarthy, U.
   Reeves, B. C.
TI The design and implementation of a study to investigate the
   effectiveness of community vs hospital eye service follow-up for
   patients with neovascular age-related macular degeneration with
   quiescent disease
SO EYE
LA English
DT Article
ID SHARED CARE; RANIBIZUMAB; OPTOMETRISTS; MANAGEMENT; GLAUCOMA;
   OPHTHALMOLOGISTS; HORIZON
AB Introduction Standard treatment for neovascular age-related macular degeneration (nAMD) is intravitreal injections of anti-VEGF drugs. Following multiple injections, nAMD lesions often become quiescent but there is a high risk of reactivation, and regular review by hospital ophthalmologists is the norm. The present trial examines the feasibility of community optometrists making lesion reactivation decisions.
   Methods The Effectiveness of Community vs Hospital Eye Service (ECHoES) trial is a virtual trial; lesion reactivation decisions were made about vignettes that comprised clinical data, colour fundus photographs, and optical coherence tomograms displayed on a web-based platform. Participants were either hospital ophthalmologists or community optometrists. All participants were provided with webinar training on the disease, its management, and assessment of the retinal imaging outputs. In a balanced design, 96 participants each assessed 42 vignettes; a total of 288 vignettes were assessed seven times by each professional group.
   The primary outcome is a participant's judgement of lesion reactivation compared with a reference standard. Secondary outcomes are the frequency of sight threatening errors; judgements about specific lesion components; participant-rated confidence in their decisions about the primary outcome; cost effectiveness of follow-up by optometrists rather than ophthalmologists.
   Discussion This trial addresses an important question for the NHS, namely whether, with appropriate training, community optometrists can make retreatment decisions for patients with nAMD to the same standard as hospital ophthalmologists. The trial employed a novel approach as participation was entirely through a web-based application; the trial required very few resources compared with those that would have been needed for a conventional randomised controlled clinical trial.
C1 [Taylor, J.; Scott, L. J.; Rogers, C. A.; Reeves, B. C.] Univ Bristol, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol BS2 8HW, Avon, England.
   [Muldrew, A.; Hogg, R.; Chakravarthy, U.] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [O'Reilly, D.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Wordsworth, S.; Violato, M.] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.
   [Mills, N.; Townsend, D.] Univ Bristol, Unit Hlth Care Res, Sch Social & Community Med, Bristol BS2 8HW, Avon, England.
   [Harding, S. P.] Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England.
   [Peto, T.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
C3 University of Bristol; Queens University Belfast; Queens University
   Belfast; University of Oxford; University of Bristol; University of
   Liverpool; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust
RP Reeves, BC (通讯作者)，Univ Bristol, Bristol Royal Infirm, Clin Trials & Evaluat Unit, Sch Clin Sci, Bristol BS2 8HW, Avon, England.
EM Barney.Reeves@bristol.ac.uk
RI Hogg, Ruth E./ABC-9602-2020; Peto, Tunde/G-8812-2018
OI Hogg, Ruth E./0000-0001-9413-2669; Peto, Tunde/0000-0001-6265-0381;
   Violato, Mara/0000-0002-0484-7706; Reeves, Barnaby/0000-0002-5101-9487;
   Elliott, Daisy/0000-0001-8143-9549; Chakravarthy,
   Usha/0000-0002-2606-3734; Mills, Nicola/0000-0002-2960-2940
FU National Institute for Health Research Technology Assessment programme
   [11/129/195]; ESRC [ES/L007509/1] Funding Source: UKRI; MRC
   [MR/K025643/1] Funding Source: UKRI; Economic and Social Research
   Council [ES/L007509/1] Funding Source: researchfish; Medical Research
   Council [MC_CF023241, MR/K025643/1] Funding Source: researchfish;
   National Institute for Health Research [NF-SI-0514-10114] Funding
   Source: researchfish; Public Health Agency [STL/4918/13] Funding Source:
   researchfish
FX This study is funded by The National Institute for Health Research
   Technology Assessment programme (ref: 11/129/195). The funder has no
   role in the design of the study, in the collection, analysis and
   interpretation of data, or in the decision to submit the manuscript for
   publication. We would like to thank Michelle McGaughey for her
   assistance in setting up and running the webinar training sessions, and
   Heike Cappel-Porter for designing and maintaining the web application.
   The views and opinions expressed are those of the authors and do not
   necessarily reflect those of the HTA programme, the NIHR, the United
   Kingdom NHS or the Department of Health.
CR Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Banes MJ, 2006, BRIT J OPHTHALMOL, V90, P579, DOI 10.1136/bjo.2005.082388
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cameron JR, 2009, EYE, V23, P1134, DOI 10.1038/eye.2008.196
   Chakravarthy U, 2015, HLTH TECHNO IN PRESS
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cochran W. G., 1992, EXPT DESIGNS, P611
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Gray SF, 2000, BRIT J OPHTHALMOL, V84, P456, DOI 10.1136/bjo.84.5.456
   Hau S, 2007, BRIT J OPHTHALMOL, V91, P437, DOI 10.1136/bjo.2006.105593
   Husereau D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-80
   Ivan SI, 2012, OPHTHALMOLOGY, V119, P1399, DOI DOI 10.1016/J.0PHTHA.2012.04.015
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   Konstantakopoulou E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004781
   Myint J, 2010, OPHTHAL PHYSL OPT, V30, P847, DOI 10.1111/j.1475-1313.2010.00792.x
   National Institute of health and Care Excellence, 2013, GUID METH TECHN APPR
   O'Connor PM, 2012, MED J AUSTRALIA, V196, P646, DOI 10.5694/mja11.10856
   Petrou S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1548
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 24
TC 3
Z9 3
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2016
VL 30
IS 1
BP 68
EP 78
DI 10.1038/eye.2015.170
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA5PW
UT WOS:000367856000011
PM 26449197
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Claxton, L
   Hodgson, R
   Taylor, M
   Malcolm, B
   Jacob, RP
AF Claxton, Lindsay
   Hodgson, Robert
   Taylor, Matthew
   Malcolm, Bill
   Jacob, Ruth Pulikottil
TI Simulation Modelling in Ophthalmology: Application to Cost Effectiveness
   of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related
   Macular Degeneration in the United Kingdom
SO PHARMACOECONOMICS
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL-ACUITY; EYES
AB Background Previously developed models in ophthalmology have generally used a Markovian structure. There are a number of limitations with this approach, most notably the ability to base patient outcomes on best-corrected visual acuity (BCVA) in both eyes, which may be overcome using a different modelling structure. Simulation modelling allows for this to be modelled more precisely, and therefore may provide more accurate and relevant estimates of the cost effectiveness of ophthalmology interventions.
   Objective This study aimed to explore the appropriateness of simulation modelling in ophthalmology, using the disease area of wet age-related macular degeneration (wAMD) as an example.
   Methods A de novo economic model was built using a patient-level simulation, which compared ranibizumab with aflibercept in wAMD. Disease progression was measured using BCVA. Health-related quality of life (HRQoL) was estimated using a regression analysis linking BCVA in each eye to utility. The analysis was from the perspective of the National Health Service in the UK. Five different regression models were explored and were based on BCVA in either one eye or both eyes.
   Results The model outputs provide some evidence to support the hypothesis that the analyses using the two-eye models for estimating HRQoL generate a more accurate estimation of incremental quality-adjusted life-years (QALYs) associated with the positive treatment effect for ranibizumab versus aflibercept. Second-order analysis broadly supported these findings, and showed that the variation in incremental costs was slightly lower than in incremental QALYs. The second-order analysis estimated similar incremental costs and a greater overall variation in incremental QALYs than the first-order analysis, suggesting important non-linearities within the model.
   Conclusions This analysis suggests that patient-level simulation models may be well suited to representing the real-world patient pathway in wAMD, particularly when aspects of disease progression cannot be adequately captured using a Markov structure. The benefits of a simulation approach can be demonstrated in the modelling of HRQoL as a function of BCVA in both eyes.
C1 [Claxton, Lindsay; Hodgson, Robert; Taylor, Matthew] Univ York, York Hlth Econ Consortium, York, N Yorkshire, England.
   [Malcolm, Bill; Jacob, Ruth Pulikottil] Novartis Pharmaceut UK Ltd, Frimley Business Pk, Surrey, England.
C3 University of York - UK; Novartis
RP Claxton, L (通讯作者)，Univ York, York Hlth Econ Consortium, York, N Yorkshire, England.
EM lindsay.claxton@york.ac.uk
OI Pulikottil-Jacob, Ruth/0000-0003-0630-960X; Hodgson,
   Robert/0000-0001-6962-2893
FU Novartis
FX The original regression analysis of the Czoski-Murray quality of life
   dataset was undertaken by David Trueman and Tim Reason at Abacus
   International, and was funded by Novartis.
CR [Anonymous], 2015, NAT LIF TABL UK 2012
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bayer, 2013, AFL SOL INJ TREAT WE
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 1998, INT OPHTHALMOL, V22, P307, DOI 10.1023/A:1006311910304
   Butt T, 2014, APPL HEALTH ECON HEA, V12, P289, DOI 10.1007/s40258-014-0090-0
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Christ SL, 2008, INVEST OPHTH VIS SCI, V49, P3318, DOI 10.1167/iovs.08-1676
   Claxton L, 2014, INT SOC PHARM OUTC R
   Colquitt JL, 2006, RANIBIZUMAB PEGAPTAN
   Cummins E, 2013, RANIBIZUMAB TREATMEN
   Cummins E, 2013, AFLIBERCEPT SOLUTION
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Davis S, 2014, 15 NICE DSU
   Ding Y, 2013, STAT MED, V32, P2613, DOI 10.1002/sim.5688
   Edwards SJ, 2011, RANIBIZUMAB TREATMEN
   ELLIOTT DB, 1995, OPTOMETRY VISION SCI, V72, P186, DOI 10.1097/00006324-199503000-00006
   Fielding S, 2014, AFLIBERCEPT TREATING
   FRISEN L, 1981, A GRAEF ARCH KLIN EX, V215, P149, DOI 10.1007/BF00413146
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Koehler E, 2009, AM STAT, V63, P155, DOI 10.1198/tast.2009.0030
   Malcolm WAHR, 2015, ISPOR 20 ANN INT M P
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   National Institute for Health and Care Excellence, 2008, RAN PEG TREATM WET A
   National Institute for Health and Care Excellence, 2013, AFL SOL INJ TREAT WE
   Novartis Pharmaceuticals UK Limited, LUCENTIS SUMM PROD C
   PSSRU, 2014, UNIT COSTS HLTH SOCI
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Shyangdan D, 2010, DEXAMETHASONE IMPLAN
   Shyangdan DS, 2013, AFLIBERCEPT TREATING
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 35
TC 12
Z9 12
U1 0
U2 10
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-7690
EI 1179-2027
J9 PHARMACOECONOMICS
JI Pharmacoeconomics
PD FEB
PY 2017
VL 35
IS 2
BP 237
EP 248
DI 10.1007/s40273-016-0459-z
PG 12
WC Economics; Health Care Sciences & Services; Health Policy & Services;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services; Pharmacology &
   Pharmacy
GA EJ3LU
UT WOS:000393114500009
PM 27787744
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ozawa, Y
   Shigeno, Y
   Nagai, N
   Suzuki, M
   Kurihara, T
   Minami, S
   Hirano, E
   Shinoda, H
   Kobayashi, S
   Tsubota, K
AF Ozawa, Yoko
   Shigeno, Yuta
   Nagai, Norihiro
   Suzuki, Misa
   Kurihara, Toshihide
   Minami, Sakiko
   Hirano, Eri
   Shinoda, Hajime
   Kobayashi, Saori
   Tsubota, Kazuo
TI Absolute and estimated values of macular pigment optical density in
   young and aged Asian participants with or without age-related macular
   degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Macular pigment; Retina; Lutein; Zeaxanthin; Age-related macular
   degeneration; Heterochromatic flicker photometry
ID FUNCTIONAL VISUAL-ACUITY; LUTEIN; SERUM; ASSOCIATION; CAROTENOIDS
AB Background: Lutein and zeaxanthin are suggested micronutrient supplements to prevent the progression of age-related macular degeneration (AMD), a leading cause of blindness worldwide. To monitor the levels of lutein/zeaxanthin in the macula, macular pigment optical density (MPOD) is measured. A commercially available device (MPSII (R), Elektron Technology, Switzerland), using technology based on heterochromatic flicker photometry, can measure both absolute and estimated values of MPOD. However, whether the estimated value is applicable to Asian individuals and/or AMD patients remains to be determined.
   Methods: The absolute and estimated values of MPOD were measured using the MPSII (R) device in 77 participants with a best-corrected visual acuity (BCVA) > 0.099 (logMAR score).
   Results: The studied eyes included 17 young (20-29 years) healthy, 26 aged (> 50 years) healthy, 18 aged and AMD-fellow, and 16 aged AMD eyes. The mean BCVA among the groups were not significantly different. Both absolute and estimated values were measurable in all eyes of young healthy group. However, absolute values were measurable in only 57.7%, 66.7%, and 43.8%, of the aged healthy, AMD-fellow, and AMD groups, respectively, and 56.7% of the eyes included in the 3 aged groups. In contrast, the estimated value was measurable in 84.6%, 88.9% and 93.8% of the groups, respectively, and 88.3% of eyes in the pooled aged group. The estimated value was correlated with absolute value in individuals from all groups by Spearman's correlation coefficient analyses (young healthy: R-2 = 0.885, P = 0. 0001; aged healthy: R-2 = 0.765, P = 0.001; AMD-fellow: R-2 = 0.851, P = 0.0001; and AMD: R-2 = 0.860, P = 0.013). Using the estimated value, significantly lower MPOD values were found in aged AMD-related eyes, which included both AMD-fellow and AMD eyes, compared with aged healthy eyes by Student's t-test (P = 0.02).
   Conclusions: Absolute, in contrast to estimated, value was measurable in a limited number of aged participants; however, it was correlated with estimated value both in young and aged Asian populations with or without AMD. These results may inform future clinical studies investigating the measurement of MPOD in understanding the role of macular pigments in the pathogenesis of AMD.
C1 [Ozawa, Yoko; Nagai, Norihiro; Suzuki, Misa] Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Ozawa, Yoko; Shigeno, Yuta; Nagai, Norihiro; Suzuki, Misa; Kurihara, Toshihide; Minami, Sakiko; Hirano, Eri; Shinoda, Hajime; Tsubota, Kazuo] Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Kobayashi, Saori] Wakasa Seikatsu Co Ltd, Shimogyo Ku, 134 Chudoujiminami Cho, Kyoto 6008813, Japan.
C3 Keio University; Keio University
RP Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.; Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Ozawa, Yoko/AAH-9888-2020; Kurihara, Toshihide/ABA-7058-2020; Kobayashi,
   Saori/GXV-3835-2022; Tsubota, Kazuo/M-1915-2013
OI Kurihara, Toshihide/0000-0002-5457-2720; Ozawa,
   Yoko/0000-0003-4797-5705; Tsubota, Kazuo/0000-0002-8874-7111
FU Wakasa Seikatsu Co. Ltd.
FX The study was supported by Wakasa Seikatsu Co. Ltd.
CR Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Bernstein PS, 2013, INVEST OPHTH VIS SCI, V54, P4034, DOI 10.1167/iovs.13-11891
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bone RA, 2004, ARCH BIOCHEM BIOPHYS, V430, P137, DOI 10.1016/j.abb.2004.04.003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Ermakov I, 2004, J BIOMED OPT, V9, P139, DOI 10.1117/1.1627776
   Goto E, 2002, AM J OPHTHALMOL, V133, P181, DOI 10.1016/S0002-9394(01)01365-4
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Koushan K, 2013, NUTRIENTS, V5, P1823, DOI 10.3390/nu5051823
   McKay GJ, 2013, OPHTHALMOLOGY, V120, P1632, DOI 10.1016/j.ophtha.2013.01.030
   Nagai N, 2015, RETINA-J RET VIT DIS, V35, P820, DOI 10.1097/IAE.0000000000000382
   Nishi Y, 2013, ACTA OPHTHALMOL, V91, pE353, DOI 10.1111/aos.12060
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Obana A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139257
   Obana A, 2011, OPHTHALMOLOGY, V118, P1852, DOI 10.1016/j.ophtha.2011.02.017
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Sasamoto Y, 2011, INVEST OPHTH VIS SCI, V52, P927, DOI 10.1167/iovs.10-5664
   Sawa M, 2014, INVEST OPHTH VIS SCI, V55, P5238, DOI 10.1167/iovs.14-14470
   Storey P, 2013, INVEST OPHTH VIS SCI, V54, P3010, DOI 10.1167/iovs.12-11412
   Tomita Y, 2016, OPTOMETRY VISION SCI, V93, P70, DOI 10.1097/OPX.0000000000000755
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Xu J, 1997, J OPT SOC AM A, V14, P953, DOI 10.1364/JOSAA.14.000953
   Yamaguchi T, 2009, J REFRACT SURG, V25, P410, DOI 10.3928/1081597X-20090422-02
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 29
TC 9
Z9 9
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 29
PY 2017
VL 17
AR 161
DI 10.1186/s12886-017-0557-5
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FF1GV
UT WOS:000408648700002
PM 28851319
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Peden, MC
   Suner, IJ
   Hammer, ME
   Grizzard, WS
AF Peden, Marc C.
   Suner, Ivan J.
   Hammer, Mark E.
   Grizzard, W. Sanderson
TI Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of
   Anti-Vascular Endothelial Growth Factor Agents for Wet Age-Related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; VEGF; VERTEPORFIN; EFFICACY; HORIZON; ANCHOR; SAFETY; TRIAL
AB Purpose: To report on long-term visual outcomes in patients receiving continuous fixed-interval dosing of anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (AMD).
   Design: Single-practice retrospective chart review.
   Participants: One hundred nine eyes with exudative AMD receiving continuous fixed-interval dosing (every 4-8 weeks) of anti-VEGF therapy (ranibizumab, bevacizumab, or aflibercept) for at least 5 years. Eyes were excluded if they averaged fewer than 6.5 injections per year.
   Methods: Snellen visual acuity was recorded at baseline and all subsequent injections. Changes from baseline were calculated at yearly intervals.
   Main Outcome Measures: The primary outcome measure was mean change in letter score at 5, 6, and 7 years; secondary outcomes included the percentage of patients with 20/40 vision or better at 7 years and the mean change in letter score at each yearly time point based on baseline visual grouping (20/40 or better, 20/50-20/100, 20/200 or worse).
   Results: Forty-four, 75, and 109 patients with 7, 6, and 5 years, respectively, of continuous treatment were identified. Mean change in letter score at year 5 was +14.0 letters (P = 3.9 x 10(-9)), +12.2 letters at 6 years (P = 1.5 x 10(-7)), and +2.1 letters at 7 years (P = 3.8 x 10(-5)). Driving vision (20/40 or better) was achieved in 43.2% of treated eyes. Subanalysis revealed that the greatest visual gains at 5 and 7 years were seen in those patients with baseline visual acuity worse than 20/200 (+24.5 and +25.5 letters), followed by those with 20/50 to 20/100 vision (+6.7 and +6.9 letters), and finally those with 20/20 to 20/40 (+3.7 and +3.4 letters). Patients received an average of 10.5 injections per year.
   Conclusions: Continuous fixed-interval dosing of anti-VEGF therapy in patients with exudative AMD results in favorable long-term preservation out to 7 years, with vision stabilizing or improving in 93.2% of eyes. Additionally, 43.2% of patients maintained driving vision in the treatment eye at 7 years compared with 10.1% at baseline. Our data suggest better outcomes with continuous therapy over published results with sporadic, as-needed therapy. (C) 2015 by the American Academy of Ophthalmology.
C1 [Peden, Marc C.; Suner, Ivan J.; Hammer, Mark E.; Grizzard, W. Sanderson] Retina Associates Florida, Tampa, FL 33609 USA.
RP Peden, MC (通讯作者)，Retina Associates Florida, PA, 602 South MacDill Ave, Tampa, FL 33609 USA.
EM mpeden@ufl.edu
FU Genentech, Inc, South San Francisco, California
FX Supported by Genentech, Inc, South San Francisco, California, as an
   Investigator Sponsored Trial (IST).
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 21
TC 98
Z9 104
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2015
VL 122
IS 4
BP 803
EP 808
DI 10.1016/j.ophtha.2014.11.018
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE3EX
UT WOS:000351710100028
PM 25596618
DA 2022-11-30
ER

PT J
AU Li, XX
   Xu, GZ
   Wang, YS
   Xu, X
   Liu, XL
   Tang, SB
   Zhang, F
   Zhang, JJ
   Tang, LS
   Wu, Q
   Luo, DL
   Ke, X
AF Li, Xiaoxin
   Xu, Gezhi
   Wang, Yusheng
   Xu, Xun
   Liu, Xiaoling
   Tang, Shibo
   Zhang, Feng
   Zhang, Junjun
   Tang, Luosheng
   Wu, Quan
   Luo, Delun
   Ke, Xiao
CA AURORA Study Grp
TI Safety and Efficacy of Conbercept in Neovascular Age-Related Macular
   Degeneration Results from a 12-Month Randomized Phase 2 Study: AURORA
   Study
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; RECEPTOR; THERAPY; BINDING;
   DOMAIN
AB Purpose: To assess the safety and efficacy of multiple injections of 0.5 and 2.0 mg conbercept using variable dosing regimens in patients with neovascular age-related macular degeneration (AMD).
   Design: Randomized, double-masked, multicenter, controlled-dose, and interval-ranging phase 2 clinical trial divided into a 3-month loading phase followed by a maintenance phase.
   Participants: Patients with choroidal neovascularization secondary to AMD with lesion sizes of 12 disc areas or less and a best-corrected visual acuity (BCVA) letter score of between 73 and 24 were enrolled.
   Methods: Patients were randomized 1:1 to receive either 0.5 or 2.0 mg intravitreal conbercept for 3 consecutive monthly does. After the third dose, each group was reassigned randomly again to monthly (Q1M group) or as-needed (pro re nata [PRN] group) treatment without changing the drug assignment.
   Main Outcome Measures: The primary end point was the mean change in BCVA from baseline to month 3, with secondary end points being the mean change in BCVA, mean change in central retinal thickness (CRT), and safety at month 12.
   Results: We enrolled 122 patients. At the primary end point at month 3, mean improvements in BCVA from baseline in the 0.5- and 2.0-mg groups were 8.97 and 10.43 letters, respectively. At month 12, mean improvements in BCVA from baseline were 14.31, 9.31, 12.42, and 15.43 letters for the 0.5-mg PRN, 0.5-mg Q1M, 2.0-mg PRN, and 2.0-mg Q1M regimens, respectively. At month 12, mean reductions in CRT in the 4 regimens were 119.8, 129.7, 152.1, and 170.8 mu m, respectively. There were no significant differences for the pairwise comparisons between all study groups. The difference in the number of injections between the 2 PRN groups was not statistically significant. Treatment with conbercept generally was safe and well tolerated.
   Conclusions: The significant gains in BCVA at 3 months were the same or better at 12 months in all conbercept dosing groups of neovascular AMD patients. During the 12 months, repeated intravitreal injections of conbercept were well tolerated in these patients. Future clinical trials are required to confirm its long-term efficacy and safety. (C) 2014 by the American Academy of Ophthalmology.
C1 [Li, Xiaoxin] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100871, Peoples R China.
   [Xu, Gezhi] Fudan Univ, Dept Ophthalmol, Eye & ENT Hosp, Shanghai 200433, Peoples R China.
   [Wang, Yusheng] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Shanxi, Peoples R China.
   [Xu, Xun] Shanghai First Peoples Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Liu, Xiaoling] Hosp Wenzhou, Coll Med, Dept Ophthalmol Optometry & Ophthalmol, Wenzhou, Fujian, Peoples R China.
   [Tang, Shibo] Sun Yat Sen Univ, Dept Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
   [Zhang, Feng] Peking Tongren Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Zhang, Junjun] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610064, Sichuan, Peoples R China.
   [Tang, Luosheng] Xiangya Med Coll, Affiliated Hosp 2, Dept Ophthalmol, Changsha, Hunan, Peoples R China.
   [Wu, Quan; Luo, Delun; Ke, Xiao] Chengdu Kanghong Biotechnol Inc, Dept Clin Res, Chengdu, Peoples R China.
C3 Peking University; Fudan University; Air Force Military Medical
   University; Sun Yat Sen University; Sichuan University
RP Li, XX (通讯作者)，Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100871, Peoples R China.
EM dr_lixiaoxin@126.com
RI TANG, Shi/GXH-5719-2022
FU Chengdu Kanghong Biotechnology, Inc., Chengdu, Sichuan, China
FX Sponsored by Chengdu Kanghong Biotechnology, Inc., Chengdu, Sichuan,
   China. The sponsor participated in the design of the study, conduct of
   the study, data collection, data management, data analysis,
   interpretation of the data, and preparation of the manuscript.
CR Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Feucht N, 2008, CLIN OPHTHALMOL, V2, P253
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Nguyen QD, 2012, J OCUL PHARMACOL TH, V28, P581, DOI 10.1089/jop.2011.0261
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283
   Tielsch JA, 1994, VISION PROBLEMS US R
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhang X, 2007, INT J OPHTHALMOL, V7, P1674
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 17
TC 127
Z9 167
U1 0
U2 33
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2014
VL 121
IS 9
BP 1740
EP 1747
DI 10.1016/j.ophtha.2014.03.026
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2KY
UT WOS:000341151800024
PM 24793528
OA hybrid
DA 2022-11-30
ER

PT J
AU Bartlett, HE
   Eperjesi, F
AF Bartlett, H. E.
   Eperjesi, F.
TI Effect of lutein and antioxidant dietary supplementation on contrast
   sensitivity in age-related macular disease: a randomized controlled
   trial
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE age-related macular disease; lutein; randomized controlled trial;
   nutrition; antioxidants
ID VISUAL IMPAIRMENT; PIGMENT; CAROTENOIDS; ZEAXANTHIN; BIOAVAILABILITY;
   DEGENERATION; MACULOPATHY; DISABILITY; RISK
AB Objective: The aim of the study is to determine the effect of lutein combined with vitamin and mineral supplementation on contrast sensitivity in people with age-related macular disease ( ARMD).
   Design: A prospective, 9-month, double-masked randomized controlled trial.
   Setting: Aston University, Birmingham, UK and a UK optometric clinical practice.
   Subjects: Age-related maculopathy ( ARM) and atrophic age-related macular degeneration (AMD) participants were randomized ( using a random number generator) to either placebo ( n = 10) or active ( n = 15) groups. Three of the placebo group and two of the active group dropped out. Interventions: The active group supplemented daily with 6 mg lutein combined with vitamins and minerals. The outcome measure was contrast sensitivity ( CS) measured using the Pelli-Robson chart, for which the study had 80% power at the 5% significance level to detect a change of 0.3 log units.
   Results: The CS score increased by 0.07 +/- 0.07 and decreased by 0.02 +/- 0.18 log units for the placebo and active groups, respectively. The difference between these values is not statistically significant ( z = -0.903, P = 0.376). Conclusion: The results suggest that 6 mg of lutein supplementation in combination with other antioxidants is not beneficial for this group. Further work is required to establish optimum dosage levels.
C1 Aston Univ, Sch Life & Hlth Sci, Opthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
C3 Aston University
RP Bartlett, HE (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Opthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
EM H.E.Bartlett@aston.ac.uk
RI Eperjesi, Frank/A-9275-2013
OI Bartlett Eperjesi, Hannah E/0000-0002-7531-6902; Eperjesi,
   Frank/0000-0003-4358-0095
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Bartlett H, 2005, OPHTHAL PHYSL OPT, V25, P179, DOI 10.1111/j.1475-1313.2005.00294.x
   Bartlett H, 2004, OPHTHAL PHYSL OPT, V24, P339, DOI 10.1111/j.1475-1313.2004.00218.x
   Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   Breithaupt DE, 2002, COMP BIOCHEM PHYS B, V132, P721, DOI 10.1016/S1096-4959(02)00096-9
   CHEW E, 2003, INVEST OPHTHALMOL VI, V44
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Dagnelie G, 2000, Optometry, V71, P147
   DEFREITAS Z, 2004, PREVALENCE LUTEIN VE
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   FLETCHER D, 2006, VIS SCI, V83, P178
   Goodwin T.W, 1980, BIOCH CAROTENOIDS, V1
   Granado F, 2002, EUR J NUTR, V41, P47, DOI 10.1007/s003940200007
   Haegerstrom-Portnoy G, 2000, OPTOMETRY VISION SCI, V77, P653, DOI 10.1097/00006324-200012000-00012
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HYVARINEN L, 1995, BRIT J OPHTHALMOL, V79, P867, DOI 10.1136/bjo.79.9.867
   HYVARINEN L, 1983, ACTA OPHTHALMOL, V61, P161
   JIN C, 1992, YEN HSUEH PAO, V8
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2004, AGRO FOOD IND HI TEC, V15, P22
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LANDRUM JT, 2004, INVEST OPHTHALMOL VI, V45
   Mares-Perlman JA, 1999, AM J CLIN NUTR, V70, P431
   Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   NEWSOME DA, 1994, PROG RETIN EYE RES, V13, P101, DOI 10.1016/1350-9462(94)90006-X
   NOY N, 2000, VITAMIN A BIOCH PHYS, P599
   PEASE PL, 1987, VISION RES, V27, P705, DOI 10.1016/0042-6989(87)90067-8
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 56
TC 39
Z9 42
U1 2
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD SEP
PY 2007
VL 61
IS 9
BP 1121
EP 1127
DI 10.1038/sj.ejcn.1602626
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 207UP
UT WOS:000249276900012
PM 17268417
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yu, JJ
   Agron, E
   Clemons, TE
   Domalpally, A
   van Asten, F
   Keenan, TD
   Cukras, C
   Chew, EY
   Ferris, FL
   SanGiovanni, JP
   Clemons, T
   Lindblad, A
   Lindblad, R
   Shah, N
   Sperduto, R
   McBee, W
   Gensler, G
   Harrington, M
   Henning, A
   Jones, K
   Thotapally, K
   Tull, D
   Watson, V
   Williams, K
   Gentry, C
   Kaufman, F
   Morrison, C
   Saverino, E
   Schenning, S
   Blodi, B
   Danis, RP
   Davis, M
   Glander, K
   Guilfoil, G
   Hubbard, LD
   Johnson, K
   Klein, R
   Nardi, B
   Neider, M
   Robinson, N
   Rosensteel, E
   Wabers, H
   Zhang, G
   Ruby, AJ
   Capone, A
   Dass, B
   Drenser, K
   Garretson, BR
   Hassan, TS
   Trese, M
   Williams, GA
   Wolfe, J
   Bell, T
   Zajechowski, M
   Bezaire, D
   McIver, F
   Medina, A
   Pagett, J
   Smith, SH
   Swartz, L
   Treuter, T
   Antoszyk, A
   Brown, J
   Browning, DJ
   Holland, W
   Karow, A
   Stalford, K
   Price, A
   Ennis, S
   Fredenberg, S
   Herby, J
   Balasubramaniam, U
   Clark, L
   McClain, D
   McOwen, M
   Watson, L
   Klein, M
   Bailey, ST
   Hwang, TJ
   Lauer, A
   Stout, JT
   McCollum, P
   Johnson, M
   Rice, PB
   Kim, I
   Loewenstein, J
   Miller, J
   Sobrin, L
   Young, L
   Sullivan, J
   Houlihan, P
   Merry, L
   Lane, AM
   Bator, UL
   Evans, C
   Brett, S
   Callahan, C
   Grillo, M
   Walsh, D
   Zimmerman, KL
   Fish, GE
   Anand, R
   Coors, LE
   Fuller, DG
   Spencer, R
   Wang, RC
   Duignan, K
   Arceneaux, S
   Aguado, H
   Hesse, N
   Mackens, M
   Swan, B
   Wong, WT
   Dalal, M
   Jacobs-El, N
   Meyerle, C
   Nicholson, B
   Wiley, H
   Shimel, KH
   Garced, A
   Oparah, J
   Short, G
   Temple, A
   Ayukawa, B
   Foster, G
   Hayes, D
   Koutsandreas, D
   Nashwinter, R
   Rowan, J
   Bono, M
   Cunningham, D
   Palmer, M
   Zetina, A
   Orth, DH
   Rezaei, K
   Civantos, J
   Hasan, S
   Packo, K
   Figliulo, C
   Stanberry, P
   Farmer, T
   Nelson, K
   Townsend-Patrick, S
   Rosenfeld, P
   Chen, R
   Doshi, R
   Dubovy, S
   Kim, BT
   Lowrance, M
   Moshfeghi, A
   Nahas, Z
   Schienbaum, G
   Vishak, J
   Weng, C
   Yehoshua, Z
   Rodriguez, B
   Rebimbas, J
   Gleichauf, J
   Kicak, M
   Mena, J
   Odem, T
   Sferza-Camp, E
   Disgdiertt, A
   Oramas, J
   Rams, I
   Thatcher, S
   Bressler, SB
   Bressler, NM
   Finkelstein, D
   Sherman, SH
   Solomon, S
   Ying, HS
   Denbow, R
   Phillips, D
   Radcliffe, E
   Belt, J
   Cain, D
   Emmert, D
   Herring, M
   McDonald, J
   Hubbard, GB
   Bergstrom, CS
   Cribbs, B
   Hendrick, A
   Johnson, B
   Laird, P
   Mehta, S
   Olsen, T
   Townsend, J
   Yan, J
   Yeh, S
   Curtis, L
   Brower, J
   Yi, H
   Dobbs, JR
   Jordan, D
   Elman, MJ
   Liss, RA
   Starr, J
   Belz, J
   Putzulo, C
   Coffey, T
   Davis, A
   Singletary, P
   Andreani, GS
   Cain, T
   Ketner, D
   Sotirakos, P
   Chandra, S
   Blodi, BA
   Altaweel, MM
   Gottlieb, JL
   Ip, M
   Nork, TM
   Stevens, TS
   Burke, K
   Olson, S
   Dietzman, K
   Soderling, B
   Somers, G
   Wealti, A
   Krolnik, D
   Peterson, J
   Reed, S
   Friberg, T
   Eller, A
   Gallagher, D
   Labriola, L
   Pokrifka, M
   Gedansky, A
   Anthony, N
   Grzybowski, C
   Matthews, D
   Murajda-Jumba, S
   Toro, J
   Callanan, DG
   Solley, WA
   Williams, P
   Lash, S
   Boleman, B
   Dock, C
   Shami, M
   Arrington, B
   Meeks, A
   Margherio, AR
   Raphaelian, P
   Markus, D
   Langdon, J
   Truax, E
   Lewis, S
   Terry, B
   Noffke, A
   Oh, K
   Sarrafizadeh, R
   Sneed, S
   Hammersley, J
   Neal, S
   Doran, M
   Jones, N
   Preston, L
   Jessick, H
   Marsh, TT
   Tolentino, M
   Berger, A
   Hamilton, R
   Misch, D
   Moon, SJ
   Sutherland, D
   Dilts, V
   Henderson, S
   Medina, E
   Trueman, D
   Holm, L
   Strickland, J
   Ie, D
   Lipkowitz, JL
   Shah, KB
   Geraghty, S
   Sannazzaro, B
   Harper, M
   Bayer, K
   Lansing, MB
   Fox, LB
   Lee, R
   Stallman, JB
   Jacobson, M
   Koh, S
   Lampert, S
   Miller, J
   Rivellese, M
   Sharma, A
   Stoltz, RA
   Vanderveldt, S
   Marcus, L
   Hendricks, S
   Hollman, R
   Betanzos, G
   Ellorin, L
   Fulbright, S
   McCormick, D
   Edwards, PA
   Hall, J
   Monk, M
   Gutkowski, M
   Mazurek, M
   Murphy, J
   Gusas, K
   Moffett, C
   Burley, D
   Chesney, N
   Kilgo, K
   Rusinek, B
   Stern, B
   Troszak, T
   Baker-Levingston, R
   Baker, CW
   Caldwell, T
   Walker, T
   Lambert, LF
   Martin, T
   Palmer, MJ
   Williams, T
   Novak, MA
   Coney, J
   Miller, DG
   Pendergast, S
   Singerman, L
   Zakov, N
   Zegarra, H
   DuBois, K
   Rath, S
   Revella, L
   Brink, T
   Drury, K
   Hogue, L
   Ilc, M
   Keller, C
   McNamara, E
   Tanner, V
   Cunningham, T
   DuBois, J
   Greanoff, G
   Nitzsche, T
   Smith-Brewer, S
   Isernhagen, RD
   Kitchens, JW
   Stone, TW
   Wood, WJ
   Holcomb, D
   Therrien, V
   Buck, M
   Van Arsdall, J
   Slade, E
   Schneiderman, TE
   Spinak, DJ
   Gaedke, J
   Brown, HD
   Helgren, D
   Pangelinan, JG
   Halperin, L
   Anagnoste, S
   Dhalla, M
   Rosenberg, K
   Taney, B
   Thompson, WS
   Lopez, J
   Hamlin, M
   Lopez, M
   Mariano, J
   Quinchia, E
   Aramayo, P
   Veksler, R
   Lee, M
   Dreyer, R
   Handelman, I
   Ma, C
   Peters, M
   Hobbs, S
   Milliron, A
   Kopfer, M
   Connaughton, M
   Hoerner, AC
   Logan, RJ
   Wohlsein, HJ
   Boyer, D
   Chu, TG
   Dayani, P
   Liao, D
   Novack, RL
   Rahhal, FM
   Roe, R
   Tabandeh, H
   Bayramyan, J
   Gasparyan, T
   Hoang, C
   Kurokouchi, J
   Lo, TE
   Ngo, R
   Nguyen, MA
   Peyton, M
   Yoon, C
   Sierra, J
   Zamboni, A
   Kessinger, J
   Protacio, E
   Smucker, A
   Rath, P
   Bergren, R
   Doft, B
   Liu, J
   Olsen, K
   Merlotti, L
   Ingram, W
   Marfisi, K
   Yeckel, K
   Carmelo, HS
   Fec, A
   McBroom, K
   Steinberg, D
   Levy, M
   Abrams, J
   Chen, M
   Torres, W
   Jelemensky, P
   Prybylski, M
   Raphael, T
   Appleby, D
   Rodman, C
   Sneath, M
   Rosa, RH
   Hoelscher, V
   Castano, A
   Parker, J
   Hoskins, J
   Anderson, N
   Googe, J
   McMillan, TA
   Miller, J
   Perkins, S
   Oliver, K
   Beerbower, J
   Gilliland, B
   Hunt, C
   Jacobus, M
   Lince, R
   Morris, C
   Oelrich, S
   Whetstone, J
   Chan, CK
   Lin, S
   Walther, K
   Gonzales, T
   Myers, L
   Huff, K
   Brown, DM
   Chen, E
   Benz, MS
   Fish, RH
   Kim, RY
   Major, J
   Wong, TP
   Wycoff, C
   Cone, C
   Gilaspia, DG
   Landaverde, N
   Smith, R
   Zamora, D
   Sneed, V
   Vela, M
   Kegley, E
   Greven, C
   Kurup, S
   Richards, C
   Slusher, M
   Everhart, C
   Fish, J
   Miller, D
   Tyler, M
   Jumper, JM
   Fu, AD
   Johnson, RN
   Lujan, B
   McDonald, HR
   Rodriguez, R
   Ansari, N
   Joaquin, J
   Linares, S
   Lopez, L
   Sabio, J
   Grout, S
   Indermill, C
   Urias, Y
   Zimmerman, R
   Margulies, L
   Schmidt, SJ
   Meier, JL
   Hadley, SL
   Rosenthal, W
   Johnson, B
   Swafford, L
   Shields, R
   Varner, RS
   Rosen, R
   Gentile, R
   Rivas, M
   Tai, KW
   Carrasquillo-Boyd, W
   Masini, R
   Stoller, G
   Carnevale, K
   LaRosa, DM
   Burger, B
   Conway, T
   Del Castillo, C
   Diaz, J
   Jones, S
   Mondoc, N
   Balfour, C
   Vitha, CH
   Lutz, J
   McGinley, B
   El Baba, F
   Lavorna, AM
   Jones, R
   Lewis, J
   Tenzler, R
   Salvas-Mladek, M
   Van Kesteren, D
   McLean, WC
   Bridges, WZ
   Stone, C
   Ammons, D
   Lamy, M
   Menzel, A
   Raymer, LD
   Campbell, B
   Hawkins, L
   Rickman, L
   Sherlin, L
   Price, P
   Sinyai, A
   Kingsley, R
   Bradford, RH
   Leonard, RE
   Icks, S
   Bergman, V
   Ross, B
   Burris, R
   Butt, A
   Richmond, R
   Lyon, A
   Gill, M
   Jampol, L
   Mizra, R
   Rozenbajgier, Z
   Chapman, J
   Kaminski, L
   Degillio, A
   Simjanoski, E
   Heier, J
   Cho, H
   Cleary, TS
   Goldman, D
   Shah, C
   Topping, T
   Weber, M
   Wiegand, T
   Schindelheim, J
   Bankert, J
   Stone, J
   Nowak, A
   Chong, S
   Williams, L
   Bennett, S
   Donovan, D
   Graham, M
   Jones, C
   Fung, A
   Bayabo, JK
   Bosch, R
   Cruz, E
   Emerson, A
   Fleming, A
   Barsness, D
   Rodriguez, J
   Soboleva, M
   Scott, IU
   Bowie, E
   Neely, KA
   Quillen, DA
   Walter, L
   Bennett, T
   Strong, J
   Wells, J
   Clark, L
   Johnson, D
   Miller, P
   Taylor, M
   Swinford, T
   Spivey, R
   Banach, M
   Ho, L
   Lanning, R
   Pheasant, TR
   Prensky, JG
   Truong, S
   Teatsworth, J
   Dietrich, M
   Wasilus, A
   Miller, A
   Rakes, M
   Slagle, T
   Richards, M
   Schuessler, P
   Stover, L
   Beer, P
   Falk, NS
   Shannon, MB
   Olmeda, J
   Berdeen, D
   Fisher, JF
   Folk, J
   Russell, S
   Taylor, B
   Hinz, C
   Walshire, J
   Stockman, H
   Critser, B
   Karakas, S
   Montague, C
   Verdick, R
   Gupta, O
   Maguire, J
   Brady, C
   DeCroos, FC
   Dollin, M
   Garg, S
   Gerstenblith, A
   Haller, J
   Ho, AC
   Hsu, J
   Kaiser, R
   Pitcher, J
   Regillo, C
   Shah, R
   Spirn, M
   Tasman, W
   Vander, J
   Senderowitsch, N
   Formoso, M
   Markun, M
   George, C
   Centinaro, C
   Grande, L
   Carey, S
   Liebenbaum, E
   Sadda, S
   Humayun, M
   Sierra, R
   Corona, E
   Padilla, M
   Nu, M
   Ramos, S
   Barnett, C
   Currie, G
   Gottlieb, C
   Garfinkel, R
   Berinstein, D
   Colyer, M
   Deegan, W
   Lai, MMS
   Murphy, R
   Osman, M
   Rivers, M
   Sanders, R
   von Fricken, MA
   Oliver, D
   Kirshon, J
   Snowden, TA
   Blondo, T
   Cronise, A
   Denny, V
   Mendez, K
   Newgen, J
   Davis, J
   Flory, M
   Frantz, R
   Murphy, B
   Rauch, S
   Kim, JE
   Bachman, J
   Connor, TB
   Han, DP
   Stepian, K
   Weinberg, DV
   Wirostko, WJ
   Packard, K
   Kaczanowski, T
   Williams, V
   Barwick, V
   Flanders, J
   Backes, D
   Beringer, J
   Keller, K
   Selchert, K
   Bernstein, P
   Teske, M
   Vitale, A
   Allman, S
   Carlstrom, B
   Wegner, K
   Haroldsen, A
   Harrison, D
   Fry, C
   Gilman, J
   Jenkins, G
   Morris, P
   Rauser, M
   Fan, J
   Suthar, M
   Santiago, G
   Halsey, KR
   Quesada, C
   Kiernan, W
   Knabb, J
   Lewis, RA
   Dorenbach, C
   Spencer, S
   Barnett, D
   Morales, J
   Fishburne, BC
   Gross, JG
   Magee, MA
   Flowers, A
   McDowell, A
   Price, R
   Huang, S
   Tang, J
   Wilker, S
   Hornsby, C
   Ferguson, L
   Krogstad, K
   Adamovsky, R
   Allchin, P
   Carlton, K
   Clow, C
   Sholtis, K
   Burke, S
   Harrod, M
   Hrvatin, S
   Pankhurst, G
   Sabates, NR
   Cassell, M
   Desai, K
   Poulose, A
   Sabates, F
   Chen, Y
   Gallimore, G
   Konior, Y
   Kim, N
   Uwaydat, S
   Troillett, D
   Aletter, K
   Frank, RN
   Abrams, G
   Puklin, J
   Tewari, A
   Milanovic, C
   Bailey, M
   Griffith, D
   McDonald, D
   Morehead, K
   Sadikovic, Z
   Schillace, L
   Silvis, E
   Joondeph, B
   Christmas, N
   Kimura, A
   Liu, MM
   Petty, S
   Zilis, J
   Benitez, J
   Catlett, CB
   Fluegel, E
   Mowry, S
   Nguyen, H
   Reflow, D
   Houghton, OM
   Garg, S
   Landers, MB
   Meredith, T
   Barnhart, S
   Karmalkar, M
   Cantrell, D
   Esquejo-Leon, RL
   Manor, L
   Pope, S
   Stines, D
   Stokely, A
   Hainsworth, D
   Helming, D
   Eichelberger, D
   Leaton, MP
   Hamm, C
   Chaum, E
   Iannaccone, A
   Jennings, B
   Murray, T
   Mastellone, J
   Millay, R
   Kim, B
   Goddard, T
   Beaudette, LJ
   Changelian-Aitken, N
   Corrada, F
   Dubuque, J
   Iezzi, R
   Bakri, SJ
   Pulido, JS
   Vogen, D
   Nielsen, R
   Berg, K
   Burrington, J
   Howard, S
   Overend, J
   Krason, Z
   Lewison, D
   Link, T
   Blinder, KJ
   Engelbrecht, NE
   Grand, MG
   Joseph, DP
   Shah, GK
   Smith, B
   Thomas, M
   Weeks, R
   Boyd, L
   Gabel, D
   Adelman, R
   Huang, J
   Kempton, J
   Parnes, A
   Dupont, J
   Perotti, E
   Donaldson, V
   Fong, K
   Ossorio, P
   Agarwal, A
   Sternberg, P
   Owings, S
   Adkins, T
   Lok, E
   Munn, G
   Skellie, B
   Bhagat, N
   Roy, MS
   Zarbin, M
   Fay, C
   Lazar, M
   Malpica, B
   Mikheyav, T
   Ulanski, L
   Lim, J
   Niec, M
   Johnson, T
   Ovando, Y
   Carroll, CN
   Janowicz, M
   Schwartz, S
   Cupp, D
   Gorin, M
   Heilweil, G
   Hosseini, H
   Hubschman, JP
   Kreiger, A
   McCannel, TY
   Pan, C
   Sarraf, D
   Tsui, I
   Udoetek, J
   Voleti, V
   Hitchcock, L
   Ostrick, R
   Chun, M
   Kageyama, J
   Davila, N
   Lipka, K
   Shin, C
   Owsley, C
   Albert, M
   Feist, R
   Mason, J
   Thomley, M
   Johnson, A
   Clark, M
   Emond, T
   Hamela, J
   Marsh, A
   Searcey, K
   Rookard, K
   He, YG
   Ufret-Vincenty, RL
   Molai, M
   Anderson, W
   Horna, J
   Letson, A
   Cebulla, C
   Chang, S
   Davidorf, F
   Salerno, J
   Sladoje, L
   Stetson, C
   Perry, J
   Savage, S
   Toth, C
   Jaffe, G
   Schuman, S
   Sarin, N
   Crowell, J
   Keaton, T
   Kelly, M
   Lutman, B
   Skelly, M
   Welch, L
   Morse, L
   Hunter, A
   Park, SSC
   Wallace, C
   Dhillon, E
   Salvador, M
   Holderreed, B
   Chandra, K
   Kaur, S
   Redenbo, E
   Hom, S
   Cooney, M
   Barbazetto, I
   Klancnik, JM
   Sorenson, JA
   Yannuzzi, L
   Scolaro, M
   Agresta, E
   Gonzalez, N
   Grover, S
   Chalam, KV
   Gupta, S
   Lyons, C
   Li, WH
   Patel, C
   Carrion, J
   Ferreyra, H
   Rodriguez, A
   Molina, I
   Balea, G
   Emory, P
   Rico, M
   Siqueiros, G
   Brucker, AJ
   Dunaief, J
   Grunwald, J
   Kim, B
   Maguire, AM
   VanderBeek, B
   Drossner, S
   DuPont, J
   Salvo, R
   Berger, J
   Devine, C
   Nyberg, B
   Weeney, L
   DiLoreto, D
   Chung, MN
   Davis, V
   MacDowell, P
   Gara, GO
   Castillo, D
   Czubinski, A
   Keim, M
   Hardy, B
   Hollar, RG
   Schueckler, L
   Lyon, AT
   Weinberg, A
   Shiloach, M
   Pelkofer, N
   Zhou, Q
   McPoland, L
   Apte, R
   Rao, PK
   Pistorius, S
   Kambarian, J
   Adcock, E
   Gould, S
   Quinn, M
   Curtis, R
   Frost, A
   Meyer, C
   Rathert, G
AF Yu, Jeannette J.
   Agron, Elvira
   Clemons, Traci E.
   Domalpally, Amitha
   van Asten, Freekje
   Keenan, Tiarnan D.
   Cukras, Catherine
   Chew, Emily Y.
   Ferris, Frederick L., III
   SanGiovanni, John Paul
   Clemons, Traci
   Lindblad, Anne
   Lindblad, Robert
   Shah, Nilay
   Sperduto, Robert
   McBee, Wendy
   Gensler, Gary
   Harrington, Molly
   Henning, Alice
   Jones, Katrina
   Thotapally, Kumar
   Tull, Diana
   Watson, Valerie
   Williams, Kayla
   Gentry, Christina
   Kaufman, Francine
   Morrison, Chris
   Saverino, Elizabeth
   Schenning, Sherrie
   Blodi, Barbara
   Danis, Ronald P.
   Davis, Matthew
   Glander, Kathy
   Guilfoil, Gregory
   Hubbard, Larry D.
   Johnson, Kristine
   Klein, Ronald
   Nardi, Barbara
   Neider, Michael
   Robinson, Nancy
   Rosensteel, Eileen
   Wabers, Hugh
   Zhang, Grace
   Ruby, Alan J.
   Capone, Antonio, Jr.
   Dass, Bawa
   Drenser, Kimberly
   Garretson, Bruce R.
   Hassan, Tarek S.
   Trese, Michael
   Williams, George A.
   Wolfe, Jeremy
   Bell, Tina
   Zajechowski, Mary
   Bezaire, Dennis
   McIver, Fran
   Medina, Anthony
   Pagett, Jackie
   Smith, Stephanie Hatch
   Swartz, Lynn
   Treuter, Tom
   Antoszyk, Andrew
   Brown, Justin
   Browning, David J.
   Holland, Walter
   Karow, Angella
   Stalford, Kelly
   Price, Angela
   Ennis, Sarah
   Fredenberg, Sherry
   Herby, Jenna
   Balasubramaniam, Uma
   Clark, Loraine
   McClain, Donna
   McOwen, Michael
   Watson, Lynn
   Klein, Michael
   Bailey, Steven T.
   Hwang, Thomas J.
   Lauer, Andreas
   Stout, J. Timothy
   McCollum, Patty
   Johnson, Milt
   Rice, Patrick B.
   Kim, Ivana
   Loewenstein, John
   Miller, Joan
   Sobrin, Lucia
   Young, Lucy
   Sullivan, Jacqueline
   Houlihan, Patricia
   Merry, Linda
   Lane, Ann Marie
   Bator, Ursula Lord
   Evans, Claudia
   Brett, Sarah
   Callahan, Charleen
   Grillo, Marcia
   Walsh, David
   Zimmerman, Kamella Lau
   Fish, Gary Edd
   Anand, Rajiv
   Coors, Lori E.
   Fuller, Dwain G.
   Spencer, Rand
   Wang, Robert C.
   Duignan, Karen
   Arceneaux, Sally
   Aguado, Hank
   Hesse, Nicholas
   Mackens, Michael
   Swan, Brian
   Wong, Wai T.
   Dalal, Monica
   Jacobs-El, Naima
   Meyerle, Catherine
   Nicholson, Benjamin
   Wiley, Henry
   Shimel, Katherine Hall
   Garced, Angel
   Oparah, Janice
   Short, Greg
   Temple, Alana
   Ayukawa, Babilonia
   Foster, Guy
   Hayes, Darryl
   Koutsandreas, Dessie
   Nashwinter, Roula
   Rowan, John
   Bono, Michael
   Cunningham, Denise
   Palmer, Marilois
   Zetina, Alicia
   Orth, David H.
   Rezaei, Kourous
   Civantos, Joseph
   Hasan, Sohail
   Packo, Kirk
   Figliulo, Celeste
   Stanberry, Pam
   Farmer, Tara
   Nelson, Kiersten
   Townsend-Patrick, Shannya
   Rosenfeld, Philip
   Chen, Royce
   Doshi, Rishi
   Dubovy, Sander
   Kim, Brian T.
   Lowrance, Matthew
   Moshfeghi, Andrew
   Nahas, Zayna
   Schienbaum, Gary
   Vishak, John
   Weng, Christina
   Yehoshua, Zohar
   Rodriguez, Belen
   Rebimbas, Jose
   Gleichauf, Jane
   Kicak, Mike
   Mena, Jason
   Odem, Tim
   Sferza-Camp, Elizabeth
   Disgdiertt, Alicia
   Oramas, Jim
   Rams, Isabel
   Thatcher, Stephanie
   Bressler, Susan B.
   Bressler, Neil M.
   Finkelstein, Daniel
   Sherman, Steven H.
   Solomon, Sharon
   Ying, Howard S.
   Denbow, Rita
   Phillips, Deborah
   Radcliffe, Elizabeth
   Belt, Judy
   Cain, Dennis
   Emmert, David
   Herring, Mark
   McDonald, Jacquelyn
   Hubbard, G. Baker
   Bergstrom, Chris S.
   Cribbs, Blaine
   Hendrick, Andrew
   Johnson, Brandon
   Laird, Philip
   Mehta, Sonia
   Olsen, Timothy
   Townsend, Justin
   Yan, Jion
   Yeh, Steven
   Curtis, Linda
   Brower, Judy
   Yi, Hannah
   Dobbs, Jannah Rutter
   Jordan, Debbie
   Elman, Michael J.
   Liss, Robert A.
   Starr, JoAnn
   Belz, Jennifer
   Putzulo, Charlene
   Coffey, Teresa
   Davis, Ashley
   Singletary, Pamela
   Andreani, Giorya Shabi
   Cain, Theresa
   Ketner, Daniel
   Sotirakos, Peter
   Chandra, Suresh
   Blodi, Barbara A.
   Altaweel, Michael M.
   Gottlieb, Justin L.
   Ip, Michael
   Nork, T. Michael
   Stevens, Thomas S.
   Burke, Kathryn
   Olson, Shelly
   Dietzman, Kristine
   Soderling, Barbara
   Somers, Guy
   Wealti, Angie
   Krolnik, Denise
   Peterson, John
   Reed, Sandra
   Friberg, Thomas
   Eller, Andrew
   Gallagher, Denise
   Labriola, Leanne
   Pokrifka, Melissa
   Gedansky, Aron
   Anthony, Natalie
   Grzybowski, Cassandra
   Matthews, Dawn
   Murajda-Jumba, Sharon
   Toro, Jessica
   Callanan, David G.
   Solley, Wayne A.
   Williams, Patrick
   Lash, Sandy
   Boleman, Bob
   Dock, Chris
   Shami, Michel
   Arrington, Brenda
   Meeks, Ashaki
   Margherio, Alan R.
   Raphaelian, Paul
   Markus, Debra
   Langdon, Justin
   Truax, Elizabeth
   Lewis, Sandy
   Terry, Brad
   Noffke, Amy
   Oh, Kean
   Sarrafizadeh, Ramin
   Sneed, Scott
   Hammersley, Julie
   Neal, Serena
   Doran, Mary
   Jones, Nan
   Preston, Lisa
   Jessick, Heather
   Marsh, Tanya Tracy
   Tolentino, Michael
   Berger, Adam
   Hamilton, Richard
   Misch, David
   Moon, Suk Jin
   Sutherland, Dawn
   Dilts, Vera
   Henderson, Sara
   Medina, Esmeralda
   Trueman, Donald
   Holm, Laura
   Strickland, Jason
   Ie, Darmakusuma
   Lipkowitz, Jeffrey L.
   Shah, Kekul B.
   Geraghty, Susan
   Sannazzaro, Beverly
   Harper, Morgan
   Bayer, Krista
   Lansing, Mary B.
   Fox, Lauren B.
   Lee, Rebecca
   Stallman, Jay B.
   Jacobson, Michael
   Koh, Sean
   Lampert, Scott
   Miller, John
   Rivellese, Mark
   Sharma, Atul
   Stoltz, Robert A.
   Vanderveldt, Stephanie
   Marcus, Leslie
   Hendricks, Starr
   Hollman, Ryan
   Betanzos, Grethel
   Ellorin, Leslie
   Fulbright, Shelly
   McCormick, Debbie
   Edwards, Paul A.
   Hall, Julianne
   Monk, Mary
   Gutkowski, Melanie
   Mazurek, Melina
   Murphy, Janet
   Gusas, Katherine
   Moffett, Crystal
   Burley, David
   Chesney, Nicole
   Kilgo, Katie
   Rusinek, Brian
   Stern, Bradley
   Troszak, Tracy
   Baker-Levingston, Rhonda
   Baker, Carl W.
   Caldwell, Tracey
   Walker, Tammy
   Lambert, Lynnette F.
   Martin, Tracey
   Palmer, Mary Jill
   Williams, Tana
   Novak, Michael A.
   Coney, Joseph
   Miller, David G.
   Pendergast, Scott
   Singerman, Lawrence
   Zakov, Nicholas
   Zegarra, Hernando
   DuBois, Kim
   Rath, Susan
   Revella, Lori
   Brink, Tammy
   Drury, Kim
   Hogue, Lisa
   Ilc, Mary
   Keller, Connie
   McNamara, Elizabeth
   Tanner, Vivian
   Cunningham, Tamara
   DuBois, John
   Greanoff, Gregg
   Nitzsche, Trina
   Smith-Brewer, Sheila
   Isernhagen, Ricky D.
   Kitchens, John W.
   Stone, Thomas W.
   Wood, William J.
   Holcomb, Diana
   Therrien, Virginia
   Buck, Michelle
   Van Arsdall, Jeanne
   Slade, Edward
   Schneiderman, Todd E.
   Spinak, David J.
   Gaedke, Jackie
   Brown, Heather Davis
   Helgren, Dan
   Pangelinan, Jenifer Garrison
   Halperin, Lawrence
   Anagnoste, Scott
   Dhalla, Mandeep
   Rosenberg, Krista
   Taney, Barry
   Thompson, W. Scott
   Lopez, Jaclyn
   Hamlin, Monica
   Lopez, Monica
   Mariano, Jamie
   Quinchia, Evelyn
   Aramayo, Patricia
   Veksler, Rita
   Lee, Michael
   Dreyer, Richard
   Handelman, Irvin
   Ma, Colin
   Peters, Mark
   Hobbs, Stephen, III
   Milliron, Amanda
   Kopfer, Marcia
   Connaughton, Michele
   Hoerner, A. Christine
   Logan, R. Joseph
   Wohlsein, Harry J.
   Boyer, David
   Chu, Thomas G.
   Dayani, Pouya
   Liao, David
   Novack, Roger L.
   Rahhal, Firas M.
   Roe, Richard
   Tabandeh, Homayoun
   Bayramyan, Janet
   Gasparyan, Tammy
   Hoang, Connie
   Kurokouchi, Janet
   Lo, Tammy Eileen
   Ngo, Richard
   Nguyen, Mary Ann
   Peyton, Michael
   Yoon, Charles
   Sierra, Julio
   Zamboni, Adam
   Kessinger, Jeff
   Protacio, Eric
   Smucker, Adam
   Rath, Pamela
   Bergren, Robert
   Doft, Bernard
   Liu, Judy
   Olsen, Karl
   Merlotti, Lori
   Ingram, Willia
   Marfisi, Kellianne
   Yeckel, Kimberly
   Carmelo, Heather Schultz
   Fec, Amanda
   McBroom, Keith
   Steinberg, David
   Levy, Marc
   Abrams, Jody
   Chen, Melvin
   Torres, Waldemar
   Jelemensky, Peggy
   Prybylski, Mark
   Raphael, Tara
   Appleby, Diana
   Rodman, Charlotte
   Sneath, Mark
   Rosa, Robert H., Jr.
   Hoelscher, Vanessa
   Castano, Adelia
   Parker, Jocelyn
   Hoskins, John
   Anderson, Nicholas
   Googe, Joseph, Jr.
   McMillan, Tod A.
   Miller, James, Jr.
   Perkins, Stephen
   Oliver, Kristina
   Beerbower, Jennifer
   Gilliland, Bruce
   Hunt, Cecile
   Jacobus, Mike
   Lince, Raul
   Morris, Christopher
   Oelrich, Sarah
   Whetstone, Jerry
   Chan, Clement K.
   Lin, Steven
   Walther, Kim
   Gonzales, Tiana
   Myers, Lenise
   Huff, Kenneth
   Brown, David M.
   Chen, Eric
   Benz, Matthew S.
   Fish, Richard H.
   Kim, Rosa Y.
   Major, James, Jr.
   Wong, Tien Pei
   Wycoff, Charles
   Cone, Cassandra
   Gilaspia, Debbie Goates
   Landaverde, Nubia
   Smith, Robert
   Zamora, Deneva
   Sneed, Veronica
   Vela, Melina
   Kegley, Eric
   Greven, Craig
   Kurup, Shree
   Richards, Charles
   Slusher, Madison
   Everhart, Cara
   Fish, Joan
   Miller, David
   Tyler, Marshall
   Jumper, J. Michael
   Fu, Arthur D.
   Johnson, Robert N.
   Lujan, Brandon
   McDonald, H. Richard
   Rodriguez, Rosa
   Ansari, Nina
   Joaquin, Jeanifer
   Linares, Silvia
   Lopez, Lizette
   Sabio, Jessica
   Grout, Sean
   Indermill, Chad
   Urias, Yesmin
   Zimmerman, Roberto
   Margulies, Linda
   Schmidt, Sara J.
   Meier, Joy L.
   Hadley, Sherry L.
   Rosenthal, William
   Johnson, Barbara
   Swafford, Lois
   Shields, Richard
   Varner, R. Scott
   Rosen, Richard
   Gentile, Ronald
   Rivas, Melissa
   Tai, Katy W.
   Carrasquillo-Boyd, Wanda
   Masini, Robert
   Stoller, Glenn
   Carnevale, Ken
   LaRosa, Diane M.
   Burger, Barbara
   Conway, Tereza
   Del Castillo, Carla
   Diaz, Julissa
   Jones, Susan
   Mondoc, Nina
   Balfour, Charlene
   Vitha, C. H.
   Lutz, Jennifer
   McGinley, Barbara
   El Baba, Fadi
   Lavorna, Ann Marie
   Jones, Renee
   Lewis, Jean
   Tenzler, Ruth
   Salvas-Mladek, Mary
   Van Kesteren, Diane
   McLean, W. Copley, Jr.
   Bridges, W. Zachery, Jr.
   Stone, Cameron
   Ammons, Denise
   Lamy, Mary
   Menzel, Andrea
   Raymer, Lea Doll
   Campbell, Barbara
   Hawkins, Lisa
   Rickman, Leslie
   Sherlin, Lorraine
   Price, Paula
   Sinyai, Albert
   Kingsley, Ronald
   Bradford, Reagan H., Jr.
   Leonard, Robert E., II
   Icks, Sonny
   Bergman, Vanessa
   Ross, Brittany
   Burris, Russ
   Butt, Amanda
   Richmond, Rob
   Lyon, Alice
   Gill, Manjot
   Jampol, Lee
   Mizra, Rukhsana
   Rozenbajgier, Zuzanna
   Chapman, Jeremy
   Kaminski, Lori
   Degillio, Andrea
   Simjanoski, Evica
   Heier, Jeffrey
   Cho, Hyung
   Cleary, Tina Scheufele
   Goldman, Darin
   Shah, Chirag
   Topping, Trexler
   Weber, Marissa
   Wiegand, Torsten
   Schindelheim, Jeremy
   Bankert, Joy
   Stone, Jennifer
   Nowak, Alison
   Chong, Sandy
   Williams, Lindsay
   Bennett, Steven
   Donovan, Dennis
   Graham, Margaret
   Jones, Cullen
   Fung, Anne
   Bayabo, Jan-Kristine
   Bosch, Razelda
   Cruz, Esperanza
   Emerson, Ashley
   Fleming, Alycia
   Barsness, Denice
   Rodriguez, Jorge
   Soboleva, Marina
   Scott, Ingrid U.
   Bowie, Esther
   Neely, Kimberly A.
   Quillen, David A.
   Walter, Laura
   Bennett, Timothy
   Strong, James
   Wells, John, III
   Clark, Lloyd
   Johnson, David
   Miller, Peggy
   Taylor, Mallie
   Swinford, Tiffany
   Spivey, Robbin
   Banach, Michael
   Ho, Lawrence
   Lanning, Richard
   Pheasant, Thomas R.
   Prensky, Jay G.
   Truong, Steven
   Teatsworth, Julia
   Dietrich, Michelle
   Wasilus, Ann
   Miller, Ann
   Rakes, Megan
   Slagle, Teresa
   Richards, Michelle
   Schuessler, Patricia
   Stover, Lacy
   Beer, Paul
   Falk, Naomi S.
   Shannon, Mary Beth
   Olmeda, Jeannie
   Berdeen, Don
   Fisher, Joseph F., Jr.
   Folk, James
   Russell, Stephen
   Taylor, Barbara
   Hinz, Connie
   Walshire, Jean
   Stockman, Heather
   Critser, Bruce
   Karakas, Stefani
   Montague, Cindy
   Verdick, Randy
   Gupta, Omesh
   Maguire, Joseph
   Brady, Christopher
   DeCroos, Francis Char
   Dollin, Michael
   Garg, Sunir
   Gerstenblith, Adam
   Haller, Julia
   Ho, Allen C.
   Hsu, Jason
   Kaiser, Richard
   Pitcher, John
   Regillo, Carl
   Shah, Rajiv
   Spirn, Marc
   Tasman, William
   Vander, James
   Senderowitsch, Noga
   Formoso, Michele
   Markun, Michelle
   George, Cedric
   Centinaro, Christina
   Grande, Lisa
   Carey, Stefanie
   Liebenbaum, Elaine
   Sadda, SriniVas
   Humayun, Mark
   Sierra, Rachel
   Corona, Elizabeth
   Padilla, Margaret
   Nu, Moonseok
   Ramos, Sylvia
   Barnett, Cullen
   Currie, Glenn
   Gottlieb, Cornelia
   Garfinkel, Richard
   Berinstein, Daniel
   Colyer, Marcus
   Deegan, William, III
   Lai, Michael Min-Shyue
   Murphy, Robert
   Osman, Michael
   Rivers, Michael
   Sanders, Reginald
   von Fricken, Manfred A.
   Oliver, Debbie
   Kirshon, Jeanne
   Snowden, Tanya Alexander
   Blondo, Thomas
   Cronise, Alysia
   Denny, Vanessa
   Mendez, Kylie
   Newgen, Janine
   Davis, Justin
   Flory, Mike
   Frantz, Robert
   Murphy, Bryan
   Rauch, Steve
   Kim, Judy E.
   Bachman, Jane
   Connor, Thomas B., Jr.
   Han, Dennis P.
   Stepian, Kimberly
   Weinberg, David, V
   Wirostko, William J.
   Packard, Krissa
   Kaczanowski, Tracy
   Williams, Vesper
   Barwick, Vicki
   Flanders, Judy
   Backes, Dennis
   Beringer, Joe
   Keller, Kristy
   Selchert, Kathy
   Bernstein, Paul
   Teske, Michael
   Vitale, Albert
   Allman, Susan
   Carlstrom, Bonnie
   Wegner, Kimberley
   Haroldsen, Anne
   Harrison, Deborah
   Fry, Cyrie
   Gilman, James
   Jenkins, Glen
   Morris, Paula
   Rauser, Michael
   Fan, Joseph
   Suthar, Mukesh
   Santiago, Gisela
   Halsey, Kara Rollins
   Quesada, Christy
   Kiernan, William
   Knabb, Jesse
   Lewis, Richard Alan
   Dorenbach, Cindy
   Spencer, Steven
   Barnett, Dana
   Morales, Joseph
   Fishburne, Barron C.
   Gross, Jeffrey G.
   Magee, Michael A.
   Flowers, Amy
   McDowell, Angie
   Price, Randall
   Huang, Suber
   Tang, Johnny
   Wilker, Shawn
   Hornsby, Cherie
   Ferguson, Lisa
   Krogstad, Kirk
   Adamovsky, Riva
   Allchin, Peggy
   Carlton, Kathleen
   Clow, Claudia
   Sholtis, Kelly
   Burke, Stephanie
   Harrod, Mark
   Hrvatin, Stacie
   Pankhurst, Geoffrey
   Sabates, Nelson R.
   Cassell, Michael
   Desai, Komal
   Poulose, Abraham
   Sabates, Felix
   Chen, Yin
   Gallimore, Gary
   Konior, Yolanda
   Kim, Nicola
   Uwaydat, Sami
   Troillett, Deborah
   Aletter, Karen
   Frank, Robert N.
   Abrams, Gary
   Puklin, James
   Tewari, Asheesh
   Milanovic, Cheryl
   Bailey, Melanie
   Griffith, David
   McDonald, Dena
   Morehead, Kit
   Sadikovic, Zlatan
   Schillace, Lisa
   Silvis, Elizabeth
   Joondeph, Brian
   Christmas, Nancy
   Kimura, Alan
   Liu, Mimi
   Petty, Stephen
   Zilis, John
   Benitez, Jenny
   Catlett, Cassandra Berryman
   Fluegel, Eric
   Mowry, Shane
   Hoang Nguyen
   Reflow, David
   Houghton, Odette M.
   Garg, Seema
   Landers, Maurice B.
   Meredith, Travis
   Barnhart, Sandy
   Karmalkar, Megha
   Cantrell, Debra
   Esquejo-Leon, Rona Lyn
   Manor, Linda
   Pope, Sue
   Stines, David
   Stokely, Amelia
   Hainsworth, Dean
   Helming, Dyann
   Eichelberger, Debbie
   Leaton, Mary Paige
   Hamm, Chuck
   Chaum, Edward
   Iannaccone, Alessandro
   Jennings, Barbara
   Murray, Tracy
   Mastellone, Joe
   Millay, Robert
   Kim, Brian
   Goddard, Theresa
   Beaudette, Liza Jarrett
   Changelian-Aitken, Nina
   Corrada, Fernando
   Dubuque, Jason
   Iezzi, Raymond
   Bakri, Sophie J.
   Pulido, Jose S.
   Vogen, Diane
   Nielsen, Rebecca
   Berg, Karin
   Burrington, Jean
   Howard, Shannon
   Overend, Joan
   Krason, Zbigniew
   Lewison, Denise
   Link, Thomas
   Blinder, Kevin J.
   Engelbrecht, Nicholas E.
   Grand, M. Gilbert
   Joseph, Daniel P.
   Shah, Gaurav K.
   Smith, Bradley
   Thomas, Matthew
   Weeks, Rhonda
   Boyd, Lynda
   Gabel, Dana
   Adelman, Ron
   Huang, John
   Kempton, James
   Parnes, Aaron
   Dupont, Jennifer
   Perotti, Elizabeth
   Donaldson, Victoria
   Fong, Kenneth
   Ossorio, Pamela
   Agarwal, Anita
   Sternberg, Paul
   Owings, Sandy
   Adkins, Tony
   Lok, Elaine
   Munn, Garvin
   Skellie, Buddy
   Bhagat, Neelakshi
   Roy, Monique S.
   Zarbin, Marco
   Fay, Catherine
   Lazar, Michael
   Malpica, Beth
   Mikheyav, Tatiana
   Ulanski, Lawrence, II
   Lim, Jennifer
   Niec, Marcia
   Johnson, Tametha
   Ovando, Yesenia
   Carroll, Catherine Nail
   Janowicz, Mark
   Schwartz, Steven
   Cupp, David
   Gorin, Michael
   Heilweil, Gad
   Hosseini, Hamid
   Hubschman, Jean-Pierre
   Kreiger, Allan
   McCannel, Tara Young
   Pan, Carolyn
   Sarraf, David
   Tsui, Irena
   Udoetek, Joshua
   Voleti, Vinad
   Hitchcock, Logan
   Ostrick, Rosaleen
   Chun, Melissa
   Kageyama, Jennie
   Davila, Nilo
   Lipka, Kristin
   Shin, Christina
   Owsley, Cynthia
   Albert, Michael, Jr.
   Feist, Richard
   Mason, John
   Thomley, Martin
   Johnson, Angelia
   Clark, Mark
   Emond, Tracy
   Hamela, Joanna
   Marsh, Angela
   Searcey, Karen
   Rookard, Kia
   He, Yu-Guang
   Ufret-Vincenty, Rafael L.
   Molai, Mike
   Anderson, William
   Horna, John
   Letson, Alan
   Cebulla, Colleen
   Chang, Susie
   Davidorf, Fred
   Salerno, Jill
   Sladoje, Laura
   Stetson, Christina
   Perry, Jeri
   Savage, Scott
   Toth, Cynthia
   Jaffe, Glenn
   Schuman, Stefanie
   Sarin, Neeru
   Crowell, Jim
   Keaton, Tiffanie
   Kelly, Michael
   Lutman, Brian
   Skelly, Marriner
   Welch, Lauren
   Morse, Lawrence
   Hunter, Allan
   Park, Susanna Soon-Chun
   Wallace, Cynthia
   Dhillon, Ember
   Salvador, Marisa
   Holderreed, Barbara
   Chandra, Karishma
   Kaur, Sashi
   Redenbo, Ellen
   Hom, Smiley
   Cooney, Michael
   Barbazetto, Irene
   Klancnik, James M., Jr.
   Sorenson, John A.
   Yannuzzi, Lawrence
   Scolaro, Maria
   Agresta, Eugene
   Gonzalez, Nancy
   Grover, Sandeep
   Chalam, K., V
   Gupta, Shailesh
   Lyons, Christopher
   Li, Wenhua
   Patel, Chirag
   Carrion, Jose
   Ferreyra, Henry
   Rodriguez, Amberly
   Molina, Iliana
   Balea, Gabriel
   Emory, Pam
   Rico, Marlene
   Siqueiros, Giorgio
   Brucker, Alexander J.
   Dunaief, Joshua
   Grunwald, Juan
   Kim, Benjamin
   Maguire, Albert M.
   VanderBeek, Brian
   Drossner, Sheri
   DuPont, Joan
   Salvo, Rebecca
   Berger, Jim
   Devine, Cheryl
   Nyberg, Bill
   Weeney, Laurel
   DiLoreto, David
   Chung, Mina
   Davis, Valerie
   MacDowell, Peter
   Gara, George O.
   Castillo, Daniel
   Czubinski, Andrea
   Keim, Melissa
   Hardy, Brandi
   Hollar, Rachel Grunhaus
   Schueckler, Lynn
   Lyon, Alice T.
   Weinberg, Aaron
   Shiloach, Mira
   Pelkofer, Nicole
   Zhou, Qin
   McPoland, Laura
   Apte, Rajendra
   Rao, P. Kumar
   Pistorius, Sam
   Kambarian, Jamie
   Adcock, Eve
   Gould, Sarah
   Quinn, Melanie
   Curtis, Rhonda
   Frost, Amy
   Meyer, Charla
   Rathert, Greg
CA Age Related Eye Dis Study 2 Res
TI Natural History of Drusenoid Pigment Epithelial Detachment Associated
   with Age-Related Macular Degeneration Age-Related Eye Disease Study 2
   Report No. 17
SO OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; EYE DISEASE; CLASSIFICATION; ARMS2; POLYMORPHISM;
   EVOLUTION; VARIANT; RISK
AB Purpose: To investigate the natural history and genetic associations of drusenoid pigment epithelial detachment ( DPED) associated with age-related macular degeneration (AMD).
   Design: Retrospective analysis of a prospective cohort study.
   Participants: Of the 4203 Age-Related Eye Disease Study 2 (AREDS2) participants, 391 eyes (325 participants) had DPED without late AMD at the time of DPED detection. Genetic analyses included 120 white AREDS2 participants and 145 Age-Related Eye Disease Study (AREDS) participants with DPED.
   Methods: Baseline and annual stereoscopic fundus photographs were graded centrally to detect DPED, a well-defined yellow elevated mound of confluent drusen >= 433 mm in diameter, and to evaluate progression rates to late AMD: geographic atrophy (GA) and neovascular (NV)-AMD. Five single nucleotide polymorphisms (CFH [rs10611670], C3 [rs2230199], CFI [rs10033900], C2/CFB [rs114254831], ARMS2 [rs10490924]) and genetic risk score (GRS) group were investigated for association with DPED development. KaplaneMeier analyses and multivariable proportional hazard regressions were performed.
   Main Outcome Measures: Progression rates to late AMD and decrease of >= 3 lines in visual acuity (VA) from the time of DPED detection; association of rate of DPED development with genotype.
   Results: Mean (standard deviation [SD]) follow-up time from DPED detection was 4.7 (0.9) years. DPED was associated with increased risk of progression to late AMD (hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.98-2.82; P < 0.001); 67% of eyes progressed to late AMD 5 years after DPED detection. Drusenoid pigment epithelial detachment was associated with increased risk of >= 3 lines of VA loss (HR, 3.08; CI, 2.41-3.93; P < 0.001) with 46% of eyes experiencing vision loss at 5 years (with or without progression to late AMD). ARMS2 risk alleles (1 vs. 0: HR, 2.72, CI, 1.58-4.70; 2 vs. 0: HR, 3.16, CI, 1.60-6.21, P < 0.001) and increasing GRS group (4 vs. 1) (HR, 12.17, CI, 3.66-40.45, P < 0.001) were significantly associated with DPED development in AREDS. There were no significant genetic results in AREDS2.
   Conclusions: This study replicates the results of previous natural history studies of eyes with DPED including the high rates of progression to late AMD and vision loss (regardless of progression to late AMD). The genetic associations are consistent with genes associated with AMD progression. Published by Elsevier on behalf of the American Academy of Ophthalmology.
C1 [Yu, Jeannette J.; Agron, Elvira; Keenan, Tiarnan D.; Cukras, Catherine; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] Emmes Corp, Rockville, MD USA.
   [Domalpally, Amitha] Univ Wisconsin, Fundus Photog Reading Ctr, Madison, WI USA.
   [van Asten, Freekje] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Agron, Elvira; Chew, Emily Y.; Ferris, Frederick L., III; SanGiovanni, John Paul; Wong, Wai T.; Dalal, Monica; Jacobs-El, Naima; Meyerle, Catherine; Nicholson, Benjamin; Wiley, Henry; Shimel, Katherine Hall; Garced, Angel; Oparah, Janice; Short, Greg; Temple, Alana; Ayukawa, Babilonia; Foster, Guy; Hayes, Darryl; Koutsandreas, Dessie; Nashwinter, Roula; Rowan, John; Bono, Michael; Cunningham, Denise; Palmer, Marilois; Zetina, Alicia] NEI, Bethesda, MD 20892 USA.
   [Clemons, Traci; Lindblad, Anne; Lindblad, Robert; Shah, Nilay; Sperduto, Robert; McBee, Wendy; Gensler, Gary; Harrington, Molly; Henning, Alice; Jones, Katrina; Thotapally, Kumar; Tull, Diana; Watson, Valerie; Williams, Kayla; Gentry, Christina; Kaufman, Francine; Morrison, Chris; Saverino, Elizabeth; Schenning, Sherrie] EMMES Corp, Coordinating Ctr, Rockville, MD USA.
   [Blodi, Barbara; Danis, Ronald P.; Davis, Matthew; Glander, Kathy; Guilfoil, Gregory; Hubbard, Larry D.; Johnson, Kristine; Klein, Ronald; Nardi, Barbara; Neider, Michael; Robinson, Nancy; Rosensteel, Eileen; Wabers, Hugh; Zhang, Grace] Fundus Photograph Reading Ctr, Beaver Dam, WA USA.
   [Ruby, Alan J.; Capone, Antonio, Jr.; Dass, Bawa; Drenser, Kimberly; Garretson, Bruce R.; Hassan, Tarek S.; Trese, Michael; Williams, George A.; Wolfe, Jeremy; Bell, Tina; Zajechowski, Mary; Bezaire, Dennis; McIver, Fran; Medina, Anthony; Pagett, Jackie; Smith, Stephanie Hatch; Swartz, Lynn; Treuter, Tom] Vis Res Fdn, Novi, MI USA.
   [Antoszyk, Andrew; Brown, Justin; Browning, David J.; Holland, Walter; Karow, Angella; Stalford, Kelly; Price, Angela; Ennis, Sarah; Fredenberg, Sherry; Herby, Jenna; Balasubramaniam, Uma; Clark, Loraine; McClain, Donna; McOwen, Michael; Watson, Lynn] Charlotte Eye Ear Nose & Throat Associates, Charlotte, NC USA.
   [Klein, Michael; Bailey, Steven T.; Hwang, Thomas J.; Lauer, Andreas; Stout, J. Timothy; McCollum, Patty; Johnson, Milt; Rice, Patrick B.] Devers Eye Inst, Portland, OR USA.
   [Kim, Ivana; Loewenstein, John; Miller, Joan; Sobrin, Lucia; Young, Lucy; Sullivan, Jacqueline; Houlihan, Patricia; Merry, Linda; Lane, Ann Marie; Bator, Ursula Lord; Evans, Claudia; Brett, Sarah; Callahan, Charleen; Grillo, Marcia; Walsh, David; Zimmerman, Kamella Lau] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Fish, Gary Edd; Anand, Rajiv; Coors, Lori E.; Fuller, Dwain G.; Spencer, Rand; Wang, Robert C.; Duignan, Karen; Arceneaux, Sally; Aguado, Hank; Hesse, Nicholas; Mackens, Michael; Swan, Brian; Callanan, David G.; Solley, Wayne A.; Williams, Patrick; Lash, Sandy; Boleman, Bob; Dock, Chris; Shami, Michel; Arrington, Brenda; Meeks, Ashaki] Texas Retina Associates, Dallas, TX USA.
   [Orth, David H.; Rezaei, Kourous; Civantos, Joseph; Hasan, Sohail; Packo, Kirk; Figliulo, Celeste; Stanberry, Pam; Farmer, Tara; Nelson, Kiersten; Townsend-Patrick, Shannya] Ingalls Mem Hosp, Harvey, IL USA.
   [Rosenfeld, Philip; Chen, Royce; Doshi, Rishi; Dubovy, Sander; Kim, Brian T.; Lowrance, Matthew; Moshfeghi, Andrew; Nahas, Zayna; Schienbaum, Gary; Vishak, John; Weng, Christina; Yehoshua, Zohar; Rodriguez, Belen; Rebimbas, Jose; Gleichauf, Jane; Kicak, Mike; Mena, Jason; Odem, Tim; Sferza-Camp, Elizabeth; Disgdiertt, Alicia; Oramas, Jim; Rams, Isabel; Thatcher, Stephanie] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Bressler, Susan B.; Bressler, Neil M.; Finkelstein, Daniel; Sherman, Steven H.; Solomon, Sharon; Ying, Howard S.; Denbow, Rita; Phillips, Deborah; Radcliffe, Elizabeth; Belt, Judy; Cain, Dennis; Emmert, David; Herring, Mark; McDonald, Jacquelyn] Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA.
   [Hubbard, G. Baker; Bergstrom, Chris S.; Cribbs, Blaine; Hendrick, Andrew; Johnson, Brandon; Laird, Philip; Mehta, Sonia; Olsen, Timothy; Townsend, Justin; Yan, Jion; Yeh, Steven; Curtis, Linda; Brower, Judy; Yi, Hannah; Dobbs, Jannah Rutter; Jordan, Debbie] Emory Univ, Eye Ctr, Atlanta, GA 30322 USA.
   [Elman, Michael J.; Liss, Robert A.; Starr, JoAnn; Belz, Jennifer; Putzulo, Charlene; Coffey, Teresa; Davis, Ashley; Singletary, Pamela; Andreani, Giorya Shabi; Cain, Theresa; Ketner, Daniel; Sotirakos, Peter] Elman Retina Grp, Glen Burnie, MD USA.
   [Chandra, Suresh; Blodi, Barbara A.; Altaweel, Michael M.; Gottlieb, Justin L.; Ip, Michael; Nork, T. Michael; Stevens, Thomas S.; Burke, Kathryn; Olson, Shelly; Dietzman, Kristine; Soderling, Barbara; Somers, Guy; Wealti, Angie; Krolnik, Denise; Peterson, John; Reed, Sandra] Univ Wisconsin, Madison, WI 53706 USA.
   [Friberg, Thomas; Eller, Andrew; Gallagher, Denise; Labriola, Leanne; Pokrifka, Melissa; Gedansky, Aron; Anthony, Natalie; Grzybowski, Cassandra; Matthews, Dawn; Murajda-Jumba, Sharon; Toro, Jessica] UPMC, Eye Ctr, Pittsburgh, PA USA.
   [Margherio, Alan R.; Raphaelian, Paul; Markus, Debra; Langdon, Justin; Truax, Elizabeth; Lewis, Sandy; Terry, Brad; Noffke, Amy; Oh, Kean; Sarrafizadeh, Ramin; Sneed, Scott; Hammersley, Julie; Neal, Serena; Doran, Mary; Jones, Nan; Preston, Lisa; Jessick, Heather; Marsh, Tanya Tracy] Vis Res Fdn, Royal Oak, MI 48073 USA.
   [Tolentino, Michael; Berger, Adam; Hamilton, Richard; Misch, David; Moon, Suk Jin; Sutherland, Dawn; Dilts, Vera; Henderson, Sara; Medina, Esmeralda; Trueman, Donald; Holm, Laura; Strickland, Jason] Ctr Retina & Macular Dis, Sebring, FL USA.
   [Ie, Darmakusuma; Lipkowitz, Jeffrey L.; Shah, Kekul B.; Geraghty, Susan; Sannazzaro, Beverly; Harper, Morgan; Bayer, Krista] Delaware Valley Retina Associates, Lawrenceville, NJ USA.
   [Lansing, Mary B.; Fox, Lauren B.; Lee, Rebecca] Eldorado Retina Associates PC, Louisville, KY USA.
   [Stallman, Jay B.; Jacobson, Michael; Koh, Sean; Lampert, Scott; Miller, John; Rivellese, Mark; Sharma, Atul; Stoltz, Robert A.; Vanderveldt, Stephanie; Marcus, Leslie; Hendricks, Starr; Hollman, Ryan; Betanzos, Grethel; Ellorin, Leslie; Fulbright, Shelly; McCormick, Debbie] Georgia Retina PC, Stockbridge, GA USA.
   [Edwards, Paul A.; Hall, Julianne; Monk, Mary; Gutkowski, Melanie; Mazurek, Melina; Murphy, Janet; Gusas, Katherine; Moffett, Crystal; Burley, David; Chesney, Nicole; Kilgo, Katie; Rusinek, Brian; Stern, Bradley; Troszak, Tracy; Baker-Levingston, Rhonda] Henry Ford Hlth Syst, Eye Care Serv, Detroit, MI USA.
   [Baker, Carl W.; Caldwell, Tracey; Walker, Tammy; Lambert, Lynnette F.; Martin, Tracey; Palmer, Mary Jill; Williams, Tana] Paducah Retinal Ctr, Paducah, KY USA.
   [Novak, Michael A.; Coney, Joseph; Miller, David G.; Pendergast, Scott; Singerman, Lawrence; Zakov, Nicholas; Zegarra, Hernando; DuBois, Kim; Rath, Susan; Revella, Lori; Brink, Tammy; Drury, Kim; Hogue, Lisa; Ilc, Mary; Keller, Connie; McNamara, Elizabeth; Tanner, Vivian; Cunningham, Tamara; DuBois, John; Greanoff, Gregg; Nitzsche, Trina; Smith-Brewer, Sheila] Retina Associates Cleveland, Cleveland, OH USA.
   [Isernhagen, Ricky D.; Kitchens, John W.; Stone, Thomas W.; Wood, William J.; Holcomb, Diana; Therrien, Virginia; Buck, Michelle; Van Arsdall, Jeanne; Slade, Edward] Retina Associates Kentucky, Lexington, KY USA.
   [Schneiderman, Todd E.; Spinak, David J.; Gaedke, Jackie; Brown, Heather Davis; Helgren, Dan; Pangelinan, Jenifer Garrison] Retina Ctr Northwest, Silverdale, WA USA.
   [Halperin, Lawrence; Anagnoste, Scott; Dhalla, Mandeep; Rosenberg, Krista; Taney, Barry; Thompson, W. Scott; Lopez, Jaclyn; Hamlin, Monica; Lopez, Monica; Mariano, Jamie; Quinchia, Evelyn; Aramayo, Patricia; Veksler, Rita] Retina Grp Florida, Plantation, FL USA.
   [Lee, Michael; Dreyer, Richard; Handelman, Irvin; Ma, Colin; Peters, Mark; Hobbs, Stephen, III; Milliron, Amanda; Kopfer, Marcia; Connaughton, Michele; Hoerner, A. Christine; Logan, R. Joseph; Wohlsein, Harry J.] Retina Northwest PC, Portland, OR USA.
   [Boyer, David; Chu, Thomas G.; Dayani, Pouya; Liao, David; Novack, Roger L.; Rahhal, Firas M.; Roe, Richard; Tabandeh, Homayoun; Bayramyan, Janet; Gasparyan, Tammy; Hoang, Connie; Kurokouchi, Janet; Lo, Tammy Eileen; Ngo, Richard; Nguyen, Mary Ann; Peyton, Michael; Yoon, Charles; Sierra, Julio; Zamboni, Adam; Kessinger, Jeff; Protacio, Eric; Smucker, Adam] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
   [Rath, Pamela; Bergren, Robert; Doft, Bernard; Liu, Judy; Olsen, Karl; Merlotti, Lori; Ingram, Willia; Marfisi, Kellianne; Yeckel, Kimberly; Carmelo, Heather Schultz; Fec, Amanda; McBroom, Keith; Steinberg, David] Retina Vitreous Consultants, Monroeville, PA USA.
   [Levy, Marc; Abrams, Jody; Chen, Melvin; Torres, Waldemar; Jelemensky, Peggy; Prybylski, Mark; Raphael, Tara; Appleby, Diana; Rodman, Charlotte; Sneath, Mark] Sarasota Retina Inst, Sarasota, FL USA.
   [Rosa, Robert H., Jr.; Hoelscher, Vanessa; Castano, Adelia; Parker, Jocelyn] Scott & White Mem Hosp & Clin, Temple, TX 76508 USA.
   [Hoskins, John; Anderson, Nicholas; Googe, Joseph, Jr.; McMillan, Tod A.; Miller, James, Jr.; Perkins, Stephen; Oliver, Kristina; Beerbower, Jennifer; Gilliland, Bruce; Hunt, Cecile; Jacobus, Mike; Lince, Raul; Morris, Christopher; Oelrich, Sarah; Whetstone, Jerry] Southeastern Retina Associates PC, Kingsport, TN USA.
   [Chan, Clement K.; Lin, Steven; Walther, Kim; Gonzales, Tiana; Myers, Lenise; Huff, Kenneth] Southern Calif Desert Retina Consultants MC, Palm Desert, CA USA.
   [Brown, David M.; Chen, Eric; Benz, Matthew S.; Fish, Richard H.; Kim, Rosa Y.; Major, James, Jr.; Wong, Tien Pei; Wycoff, Charles; Cone, Cassandra; Gilaspia, Debbie Goates; Landaverde, Nubia; Smith, Robert; Zamora, Deneva; Sneed, Veronica; Vela, Melina; Kegley, Eric] Retina Consultants Houston, Houston, TX USA.
   [Greven, Craig; Kurup, Shree; Richards, Charles; Slusher, Madison; Everhart, Cara; Fish, Joan; Miller, David; Tyler, Marshall] Wake Forest Univ, Eye Ctr, Winston Salem, NC 27109 USA.
   [Jumper, J. Michael; Fu, Arthur D.; Johnson, Robert N.; Lujan, Brandon; McDonald, H. Richard; Rodriguez, Rosa; Ansari, Nina; Joaquin, Jeanifer; Linares, Silvia; Lopez, Lizette; Sabio, Jessica; Grout, Sean; Indermill, Chad; Urias, Yesmin; Zimmerman, Roberto] West Coast Retina Med Grp Inc, Corte Madera, CA USA.
   [Margulies, Linda; Schmidt, Sara J.; Meier, Joy L.; Hadley, Sherry L.] Vet Affairs Northern Calif Hlth Care Syst, Vallejo, CA USA.
   [Rosenthal, William; Johnson, Barbara; Swafford, Lois; Shields, Richard; Varner, R. Scott] Midamer Retina Consultants PA, Kansas City, MO USA.
   [Rosen, Richard; Gentile, Ronald; Rivas, Melissa; Tai, Katy W.; Carrasquillo-Boyd, Wanda; Masini, Robert] New York Eye & Ear Infirm, New York, NY 10003 USA.
   [Stoller, Glenn; Carnevale, Ken; LaRosa, Diane M.; Burger, Barbara; Conway, Tereza; Del Castillo, Carla; Diaz, Julissa; Jones, Susan; Mondoc, Nina; Balfour, Charlene; Vitha, C. H.; Lutz, Jennifer; McGinley, Barbara] Ophthalm Consultants Long Isl, Plainview, NY USA.
   [El Baba, Fadi; Lavorna, Ann Marie; Jones, Renee; Lewis, Jean; Tenzler, Ruth; Salvas-Mladek, Mary; Van Kesteren, Diane] Res Fdn SUNY SB, Stony Brook, NY USA.
   [McLean, W. Copley, Jr.; Bridges, W. Zachery, Jr.; Stone, Cameron; Ammons, Denise; Lamy, Mary; Menzel, Andrea; Raymer, Lea Doll; Campbell, Barbara; Hawkins, Lisa; Rickman, Leslie; Sherlin, Lorraine; Price, Paula; Sinyai, Albert] Western Carolina Retinal Associates, Asheville, NC USA.
   [Kingsley, Ronald; Bradford, Reagan H., Jr.; Leonard, Robert E., II; Icks, Sonny; Bergman, Vanessa; Ross, Brittany; Burris, Russ; Butt, Amanda; Richmond, Rob] Dean McGee Eye Inst, Oklahoma City, OK USA.
   [Lyon, Alice; Gill, Manjot; Jampol, Lee; Mizra, Rukhsana; Rozenbajgier, Zuzanna; Chapman, Jeremy; Kaminski, Lori; Degillio, Andrea; Simjanoski, Evica] Northwestern Univ, Ophthalmol, Evanston, IL 60208 USA.
   [Heier, Jeffrey; Cho, Hyung; Cleary, Tina Scheufele; Goldman, Darin; Shah, Chirag; Topping, Trexler; Weber, Marissa; Wiegand, Torsten; Schindelheim, Jeremy; Bankert, Joy; Stone, Jennifer; Nowak, Alison; Chong, Sandy; Williams, Lindsay; Bennett, Steven; Donovan, Dennis; Graham, Margaret; Jones, Cullen] Ophthalm Consultants Boston, Boston, MA USA.
   [Fung, Anne; Bayabo, Jan-Kristine; Bosch, Razelda; Cruz, Esperanza; Emerson, Ashley; Fleming, Alycia; Barsness, Denice; Rodriguez, Jorge; Soboleva, Marina] Pacific Eye Associates, San Francisco, CA USA.
   [Scott, Ingrid U.; Bowie, Esther; Neely, Kimberly A.; Quillen, David A.; Walter, Laura; Bennett, Timothy; Strong, James] Penn State MS Hershey Med Ctr, Hershey, PA USA.
   [Wells, John, III; Clark, Lloyd; Johnson, David; Miller, Peggy; Taylor, Mallie; Swinford, Tiffany; Spivey, Robbin] Palmetto Retina Ctr, W Columbia, SC USA.
   [Banach, Michael; Ho, Lawrence; Lanning, Richard; Pheasant, Thomas R.; Prensky, Jay G.; Truong, Steven; Teatsworth, Julia; Dietrich, Michelle; Wasilus, Ann; Miller, Ann; Rakes, Megan; Slagle, Teresa; Richards, Michelle; Schuessler, Patricia; Stover, Lacy] Penn Retina Specialists PC, York, PA USA.
   [Beer, Paul; Falk, Naomi S.; Shannon, Mary Beth; Olmeda, Jeannie; Berdeen, Don; Fisher, Joseph F., Jr.] Retina Consultants PLLC, Charleston, WV USA.
   [Folk, James; Russell, Stephen; Taylor, Barbara; Hinz, Connie; Walshire, Jean; Stockman, Heather; Critser, Bruce; Karakas, Stefani; Montague, Cindy; Verdick, Randy] Univ Iowa, Iowa City, IA 52242 USA.
   [Gupta, Omesh; Maguire, Joseph; Brady, Christopher; DeCroos, Francis Char; Dollin, Michael; Garg, Sunir; Gerstenblith, Adam; Haller, Julia; Ho, Allen C.; Hsu, Jason; Kaiser, Richard; Pitcher, John; Regillo, Carl; Shah, Rajiv; Spirn, Marc; Tasman, William; Vander, James; Senderowitsch, Noga; Formoso, Michele; Markun, Michelle; George, Cedric; Centinaro, Christina; Grande, Lisa; Carey, Stefanie; Liebenbaum, Elaine] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Philadelphia, PA USA.
   [Sadda, SriniVas; Humayun, Mark; Sierra, Rachel; Corona, Elizabeth; Padilla, Margaret; Nu, Moonseok; Ramos, Sylvia; Barnett, Cullen; Currie, Glenn; Gottlieb, Cornelia] USC, Doheny Eye Inst, Los Angeles, CA USA.
   [Garfinkel, Richard; Berinstein, Daniel; Colyer, Marcus; Deegan, William, III; Lai, Michael Min-Shyue; Murphy, Robert; Osman, Michael; Rivers, Michael; Sanders, Reginald; von Fricken, Manfred A.; Oliver, Debbie; Kirshon, Jeanne; Snowden, Tanya Alexander; Blondo, Thomas; Cronise, Alysia; Denny, Vanessa; Mendez, Kylie; Newgen, Janine; Davis, Justin; Flory, Mike; Frantz, Robert; Murphy, Bryan; Rauch, Steve] Retina Grp Washington, Washington, DC USA.
   [Kim, Judy E.; Bachman, Jane; Connor, Thomas B., Jr.; Han, Dennis P.; Stepian, Kimberly; Weinberg, David, V; Wirostko, William J.; Packard, Krissa; Kaczanowski, Tracy; Williams, Vesper; Barwick, Vicki; Flanders, Judy; Backes, Dennis; Beringer, Joe; Keller, Kristy; Selchert, Kathy] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
   [Bernstein, Paul; Teske, Michael; Vitale, Albert; Allman, Susan; Carlstrom, Bonnie; Wegner, Kimberley; Haroldsen, Anne; Harrison, Deborah; Fry, Cyrie; Gilman, James; Jenkins, Glen; Morris, Paula] John Moran Eye Ctr, Salt Lake City, UT USA.
   [Rauser, Michael; Fan, Joseph; Suthar, Mukesh; Santiago, Gisela; Halsey, Kara Rollins; Quesada, Christy; Kiernan, William; Knabb, Jesse] Loma Linda Univ, Loma Linda, CA 92350 USA.
   [Lewis, Richard Alan; Dorenbach, Cindy; Spencer, Steven; Barnett, Dana; Morales, Joseph] Baylor Coll Med, Houston, TX 77030 USA.
   [Fishburne, Barron C.; Gross, Jeffrey G.; Magee, Michael A.; Flowers, Amy; McDowell, Angie; Price, Randall] Carolina Retina Ctr, Columbia, SC USA.
   [Huang, Suber; Tang, Johnny; Wilker, Shawn; Hornsby, Cherie; Ferguson, Lisa; Krogstad, Kirk; Adamovsky, Riva; Allchin, Peggy; Carlton, Kathleen; Clow, Claudia; Sholtis, Kelly; Burke, Stephanie; Harrod, Mark; Hrvatin, Stacie; Pankhurst, Geoffrey] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Sabates, Nelson R.; Cassell, Michael; Desai, Komal; Poulose, Abraham; Sabates, Felix; Chen, Yin; Gallimore, Gary; Konior, Yolanda] Eye Fdn Kansas City, Kansas City, MO USA.
   [Kim, Nicola; Uwaydat, Sami; Troillett, Deborah; Aletter, Karen] UAMS, Jones Eye Inst, Little Rock, AR USA.
   [Frank, Robert N.; Abrams, Gary; Puklin, James; Tewari, Asheesh; Milanovic, Cheryl; Bailey, Melanie; Griffith, David; McDonald, Dena; Morehead, Kit; Sadikovic, Zlatan; Schillace, Lisa; Silvis, Elizabeth] Kresge Eye Inst, Detroit, MI USA.
   [Joondeph, Brian; Christmas, Nancy; Kimura, Alan; Liu, Mimi; Petty, Stephen; Zilis, John; Benitez, Jenny; Catlett, Cassandra Berryman; Fluegel, Eric; Mowry, Shane; Hoang Nguyen; Reflow, David] Colorado Retina Associates PC, Parker, CO USA.
   [Houghton, Odette M.; Garg, Seema; Landers, Maurice B.; Meredith, Travis; Barnhart, Sandy; Karmalkar, Megha; Cantrell, Debra; Esquejo-Leon, Rona Lyn; Manor, Linda; Pope, Sue; Stines, David; Stokely, Amelia] UNC, Dept Ophthalmol, Chapel Hill, NC USA.
   [Hainsworth, Dean; Helming, Dyann; Eichelberger, Debbie; Leaton, Mary Paige; Hamm, Chuck] Univ Hlth Care, Mason Eye Inst, Salt Lake City, UT USA.
   [Chaum, Edward; Iannaccone, Alessandro; Jennings, Barbara; Murray, Tracy; Mastellone, Joe] Univ Tennessee HSC, Knoxville, TN 37996 USA.
   [Millay, Robert; Kim, Brian; Goddard, Theresa; Beaudette, Liza Jarrett; Changelian-Aitken, Nina; Corrada, Fernando; Dubuque, Jason] Fletcher Allen Hlth Care, Burlington, VT USA.
   [Iezzi, Raymond; Bakri, Sophie J.; Pulido, Jose S.; Vogen, Diane; Nielsen, Rebecca; Berg, Karin; Burrington, Jean; Howard, Shannon; Overend, Joan; Krason, Zbigniew; Lewison, Denise; Link, Thomas] Mayo Clin, Rochester, NY USA.
   [Blinder, Kevin J.; Engelbrecht, Nicholas E.; Grand, M. Gilbert; Joseph, Daniel P.; Shah, Gaurav K.; Smith, Bradley; Thomas, Matthew; Weeks, Rhonda; Boyd, Lynda; Gabel, Dana] Retina Inst, Richmond Hts, MO USA.
   [Adelman, Ron; Huang, John; Kempton, James; Parnes, Aaron; Dupont, Jennifer; Perotti, Elizabeth; Donaldson, Victoria; Fong, Kenneth; Ossorio, Pamela] Yale Univ, New Haven, CT 06520 USA.
   [Agarwal, Anita; Sternberg, Paul; Owings, Sandy; Adkins, Tony; Lok, Elaine; Munn, Garvin; Skellie, Buddy] Vanderbilt Eye Inst, Nashville, TN USA.
   [Bhagat, Neelakshi; Roy, Monique S.; Zarbin, Marco; Fay, Catherine; Lazar, Michael; Malpica, Beth; Mikheyav, Tatiana] UMDNJ, Newark, NJ USA.
   [Ulanski, Lawrence, II; Lim, Jennifer; Niec, Marcia; Johnson, Tametha; Ovando, Yesenia; Carroll, Catherine Nail; Janowicz, Mark] Univ Illinois, Chicago, IL 60680 USA.
   [Schwartz, Steven; Cupp, David; Gorin, Michael; Heilweil, Gad; Hosseini, Hamid; Hubschman, Jean-Pierre; Kreiger, Allan; McCannel, Tara Young; Pan, Carolyn; Sarraf, David; Tsui, Irena; Udoetek, Joshua; Voleti, Vinad; Hitchcock, Logan; Ostrick, Rosaleen; Chun, Melissa; Kageyama, Jennie; Davila, Nilo; Lipka, Kristin; Shin, Christina] Jules Stein Eye Inst, Los Angeles, CA 90024 USA.
   [Owsley, Cynthia; Albert, Michael, Jr.; Feist, Richard; Mason, John; Thomley, Martin; Johnson, Angelia; Clark, Mark; Emond, Tracy; Hamela, Joanna; Marsh, Angela; Searcey, Karen; Rookard, Kia] Univ Alabama Birmingham, Birmingham, AL USA.
   [He, Yu-Guang; Ufret-Vincenty, Rafael L.; Molai, Mike; Anderson, William; Horna, John] UT Southwestern Med Ctr, Dallas, TX USA.
   [Letson, Alan; Cebulla, Colleen; Chang, Susie; Davidorf, Fred; Salerno, Jill; Sladoje, Laura; Stetson, Christina; Perry, Jeri; Savage, Scott] Ohio State Univ, Columbus, OH 43210 USA.
   [Toth, Cynthia; Jaffe, Glenn; Schuman, Stefanie; Sarin, Neeru; Crowell, Jim; Keaton, Tiffanie; Kelly, Michael; Lutman, Brian; Skelly, Marriner; Welch, Lauren] Duke Univ, Durham, NC 27706 USA.
   [Morse, Lawrence; Hunter, Allan; Park, Susanna Soon-Chun; Wallace, Cynthia; Dhillon, Ember; Salvador, Marisa; Holderreed, Barbara; Chandra, Karishma; Kaur, Sashi; Redenbo, Ellen; Hom, Smiley] Univ Calif Davis, Davis, CA 95616 USA.
   [Cooney, Michael; Barbazetto, Irene; Klancnik, James M., Jr.; Sorenson, John A.; Yannuzzi, Lawrence; Scolaro, Maria; Agresta, Eugene; Gonzalez, Nancy; Grover, Sandeep] Manhattan Eye Ear & Throat Hosp, New York, NY 10021 USA.
   [Chalam, K., V; Gupta, Shailesh; Lyons, Christopher; Li, Wenhua; Patel, Chirag; Carrion, Jose] Univ Florida, Gainesville, FL 32611 USA.
   [Ferreyra, Henry; Rodriguez, Amberly; Molina, Iliana; Balea, Gabriel; Emory, Pam; Rico, Marlene; Siqueiros, Giorgio] Univ Calif San Diego, Shiley Eye Ctr, San Diego, CA USA.
   [Brucker, Alexander J.; Dunaief, Joshua; Grunwald, Juan; Kim, Benjamin; Maguire, Albert M.; VanderBeek, Brian; Drossner, Sheri; DuPont, Joan; Salvo, Rebecca; Berger, Jim; Devine, Cheryl; Nyberg, Bill; Weeney, Laurel] Scheie Eye Inst, Philadelphia, PA USA.
   [DiLoreto, David; Chung, Mina; Davis, Valerie; MacDowell, Peter; Gara, George O.; Castillo, Daniel; Czubinski, Andrea; Keim, Melissa; Hardy, Brandi; Hollar, Rachel Grunhaus; Schueckler, Lynn] Univ Rochester, Eye Inst, Rochester, NY 14627 USA.
   [Lyon, Alice T.; Weinberg, Aaron; Shiloach, Mira; Pelkofer, Nicole; Zhou, Qin; McPoland, Laura] NorthShore Univ HealthSyst, Evanston, IL USA.
   [Apte, Rajendra; Rao, P. Kumar; Pistorius, Sam; Kambarian, Jamie; Adcock, Eve; Gould, Sarah; Quinn, Melanie; Curtis, Rhonda; Frost, Amy; Meyer, Charla; Rathert, Greg] Washington Univ, Sch Med, St Louis, MO 63130 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; University of Wisconsin System; University of
   Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); National Institutes of Health (NIH) - USA;
   NIH National Eye Institute (NEI); Emmes Corporation; Devers Eye
   Institute; Harvard University; Massachusetts Eye & Ear Infirmary; Bascom
   Palmer Eye Institute; Johns Hopkins University; Johns Hopkins Medicine;
   Emory University; University of Wisconsin System; University of
   Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Henry Ford Health System; Henry Ford
   Hospital; Retina Associates of Cleveland, Inc.; Retina Vitreous
   Associates Medical Group; Scott & White Medical Center; Wake Forest
   University; New York Eye & Ear Infirmary of Mount Sinai; Northwestern
   University; Ophthalmic Consultants of Boston; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); Pennsylvania State University; Penn
   State Health; University of Iowa; Jefferson University; Doheny Eye
   Institute; University of Southern California; Medical College of
   Wisconsin; Loma Linda University; Baylor College of Medicine; Case
   Western Reserve University; University of Arkansas System; University of
   Arkansas Little Rock; University of North Carolina; University of North
   Carolina Chapel Hill; University of Tennessee System; University of
   Tennessee Health Science Center; University of Vermont Medical Center;
   Mayo Clinic; Yale University; Vanderbilt University; Rutgers State
   University New Brunswick; Rutgers State University Medical Center;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Alabama System;
   University of Alabama Birmingham; University of Texas System; University
   of Texas Southwestern Medical Center Dallas; University System of Ohio;
   Ohio State University; Duke University; University of California System;
   University of California Davis; Manhattan Eye Ear & Throat Hospital;
   State University System of Florida; University of Florida; University of
   California System; University of California San Diego; University of
   Pennsylvania; Pennsylvania Medicine; University of Rochester; NorthShore
   University Health System; Washington University (WUSTL)
RP Chew, EY (通讯作者)，NIH, CRC, Bldg 10,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Hwang, Thomas/AAV-5146-2020; Miller, John J/GZG-5663-2022; Hunter,
   Allan/AAJ-5848-2020; Chaum, Edward/AAR-1512-2021; Salvo,
   Rebecca/AAH-8845-2020; SanGiovanni, John Paul/AAU-3895-2020; Wong,
   Wai/B-6118-2017
OI Salvo, Rebecca/0000-0002-2992-6486; Folk, James/0000-0002-6271-2906;
   DiLoreto, David/0000-0002-1787-8069; Keenan,
   Tiarnan/0000-0002-2253-1772; Stallworth, Jeannette/0000-0003-2731-3376;
   Hubschman, Jean-Pierre/0000-0002-8631-3467; Ho,
   Allen/0000-0003-3921-608X; Russell, Stephen/0000-0003-3776-1367; Ferris,
   Frederick/0000-0002-4933-0639; Chaum, Edward/0000-0003-3542-8376; Wong,
   Wai/0000-0003-0681-4016; Elman, Michael/0000-0001-7726-9508; Domalpally,
   Amitha/0000-0002-8145-9619; Zarbin, Marco/0000-0002-7811-7132; Wolfe,
   Jeremy/0000-0003-2781-7152; Chew, Emily/0000-0003-0999-9802; Bailey,
   Steven/0000-0003-4949-1464; Scott, Ingrid/0000-0002-3908-7153; Chalam, K
   V/0000-0002-0004-9416
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda Maryland [HHS-N-260-2005-00007-C,
   NO1-EY-5-0007]; Office of Dietary Supplements; National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; National Institute of
   Neurological Disorders and Stroke; Intramural Research Program of the
   National Eye Institute [EY000546]; Nederlandse Oogonderzoek Stichting;
   Dr. P. Binkhorst Stichting; Stichting Dondersfonds; Prins Bernhard
   Cultuurfonds; Stichting A. F. Deutman Oogheelkunde Researchfonds;
   NATIONAL EYE INSTITUTE [P30EY001583] Funding Source: NIH RePORTER
FX Supported by the intramural program funds and contracts from the
   National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda Maryland (Contract
   HHS-N-260-2005-00007-C; ADB Contract NO1-EY-5-0007). Funds were
   generously contributed to these contracts by the following National
   Institutes of Health institutes: Office of Dietary Supplements, National
   Center for Complementary and Alternative Medicine, National Institute on
   Aging, National Heart, Lung, and Blood Institute, and National Institute
   of Neurological Disorders and Stroke. The sponsor and funding
   organization participated in the design and conduct of the study; data
   collection, management, analysis, and interpretation; and preparation,
   review, and approval of the manuscript. Funding for this research of FvA
   was provided by the Intramural Research Program of the National Eye
   Institute (EY000546) and grants awarded by the following organizations:
   Nederlandse Oogonderzoek Stichting, Dr. P. Binkhorst Stichting,
   Stichting Dondersfonds, Prins Bernhard Cultuurfonds, and Stichting A. F.
   Deutman Oogheelkunde Researchfonds.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Garcia CAD, 2013, RETINA-J RET VIT DIS, V33, P1558, DOI 10.1097/IAE.0b013e318285cbd2
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hoffman JD, 2016, INVEST OPHTH VIS SCI, V57, P2225, DOI 10.1167/iovs.15-18571
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarli A, 2017, CLIN OPHTHALMOL, V11, P1347, DOI 10.2147/OPTH.S134538
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
NR 29
TC 22
Z9 23
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2019
VL 126
IS 2
BP 261
EP 273
DI 10.1016/j.ophtha.2018.08.017
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HI2YI
UT WOS:000456312400023
PM 30142373
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rusu, IM
   Deobhakta, A
   Yoon, D
   Lee, M
   Slakter, JS
   Klancnik, JM
   Thompson, D
   Freund, KB
AF Rusu, Irene M.
   Deobhakta, Avnish
   Yoon, Dan
   Lee, Michele
   Slakter, Jason S.
   Klancnik, James M.
   Thompson, Desmond
   Freund, K. Bailey
TI INTRAOCULAR PRESSURE IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION SWITCHED TO AFLIBERCEPT INJECTION AFTER PREVIOUS
   ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID INTRAVITREAL INJECTIONS; RANIBIZUMAB; BEVACIZUMAB; PEGAPTANIB; TRIAL
AB Purpose: To assess for change in intraocular pressure (IOP) in neovascular age-related macular degeneration patients switched to aflibercept after receiving previous treatments of intravitreal bevacizumab or ranibizumab.
   Methods: This is a retrospective chart review of the first 53 patients (53 eyes) treated with at least 2 injections of 2 mg in 0.05 mL of aflibercept by March 6, 2013, after at least 2 previous injections of 0.5 mg in 0.05 mL of ranibizumab with or without previous injections of 1.25 mg in 0.05 mL of bevacizumab. The analysis was restricted to the first such sequence within each patient. The last previous anti-vascular endothelial growth factor injection before the switch to aflibercept was ranibizumab in all cases included in the study. Each person served as his or her own control. The pre-aflibercept IOP in the before state (treatment with bevacizumab or ranibizumab) was the preinjection IOP measure before dilation at the visit of the first aflibercept injection. Statistical analysis was performed using Microsoft Excel.
   Results: There were 41 patients who were first treated with ranibizumab followed by aflibercept and 12 patients treated with ranibizumab and bevacizumab followed by aflibercept. For each of these sequences, IOP in the treated eye during treatment with aflibercept (the after state) was computed in 3 different ways: the first IOP, the last IOP, and the mean IOP for the period when treated with aflibercept. The pooled data showed a mean pre-aflibercept (the before state) IOP of 14.87 that decreased to a mean first IOP of 14.57, mean last IOP of 13.79, and a mean IOP of 14.14 during aflibercept treatment. The inference is based on the pooled analysis. The 95% confidence interval for the differences (after minus before) were -0.30 (-1.12 to 0.52), -1.08 (-1.83 to -0.32), and -0.73 (-1.30 to -0.17) for the first, last, and mean IOPs, respectively. The corresponding P values were 0.46 for the first, 0.006 for the last, 0.01 for the mean IOP during the aflibercept treatment period.
   Conclusion: Intraocular pressure was found to be significantly lower in patients switched to aflibercept after previous treatments with ranibizumab and/or bevacizumab. Aflibercept may have a more favorable IOP safety profile in patients previously on other anti-vascular endothelial growth factor treatments.
C1 [Rusu, Irene M.; Deobhakta, Avnish; Yoon, Dan; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
   [Deobhakta, Avnish; Slakter, Jason S.; Klancnik, James M.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Deobhakta, Avnish; Lee, Michele] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA.
   [Deobhakta, Avnish; Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Slakter, Jason S.; Klancnik, James M.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Thompson, Desmond] Regeneron, Tarrytown, NY USA.
C3 New York University; Vitreous Retina Macula Consultants of New York;
   Columbia University; Columbia University; Manhattan Eye Ear & Throat
   Hospital; Regeneron
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Lee, Michele/0000-0003-4772-1908;
   Deobhakta, Avnish/0000-0001-8571-5539
FU LuEsther T. Mertz Retinal Research Foundation; Alimera; Allergan;
   Johnson and Johnson; Lpath; Ohr Pharma; Oraya; Sanofi; Digital
   Angiography Reading Center
FX Supported by the LuEsther T. Mertz Retinal Research Foundation. K.
   Bailey Freund is a consultant for Genentech, Regeneron, Bayer
   HealthCare. J. S. Slakter is a consultant for Oraya, Ohr Pharma, Lpath.
   Grants received from Alimera, Allergan, Johnson and Johnson, Lpath, Ohr
   Pharma, Oraya, Sanofi. Payments were made to Digital Angiography Reading
   Center for image evaluation services for clinical trials. Grants
   received from Oraya for lectures and SKS Ocular, LLC, for Stock/stock
   options. The other authors have no conflicting interests to disclose.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2010, AM ACAD OPHTH AAO AN
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Freund KB, 2006, RETINA-J RET VIT DIS, V26, P701, DOI 10.1097/00006982-200607000-00021
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Hoang Q V, 2012, AM ACAD OPHTH AAO AN
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kocabora MS, 2010, ACTA OPHTHALMOL, V88, pe44, DOI 10.1111/j.1755-3768.2008.01336.x
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Ladas JG, 2001, INVEST OPHTH VIS SCI, V42, P2584
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scott IU, 2009, AM J OPHTHALMOL, V148, P725, DOI 10.1016/j.ajo.2009.06.004
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
NR 26
TC 18
Z9 20
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2014
VL 34
IS 11
BP 2161
EP 2166
DI 10.1097/IAE.0000000000000264
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0DK
UT WOS:000344607100007
PM 25072648
DA 2022-11-30
ER

PT J
AU Kim, SY
   Kambhampati, SP
   Bhutto, IA
   McLeod, DS
   Lutty, GA
   Kannan, RM
AF Kim, Soo-Young
   Kambhampati, Siva P.
   Bhutto, Imran A.
   McLeod, D. Scott
   Lutty, Gerard A.
   Kannan, Rangaramanujam M.
TI Evolution of oxidative stress, inflammation and neovascularization in
   the choroid and retina in a subretinal lipid induced age-related macular
   degeneration model
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Oxidative stress; Inflammation; Microglia/macrophages; Choroidal
   neovascularization; Age-related macular degeneration
ID GEOGRAPHIC ATROPHY; PIGMENT EPITHELIUM; DAMAGE; MACROPHAGES; EXPRESSION;
   DISEASES; PRODUCTS; DRUSEN; MICE; MALONDIALDEHYDE
AB Oxidative stress, inflammation and neovascularization are the key pathological events that are implicated in human age-related macular degeneration (AMD). There are a limited number of animal models available for evaluating and developing new therapies. Most models represent late exudative or neovascular AMD (nAMD) but there is a relative paucity of models that mimic early events in AMD. The purpose of this study is to characterize the evolution of oxidative stress, inflammation, retinal degeneration and neovascularization in a rat model of AMD, created by subretinal injection of human lipid hydroperoxide (HpODE) that found in the sub-macular region in aged and AMD patients. Subretinal HpODE induced retinal pigment epithelium (RPE) and retinal degeneration resulting in loss of RPE cells, photoreceptors and retinal thinning. RPE degeneration and atrophy were detected by day 5, followed by neural tissue degeneration at day 12 with robust TUNEL positive cells. Western blot analysis confirmed an increase in pro-apoptotic Bak protein at day 12 in retinal tissues. Oxidative damage biomarkers (4-hydroxynonenal, malondialdehyde, 8-hydroxy-2'-deoxyguanosine, and nitrotyrosine) increased in retinal tissue from days 5-12. Muller glial activation was observed in the HpODE injected area at day 5 followed by its remodeling and migration in the outer retina by day 20. RT-qPCR analysis further indicated upregulation of pro-inflammatory genes (TNF-alpha, IL-1 beta and IL-6) both in retinal and RPE/choroidal tissue as early as day 2 and persisted until day 12. Upregulation of oxidative stress markers such as NADPH oxidase (NOX and DOUX family) was detected early in retinal tissue by day 2 followed by its upregulation in choroidal tissue at day 5. Neovascularization was demonstrated from day 12 to day 20 post HpODE injection in choroidal tissue. The results from this study indicate that subretinal HpODE induces advanced AMD phenotypes comprising many aspects of both dry/early and late) and neovascular/late AMD as observed in humans. Within 3 weeks via oxidative damage, upregulation of reactive oxygen species and pro-inflammatory genes, pro-apoptotic Bak and pro-angiogenic VEGF upregulation occurs leading to CNV formation. This experimental model of subretinal HpODE is an appropriate model for the study of AMD and provides an important platform for translational and basic research in developing new therapies particularly for early/dry AMD where currently no viable therapies are available.
C1 [Kim, Soo-Young; Kambhampati, Siva P.; Lutty, Gerard A.; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Ctr Nanomed, Baltimore, MD 21205 USA.
   [Kim, Soo-Young; Kambhampati, Siva P.; Bhutto, Imran A.; McLeod, D. Scott; Lutty, Gerard A.; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University
RP Kannan, RM (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, Ctr Nanomed, 400 North Broadway, Baltimore, MD 21231 USA.; Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu; krangar1@jhmi.edu
RI Kambhampati, Siva Pramodh/AAK-6269-2020; Kim, SooYoung/AAS-7899-2021
OI Kim, SooYoung/0000-0003-3632-8246
FU National Eye Institute [NEIR01EY025304, NEI-RO1EY016151, EY01765];
   Research to Prevent Blindness; Altsheler Durell foundation; Wilmer Eye
   Institute NEI
FX This work was supported by National Eye Institute [NEIR01EY025304 (RMK);
   NEI-RO1EY016151 (GL), EY01765 (Wilmer)], unrestricted funds from
   Research to Prevent Blindness, and a grant from the Altsheler Durell
   foundation (GL and RMK). The authors would like to acknowledge the
   Wilmer Eye Institute NEI-sponsored CORE imaging facility for the access
   to LSM 710 confocal microscopy and Woods animal facility for animal
   housing and procedures.
CR Armstrong D, 1998, Angiogenesis, V2, P93, DOI 10.1023/A:1009010628371
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Bai YY, 2009, J PATHOL, V219, P446, DOI 10.1002/path.2611
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto Imran A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD143, DOI 10.1167/iovs.18-24245
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cunnusamy K, 2012, PHARM PAT ANAL, V1, P193, DOI 10.4155/PPA.12.12
   Danciger M, 2004, MAMM GENOME, V15, P277, DOI 10.1007/s00335-003-2336-2
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Edwards MM, 2016, EXP EYE RES, V150, P44, DOI 10.1016/j.exer.2015.07.016
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Huang PR, 2017, INVEST OPHTH VIS SCI, V58, P1726, DOI 10.1167/iovs.16-20043
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaidzu S, 2008, EXP EYE RES, V86, P856, DOI 10.1016/j.exer.2008.01.016
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Kaur C, 2006, INVEST OPHTH VIS SCI, V47, P1126, DOI 10.1167/iovs.05-0518
   Kim Soo-Young, 2015, Macrophage (Houst), V2
   Kim SY, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.1.6
   Kim SY, 2014, INVEST OPHTH VIS SCI, V55, P6031, DOI 10.1167/iovs.14-15091
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Lau LI, 2010, INVEST OPHTH VIS SCI, V51, P5486, DOI 10.1167/iovs.10-5663
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445
   Mones J, 2016, INVEST OPHTH VIS SCI, V57, P3974, DOI 10.1167/iovs.16-19355
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   NORK TM, 1986, ARCH OPHTHALMOL-CHIC, V104, P1383, DOI 10.1001/archopht.1986.01050210137041
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Park SW, 2017, ONCOTARGET, V8, P40006, DOI 10.18632/oncotarget.16967
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Rabin DM, 2013, AGING-US, V5, P51
   Romijn HJ, 1999, J HISTOCHEM CYTOCHEM, V47, P229, DOI 10.1177/002215549904700211
   Saraswathy S, 2006, INVEST OPHTH VIS SCI, V47, P3656, DOI 10.1167/iovs.06-0221
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Song HM, 2016, INVEST OPHTH VIS SCI, V57, P2864, DOI 10.1167/iovs.15-18974
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Taskintuna I, 2016, MIDDLE EAST AFR J OP, V23, P13, DOI 10.4103/0974-9233.173134
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 71
TC 17
Z9 17
U1 2
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2021
VL 203
AR 108391
DI 10.1016/j.exer.2020.108391
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG8HN
UT WOS:000617822500001
PM 33307075
DA 2022-11-30
ER

PT J
AU Mullins, RF
   McGwin, G
   Searcey, K
   Clark, ME
   Kennedy, EL
   Curcio, CA
   Stone, EM
   Owsley, C
AF Mullins, Robert F.
   McGwin, Gerald, Jr.
   Searcey, Karen
   Clark, Mark E.
   Kennedy, Elizabeth L.
   Curcio, Christine A.
   Stone, Edwin M.
   Owsley, Cynthia
TI The ARMS2 A69S Polymorphism Is Associated with Delayed Rod-Mediated Dark
   Adaptation in Eyes at Risk for Incident Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; OUTER RETINAL TUBULATION; GENOME-WIDE ASSOCIATION;
   VISUAL-ACUITY; SUSCEPTIBILITY GENES; GEOGRAPHIC ATROPHY; RHESUS-MONKEYS;
   OLDER EYES; VARIANT; DISEASE
AB Purpose: To examine the association between sequence variants in genetic risk factors for age-related macular degeneration (AMD) and delayed rod-mediated dark adaptation (RMDA), the first functional biomarker for incident AMD, in older adults with normal macular health and early AMD.
   Design: Cross-sectional.
   Participants: Adults 60 years of age or older showing normal macular health (defined as both eyes at step 1 on the Age-Related Eye Disease Study 9-step AMD classification system) and those with AMD in one or both eyes (defined as steps 2-9).
   Methods: Single nucleotide polymorphisms were genotyped in the complement factor H (CFH) and ARMS2 genes using a Taqman assay. Rod-mediated dark adaptation was assessed in 1 eye after photobleach with targets centered at 5 degrees on the inferior vertical meridian. Rate of dark adaptation was defined by rod intercept time (RIT), duration (in minutes) required for sensitivity to reach a criterion sensitivity level in the latter half of the second component of rod recovery. Associations between CFH and ARMS2 polymorphisms and RMDA were adjusted for age and smoking.
   Main Outcome Measure: Rod intercept time.
   Results: The sample consisted of 543 participants having both genotype and RIT determination; 408 showed normal macular health and 135 demonstrated AMD, most having early AMD (124 of 135). For the combined sample, higher RIT (slower RMDA) was observed for both the A69S variant inARMS2 and the Y402H variant in CFH (adjusted P = 0.0001 and P = 0.0023, respectively). For healthy participants, the A69S variant in ARMS2 was associated with higher RIT (adjusted P = 0.0011), whereas the Y402H variant in CFH was not (adjusted P = 0.2175). For AMD patients, the A69S variant of ARMS2 and the Y402H variant of CFH were associated with higher RIT (adjusted P = 0.0182 and P = 0.0222, respectively). Those with a larger number of high-risk ARMS2 and CFH alleles showed higher RIT, in both healthy and AMD groups (adjusted P = 0.0002 and P < 0.0001, respectively).
   Conclusions: We report a novel association wherein older adults with high-risk ARMS2 and CFH genotypes are more likely to demonstrate delayed RMDA, the first functional biomarker for incident early AMD. Before the AMD clinical phenotype is present, those showing normal macular health with the ARMS2 A69S allele demonstrate delayed RMDA. Understanding ARMS2 function is a research priority. (C) 2018 by the American Academy of Ophthalmology
C1 [Mullins, Robert F.; Kennedy, Elizabeth L.; Stone, Edwin M.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
   [McGwin, Gerald, Jr.; Searcey, Karen; Clark, Mark E.; Curcio, Christine A.; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
C3 University of Iowa; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, 700 South 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891; Stone, Edwin
   M./0000-0003-3343-4414; Owsley, Cynthia/0000-0003-3424-011X
FU National Institutes of Health, Bethesda, Maryland [R01AG04212,
   R01EY027948, R01EY015520, EY026087]; National Center for Advanced
   Translational Sciences of the National Institutes of Health
   [UL1TR001417]; Dorsett Davis Discovery Fund; Alfreda J. Schueler Trust;
   EyeSight Foundation of Alabama; Research to Prevent Blindness, Inc., New
   York, New York; Macula Foundation; Common Fund of the Office of the
   Director of the National Institutes of Health; National Cancer
   Institute; National Human Genome Research Institute; National Heart,
   Lung, and Blood Institute; National Institute on Drug Abuse; National
   Institute of Mental Health; National Institute of Neurological Disorders
   and Stroke, Bethesda, Maryland; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR001417] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY021470, R01EY026087, R01EY027948,
   R01EY015520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health, Bethesda, Maryland
   (grant nos.: R01AG04212 [C.O.], R01EY027948 [C.A.C.], R01EY015520
   [C.A.C.], and EY026087 [E.M.S.]); the National Center for Advanced
   Translational Sciences of the National Institutes of Health (grant no.:
   UL1TR001417); the Dorsett Davis Discovery Fund; the Alfreda J. Schueler
   Trust; the EyeSight Foundation of Alabama; Research to Prevent
   Blindness, Inc., New York, New York; and the Macula Foundation. The
   Genotype-Tissue Expression (GTEx) Project was supported by the Common
   Fund of the Office of the Director of the National Institutes of Health,
   and by the National Cancer Institute, the National Human Genome Research
   Institute, the National Heart, Lung, and Blood Institute, the National
   Institute on Drug Abuse, the National Institute of Mental Health, and
   the National Institute of Neurological Disorders and Stroke, Bethesda,
   Maryland.
CR BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518
   Beaudoin DL, 2019, J COMP NEUROL, V527, P117, DOI 10.1002/cne.24313
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Bonyadi MHJ, 2018, ACTA OPHTHALMOL, V96, pe105, DOI 10.1111/aos.13494
   BOYCOTT BB, 1987, PROC R SOC SER B-BIO, V229, P345, DOI 10.1098/rspb.1987.0001
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ENG B, 1994, J FORENSIC SCI, V39, P1356
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaartokallio T, 2015, SCI REP-UK, V5, DOI 10.1038/srep14107
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lamb TD, 1998, J PHYSIOL-LONDON, V506P, p88P
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Lin LY, 2018, JAMA OPHTHALMOL, V136, P682, DOI 10.1001/jamaophthalmol.2018.1231
   Litts KM, 2016, INVEST OPHTH VIS SCI, V57, P2647, DOI 10.1167/iovs.16-19262
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   National Institute of Standards and Technology United States Department of Commerce, 2007, SEX TYP MARK
   Neely D, 2017, RETINA, V37, P570
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P413, DOI 10.1113/jphysiol.1975.sp010982
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tahir HJ, 2017, EXP EYE RES, V155, P47, DOI 10.1016/j.exer.2016.11.016
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JS, 2011, PROG RETIN EYE RES, V23, P307
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright AF, 2018, OPHTHALMOLOGY, V125, P962, DOI 10.1016/j.ophtha.2018.03.034
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
NR 79
TC 19
Z9 19
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2019
VL 126
IS 4
BP 591
EP 600
DI 10.1016/j.ophtha.2018.10.037
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HP9PK
UT WOS:000462025300028
PM 30389424
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Szegedi, S
   Ebner, C
   Mihaltz, K
   Wachter, T
   Vecsei-Marlovits, PV
AF Szegedi, Stephan
   Ebner, Christian
   Mihaltz, Kata
   Wachter, Tobias
   Vecsei-Marlovits, Pia Veronika
TI Long-term impact of delayed follow-up due to COVID-19 lockdown on
   patients with neovascular age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration (nAMD); Coronavirus disease
   2019 (COVID-19); Anti-vascular endothelial growth factor (anti-VEGF)
AB Background During the first wave of the coronavirus disease 2019 (COVID-19) pandemic in 2020 outpatient care of neovascular age-related macular degeneration (nAMD) patients was severely reduced due to lockdown. Missed visits are known to be detrimental to patients in need of continued anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVIs). The purpose of the study was to assess the effect of a month-long pause of regular visits and anti-VEGF IVIs in nAMD patients. Methods A retrospective study was performed. Patients were treated in a pro re nata ("as needed") scheme. Distance (logMAR) and near (logRAD) visual acuity (VA), optical coherence tomography, delay between planned and actual visit date and the indication for IVI were assessed for 3 continous visits in the 6 months before lockdown (V-3, -2, -1) and the 2 visits after lockdown (V0, V + 1). For analysis of long-term impact, records for visits 1 years before and after lockdown (V-3, V + 2) were gathered. Results We included 166 patients (120 female, 46 male) with a median (range) age of 80.88 (59.8-99.36) years. Compared to V-1, distance VA was significantly worse at both V0 (0.27 +/- 0.21 vs 0.31 +/- 0.23 logMAR, p < 0.001) and V + 1 (0.27 +/- 0.21 vs 0.30 +/- 0.23 logMAR, p = 0.021). Near VA was significantly worse at both V0 (0.31 +/- 0.21 vs 0.34 +/- 0.22 logRAD, p = 0.037) and V + 1 (0.31 +/- 0.21 vs 0.34 +/- 0.22 logRAD, p = 0.02). Visit delay (VD) at V0 was significantly longer than at V + 1 (30.81 +/- 20.44 vs 2.02 +/- 6.79 days, p < 0.0001). Linear regression analysis showed a significant association between visit delay and a reduction of near VA between V-1 and V + 1 (p = 0.0223). There was a significant loss of distance VA (p = 0.02) in the year after the lockdown period (n = 125) compared to the year before. Loss of reading acuity was not significantly increased (p = 0.3). One year post lockdown, there was no correlation between VA change and visit delay after lockdown (p > 0.05). Conclusions In nAMD patients whose visits and treatment were paused for a month during the first wave of the COVID-19 pandemic, we found a loss of VA immediately after lockdown, which persisted during follow-up despite re-established anti-VEGF treatment. In the short term, length of delay was predictive for loss of reading VA. The comparison of development of VA during the year before and after the lockdown showed a progression of nAMD related VA loss which may have been accelerated by the disruption of regular visits and treatment.
C1 [Szegedi, Stephan; Ebner, Christian; Mihaltz, Kata; Wachter, Tobias; Vecsei-Marlovits, Pia Veronika] Vienna Healthcare Grp, Clin Hietzing, Dept Ophthalmol, Vienna, Austria.
   [Szegedi, Stephan; Ebner, Christian; Mihaltz, Kata; Wachter, Tobias; Vecsei-Marlovits, Pia Veronika] Karl Landsteiner Inst Proc Optimisat & Qual Manag, Vienna, Austria.
RP Szegedi, S (通讯作者)，Vienna Healthcare Grp, Clin Hietzing, Dept Ophthalmol, Vienna, Austria.; Szegedi, S (通讯作者)，Karl Landsteiner Inst Proc Optimisat & Qual Manag, Vienna, Austria.
EM stephan.szegedi@gesundheitsverbund.at
OI Ebner, Christian/0000-0003-2344-0677
CR Allegrini D, 2021, CLIN OPHTHALMOL, V15, P4073, DOI [10.2147/OPTH.S323058, 10.2147/OPTH.S3230582021]
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Greenlee TE, 2021, RETINA-J RET VIT DIS, V41, P581, DOI 10.1097/IAE.0000000000002888
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Naravane AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247161
   R Development Core Team, 2022, R LANG ENV STAT COMP
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Stattin M, 2021, OPHTHALMOL THER, V10, P935, DOI 10.1007/s40123-021-00381-y
   Stone LG, 2021, GRAEF ARCH CLIN EXP, V259, P1773, DOI 10.1007/s00417-021-05174-4
   Szegedi S, 2021, SPEKTRUM AUGENHEILKD, V35, P70, DOI 10.1007/s00717-020-00473-3
   Yeter DY, 2021, J FR OPHTALMOL, V44, P299, DOI 10.1016/j.jfo.2021.02.001
NR 12
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 20
PY 2022
VL 22
IS 1
AR 228
DI 10.1186/s12886-022-02453-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1J8RB
UT WOS:000798179500003
PM 35596203
DA 2022-11-30
ER

PT J
AU Zhao, XY
   Meng, LH
   Liu, SZ
   Chen, YX
AF Zhao, Xin-Yu
   Meng, Li-Hui
   Liu, Sheng-zhi
   Chen, You-Xin
TI Efficacy and safety of different agents, dosages and strategies of
   anti-vascular endothelial growth factor treatment for neovascular
   age-related macular degeneration: a network meta-analysis of randomized
   controlled trials
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE neovascular age-related macular degeneration; anti-vascular endothelial
   growth factors; ranibizumab; bevacizumab; aflibercept; network
   meta-analysis
ID PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; KETOROLAC EYEDROPS;
   RANIBIZUMAB; COMBINATION; EXTEND; INCONSISTENCY; CONSISTENCY;
   DEXAMETHASONE; MONOTHERAPY
AB Purpose: To evaluate the efficacy and safety of different agents, dosages and strategies of anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD) by network meta-analysis.
   Methods: Electronic database searches were conducted on PubMed, Embase and Cochrane Central Register of Controlled Trials up to 1 December 2019 to `identify relevant randomized controlled trials (RCTs). The standardized mean difference (SMD), odds ratios (OR), 95% confidence intervals (CI), the surface under the cumulative ranking curves and the mean ranks of each outcome were estimated by Stata 14.0.
   Results: Forty-seven RCTs encompassing 17 872 nAMD patients randomly assigned to 36 regimens of anti-VEGF agents or sham treatment were included. T&E strategy shows top-level effect both in BCVA changes and the percentage of patients with a gain of 3 lines or more of BCVA. When taking the same strategy, there is no significant difference of efficacy among ranibizumab, bevacizumab and aflibercept (p > 0.05); The combination of radiation, topical NSAIDs and photodynamic therapy (PDT) might provide additional benefit in central retinal thickness (CRT) reduction; all these therapeutic regimens of different anti-VEGF agents do not significantly increase the risk of severe ocular or cardiocerebral vascular adverse events (ADEs) compared with sham treatment (p > 0.05).
   Conclusions: T&E strategy showed a satisfactory effect in visual improvement and there is no significant difference in efficacy or safety among ranibizumab, bevacizumab and aflibercept. All the included regimens have an acceptable risk of ADEs.
C1 [Zhao, Xin-Yu; Meng, Li-Hui; Chen, You-Xin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Zhao, Xin-Yu; Meng, Li-Hui; Chen, You-Xin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
   [Liu, Sheng-zhi] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Indiana University System;
   Indiana University-Purdue University Indianapolis
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM chenyx@pumch.cn
RI meng, li/GVT-2063-2022
OI Chen, Youxin/0000-0002-7231-5058
CR Amarakoon S, 2019, ACTA OPHTHALMOL, V97, P107, DOI 10.1111/aos.13774
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8
   Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897
   Cipriani Andrea, 2018, Focus (Am Psychiatr Publ), V16, P420, DOI 10.1176/appi.focus.16407
   Cipriani A, 2013, ANN INTERN MED, V159, P130, DOI 10.7326/0003-4819-159-2-201307160-00008
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Datseris I, 2015, SEMIN OPHTHALMOL, V30, P112, DOI 10.3109/08820538.2013.833268
   Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Gallemore RP, 2017, CLIN OPHTHALMOL, V11, P223, DOI 10.2147/OPTH.S119510
   Ghosh W, 2016, ADV THER, V33, P1660, DOI 10.1007/s12325-016-0367-9
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Higgins JPT, 2012, RES SYNTH METHODS, V3, P98, DOI 10.1002/jrsm.1044
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Russo A, 2013, BRIT J OPHTHALMOL, V97, P1273, DOI 10.1136/bjophthalmol-2013-303417
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Semeraro F, 2015, RETINA-J RET VIT DIS, V35, P1547, DOI 10.1097/IAE.0000000000000525
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Slee A, 2019, LANCET, V393, P768, DOI 10.1016/S0140-6736(18)31793-8
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   White IR, 2012, RES SYNTH METHODS, V3, P111, DOI 10.1002/jrsm.1045
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 32
TC 3
Z9 4
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2021
VL 99
IS 7
BP E1041
EP E1050
DI 10.1111/aos.14756
EA JAN 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WD6YR
UT WOS:000607170000001
PM 33438364
DA 2022-11-30
ER

PT J
AU Aurell, S
   Sjovall, K
   Paul, A
   Moren, A
   Granstam, E
AF Aurell, Sandra
   Sjovall, Kersti
   Paul, Anna
   Moren, Asa
   Granstam, Elisabet
TI Better visual outcome at 1 year with antivascular endothelial growth
   factor treatment according to treat-and-extend compared with pro re nata
   in eyes with neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-VEGF; neovascular AMD; pro re nata; real-world data;
   treat-and-extend; treatment regimen; visual acuity
ID VISION LOSS; RANIBIZUMAB; BEVACIZUMAB; AFLIBERCEPT; IMPAIRMENT;
   REGIMENS; THERAPY
AB Purpose To evaluate treatment outcome at 12 months in eyes with neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (anti-VEGF) injections according to either pro re nata (PRN)- or treat-and-extend (TE)-regimen in one clinical setting in Sweden. Methods Data were obtained retrospectively from the Swedish Macula Register, optical coherence tomography-database and electronic patient charts. The study included 443 eyes; 223 PRN- and 220 TE-treated eyes. Baseline (BL) characteristics and follow-up data at 6 and 12 months were collected. Statistical regression analysis was performed to evaluate association between treatment strategy and visual outcome at 12 months. Results Baseline (BL) characteristics were well balanced between cohorts. Visual acuity at 12 months was higher in TE-cohort 66.5 (13.1) compared to PRN-cohort 60.1 (17.6) (p = 0.000). Visual improvement at 12 months was +5.2 (11.8) and +1.2 (12.7) letters Early Treatment Diabetic Retinopathy Study (ETDRS) in TE- and PRN-cohorts, respectively (p = 0.002). Number of administered injections at 12 months was 10.2 (2.1) and 6.3 (2.1) in the two cohorts (p = 0.000). Statistical analysis demonstrated a strong association between TE treatment strategy and improvement in visual acuity at 12 months. Conclusion Eyes treated according to TE had better visual outcome at 12 months. The results indicate that treatment according to proactive TE-regimen is superior to treatment according to PRN-regimen in clinical routine care of nAMD.
C1 [Aurell, Sandra; Sjovall, Kersti; Paul, Anna; Moren, Asa; Granstam, Elisabet] Hosp Vastmanland, Dept Ophthalmol, Vasteras, Sweden.
   [Aurell, Sandra; Granstam, Elisabet] Reg Vastmanland Uppsala Univ, Clin Res Ctr, Hosp Vastmanland, Vasteras, Sweden.
C3 Vasteras Central Hospital; Vasteras Central Hospital
RP Aurell, S (通讯作者)，Hosp Vastmanland Vasteras, Dept Ophthalmol, SE-72189 Vasteras, Sweden.
EM sandra.aurell@regionvastmanland.se
FU Stiftelsen Kronprinsessan Margaretas Arbetsnamnd for synskadade (KMA);
   Ogonfonden; Foreningen Synskadades Vanner i Uppsala; Region Vastmanland
FX The study was supported by grants from: Stiftelsen Kronprinsessan
   Margaretas Arbetsnamnd for synskadade (KMA; SE), Ogonfonden (SE),
   Foreningen Synskadades Vanner i Uppsala (SE), Region Vastmanland (SE).
CR Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Granstam E, 2016, ACTA OPHTHALMOL, V94, P646, DOI 10.1111/aos.13187
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Lanzetta P, 2018, ACTA OPHTHALMOL
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Swedish Macula Register, 2015, ANN REPORT
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 25
TC 11
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2019
VL 97
IS 5
BP 519
EP 524
DI 10.1111/aos.13989
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IH9DK
UT WOS:000474806400011
PM 30511374
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Eter, N
   Hasanbasic, Z
   Keramas, G
   Rech, C
   Sachs, H
   Schilling, H
   Wachtlin, J
   Wiedemann, P
   Framme, C
AF Eter, Nicole
   Hasanbasic, Zoran
   Keramas, Georgios
   Rech, Christine
   Sachs, Helmut
   Schilling, Harald
   Wachtlin, Joachim
   Wiedemann, Peter
   Framme, Carsten
CA PERSEUS Study Grp
TI PERSEUS 24-month analysis: a prospective non-interventional study to
   assess the effectiveness of intravitreal aflibercept in routine clinical
   practice in Germany in patients with neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; nAMD; wAMD; Neovascular; VEGF;
   Intravitreal; Aflibercept; Real-world evidence
AB Purpose To evaluate the real-world effectiveness of intravitreal aflibercept injections in Germany in patients with neovascular age-related macular degeneration over 24 months.
   Methods PERSEUS was a prospective, non-interventional cohort study. The primary endpoint was the mean change in visual acuity (VA) from baseline. Secondary endpoints included the proportion of patients with a VA gain or loss of >= 15 letters and the frequency of injections and examinations. Patients with regular (bimonthly after 3 monthly injections during year 1 and >= 4 injections in year 2) and irregular (any other) treatment were analyzed. The last observation carried forward (LOCF) and the observed cases (OC) approach was applied for primary endpoint analysis to account for missing data.
   Results 803 patients were considered for effectivity analysis. At month 24, only 38% of the patients were still under observation. The LOCF population included 727, the OC population 279 patients. Treatment-naive patients improved by 6.3 (LOCF)/8.1 (OC) letters with regular treatment over 24 months but only by 3.3 (LOCF)/3.1 (OC) letters with irregular treatment. The proportion of treatment-naive patients achieving a VA improvement of >= 15 letters was similar between regularly and irregularly treated cohorts. However, considerably more patients in the irregular cohorts experienced a VA worsening of >= 15 letters than in the regular cohorts (LOCF: 18.7% vs. 7.4%).
   Conclusions Regular IVT-AFL treatment resulted in better VA outcomes than irregular treatment at month 24. However, only a minority of patients received regular treatment over a 2-year period.
C1 [Eter, Nicole] Univ Klinikum, Augenklin Munster, Klin Augenheilkunde, Domagkstr 15, D-48149 Munster, Germany.
   [Hasanbasic, Zoran; Keramas, Georgios] Bayer Vital GmbH, Leverkusen, Germany.
   [Rech, Christine] Bayer Vital GmbH, Data Generat, Leverkusen, Germany.
   [Sachs, Helmut] Stadt Klinikum Dresden Friedrichstadt, Augenklin, Dresden, Germany.
   [Schilling, Harald] St Johannes Hosp, Klin Augenheilkunde, Dortmund, Germany.
   [Wachtlin, Joachim] St Gertrauden Hosp, Abt Augenheilkunde, Berlin, Germany.
   [Wachtlin, Joachim] Med Hsch Brandenburg, MHB, Neuruppin, Germany.
   [Wiedemann, Peter] Univ Klinikum Leipzig, Klin & Poliklin Augenheilkunde, Leipzig, Germany.
   [Framme, Carsten] Hannover Med Sch, Klin Augenheilkunde, Hannover, Germany.
C3 University of Munster; Bayer AG; Bayer AG; Technische Universitat
   Dresden; Municipal Hospital Dresden; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; St. Johannes Hospital; Leipzig
   University; Hannover Medical School
RP Eter, N (通讯作者)，Univ Klinikum, Augenklin Munster, Klin Augenheilkunde, Domagkstr 15, D-48149 Munster, Germany.
EM eter@uni-muenster.de
OI Hasanbasic, Zoran/0000-0003-0673-012X
FU Bayer Vital GmbH [EY1313]; Bayer Vital GmbH, Leverkusen, Germany
FX This study was funded by Bayer Vital GmbH (EY1313). PERSEUS was
   sponsored by Bayer Vital GmbH, Leverkusen, Germany.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ehlken C, 2018, RETINA-J RET VIT DIS, V38, P1134, DOI 10.1097/IAE.0000000000001681
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2020, OPHTHALMOLOGE, V117, P210, DOI 10.1007/s00347-019-01005-4
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Prakash A, 2008, INT J CLIN PRACT, V62, P1147, DOI 10.1111/j.1742-1241.2008.01808.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Statement of the German Ophthalmological Society the German Retina Society and the Professional Association of German Ophthalmologists, KLIN MONATSBL AUGENH, V232, P202, DOI [10.1055/s-0034-1396162, DOI 10.1055/S-0034-1396162]
   Wachtlin J, 2021, GRAEF ARCH CLIN EXP, V259, P601, DOI 10.1007/s00417-020-04803-8
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
   Ziemssen F, 2017, ANN M ASS RES VIS OP
NR 19
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2021
VL 259
IS 8
BP 2213
EP 2223
DI 10.1007/s00417-021-05073-8
EA FEB 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TX9FL
UT WOS:000615546900004
PM 33547967
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Shah, SM
   Boopathiraj, N
   Starr, MR
   Dalvin, LA
   Abouchehade, J
   Damento, G
   Garcia, MD
   Hodge, DO
   Bakri, SJ
   Sit, AJ
   Iezzi, R
AF Shah, Saumya M.
   Boopathiraj, Nithya
   Starr, Matthew R.
   Dalvin, Lauren A.
   Abouchehade, Jackson
   Damento, Gena
   Garcia, Maria D.
   Hodge, David O.
   Bakri, Sophie J.
   Sit, Arthur J.
   Iezzi, Raymond
TI Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related
   Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial
   Growth Factor Injections
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FIBER LAYER THICKNESS; INTRAOCULAR-PRESSURE CHANGES; OPEN-ANGLE
   GLAUCOMA; ANTI-VEGF; OCULAR HYPERTENSION; VITREOUS REFLUX;
   OLMSTED-COUNTY; RANIBIZUMAB; BEVACIZUMAB; TRENDS
AB PURPOSE: To examine the risk, prevalence, and progression of glaucoma development in age-related macular degeneration (AMD) eyes receiving intravitreal anti -vascular endothelial growth factor (anti-VEGF) injections compared to controls. DESIGN: Retrospective clinical cohort study. METHODS: Retrospective review of eyes receiving intravitreal anti-VEGF injections from January 1, 2004, to December 31, 2013, for exudative AMD. Age-and sex -matched control groups of eyes included eyes with nonexudative AMD (NEAMD) and no AMD. Eyes with a diagnosis of glaucoma or glaucoma suspect were reviewed for injection details, type and date of glaucoma diagnosis, glaucoma treatments, standard automated perimetry (SAP), and spectral domain optical coherence tomography (SD-OCT). Qualitative progression was determined by indication of glaucoma progression in provider notes. Quantitative progression was assessed based on change in mean deviation (MD) on SAP, retinal nerve fiber layer thickness on SD-OCT, and intraocular pressure (IOP). RESULTS: There were 707 eyes of 504 patients treated with anti-VEGF injections and 1008 eyes in the NEAMD and no-AMD cohorts. There was no difference in glaucoma or suspect prevalence at initial presentation be-tween eyes treated with injections and NEAMD (6.9% vs 9.7%, P = .22) or no-AMD controls (vs 8.5%, P = .55). There was no difference in cumulative 5-year probability of new glaucoma diagnosis after anti-VEGF injections compared to NEAMD (1.9% vs 1.0%, P = .69) or no-AMD controls (vs 1.6%, P = .88). There was no difference in qualitative progression of glaucoma in the injection cohort vs NEAMD ( P = .19) or no-AMD controls ( P = .61). The rate of MD change in injection eyes was similar to NEAMD eyes ( P = .74) but greater than no-AMD eyes ( P = .02). Eyes receiving injections required more topical glaucoma medications compared with NEAMD ( P = .03) and more glaucoma laser treatments compared with no-AMD controls ( P = .009). Eyes receiving injections did not require more frequent incisional glaucoma surgery compared with NEAMD (21.0% vs 15.0%, P = .95) or no-AMD controls (vs 10.0%, P = .10). CONCLUSION: Eyes treated with intravitreal anti-VEGF injections for exudative AMD did not have in-creased risk of developing glaucoma compared with controls. Of those with a glaucoma diagnosis, exudative AMD eyes receiving injections required a greater number of topical glaucoma medications compared with NEAMD eyes and had a greater rate of MD loss than no-AMD controls.
C1 [Shah, Saumya M.; Boopathiraj, Nithya; Starr, Matthew R.; Dalvin, Lauren A.; Abouchehade, Jackson; Damento, Gena; Garcia, Maria D.; Bakri, Sophie J.; Sit, Arthur J.; Iezzi, Raymond] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Hodge, David O.] Mayo Clin, Dept Hlth Sci Res Biomed Stat & Informat, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic
RP Iezzi, R (通讯作者)，Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
EM iezzi.raymond@mayo.edu
OI Dalvin, Lauren/0000-0001-9710-4284; Sit, Arthur/0000-0002-3904-2625
FU National Institute on Aging of the National Institutes of Health
   [R01AG034676]; Research to Prevent Blindness, New York, NY;
   VitreoRetinal Surgery Foundation; Mayo Clinic Foundation for Medical
   Research
FX This study was made possible using the resources of the Rochester
   Epidemiology Project, which is supported by the National Institute on
   Aging of the National Institutes of Health under Award Number
   R01AG034676. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health. This work was supported in part by Research to
   Prevent Blindness, New York, NY, and the VitreoRetinal Surgery
   Foundation and the Mayo Clinic Foundation for Medical Research.
CR Acton JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039944
   Al-Abdullah AA, 2015, RETINA-J RET VIT DIS, V35, P440, DOI 10.1097/IAE.0000000000000371
   Anderson AJ, 2011, OPTOMETRY VISION SCI, V88, P806, DOI 10.1097/OPX.0b013e31821861bd
   Atchison EA, 2018, OPHTHALMOLOGY, V125, P676, DOI 10.1016/j.ophtha.2017.11.027
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   CAMPION ME, 1992, MAYO CLIN PROC, V67, P5, DOI 10.1016/S0025-6196(12)60270-5
   Carnota-Mendez P, 2014, EUR J OPHTHALMOL, V24, P771, DOI 10.5301/ejo.5000455
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   de Voogd S, 2005, OPHTHALMOLOGY, V112, P1487, DOI 10.1016/j.ophtha.2005.04.018
   de Vries VA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70269-7
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Demirel S, 2015, INT OPHTHALMOL, V35, P541, DOI 10.1007/s10792-014-9981-1
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Du J, 2019, J GLAUCOMA, V28, P1035, DOI 10.1097/IJG.0000000000001382
   Elbaz A, 2003, ARCH NEUROL-CHICAGO, V60, P91, DOI 10.1001/archneur.60.1.91
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gabrielle PH, 2020, OPHTHALMOL RETINA, V4, P861, DOI 10.1016/j.oret.2020.06.020
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hoguet A, 2019, OPHTHALMOLOGY, V126, P611, DOI 10.1016/j.ophtha.2018.11.019
   Hong SW, 2012, EUR J OPHTHALMOL, V22, P615, DOI 10.5301/ejo.5000081
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kampougeris George, 2013, J Curr Glaucoma Pract, V7, P19, DOI 10.5005/jp-journals-10008-1132
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P632, DOI 10.1007/s10384-011-0088-1
   Kim YJ, 2014, AM J OPHTHALMOL, V157, P1266, DOI 10.1016/j.ajo.2014.02.035
   Kopic A, 2017, ACTA CLIN CROAT, V56, P406, DOI 10.20471/acc.2017.56.03.07
   KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Maruyama-Inoue M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91832-w
   Murray CD, 2014, EYE, V28, P1218, DOI 10.1038/eye.2014.180
   Nanji K, 2022, OPHTHALMOLOGY, V129, P498, DOI 10.1016/j.ophtha.2021.11.024
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1401, DOI 10.1097/IAE.0000000000000476
   Pershing S, 2013, OPHTHAL SURG LAS IM, V44, P460, DOI 10.3928/23258160-20130909-07
   PHILLIPS SJ, 1988, MAYO CLIN PROC, V63, P691, DOI 10.1016/S0025-6196(12)65531-1
   Saleh R, 2017, GRAEF ARCH CLIN EXP, V255, P817, DOI 10.1007/s00417-017-3590-4
   Shah SM, 2020, RETINA-J RET VIT DIS, V40, P857, DOI 10.1097/IAE.0000000000002506
   Shin HJ, 2014, INVEST OPHTH VIS SCI, V55, P2403, DOI 10.1167/iovs.13-13769
   Starr Matthew R, 2019, Ophthalmic Surg Lasers Imaging Retina, V50, pe140, DOI 10.3928/23258160-20190503-14
   Swaminathan SS, 2021, AM J OPHTHALMOL, V226, P206, DOI 10.1016/j.ajo.2020.12.016
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Varma R, 2012, AM J OPHTHALMOL, V154, P315, DOI 10.1016/j.ajo.2012.02.014
   Wingard JB, 2019, CLIN OPHTHALMOL, V13, P2563, DOI 10.2147/OPTH.S232548
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2022
VL 243
BP 98
EP 108
DI 10.1016/j.ajo.2022.07.025
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5A8ZS
UT WOS:000863169900003
PM 35932820
DA 2022-11-30
ER

PT J
AU Yang, LH
   Jonas, JB
   Wei, WB
AF Yang, Li H.
   Jonas, Jost B.
   Wei, Wen B.
TI OPTICAL COHERENCE TOMOGRAPHIC ENHANCED DEPTH IMAGING OF POLYPOIDAL
   CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; central serous chorioretinopathy;
   choroidal thickness; choroid; optical coherence tomography; OCT;
   enhanced depth imaging
ID CENTRAL SEROUS CHORIORETINOPATHY; PIGMENT EPITHELIAL DETACHMENT; MACULAR
   DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; PHOTODYNAMIC THERAPY;
   AGE; THICKNESS; FEATURES
AB Purpose: To assess the dimensions of hyporeflective choroidal lumina and choroidal thickness in patients with polypoidal choroidal vasculopathy (PCV) without subretinal hemorrhage.
   Methods: Chinese patients with PCV and without subretinal hemorrhage and subjects of a control group underwent enhanced depth imaging by optical coherence tomography. Choroidal thickness and the largest diameter of choroidal hyporeflective lumina as surrogates for choroidal vessels were measured.
   Results: The study included 18 eyes of Chinese patients with PCV and 19 subjects of a control group, with no significant difference in age (P = 0.10) or refractive error (P = 0.89) between the groups. Mean subfoveal choroidal thickness was significantly higher in the study group than in the control group (338 +/- 107 mu m vs. 261 +/- 78 mu m; P = 0.017), and mean largest diameter of the choroidal vessels was significantly larger in the study group than in the control group (236 +/- 63 mu m vs. 137 +/- 48 mu m; P < 0.001). Choroidal thickness was significantly (P < 0.001) correlated with the largest choroidal vessel diameter. In the area of the branching choroidal vascular networks in PCV eyes, a "double-layer sign" with two highly reflective layers was noted with an undulating retinal pigment epithelial line, a hyperreflective straight line representing Bruch membrane, and a moderate hyperreflectivity between these two lines. Bruch membrane appeared to be intact. In 4 eyes (22%), a dome-shaped retinal pigment epithelial elevation was detected. It correlated spatially with the polypoidal lesions.
   Conclusion: Polypoidal choroidal vasculopathy is characterized by a thickened subfoveal choroid with dilated choroidal vessels, a double-layer sign at the level of the retinal pigment epithelium-Bruch membrane-choriocapillaris complex, and hyperreflectivity between the retinal pigment epithelium and Bruch membrane. Choroidal macular swelling in PCV is mainly associated with vascular engorgement and dilatation.
C1 [Yang, Li H.; Wei, Wen B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China.
   [Jonas, Jost B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100730, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Heidelberg, Germany.
C3 Capital Medical University; Capital Medical University; Ruprecht Karls
   University Heidelberg
RP Wei, WB (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM Trweiwenbin@yahoo.com.cn
FU Beijing Municipal Excellent Talent Foundation and Training Plan of
   High-Level-Health Talent of Health System, Beijing, China [2009-3-32];
   Beijing Natural Science Foundation [7092021, 7112031]; National Natural
   Science Foundation of China [81041018]
FX Supported by Beijing Municipal Excellent Talent Foundation and Training
   Plan of High-Level-Health Talent of Health System (2009-3-32), Beijing,
   China; Beijing Natural Science Foundation (grant #7092021, 7112031);
   National Natural Science Foundation of China (grant #81041018).
CR Bloom SM, 2011, RETINA-J RET VIT DIS, V31, P316, DOI 10.1097/IAE.0b013e3181ed8c9a
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Fujita K, 2012, AM J OPHTHALMOL, V154, P579, DOI 10.1016/j.ajo.2012.03.043
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Manjunath V, 2010, RETINA-J RET VIT DIS, V30, P1320, DOI 10.1097/IAE.0b013e3181e798b1
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 32
TC 42
Z9 48
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2013
VL 33
IS 8
BP 1584
EP 1589
DI 10.1097/IAE.0b013e318285cbb3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297CP
UT WOS:000330233200013
PM 23584691
DA 2022-11-30
ER

PT J
AU Rodanant, N
   Friberg, TR
   Cheng, LY
   Aurora, A
   Bartsch, DU
   Toyoguchi, M
   Corbin, PS
   El-Bradey, MH
   Freeman, WR
AF Rodanant, N
   Friberg, TR
   Cheng, LY
   Aurora, A
   Bartsch, DU
   Toyoguchi, M
   Corbin, PS
   El-Bradey, MH
   Freeman, WR
TI Predictors of drusen reduction after subthreshold infrared (810 nm)
   diode laser macular grid photocoagulation for nonexudative age-related
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; SOFT DRUSEN; PROPHYLACTIC TREATMENT;
   5-YEAR INCIDENCE; MACULOPATHY; RISK; COMPLICATIONS; ABNORMALITIES; EYE
AB PURPOSE: To determine the predictors of drusen reduction in eyes with nonexudative age-related macular degeneration (ARMD) treated with subthreshold infra red (810 nm) diode laser macular grid photocoagulation. Additionally, to determine the relationship of laser, induced drusen reduction and best-corrected visual acuity (BCVA) 18 months after laser treatment.
   DESIGN: Randomized controlled clinical trial.
   METHODS: Fifty patients (100 eyes) with bilateral nonexudative ARMD were enrolled at two centers. One eye of each patient was randomized to the observation; the other eye was treated with 48 subthreshold (invisible end point) applications of infrared (810 nm) diode laser in a macular grid pattern. The eyes that received subthreshold laser treatment were compared with the eyes that received no treatment. The baseline fundus characteristics (number, size, and distribution of drusen, as well as focal hyperpigmentation) from two macula areas (central 1500 mu diameter, pericentral 1500 mu ring area) on stereo color photographs, the number of laser-induced lesions, and the area of laser induced retinal pigment epithelial (RPE) lesions on fluorescein angiography 3 months after treatment were studied as predictors of major drusen reduction greater than or equal to 50% drusen reduction from baseline and 18 months later was compared in observation eyes and in laser-treated eyes.
   RESULTS: Eighteen months after randomization, 24 (48%) of 50 eyes treated with subthreshold laser had major drusen reduction compared with three (6%) of 50 observation eyes (P = .00001). At 3 months posts treatment in laser-treated eyes with major drusen reduction, the mean number of laser-induced lesions on fluorescein angiography was 30.7 and the mean area of RPE change was 0.81 mm(2) compared with 14.8 laser-induced lesions and 0.35 mm(2) area of RPE change in eyes without major drusen reduction (P = .0001 and P = .0003, respectively). At baseline, fundus characteristics were not significantly different between observation eyes and laser treated eyes or between the major drusen reduction group and the nonmajor drusen reduction group. At 18 months after treatment, BCVA was not significantly different in laser-treated eyes and in observation eyes.
   CONCLUSIONS: Subthreshold infrared (810 nm) diode laser macular grid photocoagulation in eyes with nonexudative ARMD significantly reduced drusen 18 months after laser treatment. Both the number of subthreshold laser lesions and the area of RPE changes visible on fluorescein angiography 3 months after treatment appeared to be predictors for major drusen reduction 18 months after treatment. However, it remains to be determined whether laser-induced drusen reduction is beneficial for visual acuity or reduces the incidence of choroidal neovascularization (CNV) in eyes with nonexudative ARMD. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Univ Calif San Diego, Shiley Eye Ctr, Dept Ophthalmol, La Jolla, CA 92093 USA.
   Univ Pittsburgh Eye & Ear, Pittsburgh, PA USA.
C3 University of California System; University of California San Diego;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, Dept Ophthalmol, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
FU NEI NIH HHS [EY07366] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY007366] Funding Source: NIH RePORTER
CR Banker AS, 1997, OPHTHALMOLOGY, V104, P1442, DOI 10.1016/S0161-6420(97)30118-3
   Brancato R, 1997, AM J OPHTHALMOL, V124, P554, DOI 10.1016/S0002-9394(14)70875-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1995, INVEST OPHTHALMOL  S, V36, P1028
   BURGER JW, 2000, OPHTHALMOLOGY, V107, P1019
   BURGER JW, 1999, AGE RELATED MACULAR
   BURGER JW, 1997, LASER SURG MED, V20, P409
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Hyver SW, 1997, ARCH OPHTHALMOL-CHIC, V115, P554, DOI 10.1001/archopht.1997.01100150556022
   JAVORNIK NB, 1992, INVEST OPHTH VIS SCI, V33, P1230
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   OLK RJ, 2000, INVEST OPHTHALMOL  S, P319
   Pollack JS, 1998, ARCH OPHTHALMOL-CHIC, V116, P1633, DOI 10.1001/archopht.116.12.1633
   Roider J, 1999, GRAEF ARCH CLIN EXP, V237, P45, DOI 10.1007/s004170050193
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   SATO Y, 1992, ARCH OPHTHALMOL-CHIC, V110, P277, DOI 10.1001/archopht.1992.01080140133040
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   Sternberg P, 1998, OPHTHALMOLOGY, V105, P11
   Wetzig P C, 1994, Trans Am Ophthalmol Soc, V92, P299
   Wetzig P C, 1988, Trans Am Ophthalmol Soc, V86, P276
NR 38
TC 33
Z9 40
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2002
VL 134
IS 4
BP 577
EP 585
AR PII S0002-9394(02)01691-4
DI 10.1016/S0002-9394(02)01691-4
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 601KY
UT WOS:000178446100011
PM 12383815
DA 2022-11-30
ER

PT J
AU Bhutto, IA
   McLeod, DS
   Hasegawa, T
   Kim, SY
   Merges, C
   Tong, P
   Lutty, GA
AF Bhutto, IA
   McLeod, DS
   Hasegawa, T
   Kim, SY
   Merges, C
   Tong, P
   Lutty, GA
TI Pigment epithelium-derived factor (PEDF) and vascular endothelial growth
   factor (VEGF) in aged human choroid and eyes with age-related macular
   degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE choroid; pigment epithelium-derived factor; vascular endothelial growth
   factor; RPE; Bruch's membrane; age-related macular degeneration;
   choroidal neovascularization
ID NEOVASCULAR MEMBRANES; INCREASED EXPRESSION; TRANSGENIC MICE; HUMAN
   RETINA; LOCALIZATION; ANGIOGENESIS; HETEROGENEITY; RECEPTORS; SECRETION;
   MECHANISM
AB The purpose of this study was to examine the localization and relative levels of vascular endothelial growth factor (VEGF an angiogenic factor) and pigment epithelium-derived factor (PEDF; an antiangiogenic factor) in aged human choroid and to determine if the localization or their relative levels changed in age-related macular degeneration (AMD).
   Ocular tissues were obtained from eight aged control donors (age range, 75-86 years; mean age, 79.8 years) with no evidence or history of chorioretinal disease and from 12 donors diagnosed with AMD (age range, 61-105 years; mean age, 83.9 years). Tissues were cryopreserved and streptavidin alkaline phosphatase immunohistochemistry was performed with rabbit polyclonal anti-human VEGF and rabbit polyclonal anti-human PEDF antibodies. Binding of the antibodies was blocked by preincubation of the antibody with an excess of recombinant human PEDF or VEGF peptide. Choroidal blood vessels were identified with mouse anti-human CD-34 antibody in adjacent tissue sections. Three independent observers graded the immunohistochemical reaction product.
   The most prominent sites of VEGF and PEDF localization in abed control choroid were RPE-Bruch's membrane-choriocapillaris complex including RPE basal lamina, intercapillary septa, and choroidal stroma. There was no significant difference in immunostaining intensity and localization of VEGF and PEDF in aged control choroids. The most intense VEGF immunoreactivity was observed in leukocytes within blood vessels. AMD choroid had a similar pattern and intensity of VEGF immunostaining to that observed in aged controls. However, PEDF immunoreactivity was significantly lower in RPE cells (p=0.0073), RPE basal lamina (p=0.0141), Bruch's membrane (p<0.0001), and choroidal stroma (p=0.0161) of AMD choroids. The most intense PEDF immunoreactivity was observed in disciform scars. Drusen and basal laminar deposits (BLDs) were positive for VEGF and PEDF.
   In aged control subjects, VEGF and PEDF immunostaining was the most intense in RPE-Bruch's membrane-choriocapillaris complex. In AMD, PEDF was significantly lower in RPE cells, RPE basal lamina, Bruch's membrane and choroidal stroma. These data suggest that a critical balance exists between PEDF and VEGF, and PEDF may counteract the angiogenic potential of VEGF. The decrease in PEDF may disrupt the balance and be permissive for the formation of choroidal neovascularization (CNV) in AMD. (C) 2005 Elsevier Ltd. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Wilmer Ophthalmol Inst,Dept Ophthalmol, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Lutty, GA (通讯作者)，Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Wilmer Ophthalmol Inst,Dept Ophthalmol, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM galutty@jhmi.edu
FU NEI NIH HHS [R01 EY016151, EY-01765, P30 EY001765, R01 EY016151-05]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765,
   R01EY016151] Funding Source: NIH RePORTER
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Cousins SW, 2002, AGE-RELATED MACULAR DEGENERATION, P27
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   General Accounting Office, 1999, GEN MAN PROC PHAS 2B, P1
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Neuhardt T, 1999, EXP EYE RES, V68, P75, DOI 10.1006/exer.1998.0589
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   PAGE C, 1992, AM J PATHOL, V141, P673
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Vinores SA, 2003, CURR OPIN MOL THER, V5, P673
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
NR 44
TC 195
Z9 209
U1 0
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2006
VL 82
IS 1
BP 99
EP 110
DI 10.1016/j.exer.2005.05.007
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 007BN
UT WOS:000234942500013
PM 16019000
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nolan, JM
   Stack, J
   Donovan, OO
   Loane, E
   Beatty, S
AF Nolan, John M.
   Stack, Jim
   O' Donovan, Orla
   Loane, Edward
   Beatty, Stephen
TI Risk factors for age-related maculopathy are associated with a relative
   lack of macular pigment
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; age-related maculopathy; antioxidant;
   blue light damage; lutein; macular pigment; oxidative stress; zeaxanthin
ID FOOD-FREQUENCY QUESTIONNAIRE; RESONANCE RAMAN MEASUREMENT;
   OPTICAL-DENSITY; SPATIAL-DISTRIBUTION; CIGARETTE-SMOKING; CAROTENOID
   CONCENTRATIONS; SERUM CONCENTRATIONS; DEGENERATION; LUTEIN; REFLECTANCE
AB Macular pigment (MP) is composed of the two dietary carotenoids lutein (L) and zeaxanthin (Z), and is believed to protect against age-related maculopathy (ARM). This study was undertaken to investigate MP optical density with respect to risk factors for ARM, in 828 healthy subjects from an Irish population. NIP optical density was measured psychophysically using heterochromatic flicker photometry, serum L and Z were quantified by HPLC, and dietary intake of L and Z was assessed using a validated food-frequency questionnaire. Clinical and personal details were also recorded, with particular attention directed towards risk factors for ARM. We report a statistically significant age-related decline in MP optical density (r(2) = 0.082, p < 0.01). Current and past smokers had lower average MP optical density than never smokers and this difference was statistically significant (p < 0.01). Subjects with a confirmed family history of ARM had significantly lower levels of MP optical density than subjects with no known family history of disease (p < 0.01). For each of these established risk factors, their statistically significant negative association with MP persisted after controlling for the other two, and also after controlling for other potentially confounding variables such as sex, cholesterol, dietary and serum L (p < 0.01). In the absence of retinal pathology, and in advance of disease onset, the relative lack of MP seen in association with increasing age, tobacco use and family history of ARM supports the hypothesis that the enhanced risk that these variables represent for ARM may be attributable, at least in part, to a parallel deficiency of macular carotenoids. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   Waterford Inst Technol, Dept Phys & Quantitat Sci, Waterford, Ireland.
   Waterford Inst Technol, Dept Ophthalmol, Waterford, Ireland.
C3 South East Technological University (SETU); South East Technological
   University (SETU); South East Technological University (SETU)
RP Nolan, JM (通讯作者)，Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Cork Rd, Waterford, Ireland.
EM jnolan@wit.ie
RI ; Nolan, John/N-4921-2014
OI O' Donovan, Orla/0000-0003-3980-8835; Nolan, John/0000-0002-5503-7084
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bodner CH, 1998, J HUM NUTR DIET, V11, P373, DOI 10.1046/j.1365-277X.1998.00119.x
   BOLTONSMITH C, 1991, BRIT J NUTR, V65, P337, DOI 10.1079/BJN19910094
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Chang Y, 2002, MED PHYS, V29, P2621, DOI 10.1118/1.1515761
   Chen SF, 2001, CURR EYE RES, V23, P422, DOI 10.1076/ceyr.23.6.422.6963
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dallongeville J, 1998, J NUTR, V128, P1450
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   *FOOD STAND AG, 2002, MCC WIDD COMP FOODS
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   George S, 2005, INVEST OPHTH VIS SCI, V46
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, pS233
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, pU1005
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   Holland B., 1991, MCCANCE WIDDOWSONS C, V5
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LIEW M, 2005, CENTRAL RETINAL THIC
   LIEW SHM, 2005, HERITABILITY MACULAR
   Masson LF, 2003, PUBLIC HEALTH NUTR, V6, P313, DOI 10.1079/PHN2002429
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Neelam K, 2005, INVEST OPHTH VIS SCI, V46, P1023, DOI 10.1167/iovs.04-1032
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   RAND WM, 1987, FOOD COMPOSITION DAT
   SAUAR J, 1980, ACTA MED SCAND, V208, P199
   SCHAEFER EJ, 1983, J CLIN ENDOCR METAB, V57, P262, DOI 10.1210/jcem-57-2-262
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Wooten BR, 2005, OPTOMETRY VISION SCI, V82, P378, DOI 10.1097/01.OPX.0000162654.32112.A1
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zagers NPA, 2004, J OPT SOC AM A, V21, P2257, DOI 10.1364/JOSAA.21.002257
   Zhao DY, 2003, ARCH OPHTHALMOL-CHIC, V121, P967, DOI 10.1001/archopht.121.7.967
   [No title captured]
NR 68
TC 137
Z9 142
U1 0
U2 16
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2007
VL 84
IS 1
BP 61
EP 74
DI 10.1016/j.exer.2006.08.016
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123JP
UT WOS:000243292500009
PM 17083932
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Buckle, M
   Lee, A
   Mohamed, Q
   Fletcher, E
   Sallam, A
   Healy, R
   Stratton, I
   Tufail, A
   Johnston, RL
AF Buckle, M.
   Lee, A.
   Mohamed, Q.
   Fletcher, E.
   Sallam, A.
   Healy, R.
   Stratton, I.
   Tufail, A.
   Johnston, R. L.
TI Prevalence and incidence of blindness and other degrees of sight
   impairment in patients treated for neovascular age-related macular
   degeneration in a well-defined region of the United Kingdom
SO EYE
LA English
DT Article
ID VISUAL IMPAIRMENT; LEGAL BLINDNESS; RANIBIZUMAB; MARINA; IMPACT; TRIAL
AB Aims This study aimed to evaluate the incidence and prevalence of blindness, sight impairment, and other visual acuity (VA) states in patients receiving ranibizumab for neovascular age-related macular degeneration (nAMD) in Gloucestershire.
   Methods Serial VA and injection data for all treatment-naive patients receiving their first intravitreal injections of ranibizumab for nAMD in the Gloucestershire National Health Service Ophthalmology department between 2008 and 2010 were extracted from an electronic medical record system.
   Results The prevalence of blindness (VA in the better-seeing eye <= 25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters) at the time of first intravitreal injection was 0.8%, increasing to 3.5% after 3 years. The prevalence of sight impairment (VA in the better-seeing eye 26-39 ETDRS letters) increased from 4.1% at baseline to 5.5% after 3 years. The incidence of initiating ranibizumab treatment for nAMD in people aged >= 50 years in Gloucestershire was 111 people per 100 000 population in 2009, and 97 people in 2010. The incidence of patients meeting the visual criteria for blindness and sight impairment registration from treated nAMD in people aged >= 50 years in Gloucestershire was 3.5 and 9.7 people, respectively per 100 000 population in 2010.
   Conclusion This is the first real-world study on the incidence and prevalence of eligibility for blindness and sight impairment registration in treated nAMD in the UK based on VA data. The incidence and prevalence of eligibility for certification of blindness or sight impairment in patients treated with ranibizumab for nAMD is low in Gloucestershire, with only 3.6% of the incident population progressing to blindness in 2010.
C1 [Buckle, M.; Mohamed, Q.; Fletcher, E.; Sallam, A.; Healy, R.; Johnston, R. L.] Gloucestershire Hosp NHS Fdn Trust, Dept Ophthalmol, Cheltenham Hosp, Cheltenham, Glos, England.
   [Lee, A.; Tufail, A.] Moorfields Eye Hosp, Med Retina Dept, London, England.
   [Stratton, I.] Cheltenham Gen Hosp, Gloucester Diabet Retinopathy Res Grp, Cheltenham, Glos, England.
C3 Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General
   Hospital; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust; Gloucestershire Hospitals NHS
   Foundation Trust; Cheltenham General Hospital
RP Johnston, RL (通讯作者)，Cheltenham Gen Hosp, Dept Ophthalmol, Sandford Rd, Cheltenham GL53 7AN, Glos, England.
EM rob.johnston@glos.nhs.uk
RI stratton, irene/AAZ-3627-2020; Lee, Aaron/AAT-2839-2020; Sallam,
   Ahmed/A-4791-2014
OI stratton, irene/0000-0003-1172-7865; Sallam, Ahmed/0000-0001-7207-6782;
   Buckle, Miranda/0000-0002-6722-7125; Lee, Aaron/0000-0002-7452-1648;
   Tufail, Adnan/0000-0001-6131-7640
CR Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Harding Simon P, 2009, Ophthalmology, V116, pe1, DOI 10.1016/j.ophtha.2009.10.022
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Malik ANJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001496
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 22
TC 11
Z9 11
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2015
VL 29
IS 3
BP 403
EP 408
DI 10.1038/eye.2014.296
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD2CB
UT WOS:000350880300015
PM 25592123
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Hollands, H
   Sharma, S
AF Hollands, Hussein
   Sharma, Sanjay
TI Update on utilities and cost-utility analyses
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE cost-utility analyses; macular degeneration; utilities
ID QUALITY-OF-LIFE; PHOTODYNAMIC THERAPY; DIABETIC-RETINOPATHY; MACULAR
   DEGENERATION; VALUES; NEOVASCULARIZATION; EYES
AB Purpose of review
   The purpose of this review is to summarize the recent and noteworthy utility studies and cost-utility analyses in the area of retina/vitreous during the period January 2004 to January 2006.
   Recent findings
   This review considers the cost effectiveness of treatments for wet age-related macular degeneration, dry age-related macular degeneration, telemedicine in diabetic retinopathy, and utilities and patients with age-related macular degeneration and diabetic retinopathy.
   Summary
   Utilities are being used increasingly to measure health-related quality of life. Cost-utility analyses are becoming more readily available for comparing the incremental cost-effectiveness of different ophthalmic interventions.
C1 Queens Univ, Cost Effect Ocular Hlth Policy Unit, Kingston, ON K7L 5G2, Canada.
C3 Queens University - Canada
RP Sharma, S (通讯作者)，Queens Univ, Hop Hotel Dieu, Cost Effect Ocular Hlth Policy Unit, Brock 2-224B,166 Brock St, Kingston, ON K7L 5G2, Canada.
EM sanjay_sharma60@hotmail.com
CR Aoki N, 2004, DIABETES CARE, V27, P1095, DOI 10.2337/diacare.27.5.1095
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Chakravarthy Usha, 2005, Curr Opin Ophthalmol, V16, P179, DOI 10.1097/01.icu.0000163035.37957.c2
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   MEADS C, 2001, CLIN EFFECTIVENESS C
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   SACKETT DL, 1988, CLIN EPIDEMIOLOGY BA
   Shah VA, 2004, OPHTHAL EPIDEMIOL, V11, P43, DOI 10.1076/opep.11.1.43.26436
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2003, BRIT J OPHTHALMOL, V87, P259, DOI 10.1136/bjo.87.3.259
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma Sanjay, 2005, Curr Opin Ophthalmol, V16, P155, DOI 10.1097/01.icu.0000161227.21797.3d
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   Tung TH, 2005, DIABETES RES CLIN PR, V68, P265, DOI 10.1016/j.diabres.2004.10.003
NR 24
TC 0
Z9 0
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD JUN
PY 2006
VL 17
IS 3
BP 223
EP 227
DI 10.1097/01.icu.0000193106.00089.a7
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 055XC
UT WOS:000238483500002
PM 16794433
DA 2022-11-30
ER

PT J
AU Wang, JY
   Ohno-Matsui, K
   Yoshida, T
   Shimada, N
   Ichinose, S
   Sato, T
   Mochizuki, M
   Morita, I
AF Wang, Jiying
   Ohno-Matsui, Kyoko
   Yoshida, Takeshi
   Shimada, Noriaki
   Ichinose, Shizuko
   Sato, Tetsuji
   Mochizuki, Manabu
   Morita, Ikuo
TI Amyloid-beta Up-Regulates Complement Factor B in Retinal Pigment
   Epithelial Cells Through Cytokines Released From Recruited
   Macrophages/Microglia: Another Mechanism of Complement Activation in
   Age-Related Macular Degeneration
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID CAUSE-SPECIFIC PREVALENCE; FACTOR-H POLYMORPHISM; VISUAL IMPAIRMENT;
   IFN-GAMMA; TNF-ALPHA; DRUSEN; GENE; BIOSYNTHESIS; EXPRESSION; C3
AB One of the earliest signs of age-related macular degeneration (AMD) is the formation of drusen which are extracellular deposits beneath the retinal pigmented epithelium (RPE). To investigate the relationship between drusen and AMD, we focused on amyloid beta (A beta), a major component of drusen and also of senile plaques in the brain of Alzheimer's patients. We previously reported that A beta was accumulated in drusen-like structure in senescent neprilysin gene-disrupted mice. The purpose of this study was to investigate the influence of A beta on factor B, the main activator of the complement alternative pathway. The results showed that A beta did not directly modulate factor B expression in RPE cells, but increased the production of monocyte chemoattractant protein-1 (MCP-1). A beta also increased the production of IL-1 beta and TNF-alpha in macrophages/microglia, and exposure of RPE cells to IL-1 beta and TNF-alpha significantly up-regulated factor B. Cocultures of RPE cells and macrophages/microglia in the presence of A beta significantly increased the expression of factor B in RPE. These findings indicate that cytokines produced by macrophages/microglia that were recruited by MCP-1 produced in RPE cells stimulated by A beta up-regulate factor B in RPE cells. Thus, a combined mechanism exists for A beta-induced for the activation of the complement alternative pathway in the subretinal space; cytokine-induced up-regulation of activator factor B and dysfunction of the inhibitor factor I by direct binding to A beta as suggested in our earlier study. J. Cell. Physiol. 220: 1 19-128, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, Tokyo 113, Japan.
   [Ichinose, Shizuko] Tokyo Med & Dent Univ, Instrumental Anal Res Ctr, Tokyo 113, Japan.
   [Sato, Tetsuji] Tsurumi Univ, Dept Anat, Sch Dent Med, Yokohama, Kanagawa, Japan.
   [Morita, Ikuo] Tokyo Med & Dent Univ, Sect Cellular Physiol Chem, Tokyo 113, Japan.
C3 Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental
   University (TMDU); Tsurumi University; Tokyo Medical & Dental University
   (TMDU)
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.
EM k.ohno.oph@tmd.ac.jp
FU Japan Society for the Promotion of Science, Tokyo, Japan [19390441,
   19659445]
FX The authors thank Prof. Duco Hamasaki for his critical discussion and
   revision of the final manuscript. The authors also thank Prof. Peter A.
   Campochiaro and Sean F. Hackett for the human RPE cells. This study was
   supported in part by research grant 19390441 and 19659445 from the Japan
   Society for the Promotion of Science, Tokyo, Japan.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301
   Bergamaschini L, 2001, MECH AGEING DEV, V122, P1971, DOI 10.1016/S0047-6374(01)00311-6
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   BRACHOVA L, 1993, MOL BRAIN RES, V18, P329, DOI 10.1016/0169-328X(93)90097-9
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   CAMPOCHIARO PA, 1993, EXP EYE RES, V57, P539, DOI 10.1006/exer.1993.1158
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fiala M, 1998, MOL MED, V4, P480, DOI 10.1007/BF03401753
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Gerritsma JSJ, 1996, MOL IMMUNOL, V33, P847, DOI 10.1016/0161-5890(96)84610-4
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GREEN RG, 1999, AGE RELATED MACULAR, P81
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Huang Y, 2002, J IMMUNOL, V169, P2627, DOI 10.4049/jimmunol.169.5.2627
   Huang Y, 2001, EUR J IMMUNOL, V31, P3676, DOI 10.1002/1521-4141(200112)31:12<3676::AID-IMMU3676>3.0.CO;2-K
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kawakami Y, 1997, CANCER LETT, V116, P21, DOI 10.1016/S0304-3835(97)04737-X
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LASZLO DJ, 1993, AM J PATHOL, V143, P587
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MAYER MM, 1973, SCI AM, V229, P54, DOI 10.1038/scientificamerican1173-54
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Nakamichi K, 2006, NEUROSCI LETT, V407, P205, DOI 10.1016/j.neulet.2006.08.044
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pasch MC, 2000, J INVEST DERMATOL, V114, P78, DOI 10.1046/j.1523-1747.2000.00841.x
   Rampe D, 2004, J NEUROIMMUNOL, V147, P56, DOI 10.1016/j.jneuroim.2003.10.014
   Shalit F, 1997, NEUROREPORT, V8, P3577, DOI 10.1097/00001756-199711100-00031
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Strohmeyer R, 2000, MOL BRAIN RES, V81, P7, DOI 10.1016/S0169-328X(00)00149-2
   Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506
   Takenouchi T, 2005, BBA-GEN SUBJECTS, V1726, P177, DOI 10.1016/j.bbagen.2005.08.001
   Uetama T, 2003, J CELL PHYSIOL, V197, P77, DOI 10.1002/jcp.10342
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   WITSELL AL, 1992, P NATL ACAD SCI USA, V89, P4754, DOI 10.1073/pnas.89.10.4754
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zanjani H, 2005, ALZ DIS ASSOC DIS, V19, P55, DOI 10.1097/01.wad.0000165506.60370.94
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 52
TC 84
Z9 89
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2009
VL 220
IS 1
BP 119
EP 128
DI 10.1002/jcp.21742
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 454HG
UT WOS:000266672400014
PM 19277984
DA 2022-11-30
ER

PT J
AU Chang, A
   Stokes, J
   Priestman, L
   Holmes, C
   Said, P
AF Chang, Andrew
   Stokes, John
   Priestman, Lindy
   Holmes, Connor
   Said, Peter
TI Impact of a Patient Support Program on Patient Beliefs About Neovascular
   Age-Related Macular Degeneration and Persistence to Anti-Vascular
   Endothelial Growth Factor Therapy
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE intravitreal aflibercept; patient satisfaction; illness perceptions;
   medication beliefs; neovascular macular degeneration; persistence
ID INTRAVITREAL INJECTIONS; ADHERENCE; RANIBIZUMAB; MEDICATION; BURDEN
AB Purpose: This study aimed to compare persistence between patients prescribed intravitreal aflibercept (IVT-AFL) for neovascular age-related macular degeneration (nAMD) in Australia enrolled on a patient support program (PSP) with that of a sample of patients from the Australian Pharmaceutical Benefits Scheme (PBS) dataset (10% PBS sample); explore predictors of persistence; describe changes in patient beliefs over the course of their enrollment in a PSP for patients treated with IVT-AFL for nAMD; and assess patient satisfaction.
   Participants and Methods: Participants prescribed IVT-AFL for the treatment of nAMD were invited to participate in the PSP. The PSP provided tailored support to patients through provision of a welcome pack, structured telephone calls, and information booklets. Persistence was defined in the PSP as the time from the start date in the program, until discontinuation from the program; and as the time from initial prescription until 6-months after the date of last prescription in the 10% PBS set. Persistence on the program and risk of discontinuation were modeled using Kaplan-Meier methods and Cox proportional hazards. In addition, persistence was compared between patients on the PSP and a 10% PBS sample of patients prescribed IVT-AFL for nAMD.
   Results: Persistence on treatment at 24 months was significantly higher in patients enrolled on the PSP compared to the PBS cohort (88% vs 64%, p<0.05). The risk of discontinuation in patients enrolled on the PSP was higher in patients identified at screening as "high-risk", those who were younger, or those with significant distance to travel for treatment. During the PSP, patients reported significant increase in their belief that they had control over their condition (6.1 +/- 3.5 to 6.8 +/- 3.7; p=0.0034) and a reduction in concerns about treatment. Satisfaction with the PSP was high.
   Conclusion: Patients provided with access to a PSP showed better persistence on treatment and improved beliefs about nAMD disease and its treatment compared to those in the PBS sample. Improved persistence rates may translate into better outcomes for the patient and the healthcare system, however, further research is required to determine which elements of the program are most beneficial, particularly to those at high risk of discontinuation.
C1 [Chang, Andrew] Univ Sydney, Sydney Inst Vis Sci, Save Sight Inst, Sydney Retina Clin, Sydney, NSW, Australia.
   [Stokes, John] Inservio, Sydney, NSW, Australia.
   [Stokes, John] Charles Sturt Univ, Dept Biomed Sci, Orange, NSW, Australia.
   [Priestman, Lindy; Holmes, Connor] Atlantis Healthcare Pty Ltd, Sydney, NSW, Australia.
   [Said, Peter] Bayer Australia Ltd, Med Affairs, Sydney, NSW, Australia.
C3 University of Sydney; Charles Sturt University; Bayer AG
RP Chang, A (通讯作者)，Sydney Retina Clin, 187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
FU Bayer Australia Pty Ltd, Pymble, NSW, Australia; Bayer Consumer Care AG,
   Basel, Switzerland; Bayer Australia Ltd.
FX The authors thank Eric Chung from Prospection Pty Ltd for performing an
   earlier data analysis that prompted this research, Matthew Tucker from
   Atlantis Healthcare (Australia) Pty Ltd for performing PSP and PBS 10%
   data analysis, and Rachelle Steele, BPharm (Hons), and Belinda Butcher,
   BSc (Hons), MBiostat, PhD, CMPP, of WriteSource Medical Pty Ltd, Sydney,
   NSW, Australia, for providing medical writing support (funded by Bayer
   Australia Pty Ltd, Pymble, NSW, Australia, in accordance with Good
   Publication Practice guidelines). The authors thank Dawn Lobban at
   Envision Pharma Group for support in preparing the plain language
   summary of this paper (funded by Bayer Consumer Care AG, Basel,
   Switzerland). This study was funded by Bayer Australia Ltd.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Angermann R, 2019, GRAEF ARCH CLIN EXP, V257, P2119, DOI 10.1007/s00417-019-04414-y
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Drug Utilisation Sub-Committee, 2018, RAN AFL AN US AMD DM
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foot H, 2016, PATIENT EDUC COUNS, V99, P706, DOI 10.1016/j.pec.2015.11.004
   Foreman J, 2020, CLIN EXP OPHTHALMOL, V48, P730, DOI 10.1111/ceo.13776
   Ganguli A, 2016, PATIENT PREFER ADHER, V10, P711, DOI 10.2147/PPA.S101175
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Kucukarslan SN, 2012, RES SOC ADMIN PHARM, V8, P371, DOI 10.1016/j.sapharm.2011.09.002
   Macular Degeneration Foundation, 2010, BARR ACC WET MD TREA
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mellish Leigh, 2015, BMC Res Notes, V8, P634, DOI 10.1186/s13104-015-1616-8
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   Mitchell P, 2011, DELOITTE ACCESS EC E
   Mitchell P, 2019, INVEST OPHTH VIS SCI, V60
   Muller S, 2017, GRAEF ARCH CLIN EXP, V255, P2237, DOI 10.1007/s00417-017-3739-1
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Optometry Australia, 2019, CLIN PRACT GUID DIAG
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sii S, 2018, EYE, V32, P673, DOI 10.1038/eye.2017.271
   Spooner KL, 2019, DIABETES METAB SYNDR, V12, P1913, DOI 10.2147/DMSO.S214098
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Stokes J, 2016, MIVISION, V114, P51
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   World Health Organization, 2003, ADHERENCE LONG TERM, P216
NR 38
TC 2
Z9 2
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2021
VL 15
BP 511
EP 521
DI 10.2147/PPA.S293941
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA QY2YR
UT WOS:000629911500001
PM 33688173
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhu, Y
   Liang, L
   Qian, D
   Yu, HS
   Yang, PZ
   Lei, B
   Peng, H
AF Zhu, Yi
   Liang, Liang
   Qian, Dan
   Yu, Hongsong
   Yang, Peizeng
   Lei, Bo
   Peng, Hui
TI Increase in peripheral blood mononuclear cell Toll-like receptor 2/3
   expression and reactivity to their ligands in a cohort of patients with
   wet age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULARIZATION;
   CHLAMYDIA-PNEUMONIAE; IMMUNE-SYSTEM; AQUEOUS-HUMOR; SIRNA; VEGF;
   RECOGNITION; MACULOPATHY; SUPPRESSION
AB Purpose: To investigate Toll-like receptor (TLR) expression and reactivity in patients with the wet form age-related macular degeneration (AMD).
   Methods: Blood samples were collected from 25 patients with wet AMD and 25 age-matched healthy controls. Peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll-Hypaque density gradient centrifugation. Expression of TLR1 to TLR10 mRNAs in PBMCs from 15 patients with wet AMD and 15 controls was assessed with real-time PCR. TLR2 and TLR3 protein levels in PBMCs from six patients with wet AMD and six controls were measured with flow cytometry. After PBMCs were stimulated with peptidoglycan (PGN) and poly(I:C), the specific ligands of TLR2 and TLR3, cytokines interleukin-6 (IL-6), IL-8, VEGF, and monocyte chemoattractant protein-1 (MCP-1) production in 11 patients with wet AMD and 11 controls were assessed.
   Results: TLR2 and TLR3 mRNA and protein expression in the PBMCs of the patients with wet AMD was significantly higher than that in the controls. However, the difference in TLR1 and TLR4-10 mRNA expression between the two groups was not significant. The PBMCs of the patients with wet AMD produced more IL-6 and IL-8 proteins than the controls in response to PGN, a ligand for TLR2, and more IL-6 protein than the controls in response to poly(I:C), the ligand for TLR3. However, there was no significant difference in vascular endothelial growth factor and monocyte chemoattractant protein-1 production between the wet AMD group and the control group when the PBMCs were stimulated with PGN or poly(I:C).
   Conclusions: Our data suggested that upregulation of TLR2 and TLR3 may be associated with the pathogenesis of wet AMD.
C1 [Zhu, Yi; Liang, Liang; Qian, Dan; Yu, Hongsong; Yang, Peizeng; Lei, Bo; Peng, Hui] Chongqing Med Univ, Chongqing Key Lab Ophthalmol, Affiliated Hosp 1, Dept Ophthalmol,Chongqing Eye Inst, Chongqing, Peoples R China.
C3 Chongqing Medical University
RP Peng, H (通讯作者)，Dept Ophthalmol, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM pengh9@yahoo.com.cn
RI Yu, Hongsong/J-9106-2014
OI Yu, Hongsong/0000-0002-1209-2104; Lei, Bo/0000-0002-5497-0905
FU National Basic Research Program of China [2011CB510200,
   2011ZX09302007002]; Chongqing Municipal Health Bureau [2010-1-13,
   2012-1-026]; Chongqing Key Laboratory of Ophthalmology
FX Professor Bo Lei is a co-corresponding author of this study. The email
   addresses of both corresponding authors are bolei99@126.com and
   pengh9@yahoo.com.cn. This work was supported in part by National Basic
   Research Program of China (2011CB510200, 2011ZX09302007002), Chongqing
   Municipal Health Bureau (2010-1-13, 2012-1-026) and Chongqing Key
   Laboratory of Ophthalmology. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript. The authors report no conflicts of interest.
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Alkanani AK, 2012, DIABETES, V61, P2525, DOI 10.2337/db12-0099
   Ashikari M, 2010, INVEST OPHTH VIS SCI, V51, P3820, DOI 10.1167/iovs.09-5121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Cao SJ, 2013, MOL VIS, V19, P718
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1
   Gu LP, 2010, EXP EYE RES, V91, P433, DOI 10.1016/j.exer.2010.06.019
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Iwamura C, 2008, CURR ALLERGY ASTHM R, V8, P7, DOI 10.1007/s11882-008-0003-0
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Klettner A, 2013, ACTA OPHTHALMOL, V91, pE211, DOI 10.1111/aos.12031
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Li X, 2012, PLOS ONE, V7
   Maloney SC, 2010, OPHTHALMIC RES, V44, P237, DOI 10.1159/000313989
   Miao H, 2012, MOL VIS, V18, P574
   Myles A, 2012, J CLIN IMMUNOL, V32, P488, DOI 10.1007/s10875-011-9640-5
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Ozato K, 2002, BIOTECHNIQUES, P66
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Proost P, 2003, EUR J IMMUNOL, V33, P3146, DOI 10.1002/eji.200324136
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Taneichi H, 2008, CLIN IMMUNOL, V126, P148, DOI 10.1016/j.clim.2007.10.005
   Thanigaimani S, 2011, CURR VASC PHARMACOL, V9, P358, DOI 10.2174/157016111795495503
   Yi H, 2012, PLOS ONE, V7, DOI e36560
NR 35
TC 12
Z9 13
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 6
PY 2013
VL 19
BP 1826
EP 1833
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 211EY
UT WOS:000323889200005
PM 23946637
DA 2022-11-30
ER

PT J
AU Saade, C
   Smith, RT
AF Saade, Celine
   Smith, Roland T.
TI Reticular macular lesions: a review of the phenotypic hallmarks and
   their clinical significance
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE macular degeneration; multimodal imaging; prognosis; retinal
   drusen/complications; retinal drusen/diagnosis
ID SUBRETINAL DRUSENOID DEPOSITS; COMPLEMENT FACTOR-H; AGE-RELATED
   MACULOPATHY; GEOGRAPHIC ATROPHY; RISK-FACTORS; PSEUDODRUSEN;
   DEGENERATION; PREVALENCE; EYES; VARIANT
AB Reticular macular lesions, also known as 'reticular macular disease', 'reticular drusen', 'reticular pseudodrusen', or 'subretinal drusenoid deposits', are a pattern of lesions commonly found in age-related macular degeneration and best visualized using at least two imaging techniques in combination. Reticular lesions have four stages of progression observable on spectral domain optical coherence tomography, but they do not show the usual signs of regression of soft drusen (calcification and pigment changes). Furthermore, reticular lesions correlate histologically with subretinal drusenoid deposits localized between the retinal pigment epithelium and the inner segment ellipsoid band. Reticular lesions are most commonly seen in older age groups of female patients with age-related macular degeneration and are usually bilateral. They are not clearly associated with known age-related macular degeneration genes and are highly associated with late-stage age-related macular degeneration and an increased mortality rate. They are also associated with alterations in the neural retina and choroid.
C1 [Saade, Celine; Smith, Roland T.] NYU, Sch Med, Dept Ophthalmol, New York, NY 10016 USA.
C3 New York University
RP Smith, RT (通讯作者)，NYU, Sch Med, Dept Ophthalmol, 462 First Ave NBV 5N18, New York, NY 10016 USA.
EM roland.smith@nyumc.org
OI smith, theodore/0000-0002-1693-943X
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2006, BRIT J OPHTHALMOL, V90, P396, DOI 10.1136/bjo.2005.086041
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 57
TC 20
Z9 20
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2014
VL 42
IS 9
BP 865
EP 874
DI 10.1111/ceo.12353
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW7XT
UT WOS:000346475700009
PM 24803342
DA 2022-11-30
ER

PT J
AU Honda, S
   Kohno, T
   Yamamoto, M
   Hirayama, K
   Kyo, A
   Hirabayashi, M
   Honda, S
AF Honda, Satoshi
   Kohno, Takeya
   Yamamoto, Manabu
   Hirayama, Kumiko
   Kyo, Akika
   Hirabayashi, Michiko
   Honda, Shigeru
TI Early anatomical changes and association with photodynamic therapy
   induced acute exudative maculopathy in patients with macular diseases
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; HALF-DOSE VERTEPORFIN; REDUCED FLUENCE;
   VISUAL-ACUITY; RANIBIZUMAB; SAFETY; VASCULOPATHY; COMBINATION; EFFICACY
AB The purpose of this study was to investigate the occurrence rate and predictors of photodynamic therapy (PDT) induced acute exudative maculopathy (PAEM). This retrospective study included 39 eyes of 39 patients (32 males and 7 females), who were treated with initial PDT. PAEM was defined as an increase in central retinal thickness (CRT) of 15% or more measured by OCT on day 3 after PDT compared with baseline. Sixteen of 39 eyes (41%) were classified in the PAEM+ group. CRT and central choroidal thickness (CCT) were significantly increased at 3 days in the PAEM+ group and significantly decreased at 1 month after PDT in the PAEM- group. In a multiple comparison, neovascular age-related macular degeneration (nAMD) had a significantly higher incidence of PAEM compared to polypoidal choroidal vasculopathy (PCV) and central serous chorioretinopathy (CSC). The incidence of PAEM was lower in PCV and CSC, and higher in nAMD. BCVA at 1 month was significantly worse in the PAEM group, which may be related to visual prognosis after PDT. Since both CRT and CCT decrease at 1 month, the detection of PAEM needs to be assessed a few days after PDT.
C1 [Honda, Satoshi; Kohno, Takeya; Yamamoto, Manabu; Hirayama, Kumiko; Kyo, Akika; Honda, Shigeru] Osaka City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Osaka 5458585, Japan.
   [Hirabayashi, Michiko] Shiraniwa Hosp, Osaka, Japan.
C3 Osaka Metropolitan University
RP Yamamoto, M (通讯作者)，Osaka City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Osaka 5458585, Japan.
EM myamamoto1977@gmail.com
RI Kyo, Akika/GQO-8685-2022
FU Japanese Ministry of Education, Culture, Sports, Science, and Technology
   (MEXT) [19K09997]
FX This study was supported in part by Grants-in-Aid for Scientific
   Research from the Japanese Ministry of Education, Culture, Sports,
   Science, and Technology (MEXT) -No.19K09997.
CR Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cicinelli MV, 2020, OPHTHALMOL RETINA, V4, P454, DOI 10.1016/j.oret.2019.12.003
   Fernandez-Vigo JI, 2022, RETINA-J RET VIT DIS, V42, P859, DOI 10.1097/IAE.0000000000003404
   Fernandez-Vigo JI, 2022, EUR J OPHTHALMOL, V32, pNP133, DOI 10.1177/11206721211027060
   Figurska M, 2011, MED SCI MONITOR, V17, pCS75, DOI 10.12659/MSM.881799
   FINGAR VH, 1992, CANCER RES, V52, P4914
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz ER, 2003, ARCH OPHTHALMOL-CHIC, V121, P1649, DOI 10.1001/archopht.121.11.1649
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Izumi T, 2017, BRIT J OPHTHALMOL, V101, P433, DOI 10.1136/bjophthalmol-2016-308921
   Jurklies B, 2005, GRAEF ARCH CLIN EXP, V243, P393, DOI 10.1007/s00417-004-1100-y
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282
   Mammo Zaid, 2017, Retin Cases Brief Rep, V11, P217, DOI 10.1097/ICB.0000000000000356
   Manayath GJ, 2020, RETINA-J RET VIT DIS, V40, P135, DOI 10.1097/IAE.0000000000002343
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P100, DOI 10.1007/s10384-018-0636-z
   Ohkuma Y, 2013, GRAEF ARCH CLIN EXP, V251, P1909, DOI 10.1007/s00417-013-2289-4
   Ranjan R, 2017, CAN J OPHTHALMOL, V52, P625, DOI 10.1016/j.jcjo.2017.05.013
   Ruiz-Moreno JM, 2010, ACTA OPHTHALMOL, V88, P371, DOI 10.1111/j.1755-3768.2008.01408.x
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Somani S, 2017, CAN J OPHTHALMOL, V52, P627, DOI 10.1016/j.jcjo.2017.06.005
   Sumnicht AJ, 2021, PHOTODIAGN PHOTODYN, V35, DOI 10.1016/j.pdpdt.2021.102390
   Takahashi K, 2018, CLIN OPHTHALMOL, V12, P1789, DOI 10.2147/OPTH.S171015
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tarantola RM, 2008, LASER SURG MED, V40, P671, DOI 10.1002/lsm.20720
   Varano M, 2014, OPHTHALMOLOGICA, V231, P204, DOI 10.1159/000357504
   Vasconcelos H, 2013, GRAEF ARCH CLIN EXP, V251, P1697, DOI 10.1007/s00417-013-2270-2
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 34
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 1
PY 2022
VL 12
IS 1
AR 9105
DI 10.1038/s41598-022-13208-y
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 1T5SJ
UT WOS:000804787700054
PM 35650246
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Pratt, NL
   Ramsay, EN
   Kemp, A
   Kalisch-Ellett, LM
   Shakib, S
   Caughey, GE
   Ryan, P
   Graves, S
   Roughead, EE
AF Pratt, Nicole L.
   Ramsay, Emmae N.
   Kemp, Anna
   Kalisch-Ellett, Lisa M.
   Shakib, Sepehr
   Caughey, Gillian E.
   Ryan, Philip
   Graves, Stephen
   Roughead, Elizabeth E.
TI Ranibizumab and Risk of Hospitalisation for Ischaemic Stroke and
   Myocardial Infarction in Patients with Age-Related Macular Degeneration:
   A Self-Controlled Case-Series Analysis
SO DRUG SAFETY
LA English
DT Article
ID GROWTH-FACTOR INHIBITORS; CEREBROVASCULAR ACCIDENTS; MORTALITY
AB Ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor, is used in the treatment of age-related macular degeneration. Inhibition of VEGF has an anti-angiogenic action and is associated with thrombogenicity, thus, myocardial infarction and ischaemic stroke are potential side effects of VEGF inhibitors.
   Our objective was to assess the association between use of ranibizumab and risk of hospitalisation for ischaemic stroke (IS) and myocardial infarction (MI).
   The self-controlled case series design was used, including subjects exposed to ranibizumab (Anatomical Therapeutic Chemical [ATC] code S01LA04) who were hospitalized for IS (International Classification of Diseases, tenth edition [ICD-10] code I63) or the combined endpoint of stroke or transient ischaemic attack (TIA) (ICD-10 code G45) or MI (ICD-10 code I21) were identified between August 2007 and March 2013. Rate ratios in exposed periods compared with unexposed periods were calculated using conditional Poisson regression.
   A total of 323 subjects received ranibizumab and were hospitalized for IS, 490 for IS or TIA, and 391 for MI. Median period of exposure was 8-9 months with follow-up times of approximately 2.8 years. No elevated risk of IS was seen in the 1-30 days post initiation (incidence rate ratio [IRR] 1.36; 95 % confidence interval [CI] 0.98-1.88); however, elevated risk was observed for those who received therapy for 31-60 days (IRR 1.91; 95 % CI 1.13-3.24). Sensitivity analyses adjusting for time-varying confounders found elevated risk in both the 1-30 days and 31-60 days periods. Similar results to those for IS were observed for the combined endpoint of IS or TIA. No association was seen for MI in either time period (1-30 days IRR 0.90, 95 % CI 0.65-1.23; 31-60 days IRR 0.98, 95 % CI 0.54-1.79).
   This case-series analysis suggests an increased risk of hospitalisation for ischaemic stroke for patients receiving ranibizumab in the 31-60 days risk period. Studies with larger populations are required to confirm the risk in the 1-30 days risk period. No evidence of increased risk of hospitalisation for MI was observed.
C1 [Pratt, Nicole L.; Ramsay, Emmae N.; Kalisch-Ellett, Lisa M.; Caughey, Gillian E.; Roughead, Elizabeth E.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
   [Pratt, Nicole L.] Univ S Australia, Qual Use Med & Pharm Res Ctr, Adelaide, SA 5001, Australia.
   [Kemp, Anna] Univ Western Australia, Ctr Hlth Serv Res, Crawley, WA, Australia.
   [Shakib, Sepehr] Royal Adelaide Hosp, Dept Clin Pharmacol, Adelaide, SA 5000, Australia.
   [Ryan, Philip] Univ Adelaide, Discipline Publ Hlth, Data Management & Anal Ctr, Adelaide, SA, Australia.
   [Graves, Stephen] Australian Orthopaed Assoc, Natl Joint Replacement Registry, Adelaide, SA, Australia.
C3 University of South Australia; University of South Australia; University
   of Western Australia; Royal Adelaide Hospital; University of Adelaide
RP Pratt, NL (通讯作者)，Univ S Australia, Qual Use Med & Pharm Res Ctr, GPO Box 2471, Adelaide, SA 5001, Australia.
EM Nicole.pratt@unisa.edu.au
RI Pratt, Nicole L/A-1348-2011; Ellett, Lisa M Kalisch/A-3043-2011;
   Roughead, Elizabeth E/G-4431-2010; Graves, Stephen E/A-9463-2016
OI Pratt, Nicole L/0000-0001-8730-8910; Ellett, Lisa M
   Kalisch/0000-0001-5063-6128; Roughead, Elizabeth E/0000-0002-6811-8991;
   Graves, Stephen E/0000-0002-1629-319X; Caughey,
   Gillian/0000-0003-1192-4121
FU Australian Government National Health and Medical Research Council
   Centre of Research Excellence in Post-Marketing Surveillance of
   Medicines and Medical Devices grant [APP1040938]; NHMRC Early Career
   Fellowship [GNT1035889]
FX This work was supported by an Australian Government National Health and
   Medical Research Council Centre of Research Excellence in Post-Marketing
   Surveillance of Medicines and Medical Devices grant (Grant Number
   APP1040938). NP is supported by an NHMRC Early Career Fellowship (Grant
   Number GNT1035889).
CR Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Farrington P, 2012, PHARMACOEPIDEM DR S, V21, P906, DOI 10.1002/pds.3273
   Geirsdottir A, 2012, BRIT J OPHTHALMOL, V96, P444, DOI 10.1136/bjophthalmol-2011-300304
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Islam SM, 2008, STROKE, V39, P776, DOI 10.1161/STROKEAHA.107.493643
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Rossi S, 2003, AUSTR MED HDB
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Sloan KL, 2003, MED CARE, V41, P761, DOI 10.1097/00005650-200306000-00009
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302
   Whitaker HJ, 2009, STAT METHODS MED RES, V18, P7, DOI 10.1177/0962280208092342
NR 20
TC 12
Z9 12
U1 0
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD DEC
PY 2014
VL 37
IS 12
BP 1021
EP 1027
DI 10.1007/s40264-014-0231-2
PG 7
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA AU1PE
UT WOS:000345391800004
PM 25260802
OA Green Accepted, hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Koh, KM
   Kim, HS
   Lee, TG
   Kim, CG
   Kim, JW
AF Cho, Han Joo
   Koh, Kyung Min
   Kim, Hyoung Seok
   Lee, Tae Gon
   Kim, Chul Gu
   Kim, Jong Woo
TI Anti-Vascular Endothelial Growth Factor Monotherapy in the Treatment of
   Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; MACULAR DEGENERATION; SUBRETINAL
   HEMORRHAGE; PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; PNEUMATIC
   DISPLACEMENT; RANIBIZUMAB MONOTHERAPY; EXPANSILE GAS; INJECTION;
   NEOVASCULARIZATION
AB PURPOSE: To evaluate the effect of intravitreal anti-vascular endothelial growth factor (VEGF) injections on submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
   DESIGN: Retrospective, interventional case series.
   METHODS: Twenty-seven eyes from 27 polypoidal choroidal vasculopathy patients with submacular hemorrhage involving the fovea were included in the analyses. All patients were treated by anti-VEGF injection with an initial 3 loading injections by month, followed by an as-needed reinjection. Visual acuity, central macular thickness, submacular hemorrhage size, and the occurrence of vitreous hemorrhage were examined during a 12-month follow-up period.
   RESULTS: The mean number of injections administered over the course of 12 months was 3.59 +/- 1.04. The size of submacular hemorrhages averaged 18.2 +/- 13.8 mm(2). The mean logarithm of the minimal angle of resolution (logMAR) visual acuity at baseline was 1.02 +/- 0.51 (Snellen equivalent, 20/204) and improved significantly to 0.76 +/- 0.48 (Snellen equivalent, 20/115) at 12 months (P = .02). Mean central macular thickness decreased from 311.7 +/- 124.5 pm at baseline to 246.8 +/- 102.8 mu m at 12 months (P = .01). At 12 months, visual acuity improved by 0.3 logMAR or more in 10 eyes (37%), stabilized (change between 0 and 0.3 logMAR) in 11 eyes (40.7%), and decreased by 0.3 logMAR or more in 6 eyes (22.2%). Three eyes (11.1%) were subjected to vitrectomy to clear a vitreous hemorrhage that occurred after anti-VEGF therapy.
   CONCLUSIONS: Intravitreal anti-VEGF injection monotherapy may be a valuable therapeutic option in treating eyes with submacular hemorrhage associated with polypoidal choroidal vasculopathy. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Cho, Han Joo; Koh, Kyung Min; Kim, Hyoung Seok; Lee, Tae Gon; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Coll Med, Myung Gok Eye Res Inst, Dept Ophthalmol,Kims Eye Hosp, Seoul, South Korea.
   [Lee, Tae Gon] Kyung Hee Univ, Grad Sch Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital; Kyung Hee University
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156,4Ga, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hohn F, 2010, OPHTHALMOLOGE, V107, P328, DOI 10.1007/s00347-009-2004-3
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matt G, 2010, KLIN MONATSBL AUGENH, V227, P221, DOI 10.1055/s-0028-1109750
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sawa M, 2006, RETINA-J RET VIT DIS, V26, P119, DOI 10.1097/00006982-200601000-00025
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 31
TC 23
Z9 24
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2013
VL 156
IS 3
BP 524
EP 531
DI 10.1016/j.ajo.2013.04.029
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214RM
UT WOS:000324153500014
PM 23769197
DA 2022-11-30
ER

PT J
AU Fossataro, F
   Cennamo, G
   Montorio, D
   Clemente, L
   Costagliola, C
AF Fossataro, Federica
   Cennamo, Gilda
   Montorio, Daniela
   Clemente, Lidia
   Costagliola, Ciro
TI Dark halo, a new biomarker in macular neovascularization: comparison
   between OCT angiography and ICGA-a pilot prospective study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; Choriocapillaris flow deficit; Dark halo; ICGA; Macular
   neovascularization; OCTA
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   CHORIOCAPILLARIS; DEGENERATION; PREVALENCE; CNV
AB Purpose To compare optical coherence tomography angiography (OCTA) and indocyanine green angiography (ICGA) in terms of reliability in detecting dark halo in patients affected by age-related macular degeneration (AMD) complicated with type 1 macular neovascularization (MNV).
   Methods Eighty-nine eyes of 89 patients were analyzed at the University of Naples Federico II between January 2018 and October 2021. Each patient underwent a complete ophthalmological evaluation including fluorescein angiography, ICGA, spectral domain optical coherence tomography (SD-OCT), and OCTA. OCTA and ICGA images of dark halo were compared. The paired Student's test and intraclass correlation coefficients were used to evaluate the differences in dark halo measurements between OCTA and ICGA images.
   Results Thirty-six eyes of 36 patients were included in this prospective study. Dark halo area was significantly larger in OCTA than in ICGA (1.49 +/- 1.8 mm(2) vs. 0.54 +/- 0.5 mm(2); p = 0.001). Moreover, the agreement between the two types of devices for measuring dark halo areas was poor, with a low intraclass coefficient correlation (0.397).
   Conclusion OCTA could be a useful and necessary tool to investigate dark halo in neovascular AMD due to its ability to visualize the areas of reduced vessel density around MNV in greater detail compared to ICGA.
C1 [Fossataro, Federica; Cennamo, Gilda; Montorio, Daniela; Clemente, Lidia; Costagliola, Ciro] Univ Naples Federico II, Dept Neurosci, Reprod Sci & Dent, Naples, Italy.
   [Cennamo, Gilda] Univ Naples Federico II, Publ Hlth Dept, Eye Clin, Via S Pansini 5, I-80133 Naples, Italy.
C3 University of Naples Federico II; University of Naples Federico II
RP Cennamo, G (通讯作者)，Univ Naples Federico II, Dept Neurosci, Reprod Sci & Dent, Naples, Italy.; Cennamo, G (通讯作者)，Univ Naples Federico II, Publ Hlth Dept, Eye Clin, Via S Pansini 5, I-80133 Naples, Italy.
EM xgilda@hotmail.com
RI Fossataro, Federica/AAU-9316-2021
OI Fossataro, Federica/0000-0001-5798-1899; CENNAMO,
   Gilda/0000-0003-4253-1929
CR Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Corvi F, 2020, RETINA-J RET VIT DIS, V40, P873, DOI 10.1097/IAE.0000000000002471
   Coscas G, 2018, ACTA OPHTHALMOL, V96, P200, DOI 10.1111/aos.13078
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   FLOWER RW, 1992, RETINA-J RET VIT DIS, V12, P189, DOI 10.1097/00006982-199212030-00002
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Gass JD., 1987, STEREOSCOPIC ATLAS M, P19
   Gharbiya M, 1999, EYE, V13, P621, DOI 10.1038/eye.1999.170
   Huang D, 2016, DEV OPHTHALMOL, V56, P6, DOI 10.1159/000442770
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Lutty G, 1999, MOL VIS, V5
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Scharf JM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.11
   Seddon Johanna M, 2016, JAMA Ophthalmol, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2022
VL 260
IS 10
BP 3205
EP 3211
DI 10.1007/s00417-022-05693-8
EA MAY 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4O6EP
UT WOS:000791640200001
PM 35522297
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Abramov, Y
   Borik, S
   Yahalom, C
   Fatum, M
   Avgil, G
   Brzezinski, A
   Banin, E
AF Abramov, Y
   Borik, S
   Yahalom, C
   Fatum, M
   Avgil, G
   Brzezinski, A
   Banin, E
TI The effect of hormone therapy on the risk for age-related maculopathy in
   postmenopausal women
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE age-related maculopathy; estrogen; progesterone
ID BEAVER DAM EYE; MACULAR DEGENERATION; NEOVASCULAR MACULOPATHY;
   ESTROGEN-REPLACEMENT; ASSOCIATION; PREVALENCE; METABOLISM; RECEPTOR;
   DISEASE; HEALTH
AB Objective: To evaluate the effect of postmenopausal hormone therapy (HT) as well as the use of oral contraceptives and lifetime endogenous hormone exposure on the risk for age-related maculopathy (ARM) in postmenopausal women.
   Design: This was a cross-sectional, controlled study. A total of 102 women from 60 to 80 years of age who were receiving HT and 100 controls underwent a detailed clinical funduscopic evaluation and stereoscopic fundus photography for the presence and grading of ARM. All participants completed a standardized questionnaire regarding vascular risk factors, HT, and lifetime exogenous and endogenous estrogen and progesterone exposure. Statistical analysis was performed using Student's t test, chi(2) test, and a multivariate logistic regression model.
   Results: The HT and the non-HT groups did not differ in terms of early (11% v 15%), late (6% v 6%), or wet (2% v 2%) ARM prevalence rates. Women with ARM were significantly older than controls (69 v 66 years; P = 0.001, 95% CI = 0.008 - 0.027) and were more likely to have ischemic heart disease (21% v 9%; OR = 2.86, P = 0.03, 95% Cl = 0.020 - 0.360). Lifetime exogenous and endogenous hormone exposures and other cardiovascular risk factors were not significantly different among women with ARM as compared with controls.
   Conclusion: Postmenopausal HT may not affect the risk for either early or late ARM in women aged 60 to 80 years. The risk for both entities is not necessarily affected by either exogenous or endogenous lifetime hormone exposure. A history of ischemic heart disease may be associated with an increased risk for ARM.
C1 Hadassah Med Ctr, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel.
   Hadassah Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hadassah University Medical Center
RP Abramov, Y (通讯作者)，Evanston Northwestern Healthcare, Dept Obstet & Gynecol, Div Urogynecol, 1000 Central St,Suite 730, Evanston, IL 60201 USA.
EM y-abramov@northwestern.edu
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   ERIKSSON M, 1989, J CLIN INVEST, V84, P802, DOI 10.1172/JCI114239
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Harris-Yitzhak M, 2000, AM J OPHTHALMOL, V129, P623, DOI 10.1016/S0002-9394(99)00468-7
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   INGEGNO MD, 1988, LAB INVEST, V59, P353
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lim Jennifer I, 2002, Ophthalmol Clin North Am, V15, P473, DOI 10.1016/S0896-1549(02)00044-5
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   *NAT ADV EYE COUNC, 1983, VIS RES NAT PLAN 198, V1, P2469
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sitruk-Ware R, 2000, STEROIDS, V65, P651, DOI 10.1016/S0039-128X(00)00174-4
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Snow KK, 2000, INT J FERTIL WOMEN M, V45, P301
   SPERDUTO RD, 1986, AM J EPIDEMIOL, V124, P994, DOI 10.1093/oxfordjournals.aje.a114489
   Vessey MP, 1998, BRIT J OPHTHALMOL, V82, P538, DOI 10.1136/bjo.82.5.538
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINDING T, 1995, ACTA OPHTHALMOL SC S, V214, P1
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702
   Wickham LA, 2000, ACTA OPHTHALMOL SCAN, V78, P146, DOI 10.1034/j.1600-0420.2000.078002146.x
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 36
TC 13
Z9 16
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD JAN-FEB
PY 2004
VL 11
IS 1
BP 62
EP 68
DI 10.1097/01.GME.0000074701.19603.11
PG 7
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA 765FD
UT WOS:000188255700010
PM 14716184
DA 2022-11-30
ER

PT J
AU Lee, YH
   Lee, EK
   Shin, KS
   Lee, KM
   Kim, JY
AF Lee, Yeon Hee
   Lee, Eun-Kyoung
   Shin, Kyung Sup
   Lee, Kyung-Mu
   Kim, Jung Yeul
TI INTRAVITREAL RANIBIZUMAB COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY
   FOR TREATING POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ranibizumab; verteporfin; photodynamic therapy(PDT); polypoidal
   choroidal; vasculopathy (PCV); combination treatment
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB; FAB
AB Purpose: To evaluate the efficacy of intravitreal ranibizumab (Lucentis) with verteporfin photodynamic therapy for patients with polypoidal choroidal vasculopathy.
   Methods: Retrospective interventional case series. Seventeen eyes of 17 patients with symptomatic polypoidal choroidal vasculopathy who received 3 monthly intravitreal ranibizumab injections with photodynamic therapy were retrospectively reviewed. The follow-up period lasted for more than 6 months after therapy. Best-corrected visual acuity, foveal thickness determined by optical coherence tomography, and abnormal vasculature in indocyanine green angiography were evaluated.
   Results: The mean follow-up period was 13.8 months. The mean logarithm of the minimum angle of resolution best-corrected visual acuity was 0.43 +/- 0.36 at baseline, 0.14 +/- 0.24 at 6 months (P = 0.01), and 0.11 +/- 0.23 at 12 months after treatment (P = 0.02). The mean foveal height was 351 +/- 111 mu m at baseline, 192 +/- 44 mu m at 6 months (P = 0.02), and 204 +/- 31 mu m at 12 months after treatment (P = 0.01). Patients received a mean of 3.2 ranibizumab treatments and 1.3 verteporfin photodynamic therapy treatments over the follow-up period. Re-treatment was performed in 5 of 17 eyes. The polypoidal lesions on indocyanine green angiography were regressed in six eyes, reduced in seven eyes, and unchanged in four eyes.
   Conclusion: Intravitreal ranibizumab with photodynamic therapy may stabilize visual acuity and reduce exudative retinal detachment because of decreased vascular leaking. The combination treatment appeared to be useful for regressing polypoidal lesions on indocyanine green angiography and in reducing their recurrence. RETINA 31: 1287-1293, 2011
C1 [Lee, Yeon Hee; Lee, Eun-Kyoung; Shin, Kyung Sup; Kim, Jung Yeul] Chungnam Natl Univ, Coll Med, Dept Ophthalmol, Taejon, South Korea.
   [Lee, Yeon Hee; Kim, Jung Yeul] Chungnam Natl Univ, Res Inst Med Sci, Taejon, South Korea.
   [Lee, Kyung-Mu] Myung Eye Clin, Seoul, South Korea.
C3 Chungnam National University; Chungnam National University
RP Kim, JY (通讯作者)，Chungnam Natl Univ Hosp, Dept Ophthalmol, 640 Daesa Dong, Taejon 301721, South Korea.
EM kimjy@cnu.ac.kr
OI Kim, Jung yeul/0000-0003-3679-1310; Lee, Yeon-Hee/0000-0003-0993-7548
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 21
TC 43
Z9 46
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2011
VL 31
IS 7
BP 1287
EP 1293
DI 10.1097/IAE.0b013e3182003ccd
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 794CA
UT WOS:000292871700008
PM 21386762
DA 2022-11-30
ER

PT J
AU Ertan, E
   Efe, N
   Sabaner, MC
   Dogan, M
AF Ertan, E.
   Efe, N.
   Sabaner, M. C.
   Dogan, M.
TI Results of the switch from Intravitreal Ranibizumab to Intravitreal
   Aflibercept Therapy in Patients with Neovascular Age-Related Macular
   Degeneration: A 42-month Retrospective Real-World Study
SO NIGERIAN JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
DE Aflibercept; age-related macular degeneration; ranibizumab; switch
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF THERAPY; TACHYPHYLAXIS; OUTCOMES;
   TRAP
AB Aim: The study aimed to evaluate the functional and anatomical results of patients treated with intravitreal ranibizumab (IVR) for neovascular age-related macular degeneration (n-AMD) but switched to intravitreal aflibercept (IVA) treatment due to insufficient response treatment. Material and Methods: At least six doses of n-AMD were administered IVR to 33 patients who were switched to IVA treatment due to insufficient response and were included in the study. The patients were evaluated at the beginning of the IVR treatment during the transition to IVA treatment and at 6, 12, 18, 24, 30, 36, and 42 months of IVA treatment. Results: After an average of 10.1 +/- 5.04 IVR injections, the patients who were accepted as insufficient response were treated with IVA. The central macular thickness of the patients was evaluated at the beginning of the treatment, immediately before, and after the initiation of IVA treatment at 6, 12, 18, 24, 30, 36, 42 months. It was as follows: 325.21 +/- 123.04, 351.42 & nbsp;+/- 126.09, 284.81 +/- 112.65, 296.68 & nbsp;+/- 89.17, 282.61 & nbsp;+/- 81.58, 292.27 +/- 109, 92,269.75 & nbsp;+/- 97.14, 267.50 & nbsp;+/- 87.56, and 266.82 & nbsp;+/- 88.35 mu m. According to the best-corrected visual acuity (BCVA), it was initially 0.89 +/- 0.65; 1.08 & nbsp;+/- 0.53 during the transition to IVA; 0.91 +/- 0.46 6 months after IVA; 12th 1.14 & nbsp;+/- 0.59; 0.94 & nbsp;+/- 0.55 at 18th; 1.07 & nbsp;+/- 0.49 at 24th; 1.15 +/- 0.57 at 30th; 1.06 +/- 0.45 at 36th, and 1.13 +/- 0.46 LogMAR ( Logarithm of the Minimum Angle of Resolution) at the 42nd month. Conclusion: In conclusion, in n-AMD patients with inadequate response to intravitreal ranibizumab or with relapse, and therefore, switched to aflibercept treatment, the anatomical improvement and sustainment were observed, however, functional recovery could not be achieved.
C1 [Ertan, E.] Gaziosmanpasa Training Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Efe, N.; Dogan, M.] Afyon Univ Hlth Sci, Dept Ophthalmol, Afyon, Turkey.
   [Sabaner, M. C.] Bafra State Hosp, Dept Ophthalmol, Samsun, Turkey.
C3 Bafra State Hospital
RP Ertan, E (通讯作者)，Gaziosmanpasa Training Hosp, Dept Ophthalmol, Istanbul, Turkey.
EM elif-ertan@hotmail.com
RI Sabaner, Mehmet Cem/AAI-1777-2020; DOGAN, Mustafa/C-2642-2014
OI Sabaner, Mehmet Cem/0000-0002-0958-9961; DOGAN,
   Mustafa/0000-0001-7237-9847
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cardoso PN, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/6835782
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 1119-3077
J9 NIGER J CLIN PRACT
JI Niger. J. Clin. Pract.
PD DEC
PY 2021
VL 24
IS 12
BP 1824
EP 1827
DI 10.4103/njcp.njcp_696_20
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0P0SS
UT WOS:000783933800010
PM 34889791
DA 2022-11-30
ER

PT J
AU Tong, NT
   Jin, R
   Zhou, ZY
   Wu, XW
AF Tong, Nianting
   Jin, Rong
   Zhou, Zhanyu
   Wu, Xingwei
TI Involvement of microRNA-34a in Age-Related Susceptibility to Oxidative
   Stress in ARPE-19 Cells by Targeting the Silent Mating Type Information
   Regulation 2 Homolog 1/p66shc Pathway: Implications for Age-Related
   Macular Degeneration
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE microRNA-34a; silent mating type information regulation 2 homolog 1;
   p66shc; age-related macular degeneration; oxidative stress; premature
   senescence
ID PREMATURE SENESCENCE; CELLULAR SENESCENCE; SIRT1; PREVALENCE;
   EXPRESSION; INFLAMMATION; PROTEIN; INJURY; EYE
AB The aging retinal pigment epithelium and oxidative stress, mediated by reactive oxygen species (ROS) accumulation, have been implicated in the mechanisms of age-related macular degeneration (AMD). The expression level of the adapter protein p66shc, a key protein that regulates cellular oxidative stress, is relatively low under normal conditions because of the effects of silent mating type information regulation 2 homolog 1 (SIRT1) on the binding of fully deacetylated histone H3' to the p66shc promoter region, thus inhibiting p66shc transcription and expression. The equilibrium between SIRT1 and p66shc is disrupted in the presence of various stresses, including AMD. As a major target gene, SIRT1 is regulated by microRNA-34a (miR-34a), and overexpression of miR-34a results in significant inhibition of post-transcriptional expression of SIRT1. Furthermore, our recent studies demonstrated that miR-34a is significantly upregulated, accompanied by reduced tolerance to oxidative stress in hydrogen peroxide-induced prematurely senescent ARPE-19 cells. Moreover, the expression of SIRT1 is decreased, whereas that of p66shc is increased in these cells. Accordingly, miR-34a may play a key role in age-related susceptibility to oxidative stress in ARPE-19 cells by targeting the SIRT1/p66shc pathway, leading to AMD. In this review article, we discuss the functions of miR-34a in modulating the SIRT1/p66shc pathway in age-related conditions, including AMD.
C1 [Tong, Nianting; Zhou, Zhanyu] Qingdao Municipal Hosp, Dept Ophthalmol, Qingdao, Shandong, Peoples R China.
   [Jin, Rong] Qingdao Univ, Dept Pediat, Affiliated Hosp, Qingdao, Peoples R China.
   [Wu, Xingwei] Shanghai Jiao Tong Univ, Affiliated Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Qingdao Municipal Hospital; Qingdao University; Shanghai Jiao Tong
   University
RP Wu, XW (通讯作者)，Shanghai Jiao Tong Univ, Affiliated Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai, Peoples R China.
EM eyewxw@126.com
FU National Natural Science Foundation of China [81801381, 81701587,
   81674027]
FX This study was supported by National Natural Science Foundation of China
   (No. 81801381, No. 81701587, No. 81674027).
CR ABBASI J, 2018, JAMA-J AM MED ASSOC, V319, P2263, DOI DOI 10.1001/JAMA.2018.7447
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Boon RA, 2013, NATURE, V495, P107, DOI 10.1038/nature11919
   Chuang PY, 2017, AM J PHYSIOL-RENAL, V313, pF621, DOI 10.1152/ajprenal.00255.2017
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Guo YM, 2017, AGING CELL, V16, P837, DOI 10.1111/acel.12615
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Han XL, 2016, CLIN EXP PHARMACOL P, V43, P41, DOI 10.1111/1440-1681.12496
   He XY, 2017, ONCOTARGET, V8, P69797, DOI 10.18632/oncotarget.19267
   Hekmatimoghaddam S, 2017, AGEING RES REV, V40, P120, DOI 10.1016/j.arr.2017.10.001
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hsu WW, 2016, ACS CHEM BIOL, V11, P792, DOI 10.1021/acschembio.5b00886
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Oppenheimer H, 2014, J BONE MINER RES, V29, P348, DOI 10.1002/jbmr.2052
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Smit-McBride Z, 2014, MOL VIS, V20, P1569
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Tian XY, 2016, CAN J PHYSIOL PHARM, V94, P416, DOI 10.1139/cjpp-2015-0276
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Volonte D, 2015, J BIOL CHEM, V290, P4202, DOI 10.1074/jbc.M114.598268
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu XS, 2015, ONCOTARGET, V6, P3988, DOI 10.18632/oncotarget.2905
   Yang Ming-Ming, 2013, Sichuan Da Xue Xue Bao Yi Xue Ban, V44, P1
   Ye ZM, 2016, CANCER LETT, V370, P216, DOI 10.1016/j.canlet.2015.10.023
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
NR 35
TC 14
Z9 15
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD JUN 13
PY 2019
VL 11
AR 137
DI 10.3389/fnagi.2019.00137
PG 6
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA ID7WI
UT WOS:000471893200001
PM 31249522
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wong, TY
   Klein, R
   Nieto, FJ
   Moraes, SAD
   Mosley, TH
   Couper, DJ
   Klein, BEK
   Boland, LL
   Hubbard, LD
   Sharrett, AR
AF Wong, TY
   Klein, R
   Nieto, FJ
   Moraes, SAD
   Mosley, TH
   Couper, DJ
   Klein, BEK
   Boland, LL
   Hubbard, LD
   Sharrett, AR
TI Is early age-related maculopathy related to cognitive function? The
   atherosclerosis risk in communities study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; CARDIOVASCULAR-DISEASE; RETINAL
   PATHOLOGY; POPULATION; DEMENTIA; DEGENERATION; EYE; IMPAIRMENT;
   PREVALENCE
AB PURPOSE: Age-related maculopathy (ARM) and cognitive impairment are both neurodegenerative disorders associated with aging and have been hypothesized to share common pathogenic pathways. We describe the association between cognitive function and ARM in middle,aged persons.
   DESIGN: Population based, cross-sectional study involving participants of the Atherosclerosis Risk in communities Study, an ongoing cardiovascular investigation of persons 5 1 to 70 years of age, examined every 3 years between 1987 to 1998.
   METHODS: At visit three (1993-1995), retinal photographs were obtained and evaluated for ARM using a modification of the Wisconsin ARM Grading System. Cognitive function was assessed using standardized tests (Delayed Word Recall, Digit Symbol, and Word Fluency) at visits two (1990-1992) and four (1996-1998) and averaged for analysis. Severe cognitive impairment was defined as scores falling in the lowest 10th percentile of the population.
   RESULTS: Data were available in 9286 persons after exclusion of persons with stroke or using antipsychotic medication. After adjusting for age, gender, race, education, diabetes, hypertension, cigarette smoking, and alcohol consumption, persons with severe cognitive impairment based on Word Fluency Test scores were more likely to have early ARM (odds ratio [OR]: 1.6, 95% confidence interval [Cl]: 1.1-2.2) and its components, soft drusen (OR: 1.6; 95% Cl: 1.1-2.3) and pigmentary abnormality (OR: 1.5; 95% Cl: 0.9-2.5) than those without severe impairment. However, severe cognitive impairment in scores of the other two cognitive function tests was not associated with ARM.
   CONCLUSION: These population-based data suggest a weak association between cognitive function and early ARM in middle-aged persons.
C1 Natl Univ Singapore, Dept Ophthalmol, Singapore 119074, Singapore.
   Natl Univ Singapore, Singapore Eye Res Inst, Singapore 119074, Singapore.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.
   Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA.
   Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
   Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA.
   NHLBI, NIH, Bethesda, MD 20892 USA.
C3 National University of Singapore; National University of Singapore;
   Singapore National Eye Center; University of Wisconsin System;
   University of Wisconsin Madison; Johns Hopkins University; University of
   Mississippi; University of Mississippi Medical Center; University of
   North Carolina; University of North Carolina Chapel Hill; University of
   Minnesota System; University of Minnesota Twin Cities; National
   Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood
   Institute (NHLBI)
RP Wong, TY (通讯作者)，Natl Univ Singapore, Dept Ophthalmol, 10 Lower Kent Ridge Rd, Singapore 119074, Singapore.
EM ophwty@nus.edu.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Couper, David/0000-0002-4313-9235;
   Klein, Ronald/0000-0002-4428-6237
FU DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055022,
   N01HC055021, N01HC055015, N01HC055016, N01HC055020, N01HC035126,
   N01HC055018, N01HC035125, N01HC055019] Funding Source: NIH RePORTER;
   NHLBI NIH HHS [N01-HC-55019, N01-HC-55021, N01-HC-55020, N01-HC-35125,
   N01-HC-55016, N01-HC-55015, N01-HC-55022, N01-HC-55018, N01-HC-35126]
   Funding Source: Medline
CR Adler R, 1999, MOL VIS, V5
   [Anonymous], 1983, NEUROPSYCHOLOGICAL A
   Benton AL, 1989, MULTILINGUAL APHASIA
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Blanks JC, 1996, NEUROBIOL AGING, V17, P385, DOI 10.1016/0197-4580(96)00009-7
   Cerhan JR, 1998, GERONTOLOGY, V44, P95, DOI 10.1159/000021991
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Evans DA, 1997, JAMA-J AM MED ASSOC, V277, P822, DOI 10.1001/jama.277.10.822
   Franzen MD, 1986, TEST CRITIQUES, V5, P278
   Gorin MB, 1999, MOL VIS, V5, pU31
   Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Jackson R, 1996, J CLIN EPIDEMIOL, V49, P1441, DOI 10.1016/0895-4356(95)00047-X
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Knopman D, 2001, NEUROLOGY, V56, P42, DOI 10.1212/WNL.56.1.42
   KNOPMAN DS, 1989, ARCH NEUROL-CHICAGO, V46, P141, DOI 10.1001/archneur.1989.00520380041011
   Morris MC, 1999, AM J EPIDEMIOL, V149, P789, DOI 10.1093/oxfordjournals.aje.a009893
   Mrak RE, 1997, J NEUROPATH EXP NEUR, V56, P1269, DOI 10.1097/00005072-199712000-00001
   *NAT HEART LUNG BL, 1988, OPERATIONS MANUAL NA, V2
   Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X
   SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   TABACHNICK B, 1989, USING MULTIVARIATE S, P316
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   TRANEL D, 1992, PSYCHIAT CLIN N AM, V15, P283
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wechsler D, 1958, MEASUREMENT APPRAISA
   Wechsler D., 1981, WAIS R MANUAL
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
NR 43
TC 52
Z9 54
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2002
VL 134
IS 6
BP 828
EP 835
AR PII S0002-9394(02)01672-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624BA
UT WOS:000179738600005
PM 12470750
DA 2022-11-30
ER

PT J
AU Lim, JI
   Labree, L
   Nichols, T
   Cardenas, I
AF Lim, JI
   Labree, L
   Nichols, T
   Cardenas, I
TI Comparison of nonmydriatic digitized video fundus images with standard
   35-mm slides to screen for and identify specific lesions of age-related
   macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE digitized video fundus images; 35-mm slides; age-related macular
   degeneration
ID DIABETIC-RETINOPATHY; TELEMEDICINE; MACULOPATHY; CAMERA; EYE
AB Purpose: The purpose of this study was to compare nonmydriatic digitized images obtained using a digital imaging system (resolution of 640 X 480 pixels) with 35-mm slide images for detecting specific findings of age-related macular degeneration (AMD) and to evaluate its usefulness as a screening tool in detecting signs of AMD.
   Methods: Seventeen consecutive patients (33 eyes) underwent digital color imaging (with a nonmydriatic, 45-degree, fundus camera attached to a digital back) and standard 35-mm, 30-degree retinal color photography of the fundus: posterior pole, nasal retina, and temporal retina. The images were later reviewed for the presence or absence of specific retinal findings. The images were not compressed. Primary outcome measures included the presence or absence of drusen, hard exudate, choroidal neovascularization (CNV), subretinal hemorrhage, retinal pigment epithelial (RPE) changes, subretinal fibrosis, Pigment epithelial detachment (PED), and subretinal fluid. Presence of drusen, with or without any one of the other findings, and presence of disciform scar or geographic atrophy were positive indications in screening for AMD.
   Results: Agreement between image type was highest for FED (97%), CNV (91 0/o), and subretinal fibrosis (91%); and lowest for RPE changes (63%). Sensitivity, specificity, positive predictive value, and negative predictive values were determined using the 35 mm-slide images as the reference for comparison. Sensitivity ranged from 40% (hard exudates) to 75% (subretinal hemorrhage). Specificity ranged from 88% (drusen) to 100% (hard exudate, CNV, RPE changes, PED). Positive predictive value ranged from 67% (subretinal hemorrhage) to 100% (hard exudate, CNV, RPE changes, PED). Negative predictive value ranged from 44% (drusen) to 97% (PED). For the purposes of screening for any evidence of AMD, the system was 70% sensitive.
   Conclusion: This digital fundus imaging system with 640 X 480 pixel resolution has low sensitivity and high specificity, as compared with 35-mm slide images, for detection of early AMD, but higher sensitivity for late findings (CNV, scar, atrophy) of AMD. Because of sensitivity for detecting any AMD coupled with the low sensitivity for detecting CNV, the system is not useful for evaluating AMD patients who require close follow-up and who are at risk for more severe visual loss.
C1 Doheny Eye Inst, Los Angeles, CA USA.
   Univ So Calif, Dept Prevent Med Stat Consultat, Los Angeles, CA 90089 USA.
   Univ So Calif, Res Ctr, Los Angeles, CA 90089 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Lim, JI (通讯作者)，1450 San Pablo St, Los Angeles, CA 90033 USA.
FU NEI NIH HHS [EY03040] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [P30EY003040] Funding Source: NIH RePORTER
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bursell SE, 2001, OPHTHALMOLOGY, V108, P572, DOI 10.1016/S0161-6420(00)00604-7
   Flowers C W Jr, 1997, Telemed J, V3, P43, DOI 10.1089/tmj.1.1997.3.43
   HEAVEN CJ, 1993, EYE, V7, P787, DOI 10.1038/eye.1993.185
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Li HK, 1999, SURV OPHTHALMOL, V44, P61, DOI 10.1016/S0039-6257(99)00059-4
   Lim JI, 2000, OPHTHALMOLOGY, V107, P866, DOI 10.1016/S0161-6420(00)00057-9
   Marcus DM, 1998, OPHTHALMOLOGY, V105, P1907, DOI 10.1016/S0161-6420(98)91040-5
NR 10
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2002
VL 22
IS 1
BP 59
EP 64
DI 10.1097/00006982-200202000-00011
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 529BF
UT WOS:000174279600011
PM 11884880
DA 2022-11-30
ER

PT J
AU Kim, EK
   Kim, H
   Kwon, O
   Chang, N
AF Kim, E-k
   Kim, H.
   Kwon, O.
   Chang, N.
TI Associations between fruits, vegetables, vitamin A, beta-carotene and
   flavonol dietary intake, and age-related macular degeneration in elderly
   women in Korea: the Fifth Korea National Health and Nutrition
   Examination Survey
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID LIGHT-INDUCED DAMAGE; OXIDATIVE-STRESS; RISK-FACTORS; PREVALENCE;
   PIGMENT; LUTEIN; ZEAXANTHIN; MACULOPATHY; ANTIOXIDANTS; PATHOGENESIS
AB BACKGROUND/OBJECTIVES: Age-related macular degeneration (AMD) is one of the principal causes of blindness. This study investigated the association between diet and the prevalence of AMD in elderly Korean women.
   SUBJECTS/METHODS: Study subjects were women aged >= 65 years (n = 1008) from the Korea National Health and Nutrition Examination Survey (2010-2012). The presence of early-and late-onset AMD was determined on the basis of a fundus photograph from a health examination survey. Food intake was estimated using 24 h recall.
   RESULTS: The prevalence of AMD was 18.8% in elderly women in Korea. Multiple logistic regression analysis showed a significant negative association between vegetable intake and AMD (odds ratio (OR) 0.44, 95% confidence interval (CI) 0.25, 0.77, P for trend = 0.002) after adjusting for age, body mass index, postmenopausal period, duration of hormone replacement therapy, residential area, education level, family income, smoking status, alcohol consumption, dietary supplement use and total energy intake. After adjusting for potential confounders, the ORs between extreme quartiles were 0.55 (95% CI 0.29, 1.05, P for trend = 0.070) for fruit and vegetable intake, 0.38 (95% CI 0.21, 0.68, P for trend = 0.001) for vitamin A, 0.36 (95% CI 0.19, 0.67, P for trend < 0.001) for beta-carotene and 0.45 (95% CI 0.25, 0.82, P for trend = 0.008) for flavonols.
   CONCLUSIONS: These results suggest that higher consumption of fruits and vegetables containing antioxidant nutrients and phytochemicals may provide some protection against AMD.
C1 [Kim, E-k; Kim, H.; Kwon, O.; Chang, N.] Ewha Womans Univ, Dept Nutr Sci & Food Management, 11-1 Daehyun Dong, Seoul 120750, South Korea.
C3 Ewha Womans University
RP Chang, N (通讯作者)，Ewha Womans Univ, Dept Nutr Sci & Food Management, 11-1 Daehyun Dong, Seoul 120750, South Korea.
EM nschang@ewha.ac.kr
FU Brain Korea 21 PLUS; Ministry of Science, ICT, and Future Planning
   through the National Research Foundation [NRF2012M3A9C4048761]
FX This study was supported by the Brain Korea 21 PLUS and the Ministry of
   Science, ICT, and Future Planning through the National Research
   Foundation (Bio-synergy Research Project NRF2012M3A9C4048761).
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chichili GR, 2006, BRIT J NUTR, V96, P643, DOI 10.1079/BJN20061843
   Chiu CJ, 2017, INVEST OPHTH VIS SCI, V58, P1404, DOI 10.1167/iovs.16-20454
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102816
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P4430, DOI 10.1167/iovs.14-14379
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P5702, DOI 10.1167/iovs.14-14774
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Korea Centers for Disease Control and Prevention, 2013, 5 KOR NAT HLTH NUTR
   Korea Centers for Disease Control and Prevention, 2010, REP PRES KOR NAT HLT
   Korea Centers for Disease Control and Prevention Ministry of Health & Welfare., 2014, INSTR 5 KOR NAT HLTH
   양윤경, 2012, Journal of Nutrition and Health, V45, P283, DOI 10.4163/kjn.2012.45.3.283
   Liu YX, 2012, BRIT J NUTR, V108, P16, DOI 10.1017/S000711451100523X
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   Padayachee A, 2017, CRIT REV FOOD SCI, V57, P59, DOI 10.1080/10408398.2013.850652
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Piermarocchi S, 2016, OPHTHALMIC RES, V55, P111, DOI 10.1159/000441795
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Salguero A, 2003, BIOMOL ENG, V20, P249, DOI 10.1016/S1389-0344(03)00065-0
   Saviranta NMM, 2011, FOOD RES INT, V44, P109, DOI 10.1016/j.foodres.2010.10.056
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stahl W, 2003, MOL ASPECTS MED, V24, P345, DOI 10.1016/S0098-2997(03)00030-X
   Sultana B, 2008, FOOD CHEM, V108, P879, DOI 10.1016/j.foodchem.2007.11.053
   TSO MOM, 1989, INVEST OPHTH VIS SCI, V30, P2430
   US Department of Agriculture Agricultural Research Service Nutrient Data Laboratory, 2015, USDA NAT NUTR DAT
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vina J, 2006, FREE RADICAL RES, V40, P1359, DOI 10.1080/10715760600952851
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Welfare MoHa, 2011, NAT HLTH PLAN 2020
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
NR 61
TC 16
Z9 16
U1 2
U2 27
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD JAN
PY 2018
VL 72
IS 1
BP 161
EP 167
DI 10.1038/ejcn.2017.152
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA FS4WN
UT WOS:000419795000023
PM 28952611
DA 2022-11-30
ER

PT J
AU Liu, P
   Lavine, JA
   Fawzi, A
   Quaggin, SE
   Thomson, BR
AF Liu, Pan
   Lavine, Jeremy A.
   Fawzi, Amani
   Quaggin, Susan E.
   Thomson, Benjamin R.
TI Angiopoietin-1 Is Required for Vortex Vein and Choriocapillaris
   Development in Mice
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE angiopoietin; choriocapillaris; pachychoroid; polypoidal choroidal
   vasculopathy; vortex vein
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   BLOOD-FLOW; RECEPTOR; TIE2; VEGF; NEOVASCULARIZATION; DEGENERATION;
   GENE; EPIDEMIOLOGY
AB Background: The choroidal vasculature, including the choriocapillaris and vortex veins, is essential for providing nutrients to the metabolically demanding photoreceptors and retinal pigment epithelium. Choroidal vascular dysfunction leads to vision loss and is associated with age-related macular degeneration and the poorly understood pachychoroid diseases including central serous chorioretinopathy and polypoidal choroidal vasculopathy that are characterized by formation of dilated pachyvessels throughout the choroid. Methods: Using neural crest-specific Angpt1 knockout mice, we show that Angiopoietin 1, a ligand of the endothelial receptor TEK (also known as Tie2) is essential for choriocapillaris development and vortex vein patterning. Results: Lacking choroidal ANGPT1, neural crest-specific Angpt1 knockout eyes exhibited marked choriocapillaris attenuation and 50% reduction in number of vortex veins, with only 2 vortex veins present in the majority of eyes. Shortly after birth, dilated choroidal vessels resembling human pachyvessels were observed extending from the remaining vortex veins and displacing the choriocapillaris, leading to retinal pigment epithelium dysfunction and subretinal neovascularization similar to that seen in pachychoroid disease. Conclusions: Together, these findings identify a new role for ANGPT1 in ocular vascular development and demonstrate a clear link between vortex vein dysfunction, pachyvessel formation, and disease.
C1 [Liu, Pan; Quaggin, Susan E.] Northwestern Univ, Sect Nephrol & Hypertens, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Liu, Pan; Quaggin, Susan E.; Thomson, Benjamin R.] Feinberg Cardiovasc & Renal Res Inst, Chicago, IL USA.
   [Lavine, Jeremy A.; Fawzi, Amani; Thomson, Benjamin R.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 303 E Super St Ste 8-407, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine
RP Thomson, BR (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 303 E Super St Ste 8-407, Chicago, IL 60611 USA.
EM benjamin.thomson@northwestern.edu
OI Thomson, Benjamin/0000-0001-6565-5866; Lavine,
   Jeremy/0000-0002-0884-1336; fawzi, amani/0000-0002-9568-3558
FU Brightfocus Foundation [M2021018N]; Global Ophthalmology Awards Program
   (GOAP); Bayer; NIH [K08 EY030923]; Research to Prevent Blindness Sybil
   B. Harrington Career Development Award; Brightfocus foundation new
   investigator grant in macular degeneration research; NCI CCSG [P30
   CA60553]; Research to Prevent Blindness Unrestricted Award; NIH George
   M. O'Brien kidney core grant [P30 DK114857];  [R01 EY032609];  [R01
   EY025799];  [R01 EY030121]
FX This work was supported by R01 EY032609 (to B.R. Thomson), R01 EY025799
   (to S.E. Quaggin) and R01 EY030121 (to A. Fawzi). This work was
   generously supported by the donors of the Brightfocus Foundation through
   new investigator grant in macular degeneration research M2021018N to
   B.R. Thomson. In addition, funding for this research was supported by
   the Global Ophthalmology Awards Program (GOAP), a Bayer-sponsored
   initiative committed to supporting ophthalmic research across the world.
   JAL was supported by NIH grant K08 EY030923, the Research to Prevent
   Blindness Sybil B. Harrington Career Development Award for Macular
   Degeneration and a Brightfocus foundation new investigator grant in
   macular degeneration research. Imaging was performed at the Center for
   Advanced Microscopy of the Feinberg School of Medicine supported by NCI
   CCSG P30 CA60553. Work was also supported by a Research to Prevent
   Blindness Unrestricted Award to the Northwestern University Department
   of Ophthalmology and the NIH George M. O'Brien kidney core grant P30
   DK114857 awarded to the Section of Nephrology and Hypertension.
CR Akahori T, 2017, INVEST OPHTH VIS SCI, V58, P5076, DOI 10.1167/iovs.17-21745
   Ali Z, 2020, DEV BIOL, V457, P206, DOI 10.1016/j.ydbio.2019.02.002
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chaikitmongkol V, 2020, ASIA-PAC J OPHTHALMO, V9, P260, DOI 10.1097/01.APO.0000656992.00746.48
   Chen H, 2015, INVEST OPHTH VIS SCI, V56, P1971, DOI 10.1167/iovs.14-15691
   Chen ZJ, 2021, BRIT J OPHTHALMOL, V105, P1035, DOI 10.1136/bjophthalmol-2019-315746
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Choi I, 2011, BLOOD, V117, P362, DOI 10.1182/blood-2010-07-298562
   Chu M, 2016, ELIFE, V5, DOI 10.7554/eLife.21032
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Daly C, 2004, GENE DEV, V18, P1060, DOI 10.1101/gad.1189704
   Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Hasegawa T, 2007, DEV DYNAM, V236, P2089, DOI 10.1002/dvdy.21231
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Heier JS, 2021, RETINA-J RET VIT DIS, V41, P1, DOI 10.1097/IAE.0000000000003003
   Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163
   Hoshino J, 2021, GRAEF ARCH CLIN EXP, V259, P2175, DOI 10.1007/s00417-021-05130-2
   Jeansson M, 2011, J CLIN INVEST, V121, P2278, DOI 10.1172/JCI46322
   Kenig-Kozlovsky Y, 2018, J AM SOC NEPHROL, V29, P1097, DOI 10.1681/ASN.2017090962
   KIEL JW, 1995, INVEST OPHTH VIS SCI, V36, P579
   Kim J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6732
   Kim M, 2016, J CLIN INVEST, V126, P3511, DOI 10.1172/JCI84871
   Kishi S, 2022, GRAEF ARCH CLIN EXP, V260, P3405, DOI 10.1007/s00417-022-05687-6
   Kizhatil K, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001912
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kutoglu T, 2005, CLIN ANAT, V18, P269, DOI 10.1002/ca.20092
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Lutty G, 1999, MOL VIS, V5
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Lutty GA, 2018, PROG RETIN EYE RES, V62, P58, DOI 10.1016/j.preteyeres.2017.10.001
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94412-0
   Matsumoto H, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246115
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mrejen S, 2019, OPHTHALMOLOGY, V126, P576, DOI 10.1016/j.ophtha.2018.12.048
   Nambu H, 2005, J CELL PHYSIOL, V204, P227, DOI 10.1002/jcp.20292
   Nishikawa M, 2009, OPHTHALMIC RES, V41, P53, DOI 10.1159/000165916
   Park DY, 2014, J CLIN INVEST, V124, P3960, DOI 10.1172/JCI75392
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pawlak JB, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00114
   Rousseau B, 2000, EXP EYE RES, V71, P395, DOI 10.1006/exer.2000.0892
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   Schellevis RL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43152-3
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Smith R S, 2001, BMC Dev Biol, V1, P3, DOI 10.1186/1471-213X-1-3
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P231, DOI 10.1097/IAE.0000000000003057
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P997, DOI 10.1097/IAE.0000000000003004
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468
   Team RC, 2013, R LANG ENV STAT COMP
   Thomson BR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26346-0
   Thomson BR, 2014, J CLIN INVEST, V124, P4320, DOI 10.1172/JCI77162
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wiszniak S, 2015, P NATL ACAD SCI USA, V112, P6086, DOI 10.1073/pnas.1419368112
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wykoff CC, 2022, LANCET, V399, P741, DOI 10.1016/S0140-6736(22)00018-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zhou BO, 2015, ELIFE, V4, DOI 10.7554/eLife.05521
   Zouache MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep35754
NR 82
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD NOV
PY 2022
VL 42
IS 11
BP 1413
EP 1427
DI 10.1161/ATVBAHA.122.318151
PG 15
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 5Q8OP
UT WOS:000874084600013
PM 36172864
DA 2022-11-30
ER

PT J
AU Costa, RA
   Navajas, EV
   Farah, ME
   Calucci, D
   Cardillo, JA
   Scott, IU
AF Costa, RA
   Navajas, EV
   Farah, ME
   Calucci, D
   Cardillo, JA
   Scott, IU
TI Polypoidal choroidal vasculopathy: Angiographic characterization of the
   network vascular elements and a new treatment paradigm
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
ID GREEN-MEDIATED PHOTOTHROMBOSIS; PIGMENT EPITHELIAL DETACHMENTS; INGROWTH
   SITE TREATMENT; INDOCYANINE GREEN; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; FEEDER VESSELS; CLINICOPATHOLOGICAL CORRELATION; LASER
   PHOTOCOAGULATION; NEOVASCULAR MEMBRANES
AB Macular exudative manifestations secondary to choroidal neovascular lesions remain the leading cause of definitive visual impairment and legal blindness in the elderly. During the past decade, advances in ophthalmic imaging systems have enabled the recognition of presumed new distinct choroidal neovascular lesions that share some unique clinical and angiographic peculiarities as well as better comprehension of the pathophysiologic mechanisms related to such entities.
   Amongst presumed newer exudative maculopathies, polypoidal choroidal vasculopathy, which has been described as a distinct choroidal abnormality characterized by inner choroidal vascular network of vessels ending in polyp-like structures only identified on indocyanine green angiography and mostly affecting African-American and Asian descendents, has gained special interest from the ophthalmic community particularly because of its growing recognition among patients with clinical appearance of neovascular agerelated macular degeneration. Thus far, however, the exact nature of the vascular structure of the polypoidal choroidal vasculopathy lesion remains unclear and data from recent studies have conflicted with the initial concept of a benign exudative maculopathy with long-term preservation of good vision. All together, such factors make difficult the establishment of an appropriate treatment, if any, for the entity.
   Herein, by using a modified technique of conventional indocyanine green angiography, we demonstrate new information about the morphologic characteristics, and to some extent the blood flow dynamics perfusion, of the polypoidal choroidal vasculopathy lesion. Our results suggest that the PCV lesion should be considered a variety of choroidal neovascularization rather than a distinct clinical entity, characterized by one single large neovascular complex presenting well-defined arterial neovascular vessels arising from one major "ingrowth site" and draining vessels that present aneurysm-like dilations corresponding to the polyp-like structures typically described for the entity. Finally, the visual acuity and angiographic findings observed after selective ingrowth site photothrombosis corroborate the existence of one major "ingrowth site" for the PCV neovascular complex and point toward a new treatment paradigm for this variety of choroidal neovascularization. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Hosp Olhos Araraquara, Retina Diagnost & Treatment Div, BR-14801350 Araraquara, SP, Brazil.
   Fed Univ Sao Paulo, Sao Paulo, SP, Brazil.
   Miami Univ, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL USA.
C3 Universidade Federal de Sao Paulo (UNIFESP); Bascom Palmer Eye Institute
RP Costa, RA (通讯作者)，Hosp Olhos Araraquara, Retina Diagnost & Treatment Div, Rua Italia 1905,Apto 74, BR-14801350 Araraquara, SP, Brazil.
EM roger.retina@globo.com
RI Costa, Rogerio A/E-6930-2013; Farah, Michel Eid E/F-3285-2012
OI Costa, Rogerio A/0000-0002-0800-2233; Farah, Michel Eid
   E/0000-0001-5951-0193; Scott, Ingrid/0000-0002-3908-7153; Cardillo, Jose
   Augusto/0000-0002-5791-3201
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Andrade Rafael Ernane, 2002, Arq. Bras. Oftalmol., V65, P363, DOI 10.1590/S0004-27492002000300016
   Baumler W, 1999, BRIT J CANCER, V80, P360, DOI 10.1038/sj.bjc.6690363
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2003, OPHTHALMOLOGY, V110, P1192, DOI 10.1016/S0161-6420(03)00263-X
   Costa RA, 2003, AM J OPHTHALMOL, V135, P857, DOI 10.1016/S0002-9394(02)02257-2
   Costa RA, 2003, GRAEF ARCH CLIN EXP, V241, P245, DOI 10.1007/s00417-003-0627-7
   Costa RA, 2002, CURR EYE RES, V25, P287, DOI 10.1076/ceyr.25.5.287.13496
   Costa RA, 2003, AM J OPHTHALMOL, V135, P395, DOI 10.1016/S0002-9394(02)01966-9
   Costa RA, 2003, AM J OPHTHALMOL, V135, P124, DOI 10.1016/S0002-9394(02)01863-9
   Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Costa RA, 2001, AM J OPHTHALMOL, V132, P557, DOI 10.1016/S0002-9394(01)01138-2
   DECOSTE SD, 1992, LASER SURG MED, V12, P25, DOI 10.1002/lsm.1900120107
   Farah ME, 2004, BRIT J OPHTHALMOL, V88, P1055, DOI 10.1136/bjo.2003.035808
   Flower RW, 2002, AM J OPHTHALMOL, V134, P228, DOI 10.1016/S0002-9394(02)01579-9
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Melberg NS, 1996, RETINA-J RET VIT DIS, V16, P190, DOI 10.1097/00006982-199616030-00002
   Mohand-Said M, 2002, J FR OPHTALMOL, V25, P517
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Navajas EV, 2003, EYE, V17, P563, DOI 10.1038/sj.eye.6700457
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Phillips WB, 1996, OPHTHALMIC SURG LAS, V27, P467
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schneider U, 2001, OPHTHALMOLOGE, V98, P1186, DOI 10.1007/s003470170012
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Shiraga F, 2000, OPHTHALMOLOGY, V107, P600, DOI 10.1016/S0161-6420(99)00126-8
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 57
TC 55
Z9 57
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2005
VL 24
IS 5
BP 560
EP 586
DI 10.1016/j.preteyeres.2005.01.001
PG 27
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 952LQ
UT WOS:000231005400002
PM 16005406
DA 2022-11-30
ER

PT J
AU Francelin, C
   Godoy, J
   Qi, XP
   Silva, JAF
   Grant, MB
   Boulton, ME
AF Francelin, Carolina
   Godoy, Juliana
   Qi, Xiaoping
   Silva, Juliete A. F.
   Grant, Maria B.
   Boulton, Michael E.
TI Characterizing temporal and spatial recruitment of systemically
   administered RPE65-programmed bone marrow-derived cells to the retina in
   a mouse model of age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Bone marrow-derived cells; Age-related macular degeneration; Retinal
   pigment epithelium; RPE65; Cell recruitment
ID STEM-CELLS; RPE; TRANSPLANTATION; MACROPHAGES; MICE
AB Purpose Previously, we reported that the intravenous injection of bone marrow-derived cells (BMDC) infected with lentivirus expressing the human RPE65 gene resulted in the programming of BMDC to promote visual recovery in a mouse model of age-related macular degeneration (AMD). The aim of this study was to characterize the spatial and temporal recruitment of these programmed BMDC to the retinal pigment epithelial (RPE) layer.
   Methods C57BL/6J female mice received a subretinal injection of AAV1-SOD2 ribozyme to knock down (KD) superoxide dismutase 2 (SOD2) and induce AMD-like pathology. BMDC were isolated from-GFP(+) mice and infected with a lentivirus expressing RPE65. One month after SOD2 KD, fifty thousand-GFP(+) RPE65-BMDC were injected in the mouse tail vein. Animals were terminated at different time points up to 60 min following cell administration, and localization of-GFP(+) cells was determined by fluorescence microscopy of neural retina and RPE flat mounts and tissue sections.
   Results GFP(+) RPE65-BMDC were observed in SOD2 KD neural retina and RPE as early as 1 min following administration. With increasing time, the number of cells in the neural retina decreased, while those in the RPE increased. While the number of cells in peripheral and central retina remained similar at each time point, the number of BMDC recruited to the central RPE increased in a time-dependent manner up to a maximum by 60 min post administration. Immunohistochemistry of cross-sections of the RPE layer confirmed the incorporation of donor-GFP(+) BMDC into the RPE layer and that these -GFP(+) human RPE65 expressing cells co-localized with murine RPE65. No-GFP(+) cells were observed in the neural retina or RPE layer of normal uninjured control eyes.
   Conclusions Our study shows that systemically administered-GFP(+) RPE65-BMDC can reach the retina within minutes and that the majority of these BMDC are recruited to the injured RPE layer by 60 min post injection.
C1 [Francelin, Carolina; Godoy, Juliana; Qi, Xiaoping; Silva, Juliete A. F.; Grant, Maria B.; Boulton, Michael E.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, 1670 Univ Blvd, Birmingham, AL 35233 USA.
   [Godoy, Juliana] Hosp Israelita Albert Einstein, Dept Hemotherapy & Cellular Therapy, Sao Paulo, SP, Brazil.
C3 University of Alabama System; University of Alabama Birmingham; Hospital
   Israelita Albert Einstein
RP Francelin, C; Boulton, ME (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, 1670 Univ Blvd, Birmingham, AL 35233 USA.
EM crovarotto@uabmc.edu; meboulton@uabmc.edu
RI da Silva, Juliete Aparecida Francisco/P-3314-2014
OI da Silva, Juliete Aparecida Francisco/0000-0002-4543-5169; Francelin,
   Carolina/0000-0001-7439-3124; Boulton, Michael/0000-0002-0796-1766;
   Preto de Godoy, Juliana Aparecida/0000-0003-1276-4297
FU NIH [EY023629]; NEI Core grant [P30 EY03039]; Research to Prevent
   Blindness; UAB High Resolution Imaging Facility
FX This research was supported by the NIH (EY023629), NEI Core grant P30
   EY03039 and an unrestricted grant from Research to Prevent Blindness.
   Research reported in this publication was supported by the UAB High
   Resolution Imaging Facility.
CR Bemelmans AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061618
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Boettcher C, 2008, BRIT J OPHTHALMOL, V92, P272, DOI 10.1136/bjo.2007.126318
   Caballero S, 2017, INVEST OPHTH VIS SCI, V58, P5164, DOI 10.1167/iovs.16-20736
   Chinnery HR, 2008, IMMUNOLOGY, V125, P541, DOI 10.1111/j.1365-2567.2008.02868.x
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Debbage PL, 1998, J HISTOCHEM CYTOCHEM, V46, P627, DOI 10.1177/002215549804600508
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galimi F, 2005, BLOOD, V105, P2400, DOI 10.1182/blood-2004-02-0612
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   May CA, 2013, TISSUE CELL, V45, P367, DOI 10.1016/j.tice.2013.06.003
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   Miller EB, 2019, P NATL ACAD SCI USA, V116, P16603, DOI 10.1073/pnas.1903336116
   Oishi Y, 2018, INT IMMUNOL, V30, P511, DOI 10.1093/intimm/dxy054
   Park SS, 2017, PROG RETIN EYE RES, V56, P148, DOI 10.1016/j.preteyeres.2016.10.002
   Pay SL, 2018, HUM GENE THER METHOD, V29, P44, DOI 10.1089/hgtb.2017.082
   Qi XP, 2017, MOL THER, V25, P917, DOI 10.1016/j.ymthe.2017.01.015
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Rubsam A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040942
   Ryan S, 2007, RETINAL VASCULAR DIS, P78
   Sengupta N, 2009, MOL THER, V17, P1594, DOI 10.1038/mt.2009.145
   Teh YC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00834
   VOLKMAN A, 1965, BRIT J EXP PATHOL, V46, P62
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Welsher K, 2011, P NATL ACAD SCI USA, V108, P8943, DOI 10.1073/pnas.1014501108
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Zhao ED, 2012, CELL MOL IMMUNOL, V9, P11, DOI 10.1038/cmi.2011.47
NR 30
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2021
VL 259
IS 10
BP 2987
EP 2994
DI 10.1007/s00417-021-05358-y
EA AUG 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UX9SZ
UT WOS:000682428000001
PM 34357416
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Yoo, TK
   Choi, JY
   Seo, JG
   Ramasubramanian, B
   Selvaperumal, S
   Kim, DW
AF Yoo, Tae Keun
   Choi, Joon Yul
   Seo, Jeong Gi
   Ramasubramanian, Bhoopalan
   Selvaperumal, Sundaramoorthy
   Kim, Deok Won
TI The possibility of the combination of OCT and fundus images for
   improving the diagnostic accuracy of deep learning for age-related
   macular degeneration: a preliminary experiment
SO MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING
LA English
DT Article
DE Age-related macular degeneration; Multimodal deep learning; OCT; Fundus
   photograph
ID OPTICAL COHERENCE TOMOGRAPHY; ROC CURVE; CLASSIFICATION; SEGMENTATION;
   THRESHOLD; ALGORITHM; DIFFUSION; AREA; AMD
AB Recently, researchers have built new deep learning (DL) models using a single image modality to diagnose age-related macular degeneration (AMD). Retinal fundus and optical coherence tomography (OCT) images in clinical settings are the most important modalities investigating AMD. Whether concomitant use of fundus and OCT data in DL technique is beneficial has not been so clearly identified. This experimental analysis used OCT and fundus image data of postmortems from the Project Macula. The DL based on OCT, fundus, and combination of OCT and fundus were invented to diagnose AMD. These models consisted of pre-trained VGG-19 and transfer learning using random forest. Following the data augmentation and training process, the DL using OCT alone showed diagnostic efficiency with area under the curve (AUC) of 0.906 (95% confidence interval, 0.891-0.921) and 82.6% (81.0-84.3%) accuracy rate. The DL using fundus alone exhibited AUC of 0.914 (0.900-0.928) and 83.5% (81.8-85.0%) accuracy rate. Combined usage of the fundus with OCT increased the diagnostic power with AUC of 0.969 (0.956-0.979) and 90.5% (89.2-91.8%) accuracy rate. The Delong test showed that the DL using both OCT and fundus data outperformed the DL using OCT alone (P value <0.001) and fundus image alone (P value <0.001). This multimodal random forest model showed even better performance than a restricted Boltzmann machine (P value=0.002) and deep belief network algorithms (P value=0.042). According to Duncan's multiple range test, the multimodal methods significantly improved the performance obtained by the single-modal methods. In this preliminary study, a multimodal DL algorithm based on the combination of OCT and fundus image raised the diagnostic accuracy compared to this data alone. Future diagnostic DL needs to adopt the multimodal process to combine various types of imaging for a more precise AMD diagnosis.
C1 [Yoo, Tae Keun; Seo, Jeong Gi] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, 50-1 Yonsei Ro, Seoul 03722, South Korea.
   [Choi, Joon Yul] Seoul Natl Univ, Dept Elect & Comp Engn, Seoul, South Korea.
   [Ramasubramanian, Bhoopalan; Selvaperumal, Sundaramoorthy] Syed Ammal Engn Coll, Dept Elect & Commun Engn, Ramanathapuram, Tamil Nadu, India.
   [Kim, Deok Won] Yonsei Univ, Coll Med, Dept Med Engn Seoul, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Seoul National
   University (SNU); Syed Ammal Engineering College; Yonsei University;
   Yonsei University Health System
RP Yoo, TK (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, 50-1 Yonsei Ro, Seoul 03722, South Korea.
EM eyetaekeunyoo@gmail.com
RI Sundaramoorthy, Selvaperumal/E-2950-2018; ARSLAN, Okan/AAA-3232-2020; B,
   Ramasubramanian/AAB-7011-2022; Yoo, Tae Keun/Q-3620-2019
OI B, Ramasubramanian/0000-0002-1853-8293; Yoo, Tae
   Keun/0000-0003-0890-8614; Sundaramoorthy,
   Selvaperumal/0000-0002-7398-6953
CR Bradley AP, 1997, PATTERN RECOGN, V30, P1145, DOI 10.1016/S0031-3203(96)00142-2
   BREIMAN L, 2001, MACH LEARN, V0045
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Choi JY, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0187338, 10.1371/journal.pone.0187336]
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fellah S, 2013, AM J NEURORADIOL, V34, P1326, DOI 10.3174/ajnr.A3352
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hand DJ, 2001, MACH LEARN, V45, P171, DOI 10.1023/A:1010920819831
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Lam C, 2018, INVEST OPHTH VIS SCI, V59, P590, DOI 10.1167/iovs.17-22721
   Larochelle H, 2009, J MACH LEARN RES, V10, P1
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Liu CL, 2011, STAT MED, V30, P2005, DOI 10.1002/sim.4238
   Matsuba S, 2019, INT OPHTHALMOL, V39, P1269, DOI 10.1007/s10792-018-0940-0
   Mitra J, 2014, NEUROIMAGE, V98, P324, DOI 10.1016/j.neuroimage.2014.04.056
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Ngiam J., 2011, ICML, P689
   Oh E, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-106
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Prashanth R., 2017, Machine Learning and Data Mining in Pattern Recognition. 13th International Conference, MLDM 2017. Proceedings: LNAI 10358, P391, DOI 10.1007/978-3-319-62416-7_28
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schisterman EF, 2008, STAT MED, V27, P297, DOI 10.1002/sim.2993
   Sindhwani V., 2001, SIAM, P1
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Srivastava N., 2012, ADV NEURAL INFORM PR, P2222, DOI DOI 10.1109/CVPR.2013.49
   Statnikov A, 2005, BIOINFORMATICS, V21, P631, DOI 10.1093/bioinformatics/bti033
   Tran T, 2017, ADV NEUR IN, V30
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Wallis TSA, 2017, J VISION, V17, DOI 10.1167/17.12.5
   Wang YH, 2013, BIOINFORMATICS, V29, P126, DOI 10.1093/bioinformatics/btt234
   Wei JM, 2010, EXPERT SYST APPL, V37, P3799, DOI 10.1016/j.eswa.2009.11.040
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yabuuchi H, 2008, RADIOLOGY, V249, P909, DOI 10.1148/radiol.2493072045
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Yun YS, 1993, J KOREAN OPHTHALMOL, V34, P111
   Zhang DQ, 2012, NEUROIMAGE, V59, P895, DOI 10.1016/j.neuroimage.2011.09.069
NR 44
TC 61
Z9 63
U1 10
U2 36
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0140-0118
EI 1741-0444
J9 MED BIOL ENG COMPUT
JI Med. Biol. Eng. Comput.
PD MAR
PY 2019
VL 57
IS 3
BP 677
EP 687
DI 10.1007/s11517-018-1915-z
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Mathematical & Computational Biology;
   Medical Informatics
GA HN8TJ
UT WOS:000460468800011
PM 30349958
DA 2022-11-30
ER

PT J
AU Kumar, N
   Marsiglia, M
   Mrejen, S
   Fung, ATC
   Slakter, J
   Sorenson, J
   Freund, KB
AF Kumar, Nishant
   Marsiglia, Marcela
   Mrejen, Sarah
   Fung, Adrian Tien-Chin
   Slakter, Jason
   Sorenson, John
   Freund, K. Bailey
TI VISUAL AND ANATOMICAL OUTCOMES OF INTRAVITREAL AFLIBERCEPT IN EYES WITH
   PERSISTENT SUBFOVEAL FLUID DESPITE PREVIOUS TREATMENTS WITH RANIBIZUMAB
   IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; avastin; age-related macular degeneration; bevacizumab;
   choroidal neovascularization; Eylea; Lucentis; ranibizumab
ID FACTOR TRAP-EYE; VEGF TRAP; DOSING REGIMEN; BEVACIZUMAB
AB Purpose: To assess the efficacy of intravitreal aflibercept (2.0 mg) in patients with treatment-resistant neovascular age-related macular degeneration.
   Methods: Retrospective analysis of eyes treated with aflibercept with persistent subretinal and/or intraretinal fluid despite previous treatments with intravitreal ranibizumab (0.5 mg). All patients were switched to intravitreal aflibercept (2.0 mg) and analyzed after 3 consecutive injections and after 6 months of treatment. Main outcome measures included change in visual acuity, central foveal thickness, and the height and diameter of the pigment epithelial detachment on the subfoveal scan on optical coherence tomography.
   Results: Thirty-four eyes of 33 patients were analyzed. Mean duration of symptoms and average number of previous injections with anti-vascular endothelial growth factor agents was 44.7 +/- 29.8 months (interquartile range [IQR] 24-76 months) and 28.6 +/- 20.1 (IQR 10-47), respectively. At the 6-month follow-up, mean visual acuity and central foveal thickness improved significantly from 20/75 (logarithm of minimum angle of resolution 0.57 +/- 0.36; IQR 0.30-1.0) and 416 +/- 217 mu m (IQR 263-487 mu m) at baseline to 20/60 (logarithm of minimum angle of resolution 0.47 +/- 0.32; IQR 0.30-0.60) (P = 0.004) and 248 +/- 171 mu m (IQR 235-419 mu m) (P < 0.001), respectively. Maximum pigment epithelial detachment height improved significantly from 260 +/- 162 mu m (IQR 129-368 mu m) to 214 +/- 142 mu m (IQR 111-305 mu m) (P < 0.001) and PED diameter decreased significantly from 3,265 +/- 1,622 mu m (IQR 2,353-4,555 mu m) to 2,949 +/- 1,653 mu m (IQR 1,721-4,484 mu m) (P = 0.04).
   Conclusion: Intravitreal injections of aflibercept resulted in a significant improvement in visual and anatomical outcomes in eyes with persistent subfoveal fluid despite previous treatment with ranibizumab.
C1 [Kumar, Nishant; Marsiglia, Marcela; Mrejen, Sarah; Fung, Adrian Tien-Chin; Slakter, Jason; Sorenson, John; Freund, K. Bailey] Macula Consultants New York, Retina, Vitreous, New York, NY 10022 USA.
   [Kumar, Nishant; Marsiglia, Marcela; Mrejen, Sarah; Fung, Adrian Tien-Chin; Slakter, Jason; Sorenson, John; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Kumar, Nishant] Moorfields Eye Hosp, London, England.
   [Marsiglia, Marcela; Slakter, Jason; Sorenson, John; Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Marsiglia, Marcela; Freund, K. Bailey] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; New York University;
   Columbia University
RP Freund, KB (通讯作者)，Macula Consultants New York, Retina, Vitreous, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc.; Genentech; Regeneron; Novartis
FX Supported by The Macula Foundation, Inc.; J. Slakter received research
   support from Genentech, Regeneron, and Novartis; K. B. Freund is an
   advisor and provided research support to Genentechand, Regeneron, and
   ThromboGenics. The other authors did not report any conflicts of
   interest.
CR Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Busbee BG, 2011, AM AC OPHTH OCT 24 O
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
NR 19
TC 134
Z9 138
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2013
VL 33
IS 8
BP 1605
EP 1612
DI 10.1097/IAE.0b013e31828e8551
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297CP
UT WOS:000330233200016
PM 23549101
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Mastropasqua, L
   Souied, E
   Sadda, S
   Vella, G
   Toto, L
   Miere, A
   Corradetti, G
   Sacconi, R
   Ferro, G
   Sarraf, D
   Querques, L
   Mastropasqua, R
   Bandello, F
   Querques, G
AF Borrelli, Enrico
   Mastropasqua, Leonardo
   Souied, Eric
   Sadda, SriniVas
   Vella, Giovanna
   Toto, Lisa
   Miere, Alexandra
   Corradetti, Giulia
   Sacconi, Riccardo
   Ferro, Giada
   Sarraf, David
   Querques, Lea
   Mastropasqua, Rodolfo
   Bandello, Francesco
   Querques, Giuseppe
TI Longitudinal assessment of type 3 macular neovascularization using 3D
   volume-rendering OCTA
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION;
   CLINICOPATHOLOGICAL CORRELATION; ANGIOGRAPHY; CLASSIFICATION;
   DEGENERATION
AB Objective: To investigate the evolution of treatment- naive type 3 macular neovascularization (MNV) undergoing anti-vascular endothelial growth factor (VEGF) treatment through volume rendered three-dimensional (3D) optical coherence tomography angiography (OCTA).
   Design: Retrospective observational study. Participants:
   Patients with type 3 MNV and age-related macular degeneration (AMD).
   Methods: Included subjects had three loading injections of an anti-VEGF agent. The OCTA volume data at baseline and follow-up were processed with a previously published algorithm in order to obtain a volume-rendered representation of type 3 MNV. Progressive changes in type 3 lesions were analyzed via 3D OCTA volume rendering.
   Results: A total of 14 treatment-naive eyes with type 3 MNV from 11 AMD patients (7 females) were included. At both baseline and follow-up visits, a type 3 MNV complex was identifiable. Each complex was composed of a mean number of 2.5 +/- 0.7 vascular branches at baseline and 1.4 +/- 0.6 at the follow-up visit (p < 0.0001). The mean changes in central macular thickness and visual acuity were significantly correlated with modifications in the number of type 3 MNV branches (rho = -0.533, p = 0.049, and rho = -0.581, and p = 0.040, respectively).
   Conclusions: This study demonstrated that type 3 lesions do not disappear completely after loading treatment, as indicated previously by histopathologic studies. Importantly, quantitative volume changes in type 3 lesions are directly associated with treatment response.
C1 [Borrelli, Enrico; Vella, Giovanna; Sacconi, Riccardo; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Milan, Italy.
   [Borrelli, Enrico; Vella, Giovanna; Sacconi, Riccardo; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] San Raffaele Sci Inst Res Hospitalizat & Healthca, Milan, Italy.
   [Mastropasqua, Leonardo; Toto, Lisa; Ferro, Giada] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Chieti, Italy.
   [Souied, Eric; Miere, Alexandra] Univ Paris XII, Ctr Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Sadda, SriniVas; Corradetti, Giulia; Sarraf, David] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Sadda, SriniVas; Corradetti, Giulia] Univ Calif Los Angeles, Dept Ophthalmol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Sarraf, David; Querques, Giuseppe] Univ Calif Los Angeles, Stein Eye Inst, Dept Ophthalmol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Vella, Giovanna] Univ Pisa, Ophthalmol Unit, Dept Surg Med Mol & Crit Area Pathol, Pisa, Italy.
   [Mastropasqua, Rodolfo] Univ Modena & Reggio Emilia, Inst Ophthalmol, Modena, Italy.
C3 Vita-Salute San Raffaele University; G d'Annunzio University of
   Chieti-Pescara; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI
   Creteil; Doheny Eye Institute; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Pisa; Universita di Modena e Reggio
   Emilia
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@unisr.it
OI Querques, Giuseppe/0000-0002-3292-9581; Sacconi,
   Riccardo/0000-0003-2891-2012; bandello, francesco/0000-0003-3238-9682;
   Borrelli, Enrico/0000-0003-2815-5031
CR Borrelli E, 2020, J BIOPHOTONICS, V13, DOI 10.1002/jbio.202000152
   Borrelli E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53307-x
   Borrelli E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53357-1
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Breazzano MP, 2020, RETINA-J RET VIT DIS, V40, pE55, DOI 10.1097/IAE.0000000000002892
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Han JW, 2020, RETINA-J RET VIT DIS, V40, P1245, DOI 10.1097/IAE.0000000000002562
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Kim JH, 2020, RETINA-J RET VIT DIS, V40, P1124, DOI 10.1097/IAE.0000000000002489
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Mastropasqua R, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/343515
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Skalet AH, 2017, RETINA-J RET VIT DIS, V37, P1620, DOI 10.1097/IAE.0000000000001672
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P424, DOI 10.1097/IAE.0000000000001344
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2421, DOI 10.1097/IAE.0000000000000721
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 31
TC 2
Z9 2
U1 1
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2022
VL 57
IS 4
BP 228
EP 235
DI 10.1016/j.jcjo.2021.04.020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3O2YN
UT WOS:000836703000028
PM 34058145
DA 2022-11-30
ER

PT J
AU Lai, TYY
   Lai, RYK
AF Lai, Timothy Y. Y.
   Lai, Ricky Y. K.
TI Association between Retinal Thickness Variability and Visual Acuity
   Outcome during Maintenance Therapy Using Intravitreal Anti-Vascular
   Endothelial Growth Factor Agents for Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE neovascular age-related macular degeneration; anti-VEGF therapy; optical
   coherence tomography; retinal thickness; visual acuity; variability
ID RANIBIZUMAB
AB Previous studies based on clinical trial data have demonstrated that greater fluctuations in retinal thickness during the course of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD) is associated with poorer visual acuity outcomes. However, it was unclear whether similar findings would be observed in real-world clinical settings. This study aimed to evaluate the association between retinal thickness variability and visual outcomes in eyes receiving anti-VEGF therapy for nAMD using pro re nata treatment regimen. A total of 64 eyes which received intravitreal anti-VEGF therapy (bevacizumab, ranibizumab or aflibercept) for the treatment of nAMD were evaluated. Variability in spectral-domain optical coherence tomography (OCT) central subfield thickness (CST) was calculated from the standard deviation (SD) values of all follow-up visits after three loading doses from month 3 to month 24. Eyes were divided into quartiles based on the OCT CST variability values and the mean best-corrected visual acuity values at 2 years were compared. At baseline, the mean +/- SD logMAR visual acuity and CST were 0.59 +/- 0.39 and 364 +/- 113 mu m, respectively. A significant correlation was found between CST variability and visual acuity at 2 years (Spearman's rho = 0.54, p < 0.0001), indicating that eyes with lower CST variability had better visual acuity at 2 years. Eyes with the least CST variability were associated with the highest mean visual acuity improvement at 2 years (quartile 1: +9.7 letters, quartile 2: +1.1 letters, quartile 3: -2.5 letters, quartile 4: -9.5 letters; p = 0.018). No significant difference in the number of anti-VEGF injections was found between the four CST variability quartile groups (p = 0.21). These findings showed that eyes undergoing anti-VEGF therapy for nAMD with more stable OCT CST variability during the follow-up period were associated with better visual outcomes. Clinicians should consider adopting treatment strategies to reduce CST variability during the treatment course for nAMD.
C1 [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Shatin, New Terr, Cent Ave, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.; Lai, Ricky Y. K.] 2010 Retina & Macula Ctr, Tsim Sha Tsui, Kowloon, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Shatin, New Terr, Cent Ave, Hong Kong, Peoples R China.; Lai, TYY (通讯作者)，2010 Retina & Macula Ctr, Tsim Sha Tsui, Kowloon, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk; lai_r@yahoo.com
OI Lai, Timothy/0000-0002-7832-6428
CR Adamis AP, 2020, EYE, V34, P1966, DOI 10.1038/s41433-020-0895-z
   Chaikitmongkol Voraporn, 2021, Asia Pac J Ophthalmol (Phila), V10, P507, DOI 10.1097/APO.0000000000000445
   Chandra S, 2021, EYE, V35, P409, DOI 10.1038/s41433-020-0851-y
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Eldem B, 2018, GRAEF ARCH CLIN EXP, V256, P963, DOI 10.1007/s00417-017-3890-8
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Garcia-Layana A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/412903
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P773, DOI 10.1089/jop.2017.0006
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Jeffery RHC, 2021, ASIA-PAC J OPHTHALMO, V10, P442, DOI 10.1097/APO.0000000000000415
   Iglicki M, 2021, EYE, V35, P1111, DOI 10.1038/s41433-020-01309-9
   Kaiser PK, 2021, RETINA-J RET VIT DIS, V41, P1579, DOI 10.1097/IAE.0000000000003194
   Khanani AM, 2021, CLIN OPHTHALMOL, V15, P3747, DOI 10.2147/OPTH.S231801
   Lai TYY, 2017, ASIA-PAC J OPHTHALMO, V6, P479, DOI 10.22608/APO.2017500
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Nguyen V, 2021, RETINA-J RET VIT DIS, V41, P1446, DOI 10.1097/IAE.0000000000003061
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Phadikar Prateep, 2017, Int J Retina Vitreous, V3, P1, DOI 10.1186/s40942-016-0054-7
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P1153, DOI 10.1097/IAE.0000000000003116
   Zhang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9640131
NR 27
TC 2
Z9 2
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD OCT
PY 2021
VL 11
IS 10
AR 1024
DI 10.3390/jpm11101024
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA WU0DJ
UT WOS:000716225100001
PM 34683165
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lu, Y
   Han, L
   Wang, CG
   Dou, HL
   Feng, XF
   Hu, YT
   Feng, K
   Wang, X
   Ma, ZZ
AF Lu, Yao
   Han, Liang
   Wang, Changguan
   Dou, Hongliang
   Feng, Xuefeng
   Hu, Yuntao
   Feng, Kang
   Wang, Xin
   Ma, Zhizhong
TI A comparison of autologous transplantation of retinal pigment epithelium
   (RPE) monolayer sheet graft with RPE-Bruch's membrane complex graft in
   neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; autologous retinal pigment epithelium
   (RPE) transplantation; choroidal neovascular membrane excision; RPE
   monolayer sheet graft; RPE-Bruch's membrane complex graft; subretinal
   haemorrhage
ID INTRAVITREAL BEVACIZUMAB; CHOROID TRANSLOCATION; SUBMACULAR SURGERY;
   HUMAN EYES; RANIBIZUMAB; VERTEPORFIN
AB PurposeTo compare the outcome after choroidal neovascular (CNV) membrane excision and retinal pigment epithelium (RPE) transplantation and make further evaluation of two types of RPE grafts on the visual function in patients with neovascular age-related macular degeneration (AMD), complicated by massive subretinal haemorrhage.
   MethodsWe retrospectively reviewed 80 patients who underwent CNV membrane excision with or without RPE transplantation. Two types of RPE grafts were adopted, RPE-Bruch's membrane complex graft (subgroup 1) and RPE monolayer sheet graft (subgroup 2). Outcome measures included pre- and postoperative visual acuity score (VAS), clinical findings, complications and recurrence rates.
   ResultsThe mean VAS [Early Treatment of Diabetic Retinopathy Study (ETDRS)] in the CNV membrane excision group was 11.0618.28 at baseline and 14.41 +/- 16.86 at follow-up (p=0.12) in a mean follow-up period of 24.35 +/- 9.31months. While in subgroup 1, VAS increased from 22.62 +/- 23.72 to 35.50 +/- 24.46 (p=0.02) in a mean period of 20.63 +/- 6.25months. The percentage of visual acuity (VA) improvement (at least two or more lines changed) in subgroup 1 is 62.5%, which is significantly higher than that in CNV excision group (23.5%), p=0.02. In subgroup 2, VAS increased from16.61 +/- 27.98 to 29.16 +/- 23.80 (p=0.02) in a mean period of 21.72 +/- 11.09months. The percentage of VA improvement in subgroup 2 is 58.0%, which is also significantly higher than that in CNV excision group (23.5%), p=0.02. Postoperative VA elevation was comparable between the two subgroups (p=0.05). Complications including retinal detachment, proliferative vitreal retinopathy and CNV recurrence occurred in both techniques. Central fixation stability was observed in eight eyes in subgroup 1 and five eyes in subgroup 2.
   ConclusionsThe autologous RPE transplantation can increase the vision of patients with haemorrhagic AMD. Two types of autologous RPE grafts were both effective and comparable in restoring visual function and central fixation stability.
C1 [Lu, Yao; Han, Liang; Wang, Changguan; Dou, Hongliang; Feng, Xuefeng; Hu, Yuntao; Feng, Kang; Wang, Xin; Ma, Zhizhong] Peking Univ, Hosp 3, Minist Educ, Dept Ophthalmol,Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
C3 Peking University
RP Ma, ZZ (通讯作者)，Peking Univ, Hosp 3, Dept Ophthalmol, 49 North Garden Rd, Beijing 100191, Peoples R China.
EM delichoc@sina.com; puh_yk@bjmu.edu.cn
OI Feng, Kang/0000-0002-8923-932X
FU National Basic Research Program of China (973 Program) [2011CB510200]
FX Supported by a grant from the National Basic Research Program of China
   (973 Program), no. 2011CB510200.
CR Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Han L, 2013, AM J OPHTHALMOL, V155, P474, DOI 10.1016/j.ajo.2012.09.010
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   Maaijwee K, 2008, INVEST OPHTH VIS SCI, V49, P758, DOI 10.1167/iovs.07-0510
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   MPS Group, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2007, MOL VIS, V13, P1608
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   vansMeurs JC, 2003, AM J OPHTHALMOL, V1136, P688
NR 36
TC 14
Z9 15
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2017
VL 95
IS 6
BP E443
EP E452
DI 10.1111/aos.13054
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FF1EN
UT WOS:000408642700002
PM 27496526
OA Bronze
DA 2022-11-30
ER

PT J
AU Savastano, MC
   Falsini, B
   Ferrara, S
   Scampoli, A
   Piccardi, M
   Savastano, A
   Rizzo, S
AF Savastano, Maria Cristina
   Falsini, Benedetto
   Ferrara, Silvia
   Scampoli, Alessandra
   Piccardi, Marco
   Savastano, Alfonso
   Rizzo, Stanislao
TI Subretinal Pigment Epithelium Illumination Combined With Focal
   Electroretinogram and Visual Acuity for Early Diagnosis and Prognosis of
   Non-Exudative Age-Related Macular Degeneration: New Insights for
   Personalized Medicine
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE non-exudative age-related macular degeneration; outer retina;
   personalized medicine; retinal pigment epithelium; visual acuity; focal
   electroretinogram
ID OUTER RETINAL ATROPHY; RETICULAR PSEUDODRUSEN; AUTOFLUORESCENCE;
   INTERMEDIATE; PREVALENCE
AB Purpose: To evaluate the correlation between functional visual acuity and focal electroretinograms (fERGs) and morphological abnormalities in the retinal pigment epithelium and outer retinal atrophy (RORA) assessed by subretinal illumination (SRI) parameter at optical coherence tomography (OCT) examinations as signs of early disease in early and intermediate non-exudative age-related macular degeneration (ne-AMD).
   Methods: One hundred forty-one eyes of 74 patients were retrospectively evaluated. A subgroup of patients (34/74) had a follow-up of at least 1 year. The study included both cross-sectional and longitudinal analyses. All eyes were assessed by OCT to measure the macular outer nuclear layer thickness, extent of ellipsoid zone interruption, absence or presence of drusen/reticular pseudodrusen in the foveal and perifoveal fields, and the SRI area closest to the fovea. Additionally, fERGs were performed.
   Results: In the cross-sectional analysis, visual acuity and fERG amplitude were correlated (P < 0.01) with the SRI area. The fERG amplitude was correlated (P < 0.01) with the extent of ellipsoid zone interruption and tended to be lower in reticular pseudodrusen compared with drusen. In the longitudinal analysis, fERG amplitudes and outer retinal thickness tended to decrease on average by 15% and 18%, respectively, after 1 year of follow-up. The baseline RORA area, but not fERG amplitude or visual acuity, significantly predicted with 77% accuracy (P < 0.01) morphological deterioration, which was determined by an increase in the RORA area after 1 year.
   Conclusions: Functional visual acuity and its morphological correlations can be assessed in early and intermediate ne-AMD eyes. SRI, as a result of RORA, is a potential predictor of ne-AMD progression in a short-term follow-up.
   Translational Relevance: SRI assessment, an objective method to measure RORA, is a potential biomarker for non-exudative AMD progression.
C1 [Savastano, Maria Cristina; Falsini, Benedetto; Ferrara, Silvia; Scampoli, Alessandra; Piccardi, Marco; Savastano, Alfonso; Rizzo, Stanislao] Fdn Policlin Univ A Gemelli IRCCS, Ophthalmol Unit, Rome, Italy.
   [Savastano, Maria Cristina; Falsini, Benedetto; Ferrara, Silvia; Scampoli, Alessandra; Piccardi, Marco; Savastano, Alfonso; Rizzo, Stanislao] Univ Cattolica Sacro Cuore, Rome, Italy.
   [Rizzo, Stanislao] Ist Neurosci, Consiglio Nazl Ric, Pisa, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze
   (IN-CNR)
RP Savastano, A (通讯作者)，Fdn Policlin Univ A Gemelli, Largo A Gemelli 8, I-00168 Rome, Italy.
EM alfonso.savastano@policlinicogemelli.it
RI Savastano, Maria Cristina/I-5355-2015; Savastano, Alfonso/AAJ-4173-2021
OI Savastano, Maria Cristina/0000-0003-1397-4333; Savastano,
   Alfonso/0000-0003-1575-6567
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Capoluongo E, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2012.03.008
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Galli-Resta L, 2013, INVEST OPHTH VIS SCI, V54, P6560, DOI 10.1167/iovs.13-12676
   Guymer R, 2020, CLIN EXP OPHTHALMOL, V48, P983, DOI 10.1111/ceo.13837
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Jhingan M, 2021, GRAEF ARCH CLIN EXP, V259, P2687, DOI 10.1007/s00417-021-05147-7
   Mataftsi A, 2019, GRAEF ARCH CLIN EXP, V257, P1513, DOI 10.1007/s00417-019-04344-9
   Minnella AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.28
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1236, DOI 10.1097/IAE.0000000000002995
   Reiter GS, 2019, ACTA OPHTHALMOL, V97, pE526, DOI 10.1111/aos.13987
   Rosenblatt TR, 2021, OSLI RETINA, V52, P29, DOI 10.3928/23258160-20201223-06
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Savastano MC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092973
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Wu ZC, 2021, BRIT J OPHTHALMOL, V105, P711, DOI 10.1136/bjophthalmol-2020-315935
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2022
VL 11
IS 1
AR 35
DI 10.1167/tvst.11.1.35
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0X7KJ
UT WOS:000789880100001
PM 35077530
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, LL
   Liu, WJ
   Liu, HY
   Xu, X
AF Wang, Li-Li
   Liu, Wen-Jia
   Liu, Hai-Yun
   Xu, Xun
TI Single-site Baseline and Short-term Outcomes of Clinical Characteristics
   and Life Quality Evaluation of Chinese Wet Age-related Macular
   Degeneration Patients in Routine Clinical Practice
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Chinese Version of National Eye Institute Visual Function
   Questionnaire-25; Ranibizumab; Vision-related Quality of Life; Wet
   Age-related Macular Degeneration
ID VISUAL FUNCTION QUESTIONNAIRE; NEI VFQ-25; PSYCHOMETRIC VALIDATION; EYE;
   VERSION; HYPERTENSION; POPULATION; IMPAIRMENT; PREVALENCE; DISEASE
AB Background: Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among the older population. In China, treatment of age-related ocular diseases is becoming a priority in eye care services. This study was to investigate the clinical characteristics and quality of life of Chinese patients with wet AMD and current treatment types, to evaluate short-term gains in different treatments, and to investigate associations between visual function and vision-related quality of life (VRQoL).
   Methods: A prospective, observational, noninterventional study was conducted. Basic data were collected from patients with clinical diagnoses of wet AMD before clinical assessments at baseline. VRQoL was measured with the Chinese version of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25). Correlations of the NEI VFQ-25 subscale scores with best-corrected visual acuity (BCVA) and between-group differences were analyzed.
   Results: A total of 80 wet AMD patients were enrolled, with the mean age of 68.40 years. About one-quarter of wet AMD patients received intravitreal (IVT) ranibizumab treatment, and 67% of them were treated on a pro re nata basis. The visual acuity of patients treated with IVT ranibizumab at month 3 after treatment was significantly increased, whereas patients treated with traditional Chinese medicine achieved no significant improvement. Cronbachs for the NEI VFQ-25 subscales ranged from 0.697 to 0.843. Eight subscale and overall composite scores were moderately correlated with the BCVA of the better-seeing eye. Significant differences in the overall NEI VFQ-25 scores and other subscales were observed between patients with BCVA in the better-seeing eye of less than 50 letters and the others.
   Conclusions: Patients treated with IVT ranibizumab experienced better vision improvement at short-term follow-up. The Chinese version of the NEI VFQ-25 is a valid and reliable tool for assessing the VRQoL of Chinese wet AMD patients.
C1 [Wang, Li-Li; Liu, Wen-Jia; Liu, Hai-Yun; Xu, Xun] Shanghai First Peoples Hosp, Dept Ophthalmol, Shanghai 200080, Peoples R China.
RP Liu, HY (通讯作者)，Shanghai First Peoples Hosp, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM drliuhaiyun@126.com
CR Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan CWS, 2009, BRIT J OPHTHALMOL, V93, P1431, DOI 10.1136/bjo.2009.158428
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Globe D, 2003, INVEST OPHTH VIS SCI, V44, P1470, DOI 10.1167/iovs.02-0292
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Lin JC, 2010, J EVAL CLIN PRACT, V16, P619, DOI 10.1111/j.1365-2753.2009.01253.x
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nordmann JP, 2004, PHARMACOECONOMICS, V22, P197, DOI 10.2165/00019053-200422030-00005
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Wang CW, 2008, OPTOMETRY VISION SCI, V85, P1091, DOI 10.1097/OPX.0b013e31818b9f23
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 27
TC 7
Z9 7
U1 1
U2 7
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD MAY 5
PY 2015
VL 128
IS 9
BP 1154
EP 1159
DI 10.4103/0366-6999.156083
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CH7AB
UT WOS:000354186800004
PM 25947396
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nguyen, QD
   Shah, SM
   Hafiz, G
   Quinlan, E
   Sung, J
   Chu, K
   Cedarbaum, JM
   Campochiaro, PA
AF Nguyen, Quan Dong
   Shah, Syed Mahmood
   Hafiz, Gulnar
   Quinlan, Edward
   Sung, Jennifer
   Chu, Karen
   Cedarbaum, Jesse M.
   Campochiaro, Peter A.
CA CLEAR-AMD 1 Study Grp
TI A phase I trial of an IV-administered vascular endothelial growth factor
   trap for treatment in patients with choroidal neovascularization due to
   age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID GENE-TRANSFER; TUMOR-GROWTH; VEGF; RECEPTOR; INHIBITION; ANGIOGENESIS;
   EXPRESSION; THERAPY; MODEL
AB Objectives: To assess the safety, pharmacokinetics, and biological activity of IV administration of vascular endothelial growth factor trap (VEGF Trap), a recombinant protein containing the binding domains of VEGF receptors 1 and 2, in patients with neovascular age-related macular degeneration (AMD).
   Design: Randomized, multicenter, placebo-controlled clinical trial.
   Participants: Twenty-five patients were enrolled (11 male, 14 female); 19 received VEGF Trap (0.3 [n = 7], 1.0 [n = 7], or 3.0 mg/kg [n = 5]), and 6 received a placebo.
   Methods. Patients were randomized to receive a placebo or 0.3-, 1.0-, or 3.0-mg/kg VEGF Trap-a single IV dose followed by a 4-week observation period and then 3 doses 2 weeks apart.
   Main Outcome Measures: Safety and biological activity, including change in excess retinal thickness and volume assessed by optical coherence tomography and visual acuity (VA) measured by the Early Treatment Diabetic Retinopathy Study protocol.
   Results: The majority of adverse events attributable to VEGF Trap were mild to moderate in severity, but 2 of 5 patients treated with 3.0 mg/kg experienced dose-limiting toxicity (1 with grade 4 hypertension and 1 with grade 2 proteinuria); therefore, all patients in the 3.0 mg/kg-dose group were withdrawn from the study. The mean percent changes in excess retinal thickness were -12%, -10%, -66%, and -60%, respectively, for the placebo and 0.3-, 1.0-, and 3.0-mg/kg groups at day 15 (P < 0.02 by analysis of covariance [ANCOVA]) and -5.6%, +47.1%, and -63.3% for the placebo and 0.3- and 1.0-mg/kg groups at day 71 (P < 0.02, ANCOVA). A significant change in VA was not noted in this small study.
   Conclusions: The maximum tolerated dose of IV VEGF Trap in this study population was 1.0 mg/kg. This dose resulted in elimination of about 60% of excess retinal thickness after either single or multiple administrations. Alternative routes of delivery to increase the therapeutic window are being explored.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Regeneron
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI Shah, Syed/K-2672-2018
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Mahasreshti PJ, 2001, CLIN CANCER RES, V7, P2057
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Shiose S, 2000, INVEST OPHTH VIS SCI, V41, P2395
   Takayama K, 2000, CANCER RES, V60, P2169
   Tang JR, 2004, AM J PHYSIOL-LUNG C, V287, pL344, DOI 10.1152/ajplung.00291.2003
NR 21
TC 127
Z9 134
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2006
VL 113
IS 9
BP 1522
EP 1532
DI 10.1016/j.ophtha.2006.05.055
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 080TI
UT WOS:000240270900007
DA 2022-11-30
ER

PT J
AU Geerlings, MJ
   Kremlitzka, M
   Bakker, B
   Nilsson, SC
   Saksens, NT
   Lechanteur, YT
   Pauper, M
   Corominas, J
   Fauser, S
   Hoyng, CB
   Blom, AM
   de Jong, EK
   den Hollander, AI
AF Geerlings, Maartje J.
   Kremlitzka, Mariann
   Bakker, Bjorn
   Nilsson, Sara C.
   Saksens, Nicole T.
   Lechanteur, Yara T.
   Pauper, Marc
   Corominas, Jordi
   Fauser, Sascha
   Hoyng, Carel B.
   Blom, Anna M.
   de Jong, Eiko K.
   den Hollander, Anneke I.
TI The Functional Effect of Rare Variants in Complement Genes on C3b
   Degradation in Patients With Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; FACTOR-I; FACTOR-H; HIGH-RISK; CFI GENE;
   MUTATION; ASSOCIATION; CONFERS
AB IMPORTANCE In age-related macular degeneration (AMD), rare variants in the complement system have been described, but their functional consequences remain largely unexplored.
   OBJECTIVES To identify new rare variants in complement genes and determine the functional effect of identified variants on complement levels and complement regulation in serum samples from carriers and noncarriers.
   DESIGN, SETTING, AND PARTICIPANTS This study evaluated affected (n = 114) and unaffected (n = 60) members of 22 families with AMD and a case-control cohort consisting of 1831 unrelated patients with AMD and 1367 control individuals from the European Genetic Database from March 29, 2006, to April 26, 2013, in Nijmegen, the Netherlands, and Cologne, Germany. Exome sequencing data of families were filtered for rare variants in the complement factor H (CFH), complement factor I (CFI), complement C9 (C9), and complement C3 (C3) genes. The case-control cohort was genotyped with allele-specific assays. Serum samples were obtained from carriers of identified variants (n = 177) and age-matched noncarriers (n = 157). Serum concentrations of factor H (FH), factor I (FI), C9, and C3 were measured, and C3b degradation ability was determined.
   MAIN OUTCOMES AND MEASURES Association of rare variants in the CFH, CFI, C9, and C3 genes with AMD, serum levels of corresponding proteins, and C3b degradation ability of CFH and CFI variant carriers.
   RESULTS The 1831 unrelated patients with AMD had a mean (SD) age of 75.0 (9.4) years, and 60.5% were female. The 1367 unrelated control participants had a mean (SD) age of 70.4 (7.0), and 58.7% were female. All individuals were of European descent. Rare variants in CFH, CFI, C9, and C3 contributed to an increased risk of developing AMD (odds ratio, 2.04; 95% CI, 1.47-2.82; P <.001). CFI carriers had decreased median FI serum levels (18.2 mu g/mL in Gly119Arg carriers and 16.2 mu g/mL in Leu131Arg carriers vs 27.2 and 30.4 mu g/mL in noncarrier cases and controls, respectively; both P <.001). Elevated C9 levels were observed in Pro167Ser carriers (10.7 mu g/mL vs 6.6 and 6.1 mu g/mL in noncarrier cases and controls, respectively; P <.001). The median FH serum levels were 299.4 mu g/mL for CFH Arg175Gln and 266.3 mu g/mL for CFH Ser193Leu carriers vs 302.4 and 283.0 mu g/mL for noncarrier cases and controls, respectively. The median C3 serum levels were 943.2 mu g/mL for C3 Arg161Trp and 946.7 mu g/mL for C3 Lys155Gln carriers vs 874.0 and 946.7 mu g/mL for noncarrier cases and controls, respectively. The FH and FI levels correlated with C3b degradation in noncarriers (R2 = 0.35 and R2 = 0.31, respectively; both P <.001).
   CONCLUSIONS AND RELEVANCE Reduced serum levels were associated with C3b degradation in carriers of CFI but not CFH variants, suggesting that CFH variants affect functional activity of FH rather than serum levels. Carriers of CFH (Arg175Gln and Ser193Leu) and CFI (Gly119Arg and Leu131Arg) variants have an impaired ability to regulate complement activation and may benefit more from complement-inhibiting therapy than patients with AMD in general.
C1 [Geerlings, Maartje J.; Bakker, Bjorn; Saksens, Nicole T.; Lechanteur, Yara T.; Pauper, Marc; Corominas, Jordi; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, POB 9101, NL-6500 HB Nijmegen, Netherlands.
   [Kremlitzka, Mariann; Nilsson, Sara C.; Blom, Anna M.] Lund Univ, Dept Translat Med, Div Med Prot Chem, Malmo, Sweden.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Lund University; University of Cologne;
   Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Geerlings, Maartje/P-8309-2015; Pauper, Marc/B-6342-2018; Corominas
   Galbany, Jordi/B-6356-2018; Geerlings, Maartje/P-3338-2019; Lechanteur,
   Yara/ABB-6875-2020; Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009;
   Pauper, Marc/AGZ-0438-2022; de Jong, Eiko/P-3407-2015; Bakker,
   Bjorn/E-2842-2016; Lehtimäki, Terho/AAD-1094-2022; Hollander, Anneke
   den/N-4911-2014
OI Geerlings, Maartje/0000-0003-1164-3573; Pauper,
   Marc/0000-0001-6274-9891; Corominas Galbany, Jordi/0000-0003-1736-1278;
   Geerlings, Maartje/0000-0003-1164-3573; Lechanteur,
   Yara/0000-0003-0951-4625; Blom, Anna/0000-0002-1348-1734; Pauper,
   Marc/0000-0001-6274-9891; de Jong, Eiko/0000-0001-6520-0407; Lehtimäki,
   Terho/0000-0002-2555-4427; 
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   Duvvari MR, 2015, MOL VIS, V21, P285
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kavanagh D, 2012, CLIN J AM SOC NEPHRO, V7, P417, DOI 10.2215/CJN.05750611
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Loirat C, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-60
   Martinez-Barricarte R, 2015, MOL IMMUNOL, V66, P263, DOI 10.1016/j.molimm.2015.03.248
   Miller E., 2012, CHARACTERIZATION COM
   Mohlin FC, 2015, MOL IMMUNOL, V65, P367, DOI 10.1016/j.molimm.2015.02.013
   Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005
   Nilsson SC, 2011, MOL IMMUNOL, V48, P1611, DOI 10.1016/j.molimm.2011.04.004
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rodriguez E, 2014, BIOSCIENCE REP, V34, P635, DOI 10.1042/BSR20140117
   Roumenina LT, 2012, BLOOD, V119, P4182, DOI 10.1182/blood-2011-10-383281
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Schramm EC, 2015, BLOOD, V125, P2359, DOI 10.1182/blood-2014-10-609073
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Untergasser A, 2007, NUCLEIC ACIDS RES, V35, pW71, DOI 10.1093/nar/gkm306
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Volokhina E, 2012, PEDIATR NEPHROL, V27, P1519, DOI 10.1007/s00467-012-2183-z
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 40
TC 35
Z9 35
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JAN
PY 2017
VL 135
IS 1
BP 39
EP 46
DI 10.1001/jamaophthalmol.2016.4604
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK9PJ
UT WOS:000394256100010
PM 27918759
OA Bronze
DA 2022-11-30
ER

PT J
AU Kuan, V
   Warwick, A
   Hingorani, A
   Tufail, A
   Cipriani, V
   Burgess, S
   Sofat, R
AF Kuan, Valerie
   Warwick, Alasdair
   Hingorani, Aroon
   Tufail, Adnan
   Cipriani, Valentina
   Burgess, Stephen
   Sofat, Reecha
CA Int Amd Genomics Consortium IAMDGC
TI Association of Smoking, Alcohol Consumption, Blood Pressure, Body Mass
   Index, and Glycemic Risk Factors With Age-Related Macular Degeneration A
   Mendelian Randomization Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CIGARETTE-SMOKING; OXIDATIVE STRESS; CAUSAL
   INFERENCE; 5-YEAR INCIDENCE; PROGRESSION; DISEASE
AB IMPORTANCE Advanced age-related macular degeneration (AMD) is a leading cause of blindness in Western countries. Causal, modifiable risk factors need to be identified to develop preventive measures for advanced AMD.
   OBJECTIVE To assess whether smoking, alcohol consumption, blood pressure, body mass index, and glycemic traits are associated with increased risk of advanced AMD.
   DESIGN, SETTING, PARTICIPANTS This study used 2-sample mendelian randomization. Genetic instruments composed of variants associated with risk factors at genome-wide significance (P < 5 x 10(-8)) were obtained from published genome-wide association studies. Summary-level statistics for these instruments were obtained for advanced AMD from the International AMD Genomics Consortium 2016 data set, which consisted of 16 144 individuals with AMD and 17 832 control individuals. Data were analyzed from July 2020 to September 2021.
   EXPOSURES Smoking initiation, smoking cessation, lifetime smoking, age at smoking initiation, alcoholic drinks per week, body mass index, systolic and diastolic blood pressure, type 2 diabetes, glycated hemoglobin, fasting glucose, and fasting insulin.
   MAIN OUTCOMES AND MEASURES Advanced AMD and its subtypes, geographic atrophy (GA), and neovascular AMD.
   RESULTS A 1-SD increase in logodds of genetically predicted smoking initiation was associated with higher risk of advanced AMD (odds ratio [OR], 1.26; 95% CI, 1.13-1.40; P < .001), while a 1-SD increase in logodds of genetically predicted smoking cessation (former vs current smoking) was associated with lower risk of advanced AMD (OR, 0.66; 95% CI, 0.50-0.87; P = .003). Genetically predicted increased lifetime smoking was associated with increased risk of advanced AMD (OR per 1-SD increase in lifetime smoking behavior, 1.32; 95% CI, 1.09-1.59; P = .004). Genetically predicted alcohol consumption was associated with higher risk of GA (OR per 1-SD increase of log-transformed alcoholic drinks per week, 2.70; 95% CI, 1.48-4.94; P = .001). There was insufficient evidence to suggest that genetically predicted blood pressure, body mass index, and glycemic traits were associated with advanced AMD.
   CONCLUSIONS AND RELEVANCE This study provides genetic evidence that increased alcohol intake may be a causal risk factor for GA. As there are currently no known treatments for GA, this finding has important public health implications. These results also support previous observational studies associating smoking behavior with risk of advanced AMD, thus reinforcing existing public health messages regarding the risk of blindness associated with smoking.
C1 [Kuan, Valerie; Sofat, Reecha] UCL, Inst Hlth Informat, 222 Euston Rd, London NW1 2DA, England.
   [Kuan, Valerie; Hingorani, Aroon; Sofat, Reecha] UCL, Hlth Data Res UK London, London, England.
   [Kuan, Valerie; Hingorani, Aroon; Sofat, Reecha] UCL, British Heart Fdn Res Accelerator, London, England.
   [Warwick, Alasdair; Hingorani, Aroon] UCL, Inst Cardiovasc Sci, London, England.
   [Warwick, Alasdair; Tufail, Adnan; Cipriani, Valentina] Moorfields Eye Hosp, London, England.
   [Tufail, Adnan; Cipriani, Valentina] UCL, UCL Inst Ophthalmol, London, England.
   [Cipriani, Valentina] Queen Mary Univ London, William Harvey Res Inst, Clin Pharmacol, London, England.
   [Cipriani, Valentina] UCL, UCL Genet Inst, London, England.
   [Burgess, Stephen] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
   [Burgess, Stephen] Univ Cambridge, MRC Biostat Unit, Cambridge, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London; University of London; University College London; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London;
   University of London; Queen Mary University London; University of
   London; University College London; University of Cambridge; MRC
   Biostatistics Unit; University of Cambridge
RP Kuan, V (通讯作者)，UCL, Inst Hlth Informat, 222 Euston Rd, London NW1 2DA, England.
EM v.kuan@ucl.ac.uk
OI Leveillard, Thierry/0000-0001-5692-8770; Hingorani,
   Aroon/0000-0001-8365-0081; Tufail, Adnan/0000-0001-6131-7640; Weeks,
   Daniel/0000-0001-9410-7228; Burgess, Stephen/0000-0001-5365-8760
FU Dunhill Medical Trust [RPGF1806\67]; Wellcome Trust [220558/Z/20/Z]; BHF
   Research Accelerator Award [AA/18/6/34223]; National Institute for
   Health Research; Biomedical Research Centre for Ophthalmology; Sir Henry
   Dale Fellowship - Wellcome Trust [204623/Z/16/Z]; Sir Henry Dale
   Fellowship - Royal Society [204623/Z/16/Z]; National Institute for
   Health Research, University College London Hospitals Biomedical Research
   Centre; NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]
FX Dr Kuan is funded by the Dunhill Medical Trust (RPGF1806\67). DrWarwick
   is supported by the Wellcome Trust (220558/Z/20/Z). Dr Hingorani is
   supported by a BHF Research Accelerator Award (AA/18/6/34223). Dr Tufail
   is supported by the National Institute for Health Research to Moorfields
   Eye Hospital and the Biomedical Research Centre for Ophthalmology. Dr
   Burgess is supported by Sir Henry Dale Fellowship, jointly funded by
   theWellcome Trust and the Royal Society (204623/Z/16/Z) Dr Sofat is
   supported by the National Institute for Health Research, University
   College London Hospitals Biomedical Research Centre. This research was
   supported by the NIHR Cambridge Biomedical Research Centre
   (BRC-1215-20014).
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Akishima S, 2007, CIRC J, V71, P418, DOI 10.1253/circj.71.418
   Alberg AJ, 2002, TOXICOLOGY, V180, P121, DOI 10.1016/S0300-483X(02)00386-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bikbov MM, 2020, AM J OPHTHALMOL, V210, P146, DOI 10.1016/j.ajo.2019.10.004
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Boekhoorn SS, 2008, ARCH OPHTHALMOL-CHIC, V126, P834, DOI 10.1001/archopht.126.6.834
   Bowden J, 2019, RES SYNTH METHODS, V10, P486, DOI 10.1002/jrsm.1346
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Burgess Stephen, 2019, Wellcome Open Res, V4, P186, DOI 10.12688/wellcomeopenres.15555.1
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgess S, 2017, EPIDEMIOLOGY, V28, P30, DOI 10.1097/EDE.0000000000000559
   Burgess S, 2015, EUR J EPIDEMIOL, V30, P543, DOI 10.1007/s10654-015-0011-z
   CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Cummings M, 2008, CLIN OPHTHALMOL, V2, P369
   Das SK, 2007, LIFE SCI, V81, P177, DOI 10.1016/j.lfs.2007.05.005
   Davey Smith G, 2008, ANN MED, V40, P524, DOI 10.1080/07853890802010709
   Davies NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k601
   Didelez V, 2007, STAT METHODS MED RES, V16, P309, DOI 10.1177/0962280206077743
   Dinu M, 2019, EUR J NUTR, V58, P2123, DOI 10.1007/s00394-018-1771-5
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gibson J, 2012, IMMUNOBIOLOGY, V217, P251, DOI 10.1016/j.imbio.2011.07.015
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hingorani A, 2005, LANCET, V366, P1906, DOI 10.1016/S0140-6736(05)67767-7
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katsi VK, 2015, J HYPERTENS, V33, P2382, DOI 10.1097/HJH.0000000000000766
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lawlor DA, 2016, INT J EPIDEMIOL, V45, P908, DOI 10.1093/ije/dyw127
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sander B, 2001, INVEST OPHTH VIS SCI, V42, P433
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Slob EAW, 2020, GENET EPIDEMIOL, V44, P313, DOI 10.1002/gepi.22295
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VanderWeele TJ, 2014, EPIDEMIOLOGY, V25, P427, DOI 10.1097/EDE.0000000000000081
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wootton RE, 2020, PSYCHOL MED, V50, P2435, DOI 10.1017/S0033291719002678
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 74
TC 7
Z9 7
U1 3
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC
PY 2021
VL 139
IS 12
BP 1299
EP 1306
DI 10.1001/jamaophthalmol.2021.4601
EA NOV 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YH7DZ
UT WOS:000714699100003
PM 34734970
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Gao, M
   Liu, LM
   Liang, XD
   Yu, YP
   Liu, XX
   Liu, W
AF Gao, Meng
   Liu, LiMei
   Liang, XiDa
   Yu, YanPing
   Liu, XinXin
   Liu, Wu
TI Influence of vitreomacular interface on anti-vascular endothelial growth
   factor treatment outcomes in neovascular age-related macular
   degeneration A MOOSE-compliant meta-analysis
SO MEDICINE
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; vitreomacular adhesion; vitreomacular traction
ID FACTOR THERAPY; RANIBIZUMAB; ADHESION; TRACTION
AB The aim of the study was to evaluate the influence of vitreomacular interface configuration on treatment outcomes after intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (AMD).
   The Pubmed, Embase, and Cochrane Central Register of Controlled Trials databases were searched to identify relevant prospective or retrospective studies that evaluate the influence of vitreomacular adhesion (VMA) or vitreomacular traction (VMT) on functional and anatomical outcomes in neovascular AMD patients treated with anti-VEGF agents. The outcome measures were the mean change in best corrected visual acuity (BCVA) from baseline, the mean change in central macular thickness (CMT) from baseline, and the mean injection numbers of anti-VEGF treatment from baseline.
   In total, 9 studies were selected for this meta-analysis, including 2156 eyes (404 eyes in the VMA/VMT group and 1752 eyes in the non-VMA/VMT group). In neovascular AMD patients treated with anti-VEGF agents, the VMA/VMT group was associated with poorer visual acuity gains and CMT reductions at 1 year (WMD [95% CI], -6.17 [-11.91, -0.43] early treatment diabetic retinopathy study (ETDRS) letters, P=. 04; WMD[95% CI], 22.19 [2.01, 42.38] mm, P=. 03, respectively). There was no significant difference between 2 groups in the mean BCVA change and the CMT change over 2 years (WMD [95% CI], -5.59 [-21.19, 10.01] ETDRS letters, P=. 48; WMD [95% CI], 6.56 [-24.78, 37.90] mm, P=. 68, respectively). There was no significant difference in the mean injection numbers between 2 groups at 1 year (WMD [95% CI], 0.36 [-0.19, 0.90], P=. 21), whereas the VMA/VMT group had a significantly higher mean injection numbers over 2 years (WMD [95% CI], 1.14 [0.11, 2.16], P=. 03).
   The limited evidence suggests that vitreomacular interface configuration have a significant influence on the visual acuity gain and CMT reduction at 1 year, injection numbers at 2 years in neovascular AMD patients treated with anti-VEGF agents. However, the results of this meta-analysis should be interpreted with caution because of the heterogeneity among study designs. Eyes with VMA/VMT on optical coherence tomography at baseline may require more intensive treatment with decreased response to anti-VEGF agents.
C1 [Gao, Meng; Liang, XiDa; Yu, YanPing; Liu, Wu] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
   [Liu, LiMei] Qingdao Univ, Dept Ophthalmol, Yantai Yuhuangding Hosp, Affiliated Hosp Med Coll, Yantai, Shandong, Peoples R China.
   [Liu, XinXin] Kailuan Gen Hosp, Dept Ophthalmol, Tangshan, Peoples R China.
C3 Capital Medical University; Qingdao University
RP Liu, W (通讯作者)，Beijing Tongren Hosp, Beijing, Peoples R China.
EM wuliubj@sina.com
RI Yu, Yan/GYV-4514-2022
FU National Nature Science Foundation of China [81541106]
FX This research is financed by National Nature Science Foundation of China
   (No. 81541106).
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Filloy A, 2013, Arch Soc Esp Oftalmol, V88, P380, DOI 10.1016/j.oftal.2013.01.016
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Green-Simms AE, 2013, RETINA-J RET VIT DIS, V33, P1359, DOI 10.1097/IAE.0b013e3182845d18
   Green-Simms AE, 2011, SEMIN OPHTHALMOL, V26, P137, DOI 10.3109/08820538.2011.559512
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Kang EC, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865083
   Krishnan R, 2015, RETINA-J RET VIT DIS, V35, P1750, DOI 10.1097/IAE.0000000000000714
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   McKibbin MA, 2015, RETINA-J RET VIT DIS, V35, P1951, DOI 10.1097/IAE.0000000000000587
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rotsos T, 2010, BRIT J OPHTHALMOL, V94, P1205, DOI 10.1136/bjo.2009.173765
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Wells G, 3 S SYST REV BAS 200, P3
NR 28
TC 4
Z9 4
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC
PY 2017
VL 96
IS 50
AR e9345
DI 10.1097/MD.0000000000009345
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FT2QG
UT WOS:000422990500157
PM 29390407
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Adrean, SD
   Chaili, SY
   Ramkumar, H
   Pirouz, A
   Grant, S
AF Adrean, Sean D.
   Chaili, Siyang
   Ramkumar, Hema
   Pirouz, Ash
   Grant, Scott
TI Consistent Long-Term Therapy of Neovascular Age-Related Macular
   Degeneration Managed by 50 or More Antie VEGFInjections Using a
   Treat-Extend-Stop Protocol
SO OPHTHALMOLOGY
LA English
DT Article
ID TREATMENT OUTCOMES; RANIBIZUMAB; ANCHOR; HORIZON; MARINA
AB Purpose: To examine the clinical results for patients with neovascular age-related macular degeneration (nAMD) who were managed with a treat-extend-stop (TES) protocol and received 50 or more injections of antievascular endothelial growth factor (VEGF) agents.
   Design: Retrospective case study.
   Participants: Data for patients from a private retina practice meeting the following criteria were included: diagnosis of nAMD and having received 50 or more intravitreal injections of anti-VEGF agents.
   Methods: The patients' baseline visual acuity (VA; obtained using Snellen charts and converted to Early Treatment Diabetic Retinopathy Study [ETDRS] letters), age, length of follow-up, anti-VEGF agents used, and interval between treatments were obtained. These data were examined through the 51st injection and at the last follow-up examination. Patients were excluded if they lost significant vision because of a diagnosis unrelated to AMD during therapy.
   Main Outcome Measures: Visual acuity and complications.
   Results: Seventy-one eyes of 67 patients were identified who met inclusion criteria. The mean age of patients was 83.0 years. Women made up 58.2% of the study population, whereas men constituted 41.8%. The mean initial VA was 55.6 ETDRS letters. The mean duration of follow-up at the 51st visit for an injection was 6.5 years, and the mean duration of follow-up at the last visit was 8 years. The mean number of injections at final follow-up was 63.7. The mean interval between treatments at the 51st follow-up was 5.4 weeks, and the mean follow-up at the last examination was 6.4 weeks. Mean VA at the 51st injection was 65.3 letters, and the mean change from baseline was 9.7 letters (P < 0.001, Student paired t test). The mean vision gained at last follow-up was 8.7 letters from baseline (P < 0.001), or 64.3 letters.
   Conclusions: In this study, patients gained a mean of 2 ETDRS lines after 50 injections. This study had a mean follow-up of 8 years, and 35.2% of eyes had a 3-line or more gain in VA at the last follow-up examination. Patients who require consistent long-term anti-VEGF therapy, managed with a TES protocol, are likely able to maintain or improve their vision. (C) 2018 by the American Academy of Ophthalmology
C1 [Adrean, Sean D.; Chaili, Siyang; Ramkumar, Hema; Pirouz, Ash; Grant, Scott] Retina Consultants Orange Cty, 301 West Bastanchury Ave,285, Fullerton, CA 92835 USA.
RP Adrean, SD (通讯作者)，Retina Consultants Orange Cty, 301 West Bastanchury Ave,285, Fullerton, CA 92835 USA.
EM seadrean@yahoo.com
RI Adrean, Sean/AAN-2683-2021
OI Adrean, Sean/0000-0001-6004-0643
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Arevalo JF, 2015, RETINA, V36, P859
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   DiLoreto DA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1586, DOI 10.1001/archopht.121.11.1586
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Gale R, 2016, OPHTHALMOLOGICA, V236, P193, DOI 10.1159/000451065
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Haddad WM, 2017, RETINA-J RET VIT DIS, V37, P951, DOI 10.1097/IAE.0000000000001282
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 31
TC 41
Z9 43
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2018
VL 125
IS 7
BP 1047
EP 1053
DI 10.1016/j.ophtha.2018.01.012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GL0DD
UT WOS:000436632700022
PM 29439828
DA 2022-11-30
ER

PT J
AU Vardarinos, A
   Gupta, N
   Janjua, R
   Iron, A
   Empeslidis, T
   Tsaousis, KT
AF Vardarinos, Athanasios
   Gupta, Nitin
   Janjua, Raazia
   Iron, Abigail
   Empeslidis, Theo
   Tsaousis, Konstantinos T.
TI 24-month clinical outcomes of a treat-and-extend regimen with
   ranibizumab for wet age-related macular degeneration in a real life
   setting
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Ranibizumab; Treat and extend; Age related macular degeneration
ID DOSING REGIMEN; TRIAL; ATROPHY
AB Background: To evaluate the clinical effectiveness and analyze the outcomes of a treat-and-extend (T&E) treatment regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life clinical settings over the first 2 years (24 months) of treatment.
   Methods: Retrospective analysis of visual acuity, spectral domain optical coherence tomography (SD-OCT) parameters and treatment burden data of 56 eyes of 54 unselected treatment naive patients diagnosed with exudative ARMD. Monthly injections were offered until no signs of disease activity such as intra-retinal (IRF) or sub-retinal fluid (SRF) were evident on SD-OCT, followed by a gradual extension of the treatment interval by 2 weeks until a maximum of 12 weeks.
   Results: The study met its main objective, demonstrating a mean best-corrected visual acuity gain of 8.3 letters (mean 68.8 +/- 11) at month 12 and 5.2 letters (mean 65.7 +/- 12.3) at 24 months compared to baseline (mean 60. 5 +/- 8.9). Anatomical improvement was also documented with a mean reduction of central retinal thickness by 139. 7 mu m at 24 months (244.9 +/- 48.3) compared to baseline (384.6 +/- 154.9). Forty-seven eyes (83.9% N = 56) gained vision or preserved baseline vision with 23 eyes (41.1%) gaining 10 letters or more at month 12. Out of the 46 eyes that completed 24 months of treatment and monitoring, 27 (58.7% N = 46) kept a BCVA above baseline with 18 of those (39% N = 46) maintaining a 10-letter gain throughout the 24 months. Six eyes (13% N = 46) lost more than 10 letters by month 24. The mean number of injections was 12.1 +/- 2.8 over the 24-month period. Twenty-seven eyes (55.1% N = 56) achieved a treatment interval of 10 weeks or more at month 12, while the respective number at month 24 was 20 eyes (43.4% N = 46) in addition though to four more patients (8.7% N = 46) who were not receiving injections at month 24 since they were placed on a Monitor & Extend regime.
   Conclusions: This is the first UK real-life study of a T& E treatment protocol with ranibizumab for exudative ARMD in a 24-month period and suggests that such a regimen is clinically effective and can achieve favourable outcomes with a significant reduction of the treatment burden compared to monthly PRN.
C1 [Vardarinos, Athanasios; Gupta, Nitin; Janjua, Raazia; Iron, Abigail] West Suffolk Hosp, Eye Treatment Ctr, Bury St Edmunds, Suffolk, England.
   [Empeslidis, Theo; Tsaousis, Konstantinos T.] Univ Hosp Leicester, Dept Ophthalmol, Leicester Royal Infirm, Leicester, Leics, England.
C3 University Hospitals of Leicester NHS Trust; University of Leicester
RP Tsaousis, KT (通讯作者)，Univ Hosp Leicester, Dept Ophthalmol, Leicester Royal Infirm, Leicester, Leics, England.
EM konstantinos.tsaousis@gmail.com
FU Hellenic Society of Intraocular Implants and Refractive Surgery
FX Dr. Tsaousis received a scholarship (2015) from the Hellenic Society of
   Intraocular Implants and Refractive Surgery for postgraduate training.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hatz K, 2016, BR J OPHTHALMOL, P1
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 27
TC 18
Z9 18
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 27
PY 2017
VL 17
AR 58
DI 10.1186/s12886-017-0451-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ET4HO
UT WOS:000400240300001
PM 28449645
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Behboudi, H
   Nikkhah, H
   Alizadeh, Y
   Katibeh, M
   Pakbin, M
   Ahmadieh, H
   Sabbaghi, H
   Nourinia, R
   Karimi, S
   Behnaz, N
   Piryaiee, G
   Yaseri, M
   Kheiri, B
   Moradian, S
AF Behboudi, Hassan
   Nikkhah, Homayoun
   Alizadeh, Yousef
   Katibeh, Marzieh
   Pakbin, Mojgan
   Ahmadieh, Hamid
   Sabbaghi, Hamideh
   Nourinia, Ramin
   Karimi, Saeed
   Behnaz, Nazanin
   Piryaiee, Golbarg
   Yaseri, Mehdi
   Kheiri, Bahareh
   Moradian, Siamak
TI A Population-based Study on the Prevalence and Associated Factors of
   Age-related Macular Degeneration in Northern Iran the Gilan Eye Study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related Macular Degeneration; prevalence; associated factor; Iran
ID NUTRITION EXAMINATION SURVEY; RISK-FACTORS; DIABETIC-RETINOPATHY;
   GEOGRAPHIC REGION; REFRACTIVE ERRORS; NATIONAL-HEALTH; MACULOPATHY;
   DISEASE; BLINDNESS; CHINESE
AB Purpose: To estimate the prevalence and associated factors of AMD in an Iranian population in 2014. Methods: In this population-based cross-sectional study, a total of 2975 Iranian residents (age: >= 50 years) from the urban and rural areas of Gilan province were included. The prevalence of different grades of AMD was determined using the International Age-Related Maculopathy Epidemiological Study Group grading system. Results: Of 2975 eligible individuals, 2587 (87.0%) subjects participated and 2275 (76.5%) subjects (62.6 +/- 8.8 years old) had gradable fundus photographs. Age- and sex-standardized prevalence of early and late AMD based on the 2016 Iran census were 13.2% (95% confidence interval [CI], 10.6-16.2) and 0.7% (95% CI, 0.4-1.3), respectively. In multivariate analysis, each decade increase in age was associated with the adjusted odds of any (adjusted odds ratio [AOR] = 1.31, 95% CI, 1.09-1.56; P = .0031), early (AOR = 1.27, 95% CI, 1.06-1.53; P = .012) and late AMD (AOR = 2.39, 95% CI, 1.08-5.28; P = .031). Hyperopia was identified to be less frequent in late AMD (AOR = 0.20, 95% CI, 0.04-0.80; P = .024). No significant association was found between AMD and sex, smoking, outdoor working, diabetes, hypertension, pseudophakia, hyperlipidemia and myopia. Conclusion: Gilan Eye Study demonstrated the first estimate of age-specific AMD prevalence in Iran being compatible with other WHO regions. With the expected increase in the life expectancy and aging of Iranians, the number of people affected by AMD will be increasing in future. Healthcare policy makers should be advised to provide more efficient eye care services and preventive strategies in this regard.
C1 [Behboudi, Hassan; Alizadeh, Yousef] Guilan Univ Med Sci, Dept Ophthalmol, Rasht, Iran.
   [Nikkhah, Homayoun; Ahmadieh, Hamid; Sabbaghi, Hamideh; Karimi, Saeed; Behnaz, Nazanin; Piryaiee, Golbarg; Kheiri, Bahareh; Moradian, Siamak] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, 23 Paidar Fard,Bostan 9,Pasdaran Ave, Tehran 16666, Iran.
   [Nikkhah, Homayoun; Karimi, Saeed] Shahid Beheshti Univ Med Sci, Torfeh Eye Hosp, Dept Ophthalmol, Tehran, Iran.
   [Katibeh, Marzieh] Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, Iran.
   [Katibeh, Marzieh] Aarhus Univ, Ctr Global Hlth, Dept Publ Hlth, Aarhus, Denmark.
   [Pakbin, Mojgan] Noor Eye Hosp, Noor Res Ctr Ophthalm Epidemiol, Tehran, Iran.
   [Pakbin, Mojgan] Univ Tehran Med Sci, Translat Ophthalmol Res Ctr, Tehran, Iran.
   [Sabbaghi, Hamideh] Shahid Beheshti Univ Med Sci, Sch Rehabil, Dept Optometry, Tehran, Iran.
   [Nourinia, Ramin] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences; Shahid Beheshti University Medical Sciences; Aarhus
   University; Tehran University of Medical Sciences; Shahid Beheshti
   University Medical Sciences; Shahid Beheshti University Medical
   Sciences; Tehran University of Medical Sciences
RP Moradian, S (通讯作者)，Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, 23 Paidar Fard,Bostan 9,Pasdaran Ave, Tehran 16666, Iran.
EM moradian33195@yahoo.com
RI Behnaz, Nazanin/AAX-1375-2021; Karimi, Saeed/AAW-4905-2020; nourinia,
   ramin/AAW-6943-2020; Nikkhah, Homayoun/AAW-4663-2020; Sabbaghi,
   Hamideh/AAT-2398-2021; moradian, siamak/AAW-6294-2020; Ahmadieh,
   Hamid/M-4853-2017; Yaseri, Mehdi/I-1645-2018
OI Nikkhah, Homayoun/0000-0002-2414-4661; kheiri,
   bahareh/0000-0001-9448-8104; Ahmadieh, Hamid/0000-0002-8139-2661;
   Pakbin, Mojgan/0000-0002-8668-513X; Yaseri, Mehdi/0000-0002-4066-873X
CR Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Center E-W, 2002, FUT POP AS
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Creuzot-Garcher C, 2016, ACTA OPHTHALMOL, V94, pE90, DOI 10.1111/aos.12842
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fujiwara T, 2018, JAMA CARDIOL, V3, P583, DOI 10.1001/jamacardio.2018.1233
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Hashemi H, 2017, OPHTHAL EPIDEMIOL, V24, P222, DOI 10.1080/09286586.2016.1270335
   Hatef E, 2008, RETINA-J RET VIT DIS, V28, P755, DOI 10.1097/IAE.0b013e3181613463
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Husten CG, 2009, NICOTINE TOB RES, V11, P111, DOI 10.1093/ntr/ntp010
   KATIBEH M, 2019, E MEDITERR HLTH J, V25
   Katibeh M, 2017, OPHTHAL EPIDEMIOL, V24, P381, DOI 10.1080/09286586.2017.1307993
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Krasnik V, 2018, SEMIN OPHTHALMOL, V33, P506, DOI 10.1080/08820538.2017.1316861
   Li Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090897
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P141
   Rim TH, 2017, SEMIN OPHTHALMOL, V32, P466, DOI 10.3109/08820538.2015.1119861
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   Thapa R, 2017, CLIN OPHTHALMOL, V11, P963, DOI 10.2147/OPTH.S132338
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Varma R, 2016, JAMA OPHTHALMOL, V134, P571, DOI 10.1001/jamaophthalmol.2016.0588
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia T, 2017, VISION RES, V139, P72, DOI 10.1016/j.visres.2017.02.006
   Yip JLY, 2015, PUBLIC HEALTH, V129, P103, DOI 10.1016/j.puhe.2014.10.012
NR 51
TC 1
Z9 1
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD MAY 3
PY 2020
VL 27
IS 3
BP 209
EP 218
DI 10.1080/09286586.2020.1716379
EA JAN 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KU8VC
UT WOS:000508336100001
PM 31960781
DA 2022-11-30
ER

PT J
AU Keenan, TD
   Agron, E
   Mares, J
   Clemons, TE
   van Asten, F
   Swaroop, A
   Chew, EY
AF Keenan, Tiarnan D.
   Agron, Elvira
   Mares, Julie
   Clemons, Traci E.
   van Asten, Freekje
   Swaroop, Anand
   Chew, Emily Y.
CA Age-Related Eye Dis Studies AREDS
   Age-Related Eye Dis Studies AREDS
TI Adherence to the Mediterranean Diet and Progression to Late Age-Related
   Macular Degeneration in the Age-Related Eye Disease Studies 1 and 2
SO OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; BETA-CAROTENE; ASSOCIATION; PREVALENCE;
   MORTALITY; RISK; CONSUMPTION; ADULTS; AREDS; REPRODUCIBILITY
AB Purpose: To determine whether closer adherence to a Mediterranean diet (and its individual components) was associated with altered risk of progression to late age-related macular degeneration (AMD) and large drusen. Additional objectives were to assess interactions with AMD genotype.
   Design: Retrospective analysis of 2 controlled clinical trial cohorts: Age-Related Eye Disease Study (AREDS) and AREDS2.
   Participants: Eyes with no late AMD at baseline in AREDS participants (n = 4255) and AREDS2 participants (n = 3611): total of 13 204 eyes (7756 participants). Mean age was 71 years (standard deviation, 6.6); 56.5% were female.
   Methods: Color fundus photographs were collected at annual study visits and graded centrally for late AMD. The modified Alternative Mediterranean Diet Index (aMedi) score was calculated for each participant from food frequency questionnaires.
   Main Outcome Measures: Progression to late AMD, geographic atrophy (GA), and neovascular AMD; progression to large drusen.
   Results: Over a median follow-up of 10.2 years, of the 13 204 eyes, 34.0% progressed to late AMD. Hazard ratios (HRs) for progression in aMedi tertile 3 versus 1 were 0.78 (95% confidence interval [CI], 0.71-0.85, P < 0.0001) for late AMD, 0.71 (0.63-0.80, P < 0.0001) for GA, and 0.84 (0.75-0.95, P = 0.005) for neovascular AMD. For fish consumption, HRs for late AMD in quartile 4 versus 1 were 0.69 (0.58-0.82, P < 0.0001; AREDS) and 0.92 (0.78-1.07, P = 0.28; AREDS2). In AREDS, both aMedi and its fish component interacted with CFH rs10922109 for late AMD (P = 0.01 and P = 0.0005, respectively); higher aMedi and fish intake were each associated with decreased risk only in participants with protective alleles. In separate analyses (n = 5029 eyes of 3026 AREDS participants), the HR for progression to large drusen in aMedi tertile 3 versus 1 was 0.79 (0.68-0.93, P = 0.004).
   Conclusions: Closer adherence to a Mediterranean-type diet was associated with lower risk of progression to late AMD and to large drusen. The signal was greater for GA than neovascular AMD. Fish intake contributed to this protective association. CFH genotype strongly influenced these relationships. These findings may help inform evidence-based dietary recommendations. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Keenan, Tiarnan D.; Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Mares, Julie] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Clemons, Traci E.] Emmes Co LLC, Rockville, MD USA.
   [van Asten, Freekje; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Wisconsin System; University of Wisconsin Madison;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, EY (通讯作者)，NIH, Bldg 10,CRC,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih
OI Folk, James/0000-0002-6271-2906; Russell, Stephen/0000-0003-3776-1367
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland [NOI-EY-0-2127,
   HHS-N-260-2005-00007-C, N01-EY-5-0007]; National Institutes of Health
   institute: Office of Dietary Supplements; National Institutes of Health
   institute: National Center for Complementary and Alternative Medicine;
   National Institutes of Health institute: National Institute on Aging;
   National Institutes of Health institute: National Heart, Lung, and Blood
   Institute; National Institutes of Health institute: National Institute
   of Neurological Disorders and Stroke
FX Supported by intramural program funds and contracts (AREDS (Contract
   NOI-EY-0-2127) and AREDS2 (Contract HHS-N-260-2005-00007-C; ADB Contract
   N01-EY-5-0007) from the National Eye Institute/National Institutes of
   Health, Department of Health and Human Services, Bethesda, Maryland.
   Funds were generously contributed to these contracts by the following
   National Institutes of Health institutes: Office of Dietary Supplements;
   National Center for Complementary and Alternative Medicine; National
   Institute on Aging; National Heart, Lung, and Blood Institute; National
   Institute of Neurological Disorders and Stroke. The sponsor and funding
   organization participated in the design and conduct of the study, data
   collection, management, analysis, and interpretation, and preparation,
   review, and approval of the manuscript.
CR Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis C, 2015, NUTRIENTS, V7, P9139, DOI 10.3390/nu7115459
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Dinu M, 2018, EUR J CLIN NUTR, V72, P30, DOI 10.1038/ejcn.2017.58
   Do KV, 2019, P NATL ACAD SCI USA, V116, P24317, DOI 10.1073/pnas.1912959116
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fung TT, 2009, CIRCULATION, V119, P1093, DOI 10.1161/CIRCULATIONAHA.108.816736
   Gopinath B, 2018, J ACAD NUTR DIET, V118, P2311, DOI 10.1016/j.jand.2018.07.012
   Gopinath B, 2018, AM J CLIN NUTR, V108, P381, DOI 10.1093/ajcn/nqy114
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Graf Daniela, 2015, Microbial Ecology in Health and Disease, V26, P26164, DOI 10.3402/mehd.v26.26164
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Kaczmarek JL, 2019, J NUTR BIOCHEM, V63, P27, DOI 10.1016/j.jnutbio.2018.09.015
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kipnis V, 2003, AM J EPIDEMIOL, V158, P14, DOI 10.1093/aje/kwg091
   Kleinbaum DG, 2012, STAT BIOL HEALTH, P201, DOI 10.1007/978-1-4419-6646-9_5
   Liese AD, 2015, J NUTR, V145, P393, DOI 10.3945/jn.114.205336
   Lopez-Garcia E, 2014, AM J CLIN NUTR, V99, P172, DOI 10.3945/ajcn.113.068106
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Menotti A, 1999, EUR J EPIDEMIOL, V15, P507, DOI 10.1023/A:1007529206050
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283
   Nagpal R, 2019, EBIOMEDICINE, V47, P529, DOI 10.1016/j.ebiom.2019.08.032
   National Institutes of Health Office of Dietary Supplements, 2019, OM 3 FATT AC FACT SH
   Neale EP, 2016, NUTR RES, V36, P391, DOI 10.1016/j.nutres.2016.02.009
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Obata R, 2018, BRIT J OPHTHALMOL, V102, P1047, DOI 10.1136/bjophthalmol-2016-309980
   Piermarocchi S, 2016, OPHTHALMIC RES, V55, P111, DOI 10.1159/000441795
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Reedy J, 2014, J NUTR, V144, P881, DOI 10.3945/jn.113.189407
   RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Rowan S, 2016, ADV EXP MED BIOL, V854, P95, DOI 10.1007/978-3-319-17121-0_14
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092
   TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457
   Trichopoulou A, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-112
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 59
TC 18
Z9 18
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2020
VL 127
IS 11
BP 1515
EP 1528
DI 10.1016/j.ophtha.2020.04.030
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OD6CO
UT WOS:000579939800024
PM 32348832
DA 2022-11-30
ER

PT J
AU Curcio, CA
   Presley, JB
   Malek, G
   Medeiros, NE
   Avery, DV
   Kruth, HS
AF Curcio, CA
   Presley, JB
   Malek, G
   Medeiros, NE
   Avery, DV
   Kruth, HS
TI Esterified and unesterified cholesterol in drusen and basal deposits of
   eyes with age-related maculopathy
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE cholesterol; drusen; basal deposits; lipoproteins; Bruch's membrane;
   age-related maculopathy
ID PHOTORECEPTOR OUTER SEGMENTS; PIGMENT-EPITHELIUM; GEOGRAPHIC ATROPHY;
   VITRONECTIN GENE; TRANSFER PROTEIN; BRUCHS MEMBRANE; IN-VITRO;
   ACCUMULATION; EXPRESSION; RETINA
AB To address the potential for an outer segment (OS) contribution to the sub-retinal pigment epithelium (RPE) lesions of age-related maculopathy (ARM), we quantified esterified and unesterified cholesterol (EC, UC) with the sterol-specific fluorescent probe filipin in cryosections of ARM eyes. Twenty six eyes from 20 donors were preserved < 5 hr after death in 4% paraformaldehyde (n = 16) or 2.5% glutaraldehyde/1% paraformaldehyde (n = 10). Eyes had exudative late ARM (n = 6), geographic atrophy (n = 15), and drusen ! 125 Pm (n = 11). Sections were stained with filipin for UC or were extracted and hydrolysed with cholesterol esterase before filipin staining for EC. Drusen varied in cholesterol content, with a rough correlation between EC and UC. Dome-shaped drusen contained distinctive, loosely packed UC-rich loops. In basal deposits, EC and UC were more prominent near Bruch's membrane than near the RPE. A UC-rich material was localized within the subretinal space (n=4). Maximum filipin fluorescence due to UC was quantified in 47 lesions (19 drusen, 24 basal deposits, and 4 sub-retinal) from 12 ARM eyes and compared to OS and inner plexiform layer (IPL) of uninvolved retina in the same sections. Relative to IPL, UC fluorescence was higher in lesions (mean +/- S.D: 1.63 +/- 0.69) and lower in OS (0.64 +/- 0.18). If only the packing of membranes explained fluorescence intensity, then one would expect much higher intensities in membrane-rich OS than in lesions. Because the converse is true, the membranous material in lesions must be more highly enriched in cholesterol on a per unit area basis. UC in sub-RPE deposits cannot be derived directly from OS without considerable intracellular processing within RPE, additional cholesterol sources, or both. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Alabama Birmingham, Callahan Eye Fdn Hosp, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Retina Specialists N Alabama, Huntsville, AL USA.
   NHLBI, Sect Expt Atherosclerosis, Bethesda, MD 20892 USA.
C3 University of Alabama System; University of Alabama Birmingham; National
   Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood
   Institute (NHLBI)
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Callahan Eye Fdn Hosp, Sch Med, Dept Ophthalmol, 700 S 18th St,Room H020, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Avery, Dina/W-9002-2019
OI Malek, Goldis/0000-0003-0026-2388; Avery, Dina/0000-0003-4486-0312
FU NEI NIH HHS [EY06109] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY006109] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [Z01HL002832] Funding Source: NIH RePORTER
CR Amin S, 2004, INVEST OPHTH VIS SCI, V45, P1281, DOI 10.1167/iovs.03-0671
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   BAKER BN, 1986, EXP EYE RES, V42, P547, DOI 10.1016/0014-4835(86)90045-X
   Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663
   Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200
   BJORKHEM I, 2004, ARTERIOSCLER THROMB, V5, P5
   BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867
   CALDWELL RB, 1985, J COMP NEUROL, V236, P523, DOI 10.1002/cne.902360408
   CHAO FF, 1990, AM J PATHOL, V136, P169
   Chowers I, 2004, INVEST OPHTH VIS SCI, V45, P2098, DOI 10.1167/iovs.03-0863
   CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   de Turco EBR, 1999, J NEUROSCI RES, V57, P479
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DERETIC D, 1994, J BIOL CHEM, V269, P16853
   DOWHAN W, 2002, BIOCH LIPIDS LIPOPRO, P1
   ERSHOV AV, 1996, J BIOL CHEM, V24
   FEENEYBURNS L, 1988, INVEST OPHTH VIS SCI, V29, P708
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FRANCIS CM, 1955, J COMP NEUROL, V103, P355, DOI 10.1002/cne.901030209
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Iqbal J, 2003, J BIOL CHEM, V278, P31610, DOI 10.1074/jbc.M301177200
   Kane J, 2001, METAB MOL BASES INHE, P2717
   Kruth H S, 1997, Subcell Biochem, V28, P319
   KRUTH HS, 1985, LAB INVEST, V53, P634
   Kruth HS, 2001, J LIPID RES, V42, P1492
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   LI CM, IN PRESS INVEST OPHT
   Madsen EM, 2004, J BIOL CHEM, V279, P55271, DOI 10.1074/jbc.M411404200
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Mori T, 2001, J NEUROPATH EXP NEUR, V60, P778, DOI 10.1093/jnen/60.8.778
   NORMAN AW, 1972, J BIOL CHEM, V247, P1918
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   RUNGGERBRANDLE E, 1987, INVEST OPHTH VIS SCI, V28, P2026
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SKARLATOS SI, 1993, VIRCHOWS ARCH B, V64, P241, DOI 10.1007/BF02915118
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zernii EY, 2003, BIOCHEMISTRY-MOSCOW+, V68, P129, DOI 10.1023/A:1022114006396
NR 55
TC 174
Z9 179
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2005
VL 81
IS 6
BP 731
EP 741
DI 10.1016/j.exer.2005.04.012
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 998QA
UT WOS:000234332700014
PM 16005869
DA 2022-11-30
ER

PT J
AU Paunksnis, A
   Cimbalas, A
   Cerniauskiene, LR
   Luksiene, DI
   Margeviciene, L
   Domarkiene, S
   Tamosiunas, A
   Norkus, A
AF Paunksnis, A
   Cimbalas, A
   Cerniauskiene, LR
   Luksiene, DI
   Margeviciene, L
   Domarkiene, S
   Tamosiunas, A
   Norkus, A
TI Early age-related maculopathy and risk factors of cardiovascular disease
   in middle-aged Lithuanian urban population
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related maculopathy; smoking; arterial hypertension; obesity;
   hyperglycemia; hypercholesterolemia; hypertriglyceridemia
ID MACULAR DEGENERATION; PREVALENCE; CLASSIFICATION; CHOLESTEROL; SYSTEM;
   EYE
AB PURPOSE. To assess the prevalence of age-related maculopathy (ARM) in a middle-aged urban population and the relationship between ARM and the main risk factors of cardiovascular disease (CVD).
   METHODS. The survey according to the WHO MONICA study protocol was carried out in Kaunas city, Lithuania, from 2001 to 2002. A total of 1403 persons aged 35 to 64 years were screened (626 men and 777 women: response rate 62.4%). Ophthalmologic investigation was performed for 1337 respondents (594 men and 743 women). Analysis of the relationship between ARM and risk factors of CVD was performed in case-control subdivision matching for sex, age, and education level.
   RESULTS. Early ARM was diagnosed in 7.4% of men and 5.4% of women. Rate of current smoking in case and control groups did not differ in men but in case group of women it was greater than in control group. Mean systolic and diastolic blood pressure and body mass index (BMI) in male case group and mean fasting blood glucose concentration in female case group were higher than in corresponding control groups. Frequency of diastolic hypertension (diastolic blood pressure >= 90 mmHg) and obesity (BMI >= 30 kg/m(2)) in male case group was higher than in control group. ARM was not associated with cholesterol and triglyceride levels in men and women.
   CONCLUSIONS. Early ARM in middle-aged Lithuanian urban population was associated with current smoking in women but not in men; it was associated with diastolic blood pressure and BMI in men and with fasting glucose level in women.
C1 Kaunas Univ Med, Biomed Res Inst, Kaunas, Lithuania.
   Kaunas Univ Med, Inst Cardiol, Kaunas, Lithuania.
   Kaunas Univ Med, Inst Endocrinol, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Paunksnis, A (通讯作者)，Kaunas Univ Med, Biomed Res Inst, Eiveniu St 2, Kaunas, Lithuania.
EM apaun@medi.lt
RI Tamosiunas, Abdonas/AAD-4274-2021
OI Paunksnis, Alvydas/0000-0002-1224-5588
CR ALGVERE P, 1985, BRIT J OPHTHALMOL, V69, P416, DOI 10.1136/bjo.69.6.416
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cimbalas Andrius, 2003, Medicina (Kaunas), V39, P1237
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Domarkiene Stanislava, 2003, Medicina (Kaunas), V39, P1193
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Pardini H, 1998, DIABETOLOGIA, V41, pA122
   SIEDEL J, 1983, CLIN CHEM, V29, P1075
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   STEIN EA, 1995, CLIN CHEM, V41, P1421
   TAMOIUNAS A, 1997, BEHAV RISK FACTORS P, P5
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VINORES SA, 1988, EXP EYE RES, V46, P545, DOI 10.1016/S0014-4835(88)80011-3
   *WHO MONICA PROJEC, 1990, MONICA MAN MON TREND
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 34
TC 8
Z9 8
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2005
VL 15
IS 2
BP 255
EP 262
DI 10.1177/112067210501500213
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 918IU
UT WOS:000228536300013
PM 15812769
DA 2022-11-30
ER

PT J
AU Holz, FG
   Schmitz-Valckenberg, S
   Wolf, A
   Agostini, H
   Lorenz, K
   Pielen, A
   Feltgen, N
   Guthoff, R
   Quiering, C
   Clemens, A
   Jaeger, K
AF Holz, F. G.
   Schmitz-Valckenberg, Steffen
   Wolf, A.
   Agostini, H.
   Lorenz, K.
   Pielen, A.
   Feltgen, N.
   Guthoff, R.
   Quiering, C.
   Clemens, A.
   Jaeger, K.
TI A randomized, open-label, multicenter study of switching to brolucizumab
   with or without a loading dose for patients with suboptimal anatomically
   controlled neovascular age-related macular degeneration-the FALCON study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Anti-VEGF; Brolucizumab;
   Switch
ID TREAT-AND-EXTEND; RANIBIZUMAB; BLINDNESS
AB Background Treatment initiation with brolucizumab, a new potent anti-vascular endothelial growth factor (VEGF) agent, is typically performed with three monthly injections (loading dose) and has been well studied in treatment-naive patients. However, no clinical data are available yet on whether or not anti-VEGF pretreated patients also benefit from a loading dose. In the clinical setting, different heterogeneous treatment patterns are used as no clinical trial has addressed this so far in a head-to-head comparison. Therefore, the FALCON study is investigating whether patients with unsatisfactory response to previous anti-VEGF treatments benefit from a loading dose at the switch to brolucizumab treatment.
   Methods FALCON is a 52-week, two-arm, randomized, open-label, multicenter, multinational study in patients with residually active neovascular age-related macular degeneration (nAMD) who will be randomized 1:1 and started with brolucizumab 6 mg loading (three monthly loading doses) or brolucizumab 6 mg non-loading (one initial injection) and consecutive treatment every 12 weeks, respectively. The primary objective is to demonstrate non-inferiority of the non-loading vs. loading arm in mean change of best-corrected visual acuity (BCVA) from baseline to the mean value at week 40 to week 52. Secondary objectives include the assessment of anatomical outcomes, treatment intervals, safety and tolerability.
   Results FALCON will be the first study to assess treatment initiation with an anti-VEGF agent in a switch situation with or without loading dose in patients with nAMD.
   Conclusions The results will support the optimization of treatment of patients with previous unsatisfactory anti-VEGF response. Therefore, we expect to see an impact on current clinical practice which has been established for more than a decade.
C1 [Holz, F. G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Holz, F. G.; Schmitz-Valckenberg, Steffen] Univ Bonn, GRADE Reading Ctr, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 North Mario Capecchi Dr, Salt Lake City, UT 84312 USA.
   [Wolf, A.] Univ Ulm, Dept Ophthalmol, Ulm, Germany.
   [Agostini, H.] Univ Freiburg, Fac Med, Eye Ctr, Freiburg, Germany.
   [Lorenz, K.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Mainz, Germany.
   [Pielen, A.] Hannover Med Sch, Univ Eye Hosp, Hannover, Germany.
   [Feltgen, N.] Univ Goettingen, Fac Med, Eye Ctr, Gottingen, Germany.
   [Guthoff, R.] Univ Duesseldorf, Eye Hosp, Fac Med, Dusseldorf, Germany.
   [Quiering, C.; Jaeger, K.] Novartis Pharma GmbH, Nurnberg, Germany.
   [Clemens, A.] Novartis Pharma AG, Basel, Switzerland.
   [Clemens, A.] Univ Freiburg, Heart Ctr, Fac Med, Dept Cardiol & Angiol 1, Freiburg, Germany.
C3 University of Bonn; University of Bonn; Utah System of Higher Education;
   University of Utah; Ulm University; University of Freiburg; Johannes
   Gutenberg University of Mainz; Hannover Medical School; University of
   Gottingen; Novartis; Novartis; Universitats Herzzentrum Freiburg;
   University of Freiburg
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Bonn, Germany.; Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, GRADE Reading Ctr, Bonn, Germany.; Schmitz-Valckenberg, S (通讯作者)，Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 North Mario Capecchi Dr, Salt Lake City, UT 84312 USA.
EM steffen.valckenberg@utah.edu
FU Novartis Pharma GmbH, Nuernberg, Germany; Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL. The study is
   funded by the Novartis Pharma GmbH, Nuernberg, Germany.
CR Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2021, OPHTHALMOLOGE, V118, P248, DOI 10.1007/s00347-021-01321-8
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Kodjikian L, 2021, EYE, V35, P2119, DOI 10.1038/s41433-021-01487-0
   Marquis LM, 2020, GRAEF ARCH CLIN EXP, V258, P1591, DOI 10.1007/s00417-020-04730-8
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Pikkel J, 2018, INT OPHTHALMOL, V38, P2031, DOI 10.1007/s10792-017-0695-z
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sagkriotis A, 2021, CONTEMP CLIN TRIALS, V104, DOI 10.1016/j.cct.2021.106364
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
NR 23
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2022
VL 260
IS 8
BP 2695
EP 2702
DI 10.1007/s00417-022-05591-z
EA FEB 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3F5UF
UT WOS:000758952100001
PM 35188581
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Agostini, H
   Mulyukov, Z
   Tsilimbaris, M
   Calvo, P
   Bucher, F
   Gaucher, D
   Pigeolet, E
   Colafrancesco, V
   Clemens, A
AF Agostini, Hansjuergen
   Mulyukov, Zufar
   Tsilimbaris, Miltiadis
   Calvo, Pilar
   Bucher, Felicitas
   Gaucher, David
   Pigeolet, Etienne
   Colafrancesco, Valeria
   Clemens, Andreas
TI Comparison of the Efficacy of Brolucizumab with Natural Disease
   Progression in Wet AMD Using Clinical Data from the Phase III HAWK and
   HARRIER Trials and Modelled Placebo Data
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Brolucizumab; wet age-related macular degeneration; natural disease
   course; putative placebo; indirect response model
ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   VERTEPORFIN; MANAGEMENT; BLINDNESS; OUTCOMES; THERAPY; IMPACT
AB Aim: To compare the treatment effect of brolucizumab, a novel anti-vascular endothelial growth factor therapeutic, with a putative placebo in patients with wet age-related macular degeneration. Materials and Methods: Clinical treatment-effect data from patients receiving brolucizumab 6 mg in the HAWK and HARRIER studies were compared with modelled placebo data using a previously developed and validated indirect response, non-linear, mixed effects model describing the natural visual acuity decline in wet age-related macular degeneration. The placebo model incorporated patient-level data from the sham injection arms of the MARINA and PIER studies, corrected for baseline best corrected visual acuity and age difference between these studies and the HAWK and HARRIER studies. Results: Compared with a modelled placebo, brolucizumab treatment was associated with an overall best corrected visual acuity gain of approximately 22 Early Treatment Diabetic Retinopathy Study letters at Week 48 and 28 letters at Week 96. Conclusions: As anti-vascular endothelial growth factor therapy is now a standard of care for wet age-related macular degeneration, it is not feasible to conduct placebo-controlled trials for new wet age-related macular degeneration treatments. By allowing comparison with the natural decline in visual acuity without treatment, this analysis conveys the clinical importance of brolucizumab for the treatment of wet age-related macular degeneration.
C1 [Agostini, Hansjuergen; Bucher, Felicitas] Univ Freiburg, Eye Ctr, Med Ctr, Fac Med, Freiburg, Germany.
   [Mulyukov, Zufar; Pigeolet, Etienne; Clemens, Andreas] Novartis Pharma AG, Basel, Switzerland.
   [Tsilimbaris, Miltiadis] Univ Hosp Heraklion, Dept Ophthalmol, Iraklion, Greece.
   [Calvo, Pilar] Miguel Servet Univ Hosp, Dept Ophthalmol, IIS Aragon, Zaragoza, Spain.
   [Gaucher, David] Hop Univ Strasbourg, Nouvel Hop Civil, Strasbourg, France.
   [Colafrancesco, Valeria] Novartis Farmaceut SA, Barcelona, Spain.
   [Clemens, Andreas] Univ Freiburg, Dept Cardiol & Angiol 1, Heart Ctr Freiburg Univ, Fac Med, Freiburg, Germany.
C3 University of Freiburg; Novartis; University Hospital of Heraklion;
   Miguel Servet University Hospital; CHU Strasbourg; UDICE-French Research
   Universities; Universites de Strasbourg Etablissements Associes;
   Universite de Strasbourg; Novartis; Universitats Herzzentrum Freiburg;
   University of Freiburg
RP Clemens, A (通讯作者)，Novartis Pharma AG, Dept Ophthalmol, CH-4002 Basel, Switzerland.
EM andreas.clemens@novartis.com
OI Bucher, Felicitas/0000-0003-0081-1420
FU Novartis Pharmaceuticals Corporation
FX This work was supported by the Novartis Pharmaceuticals Corporation.
CR [Anonymous], 2009, REV OPHTHALMOL
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2018, AM AC OPHTH 122 ANN
   Escher D, 2015, EUR SOC RET SPEC 15
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Ladas ID, 2012, OPHTHALMOLOGICA, V228, P93, DOI 10.1159/000337347
   Mulyukov Z, 2018, CPT-PHARMACOMET SYST, V7, P660, DOI 10.1002/psp4.12322
   Nimz EL, 2016, INVEST OPHTH VIS SCI, V57
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 21
TC 6
Z9 7
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD OCT 2
PY 2020
VL 45
IS 10
BP 1298
EP 1301
DI 10.1080/02713683.2020.1731832
EA FEB 2020
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NR0FX
UT WOS:000516739700001
PM 32065533
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Iida, T
   Yannuzzi, LA
   Freund, KB
   Ciardella, AP
   Costa, DLL
   Huang, SJ
   Golub, BM
AF Iida, T
   Yannuzzi, LA
   Freund, KB
   Ciardella, AP
   Costa, DLL
   Huang, SJ
   Golub, BM
TI Retinal angiopathy and polypoidal choroidal vasculopathy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; detachment; fluorescein angiography;
   indocyanine green angiography; laser photocoagulation; lipid exudation;
   macula; polypoidal choroidal vasculopathy; retinal angiomatous
   proliferation; retinal microangiopathy
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY;
   VASCULAR-PERMEABILITY FACTOR; MACULAR DEGENERATION; CLINICOPATHOLOGICAL
   CORRELATION; DETACHMENTS; NEOVASCULARIZATION; ANASTOMOSES; EXPRESSION;
   PRIMATE
AB Purpose: To describe the clinical and angiographic features of patients with polypoidal choroidal vasculopathy, exudative detachment of the macula, and an associated retinal microangiopathy.
   Methods: Case series.
   Results: Four patients with chronic exudative detachment of the macula with a variable degree of lipid deposition are described. The retina in the detached area, but not beyond, was noted to have a microangiopathy. There was capillary telangiectasia, microaneurysm formation, patchy nonperfusion, and intraretinal leakage. In each patient, there were no other retinal vascular changes in the fundus of either eye. The fluorescein angiogram showed subretinal leakage suspicious for occult choroidal neovascularization. The indocyanine green angiogram showed the presence of underlying polypoidal choroidal neovascularization, accounting for the exudative detachment. After photocoagulation, the retinal angiopathy improved, but not completely.
   Conclusion: Retinal microangiopathy may occur in a chronic macular detachment secondary to polypoidal choroidal neovascularization. The development of these secondary retinal changes is not clearly understood; however, hypoxia from the chronic detachment, a neurotoxic effect from the lipid deposition, or a biochemically induced microvascular abnormality from secretion of vasogenic mediators are possible mechanisms. Indocyanine green angiography is helpful in making a definitive diagnosis. Clinicians should be aware that a retinal microangiopathy may occur in such eyes so that the proper diagnosis can be made and appropriate treatment administered.
C1 Manhattan Eye Ear & Throat Hosp, Luesther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Manhattan Eye Ear & Throat Hospital
RP Freund, KB (通讯作者)，Manhattan Eye Ear & Throat Hosp, Luesther T Mertz Retinal Res Ctr, 210 E 64th st, New York, NY 10021 USA.
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   AKIYAMA K, 1987, OPHTHALMOLOGY, V94, P1605
   DUKEELDER S, 1967, SYSTEM OPHTHALMOLOGY, P10
   FELDER KS, 1982, AM J OPHTHALMOL, V93, P773, DOI 10.1016/0002-9394(82)90473-1
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   KOHNER EM, 2001, RETINA, P982
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   MILLER JW, 1994, AM J PATHOL, V145, P574
   PEER J, 1995, LAB INVEST, V72, P638
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   SHIMIZU K, 1973, FLUORESCEIN MICROANG, P136
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tolentino F I, 1976, Int Ophthalmol Clin, V16, P13, DOI 10.1097/00004397-197601610-00005
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   WISE GN, 1971, RETINAL CIRCULATION, P245
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 32
TC 11
Z9 11
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2002
VL 22
IS 4
BP 455
EP 463
DI 10.1097/00006982-200208000-00010
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 583XT
UT WOS:000177437200010
PM 12172113
DA 2022-11-30
ER

PT J
AU Chew, EY
   Clemons, TE
   Bressler, SB
   Elman, MJ
   Danis, RP
   Domalpally, A
   Heier, JS
   Kim, JE
   Garfinkel, RA
AF Chew, Emily Y.
   Clemons, Traci E.
   Bressler, Susan B.
   Elman, Michael J.
   Danis, Ronald P.
   Domalpally, Amitha
   Heier, Jeffrey S.
   Kim, Judy E.
   Garfinkel, Richard A.
CA AREDS2 Home Study Res Grp
TI Randomized trial of the ForeseeHome monitoring device for early
   detection of neovascular age-related macular degeneration. The HOme
   Monitoring of the Eye (HOME) study design - HOME Study report number 1
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Age-related macular degeneration; Controlled clinical trial;
   Home-monitoring; Choroidal neovascularization; Best-corrected visual
   acuity
ID FACTOR TRAP-EYE; VISUAL IMPAIRMENT; SUBGROUP ANALYSIS; RANIBIZUMAB;
   BEVACIZUMAB; MULTICENTER; PREVALENCE
AB Objective: To evaluate the effects of a home-monitoring device with tele-monitoring compared with standard care in detection of progression to choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), the leading cause of blindness in the US. Patients and methods: Participants, aged 55 to 90 years, at high risk of developing CNV associated with AMD were recruited to the HOme Monitoring of Eye (HOME) Study, an unmasked, multi-center, randomized trial of the ForeseeHome (FH) device plus standard care vs. standard care alone. The FH device utilizes preferential hyperacuity perimetry and tele-monitoring to detect changes in vision function associated with development of CNV, potentially prior to symptom and visual acuity loss. After establishing baseline measurements, subsequent changes on follow-up are detected by the device, causing the monitoring center to alert the clinical center to recall participants for an exam. Standard care consists of instructions for self-monitoring visual changes with subsequent self-report to the clinical center. The primary objective of this study is to determine whether home monitoring plus standard care in comparison with standard care alone, results in earlier detection of incident CNV with better present visual acuity. The primary outcome is the decline in visual acuity at CNV diagnosis from baseline. Detection of CNV prior to substantial vision loss is critical as vision outcome following anti-angiogenic therapy is dependent on the visual acuity at initiation of treatment. Discussion: HOME Study is the first large scale study to test the use of home tele-monitoring system in the management of AMD patients. Published by Elsevier Inc.
C1 [Chew, Emily Y.] NEI, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Bressler, Susan B.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Elman, Michael J.] Elman Retina Grp, Baltimore, MD USA.
   [Danis, Ronald P.; Domalpally, Amitha] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53706 USA.
   [Heier, Jeffrey S.] Ophthalm Consultant Boston, Boston, MA USA.
   [Kim, Judy E.] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA.
   [Garfinkel, Richard A.] Retina Grp Washington, Bethesda, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; Johns Hopkins University; Johns Hopkins
   Medicine; University of Wisconsin System; University of Wisconsin
   Madison; Ophthalmic Consultants of Boston; Medical College of Wisconsin
RP Chew, EY (通讯作者)，NIH, CRC, Bldg 10,Room 3-2531,10 Ctr Dr,MSC-1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Domalpally, Amitha/B-2367-2015
OI Chew, Emily/0000-0003-0999-9802; Heier, Jeffrey/0000-0003-4625-3145;
   Domalpally, Amitha/0000-0002-8145-9619; Elman,
   Michael/0000-0001-7726-9508
FU Notal Vision through a clinical trial agreement with the NEI
   [CTA-00833]; EMMES Corporation; National Eye Institute/National
   Institutes of Health (NEI/NIH); Department of Health and Human Services,
   Bethesda, MD [HHS-N-260-2005-00007-C]; ADB [N01-EY-5-0007]; Office of
   Dietary Supplements (ODS); National Center for Complementary and
   Alternative Medicine (NCCAM); National Institute on Aging (NIA);
   National Heart, Lung and Blood Institute (NHLBI); National Institute of
   Neurological Disorders and Stroke (N1NDS); NATIONAL EYE INSTITUTE
   [ZIAEY000485] Funding Source: NIH RePORTER
FX Financial support to the study was provided by the Notal Vision through
   a clinical trial agreement with the NEI (CTA-00833) and a service
   agreement with EMMES Corporation. The AREDS2 study is supported by the
   intramural program funds and contracts from the National Eye
   Institute/National Institutes of Health (NEI/NIH), Department of Health
   and Human Services, Bethesda, MD. Contract No. HHS-N-260-2005-00007-C.
   ADB Contract No. N01-EY-5-0007. Funds were generously contributed to
   these contracts by the following NIH institutes: Office of Dietary
   Supplements (ODS), National Center for Complementary and Alternative
   Medicine (NCCAM), National Institute on Aging (NIA), National Heart,
   Lung and Blood Institute (NHLBI), and National Institute of Neurological
   Disorders and Stroke (N1NDS). The study medications and raw materials
   were provided by Alcon, Bausch and Lomb, DSM, and Pfizer.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   The AREDS2-HOME Study Research Group, 2013, OPHTHALMOLOGY
   WESTHEIMER G, 1975, INVEST OPHTH VISUAL, V14, P570
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 19
TC 42
Z9 42
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAR
PY 2014
VL 37
IS 2
BP 294
EP 300
DI 10.1016/j.cct.2014.02.003
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AG7ZA
UT WOS:000335636100016
PM 24530651
DA 2022-11-30
ER

PT J
AU Feigl, B
   Cao, DC
   Morris, CP
   Zele, AJ
AF Feigl, Beatrix
   Cao, Dingcai
   Morris, Charles P.
   Zele, Andrew J.
TI Persons with Age-Related Maculopathy Risk Genotypes and Clinically
   Normal Eyes Have Reduced Mesopic Vision
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; MEDIATED MULTIFOCAL ELECTRORETINOGRAM; MACULAR
   DEGENERATION; FUNDUS PERIMETRY; ROD; SUSCEPTIBILITY; POLYMORPHISM; GENE;
   LOC387715-A69S; ASSOCIATION
AB PURPOSE. To determine whether participants with normal visual acuity, no ophthalmoscopically signs of age-related maculopathy (ARM) in both eyes, and who are carriers of the CFH, LOC387715, and HRTA1 high-risk genotypes (gene-positive) have impaired rod-and cone-mediated mesopic visual function compared with persons who do not carry the risk genotypes (gene-negative).
   METHODS. Fifty-three Caucasian study participants (mean 55.8 +/- 6.1) were genotyped for CFH, LOC387715/ARMS2, and HRTA1 polymorphisms. Single-nucleotide polymorphisms were genotyped in the CFH (rs380390), LOC387715/ARMS2 (rs10490924), and HTRA1 (rs11200638) genes using optimized gene-expression assays. The critical fusion frequency (CFF) mediated by cones alone (long-, middle-, and short-wavelength sensitive cones, LMS) and by the combined activities of cones and rods (LMSR) were determined. The stimuli were generated using a four-primary photostimulator that provides independent control of the photoreceptor excitation under mesopic light levels. Visual function was further assessed using standard clinical tests, flicker perimetry, and microperimetry.
   RESULTS. The mesopic CFF mediated by rods and cones (LMSR) was significantly reduced in gene-positive compared to genenegative participants after correction for age (P = 0.03). Conemediated CFF (LMS) was not significantly different between gene-positive and -negative participants. There were no significant associations between flicker perimetry and microperimetry and genotype.
   CONCLUSIONS. This is the first study to relate ARM risk genotypes with mesopic visual function in clinically normal persons. These preliminary results could become of clinical importance because mesopic vision may be used as a biomarker to document subclinical retinal changes in persons with risk genotypes and to determine whether those persons progress into manifest disease. (Invest Ophthalmol Vis Sci. 2011; 52:1145-1150) DOI:10.1167/iovs.10-5967
C1 [Feigl, Beatrix] Queensland Univ Technol, Med Retina Lab, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Cao, Dingcai] Univ Chicago, Dept Surg, Sect Surg Res, Chicago, IL 60637 USA.
   [Cao, Dingcai] Univ Chicago, Sect Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
C3 Queensland University of Technology (QUT); University of Chicago;
   University of Chicago
RP Feigl, B (通讯作者)，Queensland Univ Technol, Med Retina Lab, Inst Hlth & Biomed Innovat, 60 Musk Ave, Brisbane, Qld 4059, Australia.
EM b.feigl@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373; Zele, Andrew/0000-0003-0291-9929;
   Morris, Phillip/0000-0001-8976-619X
FU Queensland University of Technology; Australian Research Council
   [DP1096354]; NIH National Eye Institute [R01-EY019651]; NATIONAL EYE
   INSTITUTE [R01EY019651] Funding Source: NIH RePORTER
FX Supported by a Queensland University of Technology Vice Chancellor
   Research Fellowship (BF), Australian Research Council Discovery Projects
   DP1096354 (AJZ), and NIH National Eye Institute Grant R01-EY019651 (DC).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   Cao DC, 2006, VISUAL NEUROSCI, V23, P531, DOI 10.1017/S0952523806233376
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2006, CURR EYE RES, V31, P635, DOI 10.1080/02713680600762739
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Hogg RE, 2009, OPHTHALMOLOGY, V116, P263, DOI 10.1016/j.ophtha.2008.09.002
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KIRYU J, 1995, INVEST OPHTH VIS SCI, V36, P1240
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Landers J, 2007, BRIT J OPHTHALMOL, V91, P1285, DOI 10.1136/bjo.2007.114926
   Lawford BR, 2005, SCHIZOPHR RES, V73, P31, DOI 10.1016/j.schres.2004.08.020
   MACLEOD DIA, 1979, J OPT SOC AM, V69, P1183, DOI 10.1364/JOSA.69.001183
   Maier M, 2010, GRAEF ARCH CLIN EXP, V248, P409, DOI 10.1007/s00417-009-1270-8
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   Neuville JM, 2009, OPTOMETRY VISION SCI, V86, P810, DOI 10.1097/OPX.0b013e3181adff59
   Osterberg G, 1935, Acta Ophthalmol., V13, P11
   Ott J., 1988, UTILITY PROGRAMS ANA
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Petzold A, 2006, OPHTHAL PHYSL OPT, V26, P326, DOI 10.1111/j.1475-1313.2006.00417.x
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Pokorny J, 2004, VISUAL NEUROSCI, V21, P263, DOI 10.1017/S0952523804213207
   Puts MJH, 2005, J NEUROSCI METH, V142, P77, DOI 10.1016/j.jneumeth.2004.07.013
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shapiro AG, 1996, J OPT SOC AM A, V13, P2319, DOI 10.1364/JOSAA.13.002319
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SONDEL SA, 2010, ANN M ASS RES VIS OP
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   SWANSON WH, 1987, J OPT SOC AM A, V4, P1992, DOI 10.1364/JOSAA.4.001992
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   VINGRYS AJ, 1990, CLIN EXP OPTOM, V1, P10
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zele AJ, 2008, OPTOMETRY VISION SCI, V85, P309, DOI 10.1097/OPX.0b013e31816be9e3
   Zele AJ, 2008, VISION RES, V48, P2593, DOI 10.1016/j.visres.2008.04.003
NR 48
TC 33
Z9 34
U1 0
U2 15
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2011
VL 52
IS 2
BP 1145
EP 1150
DI 10.1167/iovs.10-5967
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 728AQ
UT WOS:000287846300069
PM 20881291
OA Green Published
DA 2022-11-30
ER

PT J
AU Hubbard, B
   Sternberg, P
   Capone, A
   Aaberg, TM
   Brown, JM
   Dubois, LG
   Johnson, J
   Schmitz, N
   Haller, JA
   Campochiaro, PA
   de Juan, E
   Pieramici, D
   Zimmer-Galler, I
   Hartnett, M
   Hawse, P
   Porter, T
   Youngblood, AE
   Orr, PR
   Arroyo, J
   MacCumber, MW
   Civantos, J
   Packo, KH
   De Alba, M
   Franzyck, M
   Gaynes, BL
   Morrison, C
   Rago, L
   Violetto, C
   Bryant, DA
   Doherty, D
   Morini, F
   Weinberg, DV
   Schroeder, R
   Koecher, J
   Strugala, Z
   Lewis, H
   Kaiser, PK
   Holody, L
   Schaaf, LS
   Ambrose, G
   Fatori, A
   Bartram, GM
   Burke, SL
   Fecko, T
   Ross, DJ
   Singerman, LJ
   Novak, MA
   Pendergast, S
   Campana, LM
   Tilocco, K
   Rath, SC
   Tanner, V
   Greanoff, G
   Lehnhardt, D
   Smith-Brewer, S
   Spagnoletta, K
   Davidorf, FH
   Chambers, R
   Milliron, J
   Perry, J
   Callanan, DG
   Creighton, JR
   Resmini, N
   Rollins, R
   Andrews, M
   Toth, C
   Anderson, MW
   Caldwell, JV
   Atebara, NH
   Pelke, S
   Rosenthal, WN
   Dyer, DS
   Moore, D
   Petro, B
   Thibodeaux, DJ
   Hoskins, JC
   Googe, JM
   Carter, KE
   Evans, SM
   Higdon, TT
   Holton, JL
   Gilliland, BD
   Wood, WJ
   Isernhagen, R
   Cruz, JL
   Buck, ML
   James, JD
   Jordan, TL
   Wolfe, JL
   Brown, C
   Heath, W
   Millet, C
   Reid, M
   Slade, E
   Schwartz, SD
   Engstrom, R
   Small, K
   Eure, J
   Hsu, J
   Ostrick, R
   Tran, D
   Wong, T
   Barnhart, L
   Chen, J
   Chun, M
   Johnson, L
   Kageyama, JY
   Tetreault, M
   Thayer, D
   Trump, B
   Blumenkranz, MS
   Mattio, P
   Williams, DF
   Mittra, RA
   Dev, S
   Enloe, J
   Marella, SD
   Oestrich, N
   Bradford, RH
   Nanda, SK
   Monlux, A
   Ogilbee, LM
   Sipperley, JO
   Sneed, SR
   Jacobsen, JJ
   Tysiac, E
   Freistroffer, D
   Perez, N
   Rosas, P
   Tomaszewski, T
   Bergren, RL
   Doft, B
   Metz, DJ
   Sedory, K
   Trombetta, C
   Rigoni, G
   Wellman, L
   Wilcox, L
   Campbell, A
   Steinberg, D
   Vagstad, G
   Wilson, DJ
   Redenbo, E
   Steinkamp, P
   Wallace, P
   Williams, GA
   Garretson, BR
   Ruby, A
   Cumming, KL
   Lewis, B
   Manatry, P
   Zajechewski, M
   Holekamp, NM
   Thomas, MA
   Joseph, DP
   Boyd, L
   Gualdoni, J
   Nobel, V
   Allen, R
   Barts, B
   Dahl, J
   Holle, TS
   Ort, E
   Raeber, M
   Rogers, JM
   McDonald, HR
   Johnson, RN
   Stolarczuk, M
   Wood, P
   Curren, KE
   DeBoer, KA
   Huggans, SM
   Miller, JR
   Uy, J
   Pesin, SR
   Leonardy, NJ
   Dabbs, CK
   Haener, JM
   Bressler, NM
   Cumming, L
   Orr, PR
   Haener, JM
   Hartnett, M
   Hawse, P
   Bass, EB
   Childs, D
   Lawson, C
   Goldsborough, IL
   Staflin, P
   Hawkins, BS
   Dong, LM
   Marsh, MJ
   Miskala, H
   Casper, RG
   Keith, AD
   Smith, DK
   McCaffrey, LD
   Newhouse, MM
   Dreger, K
   Jaffee, HA
   Grubb, SC
   Lassiter, L
   James, PA
   Alden, CB
   Kiah, TR
   Prusakowski, NA
   Pieramici, D
   Sadda, S
   Schein, OD
   Solomon, SD
   Mbah, L
   Strozykowski, RW
   Mills, I
   Sieving, PA
   Kupfer, C
   McLaughlin, JA
   Redford, M
   Cotch, MF
   Childs, AL
   Mangione, CM
   Bass, EB
   Bressler, NM
   Hawkins, BS
   Marsh, MJ
   Miskala, PH
   Jaffee, A
   McCaffrey, LD
   Hillis, AI
   Abrams, GW
   Connett, JE
   Grady, C
   Harrison, EG
   Jampol, LM
   Bressler, NM
   Marsh, MJ
   Redford, M
   Sternberg, P
   Thomas, MA
   Redford, M
   Grossniklaus, HE
   Halter, JA
   Mangione, CM
   Brown, JM
   Holekamp, NM
   Pesin, SR
   Wilson, DJ
AF Hubbard, B
   Sternberg, P
   Capone, A
   Aaberg, TM
   Brown, JM
   Dubois, LG
   Johnson, J
   Schmitz, N
   Haller, JA
   Campochiaro, PA
   de Juan, E
   Pieramici, D
   Zimmer-Galler, I
   Hartnett, M
   Hawse, P
   Porter, T
   Youngblood, AE
   Orr, PR
   Arroyo, J
   MacCumber, MW
   Civantos, J
   Packo, KH
   De Alba, M
   Franzyck, M
   Gaynes, BL
   Morrison, C
   Rago, L
   Violetto, C
   Bryant, DA
   Doherty, D
   Morini, F
   Weinberg, DV
   Schroeder, R
   Koecher, J
   Strugala, Z
   Lewis, H
   Kaiser, PK
   Holody, L
   Schaaf, LS
   Ambrose, G
   Fatori, A
   Bartram, GM
   Burke, SL
   Fecko, T
   Ross, DJ
   Singerman, LJ
   Novak, MA
   Pendergast, S
   Campana, LM
   Tilocco, K
   Rath, SC
   Tanner, V
   Greanoff, G
   Lehnhardt, D
   Smith-Brewer, S
   Spagnoletta, K
   Davidorf, FH
   Chambers, R
   Milliron, J
   Perry, J
   Callanan, DG
   Creighton, JR
   Resmini, N
   Rollins, R
   Andrews, M
   Toth, C
   Anderson, MW
   Caldwell, JV
   Atebara, NH
   Pelke, S
   Rosenthal, WN
   Dyer, DS
   Moore, D
   Petro, B
   Thibodeaux, DJ
   Hoskins, JC
   Googe, JM
   Carter, KE
   Evans, SM
   Higdon, TT
   Holton, JL
   Gilliland, BD
   Wood, WJ
   Isernhagen, R
   Cruz, JL
   Buck, ML
   James, JD
   Jordan, TL
   Wolfe, JL
   Brown, C
   Heath, W
   Millet, C
   Reid, M
   Slade, E
   Schwartz, SD
   Engstrom, R
   Small, K
   Eure, J
   Hsu, J
   Ostrick, R
   Tran, D
   Wong, T
   Barnhart, L
   Chen, J
   Chun, M
   Johnson, L
   Kageyama, JY
   Tetreault, M
   Thayer, D
   Trump, B
   Blumenkranz, MS
   Mattio, P
   Williams, DF
   Mittra, RA
   Dev, S
   Enloe, J
   Marella, SD
   Oestrich, N
   Bradford, RH
   Nanda, SK
   Monlux, A
   Ogilbee, LM
   Sipperley, JO
   Sneed, SR
   Jacobsen, JJ
   Tysiac, E
   Freistroffer, D
   Perez, N
   Rosas, P
   Tomaszewski, T
   Bergren, RL
   Doft, B
   Metz, DJ
   Sedory, K
   Trombetta, C
   Rigoni, G
   Wellman, L
   Wilcox, L
   Campbell, A
   Steinberg, D
   Vagstad, G
   Wilson, DJ
   Redenbo, E
   Steinkamp, P
   Wallace, P
   Williams, GA
   Garretson, BR
   Ruby, A
   Cumming, KL
   Lewis, B
   Manatry, P
   Zajechewski, M
   Holekamp, NM
   Thomas, MA
   Joseph, DP
   Boyd, L
   Gualdoni, J
   Nobel, V
   Allen, R
   Barts, B
   Dahl, J
   Holle, TS
   Ort, E
   Raeber, M
   Rogers, JM
   McDonald, HR
   Johnson, RN
   Stolarczuk, M
   Wood, P
   Curren, KE
   DeBoer, KA
   Huggans, SM
   Miller, JR
   Uy, J
   Pesin, SR
   Leonardy, NJ
   Dabbs, CK
   Haener, JM
   Bressler, NM
   Cumming, L
   Orr, PR
   Haener, JM
   Hartnett, M
   Hawse, P
   Bass, EB
   Childs, D
   Lawson, C
   Goldsborough, IL
   Staflin, P
   Hawkins, BS
   Dong, LM
   Marsh, MJ
   Miskala, H
   Casper, RG
   Keith, AD
   Smith, DK
   McCaffrey, LD
   Newhouse, MM
   Dreger, K
   Jaffee, HA
   Grubb, SC
   Lassiter, L
   James, PA
   Alden, CB
   Kiah, TR
   Prusakowski, NA
   Pieramici, D
   Sadda, S
   Schein, OD
   Solomon, SD
   Mbah, L
   Strozykowski, RW
   Mills, I
   Sieving, PA
   Kupfer, C
   McLaughlin, JA
   Redford, M
   Cotch, MF
   Childs, AL
   Mangione, CM
   Bass, EB
   Bressler, NM
   Hawkins, BS
   Marsh, MJ
   Miskala, PH
   Jaffee, A
   McCaffrey, LD
   Hillis, AI
   Abrams, GW
   Connett, JE
   Grady, C
   Harrison, EG
   Jampol, LM
   Bressler, NM
   Marsh, MJ
   Redford, M
   Sternberg, P
   Thomas, MA
   Redford, M
   Grossniklaus, HE
   Halter, JA
   Mangione, CM
   Brown, JM
   Holekamp, NM
   Pesin, SR
   Wilson, DJ
CA Submalular Surgery Trials Res Grp
TI Health- and vision-related quality of life among patients with choroidal
   neovascularization secondary to age-related macular degeneration at
   enrollment in randomized trials of submacular surgery: SST report no. 4
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; DEPRESSION SCALE; HOSPITAL ANXIETY;
   GENERAL HEALTH; NEI-VFQ; ACUITY; EYE
AB PURPOSE: To describe the effect of subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD) on health-related quality of life (HRQOL) of patients at enrollment in two randomized clinical trials; to examine the relation of visual acuity to HRQOL; to compare HRQOL scores between participants with unilateral and bilateral CNV independent of other characteristics.
   DESIGN: Randomized clinical trials.
   METHODS: Two Submacular Surgery Trials (SST) recruited patients with AMD and either new subfoveal CNV (Group N Trial) or predominantly hemorrhagic CNV (Group B Trial). Health-related quality of life interviews included the National Eye Institute Visual Function Questionnaire [NEI-VFQ], the SF-36 Health Survey, and the Hospital Anxiety and Depression Scale [HADS]. Linear correlation and regression analyses were used to relate baseline HRQOL scores to visual acuity and bilateral disease.
   RESULTS: Interview data were analyzed for 789 AMD patients: 454 patients in the Group N Trial and 335 patients in the Group B Trial. Participants reported poor vision-related functioning in many domains measured by the NEI-VFQ (mean overall scores of 65 for Group N and 63 for Group B). Visual acuity of the better eye was strongly associated with NEI-VFQ scores but not with SF-36 or HADS scores. After adjusting for visual acuity of the better eye and other factors, bilateral cases had NEI-VFQ overall scores six points lower than unilateral cases in Group N Trial and 10 points lower than unilateral cases in the Group B Trial.
   CONCLUSIONS: Subfoveal CNV profoundly affects vision-related quality of life. The effect is more pronounced with bilateral disease, even after controlling for visual acuity. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Care of Childs Ashely L, Wilmer Clin Trials & Biometry, Baltimore, MD 21205 USA.
RP Childs, D (通讯作者)，Care of Childs Ashely L, Wilmer Clin Trials & Biometry, 550 N Broadway,9th Floor, Baltimore, MD 21205 USA.
EM achilds1@jhmi.edu
RI Bidyuk, Petro/S-1161-2016; Mittra, Robert/AAC-8249-2021; toth, cynthia
   a/F-5614-2011; Toth, Cynthia/L-5534-2019; Moller, Jens/H-1204-2017;
   Marsh, Herb/B-3134-2017
OI Toth, Cynthia/0000-0002-2324-0854; Scherer, Ronny/0000-0003-3630-0710;
   Arroyo, Jorge/0000-0001-9812-296X; Moller, Jens/0000-0003-1767-5859;
   Mann, Ashley/0000-0003-3553-5470; Marsh, Herb/0000-0002-1078-9717
FU NEI NIH HHS [U10 EY 11547, EY 11558, EY 11557, U10 EY011558-07, U10
   EY011547-07, U10 EY011557-08] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [U10EY011557, U10EY011547, U10EY011558] Funding Source: NIH
   RePORTER
CR Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   *DEP HHS, 2003, PREV BLINDN AM
   Dong LM, 2003, OPHTHAL EPIDEMIOL, V10, P149, DOI 10.1076/opep.10.3.149.15080
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   *NAT EY I, 2003, NEWS REL
   Schiffman RM, 2001, ARCH OPHTHALMOL-CHIC, V119, P841
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   *SUBM SURG TRIALS, 1998, SUBM SURG TRIALS MAN
   *SUBM SURG TRIALS, IN PRESS SST
   Tukey John W., 1977, EXPLORATORY DATA ANA, P39
   Ware J, 1994, SF 36 PHYS MENT HLTH
   Ware JE., 1993, SCORING SF 36 SF 36
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   2003, VFQ 14 RAND HLTH
NR 20
TC 31
Z9 31
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2004
VL 138
IS 1
BP 91
EP 108
DI 10.1016/j.ajo.2004.02.011
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 836PO
UT WOS:000222568200012
PM 15234287
DA 2022-11-30
ER

PT J
AU Luke, M
   Ziemssen, F
   Bartz-Schmidt, KU
   Gelisken, F
AF Lueke, Matthias
   Ziemssen, Focke
   Bartz-Schmidt, Karl Ulrich
   Gelisken, Faik
TI Quality of life in a prospective, randomised pilot-trial of photodynamic
   therapy versus full macular translocation in treatment of neovascular
   age-related macular degeneration - a report of 1 year results
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE full macular translocation; photodynamic therapy; quality of life;
   age-related macular degeneration
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VISUAL FUNCTION QUESTIONNAIRE;
   CLINICAL-TRIALS; EYE; VERTEPORFIN; RETINECTOMY
AB Purpose To assess visual function and its effects on vision-targeted, health-related quality of life (QOL) of patients with neovascular age-related macular degeneration (AMD) treated with photodynamic therapy (PDT) or full macular translocation (FMT).
   Methods Fifty patients with predominantly classic subfoveal choroidal neovascularisation (CNV) secondary to AMD were randomised to PDT or FMT. To test the vision-targeted QOL, the 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25 plus supplement) was administered prior to and 1 year after therapy. The change of vision-related QOL at 1 year in comparison to baseline was defined as primary end point.
   Results The vision-related subscales showed a stabilisation or even higher mean scores at 1 year in both treatment groups. A significant improvement in the quality of the subject's vision-related subscales was only observed after FMT correlating with a more frequent increase in visual acuity. Comparing the results of the QOL scores after 1 year, the improvement of the subscale scores general vision (p = 0.03), mental health (p = 0.02) and dependency (p = 0.03) were significantly higher in the FMT arm.
   Conclusions FMT and PDT can achieve a stabilisation in vision-related QOL, in which FMT was superior to the PDT after 1 year. The discrepancy between the amount of patients with an increased visual acuity after FMT and a moderate improvement in QOL might be caused by the onset of complications related to this surgical procedure. Besides visual acuity, the impact of therapy-related complications has to be taken into consideration when evaluating new therapeutic concepts in exudative AMD.
C1 Univ Tubingen, Ctr Ophthalmol, Univ Eye Hosp, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Luke, M (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Univ Eye Hosp, Schleichstr 12-16, D-72076 Tubingen, Germany.
EM matthias.lueke@med.uni-tuebingen.de
RI Ziemssen, Focke/AAY-1686-2021; , Ziemssen/B-9564-2009
OI , Ziemssen/0000-0002-3873-0581
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Franke GH, 1998, Z MED PSYCHOL, P178
   GELISKEN F, 2007, GRAEFES ARCH CLIN EX
   Hewitt AW, 2006, GRAEF ARCH CLIN EXP, V244, P972, DOI 10.1007/s00417-005-0218-x
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MANGIONE CM, 2000, NEI VFQ 25 SCORING A
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
NR 20
TC 10
Z9 11
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2007
VL 245
IS 12
BP 1831
EP 1836
DI 10.1007/s00417-007-0558-9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 232HX
UT WOS:000251010600012
PM 17347809
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Ohtsuka, H
   Higuchi, M
   Matsushita, T
   Ariga, H
   Kosaka, S
   Matsushita, R
AF Hikichi, Taiichi
   Ohtsuka, Hideo
   Higuchi, Makoto
   Matsushita, Takuro
   Ariga, Hiroko
   Kosaka, Shoko
   Matsushita, Reiko
TI CAUSES OF MACULAR SEROUS RETINAL DETACHMENTS IN JAPANESE PATIENTS 40
   YEARS AND OLDER
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; central serous chorioretinopathy;
   indocyanine green angiography; occult choroidal neovascularization;
   polypoidal choroidal vasculopathy; serous retinal detachment
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INDOCYANINE GREEN ANGIOGRAPHY; GUIDED
   PHOTODYNAMIC THERAPY; TERM-FOLLOW-UP; CHORIORETINOPATHY; AGE; FEATURES;
   VIDEOANGIOGRAPHY; NEOVASCULARIZATION; DEGENERATION
AB Purpose: To investigate the causes of macular serous retinal detachment without hemorrhage at the macula in patients 40 years and older.
   Methods: Seventy-one eyes of 71 consecutive Japanese patients 40 years and older with the disease were examined using optical coherence tomography, digital simultaneous fluorescein and indocyanine green angiographies with a confocal laser scanning system.
   Results: Of 71 eyes, 17 eyes (24%) had central serous chorioretinopathy, including three eyes with chronic central serous chorioretinopathy, 40 eyes (56%.) had polypoidal choroidal vasculopathy (PCV), 10 eyes (14%) had occult choroidal neovascularization secondary to age-related macular degeneration, one had Harada disease, and another had retinal macroaneurysms. In two eyes, the diagnosis could not be established because of difficulty differentiating among chronic central serous chorioretinopathy, PCV, and occult choroidal neovascularization. Thirty-eight of 59 (64%) eyes of patients in the sixth decade of life and older had PCV.
   Conclusions: Polypoidal choroidai vasculopathy is a primary cause of macular serous retinal detachment without hemorrhage in Japanese patients over 50 years of age. Since clinical and fluorescein angiographic, findings are indistinguishable among central serous chorioretinopathy, PCV, and occult choroidal neovascularization, indocyanine green angiography might help to establish a more definitive diagnosis.
C1 [Hikichi, Taiichi] Ohtsuka Eye Hosp, Kita Ku, Sapporo, Hokkaido 0010016, Japan.
RP Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Kita Ku, Kita 16 Nishi 4, Sapporo, Hokkaido 0010016, Japan.
EM taiichi-hikichi@hokkaido.med.or.jp
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   BERGER AR, 1991, OPHTHALMIC SURG LAS, V22, P583
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   CASTROCORREIA J, 1992, DOC OPHTHALMOL, V81, P379
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Freeman WR, 1998, ARCH OPHTHALMOL-CHIC, V116, P455, DOI 10.1001/archopht.116.4.455
   GILBERT CM, 1984, BRIT J OPHTHALMOL, V68, P815, DOI 10.1136/bjo.68.11.815
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   HAYASHI K, 1986, INT OPHTHALMOL, V9, P37
   HUANG WC, 2008, EYE             0314
   Iida T, 2002, ARCH OPHTHALMOL-CHIC, V120, P37
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   JALKH AE, 1984, OPHTHALMOLOGY, V91, P1544
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   Kitaya N, 2003, BRIT J OPHTHALMOL, V87, P709, DOI 10.1136/bjo.87.6.709
   KLEIN ML, 1974, ARCH OPHTHALMOL-CHIC, V91, P247
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   LE D, 1993, BR J OPHTHALMOL, V77, P349
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MATSUDA N, 2006, NIPPON KANNKA KIYOU, V57, P23
   NIEGEL MF, 2008, OPHTHALMOLOGE   0124
   Okushiba Utako, 1997, Nippon Ganka Gakkai Zasshi, V101, P74
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   REGILLO CD, 1994, OPHTHALMOLOGY, V101, P280
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SCHATZ H, 1992, OPHTHALMOLOGY, V99, P63
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P820, DOI 10.1097/00006982-200312000-00013
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   SPITZNAS M, 1987, GRAEF ARCH CLIN EXP, V225, P437, DOI 10.1007/BF02334172
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 47
TC 11
Z9 13
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2009
VL 29
IS 3
BP 395
EP 404
DI 10.1097/IAE.0b013e318192f53a
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 420RK
UT WOS:000264306700017
PM 19092728
DA 2022-11-30
ER

PT J
AU Curcio, CA
   Presley, JB
   Millican, CL
   Medeiros, NE
AF Curcio, CA
   Presley, JB
   Millican, CL
   Medeiros, NE
TI Basal deposits and drusen in eyes with age-related maculopathy: evidence
   for solid lipid particles
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related maculopathy; lipids; lipoproteins; electron microscopy;
   ultrastructural pathology; basal deposit; drusen
ID ONSET RETINAL DEGENERATION; MACULAR DEGENERATION; BRUCHS MEMBRANE;
   PIGMENT-EPITHELIUM; CHOROIDAL NEOVASCULARIZATION; ATHEROSCLEROTIC
   LESIONS; DENSITY-LIPOPROTEINS; APOLIPOPROTEIN-E; LINEAR DEPOSIT; HUMAN
   RPE
AB Neutral lipid, including esterified cholesterol, and apolipoproteins B and E are abundant in basal deposits and drusen of aged and age-related maculopathy (ARM) eyes. The principal component of basal linear deposit (BlinD), a specific ARM lesion, is membranous debris, which if actually derived from membranes cannot account for extracellular neutral lipid. We therefore used a lipid-preserving ultrastructural method to obtain improved images of membranous debris. Maculas from 44 human donors (71-96 yr) were preserved < 7.5 hr after death. Blocks were post-fixed in 2% osmium or osmium-tannic acid-paraphenylenediamine (OTAP) to preserve neutral lipid for thin-section transmission electron microscopic (TEM) examination. Solid particles identified by OTAP were considered closest to the in vivo state of extracellular lipids. Micrographs were examined for intermediate forms, with greatest weight given to comparable images from different preparations of same or fellow eyes. Twenty eyes of older adults (12 with ARM including fellows treated with photodynamic and radiation therapies) had adequately preserved extracellular lipid. The exterior surface of membranous debris was thicker and more electron-dense than basal infoldings of retinal pigment epithelium (RPE) cells. By OTAP, individual membranous debris profiles were solid (diameters, 80200 nm) and formed tracks across or aggregations within basal laminar deposits. Solid particles and/or pools of neutral lipid were visible in BlinD and drusen. When processed to preserve lipid, membranous debris resembles neither membranes of surrounding cells nor vesicles possessing aqueous interiors but rather solid particles. These results are consistent with recent evidence implicating lipoprotein particles of intra-ocular origin as a potential source of neutral lipids, including esterified cholesterol, in the specific lesions of ARM. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, High Resolut Imaging Facil, Birmingham, AL 35294 USA.
   Retina Specialists N Alabama, Huntsville, AL 35801 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St, Birmingham, AL 35294 USA.
FU NEI NIH HHS [EY 06109] Funding Source: Medline
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   BAIRATI A, 1963, J ULTRA MOL STRUCT R, V9, P484, DOI 10.1016/S0022-5320(63)80080-5
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BOCAN TMA, 1986, AM J PATHOL, V123, P413
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   CasaroliMarano RP, 1996, J LIPID RES, V37, P1037
   CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   DOWHAN W, 2002, BIOCH LIPIDS LIPOPRO, P1
   ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, RETINA-J RET VIT DIS, V22, P818, DOI 10.1097/00006982-200212000-00027
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   GUYTON JR, 1991, J LIPID RES, V32, P953
   GUYTON JR, 1994, ARTERIOSCLER THROMB, V14, P1305, DOI 10.1161/01.ATV.14.8.1305
   Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   HAVEL RJ, 2001, METABOLIC MOL BASIS, P2707
   Hayat MA, 2000, PRINCIPLES AND TECHNIQUES OF ELECTRON MICROSCOPY: BIOLOGICAL APPLICATIONS, FOURTH EDITION, P1
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   HIGH O.B., 1984, LIPID HISTOCHEMISTRY
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   ISHIDA BY, 2003, J LIPID RES, V45, P22
   Ishii T, 2001, ATHEROSCLEROSIS, V158, P215, DOI 10.1016/S0021-9150(01)00416-6
   KATZ SS, 1981, J BIOL CHEM, V256, P2275
   KATZ SS, 1980, J BIOL CHEM, V255, P9753
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kruth H S, 1997, Subcell Biochem, V28, P319
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   LaDu MJ, 1998, J NEUROCHEM, V70, P2070
   Lambooij AC, 2001, GRAEF ARCH CLIN EXP, V239, P539, DOI 10.1007/s004170100314
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Malek G, 1999, INVEST OPHTH VIS SCI, V40, pS921
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NAKAIZUMI Y, 1964, ARCH OPHTHALMOL-CHIC, V72, P395, DOI 10.1001/archopht.1964.00970020395018
   Oorni K, 2000, J LIPID RES, V41, P1703
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   RUNGGERBRANDLE E, 1987, INVEST OPHTH VIS SCI, V28, P2026
   SARIG S, 1994, LAB INVEST, V71, P782
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103
   Smith E B, 1974, Adv Lipid Res, V12, P1
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Wong P, 2000, MOL VIS, V6, P184
NR 75
TC 120
Z9 123
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2005
VL 80
IS 6
BP 761
EP 775
DI 10.1016/j.exer.2004.09.017
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 940RM
UT WOS:000230161700003
PM 15939032
DA 2022-11-30
ER

PT J
AU Cho, EY
   Seddon, JM
   Rosner, B
   Willett, WC
   Hankinson, SE
AF Cho, EY
   Seddon, JM
   Rosner, B
   Willett, WC
   Hankinson, SE
TI Prospective study of intake of fruits, vegetables, vitamins, and
   carotenoids and risk of age-related maculopathy
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID 1ST NATIONAL-HEALTH; MACULAR DEGENERATION; DIETARY-FAT;
   CARDIOVASCULAR-DISEASE; PROSPECTIVE COHORT; ALPHA-TOCOPHEROL;
   BETA-CAROTENE; ANTIOXIDANT; SERUM; REPRODUCIBILITY
AB Objective: To examine the intake of antioxidant vitamins and carotenoids as well as fruits and vegetables in relation to the development of age-related maculopathy (ARM).
   Methods: We conducted a prospective follow-up study of women in the Nurses' Health Study and men in the Health Professionals Follow-up Study. We followed 77 562 women and 40 866 men who were at least 50 years of age and had no diagnosis of ARM or cancer at baseline for up to 18 years for women and up to 12 years for men. Fruit and vegetable intakes were assessed with a validated semi-quantitative food-frequency questionnaire up to 5 times for women and up to 3 times for men during follow-up.
   Results: A total of 464 (329 women and 135 men) incident cases of early ARM and 316 (217 women and 99 men) cases of neovascular ARM, all with visual loss of 20/30 or worse due primarily to ARM, were diagnosed during follow-up. Fruit intake was inversely associated with the risk of neovascular ARM. Participants who consumed 3 or more servings per day of fruits had a pooled multivariate relative risk of 0.64 (95% confidence interval, 0.44-0.93; P value for trend = .004) compared with those who consumed less than 1.5 servings per day. The results were similar in women and men. However, intakes of vegetables, antioxidant vitamins, or carotenoids were not strongly related to either early or neovascular ARM.
   Conclusion: These data suggest a protective role for fruit intake on the risk of neovascular ARM.
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Epidemiol Unit, Boston, MA USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Harvard
   T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan
   School of Public Health; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary
RP Cho, EY (通讯作者)，Harvard Univ, Sch Med, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM eunyoung.cho@channing.harvard.edu
FU NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY009611] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source:
   NIH RePORTER; NCI NIH HHS [CA55075, CA87969] Funding Source: Medline;
   NEI NIH HHS [EY09611] Funding Source: Medline; NHLBI NIH HHS [HL35464]
   Funding Source: Medline
CR ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792
   Bazzano LA, 2002, AM J CLIN NUTR, V76, P93
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho E, 1998, AGE RELATED MACULAR, P57
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   CHUNGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318
   Cox DavidRoxbee., 1984, ANAL SURVIVAL DATA, DOI [10.1201/9781315137438/analysis-survival-data-cox-oakes, DOI 10.1201/9781315137438/ANALYSIS-SURVIVAL-DATA-COX-OAKES]
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Joshipura KJ, 1999, JAMA-J AM MED ASSOC, V282, P1233, DOI 10.1001/jama.282.13.1233
   Joshipura KJ, 2001, ANN INTERN MED, V134, P1106, DOI 10.7326/0003-4819-134-12-200106190-00010
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Liu S, 2000, AM J CLIN NUTR, V72, P922
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   MARSHALL RJ, 1985, STAT MED, V4, P337, DOI 10.1002/sim.4780040313
   Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283
   RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
   Rosner B., 2000, FUNDAMENTALS BIOSTAT, V5th ed.
   SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SAS Institute, 1991, SAS STAT SOFTW PHREG
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Taylor HR, 2002, BRIT MED J, V325, P1
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Therneau TM., 1997, P 1 SEATTL S BIOST S, V123, P51
   TONUCCI LH, 1995, J AGR FOOD CHEM, V43, P579, DOI 10.1021/jf00051a005
   US Department of Agriculture, 1993, AGR HDB, V8, P1963
   Van Duyn MS, 2000, J AM DIET ASSOC, V100, P1511, DOI 10.1016/S0002-8223(00)00420-X
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
NR 59
TC 179
Z9 190
U1 0
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2004
VL 122
IS 6
BP 883
EP 892
DI 10.1001/archopht.122.6.883
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 828IS
UT WOS:000221967600010
PM 15197064
DA 2022-11-30
ER

PT J
AU Stevenson, MR
   Hart, PM
   Montgomery, AM
   McCulloch, DW
   Chakravarthy, U
AF Stevenson, MR
   Hart, PM
   Montgomery, AM
   McCulloch, DW
   Chakravarthy, U
TI Reduced vision in older adults with age related macular degeneration
   interferes with ability to care for self and impairs role as carer
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; QUALITY-OF-LIFE; VISUAL IMPAIRMENT; HEALTH; IMPACT;
   POPULATION; DISABILITY; COMMUNITY; SERVICES; DISEASE
AB Aim: To study the relation between visual impairment and ability to care for oneself or a dependant in older people with age related macular degeneration (AMD). Method: Cross sectional study of older people with visual impairment due to AMD in a specialised retinal service clinic. 199 subjects who underwent visual function assessment (fully corrected distance and near acuity and contrast sensitivity in both eyes), followed by completion of a package of questionnaires dealing with general health status (SF36), visual functioning (Daily Living Tasks Dependent on Vision, DLTV) and ability to care for self or provide care to others. The outcome measure was self reported ability to care for self and others. Three levels of self reported ability to care were identified-inability to care for self (level 1), ability to care for self but not others (level 2), and ability to care for self and others (level 3). Results: People who reported good general health status and visual functioning (that is, had high scores on SF36 and DLTV) were more likely to state that they were able to care for self and others. Similarly people with good vision in the better seeing eye were more likely to report ability to care for self and others. People with a distance visual acuity (DVA) worse than 0.4 logMAR (Snellen 6/15) had less than 50% probability of assigning themselves to care level 3 and those with DVA worse than 1.0 logMAR (Snellen 6/60) had a probability of greater than 50% or for assigning themselves to care level 1. Regression analyses with level of care as the dependent variable and demographic factors, DLTV subscales, and SF36 dimensions as the explanatory variables confirmed that the DLTV subscale 1 was the most important variable in the transition from care level 3 to care level 2. The regression analyses also confirmed that the DLTV subscale 2 was the most important in the transition from care level 3 to care level 1. Conclusions: Ability to care for self and dependants has a strong relation with self reported visual functioning and quality of life and is adversely influenced by visual impairment. The acuity at which the balance of probability shifts in the direction of diminished ability to care for self or others is lower than the level set by social care agencies for provision of support. These findings have implications for those involved with visual rehabilitation and for studies of the cost effectiveness of interventions in AMD.
C1 Queens Univ Belfast, Ctr Ophthalmol & Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
   Royal Grp Hosp, Belfast, Antrim, North Ireland.
   Univ Ulster, Dept Social Policy, Coleraine BT52 1SA, Londonderry, North Ireland.
C3 Queens University Belfast; Ulster University
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Ophthalmol & Vis Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
OI Chakravarthy, Usha/0000-0002-2606-3734
CR Cumming RG, 2000, J GERONTOL A-BIOL, V55, pM299, DOI 10.1093/gerona/55.5.M299
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Guralnik JM, 1999, J AM GERIATR SOC, V47, P1029, DOI 10.1111/j.1532-5415.1999.tb01301.x
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   HOROWITZ A, 1988, MONOGRAPH LIGHTHOUSE
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Jenkinson C, 1996, UK SF 36 ANAL INTERP
   JOHNSON RJ, 1993, J HEALTH SOC BEHAV, V34, P105, DOI 10.2307/2137238
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LIPSITZ LA, 1991, J GERONTOL, V46, pM114, DOI 10.1093/geronj/46.4.M114
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   MELSZER D, 1999, BRIT MED J, V318, P1108
   MONTGOMERY AM, UNPUB VALIDATION ASS
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   van der Pols JC, 2000, BRIT J OPHTHALMOL, V84, P165, DOI 10.1136/bjo.84.2.165
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   WHITMORE WG, 1989, OPHTHALMOLOGY, V96, P393, DOI 10.1016/S0161-6420(89)32880-6
   WORMALD RP, 1992, BRIT MED J, V304, P1266
NR 26
TC 44
Z9 44
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2004
VL 88
IS 9
BP 1125
EP 1130
DI 10.1136/bjo.2003.032383
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 846YN
UT WOS:000223355700007
PM 15317701
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Nicolo, M
   Ciucci, F
   Nardi, M
   Parolini, B
   Russo, A
   Scupola, A
   Torregrossa, S
   Vadala, M
AF Nicolo, Massimo
   Ciucci, Francesco
   Nardi, Marco
   Parolini, Barbara
   Russo, Andrea
   Scupola, Andrea
   Torregrossa, Salvatore
   Vadala, Maria
CA PERSEUS-IT Study Investigators
TI PERSEUS-IT 24-month analysis: a prospective observational study to
   assess the effectiveness of intravitreal aflibercept in routine clinical
   practice in Italy in patients with neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Intravitreal injections; Neovascular age-related macular
   degeneration; Observational study; Treatment outcomes
ID ENDOTHELIAL GROWTH-FACTOR; TREAT-AND-EXTEND; ANTI-VEGF; OUTCOMES;
   RANIBIZUMAB; MANAGEMENT; INJECTION; EFFICACY; THERAPY; REGIMEN
AB Purpose PERSEUS-IT (NCT02289924) was a prospective, observational, 2-year study evaluating the effectiveness and treatment patterns of intravitreal aflibercept (IVT-AFL) in patients with neovascular age-related macular degeneration (nAMD) in routine clinical practice in Italy.
   Methods Treatment-naive patients with nAMD receiving IVT-AFL per routine clinical practice were enrolled. The primary endpoint was mean change in visual acuity (VA; decimals) from baseline to month (M) 12 and M24. Outcomes were evaluated for the overall study population and independently for the 2 treatment cohorts: regular (3 initial monthly doses, >= 7 injections by M12, and >= 4 injections between M12 and M24) and irregular (any other pattern).
   Results Of 813 patients enrolled, 709 were included in the full analysis set (FAS); VA assessments were available for 342 patients at M12 (FAS1Y, 140 regular and 202 irregular) and 233 patients at M24 (FAS2Y, 37 regular and 196 irregular). In the overall FAS, the mean + SD change in VA from baseline to M12 and M24 was + 0.09 +/- 0.24 and + 0.02 +/- 0.25 decimals, and there was a statistically significant difference between the regular and irregular cohorts in both FAS1Y (p = 0.0034) and FAS2Y (p = 0.0222). Ocular treatment-emergent adverse events were reported in 4.1% (n = 33/810 [safety set]) of patients.
   Conclusion In PERSEUS-IT, clinically relevant functional and anatomic improvements were observed within the first 12 months of IVT-AFL treatment in routine clinical practice in Italy in patients with treatment-naive nAMD. These gains were generally maintained across the 2-year study. The safety profile of IVT-AFL was consistent with prior studies.
C1 [Nicolo, Massimo] Univ Genoa, Osped Policlin San Martino IRCCS, Clin Oculist DiNOGMI, Genoa, Italy.
   [Ciucci, Francesco] San Pietro Fatebenefratelli Hosp, Rome, Italy.
   [Nardi, Marco] Univ Pisa, Pisa, Italy.
   [Parolini, Barbara] Clin St Anna, Brescia, Italy.
   [Russo, Andrea] Univ Catania, Catania, Italy.
   [Scupola, Andrea] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy.
   [Torregrossa, Salvatore] Villa Sofia Cervello Hosp, Palermo, Italy.
   [Vadala, Maria] Univ Palermo, BIND Dept, Palermo, Italy.
C3 University of Genoa; University of Pisa; University of Catania; Catholic
   University of the Sacred Heart; IRCCS Policlinico Gemelli; University of
   Palermo
RP Nicolo, M (通讯作者)，Univ Genoa, Osped Policlin San Martino IRCCS, Clin Oculist DiNOGMI, Genoa, Italy.
EM massimonicolo@gmail.com
OI Nicolo, Massimo/0000-0002-7824-3091
FU Bayer S.p.A, Milan, Italy
FX The PERSEUS-IT study was funded by Bayer S.p.A, Milan, Italy. The study
   sponsor participated in the design of the study; analysis and
   interpretation of the data; preparation, review, and approval of the
   manuscript; and the decision to submit the manuscript for publication.
   Additionally, the study sponsor was responsible for the conduct of the
   study and oversight of the collection and management of data.
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Arrigo A, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/5516981
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Eter N, 2021, GRAEF ARCH CLIN EXP, V259, P2213, DOI 10.1007/s00417-021-05073-8
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kiernan DF, 2009, AM J OPHTHALMOL, V147, P267, DOI 10.1016/j.ajo.2008.08.018
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lovie-Kitchin JE, 2015, OPHTHAL PHYSL OPT, V35, P631, DOI 10.1111/opo.12252
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P1911, DOI 10.1097/IAE.0000000000003128
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P671, DOI 10.1097/IAE.0000000000003083
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scondotto G, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7582763
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Weber M, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000377
   Weber M, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01468-z
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2022
VL 260
IS 10
BP 3185
EP 3195
DI 10.1007/s00417-022-05679-6
EA MAY 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4O6EP
UT WOS:000791102500001
PM 35511286
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Rim, TH
   Kim, HK
   Kim, JW
   Lee, JS
   Kim, DW
   Kim, SS
AF Rim, Tyler Hyungtaek
   Kim, Hong Kyu
   Kim, Ji Won
   Lee, Jihei Sara
   Kim, Dong Wook
   Kim, Sung Soo
TI A Nationwide Cohort Study on the Association Between Past Physical
   Activity and Neovascular Age-Related Macular Degeneration in an East
   Asian Population
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID LONG-TERM INCIDENCE; RISK-FACTORS; SMOKING; EYE; PREVALENCE; DISEASE;
   MEN; METAANALYSIS; PROGRESSION
AB IMPORTANCE It has been suggested that physical activity (PA) is associated with reduced risk for early age-related macular degeneration (AMD). Systematic evaluation has been examining the association between lifestyle and neovascular AMD in an East Asian population, with a particular focus on past vigorous PA.
   OBJECTIVE To investigate the association between neovascular AMD and past PA, particularly a history of vigorous exercise, in the overall study population and among 2 a priori-defined subgroups.
   DESIGN, SETTING, AND PARTICIPANTS In this propensity score-matched cohort study, individuals between ages 45 and 79 years who were included in the South Korean National Health Insurance Service database from 2002 through 2013 were evaluated. Physical activity and incident neovascular AMD were recorded at baseline (2002-2003) and at follow-up (August 1, 2009, to December 31, 2013), respectively. Using a 1:1 propensity score-matched analysis, the incidence of neovascular AMD was compared using hazard ratios (HRs) for neovascular AMD between 105 980 participants who did and 105 980 who did not (no-PA) engage in vigorous PA. The data analysis was performed from April 19, 2017, to June 5, 2017.
   EXPOSURES Physical activity.
   MAIN OUTCOMES AND MEASURES Incident cases of neovascular AMD.
   RESULTS Of the 211 960 participants (92 036 [43.4%] women; mean [SD] age, 55.1 [7.8] years), neovascular AMD was detected at follow-up in 250 (0.24%) individuals who engaged in past vigorous PA and in 198 (0.19%) of those who did not (HR, 1.23; 95% CI, 1.02-1.49). In subgroup analysis, vigorous PA was associated with a greater HR for neovascular AMD in participants aged 45 to 64 years (HR, 1.30; 95% CI, 1.04-1.63) and in men (HR, 1.36; 95% CI, 1.09-1.69). In the high-PA (>= 5 times/wk: HR, 1.54; 95% CI, 1.15-2.06) and moderate-PA (1-4 times/wk: HR, 1.28; 95% CI, 1.01-1.63) groups, there was a greater incidence of neovascular AMD in the vigorous PA than in the no-PA group for men; no association was found for women.
   CONCLUSIONS AND RELEVANCE Self-reported past vigorous PA in men aged 45 to 64 years was associated with an increased risk for neovascular AMD. To our knowledge, no previous study has reported such an association; replication of the results would seem warranted to strengthen the likelihood of a cause and effect relationship.
C1 [Rim, Tyler Hyungtaek; Kim, Hong Kyu; Kim, Ji Won; Lee, Jihei Sara; Kim, Sung Soo] Yonsei Univ, Coll Med, Severance Hosp, Inst Vis Res,Dept Ophthalmol, 50 Yonsei Ro, Seoul 03722, South Korea.
   [Kim, Dong Wook] Natl Hlth Insurance Serv, Ilsan Hosp, Dept Policy Res Affairs, Goyang, Gyeonggi Do, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Coll Med, Yonsei Healthcare Big Data Based Knowledge Integr, Seoul, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Coll Med, Inst Convergence Sci, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; National Health
   Insurance Service; NHIS Ilsan Hospital; Yonsei University; Yonsei
   University Health System; Yonsei University; Yonsei University Health
   System
RP Kim, SS (通讯作者)，Yonsei Univ, Coll Med, Severance Hosp, Inst Vis Res,Dept Ophthalmol, 50 Yonsei Ro, Seoul 03722, South Korea.
EM semekim@yuhs.ac
OI Kim, Sung Soo/0000-0002-0574-7993; Lee, Jihei Sara/0000-0002-1585-168X
FU Yonsei University College of Medicine [6-2017-0089]
FX This study was supported by faculty research grant 6-2017-0089 of Yonsei
   University College of Medicine for 2017.
CR Armstrong MEG, 2015, CIRCULATION, V131, P721, DOI 10.1161/CIRCULATIONAHA.114.010296
   Chun MY, 2012, KOREAN J FAM MED, V33, P144, DOI 10.4082/kjfm.2012.33.3.144
   Colijn JM, OPHTHALMOLOGY
   Desai M, 2014, CURR CARDIOL REP, V16, DOI 10.1007/s11886-014-0531-2
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Gopinath B, 2014, INVEST OPHTH VIS SCI, V55, P7799, DOI 10.1167/iovs.14-15575
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P229, DOI 10.1080/09286586.2016.1276934
   McGuinness MB, 2016, BRIT J OPHTHALMOL, V100, P1353, DOI 10.1136/bjophthalmol-2015-307663
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Nguyen AM, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0062-8
   PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804
   Park SJ, 2015, OPHTHALMOLOGY, V122
   POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706
   Rahman I, 2015, JACC-HEART FAIL, V3, P681, DOI 10.1016/j.jchf.2015.05.006
   Rim TH, 2017, BRIT J OPHTHALMOL, V101, P1367, DOI 10.1136/bjophthalmol-2016-309952
   Rim TH, 2016, RETINA-J RET VIT DIS, V36, P2166, DOI 10.1097/IAE.0000000000001084
   Rim TH, 2015, BRIT J OPHTHALMOL, V99, P493, DOI 10.1136/bjophthalmol-2014-305525
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seong SC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016640
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 31
TC 11
Z9 11
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB
PY 2018
VL 136
IS 2
BP 132
EP 139
DI 10.1001/jamaophthalmol.2017.5682
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FV6OF
UT WOS:000424700200006
PM 29242918
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Gangnon, RE
   Lee, KE
   Klein, BEK
   Iyengar, SK
   Sivakumaran, TA
   Klein, R
AF Gangnon, Ronald E.
   Lee, Kristine E.
   Klein, Barbara E. K.
   Iyengar, Sudha K.
   Sivakumaran, Theru A.
   Klein, Ronald
TI Effect of the Y402H Variant in the Complement Factor H Gene on the
   Incidence and Progression of Age-Related Macular Degeneration Results
   From Multistate Models Applied to the Beaver Dam Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID 5-YEAR INCIDENCE; VISUAL-ACUITY; 10-YEAR INCIDENCE; FOLLOW-UP;
   MACULOPATHY; DISEASE; RISK; MORTALITY; POPULATION; DRUSEN
AB Objectives: To investigate the effect of age, sex, and the Y402H variant in the complement factor H (CFH) gene on the incidence, progression, and regression of age-related macular degeneration (AMD) as well as the effect of these factors and AMD on mortality, using multistate models.
   Methods: Analyses included 4379 persons aged 43 to 84 years at the time of the census. The status of AMD on a 5-level severity scale was graded from retinal photographs taken at up to 5 study visits between 1988 and 2010. Multistate models in continuous time were used to model the effects of age, sex, and CFH genotype on the incidence, progression, and regression of AMD and mortality.
   Results: The CFH Y402H genotype CC was associated, relative to genotype TT (reported as hazard ratio; 95% CI), with increased incidence of AMD (no to minimally severe early AMD, 1.98; 1.57-2.49), progression of AMD (minimally severe early to moderately severe early AMD, 1.73; 1.29-2.33; moderately severe early to severe early AMD, 1.30; 0.86-1.94; and severe early to late AMD, 1.72; 1.01-2.91) but not with regression of AMD or mortality. Late AMD was associated with increased mortality (1.37; 1.15-1.62) relative to no AMD, but earlier stages of AMD were not.
   Conclusions: Using the multistate models, we show that the Y402H risk variant is associated with lifetime incidence of early AMD and progression of early to late AMD and that late AMD is associated with mortality risk.
C1 [Lee, Kristine E.; Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; Cincinnati Children's Hospital Medical
   Center
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Gangnon, Ronald/0000-0003-2587-6714; Klein,
   Ronald/0000-0002-4428-6237
FU National Institutes of Health [EY06594]; Research to Prevent Blindness;
   NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH RePORTER
FX The National Institutes of Health grant EY06594 (Drs R. Klein and B. E.
   K. Klein) provided funding for the entire study, including collection
   and analyses of data; further support for data analyses was provided by
   Research to Prevent Blindness Senior Scientific Investigator Awards (Drs
   R. Klein and B. E. K. Klein).
CR Andersen PK, 2002, STAT METHODS MED RES, V11, P91, DOI 10.1191/0962280202SM276ra
   Andersen PK., 2012, STAT MODELS BASED CO
   [Anonymous], [No title captured]
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Commenges D, 2002, STAT METHODS MED RES, V11, P167, DOI 10.1191/0962280202sm279ra
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Efron B., 1994, INTRO BOOTSTRAP
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GENTLEMAN RC, 1994, STAT MED, V13, P805, DOI 10.1002/sim.4780130803
   GRUGER J, 1991, BIOMETRICS, V47, P595, DOI 10.2307/2532149
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1995, BEAVER DAM EYE STUDY
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Lawless J. F., 2002, STAT MODELS METHODS, V2nd, DOI DOI 10.1002/9781118033005
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   MARSHALL G, 1995, STAT MED, V14, P1975, DOI 10.1002/sim.4780141804
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   R Development Core Team, 2020, R VERS 4 0 3 LANG EN
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   THERNEAU TM, 2000, STAT BIOL HEALTH, pR7
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wong D, 2011, GRAEF ARCH CLIN EXP, V249, P161, DOI 10.1007/s00417-010-1574-8
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
NR 51
TC 31
Z9 31
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2012
VL 130
IS 9
BP 1169
EP 1176
DI 10.1001/archophthalmol.2012.693
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 002TQ
UT WOS:000308559200008
PM 22965593
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Dunbar, HMP
   Behning, C
   Abdirahman, A
   Higgins, BE
   Binns, AM
   Terheyden, JH
   Zakaria, N
   Poor, S
   Finger, RP
   Leal, S
   Holz, FG
   Schmid, M
   Crabb, DP
   Rubin, GS
   Luhmann, UFO
AF Dunbar, Hannah M. P.
   Behning, Charlotte
   Abdirahman, Amina
   Higgins, Bethany E.
   Binns, Alison M.
   Terheyden, Jan H.
   Zakaria, Nadia
   Poor, Stephen
   Finger, Robert P.
   Leal, Sergio
   Holz, Frank G.
   Schmid, Matthias
   Crabb, David P.
   Rubin, Gary S.
   Luhmann, Ulrich F. O.
TI Repeatability and Discriminatory Power of Chart-Based Visual Function
   Tests in Individuals With Age-Related Macular Degeneration A MACUSTAR
   Study Report
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID TEST-RETEST VARIABILITY; INTERSESSION REPEATABILITY; READING
   PERFORMANCE; ACUITY LOSS; RELIABILITY; ATROPHY; DESIGN; RANIBIZUMAB;
   PROGRESSION; BURDEN
AB IMPORTANCE There is a need for validated clinical end points that are reliably able to quantify potential therapeutic effects of future treatments targeting age-related macular degeneration (AMD) before the onset of serious visual impairment.
   OBJECTIVE To assess the reliability and discriminatory power of 5 simple chart-based visual function (VF) tests as potential measures for clinical trial end points with regulatory and patient-access intention in intermediate AMD (iAMD).
   DESIGN, SETTING, AND PARTICIPANTS This international noninterventional study took place at 18 tertiary ophthalmology departments across Europe. Participants were recruited between April 2018 and March 2020 and were identified during routine clinical review. Participants with no AMD and early AMD were recruited from hospital staff, friends, and family of participants with AMD and via referrals from community ophthalmologists and optometrists. The repeatability and discriminatory power of 5 simple chart-based assessments of VF (best-corrected visual acuity [BCVA], low-luminance visual acuity [LLVA], Moorfields Acuity Test [MAT], Pelli-Robson Contrast Sensitivity [CS], and International Reading Speed Test [IReST]) were assessed in a repeated-measures design. VF assessments were performed on day 0 and day 14. Participants with early AMD, iAMD, late AMD, and no AMD were recruited.
   MAIN OUTCOMES AND MEASURES Intraclass correlation coefficients (ICCs) and Bland-Altman 95% limits of agreement (LoA) were computed to assess repeatability. Area under the receiver operating characteristic curves (AUCs) determined the discriminatory ability of all measures to classify individuals as having no AMD or iAMD and to differentiate iAMD from its neighboring disease states.
   RESULTS A total of 301 participants (mean [SD] age, 71 [7] years; 187 female participants [62.1%]) were included in the study. Thirty-four participants (11.3%) had early AMD, 168 (55.8%) had iAMD, 43 (14.3%) had late AMD, and 56 (18.6%) had no AMD. ICCs for all VF measures ranged between 0.88 and 0.96 when all participants were considered, indicating good to excellent repeatability. All measures displayed excellent discrimination between iAMD and late AMD (AUC, 0.92-0.99). Early AMD was indistinguishable from iAMD on all measures (AUC, 0.54-0.64). CS afforded the best discrimination between no AMD and iAMD (AUC, 0.77). Under the same conditions, BCVA, LLVA, and MAT were fair discriminators (AUC, 0.69-0.71), and IReST had poor discrimination (AUC, 0.57 0.61).
   CONCLUSIONS AND RELEVANCE BCVA, LLVA, MAT, CS, and IReST had adequate repeatability in this multicenter, multiexaminer setting but limited power to discriminate between no AMD and iAMD. The prognostic power of these variables to predict conversion from iAMD to late AMD is being examined in the ongoing longitudinal part of the MACUSTAR study.
C1 [Dunbar, Hannah M. P.; Abdirahman, Amina; Rubin, Gary S.] UCL, Inst Ophthalmol, Dept Visual Neurosci & Funct, 11-43 Bath St, London EC1V 9EL, England.
   [Dunbar, Hannah M. P.; Rubin, Gary S.] Natl Hlth Serv Fdn Trust, Moorfields Eye Hosp, London, England.
   [Behning, Charlotte; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Fac Med, Bonn, Germany.
   [Higgins, Bethany E.; Binns, Alison M.; Crabb, David P.] City Univ London, Dept Optometry & Visual Sci, Sch Hlth Sci, London, England.
   [Terheyden, Jan H.; Finger, Robert P.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Zakaria, Nadia] Novartis Inst Biomed Res, Translat Med, Cambridge, MA USA.
   [Poor, Stephen] Novartis Inst Biomed Res, Ophthalmol Res, Cambridge, MA USA.
   [Leal, Sergio] Bayer AG, Berlin, Germany.
   [Luhmann, Ulrich F. O.] Roche Innovat Ctr Basel, Roche Pharmaceut Res & Early Dev, Translat Med Ophthalmol, Basel, Switzerland.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of Bonn; City University London; University of Bonn;
   Novartis; Novartis; Bayer AG; Roche Holding
RP Dunbar, HMP (通讯作者)，UCL, Inst Ophthalmol, Dept Visual Neurosci & Funct, 11-43 Bath St, London EC1V 9EL, England.
EM h.dunbar@ucl.ac.uk
OI Tufail, Adnan/0000-0001-6131-7640
FU Innovative Medicines Initiative 2 Joint Undertaking [116076]; European
   Union Horizon 2020 Research and Innovation Programme; European
   Federation of Pharmaceutical Industries and Associations
FX This project has received funding from the Innovative Medicines
   Initiative 2 Joint Undertaking under grant agreement 116076. This joint
   undertaking receives support from the European Union Horizon 2020
   Research and Innovation Programme and European Federation of
   Pharmaceutical Industries and Associations.
CR ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Aslam T, 2014, GRAEF ARCH CLIN EXP, V252, P201, DOI 10.1007/s00417-013-2421-5
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Curcio CA, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01467-0
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   ELLIOTT DB, 1988, OPHTHAL PHYSL OPT, V8, P397, DOI 10.1111/j.1475-1313.1988.tb01176.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   GARNAUT R, 1992, ECONOMIC REFORM AND INTERNATIONALISATION: CHINA AND THE PACIFIC REGION, P1
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Haegerstrom-Portnoy G, 2000, OPTOMETRY VISION SCI, V77, P653, DOI 10.1097/00006324-200012000-00012
   Hahn GA, 2006, BRIT J OPHTHALMOL, V90, P480, DOI 10.1136/bjo.2005.087379
   Hsu ST, 2019, OPHTHALMOL RETINA, V3, P637, DOI 10.1016/j.oret.2019.03.010
   Iftikhar M, 2019, CLIN EXP OPHTHALMOL, V47, P605, DOI 10.1111/ceo.13458
   Kiser AK, 2005, OPTOMETRY VISION SCI, V82, P946, DOI 10.1097/01.opx.0000187863.12609.7b
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Lesmes Luis Andres, 2013, Drug Discov Today Ther Strateg, V10, pe43, DOI 10.1016/j.ddstr.2012.11.002
   Lin RJ, 2015, OPTOMETRY VISION SCI, V92, P559, DOI 10.1097/OPX.0000000000000584
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Meinert CL., 2012, CLIN TRIALS DESIGN C, V39
   Ou WC, 2021, AM J OPHTHALMOL, V226, P148, DOI 10.1016/j.ajo.2021.01.017
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P2621, DOI 10.1167/iovs.08-2407
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pondorfer SG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231748
   Pondorfer SG, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.55
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosser DA, 2004, INVEST OPHTH VIS SCI, V45, P1076, DOI 10.1167/iovs.03-1320
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SaSSmannshausen Marlene, 2022, Transl Vis Sci Technol, V11, P27, DOI 10.1167/tvst.11.3.27
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Shah N, 2014, INVEST OPHTH VIS SCI, V55, P1386, DOI 10.1167/iovs.13-13340
   Strauss RW, 2016, OPHTHALMOLOGY, V123, P817, DOI 10.1016/j.ophtha.2015.12.009
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Terheyden JH, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04595-6
   Terheyden JH, 2021, BMC MED RES METHODOL, V21, DOI 10.1186/s12874-021-01243-8
   Trauzettel-Klosinski S, 2012, INVEST OPHTH VIS SCI, V53, P5452, DOI 10.1167/iovs.11-8284
   Wood LJ, 2021, OPHTHAL PHYSL OPT, V41, P213, DOI 10.1111/opo.12775
   Woods RL., 1995, VISION SCI ITS APPL, P246
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yang YS, 2021, OPHTHALMOLOGICA, V244, P418, DOI 10.1159/000515148
NR 47
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2022
VL 140
IS 8
BP 780
EP 789
DI 10.1001/jamaophthalmol.2022.2113
EA JUN 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3Y5TL
UT WOS:000815252500001
PM 35737401
OA hybrid, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Reeves, BC
   Scott, LJ
   Taylor, J
   Hogg, R
   Rogers, CA
   Wordsworth, S
   Townsend, D
   Muldrew, A
   Peto, T
   Violato, M
   Dakin, H
   Cappel-Porter, H
   Mills, N
   O'Reilly, D
   Harding, SP
   Chakravarthy, U
AF Reeves, Barnaby C.
   Scott, Lauren J.
   Taylor, Jodi
   Hogg, Ruth
   Rogers, Chris A.
   Wordsworth, Sarah
   Townsend, Daisy
   Muldrew, Alyson
   Peto, Tunde
   Violato, Mara
   Dakin, Helen
   Cappel-Porter, Heike
   Mills, Nicola
   O'Reilly, Dermot
   Harding, Simon P.
   Chakravarthy, Usha
TI The Effectiveness, cost-effectiveness and acceptability of Community
   versus Hospital Eye Service follow-up for patients with neovascular
   age-related macular degeneration with quiescent disease (ECHoES): a
   virtual randomised balanced incomplete block triald
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Article
ID SHARED CARE GLAUCOMA; OPTOMETRISTS; RANIBIZUMAB; OPHTHALMOLOGISTS;
   PREVALENCE; QUALITY
AB Background: Patients with neovascular age-related macular degeneration (nAMD) usually attend regular reviews, even when the disease is quiescent. Reviews are burdensome to health services, patients and carers.
   Objectives: To compare the proportion of correct lesion classifications made by community-based optometrists and ophthalmologists from vignettes of patients; to estimate the cost-effectiveness of community follow-up by optometrists compared with follow-up by ophthalmologists in the Hospital Eye Service (HES); to ascertain views of patients, their representatives, optometrists, ophthalmologists and clinical commissioners on the proposed shared care model.
   Design: Community-based optometrists and ophthalmologists in the HES classified lesions from vignettes comprising clinical information, colour fundus photographs and optical coherence tomography images. Participants' classifications werevalidated against experts' classifications (reference standard).
   Setting: Internet-based application.
   Participants: Ophthalmologists had to have >= 3 years post-registration experience in ophthalmology, have passed part 1 of the Royal College of Ophthalmologists, Diploma in Ophthalmology or equivalent examination, and have experience in the age-related macular degeneration service. Optometrists had to be fully qualified, be registered with the General Optical Council for >= 3 years and not be participating in nAMD shared care.
   Interventions: The trial sought to emulate a conventional trial in comparing optometrists' and ophthalmologists' decision-making, but vignettes, not patients, were assessed; therefore, there were no interventions. Participants received training prior to assessing vignettes.
   Main outcome measures: Primary outcome-correct classification of the activity status of a lesion based on a vignette, compared with a reference standard. Secondary outcomes-frequencies of potentially sight-threatening errors, participants' judgements about specific lesion components, participant-rated confidence in their decisions and cost-effectiveness of follow-up by community-based optometrists compared with HES ophthalmologists.
   Results: In total, 155 participants registered for the trial; 96 (48 in each professional group) completed training and main assessments and formed the analysis population. Optometrists and ophthalmologists achieved 1702 out of 2016 (84.4%) and 1722 out of 2016 (85.4%) correct classifications, respectively [odds ratio (OR) 0.91, 95% confidence interval (CI) 0.66 to 1.25; p = 0.543]. Optometrists' decision-making was non-inferior to ophthalmologists' with respect to the pre-specified limit of 10% absolute difference (0.298 on the odds scale). Frequencies of sight-threatening errors were similar for optometrists and ophthalmologists [57/994 (5.7%) vs. 62/994 (6.2%), OR 0.93, 95% CI 0.55 to 1.57; p = 0.789]. Ophthalmologists assessed lesion components as present less often than optometrists and were more confident about their lesion classifications than optometrists. The mean care-pathway cost for assessment was very similar by group, namely 397.33 pound for ophthalmologists and 410.78 pound for optometrists. The optometrist-led monitoring reviews were slightly more costly and less effective than ophthalmologist-led reviews, although the differences were extremely small. There was consensus that optometrist-led monitoring has the potential to reduce clinical workload and be more patient-centred. However, potential barriers are ophthalmologists' perceptions of optometrists' competence, the need for clinical training, the ability of the professions to work collaboratively and the financial feasibility of shared care for Clinical Commissioning Groups.
   Conclusions: The ability of optometrists to make nAMD retreatment decisions from vignettes is non-inferior to that of ophthalmologists. Various barriers to implementing shared cared for nAMD were identified.
C1 [Reeves, Barnaby C.; Scott, Lauren J.; Taylor, Jodi; Rogers, Chris A.; Cappel-Porter, Heike] Univ Bristol, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol, Avon, England.
   [Hogg, Ruth; Muldrew, Alyson; Chakravarthy, Usha] Queens Univ Belfast, Ctr Med Expt, Inst Clin Sci, Belfast, Antrim, North Ireland.
   [Wordsworth, Sarah; Violato, Mara; Dakin, Helen] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.
   [Townsend, Daisy; Mills, Nicola] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England.
   [Peto, Tunde] UCL Inst Ophthalmol, London, England.
   [Violato, Mara] Univ Oxford, Natl Inst Hlth Res, Hlth Protect Res Unit Gastrointestinal Infect, Oxford, England.
   [O'Reilly, Dermot] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [Harding, Simon P.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
C3 University of Bristol; Queens University Belfast; University of Oxford;
   University of Bristol; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; University of Oxford; Queens University
   Belfast; University of Liverpool
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Med Expt, Inst Clin Sci, Belfast, Antrim, North Ireland.
RI Peto, Tunde/G-8812-2018; Hogg, Ruth E./ABC-9602-2020
OI Peto, Tunde/0000-0001-6265-0381; Hogg, Ruth E./0000-0001-9413-2669;
   Mills, Nicola/0000-0002-2960-2940; Elliott, Daisy/0000-0001-8143-9549;
   Chakravarthy, Usha/0000-0002-2606-3734; Reeves,
   Barnaby/0000-0002-5101-9487; Cappel-Porter, Heike/0000-0001-6320-4834
FU National Institute for Health Research (NIHR) Health Technology
   Assessment programme; ESRC [ES/L007509/1] Funding Source: UKRI; MRC
   [MR/K025643/1] Funding Source: UKRI
FX This project was funded by the National Institute for Health Research
   (NIHR) Health Technology Assessment programme and will be published in
   full in Health Technology Assessment; Vol. 20, No. 80. See the NIHR
   Journals Library website for further project information.
CR Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Banes MJ, 2006, BRIT J OPHTHALMOL, V90, P579, DOI 10.1136/bjo.2005.082388
   Bhargava JS, 2008, BRIT J OPHTHALMOL, V92, P1601, DOI 10.1136/bjo.2008.140483
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burton AE, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003306
   Cameron JR, 2009, EYE, V23, P1134, DOI 10.1038/eye.2008.196
   Chakravarthy U, 2015, HLTH TECHNOL ASSESS, V19
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cochran W. G., 1992, EXPT DESIGNS, P611
   Collett JL, 2011, SOC SCI RES, V40, P513, DOI 10.1016/j.ssresearch.2010.08.008
   Curtis L, 2013, UNIT COSTS HLTH SOCI
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Donaldson C, 2010, QJM-INT J MED, V103, P801, DOI 10.1093/qjmed/hcq086
   Drummond MF, 2005, METHODS EC EVALUATIO
   FLEISS JL, 1981, APPL PSYCH MEAS, V5, P105, DOI 10.1177/014662168100500115
   Gray SF, 1997, J PUBLIC HEALTH MED, V19, P431, DOI 10.1093/oxfordjournals.pubmed.a024673
   Gray SF, 2000, BRIT J OPHTHALMOL, V84, P456, DOI 10.1136/bjo.84.5.456
   Gulliford MC, 2010, DIABETIC MED, V27, P282, DOI 10.1111/j.1464-5491.2010.02946.x
   Hau S, 2007, BRIT J OPHTHALMOL, V91, P437, DOI 10.1136/bjo.2006.105593
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holtzer-Goor KM, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-14
   Husereau D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-80
   Joint Formulary Committee, BRIT NATL FORMULARY
   Kanski J.J., 2011, CLIN OPHTHALMOLOGY S, V7th
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Konstantakopoulou E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004781
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   Myint J, 2010, OPHTHAL PHYSL OPT, V30, P847, DOI 10.1111/j.1475-1313.2010.00792.x
   National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR
   National Institute for Health and Care Excellence (NICE), TA294 NICE
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE
   National Institute for Health Research, 2013, ECHOES TRIAL PROT
   O'Connor PM, 2012, MED J AUSTRALIA, V196, P646, DOI 10.5694/mja11.10856
   Office of National Statistics, POP ENGL AG 50 YEARS
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Patton MichaelP, 2002, QUALITATIVE RES EVAL
   Petrou S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1548
   Rahi JS, 2008, BRIT J OPHTHALMOL, V92, P1190, DOI 10.1136/bjo.2007.133454
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Strauss A, 1994, LINCOLN HDB QUALITAT, P237
   Taylor J, 2015, EYE LOND
   Violato M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011121
   WILLIG CARLA, 2008, INTRODUCING QUALITAT
   Wilson J., 1998, J INTERPROF CARE, V12, P79, DOI [https://doi.org/10.3109/13561829809014090, DOI 10.3109/13561829809014090]
NR 49
TC 4
Z9 4
U1 0
U2 7
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD OCT
PY 2016
VL 20
IS 80
BP 1
EP +
DI 10.3310/hta20800
PG 121
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA EC5SF
UT WOS:000388195800001
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Stepanov, A
   Nemcansky, J
   Veith, M
   Manethova, K
   Stredova, M
   Pencak, M
   Tarkova, A
   Studnicka, J
AF Stepanov, Alexandr
   Nemcansky, Jan
   Veith, Miroslav
   Manethova, Katerina
   Stredova, Marketa
   Pencak, Martin
   Tarkova, Anna
   Studnicka, Jan
TI Two-year results of a combined regimen of aflibercept treatment in three
   types of choroidal neovascular membrane in the wet form of age-related
   macular degeneration: Real-life evidence in the Czech Republic
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF therapy; aflibercept; neovascular age-related macular
   degeneration; real-life practice; CNV
ID GROWTH-FACTOR THERAPY; RANIBIZUMAB
AB Aim: To present the results of a 2-year therapy with aflibercept in real-life practice in a mixed regimen in patients with a neovascular form of age-related macular degeneration (nAMD) and to evaluate the treatment response of various types of choroidal neovascular membranes (CNV) - occult (Type 1), classic (Type 2) and minimally classic (Type 4). Methods: This was a multicentric, prospective, observational study of a series of cases. Patients diagnosed with the wet form of AMD were treated in a fixed regimen (3 injections at intervals of 1 month and then injections at 8-week intervals) in the first year, and in a pro re nata regimen (PRN) in the second year. The period of investigation was 24 months. The development of the best corrected visual acuity (BCVA) was evaluated by means of ETDRS optotypes (Early Treatment Diabetic Retinopathy Study) and the central retinal thickness (CRT). Measurements were performed prior to the commencement of therapy and then after 4, 8, 12, 16, 20 and 24 months. Results: The therapeutically naive group consisted of 135 eyes of 135 patients. Sixty-one eyes suffered from CNV of the 1st type, 50 eyes from CNV of the 2nd type and 24 eyes from CNV of the 4th type. The average baseline of BCVA +/- SD in Type 1 CNV was 56.1 +/- 10.8 letters of ETDRS, and then, respectively, 62.2 +/- 12.9 letters, 62.8 +/- 15.1 letters and 59.4 +/- 13.2 letters after 4, 12 and 24 months. The average baseline value of CRT +/- SD for Type 1 CNV was 442.4 +/- 194.9 mu m, and then 302.5 +/- 144.4 mu m, 277.7 +/- 106.5 mu m and 327.6 +/- 138.6 mu m at months 4, 12 and 24. The average baseline value of BCVA +/- SD in Type 2 CNV was 55.6 +/- 9.9 letters of ETDRS, and then 62.5 +/- 11.1 letters, 62.5 +/- 14.2 letters and 60.6 +/- 15.1 letters after 4, 12 and 24 months. The average baseline value of CRT +/- SD in Type 2 CNV was 446.8 +/- 159.1 mu m, and then 327.4 +/- 127.0 mu m, 316.7 +/- 139.1 mu m and 352.5 +/- 132.4 mu m at 4, 12 and 24 months. In Type 4 CNV, the average baseline value of BCVA +/- SD was 56.7 +/- 9.0 letters of ETDRS, and then 59.1 +/- 10.6 letters, 59.2 +/- 12.6 letters and 58 +/- 8.8 letters after 4, 12 and 24 months. The average baseline value of CRT +/- SD in Type 4 CNV was 492.1 +/- 187.0 mu m, and then 333.3 +/- 137.5 mu m, 326.7 +/- 122.4 mu m and 328.4 +/- 132 mu m at months 4, 12 and 24. All these changes were statistically significant (p < 0.05). Conclusion: Therapy with aflibercept in a mixed regimen in patients with the wet form of AMD during the investigation resulted in a statistically significant improvement in BCVA and decrease in CRT in both the occult and classic type of CNV. Both the functional and anatomical response to therapy was worse in the minimally classic type (Type 4) of CNV. Summary declaration: Patients suffering from the neovascular form of age-related macular degeneration were treated with aflibercept in a mixed regimen (fixed in the first year and PRN in the second year). After 24 months of examination, a significant improvement of both morphological and functional results was observed in three types of choroidal neovascular membrane.
C1 [Stepanov, Alexandr; Stredova, Marketa; Tarkova, Anna; Studnicka, Jan] Fac Hosp Hradec Kralove, Dept Ophthalmol, Sokolska 581, Hradec Kralove 50005, Czech Republic.
   [Stepanov, Alexandr; Stredova, Marketa; Tarkova, Anna; Studnicka, Jan] Charles Univ Prague, Fac Med Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic.
   [Nemcansky, Jan] Fac Hosp Ostrava, Dept Ophthalmol, Ostrava, Czech Republic.
   [Nemcansky, Jan] Univ Ostrava, Fac Med, Ostrava, Czech Republic.
   [Veith, Miroslav; Pencak, Martin] Fac Hosp Kralovske Vinohrady, Dept Ophthalmol, Prague, Czech Republic.
   [Veith, Miroslav; Pencak, Martin] Charles Univ Prague, Fac Med 3, Prague, Czech Republic.
   [Manethova, Katerina] Thomayer Hosp, Dept Ophthalmol, Prague, Czech Republic.
C3 University Hospital Hradec Kralove; Charles University Prague;
   University of Ostrava; University Hospital Vinohrady; Charles University
   Prague; Thomayer Hospital
RP Stepanov, A (通讯作者)，Fac Hosp Hradec Kralove, Dept Ophthalmol, Sokolska 581, Hradec Kralove 50005, Czech Republic.; Stepanov, A (通讯作者)，Charles Univ Prague, Fac Med Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic.
EM stepanov.doctor@gmail.com
RI Nemcansky, Jan/AAC-6619-2019; Stepanov, Alexandr/N-9961-2017; Studnička,
   Jan/AAC-4127-2022; Tarkova, Anna/B-2911-2019
OI Nemcansky, Jan/0000-0003-1979-6419; Stepanov,
   Alexandr/0000-0002-8462-8756; Tarkova, Anna/0000-0002-0934-5094
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Krebs I, 2011, INVEST OPHTH VIS SCI, V52, P6925, DOI 10.1167/iovs.10-6612
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nemcansky J, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/2635689
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
NR 19
TC 2
Z9 3
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2021
VL 31
IS 5
BP 2488
EP 2495
AR 1120672120971190
DI 10.1177/1120672120971190
EA NOV 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XG9FP
UT WOS:000678263300001
PM 33198503
DA 2022-11-30
ER

PT J
AU Wei, QQ
   Liu, JL
   Liu, QY
   Ren, CD
   Cai, WT
   Liang, XW
   Wen, J
   Yu, J
AF Wei, Qingquan
   Liu, Junling
   Liu, Qingyu
   Ren, Chengda
   Cai, Wenting
   Liang, Xiuwei
   Wen, Jing
   Yu, Jing
TI Combination of bevacizumab and photodynamic therapy vs. bevacizumab
   monotherapy for the treatment of wet age-related macular degeneration: A
   meta-analysis of randomized controlled trials
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE meta-analysis; bevacizumab; photodynamic therapy; age-related macular
   degeneration; treatment
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF ENDOPHTHALMITIS; INTRAVITREAL
   BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; COST-EFFECTIVENESS;
   CLINICAL-TRIALS; RANIBIZUMAB; VERTEPORFIN; INJECTIONS; REGIMEN
AB The purpose of this meta-analysis was to compare the efficacy and safety of the combination of bevacizumab and photodynamic therapy (PDT) with bevacizumab monotherapy for the treatment of age-related macular degeneration (AMD). Patients with active choroidal neovascularization (CNV) secondary to AMD were included in the present study. The treatment group included patients treated with a combination of bevacizumab and PDT and patients treated with bevacizumab monotherapy. Only randomized controlled trials (RCTs) were included in the analysis. The PubMed, EMBASE and Cochrane Central Register of Controlled Trials databases were searched. Meta-analysis was performed using RevMan v.5.3 software, and best-corrected visual acuity (BCVA), central retinal thickness (CRT) and the average number of bevacizumab retreatments were assessed. A total of 5 RCTs were included in the analysis. There were no significant differences observed in the mean BCVA change between the combination treatment group and the bcvacizumab monotherapy group [standard mean difference 0.20; 95% confidence interval (CI) -0.53, 0.93, P=0.59]. There were also no significant differences in the CRT increases between the two groups [weighted mean difference (WMD) -22.16, 95% CI -52.01 to 7.69, P=0.15]. No significant differences were observed in the proportions of patients gaining >15 letters between the two groups frisk ratio (RR) 0.86, 95% CI 0.64, 1.15, P=0.30]. However, the average number of the ranibizumab retreatments was significantly lower in the combination treatment group compared with the bevacizumab monotherapy group (WMD, -2.70, 95% CI -3.93 to -1.46; P<0.0001). Additionally, there were no significant differences in the rate of ocular adverse events (RR, 0.57; 95% CI, 0.27 to 1.22; P=0.15) and systemic adverse events (RR, 5.42; 95% CI, 0.29 to 101.77; P=0.26) between the two groups. In conclusion there were no significant differences in mean BCVA change, CRT increases, the proportions of patients gaining >15 letters, or the incidences of ocular adverse events and systemic adverse events. However, combination treatment may significantly reduce the average number of bevacizumab retreatments compared with monotherapy.
C1 [Wei, Qingquan; Liu, Junling; Liu, Qingyu; Ren, Chengda; Cai, Wenting; Liang, Xiuwei; Yu, Jing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
   [Wen, Jing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Educ, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
   [Yu, Jing] Ninghai First Hosp, Dept Ophthalmol, Ninghai 315600, Zhejiang, Peoples R China.
C3 Tongji University; Tongji University
RP Yu, J (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.; Wen, J (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Educ, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
EM 13764341057@163.com; dryujing@aliyun.com
OI Cai, Wenting/0000-0002-2880-302X
FU National Natural Science Foundation of China [81470648]
FX The present study was financially supported by the National Natural
   Science Foundation of China (grant no. 81470648).
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Dabkeviciene D, 2012, PHOTOCHEM PHOTOBIOL, V88, P432, DOI 10.1111/j.1751-1097.2011.01062.x
   Datseris I, 2015, SEMIN OPHTHALMOL, V30, P112, DOI 10.3109/08820538.2013.833268
   El-Mollayess GM, 2011, SEMIN OPHTHALMOL, V26, P69, DOI 10.3109/08820538.2010.545100
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Haddock LJ, 2014, SEMIN OPHTHALMOL, V29, P257, DOI 10.3109/08820538.2014.959616
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Inoue M, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329863
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kanchanaranya Navapol, 2015, Journal of the Medical Association of Thailand, V98, P489
   Kim Hyun Woong, 2011, Korean J Ophthalmol, V25, P231, DOI 10.3341/kjo.2011.25.4.231
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Position of the Retinological Society, 2007, KLIN MONATSBL AUGENH, V224, P559
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Saviano Sandro, 2016, Digit J Ophthalmol, V22, P46, DOI 10.5693/djo.01.2014.01.004
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stewart MW, 2011, RETINA-J RET VIT DIS, V31, P1981, DOI 10.1097/IAE.0B013E318234CB33
   Takahashi M, 2010, JPN J OPHTHALMOL, V54, P565, DOI 10.1007/s10384-010-0864-3
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
NR 38
TC 4
Z9 4
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD AUG
PY 2018
VL 16
IS 2
BP 1187
EP 1194
DI 10.3892/etm.2018.6305
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GR1GO
UT WOS:000442280500100
PM 30116368
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Tranos, P
   Tsiropoulos, GN
   Koronis, S
   Vakalis, A
   Asteriadis, S
   Stavrakas, P
AF Tranos, Paris
   Tsiropoulos, Georgios N.
   Koronis, Spyridon
   Vakalis, Athanasios
   Asteriadis, Solon
   Stavrakas, Panagiotis
TI Comparison of subretinal versus intravitreal injection of recombinant
   tissue plasminogen activator with gas for submacular hemorrhage
   secondary to wet age-related macular degeneration: treatment outcomes
   and brief literature review
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
DE Submacular hemorrhage; Wet age-related macular degeneration; Vitrectomy;
   Subretinal recombinant tissue plasminogen activator; Intravitreal
   recombinant tissue plasminogen activator
ID PNEUMATIC DISPLACEMENT; MANAGEMENT; BEVACIZUMAB
AB Purpose Contradictory evidence exists over the best approach for the management of submacular hemorrhage (SMH). In this study, we compared the outcomes of subretinal versus intravitreal injection of recombinant tissue plasminogen activator (r-tPA) and gas in cases of SMH secondary to age-related macular degeneration (AMD). Methods Twenty five eyes with SMH were retrospectively divided in 2 groups. Group A underwent vitrectomy, subretinal r-tPA and gas (Vitrectomy group, n = 14), and group B received intravitreal r-tPA and gas (Pneumatic group, n = 11). SMH displacement and change in subfoveal hemorrhage thickness (SFHT) at 1 month post-op were assessed. Additionally, best corrected visual acuity (BCVA) and central retinal thickness (CRT) at the end of the 12 month follow-up (FU) were analyzed. Clinical and epidemiological prognostic factors were tested. Results Mean duration of SMH prior intervention was 8.2(+/- 7.3) days. Baseline BCVA was 1.53 +/- 0.73 LogMAR, mean extension of SMH was 4.604 +/- 2079 mu m and mean CRT pre-treatment was 795 +/- 365 mu m. SMH displacement at 1 month post-treatment was total in 9/14 versus 6/11 and partial in 4/14 versus 2/11 in Group A and Group B, respectively (Fisher's exact test p = 0.38). SFHT reduced by 404 +/- 312 mu m in Group A versus 376 +/- 405 mu m in group B (p = 0.86). BCVA improvement and reduction of CRT were highly significant at the end of FU (p = 0.002 and p < 0.001 respectively) but did not differ between the 2 groups. Only baseline BCVA and preoperative CRT proved to be significant prognostic factors for the final functional outcome (p = 0.013 and p = 0.047 respectively). Conclusion Both treatment options proved equal efficacy in displacing SMH in AMD. A multicenter trial may delineate a desirable algorithm of treatment.
C1 [Tranos, Paris; Vakalis, Athanasios; Asteriadis, Solon] Ophthalm Eye Inst, Thessaloniki, Greece.
   [Tsiropoulos, Georgios N.] Swiss Visio Montchoisi, Lausanne, Switzerland.
   [Tsiropoulos, Georgios N.] Aristotle Univ Thessaloniki, Med Sch, Dept Hlth Sci, Thessaloniki, Greece.
   [Koronis, Spyridon] Papageorgiou Univ Hosp, Thessaloniki, Greece.
   [Stavrakas, Panagiotis] Univ Patras, Sch Med, Dept Ophthalmol, Rion 26504, Greece.
C3 Aristotle University of Thessaloniki; Papageorgiou Hospital; University
   of Patras
RP Stavrakas, P (通讯作者)，Univ Patras, Sch Med, Dept Ophthalmol, Rion 26504, Greece.
EM tranos@ophthalmica.gr; georgiosntsiropoulos@gmail.com;
   spyridonkoronis@gmail.com; vakalis@ophthalmica.gr;
   asteriadis@ophthalmica.gr; panos.stavrakas@yahoo.com
OI Stavrakas, Panagiotis/0000-0002-0570-6438
CR Al-Hity A, 2019, EYE, V33, P486, DOI 10.1038/s41433-018-0239-4
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hattenbach LO, 2002, KLIN MONATSBL AUGENH, V219, P512, DOI 10.1055/s-2002-33584
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Juncal VR, 2018, CAN J OPHTHALMOL, V53, P408, DOI 10.1016/j.jcjo.2017.10.010
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Martel JN, 2013, JAMA OPHTHALMOL, V131, P1632, DOI 10.1001/jamaophthalmol.2013.5464
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mozaffarieh M, 2006, GRAEF ARCH CLIN EXP, V244, P1421, DOI 10.1007/s00417-005-0232-z
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Rishi E, 2012, INDIAN J OPHTHALMOL, V60, P521, DOI 10.4103/0301-4738.103779
   Ritzau-Tondrow U, 2012, OPHTHALMOLOGE, V109, P670, DOI 10.1007/s00347-012-2568-1
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Tsymanava A, 2012, ACTA OPHTHALMOL, V90, P633, DOI 10.1111/j.1755-3768.2011.02115.x
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   WJ H, 1996, INTRAVITREAL TPA OUT
   Yorston D, 2014, INVEST OPHTH VIS SCI, V55, P662
NR 30
TC 5
Z9 5
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD DEC
PY 2021
VL 41
IS 12
BP 4037
EP 4046
DI 10.1007/s10792-021-01976-x
EA JUL 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WS5OU
UT WOS:000679603600002
PM 34331185
DA 2022-11-30
ER

PT J
AU Aghdam, KA
   Seidensticker, F
   Pielen, A
   Framme, C
   Junker, B
AF Aghdam, Kaveh Abri
   Seidensticker, Florian
   Pielen, Amelie
   Framme, Carsten
   Junker, Bernd
TI The short-term effects of aflibercept on the size of choroidal
   neovascularization lesion in treatment-resistant neovascular age-related
   macular degeneration as determined by spectral-domain optical coherence
   tomography
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE aflibercept; choroidal neovascularization; ranibizumab; spectral
   domain-optical coherence tomography
ID ANTI-VEGF THERAPY; INTRAVITREAL AFLIBERCEPT; ANATOMICAL OUTCOMES;
   RANIBIZUMAB; TACHYPHYLAXIS; EYES; AMD
AB Background and ObjectivesTo evaluate the changes in the size of choroidal neovascularization (CNV) lesion using spectral domain-optical coherence tomography (SD-OCT) in patients with treatment-resistant neovascular age-related macular degeneration (AMD) who were switched from ranibizumab to aflibercept.
   Materials and MethodsIn this prospective case-series, 33 eyes of 30 patients with treatment-resistant neovascular AMD were included. Treatment-resistant neovascular AMD was defined as choriodal neovascularization secondary to AMD determined by subretinal fluid and/or intraretinal fluid/cysts after more than 6 months of monthly ranibizumab therapy. Enrolled eyes were received intravitreal aflibercept injections at weeks 0, 4, and 8. Maximum area of CNV lesion in the cross-sectional area in the B-scan was measured using Heidelberg Eye Explorer software. The same cross-sectional sections containing maximum area of CNV lesion were used during the follow-up. CNV subtypes were determined based on fluorescein angiography images prior to ranibizumab therapy. Main outcome measures were changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), and area of CNV lesion.
   ResultsThere were five classic (15%), seven minimally classic (21%), and 21 occult subtypes of CNV (64%). Four weeks after the third injection, BCVA improvement and reduction of the retinal thickness in nine standard ETDRS subfields were significant (both P<0.001). Regarding and regardless of CNV subtypes, mean area of CNV lesion decreased significantly at final visit. Overall, a dry macula was achieved in 21 eyes (64%) and 12 eyes (36%) showed decreased or unchanged edema.
   ConclusionsSwitching to aflibercept seems to result in reduction of CNV lesion area in short-term follow-up of patients with treatment-resistant neovascular AMD. Lasers Surg. Med. 48:668-677, 2016. (c) 2016 Wiley Periodicals, Inc.
C1 [Aghdam, Kaveh Abri; Seidensticker, Florian; Pielen, Amelie; Framme, Carsten; Junker, Bernd] Hannover Med Sch, Univ Eye Hosp, Dept Ophthalmol, Hannover, Germany.
   [Aghdam, Kaveh Abri] Univ Tehran Med Sci, Neurosci Inst, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran.
C3 Hannover Medical School; Tehran University of Medical Sciences
RP Aghdam, KA (通讯作者)，Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM kaveh.abri@gmail.com
RI Abri Aghdam, Kaveh/M-6352-2018
OI Abri Aghdam, Kaveh/0000-0001-7568-6455
FU "Niedersachsen Vorab"; German Ministry of Lower Saxony
FX The authors would like to thank the German Ministry of Lower Saxony for
   its scientific and cultural organization to support our retinal imaging
   studies in the Ophthalmology Department of Hannover Medical School
   financed by the "Niedersachsen Vorab."
CR Aghdam KA, 2016, EUR J OPHTHALMOL, V26, P473, DOI 10.5301/ejo.5000757
   Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Chen YX, 2012, THER CLIN RISK MANAG, V8, P343, DOI 10.2147/TCRM.S32801
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas F, 2012, INVEST OPHTH VIS SCI, V53, P4147, DOI 10.1167/iovs.12-9878
   Costa RA, 2005, AM J OPHTHALMOL, V140, P107, DOI 10.1016/j.ajo.2005.02.042
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   HAMMER M, 1995, PHYS MED BIOL, V40, P963, DOI 10.1088/0031-9155/40/6/001
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Jorstad OK, 2015, ACTA OPHTHALMOL, V93, pE510, DOI 10.1111/aos.12681
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Traynor K, 2012, AM J HEALTH-SYST PH, V69, P6, DOI 10.2146/news120001
   Trichonas G, 2013, OPHTHALMOL THER, V2, P89, DOI 10.1007/s40123-013-0015-2
   Van Steenkiste C, 2011, HEPATOLOGY, V53, P1629, DOI 10.1002/hep.24238
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 29
TC 5
Z9 5
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD SEP
PY 2016
VL 48
IS 7
BP 668
EP 677
DI 10.1002/lsm.22531
PG 10
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology; Surgery
GA DW0YS
UT WOS:000383370200005
PM 27111455
DA 2022-11-30
ER

PT J
AU Richer, S
   Cho, J
   Stiles, W
   Levin, M
   Wrobel, JS
   Sinai, M
   Thomas, C
AF Richer, Stuart
   Cho, Jane
   Stiles, William
   Levin, Marc
   Wrobel, James S.
   Sinai, Michael
   Thomas, Carla
TI Retinal Spectral Domain Optical Coherence Tomography in Early Atrophic
   Age-Related Macular Degeneration (AMD) and a New Metric for Objective
   Evaluation of the Efficacy of Ocular Nutrition
SO NUTRIENTS
LA English
DT Article
DE atrophic age-related macular degeneration (AMD); spectral domain OCT (SD
   OCT); contrast sensitivity function (CSF); extrafoveal blue-cone
   increment thresholds
ID VISUAL FUNCTION-TESTS; RISK-FACTORS; PIGMENT; MACULOPATHY; CATARACT
AB Purpose: A challenge in ocular preventive medicine is identification of patients with early pathological retinal damage that might benefit from nutritional intervention. The purpose of this study is to evaluate retinal thinning (RT) in early atrophic age-related macular degeneration (AMD) against visual function data from the Zeaxanthin and Visual Function (ZVF) randomized double masked placebo controlled clinical trial (FDA IND #78973). Methods: Retrospective, observational case series of medical center veterans with minimal visible AMD retinopathy (AREDS Report #18 simplified grading 1.4/4.0 bilateral retinopathy). Foveal and extra-foveal four quadrant SDOCT RT measurements were evaluated in n = 54 clinical and ZVF AMD patients. RT by age was determined and compared to the OptoVue SD OCT normative database. RT by quadrant in a subset of n = 29 ZVF patients was correlated with contrast sensitivity and parafoveal blue cone increment thresholds. Results: Foveal RT in AMD patients and non-AMD patients was preserved with age. Extrafoveal regions, however, showed significant slope differences between AMD patients and non-AMD patients, with the superior and nasal quadrants most vulnerable to retinal thinning (sup quad: -5.5 mu m/decade thinning vs. Non-AMD: -1.1 mu m/decade, P < 0.02; nasal quad: -5.0 mu m/decade thinning vs. Non-AMD: -1.0 mu m/decade, P < 0.04). Two measures of extrafoveal visual deterioration were correlated: A significant inverse correlation between % RT and contrast sensitivity (r = -0.33, P = 0.01, 2 Tailed Paired T) and an elevated extrafoveal increment blue cone threshold (r = +0.34, P = 0.01, 2 Tailed T). Additional SD OCT RT data for the non-AMD oldest age group (ages 82-91) is needed to fully substantiate the model. Conclusion: A simple new SD OCT clinical metric called "% extra-foveal RT" correlates well with functional visual loss in early AMD patients having minimal visible retinopathy. This metric can be used to follow the effect of repleting ocular nutrients, such as zinc, antioxidants, carotenoids, n-3 essential fats, resveratrol and vitamin D.
C1 [Richer, Stuart; Cho, Jane; Stiles, William; Levin, Marc; Thomas, Carla] James A Lovell Fed Hlth Care Ctr, Eye Clin, N Chicago, IL 60064 USA.
   [Richer, Stuart; Cho, Jane] RFUMS Chicago Med Sch, N Chicago, IL 60064 USA.
   [Wrobel, James S.] Univ Michigan, Podiatry Serv, Ann Arbor, MI 48105 USA.
   [Sinai, Michael] Optovue Inc, Fremont, CA 94538 USA.
C3 Chicago Medical School; University of Michigan System; University of
   Michigan
RP Richer, S (通讯作者)，James A Lovell Fed Hlth Care Ctr, Eye Clin, N Chicago, IL 60064 USA.
EM Stuart.Richer1@VA.Gov; jane.cho@my.rfums.org; ilovemabel@aol.com;
   medpat@comcast.net; jswrobel@med.umich.edu; mike_sinai@optovue.com;
   carla.thomas2@va.gov
FU James A Lovell Federal Health Care Center, Eye Clinic (North Chicago,
   IL); Department of Veterans Affairs Research Service/CARES (Hines, IL);
   Chrysantis/Ball Horticulture (West Chicago, IL); Kemin Health LC (Des
   Moines, IA); Stereo Optical, Inc. (Chicago, IL); Optovue (Fremont, CA)
   [78, 973]
FX This material is based on original work supported by the James A Lovell
   Federal Health Care Center, Eye Clinic (North Chicago, IL) and the
   Department of Veterans Affairs Research Service/CARES (Hines, IL).
   Chrysantis/Ball Horticulture (West Chicago, IL) and Kemin Health LC (Des
   Moines, IA) were the primary granting sponsors of ZVF and LAST
   respectively. Stereo Optical, Inc. (Chicago, IL) and Optovue (Fremont,
   CA) provided instrumentation as secondary sponsors of ZVF: FDA IND #78,
   973 and our Ocular-Nutrition Laboratory.
CR Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Chew FLM, 2010, AGE AGEING, V39, P239, DOI 10.1093/ageing/afp259
   CHYLACK LT, 1999, CRC MOD NUT, P25
   Colenbrander A, 2010, ACTA OPHTHALMOL, V88, P163, DOI 10.1111/j.1755-3768.2009.01670.x
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Harris G, 2012, STRATEGIES MED DOCTO
   Ivers RQ, 2000, CLIN EXP OPHTHALMOL, V28, P41, DOI 10.1046/j.1442-9071.2000.00236.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Liew SHM, 2006, EXP EYE RES, V82, P915, DOI 10.1016/j.exer.2005.10.014
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer S, 2009, OPTOMETRY, V80, P695, DOI 10.1016/j.optm.2009.03.018
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Sabeti F, 2010, P ASS RES VIS OPHTH
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Sheedy J, 2010, COMMUNICATION
   Sivagnanavel V., 2005, INVEST OPHTHALMOL VI, V46, P1398
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   van de Kraats J, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2899151
   Wong R, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-15
NR 27
TC 3
Z9 5
U1 0
U2 17
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD DEC
PY 2012
VL 4
IS 12
BP 1812
EP 1827
DI 10.3390/nu4121812
PG 16
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 060KO
UT WOS:000312776900002
PM 23363992
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Scholl, HPN
   Peto, T
   Dandekar, S
   Bunce, C
   Xing, W
   Jenkins, S
   Bird, AC
AF Scholl, HPN
   Peto, T
   Dandekar, S
   Bunce, C
   Xing, W
   Jenkins, S
   Bird, AC
TI Inter- and intra-observer variability in grading lesions of age-related
   maculopathy and macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID STARGARDT-DISEASE; TWINS; ABCR; HEREDITY; RISK; GENE
AB Purpose: To introduce a revised version of the grading system established by the International ARM Epidemiological Study Group for identifying and quantifying abnormalities of age-related maculopathy (ARM) and age-related degeneration (AMD) and to investigate its reliability, specifically the inter- and intra-observer variability. Methods: Fifty eyes of 25 patients with ARM or AMD in at least one eye were randomly selected from a large ongoing collection of clinical data and DNA in a tertiary referral UK population. Stereoscopic color fundus photographs were taken with a 30degrees fundus camera and were centered on the macula. Presence and severity of fundus abnormalities in ARM and AMD were graded using a grid to define macular subfields and standard circles to define the size of lesions. Inter-observer variability was assessed by having three retinal specialists evaluate the color slides and intra-observer variability by regrading the same set. Results: The inter-observer agreement for all subfields was fair to substantial for small hard drusen (70-89%; kappa=0.26-0.63) and intermediate soft drusen (76-94%; kappa=0.27-0.69). Agreement ranged between 87% and 100%, between 50% and 92%, and between 78% and 100% for larger drusen, the presence of hyperpigmentation, and the presence of hypopigmentation, respectively. Agreement was moderate to almost perfect for the presence of geographic atrophy (88-98%; kappa=0.60-0.95) and substantial to almost perfect for the presence of choroidal neovascularization (84-100%; kappa=0.62-1.00). The intra-observer variability for the grading of drusen characteristics and pigmentary changes was similar in magnitude, but slightly greater for features of advanced AMD. Conclusion: Reproducibility was achieved using a revised version of the grading system established by the International ARM Epidemiological Study Group. This grading system may therefore be used for phenotyping of ARM and AMD.
C1 Moorfields Eye Hosp, Inst Ophthalmol, London EC1 V2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Scholl, HPN (通讯作者)，Moorfields Eye Hosp, Inst Ophthalmol, 162 City Rd, London EC1 V2PD, England.
EM hendrikscholl@hotmail.com
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381; Bunce, Catey/0000-0002-0935-3713
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491
   DOSSO AA, 1992, OPHTHALMOLOGICA, V205, P24, DOI 10.1159/000310307
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KNOBLOCH WH, 1985, OPHTHALMIC PAED GEN, V5, P59, DOI 10.3109/13816818509007856
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   MELROSE MA, 1985, OPHTHALMIC SURG LAS, V16, P648
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   THOMPSON WD, 1988, J CLIN EPIDEMIOL, V41, P949, DOI 10.1016/0895-4356(88)90031-5
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 23
TC 42
Z9 44
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2003
VL 241
IS 1
BP 39
EP 47
DI 10.1007/s00417-002-0602-8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 647ZE
UT WOS:000181123300007
PM 12545291
DA 2022-11-30
ER

PT J
AU Lanzetta, P
   Cruess, AF
   Cohen, SY
   Slakter, JS
   Katz, T
   Sowade, O
   Zeitz, O
   Ahlers, C
   Mitchell, P
AF Lanzetta, Paolo
   Cruess, Alan F.
   Cohen, Salomon Y.
   Slakter, Jason S.
   Katz, Todd
   Sowade, Olaf
   Zeitz, Oliver
   Ahlers, Christiane
   Mitchell, Paul
TI Predictors of visual outcomes in patients with neovascular age-related
   macular degeneration treated with anti-vascular endothelial growth
   factor therapy: post hoc analysis of the VIEW studies
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; anti-vascular endothelial growth factor; neovascular
   age-related macular degeneration; predictors
ID SUBGROUP ANALYSIS; RANIBIZUMAB
AB Purpose Identify predictors for response to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular (wet) age-related macular degeneration (nAMD). Methods Retrospective, post hoc analysis of VIEW 1/2. Patients were randomized 1:1:1:1 to 0.5 mg intravitreal aflibercept (IVT-AFL) injection every 4 weeks (0.5q4); 2 mg IVT-AFL every 4 weeks (2q4); 2 mg IVT-AFL every 8 weeks (2q8) after an initial three injections at weeks 0, 4 and 8 or 0.5 mg intravitreal ranibizumab every 4 weeks (0.5q4). Results 1815 patients [IVT-AFL 2q4 (n = 613); IVT-AFL 2q8 (n = 607); ranibizumab 0.5q4 (n = 595)] were included. Baseline demographics/characteristics were evenly balanced. Younger age (49-69 years), lower visual acuity (VA) [10.0-<= 45.0 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] and smaller choroidal neovascularization (CNV) size [0.0-<= 3.1 disc areas (DA)] at baseline were associated with the most vision gain (>= 15 letters) over 52 weeks (all nominal p < 0.0001).Younger age, higher baseline VA (>64.0-<= 83.0 letters) and smaller CNV size were associated with a VA >= 20/40 at week 52. Predominantly classic CNV at baseline (nominal p = 0.0007), older age (>= 90 years), lower baseline VA (10.0-<= 45.0 ETDRS letters) and larger CNV size (>10.1-<= 32.6 DA) were all associated with a VA <= 20/200 at week 52 (all nominal p < 0.0001). Along with treatment (nominal p < 0.0001), lower VA (p = 0.0166) and smaller central retinal thickness (both nominal p = 0.0190) were predictors for dry retina development. Conclusion Younger age, lower VA and smaller CNV size at baseline were all associated with greater vision gains over 52 weeks while younger age, higher VA and smaller CNV size at treatment start were more likely to achieve best-corrected VA 20/40 or better after a year's treatment, suggesting the benefit of early anti-VEGF treatment.
C1 [Lanzetta, Paolo] Univ Udine, Dept Med Ophthalmol, Piazzale S Maria Misericordia, I-33100 Udine, Italy.
   [Cruess, Alan F.] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.
   [Cohen, Salomon Y.] Ophthalmol Ctr Imaging & Laser, Paris, France.
   [Slakter, Jason S.] Vitreous Retina Macula Consultants, New York, NY USA.
   [Katz, Todd] Bayer US LLC, Whippany, NJ USA.
   [Sowade, Olaf; Zeitz, Oliver; Ahlers, Christiane] Bayer AG, Berlin, Germany.
   [Mitchell, Paul] Univ Sydney, Westmead Inst, Dept Ophthalmol, Sydney, NSW, Australia.
C3 University of Udine; Dalhousie University; Vitreous Retina Macula
   Consultants of New York; Bayer AG; University of Sydney; Westmead
   Institute for Medical Research
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Med Ophthalmol, Piazzale S Maria Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
RI Zeitz, Oliver/AAJ-9728-2021
FU Bayer; Regeneron Pharmaceuticals, Inc.; Apellis; Roche; Santen; Sanofi;
   Tyrogenex; Thrombogenics; Regeneron; Opthea; Ocucure
FX The VIEW 1 and VIEW 2 studies were funded by Bayer and Regeneron
   Pharmaceuticals, Inc. Medical writing support was provided by Leigh
   Prevost, BSc Pharm Hons, of PAREXEL, which was funded by Bayer. Data
   included in this article have previously been presented by Professor
   Lanzetta as an abstract at ARVO 2014 in Orlando, Florida. PL is a
   consultant to Alcon, Alimera, Allergan, Bausch & Lomb, Bayer,
   Boerhinger, Centervue, Genentech, Lupin, Lutronic, Novartis, Roche, Teva
   and Topcon. In addition, PL has a patent with Iridex. AC is a consultant
   to Bayer; SC is a consultant to Bayer; JS is a consultant to Regeneron,
   Tyrogenex and Opthea. He has also received grant payments for reading
   centre services from Apellis, Roche, Santen, Sanofi, Tyrogenex,
   Thrombogenics, Regeneron, Opthea and Ocucure. JS is a shareholder and
   employee of Ohr Pharmaceutical; PM is a consultant to Bayer; TK, OS, OZ
   and CA are all employees of Bayer AG Berlin.
CR Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Li X, 2016, 31 AS PAC AC OPHTH A
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 13
TC 16
Z9 16
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2018
VL 96
IS 8
BP E911
EP E918
DI 10.1111/aos.13751
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HC3IB
UT WOS:000451694500016
PM 29659183
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Maruyama-Inoue, M
   Sato, S
   Yamane, S
   Kadonosono, K
AF Maruyama-Inoue, Maiko
   Sato, Shimpei
   Yamane, Shin
   Kadonosono, Kazuaki
TI INTRAVITREAL INJECTION OF AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL
   CHOROIDAL VASCULOPATHY A 3-YEAR FOLLOW-UP
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; aflibercept; fixed dosing; pro re
   nata
ID ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY; LASER PHOTOCOAGULATION;
   MACULAR DEGENERATION; EXTEND REGIMEN; RANIBIZUMAB; VEGF; OUTCOMES;
   VERTEPORFIN; THICKNESS
AB Purpose: To compare the 3-year follow-up results of intravitreal injections of aflibercept between fixed dosing (FD) regimen and a pro re nata (PRN) regimen after three initial monthly doses for the treatment of polypoidal choroidal vasculopathy and to analyze factors influencing improvement in visual acuity.
   Methods: We retrospectively studied all treatment-naive patients with polypoidal choroidal vasculopathy who were scheduled to receive intravitreal aflibercept injections FD or PRN after induction treatment between March 2013 and May 2014. Best-corrected visual acuity was evaluated before treatment and at 4, 12, 24, and 36 months after initial treatment. Factors that influence improvement in visual acuity were also investigated.
   Results: Thirty-three eyes were assessed at the 3-year follow-up examination. Twenty-three eyes were treated with intravitreal aflibercept injections every 2 months for at least 1 year after three initial monthly doses (FD group), and 10 eyes were treated PRN after loading doses (PRN group). In the FD group, during the follow-up period from 1 to 3 years, quarterly dosing with capped PRN or a treat and extend regimen were selected. The mean number of administered intravitreal aflibercept was 15.3 +/- 4.6 in the FD group and 9.0 +/- 8.9 in the PRN group, with a significant difference between the two groups (P = 0.004). Significant improvement of the mean logarithm of the minimum angle of resolution values for best-corrected visual acuity was shown at 36 months, as compared to baseline values (P = 0.019). No significant difference in the improvement of best-corrected visual acuity between the two groups was observed at baseline or at 4, 12, 24, and 36 months after treatment (all P > 0.05), although there was a trend toward better results in the FD group. Multiple regression analysis showed that the FD group had better visual acuity at 36 months and greater improvement in visual acuity than the PRN group (P = 0.031 for both comparisons).
   Conclusion: Intravitreal aflibercept was effective in improving the vision of patients with polypoidal choroidal vasculopathy, as evaluated at the 3-year follow-up. Fixed treatment might be an important factor influencing improvement in visual acuity.
C1 [Maruyama-Inoue, Maiko; Sato, Shimpei; Yamane, Shin; Kadonosono, Kazuaki] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa, Japan.
C3 Yokohama City University
RP Maruyama-Inoue, M (通讯作者)，4-57 Urafune Cho,Minami Ku, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Pak KY, 2017, RETINA-J RET VIT DIS, V37, P561, DOI 10.1097/IAE.0000000000001195
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 38
TC 12
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2018
VL 38
IS 10
BP 2001
EP 2009
DI 10.1097/IAE.0000000000001818
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VS
UT WOS:000454005600023
PM 28816730
DA 2022-11-30
ER

PT J
AU Lawrenson, JG
   Evans, JR
AF Lawrenson, John G.
   Evans, Jennifer R.
TI Advice about diet and smoking for people with or at risk of age-related
   macular degeneration: a cross-sectional survey of eye care professionals
   in the UK
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Age-related macular degeneration; Lifestyle modification; Nutrition;
   Smoking cessation
ID COMMUNITY OPTOMETRISTS; BETA-CAROTENE; METAANALYSIS; ATTITUDES;
   CESSATION; SUPPLEMENTATION; ANTIOXIDANTS; PREVALENCE
AB Background: In the absence of a cure, there has been considerable interest in attempts to prevent or reduce the progression of age-related macular degeneration (AMD) by targeting particular modifiable risk factors. The aim of this study was to conduct a cross-sectional survey of the current practice of UK eye care professionals in relation to advice given on diet and other lifestyle modifications for patients with or at risk of AMD.
   Methods: Optometrists and ophthalmologists on the membership databases of professional organisations for the two professions were invited to participate in an online survey. The survey was open for 12 weeks between July and September 2012.
   Results: A total of 1,468 responses were received (96.3% from optometrists and 3.7% from ophthalmologists). The response rate of those receiving the invitation was 16.2% (1,414/8735) for optometrists and 6% (54/1460) for ophthalmologists. A majority of respondents reported that they frequently provide dietary advice to patients with established AMD (67.9%) and those at risk of AMD (53.6%). Typical advice consisted of a recommendation to eat plenty of leafy green vegetables and eat more oily fish. The decision to recommend nutritional supplements was based on the risk of progression to advanced AMD, with approximately 93% of respondents recommending supplementation in a patient with advanced AMD in one eye. However for the majority, the type of supplement recommended did not comply with current best research evidence, based on the findings of the Age-related Eye Disease Study (AREDS). Only one in three optometrists regularly assessed smoking status and advised on smoking cessation.
   Conclusions: Within a large sample of eye care professionals, consisting predominantly of optometrists, who responded to a cross-sectional survey, there was active engagement in providing nutritional advice to patients with or at risk of AMD. However, the results demonstrate a need to raise awareness of the evidence underpinning the use of nutritional supplements together with an increased involvement in targeted smoking cessation.
C1 [Lawrenson, John G.] City Univ London, Div Optometry & Visual Sci, London EC1V 0HB, England.
   [Evans, Jennifer R.] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1, England.
C3 City University London; University of London; London School of Hygiene &
   Tropical Medicine
RP Lawrenson, JG (通讯作者)，City Univ London, Div Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
EM J.G.Lawrenson@city.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030; Lawrenson, John/0000-0002-2031-6390
CR Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955
   Brule J, 2012, CLIN EXP OPTOM, V95, P599, DOI 10.1111/j.1444-0938.2012.00748.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   College of Optometrists, HLTH LIF HLTH EYES
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Druesne-Pecollo N, 2010, INT J CANCER, V127, P172, DOI 10.1002/ijc.25008
   Edgar DF, 2010, OPTOMETRY PRACTICE, V11, P31
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   GLOBOCAN, 2018, TITLE ERROR
   Kansagara D, 2012, NUTR SUPPLEMENTS AGE
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LANCASTER T, 2004, COCHRANE DB SYST REV, V4, DOI [DOI 10.1002/14651858.CD000165.PUB2, 10.1002/14651858.CD000165.pub2]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lizarondo L, 2011, J MULTIDISCIP HEALTH, V4, P261, DOI 10.2147/JMDH.S23144
   Mares JA, 2006, AM J CLIN NUTR, V83, P733, DOI 10.1093/ajcn/83.4.733
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Myint J, 2011, OPHTHAL PHYSL OPT, V31, P353, DOI 10.1111/j.1475-1313.2011.00844.x
   Needle JJ, 2008, OPHTHAL PHYSL OPT, V28, P193, DOI 10.1111/j.1475-1313.2008.00551.x
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Royal College of Ophthalmologists, AG REL MAC DEG 2009
   Sahu A, 2008, EYE, V22, P246, DOI 10.1038/sj.eye.6702592
   Suttle CM, 2012, CLIN EXP OPTOM, V95, P28, DOI 10.1111/j.1444-0938.2011.00663.x
   Thompson C, 2007, OPHTHAL PHYSL OPT, V27, P389, DOI 10.1111/j.1475-1313.2007.00483.x
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
NR 32
TC 45
Z9 45
U1 0
U2 35
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD JUN 10
PY 2013
VL 13
AR 564
DI 10.1186/1471-2458-13-564
PG 10
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 172QR
UT WOS:000321019700001
PM 23759079
OA gold, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Gomi, F
   Oshima, Y
   Mori, R
   Kano, M
   Saito, M
   Yamashita, A
   Iwata, E
   Maruko, R
AF Gomi, Fumi
   Oshima, Yuji
   Mori, Ryusaburo
   Kano, Mariko
   Saito, Masaaki
   Yamashita, Ayana
   Iwata, Eiji
   Maruko, Ruka
CA Fujisan Study Grp
TI INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH
   RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY The
   Fujisan Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; photodynamic therapy; ranibizumab;
   combination
ID MACULAR DEGENERATION; JAPANESE PATIENTS; INTRAVITREAL RANIBIZUMAB;
   NEOVASCULARIZATION SECONDARY; VERTEPORFIN; EFFICACY; BEVACIZUMAB;
   INJECTIONS; SAFETY; LAPTOP
AB Purpose:To compare the 1-year results of initial or deferred photodynamic therapy (PDT) combined with intravitreal ranibizumab (IVR) for eyes with polypoidal choroidal vasculopathy.Methods:Prospectively, 72 men with treatment-naive polypoidal choroidal vasculopathy were randomized to initial or later PDT combined with IVR. In both groups, 2 additional monthly IVR followed. From Month 3, PDT and IVR were administered according to the retreatment criteria. Mean changes in the best-corrected visual acuity between baseline and Month 12 and central retinal thickness, the rate of eyes showing regression of polypoidal lesions, and number of additional treatments were compared.Results:The best-corrected visual acuity increased by a mean of 8.1 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters in the initial PDT group and 8.8 ETDRS letters in the later PDT group, and there was a no significant difference (P = 0.59). The mean central retinal thickness decreased significantly in both groups but more so with combination therapy within the first 4 months; the difference was not significant at Month 12 (P = 0.30). The rate of eyes showing resolution of polypoidal lesions at 12 months was 62.1% in the initial PDT group and 54.8% in the later PDT group and again, there was no significant difference (P = 0.53). The mean number of additional IVR was 1.5 in initial PDT and 3.8 in later PDT; that of additional PDTs was 0.14 and 0.45, respectively, and they were significantly different (P < 0.001 and P = 0.013, respectively).Conclusion:Both initial and deferred PDT combined with IVR to treat polypoidal choroidal vasculopathy show the similar visual and anatomical improvements at 12 months. Initial PDT combination leads to significantly fewer additional treatments.
C1 [Gomi, Fumi] Sumitomo Hosp, Dept Ophthalmol, Osaka 5300005, Japan.
   [Gomi, Fumi] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Osaka, Japan.
   [Oshima, Yuji] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 812, Japan.
   [Mori, Ryusaburo] Surugadai Nihon Univ Hosp, Dept Ophthalmol, Fukuoka, Japan.
   [Kano, Mariko; Saito, Masaaki] Fukushima Med Univ, Dept Ophthalmol, Fukuoka, Japan.
   [Yamashita, Ayana] Kagawa Univ, Dept Ophthalmol, Fac Med, Takamatsu, Kagawa 760, Japan.
   [Iwata, Eiji; Maruko, Ruka] Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Nagoya, Aichi 4648601, Japan.
C3 Sumitomo Hospital; Osaka University; Kyushu University; Nihon
   University; Fukushima Medical University; Kagawa University; Nagoya
   University
RP Gomi, F (通讯作者)，Sumitomo Hosp, Dept Ophthalmol, Kita Ku, 5-3-20 Nakanoshima, Osaka 5300005, Japan.
EM gomi.fumi@gmail.com
RI Saito, Masaaki/ABI-2783-2020; Maruko, Ruka/M-4929-2014
OI Saito, Masaaki/0000-0003-1494-6350; Maruko, Ruka/0000-0003-0208-1011;
   Gomi, Fumi/0000-0003-0807-8817
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 37
TC 82
Z9 85
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2015
VL 35
IS 8
BP 1569
EP 1576
DI 10.1097/IAE.0000000000000526
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP4HX
UT WOS:000359843700010
PM 25830698
DA 2022-11-30
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Brolucizumab (Beovu) for Age-Related Macular Degeneration
SO MEDICAL LETTER ON DRUGS AND THERAPEUTICS
LA English
DT Article
CR American Academy of Ophthalmology, 2019, AG REL MAC DEG PPP 2
   [Anonymous], 2019, MED LETT DRUGS THER, V61, P187
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
NR 4
TC 3
Z9 3
U1 1
U2 6
PU MED LETTER INC
PI NEW ROCHELLE
PA 145 HUGUENOT ST, SUITE 312, NEW ROCHELLE, NY 10801-7537 USA
SN 0025-732X
EI 1523-2859
J9 MED LETT DRUGS THER
JI Med. Lett. Drugs Ther.
PD FEB 10
PY 2020
VL 62
IS 1591
BP 23
EP 24
PG 2
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KK9TK
UT WOS:000513076900004
PM 32022789
DA 2022-11-30
ER

PT J
AU van Leeuwen, R
   Chakravarthy, U
   Vingerling, JR
   Brussee, C
   Hooghart, AJ
   Mulder, PG
   de Jong, PTVM
AF van Leeuwen, R
   Chakravarthy, U
   Vingerling, JR
   Brussee, C
   Hooghart, AJ
   Mulder, PG
   de Jong, PTVM
TI Grading of age-related maculopathy for epidemiological studies - Is
   digital imaging as good as 35-mm film?
SO OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY; MACULAR DEGENERATION; FUNDUS PHOTOGRAPHY;
   PREVALENCE; SYSTEM; SLIDES; EYE
AB Purpose: To compare stereo digital images with stereo 35-mm color transparencies as to the quality and reliability of grading age-related maculopathy (ARM) in the context of a multicenter European epidemiologic study (the EUREYE Study).
   Design: Instrument validation study.
   Participants: Ninety-one subjects (137 eyes) with varying degrees of ARM, including no ARM.
   Methods: From both eyes of the participants, 35-mm film and digital stereoscopic fundus images were obtained with two identical eTopcon fundus cameras. Two experienced graders classified all signs of ARM according to the International Classification System. Agreement between eimaging techniques and between graders was calculated using the weighted K statistic.
   Main Outcome Measures: Signs of ARM (number, size, and morphologic characteristics of drusen; pigmentary changes; geographic atrophy; and neovascular macular degeneration) as well as an overall staging system of increasing ARM severity.
   Results: The weighted K value for between-technique agreement ranged from 0.41 for number of drusen <63 mum to 0.79 for drusen type and total area occupied by drusen. The K values for atrophic and neovascular end-stage ARM were 0.87 and 0.94, respectively. The between-technique agreement on stages of ARM was approximately 0.76. The agreement between graders was largely the same for both techniques of imaging.
   Conclusions: In the described setting, digital images were as good as 35-mm film for the grading of ARM. Considering the practical advantages of digital imaging, this technique may serve well in epidemiologic studies of ARM. (C) 2003 by the American Academy of Ophthalmology.
C1 Netherlands Ophthalm Res Inst, KNAW, NL-1105 BA Amsterdam, Netherlands.
   Erasmus Med Ctr, EUREYE Grading Ctr, Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Queens Univ Belfast, Dept Ophthalmol & Visual Sci, Belfast, Antrim, North Ireland.
   Erasmus MC Univ, Ctr Med, Dept Ophthalmol, Rotterdam, Netherlands.
   Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; Queens University Belfast;
   Erasmus University Rotterdam; Erasmus MC; University of Amsterdam;
   Academic Medical Center Amsterdam
RP de Jong, PTVM (通讯作者)，Netherlands Ophthalm Res Inst, KNAW, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
OI Chakravarthy, Usha/0000-0002-2606-3734
CR Altman DG, 1991, PRACTICAL STAT MED R, P403, DOI [DOI 10.1002/SIM.4780101015, 10.1002/sim.4780101015]
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bursell SE, 2001, OPHTHALMOLOGY, V108, P572, DOI 10.1016/S0161-6420(00)00604-7
   George LD, 1998, DIABETIC MED, V15, P250, DOI 10.1002/(SICI)1096-9136(199803)15:3<250::AID-DIA565>3.0.CO;2-G
   Henricsson M, 2000, ACTA OPHTHALMOL SCAN, V78, P164, DOI 10.1034/j.1600-0420.2000.078002164.x
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Liesenfeld B, 2000, DIABETES CARE, V23, P345, DOI 10.2337/diacare.23.3.345
   Lim JI, 2000, OPHTHALMOLOGY, V107, P866, DOI 10.1016/S0161-6420(00)00057-9
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rudnisky CJ, 2002, OPHTHALMOLOGY, V109, P267, DOI 10.1016/S0161-6420(01)00933-2
NR 13
TC 61
Z9 61
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2003
VL 110
IS 8
BP 1540
EP 1544
DI 10.1016/S0161-6420(03)00501-3
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 710VK
UT WOS:000184703400013
PM 12917169
DA 2022-11-30
ER

PT J
AU Zehetner, C
   Kirchmair, R
   Huber, S
   Kralinger, MT
   Kieselbach, GF
AF Zehetner, Claus
   Kirchmair, Rudolf
   Huber, Stefan
   Kralinger, Martina T.
   Kieselbach, Gerhard F.
TI Plasma levels of vascular endothelial growth factor before and after
   intravitreal injection of bevacizumab, ranibizumab and pegaptanib in
   patients with age-related macular degeneration, and in patients with
   diabetic macular oedema
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ARTERIAL THROMBOEMBOLIC EVENTS; RHESUS-MONKEYS; PHARMACOKINETICS; VEGF;
   FRAGMENT; APTAMER; BINDING
AB Aims To determine the level of vascular endothelial growth factor (VEGF) in the plasma of patients with diabetic macular edema (DME) and of patients with exudative age-related macular degeneration (ARMD) before and after intravitreal injection of bevacizumab, ranibizumab or pegaptanib.
   Methods 30 patients with DME and 30 patients with ARMD were included in this randomized controlled study. Patients were randomized to treatment with ranibizumab (0.5 mg), bevacizumab (1.25 mg) or pegaptanib (0.3 mg). 10 patients with DME received bevacizumab, 10 ranibizumab and 10 pegaptanib. The same randomized treatment allocation applied to the 30 patients with ARMD. The concentrations of VEGF were measured by ELISA just before the injection, after 7 days and 1 month.
   Results Plasma VEGF in patients with exudative ARMD before the injection of bevacizumab was 89.7 pg/ml. It was significantly reduced to 25.1 pg/ml after 7 days (p=0.01), and to 22.8 pg/ml after 1 month (p=0.008). In patients with DME the same systemic reduction by bevacizumab was observed with a significant decrease of baseline VEGF level from 72.2 pg/ml to 13.7 pg/ml after 7 days (p=0.008) and 17.1 pg/ml at 4 weeks with (p=0.012). No significant reductions of plasma VEGF levels were observed in patients receiving ranibizumab or pegaptanib during follow-up.
   Conclusions Bevacizumab significantly reduces the level of VEGF in the blood plasma for up to one month in patients with DME as well as in those with ARMD. No significant systemic effects of intravitreal ranibizumab or pegaptanib on plasma VEGF could be observed.
C1 [Zehetner, Claus; Huber, Stefan; Kralinger, Martina T.; Kieselbach, Gerhard F.] Med Univ Innsbruck, Dept Ophthalmol, A-6020 Innsbruck, Austria.
   [Kirchmair, Rudolf] Med Univ Innsbruck, Dept Internal Med, A-6020 Innsbruck, Austria.
C3 Medical University of Innsbruck; Medical University of Innsbruck
RP Zehetner, C (通讯作者)，Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
EM claus.zehetner@i-med.ac.at
OI Zehetner, Claus/0000-0003-1405-7457
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
   De Vriese AS, 2000, BRIT J PHARMACOL, V130, P963, DOI 10.1038/sj.bjp.0703393
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Julien S, 2008, BRIT J OPHTHALMOL, V92, P1424, DOI 10.1136/bjo.2008.141317
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Matsuyama K, 2011, J OCUL PHARMACOL TH, V27, P379, DOI 10.1089/jop.2010.0194
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Reff Mitchell E, 2002, Cancer Control, V9, P152
   Roh MI, 2009, OPHTHALMOLOGY, V116, P80, DOI 10.1016/j.ophtha.2008.09.036
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Sohn HJ, 2011, AM J OPHTHALMOL, V152, P686, DOI 10.1016/j.ajo.2011.03.033
   Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   Zachary I, 2000, ARTERIOSCL THROM VAS, V20, P1512, DOI 10.1161/01.ATV.20.6.1512
NR 30
TC 123
Z9 129
U1 1
U2 16
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2013
VL 97
IS 4
BP 454
EP 459
DI 10.1136/bjophthalmol-2012-302451
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 107ZM
UT WOS:000316259900017
PM 23385630
DA 2022-11-30
ER

PT J
AU Mikacic, I
   Bosnar, D
AF Mikacic, Ivana
   Bosnar, Damir
TI Intravitreal Bevacizumab and Cardiovascular Risk in Patients with
   Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of
   Randomized Controlled Trials and Observational Studies
SO DRUG SAFETY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF DRUGS; ADVERSE EVENTS;
   MYOCARDIAL-INFARCTION; FACTOR INHIBITORS; PHOTODYNAMIC THERAPY;
   VISUAL-ACUITY; RANIBIZUMAB; QUALITY; MANAGEMENT
AB Introduction Intravitreal bevacizumab (IVTB) is used to treat age-related macular degeneration (ARMD), although its use is off-label and its cardiovascular safety has not been unequivocally established.
   Objective Our objective was to assess the cardiovascular safety of IVTB in patients with ARMD.
   Methods We conducted a systematic review and meta-analysis of published randomized controlled trials (RCTs) and observational studies.
   Results Of the 2028 non-duplicate records, five RCTs versus ranibizumab (N = 3038, 12/24 months), four RCTs comparing different regimens (N = 809, 12/23 months), one RCT versus pegaptanib, photodynamic therapy (PDT), or sham (N = 131, 12 months), and three observational studies versus PDT, ranibizumab, or pegaptanib (similar to 150,000 or 1666 patients/12 months and 317 patients/1-2 years, respectively) had a low risk of bias/high quality and a parts per thousand yen20 patients per arm with a parts per thousand yen6 months and a parts per thousand yen3 injections of treatment. RCT-based comparisons with PDT or pegaptanib are negligible. Observational data have not demonstrated differences [all-cause mortality, myocardial infarction (MI), stroke], but the level of evidence is "very low" (imprecise, indirect). RCT-based comparisons with ranibizumab did not demonstrate differences regarding some outcomes, although certain point estimates were at the level of a relevant harm/benefit [all-cause mortality odds ratio (OR) 1.103, 95 % confidence interval (CI) 0.641-1.898; vascular mortality OR 1.380, 95 % CI 0.476-3.997; MI OR 0.551, 95 % CI 0.265-1.146; stroke OR 0.657, 95 % CI 0.260-1.660; transitory ischemic attack OR 1.536, 95 % CI 0.444-5.313; atherothrombotic events (ATEs) OR 1.007, 95 % CI 0.641-1.593; venous thromboembolism OR 2.325, 95 % CI 0.963-5.612] or suggested a higher risk with bevacizumab (hypertension OR 7.512, 95 % CI 1.056-52.3), but estimates were based on sparse data, were extremely imprecise, and commonly exhibited considerable heterogeneity/inconsistency. The level of evidence per outcome was "low" or "very low". Observational data did not demonstrate difference (all-cause mortality, MI, stroke), or suggested a higher risk with bevacizumab (ATE), but were imprecise and indirect (level of evidence "very low"). RCT-based comparisons of different IVTB regimens suffered from the same limitations.
   Conclusion Published data on IVTB in AMRD provide only a low level of evidence on its cardiovascular safety and do not support any finite conclusions.
C1 [Mikacic, Ivana] Univ Hosp Sveti Duh, Clin Pharmacol Unit, Dept Internal Med, Sv Duh 64, Zagreb 10000, Croatia.
   [Bosnar, Damir] Univ Hosp Sveti Duh, Univ Eye Clin, Zagreb 10000, Croatia.
   [Bosnar, Damir] Josip Juraj Strossmayer Univ Osijek, Univ Eye Clin, Osijek, Croatia.
C3 University of JJ Strossmayer Osijek
RP Mikacic, I (通讯作者)，Univ Hosp Sveti Duh, Clin Pharmacol Unit, Dept Internal Med, Sv Duh 64, Zagreb 10000, Croatia.
EM imikacic@kbsd.hr
CR Ahmadieh H, 2011, RETINA-J RET VIT DIS, V31, P1819, DOI 10.1097/IAE.0b013e31820d58f2
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   [Anonymous], 2011, COCHRANE HDB SYSTEMA
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Barikian A, 2015, AM J OPHTHALMOL, V159, P131, DOI 10.1016/j.ajo.2014.10.005
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Blumenkranz MS, 2013, RETINA, P1213
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Datseris I, 2015, SEMIN OPHTHALMOL, V30, P112, DOI 10.3109/08820538.2013.833268
   Dunavoelgyi R, 2012, RETINA-J RET VIT DIS, V32, P1471, DOI 10.1097/IAE.0b013e318236e805
   El-Mollayess GM, 2013, RETINA-J RET VIT DIS, V33, P1828, DOI 10.1097/IAE.0b013e3182877a0d
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   Eylea: European public assessment report (EPAR), EYL EUR PUBL ASS REP
   Feng XF, 2011, INT J OPHTHALMOL-CHI, V4, P85, DOI 10.3980/j.issn.2222-3959.2011.01.20
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1303, DOI 10.1016/j.jclinepi.2011.04.014
   Hedges LV, 2001, PSYCHOL METHODS, V6, P203, DOI 10.1037/1082-989X.6.3.203
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   International Council of Ophthalmology, 2013, SECT 21 OPHTH PREP B
   Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Li J, 2013, INT J OPHTHALMOL-CHI, V6, P169, DOI 10.3980/j.issn.2222-3959.2013.02.12
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Mahmood S, 2015, OPHTHALMOLOGY, V122, P1348, DOI 10.1016/j.ophtha.2015.03.017
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Modarreszadeh Mehdi, 2008, J Ophthalmic Vis Res, V3, P102
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Ng WY, 2015, AM J OPHTHALMOL, V159, P557, DOI 10.1016/j.ajo.2014.12.005
   Ozkaya A, 2013, ISRN OPHTHALMOL, V2013
   Parodi MB, 2013, ACTA OPHTHALMOL, V91, P267, DOI 10.1111/j.1755-3768.2011.02265.x
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Qian J, 2011, RETINA-J RET VIT DIS, V31, P161, DOI 10.1097/IAE.0b013e3181e46ad8
   Riazi-Esfahani Mohammad, 2008, J Ophthalmic Vis Res, V3, P95
   Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmid-Kubista KE, 2009, BRIT J OPHTHALMOL, V93, P914, DOI 10.1136/bjo.2008.144410
   Scott LJ, 2015, EXPERT OPIN DRUG SAF, V14, P379, DOI 10.1517/14740338.2015.991712
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Turner RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059202
   Wang WJ, 2015, INT J OPHTHALMOL-CHI, V8, P138, DOI 10.3980/j.issn.2222-3959.2015.01.26
   Weigert G, BR J OPHTHALMOL, V92, P356
   Wells GA., NEWCASTLE OTTAWA SCA
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 77
TC 13
Z9 14
U1 0
U2 11
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD JUN
PY 2016
VL 39
IS 6
BP 517
EP 541
DI 10.1007/s40264-016-0408-y
PG 25
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA DM5UO
UT WOS:000376415900005
PM 26951234
DA 2022-11-30
ER

PT J
AU Dolz-Marco, R
   Phasukkijwatana, N
   Sarraf, D
   Freund, KB
AF Dolz-Marco, Rosa
   Phasukkijwatana, Nopasak
   Sarraf, David
   Freund, K. Bailey
TI REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER
   INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; AMD; choroidal neovascularization;
   OCT-A; OCT-angiography; type 1 neovascularization; type 2
   neovascularization
ID CHOROIDAL NEOVASCULARIZATION; ANGIOGRAPHY; EYES; MANAGEMENT; SECONDARY;
   OUTCOMES
AB Purpose: To study eyes with Type 2 (subretinal) neovascularization (NV) secondary to neovascular age-related macular degeneration (nAMD) that shows lesion regression into a Type 1 (subretinal pigment epithelium) pattern after treatment with intravitreal anti-vascular endothelial growth factor (VEGF) therapy.
   Methods: Retrospective consecutive case series. Patients showing regression of Type 2 neovascularization into a Type 1 pattern after envelopment by retinal pigment epithelium were included in this analysis. A review of the clinical records and multimodal imaging of these cases was performed at baseline, 1, 3, 6, and 12 months. Demographic data, best-corrected visual acuity (BCVA), color fundus photography, fundus autofluorescence (FAF), fluorescein angiography, near-infrared reflectance (NIR), and structural spectral-domain optical coherence tomography (SD-OCT) were reviewed and analyzed. When available, optical coherence tomography angiography images were analyzed as well.
   Results: Ten eyes of 9 patients (6 males) diagnosed with treatment-naive pure Type 2 neovascularization secondary to nAMD were included. The mean age was 80.7 years (SD +/- 4.30). Mean best-corrected visual acuity expressed in logMAR (Snellen) was 0.45 +/- 0.20 (20/55) at baseline and significantly improved to 0.22 +/- 0.13 (20/32) at 3-month follow-up (P-value: 0.007). At baseline, color photographs and fundus autofluorescence showed a pigment ring around the neovascular lesion in 6 eyes. A hyperreflective ring was visible on NIR in all eyes at 3-month follow-up. Color photographs showed a tessellated fundus appearance in 9 of the 10 eyes. Serial structural spectral-domain optical coherence tomography scans showed the gradual regression of the Type 2 lesions into a Type 1 pattern with envelopment by the retinal pigment epithelium. En face and cross-sectional optical coherence tomography angiography showed baseline subretinal flow patterns which, after treatment, exhibited reduced flow beneath an intact hyperreflective retinal pigment epithelium (RPE) band.
   Conclusion: Pure Type 2 lesions are infrequent in nAMD, often leading to poor visual outcomes related to subretinal fibrosis. We describe an alternate regression pattern occurring in eyes with early Type 2 lesions treated with intravitreal anti-vascular endothelial growth factor therapy in which the neovascular tissue is enveloped by retinal pigment epithelium producing a Type 1 pattern. These eyes appear to have better visual outcomes than typically seen with Type 2 lesions related to reduced outer retinal damage.
C1 [Dolz-Marco, Rosa; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Dolz-Marco, Rosa] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
   [Freund, K. Bailey] Columbia Univ, Coll Phys & Surg, Edward S Harkness Eye Inst, Dept Ophthalmol, New York, NY USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; University of California System; University of
   California Los Angeles; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); VA Greater Los Angeles Healthcare System;
   Columbia University; New York University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Phasukkijwatana, Nopasak/T-8630-2019; Freund, K. Bailey/V-7488-2018
OI Dolz-Marco, Rosa/0000-0002-2963-2541; Freund, K.
   Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and
   Throat Hospital, New York, NY; Macula Foundation Inc, New York, NY;
   Alcon; Allergan; Bayer; Heidelberg Engineering; Novartis; Thea;
   Genentech; Regeneron; Optovue
FX This work was supported by a research grant from the LuEsther T. Mertz
   Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New
   York, NY, and The Macula Foundation Inc, New York, NY.; R. Dolz-Marco:
   Research grants from Alcon, Allergan, Bayer, Heidelberg Engineering,
   Novartis, Thea; N. Phasukkijwatana: None; D. Sarraf: Research grants
   from Genentech, Regeneron and Optovue. Consultant to Genentech and
   Optovue; K. B. Freund: Consultant to Genentech, Optos, Optovue,
   Heidelberg Engineering, and Bayer HealthCare.
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Camacho N, 2015, BRIT J OPHTHALMOL, V99, P1277, DOI 10.1136/bjophthalmol-2014-306226
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chang LK, 2008, ARCH OPHTHALMOL-CHIC, V126, P941, DOI 10.1001/archopht.126.7.941
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Freund KB, 2015, OSLI RETINA, V46, P508, DOI 10.3928/23258160-20150521-01
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hwang JC, 2008, ARCH OPHTHALMOL-CHIC, V126, P941
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Lee Ji Young, 2016, Korean J Ophthalmol, V30, P17, DOI 10.3341/kjo.2016.30.1.17
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Myung JS, 2010, RETINA-J RET VIT DIS, V30, P748, DOI 10.1097/IAE.0b013e3181c596b1
   Parodi MB, 2016, RETINA-J RET VIT DIS, V36, P104, DOI 10.1097/IAE.0000000000000684
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P717, DOI 10.1097/IAE.0b013e318203c1ef
   Weber ML, 2016, DEV OPHTHALMOL, V55, P167, DOI 10.1159/000431194
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 26
TC 22
Z9 21
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2017
VL 37
IS 2
BP 222
EP 233
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK1FO
UT WOS:000393671400011
PM 27627752
DA 2022-11-30
ER

PT J
AU Andreoli, CM
   Miller, JW
AF Andreoli, Christopher M.
   Miller, Joan W.
TI Anti-vascular endothelial growth factor therapy for ocular neovascular
   disease
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; diabetic retinopathy; neovascular
   glaucoma; neovascularization; retinopathy of prematurity; vascular
   endothelial growth factor
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB;
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; PEGAPTANIB; INJECTION;
   VESSELS; AVASTIN; TRIAL; RUBOXISTAURIN
AB Purpose of review
   Recent research has shown that vascular endothelial growth factor (VEGF) is responsible for many ocular pathologies involving neovascularization. Over the past several years several new agents targeting VEGF have become commercially available for intraocular use. These agents have revolutionized the care of neovascular age related macular degeneration and have great potential for other blinding conditions such as diabetic retinopathy, retinopathy of prematurity, and neovascular glaucoma.
   Recent findings
   The VEGF Inhibition Study in Ocular Neovascularization (VISION) trial first showed that an anti-VEGF agent (pegaptanib) was able to prevent vision loss in neovascular age related macular degeneration. The Minimally Classic/ Occult Trial of Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trials showed that ranibizumab prevented moderate vision loss in neovascular age related macular degeneration and for the first time that a substantial proportion of patients regained vision. Smaller case series have shown that bevacizumab can regress retinal, iris and disc neovascularization. Ongoing trials are investigating the utility of anti-VEGF therapy in retinopathy of prematurity, diabetic retinopathy, and neovascular glaucoma.
   Summary
   Newer anti-VEGF therapies have shown unprecedented efficacy in treating age related macular degeneration with many patients experiencing improvement in vision. Ongoing trials will help guide their use in age related macular degeneration and expand their indications to many other blinding diseases.
C1 Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Miller, JW (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM joan_miller@meei.harvard.edu
OI Miller, Joan/0000-0003-2046-3996
CR Abraham P, 2006, OPHTHALMOLOGY, V113, P2221, DOI 10.1016/j.ophtha.2006.07.032
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Aiello LP, 2005, NEW ENGL J MED, V353, P839, DOI 10.1056/NEJMe058142
   Aiello LP, 2005, DIABETES, V54, P2188
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   AVERY RL, 2006, OPHTHALMOLOGY, V113
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chen E, 2006, RETINA-J RET VIT DIS, V26, P699, DOI 10.1097/01.iae.0000225351.87205.69
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Davidorf FH, 2006, RETINA-J RET VIT DIS, V26, P354, DOI 10.1097/00006982-200603000-00017
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedlander SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1363
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAUGHNEY PC, 2005, CLIN PHARMACOKINETIC
   HEIER JS, 2006, RANDOMIZED CONTROLLE
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Isaacs TW, 2006, CLIN EXP OPHTHALMOL, V34, P802, DOI 10.1111/j.1442-9071.2006.01378.x
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P144, DOI 10.3928/1542-8877-20060301-11
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kinose F, 2005, MOL VIS, V11, P366
   Konner Jason, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS81
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P839, DOI 10.1097/01.iae.0000230425.31296.3b
   Mason JO, 2006, AM J OPHTHALMOL, V142, P685, DOI 10.1016/j.ajo.2006.04.058
   Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098
   NGUYEN D, 2006, RESULTS PHASE 1 DOSE
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Palmer EA, 2005, ARCH OPHTHALMOL-CHIC, V123, P311
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963
   Strom C, 2005, INVEST OPHTH VIS SCI, V46, P3855, DOI 10.1167/iovs.05-0096
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Terry TL, 1943, ARCH OPHTHALMOL-CHIC, V29, P36, DOI 10.1001/archopht.1943.00880130054003
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   Tuttle KR, 2005, DIABETES CARE, V28, P2686, DOI 10.2337/diacare.28.11.2686
   Wand M, 1989, GLAUCOMAS, P1063
   Wang FE, 2007, EXP EYE RES, V84, P922, DOI 10.1016/j.exer.2007.01.022
   Young T L, 1997, J AAPOS, V1, P105, DOI 10.1016/S1091-8531(97)90008-2
NR 49
TC 207
Z9 215
U1 0
U2 28
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD NOV
PY 2007
VL 18
IS 6
BP 502
EP 508
DI 10.1097/ICU.0b013e3282f0ca54
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 228AJ
UT WOS:000250698900010
PM 18163003
DA 2022-11-30
ER

PT J
AU Imrie, FR
   Bailey, C
AF Imrie, Fraser R.
   Bailey, Clare
TI New treatments for age-related macular degeneration
SO AGE AND AGEING
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   PHOTODYNAMIC THERAPY; BEVACIZUMAB AVASTIN; VERTEPORFIN; RANIBIZUMAB;
   MACULOPATHY
C1 Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.
C3 Bristol Eye Hospital
EM fraser.imrie@ubht.nhs.uk
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KOROTKIN A, 2006, INVEST OPHTH VIS SCI, V47, P2961
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
NR 14
TC 5
Z9 5
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-0729
J9 AGE AGEING
JI Age Ageing
PD JAN
PY 2007
VL 36
IS 1
BP 8
EP 10
DI 10.1093/ageing/afl135
PG 3
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 138MF
UT WOS:000244366000004
PM 17264135
OA Bronze
DA 2022-11-30
ER

PT J
AU Lu, Y
   Zhao, JQ
   Wang, JC
   Feng, ZH
   Yao, L
   Zhang, XH
AF Ye, Lu
   Jiaqi, Zhao
   Jianchao, Wang
   Zhaohui, Feng
   Liang, Yao
   Xiaohui, Zhang
TI Comparative efficacy and safety of anti-vascular endothelial growth
   factor regimens for neovascular age-related macular degeneration:
   systematic review and Bayesian network meta-analysis
SO THERAPEUTIC ADVANCES IN CHRONIC DISEASE
LA English
DT Review
DE anti-VEGF; regimen; Bayesian meta-analysis; neovascular macular
   degeneration
ID TREAT-AND-EXTEND; INTRAVITREAL AFLIBERCEPT; PHOTODYNAMIC THERAPY;
   COST-EFFECTIVENESS; 0.5 MG; RANIBIZUMAB; BEVACIZUMAB; COMBINATION;
   BROLUCIZUMAB; MONOTHERAPY
AB Background: As a debilitating neurodegenerative disease, neovascular age-related macular degeneration (nAMD) accounts for more than 90% of severe visual loss or legal blindness among AMD patients. Anti-vascular endothelial growth factor (VEGF) had been applied widely in nAMD treatment. To date, debate regarding efficacy and safety still exists among different anti-VEGF regimens as management of nAMD. To provide substantial evidence for clinical nAMD treatment, this study ranks the priority of anti-VEGF regimensviaBayesian network meta-analysis (NMA), comparing data collected from randomized controlled trials (RCTs).
   Methods: We searched PubMed Central, MEDLINE Ovid, Embase Ovid, ISRCTN, ICTRP and ClinicalTrials. gov from a database established until 1 April 2019 systematically for anti-VEGF regimens. Bayesian NMA with random-effect was conducted to compare efficacy and safety and rank priority of anti-VEGF regimens. The primary efficacy and safety outcomes were the proportion of patients gaining 15 or more letters, and the incidence of arterial thromboembolic (ATC) events. The effect measure is the standard mean difference (SMD), or the odds ratio (OR) with their 95% confidence interval (CI). The study protocol is registered with PROSPERO, number CRD42019132243.
   Results: We obtained 6467 citations and identified 29 RCTs including 13,596 participants; 86% of these trials were low risk or of uncertain risk bias. In NMA, ORs compared with sham injection for the proportion of patients gaining 15 or more letters (12,699 participants from 23 trials) ranged from 4.05 [95% Bayesian credible interval (CrI) 1.62-10.11] for ranibizumab quarterly regimen to 8.57 (95% CrI 4.66-15.73) for a ranibizumab treat-and-extend regimen. No difference was found between sham injection and anti-VEGF regimens for ATC events (11,500 participants from 18 trials). Results for the primary outcome did not substantially change in sensitivity analyses after removing studies at high risk of bias and small sample size (n < 100), respectively.
   Conclusion: The treat-and-extend regimen of ranibizumab and aflibercept are the preferred anti-VEGF regimens for nAMD. Bevacizumab treat-and-extend regimens need more head-to-head comparisons with other regimens or sham injection for advanced application. The treat-and-extend regimen proved to be the most effective regimen for each anti-VEGF drug in the NMA. Pegaptanib every 6 weeks and Conbercept quarterly are unable to satisfy the best corrected visual acuity (BCVA) improvement requirement of nAMD patients.
C1 [Ye, Lu; Jiaqi, Zhao; Jianchao, Wang; Zhaohui, Feng; Liang, Yao; Xiaohui, Zhang] Xi An Jiao Tong Univ, Affiliated Hosp 2, Med Coll, Ophthalmol Dept, 157 Xiwu Rd, Xian 710004, Peoples R China.
C3 Xi'an Jiaotong University
RP Zhang, XH (通讯作者)，Xi An Jiao Tong Univ, Affiliated Hosp 2, Med Coll, Ophthalmol Dept, 157 Xiwu Rd, Xian 710004, Peoples R China.
EM tuotuoyanke@163.com
OI zhang, xiaohui/0000-0002-7938-7134; Zhang, Xiaohui/0000-0001-9020-5410
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Amarakoon S, 2019, ACTA OPHTHALMOL, V97, P107, DOI 10.1111/aos.13774
   [Anonymous], 2018, LANCET, V392, pe2
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Borenstein M, 2017, RES SYNTH METHODS, V8, P5, DOI 10.1002/jrsm.1230
   Boyer DS, 2014, BRIT J OPHTHALMOL, V98, P1543, DOI 10.1136/bjophthalmol-2013-304075
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654
   Chang A, 2016, CLIN EXP OPHTHALMOL, V44, P123
   Chen P, 2019, J CELL PHYSIOL, V234, P21915, DOI 10.1002/jcp.28755
   Cipriani A, 2016, LANCET, V388, P881, DOI 10.1016/S0140-6736(16)30385-3
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cui CM, 2018, CLIN INTERV AGING, V13, P51, DOI 10.2147/CIA.S151225
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   Dias S, 2016, NATL I HLTH CARE EXC, V256, P450
   Dias S, 2012, NATL I HLTH CARE EXC, V94, P1
   Dong Y, 2016, EXP THER MED, V12, P3923, DOI 10.3892/etm.2016.3886
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Gallemore RP, 2017, CLIN OPHTHALMOL, V11, P223, DOI 10.2147/OPTH.S119510
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Garczorz W, 2019, PHARMACOL REP, V71, P175, DOI 10.1016/j.pharep.2018.10.003
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grzybowski A, 2018, ACTA OPHTHALMOL, V96, pE885, DOI 10.1111/aos.13756
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hatz K, 2017, EUR J OPHTHALMOL, V27, P470, DOI 10.5301/ejo.5000886
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Katz D, 2019, ANN INTERN MED, V171, pITC17, DOI 10.7326/AITC201908060
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lass JH, 2018, CORNEA, V37, P596, DOI 10.1097/ICO.0000000000001535
   Leppink J, 2016, PERSPECT MED EDUC, V5, P347, DOI 10.1007/s40037-016-0308-y
   Li XX, 2017, J OCUL PHARMACOL TH, V33, P435, DOI 10.1089/jop.2016.0071
   Li XX, 2016, OPHTHALMOLOGICA, V236, P20
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maugeri A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020159
   Moschos MM, 2018, SEMIN OPHTHALMOL, V33, P461, DOI 10.1080/08820538.2017.1301496
   Motarjemizadeh Q, 2018, MIDDLE EAST AFR J OP, V25, P1, DOI 10.4103/meajo.MEAJO_292_16
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P516, DOI 10.1097/IAE.0000000000001572
   National Institute for Health and Clinical Excellence, 2018, AG REL MAC DEG
   Ng ALK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081720
   Russo A, 2018, CLIN OPHTHALMOL, V12, P587, DOI 10.2147/OPTH.S159672
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Slee A, 2019, LANCET, V393, P768, DOI 10.1016/S0140-6736(18)31793-8
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P761, DOI 10.1080/13543776.2019.1671353
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub6
   Vottonen P, 2018, ACTA OPHTHALMOL, V96, P1, DOI 10.1111/aos.13706
   Wang LP, 2018, DRUG DES DEV THER, V12, P3625, DOI 10.2147/DDDT.S176021
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Y, 2019, CLIN INTERV AGING, V14, P1277, DOI 10.2147/CIA.S200637
   Xia T, 2017, VISION RES, V139, P72, DOI 10.1016/j.visres.2017.02.006
   Xu JW, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109606
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
NR 66
TC 8
Z9 9
U1 0
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 2040-6223
EI 2040-6231
J9 THER ADV CHRONIC DIS
JI Ther. Adv. Chronic Dis.
PD SEP
PY 2020
VL 11
AR 2040622320953349
DI 10.1177/2040622320953349
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NM2EV
UT WOS:000567916200001
PM 32953000
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schick, JH
   Iyengar, SK
   Klein, BE
   Klein, R
   Reading, K
   Liptak, R
   Millard, C
   Lee, KE
   Tomany, SC
   Moore, EL
   Fijal, BA
   Elston, RC
AF Schick, JH
   Iyengar, SK
   Klein, BE
   Klein, R
   Reading, K
   Liptak, R
   Millard, C
   Lee, KE
   Tomany, SC
   Moore, EL
   Fijal, BA
   Elston, RC
TI A whole-genome screen of a quantitative trait of age-related maculopathy
   in sibships from the Beaver Dam Eye Study
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID MACULAR DEGENERATION; VISUAL-ACUITY; STARGARDT-DISEASE; 5-YEAR
   INCIDENCE; GRADING SYSTEM; FRAMINGHAM EYE; GENE ABCR; PREVALENCE;
   POPULATION; APOPTOSIS
AB Age-related maculopathy (ARM) is a leading cause of visual impairment among the elderly in Western populations. To identify ARM-susceptibility loci, we genotyped a subset of subjects from the Beaver Dam (WI) Eye Study and performed a model-free genomewide linkage analysis for markers linked to a quantitative measure of ARM. We initially genotyped 345 autosomal markers in 325 individuals (N = 263 sib pairs) from 102 pedigrees. Ten regions suggestive of linkage with ARM were observed on chromosomes 3, 5, 6, 12, 15, and 16. Prior to fine mapping, the most significant regions were an 18-cM region on chromosome 12, near D12S1300 (P = .0159); a region on chromosome 3, near D3S1763, with a P value of .0062; and a 6-cM region on chromosome 16, near D16S769, with a P value of .0086. After expanding our analysis to include 25 additional fine-mapping markers, we found that a 14-cM region on chromosome 12, near D12S346 (located at 106.89 cM), showed the strongest indication of linkage, with a P value of .004. Three other regions, on chromosomes 5, 6, and 15, that were nominally significant at P less than or equal to .01 are also appropriate for fine mapping.
C1 Case Western Reserve Univ, Dept Epidemiol & Biostat, Metrohlth Med Ctr, Cleveland, OH 44109 USA.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Case Western Reserve University; MetroHealth System; University of
   Wisconsin System; University of Wisconsin Madison
RP Schick, JH (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Metrohlth Med Ctr, Rammelkamp Bldg,Room 258,2500 Metrohlth Dr, Cleveland, OH 44109 USA.
EM texilene@darwin.EPBI.cwru.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Klein, Ronald/0000-0002-4428-6237
FU NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [U10EY006594, R01EY010605] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [R01GM028356, R37GM028356] Funding Source: NIH RePORTER; NCRR NIH HHS
   [P41 RR003655, RR03655] Funding Source: Medline; NEI NIH HHS [EY10605,
   U10 EY006594, U10-EY06594] Funding Source: Medline; NHLBI NIH HHS [T32
   HL007567, HL07567] Funding Source: Medline; NIGMS NIH HHS [R37 GM028356,
   GM28356, R01 GM028356] Funding Source: Medline
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   [Anonymous], [No title captured]
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BONNEY GE, 1984, AM J MED GENET, V18, P731, DOI 10.1002/ajmg.1320180420
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DOSSO AA, 1992, OPHTHALMOLOGICA, V205, P24, DOI 10.1159/000310307
   Elston RC, 2000, GENET EPIDEMIOL, V19, P1, DOI 10.1002/1098-2272(200007)19:1<1::AID-GEPI1>3.0.CO;2-E
   ELSTON RC, 1979, AM J HUM GENET, V31, P655
   ELSTON RC, 1972, GENESCREEN, V1, P63
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Gomes I, 1999, ANN HUM GENET, V63, P535, DOI 10.1017/S0003480099007824
   GOURIEROUX C, 1984, ECONOMETRICA, V52, P681, DOI 10.2307/1913471
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hoyng CB, 1996, HUM GENET, V98, P500, DOI 10.1007/s004390050247
   Huber P.J., 1967, P 5 BERK S MATH STAT, V5, P221
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Olson JM, 1999, AM J HUM GENET, V65, P1760, DOI 10.1086/302662
   Putter H, 2002, GENET EPIDEMIOL, V22, P345, DOI 10.1002/gepi.01104
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schick James H., 2001, International Journal of Human Genetics, V1, P11
   SHETE S, IN PRESS HUM HERED
   SMALL KW, 1992, GENOMICS, V13, P681, DOI 10.1016/0888-7543(92)90141-E
   Small KW, 1999, MOL VIS, V5
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tarttelin EE, 2001, J MED GENET, V38, P381, DOI 10.1136/jmg.38.6.381
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tielsch JA, 1995, VISION PROBLEMS US R, P1
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WILSON AF, 1991, AM J HUM GENET, V48, P862
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   YOSHIMURA S, 1994, GENE, V145, P293
NR 64
TC 76
Z9 81
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUN
PY 2003
VL 72
IS 6
BP 1412
EP 1424
DI 10.1086/375500
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 685QV
UT WOS:000183275500005
PM 12717633
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Elshout, M
   van der Reis, MI
   Webers, CAB
   Schouten, JSAG
AF Elshout, Mari
   van der Reis, Margriet I.
   Webers, Carroll A. B.
   Schouten, Jan S. A. G.
TI The cost-utility of aflibercept for the treatment of age-related macular
   degeneration compared to bevacizumab and ranibizumab and the influence
   of model parameters
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Cost-effectiveness; Aflibercept;
   Bevacizumab; Ranibizumab
ID VISUAL IMPAIRMENT; PREVALENCE; EYE
AB Age-related macular degeneration (AMD) is a blinding disease placing considerable burden on society due to blindness-associated costs. Intravitreal anti-vascular endothelial growth factors (anti-VEGFs) are effective in reducing the incidence of blindness, but at potentially high costs, depending on the cost of the drug used. Aflibercept has been introduced as an anti-VEGF equally effective to ranibizumab, but less costly. For this new drug, new cost-effectiveness analyses are needed, and AMD models used today give biased results. We investigated the cost-effectiveness of aflibercept compared to bevacizumab, ranibizumab, and no treatment and studied the influence of commonly used model parameters.
   A patient-level, visual acuity-based, 2-eye model was developed. Data on effectiveness were derived from randomized controlled trials evaluating the outcomes of aflibercept, bevacizumab, and ranibizumab. Utility and resource utilization were assessed in interviews with AMD patients. Costs were based on standard health care cost prices. Time horizons were two and five years. A societal perspective was employed.
   Over five years, costs associated with aflibercept treatment were a,not sign36,030, with 2.15 QALYs. Costs associated with the bevacizumab regimens, ABC study as-needed (PRN); CATT study PRN; and CATT study 1x/month, were a,not sign19,367; a,not sign26,746; and a,not sign30,520, with 2.16; 2.17; and 2.15 QALYs, respectively. Costs associated with ranibizumab PRN and 1x/month were a,not sign45,491 and a,not sign74,837 with 2.16 and 2.15 QALYs, respectively. 'No treatment' was associated with a,not sign9530 and 1.96 QALYs. The incremental cost-effectiveness ratios versus 'no treatment' were: aflibercept-a,not sign140,274; bevacizumab-a,not sign51,062 (ABC PRN), a,not sign83,256 (CATT PRN) and a,not sign110,361 (1x/month); ranibizumab-a,not sign181,667 (PRN) and a,not sign349,773 (1x/month). Results were highly dependent on whether only one or both eyes were included, length of time horizon, and whether the costs of blindness and low-vision were included in the analysis.
   Aflibercept is a cost-effective treatment for AMD over ranibizumab. However, aflibercept is not a cost-effective treatment when compared to bevacizumab. Application of inappropriate model assumptions leads to a biased cost-saving estimate of the cost-effectiveness of aflibercept. Therefore, cost-effectiveness analyses should be conducted with appropriate models.
C1 [Elshout, Mari; van der Reis, Margriet I.; Webers, Carroll A. B.; Schouten, Jan S. A. G.] Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, NL-6202 AZ Maastricht, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC)
RP Elshout, M (通讯作者)，Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM m.elshout@mumc.nl
RI Webers, Carroll A.B./D-1130-2010; Schouten, Johannes S.A.G./M-9376-2016
OI Schouten, Johannes S.A.G./0000-0001-6495-7758
FU Dutch organization for health research and development ZonMw, The Hague,
   The Netherlands [152001002]
FX This study was supported by the Dutch organization for health research
   and development ZonMw, The Hague, The Netherlands, grant number
   152001002.
CR [Anonymous], 2010, GEN OV GESL LEEFT PE
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Larouche K, 2004, EVALUATION PHOTODYNA, P101
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oostenbrink J, 2004, HANDLEIDING KOSTENON
   Roijen LH-v, 2010, HANDL KOST METH STAN
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Statistics Netherlands, 2017, CONS PRIC PRIC IND 2
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 18
TC 41
Z9 44
U1 1
U2 34
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2014
VL 252
IS 12
BP 1911
EP 1920
DI 10.1007/s00417-014-2641-3
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU4NW
UT WOS:000345589300006
PM 24777708
DA 2022-11-30
ER

PT J
AU Etheridge, T
   Liu, Z
   Nalbandyan, M
   Cleland, S
   Blodi, BA
   Mares, JA
   Bailey, S
   Wallace, R
   Gehrs, K
   Tinker, LF
   Gangnon, R
   Domalpally, A
AF Etheridge, Tyler
   Liu, Zhe
   Nalbandyan, Marine
   Cleland, Spencer
   Blodi, Barbara A.
   Mares, Julie A.
   Bailey, Steven
   Wallace, Robert
   Gehrs, Karen
   Tinker, Lesley F.
   Gangnon, Ronald
   Domalpally, Amitha
CA CAREDS2 Res Study Grp
TI Association of Macular Thickness With Age and Age-Related Macular
   Degeneration in the Carotenoids in Age-Related Eye Disease Study 2
   (CAREDS2), An Ancillary Study of the Women's Health Initiative
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; carotenoids in age-related eye disease
   study 2; macular thickness; optical coherence tomography; women?s health
   initiative; postmenopausal; women
AB Purpose: To evaluate the relationship of retinal layer thickness with age and age-related macular degeneration (AMD) in the Carotenoids in Age-Related Eye Disease Study 2. Methods: Total retinal thickness within the macular area, and individual layer thickness was determined for CAREDS2 participants (n = 906 eyes, 473 women) from the Women?s Health Initiative using Heidelberg optical coherence tomography (OCT). Mean measurements within the OCT grid were compared across age tertiles (69?78, 78?83, and 83?101 years) and AMD outcomes. Results: Mean retinal thickness in the central circle, inner ring, and outer ring were 277 ? 34 ?m, 326 ? 20 ?m, and 282 ? 15 ?m, respectively. Thickness did not vary by age in the central circle, but decreased with age in the inner and outer circles (P < 0.004). Specifically, ganglion cell (GCL), inner plexiform, and outer nuclear (ONL) layer thickness decreased with age (P < 0.003). Age-adjusted retinal thickness in all three circles did not vary by AMD outcomes (486 without AMD and 413 with AMD). However, individual layers showed changes with GCL and photoreceptor thinning and retinal pigment epithelial thicknening in eyes with late AMD. After controlling for age and AMD, higher ONL thickness was associated with better visual acuity. Conclusions: In this cohort of older women, a decrease in perifoveal thickness was associated with increasing age, particularly in the inner retinal layers. Variabilty in thickness in AMD eyes was primarily due to outer retinal layers. Among all retinal layers, the ONL plays an important role in preserving visual acuity. Translational Relevance: The study provides a deeper understanding of age related changes to the retinal layers and their effect on visual loss.
C1 [Etheridge, Tyler; Liu, Zhe; Nalbandyan, Marine; Cleland, Spencer; Blodi, Barbara A.; Mares, Julie A.; Domalpally, Amitha] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI USA.
   [Bailey, Steven] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR USA.
   [Wallace, Robert] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA.
   [Gehrs, Karen] Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA.
   [Tinker, Lesley F.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Canc Res Program, 1124 Columbia St, Seattle, WA 98104 USA.
   [Gangnon, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA.
   [Gangnon, Ronald] Univ Wisconsin Madison, Dept Biostat & Med Informat, Madison, WI USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Oregon
   Health & Science University; University of Iowa; University of Iowa;
   Fred Hutchinson Cancer Center; University of Wisconsin System;
   University of Wisconsin Madison; University of Wisconsin System;
   University of Wisconsin Madison
RP Domalpally, A (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Fundus Photograph Reading Ctr, 310 N Midvale Blvd,Suite 205, Madison, WI 53705 USA.
EM domalpally@wisc.edu
RI Nalbandyan, Marine/AAN-4163-2021
OI Nalbandyan, Marine/0000-0003-0604-5333; Wall,
   Michael/0000-0002-9802-4806; Bailey, Steven/0000-0003-4949-1464
FU National Eye Institute [EY013018, EY016886, EY025292]; Office of Dietary
   Supplements [EY025292-01S1]; Research to Prevent Blindness, Inc.;
   National Eye Institute Vision Research Core grant [P30 EY016665];
   National Heart, Lung, and Blood Institute, National Institutes of Health
   [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115,
   32118-32119, 32122, 2107-26, 42129-32, 44221]; Clinical and
   Translational Science Award (CTSA) program, through the NIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002373];
   National Heart, Lung, and Blood Institute, National Institutes of
   Health, U.S. Department of Health and Human Services [HHSN268201600018C,
   HHSN268201600001C, HHSN268201600002C, HHSN268201600003C,
   HHSN268201600004C]
FX Supported by National Eye Institute grants EY013018, EY016886 and
   EY025292, and a supplement to EY025292-01S1 from the Office of Dietary
   Supplements. This work was also supported in part by an unrestricted
   grant from Research to Prevent Blindness, Inc. to the UW Madison
   Department of Ophthalmology and Visual Sciences, and in part by a
   National Eye Institute Vision Research Core grant (P30 EY016665) to the
   UW Madison Department of Ophthalmology and Visual Sciences. The WHI
   program is funded by the National Heart, Lung, and Blood Institute,
   National Institutes of Health through contracts N01WH22110, 24152,
   32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 2107-26,
   42129-32, and 44221. The project described was supported by the Clinical
   and Translational Science Award (CTSA) program, through the NIH National
   Center for Advancing Translational Sciences (NCATS), grant UL1TR002373.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the NIH. The WHI program is
   funded by the National Heart, Lung, and Blood Institute, National
   Institutes of Health, U.S. Department of Health and Human Services
   through contracts HHSN268201600018C, HHSN268201600001C,
   HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Ctori I, 2015, GRAEF ARCH CLIN EXP, V253, P733, DOI 10.1007/s00417-014-2915-9
   Cuenca N, 2018, OPHTHALMOLOGY, V125, P407, DOI 10.1016/j.ophtha.2017.09.016
   Dai W, 2019, BRIT J OPHTHALMOL, V103, P64, DOI 10.1136/bjophthalmol-2018-313159
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Demirkaya N, 2013, INVEST OPHTH VIS SCI, V54, P4934, DOI 10.1167/iovs.13-11913
   Duan XR, 2010, OPHTHALMOLOGY, V117, P1585, DOI 10.1016/j.ophtha.2009.12.036
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Girkin CA, 2011, OPHTHALMOLOGY, V118, P2403, DOI 10.1016/j.ophtha.2011.06.013
   Gupta P, 2013, INVEST OPHTH VIS SCI, V54, P7968, DOI 10.1167/iovs.13-12436
   Invernizzi A, 2018, OPHTHALMOL RETINA, V2, P808, DOI 10.1016/j.oret.2017.12.012
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kelty PJ, 2008, INVEST OPHTH VIS SCI, V49, P2668, DOI 10.1167/iovs.07-1000
   Khawaja AP, 2020, OPHTHALMOLOGY, V127, P62, DOI 10.1016/j.ophtha.2019.08.015
   Kim JH, 2014, INVEST OPHTH VIS SCI, V55, P4801, DOI 10.1167/iovs.13-13052
   Koo HC, 2012, GRAEF ARCH CLIN EXP, V250, P491, DOI 10.1007/s00417-011-1848-9
   Lam DSC, 2007, INVEST OPHTH VIS SCI, V48, P376, DOI 10.1167/iovs.06-0426
   Langer RD, 2003, ANN EPIDEMIOL, V13, pS107, DOI 10.1016/S1047-2797(03)00047-4
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Myers CE, 2015, AM J OPHTHALMOL, V159, P445, DOI 10.1016/j.ajo.2014.11.025
   National Eye Institute (NEI) Age-Related Eye Disease Study (AREDS), CHAPTER 7 EXAMINATIO
   Pierro L, 2010, AM J OPHTHALMOL, V150, P199, DOI 10.1016/j.ajo.2010.03.015
   Pinilla I, 2020, RETINA-J RET VIT DIS, V40, P1379, DOI 10.1097/IAE.0000000000002576
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rao HL, 2011, INVEST OPHTH VIS SCI, V52, P1103, DOI 10.1167/iovs.10-5997
   Rock T, 2014, INVEST OPHTH VIS SCI, V55, P7494, DOI 10.1167/iovs.14-14043
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Satue M, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/8503859
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Sohn EH, 2013, INVEST OPHTH VIS SCI, V54, P4184, DOI 10.1167/iovs.12-10420
   Song WK, 2010, INVEST OPHTH VIS SCI, V51, P3913, DOI 10.1167/iovs.09-4189
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Sung KR, 2009, OPHTHALMOLOGY, V116, P1119, DOI 10.1016/j.ophtha.2009.01.004
   Tariq YM, 2011, CLIN EXP OPHTHALMOL, V39, P893, DOI 10.1111/j.1442-9071.2011.02593.x
   von Hanno T, 2017, ACTA OPHTHALMOL, V95, P262, DOI 10.1111/aos.13337
   Waldstein SM, 2015, BRIT J OPHTHALMOL, V99, P794, DOI 10.1136/bjophthalmol-2014-305573
   Wang Q, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1296-6
NR 40
TC 2
Z9 2
U1 1
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2021
VL 10
IS 2
DI 10.1167/tvst.10.2.39
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RG2SX
UT WOS:000635394600009
PM 34003924
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Aflibercept (Eylea) for Age-Related Macular Degeneration
SO MEDICAL LETTER ON DRUGS AND THERAPEUTICS
LA English
DT Article
ID BEVACIZUMAB
CR Frost BA, 2011, NEW ENGL J MED, V365, P2238, DOI 10.1056/NEJMc1105759
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Stewart MW, 2011, RETINA
NR 3
TC 5
Z9 5
U1 0
U2 3
PU MED LETTER INC
PI NEW ROCHELLE
PA 1000 MAIN STREET, NEW ROCHELLE, NY 10801 USA
SN 0025-732X
J9 MED LETT DRUGS THER
JI Med. Lett. Drugs Ther.
PD FEB 6
PY 2012
VL 54
IS 1383
BP 9
EP 10
PG 2
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 895CU
UT WOS:000300474600001
PM 22354219
DA 2022-11-30
ER

PT J
AU Reddy, P
   Gao, X
   Barnes, R
   Fairchild, C
   Boci, K
   Waycaster, C
   Pashos, C
AF Reddy, Prabashni
   Gao, Xin
   Barnes, Rod
   Fairchild, Carol
   Boci, Kreda
   Waycaster, Curtis
   Pashos, Chris
TI The economic impact of blue-light filtering intraocular lenses on
   age-related macular degeneration associated with cataract surgery: a
   third-party payer's perspective
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE age-related macular degeneration; blue-light filtering; cataract
   surgery; economics; intraocular lenses
ID 5-YEAR INCIDENCE; BEAVER DAM; MACULOPATHY; EYE
AB Objectives: Epidemiological data support an association between age-related macular degeneration (AMD) and cataract surgery that may be attributed to post-operative blue light exposure. By limiting the retina's blue light exposure, new blue-light filtering intraocular lenses (BLF IOLs) have the potential to reduce the development of AMD following cataract surgery. In the current economic healthcare environment, there is increased interest in the cost impact of new medical technologies. The objective of this analysis was to evaluate the cost impact of a BLF IOL versus a non-BLF IOL in cataract surgery.
   Methods: An economic model was developed to emulate three age-specific cohorts and to assess the clinical and economic outcomes over 5 years. Data from the published literature was supplemented with clinical expert opinion. Key literature inputs involved the risk of AMD after cataract surgery as well as laboratory and animal data on the effectiveness of the BLF IOL in reducing the risk of AMD. Clinical experts provided information on the management of AMD. Direct medical costs including the cost of the IOL, monitoring, and AMD prophylaxis and treatment were incorporated into the model. All costs were standardized to 2004 US dollars. Age-stratified sensitivity analyses were conducted.
   Results: In the BLF IOL group, the 5-year age- stratified incidence of AMD ranged from 0.58 to 9.23 per 100 eyes, compared with 1.69 to 24.55 per 100 eyes in the non-BLF IOL group. The incremental cost of the BLF was offset by reduced costs associated with averted AMD treatment. Estimated savings with BLF IOLs per 100 eyes were $4275, $29 997, and $111 734 in the 55 to 64 year-old, 65 to 74 year-old, and 75-year-old cohorts, respectively; these findings remained robust throughout the sensitivity analyses.
   Conclusion: Limitations of this analysis include the lack of prospective clinical trial data that definitively demonstrate the efficacy of a BLF IOL in preventing AMD. Moreover, the efficacy data used to populate the model were derived from laboratory and animal studies. Thus, based on preliminary data, this study suggests that the economic benefits of implanting BLF IOLs during cataract surgery are observed in all patients over a 5-year timeframe although cost savings are greatest in patients 75 years.
C1 ABT Associates Inc, HERQuLES, Lexington, MA 02421 USA.
   Alcon Labs Inc, Hlth Econ, Ft Worth, TX 76134 USA.
C3 ABT Associates; Novartis; Alcon
RP Reddy, P (通讯作者)，ABT Associates Inc, HERQuLES, 181 Spring St, Lexington, MA 02421 USA.
EM prabashni_reddy@abtassoc.com
CR *AC MAN CAR PHARM, 2005, HLTH SYST GUID MAN V
   *ALC LAB, VIG PACK INS
   *AM MED ASS, 2003, CURR PROC TERM 2003
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   Das Taraprasad, 2003, Semin Ophthalmol, V18, P109, DOI 10.1080/08820530390899132
   *DEP HLT, 2004, OE1060200710 DEP HLT
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   GORDIS L, MORE RISK ESTIMATING, P155
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   *MED EC, 2004, REDB PHARM FUND REF
   *NAT FEE AN, 2004, CHARG DAT EV FEES NA
   Nilsson SE, 2004, ACTA OPHTHALMOL SCAN, V82, P123, DOI 10.1111/j.1600-0420.2004.00248.x
   NILSSON SEG, 1990, LASERS LIGHT OPHTHAL, V3, P1
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   Shah VA, 2004, OPHTHAL EPIDEMIOL, V11, P43, DOI 10.1076/opep.11.1.43.26436
   Sliney D., 1985, SAFETY LASERS OTHER
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 25
TC 6
Z9 6
U1 0
U2 4
PU LIBRAPHARM
PI NEWBURY
PA 29-35  VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE,
   ENGLAND
SN 0300-7995
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JUL
PY 2006
VL 22
IS 7
BP 1311
EP 1318
DI 10.1185/030079906X115586
PG 8
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 062PR
UT WOS:000238957500009
PM 16834830
DA 2022-11-30
ER

PT J
AU Parsons, CG
   Ruitenberg, M
   Freitag, CE
   Sroka-Saidi, K
   Russ, H
   Rammes, G
AF Parsons, Christopher G.
   Ruitenberg, Maarten
   Freitag, Christine E.
   Sroka-Saidi, Kamila
   Russ, Hermann
   Rammes, Gerhard
TI MRZ-99030-A novel modulator of A beta aggregation: I - Mechanism of
   action (MoA) underlying the potential neuroprotective treatment of
   Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
SO NEUROPHARMACOLOGY
LA English
DT Article
DE Alzheimer's disease; Glaucoma; Age related macular degeneration (AMD);
   beta-amyloid; Oligomers; Aggregation modulator; SDS-PAGE; Fluorescence
   resonance energy transfer (TR-FRET); Dynamic light scattering (DLS);
   Atomic force microscopy (AFM)
ID AMYLOID PRECURSOR PROTEIN; COMPLEMENT ACTIVATION; RETINAL PATHOLOGY;
   SYNAPTIC PLASTICITY; UNITED-STATES; MOUSE MODEL; PEPTIDE; OLIGOMERS;
   TOXICITY; NEURONS
AB Therapeutic approaches addressing beta-amyloid(1-42) (A beta(1-42)) aggregation represent a promising neuroprotective strategy for the treatment of Alzheimer's disease, dry age-related macular degeneration (AMD) and glaucoma. MRZ-99030 is a dipeptide containing D-tryptophan and 2-amino-2-methylpropionic acid in clinical development for the topical treatment of glaucoma and AMD.
   MRZ-99030 is an A beta aggregation modulator, previously reported to prevent the formation of soluble toxic oligomeric A beta species. The present study confirmed that MRZ-99030 prevents the formation of oligomeric A beta species using similar SDS-PAGE experiments. However, additional data from TR-FRET, DLS and AFM experiments revealed that MRZ-99030 does not directly prevent early protein/protein interactions between monomeric A beta, but rather promotes the formation of large, non-amyloidogenic, amorphous A beta aggregates and thereby reduces the amount of intermediate toxic soluble oligomeric A beta species.
   The affinity of MRZ-99030 to A beta(1-42) determined by SPR was 28.4 nM but the ratio of compound to A beta is also important: a 10-20 fold excess of MRZ-99030 over A beta is probably required for effective modulation of protein/protein interactions. For example, in glaucoma, assuming a maximal A beta concentration of 1-15 nM in the retina, up to 150 nM MRZ-99030 could be required at the protein target. In line with this consideration, MRZ-99030 was able to prevent A beta-induced toxicity on PC12 cells, retinal ganglion cells and retinal pigment epithelium cells when present at a 10-20 fold stoichiometric excess over A beta. Moreover, in vivo studies demonstrate the neuroprotective potential of MRZ-99030 after systemic and topical administration in animal models of Alzheimer's disease and glaucoma/AMD respectively. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Parsons, Christopher G.; Ruitenberg, Maarten; Freitag, Christine E.; Sroka-Saidi, Kamila; Russ, Hermann] Merz Pharmaceut, D-60318 Frankfurt, Germany.
   [Rammes, Gerhard] Tech Univ Munich, Dept Anaesthesiol, D-81675 Munich, Germany.
C3 Merz Pharmaceuticals GmbH; Technical University of Munich
RP Parsons, CG (通讯作者)，Merz Pharmaceut, Eckenheimer Landstr 100, D-60318 Frankfurt, Germany.
EM christopher.parsons@merz.de
OI Parsons, Christopher/0000-0002-3122-8572
CR Abramov E, 2009, NAT NEUROSCI, V12, P1567, DOI 10.1038/nn.2433
   Alberdi E, 2010, CELL CALCIUM, V47, P264, DOI 10.1016/j.ceca.2009.12.010
   Alzheimer A., 1907, Z GESAMTE NEUROL PSY, V18, P177
   BAO F, 2011, NEUROBIOL AGING
   Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x
   Bell KFS, 2006, EUR J PHARMACOL, V545, P11, DOI 10.1016/j.ejphar.2006.06.045
   Bi X, 2002, NEUROSCIENCE, V112, P827, DOI 10.1016/S0306-4522(02)00132-X
   Bieschke J., 2011, NAT CHEM BIOL
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Blanks JC, 1996, NEUROBIOL AGING, V17, P385, DOI 10.1016/0197-4580(96)00009-7
   BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203
   BRAAK H, 1993, EUR NEUROL, V33, P403, DOI 10.1159/000116984
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Citron M, 2010, NAT REV DRUG DISCOV, V9, P387, DOI 10.1038/nrd2896
   DEFELICE FG, 2007, NEUROBIOL AGING
   Demuro A, 2010, J BIOL CHEM, V285, P12463, DOI 10.1074/jbc.R109.080895
   Dentchev T, 2003, MOL VIS, V9, P184
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Ferreira A, 2011, METHODS MOL BIOL, V670, P141, DOI 10.1007/978-1-60761-744-0_11
   Ferreira S.T., 2011, NEUROBIOL LEARN MEM
   Ferreira ST, 2007, IUBMB LIFE, V59, P332, DOI 10.1080/15216540701283882
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Frydman-Marom A, 2011, AMYLOID, V18, P119, DOI 10.3109/13506129.2011.582902
   Frydman-Marom A, 2009, ANGEW CHEM INT EDIT, V48, P1981, DOI 10.1002/anie.200802123
   Funke SA, 2010, ACS CHEM NEUROSCI, V1, P639, DOI 10.1021/cn100057j
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Giuffrida ML, 2009, J NEUROSCI, V29, P10582, DOI 10.1523/JNEUROSCI.1736-09.2009
   Goldblum D, 2007, INVEST OPHTH VIS SCI, V48, P5085, DOI 10.1167/iovs.06-1249
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067
   Heininger K, 1999, HUM PSYCHOPHARM CLIN, V14, P525, DOI 10.1002/(SICI)1099-1077(199912)14:8<525::AID-HUP140>3.0.CO;2-T
   Hoh Kam J., 2010, PLOS ONE, V5
   Iseri PK, 2006, J NEURO-OPHTHALMOL, V26, P18, DOI 10.1097/01.wno.0000204645.56873.26
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kipfer-Kauer A, 2010, CURR EYE RES, V35, P828, DOI 10.3109/02713683.2010.494240
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klyubin I, 2004, EUR J NEUROSCI, V19, P2839, DOI 10.1111/j.1460-9568.2004.03389.x
   Koeberle MJ, 2003, J CHROMATOGR B, V787, P313, DOI 10.1016/S1570-0232(02)00957-1
   Kokkoni N, 2006, BIOCHEMISTRY-US, V45, P9906, DOI 10.1021/bi060837s
   Kumar J, 2014, PRION, V8, P118, DOI 10.4161/pri.28220
   Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007
   Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533
   MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992
   McKinnon SJ, 2003, FRONT BIOSCI-LANDMRK, V8, pS1140, DOI 10.2741/1172
   MORRIS RG, 1986, Q J EXP PSYCHOL-A, V38, P575, DOI 10.1080/14640748608401615
   Neniskyte U, 2011, J BIOL CHEM, V286, P39904, DOI 10.1074/jbc.M111.267583
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Parisi V, 2001, CLIN NEUROPHYSIOL, V112, P1860, DOI 10.1016/S1388-2457(01)00620-4
   Pitkanen L, 2007, PHARM RES-DORDR, V24, P2063, DOI 10.1007/s11095-007-9342-0
   Puzzo D, 2008, J NEUROSCI, V28, P14537, DOI 10.1523/JNEUROSCI.2692-08.2008
   Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103
   Rammes G., 2011, SOC NEUR 41 SOC NEUR
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Rottenberg H, 1979, Methods Enzymol, V55, P547
   Scorneaux B, 1998, J VET PHARMACOL THER, V21, P257, DOI 10.1046/j.1365-2885.1998.00133.x
   Selkoe DJ, 2008, BEHAV BRAIN RES, V192, P106, DOI 10.1016/j.bbr.2008.02.016
   Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007
   Shelat P. B., 2008, J NEUROCHEM
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Sokolow S, 2012, NEUROBIOL AGING, V33, P1545, DOI 10.1016/j.neurobiolaging.2011.05.011
   Sun LW, 2006, EUR J NEUROSCI, V24, P1011, DOI 10.1111/j.1460-9568.2006.04951.x
   Surguchev A, 2010, BRAIN RES BULL, V81, P12, DOI 10.1016/j.brainresbull.2009.09.015
   Tomiyama T, 2010, J NEUROSCI, V30, P4845, DOI 10.1523/JNEUROSCI.5825-09.2010
   Tsuruma K, 2010, J NEUROCHEM, V113, P1545, DOI 10.1111/j.1471-4159.2010.06724.x
   van Helmond Z, 2010, BRAIN PATHOL, V20, P787, DOI 10.1111/j.1750-3639.2010.00374.x
   Von Thun und Hohenstein-Blaul N., 2013, BETA AMYLOID DEPOSIT, P1139
   Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wilcox KC, 2011, CELL MOL NEUROBIOL, V31, P939, DOI 10.1007/s10571-011-9691-4
   Xia WM, 2010, NEUROPSYCH DIS TREAT, V6, P605, DOI 10.2147/NDT.S7460
   Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4
   Yoneda S, 2005, JPN J OPHTHALMOL, V49, P106, DOI 10.1007/s10384-004-0156-x
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhu X, 2009, BIOCHEM BIOPH RES CO, V384, P110, DOI 10.1016/j.bbrc.2009.04.080
NR 75
TC 23
Z9 24
U1 1
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD MAY
PY 2015
VL 92
BP 158
EP 169
DI 10.1016/j.neuropharm.2014.12.038
PG 12
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA CE4IG
UT WOS:000351793700019
PM 25634238
DA 2022-11-30
ER

PT J
AU Berg, K
   Hadzalic, E
   Gjertsen, I
   Forsaa, V
   Berger, LH
   Kinge, B
   Henschien, H
   Fossen, K
   Markovic, S
   Pedersen, TR
   Sandvik, L
   Bragadottir, R
AF Berg, Karina
   Hadzalic, Emina
   Gjertsen, Inger
   Forsaa, Vegard
   Berger, Lars Haakon
   Kinge, Bettina
   Henschien, Hans
   Fossen, Kristian
   Markovic, Slavica
   Pedersen, Terje R.
   Sandvik, Leiv
   Bragadottir, Ragnheiour
TI Ranibizumab or Bevacizumab for Neovascular Age-Related Macular
   Degeneration According to the Lucentis Compared to Avastin Study
   Treat-and-Extend Protocol Two-Year Results
SO OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR THERAPY; REGIMEN; TRIAL
AB Purpose: To compare the efficacy and safety of bevacizumab (Avastin; F. Hoffmann-La Roche Ltd, Basel, Switzerland) versus ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) for neovascular age-related macular degeneration (nAMD) after 2 years when using a treat-and-extend protocol.
   Design: Multicenter, randomized, noninferiority trial with a noninferiority limit of 5 letters.
   Participants: Patients 50 years of age or older with previously untreated nAMD in 1 eye and best-corrected visual acuity 20/25 to 20/320.
   Methods: Patients were assigned randomly to receive intravitreal injections with either ranibizumab 0.5 mg or bevacizumab 1.25 mg. Injections were given every 4 weeks until inactive disease was achieved. The treatment interval then was extended by 2 weeks at a time up to a maximum of 12 weeks. In the event of a recurrence, the treatment interval was shortened by 2 weeks at a time.
   Main Outcome Measure: Mean change in visual acuity at 2 years.
   Results: Of a total of 441 randomized patients, 339 patients (79%) completed the 2-year visit. According to per-protocol analysis at 2 years, bevacizumab was equivalent to ranibizumab, with 7.4 and 6.6 letters gained, respectively (95% confidence interval [CI] of mean difference, -4.1 to 2.5; P = 0.634). Intention-to-treat analysis was concordant, with a gain of 7.8 letters for bevacizumab and 7.5 letters for ranibizumab (95% CI of mean difference, -3.2 to 2.7; P = 0.873). The 2-year results did not show any significant difference in mean central retinal thickness, with a decrease of -113 mu m for bevacizumab and -122 mu m for ranibizumab (95% CI of mean difference, -32 to 15; P = 0.476). There was a statistically significant difference between the drugs regarding the number of treatments given, with 18.2 injections for bevacizumab and 16.0 injections for ranibizumab (95% CI of mean difference, -3.4 to -1.0; P <= 0.001). The number of serious adverse events was similar between the groups over the course of the study.
   Conclusions: At 2 years, bevacizumab and ranibizumab had an equivalent effect on visual acuity and reduction of central retinal thickness when administered according to a treat-and-extend protocol for nAMD. There was no significant difference in the number of serious adverse events between the treatment groups. (C) 2016 by the American Academy of Ophthalmology.
C1 [Berg, Karina; Bragadottir, Ragnheiour] Oslo Univ Hosp, Dept Ophthalmol, N-0424 Oslo, Norway.
   [Hadzalic, Emina] Betanien Hosp, Dept Ophthalmol, Skien, Norway.
   [Gjertsen, Inger] Vestre Viken Hosp Trust, Dept Ophthalmol, Drammen, Norway.
   [Forsaa, Vegard] Stavanger Univ Hosp, Dept Ophthalmol, Stavanger, Norway.
   [Berger, Lars Haakon] Ostfold Hosp, Dept Ophthalmol, Moss, Norway.
   [Kinge, Bettina] Aleris, Retina Clin, Oslo, Norway.
   [Henschien, Hans] Vestfold Hosp, Dept Ophthalmol, Tonsberg, Norway.
   [Fossen, Kristian] Univ Hosp Northern Norway, Dept Ophthalmol, Tromso, Norway.
   [Markovic, Slavica] Innlandet Hosp, Dept Ophthalmol, Elverum, Norway.
   [Pedersen, Terje R.] Oslo Univ Hosp, Dept Endocrinol, Morbid Obes & Prevent Med, Oslo, Norway.
   [Sandvik, Leiv] Oslo Univ Hosp, Dept Biostat & Epidemiol, Oslo, Norway.
C3 University of Oslo; Stavanger University Hospital; UiT The Arctic
   University of Tromso; University Hospital of North Norway; Innlandet
   Hospital Trust; University of Oslo; University of Oslo
RP Berg, K (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Kirkeveien 166, N-0424 Oslo, Norway.
EM karinabb@medisin.uio.no
FU Ophthotech Corporation (Princeton, NJ); Novartis Pharma AG (Basel,
   Switzerland)
FX V.F.: Financial support - Ophthotech Corporation (Princeton, NJ); B.K.:
   Advisory board - Novartis (Oslo, Norway); Financial support - Novartis
   Pharma AG (Basel, Switzerland)
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
NR 19
TC 110
Z9 114
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2016
VL 123
IS 1
BP 51
EP 59
DI 10.1016/j.ophtha.2015.09.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4GE
UT WOS:000367060700025
PM 26477842
DA 2022-11-30
ER

PT J
AU Pons, M
   Cousins, SW
   Csaky, KG
   Striker, G
   Marin-Castano, ME
AF Pons, Marianne
   Cousins, Scott W.
   Csaky, Karl G.
   Striker, Gary
   Marin-Castano, Maria E.
TI Cigarette Smoke-Related Hydroquinone Induces Filamentous Actin
   Reorganization and Heat Shock Protein 27 Phosphorylation through p38 and
   Extracellular Signal-Regulated Kinase 1/2 in Retinal Pigment Epithelium
   Implications for Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID NONLETHAL OXIDANT INJURY; SUB-RPE DEPOSITS; OXIDATIVE STRESS; MAP
   KINASE; GENE-EXPRESSION; CROSS-TALK; IN-VIVO; HSP27; ERK; CELL
AB Retinal pigment epithelium (RPE)-derived membranous debris named blebs, may accumulate and contribute to sub-RPE deposit formation, which is the earliest sign of age-related macular degeneration (AMD). Oxidative injury to the RPE might play a significant role in AMD. However, the underlying mechanisms are unknown. We previously reported that hydroquinone (HQ), a major pro-oxidant in cigarette smoke, foodstuff, and atmospheric pollutants, induces actin rearrangement and membrane blebbing in RPE cells as well as sub-RPE deposits in mice. Here, we show for the first time that phosphorylated Heat shock protein 27 (Hsp27), a key regulator of actin filaments dynamics, is up-regulated in RPE from patients with AMD. Also, HQ-induced nonlethal oxidative injury led to Hsp27mRNA up-regulation, dimer formation, and Hsp27 phosphorylation in ARPE-19 cells. Furthermore, we found that a cross talk between p38 and extracellular signal-regulated kinase (ERK) mediates HQ-induced Hsp27 phosphorylation and actin aggregate formation, revealing ERK as a novel upstream mediator of Hsp27 phosphorylation. Finally, we demonstrated that Hsp25, p38, and ERK phosphorylation are increased in aging C57BL/6 mice chronically exposed to HQ, whereas Hsp25 expression is decreased. Our data suggest that phosphorylated Hsp27 might be a key mediator in AMD and HQ-induced oxidative injury to the RPE, which may provide helpful insights into the early cellular events associated with actin reorganization and bleb formation involved in sub-RPE deposits formation relevant to the pathogenesis of AMD. (Am J Pathol 2010, 177:1198-1213; DOI: 10.2353/ajpath.2010.091108)
C1 [Pons, Marianne; Marin-Castano, Maria E.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Cousins, Scott W.; Csaky, Karl G.] Duke Univ, Ctr Eye, Duke Ctr or Macular Dis, Durham, NC USA.
   [Striker, Gary] Mt Sinai Sch Med, Div Expt Diabet & Aging, New York, NY USA.
C3 Bascom Palmer Eye Institute; University of Miami; Duke University; Icahn
   School of Medicine at Mount Sinai
RP Marin-Castano, ME (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 1638 NW 10th Ave, Miami, FL 33136 USA.
FU National Eye Institute [R01 EY015249-01A1, EY015249-01A1S1, EY014801];
   NATIONAL EYE INSTITUTE [P30EY014801, R01EY015249, P30EY005722] Funding
   Source: NIH RePORTER
FX Supported by National Eye Institute grants R01 EY015249-01A1.
   EY015249-01A1S1, and EY014801
CR Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709
   Alcazar O, 2007, INVEST OPHTH VIS SCI, V48, P5662, DOI 10.1167/iovs.07-0392
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENNDORF R, 1994, J BIOL CHEM, V269, P20780
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   CAIRNS J, 1994, J BIOL CHEM, V269, P9176
   Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CIEMONS TE, 2005, OPHTHALMOLOGY, V112, P533
   Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F
   Cunningham LL, 2006, JARO-J ASSOC RES OTO, V7, P299, DOI 10.1007/s10162-006-0043-x
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DeCaprio AP, 1999, CRIT REV TOXICOL, V29, P283, DOI 10.1080/10408449991349221
   Deisinger PJ, 1996, J TOXICOL ENV HEALTH, V47, P31, DOI 10.1080/009841096161915
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Gain P, 2001, BRIT J OPHTHALMOL, V85, P996, DOI 10.1136/bjo.85.8.996
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Green W R, 1999, Mol Vis, V5, P27
   Guay J, 1997, J CELL SCI, V110, P357
   Gusev NB, 2002, BIOCHEMISTRY-MOSCOW+, V67, P511, DOI 10.1023/A:1015549725819
   Henklova P, 2008, EUR J PHARMACOL, V593, P16, DOI 10.1016/j.ejphar.2008.07.007
   Hong Z, 2009, J PROTEOME RES, V8, P2768, DOI 10.1021/pr801052v
   HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x
   Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361
   Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   KASSERN H, 2002, INT J CANCER, V1, P454
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   KIEIN R, 2004, AM J OPHTHALMOL, V137, P486
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Kogkopoulou O, 2006, J LEUKOCYTE BIOL, V79, P1052, DOI 10.1189/jlb.0705418
   Kostenko S, 2009, CELL MOL LIFE SCI, V66, P3289, DOI 10.1007/s00018-009-0086-3
   LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505
   Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4
   Milzani A, 1997, ARCH BIOCHEM BIOPHYS, V339, P267, DOI 10.1006/abbi.1996.9847
   New LG, 2001, J CELL BIOCHEM, V83, P585, DOI 10.1002/jcb.1253
   Numazawa S, 2003, J BIOCHEM, V133, P599, DOI 10.1093/jb/mvg077
   Praddaude F, 2009, EXP EYE RES, V89, P109, DOI 10.1016/j.exer.2009.02.020
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.3.CO;2-T
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shi B, 2006, CORNEA, V25, P948, DOI 10.1097/01.ico.0000224643.43601.5d
   Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   van Gorp RMA, 2002, BBA-MOL CELL RES, V1591, P129, DOI 10.1016/S0167-4889(02)00273-2
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wang Z, 2006, INVEST OPHTH VIS SCI, V47, P5267, DOI 10.1167/iovs.06-0642
   Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001
   Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200
NR 65
TC 29
Z9 29
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD SEP
PY 2010
VL 177
IS 3
BP 1198
EP 1213
DI 10.2353/ajpath.2010.091108
PG 16
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 648TR
UT WOS:000281717700017
PM 20651235
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Yamashiro, K
   Tsujikawa, A
   Nishida, A
   Mandai, M
   Kurimoto, Y
AF Yamashiro, Kenji
   Tsujikawa, Akitaka
   Nishida, Akihiro
   Mandai, Michiko
   Kurimoto, Yasuo
TI Recurrence of polypoidal choroidal vasculopathy after photodynamic
   therapy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE photodynamic therapy; polypoidal choroidal vasculopathy; recurrence
ID PIGMENT EPITHELIAL DETACHMENTS; MACULAR DEGENERATION; VERTEPORFIN
AB To evaluate the recurrence of polypoidal lesions after photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV).
   This is a retrospective review of data on 28 patients with PCV treated with PDT. The recurrent polypoidal lesions were observed with fluorescein and indocyanine green angiography.
   In 26 of the 28 eyes the PCV remained inactive for more than 12 months after one to three treatments with PDT. Recurrence of the polypoidal lesions after more than a 12-month inactive period was reported in eight eyes: three at 15 months, two at 18 months, and three at 21 months. Kaplan-Meier estimates of recurrence were 11.5% at 15 months, 20.4% at 18 months, and 38.8% at 21 months, with no subsequent recurrence until passage of 36 months of inactivity after the last PDT. Additional PDT after recurrence improved or preserved visual acuity in 80% of those treated compared to the visual acuity before the first PDT.
   Recurrence of PCV occurs in about 40% of eyes treated for PCV even after a long period of inactivity, so careful follow-up is needed.
C1 [Yamashiro, Kenji; Nishida, Akihiro; Mandai, Michiko; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, Kobe, Hyogo 6500046, Japan.
   [Yamashiro, Kenji; Nishida, Akihiro; Kurimoto, Yasuo] Inst Biomed Res & Innovat, Dept Regenerat Med, Kobe, Hyogo, Japan.
   [Yamashiro, Kenji; Mandai, Michiko] RIKEN, Ctr Dev Biol, Kobe, Hyogo, Japan.
   [Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Kobe City Medical Center General Hospital; Institute for Biomedical
   Research & Innovation (IBRI); RIKEN; Kyoto University
RP Yamashiro, K (通讯作者)，Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, 4-6 Minatojima Nakamachi, Kobe, Hyogo 6500046, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Mandai, Michiko/E-7986-2011
OI Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 24
TC 18
Z9 19
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2008
VL 52
IS 6
BP 457
EP 462
DI 10.1007/s10384-008-0582-2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 385CB
UT WOS:000261789400005
PM 19089566
DA 2022-11-30
ER

PT J
AU Falsini, B
   Ziccardi, L
   Stifano, G
   Iarossi, G
   Merendino, E
   Minnella, AM
   Fadda, A
   Balestrazzi, E
AF Falsini, Benedetto
   Ziccardi, Lucia
   Stifano, Giovanna
   Iarossi, Giancarlo
   Merendino, Erasmo
   Minnella, Angelo M.
   Fadda, Antonello
   Balestrazzi, Emilio
TI Temporal response properties of the macular cone system: Effect of
   normal aging and age-related maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FLICKER ELECTRORETINOGRAM; RETINITIS-PIGMENTOSA; SCOTOPIC SENSITIVITY;
   FUNDUS APPEARANCE; DARK-ADAPTATION; FELLOW EYES; DEGENERATION; ERG;
   DYSFUNCTION; MODULATION
AB PURPOSE. To evaluate the influence of aging and age-related maculopathy (ARM) on the temporal frequency response function (TFR) of macular focal electroretinography.
   METHODS. Macular (18 degrees) focal electroretinograms (FERGs) in response to sinusoidal flicker, modulated at TFs between 3.7 and 52 Hz, were recorded from 13 young (age range, 14 -29 years) and 9 old (age range, 55 -80 years) healthy subjects and from 18 patients with ARM (stage 2 disease; age range, 55-80 years; visual acuity >= 0.4). Amplitude and phase of the Fourier-analyzed response fundamental (1F) and seconnd harmonic (2F) were measured.
   RESULTS. In young healthy subjects, mean 1F TFR showed a maximum amplitude at 41 Hz, a secondary peak at 3.7 Hz, a minimum at 8 Hz, and a high TF (3252 Hz) roll-off. Mean 1F TFR of old, compared with young, healthy subjects showed amplitude enhancement at 10 to 14 Hz and a small loss at high TF. Mean 2F TFR of young and old healthy subjects had a maximum at 5.7 to 8 Hz and an attenuation beyond 10 Hz. Mean 1F and 2F TFRs of ARM patients were similar to those of old healthy subjects but were depressed in mean amplitude. FERG TFR changes of old healthy subjects and ARM patients were not mimicked by reducing stimulus retinal illuminance or modulation depth in young healthy subjects.
   CONCLUSIONS. FERG temporal properties are affected by normal aging and ARM. Because FERG TFR is shaped mainly by postreceptoral activity, the findings suggest that photoreceptor and postsynaptic dysfunction underlie aging- and ARM-related FERG changes.
C1 Univ Cattolica Sacro Cuore, Inst Ophthalmol, I-00168 Rome, Italy.
   GB Bietti Eye Fdn IRCCS, Rome, Italy.
   Ist Super Sanita, Technol & Hlth Dept, I-00161 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; Istituto Superiore di Sanita (ISS)
RP Falsini, B (通讯作者)，Univ Cattolica Sacro Cuore, Inst Ophthalmol, Lgo Francesco Vito 1, I-00168 Rome, Italy.
EM md0571@mclink.it
RI Falsini, Benedetto/V-1070-2019; Ziccardi, Lucia/AAQ-9066-2020; Falsini,
   Benedetto/AAC-5907-2022; minnella, angelo maria/AAQ-6250-2020; Fadda,
   Antonello/J-1560-2012; Iarossi, giancarlo/AAB-4916-2020
OI Falsini, Benedetto/0000-0002-1694-1062; Ziccardi,
   Lucia/0000-0002-5563-1243; minnella, angelo maria/0000-0001-5896-5313;
   Fadda, Antonello/0000-0001-7004-5245; Falsini,
   Benedetto/0000-0002-3569-4968
CR ABRAHAM FA, 1985, J PHYSIOL-LONDON, V363, P135, DOI 10.1113/jphysiol.1985.sp015700
   BAKER CL, 1988, J PHYSIOL-LONDON, V407, P155, DOI 10.1113/jphysiol.1988.sp017408
   BAKER CL, 1984, J NEUROPHYSIOL, V51, P952, DOI 10.1152/jn.1984.51.5.952
   BARON WS, 1974, VISION RES, V14, P491
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BURNS SA, 1992, OPTOMETRY VISION SCI, V69, P95, DOI 10.1097/00006324-199202000-00002
   Bush RA, 1996, J OPT SOC AM A, V13, P557, DOI 10.1364/JOSAA.13.000557
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fadda A, 1997, MED BIOL ENG COMPUT, V35, P441, DOI 10.1007/BF02534106
   Falsini B, 1999, CLIN NEUROPHYSIOL, V110, P1554, DOI 10.1016/S1388-2457(99)00106-6
   FALSINI B, 1994, INVEST OPHTH VIS SCI, V35, P4282
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   FALSINI B, 1995, DOC OPHTHALMOL, V90, P157, DOI 10.1007/BF01203335
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   FALSINI B, 2002, INVEST OPHTHALMOL VI
   FIORENTINI A, 1981, INVEST OPHTH VIS SCI, V21, P490
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Iarossi G, 2003, INVEST OPHTH VIS SCI, V44, P866, DOI 10.1167/iovs.01-1256
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 2002, J OPT SOC AM A, V19, P185, DOI 10.1364/JOSAA.19.000185
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kondo M, 2001, INVEST OPHTH VIS SCI, V42, P305
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SEIPLE W, 1992, VISION RES, V32, P2043, DOI 10.1016/0042-6989(92)90065-Q
   SEIPLE WH, 1986, AM J OPTOM PHYS OPT, V63, P1
   Viswanathan Suresh, 2002, Documenta Ophthalmologica, V105, P223, DOI 10.1023/A:1020505104334
   Zar JH, 1974, BIOSTATISTICAL ANAL, V22, P310
NR 40
TC 8
Z9 8
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2007
VL 48
IS 10
BP 4811
EP 4817
DI 10.1167/iovs.07-0306
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214SE
UT WOS:000249757600055
PM 17898308
DA 2022-11-30
ER

PT J
AU Lim, JH
   Han, YS
   Lee, SJ
   Nam, KY
AF Lim, Jun Hyun
   Han, Yong Seop
   Lee, Sang Joon
   Nam, Ki Yup
TI Risk factors for breakthrough vitreous hemorrhage after intravitreal
   tissue plasminogen activator and gas injection for submacular hemorrhage
   associated with age related macular degeneration
SO PLOS ONE
LA English
DT Article
ID PNEUMATIC DISPLACEMENT; SUBRETINAL HEMORRHAGE; MANAGEMENT; SECONDARY;
   VITRECTOMY; THERAPY
AB Purpose
   We investigated risk factors for breakthrough vitreous hemorrhage (VH) after an intravitreal tissue plasminogen activator (tPA) and gas injection in patients with submacular hemorrhage (SMH) associated with age-related macular degeneration (AMD).
   Methods
   The medical records of patients diagnosed with SMH associated with AMD who received an intravitreal tPA (50 mu g/0.05 mL) and perfluoropropane gas (0.3 mL) injection were reviewed retrospectively. We analyzed the associations of breakthrough VH with age, sex, best-corrected visual acuity, intraocular pressure, AMD subtype, accompanying sub-retinal pigment epithelium (RPE) hemorrhage, history of cataract surgery, history of hypertension and diabetes mellitus, history of drinking and smoking, and history of antiplatelet or anticoagulant medication. We also examined the relationships between various parameters, including the area ratio of the SMH to the optic disc (AHD) and the height of the SMH obtained from optical coherence tomography.
   Results
   In total, 52 eyes from 52 patients were enrolled in this study; 16 eyes (30%) showed breakthrough VH. The proportions of patients with a current smoking history were 75.0% in the VH group and 22.2% in the non-VH group (p = 0.010). Other factors did not differ significantly between the two groups. The proportion of cases with accompanying sub-RPE hemorrhage was 50.0% and 58.3% in the VH and non-VH groups, respectively (p = 0.763). The AHD (p = 0.001) and SMH height (p < 0.001) were significantly greater in the VH group. In a receiver operating characteristic curve analysis, the cut-off values of AHD and SMH height were 20.1 and 1208 mu m, respectively. According to logistic regression analysis, when the AHD and SMH height were greater than the individual cut-off values, the odds ratio of VH increased by 10.286 fold (95% confidence interval [CI], 2.452-43.148; p = 0.001) and 75.400 fold (95% CI, 7.991-711.441; p < 0.001), respectively, with respect to their respective reference groups (less than the cut-off value). Among the significant factors associated with VH occurrence, including current smoking, AHD, and SMH height, only current smoking and SMH height were found to be significant in multiple regression analysis (p = 0.040, 0.016).
   Conclusions
   The incidence of breakthrough VH was significantly higher in those with current smoking status and for SMH with a larger AHD and greater height. The height of the SMH was more predictable of the possibility of VH than AHD.
C1 [Lim, Jun Hyun; Lee, Sang Joon] Kosin Univ Hosp, Dept Ophthalmol, Busan, South Korea.
   [Han, Yong Seop] Gyeonsang Natl Univ, Coll Med, Dept Ophthalmol, Jinju, South Korea.
   [Han, Yong Seop; Nam, Ki Yup] Gyeonsang Natl Univ, Dept Ophthalmol, Changwon Hosp, Chang Won, South Korea.
   [Lee, Sang Joon] Kosin Univ, Coll Med, Dept Ophthalmol, Busan, South Korea.
   [Nam, Ki Yup] Chungnnam Natl Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
C3 Gyeongsang National University; Gyeongsang National University
RP Nam, KY (通讯作者)，Gyeonsang Natl Univ, Dept Ophthalmol, Changwon Hosp, Chang Won, South Korea.; Nam, KY (通讯作者)，Chungnnam Natl Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
EM oksnam1231@daum.net
OI Nam, Ki Yup/0000-0002-3602-8422
CR BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kapran Z, 2013, OSLI RETINA, V44, P471, DOI 10.3928/23258160-20130909-09
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Kunavisarut P, 2018, ASIA-PAC J OPHTHALMO, V7, P109, DOI 10.22608/APO.2017389
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   Malik Farhan F, 2014, Int Ophthalmol Clin, V54, P51, DOI 10.1097/IIO.0000000000000018
   Martel JN, 2013, JAMA OPHTHALMOL, V131, P1632, DOI 10.1001/jamaophthalmol.2013.5464
   Moschos MM, 2016, OXID MED CELL LONGEV
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin YI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28938-1
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   Wu TT, 2005, J OCUL PHARMACOL TH, V21, P62, DOI 10.1089/jop.2005.21.62
NR 26
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 3
PY 2020
VL 15
IS 12
AR e0243201
DI 10.1371/journal.pone.0243201
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PC7AH
UT WOS:000597149100123
PM 33270725
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hogg, R
   Chakravarthy, U
AF Hogg, R
   Chakravarthy, U
TI AMD and micronutrient antioxidants - Mini-review
SO CURRENT EYE RESEARCH
LA English
DT Review
DE age-related maculopathy; age related macular degeneration; antioxidants;
   macular pigment; lutein; oxidative stress
ID AGE-RELATED MACULOPATHY; MACULAR PIGMENT DENSITY; BLUE-MOUNTAINS-EYE;
   CHOROIDAL NEOVASCULARIZATION SECONDARY; NUTRITION EXAMINATION SURVEY;
   BEAVER DAM EYE; RISK-FACTORS; BETA-CAROTENE; TISSUE CONCENTRATIONS;
   SERUM CONCENTRATIONS
AB Age-related maculopathy (ARM) is a common clinical entity. The late-stage manifestations of ARM, which are known as age-related macular degeneration (AMD), have devastating consequences for vision. Various risk factors have been identified in the development of the condition, which are consistent with the premise that oxidative stress plays an important role in its pathogenesis. Thus, the possibility that antioxidant balance can be manipulated through diet or supplementation has created much interest. Associations between diet and nutrition and the clinical features of ARM have been described. Scrutiny of the literature shows consistency in the report of notable reductions in serum micronutrients in wet AMD, however, the evidence for causation is still circumstantial. In this comprehensive review of the clinical literature, we have assessed the evidence for a link between diet and nutrition as risk factors for the development of ARM and AMD. All published case control, population-based, and interventional studies on ARM were examined. Although initial support appeared to be moderate and somewhat contradictory, the evidence that lifetime oxidative stress plays an important role in the development of ARM is now compelling. The positive outcomes in the Age-Related Eye Diseases Study, a major controlled clinical trial, have given hope that modulation of the antioxidant balance through supplementation can help prevent progression of ARM to AMD.
C1 Royal Victoria Hosp, Inst Clin Sci, Belfast BT12 6BA, Antrim, North Ireland.
RP Chakravarthy, U (通讯作者)，Royal Victoria Hosp, Inst Clin Sci, Belfast BT12 6BA, Antrim, North Ireland.
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Chakravarthy,
   Usha/0000-0002-2606-3734
CR *AG REL EY DIS STU, 2001, ARCH OPHTHALMOL-CHIC, V119, P1147
   ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Anderson JW, 2000, J AM COLL NUTR, V19, p291S, DOI 10.1080/07315724.2000.10718963
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Belda JI, 1999, MECH AGEING DEV, V107, P159, DOI 10.1016/S0047-6374(98)00144-4
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLOCK G, 1994, AM J CLIN NUTR, V59, p232S, DOI 10.1093/ajcn/59.1.232S
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   DEMARTE ML, 1986, MECH AGEING DEV, V36, P161, DOI 10.1016/0047-6374(86)90017-5
   El-Sohemy A, 2002, AM J CLIN NUTR, V76, P172, DOI 10.1093/ajcn/76.1.172
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fairfield KM, 2002, JAMA-J AM MED ASSOC, V287, P3116, DOI 10.1001/jama.287.23.3116
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HANDELMAN GJ, 1986, ADV FREE RADICAL BIO, V2, P1, DOI 10.1016/S8755-9668(86)80024-2
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Holz F., 1993, GER J OPHTHALMOL, V2, P391
   Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   ISHIHARA N, 1997, NIPPO GANKA GAKKAI Z, V3, P248
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kant AK, 2000, JAMA-J AM MED ASSOC, V283, P2109, DOI 10.1001/jama.283.16.2109
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krinsky NI, 2001, NUTRITION, V17, P815, DOI 10.1016/S0899-9007(01)00651-7
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lyle BJ, 1998, J NUTR, V128, P2355, DOI 10.1093/jn/128.12.2355
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mannisto S, 2004, CANCER EPIDEM BIOMAR, V13, P40, DOI 10.1158/1055-9965.EPI-038-3
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8
   Mayne ST, 2003, J NUTR, V133, p933S, DOI 10.1093/jn/133.3.933S
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Pollard J, 2003, EUR J CLIN NUTR, V57, P988, DOI 10.1038/sj.ejcn.1601634
   Potischman N, 2003, J NUTR, V133, p875S, DOI 10.1093/jn/133.3.875S
   RICHER S, 1996, J AM OPTOMETRIC ASS, V0067
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer S, 1999, J Am Optom Assoc, V70, P24
   RIGGS JE, 1995, J CLIN EPIDEMIOL, V48, P1087, DOI 10.1016/0895-4356(95)00008-R
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SCHALCH W, NUTR ENV INFLUENCES, P215
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 2000, INVEST OPHTH VIS SCI, V45, P115
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   STARK H, 1985, KLIN MONATSBL AUGENH, V187, P296, DOI 10.1055/s-2008-1054317
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   TAYLOR HR, 2002, BRIT MED J, V11, P325
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Tikellis G, 1999, Ophthalmic Epidemiol, V6, P181, DOI 10.1076/opep.6.3.181.1502
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   van Kappel AL, 2001, PUBLIC HEALTH NUTR, V4, P829, DOI 10.1079/PHN2000115
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VANNAS S, 1958, Acta Ophthalmol (Copenh), V36, P601
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   Winkler BS, 1999, MOL VIS, V5
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149
   Zimmerman JA, 2003, EXP GERONTOL, V38, P47, DOI 10.1016/S0531-5565(02)00149-3
NR 93
TC 42
Z9 44
U1 2
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD DEC
PY 2004
VL 29
IS 6
BP 387
EP 401
DI 10.1080/02713680490517890
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 890OL
UT WOS:000226520600003
PM 15764083
DA 2022-11-30
ER

PT J
AU de Jong, PTVM
AF de Jong, Paulus T. V. M.
TI Mechanisms of disease: Age-related macular degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Review
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; APOLIPOPROTEIN-E GENE;
   BRUCHS MEMBRANE; MORPHOMETRIC-ANALYSIS; CIGARETTE-SMOKING; OXIDATIVE
   STRESS; AGING CHANGES; LIGHT; RISK
C1 Royal Netherlands Acad Arts & Sci, KNAW, Netherlands Inst Neurosci, Dept Ophthalmogenet, NL-1105 BA Amsterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical
   Center Amsterdam; Erasmus University Rotterdam; Erasmus MC
RP de Jong, PTVM (通讯作者)，Royal Netherlands Acad Arts & Sci, KNAW, Netherlands Inst Neurosci, Dept Ophthalmogenet, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM p.dejong@nin.knaw.nl
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Assink JJM, 2005, OPHTHALMOLOGY, V112, P482, DOI 10.1016/j.ophtha.2004.10.035
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BESHARSE JC, 1998, RETINAL PIGMENT EPIT, P152
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D., 1979, RETINAL PIGMENT EPIT, P148
   BONNET M, 1976, ARCH OPHTALMOL-PARIS, V36, P465
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Collard CD, 2000, AM J PATHOL, V156, P1549, DOI 10.1016/S0002-9440(10)65026-2
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DeCaprio AP, 1999, CRIT REV TOXICOL, V29, P283, DOI 10.1080/10408449991349221
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DOSSO AA, 1992, OPHTHALMOLOGICA, V205, P24, DOI 10.1159/000310307
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   FORRESTER JV, 1994, INVEST OPHTH VIS SCI, V35, P64
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Guymer R., 1998, RETINAL PIGMENT EPIT, P693
   Guymer RH, 2004, INVEST OPHTH VIS SCI, V45, P1660, DOI 10.1167/iovs.03-0913
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hu DN, 2002, INT J TOXICOL, V21, P465, DOI 10.1080/10915810290169891
   Hutchinson J., 1874, R LOND OPHTHALMIC HO, V8, P231
   Issa PC, 2005, OPHTHALMOLOGE, V102, P1036, DOI 10.1007/s00347-005-1269-4
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   JUNG H, 1994, GRAEF ARCH CLIN EXP, V232, P167, DOI 10.1007/BF00176787
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SR, 2004, P NATL ACAD SCI USA, V101, P11668, DOI 10.1073/pnas.0403499101
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KLIFFEN M, 1995, LAB INVEST, V73, P267
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   LYDA W, 1957, AM J OPHTHALMOL, V44, P362, DOI 10.1016/0002-9394(57)93133-1
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   MELROSE MA, 1985, OPHTHALMIC SURG LAS, V16, P648
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Monks Terrence J, 2002, Curr Drug Metab, V3, P425, DOI 10.2174/1389200023337388
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Peto R, 1997, BRIT MED J, V315, P1030, DOI 10.1136/bmj.315.7115.1030
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Powell DEB, 1998, BRIT MED J, V316, P1531, DOI 10.1136/bmj.316.7143.1531
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   REINBOTH JJ, 1995, CURR EYE RES, V14, P1001, DOI 10.3109/02713689508998521
   Reme C, 2005, INVEST OPHTH VIS SCI, V46, P2672, DOI 10.1167/iovs.04-1095
   Reme CE, 1998, RETINAL PIGMENT EPIT, P563
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   RUDNEW A, 1871, ARCH PATHOL ANAT PHY, V53, P455
   RUYSCH F, 1722, ASSER PRIMUS THESAUR, P3
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1979, 23RD P INT C OPHTH, V1, P228
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957
   Schachat AP, 2005, OPHTHALMOLOGY, V112, P531, DOI 10.1016/j.ophtha.2005.01.018
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Spilsbury K, 2000, AM J PATHOL, V157, P1413
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STREETEN BW, 1961, ARCH OPHTHALMOL-CHIC, V66, P391
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   TERMAN M, 1990, PHOTOCHEM PHOTOBIOL, V51, P781, DOI 10.1111/php.1990.51.6.781
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   Wolfrum M., 1908, Graefes Archiv fuer Ophthalmologie Leipzig, V67
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1971, J ULTRA MOL STRUCT R, V34, P190, DOI 10.1016/S0022-5320(71)90014-1
   Yu DY, 2002, COMP BIOCHEM PHYS A, V132, P47, DOI 10.1016/S1095-6433(01)00528-1
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 127
TC 690
Z9 726
U1 2
U2 90
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 5
PY 2006
VL 355
IS 14
BP 1474
EP 1485
DI 10.1056/NEJMra062326
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 090UA
UT WOS:000240976200009
PM 17021323
DA 2022-11-30
ER

PT J
AU Okubo, A
   Sameshima, M
   Sakamoto, T
AF Okubo, A
   Sameshima, M
   Sakamoto, T
TI Plasticity of polypoidal lesions in polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; BLACK-WOMEN
AB Purpose: The aim of this study was to describe the clinical course in a patient with polypoidal choroidal vasculopathy (PCV). Methods: A 68-year-old man with PCV in the left eye was followed up by means of routine examinations including fluorescein angiography and indocyanine green angiography for over 60 months. Results: Throughout the follow-up period, the patient experienced repeated lesions in the macula, such as serosanguineous detachment of the retinal pigment epithelium and neurosensory retina, but retained good visual acuity. Indocyanine green angiography disclosed spontaneous regression of polypoidal vessels followed by significant changes in the choroidal circulation: a group of polypoidal structures disappeared, and after several months a small choroidal vessel became apparent that was distant from the previously observed polypoidal structure rather than representing an extension of the original lesion. Conclusion: The clinical observation suggests that in some cases of PCV the choroidal vasculature may be altered with time, in that some vessels in the inner choroid and even the choriocapillaris may close and collateral vessels and/or new vessels may develop to form complex such as that described here.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 8908520, Japan.
C3 Kagoshima University
RP Okubo, A (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
EM akiko@m2.kufm.kagoshima-u.ac.jp
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   BOWERS DK, 1987, RETINA-J RET VIT DIS, V7, P252, DOI 10.1097/00006982-198707040-00011
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1132
   FRYCZKOWSKI AW, 1997, INDOCYANINE GREEN AN, P29
   Helisch A, 2003, MICROCIRCULATION, V10, P83, DOI 10.1038/sj.mn.7800173
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   MICHELS RG, 1974, T AM ACAD OPHTHALMOL, V78, P166
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 17
TC 11
Z9 13
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2004
VL 242
IS 11
BP 962
EP 965
DI 10.1007/s00417-004-0920-0
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 882XI
UT WOS:000225973300010
PM 15221299
DA 2022-11-30
ER

PT J
AU Bora, NS
   Jha, P
   Bora, PS
AF Bora, Nalini S.
   Jha, Purushottam
   Bora, Puran S.
TI The role of complement in ocular pathology
SO SEMINARS IN IMMUNOPATHOLOGY
LA English
DT Review
DE complement system; complement regulatory proteins; eye; corneal
   inflammation; uveitis; age-related macular degeneration
ID DECAY-ACCELERATING FACTOR; MEMBRANE-ATTACK-COMPLEX; EXPERIMENTAL
   AUTOIMMUNE UVEORETINITIS; INDUCED CHOROIDAL NEOVASCULARIZATION; FACTOR-H
   POLYMORPHISM; COFACTOR PROTEIN MCP; HUMAN DONOR CORNEAS; MACULAR
   DEGENERATION; REGULATORY PROTEINS; AQUEOUS-HUMOR
AB Functionally active complement system and complement regulatory proteins are present in the normal human and rodent eye. Complement activation and its regulation by ocular complement regulatory proteins contribute to the pathology of various ocular diseases including keratitis, uveitis and age-related macular degeneration. Furthermore, a strong relationship between age-related macular degeneration and polymorphism in the genes of certain complement components/complement regulatory proteins is now well established. Recombinant forms of the naturally occurring complement regulatory proteins have been exploited in the animal models for treatment of these ocular diseases. It is hoped that in the future recombinant complement regulatory proteins will be used as novel therapeutic agents in the clinic for the treatment of keratitis, uveitis, and age-related macular degeneration.
C1 [Bora, Nalini S.; Jha, Purushottam; Bora, Puran S.] Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Bora, NS (通讯作者)，Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, 4301 W Markham,Mail Slot 523, Little Rock, AR 72205 USA.
EM nbora@uams.edu
OI Bora, Puran/0000-0003-4781-1217
FU NATIONAL EYE INSTITUTE [R01EY016205, R01EY014623] Funding Source: NIH
   RePORTER; NEI NIH HHS [R01 EY014623, EY016205, R01 EY016205, EY014623]
   Funding Source: Medline
CR Alexander JJ, 2007, MOL IMMUNOL, V44, P123, DOI 10.1016/j.molimm.2006.07.287
   ATKINSON JP, 1987, IMMUNOL TODAY, V8, P212, DOI 10.1016/0167-5699(87)90167-8
   ATKINSON JP, 1980, CLIN IMMUNOLOGY, P219
   BANDO Y, 1989, Nippon Ganka Gakkai Zasshi, V93, P369
   Bardenstein DS, 1999, INVEST OPHTH VIS SCI, V40, P519
   BARDENSTEIN DS, 1994, CURR EYE RES, V13, P851, DOI 10.3109/02713689409015085
   Blom AM, 2004, ARCH IMMUNOL THER EX, V52, P83
   Bora Nalini S, 2007, Chem Immunol Allergy, V92, P213, DOI 10.1159/000099272
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora NS, 2004, J IMMUNOL, V172, P7086, DOI 10.4049/jimmunol.172.11.7086
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Bora PS, 2006, FEBS J, V273, P1403, DOI 10.1111/j.1742-4658.2006.05163.x
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bora PS, 2007, FEBS LETT, V581, P1977, DOI 10.1016/j.febslet.2007.04.024
   Bykov I, 2007, CLIN IMMUNOL, V124, P213, DOI 10.1016/j.clim.2007.05.008
   Caspi R.R., 2006, DRUG DISCOV TODAY, V3, P199, DOI 10.1016/j.ddmec.2006.05.006.
   CLEVELAND RP, 1983, INVEST OPHTH VIS SCI, V24, P237
   Cocuzzi E, 2000, CURR EYE RES, V21, P856, DOI 10.1076/ceyr.21.5.856.5539
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Davis AE, 2004, DRUG NEWS PERSPECT, V17, P439, DOI 10.1358/dnp.2004.17.7.863703
   Diehn JJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r74
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483
   FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I
   FUNABASHI K, 1994, IMMUNOLOGY, V81, P444
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GREGERSON DS, 1990, CELL IMMUNOL, V128, P209, DOI 10.1016/0008-8749(90)90019-N
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAZLETT LD, 1984, INFECT IMMUN, V43, P783, DOI 10.1128/IAI.43.3.783-790.1984
   HOLGUIN MH, 1992, CURR TOP MICROBIOL, V178, P61
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Jha P, 2006, INVEST OPHTH VIS SCI, V47, P1030, DOI 10.1167/iovs.05-1062
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Jha P, 2006, J IMMUNOL, V176, P7221, DOI 10.4049/jimmunol.176.12.7221
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   KIM YU, 1995, J EXP MED, V181, P151, DOI 10.1084/jem.181.1.151
   KIMURA H, 1995, INVEST OPHTH VIS SCI, V36, P2110
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krych-Goldberg M, 2001, IMMUNOL REV, V180, P112, DOI 10.1034/j.1600-065X.2001.1800110.x
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   LASS JH, 1990, INVEST OPHTH VIS SCI, V31, P1136
   LI B, 1993, J IMMUNOL, V151, P4295
   Liszewski MK, 1996, ADV IMMUNOL, V61, P201
   LISZEWSKI MK, 1992, CURR TOP MICROBIOL, V178, P45
   LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243
   Liu Mimi, 2004, Curr Opin Ophthalmol, V15, P221, DOI 10.1097/01.icu.0000122122.24016.f1
   LUBLIN DM, 1989, CURR TOP MICROBIOL I, V153, P123
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   MARAK GE, 1979, OPHTHALMIC RES, V11, P97
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   Miwa T, 1998, IMMUNOGENETICS, V48, P363, DOI 10.1007/s002510050447
   MONDINO BJ, 1990, INVEST OPHTH VIS SCI, V31, P1945
   Mondino BJ, 1996, INVEST OPHTH VIS SCI, V37, P1576
   MONDINO BJ, 1978, ARCH OPHTHALMOL-CHIC, V96, P1659
   MONDINO BJ, 1980, ARCH OPHTHALMOL-CHIC, V98, P346
   MONDINO BJ, 1980, ARCH OPHTHALMOL-CHIC, V98, P2041
   MONDINO BJ, 1983, ARCH OPHTHALMOL-CHIC, V101, P465
   MONDINO BJ, 1984, INVEST OPHTH VIS SCI, V25, P871
   MONDINO BJ, 1981, ARCH OPHTHALMOL-CHIC, V99, P1430
   MONDINO BJ, 1986, INVEST OPHTH VIS SCI, V27, P1288
   Montalvo V, 2007, CURR EYE RES, V32, P917, DOI 10.1080/02713680701656343
   Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x
   MORGAN BP, 1999, COMPLEMENT REGULATOR, P1
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NICHOLSONWELLER A, 1992, CURR TOP MICROBIOL, V178, P7
   NICKELLS MW, 1994, J IMMUNOL, V152, P676
   Niederkorn JY, 2002, CRIT REV IMMUNOL, V22, P13
   NONAKA M, 1995, J IMMUNOL, V155, P3037
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   NUSSENBLATT RB, 1991, INVEST OPHTH VIS SCI, V32, P3131
   PLEYER U, 1992, INVEST OPHTH VIS SCI, V33, P2212
   Powell MB, 1997, J IMMUNOL, V158, P1692
   Prendergast RA, 1998, INVEST OPHTH VIS SCI, V39, P754
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Qian YM, 2000, J IMMUNOL, V165, P2528, DOI 10.4049/jimmunol.165.5.2528
   Read RW, 2006, EXP EYE RES, V82, P389, DOI 10.1016/j.exer.2005.07.011
   REID KBM, 1986, ESSAYS BIOCHEM, V22, P27
   ROSENBAUM JT, 1984, INVEST OPHTH VIS SCI, V25, P1184
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Sohn JH, 2003, NAT MED, V9, P206, DOI 10.1038/nm814
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P4195
   SPICER AP, 1995, J IMMUNOL, V155, P3079
   TAKIZAWA H, 1994, J IMMUNOL, V152, P3032
   VERHAGEN C, 1994, INVEST OPHTH VIS SCI, V35, P236
   WATTS MJ, 1990, BIOCHEM J, V265, P471, DOI 10.1042/bj2650471
   Wheeler SF, 2002, GLYCOBIOLOGY, V12, P261, DOI 10.1093/glycob/12.4.261
   Willcox MDP, 1997, INVEST OPHTH VIS SCI, V38, P1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 99
TC 46
Z9 61
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1863-2297
J9 SEMIN IMMUNOPATHOL
JI Semin. Immunopathol.
PD APR
PY 2008
VL 30
IS 2
BP 85
EP 95
DI 10.1007/s00281-008-0110-y
PG 11
WC Immunology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pathology
GA 296CA
UT WOS:000255519900003
PM 18299835
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kuzniarz, M
   Mitchell, P
   Flood, VM
   Wang, JJ
AF Kuzniarz, M
   Mitchell, P
   Flood, VM
   Wang, JJ
TI Use of vitamin and zinc supplements and age-related maculopathy: The
   Blue Mountains Eye Study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; vitamin supplements; zinc supplements;
   diet; Blue Mountains Eye Study
ID BEAVER DAM EYE; MACULAR DEGENERATION; FAMILIAL AGGREGATION;
   CIGARETTE-SMOKING; GRADING SYSTEM; RISK-FACTORS; ORAL ZINC;
   ANTIOXIDANTS; ROTTERDAM; QUESTIONNAIRE
AB PURPOSE To investigate relationships between vitamin and zinc supplement use and age-related maculopathy in a population-based sample.
   METHODS We studied 2873 (79%) of the 3654 participants aged 4997 years who attended the cross-sectional Blue Mountains Eye Study and completed a detailed food frequency questionnaire, including type, dose and duration of supplement use. ARM was assessed during a masked grading of macular photographs. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using logistic regression.
   RESULTS After adjusting for multiple confounders, we found that no vitamin or zinc supplements. were significantly associated with reduced prevalence of any ARM lesions in either eye. The OR for use of any vitamin supplement was 1.3 (CI 0.9-1.7, p = 0.11) for individuals with any retinal pigment changes. It was 1.1 (CI 0.8-1.5, p = 0.59) for those with any soft (large) drusen and 1.5 (CI 0.7-3.0, p = 0.31) for those with late ARM lesions. The lack of association between supplement intake and ARM persisted regardless of their duration of use, dose or the smoking status of participants. The Breslow-Day test for heterogeneity was 0.24 with an OR for early ARM lesions among smokers of 0.7 (CI 0.4-1.3, p = 0.27), and 1.2 (CI 0.9-1.5, p = 0.24) among non-smokers.
   CONCLUSIONS This cross-sectional population-based study investigated associations between vitamin and zinc supplement use and the prevalence of ARM lesions. Our findings provide no support for a protective association between vitamin and zinc supplement use and lesions indicating early ARM. The small numbers of subjects with late ARM lesions precluded any detailed investigation of benefits from supplement use on the prevalence of these lesions.
C1 Univ Sydney, Westmead Hosp, Dept Ophthalmol, Eye Clin,Ctr Vis Res, Westmead, NSW 2145, Australia.
   Univ Sydney, Westmead Hosp, Ctr Vis Res, Save Sight Inst, Westmead, NSW 2145, Australia.
   Univ Sydney, Westmead Hosp, Ctr Vis Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   Univ Sydney, Dept Publ Hlth & Community Med, Westmead, NSW 2145, Australia.
C3 University of Sydney; University of Sydney; University of Sydney;
   Westmead Institute for Medical Research; University of Sydney
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Eye Clin,Ctr Vis Res, Westmead, NSW 2145, Australia.
EM paulmi@westgate.wh.usyd.edu.au
RI Flood, Victoria M/A-8732-2016; Flood, Victoria/H-2279-2011
OI Flood, Victoria M/0000-0001-5310-7221; 
CR [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Armitage P, 1994, STAT METHODS MED RES
   Ashton BA, 1997, AUST NZ J PUBL HEAL, V21, P699, DOI 10.1111/j.1467-842X.1997.tb01783.x
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Brown NAP, 1998, EYE, V12, P127, DOI 10.1038/eye.1998.21
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cumming RG, 2000, OPHTHALMOLOGY, V107, P450, DOI 10.1016/S0161-6420(99)00024-X
   Cumming RG, 1998, OPHTHALMOLOGY, V105, P1751, DOI 10.1016/S0161-6420(98)99049-2
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hawkins BS, 1999, MOL VIS, V5
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   *NAT HLTH MED RES, 2000, REC DIET INT US AUST
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Perlman J. A. M., 1996, ARCH OPHTHALMOL-CHIC, V114, P991
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   van der Hagen A M, 1993, J Am Optom Assoc, V64, P871
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Winkler BS, 1999, MOL VIS, V5
   Yu X. Q., 1999, Australian Journal of Nutrition and Dietetics, V56, P69
NR 45
TC 13
Z9 15
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD OCT
PY 2002
VL 9
IS 4
BP 283
EP 295
DI 10.1076/opep.9.4.283.1511
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 606FF
UT WOS:000178723000006
PM 12187426
DA 2022-11-30
ER

PT J
AU Jeon, YJ
   Kim, JH
   Kim, JW
   Kim, CG
AF Jeon, Young-Joon
   Kim, Jae-Hui
   Kim, Jong-Woo
   Kim, Chul-Gu
TI Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal
   Vasculopathy Resistant to Aflibercept Therapy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE polypoidal choroidal vasculopathy; aflibercept; ranibizumab; switching;
   resistant; refractory
ID PIGMENT EPITHELIAL DETACHMENT; MACULAR DEGENERATION; INTRAVITREAL
   AFLIBERCEPT; RECURRENCE; DIAGNOSIS
AB Background: To evaluate the short-term outcomes of switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy (PCV). Methods: This retrospective study included 18 eyes diagnosed with aflibercept-resistant PCV. All patients were treated with two to four consecutive ranibizumab injections at 4-5-week intervals. The best-corrected visual acuity (BCVA), and central retinal thickness (CRT) values before and after switching to ranibizumab were compared. The proportion of eyes showing >= 100 mu m decrease in retinal thickness and/or complete resolution of fluid after switching was identified. Results: The mean number of aflibercept injections before switching was 5.7 +/- 3.3. After switching, a mean of 2.8 +/- 0.6 consecutive ranibizumab injections was performed. The mean logarithm of minimal angle of resolution (logMAR) BCVA was 0.41 +/- 0.26 (Snellen equivalents = 20/51) before switching, and 0.40 +/- 0.30 (20/50) after switching (p = 0.574). The mean CRT was 422.2 +/- 152.4 mu m before switching, and 400.7 +/- 182.0 mu m after switching (p = 0.236). A decrease in CRT of >= 100 mu m, and/or complete resolution of fluid was noted in three eyes (16.7%). Conclusions: Switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy was not effective in most patients, suggesting the need for further investigation to seek more effective treatment options for this condition.
C1 [Jeon, Young-Joon; Kim, Jae-Hui; Kim, Jong-Woo; Kim, Chul-Gu] Kims Eye Hosp, Dept Ophthalmol, Seoul 150034, South Korea.
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, Seoul 150034, South Korea.
EM yjipnida@kimeye.com; kimoph@gmail.com; kjwood@kimeye.com;
   chulgukim@kimeye.com
OI Kim, Jae Hui/0000-0001-8121-6353
CR Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chan EW, 2017, AM J OPHTHALMOL, V177, P195, DOI 10.1016/j.ajo.2016.12.008
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chhablani J, 2019, ASIA-PAC J OPHTHALMO, V8, P43, DOI 10.22608/APO.2018136
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Hara C, 2019, GRAEF ARCH CLIN EXP, V257, P2559, DOI 10.1007/s00417-019-04456-2
   Kang HM, 2016, GRAEF ARCH CLIN EXP, V254, P1519, DOI 10.1007/s00417-015-3241-6
   Kim J, 2017, EYE, V31, P1678, DOI 10.1038/eye.2017.126
   Kim JH, 2021, J CLIN MED, V10, DOI 10.3390/jcm10163580
   Kim JY, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-00904-4
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Park UC, 2021, ACTA OPHTHALMOL, V99, pE899, DOI 10.1111/aos.14719
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Sohn EH, 2013, INVEST OPHTH VIS SCI, V54, P4184, DOI 10.1167/iovs.12-10420
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Teo KYC, 2019, OPHTHALMOL RETINA, V3, P220, DOI 10.1016/j.oret.2018.11.003
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 28
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD DEC
PY 2021
VL 10
IS 24
AR 5739
DI 10.3390/jcm10245739
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XZ2UK
UT WOS:000737512700001
PM 34945034
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ulanczyk, Z
   Grabowicz, A
   Cecerska-Heryc, E
   Sleboda-Taront, D
   Krytkowska, E
   Mozolewska-Piotrowska, K
   Safranow, K
   Kawa, MP
   Dolegowska, B
   Machalinska, A
AF Ulanczyk, Zofia
   Grabowicz, Aleksandra
   Cecerska-Heryc, Elzbieta
   sleboda-Taront, Daria
   Krytkowska, Elzbieta
   Mozolewska-Piotrowska, Katarzyna
   Safranow, Krzysztof
   Kawa, Milosz Piotr
   Dolegowska, Barbara
   Machalinska, Anna
TI Dietary and Lifestyle Factors Modulate the Activity of the Endogenous
   Antioxidant System in Patients with Age-Related Macular Degeneration:
   Correlations with Disease Severity
SO ANTIOXIDANTS
LA English
DT Article
DE age-related macular degeneration (AMD); antioxidants; diet
ID 15-YEAR CUMULATIVE INCIDENCE; GLUTATHIONE-PEROXIDASE 4; OXIDATIVE
   STRESS; PHYSICAL-ACTIVITY; INFLAMMATION; ENZYMES; PIGMENT; PATHOGENESIS;
   POLYMORPHISM; ASSOCIATION
AB Age-related macular degeneration (AMD) is a common cause of blindness in the elderly population, but the pathogenesis of this disease remains largely unknown. Since oxidative stress is suggested to play a major role in AMD, we aimed to assess the activity levels of components of the antioxidant system in patients with AMD. We also investigated whether lifestyle and dietary factors modulate the activity of these endogenous antioxidants and clinical parameters of disease severity. We recruited 330 patients with AMD (39 with early, 100 with intermediate and 191 with late form of AMD) and 121 controls in this study. At enrolment, patients' dietary habits and physical activity were assessed, and each study participant underwent a thorough ophthalmologic examination. The activity of several components of the antioxidant system were measured in red blood cells and platelets using both kinetic and spectrophotometric methods. Patients with AMD consumed much lower levels of fatty fish and eggs than the control group (p = 0.008 and p = 0.04, respectively). In the nAMD group, visual acuity (VA) correlated positively with green vegetable consumption (Rs = +0.24, p = 0.004) and omega-3-rich oil intake (Rs = +0.17, p = 0.03). In the AMD group, the total physical activity MET score correlated positively with VA (Rs = +0.17, p = 0.003) and correlated negatively with the severity of AMD (Rs = -0.14, p = 0.01). A multivariate analysis of patients and controls adjusted for age, sex, and smoking status (pack-years) revealed that AMD was an independent variable associated with a lower RBC catalase (beta = -0.37, p < 0.001) and higher PLT catalase (beta = +0.25, p < 0.001), RBC GPx (beta = +0.26, p < 0.001), PLT GPx (beta = +0.16, p = 0.001), RBC R-GSSG (beta = +0.13, p = 0.009), PLT R-GSSG (beta = +0.12, p = 0.02) and RBC GSH transferase (beta = +0.23, p < 0.001) activity. The activities of components of the antioxidant system were associated with disease severity and depended on dietary habits. The observed substantial increase in the activity of many critical endogenous antioxidants in patients with AMD further indicates that the required equilibrium in the antioxidant system is disturbed throughout the course of the disease. Our findings explicitly show that a diet rich in green vegetables, fish and omega-3-rich oils, supplemented by physical exercise, is beneficial for patients with AMD, as it might delay disease progression and help retain better visual function.
C1 [Ulanczyk, Zofia; Kawa, Milosz Piotr] Pomeranian Med Univ, Dept Gen Pathol, PL-70111 Szczecin, Poland.
   [Grabowicz, Aleksandra; Krytkowska, Elzbieta; Mozolewska-Piotrowska, Katarzyna; Machalinska, Anna] Pomeranian Med Univ, Dept Ophthalmol 1, PL-70111 Szczecin, Poland.
   [Cecerska-Heryc, Elzbieta; sleboda-Taront, Daria; Dolegowska, Barbara] Pomeranian Med Univ, Dept Lab Med, PL-70111 Szczecin, Poland.
   [Safranow, Krzysztof] Pomeranian Med Univ, Dept Biochem & Med Chem, PL-70111 Szczecin, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University; Pomeranian Medical University
RP Machalinska, A (通讯作者)，Pomeranian Med Univ, Dept Ophthalmol 1, PL-70111 Szczecin, Poland.
EM zofia.litwinska@pum.edu.pl; aleksandra.grabowicz@pum.edu.pl;
   cecerskaela@wp.pl; daria.sleboda@pum.edu.pl; oko1@pum.edu.pl;
   kawamilosz@gmail.com; chrissaf@mp.pl; kmp@pum.edu.pl;
   barbara.dolegowska@pum.edu.pl; annam@pum.edu.pl
RI Safranow, Krzysztof/B-5127-2015; Cecerska-Heryć, Elżbieta/AAC-3703-2019
OI Safranow, Krzysztof/0000-0001-9415-2758; Cecerska-Heryć,
   Elżbieta/0000-0002-7313-7193
FU Polish National Centre for Research and Development
   [STRATEGMED1/234261/2NCBR/2014]
FX This work was supported by Polish National Centre for Research and
   Development (grant number: STRATEGMED1/234261/2NCBR/2014).
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Age-Related Eye Dis Study Res Grp, 2000, J NUTR, V130, p1516S, DOI 10.1093/jn/130.5.1516S
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alswailmi FK, 2018, PAK J MED SCI, V34, P751, DOI 10.12669/pjms.343.14510
   Astrup A, 2001, Public Health Nutr, V4, P499
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Colak E, 2012, AGING CLIN EXP RES, V24, P588, DOI 10.3275/8593
   Conley SM, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017376
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FLEISCH HERBERT, 1960, HELVETICA MED ACTA, V27, P383
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gopinath B, 2020, CLIN NUTR, V39, P580, DOI 10.1016/j.clnu.2019.03.009
   Gopinath B, 2014, INVEST OPHTH VIS SCI, V55, P7799, DOI 10.1167/iovs.14-15575
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hernandez JA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1543809
   Hunter AA, 2016, CURR EYE RES, V41, P410, DOI 10.3109/02713683.2015.1016179
   HUNTER FT, 1950, AM J CLIN PATHOL, V20, P429
   Ighodaro OM, 2018, ALEX J MED, V54, P287, DOI 10.1016/j.ajme.2017.09.001
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Lee J, 2012, J DENT RES, V91, P142, DOI 10.1177/0022034511421200
   Liguori I, 2018, CLIN INTERV AGING, V13, P757, DOI 10.2147/CIA.S158513
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu ZB, 2007, J NEUROCHEM, V103, P2690, DOI 10.1111/j.1471-4159.2007.04954.x
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   Mrowicka M, 2017, ACTA OPHTHALMOL, V95, P530, DOI 10.1111/aos.13289
   NITA M, 2016, OXID MED CELL LONGEV, V2016
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   Plestina-Borjan I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/804054
   Poljsak B, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/956792
   Qin S, 2008, J INFLAMM RES, V1, P49
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Schneider CD, 2018, BIOL SPORT, V35, P181, DOI 10.5114/biolsport.2018.74194
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Singh N, 2017, ASIA-PAC J OPHTHALMO, V6, P520, DOI 10.22608/APO.2017416
   Smith Alison, 2016, Br J Community Nurs, V21, P305, DOI 10.12968/bjcn.2016.21.6.305
   TABATABAIE T, 1994, ARCH BIOCHEM BIOPHYS, V314, P112, DOI 10.1006/abbi.1994.1418
   Tan BL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01162
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Ueta T, 2012, J BIOL CHEM, V287, P7675, DOI 10.1074/jbc.M111.335174
   Ulanczyk Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225750
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Vina J, 2012, BRIT J PHARMACOL, V167, P1, DOI 10.1111/j.1476-5381.2012.01970.x
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
NR 74
TC 5
Z9 5
U1 2
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD OCT
PY 2020
VL 9
IS 10
AR 954
DI 10.3390/antiox9100954
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA OJ8KF
UT WOS:000584202200001
PM 33027903
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Agron, E
   Domalpally, A
   Cukras, CA
   Clemons, TE
   Chen, QY
   Lu, ZY
   Chew, EY
   Keenan, TDL
AF Agron, Elvira
   Domalpally, Amitha
   Cukras, Catherine A.
   Clemons, Traci E.
   Chen, Qingyu
   Lu, Zhiyong
   Chew, Emily Y.
   Keenan, Tiarnan D. L.
CA AREDS Res Grp
   AREDS2 Res Grp
TI Reticular Pseudodrusen: The Third Macular Risk Feature for Progression
   to Late Age-Related Macular Degeneration Age-Related Eye Disease Study 2
   Report 30
SO OPHTHALMOLOGY
LA English
DT Article
DE Age-Related Eye Disease Study; Age-Related Eye Disease Study 2;
   Age-related macular degeneration; Choroidal neovascularization; Disease
   progression; Geographic atrophy; Reticular pseudodrusen; Risk
   calculator; Risk factor; Severity scale; Subretinal drusenoid deposits
ID EYE DISEASE; FELLOW-EYES; GEOGRAPHIC-ATROPHY; SEVERITY SCALE;
   MACULOPATHY; PREVALENCE; REGRESSION; DESIGN; TRIAL; TIME
AB Purpose: To analyze reticular pseudodrusen (RPD) as an independent risk factor for progression to late age-related macular degeneration (AMD), alongside traditional macular risk factors (soft drusen and pigmentary abnormalities) considered simultaneously.
   Design: Post hoc analysis of 2 clinical trial cohorts: Age-Related Eye Disease Study (AREDS) and AREDS2.
   Participants: Eyes with no late AMD at baseline in AREDS (6959 eyes, 3780 participants) and AREDS2 (3355 eyes, 2056 participants).
   Methods: Color fundus photographs (CFPs) from annual visits were graded for soft drusen, pigmentary abnormalities, and late AMD. Presence of RPD was from grading of fundus autofluorescence images (AREDS2) and deep learning grading of CFPs (AREDS). Proportional hazards regression analyses were performed, considering AREDS AMD severity scales (modified simplified severity scale [person] and 9-step scale [eye]) and RPD presence simultaneously.
   Main Outcome Measures: Progression to late AMD, geographic atrophy (GA), and neovascular AMD.
   Results: In AREDS, for late AMD analyses by person, in a model considering the simplified severity scale simultaneously, RPD presence was associated with a higher risk of progression: hazard ratio (HR), 2.15 (95% confidence interval [CI], 1.75-2.64). However, the risk associated with RPD presence differed at different severity scale levels: HR, 3.23 (95% CI, 1.60-6.51), HR, 3.81 (95% CI, 2.38-6.10), HR, 2.28 (95% CI, 1.59-3.27), and HR, 1.64 (95% CI, 1.20-2.24), at levels 0-1, 2, 3, and 4, respectively. Considering the 9-step scale (by eye), RPD presence was associated with higher risk: HR, 2.54 (95% CI, 2.07-3.13). The HRs were 5.11 (95% CI, 3.93-6.66) at levels 1-6 and 1.78 (95% CI, 1.43-2.22) at levels 7 and 8. In AREDS2, by person, RPD presence was not associated with higher risk: HR, 1.18 (95% CI, 0.90-1.56); by eye, it was HR, 1.57 (95% CI, 1.31-1.89). In both cohorts, RPD presence carried a higher risk for GA than neovascular AMD.
   Conclusions: Reticular pseudodrusen represent an important risk factor for progression to late AMD, particularly GA. However, the added risk varies markedly by severity level, with highly increased risk at lower/ moderate levels and less increased risk at higher levels. Reticular pseudodrusen status should be included in updated AMD classification systems, risk calculators, and clinical trials. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Agron, Elvira; Cukras, Catherine A.; Chew, Emily Y.; Keenan, Tiarnan D. L.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Domalpally, Amitha] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI USA.
   [Clemons, Traci E.] Emmes Co LLC, Rockville, MD USA.
   [Chen, Qingyu; Lu, Zhiyong] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Wisconsin System; University of Wisconsin Madison;
   National Institutes of Health (NIH) - USA; NIH National Library of
   Medicine (NLM)
RP Keenan, TDL (通讯作者)，NIH, CRC, Bldg 10,Room 10D45,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.; Chew, EY (通讯作者)，NIH, CRC, Bldg 10,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov; tiarnan.keenan@nih.gov
OI Domalpally, Amitha/0000-0002-8145-9619; Agron,
   Elvira/0000-0002-2829-4042; Keenan, Tiarnan/0000-0002-2253-1772; Chew,
   Emily/0000-0003-0999-9802
CR Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   American Academy of Ophthalmology, 2015, AGE RELATED MACULAR
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Chen QY, 2021, J AM MED INFORM ASSN, V28, P1135, DOI 10.1093/jamia/ocaa302
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P721, DOI 10.1016/j.oret.2020.12.019
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Domalpally A, 2019, OPHTHALMOL RETINA, V3, P326, DOI 10.1016/j.oret.2019.01.004
   Dutheil C, 2020, JAMA OPHTHALMOL, V138, P467, DOI 10.1001/jamaophthalmol.2020.0266
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Hogg RE, 2019, OPHTHALMOLOGY, V126, P391, DOI 10.1016/j.ophtha.2018.09.032
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Keenan TDL, 2020, OPHTHALMOLOGY, V127, P1674, DOI 10.1016/j.ophtha.2020.05.036
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schwartz R, 2022, ARXIV
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   van Grinsven MJJP, 2015, INVEST OPHTH VIS SCI, V56, P633, DOI 10.1167/iovs.14-15019
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Wittenborn JS, 2017, JAMA OPHTHALMOL, V135, P452, DOI 10.1001/jamaophthalmol.2017.0255
   Wu ZC, 2022, PROG RETIN EYE RES, V88, DOI 10.1016/j.preteyeres.2021.101017
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 44
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2022
VL 129
IS 10
BP 1107
EP 1119
DI 10.1016/j.ophtha.2022.05.021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5V6LH
UT WOS:000877338600019
PM 35660417
OA Bronze
DA 2022-11-30
ER

PT J
AU Yoneda, A
   Wakiyama, H
   Kurihara, J
   Kitaoka, T
AF Yoneda, Ai
   Wakiyama, Harumi
   Kurihara, Junko
   Kitaoka, Takashi
TI Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab
   combined with photodynamic therapy or fixed-dosing aflibercept
   monotherapy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; combination therapy; photodynamic therapy; polypoidal
   choroidal vasculopathy; ranibizumab
ID INTRAVITREAL RANIBIZUMAB; COMBINATION THERAPY; PREDICTIVE FACTORS;
   JAPANESE PATIENTS; EFFICACY; BEVACIZUMAB; INJECTIONS; OUTCOMES;
   DIAGNOSIS; SAFETY
AB Purpose: To compare the 2-year outcomes of combination therapy using intravitreal ranibizumab and photodynamic therapy with those of fixed-dosing intravitreal aflibercept monotherapy as initial treatment for treatment-naive polypoidal choroidal vasculopathy. Methods: We retrospectively reviewed 63 eyes of 61 patients with treatment-naive polypoidal choroidal vasculopathy who had undergone at least 24 months of follow-up. In total, 43 eyes underwent intravitreal ranibizumab-photodynamic therapy combination therapy and 20 eyes underwent fixed-dosing intravitreal aflibercept monotherapy. Visual outcomes and the number of treatments were compared between the two groups. Results: The mean logarithm of minimal angle of resolution best-corrected visual acuity significantly improved from 0.48 +/- 0.41 at baseline to 0.30 +/- 0.47 at 24 months in the intravitreal ranibizumab-photodynamic therapy group (p = .0002) and from 0.30 +/- 0.18 at baseline to 0.16 +/- 0.18 at 24 months in the intravitreal aflibercept group (p = .004), with no significant intergroup differences. The mean number of intravitreal ranibizumab or intravitreal aflibercept injections over 24 months was 5.7 +/- 4.5 in the intravitreal ranibizumab-photodynamic therapy group and 12.2 +/- 3.8 in the intravitreal aflibercept group (p < .0001). Conclusion: The intravitreal ranibizumab-photodynamic therapy combination therapy was noninferior to fixed-dosing intravitreal aflibercept monotherapy in improving visual acuity and required fewer injections.
C1 [Yoneda, Ai; Wakiyama, Harumi; Kurihara, Junko] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Ophthalmol, 3-15 Mori Machi, Nagasaki 8528511, Japan.
   [Yoneda, Ai; Wakiyama, Harumi; Kurihara, Junko; Kitaoka, Takashi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Nagasaki, Japan.
C3 Nagasaki University
RP Yoneda, A (通讯作者)，Japanese Red Cross Nagasaki Genbaku Hosp, Dept Ophthalmol, 3-15 Mori Machi, Nagasaki 8528511, Japan.
EM aiyoneda@nagasaki-med.jrc.or.jp
OI Yoneda, Ai/0000-0002-3173-9145
CR Arakawa A, 2017, CLIN OPHTHALMOL, V11, P797, DOI 10.2147/OPTH.S129164
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Sakai T, 2014, BRIT J OPHTHALMOL, V98, P1642, DOI 10.1136/bjophthalmol-2014-305189
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Zhao M, 2017, INT J OPHTHALMOL-CHI, V10, P413, DOI 10.18240/ijo.2017.03.14
NR 37
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2020
VL 30
IS 6
BP 1473
EP 1479
AR 1120672119871886
DI 10.1177/1120672119871886
EA SEP 2019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PF7SQ
UT WOS:000485203900001
PM 31476891
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Remky, A
   Weber, A
   Arend, O
   Sponsel, WE
AF Remky, A
   Weber, A
   Arend, O
   Sponsel, WE
TI Topical dorzolamide increases pericentral visual function in age-related
   maculopathy: pilot study findings with short-wavelength automated
   perimetry
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE visual field; perimetry; age-related macular degeneration; age-related
   maculopathy
ID CEREBRAL-BLOOD-FLOW; BLUE-ON-YELLOW; CARBON-DIOXIDE;
   INTRAOCULAR-PRESSURE; OXYGEN AVAILABILITY; FIELD LOSS; PERFUSION;
   HYDROCHLORIDE; HEMODYNAMICS; VARIABILITY
AB Purpose: Numerous studies have confirmed the enhancement of ocular circulation by carbonic anhydrase inhibitors (CAIs). Topical CAI treatment with dorzolamide averts the significant pericentral visual function loss accompanying retinal and choroidal vasoconstriction during acute hyperventilation-induced hypocapnia. This study was designed to discern whether dorzolamide might similarly enhance macular function in patients with age-related maculopathy (ARM).
   Methods: In a masked, placebo-controlled study, 40 patients with ARM and acuity > 20/50 were randomized to receive either dorzolamide or placebo for 12 weeks, thrice daily. After pre-study perimetric training, pericentral function (mean sensitivity) was quantified using Humphrey 10-2 short-wavelength automated perimetry (SWAP), before and after 12 weeks of topical therapy.
   Results: Dorzolamide-treated eyes demonstrated a significant increase in mean sensitivity of + 1.55 dB (p = 0.04); placebo-treated eyes showed no significant change (+ 0.58 dB; p = 0.10). Given the non-significant increase of mean sensitivity in the placebo-treated group, fewer than 100 subjects per group would be required to afford > 70% power to yield a significant direct comparative difference between treatment and placebo in a prospective, randomized study of equally short duration.
   Conclusions: This study demonstrated a significant increase in short-wavelength sensitivity in ARM with dorzolamide and the lack thereof with placebo. These encouraging pilot study data suggest a potential role for topical CAIs in ARM patients, and establish objective parameters for prospective studies to further evaluate the effects of dorzolamide in ARM.
C1 Univ Klinikum, Augenklin, D-52057 Aachen, Germany.
   Univ Texas, Ctr Hlth Sci, Dept Ophthalmol, San Antonio, TX USA.
   Rhein Westfal TH Aachen, Sch Med, Dept Ophthalmol, Aachen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of
   Hamburg; University Medical Center Hamburg-Eppendorf; University of
   Texas System; University of Texas Health San Antonio; RWTH Aachen
   University
RP Remky, A (通讯作者)，Univ Klinikum, Augenklin, Pauwelsstr 30, D-52057 Aachen, Germany.
EM andreas.remky@post.rwth-aachen.de
CR ALBERTI E, 1975, BRIT J ANAESTH, V47, P941, DOI 10.1093/bja/47.9.941
   ALM A, 1972, ACTA PHYSIOL SCAND, V84, P306, DOI 10.1111/j.1748-1716.1972.tb05182.x
   ANDERSON B, 1968, T AM OPHTHAL SOC, V66, P424
   Arend O, 2003, ACTA OPHTHALMOL SCAN, V81, P474, DOI 10.1034/j.1600-0420.2003.00122.x
   BENGTSSON B, 2003, OPHTHALMIC RES, V35, P65
   BILL ANDERS, 1962, ACTA SOC MED UPSALIENSIS, V67, P122
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   CROGNALE MA, 1993, COLOUR VISION DEFICI, V11, P229
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   FRIEDMAN E, 1965, ARCH OPHTHALMOL-CHIC, V73, P70
   GIBBS FA, 1943, J AVIAT MED, V14, P250
   GOTOH F, 1966, ARCH INTERN MED, V117, P39, DOI 10.1001/archinte.117.1.39
   GREENSTEIN VC, 1992, INVEST OPHTH VIS SCI, V33, P2781
   Grover S, 1997, RETINA-J RET VIT DIS, V17, P222, DOI 10.1097/00006982-199705000-00009
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Harris A, 1996, ACTA OPHTHALMOL SCAN, V74, P569
   Harris A, 2003, BRIT J OPHTHALMOL, V87, P753, DOI 10.1136/bjo.87.6.753
   Harris A, 1999, J OCUL PHARMACOL TH, V15, P189, DOI 10.1089/jop.1999.15.189
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Hudson C, 1998, DIABETOLOGIA, V41, P918, DOI 10.1007/s001250051008
   JOHNSON CA, 1993, ARCH OPHTHALMOL-CHIC, V111, P645, DOI 10.1001/archopht.1993.01090050079034
   JOHNSON CA, 1988, J OPT SOC AM A, V5, P2131, DOI 10.1364/JOSAA.5.002131
   JOHNSON CA, 1995, ARCH OPHTHALMOL-CHIC, V113, P70, DOI 10.1001/archopht.1995.01100010072023
   JOHNSON CA, 1993, ARCH OPHTHALMOL-CHIC, V111, P651, DOI 10.1001/archopht.1993.01090050085035
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KENNEALY JA, 1978, J SURG RES, V24, P150, DOI 10.1016/0022-4804(78)90167-1
   KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kruger A, 1998, ARCH OPHTHALMOL-CHIC, V116, P27
   Krumpaszky H. G., 1996, Ophthalmologica, V210, P1
   Kwon YH, 1998, AM J OPHTHALMOL, V126, P29, DOI 10.1016/S0002-9394(98)00062-2
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leske MC, 1999, OPHTHALMOLOGY, V106, P2144, DOI 10.1016/S0161-6420(99)90497-9
   Marre M, 1986, ERWORBENE STORUNGEN
   Martinez A, 1999, INVEST OPHTH VIS SCI, V40, P1270
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   Remky A, 2000, OPHTHALMOLOGE, V97, P774, DOI 10.1007/s003470070027
   Remky A, 2003, GRAEF ARCH CLIN EXP, V241, P468, DOI 10.1007/s00417-003-0666-0
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Remky A, 2000, INVEST OPHTH VIS SCI, V41, P274
   REMKY A, 2003, INVEST OPHTHALMOL VI, V44
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   SAMPLE PA, 1994, AM J OPHTHALMOL, V118, P632, DOI 10.1016/S0002-9394(14)76578-X
   SAMPLE PA, 1990, INVEST OPHTH VIS SCI, V31, P1869
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Siik S, 1999, ACTA OPHTHALMOL SCAN, V77, P509, DOI 10.1034/j.1600-0420.1999.770504.x
   SOM A, 1995, INVEST OPHTH VIS SCI, V36, pS233
   Sponsel WE, 1997, AM J OPHTHALMOL, V123, P759, DOI 10.1016/S0002-9394(14)71124-9
   SPONSEL WE, 1999, CURRENT CONCEPTS OCU, P251
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Sugrue MF, 2000, PROG RETIN EYE RES, V19, P87, DOI 10.1016/S1350-9462(99)00006-3
   TROKEL S, 1965, ARCH OPHTHALMOL-CHIC, V73, P838
   TSACOPOULOS M, 1973, INVEST OPHTH VISUAL, V12, P449
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEBER A, 2003, INVEST OPHTHALMOL VI, V44
   Widder RA, 1999, INVEST OPHTH VIS SCI, V40, pS377
   Wild JM, 1998, INVEST OPHTH VIS SCI, V39, P54
   YANG SP, 1995, J CEREBR BLOOD F MET, V15, P115, DOI 10.1038/jcbfm.1995.13
   ZETLAN SR, 1992, INVEST OPHTH VIS SCI, V33, P1857
   ZHAO JL, 1993, OPHTHALMOLOGY, V100, P423
NR 71
TC 6
Z9 6
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD APR
PY 2005
VL 83
IS 2
BP 154
EP 160
DI 10.1111/j.1600-0420.2005.00406.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 910ZB
UT WOS:000227969600003
PM 15799725
DA 2022-11-30
ER

PT J
AU Reche-Frutos, J
   Calvo-Gonzalez, C
   Donate-Lopez, J
   Garcia-Feijoo, J
   Leila, M
   Garcia-Sanchez, J
AF Reche-Frutos, J.
   Calvo-Gonzalez, C.
   Donate-Lopez, J.
   Garcia-Feijoo, J.
   Leila, M.
   Garcia-Sanchez, J.
TI Short-term anatomic effect of ranibizumab for polypoidal choroidal
   vasculopathy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Ranibizumab; Optical coherence
   tomography; Indocyanine green angiography
AB PURPOSE. To assess the short-term anatomic effect of intravitreal ranibizumab for polypoidal choroidal vasculopathy.
   METHODS. All patients had undergone a full ophthalmic examination. A monthly injection of ranibizumab was performed for 3 months. Indocyanine angiography (ICG) and optical coherence tomography (OCT) were performed 1 month after the third-month ranibizumab injection.
   RESULTS. Polyps disappeared on ICG angiography in 9 out of 13 lesions (69.2%). Retinal thickness diminished significantly on OCT (p=0.02). In our series we noticed a significant reduction of the percentage of patients presenting with subretinal fluid (p=0.02) and pigment epithelium detachment between the initial and final visits (0.016). In addition, we noticed that BCVA increased significantly (p=0.02).
   CONCLUSIONS. Monthly intravitreal injection of ranibizumab for 3 months has a short-term beneficial anatomic effect. (Eur J Ophthalmol 2008; 18: 645-8)
C1 [Reche-Frutos, J.] Hosp Clin Univ San Carlos, Dept Ophthalmol, Madrid 28040, Spain.
RP Reche-Frutos, J (通讯作者)，Hosp Clin Univ San Carlos, Dept Ophthalmol, Calle Prof Martin Lagos S-N, Madrid 28040, Spain.
EM rechejuan@yahoo.es
RI ; GARCIA FEIJOO, JULIAN/G-9762-2017
OI DONATE, JUAN/0000-0002-9944-6736; GARCIA FEIJOO,
   JULIAN/0000-0002-7772-5718
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 6
TC 32
Z9 35
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2008
VL 18
IS 4
BP 645
EP 648
DI 10.1177/112067210801800427
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V20HH
UT WOS:000208130600027
PM 18609492
DA 2022-11-30
ER

PT J
AU Doble, B
   Finkelstein, EA
   Tian, Y
   Saxena, N
   Patil, S
   Wong, TY
   Cheung, CMG
AF Doble, Brett
   Finkelstein, Eric Andrew
   Tian, Yubing
   Saxena, Nakul
   Patil, Shiva
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin
   Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients
   With Polypoidal Choroidal Vasculopathy
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; MACULAR DEGENERATION; VISUAL-ACUITY; BEVACIZUMAB;
   EDEMA; AFLIBERCEPT; IMPACT
AB Question What is the incremental cost-effectiveness of intravitreal ranibizumab with verteporfin photodynamic therapy (combination therapy) relative to ranibizumab monotherapy for patients with polypoidal choroidal vasculopathy? Findings In this economic evaluation of a hypothetical cohort of patients with polypoidal choroidal vasculopathy, combination therapy generated slightly greater quality-adjusted life-years (7.87 vs 7.85) at roughly equal lifetime costs during a lifetime horizon. For a 10-year horizon, combination therapy may not be cost-effective. Meaning These results suggest that, from a lifetime cost-effectiveness perspective, combination therapy with ranibizumab should be considered as an alternative to standard care for patients with polypoidal choroidal vasculopathy.
   This economic evaluation assesses the incremental cost-effectiveness of combination intravitreal ranibizumab and verteporfin photodynamic therapy compared with ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy.
   Importance The EVEREST II trial showed that for patients with polypoidal choroidal vasculopathy (PCV), intravitreal ranibizumab in combination with verteporfin photodynamic therapy improves visual acuity relative to ranibizumab monotherapy. However, whether combination therapy is incrementally cost-effective relative to monotherapy during a lifetime is unclear. Objective To assess the incremental cost-effectiveness of combination therapy compared with ranibizumab monotherapy in patients with PCV. Design, Setting, and Participants This model-based, economic evaluation used 2018 unit cost data from a tertiary eye hospital in Singapore, first- and second-year outcomes and resource use data from a multicenter trial across various Asian countries (EVEREST II) to model a hypothetical cohort of patients with symptomatic PCV. Scenario analyses and deterministic and probabilistic sensitivity analyses were performed to examine uncertainty. Data were collected from October 2018 through April 2019 and analyzed from March through October 2019. Interventions This model used data from the EVEREST II trial, in which all participants were given 0.5 mg of intravitreal ranibizumab once every 4 weeks for the first 3 months. Subsequent administration occurred as needed. For participants receiving combination therapy, standard fluence (50 J/cm(3)) photodynamic therapy with 6-mg/m(2) verteporfin was administered once during the first 3 months and thereafter as needed. Main Outcomes and Measures Incremental cost per quality-adjusted life-year (QALY) gained for combination therapy relative to monotherapy for patients with PCV. Results In this model based on a cohort of 1000 patients aged 68 years, a patient with PCV incurred a total cost in Singapore dollars (SGD) of 92327 (US $67399) with combination therapy and SGD 92371 (US $67431) with monotherapy during a lifetime horizon, generating a modest cost savings of SGD 44 (US $32) per patient undergoing combination therapy. Lifetime QALYs were estimated to be 7.87 for combination therapy and 7.85 for monotherapy, for an incremental gain of 0.02 QALYs. Combination therapy remained cost-saving or cost-effective in all lifetime scenarios modeled, but during shorter time horizons and at lower monotherapy costs, it may not be cost-effective. Conclusions and Relevance This study found combination therapy to be a dominant (more effective and less costly) strategy, being similar in costs and slightly more effective than ranibizumab monotherapy during a lifetime horizon. However, decreasing the time horizon to less than 10 years and/or reductions in the cost of monotherapy may result in combination therapy no longer being cost-effective.
C1 [Doble, Brett; Finkelstein, Eric Andrew; Tian, Yubing] Duke NUS Natl Univ Singapore, Programme Hlth Serv & Syst Res, Med Sch, Singapore, Singapore.
   [Saxena, Nakul; Patil, Shiva] Novartis Singapore Pte Ltd, Singapore, Singapore.
   [Wong, Tien Yin; Cheung, Chui Ming Gemmy] Duke NUS Med Sch, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
C3 Novartis; National University of Singapore; Singapore National Eye
   Center
RP Doble, B (通讯作者)，Duke NUS Med Sch, Programme Hlth Serv & Syst Res, Eight Coll Rd, Singapore 169857, Singapore.
EM brett.doble@duke-nus.edu.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU Novartis Singapore Pte, Ltd.
FX This study was supported by a grant from Novartis Singapore Pte, Ltd.
CR [Anonymous], 2018, DRUG EV METH PROC GU
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Cai S, 2017, CURR OPIN OPHTHALMOL, V28, P636, DOI 10.1097/ICU.0000000000000424
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Department of Statistics, 2018, COMPL LIF TABL SING
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Herring W, 2017, VALUE HEALTH, V20, pA159
   Hutton DW, 2017, JAMA OPHTHALMOL, V135, P576, DOI 10.1001/jamaophthalmol.2017.0837
   Hykin P, 2019, JAMA OPHTHALMOL, V137, P1256, DOI 10.1001/jamaophthalmol.2019.3305
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Lee BS, 2008, OPHTHALMOLOGY, V115, P898, DOI 10.1016/j.ophtha.2007.06.008
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitchell P, 2012, BRIT J OPHTHALMOL, V96, P688, DOI 10.1136/bjophthalmol-2011-300726
   Ng WY, 2014, OPTOMETRY VISION SCI, V91, P872, DOI 10.1097/OPX.0000000000000283
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Scott IU, 2017, JAMA-J AM MED ASSOC, V317, P2072, DOI 10.1001/jama.2017.4568
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Singh SR, 2018, RETIN PHYS, V15, P36
   TreeAge Pro,, 2018, TREEAGE PRO R2 COMP
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
NR 31
TC 6
Z9 6
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2020
VL 138
IS 3
BP 251
EP 259
DI 10.1001/jamaophthalmol.2019.5628
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW1MQ
UT WOS:000520936000004
PM 31917395
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Cachulo, MD
   Lains, I
   Lobo, C
   Figueira, J
   Ribeiro, L
   Marques, JP
   Costa, J
   Vieira, A
   Rodrigues, J
   Alves, D
   Nunes, S
   Costa, M
   Rodrigues, V
   Cunha-Vaz, J
   Delcourt, C
   Silva, R
AF Cachulo, Maria da Luz
   Lains, Ines
   Lobo, Conceicao
   Figueira, Joao
   Ribeiro, Luisa
   Marques, Joao P.
   Costa, Jose
   Vieira, Antonio
   Rodrigues, Joao
   Alves, Dalila
   Nunes, Sandrina
   Costa, Miguel
   Rodrigues, Victor
   Cunha-Vaz, Jose
   Delcourt, Cecile
   Silva, Rufino
TI Age-related macular degeneration in Portugal: prevalence and risk
   factors in a coastal and an inland town. The Coimbra Eye Study - Report
   2
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; prevalence; risk factors
ID CIGARETTE-SMOKING; VISUAL IMPAIRMENT; DIETARY PATTERNS; POOLED FINDINGS;
   MACULOPATHY; POPULATION; VEGETABLES; DISEASES; CANCER; FRUIT
AB PurposeTo determine the age- and sex-specific prevalence of early and late age-related macular degeneration (AMD) in two Portuguese population-based samples and to identify its risk factors.
   PopulationA population of 6023 adults aged 55years was recruited from two Portuguese primary healthcare units in the central region of Portugal - one from a coastal (n=3000) and another from an inland town (n=3023).
   MethodsCross-sectional population-based study. Participants were enrolled in the two locations between August 2009 and October 2013. Responders underwent standardized interviews and ophthalmologic examination, including digital fundus imaging. All fundus photographs were graded according to an International Classification and Grading System. The main outcome measures consisted of age- and sex-adjusted prevalence of early and late AMD. Potential epidemiologic risk factors were also evaluated using logistic regression analysis.
   ResultsOf the 6023 subjects enrolled, 5996 had gradable fundus images and were included in the analysis. The crude prevalence of early and late AMD was 6.99 and 0.67%, respectively, for the coastal town and 15.39 and 1.29% for the inland town. Age- and sex-adjusted prevalence of any AMD for the Portuguese population was 12.48% (95% CI: 11.61-13.33) with late AMD accounting for 1.16% (95% CI: 0.85-1.46). Neovascular AMD (NV-AMD) and geographic atrophy (GA) accounted for 0.55% (95% CI: 0.36-0.75) and 0.61% (95% CI: 0.37-0.84) of individuals, respectively. After adjusting for possible confounding factors, prevalence of early and late AMD increased with increasing age (OR=1.35; 95% CI: 1.23-1.49 for early and OR=3.01; 95% CI: 2.22-4.08 for late AMD, per each decade of age increase, p<0.001). After adjustment for age, sex, family history, smoking history, hypertension, diabetes and BMI, subjects from the inland town presented a significantly higher OR of early and late AMD than subjects from the coastal town (OR=2.57, 95% CI: 2.12-3.12, p<0.001 for early and OR=2.06, 95% CI: 1.07-3.95, p=0.029 for late AMD).
   ConclusionsThe prevalence of early and late AMD in this Portuguese population was similar to other large-scale population-based cohorts. After controlling for confounders, age and study site of inclusion were significant independent predictors for both early and late forms of the disease. Further analysis will be needed to completely unravel the underlying reasons for this difference regarding geographic location.
C1 [Cachulo, Maria da Luz; Lains, Ines; Lobo, Conceicao; Figueira, Joao; Marques, Joao P.; Costa, Jose; Silva, Rufino] CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Cachulo, Maria da Luz; Lobo, Conceicao; Figueira, Joao; Ribeiro, Luisa; Alves, Dalila; Nunes, Sandrina; Costa, Miguel; Cunha-Vaz, Jose; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Cachulo, Maria da Luz; Lains, Ines; Lobo, Conceicao; Figueira, Joao; Ribeiro, Luisa; Rodrigues, Victor; Silva, Rufino] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Vieira, Antonio] Primary Hlth Care Ctr Mira, Coimbra, Portugal.
   [Rodrigues, Joao] Unidade Saude Familiar Serra Lousa & Trevim Sol, Primary Hlth Care Unit Lousa, Coimbra, Portugal.
   [Rodrigues, Victor] Univ Coimbra, Fac Med, Inst Higiene & Med Social, Coimbra, Portugal.
   [Delcourt, Cecile] Univ Bordeaux, Bordeaux, France.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra; Universidade de Coimbra; UDICE-French Research Universities;
   Universite de Bordeaux
RP Cachulo, MD (通讯作者)，Azinhaga Santa Comba Celas, Assoc Innovat & Biomed Res Light & Image, P-3000548 Coimbra, Portugal.
EM mluzcachulo@gmail.com
RI Delcourt, Cecile/I-2627-2013; Rodrigues, Vitor/AAU-9992-2020; Lobo,
   Conceição/ABB-8609-2021; Marques, João Pedro/J-3584-2012; Silva, Rufino
   M/J-2817-2012; Rodrigues, Vitor/S-1470-2016; Lobo, Conceicao/B-4122-2016
OI Delcourt, Cecile/0000-0002-2099-0481; Rodrigues,
   Vitor/0000-0003-4174-9061; Marques, João Pedro/0000-0002-1014-0483;
   Silva, Rufino M/0000-0001-8676-0833; Rodrigues,
   Vitor/0000-0003-4174-9061; Cachulo, Maria Luz/0000-0002-0900-4548;
   Alves, Dalila/0000-0003-3296-179X; Lains, Ines/0000-0002-8136-4724;
   Cunha-Vaz, Jose/0000-0002-0947-9850; Nunes,
   Sandrina/0000-0001-5401-9637; Ribeiro, Maria Luisa/0000-0002-5801-8487;
   Lobo, Conceicao/0000-0001-5831-7711; Figueira, Joao
   P/0000-0002-3511-1515; Costa, Miguel Angelo/0000-0002-0362-1713
FU Novartis
FX This study was financially supported by Novartis.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Berrigan D, 2003, PREV MED, V36, P615, DOI 10.1016/S0091-7435(02)00067-1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Carresi C, 2009, CLIN TER, V160
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dallongeville J, 1998, J NUTR, V128, P1450
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Galan I, 2006, PREV MED, V42, P343, DOI 10.1016/j.ypmed.2006.01.018
   Hercberg S, 1998, NUTRITION, V14, P513, DOI 10.1016/S0899-9007(98)00040-9
   Holick CN, 2002, AM J EPIDEMIOL, V156, P536, DOI 10.1093/aje/kwf072
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jonas JB, 2014, BRIT J OPHTHALMOL, V98, P592, DOI 10.1136/bjophthalmol-2013-303998
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Knoops KTB, 2006, EUR J CLIN NUTR, V60, P746, DOI 10.1038/sj.ejcn.1602378
   Koh WP, 2005, J NUTR, V135, P2473, DOI 10.1093/jn/135.10.2473
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Marques J.P., 2013, ISRN OPHTHALMOL, V2013
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1
   OECD, 2012, HLTH GLANC EUR
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Padrao P, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-138
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 56
TC 13
Z9 14
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2016
VL 94
IS 6
BP E442
EP E453
DI 10.1111/aos.12950
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW3CX
UT WOS:000383520800011
PM 26806024
OA Bronze
DA 2022-11-30
ER

PT J
AU Sagong, M
   Lim, S
   Chang, WY
AF Sagong, Min
   Lim, Suho
   Chang, Woohyok
TI Reduced-Fluence Photodynamic Therapy Combined With Intravitreal
   Bevacizumab for Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; EFFICACY; RANIBIZUMAB; VERTEPORFIN; EXPRESSION; AVASTIN;
   NETWORK
AB PURPOSE: To evaluate the efficacy and safety of reduced-fluence photodynamic therapy (PDT) combined with bevacizumab for polypoidal choroidal vasculopathy (PCV).
   DESIGN: Prospective, noncomparative, interventional case series.
   METHODS: Sixteen treatment-naive patients with polypoidal choroidal vasculopathy were treated with reduced-fluence PDT combined with bevacizumab. All patients were followed up monthly for 12 months with measurements of best-corrected visual acuity (BCVA) and central foveal thickness by optical coherence tomography. Indocyanine green angiography and fluorescein angiography were performed every 3 months. Patients were re-treated with reduced-fluence PDT combined with bevacizumab or with sole injection of bevacizumab when indicated.
   RESULTS: The mean logMAR BCVA showed significant improvement from 0.76 at baseline to 0.46 at 12 months (P = .002). At 12 months, the BCVA improved in 9 eyes (56.3%) by 3 lines or more, was stable in 6 eyes (37.5%), and decreased in 1 eye (6.3%) because of recurrence of polyps. During the study period, 3 patients (18.8%) had recurrence of polyps and 2 patients (12.5%) had persistent polyps. Mean episodes of reduced-fluence PDT and mean injections of intravitreal bevacizumab over 12 months were 1.44 and 2.44, respectively. Although 3 patients had mild choroidal non-perfusion-1 eye after 1 session of PDT and 2 eyes after 2 sessions no severe complications, including endophthalmitis, uveitis, or subretinal hemorrhage, developed.
   CONCLUSION: Reduced-fluence PDT combined with bevacizumab for PCV seemed to be effective for improving vision and reducing complications. Further study to optimize the light dose of PDT in combination therapy is needed in order to achieve better treatment outcomes for PCV. (Am J Ophthalmol 2012;153:873-882. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Sagong, Min; Lim, Suho; Chang, Woohyok] Yeungnam Univ, Dept Ophthalmol, Coll Med, Taegu 705717, South Korea.
C3 Yeungnam University
RP Chang, WY (通讯作者)，Yeungnam Univ, Dept Ophthalmol, Coll Med, 317-1 Daemyoung Dong, Taegu 705717, South Korea.
EM changwh@ynu.ac.kr
RI LIM, SU-HO/AAE-4344-2019
OI LIM, SU-HO/0000-0003-3807-4163
FU YEUNGNAM UNIVERSITY
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY A YEUNGNAM UNIVERSITY
   RESEARCH GRANT IN 2010. THE AUTHORS indicate no financial conflict of
   interest. Involved in design of study (M.S., W.C.); conduct of study
   (M.S., W.C.); collection and management of data (M.S., S.L.); analysis
   and interpretation of data (M.S., S.L.); preparation of manuscript
   (M.S.); and review or approval of manuscript (W.C.). This study was
   approved prospectively by the Institutional Review Board (IRB) of
   Yeungnam University Faculty of Medicine. Informed consent was obtained
   from all patients, and this study adhered to the tenets of the
   Declaration of Helsinki.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Kriechbaum K, 2008, BRIT J OPHTHALMOL, V92, P518, DOI 10.1136/bjo.2007.127282
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Nagasawa T, 2009, J MED INVESTIG, V56, P111, DOI 10.2152/jmi.56.111
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Pai SA, 2009, ACTA OPHTHALMOL, V87, P806, DOI 10.1111/j.1755-3768.2008.01330.x
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 41
TC 24
Z9 26
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2012
VL 153
IS 5
BP 873
EP 882
DI 10.1016/j.ajo.2011.09.031
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941LN
UT WOS:000303964800012
PM 22265146
DA 2022-11-30
ER

PT J
AU Teper, SJ
   Nowinska, A
   Pilat, J
   Wylegala, E
AF Teper, Slawomir J.
   Nowinska, Anna
   Pilat, Jaroslaw
   Wylegala, Edward
TI Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic
   study in age-related macular degeneration assessed with swept-source
   optical coherence tomography
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Age-related macular degeneration; Photodynamic therapy; Swept-source
   optical coherence tomography; Pharmacogenetics; CFH; ARMS2
ID BEVACIZUMAB
AB Background: Treatment of neovascular age-related macular degeneration (nAMD) remains a major challenge in ophthalmology. It is essential to determine which of VEGF inhibition non-responders can benefit from photodynamic therapy (PDT). As AMD is strongly related to gene polymorphisms, genetic factors can modify efficacy of treatment. Swept-source optical coherence tomography (SS-OCT) gives exceptional insight into the retina and choroid. SS-OCT usefulness needs to be evaluated in nAMD patients.
   Methods: Prospective 6-month study included consecutive 110 patients (110 eyes) with predominantly classic neovascular AMD treated with photodynamic therapy. Only non-responders to anti-VEGF were included in the study. Greatest linear dimension (GLD) of the lesion, best corrected visual acuity (BCVA), central subfield macular thickness (CSMT) and central choroidal thickness were assessed and compared between CFH and ARMS2 genotype groups. Success rate was the main endpoint. It was defined as not active CNV in the center of the fovea and no worsening in BCVA. Multiple regression was used to assess gene polymorphisms influence on PDT results. Wilcoxon tests were performed to determine significance of changes from baseline values.
   Results: Following genotype frequencies were obtained CFH CC 35 patients (31.8%), CT 52 (47.3%), TT 23 (20.9%); ARMS2 TT 28 patients (25.4%), GT 43 (39.1%), GG 39 (35.4%) success rate in CC/CT/TT CFH and TT/GT/GG ARMS2 groups were as follows respectively: 22.9%, 28.8%, 30.4% and 28.6%, 25.6%, 28.2%. The differences were not significant with highest odds ratio TT vs. CC CFH 1.57 (95% CI 0.48-5.2, p = 0.4). Significant increase in GLD was observed only in CC CFH group. Overall mean following measured parameters were obtained at baseline/day 7/month 3/month 6 (significant changes from baseline are marked with asterisk): GLD-3825 +/- 1301 mu m/3901 +/- 1579 mu m/3861 +/- 1463 mu m/3925 +/- 1523 mu m; CSMT-405 +/- 203 mu m/434 +/- 257 mu m*/321 +/- 163 mu m(psi)/295 157* mu m; CCT-235 +/- 103 mu m/278 +/- 157* mu m/211 +/- 113 mu m*/201 +/- 107* mu m; BCVA-49.3 +/- 12.5/43.2 +/- 14.2*/49.6 +/- 11.6/48.7 +/- 12.2 letters on ETDRS charts. In all patients classic component of the lesion was assessed with SS-OCT with no need to be reaffirmed in FA. Thus FA was used mainly for lesion size calculation.
   Conclusions: Common genetic factors seem not to influence PDT effectiveness in VEGF inhibitors non-responders. SS-OCT is a valuable tool of nAMD monitoring, especially for choroid assessment. Deterioration of retinal structure and function is observed one week after PDT. It is related to increase in both retinal and choroidal thickness and is accompanied by mild temporary BCVA decrease. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Teper, Slawomir J.; Nowinska, Anna; Wylegala, Edward] Med Univ Silesia, Sch Med, Div Dent Zabrze, Dept Clin Ophthalmol, Ul Panewnicka 65, PL-40760 Katowice, Poland.
   [Teper, Slawomir J.; Nowinska, Anna; Pilat, Jaroslaw; Wylegala, Edward] Dist Railway Hosp Katowice, Dept Ophthalmol, Ul Panewnicka 65, PL-40760 Katowice, Poland.
C3 Medical University Silesia
RP Teper, SJ (通讯作者)，Med Univ Silesia, Sch Med, Div Dent Zabrze, Dept Clin Ophthalmol, Ul Panewnicka 65, PL-40760 Katowice, Poland.
EM slawomir.teper@sum.edu.pl; atrum2@gmail.com; jaroslaw.pilat6@gmail.com;
   wylegala@gmail.com
RI Nowinska, Anna K/G-6165-2013; Wylęgała, Edward Aleksander/AGL-6056-2022;
   Wylegala, Edward/AAD-3961-2019; Teper, Slawomir/AAQ-1938-2021
OI Nowinska, Anna K/0000-0002-8418-3486; Wylęgała, Edward
   Aleksander/0000-0002-6707-5790; Teper, Slawomir/0000-0002-0935-8880
FU National Centre for Research and Development, Poland
   [STRATEGMED1/234261/2/NCBR/2014]
FX This work was supported by the National Centre for Research and
   Development, Poland grant STRATEGMED1/234261/2/NCBR/2014.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Tatar O., 2016, RETINA, V27, P713
   Teper SJ, 2012, MED SCI MONITOR, V18, pPR1, DOI 10.12659/MSM.882447
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tsuchihashi T, 2014, CLIN OPHTHALMOL, V8, P2471, DOI 10.2147/OPTH.S71305
   Waldstein SM, 2015, EYE, V29, P409, DOI 10.1038/eye.2014.319
   Wylegala EA, 2007, EUR J OPHTHALMOL, V17, P768, DOI 10.1177/112067210701700513
NR 14
TC 7
Z9 7
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD MAR
PY 2016
VL 13
BP 108
EP 113
DI 10.1016/j.pdpdt.2016.01.006
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DG9AZ
UT WOS:000372376500017
PM 26780119
DA 2022-11-30
ER

PT J
AU Javidi, S
   Dirani, A
   Antaki, F
   Saab, M
   Rahali, S
   Cordahi, G
AF Javidi, Simon
   Dirani, Ali
   Antaki, Fares
   Saab, Marc
   Rahali, Sofiane
   Cordahi, Ghassan
TI Long-Term Visual Outcomes for a Treat-and-Extend Antivascular
   Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related
   Macular Degeneration: Up to Seven-Year Follow-Up
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF AGENTS; RANIBIZUMAB; PREVALENCE
AB Purpose. To report long-term visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) treated with a treat-and-extend regimen (TER) of intravitreal antivascular endothelial growth factor (anti-VEGF) injections in real-world settings.Methods. Retrospective cohort study of consecutive patients with nAMD treated with a TER of anti-VEGF intravitreal injections by a single retina specialist (GC). Patients with nAMD who had at least one year of follow-up were identified using an electronic database. Best-corrected visual acuity (BCVA), comprehensive ophthalmologic examination, and macular OCT were performed at each visit. Patients received a loading dose of three monthly intravitreal injections and then were treated according to a TER of bevacizumab, ranibizumab, and/or aflibercept. The number of injections, BCVA, and central retinal thickness (CRT) were evaluated during the follow-up period.Results. 180 eyes from 180 patients were included in the study. Mean age was 75 +/- 9 (range: 51-96). Mean BCVA was 0.77 +/- 0.64 LogMAR at baseline, 0.69 +/- 0.58 LogMAR (p=0.0057) after loading phase, 0.64 +/- 0.55 LogMAR (p=0.0001) after 6 months of TER, and 0.76 +/- 0.71 LogMAR after 6 years of treatment (n = 32 at year 6). CRT decreased significantly after the loading phase (p=0.0002). The mean number of intravitreal injections per year was 7.6 during the first three years of treatment and then decreased to 5.9 during year 4 to 7.Conclusions. This retrospective study of 180 nAMD patients treated with a TER of intravitreal anti-VEGF demonstrates an initial improvement of BCVA after loading phase, followed by long-term visual stabilization for at least six years. These results were obtained with a high number of injections, averaging close to six injections per year during long-term follow-up. In light of the natural evolution of nAMD, these data support the long-term efficacy of this treatment under real-world conditions of heterogeneity of patients and type of anti-VEGF used.
C1 [Javidi, Simon; Dirani, Ali; Antaki, Fares; Rahali, Sofiane; Cordahi, Ghassan] Univ Montreal, Ctr Univ Ophtalmol, Hop Maisonneuve Rosemont, Montreal, PQ, Canada.
   [Dirani, Ali] Univ Laval, Ctr Univ Ophtalmol, Hop St Sacrement, Quebec City, PQ, Canada.
   [Saab, Marc] Univ Sherbrooke, Dept Ophthalmol, Hop Charles Le Moyne, Greenfield Pk, PQ, Canada.
C3 Universite de Montreal; Laval University; University of Sherbrooke
RP Dirani, A (通讯作者)，Univ Montreal, Ctr Univ Ophtalmol, Hop Maisonneuve Rosemont, Montreal, PQ, Canada.; Dirani, A (通讯作者)，Univ Laval, Ctr Univ Ophtalmol, Hop St Sacrement, Quebec City, PQ, Canada.
EM simon.javidi@gmail.com; drdirani@gmail.com;
   fares.antaki@windowslive.com; marcsaab@yahoo.com;
   rahalisofiane@yahoo.com; ghassan@cordahi.com
RI Antaki, Fares/GSI-6622-2022; Antaki, Fares/AAC-4944-2021
OI Antaki, Fares/0000-0001-6679-7276; Javidi, Simon/0000-0003-1989-5476
CR Agency for Drugs and Technologies in Health, 2015, RAN LUC VIS IMP DUE
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Bragadottir R., 2017, ACTA OPHTHALMOLOGICA, V95, P796, DOI [10.1111/aos.13522, DOI 10.1111/AOS.13522]
   Brown D. M., 2015, OPHTHALMOLOGY, V122, P2514, DOI [10.1016/j.ophtha.2015.08.009, DOI 10.1016/J.OPHTHA.2015.08.009]
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown U., 2014, OPHTHALMOLOGY, V121, P193
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P755, DOI 10.1111/aos.13120
   Khanani AM, 2019, CLIN OPHTHALMOL, V13, P347, DOI 10.2147/OPTH.S191170
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Merani Rohan, 2015, Int J Retina Vitreous, V1, P9
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Rayat JS, 2016, CAN J OPHTHALMOL, V51, P233, DOI 10.1016/j.jcjo.2015.10.014
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Terry L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162001
   Vedula SS, 2008, COCHRANE DB SYST REV, V2
NR 37
TC 3
Z9 3
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUL 31
PY 2020
VL 2020
AR 3207614
DI 10.1155/2020/3207614
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NC6OQ
UT WOS:000561337200004
PM 32802487
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Amaro, MH
   Holler, AB
AF Amaro, Miguel Hage
   Holler, Aaron Brock
TI Age-related macular degeneration with choroidal neovascularization in
   the setting of pre-existing geographic atrophy and ranibizumab
   treatment. Analysis of a case series and revision paper
SO REVISTA BRASILEIRA DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration; Geographic atrophy; Choroidal neovascularization;
   Antibodies, monoclonal/therapeutic use; Retina
ID VERTEPORFIN
AB Purpose: To report the response of choroidal neovascularization (CNV) to intravitreal ranibizumab treatment in the setting of age-related macular degeneration (AMD) with extensive pre-existing geographic atrophy (GA) and a revision paper. Methods: This is a revision paper and a retrospective case series of 10 eyes in nine consecutive patients from a photographic database. The patients were actively treated with ranibizumab for neovascular AMD with extensive pre-existing GA. Patients were included if they had GA at or adjacent to the foveal center that was present before the development of CNV. The best corrected visual acuity and optical coherence tomography (OCT) analysis of the central macular thickness were recorded for each visit. Serial injections of ranibizumab were administered until there was resolution of any subretinal fluid clinically or on OCT. Data over the entire follow-up period were analyzed for overall visual and OCT changes. All patients had been followed for at least 2 years since diagnosis. Results: The patients received an average of 6 +/- 3 intravitreal injections over the treatment period. Eight eyes had reduced retinal thickening on OCT. On average, the central macular thickness was reduced by 94 +/- 101 mu m. Eight eyes had improvement of one or more lines of vision, whereas one eye had dramatic vision loss and one had no change. The average treatment outcome for all patients was -0.07 +/- 4.25 logMAR units, which corresponded to a gain of 0.6 +/- 4.4 lines of Snellen acuity. The treatment resulted in a good anatomic response with the disappearance of the subretinal fluid, improved visual acuity, and stabilized final visual results. Conclusion: The results of this case series suggest that the use of an intravitreal anti-vascular endothelial growth factor (VEGF) agent (ranibizumab) for CNV in AMD with extensive pre-existing GA is effective. Our results are not as striking as published results from large-scale trials of anti-VEGF therapy for subfoveal CNV, presumably due to the limitation in the baseline visual acuity caused by the underlying GA. The good anatomic response with the disappearance of the subretinal fluid, improved visual acuity, and stabilized final visual results were consistent with other ranibizumab studies.
C1 [Amaro, Miguel Hage] Inst Olhos & Laser Belem, Belem, PA, Brazil.
   [Amaro, Miguel Hage] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Holler, Aaron Brock] Univ Iowa, Retina Serv, Iowa City, IA 52242 USA.
C3 Universidade Federal de Sao Paulo (UNIFESP); University of Iowa
RP Amaro, MH (通讯作者)，Trav Quintino Bocaiuva 516, BR-66053240 Belem, PA, Brazil.
EM miguelhamaro@yahoo.com.br
CR Age-Related Eye Disease Study Research Group, 2003, ARCH OPHTHALMOL-CHIC, V121, P416
   Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V120, P997
   Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P147
   Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P146
   Age-Related Eye Disease Study Research Group, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   Age-Related Eye Disease Study Research Group, 2001, JAMA-J AM MED ASSOC, V286, P2466
   Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Age-Related Eye Disease Study Research Group, 2002, ARCH OPHTHALMOL-CHIC, V120, P1602
   Age-Related Eye Disease Study Research Group, 2002, J FAM PRACTICE, V51, P105
   Amaro MH, 2011, INVEST OPHTHALMOL VI, V52
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2006, NEW ENGL J MED, V355, P1493
   Brown DM, 2006, NEW ENGL J MED, V355, P1409
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Cardillo JA, 2008, BRIT J OPHTHALMOL, V92, P276, DOI 10.1136/bjo.2007.129395
   Friedman DS, 2011, ARCH OPHTHALMOL-CHIC, V129, P1188
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, P70
   Gragoudas ES, 2005, NEW ENGL J MED, V352, P1721
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAGOUDAS ES, 2005, ACP J CLUB, V143, P18
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jampol LM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1533
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Macular Photocoagulation Study Group, 1991, ARCH OPHTHALMOL-CHIC, V109, P1217
   Miller, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Roller AB, 2012, INTRAVITREA IN PRESS
   Rosenfeld PJ, 2007, NEW ENGL J MED, V356, P749
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   ROSENFELD PJ, 2005, OPHTHAL SURG LAS IM, V36, P270
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   1994, ARCH OPHTHALMOL, V112, P874
NR 46
TC 1
Z9 1
U1 1
U2 1
PU SOC BRASILEIRA OFTALMOLOGIA
PI RIO DE JANEIRO
PA RUA SAO SALVADOR 107, RIO DE JANEIRO, 22231-170, BRAZIL
SN 0034-7280
J9 REV BRAS OFTALMOL
JI Rev. Bras. Oftalmol.
PD NOV-DEC
PY 2012
VL 71
IS 6
BP 407
EP 411
DI 10.1590/S0034-72802012000600015
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 076VU
UT WOS:000313987800015
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Celebiler, A
   Seker, H
   Yuksel, B
   Orun, A
   Bilgili, S
   Karaca, MB
AF Celebiler, Aydan
   Seker, Huseyin
   Yuksel, Bora
   Orun, Ahmet
   Bilgili, Sibel
   Karaca, Muhammet Baysal
TI Discovery of the connection among age-related macular degeneration,
   MTHFR C677T and PAI 1 4G/5G gene polymorphisms, and body mass index by
   means of Bayesian inference methods
SO TURKISH JOURNAL OF ELECTRICAL ENGINEERING AND COMPUTER SCIENCES
LA English
DT Article
DE Age-related macular degeneration; body mass index; MTHFR C677T; PAI-1
   4G/5G; gene-gene interaction; Bayesian network
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; BLUE-MOUNTAINS-EYE; RISK-FACTORS;
   CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; MYOCARDIAL-INFARCTION;
   PLASMA HOMOCYSTEINE; DISEASE; MACULOPATHY; EXPRESSION
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly. The aim of this study was therefore to explore the relationship between the presence of multiple gene polymorphisms and 2 distinct advanced 'dry and wet' AMD phenotypes, and to assess gene interactions with the influence of personal factors in a Turkish population as a pilot study.
   For the analysis, the data were collected from 73 unrelated participants, grouped as 29 wet and 26 dry AMD patients, and 18 healthy controls. They were all genotyped for the multiple gene polymorphisms in 12 different genes. The data set collected was then analyzed using the Bayesian inference methods and visualized by means of the Bayesian networks.
   The results suggest that: 1) the PAI-1 4G/5G and FV G1691A genes have joint roles in the separation of the 3 groups; 2) both wet and dry AMD can be separated from the control group using the genes PAI-1 4G/5G, FV G1691A, FXH V34L, and PT G20210A; 3) although the wet AMD and control groups can be separated by the combination of the ACE I I D and B-fibrinogen-455 G-A gene polymorphisms, there seems to be no significant effect of the genes on the separation between the dry AMD and control groups; 4) the wet AMD and control groups can be distinguished by the combination of body mass index and the MTHFR-C677T and PAI-1 genes; and 5) there is a correlation between wet AMD and a high body mass index (>30 kg/m(2)). It was also found that the impact of body mass index on the disease development seems only in question with the connective availability of the genes MTHFR C677T and PAI-1. It can be concluded that the combination of the MTHFR C677T and PAI-1 4G/5G gene polymorphisms in the presence of obesity may increase the risk of wet AMD. In addition, the results further support a complex interplay among genetic and environmental factors in the development of different phenotypes.
C1 [Celebiler, Aydan] Izmir Univ, Fac Med, Dept Clin Biochem, Izmir, Turkey.
   [Seker, Huseyin; Orun, Ahmet] De Montfort Univ, Ctr Computat Intelligence, Biohlth Informat Res Grp, Leicester LE1 9BH, Leics, England.
   [Yuksel, Bora] Izmir Educ & Res Hosp, Dept Ophthalmol, Izmir, Turkey.
   [Bilgili, Sibel; Karaca, Muhammet Baysal] Izmir Educ & Res Hosp, Dept Clin Biochem, Izmir, Turkey.
C3 Izmir University; De Montfort University; Izmir Bozyaka Training &
   Research Hospital; Izmir Bozyaka Training & Research Hospital
RP Celebiler, A (通讯作者)，Izmir Univ, Fac Med, Dept Clin Biochem, Izmir, Turkey.
EM aydanc@hotmail.com
RI Seker, Huseyin/AAO-7173-2020
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bernardi F, 2002, PATHOPHYSIOL HAEMO T, V32, P335, DOI 10.1159/000076692
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown ET, 1998, BLOOD, V92, P3286, DOI 10.1182/blood.V92.9.3286.421k20_3286_3293
   Busquets Xavier, 2007, Int J Chron Obstruct Pulmon Dis, V2, P329
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   CASWELL AG, 1985, BR J OPHTHALMOL, V69, P397
   Chakraborty S, 2011, COMPUT STAT DATA AN, V55, P1342, DOI 10.1016/j.csda.2010.09.024
   Cheng J, 2002, ARTIF INTELL, V137, P43, DOI 10.1016/S0004-3702(02)00191-1
   Collet JP, 2003, CIRCULATION, V108, P391, DOI 10.1161/01.CIR.0000083471.33820.3C
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamdi HK, 2003, BIOCHEM BIOPH RES CO, V310, P1227, DOI 10.1016/j.bbrc.2003.09.149
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Ji Y., 2006, COMPUTATIONAL STAT D, V50, P3592
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kostamaa H.J., 2004, INVESTIGATIVE OPHTHA, V45
   Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179
   Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532
   Lin JH, 2008, J BIOMED INFORM, V41, P1, DOI 10.1016/j.jbi.2007.06.001
   Lindgaard G, 2009, INT J IND ERGONOM, V39, P524, DOI 10.1016/j.ergon.2008.10.011
   LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Mavri A, 2001, DIABETOLOGIA, V44, P2025, DOI 10.1007/s001250100007
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76
   Nott DJ, 2007, J MULTIVARIATE ANAL, V98, P852, DOI 10.1016/j.jmva.2006.10.001
   Orun A, 2012, COMPUT HUM BEHAV, V28, P1332, DOI 10.1016/j.chb.2012.02.017
   RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844
   Rocken C, 2005, CLIN CANCER RES, V11, P2526, DOI 10.1158/1078-0432.CCR-04-1922
   SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shiose S, 2004, GRAEF ARCH CLIN EXP, V242, P777, DOI 10.1007/s00417-004-0910-2
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Stajduhar I, 2009, ARTIF INTELL MED, V47, P199, DOI 10.1016/j.artmed.2009.08.001
   Terruzzi I, 2007, J ENDOCRINOL INVEST, V30, P747, DOI 10.1007/BF03350812
   Touretzky DS, 1996, ADV NEURAL INFORM PR, V8
   van't Hooft FM, 1999, ARTERIOSCL THROM VAS, V19, P3063, DOI 10.1161/01.ATV.19.12.3063
   Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159, DOI 10.1136/bjo.80.2.159
   YE S, 1995, THROMB HAEMOSTASIS, V74, P837
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang Y, 2006, AM J HUM GENET, V79, P313, DOI 10.1086/506276
NR 54
TC 3
Z9 3
U1 0
U2 12
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0632
EI 1303-6203
J9 TURK J ELECTR ENG CO
JI Turk. J. Electr. Eng. Comput. Sci.
PY 2013
VL 21
SU 1
BP 2062
EP 2078
DI 10.3906/elk-1111-21
PG 17
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA 241IY
UT WOS:000326161300018
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ding, K
   Eaton, L
   Bowley, D
   Rieser, M
   Chang, Q
   Harris, MC
   Clabbers, A
   Dong, F
   Shen, JK
   Hackett, SF
   Touw, DS
   Bixby, J
   Zhong, SJ
   Benatuil, L
   Bose, S
   Grinnell, C
   Preston, GM
   Iyer, R
   Sadhukhan, R
   Marchie, S
   Overmeyer, G
   Ghayur, T
   van Riet, DA
   Tang, SB
   Campochario, PA
   Gu, JJ
AF Ding, Kun
   Eaton, Lucia
   Bowley, Diana
   Rieser, Matthew
   Chang, Qing
   Harris, Maria C.
   Clabbers, Anca
   Dong, Feng
   Shen, Jikui
   Hackett, Sean F.
   Touw, Debra S.
   Bixby, Jacqueline
   Zhong, Suju
   Benatuil, Lorenzo
   Bose, Sahana
   Grinnell, Christine
   Preston, Gregory M.
   Iyer, Ramesh
   Sadhukhan, Ramkrishna
   Marchie, Susan
   Overmeyer, Gary
   Ghayur, Tariq
   van Riet, Deborah A.
   Tang, Shibo
   Campochario, Peter A.
   Gu, Jijie
TI Generation and characterization of ABBV642, a dual variable domain
   immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and
   PDGF-BB and is designed for the treatment of exudative age-related
   macular degeneration
SO MABS
LA English
DT Article
DE ABBV642; angiogenesis age-related macular degeneration; bispecific
   antibody; DVD-Ig; ophthalmology; PDGF-BB; therapeutic antibody VEGF-A;
   wet AMD
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR THERAPY; EXPRESSION; PHARMACOKINETICS;
   BINDING; MODEL; MICE; WET; NEOVASCULARIZATION; ANGIOGENESIS
AB Exudative age-related macular degeneration (AMD) is the most common cause of moderate and severe vision loss in developed countries. Intraocular injections of vascular endothelial growth factor (VEGF or VEGF-A)-neutralizing proteins provide substantial benefit, but frequent, long-term injections are needed. In addition, many patients experience initial visual gains that are ultimately lost due to subretinal fibrosis. Preclinical studies and early phase clinical trials suggest that combined suppression of VEGF and platelet-derived growth factor-BB (PDGF-BB) provides better outcomes than suppression of VEGF alone, due to more frequent regression of neovascularization (NV) and suppression of subretinal fibrosis. We generated a dual variable domain immunoglobulin molecule, ABBV642 that specifically and potently binds and neutralizes VEGF and PDGF-BB. ABBV642 has been optimized for treatment of exudative AMD based on the following design characteristics: 1) high affinity binding to all VEGF-A isoforms and both soluble and extracellular matrix (ECM)-associated PDGF-BB; 2) potential for extended residence time in the vitreous cavity to decrease the frequency of intraocular injections; 3) rapid clearance from systemic circulation compared with molecules with wild type Fc region for normal FcRn binding, which may reduce the risk of systemic complications; and 4) low risk of potential effector function. The bispecificity of ABBV642 allows for a single injection of a single therapeutic agent, and thus a more streamlined development and regulatory path compared with combination products. In a mouse model of exudative AMD, ABBV642 was observed to be more effective than aflibercept. ABBV642 has potential to improve efficacy with reduced injection frequency in patients with exudative AMD, thereby reducing the enormous disease burden for patients and society.
C1 [Ding, Kun; Shen, Jikui; Hackett, Sean F.; Campochario, Peter A.] John Hopkins Wilmer Eye Inst, Baltimore, MD USA.
   [Ding, Kun] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Eaton, Lucia; Chang, Qing; Dong, Feng; Ghayur, Tariq; van Riet, Deborah A.; Gu, Jijie] AbbVie Biores Ctr, Immunol Discovery, Worcester, MA USA.
   [Bowley, Diana; Chang, Qing; Harris, Maria C.; Clabbers, Anca; Dong, Feng; Touw, Debra S.; Bixby, Jacqueline; Zhong, Suju; Benatuil, Lorenzo; Bose, Sahana; Iyer, Ramesh; Sadhukhan, Ramkrishna; Marchie, Susan; Overmeyer, Gary; Gu, Jijie] AbbVie Biores Ctr, Global Biol, Worcester, MA USA.
   [Rieser, Matthew; Grinnell, Christine; Preston, Gregory M.] AbbVie Inc, DMPK BA, Libertyville, IL USA.
   [Tang, Shibo] Cent S Univ, Aier Sch Ophthalmol, Changsha, Peoples R China.
C3 Johns Hopkins University; Johns Hopkins Medicine; Sun Yat Sen
   University; AbbVie; AbbVie; AbbVie; Central South University
RP Gu, JJ (通讯作者)，AbbVie Biores Ctr, 381 Plantat St, Worcester, MA 01605 USA.
EM jijie.gu@abbvie.com
RI Bowley, Diana R/X-6976-2018; TANG, Shi/GXH-5719-2022
OI Bowley, Diana R/0000-0002-3351-234X; 
FU AbbVie; China Scholarship Council; John Hopkins University
FX Lucia Eaton, Diana Bowley, Maria C Harris, Debra Touw, Jacqueline Bixby,
   Suju Zhong, Lorenzo Benatuil, Feng Dong, Qing Chang, Anca Clabbers,
   Sahana Bose, Matthew Rieser, Christine Grinnell, Gregory M. Preston,
   Ramesh Iyer, Ramkrishna Sadhukhan, Susan Marchie, Gary Overmeyer, Tariq
   Ghayur, Deborah A van Riet, and Jijie Gu are employees of North Chicago,
   IL-based AbbVie Inc. and may own AbbVie stocks or stock options. The
   authors have no other relevant affiliations or financial involvement
   with any other organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed. The design, study conduct, and
   financial support for this research were provided by AbbVie. AbbVie
   participated in the interpretation of data, review, and approval of the
   publication.; Kun Ding is a Ph.D student in Shibo Tang's laboratory at
   State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
   Yatsen University, Guangzhou, China. Kun Ding was awarded a scholarship
   under the State Scholarship Fund by the China Scholarship Council to
   support his study as a joint PhD in US. Kun Ding conducted animal model
   study as a joint Ph.D. student under supervision of Dr. Peter A.
   Campochario in his laboratory at John Hopkins Wilmer Eye Institute. Kun
   Ding, Jikui She, Sean F. Hackett and Peter A. Campochario are employees
   of John Hopkins Wilmer Eye Institute, 600 N. Wolfe Street, Baltimore, MD
   21287. AbbVie contracted with John Hopkins University and provided
   funding for conducting the animal model study at John Hopkins
   University. Dr. Peter A. Campochario also provides consultant service to
   several other biotechnology and pharmaceutical companies.
CR Abramsson A, 2007, GENE DEV, V21, P316, DOI 10.1101/gad.398207
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P576
   CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459
   Chakravarthy U, 2014, AM AC OPHTH ANN M 20
   Chu HH, 2012, THER DELIV, V3, P693, DOI 10.4155/TDE.12.50
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrara N, 2010, MOL BIOL CELL, V21, P687, DOI 10.1091/mbc.E09-07-0590
   Gadkar K, 2015, INVEST OPHTH VIS SCI, V56, P5390, DOI 10.1167/iovs.15-17108
   Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hezareh M, 2001, J VIROL, V75, P12161, DOI 10.1128/JVI.75.24.12161-12168.2001
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hutton-Smith LA, 2016, MOL PHARMACEUT, V13, P2941, DOI 10.1021/acs.molpharmaceut.5b00849
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kim JK, 1999, EUR J IMMUNOL, V29, P2819, DOI 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lei HT, 2010, EXP EYE RES, V90, P376, DOI 10.1016/j.exer.2009.11.003
   LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875
   Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mineur P, 2007, J CELL BIOL, V179, P1261, DOI 10.1083/jcb.200703052
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2001
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Pharmacokinetics M.W. S., 2014, EXPERT REV CLIN PHAR, V7, P167
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489
   Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3
   The Angiogenesis Foundation, 2012, ADV IMPR TREATM OUTC
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Vinores SA, 2006, INT J NANOMED, V1, P263
   Wu CB, 2007, NAT BIOTECHNOL, V25, P1290, DOI 10.1038/nbt1345
   Xu DL, 2000, CELL IMMUNOL, V200, P16, DOI 10.1006/cimm.2000.1617
NR 41
TC 10
Z9 12
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1942-0862
EI 1942-0870
J9 MABS-AUSTIN
JI mAbs
PY 2017
VL 9
IS 2
BP 269
EP 284
DI 10.1080/19420862.2016.1268305
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EK4NH
UT WOS:000393903200007
PM 27929753
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Snyder, K
   Yazdanyar, A
   Mahajan, A
   Yiu, G
AF Snyder, Kiersten
   Yazdanyar, Amirfarbod
   Mahajan, Aditi
   Yiu, Glenn
TI Association Between the Cilioretinal Artery and Choroidal
   Neovascularization in Age-Related Macular Degeneration A Secondary
   Analysis From the Age-Related Eye Disease Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID CHORIOCAPILLARIS; PATHOGENESIS; RPE
AB IMPORTANCE A hemodynamic role in the pathogenesis of age-related macular degeneration (AMD) has been proposed, but to our knowledge, an association between retinal vasculature and late AMD has not been investigated.
   OBJECTIVE To determine whether the presence and location of a cilioretinal artery may be associated with the risk of late AMD in the Age-Related Eye Disease Study (AREDS).
   DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of prospective, randomized clinical trial data from 3647 AREDS participants. Fundus photographs of AREDS participants were reviewed by 2 masked graders for the presence or absence of a cilioretinal artery and whether any branch extended within 500 mu m of the central macula. Multivariate regressions were used to determine the association of the cilioretinal artery and vessel location, adjusted for age, sex, and smoking status, with the prevalence of choroidal neovascularization (CNV) or central geographic atrophy (CGA) and AMD severity score for eyes at randomization and progression at 5 years.
   MAIN OUTCOMES AND MEASURES Association of cilioretinal artery with prevalence and 5-year incidence of CNV or CGA.
   RESULTS Among AREDS participants analyzed, mean (SD) age was 69.0 (5.0) years, with 56.3% female, 46.6% former smokers, and 6.9% current smokers. A total of 26.9% of patients had a cilioretinal artery in 1 eye, and 8.4% had the vessel bilaterally. At randomization, eyes with a cilioretinal artery had a lower prevalence of CNV (5.0% vs 7.6%; OR, 0.66; 95% CI, 0.51-0.85; P = .001) but no difference in CGA (1.1% vs 0.8%; OR, 1.33; 95% CI. 0.76-2.32; P = .31). In eyes without late AMD, those with a cilioretinal artery also had a lower mean (SD) AMD severity score (3.00 [2.35] vs 3.19 [2.40]; P = .02). At 5 years, eyes at risk with a cilioretinal artery had lower rates of progression to CNV (4.1% vs 53%; OR, 0.75; 95% CI, 0.56-1.00; P = .05) but no difference in developing CGA (2.2% vs 2.7%; OR, 0.83; 95% CI, 0.56-1.23; P = .35) or change in AMD severity score (0.65 [1.55] vs 0.73 [1.70]; P = .11). In patients with a unilateral cilioretinal artery, eyes with the vessel showed a lower prevalence of CNV than fellow eyes (4.7% vs 7.2%; P = .01).
   CONCLUSIONS AND RELEVANCE The presence of a cilioretinal artery is associated with a lower risk of developing CNV, but not CGA, suggesting a possible retinal hemodynamic contribution to the pathogenesis of neovascular AMD.
C1 [Snyder, Kiersten; Yazdanyar, Amirfarbod; Mahajan, Aditi; Yiu, Glenn] Univ Calif Davis, Dept Ophthalmol & Vis Sci, 4860 Y St,Ste 2400, Sacramento, CA 95817 USA.
   [Snyder, Kiersten] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.
C3 University of California System; University of California Davis; George
   Washington University
RP Yiu, G (通讯作者)，Univ Calif Davis, Dept Ophthalmol & Vis Sci, 4860 Y St,Ste 2400, Sacramento, CA 95817 USA.
EM gyiu@ucdavis.edu
RI Yiu, Glenn/AAF-2858-2020
OI Snyder, Kiersten/0000-0003-2802-0524; Yiu, Glenn/0000-0003-3061-3310
FU National Institutes of Health [K08 EY026101]; E. Matilda Ziegler
   Foundation for the Blind; Barr Foundation for Retinal Research; Alcon
   Research Institute; ARVO Foundation; California National Primate
   Research Center; National Eye Institute [HHS-NOI-EY-0-2127]; NATIONAL
   EYE INSTITUTE [K08EY026101] Funding Source: NIH RePORTER
FX Dr Yiu is supported by National Institutes of Health grant K08 EY026101,
   E. Matilda Ziegler Foundation for the Blind, Barr Foundation for Retinal
   Research, Alcon Research Institute, ARVO Foundation, and the California
   National Primate Research Center. The AREDS study was supported by the
   National Eye Institute (grant HHS-NOI-EY-0-2127).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Beasley TM, 1995, J EXP EDUC, V64, P79, DOI 10.1080/00220973.1995.9943797
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Ebraheem A, 2017, OPHTHALMOL RETINA, V2, P469
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hayreh SS, 2011, PROG RETIN EYE RES, V30, P359, DOI 10.1016/j.preteyeres.2011.05.001
   Hayreh SS, 2014, OCULAR VASCULAR OCCL, P55
   Hegde V, 2006, CLIN ANAT, V19, P645, DOI 10.1002/ca.20362
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim LA, 2017, AM SOC RET SPEC ANN
   LORENTZEN SE, 1970, ACTA OPHTHALMOL, V48, P518
   Lutty G, 1999, MOL VIS, V5
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Parsa C F, 1998, Trans Am Ophthalmol Soc, V96, P95
   Salzman M.., 1912, ANATOMY HISTOLOGY HU
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   WINTHERTHAM C, 1994, ACTA OPHTHALMOL, V72, P397
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 27
TC 22
Z9 22
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2018
VL 136
IS 9
BP 1008
EP 1014
DI 10.1001/jamaophthalmol.2018.2650
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GT6QH
UT WOS:000444641800013
PM 29978186
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Demirel, S
   Bilici, S
   Batioglu, F
   Ozmert, E
AF Demirel, Sibel
   Bilici, Serdar
   Batioglu, Figen
   Ozmert, Emin
TI Is There Any Difference between Ranibizumab and Aflibercept Injections
   in Terms of Inflammation Measured with Anterior Chamber Flare Levels in
   Age-Related Macular Degeneration Patients: A Comparative Study
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Aflibercept; Anterior chamber flare; Ranibizumab; Inflammation
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL INJECTION; VEGF-TRAP;
   AQUEOUS FLARE; BEVACIZUMAB; PHOTOMETRY; ENDOTOXIN; BINDING; CELLS
AB Purpose: To evaluate the inflammatory reaction to intravitreal aflibercept (IVA) or ranibizumab (IVR) in patients with age-related macular degeneration (AMD). Methods: A total of 60 eyes of 60 neovascular AMD patients and 30 eyes of 30 age-matched healthy people as a control group were included in this observational, prospective, comparative study. The AMD patients received 1:1 either IVA or IVR. Anterior chamber flare was measured with the Kowa FM-600 laser flare meter (Kowa Company, Ltd., Tokyo, Japan) at days 0, 1, and 30. The mean flare value and standard deviation are expressed as photon counts per millisecond. Results: There were 51 (56.7%) men and 39 (43.3%) women, with a mean age of 72.7 +/- 7.5 years. Mean aqueous flare values at baseline, day 1 and day 30 were 7.08 +/- 2.44, 7.23 +/- 2.56, and 6.99 +/- 2.29, respectively, for the IVR group, 6.87 +/- 3.18, 6.86 +/- 3.19, and 6.53 +/- 2.79, respectively, for the IVA group, and 6.4 +/- 3.29, 6.41 +/- 3.06, and 6.42 +/- 3.05, respectively, for the control group. There was no statistically significant difference in terms of baseline flare values for these three groups (p = 0.666). At the 1-day follow-up, a slight but not significant increase in flare was observed in the ranibizumab group. However, there was no significant change in aqueous flare values in either the ranibizumab- or the aflibercept-injected patients (p = 0.768 and p = 0.387, respectively) or between the groups (p = 0.635). No significant clinical inflammatory reactions were noted before or after intravitreal injections of either ranibizumab or aflibercept. Conclusion: No significant short-term intraocular inflammation was noted in the eyes receiving aflibercept or ranibizumab for the treatment of neovascular AMD. Although aflibercept has more immunogenic properties than ranibizumab, such as having an extra Fc portion and being a larger molecule, it is likely that its more potent anti-inflammatory effects prevent it from inducing inflammation. (C) 2016 S. Karger AG, Basel
C1 [Demirel, Sibel; Bilici, Serdar; Batioglu, Figen; Ozmert, Emin] Ankara Univ, Fac Med, Dept Ophthalmol, TR-06590 Ankara, Turkey.
C3 Ankara University
RP Demirel, S (通讯作者)，Ankara Univ, Fac Med, Dept Ophthalmol, Vehbi Koc Eye Hosp, Mamak Caddesi, TR-06590 Ankara, Turkey.
EM drsibeldemireltr@yahoo.com.tr
RI DEMIREL, SIBEL/GQH-3232-2022; Demirel, Sibel/AAQ-4282-2020; Batıoğlu,
   Figen/AAQ-3727-2020
OI DEMIREL, SIBEL/0000-0002-2477-9974; Demirel, Sibel/0000-0002-6430-6565;
   Batıoğlu, Figen/0000-0002-5834-7512; Bilici, Serdar/0000-0003-1346-0850
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Agrawal S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/943409
   Blaha GR, 2015, RETINA-J RET VIT DIS, V35, P577, DOI 10.1097/IAE.0000000000000334
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chong DY, 2010, RETINA-J RET VIT DIS, V30, P1432, DOI 10.1097/IAE.0b013e3181dc04da
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fine HF, 2015, CURR OPIN OPHTHALMOL, V26, P184, DOI 10.1097/ICU.0000000000000154
   GUEXCROSIER Y, 1995, OPHTHALMOLOGY, V102, P613, DOI 10.1016/S0161-6420(95)30976-1
   GuillenMonterrubio OM, 1997, ACTA OPHTHALMOL SCAN, V75, P58
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kuchle M, 1998, GRAEF ARCH CLIN EXP, V236, P426, DOI 10.1007/s004170050101
   Ladas JG, 2005, SURV OPHTHALMOL, V50, P27, DOI 10.1016/j.survophthal.2004.10.004
   Magalhaes PO, 2007, J PHARM PHARM SCI, V10, P388
   Marticorena J, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/928123
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ness T, 2010, RETINA-J RET VIT DIS, V30, P332, DOI 10.1097/IAE.0b013e3181baf691
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V13, P1
   SHAH SM, 1991, BRIT J OPHTHALMOL, V75, P348, DOI 10.1136/bjo.75.6.348
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Tugal-Tutkun Ilknur, 2010, International Ophthalmology, V30, P453, DOI 10.1007/s10792-009-9310-2
   Wang FH, 2013, OPHTHALMOLOGY, V120, P355, DOI 10.1016/j.ophtha.2012.07.083
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yeniad B, 2011, EUR J OPHTHALMOL, V21, P156, DOI 10.5301/EJO.2010.5239
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P922, DOI 10.1136/bjo.2006.092262
NR 33
TC 6
Z9 6
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 56
IS 1
BP 35
EP 40
DI 10.1159/000444497
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DN1FR
UT WOS:000376812200006
PM 27027523
DA 2022-11-30
ER

PT J
AU Clemens, CR
   Wolf, A
   Alten, F
   Milojcic, C
   Heiduschka, P
   Eter, N
AF Clemens, Christoph R.
   Wolf, Armin
   Alten, Florian
   Milojcic, Carolin
   Heiduschka, Peter
   Eter, Nicole
TI Response of vascular pigment epithelium detachment due to age-related
   macular degeneration to monthly treatment with ranibizumab: the
   prospective, multicentre RECOVER study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; confocal scanning laser ophthalmoscopy; pigment epithelium
   detachment; ranibizumab; retinal pigment epithelium tear;
   spectral-domain optical coherence tomography
ID CLINICOPATHOLOGICAL CORRELATION; TEARS; PATHOGENESIS; MICRORIPS; RISK
AB Purpose: To assess the effects of monthly intravitreal ranibizumab injections in patients with vascularized pigment epithelium detachment (vPED) secondary to age-related macular degeneration (AMD).
   Methods: A total of 40 patients were prospectively observed and treated monthly with 0.5mg ranibizumab injections (ClinicalTrials.gov Ident. NCT00976222). Inclusion criterion was a treatment-naive vPED lesion with a minimum height of 200m. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) were evaluated at all visits. Fluorescein angiography and indocyanine green angiography were performed at baseline and quarterly. Lesions were differentiated between serous vascular PED (svPED, group A, 29 patients) and fibrovascular PED (fPED, group B, 11 patients). Primary outcome was the effectivity of continuous monthly treatment during a 12-month period as measured in change in BCVA. Secondary outcomes were change in PED height and PED greatest linear diameter (GLD). Further secondary outcomes were the presence of subretinal fluid and prognostic markers of an impending retinal pigment epithelium (RPE) tear: PED lesion height and diameter, ratio of choroidal neovascularization (CNV) size to PED size, hyperreflective lines in near-infrared images, microrips and subretinal cleft.
   Results: Mean BCVA was 56.911.5 letters (A: 55.4 +/- 10.8; B: 59.1 +/- 13.4) at baseline and 55.1 +/- 15.9 (A: 53.7 +/- 17.0; B: 58.9 +/- 12.7) at 12-month follow-up. Excluding the RPE tear patients, the svPED group showed an increase in BCVA from 56.1 +/- 10.3 at baseline to 62.4 +/- 10.2 at 12-month follow-up (p=0.048). Best-corrected visual acuity in patient who developed a RPE tear was 55.8 +/- 12.5 at baseline and 37.1 +/- 14.9 at 12-month follow-up. The mean change in PED height was -242.1m +/- 285.5 (A: -427.3m +/- 299.7; B: -51.6m +/- 99.5). The mean decrease in PED GLD was -471.8m +/- 727.6 (A: -738.9m +/- 788.2; B: -10.4m +/- 185.6). In group A, 10 patients developed a RPE tear (25%) after a mean of 3.6 injections. No tear was documented in group B. Lesion height, ratio of CNV size to PED size and presence of hyperreflective lines differed significantly between patients with and without RPE tear development.
   Conclusion: Serous vascular PED lesions showed an improvement regarding BCVA and morphologic characteristics unless an RPE tear occurred. In fPED lesions, a functional and morphological stabilization was observed. Monthly ranibizumab injections are an effective treatment regarding the resorption of subretinal fluid in vPED due to AMD. Patients should be screened for the presence of morphologic risk factors for RPE tear development before and during treatment.
C1 [Clemens, Christoph R.; Alten, Florian; Heiduschka, Peter; Eter, Nicole] Univ Muenster Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
   [Wolf, Armin] Univ Munich, Dept Ophthalmol, Munich, Germany.
   [Milojcic, Carolin] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
C3 University of Munich; University of Bonn
RP Clemens, CR (通讯作者)，Univ Muenster Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM christoph.clemens@ukmuenster.de
RI Heiduschka, Peter/AAX-3882-2021
FU Novartis Ophthalmics (Nurnberg, Germany)
FX This is an investigator-initiated trial. Novartis Ophthalmics (Nurnberg,
   Germany) provided the study medication ranibizumab and additional
   funding for the trial. The sponsor had no role in the design or conduct
   of this research. The contents of this publication reflect only the
   author's views and not the views of the sponsor. C.R. Clemens,
   Heidelberg Engineering, Novartis, Bayer; Wolf A, Novartis, Bayer, Oertli
   Instruments F. Alten, Bayer; C. Milojcic C, none; P. Heiduschka N.
   Novartis, Bayer; Eter, Heidelberg Engineering, Novartis, Bayer, Sanofi
   Aventis, Allergan, Bausch and Lomb.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Clemens CR, 2015, ACTA OPHTHALMOL, V93, pE600, DOI 10.1111/aos.12683
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   IE D, 1992, ARCH OPHTHALMOL-CHIC, V110, P1443, DOI 10.1001/archopht.1992.01080220105030
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mukai R, 2014, ACTA OPHTHALMOL, V92, pE407, DOI 10.1111/aos.12350
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Wolf A, 2013, RETINA-J RET VIT DIS, V33, P1843, DOI 10.1097/IAE.0b013e318287d9be
NR 30
TC 6
Z9 7
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2017
VL 95
IS 7
BP 683
EP 689
DI 10.1111/aos.13359
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM0JE
UT WOS:000414648500030
PM 28084038
OA Bronze
DA 2022-11-30
ER

PT J
AU Radeck, VMM
   Helbig, H
   Valmaggia, C
   Barthelmes, D
AF Radeck, Viola Maria Margarete
   Helbig, Horst
   Valmaggia, Christophe
   Barthelmes, Daniel
TI Thermal Laser Monotherapy for Extrafoveal Polypoidal Choroidal
   Vasculopathy
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE laser treatment; polypoidal choroidal vasculopathy; macula edema;
   indocyanine green angiography; retina; choroid
ID ARGON-LASER; PHOTODYNAMIC THERAPY; PHOTOCOAGULATION
AB Introduction Polypoidal choroidal vasculopathy (PCV) is a vascular disease of the choroid. Diagnosis is mainly based on polypoidal aneurysm-like lesions seen in indocyanine green (ICG) angiography. Various therapeutic options have been proposed.
   Methods Outcomes of 10 cases with extrafoveal PCV and consecutive macular edema treated with thermal laser are reported. Diagnosis of PCV was confirmed by ICG angiography.
   Results Upon successful occlusion of the polyps in 10 eyes after thermal laser treatment demonstrated in ICG angiography, a regression of central foveal edema was seen in optical coherence tomography and color fundus photography. Visual acuity improved from logMAR 0.8 to logMAR 0.3. Follow-up ranged from 4 months to 15 years, with a median of 1 year. Two eyes had a recurrence of exudative maculopathy 5 and 7 years after laser treatment, respectively.
   Conclusion A careful differentiation between various subforms of exudative maculopathy using fluorescein and ICG angiography can identify certain selected patients with extrafoveal PCV, for whom thermal laser monotherapy can be a therapeutic option.
C1 [Radeck, Viola Maria Margarete; Helbig, Horst] Klinikum Univ Regensburg, Klin & Poliklin Augenheilkunde, Regensburg, Germany.
   [Valmaggia, Christophe] Kantonsspital St Gallen, Augenklin, St Gallen, Switzerland.
   [Barthelmes, Daniel] Univ Spital Zurich, Ophthalmol, Augenklin & Poliklin, Zurich, Switzerland.
C3 University of Regensburg; Kantonsspital St. Gallen; University of
   Zurich; University Zurich Hospital
RP Radeck, VMM (通讯作者)，Univ Klinikum Regensburg, Augenheilkunde, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
OI Radeck, Viola/0000-0001-9312-4085
CR Castro-Navarro V, 2021, GRAEF ARCH CLIN EXP, V259, P1385, DOI 10.1007/s00417-020-04940-0
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Helbig H, 2005, KLIN MONATSBL AUGENH, V222, P202, DOI 10.1055/s-2005-858011
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jordan-Yu JM, 2021, BRIT J OPHTHALMOL, V105, P1716, DOI 10.1136/bjophthalmol-2020-317537
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Sahu Y, 2021, INT OPHTHALMOL, V41, P753, DOI 10.1007/s10792-020-01620-0
   Simao JM, 2021, OPHTHALMOLOGICA, V244, P315, DOI 10.1159/000515295
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 18
TC 0
Z9 0
U1 0
U2 3
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD DEC
PY 2021
VL 238
IS 12
BP 1299
EP 1304
DI 10.1055/a-1608-1946
EA SEP 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YR5SY
UT WOS:000701997900001
PM 34587630
DA 2022-11-30
ER

PT J
AU Ishida, T
   Moriyama, M
   Morohoshi, K
   Furuse, Y
   Fukuda, T
   Ohno-Matsui, K
AF Ishida, Tomoka
   Moriyama, Muka
   Morohoshi, Kei
   Furuse, Yuu
   Fukuda, Taiko
   Ohno-Matsui, Kyoko
TI Polypoidal choroidal vasculopathy in a case with retinitis pigmentosa
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
ID CYSTOID MACULAR EDEMA; BLOOD-FLOW
AB There have been no reports describing polypoidal choroidal vasculopathy (PCV) in eyes with retinitis pigmentosa (RP). A 63-year-old woman who had been diagnosed as having RP was referred to us because of sudden onset of blurred vision in her right eye. Funduscopic examination revealed retinal findings typical of RP in both eyes. The macular area of the right fundus showed polypoidal lesions with massive hemorrhages. Fluorescein angiography and indocyanine green angiography showed multiple polypoidal lesions. Optical coherence tomography showed a large hemorrhagic retinal pigment epithelial (RPE) detachment and polypoidal lesions. The PCV subsided after three applications of anti-vascular endothelial growth factor (VEGF) therapy and a single application of photodynamic therapy, but "mottled lesions" with hyper- and hypofluorescence appeared temporal to the macula after disappearance of hemorrhage. We present a case of PCV in an eye with RP. Further studies are necessary to clarify whether anti-VEGF therapies could affect RPE status in eyes with RP.
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1130034, Japan.
EM k.ohno.oph@tmd.ac.jp
OI Morohoshi, Kei/0000-0002-2891-9073
CR Artunay O, 2009, J OCUL PHARMACOL TH, V25, P545, DOI 10.1089/jop.2009.0089
   Baillif-Gostoli S, 2010, GRAEF ARCH CLIN EXP, V248, P1845, DOI 10.1007/s00417-010-1328-7
   Battaglia PM, 2011, J OCUL PHARM THER
   Falsini B, 2011, INVEST OPHTH VIS SCI, V52, P1064, DOI 10.1167/iovs.10-5964
   LANGHAM ME, 1990, EYE, V4, P374, DOI 10.1038/eye.1990.50
   Malik Archana, 2010, International Ophthalmology, V30, P425, DOI 10.1007/s10792-009-9337-4
   Marano F, 2000, GRAEF ARCH CLIN EXP, V238, P760, DOI 10.1007/s004170000186
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Melo GB, 2007, ACTA OPHTHALMOL SCAN, V85, P461, DOI 10.1111/j.1600-0420.2006.00872.x
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Shintani K, 2009, OPTOMETRY, V80, P384, DOI 10.1016/j.optm.2008.01.026
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
NR 12
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JUN
PY 2013
VL 33
IS 3
BP 305
EP 308
DI 10.1007/s10792-012-9657-7
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 137DG
UT WOS:000318414700017
PM 23132213
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ojima, Y
   Tsujikawa, A
   Otani, A
   Hirami, Y
   Aikawa, H
   Yoshimura, N
AF Ojima, Yurniko
   Tsujikawa, Akitaka
   Otani, Atsushi
   Hirami, Yasuhiko
   Aikawa, Hiroko
   Yoshimura, Nagahisa
TI Recurrent bleeding after photodynamic therapy in polypoidal choroidal
   vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN
AB PURPOSE: To report a case of recurrent bleeding after photodynamic therapy (PDT) in an eye with polypoidal choroidal vasculopathy (PCV).
   DESIGN: Interventional case report.
   METHODS: A 73,year-old man was treated in the left eye for PCV with PDT.
   RESULTS: Two weeks after PDT, his left eye showed extensive subretinal hemorrhage, with a slight vision loss. Three months after PDT, subretinal hemorrhage was almost absorbed. He received a second session of PDT to the remaining choroidal neovascularization. Two weeks thereafter, his left eye showed massive suprachoroidal hemorrhage with further vision loss. One month after the second PDT, visual acuity was decreased to no light perception as a result of massive vitreous hemorrhage. Although the patient underwent pars plana vitrectomy, visual acuity in the left eye remained hand motion as a result of massive suprachoroidal hemorrhage.
   CONCLUSIONS:: Ophthalmologists and patients should be aware of the risk of massive bleeding after PDT in eyes with PCV.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
OI Tsujikawa, Akitaka/0000-0003-0779-7799
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
NR 5
TC 52
Z9 62
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2006
VL 141
IS 5
BP 958
EP 960
DI 10.1016/j.ajo.2005.12.002
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 043JW
UT WOS:000237598300032
PM 16678520
DA 2022-11-30
ER

PT J
AU Visser, MS
   Amarakoon, S
   Missotten, T
   Timman, R
   Busschbach, JJV
AF Visser, Martijn S.
   Amarakoon, Sankha
   Missotten, Tom
   Timman, Reinier
   Busschbach, Jan J., V
TI Six and eight weeks injection frequencies of bevacizumab are
   non-inferior to the current four weeks injection frequency for quality
   of life in neovascular age-related macular degeneration: a randomized
   controlled trial
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Injection frequency; NEI
   VFQ-39; Quality of life
ID VISUAL FUNCTION QUESTIONNAIRE; SINGLE INTRAVITREAL INJECTION; SF-36
   HEALTH SURVEY; INTRAOCULAR PHARMACOKINETICS; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB; EYE; DISEASE; RESPONSIVENESS;
   NONINFERIORITY
AB Purpose Patients with neovascular age-related macular degeneration (nARMD) will not deteriorate on visual acuity and retinal thickness when treated with bevacizumab injection frequencies of 6 or 8 weeks compared to 4 weeks. This study aimed to investigate this non-inferiority in quality of life (QoL). We hypothesized that less frequent bevacizumab injections are not inferior regarding patients reported QoL. Methods Patients were randomized to bevacizumab every 4 (n = 64), 6 (n = 63), and 8 weeks (n = 64). Patients were at least 65 years old, have a best-corrected visual acuity of 20/200 to 20/20, no previous ARMD treatment and active leakage. Vision-related QoL questionnaire NEI VFQ-39 was used to assess QoL at baseline and after 1 year. General QoL questionnaire SF-36 was included for secondary analysis. Multilevel analyses were performed, correcting for age, gender and baseline. Results The 6 (3.68; 95% CI - 0.63 to 8.00) and 8 (2.15; 95% CI - 2.26 to 6.56) weeks bevacizumab regimens resulted in non-inferior QoL differences compared to 4 weeks on the NEI VFQ-39. Also on the SF-36 the differences were well within the non-inferiority limits. Conclusion Non-inferiority of the 6 and 8 weeks frequencies was demonstrated compared to 4 weeks on vision-related and general QoL in patients with nARMD. These results are in line with previously published results of lower frequency injections regarding visual acuity and central retinal thickness. Lower injection frequency may reduce burden, side effects, and treatment costs. In consideration of these results, 8 weeks frequency injections of intravitreal bevacizumab could be considered in patients with nARMD.
C1 [Visser, Martijn S.; Timman, Reinier; Busschbach, Jan J., V] Erasmus MC, Dept Psychiat, Sect Med Psychol & Psychotherapy, POB 2040, NL-3000 CA Rotterdam, Netherlands.
   [Visser, Martijn S.; Amarakoon, Sankha; Missotten, Tom] Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC
RP Visser, MS (通讯作者)，Erasmus MC, Dept Psychiat, Sect Med Psychol & Psychotherapy, POB 2040, NL-3000 CA Rotterdam, Netherlands.; Visser, MS (通讯作者)，Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
EM m.s.visser@erasmusmc.nl
FU Foundation for scientific research of the Rotterdam Eye Hospital
   (SWOO-Flieringa), Rotterdam, the Netherlands; Theia Foundation, Leiden,
   the Netherlands [2010157]; CZ foundation, Zeist, the Netherlands
   [AFVV09-168]
FX This work was financially supported by the Foundation for scientific
   research of the Rotterdam Eye Hospital (SWOO-Flieringa), Rotterdam, the
   Netherlands; the Theia Foundation (Grant Number: 2010157), Leiden, the
   Netherlands and the CZ foundation (Grant Number: AFVV09-168), Zeist, the
   Netherlands. The funding organizations had no role in the design or
   conduct of this research.
CR Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3
   Amarakoon S, 2019, ACTA OPHTHALMOL, V97, P107, DOI 10.1111/aos.13774
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bird A C, 1999, Community Eye Health, V12, P8
   BIRD AC, 1993, BRIT J OPHTHALMOL, V77, P614, DOI 10.1136/bjo.77.10.614
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lesaffre E, 2008, BULL HOSP JT DIS, V66, P150
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin DF, 2011, CLIN EXP OPHTHALMOL, V39, P718, DOI 10.1111/j.1442-9071.2011.02703.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McAlinden C, 2011, OPHTHALMOLOGY, V118, P2374, DOI 10.1016/j.ophtha.2011.06.008
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Mitchell J, 2007, QUAL LIFE RES, V120, P2
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   Nilsson E, 2016, J INTERN MED, V279, P141, DOI 10.1111/joim.12409
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008
   Ware JE, 1994, SF 36 PHYS MENTAL HL
NR 39
TC 2
Z9 2
U1 1
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD DEC
PY 2020
VL 29
IS 12
BP 3305
EP 3313
DI 10.1007/s11136-020-02580-9
EA JUL 2020
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA OV4HP
UT WOS:000548481800002
PM 32666333
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Jakobsdottir, J
   Conley, YP
   Weeks, DE
   Ferrell, RE
   Gorin, MB
AF Jakobsdottir, Johanna
   Conley, Yvette P.
   Weeks, Daniel E.
   Ferrell, Robert E.
   Gorin, Michael B.
TI C2 and CFB Genes in Age-Related Maculopathy and Joint Action with CFH
   and LOC387715 Genes
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; MACULAR DEGENERATION;
   CIGARETTE-SMOKING; Y402H VARIANT; JAPANESE POPULATION; SUSCEPTIBILITY
   LOCI; GEOGRAPHIC ATROPHY; HEMICENTIN-1 GENES; STRONG ASSOCIATION
AB Background: Age-related maculopathy (ARM) is a common cause of visual impairment in the elderly populations of industrialized countries and significantly affects the quality of life of those suffering from the disease. Variants within two genes, the complement factor H (CFH) and the poorly characterized LOC387715 (ARMS2), are widely recognized as ARM risk factors. CFH is important in regulation of the alternative complement pathway suggesting this pathway is involved in ARM pathogenesis. Two other complement pathway genes, the closely linked complement component receptor (C2) and complement factor B (CFB), were recently shown to harbor variants associated with ARM.
   Methods/Principal Findings: We investigated two SNPs in C2 and two in CFB in independent case-control and family cohorts of white subjects and found rs547154, an intronic SNP in C2, to be significantly associated with ARM in both our case-control (P-value 0.00007) and family data (P-value 0.00001). Logistic regression analysis suggested that accounting for the effect at this locus significantly (P-value 0.002) improves the fit of a genetic risk model of CFH and LOC387715 effects only. Modeling with the generalized multifactor dimensionality reduction method showed that adding C2 to the two-factor model of CFH and LOC387715 increases the sensitivity (from 63% to 73%). However, the balanced accuracy increases only from 71% to 72%, and the specificity decreases from 80% to 72%.
   Conclusions/Significance: C2/CFB significantly influences AMD susceptibility and although accounting for effects at this locus does not dramatically increase the overall accuracy of the genetic risk model, the improvement over the CFH-LOC387715 model is statistically significant.
C1 [Jakobsdottir, Johanna; Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA USA.
   [Conley, Yvette P.; Weeks, Daniel E.; Ferrell, Robert E.; Gorin, Michael B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA USA.
   [Gorin, Michael B.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh
RP Jakobsdottir, J (通讯作者)，Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
EM gorin@jsei.ucla.edu
RI Weeks, Daniel E/B-2995-2012
OI Weeks, Daniel E/0000-0001-9410-7228; Jakobsdottir,
   Johanna/0000-0002-8019-9683
FU NEI [R01EY009859]; The Steinbach Foundation, New York; Research to
   Prevent Blindness, New York; Eye and Ear Foundation of Pittsburgh;
   American Health Assistance Foundation, Clarksburg, Maryland; Jules Stein
   Eye Institute, Los Angeles, California; NATIONAL EYE INSTITUTE
   [R01EY009859] Funding Source: NIH RePORTER
FX This study was supported by NEI grant R01EY009859, The Steinbach
   Foundation, New York, Research to Prevent Blindness, New York, the Eye
   and Ear Foundation of Pittsburgh, American Health Assistance Foundation,
   Clarksburg, Maryland, and the Jules Stein Eye Institute, Los Angeles,
   California (all to M.B.G.).
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Browning SR, 2005, GENET EPIDEMIOL, V28, P110, DOI 10.1002/gepi.20051
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen LJ, 2006, MOL VIS, V12, P1536
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2007, BRIT J OPHTHALMOL, V91, P966, DOI 10.1136/bjo.2007.114090
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lou XY, 2007, AM J HUM GENET, V80, P1125, DOI 10.1086/518312
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mukhopadhyay N, 2004, HUM HERED, V58, P175, DOI 10.1159/000083545
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   North BV, 2005, HUM HERED, V59, P79, DOI 10.1159/000085222
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Okamoto H, 2006, MOL VIS, V12, P156
   R Development Core Team, 2005, R LANG ENV STAT COMP
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Souied EH, 2005, MOL VIS, V11, P1135
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   THOMPSON CL, 2007, HUM MOL GENET
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   WANG JJ, 2007, LOC387715 POLYMORPHI
   WARNES G, 2006, POPULATION GENETICS
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wigginton JE, 2005, BIOINFORMATICS, V21, P3445, DOI 10.1093/bioinformatics/bti529
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YATES JR, 2007, COMPLEMENT C3 VARIAN
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 78
TC 73
Z9 88
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2008
VL 3
IS 5
AR e2199
DI 10.1371/journal.pone.0002199
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 391UK
UT WOS:000262258700008
PM 18493315
OA Green Published, Green Submitted, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Nowak-Sliwinska, P
   van den Bergh, H
   Sickenberg, M
   Koh, AHC
AF Nowak-Sliwinska, Patrycja
   van den Bergh, Hubert
   Sickenberg, Michel
   Koh, Adrian H. C.
TI Photodynamic therapy for polypoidal choroidal vasculopathy
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Anti-Angiogenesis; Choroidal
   neovascularization; Optical coherence tomography; Polypoidal choroidal
   vasculopathy; Visudyne (R)-photodynamic therapy
ID OPTICAL COHERENCE TOMOGRAPHY; EPITHELIUM-DERIVED FACTOR; INTRAVITREAL
   BEVACIZUMAB AVASTIN; RANDOMIZED CLINICAL-TRIALS; ENDOTHELIAL
   GROWTH-FACTOR; REPORT NO. 3; MACULAR DEGENERATION; VERTEPORFIN THERAPY;
   PIGMENT-EPITHELIUM; TRIAMCINOLONE ACETONIDE
AB The first effective therapy for exudative macular degeneration (AMD) was Photodynamic Therapy (PDT). Diagnosis of the disease was to a large extent by fluorescein angiography (FA). Distinguishing between the leaky choroidal neovessels (CNV) associated with exudative AMD, and the polypoidal structures associated with Polypoidal Choroidal Vasculopathy (PCV) is not always easy using FA alone. The switch to Indocyanine Green angiography helped to pinpoint PCV, and thus to study the efficacy of photodynamic therapy of this particular form of retinal disease, which is more frequently encountered among pigmented individuals. The results appear to be quite promising, and in the year following treatment only a small fraction of the patients had to be retreated. Alternatively, treating PCV with repeated intravitreal VEGF blocking agents was not as successful as it was in the treatment of wet AMD. However, combining PDT-induced angio-occlusion of the polypoidal lesions with anti-vascular endothelial growth factor therapy was shown to be quite effective, and the combination of PDT with an anti-angiogenic agent as well as a steroid, in a triple therapy, was recently also shown to be a quite promising option. In the present article we review the data on PDT of PCV, including combination therapies and alternative treatments. We also report on similarities and differences between AMD and PCV. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Nowak-Sliwinska, Patrycja; van den Bergh, Hubert] Swiss Fed Inst Technol EPFL, Inst Chem Sci & Engn, CH-1015 Lausanne, Switzerland.
   [Nowak-Sliwinska, Patrycja] Univ Hosp CHUV, CH-1011 Lausanne, Switzerland.
   [Sickenberg, Michel] Save Sight, Lausanne, Switzerland.
   [Koh, Adrian H. C.] Eye & Retina Surg, Camden Med Ctr, Singapore 248649, Singapore.
C3 Swiss Federal Institutes of Technology Domain; Ecole Polytechnique
   Federale de Lausanne; University of Lausanne; Centre Hospitalier
   Universitaire Vaudois (CHUV)
RP Nowak-Sliwinska, P (通讯作者)，Swiss Fed Inst Technol EPFL, CH-1015 Lausanne, Switzerland.
EM Patrycja.Nowak-Sliwinska@epfl.ch; dradriankoh@eyeretinasurgeons.com
RI Nowak-Sliwinska, Patrycja/T-7663-2018
OI Nowak-Sliwinska, Patrycja/0000-0002-8299-0444
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 2010, SAFETY STUDY HIGH DO
   [Anonymous], 2012, STUDY EVALUATING SAF
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Augustin A., 2009, RETINA, V29, pS8
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   BENHUR E, 1988, FEBS LETT, V236, P105, DOI 10.1016/0014-5793(88)80294-1
   Bertossi M, 1999, Angiogenesis, V3, P305, DOI 10.1023/A:1026550510585
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   CHANG W H J, 1980, Journal of Microsurgery, V2, P27
   Chen HY, 2012, MOL VIS, V18, P816
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cook KM, 2010, CA-CANCER J CLIN, V60, P222, DOI 10.3322/caac.20075
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   DOUKAS J, 1989, MICROVASC RES, V37, P125, DOI 10.1016/0026-2862(89)90032-0
   Ehmann D, 2010, CAN J OPHTHALMOL, V45, P36, DOI 10.3129/i09-243
   FOSTER TH, 1991, CANCER RES, V51, P3261
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   GILISSEN MJ, 1993, CANCER RES, V53, P2548
   Giovannini A, 1999, DOC OPHTHALMOL, V97, P367, DOI 10.1023/A:1002102630242
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   HAMBLIN MR, 2008, ADV PHOTODYNAMIC THE
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V56, P513, DOI 10.1111/j.1751-1097.1992.tb02195.x
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2012, MOL VIS, V18, P2796
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Hudson H.L, 2008, RETINA TODAY, V1, P59
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kessel D, 2010, METHODS MOL BIOL, V635, P35, DOI 10.1007/978-1-60761-697-9_3
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2011, SINGAP MED J, V52, P232
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koh S., 2004, PHOTODYNAMIC THERAPY
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Lam DSC, 2004, BRIT J OPHTHALMOL, V88, P1315, DOI 10.1136/bjo.2004.041624
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu X, 2011, BIOMED OPT EXPRESS, V2, P2995, DOI 10.1364/BOE.2.002995
   Madar-Balakirski N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010282
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   McKeage MJ, 2010, CANCER-AM CANCER SOC, V116, P1859, DOI 10.1002/cncr.24975
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Negrier S, 2012, INVEST NEW DRUG, V30, P1791, DOI 10.1007/s10637-011-9677-6
   NELSON JS, 1987, PHOTOCHEM PHOTOBIOL, V46, P829, DOI 10.1111/j.1751-1097.1987.tb04855.x
   Nowak-Sliwinska P., 2012, CURR ANGIOGENESIS, V1, P318
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   OGLETREE ML, 1987, FED PROC, V46, P133
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Pazos MDC, 2007, BRAZ J MED BIOL RES, V40, P1025, DOI 10.1590/S0100-879X2006005000142
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   REED MWR, 1988, J SURG RES, V45, P452, DOI 10.1016/0022-4804(88)90195-3
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Robertson CA, 2009, J PHOTOCH PHOTOBIO B, V96, P1, DOI 10.1016/j.jphotobiol.2009.04.001
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2007, AM J OPHTHALMOL, V144, P970, DOI 10.1016/j.ajo.2007.08.017
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saari JC, 2012, ANNU REV NUTR, V32, P125, DOI 10.1146/annurev-nutr-071811-150748
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saito K, 2009, JPN J OPHTHALMOL, V53, P512, DOI 10.1007/s10384-009-0703-6
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SOLOMON HM, 1966, J CELL PHYSIOL, V67, P281, DOI 10.1002/jcp.1040670208
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spitzer MS, 2008, CLIN OPHTHALMOL, V2, P1
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Sridhar SS, 2013, INVEST NEW DRUG, V31, P1008, DOI 10.1007/s10637-013-9931-1
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tsuchihashi T, 2013, CLIN OPHTHALMOL, V7, P615, DOI 10.2147/OPTH.S43566
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Van den Bergh H, 2003, LASERS IN OPHTHALMOLOGY: BASIC, DIAGNOSTIC AND SURGICAL ASPECTS, P183
   van den Bergh H, 2004, J FR OPHTALMOL, V27, P75, DOI 10.1016/S0181-5512(04)96097-4
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Weiss A, 2012, BBA-REV CANCER, V1826, P53, DOI 10.1016/j.bbcan.2012.03.003
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wielgus AR, 2012, PHOTOCHEM PHOTOBIOL, V88, P1320, DOI 10.1111/j.1751-1097.2012.01174.x
   Yamashita A., 2012, AM J OPHTHALMOL, V57, P283
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
   ZIEVE PD, 1966, J CELL PHYSIOL, V67, P271, DOI 10.1002/jcp.1040670207
NR 147
TC 67
Z9 69
U1 1
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2013
VL 37
BP 182
EP 199
DI 10.1016/j.preteyeres.2013.09.003
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 264VI
UT WOS:000327908700009
PM 24140257
OA hybrid
DA 2022-11-30
ER

PT J
AU Arnold, J
   Bauer, B
   Blumenkranz, MS
   Bressler, NM
   Bressler, SB
   Chader, GJ
   Chakravarthy, U
   Corcostegui, B
   Fine, SL
   Foerster, MH
   Gragoudas, ES
   Harvey, PT
   Hendrikse, F
   Immonen, I
   Johnson, M
   Kaiser, PK
   Kieselbach, GF
   Larsen, M
   Leys, A
   Margherio, RR
   Menchini, U
   Mieler, WF
   Mones, J
   Moreira, C
   Ohji, M
   Prunte, C
   Rosenfeld, P
   Saperstein, DA
   Singerman, L
   Soubrane, G
   Straatsma, BR
   Syrdalen, P
   Tornambe, PE
   Verdaguer, J
   Wolf, S
   Olson, J
   Aabert, TM
   Schachat, AP
   Bressler, SB
   Mones, J
   Miller, JW
   Lewis, H
   Singerman, L
   Soubrane, G
   Fish, GE
   Jurklies, B
   Pournaras, CJ
   Sickenberg, M
   Lim, JI
   Schmidt-Erfurth, U
   Blumenkranz, MS
   Rosenfeld, PJ
   Slakter, JS
   Johansson, I
   Lobes, L
   Ma, C
   Margherio, RR
   Williams, GA
   Koenig, F
   Meredith, T
   Harvey, PT
   Menchini, U
   Potter, MJ
   Stur, M
   Bressler, NM
   Bressler, SB
   Deslandes, JY
   Huber, G
   Manjuris, U
   Miller, JW
   Reaves, A
   Sickenberg, M
   Schmidt-Erfurth, U
   Strong, A
   Terlouw, G
AF Arnold, J
   Bauer, B
   Blumenkranz, MS
   Bressler, NM
   Bressler, SB
   Chader, GJ
   Chakravarthy, U
   Corcostegui, B
   Fine, SL
   Foerster, MH
   Gragoudas, ES
   Harvey, PT
   Hendrikse, F
   Immonen, I
   Johnson, M
   Kaiser, PK
   Kieselbach, GF
   Larsen, M
   Leys, A
   Margherio, RR
   Menchini, U
   Mieler, WF
   Mones, J
   Moreira, C
   Ohji, M
   Prunte, C
   Rosenfeld, P
   Saperstein, DA
   Singerman, L
   Soubrane, G
   Straatsma, BR
   Syrdalen, P
   Tornambe, PE
   Verdaguer, J
   Wolf, S
   Olson, J
   Aabert, TM
   Schachat, AP
   Bressler, SB
   Mones, J
   Miller, JW
   Lewis, H
   Singerman, L
   Soubrane, G
   Fish, GE
   Jurklies, B
   Pournaras, CJ
   Sickenberg, M
   Lim, JI
   Schmidt-Erfurth, U
   Blumenkranz, MS
   Rosenfeld, PJ
   Slakter, JS
   Johansson, I
   Lobes, L
   Ma, C
   Margherio, RR
   Williams, GA
   Koenig, F
   Meredith, T
   Harvey, PT
   Menchini, U
   Potter, MJ
   Stur, M
   Bressler, NM
   Bressler, SB
   Deslandes, JY
   Huber, G
   Manjuris, U
   Miller, JW
   Reaves, A
   Sickenberg, M
   Schmidt-Erfurth, U
   Strong, A
   Terlouw, G
CA Verteporfin Roundtable 2000 and 20
   Verteporfin Photodynamic Therapy
TI Guidelines for using verteporfin (Visudyne (R)) in photodynamic therapy
   to treat choroidal neovascularization due to age-related macular
   degeneration and other causes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization
   guidelines photodynamic therapy; randomized clinical trials; verteporfin
   therapy
AB Objective: Guidelines were developed based on best available scientific data as well as consensus of expert opinion in absence of controlled clinical trial data to: 1) assist ophthalmologists with selection of patients for whom photodynamic therapy with verteporfin, termed "verteporfin therapy," should be considered; and 2) offer suggestions regarding treatment, follow-up, and re-treatment.
   Methods: Consensus from roundtable of retina specialists who either participated in randomized clinical trials evaluating verteporfin therapy or had clinical experience with verteporfin therapy was based on results of these trials and expert opinion. Additional input and advice were received from representatives on behalf of the Macula Society, the Retina Society, and the Vitreous Society, as well as principal investigators of randomized clinical trials evaluating verteporfin therapy.
   Results: Patient selection criteria included the following: 1) in cases due to age-related macular degeneration (AMD), lesion composition either predominantly classic choroidal neovascularization (CNV) or occult with no classic CNV; 2) CNV location subfoveal or so close to the foveal center that conventional laser photocoagulation treatment almost certainly would extend under the center; 3) lesion etiology from AMD, pathologic myopia, or other causes in which the outcome without treatment is likely to be worse than with treatment; 4) vision at a level where further loss would be recognized as detrimental to the quality of life of the patient. Criteria did not include lesion size, except in cases composed of occult with no classic CNV in AMD in which therapy for lesions >4 Macular Photocoagulation Study (MPS) disc areas usually should be considered only when presenting with lower levels of best-corrected visual acuity. Criteria also did not include patient age, history of systemic arterial hypertension, or prior laser photocoagulation. Therapy should occur ideally within 1 week of the initial fluorescein angiogram on which the clinical decision to treat is based. Patients should return for follow-up at least as often as every 3 months after any initial or subsequent treatment to determine if there is fluorescein leakage from CNV. Re-treatment should be considered as often as every 3 months if fluorescein leakage from CNV is noted at that time. Re-treatment could be deferred if the biomicroscopic and fluorescein angiographic appearance of the lesion is unchanged and shows minimal leakage, especially when there is no subretinal fluid or fluorescein leakage from CNV underlying the center of the foveal avascular zone. Patients should avoid exposure of skin or eyes to direct sunlight or bright indoor light for 48 hours after treatment or until resolution of any swelling or discoloration from extravasation.
   Conclusion: These recommendations provide guidelines on the role of verteporfin therapy in the management of CNV due to AMD and other causes. Revisions of these guidelines may be required as new data become available.
C1 Novartis Ophthalm Inc, Med Affairs, Duluth, GA 30097 USA.
C3 Novartis
RP Arnold, J (通讯作者)，Novartis Ophthalm Inc, Med Affairs, 11460 Johns Creek Pkwy, Duluth, GA 30097 USA.
RI Larsen, Michael/E-9620-2010
OI Larsen, Michael/0000-0002-5172-5891
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Houle J, 2001, INVEST OPHTH VIS SCI, V42, pS437
   Packo KH, 2001, INVEST OPHTH VIS SCI, V42, pS449
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Rosenfeld PJ, 2001, INVEST OPHTH VIS SCI, V42, pS512
   *TAP STUD GROUP, 2002, IN PRESS ARCH OPHTHA
   TUNIS SR, 2000, CAG00066
NR 10
TC 64
Z9 66
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2002
VL 22
IS 1
BP 6
EP 18
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 529BF
UT WOS:000174279600003
PM 11884872
DA 2022-11-30
ER

PT J
AU Qu, JF
   Cheng, Y
   Li, XX
   Yu, LY
   Ke, X
AF Qu, Jinfeng
   Cheng, Yong
   Li, Xiaoxin
   Yu, Liyun
   Ke, Xiao
CA AURORA Study Grp
TI EFFICACY OF INTRAVITREAL INJECTION OF CONBERCEPT IN POLYPOIDAL CHOROIDAL
   VASCULOPATHY Subgroup Analysis of the Aurora Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE conbercept; polypoidal choroidal vasculopathy; AURORA Study; anti-VEGF;
   visual outcome; pigment epithelial detachment; polyp regression
ID INDOCYANINE GREEN ANGIOGRAPHY; EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL
   GROWTH-FACTOR; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; FOLLOW-UP;
   PIGMENT-EPITHELIUM; RANIBIZUMAB INJECTIONS; VERTEPORFIN; BEVACIZUMAB
AB Purpose: To evaluate the efficacy of different doses of conbercept in patients with polypoidal choroidal vasculopathy in the AURORA study.
   Methods: Retrospective subgroup analyses of 12-month data from the AURORA study. Fifty-three patients (32 in 0.5-mg group and 21 in 2.0-mg group) diagnosed with polypoidal choroidal vasculopathy in AURORA study were retrospectively evaluated. Efficacy outcomes were compared between the two dosage groups.
   Results: At Month 12, mean changes in best-corrected visual acuity from baseline were 14.4 +/- 14.1 letter scores for the 0.5-mg group and 14.2 +/- 21.0 letter scores for the 2.0-mg group; mean central retinal thickness decreased by 104.5 +/- 127.3 mu m in the 0.5-mg group and 140.7 +/- 127.9 mu m in the 2.0-mg group; mean total macular volume decreased by 0.9 +/- 2.3 mm(3) and 1.0 +/- 1.2 mm(3) in the 0.5-mg and 2.0-mg groups, respectively. The mean subretinal fluid thickness decreased by 111.9 +/- 122.5 mu m and 76.3 +/- 112.6 mu m in the 0.5-mg and 2.0-mg groups, respectively. The mean pigment epithelial detachment height decreased by 79.3 +/- 217.8 mu m and 61.3 +/- 161.5 mu m in the 0.5-mg and 2.0-mg groups, respectively. The mean area of polyps decreased by 0.46 +/- 0.76 mm(2) and 0.55 +/- 1.34 mm(2) in the 0.5-mg and 2.0-mg groups, respectively. The mean total lesion area decreased by 2.51 +/- 5.94 mm(2) (P = 0.088) and 4.62 +/- 5.51 mm(2) in the 0.5-mg group and 2.0-mg groups, respectively. Complete regression of polyps was observed in 56.5% of patients in the 0.5-mg group and 52.9% of those in the 2.0-mg group, whereas partial regression was observed in 26.1% and 35.3% of patients in the 0.5-mg and 2.0-mg groups, respectively.
   Conclusion: Intravitreal injection of conbercept appears to significantly improve visual acuity and anatomical outcomes in patients with polypoidal choroidal vasculopathy.
C1 [Qu, Jinfeng; Cheng, Yong; Li, Xiaoxin] Peking Univ, Peoples Hosp, Beijing Key Lab Diag & Treatment Retinal & Choroi, Key Lab Vis Loss & Restorat,Minist Educ,Dept Opht, Beijing 100044, Peoples R China.
   [Yu, Liyun; Ke, Xiao] Chengdu Kanghong Biotechnol Inc, Chengdu, Peoples R China.
C3 Peking University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, 11 South Ave, Beijing 100044, Peoples R China.
EM dr_lixiaoxin@163.com
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chhablani JK, 2013, INDIAN J OPHTHALMOL, V61, P136, DOI 10.4103/0301-4738.109390
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kokame GT, 2013, OPEN OPHTHALMOL J, V31, P82
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2012, ASIA-PAC J OPHTHALMO, V1, P97, DOI 10.1097/APO.0b013e31823e5a95
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee Y-A, 2012, TAIWAN J OPHTHALMOL, V2, P64
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 55
TC 31
Z9 34
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2016
VL 36
IS 5
BP 926
EP 937
DI 10.1097/IAE.0000000000000875
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL2RG
UT WOS:000375482100018
PM 26595362
DA 2022-11-30
ER

PT J
AU Wu, L
   Arevalo, JF
   Hernandez-Bogantes, E
   Regatieri, CV
   Roca, JA
   Farah, ME
AF Wu, Lihteh
   Arevalo, J. Fernando
   Hernandez-Bogantes, Erick
   Regatieri, Caio V.
   Roca, Jose A.
   Farah, Michel E.
TI Intravitreal Tumor Necrosis Factor-Alpha Inhibitors for Neovascular
   Age-Related Macular Degeneration Suboptimally Responsive to Antivascular
   Endothelial Growth Factor Agents: A Pilot Study from the Pan American
   Collaborative Retina Study Group
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; FACTOR-H POLYMORPHISM;
   MONOCLONAL-ANTIBODY; ADALIMUMAB HUMIRA; ANIMAL-MODEL; INFLIXIMAB;
   THERAPY; RABBIT; RANIBIZUMAB; TOXICITY
AB Purpose: To compare the short-term visual and anatomic outcomes after intravitreal injections of 2 different tumor necrosis factor-a inhibitors to continued antivascular endothelial growth factor (VEGF) therapy in eyes with choroidal neovascularization (CNV) secondary to age-related macular degeneration that responded suboptimally to anti-VEGF agents.
   Methods: Retrospective comparative case series of 26 eyes. Eyes were injected intravitreally with 1 mg infliximab, 2 mg infliximab, 2 mg adalimumab, or 1.25 mg bevacizumab. The main outcomes measured were the best-corrected visual acuity (BCVA) and the central macular thickness (CMT) at 3 months of follow-up.
   Results: The mean log minimal angle of resolution BCVA changed from 1.04 +/- 0.23 at baseline to 1.06 +/- 0.51 at 3 months (P = 0.9455) in the 1-mg infliximab group; 0.94 +/- 0.48 at baseline to 0.85 +/- 0.43 in the 2-mg infliximab group (P = 0.2802); 1.58 +/- 0.50 at baseline to 1.38 +/- 0.43 in the adalimumab group (P = 0.1116); and 1.08 +/- 0.1 at baseline to 1.03 +/- 0.16 in the bevacizumab group (P = 0.9928). The mean CMT changed from 387 +/- 54 mm at baseline to 342 +/- 108 mm (P = 0.1053) in the 1-mg infliximab group; 301 +/- 42 mm at baseline to 284 +/- 73 mm (P = 0.4854) in the 2-mg infliximab group; remained unchanged at 348 +/- 106 mm (P = 0.308) in the adalimumab group; and 362 +/- 66 mm to 340-27 mm in the bevacizumab group (P = 0.4622). Adverse events included uveitis in 37.5% (6/16) of eyes injected with infliximab.
   Conclusion: Intravitreal infliximab and adalimumab do not appear to benefit eyes with CNV that responded suboptimally to anti-VEGF agents. Intravitreal injections of infliximab may elicit a severe intraocular inflammatory reaction.
C1 [Wu, Lihteh; Hernandez-Bogantes, Erick] Inst Cirugia Ocular, San Jose 1225, Costa Rica.
   [Arevalo, J. Fernando] King Khalid Eye Specialist Hosp, Riyadh 11462, Saudi Arabia.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Regatieri, Caio V.; Farah, Michel E.] Univ Fed Sao Paulo, Dept Oftalmol, Inst Visao, Sao Paulo, Brazil.
   [Roca, Jose A.] Clin Ricardo Palma, Dept Ophthalmol, Lima, Peru.
C3 King Khaled Eye Specialist Hospital; Johns Hopkins University; Johns
   Hopkins Medicine; Universidade Federal de Sao Paulo (UNIFESP)
RP Wu, L (通讯作者)，Inst Cirugia Ocular, Apdo 144-1225 Plaza Mayor, San Jose 1225, Costa Rica.
EM lw65@cornell.edu
RI Fromow-Guerra, J. Jans/A-3346-2015; Regatieri, Caio/G-8152-2014; Farah,
   Michel Eid E/F-3285-2012
OI Fromow-Guerra, J. Jans/0000-0001-5335-1275; Regatieri,
   Caio/0000-0003-1511-8696; Farah, Michel Eid E/0000-0001-5951-0193;
   Arevalo Suarez, Fernando Antonio/0000-0002-4114-5949
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Androudi S, 2010, OPHTHALMOLOGY, V117, P1612, DOI 10.1016/j.ophtha.2009.12.011
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Giansanti F, 2008, INVEST OPHTH VIS SCI, V49, P1151, DOI 10.1167/iovs.07-0932
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Joussen AM, 2009, MOL VIS, V15, P1418
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0
   Manzano RPA, 2008, GRAEF ARCH CLIN EXP, V246, P907, DOI 10.1007/s00417-008-0765-z
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pulido JS, 2010, RETINA-J RET VIT DIS, V30, P1, DOI 10.1097/IAE.0b013e3181cde727
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Schachat AP, 2003, OPHTHALMOLOGY, V110, P2073, DOI 10.1016/S0161-6420(03)01004-2
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Theodossiadis P, 2009, GRAEF ARCH CLIN EXP, V247, P273, DOI 10.1007/s00417-008-0967-4
   Tsilimbaris M, 2009, GRAEF ARCH CLIN EXP, V247, P1119, DOI 10.1007/s00417-009-1065-y
   Wan L, 2010, RETINA-J RET VIT DIS, V30, P1595, DOI 10.1097/IAE.0b013e3181dc58a6
   Wiedmann Marcus W., 2009, Endocrine Metabolic & Immune Disorders-Drug Targets, V9, P295
NR 35
TC 27
Z9 27
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD APR
PY 2013
VL 29
IS 3
BP 366
EP 371
DI 10.1089/jop.2012.0203
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 117IP
UT WOS:000316947100017
PM 23215543
DA 2022-11-30
ER

PT J
AU Wu, KHC
   Tan, AG
   Rochtchina, E
   Favaloro, EJ
   Williams, A
   Mitchell, P
   Wang, JJ
AF Wu, Kathy H. C.
   Tan, Ava Grace
   Rochtchina, Elena
   Favaloro, Emmanuel J.
   Williams, Andrew
   Mitchell, Paul
   Wang, Jie Jin
TI Circulating inflammatory markers and hemostatic factors in age-related
   maculopathy: A population-based case-control study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID C-REACTIVE PROTEIN; ACTIVATOR INHIBITOR TYPE-1; FACTOR-H POLYMORPHISM;
   MACULAR DEGENERATION; RISK-FACTORS; ENDOTHELIAL DYSFUNCTION;
   CARDIOVASCULAR-DISEASE; PLASMA HOMOCYSTEINE; NATIONAL-HEALTH;
   ATHEROSCLEROSIS
AB PURPOSE. To examine the relationship between circulating inflammatory markers, hemostatic factors, and age-related maculopathy (ARM).
   METHODS. A population-based, cross-sectional case-control study drawn from the Blue Mountains Eye Study included 159 early and 38 late ARM cases, and 433 controls matched for age, gender, and smoking. ARM lesions were assessed from retinal photographs according to the Wisconsin ARM grading system. Circulating inflammatory markers (high-sensitivity C-reactive protein [hsCRP], intercellular adhesion molecule [ICAM]-1, and interleukin [IL]-6), white cell count (WCC), and hemostatic factors (fibrinogen, homocysteine, plasminogen activator inhibitor [PAI]-1 and von Willebrand factor [vWF]) were assessed. Age, gender, current smoking, body mass index, hypertension, history of stroke, and cardiovascular events were adjusted for. Adjusted mean levels of each marker were compared between persons with early ARM, those with late ARM, and control subjects, and are presented as probabilities. Adjusted associations with ARM were examined continuously (per SD), and are presented as odds ratios (ORs) and 95% confidence intervals (CIs). Summarizing z scores for inflammation and hemostatic dysfunction were calculated.
   RESULTS. Increased PAI-1 level was associated with both early (OR 1.2, 95% Cl 1.0-1.4 per SD increase) and late ARM (OR 1.3, 95% CI 0.9-1.9 per SD increase). Elevated ICAM-1 level was marginally associated with late ARM (OR 1.3, 95% Cl 1.0-1.7 per SD increase). No other significant associations were found between the remaining inflammatory or hemostatic markers and either early or late ARM. Summarized z scores for inflammatory or hemostatic markers also did not suggest any associations.
   CONCLUSIONS. There was no consistent pattern of association found between ARM and circulating inflammatory markers or hemostatic factors in this population-based case-control study.
C1 Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW 2145, Australia.
   Westmead Hosp, Dept Hematol, Inst Clin Pathol & Med Res, Westmead, NSW 2145, Australia.
   Royal Prince Alfred Hosp, Dept Clin Immunol, Camperdown, NSW 2050, Australia.
C3 University of Sydney; University of Sydney; University of Sydney
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Favaloro, Emmanuel J./J-7689-2019; Wang, Jie Jin/P-1499-2014; Mitchell,
   Paul/P-1498-2014; wang, jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; Favaloro, Emmanuel
   J/0000-0002-2103-1661; Tan, Ava Grace/0000-0003-3344-0339
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Favaloro EJ, 1997, CLIN APPL THROMB-HEM, V3, P110, DOI 10.1177/107602969700300208
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koh AHC, 2002, ANN ACAD MED SINGAP, V31, P399
   Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ng MKC, 2002, ARTERIOSCL THROM VAS, V22, P1136, DOI 10.1161/01.ATV.0000022167.80130.A6
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Roberts WL, 2000, CLIN CHEM, V46, P461
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEDDON JM, 2001, RETINA, P1039
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   van Hecke MV, 2005, DIABETOLOGIA, V48, P1300, DOI 10.1007/s00125-005-1799-y
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WIMAN B, 1990, AM J CARDIOL, V66, pG54, DOI 10.1016/0002-9149(90)90397-J
   Yamamoto K, 2005, CARDIOVASC RES, V66, P276, DOI 10.1016/j.cardiores.2004.11.013
NR 59
TC 40
Z9 42
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2007
VL 48
IS 5
BP 1983
EP 1988
DI 10.1167/iovs.06-0223
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 162DU
UT WOS:000246067800012
PM 17460250
DA 2022-11-30
ER

PT J
AU Liu, Y
   Zhu, M
   Gong, RW
   Wang, X
   Li, L
   Xu, GZ
AF Liu, Yang
   Zhu, Min
   Gong, Ruowen
   Wang, Xin
   Li, Lei
   Xu, Gezhi
TI Pre-treatment With Ranibizumab Aggravates PDT Injury and Alleviates
   Inflammatory Response in Choroid-Retinal Endothelial Cells
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE PDT; anti-VEGF; pre-treatment; necroptosis; NLRP3; IL-1 beta
   inflammatory response
ID FLUENCE PHOTODYNAMIC THERAPY; INTRAVITREAL RANIBIZUMAB; MACULAR
   DEGENERATION; GROWTH-FACTOR; RIP KINASES; VASCULOPATHY; NECROPTOSIS;
   MEMBRANE; BEVACIZUMAB; SURVIVAL
AB Polypoidal choroidal vasculopathy (PCV) is the predominant subtype of exudative age-related macular degeneration in Asians. Although photodynamic therapy (PDT) is widely used for PCV treatment, its long-term beneficial effects are unsatisfactory. Accumulating clinical investigations suggest that combined therapy with anti-vascular endothelial growth factor (anti-VEGF) and PDT is superior to PDT monotherapy. However, the optimal time of anti-VEGF before or after PDT remains controversial, hence it needs to further explore the mechanism underlying combined therapy. PDT causes selective damage to endothelial cells, which determines its angio-occlusive efficiency, yet the impact of anti-VEGF on PDT-induced endothelial injury is unclear. Here, we found that pre- compared to post-treatment with anti-VEGF ranibizumab (rani) significantly aggravates PDT injury in the rhesus macaque choroid-retinal endothelial (RF/6A) cell line. PDT activates apoptosis, necroptosis and NLRP3 inflammasome in RF/6A cells. Pre-treatment with rani promotes PDT-caused apoptosis via triggering caspase 8-mediated extrinsic apoptosis, and caspase 8 might also play a pivotal role in the rani's function of suppressing PDT-induced necroptosis and NLRP3 inflammasome activation. Our results implicate that pre-treatment with rani may enhance the angio-occlusive efficiency of PDT and alleviate endothelial inflammatory response, which gives it a great advantage over post-treatment.
C1 [Liu, Yang; Zhu, Min; Gong, Ruowen; Wang, Xin; Li, Lei; Xu, Gezhi] Fudan Univ, Eye & ENT Hosp, Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.
   [Liu, Yang; Zhu, Min; Gong, Ruowen; Wang, Xin; Li, Lei; Xu, Gezhi] Fudan Univ, Chinese Acad Med Sci, NHC Key Lab Myopia, Key Lab Myopia, Shanghai, Peoples R China.
C3 Fudan University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Fudan University
RP Li, L; Xu, GZ (通讯作者)，Fudan Univ, Eye & ENT Hosp, Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.; Li, L; Xu, GZ (通讯作者)，Fudan Univ, Chinese Acad Med Sci, NHC Key Lab Myopia, Key Lab Myopia, Shanghai, Peoples R China.
EM drlilei3028@163.com; drxugezhi@163.com
FU National Natural Science Foundation of China [NSFC81400393,
   NSFC81570854, NSFC81770944]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC81400393, NSFC81570854, and NSFC81770944).
CR Ardestani S, 2013, CANCER RES, V73, P3938, DOI 10.1158/0008-5472.CAN-13-0002
   Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001
   Domigan CK, 2015, J CELL SCI, V128, P2236, DOI 10.1242/jcs.163774
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Hogarth MW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10438-z
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Kang TB, 2013, IMMUNITY, V38, P27, DOI 10.1016/j.immuni.2012.09.015
   KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777
   Keller N, 2018, SEMIN CELL DEV BIOL, V82, P105, DOI 10.1016/j.semcdb.2018.01.009
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Liu YP, 2019, INT J MOL MED, V44, P771, DOI 10.3892/ijmm.2019.4244
   Luo QH, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5241941
   Makin RD, 2018, INVEST OPHTH VIS SCI, V59, P5795, DOI 10.1167/iovs.18-25215
   Mandal P, 2014, MOL CELL, V56, P481, DOI 10.1016/j.molcel.2014.10.021
   Miki Y, 2015, LASER MED SCI, V30, P1739, DOI 10.1007/s10103-015-1783-9
   Mitsiades N, 2001, CANCER RES, V61, P577
   Mocarski ES, 2012, NAT REV IMMUNOL, V12, P79, DOI 10.1038/nri3131
   Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132
   Moon SW, 2011, OPHTHALMOLOGICA, V225, P169, DOI 10.1159/000323811
   Moriwaki K, 2016, CELL MOL LIFE SCI, V73, P2325, DOI 10.1007/s00018-016-2203-4
   Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113
   Morris G, 2018, MOL NEUROBIOL, V55, P5767, DOI 10.1007/s12035-017-0793-y
   Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516
   Nowak-Sliwinska P, 2010, ANGIOGENESIS, V13, P281, DOI 10.1007/s10456-010-9185-x
   Pajuelo D, 2018, CELL REP, V24, P429, DOI 10.1016/j.celrep.2018.06.042
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205
   Silke J, 2015, NAT IMMUNOL, V16, P689, DOI [10.1038/ni0815-889b, 10.1038/ni.3206]
   Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200
   Songane M, 2018, SEMIN CELL DEV BIOL, V82, P137, DOI 10.1016/j.semcdb.2018.01.001
   Sun MX, 2015, PHOTOCHEM PHOTOBIOL, V91, P533, DOI 10.1111/php.12424
   Takahashi N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.176
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tummers B, 2017, IMMUNOL REV, V277, P76, DOI 10.1111/imr.12541
   Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003
   Watson EC, 2016, CELL DEATH DIFFER, V23, P1371, DOI 10.1038/cdd.2016.20
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
   ZHANG Y, 2017, CELL DEATH DIS, V8, DOI DOI 10.1038/cddis.2017.308cddis2017308
   Zhang YY, 2018, CELL RES, V28, P9, DOI 10.1038/cr.2017.133
   Zhao M, 2017, INT J OPHTHALMOL-CHI, V10, P413, DOI 10.18240/ijo.2017.03.14
   zu Horste GM, 2018, IMMUNITY, V48, P556, DOI 10.1016/j.immuni.2018.03.008
NR 56
TC 0
Z9 0
U1 1
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JUL 9
PY 2020
VL 8
AR 608
DI 10.3389/fcell.2020.00608
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA MU7GH
UT WOS:000555837400001
PM 32733897
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tran, TL
   Bek, T
   la Cour, M
   Prause, JU
   Hamann, S
   Heegaard, S
AF Thuy Linh Tran
   Bek, Toke
   la Cour, Morten
   Prause, Jan Ulrik
   Hamann, Steffen
   Heegaard, Steffen
TI Aquaporin-1 Expression in Retinal Pigment Epithelial Cells Overlying
   Retinal Drusen
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Aquaporin-1; Retinal pigment epithelial cells; Drusen
ID AGE-RELATED MACULOPATHY; EYE; CHANNELS
AB Purpose: In the outer retina, age-related macular degeneration (AMD) results in reduced hydraulic conductivity in Bruch's membrane, possibly leading to altered water transport in retinal pigment epithelial (RPE) cells. We hypothesize that RPE cells may express aquaporin-1 (AQP1) to compensate for these changes. Therefore, we wanted to investigate the expression of AQP1 in RPE cells of human eyes with age related maculopathy (ARM) and AMD, and eyes with tumour-associated drusen. Methods: Nine human eyes with ARM, 6 eyes with AMD and 9 eyes with choroidal malignant melanoma were examined for immunoreactivity to AQP1. AQP1 labelling in the RPE cells was evaluated for each drusen and grouped according to size and AQP1 labelling. AQP1 labelling in the RPE outside drusen was also evaluated. Results: AQP1 labelling was observed in the apical membrane of the RPE cells situated above drusen in all three groups. There was a significant association between AQP1 labelling and drusen size (p < 0.001), and AQP1 labelling was more frequently observed in large drusen. Conclusion: AQP1 was expressed in RPE cells covering drusen but not in RPE cells outside drusen. We suggest that AQP1 expression is upregulated in the cell membranes of RPE cells above drusen in order to alleviate the increased need for fluid transport across the growing drusen. (C) 2016 S. Karger AG, Basel
C1 [Thuy Linh Tran; Prause, Jan Ulrik; Heegaard, Steffen] Univ Copenhagen, Rigshosp Glostrup, Dept Neurosci & Pharmacol, Eye Pathol Inst, Copenhagen, Denmark.
   [Thuy Linh Tran; la Cour, Morten; Hamann, Steffen; Heegaard, Steffen] Univ Copenhagen, Rigshosp Glostrup, Dept Ophthalmol, Copenhagen, Denmark.
   [Bek, Toke] Aarhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus, Denmark.
   [Heegaard, Steffen] Univ Copenhagen, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen; Aarhus University;
   Rigshospitalet; University of Copenhagen
RP Heegaard, S (通讯作者)，Univ Copenhagen, Fac Hlth Sci, Dept Neurosci & Pharmacol, Eye Pathol Inst, Frederik Vs Vej 11,1, DK-2100 Copenhagen, Denmark.
EM sthe@sund.ku.dk
RI Hamann, Steffen/E-2090-2013; la Cour, Morten/L-1600-2013
OI Hamann, Steffen/0000-0003-4318-2716; Dornonville de la Cour,
   Morten/0000-0002-7712-9772; Bek, Toke/0000-0002-0409-2534
FU Danish Eye Research Foundation; Fight for Sight - Denmark; Synoptik
   Foundation; Aase and Ejnar Danielsen Foundation; Civilingenior Lars
   Andersen Legat; Overlaerer Svend Hansens Fond
FX This study was supported by grants from the Danish Eye Research
   Foundation, Fight for Sight - Denmark, the Synoptik Foundation, the Aase
   and Ejnar Danielsen Foundation, Civilingenior Lars Andersen Legat and
   Overlaerer Svend Hansens Fond.
CR Baetz NW, 2012, INVEST OPHTH VIS SCI, V53, P2127, DOI 10.1167/iovs.11-8471
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Goodyear MJ, 2009, VISUAL NEUROSCI, V26, P159, DOI 10.1017/S0952523809090038
   Hamann S, 2003, EXP EYE RES, V76, P493, DOI 10.1016/S0014-4835(02)00329-9
   Hamann S, 1998, AM J PHYSIOL-CELL PH, V274, pC1332, DOI 10.1152/ajpcell.1998.274.5.C1332
   Hara-Chikuma M, 2008, J MOL MED-JMM, V86, P221, DOI 10.1007/s00109-007-0272-4
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   NAUMANN G, 1966, ARCH OPHTHALMOL-CHIC, V76, P784, DOI 10.1001/archopht.1966.03850010786004
   Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001
   NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371
   Ortak H, 2013, ACTA HISTOCHEM, V115, P382, DOI 10.1016/j.acthis.2012.09.013
   Rojek A, 2008, ANNU REV PHYSIOL, V70, P301, DOI 10.1146/annurev.physiol.70.113006.100452
   Stamer WD, 2003, INVEST OPHTH VIS SCI, V44, P2803, DOI 10.1167/iovs.03-0001
   Tran TL, 2013, ACTA OPHTHALMOL, V91, P557, DOI 10.1111/j.1755-3768.2012.02547.x
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Verkman AS, 2008, PROG RETIN EYE RES, V27, P420, DOI 10.1016/j.preteyeres.2008.04.001
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 20
TC 5
Z9 6
U1 1
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 55
IS 4
BP 180
EP 184
DI 10.1159/000443207
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI1IB
UT WOS:000373248700003
PM 26871693
DA 2022-11-30
ER

PT J
AU Adrian, ML
   Vassilev, ZP
   Westborg, I
AF Adrian, Monica Lovestam
   Vassilev, Zdravko P.
   Westborg, Inger
TI Baseline visual acuity as a prognostic factor for visual outcomes in
   patients treated with aflibercept for wet age-related macular
   degeneration: data from the INSIGHT study using the Swedish Macula
   Register
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; age-related macular degeneration; neovascular AMD;
   prognosis; visual acuity; wet AMD
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL RANIBIZUMAB; INJECTION; TIME;
   LIFE
AB Purpose To assess mean change in visual acuity (VA) overall and stratified by baseline VA after 1 and 2 years' treatment with aflibercept in a real-life setting. Methods This was an observational cohort study using nationwide data from the Swedish Macula Register. Treatment-naive patient eyes with wet age-related macular degeneration and prescribed aflibercept from January 2013 to December 2014 were followed for 1 year (2478 eyes) or 2 years (831 eyes) to assess VA. Eyes were grouped by baseline VA. Results Mean number of injections in patients treated according to label (72%) versus patients treated not according to label was 8.0 +/- 1.5 versus 4.4 +/- 0.8 (p < 0.0001) at 1 year, and 12.5 +/- 3.2 versus 7.3 +/- 1.9 (p < 0.0001) at 2 years. Among all eyes, mean VA increased from 61.3 +/- 13.4 Early Treatment Diabetic Retinopathy Study letters at baseline to 64.5 +/- 15.6 at 1 year and 65.1 +/- 15.1 letters at 2 years. At 2 years, eyes with good baseline vision (>= 70 letters) lost a mean of 2.4 +/- 11.3 to 72.3 letters, eyes with intermediate baseline VA (36-69 letters) gained 5.7 +/- 14.1 to 62.7 letters, and eyes with poor baseline VA (<= 35 letters) gained 13.2 +/- 18.3 to 41.0 letters. Also at 2 years, 75% of treated eyes were stable or had improved VA. Among eyes with intermediate baseline VA, near vision was significantly better among those treated according to label versus not according to label at 3 (p = 0.019), 6 (p = 0.0002) and 12 months (p <= 0.0001). Conclusion While gain in vision was especially pronounced in eyes with poor baseline VA, good baseline VA was important for best prognosis.
C1 [Adrian, Monica Lovestam] Lund Univ, Dept Ophthalmol, SE-22185 Lund, Sweden.
   [Vassilev, Zdravko P.] Bayer US, Whippany, NJ USA.
   [Westborg, Inger] Uppsala Univ, Dept Neurosci, Ophthalmol, Uppsala, Sweden.
C3 Lund University; Uppsala University
RP Adrian, ML (通讯作者)，Lund Univ, Dept Ophthalmol, SE-22185 Lund, Sweden.
EM monica.lovestam_adrian@med.lu.se
RI Westborg, Inger/AAD-7108-2021
FU Bayer AG
FX This study was supported by grants from Bayer AG. MLA is a member of
   Global Academy, Bayer; IW has received lecture fees from Bayer and
   Novartis; ZPV is a full-time employee of Bayer US. We thank EpiMed
   Communications Ltd for editorial support funded by Bayer AG.
CR Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Cazet-Supervielle A, 2015, OPHTHALMOLOGICA, V234, P26, DOI 10.1159/000430470
   Epstein D, 2016, RETINA-J RET VIT DIS, V36, P1773, DOI 10.1097/IAE.0000000000000978
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lanzetta P, 2018, ACTA OPHTHALMOL, V96, pE911, DOI 10.1111/aos.13751
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rung L, 2013, CLIN OPHTHALMOL, V7, P395, DOI 10.2147/OPTH.S41585
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schroeder M, 2017, CLIN OPHTHALMOL, V11, P1105, DOI 10.2147/OPTH.S130182
   Tah V, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/627674
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Westborg I, 2017, RETINA-J RET VIT DIS, V37, P2035, DOI 10.1097/IAE.0000000000001431
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 22
TC 13
Z9 14
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2019
VL 97
IS 1
BP 91
EP 98
DI 10.1111/aos.13864
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ0SF
UT WOS:000456872000025
PM 30238648
OA Bronze
DA 2022-11-30
ER

PT J
AU Merle, B
   Delyfer, MN
   Korobelnik, JF
   Rougier, MB
   Colin, J
   Malet, F
   Feart, C
   Le Goff, M
   Dartigues, JF
   Barberger-Gateau, P
   Delcourt, C
AF Merle, Benedicte
   Delyfer, Marie-Noelle
   Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Colin, Joseph
   Malet, Florence
   Feart, Catherine
   Le Goff, Melanie
   Dartigues, Jean-Francois
   Barberger-Gateau, Pascale
   Delcourt, Cecile
TI Dietary Omega-3 Fatty Acids and the Risk for Age-Related Maculopathy:
   The Alienor Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FATTY-ACID INTAKE; MACULAR DEGENERATION; PRIMARY PREVENTION; FISH
   CONSUMPTION; 5-YEAR INCIDENCE; ASSOCIATION; PROGRESSION; EYE;
   PREVALENCE; HEALTH
AB PURPOSE. Previous studies have suggested a lower risk for age-related maculopathy (ARM) in subjects with high dietary intake of long-chain omega-3 polyunsaturated fatty acids (PUFA). The authors report the associations of ARM with past dietary intakes in French elderly subjects.
   METHODS. The Alienor Study is a population-based epidemiologic study on nutrition and age-related eye diseases performed in residents of Bordeaux 73 years of age and older. Six hundred sixty-six subjects (1289 eyes) with complete data were included in the analyses. ARM was classified from retinal photographs taken in 2006 to 2008 in five exclusive stages: late neovascular ARM (n = 21 subjects, 29 eyes); late atrophic ARM (n = 19 subjects, 33 eyes); large soft indistinct drusen and/or reticular drusen and/or large distinct drusen with pigment abnormalities (early ARM2, n = 67 subjects, 100 eyes); large soft distinct drusen alone or pigment abnormalities alone (early ARM1, n = 119 subjects, 163 eyes); and no ARM (n = 440 subjects, 964 eyes). Dietary intakes were estimated from a 24-hour dietary recall performed by dieticians (2001-2002). Associations were estimated using logistic Generalized Estimating Equation.
   RESULTS. After multivariate adjustment, subjects with high intake of long-chain omega-3 PUFA showed a decreased risk for early ARM1 (odds ratio [OR], 0.83; 95% confidence interval [95% CI], 0.71-0.98; P = 0.03) and late neovascular ARM (OR, 0.26; 95% CI, 0.08-0.83; P = 0.02). Associations with late atrophic ARM were in the same direction but did not reach statistical significance (OR, 0.74; 95% CI, 0.52-1.06; P = 0.10). Overall, high intakes of long-chain omega-3 PUFA were associated with reduced risk for late ARM (OR, 0.59; 95% CI, 0.39-0.88; P = 0.01).
   CONCLUSIONS. These results confirm a decreased risk for ARM in subjects with high intake of long-chain omega-3 PUFA. (Invest Ophthalmol Vis Sci. 2011;52:6004-6011) DOI:10.1167/iovs.117254
C1 [Merle, Benedicte; Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Feart, Catherine; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Delcourt, Cecile] Univ Bordeaux Segalen, INSERM, U897, F-33076 Bordeaux, France.
   [Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Colin, Joseph; Malet, Florence] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux
RP Merle, B (通讯作者)，Univ Bordeaux Segalen, INSERM, U897, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM benedicte.merle@isped.u-bordeaux2.fr
RI LE GOFF, Mélanie/A-3541-2016; Delcourt, Cecile/I-2627-2013; Merle,
   Benedicte MJ/F-1247-2015; Delyfer, Marie-Noelle/T-3304-2019; Merle,
   Benedicte MJ/AAQ-5021-2021; DARTIGUES, Jean François/T-4513-2019; FEART,
   Catherine/A-3339-2016; KOROBELNIK, Jean-Francois/A-5448-2016
OI Delcourt, Cecile/0000-0002-2099-0481; Merle, Benedicte
   MJ/0000-0003-1332-0954; Merle, Benedicte MJ/0000-0003-1332-0954; FEART,
   Catherine/0000-0002-7959-1610; LE GOFF, Melanie/0000-0003-2848-6287
FU Laboratoires Thea (Clermont-Ferrand, France); Fondation Voir et Entendre
   (Paris, France); Conseil Regional d'Aquitaine [20091301029]
FX Supported by Laboratoires Thea (Clermont-Ferrand, France), Fondation
   Voir et Entendre (Paris, France), and Conseil Regional d'Aquitaine Grant
   20091301029. Laboratoires Thea participated in the design of the study
   but not in the collection, management, or statistical analysis and
   interpretation of the data or in the preparation, review, or approval of
   the present manuscript.
CR Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   DELCOURT CDM, INVEST OPHT IN PRESS
   Favier JC, 1995, REPERTOIRE GEN ALIME
   Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hercberg S, 1998, CONTROL CLIN TRIALS, V19, P336, DOI 10.1016/S0197-2456(98)00015-4
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   RENAUD S, 1979, TABLE COMPOSITION AL, P105
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souci S, 2000, FOOD COMPOSITION NUT, P1182
   *SU VI MAX, 2000, PORT AL MAN PHOT EST
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Willett W, 2001, AM J EPIDEMIOL, V154, P1107, DOI 10.1093/aje/154.12.1107
   Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 48
TC 53
Z9 54
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2011
VL 52
IS 8
BP 6004
EP 6011
DI 10.1167/iovs.11-7254
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800QC
UT WOS:000293377400127
PM 21705687
DA 2022-11-30
ER

PT J
AU Voutsas, NT
   Papageorgiou, E
   Tantou, A
   Dimitriou, VA
   Tsironi, EE
   Kotoula, M
AF Voutsas, Nikolaos T.
   Papageorgiou, Eleni
   Tantou, Alexandra
   Dimitriou, Vassilis A.
   Tsironi, Evangelia E.
   Kotoula, Maria
TI Quality-adjusted life years in macular oedema due to age-related macular
   degeneration, diabetes and central retinal vein occlusion: the impact of
   anti-VEGF agents in a tertiary centre in Greece
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Diabetic macular oedema; Age-related macular degeneration; Central
   retinal vein occlusion; Quality adjusted life years (QALY);
   Anti-vascular endothelial Growth factor (anti-VEGF)
ID COST-EFFECTIVENESS; GLOBAL PREVALENCE; UTILITY VALUES; RANIBIZUMAB;
   CARE; RETINOPATHY; BURDEN; VERTEPORFIN; BEVACIZUMAB; AFLIBERCEPT
AB Introduction Neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), and macular oedema due to central retinal vein occlusion (CRVO) are leading causes of vision loss, currently managed with anti-vascular endothelial growth factor injections (anti-VEGF). The aim of this study was to calculate QALYs in patients with nAMD, DME, and CRVO treated with anti-VEGF agents (QALYs(+)) in a Greek tertiary hospital setting and compare them to theoretical QALYs that the patients would have without treatment (QALYs(-)). Material and Methods The study included 143 treatment-naive patients with macular oedema due to nAMD (n = 79), DME (n = 57), and CRVO (n = 7), who received anti-VEGF injections as monotherapy according to the Treat-and-Extend (T&E) protocol. The anti-VEGF agents were ranibizumab and aflibercept in equivalent fractions. QALYs where calculated by the formula QALY = Utility Value x Time, where "Time" refers to the follow-up period of the study. For QALYs(-), we assumed that visual acuity remained unchanged during this period. Results Mean follow-up time was 1.3 +/- 1.2 years in the nAMD group, 1 +/- 1.3 years in the DME group, and 0.5 +/- 1 years in the CRVO group. There was no statistically significant difference between QALYs(-) and QALYs(+) in all three ocular pathologies for the study period (p > 0.05 for each of the three statistical tests performed). Discussion/Conclusion Possible explanations for the lack of significant difference between QALYs - and QALYs + in nAMD, DME, and CRVO groups, may be the short time horizon used in this analysis, the inclusion of data from the better-seeing eye (BSE) and the specific socio-economic, geographical and health care characteristics of this rural Greek area.
C1 [Voutsas, Nikolaos T.; Papageorgiou, Eleni; Tantou, Alexandra; Tsironi, Evangelia E.; Kotoula, Maria] Univ Hosp Larissa, Dept Ophthalmol, Mezourlo Area 41110, Larissa, Greece.
   [Dimitriou, Vassilis A.] Aristotle Univ Thessaloniki, Dept Math, Thessaloniki, Greece.
   [Tsironi, Evangelia E.] Univ Thessaly, Fac Med, Dept Ophthalmol, Larisa, Greece.
C3 General University Hospital of Larissa; Aristotle University of
   Thessaloniki; University of Thessaly
RP Voutsas, NT (通讯作者)，Univ Hosp Larissa, Dept Ophthalmol, Mezourlo Area 41110, Larissa, Greece.
EM ni_vo17@hotmail.com; e_papage@yahoo.com; sandrina_tant@hotmail.com;
   vasdimi@math.auth.gr; e_tsironi@hotmail.com; mariarkotoula@gmail.com
OI Voutsas, Nikolaos/0000-0002-2591-9326
CR Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Bressler NM, 2018, JAMA OPHTHALMOL, V136, P257, DOI 10.1001/jamaophthalmol.2017.6565
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown G, 2017, OPHTHALMOL RETINA, V1, P404, DOI 10.1016/j.oret.2017.01.018
   Brown GC, 2018, OPHTHALMOLOGY, V125, P965, DOI 10.1016/j.ophtha.2017.12.033
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown Melissa M., 2001, International Ophthalmology, V24, P123, DOI 10.1023/A:1021171000838
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Butt T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006535
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P209, DOI 10.1016/j.ophtha.2013.08.038
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Claxton L, 2017, PHARMACOECONOMICS, V35, P237, DOI 10.1007/s40273-016-0459-z
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Economou C, 2017, HEALT SYST TRANSIT, V19, P1
   Elshout M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0514-3
   Field A., 2013, DISCOVERING STAT USI
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Gonzalez VH, 2016, AM J OPHTHALMOL, V172, P72, DOI 10.1016/j.ajo.2016.09.012
   Gross JG, 2018, JAMA OPHTHALMOL, V136, P1138, DOI 10.1001/jamaophthalmol.2018.3255
   Hodgson N, 2016, MOL PHARMACEUT, V13, P2877, DOI 10.1021/acs.molpharmaceut.5b00775
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Hutton DW, 2017, JAMA OPHTHALMOL, V135, P576, DOI 10.1001/jamaophthalmol.2017.0837
   Hykin P, 2019, JAMA OPHTHALMOL, V137, P1256, DOI 10.1001/jamaophthalmol.2019.3305
   IBM Corp, 2016, IBM SPSS STAT WINDOW
   Investopedia, 2021, CENTRAL LIMIT THEORE
   Karanikolos M, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0374-0
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   Kornhauser T, 2016, GRAEF ARCH CLIN EXP, V254, P835, DOI 10.1007/s00417-015-3130-z
   Kourlaba G, 2016, COST EFFECT RESOUR A, V14, DOI 10.1186/s12962-016-0056-1
   Labiris G, 2003, J TELEMED TELECARE, V9, P296, DOI 10.1258/135763303769211337
   Lanzetta Paolo, 2011, ARVO Annual Meeting Abstract Search and Program Planner, V2011, P5532
   Laouri M, 2011, EYE, V25, P981, DOI 10.1038/eye.2011.92
   Liatis S, 2019, BMC ENDOCR DISORD, V19, DOI 10.1186/s12902-019-0364-5
   Lin J, 2021, OPHTHALMOL RETINA, V5, P656, DOI 10.1016/j.oret.2020.09.017
   MEHREZ A, 1993, MED DECIS MAKING, V13, P287, DOI 10.1177/0272989X9301300404
   Mitchell P, 2012, BRIT J OPHTHALMOL, V96, P688, DOI 10.1136/bjophthalmol-2011-300726
   Pagkalos E, 2018, EXP CLIN ENDOCR DIAB, V126, P53, DOI 10.1055/s-0043-109242
   Pershing S, 2014, ANN INTERN MED, V160, P18, DOI 10.7326/M13-0768
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosner, 2016, FUNDAMENTAL BIOSTATI
   Ross EL, 2016, JAMA OPHTHALMOL, V134, P888, DOI 10.1001/jamaophthalmol.2016.1669
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Smiddy WE, 2012, OPHTHALMOLOGY, V119, P2558, DOI 10.1016/j.ophtha.2012.09.015
   Souliotis K, 2016, INT J HEALTH POLICY, V5, P83, DOI 10.15171/ijhpm.2015.173
   Sun JK, 2019, OPHTHALMOLOGY, V126, P87, DOI 10.1016/j.ophtha.2018.08.001
   Taylor Matthew, 2014, J Med Econ, V17, P423, DOI 10.3111/13696998.2014.909435
   Towers Isabel, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P245, DOI 10.1586/14737167.5.3.245
   Vavouranakis I, 2010, RURAL REMOTE HEALTH, V10
   Vottonen P, 2016, ACTA OPHTHALMOL, V94, P652, DOI 10.1111/aos.13185
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 56
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD SEP
PY 2022
VL 42
IS 9
BP 2673
EP 2684
DI 10.1007/s10792-022-02256-y
EA APR 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4C2LU
UT WOS:000782328600002
PM 35416615
DA 2022-11-30
ER

PT J
AU Gomi, F
   Sawa, M
   Wakabayashi, T
   Sasamoto, Y
   Suzuki, M
   Tsujikawa, M
AF Gomi, Fumi
   Sawa, Miki
   Wakabayashi, Taku
   Sasamoto, Yuzuru
   Suzuki, Mihoko
   Tsujikawa, Motokazu
TI Efficacy of Intravitreal Bevacizumab Combined With Photodynamic Therapy
   for Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CLINICAL CHARACTERISTICS; PIGMENT EPITHELIUM;
   JAPANESE PATIENTS; FOLLOW-UP; VERTEPORFIN; NEOVASCULARIZATION; AVASTIN;
   VEGF
AB PURPOSE: To compare the efficacy of photodynamic therapy (PDT) with or without intravitreal bevacizumab injection for polypoidal choroidal vasculopathy.
   DESIGN: Retrospective, comparative, interventional case series.
   METHODS: We included 146 eyes of 146 patients with treatment-naive polypoidal choroidal vasculopathy including the subfoveal region treated with PDT monotherapy or combined with intravitreal bevacizumab injection. Treatments were chosen according to the time period. For eyes that received combination therapy, bevacizumab (1.25 mg) was administrated 1 day before PDT. All eyes were followed up for at least 12 months. Ophthalmic evaluations, including measurement of the best-corrected visual acuity and optical coherence tomography, were performed at every visit. Indocyanine green angiography and fluorescein angiography were performed every 3 months.
   RESULTS: Sixty-one eyes were treated with PDT combined with bevacizumab and 85 eyes were treated with PDT monotherapy. The mean best-corrected visual acuity was significantly better in the combined treatment group than in the monotherapy group at 3 months (P = .0016), 6 months (P = .028), 9 months (P = .038), and 12 months (P = .048). However, lesions resolved in 78.7% of eyes in the combined group and in 75.3% in the monotherapy group; the recurrence rates were 43.8% and 40.6%, respectively, and did not differ significantly. The rate of development of subretinal hemorrhage within 1 month from the initial treatment was significantly lower in the combined group than in the PDT monotherapy group (4.5% vs 17.7%; P = .023).
   CONCLUSIONS: Photodynamic therapy combined with bevacizumab injection offers significantly better early visual outcomes than PDT alone. Combined treatment did not affect the resolution and recurrence of lesions; however, it decreased the rate of development of PDT-related hemorrhages. (Am J Ophthalmol 2010;150:48-54. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Gomi, Fumi; Sawa, Miki; Wakabayashi, Taku; Sasamoto, Yuzuru; Suzuki, Mihoko; Tsujikawa, Motokazu] Osaka Univ, Dept Ophthalmol, Sch Med, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Dept Ophthalmol, Sch Med, E7,2-2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007/s10384-008-0551-9
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Navea A, 2009, RETINA-J RET VIT DIS, V29, P13, DOI 10.1097/IAE.0b013e31818a1fd3
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 34
TC 78
Z9 90
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2010
VL 150
IS 1
BP 48
EP 54
DI 10.1016/j.ajo.2010.02.008
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624FW
UT WOS:000279803200010
PM 20609707
DA 2022-11-30
ER

PT J
AU Athanasakis, K
   Fragoulakis, V
   Tsiantou, V
   Masaoutis, P
   Maniadakis, N
   Kyriopoulos, J
AF Athanasakis, Kostas
   Fragoulakis, Vasilios
   Tsiantou, Vasiliki
   Masaoutis, Panagiotis
   Maniadakis, Nikolaos
   Kyriopoulos, John
TI Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin
   Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for
   the Treatment of Age-Related Macular Degeneration in Greece
SO CLINICAL THERAPEUTICS
LA English
DT Article
DE age-related macular degeneration; cost-effectiveness analysis;
   cost-utility analysis; ranibizumab
ID VISUAL-ACUITY; BURDEN
AB Background: Age-related macular degeneration (AMD) is a progressive disease that results in loss of central vision, significant functional impairment, and a subsequent heavy socioeconomic burden. AMD treatments delay disease progression, improve patient outcomes, and reduce resource use associated with visual impairment, however, in a varying way concerning costs and effects. Objective: The purpose of this study was to investigate the cost effectiveness of ranibizumab compared with verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of AMD in Greece.
   Methods: A 6-state Markov model was constructed according to patient visual acuity in the better-seeing eye. Data on effectiveness were derived from randomized controlled trials evaluating the outcomes of ranibizumab versus alternative AMD treatments. Resource utilization reflected the Greek health care setting and was defined by a panel of experts. All treatments were administered for a 2-year period and evaluated during a 10-year time frame from a third-party payer perspective and discounted at 3.5% per annum.
   Results: Estimated mean 10-year direct costs of treatment in the ranibizumab arm ranged from (sic)23,733 to (sic)31,795 (2011 Euros), with a projected gain of 4.50 to 4.74 quality-adjusted life years (QALYs) or 2.97 to 4.47 vision years, depending on type of lesion. For predominantly classic lesions, the cost per QALY gained with ranibizumab was estimated at (sic)6444/QALY (95% uncertainty interval [UI], (sic)-30,403/QALY to (sic)44,524/QALY), (sic)15,344 (95% UI, (sic)-11,433 to (sic)53,554) and dominant relative to photodynamic therapy, best supportive care, and pegaptanib, respectively. Corresponding ratios for patients with minimally classic lesions were (sic)24,580/QALY (95% UI, (sic)-5580/QALY to (sic)76,229/QALY) and (sic)13,112/QALY (95% UI, (sic)-3839/QALY to (sic) 37,527/QALY) for ranibizumab relative to best supportive care and pegaptanib, and for patients with occult lesions were estimated at (sic)19,407/QALY (95% UI, (sic)-1486 to (sic)46,434) and (sic)28,561/QALY (95% UI, (sic)6143 to 73,431), respectively. Sensitivity analysis provided robust results in all cases.
   Conclusion: Ranibizumab can be a cost-effective option for the treatment of AMD compared with selected alternatives in the Greek health care setting. (Clin Ther. 2012;34:446-456) (C) 2012 Elsevier HS Journals, Inc. All rights reserved.
C1 [Athanasakis, Kostas; Tsiantou, Vasiliki; Kyriopoulos, John] Natl Sch Publ Hlth, Dept Hlth Econ, Athens 11521, Greece.
   [Fragoulakis, Vasilios; Maniadakis, Nikolaos] Natl Sch Publ Hlth, Dept Hlth Serv Org & Management, Athens 11521, Greece.
   [Masaoutis, Panagiotis] G Gennimatas Hosp, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens
RP Athanasakis, K (通讯作者)，Natl Sch Publ Hlth, Dept Hlth Econ, 196 Alexandras Ave, Athens 11521, Greece.
EM kathanasakis@esdy.edu.gr
RI Athanasakis, Kostas/AAZ-2148-2020
FU Novartis (Hellas) S.A.C.I.
FX The present study was financially supported by Novartis (Hellas)
   S.A.C.I. Drs. Athanasakis, Fragoulakis and Maniadakis were responsible
   for the analyses and interpretation of the results. Drs. Tsiantou,
   Athanasakis and Masaoutis reviewed the literature. Drs. Athanasakis,
   Fragoulakis, Tsiantou and Masaoutis developed the manuscript, which was
   critically reviewed by Dr. Tsiantou.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Briggs A., 2006, DECISION MODELLING H
   Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gatto Barbara, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P287, DOI 10.2174/187152006777698178
   General Secretariat of the National Statistical Service of Greece, VIT STAT 2009
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Maniadakis Nikolaos, 2005, Hellenic J Cardiol, V46, P212
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   [World Health Organization Vision 2020], VIS 2020 GLOB IN EL
NR 36
TC 15
Z9 17
U1 0
U2 6
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD FEB
PY 2012
VL 34
IS 2
BP 446
EP 456
DI 10.1016/j.clinthera.2012.01.005
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 896TZ
UT WOS:000300595600017
PM 22289279
DA 2022-11-30
ER

PT J
AU Han, XK
   Lee, SSY
   Ingold, N
   McArdle, N
   Khawaja, AP
   MacGregor, S
   Mackey, DA
AF Han, Xikun
   Lee, Samantha Sze-Yee
   Ingold, Nathan
   McArdle, Nigel
   Khawaja, Anthony P.
   MacGregor, Stuart
   Mackey, David A.
TI Associations of sleep apnoea with glaucoma and age-related macular
   degeneration: an analysis in the United Kingdom Biobank and the Canadian
   Longitudinal Study on Aging
SO BMC MEDICINE
LA English
DT Article
DE Sleep apnoea; Glaucoma; Age-related macular degeneration; UK Biobank;
   CLSA; Cohort study
ID FIBER LAYER THICKNESS; APNEA/HYPOPNEA SYNDROME; OPTIC NEUROPATHY;
   INCREASED RISK; UK BIOBANK; PREVALENCE; INFLAMMATION; PATHOGENESIS;
   BEVACIZUMAB; DISC
AB Background Sleep apnoea, a common sleep-disordered breathing condition, is characterised by upper airway collapse during sleep resulting in transient hypoxia, hypoperfusion of the optic nerve, and spike in intracranial pressure. Previous studies have reported conflicting findings on the association of sleep apnoea with glaucoma, and there are limited reports on the link between sleep apnoea and age-related macular degeneration (AMD). Methods Middle-aged and older participants from the longitudinal United Kingdom (UK) Biobank (n = 502,505) and the Canadian Longitudinal Study on Aging (CLSA; n = 24,073) were included in this analysis. Participants in the UK Biobank and the CLSA were followed for 8 and 3 years, respectively. Participants with diagnosed glaucoma or AMD at baseline were excluded from the analysis. In the UK Biobank, sleep apnoea and incident cases of glaucoma and AMD were identified through hospital inpatient admission, primary care records, and self-reported data. Multivariable Cox proportional hazards models were used to explore associations of sleep apnoea with incidence of glaucoma or AMD. Results During the 8-year follow-up in the UK Biobank, glaucoma incidence rates per 1000 person-years were 2.46 and 1.59 for participants with and without sleep apnoea, and the AMD incidence rates per 1000 person-years were 2.27 and 1.42 for participants with and without sleep apnoea, respectively. Multivariable adjusted hazard ratios of glaucoma and AMD risk for sleep apnoea were 1.33 (95% confidence interval [CI] 1.10-1.60, P = 0.003) and 1.39 (95% CI 1.15-1.68, P < 0.001) relative to participants without sleep apnoea. In the CLSA cohort, disease information was collected through in-person interview questionnaires. During the 3-year follow-up, glaucoma incidence rates per 1000 person-years for those with and without sleep apnoea were 9.31 and 6.97, and the AMD incidence rates per 1000 person-years were 8.44 and 6.67, respectively. In the CLSA, similar associations were identified, with glaucoma and AMD odds ratios of 1.43 (95% CI 1.13-1.79) and 1.39 (95% CI 1.08-1.77), respectively, in participants with sleep apnoea compared to those without sleep apnoea (both P < 0.001). Conclusions In two large-scale prospective cohort studies, sleep apnoea is associated with a higher risk of both glaucoma and AMD. These findings indicate that patients with sleep apnoea might benefit from regular ophthalmologic examinations.
C1 [Han, Xikun; Ingold, Nathan; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Stat Genet, 300 Herston Rd, Brisbane, Qld 4006, Australia.
   [Han, Xikun] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
   [Lee, Samantha Sze-Yee; Mackey, David A.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Nedlands, WA, Australia.
   [Ingold, Nathan] Queensland Univ Technol, Fac Hlth, Sch Biomed Sci, Brisbane, Qld, Australia.
   [McArdle, Nigel] Univ Western Australia, Ctr Sleep Sci, Sch Human Sci, Nedlands, WA, Australia.
   [McArdle, Nigel] Sir Charles Gairdner Hosp, West Australian Sleep Disorders Res Inst, Dept Pulm Physiol & Sleep Med, Nedlands, WA, Australia.
   [Khawaja, Anthony P.] Moorfields Eye Hosp NHS Fdn Trust, Res Biomed Res Ctr, Natl Inst Hlth, London, England.
   [Khawaja, Anthony P.] UCL Inst Ophthalmol, London, England.
C3 QIMR Berghofer Medical Research Institute; University of Queensland;
   Lions Eye Institute; University of Western Australia; Queensland
   University of Technology (QUT); University of Western Australia;
   University of Western Australia; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of London; University College London
RP Han, XK (通讯作者)，QIMR Berghofer Med Res Inst, Stat Genet, 300 Herston Rd, Brisbane, Qld 4006, Australia.; Han, XK (通讯作者)，Univ Queensland, Sch Med, Brisbane, Qld, Australia.
EM Xikun.Han@qimrberghofer.edu.au
RI Macgregor, Stuart/C-6442-2009; Han, Xikun/AAN-9012-2020; Mackey, David
   A/H-5340-2014; Lee, Sze-Yee/AAW-6016-2020
OI Macgregor, Stuart/0000-0001-6731-8142; Han, Xikun/0000-0002-3823-7308;
   Mackey, David A/0000-0001-7914-4709; Lee, Sze-Yee/0000-0001-6635-1098
FU Welsh Assembly Government; British Heart Foundation; Diabetes UK; NHMRC;
   National Health and Medical Research Council (NHMRC) of Australia
   [1116360, 1150144]; Government of Canada through the Canadian Institutes
   of Health Research (CIHR) [LSA 94473]; Canada Foundation for Innovation
FX This work was conducted using the UK Biobank Resource (application
   number 25331). The UK Biobank was established by the Wellcome Trust
   medical charity, Medical Research Council (UK), Department of Health
   (UK), Scottish Government, and Northwest Regional Development Agency. It
   also had funding from the Welsh Assembly Government, British Heart
   Foundation, and Diabetes UK. S.M. and D.A.M. are supported by NHMRC
   Fellowships. This work was also supported by grants from the National
   Health and Medical Research Council (NHMRC) of Australia (#1116360,
   #1150144).; This research was made possible using the data/biospecimens
   collected by the Canadian Longitudinal Study on Aging (CLSA). Funding
   for the Canadian Longitudinal Study on Aging (CLSA) is provided by the
   Government of Canada through the Canadian Institutes of Health Research
   (CIHR) under grant reference: LSA 94473 and the Canada Foundation for
   Innovation. This research has been conducted using the CLSA dataset
   [Baseline Comprehensive Dataset version 4.0, Follow-up 1 Comprehensive
   Dataset version 1.0], under Application Number 190225. The CLSA is led
   by Drs. Parminder Raina, Christina Wolfson, and Susan Kirkland.
CR ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   Aptel F, 2014, SLEEP MED, V15, P576, DOI 10.1016/j.sleep.2013.11.790
   Bahr K, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01533-7
   Batty GD, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m131
   Boyle-Walker Megan, 2011, ISRN Ophthalmol, V2011, P920767, DOI 10.5402/2011/920767
   Chen HY, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/838912
   Chervin RD, 1996, NEUROL CLIN, V14, P583, DOI 10.1016/S0733-8619(05)70275-9
   Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Curcio CA, 2017, JAMA OPHTHALMOL, V135, P843, DOI 10.1001/jamaophthalmol.2017.2008
   DeBoever C, 2020, AM J HUM GENET, V106, P611, DOI 10.1016/j.ajhg.2020.03.007
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Foster HME, 2018, LANCET PUBLIC HEALTH, V3, pE576, DOI 10.1016/S2468-2667(18)30200-7
   Fry A, 2017, AM J EPIDEMIOL, V186, P1026, DOI 10.1093/aje/kwx246
   Garvey JF, 2009, EUR RESPIR J, V33, P1195, DOI 10.1183/09031936.00111208
   Girkin CA, 2006, BRIT J OPHTHALMOL, V90, P679, DOI 10.1136/bjo.2005.086082
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Hashim SP, 2014, EYE, V28, P1304, DOI 10.1038/eye.2014.195
   He M, 2016, SLEEP BREATH, V20, P369, DOI 10.1007/s11325-015-1306-8
   Huseyinoglu N, 2014, SLEEP BREATH, V18, P95, DOI 10.1007/s11325-013-0854-z
   Kargi SH, 2005, EYE, V19, P575, DOI 10.1038/sj.eye.6701582
   Keenan TDL, 2017, BRIT J OPHTHALMOL, V101, P155, DOI 10.1136/bjophthalmol-2015-308278
   Lee SSY, 2019, OPHTHALMOLOGY, V126, P1372, DOI 10.1016/j.ophtha.2019.04.041
   Lee SSY, 2020, J GLAUCOMA, V29, P337, DOI 10.1097/IJG.0000000000001485
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin CC, 2013, OPHTHALMOLOGY, V120, P1559, DOI 10.1016/j.ophtha.2013.01.006
   Lin PW, 2011, GRAEF ARCH CLIN EXP, V249, P585, DOI 10.1007/s00417-010-1544-1
   Lin PW, 2011, J GLAUCOMA, V20, P553, DOI 10.1097/IJG.0b013e3181f3eb81
   Liu SL, 2016, J GLAUCOMA, V25, P1, DOI 10.1097/IJG.0000000000000357
   McNicholas WT, 2009, AM J RESP CRIT CARE, V180, P692, DOI 10.1164/rccm.200903-0347PP
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Ollier W, 2005, PHARMACOGENOMICS, V6, P639, DOI 10.2217/14622416.6.6.639
   Palombi K, 2006, BRIT J OPHTHALMOL, V90, P879, DOI 10.1136/bjo.2005.087452
   Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342
   Perez-Rico C, 2014, GRAEF ARCH CLIN EXP, V252, P1345, DOI 10.1007/s00417-014-2669-4
   Peter L, 2007, J SLEEP RES, V16, P313, DOI 10.1111/j.1365-2869.2007.00598.x
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Raina P, 2019, INT J EPIDEMIOL, V48, P1752, DOI 10.1093/ije/dyz173
   Raina PS, 2009, CAN J AGING, V28, P221, DOI 10.1017/S0714980809990055
   Schaal S, 2016, RETINA-J RET VIT DIS, V36, P791, DOI 10.1097/IAE.0000000000000981
   Sergi M, 2007, J GLAUCOMA, V16, P42, DOI 10.1097/01.ijg.0000243472.51461.24
   Shi YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115625
   Stein JD, 2011, AM J OPHTHALMOL, V152, P989, DOI 10.1016/j.ajo.2011.04.030
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Velentgas P., 2013, DEV PROTOCOL OBSERVA
   White IR, 2009, STAT MED, V28, P1982, DOI 10.1002/sim.3618
   WHO, 2011, WORLD REPORT ON DISABILITY, P1
   Wozniak D, 2018, THORAX, V73, pA130, DOI 10.1136/thorax-2018-212555.214
   Wu XH, 2015, INT J CLIN EXP MED, V8, P297
   Yu JG, 2016, OPHTHALMIC RES, V56, P57, DOI 10.1159/000444301
   Zhang Z., ANN TRANSL MED
NR 53
TC 4
Z9 4
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD MAY 11
PY 2021
VL 19
IS 1
AR 104
DI 10.1186/s12916-021-01973-y
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA RZ9YI
UT WOS:000648955700001
PM 33971878
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cugati, S
   Mitchell, P
   Rochtchina, E
   Tan, AG
   Smith, W
   Wang, JJ
AF Cugati, Sudha
   Mitchell, Paul
   Rochtchina, Elena
   Tan, Ava G.
   Smith, Wayne
   Wang, Jie Jin
TI Cataract surgery and the 10-year incidence of age-related maculopathy -
   The Blue Mountains Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; VISUAL IMPAIRMENT; RISK-FACTORS; INTRAOCULAR-LENS;
   BEAVER DAM; PREVALENCE; EXTRACTION; ASSOCIATION; POPULATION; AUSTRALIA
AB Purpose: To assess the long-term (10-year) risk of late age-related maculopathy (ARM) in eyes that had previously undergone cataract surgery (before the baseline examination).
   Design: Population-based cohort study.
   Participants: In the Blue Mountains Eye Study (BMES) cohort, 2335 of 3654 baseline participants >= 49 years old (75% of survivors) were reexamined after 5 years and 1952 (76% of survivors) were reexamined after 10 years.
   Methods: At the baseline examination, nonphakic (aphakic or pseudophakic) eyes were identified at slit-lamp examination and confirmed at lens photographic grading. Side-by-side grading of baseline and follow-up stereoretinal photographs was performed using the Wisconsin ARM grading system. Eye-specific data were analyzed using Kaplan-Meier estimates and generalized estimating equation models, adjusting for correlation between the 2 eyes.
   Main Outcome Measures: Incident late ARM was defined if either neovascular ARM or geographic atrophy developed in eyes without either lesion at baseline.
   Results: After excluding eyes with either late ARM lesion at baseline or that had missing photographs at either examination, 4763 eyes were considered at risk of incident late ARM, including 132 eyes that had cataract surgery before the baseline examination. Late ARM developed in 10 of 132 nonphakic eyes (7.6%) compared to 96 of 4631 phakic eyes (2.1%). After adjusting for baseline age, gender, smoking, and presence of early ARM lesions, nonphakic (cataract surgical) eyes had a 3-fold risk of developing late-stage ARM (odds ratio [OR], 3.3; 95% confidence interval [CI], 1.1-9.9) or neovascular ARM (OR, 3.4; 95% Cl, 1.1-10.9) compared to phakic eyes.
   Conclusions: Our findings support the hypothesis that the long-term risk of developing late ARM is higher in cataract surgical eyes, consistent with findings from the Beaver Dam Eye Study. (c) 2006 by the American Academy of Ophthalmology.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   Univ Newcastle, Ctr Biostat & Epidemiol, Newcastle, NSW 2308, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Newcastle
RP Wang, JJ (通讯作者)，Univ Sydney, Dept Ophthalmol, Westmead Millennium Inst, Westmead Hosp, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Wang, Jie Jin/P-1499-2014; wang, jie/GRS-0942-2022; Cugati,
   Sudha/ABB-1331-2021; Mitchell, Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; Tan, Ava Grace/0000-0003-3344-0339
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   de Jong PTVM, 2004, GRAEF ARCH CLIN EXP, V242, P103, DOI 10.1007/s00417-003-0833-3
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Libre PE, 2003, AM J OPHTHALMOL, V136, P961, DOI 10.1016/S0002-9394(03)00906-1
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P927
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   OLIVER M, 1966, AM J OPHTHALMOL, V62, P1145, DOI 10.1016/0002-9394(66)92567-0
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
NR 35
TC 121
Z9 125
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2006
VL 113
IS 11
BP 2020
EP 2025
DI 10.1016/j.ophtha.2006.05.047
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 101CS
UT WOS:000241717100016
PM 16935334
DA 2022-11-30
ER

PT J
AU Flood, V
   Smith, W
   Wang, JJ
   Manzi, F
   Webb, K
   Mitchell, P
AF Flood, V
   Smith, W
   Wang, JJ
   Manzi, F
   Webb, K
   Mitchell, P
TI Dietary antioxidant intake and incidence of early age-related
   maculopathy - The Blue Mountains Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; MACULAR DEGENERATION; CATARACT-EXTRACTION; 5-YEAR
   INCIDENCE; ZINC INTAKE; VITAMIN-A; RISK; AUSTRALIA; PIGMENT;
   QUESTIONNAIRE
AB Objective: To investigate associations between dietary intake, including modest supplement intake, of antioxidant vitamins and zinc at baseline and the 5-year incidence of early age-related maculopathy (ARM).
   Design: Population-based cohort study.
   Participants: From 1992 through 1994, 3654 persons aged 49 years or more (82% of those eligible) living in two postcode areas west of Sydney, Australia, were examined for the Blue Mountains Eye Study baseline. Five years later, 2335 persons (75% of known survivors) were reexamined.
   Methods: A 145-item Food Frequency Questionnaire (FFQ) was used to assess nutrient intakes. Of the 2335 people who attended a follow-up visit, 1989 (85%) had completed a FFQ at baseline. The nutrients examined in this study included: a-carotene, beta-carotene, beta-cryptoxanthin, lutein and zeaxanthin, lycopene, retinol, vitamin A, vitamin C, and zinc.
   Main Outcome Measures: Early ARM was assessed by masked grading of stereo retinal photographs. Definitions for incidence closely followed those used in the Beaver Dam Eye Study.
   Results: Early ARM developed in 192 persons (8.7% 5-year incidence) who did not have either late or early ARM at baseline. Of these, 159 persons completed the FFQ at baseline. After adjusting for age, gender, family history of ARM, and smoking status at baseline, no associations, or any trends suggesting possible association, were found between baseline intake of the nutrients examined, apart from vitamin C, and the 5-year incidence of early ARM. Compared with the lowest quintile, increasing baseline intakes of vitamin C, from diet and supplements, was associated with an increased risk of incident early ARM (odds ratio [OR], 1.7; 95% confidence interval [Cl], 1.0-3.0; and OR, 2.3; 95% Cl, 1.3-4.0 for the fourth and fifth quintiles, respectively).
   Conclusions: Our cohort study of an older population could not find evidence of protection associated with usual dietary antioxidant or zinc intakes (including use of supplements) on the 5-year incidence of early ARM. Ophthalmology 2002;109:2272-2278 (C) 2002 by the American Academy of Ophthalmology.
C1 Univ Sydney, Westmead Hosp, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia.
   Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia.
   Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   Univ Sydney, Dept Publ Hlth, Sydney, NSW 2006, Australia.
   Univ Sydney, Dept Community Med, Sydney, NSW 2006, Australia.
   Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.
C3 University of Sydney; Australian National University; University of
   Sydney; University of Sydney; University of Sydney; University of Sydney
RP Mitchell, P (通讯作者)，Univ Sydney, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
RI Flood, Victoria/H-2279-2011; Flood, Victoria M/A-8732-2016
OI Flood, Victoria M/0000-0001-5310-7221
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   CHAN CWC, 1991, AUST NZ J OPHTHALMOL, V19, P321, DOI 10.1111/j.1442-9071.1991.tb00680.x
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9
   COOPER RL, 1990, AUST NZ J OPHTHALMOL, V18, P421, DOI 10.1111/j.1442-9071.1990.tb01828.x
   FARNSWORTH CC, 1976, BIOCHIM BIOPHYS ACTA, V443, P556, DOI 10.1016/0005-2736(76)90473-9
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   *NUTTAB DEP COMM S, 1990, 90 NUTTAB DEP COMM S
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Willett WC, 1998, AM J EPIDEMIOL, V148, P1157
NR 36
TC 80
Z9 85
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2002
VL 109
IS 12
BP 2272
EP 2278
AR PII S0161-6420(02)01263-0
DI 10.1016/S0161-6420(02)01263-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 622MZ
UT WOS:000179652000017
PM 12466170
DA 2022-11-30
ER

PT J
AU Dalvin, LA
   Starr, MR
   AbouChehade, JE
   Damento, GM
   Garcia, M
   Shah, SM
   Hodge, DO
   Meissner, I
   Bakri, SJ
   Iezzi, R
AF Dalvin, Lauren A.
   Starr, Matthew R.
   AbouChehade, Jackson E.
   Damento, Gena M.
   Garcia, Maria
   Shah, Saumya M.
   Hodge, David O.
   Meissner, Irene
   Bakri, Sophie J.
   Iezzi, Raymond
TI Association of Intravitreal Anti-Vascular Endothelial Growth Factor
   Therapy With Risk of Stroke, Myocardial Infarction, and Death in
   Patients With Exudative Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BEVACIZUMAB AVASTIN; SYSTEMIC SAFETY; OLMSTED-COUNTY; RANIBIZUMAB;
   ROCHESTER; MORTALITY; DISEASES
AB IMPORTANCE Current studies assessing the risk of stroke, myocardial infarction (MI), and death in patients undergoing intravitreal anti-vascular endothelial growth factor (VEGF) therapy are inconclusive. To our knowledge, no population-based studies have been performed to examine these potential risks.
   OBJECTIVE To examine whether patients with exudative age-related macular degeneration (AMD) receiving intravitreal anti-VEGF injections have a higher incidence of MI, stroke, or death compared with control populations.
   DESIGN, SETTING, AND PARTICIPANTS This population-based, retrospective cohort study included 504 patients from Olmsted County, Minnesota, identified through the Rochester Epidemiology Project (REP) database as receiving at least 1 intravitreal anti-VEGF injection for exudative AMD from January 1, 2004, to December 31, 2013. Three age-and sex-matched control groups of individuals who did not receive anti-VEGF treatment and were derived from the REP database were also studied: control individuals with exudative AMD in the era before anti-VEGF (January 1, 1990, to December 31, 2003), controls with dry AMD, and controls without AMD. Data analysis was performed from September 1, 2016, to September 1, 2017.
   MAIN OUTCOMES AND MEASURES Five-year risk of stroke, MI, and death were assessed in patients compared with controls using Kaplan-Meier and multivariate analysis with Cox proportional hazards regression models.
   RESULTS The study included 504 patients (321 female [63.7%]; mean [SD] age, 76.5 [10.0] years) who received at least 1 intravitreal anti-VEGF injection for exudative AMD during the study period. Kaplan-Meier analysis revealed a 5-year risk of 7.2% for stroke, 6.1% for MI, and 30.0% for death. Patients who received anti-VEGF had no increased risk of stroke or MI compared with controls with dry AMD (n = 504), controls with exudative AMD (n = 473), or controls without AMD (n = 504). There was an increased risk of mortality compared with controls with exudative AMD in the era prior to anti-VEGF therapy but not the other control groups on multivariate analysis (hazard ratio, 1.63; 95% CI, 1.30-2.04; P < .001).
   CONCLUSIONS AND RELEVANCE This population-based study revealed that intravitreal anti-VEGF therapy for exudative AMD was not associated with consistent increases in the risk of stroke, MI, or death compared with no therapy in patients with or without AMD. It appears to be likely the cardiac events these patients experience are not attributable to their anti-VEGF therapy.
C1 [Dalvin, Lauren A.; Starr, Matthew R.; AbouChehade, Jackson E.; Bakri, Sophie J.; Iezzi, Raymond] Mayo Clin, Dept Ophthalmol, 200 First St SW, Rochester, MN 55905 USA.
   [Damento, Gena M.; Garcia, Maria; Shah, Saumya M.] Mayo Clin, Sch Med, Rochester, MN 55905 USA.
   [Hodge, David O.] Mayo Clin, Dept Hlth Sci Res Biomed Stat & Informat, Jacksonville, FL 32224 USA.
   [Meissner, Irene] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Iezzi, R (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St SW, Rochester, MN 55905 USA.
EM iezzi.raymond@mayo.edu
OI Starr, Matthew/0000-0002-3021-5630
FU Research to Prevent Blindness Inc; Mayo Foundation for Medical Research;
   VitreoRetinal Surgery Foundation; NATIONAL INSTITUTE ON AGING
   [R01AG034676] Funding Source: NIH RePORTER
FX This work was supported in part by an unrestricted grant from Research
   to Prevent Blindness Inc, the Mayo Foundation for Medical Research, and
   the VitreoRetinal Surgery Foundation (Dr Dalvin).
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CAMPION ME, 1992, MAYO CLIN PROC, V67, P5, DOI 10.1016/S0025-6196(12)60270-5
   Cleary C A, 2011, Ir Med J, V104, P146
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Davis J, 2011, AM J OPHTHALMOL, V152, P509, DOI 10.1016/j.ajo.2011.07.004
   Dedania VS, 2016, CURR OPIN OPHTHALMOL, V27, P224, DOI 10.1097/ICU.0000000000000257
   Elbaz A, 2003, ARCH NEUROL-CHICAGO, V60, P91, DOI 10.1001/archneur.60.1.91
   Fischer C, 2016, OPHTHALMOLOGE, V113, P589, DOI 10.1007/s00347-015-0214-4
   Gopinath B, 2016, MATURITAS, V84, P63, DOI 10.1016/j.maturitas.2015.11.001
   Hanhart J, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0586-0
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266
   Meyerhardt JA, 2012, J CLIN ONCOL, V30, P608, DOI 10.1200/JCO.2011.38.9650
   Mikacic I, 2016, DRUG SAFETY, V39, P517, DOI 10.1007/s40264-016-0408-y
   Ng WY, 2015, AM J OPHTHALMOL, V159, P557, DOI 10.1016/j.ajo.2014.12.005
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   PHILLIPS SJ, 1988, MAYO CLIN PROC, V63, P691, DOI 10.1016/S0025-6196(12)65531-1
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rim TH, 2016, RETINA-J RET VIT DIS, V36, P2166, DOI 10.1097/IAE.0000000000001084
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlenker MB, 2015, AM J OPHTHALMOL, V160, P569, DOI 10.1016/j.ajo.2015.06.011
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   [Anonymous], 2000, JAMA, V284, P3043, DOI 10.1001/jama.2013.281053
   Yannuzzi NA, 2015, JAMA OPHTHALMOL, V133, P32, DOI 10.1001/jamaophthalmol.2014.3591
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
NR 38
TC 29
Z9 29
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2019
VL 137
IS 5
BP 483
EP 490
DI 10.1001/jamaophthalmol.2018.6891
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HX6HB
UT WOS:000467503600007
PM 30703203
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Elsen, MKN
   Molbech, CR
   Oishi, A
   Singh, A
   Nissen, MH
   Srensen, TL
AF Subhi, Yousif
   Elsen, Marie Krogh Ni.
   Molbech, Christopher Rue
   Oishi, Akio
   Singh, Amardeep
   Nissen, Mogens Holst
   Srensen, Torben Lykke
TI CD11b and CD200 on Circulating Monocytes Differentiate Two Angiographic
   Subtypes of Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; immunology; microglia; blood;
   monocytes
ID RETINAL-PIGMENT EPITHELIUM; C-REACTIVE PROTEIN; FACTOR-H CFH; MACULAR
   DEGENERATION; INCREASED EXPRESSION; RECEPTOR; RANIBIZUMAB; MACROPHAGES;
   VARIANTS; OUTCOMES
AB PURPOSE. To investigate surface expression of CD11b and CD200 on circulating monocytes in patients with polypoidal choroidal vasculopathy (PCV).
   METHODS. This was a prospective case-control study of patients with PCV (n = 27), agematched healthy controls (n = 27), and patients with neovascular AMD (n 49). All participants underwent a comprehensive ocular examination. Fluorescein and indocyanine green angiography were performed in patients suspected of neovascular AMD or PCV Polypoidal choroidal vasculopathy was angiographically categorized into those with a strong presence of a branching vascular network (BVN) (type 1) or with a faint/no clear presence of a BVN (type 2). Fresh venous blood was stained with fluorescent antibodies for flow cytometric analyses. We compared the percentages of CD11b(+), CD200(+), and CD11b(+) CD200(+) monocytes between groups of diagnosis and between different angiographic subtypes of PCV.
   RESULTS. Overall, CD11b(+) monocytes were both increased in patients with PCV and neovascular AMD. CD200(+) and CD11b(+) CD200(+) monocytes were increased in patients with neovascular AMD. An age-related increase in CD11b(+) CD200(+) monocytes was absent in patients with PCV and neovascular AMD. Patients with PCV type 1 had significantly higher CD11b(+), CD200(+), and CD11b(+) CD200(+) monocytes, whereas patients with PCV type 2 had levels similar to that in healthy controls.
   CONCLUSIONS. We found that PCV is immunologically heterogeneous with significant differences between angiographic subtypes. Increased CD11b(+) and CD200(+) monocytes in those with a strong presence of BVN indicate that BVN development may be associated with retinal injury and a VEGF-mediated process that is either reflected or propelled by systemic changes in monocytes.
C1 [Subhi, Yousif; Elsen, Marie Krogh Ni.; Molbech, Christopher Rue; Singh, Amardeep; Srensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Subhi, Yousif; Elsen, Marie Krogh Ni.; Molbech, Christopher Rue; Nissen, Mogens Holst; Srensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Oishi, Akio] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Singh, Amardeep] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Ophthalmol, Lund, Sweden.
   [Nissen, Mogens Holst] Univ Copenhagen, Dept Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
C3 University of Copenhagen; Kyoto University; Lund University; Skane
   University Hospital; University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Singh, Amardeep/ABI-4544-2020; Subhi, Yousif/ABG-6330-2020; Oishi,
   Akio/AAE-9996-2020
OI Subhi, Yousif/0000-0001-6620-5365; Oishi, Akio/0000-0002-0977-9458;
   Krogh Nielsen, Marie/0000-0003-3804-7296
FU Danish Eye Research Foundation (Taastrup, Denmark); Fight for Sight
   Denmark (Copenhagen, Denmark); Velux Foundation (Soborg, Denmark)
FX Supported by grants from the Danish Eye Research Foundation (Taastrup,
   Denmark), Fight for Sight Denmark (Copenhagen, Denmark), and the Velux
   Foundation (Soborg, Denmark).
CR Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Benhar I, 2016, EMBO J, V35, P1219, DOI 10.15252/embj.201694202
   Brekke OL, 2007, J LEUKOCYTE BIOL, V81, P1404, DOI 10.1189/jlb.0806538
   Carter DA, 2004, CURR EYE RES, V28, P427, DOI 10.1080/02713680490503778
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Cheng Y, 2016, CHINESE MED J-PEKING, V129, P2610, DOI 10.4103/0366-6999.192779
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Dick AD, 2017, EYE, V31, P87, DOI 10.1038/eye.2016.177
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Dick AD, 2001, INVEST OPHTH VIS SCI, V42, P170
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Gharehbagh SS, 2018, ACTA OPHTHALMOL, V96, pE94, DOI 10.1111/aos.13461
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Idzkowska E, 2015, SCAND J IMMUNOL, V82, P163, DOI 10.1111/sji.12314
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kapinsky M, 2001, ARTERIOSCL THROM VAS, V21, P1004, DOI 10.1161/01.ATV.21.6.1004
   Karlstetter M, 2014, ADV EXP MED BIOL, V801, P207, DOI 10.1007/978-1-4614-3209-8_27
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lima LH, 2011, OPHTHALMIC GENET, V32, P80, DOI 10.3109/13816810.2010.544362
   LIU K, 2015, SCI REP UK, V5
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Nakai S, 2017, OPHTHALMOLOGICA, V237, P123, DOI 10.1159/000455273
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Rifai N, 2001, CLIN CHEM, V47, P28
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sawilowsky SS, 2009, J MOD APPL STAT METH, V8, P597, DOI 10.22237/jmasm/1257035100
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Skrzeczynska-Moncznik J, 2008, SCAND J IMMUNOL, V67, P152, DOI 10.1111/j.1365-3083.2007.02051.x
   SUBHI Y, 2016, DAN MEDJ, V63
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsukamoto M, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-016-1216-6
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yannuzzi LA, 1982, MAC SOC M MIAM FLOR
   Zeng RP, 2013, MOL VIS, V19, P729
   Ziv Y, 2006, P NATL ACAD SCI USA, V103, P13174, DOI 10.1073/pnas.0603747103
NR 60
TC 17
Z9 17
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2017
VL 58
IS 12
BP 5242
EP 5250
DI 10.1167/iovs.17-22479
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL5JN
UT WOS:000414272100024
PM 29049725
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tsiropoulos, GN
   Vallee, R
   Castro, DG
   Ambresin, A
AF Tsiropoulos, G. N.
   Vallee, R.
   Castro, D. Gallo
   Ambresin, A.
TI The importance of monitoring wet age-related macular degeneration
   patients during Coronavirus disease 19 pandemic: A retrospective study
   of assessment of functional and structural outcomes
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Anti-vascular endothelial growth factor; Wet age-related macular
   degeneration; Coronavirus disease 2019; Anti-VEGF; Wet AMD; COVID-19
AB Objectives. - Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are the gold standard treatment for wet age-related macular degeneration (wet AMD). Coronavirus disease 2019 (COVID-19) has led to the cancellation of many scheduled intravitreal anti-VEGF injection visits. We compared the functional and structural visual outcomes of wet AMD patients who did not adhere to their planned intervals (group 1) with those who did (group 2).Methods. - Wet AMD patients of Swiss Visio Montchoisi and RetinElysee were included. Best -corrected visual acuity (BCVA) and optical coherence tomography (OCT) changes between their first visit after the end of the first national lockdown in Switzerland (27 April 2020, first post-lockdown visit) and their last visit before the beginning of the first national lockdown in Switzerland (13 March 2020, last pre-lockdown visit) were assessed. The BCVA outcome was defined as unfavorable when there was a loss of > 5 ETDRS letters in the first post-lockdown visit compared to the BCVA at last pre-lockdown visit. The OCT outcome was defined as unfavorable when there was an increase in at least one of the parameters, intraretinal fluid (IRF), subretinal fluid (SRF), or pigment epithelial detachment (PED), at the first post-lockdown visit compared to the last pre-lockdown visit.Main results. - Group 1 (89 patients, 109 eyes) had a 13.41% greater rate of unfavorable BCVA outcomes and a 38.27% greater rate of unfavorable OCT outcomes than group 2 (96 patients, 122 eyes) (P = 0.04, P < 0.0001, respectively). Multivariate analysis showed that the more the patients deviated from their programmed injections and the higher the BCVA pre-lockdown, the higher the rate of unfavorable BCVA outcomes (P = 0.03 and P = 0.02, respectively). OCT outcomes were not a predictive factor for an unfavorable BCVA outcome.Conclusions. - The cancellation of many intravitreal anti-VEGF injection appointments resulted in worse functional and structural outcomes in wet AMD patients. The COVID-19 pandemic led many patients to refrain from their routine intravitreal anti-VEGF injection appointments, allowing us to analyze the role of designated intervals in the treatment of wet AMD. During any future lockdown due to COVID-19 or similar circumstances, continuity of care for wet AMD patients should be maintained.(c) 2022 Elsevier Masson SAS. All rights reserved.
C1 [Tsiropoulos, G. N.; Vallee, R.; Castro, D. Gallo; Ambresin, A.] Swiss Visio Montchoisi, Ave Servan 38, CH-1006 Lausanne, Switzerland.
   [Tsiropoulos, G. N.; Castro, D. Gallo; Ambresin, A.] RetinElysee, Ophthalmol Ctr, Ave Ouchy 14, CH-1006 Lausanne, Switzerland.
   [Tsiropoulos, G. N.] Aristotle Univ Thessaloniki AUTh, Med Sch, Dept Hlth Sci, Thessaloniki, Greece.
   [Vallee, R.] Univ Poitiers, Lab Math & Applicat LMA, Data Anal & Computat Through Imaging Modeling Math, CNRS 7348, 15 Rue lHotel Dieu,TSA 71117, F-86000 Poitiers, France.
   [Ambresin, A.] Univ Lausanne UNIL, Fac Biol & Med, CH-1015 Lausanne, Switzerland.
C3 Aristotle University of Thessaloniki; Universite de Poitiers; University
   of Lausanne
RP Ambresin, A (通讯作者)，Swiss Visio Montchoisi, Ave Servan 38, CH-1006 Lausanne, Switzerland.
EM AAmbresin@swissvisio.net
OI Tsiropoulos, Georgios/0000-0002-2441-545X; Vallee,
   Rodolphe/0000-0001-9569-687X
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   American Academy of Ophthalmology. American Academy of Ophthalmology, 2020, REC URG NON PAT CAR
   [Anonymous], 1997, JAMA-J AM MED ASSOC, V277, P925
   Antaki F, 2020, GRAEF ARCH CLIN EXP, V258, P1567, DOI 10.1007/s00417-020-04693-w
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Colantuono D, 2020, ACTA OPHTHALMOL, V98, pE925, DOI 10.1111/aos.14469
   Corradetti G, 2020, OPHTHALMOL RETINA, V4, P757, DOI 10.1016/j.oret.2020.05.015
   Dawood AA, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100673
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung THM, 2021, ACTA OPHTHALMOL, V99, pE285, DOI 10.1111/aos.14520
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Kodjikian L, 2020, J FR OPHTALMOL, V43, P539, DOI 10.1016/j.jfo.2020.04.019
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Naravane AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247161
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Royal College of Ophthalmologists, 2020, MAN OPHTH SERV COVID
   Saleh OA, 2020, CLIN OPHTHALMOL, V14, P2473, DOI 10.2147/OPTH.S269179
   Salmon JF, 2020, KANSKIS CLIN OPHTHAL, V9, P572
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Teo KYC, 2021, EYE, V35, P2793, DOI 10.1038/s41433-020-01315-x
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Yeter DY, 2021, J FR OPHTALMOL, V44, P299, DOI 10.1016/j.jfo.2021.02.001
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
NR 26
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD OCT
PY 2022
VL 45
IS 8
BP 852
EP 859
DI 10.1016/j.jfo.2022.05.005
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6E4GY
UT WOS:000883339400003
PM 35908993
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Johnston, RL
   Lee, AY
   Buckle, M
   Antcliff, R
   Bailey, C
   McKibbin, M
   Chakravarthy, U
AF Johnston, Robert L.
   Lee, Aaron Y.
   Buckle, Miranda
   Antcliff, Richard
   Bailey, Clare
   McKibbin, Martin
   Chakravarthy, Usha
CA Uk Amd Emr Users Group
TI UK Age-Related Macular Degeneration Electronic Medical Record System
   (AMD EMR) Users Group Report IV Incidence of Blindness and Sight
   Impairment in Ranibizumab-Treated Patients
SO OPHTHALMOLOGY
LA English
DT Article
ID PUBLIC-HEALTH IMPACT; VISUAL IMPAIRMENT; LEGAL BLINDNESS; OUTCOMES;
   MARINA; TRIAL
AB Purpose: To study the incidence of blindness and sight impairment in treatment-naive patients receiving ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) in the United Kingdom (UK) National Health Service.
   Design: Multicenter nAMD database study.
   Participants: A total of 11 135 patients who collectively received 92 976 treatment episodes to 12 951 eyes.
   Methods: Data were extracted from 14 UK centers using the same electronic medical record system (EMR). The EMR-mandated collection of a data set (defined before first data entry) including: age, Early Treatment Diabetic Retinopathy Study visual acuity letter score (VA) for both eyes at all visits, and injection episodes. Participating centers used overwhelmingly a pro re nata re-treatment posology at intended monthly follow-up visits following a loading phase of 3 monthly injections.
   Main Outcome Measures: Incidence of blindness and sight impairment (VA in the better-seeing eye < 38 letters [<= 20/200 Snellen, approximately], and < 68 letters [<= 20/50 Snellen, approximately] at 2 consecutive visits, or 1 visit if no further follow-up data) in each year after initiating treatment.
   Results: Information from > 300 000 clinic visits (2.8 million data points) collected over 5 years was collated from 14 centers. Mean age at first treatment was 79.7 years (standard deviation = 9.19 years), with a female preponderance (63%). The mean (median) VA at baseline in the better-seeing eye was 67.2 (72.0) letters, 20/40-(20/40+) approximate Snellen conversion. The cumulative incidence of new blindness and sight impairment in patients with treated nAMD in at least 1 eye at years 1 to 4 after first injection were 5.1%, 8.6%, 12% and 15.6% for new blindness and 29.6%, 41.0%, 48.7%, and 53.7% for new sight impairment, but with significant reductions in the rates between year cohorts initiating treatment (blindness [P = 4.72 x 10(-08)], sight impaired [P = 3.27 x 10(-06)]).
   Conclusions: To the best of our knowledge, this is the first multicenter real-world study on the incidence of blindness and sight impairment based on VA data in patients treated with ranibizumab for nAMD, and its results show low incidences of both blindness and sight impairment, which both declined during the study period. (C) 2016 by the American Academy of Ophthalmology
C1 [Johnston, Robert L.] Gloucestershire Hosp Natl Hlth Serv Fdn Trust, Cheltenham Hosp, Dept Ophthalmol, Cheltenham, Glos, England.
   [Lee, Aaron Y.] Univ Washington, Dept Ophthalmol, Box 359608,325 Ninth Ave, Seattle, WA 98104 USA.
   [Lee, Aaron Y.; Uk Amd Emr Users Group] Moorfields Eye Hosp, City Rd, London, England.
   [Antcliff, Richard] Bath Natl Hlth Serv Fdn Trust, Royal United Hosp, Dept Ophthalmol, Bath, Avon, England.
   [Buckle, Miranda; Bailey, Clare] Bristol Eye Hosp, Retina Serv, Bristol, Avon, England.
   [McKibbin, Martin] St James Univ Hosp, Eye Clin, Leeds, W Yorkshire, England.
   [Chakravarthy, Usha] Queens Univ, Ctr Vasc & Vis Sci, Belfast, Antrim, North Ireland.
C3 Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General
   Hospital; University of Washington; University of Washington Seattle;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Bristol Eye Hospital; Saint James's University
   Hospital; Queens University Belfast
RP Lee, AY (通讯作者)，Univ Washington, Dept Ophthalmol, Box 359608,325 Ninth Ave, Seattle, WA 98104 USA.
EM leeay@uw.edu
RI Lee, Aaron/AAT-2839-2020
OI McKibbin, Martin/0000-0003-4388-243X; Lee, Aaron/0000-0002-7452-1648;
   Buckle, Miranda/0000-0002-6722-7125; Chakravarthy,
   Usha/0000-0002-2606-3734; Tufail, Adnan/0000-0001-6131-7640
FU Novartis (Basel, Switzerland); Bayer (Leverkusen, Germany); Alcon
   Laboratories; Novartis; Bayer; Roche; Allergan (Dublin, Ireland)
FX The author(s) have made the following disclosure(s): R.L.J.:
   Directorship, Shares, Dividends - Medisoft Limited (Leeds, UK); Travel
   and lecture fees - Novartis (Basel, Switzerland), Bayer (Leverkusen,
   Germany).; M.M.: Grant - Alcon Laboratories; Personal fees - Novartis,
   Bayer.; U.C.: Grants - Novartis, Roche, Bayer; Personal fees - Allergan
   (Dublin, Ireland), Novartis, Roche, Bayer; A.T.: Grant - Novartis;
   Advisory boards - Bayer, Allergan.
CR Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Bunce C., 2008, EYE LOND, V22, P905
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Harding SP, 2009, OPHTHALMOLOGY, V116, P1
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Malik ANJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001496
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   The National Institute for Health and Care Excellence, RAN PEG TREATM AG RE
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Varma R, 2015, OPHTHALMOLOGY, V122, P982, DOI 10.1016/j.ophtha.2014.12.007
   WHO, 2011, INT STAT CLASS DIS R
NR 29
TC 24
Z9 24
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2016
VL 123
IS 11
BP 2386
EP 2392
DI 10.1016/j.ophtha.2016.07.037
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QK
UT WOS:000389509500023
PM 27615601
DA 2022-11-30
ER

PT J
AU Augood, C
   Fletcher, A
   Bentham, G
   Chakravarthy, U
   de Jong, PVTM
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Vioque, J
   Young, I
AF Augood, C
   Fletcher, A
   Bentham, G
   Chakravarthy, U
   de Jong, PVTM
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Vioque, J
   Young, I
TI Methods for a population-based study of the prevalence of and risk
   factors for age-related maculopathy and macular degeneration in elderly
   European populations: the EUREYE study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE macular degeneration; age-related maculopathy; vision loss; elderly
   persons; UVR exposure; antioxidants; risk factors; quality of life;
   research protocol
ID VISUAL IMPAIRMENT; VITAMIN-E; BLINDNESS; DISEASE
AB PURPOSE The aims of the EUREYE study are to evaluate the prevalence of age-related maculopathy (ARM), including macular degeneration (AMD), in elderly European populations, to investigate risk especially solar radiation and diet, and to factors for ARM and AMD, measure the impact of these conditions on vision-related quality of life.
   METHODS A population-based cross-sectional study with retrospective and current exposure measurements. Risk factor assessment is via questionnaires (for lifestyle factors such as smoking and alcohol, dietary risk factors, outdoor exposure) and blood analysis. Participants are people aged 65 and over. The study is carried out in 7 centres with locations spanning north to south Europe. The main outcome measure is grading of fundus photographs (for stage and type of ARM, using the International ARM Epidemiological Study Group grading system).
C1 Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Noncommunicable Dis Epidemiol Unit, London WC1E 7HT, England.
   Univ E Anglia, Sch Environm Sci, Ctr Environm Risk, Norwich NR4 7TJ, Norfolk, England.
   Royal Victoria Hosp, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland.
   Queens Univ Belfast, Inst Clin Sci, Dept Clin Biochem, Belfast BT12 6BJ, Antrim, North Ireland.
   NORI, Amsterdam, Netherlands.
   Inst Clin & Expt Med, Tallinn, Estonia.
   Haukeland Hosp, Oyeavdelingen, N-5021 Bergen, Norway.
   Univ Creteil Univ Paris Val de Marne, Fac Med, Clin Ophtalmol, Creteil, France.
   Univ Verona, Osped Civile Maggiore, Clin Oculist, I-37100 Verona, Italy.
   Aristotle Univ Thessaloniki, Ahepa Univ Hosp, Sch Med, Dept Ophthalmol, GR-54006 Thessaloniki, Greece.
   Univ Miguel Hernandez, Elche, Spain.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of East Anglia; Queens University Belfast; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of Bergen; Haukeland University Hospital;
   Universite de Franche-Comte; Universite Paris-Est-Creteil-Val-de-Marne
   (UPEC); University of Verona; Aristotle University of Thessaloniki;
   Ahepa University Hospital; Universidad Miguel Hernandez de Elche
RP Fletcher, A (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Noncommunicable Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
RI Vioque, Jesus/A-1066-2008; Rahu, Mati/A-9981-2008
OI Vioque, Jesus/0000-0002-2284-148X; Young, Ian/0000-0003-3890-3152;
   Chakravarthy, Usha/0000-0002-2606-3734; Topouzis,
   Fotis/0000-0002-8966-537X
CR ASSINK J, 2000, THESIS ERASMUS U ROT
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   DIFFEY BL, 1993, EPIDEMIOLOGICAL ASPE, P81
   EVANS JR, 2002, COCHRANE LIB
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   Hawkins BS, 1999, MOL VIS, V5
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLAVER CCW, 2000, THESIS ERASMUS U ROT
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   NICOLOSI A, 1994, INT J EPIDEMIOL, V23, P359, DOI 10.1093/ije/23.2.359
   O'Brien E, 2001, BMJ-BRIT MED J, V322, P531, DOI 10.1136/bmj.322.7285.531
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Vassileva P, 1996, Ophthalmic Epidemiol, V3, P143, DOI 10.3109/09286589609080120
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Willett W., 1990, NUTR EPIDEMIOLOGY
   YOUNG RW, 1994, OPTOMETRY VISION SCI, V71, P125, DOI 10.1097/00006324-199402000-00013
NR 29
TC 58
Z9 59
U1 0
U2 20
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD APR
PY 2004
VL 11
IS 2
BP 117
EP 129
DI 10.1076/opep.11.2.117.28160
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815RG
UT WOS:000221058800002
PM 15255027
DA 2022-11-30
ER

PT J
AU Liao, SM
   Zheng, W
   Zhu, J
   Lewis, CA
   Delgado, O
   Crowley, MA
   Buchanan, NM
   Jaffee, BD
   Dryja, TP
AF Liao, Sha-Mei
   Zheng, Wei
   Zhu, Jiang
   Lewis, Casey A.
   Delgado, Omar
   Crowley, Maura A.
   Buchanan, Natasha M.
   Jaffee, Bruce D.
   Dryja, Thaddeus P.
TI Specific correlation between the major chromosome 10q26 haplotype
   conferring risk for age-related macular degeneration and the expression
   of HTRA1
SO MOLECULAR VISION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; PROMOTER POLYMORPHISM;
   GENE; VARIANTS; ARMS2; SUSCEPTIBILITY; LOC387715; JAPANESE; LOCUS
AB Purpose: A region within chromosome 10q26 has a set of single nucleotide polymorphisms ( SNPs) that define a haplotype that confers high risk for age-related macular degeneration (AMD). We used a bioinformatics approach to search for genes in this region that may be responsible for risk for AMD by assessing levels of gene expression in individuals carrying different haplotypes and by searching for open chromatin regions in the retinal pigment epithelium (RPE) that might include one or more of the SNPs.
   Methods: We surveyed the PubMed and the 1000 Genomes databases to find all common (minor allele frequency > 0.01) SNPs in 10q26 strongly associated with AMD. We used the HaploReg and LDlink databases to find sets of SNPs with alleles in linkage disequilibrium and used the Genotype-Tissue Expression (GTEx) database to search for correlations between genotypes at individual SNPs and the relative level of expression of the genes. We also accessed Encyclopedia of DNA Elements (ENCODE) to find segments of open chromatin in the region with the AMD-associated SNPs. Predicted transcription factor binding motifs were identified using HOMER, PROMO, and RegulomeDB software programs.
   Results: There are 34 polymorphisms within a 30-kb region that are in strong linkage disequilibrium (r(2)>0.8) with the reference SNP rs10490924 previously associated with risk for AMD. The expression of three genes in this region, PLEKHA1, ARMS2, and HTRA1 varies between people who have the low-AMD-risk haplotype compared with those with the high-AMD-risk haplotype. For PLEKHA1, 44 tissues have an expression pattern with the high-AMD-risk haplotype associated with low expression (rs10490924 effect size -0.43, p = 3.8 x 10(-5) in ovary). With regard to ARMS2, the variation is most pronounced in testes: homozygotes with the high-AMD-risk haplotype express ARMS2 at lower levels than homozygotes with the low-AMD-risk haplotype; expression in heterozygotes falls in between (rs10490924 effect size -0.79, p = 7.5 x 10(-24)). For HTRA1, the expression pattern is the opposite; the high-AMD-risk haplotype has higher levels of expression in 27 tissues (rs10490924 effect size 0.40, p = 1.5 x 10(-7) in testes). None of the other 22 genes within one megabase of rs10490924, or any gene in the entire genome, have mRNA expression levels that correlate with the highAMD- risk haplotype. More than 100 other SNPs in the 10q26 region affect the expression of PLEKHA1 and ARMS2 but not that of HTRA1; none of these SNPs affects the risk for AMD according to published genome-wide association studies (GWASs). Two of the AMD-risk SNPs (rs36212732 and rs36212733) affect transcription factor binding sites in proximity to a DNase I hypersensitive region (i.e., a region of open chromatin) in RPE cells.
   Conclusions: SNPs in chromosome 10q26 that influence the expression of only PLEKHA1 or ARMS2 are not associated with risk for AMD, while most SNPs that influence the expression of HTRA1 are associated with risk for AMD. Two of the AMD-risk SNPs affect transcription factor binding sites that may control expression of one of the linked genes in the RPE. These findings suggest that the variation in the risk for AMD associated with chromosome 10q26 is likely due to variation in HTRA1 expression. Modulating HTRA1 activity might be a potential therapy for AMD.
C1 [Liao, Sha-Mei; Zheng, Wei; Lewis, Casey A.; Delgado, Omar; Crowley, Maura A.; Buchanan, Natasha M.; Jaffee, Bruce D.; Dryja, Thaddeus P.] Novartis Inst Biomed Res, NIBR Informat, Dept Ophthalmol, Cambridge, MA USA.
   [Zhu, Jiang] Novartis Inst Biomed Res, NIBR Informat, Sci Data Anal, Cambridge, MA USA.
   [Zheng, Wei] GNS Hlthcare, Cambridge, MA USA.
C3 Novartis; Novartis
RP Liao, SM (通讯作者)，Novartis Inst Biomed Res, Dept Ophthalmol, 22 Windsor St, Cambridge, MA 02139 USA.
EM sha-mei.liao@novartis.com
FU Common Fund of the Office of the Director of the National Institutes of
   Health; NCI; NHGRI; NHLBI; NIDA; NIMH; NINDS; NCI\SAIC-Frederick, Inc.
   (SAIC-F) [10XS170]; Roswell Park Cancer Institute [10XS171]; Science
   Care, Inc. [X10S172]; Laboratory, Data Analysis, and Coordinating Center
   (LDACC) [HHSN268201000029C]; SAIC-F [10ST1035]; University of Geneva
   [MH090941, MH101814]; University of Chicago [MH090951, MH090937,
   MH101820, MH101825]; University of North Carolina - Chapel Hill
   [MH090936, MH101819]; Harvard University [MH090948]; Stanford University
   [MH101782]; Washington University St Louis [MH101810]; University of
   Pennsylvania [MH101822];  [DA006227];  [DA033684];  [N01MH000028]
FX The authors thank Eric Marshall for assisting with the GTEx data
   analysis. The GTEx website asks for the following acknowledgment: "The
   Genotype-Tissue Expression (GTEx) Project was supported by the Common
   Fund of the Office of the Director of the National Institutes of Health.
   Additional funds were provided by the NCI, NHGRI, NHLBI, NIDA, NIMH, and
   NINDS. Donors were enrolled at Biospecimen Source Sites funded by
   NCI\SAIC-Frederick, Inc. (SAIC-F) subcontracts to the National Disease
   Research Interchange (10XS170), Roswell Park Cancer Institute (10XS171),
   and Science Care, Inc. (X10S172). The Laboratory, Data Analysis, and
   Coordinating Center (LDACC) was funded through a contract
   (HHSN268201000029C) to The Broad Institute, Inc. Biorepository
   operations were funded through an SAIC-F subcontract to Van Andel
   Institute (10ST1035). Additional data repository and project management
   were provided by SAIC-F (HHSN261200800001E). The Brain Bank was
   supported by supplements to University of Miami grants DA006227 &
   DA033684 and to contract N01MH000028. Statistical Methods development
   grants were made to the University of Geneva (MH090941 & MH101814), the
   University of Chicago (MH090951, MH090937, MH101820, MH101825), the
   University of North Carolina - Chapel Hill (MH090936 & MH101819),
   Harvard University (MH090948), Stanford University (MH101782),
   Washington University St Louis (MH101810), and the University of
   Pennsylvania (MH101822). The data used for the analyses described in
   this manuscript were obtained from the GTEx Portal from 11/01/2015 to
   12/04/2016. Parts of the data (Figure 2-4 and Table 2-4) have been
   presented at ARVO 2016. All work was performed at Novartis.
CR Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chan CC, 2007, T AM OPHTHAL SOC, V105, P97
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chowers I, 2008, MOL VIS, V14, P2263
   Consortium EP, 2011, PLOS BIOL, V9
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Grassmann F, 2016, GENETICS
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kortvely E, 2016, ADV EXP MED BIOL, V854, P23, DOI 10.1007/978-3-319-17121-0_4
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Minor EA, 2013, INVEST OPHTH VIS SCI, V54, P5913, DOI 10.1167/iovs.13-12273
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mu XJ, 2011, NUCLEIC ACIDS RES, V39, P7058, DOI 10.1093/nar/gkr342
   Munoz-Erazo L, 2012, MOL VIS, V18, P730
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Teper SJ, 2012, MED SCI MONITOR, V18, pPR1, DOI 10.12659/MSM.882447
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Wang GF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1491, DOI 10.1001/archophthalmol.2010.256
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Yu WH, 2013, MOL BIOL REP, V40, P5551, DOI 10.1007/s11033-013-2656-6
NR 60
TC 13
Z9 13
U1 1
U2 7
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUN 14
PY 2017
VL 23
BP 318
EP 333
PG 16
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA EX9UL
UT WOS:000403603700001
PM 28659708
DA 2022-11-30
ER

PT J
AU Perepechaeva, ML
   Stefanova, NA
   Grishanova, AY
AF Perepechaeva, M. L.
   Stefanova, N. A.
   Grishanova, A. Yu.
TI Expression of Genes for AhR and Nrf2 Signal Pathways in the Retina of
   OXYS Rats during the Development of Retinopathy and Melatonin-Induced
   Changes in This Process
SO BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE age-related macular degeneration; OXYS rats; arylhydrocarbon receptor;
   transcription factor Nrf2; melatonin
ID MACULAR DEGENERATION; TRANSCRIPTION; INDUCTION
AB Modulation of oxidative stress is one of the experimental approaches to the therapy of age-related macular degeneration. Melatonin holds much promise in this respect. It was hypothesized that the efficiency of melatonin in age-related macular degeneration is associated with its ability to modulate gene expression for the AhR and Nrf2 signal pathways. Experiments were performed on premature aging OXYS rats, which serve as a reliable model of age-related macular degeneration in humans. We studied the effect of melatonin on gene mRNA for the AhR and Nrf2 signal pathways. Melatonin was shown to decrease the level of mRNA for AhR-dependent genes of CYP1A2 and CYP1B1 cytochromes in the retina, but had no effect on the content of mRNA for Nrf2-dependent genes in OXYS rats.
C1 [Perepechaeva, M. L.; Grishanova, A. Yu.] Russian Acad Med Sci, Res Inst Mol Biol & Biophys, Siberian Div, Novosibirsk, Russia.
   [Stefanova, N. A.] Russian Acad Sci, Inst Cytol & Genet, Siberian Div, Novosibirsk 630090, Russia.
C3 Russian Academy of Medical Sciences; Russian Academy of Sciences;
   Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS
RP Perepechaeva, ML (通讯作者)，Russian Acad Med Sci, Res Inst Mol Biol & Biophys, Siberian Div, Novosibirsk, Russia.
EM perepech@soramn.ru
RI Grishanova, Alevtina/C-1759-2014; Perepechaeva, Maria/AAG-1840-2020;
   Stefanova, Natalia/V-1530-2018
OI Grishanova, Alevtina/0000-0002-5894-1159; Perepechaeva,
   Maria/0000-0001-5791-3714; Stefanova, natalia/0000-0001-5127-5993
FU Russian Foundation for Basic Research [12-04-01352-a]
FX This work was supported by the Russian Foundation for Basic Research
   (grant No. 12-04-01352-a).
CR Anisimov VN, 2008, MOL PHYSL MECH AGING, V1
   Chang TKH, 2010, J PINEAL RES, V48, P55, DOI 10.1111/j.1600-079X.2009.00724.x
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Hayes JD, 2009, TOXICOL SCI, V111, P199, DOI 10.1093/toxsci/kfp168
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Kato K, 2010, RADIAT RES, V174, P177, DOI 10.1667/RR2146.1
   Kulic U., 2013, NUTR METAB, V10, P7
   Ma Q, 2001, CURR DRUG METAB, V2, P149, DOI 10.2174/1389200013338603
   Markovets AM, 2011, AGING-US, V3, P44
   Nebert DW, 2006, NAT REV CANCER, V6, P947, DOI 10.1038/nrc2015
   Stefanova N A, 2013, Adv Gerontol, V26, P122
   Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x
   Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103
   Yeager RL, 2009, TOXICOL SCI, V111, P238, DOI 10.1093/toxsci/kfp115
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
NR 15
TC 11
Z9 11
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0007-4888
EI 1573-8221
J9 B EXP BIOL MED+
JI Bull. Exp. Biol. Med.
PD AUG
PY 2014
VL 157
IS 4
BP 424
EP 429
DI 10.1007/s10517-014-2582-1
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AN5VY
UT WOS:000340661000005
PM 25110076
DA 2022-11-30
ER

PT J
AU Shen, MX
   Zhang, QQ
   Yang, J
   Zhou, H
   Chu, ZD
   Zhou, X
   Feuer, W
   Jiang, XS
   Shi, YY
   de Sisternes, L
   Durbin, MK
   Wang, RK
   Gregori, G
   Rosenfeld, PJ
AF Shen, Mengxi
   Zhang, Qinqin
   Yang, Jin
   Zhou, Hao
   Chu, Zhongdi
   Zhou, Xiao
   Feuer, William
   Jiang, Xiaoshuang
   Shi, Yingying
   de Sisternes, Luis
   Durbin, Mary K.
   Wang, Ruikang K.
   Gregori, Giovanni
   Rosenfeld, Philip J.
TI Swept-Source OCT Angiographic Characteristics of Treatment-Naive
   Nonexudative Macular Neovascularization in AMD Prior to Exudation
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; nonexudative macular
   neovascularization; swept-source OCT angiography
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   SUBCLINICAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; NATURAL-HISTORY;
   BLOOD-FLOW; DEGENERATION; CHORIOCAPILLARIS; INSIGHTS; RETINA
AB PURPOSE. To investigate the characteristics of treatment-naive nonexudative macular neovascularization (MNV) in age-related macular degeneration before the onset of exudation using swept-source optical coherence tomography angiography.
   METHODS. MNV area, choriocapillaris (CC) flow deficits (FDs), vessel area density (VAD), vessel skeleton density (VSD), retinal pigment epithelial detachment (PED) volume, mean choroidal thickness (MCT), and choroid vascularity index (CVI) measurements were assessed at two visits prior to exudation. We compared measurements made at the second visit and the rate of change between visits in eyes with and without exudation. The differences in these parameters between eyes with and without subsequent exudation were summarized with 95% confidence intervals (CIs).
   RESULTS. Twenty-one eyes with nonexudative MNV were identified and followed. Nine eyes developed exudation, and 12 eyes did not develop exudation. Differences between these groups of eyes for all parameters tended to be small, and the 95% CIs largely ruled out any substantial differences. Overall, eyes with exudation had 24% smaller VAD, 20% smaller VSD, and 33% smaller PED volume measurements. No noteworthy differences were observed for MNV area, CC FDs, MCT, or CVI measurements.
   CONCLUSIONS. The onset of exudation was correlated with lesions having less vascularity and smaller PED volume measurements, but measurements of MNV area, CC FDs, MCT, and CVI were not correlated with near-term exudation. Investigations are ongoing to further explore these and other anatomic changes as harbingers of near-term exudation.
C1 [Shen, Mengxi; Yang, Jin; Feuer, William; Jiang, Xiaoshuang; Shi, Yingying; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
   [Zhang, Qinqin; Zhou, Hao; Chu, Zhongdi; Zhou, Xiao; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [de Sisternes, Luis; Durbin, Mary K.] Carl Zeiss Meditec Inc, Res & Dev, Dublin, CA USA.
C3 Bascom Palmer Eye Institute; University of Miami; University of
   Washington; University of Washington Seattle; Carl Zeiss AG
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
RI Wang, Ruikang/L-3889-2019; Shen, Mengxi/ABC-6941-2021
OI Wang, Ruikang/0000-0001-5169-8822; Shen, Mengxi/0000-0002-1336-1695
FU National Eye Institute [R01EY028753, R01AG060942]; Carl Zeiss Meditec,
   Inc. (Dublin, CA); Salah Foundation; Research to Prevent Blindness,
   Inc., New York, NY; National Eye Institute Center Core Grant
   [P30EY014801]
FX Supported by Grants from the National Eye Institute (R01EY028753,
   R01AG060942), Carl Zeiss Meditec, Inc. (Dublin, CA), the Salah
   Foundation, an unrestricted grant from the Research to Prevent
   Blindness, Inc., New York, NY, and the National Eye Institute Center
   Core Grant (P30EY014801) to the Department of Ophthalmology, University
   of Miami Miller School of Medicine. The funding organizations had no
   role in the design or conduct of this research.
CR Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Chen Katherine G, 2021, Retin Cases Brief Rep, V15, P207, DOI 10.1097/ICB.0000000000000826
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Chu ZD, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.12.121705
   Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dwivedi AK, 2017, STAT MED, V36, P2187, DOI 10.1002/sim.7263
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Heier JS, 2019, AM SOC RET SPEC 2019
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Lai KB, 2011, INVEST OPHTH VIS SCI, V52, P5702, DOI 10.1167/iovs.10-6370
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Luis DS, 2019, INVEST OPHTHALMOL VI, V60, P3487
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Ploner SB, 2016, RETINA-J RET VIT DIS, V36, pS118, DOI 10.1097/IAE.0000000000001328
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Rebhun CB, 2018, OPHTHALMOL RETINA, V2, P306, DOI 10.1016/j.oret.2017.08.013
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Tan BY, 2019, BIOMED OPT EXPRESS, V10, P356, DOI 10.1364/BOE.10.000356
   Teo KYC, 2021, OPHTHALMOL RETINA, V5, P126, DOI 10.1016/j.oret.2020.07.005
   Tibshirani R.J., 1993, MONOGRAPHS STAT APPL, V57, P1
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Valler D, 2020, OPHTHALMOLOGE, V117, P529, DOI 10.1007/s00347-019-01003-6
   von der Emde L, 2020, OPHTHALMOLOGICA, V243, P120, DOI 10.1159/000503609
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
   Zhou H, 2020, OPHTHALMOL RETINA, V4, P204, DOI 10.1016/j.oret.2019.09.012
   Zhou H, 2018, BIOMED OPT EXPRESS, V9, P6067, DOI 10.1364/BOE.9.006067
NR 51
TC 5
Z9 5
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2021
VL 62
IS 6
AR 14
DI 10.1167/iovs.62.6.14
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UA5IZ
UT WOS:000685196300006
PM 33984121
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Miyamoto, N
   Mandai, M
   Oishi, A
   Nakai, S
   Honda, S
   Hirashima, T
   Oh, H
   Matsumoto, Y
   Uenishi, M
   Kurimoto, Y
AF Miyamoto, Noriko
   Mandai, Michiko
   Oishi, Akio
   Nakai, Shunichiro
   Honda, Shigeru
   Hirashima, Takafumi
   Oh, Hideyasu
   Matsumoto, Yoshiko
   Uenishi, Mamoru
   Kurimoto, Yasuo
TI Long-term results of photodynamic therapy or ranibizumab for polypoidal
   choroidal vasculopathy in LAPTOP study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION; 7-YEAR OUTCOMES;
   VISUAL-ACUITY; VERTEPORFIN; EFFICACY; HORIZON; ANCHOR; SAFETY; MARINA
AB Background/aim We previously reported that ranibizumab performed better on visual prognosis than photodynamic therapy (PDT) in a Ranibizumab (Lucentis) And Photodynamic Therapy On Polypoidal choroidal vasculopathy (LAPTOP) study. To determine if the firstchoice treatment, either PDT or intravitreal ranibizumab, has a long-term effect in patients with polypoidal choroidal vasculopathy (PCV).
   Methods We reviewed medical records of patientsrandomised to either PDT (29 eyes) or ranibizumab (27 eyes) from July 2009 to June 2011 in LAPTOP study. Retreatment or switching to other treatments were at the investigator's discretion after release from the 2-year LAPTOP study up to 5years. We evaluated visual acuity (VA), continuity of initial treatment, percentage of dry macula achievement and macular atrophy at 5 years.
   Results The logarithm of minimal angle of resolution VA was 0.56 in the PDT and 0.44 in the ranibizumab groups at baseline (p=0.101) and was 0.55 and 0.28 at 5years, respectively (p<0.05). More than 70% of the patients converted to aflibercept in following years. Achievement percentages of dry macula were 74% (PDT) and 63% (ranibizumab) at 5years, and macular atrophy was detected in 78% (PDT) and 60% (ranibizumab) with a mean area of 7.7 and 3.5 mm2, respectively (p=0.155).
   Conclusions The better VA in the initial ranibizumab group compared with the PDT group at 2 years was retained at the 5-year follow-up.
C1 [Miyamoto, Noriko; Mandai, Michiko; Kurimoto, Yasuo] Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Miyamoto, Noriko; Oishi, Akio; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Mandai, Michiko] RIKEN Ctr Dev Biol, Lab Retinal Regenerat, Kobe, Hyogo, Japan.
   [Nakai, Shunichiro; Honda, Shigeru] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan.
   [Hirashima, Takafumi; Oh, Hideyasu] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Ophthalmol, Amagasaki, Hyogo, Japan.
   [Matsumoto, Yoshiko; Uenishi, Mamoru] Mitsubishi Kobe Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
C3 Kobe City Medical Center General Hospital; RIKEN; Kobe University
RP Miyamoto, N (通讯作者)，Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
EM miyacy_fr@hotmail.com
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458
CR Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Figurska M, 2011, MED SCI MONITOR, V17, pCS75, DOI 10.12659/MSM.881799
   Gonzalez-Buendia L, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0544-x
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Miyamoto N, 2017, CLIN OPHTHALMOL, V11, DOI 10.2147/OPTH.S133332
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
NR 24
TC 18
Z9 18
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2019
VL 103
IS 6
BP 844
EP 848
DI 10.1136/bjophthalmol-2018-312419
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID7PW
UT WOS:000471875800021
PM 30077969
DA 2022-11-30
ER

PT J
AU Choudhary, M
   Ildefonso, CJ
   Lewin, AS
   Malek, G
AF Choudhary, Mayur
   Ildefonso, Cristhian J.
   Lewin, Alfred S.
   Malek, Goldis
TI Gene Delivery of a Caspase Activation and Recruitment Domain Improves
   Retinal Pigment Epithelial Function and Modulates Inflammation in a
   Mouse Model with Features of Dry Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE inflammation; retinal function; age-related macular degeneration;
   prevention; AAV therapy; NLRP3 inflammasome
ID NLRP3 INFLAMMASOME; CHOROIDAL NEOVASCULARIZATION; LYSOSOMAL
   DESTABILIZATION; MULLER CELLS; RPE CELLS; EXPRESSION; IL-1-BETA;
   MICROGLIA; THERAPY; DISEASE
AB Purpose: The NLRP3 inflammasome, a cytoplasmic signal transduction complex that regulates inflammation, has been implicated in the pathogenesis of age-related macular degeneration (AMD), the leading cause of visual impairment in industrialized countries. We tested the therapeutic effect of anti-inflammatory gene therapy, delivered preventively, in Liver-X-Receptor alpha knockout (LXR alpha(-/-)) mice, which exhibit features of dry AMD. Methods: LXR alpha(-/-) mice were treated with an adeno-associated virus (AAV) vector that delivers a secretable and cell-penetrating form of the caspase activation and recruitment domain (CARD). A sGFP-FCS-TatCARD-AAV or sGFP-FCS (control) vector was delivered intravitreally to 3-5 month-old, LXR alpha(-/-) mice, who were then aged to 15-18 months (12-13 month treatment). Retinal function and morphology were assessed pre- and post-treatment.Results: TatCARD treated LXR alpha(-/-) mice did not show improvement in rod and cone photoreceptor function, measured by dark adapted a- and b-wave amplitudes, and rod-saturated b-wave amplitudes. We found a sex-dependent, significant therapeutic effect in c-wave amplitudes in the TatCARD treated mice, which exhibited maintenance of amplitudes in comparison to the significant decline recorded in the control treated group, indicating a therapeutic effect mediated in part through retinal pigment epithelial (RPE) cells. Additionally, the retinas of the TatCARD treated mice exhibited a significant decline in the concentration of interleukin-1 beta (IL-1 beta) concomitant with modulation of several inflammatory cytokines in the retina and RPE-choroid tissues, as measured by ELISA and cytokine array, respectively.Conclusion: Collectively, these results support that anti-inflammatory gene constructs such as AAV-TatCARD may be considered for the treatment of inflammation in AMD and other ocular diseases of the posterior pole in which inflammation may play a role. Furthermore, our findings emphasize the need to carefully consider potential sex-different responses when assessing potential therapies in pre-clinical models.
C1 [Choudhary, Mayur; Malek, Goldis] Duke Univ, Albert Eye Res Inst, Duke Eye Ctr, Sch Med, Durham, NC USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC USA.
   [Ildefonso, Cristhian J.] Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL USA.
   [Lewin, Alfred S.] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA.
   [Malek, Goldis] Duke Univ, Albert Eye Res Inst, Duke Eye Ctr, Sch Med, Room 4006, Durham, NC 27710 USA.
C3 Duke University; Duke University; State University System of Florida;
   University of Florida; State University System of Florida; University of
   Florida; Duke University
RP Malek, G (通讯作者)，Duke Univ, Albert Eye Res Inst, Duke Eye Ctr, Sch Med, Room 4006, Durham, NC 27710 USA.
EM gmalek@duke.edu
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Ansari AM, 2016, STEM CELL REV REP, V12, P553, DOI 10.1007/s12015-016-9670-8
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Choudhary M, 2018, BBA-MOL BASIS DIS, V1864, P1583, DOI 10.1016/j.bbadis.2018.02.015
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Choudhary M, 2015, J PATHOL, V235, P101, DOI 10.1002/path.4433
   Claybon A, 2011, JOVE-J VIS EXP, DOI 10.3791/2563
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR246, DOI 10.1093/hmg/ddx343
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duez H, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.630536
   Ferrari CC, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/436813
   Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fletcher EL, 2020, OPHTHAL PHYSL OPT, V40, P128, DOI 10.1111/opo.12671
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Ildefonso CJ, 2015, MOL THER, V23, P875, DOI 10.1038/mt.2015.30
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Li X, 2011, INVEST OPHTH VIS SCI, V52, P7, DOI 10.1167/iovs.10-6138
   Liu F, 2016, MOL VIS, V22, P352
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Makhoul M, 2012, EXP EYE RES, V101, P27, DOI 10.1016/j.exer.2012.05.012
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mo JS, 1998, EXP EYE RES, V66, P547, DOI 10.1006/exer.1997.0451
   Mullins RF, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-58
   Multhoff G, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00098
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Newman NJ, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.662838
   O'Koren EG, 2019, IMMUNITY, V50, P723, DOI 10.1016/j.immuni.2019.02.007
   Pang JJ, 2008, INVEST OPHTH VIS SCI, V49, P4278, DOI 10.1167/iovs.07-1622
   Park TK, 2009, GENE THER, V16, P916, DOI 10.1038/gt.2009.61
   Patel JI, 2008, EYE, V22, P223, DOI 10.1038/sj.eye.6702584
   Ridley RB, 2021, METHODS MOL BIOL, V2225, P77, DOI 10.1007/978-1-0716-1012-1_5
   Rodriguez AR, 2014, J COMP NEUROL, V522, P1411, DOI 10.1002/cne.23521
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Sarra GM, 2002, VISION RES, V42, P541, DOI 10.1016/S0042-6989(01)00230-9
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shi GP, 2015, INVEST OPHTH VIS SCI, V56, P1658, DOI 10.1167/iovs.14-14557
   Sun X, 2010, GENE THER, V17, P117, DOI 10.1038/gt.2009.104
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thomas CN, 2022, BRIT J PHARMACOL, V179, P1908, DOI 10.1111/bph.15459
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Xu YJ, 2016, BRAIN BEHAV IMMUN, V56, P175, DOI 10.1016/j.bbi.2016.02.022
   Young BM, 2019, MOL THER-METH CLIN D, V14, P113, DOI 10.1016/j.omtm.2019.06.001
   Yu C, 2020, TRENDS NEUROSCI, V43, P433, DOI 10.1016/j.tins.2020.03.012
   Yu-Wai-Man P, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz7423
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
NR 59
TC 0
Z9 0
U1 1
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUN 1
PY 2022
VL 38
IS 5
BP 359
EP 371
DI 10.1089/jop.2022.0002
EA APR 2022
PG 13
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 2H0YB
UT WOS:000790962800001
PM 35446130
DA 2022-11-30
ER

PT J
AU Ibrahim, AS
   Hussein, K
   Wang, F
   Wan, M
   Saad, N
   Essa, M
   Kim, I
   Shakoor, A
   Owen, LA
   DeAngelis, MM
   Al-Shabrawey, M
AF Ibrahim, Ahmed S.
   Hussein, Khaled
   Wang, Fang
   Wan, Ming
   Saad, Nancy
   Essa, Maamon
   Kim, Ivana
   Shakoor, Akbar
   Owen, Leah A.
   DeAngelis, Margaret M.
   Al-Shabrawey, Mohamed
TI Bone Morphogenetic Protein (BMP)4 But Not BMP2 Disrupts the Barrier
   Integrity of Retinal Pigment Epithelia and Induces Their Migration: A
   Potential Role in Neovascular Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age related macular degeneration (AMD); BMP4; BMP2; retinal pigment
   epithelial cells (RPE); ARPE-19
ID ENDOTHELIAL GROWTH-FACTOR; MATRIX-METALLOPROTEINASE; MICROVASCULAR
   DYSFUNCTION; GLOBAL PREVALENCE; CELLS; VEGF; 12/15-LIPOXYGENASE;
   PATHOGENESIS; EXPRESSION; MANAGEMENT
AB Disruption of retinal pigment epithelial (RPE) barrier integrity and RPE migration are hallmark features in neovascular age-related macular degeneration (nAMD), but the underlying causes and pathophysiology are not completely well-defined. Herein, we aimed to evaluate the effect of bone morphogenetic proteins (BMPs) on the barrier function and migration of RPE. In particular, we investigated the role of BMP2 and BMP4 in these processes as our analysis of RNA-sequencing (seq) data from human donor eyes demonstrated that they are highly differentially expressed BMP members in macular RPE/choroidversus macular retina. We used electrical cell-substrate impedance sensing (ECIS) system to monitor precisely in real time the barrier integrity and migration of ARPE-19 after treatment with various concentrations of BMP2 or BMP4. Immunofluorescence was also used to assess the changes in the expression and the organization of the key tight junction protein, zona occludens (ZO)-1, in ARPE-19 cells under BMP2 or BMP4 treatment. This was followed by measuring the activity of matrix metalloproteinases (MMPs). Finally, RNA-seq and ELISA were used to determine the local and circulating levels of BMP2 and BMP4 in retinas and serum samples from nAMD donors. Our ECIS results showed that BMP4 but not BMP2 decreased the transcellular electrical resistance (TER) of ARPE-19 and increased their migration in comparison with control (vehicle-treated cells). Furthermore, immunofluorescence showed a disorganization of ZO-1 in BMP4-treated ARPE-19 not in BMP2-treated cells or vehicle-treated controls. This effect of BMP4 was associated with significant increases in the activity of MMPs, specifically MMP2. Lastly, these results were corroborated by additional findings that circulating but not local BMP4 levels were significantly higher in nAMD donor samples compared to controls. Collectively, our results demonstrated unreported effects of BMP4 on inducing RPE dysfunction and suggest that BMP4 but not BMP2 may represent a potential therapeutic target in nAMD.
C1 [Ibrahim, Ahmed S.] Wayne State Univ, Dept Pharmacol, Dept Ophthalmol Visual & Anat Sci, Detroit, MI 48201 USA.
   [Ibrahim, Ahmed S.] Mansoura Univ, Dept Biochem, Fac Pharm, Mansoura 35516, Egypt.
   [Hussein, Khaled] Natl Res Ctr, Oral & Dent Res Div, Dept Med & Surg, Cairo 12622, Egypt.
   [Hussein, Khaled; Wang, Fang; Wan, Ming; Saad, Nancy; Essa, Maamon; Al-Shabrawey, Mohamed] Augusta Univ, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.
   [Wang, Fang; Wan, Ming] Jianghan Univ, Sch Med, Dept Tradit Chinese Med, Wuhan 430199, Peoples R China.
   [Saad, Nancy] Univ Alberta Canada, Dent Sch, Edmonton, AB T6G 2R3, Canada.
   [Essa, Maamon] Mansoura Univ, Mansoura Fac Med, Dept Med Biochem, Mansoura 35516, Egypt.
   [Kim, Ivana] Harvard Med Sch, Massachusetts Eye & Ear, Retina Serv, Boston, MA 02115 USA.
   [Shakoor, Akbar; Owen, Leah A.; DeAngelis, Margaret M.] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA.
   [DeAngelis, Margaret M.] Univ Utah, Sch Med, Dept Populat Hlth Sci, Salt Lake City, UT 84132 USA.
   [Al-Shabrawey, Mohamed] SUNY Buffalo, Jacobs Sch Med & Biomed Engn, Dept Ophthalmol, Buffalo, NY 14215 USA.
   [Al-Shabrawey, Mohamed] VA Western New York Healthcare Syst, Buffalo, NY 14215 USA.
   [Al-Shabrawey, Mohamed] Augusta Univ, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.
   [Al-Shabrawey, Mohamed] Augusta Univ, Dept Ophthalmol, Augusta, GA 30912 USA.
   [Al-Shabrawey, Mohamed] Augusta Univ, Culver Vis Discovery Inst, Augusta, GA 30912 USA.
   [Al-Shabrawey, Mohamed] Mansoura Univ, Mansoura Fac Med, Dept Anat, Dakahlia Governorate 35516, Egypt.
C3 Wayne State University; Egyptian Knowledge Bank (EKB); Mansoura
   University; Egyptian Knowledge Bank (EKB); National Research Centre
   (NRC); University System of Georgia; Augusta University; Jianghan
   University; Egyptian Knowledge Bank (EKB); Mansoura University; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary;
   Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; State University of New York
   (SUNY) System; State University of New York (SUNY) Buffalo; University
   System of Georgia; Augusta University; University System of Georgia;
   Augusta University; University System of Georgia; Augusta University;
   Egyptian Knowledge Bank (EKB); Mansoura University
RP Ibrahim, AS (通讯作者)，Wayne State Univ, Dept Pharmacol, Dept Ophthalmol Visual & Anat Sci, Detroit, MI 48201 USA.; Ibrahim, AS (通讯作者)，Mansoura Univ, Dept Biochem, Fac Pharm, Mansoura 35516, Egypt.; Al-Shabrawey, M (通讯作者)，Augusta Univ, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.; Al-Shabrawey, M (通讯作者)，Augusta Univ, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.; Al-Shabrawey, M (通讯作者)，Augusta Univ, Dept Ophthalmol, Augusta, GA 30912 USA.; Al-Shabrawey, M (通讯作者)，Augusta Univ, Culver Vis Discovery Inst, Augusta, GA 30912 USA.; Al-Shabrawey, M (通讯作者)，Mansoura Univ, Mansoura Fac Med, Dept Anat, Dakahlia Governorate 35516, Egypt.
EM ahmed.ibrahim@wayne.edu; hussein.k.nrc@gmail.com; tealiking@aliyun.com;
   brightwan@sina.com; Abdelhay@ualberta.ca; maamonessa@gmail.com;
   ivana_kim@meei.harvard.edu; akbar.shakoor@hsc.utah.edu;
   Leah.Owen@hsc.utah.edu; mmdeange@buffalo.edu; malshabrawey@augusta.edu
RI Hussein, Khaled/GXN-2993-2022; ibrahim, ahmed/D-5241-2017
OI ibrahim, ahmed/0000-0001-8480-6252
FU National Eye Institute [R01EY030054-01A1, R01EY023315]; American Heart
   Association [18CDA34080403]; NIH [P30EY004068]; Research to Prevent
   Blindness; Chinese Cultural Bureau; Macular Degeneration Foundation;
   Carl Marshall Reeves & Mildred Almen Reeves Foundation, Inc; National
   Institutes of Health [EY014800]; Research to Prevent Blindness, Inc.,
   New York, NY; Eunice Kennedy Shriver National Institute of Child Health
   & Human Development; Office of Research on Women's Eye Health of the
   National Institutes of Health [K12HD08582]
FX This research was funded by the National Eye Institute grants
   R01EY030054-01A1 and R01EY023315 (M.A.-S.); the American Heart
   Association Grant 18CDA34080403 (A.S.I.), NIH core grant P30EY004068 to
   the Department of Ophthalmology, Visual and Anatomical Sciences (OVAS)
   and a Research to Prevent Blindness unrestricted grant to the Department
   of OVAS, Wayne State University, Detroit, MI, USA; Chinese Cultural
   Bureau to (F.W.) and (M.W.). Research reported in this publication was
   additionally supported by The Macular Degeneration Foundation, The Carl
   Marshall Reeves & Mildred Almen Reeves Foundation, Inc, the National
   Institutes of Health Core Grant EY014800, Unrestricted Grant from
   Research to Prevent Blindness, Inc., New York, NY, to the Department of
   Ophthalmology & Visual Sciences, University of Utah, Eunice Kennedy
   Shriver National Institute of Child Health & Human Development and the
   Office of Research on Women's Eye Health of the National Institutes of
   Health under Award K12HD08582. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the national Institutes of Health.
CR Arnold JJ, 2007, BMJ CLIN EVID, V2007
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Chang K, 2007, CIRCULATION, V116, P1258, DOI 10.1161/CIRCULATIONAHA.106.683227
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Cho MJ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0327-y
   Chung M, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700028
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   de Vinuesa AG, 2016, CYTOKINE GROWTH F R, V27, P65, DOI 10.1016/j.cytogfr.2015.12.005
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Farnoodian M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12266
   Finkenzeller G, 2012, MICROVASC RES, V84, P81, DOI 10.1016/j.mvr.2012.03.010
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Gupta A, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011140.pub2
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Helbing T, 2017, INFLAMMATION, V40, P442, DOI 10.1007/s10753-016-0490-4
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hussein KA, 2014, EXP EYE RES, V125, P79, DOI 10.1016/j.exer.2014.05.012
   Ibrahim AS, 2017, BBA-MOL CELL BIOL L, V1862, P636, DOI 10.1016/j.bbalip.2017.03.010
   Ibrahim AS, 2016, ONCOTARGET, V7, P8532, DOI 10.18632/oncotarget.7384
   Ibrahim AS, 2015, J LIPID RES, V56, P599, DOI 10.1194/jlr.M056069
   Ibrahim AS, 2015, BBA-MOL CELL BIOL L, V1851, P290, DOI 10.1016/j.bbalip.2014.12.017
   Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899
   Kim S, 2019, P NATL ACAD SCI USA, V116, P10824, DOI 10.1073/pnas.1901572116
   Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678
   Liang QN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12917-9
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Owen Leah A, 2019, Invest Ophthalmol Vis Sci, V60, P1204, DOI 10.1167/iovs.18-24254
   Park CS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001530
   Qin S, 2008, J INFLAMM RES, V1, P49
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Roberts PK, 2017, BRIT J OPHTHALMOL, V101, P1361, DOI 10.1136/bjophthalmol-2016-310004
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Son JW, 2011, BIOMARK MED, V5, P827, DOI [10.2217/BMM.11.81, 10.2217/bmm.11.81]
   Son JW, 2011, ENDOCR J, V58, P39, DOI 10.1507/endocrj.K10E-248
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Vogt RR, 2006, J CELL BIOCHEM, V98, P1196, DOI 10.1002/jcb.20831
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yurekli BS, 2018, HORM-INT J ENDOCRINO, V17, P247, DOI 10.1007/s42000-018-0041-5
   Zender L, 2009, AGING-US, V1, P438, DOI 10.18632/aging.100046
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   2001, AM J OPHTHALMOL, V132, P668, DOI DOI 10.1016/S0002-9394(01)01218-1
NR 61
TC 7
Z9 7
U1 3
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2020
VL 9
IS 7
AR 2293
DI 10.3390/jcm9072293
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA MV6OB
UT WOS:000556473600001
PM 32707711
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Maruko, I
   Iida, T
   Sugano, Y
   Saito, M
   Sekiryu, T
AF Maruko, Ichiro
   Iida, Tomohiro
   Sugano, Yukinori
   Saito, Masaaki
   Sekiryu, Tetsuju
TI Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic
   Therapy for Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; MACULAR
   DEGENERATION; INTRAVITREAL BEVACIZUMAB; SUBGROUP ANALYSIS; RANIBIZUMAB;
   NEOVASCULARIZATION; OCCLUSION; MARINA; VEGF
AB PURPOSE: To evaluate the morphologic retinal and choroidal changes after verteporfin photodynamic therapy (PDT) with and without ranibizumab for polypoidal choroidal vasculopathy using spectral-domain optical coherence tomography.
   DESIGN: Retrospective, comparative series.
   METHODS: The enhanced depth imaging optical coherence tomography technique was used in this retrospective, comparative series to measure the subfoveal retinal and choroidal thicknesses before and after treatment.
   RESULTS: Twenty-seven eyes with polypoidal choroidal vasculopathy were examined retrospectively. Sixteen eyes were treated with PDT monotherapy (PDT group). Eleven eyes were treated with PDT after intravitreal ranibizumab injection (ranibizumab plus PDT group). The polypoidal lesions regressed in all cases at 3 months. The mean retinal thickness, including the retinal detachment, increased from 401 +/- 157 mu m before treatment to 506 +/- 182 mu m 2 days after PDT (P < .001) and decreased to 365 +/- 116 mu m by 1 week after treatment (P = .03) and 265 +/- 127 mu m by 6 months after treatment (P < .001). The mean choroidal thickness increased from 269 +/- 107 mu m before treatment to 336 +/- 96 mu m 2 days after PDT treatment (P < .001 compared with baseline) and decreased to 262 +/- 96 mu m by 1 week after treatment (P = .24) and 229 +/- 104 mu m by 6 months (P < .001). Although the choroidal thickness showed a similar trend with both therapies, the retinal thickness in the ranibizumab plus PDT group remained thinner than that in the PDT group until 6 months after treatment.
   CONCLUSIONS: PDT was associated with decreased retinal and choroidal thicknesses. Combination therapy reduced the transient exudation after PDT in some cases, and monthly intravitreal ranibizumab injections maintained retinal thinning and seemed to improve vision better than PDT monotherapy. (Am J Ophthalmol 2011;151:594-603. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Maruko, Ichiro; Iida, Tomohiro; Sugano, Yukinori; Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
C3 Fukushima Medical University
RP Maruko, I (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima, Japan.
EM imaruko@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Maruko, Ichiro/AFP-1311-2022
OI Saito, Masaaki/0000-0003-1494-6350; Maruko, Ichiro/0000-0001-5647-6372;
   Sekiryu, Tetsuju/0000-0001-8042-2729
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Isola V, 2006, AM J OPHTHALMOL, V142, P885, DOI 10.1016/j.ajo.2006.06.008
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Koizumi Hideki, 2008, Retin Cases Brief Rep, V2, P12, DOI 10.1097/01.iae.0000242763.95189.05
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Mukai R, 2010, OPHTHALMOLOGICA, V224, P267, DOI 10.1159/000287348
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2008, AM J OPHTHALMOL, V146, P935, DOI 10.1016/j.ajo.2008.06.033
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   Wygnanski-Jaffe T, 2006, OPHTHAL SURG LAS IM, V37, P358, DOI 10.3928/15428877-20060901-01
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 46
TC 124
Z9 134
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2011
VL 151
IS 4
BP 594
EP 603
DI 10.1016/j.ajo.2010.10.030
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 742VZ
UT WOS:000288974700007
PM 21295766
DA 2022-11-30
ER

PT J
AU Piccardi, M
   Ziccardi, L
   Stifano, G
   Montrone, L
   Iarossi, G
   Minnella, A
   Fadda, A
   Balestrazzi, E
   Falsini, B
AF Piccardi, Marco
   Ziccardi, Lucia
   Stifano, Giovanna
   Montrone, Lucrezia
   Iarossi, Giancarlo
   Minnella, Angelo
   Fadda, Antonello
   Balestrazzi, Emilio
   Falsini, Benedetto
TI Regional Cone-Mediated Dysfunction in Age-Related Maculopathy Evaluated
   by Focal Electroretinograms: Relationship with Retinal Morphology and
   Perimetric Sensitivity
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related maculopathy; Cone-mediated function; Drusen; Focal
   electroretinogram; Regional dysfunction
ID CHOROIDAL BLOOD-FLOW; MACULAR DEGENERATION; MULTIFOCAL
   ELECTRORETINOGRAM; FELLOW EYES; FUNDUS APPEARANCE; DRUSEN; ERGS;
   AMPLITUDE; SYSTEM
AB Purpose: To assess regional cone-mediated function in age-related maculopathy (ARM) by focal electroretinograms (FERGs), and to compare FERGs with morphologic changes and perimetric sensitivity at corresponding locations. Methods: Twenty-six ARM patients and 12 age-matched controls were evaluated. FERGs were elicited by either a central (0-2.25 degrees, C) or a paracentral annular (2.25-9 degrees, PC) flickering (41 Hz) field, presented on a light-adapting background. Morphological changes (soft drusen and/or retinal pigment epithelium defects) at matched locations were assessed by fundus photography and fluorescein angiography. Perimetric sensitivity was measured by Octopus 10 program (tM2). Results: When compared to controls, mean C and PC FERG amplitudes of patients were reduced (p < 0.01), and the mean PC FERG phase was delayed (p < 0.01). Both FERG delays and morphologic lesions tended to involve to a greater extent the PC compared to the C region. In the C region, perimetric losses were correlated with the extent of morphologic lesions (p < 0.05). In the PC region, perimetric losses were correlated with FERG amplitudes (p < 0.05). Conclusions: In ARM, FERG losses are eccentricity-dependent, not quantitatively linked to retinal morphology, and correlated with perimetric losses, suggesting a heterogeneous dysfunction with loss of both C and PC perimetric sensitivities. Copyright (C) 2009 S. Karger AG, Basel
C1 [Piccardi, Marco; Stifano, Giovanna; Montrone, Lucrezia; Iarossi, Giancarlo; Minnella, Angelo; Balestrazzi, Emilio; Falsini, Benedetto] Catholic Univ, Inst Ophthalmol, IT-00168 Rome, Italy.
   [Ziccardi, Lucia] IRCCS, Fdn GB Bietti Oftalmol, Rome, Italy.
   [Fadda, Antonello] Ist Super Sanita, Technol & Hlth Dept, I-00161 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; Istituto Superiore di Sanita (ISS)
RP Falsini, B (通讯作者)，Catholic Univ, Inst Ophthalmol, Lgo F Vito 1, IT-00168 Rome, Italy.
EM md0571@mclink.it
RI Falsini, Benedetto/V-1070-2019; minnella, angelo maria/AAQ-6250-2020;
   Iarossi, giancarlo/AAB-4916-2020; Falsini, Benedetto/AAC-5907-2022;
   Piccardi, Marco/AAA-7849-2019; Ziccardi, Lucia/AAQ-9066-2020; Fadda,
   Antonello/J-1560-2012
OI Falsini, Benedetto/0000-0002-1694-1062; minnella, angelo
   maria/0000-0001-5896-5313; Ziccardi, Lucia/0000-0002-5563-1243; Fadda,
   Antonello/0000-0001-7004-5245; Falsini, Benedetto/0000-0002-3569-4968;
   PICCARDI, Marco/0000-0002-9836-7534
CR ABRAHAM FA, 1985, J PHYSIOL-LONDON, V363, P135, DOI 10.1113/jphysiol.1985.sp015700
   Binns AM, 2007, INVEST OPHTH VIS SCI, V48, P2806, DOI 10.1167/iovs.06-0392
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRODIE SE, 1992, OPHTHALMOLOGY, V99, P522
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Fadda A, 1997, MED BIOL ENG COMPUT, V35, P441, DOI 10.1007/BF02534106
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   FIORENTINI A, 1981, INVEST OPHTH VIS SCI, V21, P490
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Iarossi G, 2003, INVEST OPHTH VIS SCI, V44, P866, DOI 10.1167/iovs.01-1256
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Montrone L, 2005, DOC OPHTHALMOL, V110, P103, DOI 10.1007/s10633-005-7554-3
   NAGATA M, 1971, VISION RES, V11, P1214, DOI 10.1016/0042-6989(71)90165-9
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Porciatti V, 2004, OPHTHALMOLOGY, V111, P161, DOI 10.1016/j.ophtha.2003.04.007
   Qiu AQ, 2006, NEUROIMAGE, V31, P125, DOI 10.1016/j.neuroimage.2005.11.049
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   YAMAMOTO S, 1995, VISION RES, V35, P1641, DOI 10.1016/0042-6989(94)00271-M
NR 36
TC 9
Z9 9
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2009
VL 41
IS 4
BP 194
EP 202
DI 10.1159/000217723
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 446DC
UT WOS:000266099600003
PM 19451732
DA 2022-11-30
ER

PT J
AU Ziemssen, F
   Heimann, H
AF Ziemssen, Focke
   Heimann, Heinrich
TI Evaluation of verteporfin pharmakokinetics - redefining the need of
   photosensitizers in ophthalmology
SO EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
LA English
DT Review
DE central serous chorioretinopathy; choroidal haemangioma; choroidal
   melanoma; choroidal neovascularization; low fluence; polypoidal
   choroidal vasculopathy; retinal angioma; verteporfin
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   OPTICAL COHERENCE TOMOGRAPHY; RETINAL CAPILLARY HEMANGIOMA; PIGMENT
   EPITHELIAL DETACHMENT; FLUENCE PHOTODYNAMIC THERAPY; HALF-DOSE
   VERTEPORFIN; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB;
   VASOPROLIFERATIVE TUMORS
AB Introduction: The benzoporphyrine derivative verteporfin has lost its importance to the treatment of the most frequent neovascular eye diseases. Nevertheless, it is still mandatory to define the remaining applications, role, and potential of verteporfin in ocular photodynamic therapy (PDT), including the dosages of administration, effectiveness, and safety profile.
   Areas covered: Although verteporfin PDT has forfeited the first-line status and value of treating subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration or pathologic myopia, the treatment remains the standard of care for choroidal haemangioma and polypoidal choroidal vasculopathy. PDT is effective in less pigmented choroidal melanoma as well as in retinal vascular proliferations and retinal angioma. Verteporfin was granted the orphan drug designation for the treatment of chronic or recurrent central serous chorioretinopathy (CSC).
   Expert opinion: Evidence-based data regarding optimized parameters (low fluence, reduced dose, fractionated irradiation) adapted to the treated diseases (target structure, dosimetry, blood supply) are scarce. Prospective and large clinical trials are missing, although the scientific community agrees on the fact that the standard treatment protocol does not necessarily provide the optimal efficacy to the specific disease or individual patient. Within the reviewed indications, the adverse effect profile is favorable compared with other therapies.
C1 [Ziemssen, Focke] Univ Tubingen, Ctr Ophthalmol, D-72076 Tubingen, Germany.
   [Heimann, Heinrich] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Royal Liverpool & Broadgreen University Hospitals NHS Trust;
   Royal Liverpool University Hospital; University of Liverpool
RP Ziemssen, F (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Schleichstr 12, D-72076 Tubingen, Germany.
EM focke.ziemssen@med.uni-tuebingen.de
RI , Ziemssen/B-9564-2009; Heimann, Heinrich/AAP-8747-2020; Ziemssen,
   Focke/AAY-1686-2021
OI , Ziemssen/0000-0002-3873-0581; Heimann, Heinrich/0000-0002-3298-4644; 
CR Ach T, 2010, ACTA OPHTHALMOL, V88, pe137, DOI 10.1111/j.1755-3768.2009.01594.x
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   ALLISON BA, 1990, PHOTOCHEM PHOTOBIOL, V52, P501, DOI 10.1111/j.1751-1097.1990.tb01792.x
   Allison RR, 2004, PHOTODIAGN PHOTODYN, V1, P27, DOI 10.1016/S1572-1000(04)00007-9
   Ansari-Shahrezaei S, 2007, GRAEF ARCH CLIN EXP, V245, P333, DOI 10.1007/s00417-006-0419-y
   Ansari-Shahrezaei S, 2011, GRAEF ARCH CLIN EXP, V249, P11, DOI 10.1007/s00417-010-1460-4
   Aquaron R, 2002, CELL MOL BIOL, V48, P925
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Atebara NH, 2002, AM J OPHTHALMOL, V134, P788, DOI 10.1016/S0002-9394(02)01648-3
   Ayaru L, 2007, PANCREATOLOGY, V7, P20, DOI 10.1159/000101874
   Baba T, 2011, CASE REP OPHTHALM, V2, P134, DOI 10.1159/000328384
   Bae SH, 2011, AM J OPHTHALMOL, V152, P784, DOI 10.1016/j.ajo.2011.04.008
   Bakri SJ, 2004, EXPERT OPIN PHARMACO, V5, P195, DOI 10.1517/14656566.5.1.195
   Bandello F, 2001, J FR OPHTALMOL, V24, P448
   Barbazetto I, 2000, GRAEF ARCH CLIN EXP, V238, P214, DOI 10.1007/s004170050346
   Barbazetto IA, 2003, AM J OPHTHALMOL, V135, P898, DOI 10.1016/S0002-9394(02)02222-5
   Barbezetto IA, 2003, RETINA-J RET VIT DIS, V23, P565, DOI 10.1097/00006982-200308000-00026
   Barnes LD, 2010, VET OPHTHALMOL, V13, P158, DOI 10.1111/j.1463-5224.2010.00775.x
   Berdugo M, 2008, INVEST OPHTH VIS SCI, V49, P1633, DOI 10.1167/iovs.07-0767
   Blasi MA, 2006, RETINA-J RET VIT DIS, V26, P404, DOI 10.1097/00006982-200604000-00004
   Blasi MA, 2010, OPHTHALMOLOGY, V117, P1630, DOI 10.1016/j.ophtha.2009.12.033
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blom DJR, 1997, CANCER LETT, V112, P239, DOI 10.1016/S0304-3835(96)04578-8
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boixadera A, 2009, OPHTHALMOLOGY, V116, P100, DOI 10.1016/j.ophtha.2008.08.029
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brancaleon L, 2002, LASER MED SCI, V17, P173, DOI 10.1007/s101030200027
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bullous AJ, 2011, PHOTOCH PHOTOBIO SCI, V10, P721, DOI 10.1039/c0pp00266f
   Busch TM, 2010, RADIAT RES, V174, P331, DOI 10.1667/RR2075.1
   Campbell WG, 2011, RETINA
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chan RPS, 2010, ACTA OPHTHALMOL, V88, P711, DOI 10.1111/j.1755-3768.2008.01447.x
   Chan WM, 2010, GRAEF ARCH CLIN EXP, V248, P613, DOI 10.1007/s00417-010-1307-z
   Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P85, DOI 10.1097/IAE.0b013e318156777f
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Chen B, 2005, INT J RADIAT ONCOL, V61, P1216, DOI 10.1016/j.ijrobp.2004.08.006
   Cheung J, 2012, CASE REP OPHTHALM, V3, P1, DOI 10.1159/000335954
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chowdhary RK, 2003, J PHARM PHARM SCI, V6, P13
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Ciulla TA, 2005, BRIT J OPHTHALMOL, V89, P113, DOI 10.1136/bjo.2004.043075
   Criswell MH, 2005, INVEST OPHTH VIS SCI, V46, P2168, DOI 10.1167/iovs.04-1442
   Damato B, 2011, PROG RETIN EYE RES, V30, P285, DOI 10.1016/j.preteyeres.2011.05.003
   Damato BE, 2012, DEV OPHTHALMOL, V49, P16, DOI 10.1159/000328251
   Debefve E, 2010, J PHOTOCH PHOTOBIO B, V98, P69, DOI 10.1016/j.jphotobiol.2009.11.006
   Debefve E, 2011, LASER SURG MED, V43, P696, DOI 10.1002/lsm.21115
   Detty MR, 2004, J MED CHEM, V47, P3897, DOI 10.1021/jm040074b
   Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Elizalde J, 2012, CAN J OPHTHALMOL, V47, P16, DOI 10.1016/j.jcjo.2011.12.008
   FAVILLA I, 1995, MELANOMA RES, V5, P355, DOI 10.1097/00008390-199510000-00009
   Fingar VH, 1999, BRIT J CANCER, V79, P1702, DOI 10.1038/sj.bjc.6690271
   Firczuk M, 2011, PHOTOCH PHOTOBIO SCI, V10, P653, DOI 10.1039/c0pp00308e
   Fong AHC, 2011, GRAEF ARCH CLIN EXP, V249, P625, DOI 10.1007/s00417-010-1453-3
   Framme C, 2006, GRAEF ARCH CLIN EXP, V244, P773, DOI 10.1007/s00417-005-0221-2
   Fujita K, 2011, RETINA-J RET VIT DIS, V31, P772, DOI 10.1097/IAE.0b013e3181f049d3
   Gambrelle J, 2010, J FR OPHTALMOL, V33, P497, DOI 10.1016/j.jfo.2010.06.002
   Garcia-Arumi J, 2012, RETINA-J RET VIT DIS, V32, P936, DOI 10.1097/IAE.0b013e318232c366
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Gharbiya M, 2010, AM J OPHTHALMOL, V149, P458, DOI 10.1016/j.ajo.2009.10.010
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gupta M, 2004, EYE, V18, P139, DOI 10.1038/sj.eye.6700597
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   Harding Simon P, 2009, Ophthalmology, V116, pe1, DOI 10.1016/j.ophtha.2009.10.022
   He C, 2008, PHARM RES-DORDR, V25, P1873, DOI 10.1007/s11095-008-9604-5
   Heimann H, 2000, BRIT J OPHTHALMOL, V84, P1162, DOI 10.1136/bjo.84.10.1162
   Henderson BW, 2006, LASER SURG MED, V38, P489, DOI 10.1002/lsm.20327
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   Imasawa M, 2011, JPN J OPHTHALMOL, V55, P241, DOI 10.1007/s10384-011-0006-6
   Inoue R, 2010, AM J OPHTHALMOL, V149, P441, DOI 10.1016/j.ajo.2009.10.011
   Irigoyen C, 2012, GRAEF ARCH CLIN EXP, V250, P499, DOI 10.1007/s00417-011-1851-1
   Ishikawa K, 2011, GRAEF ARCH CLIN EXP, V249, P273, DOI 10.1007/s00417-010-1548-x
   Jalil A, 2009, EUR J OPHTHALMOL, V19, P490, DOI 10.1177/112067210901900330
   JAMIESON CHM, 1990, LEUKEMIA RES, V14, P209, DOI 10.1016/0145-2126(90)90128-V
   Jarvi MT, 2012, BIOPHYS J, V102, P661, DOI 10.1016/j.bpj.2011.12.043
   Jurklies B, 2003, BRIT J OPHTHALMOL, V87, P84, DOI 10.1136/bjo.87.1.84
   Jyothi S, 2010, EYE, V24, P1018, DOI 10.1038/eye.2009.266
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Karsten AE, 2012, LASER MED SCI, V27, P79, DOI 10.1007/s10103-011-0926-x
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Khanum Farhath, 1997, Indian Journal of Experimental Biology, V35, P348
   Kim RY, 1996, OPHTHALMOLOGY, V103, P2029, DOI 10.1016/S0161-6420(96)30391-6
   Kim SW, 2009, OPHTHAL SURG LAS IM, V40, P300, DOI 10.3928/15428877-20090430-14
   Koh A, 2012, RETINA
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Krammer B, 2001, ANTICANCER RES, V21, P4271
   Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282
   Landau IME, 2002, ACTA OPHTHALMOL SCAN, V80, P531, DOI 10.1034/j.1600-0420.2002.800513.x
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee PY, 2009, JPN J OPHTHALMOL, V53, P52, DOI 10.1007/s10384-008-0613-z
   LEWIS RA, 1984, ARCH OPHTHALMOL-CHIC, V102, P839
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Lu F, 2009, INVEST OPHTH VIS SCI, V50, P3890, DOI 10.1167/iovs.08-2833
   Maar N, 2009, ACTA OPHTHALMOL, V87, P631, DOI 10.1111/j.1755-3768.2008.01311.x
   Machida S, 2011, DOC OPHTHALMOL, V124, P91
   Madreperla SA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1606
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Matsubara A, 2007, INVEST OPHTH VIS SCI, V48, P4741, DOI 10.1167/iovs.06-1534
   Matsubara A, 2006, INVEST OPHTH VIS SCI, V47, P2498, DOI 10.1167/iovs.05-0959
   Mayo GL, 2003, AM J OPHTHALMOL, V136, P1151, DOI 10.1016/S0002-9394(03)00675-5
   Mennel S, 2007, OPHTHALMOLOGICA, V221, P282, DOI 10.1159/000104757
   Mennel S, 2010, ACTA OPHTHALMOL, V88, P610, DOI 10.1111/j.1755-3768.2008.01449.x
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Michels S, 2005, RETINA-J RET VIT DIS, V25, P697, DOI 10.1097/00006982-200509000-00003
   Middelburg TA, 2010, PHOTOCHEM PHOTOBIOL, V86, P1140, DOI 10.1111/j.1751-1097.2010.00760.x
   Miller Joan W, 2008, Trans Am Ophthalmol Soc, V106, P357
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Moon JW, 2010, CURR EYE RES, V35, P314, DOI 10.3109/02713680903548962
   Moon JW, 2009, GRAEF ARCH CLIN EXP, V247, P1315, DOI 10.1007/s00417-009-1104-8
   Moreau-Gaudry VV, 2010, EYE, V24, P706, DOI 10.1038/eye.2009.130
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Moshfeghi DM, 1998, OPHTHALMIC SURG LAS, V29, P663
   Mozaffarieh M, 2009, MOL VIS, V15, P1194
   Naghavi N, 2011, AUSTRALAS PHYS ENG S, V34, P203, DOI 10.1007/s13246-011-0064-6
   Obana A, 2001, INVEST OPHTH VIS SCI, V42, P2639
   Ober MD, 2005, OPHTHALMOLOGY, V112, P2088, DOI 10.1016/j.ophtha.2005.06.026
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Oner A, 2005, DOC OPHTHALMOL, V111, P83, DOI 10.1007/s10633-005-4410-4
   Osman SA, 2007, CLIN EXP OPHTHALMOL, V35, P191, DOI 10.1111/j.1442-9071.2007.01440.x
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Ozmert E, 2009, OPHTHALMOLOGICA, V223, P263, DOI 10.1159/000210386
   Petermeier K, 2006, BRIT J OPHTHALMOL, V90, P1034, DOI 10.1136/bjo.2006.090852
   Pilotto E, 2011, EUR J OPHTHALMOL, V21, P452, DOI 10.5301/EJO.2011.6263
   Polo L, 2002, INT J BIOCHEM CELL B, V34, P10, DOI 10.1016/S1357-2725(01)00092-9
   Porrini G, 2003, OPHTHALMOLOGY, V110, P674, DOI 10.1016/S0161-6420(02)01968-1
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Pryds A, 2011, ACTA OPHTHALMOL
   Reibaldi M, 2011, AM J OPHTHALMOL, V151, P953, DOI 10.1016/j.ajo.2010.12.007
   Reibaldi M, 2010, AM J OPHTHALMOL, V149, P307, DOI 10.1016/j.ajo.2009.08.026
   Rennie IG, 2010, EYE, V24, P468, DOI 10.1038/eye.2009.305
   Renno RZ, 2000, INVEST OPHTH VIS SCI, V41, P3963
   Richter A M, 1996, J Clin Laser Med Surg, V14, P335
   RICHTER AM, 1990, J PHOTOCH PHOTOBIO B, V5, P231, DOI 10.1016/1011-1344(90)80008-L
   RICHTER AM, 1991, BRIT J CANCER, V63, P87, DOI 10.1038/bjc.1991.18
   RICHTER AM, 1990, PHOTOCHEM PHOTOBIOL, V52, P495, DOI 10.1111/j.1751-1097.1990.tb01791.x
   RICHTER AM, 1987, J NATL CANCER I, V79, P1327
   RICHTER AM, 1993, PHOTOCHEM PHOTOBIOL, V57, P1000, DOI 10.1111/j.1751-1097.1993.tb02962.x
   Rodrigues M, 2009, AUST NZ J OBSTET GYN, V49, P236, DOI 10.1111/j.1479-828X.2009.00951.x
   Rodriguez-Coleman H, 2002, RETINA-J RET VIT DIS, V22, P228, DOI 10.1097/00006982-200204000-00019
   Ross A, 2011, CURR OPIN OPHTHALMOL, V22, P166, DOI 10.1097/ICU.0b013e3283459826
   Rousset N, 2000, RES EXP MED, V199, P341, DOI 10.1007/s004339900044
   Rudnisky CJ, 2010, RETINA-J RET VIT DIS, V30, P548, DOI 10.1097/IAE.0b013e3181bcf1b8
   Sachdeva R, 2010, ACTA OPHTHALMOL, V88, pe334, DOI 10.1111/j.1755-3768.2010.02008.x
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saldanha MJ, 2008, OPHTHAL SURG LAS IM, V39, P143, DOI 10.3928/15428877-20080301-13
   Samkoe KS, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2750663
   Sandell JL, 2011, J BIOPHOTONICS, V4, P773, DOI 10.1002/jbio.201100062
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P1256, DOI 10.1016/S0161-6420(02)01059-X
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Schmitt F, 2012, ANTI-CANCER AGENT ME, V12, P500, DOI 10.2174/187152012800617830
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Senturk F, 2011, AM J OPHTHALMOL, V151, P303, DOI 10.1016/j.ajo.2010.08.019
   SERY TW, 1987, OPHTHALMIC SURG LAS, V18, P413
   Sharma KV, 2011, CELL BIOL INT, V35, P939, DOI 10.1042/CBI20110103
   SHIELDS CL, 1995, ARCH OPHTHALMOL-CHIC, V113, P615, DOI 10.1001/archopht.1995.01100050083035
   Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040
   Soucek P, 2004, NEUROENDOCRINOL LETT, V25, P109
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tarantola RM, 2008, LASER SURG MED, V40, P671, DOI 10.1002/lsm.20720
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsipursky MS, 2011, SURV OPHTHALMOL, V56, P68, DOI 10.1016/j.survophthal.2010.08.002
   Tsuchihashi T, 2009, RETINA-J RET VIT DIS, V29, P1450, DOI 10.1097/IAE.0b013e3181ac2403
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Turkcuoglu P, 2011, INDIAN J OPHTHALMOL, V59, P5, DOI 10.4103/0301-4738.73705
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Verbraak FD, 2006, GRAEF ARCH CLIN EXP, V244, P1178, DOI 10.1007/s00417-005-0152-y
   VIP Report No 5 Writing Comm, 2004, OPHTHALMOLOGY, V111, P2144
   von Buelow M, 2007, ACTA OPHTHALMOL SCAN, V85, P114, DOI 10.1111/j.1600-0420.2006.00825.x
   von Tappeiner H, 1903, MED WOCHENSCHR, V47, P2042
   Wachtlin J, 2005, OPHTHALMOLOGE, V102, P241, DOI 10.1007/s00347-004-1092-3
   Wachtlin J, 2009, KLIN MONATSBL AUGENH, V226, P933, DOI 10.1055/s-0028-1109635
   Wang KKH, 2007, MED PHYS, V34, P282, DOI 10.1118/1.2401041
   Wang KKH, 2010, J BIOPHOTONICS, V3, P304, DOI 10.1002/jbio.200900101
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Wilson BC, 2008, PHYS MED BIOL, V53, pR61, DOI 10.1088/0031-9155/53/9/R01
   Wong WT, 2008, CURR OPIN OPHTHALMOL, V19, P213, DOI 10.1097/ICU.0b013e3282fb7c04
   Wong YM, 2010, CAN J OPHTHALMOL, V45, P299, DOI 10.3129/i09-258
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Yannuzzi LA, 2010, AM J OPHTHALMOL, V149, P361, DOI 10.1016/j.ajo.2009.11.017
   You IC, 2011, CORNEA, V30, P30, DOI 10.1097/ICO.0b013e3181dc81a0
   Young LHY, 1996, ARCH OPHTHALMOL-CHIC, V114, P186, DOI 10.1001/archopht.1996.01100130180013
   Zhao MW, 2009, RETINA-J RET VIT DIS, V29, P1155, DOI 10.1097/IAE.0b013e3181a6c028
   Ziemssen F, 2007, EYE, V21, P1125, DOI 10.1038/sj.eye.6702896
NR 199
TC 25
Z9 25
U1 0
U2 29
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5255
EI 1744-7607
J9 EXPERT OPIN DRUG MET
JI Expert Opin. Drug Metab. Toxicol.
PD AUG
PY 2012
VL 8
IS 8
BP 1023
EP 1041
DI 10.1517/17425255.2012.701617
PG 19
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA 975PT
UT WOS:000306524000009
PM 22762303
DA 2022-11-30
ER

PT J
AU Kunavisarut, P
   Thithuan, T
   Patikulsila, D
   Choovuthayakorn, J
   Watanachai, N
   Chaikitmongkol, V
   Pathanapitoon, K
   Rothova, A
AF Kunavisarut, Paradee
   Thithuan, Tipparut
   Patikulsila, Direk
   Choovuthayakorn, Janejit
   Watanachai, Nawat
   Chaikitmongkol, Voraporn
   Pathanapitoon, Kessara
   Rothova, Aniki
TI Submacular Hemorrhage: Visual Outcomes and Prognostic Factors
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE submacular hemorrhage; polypoidal choriodal vasculopathy; neovascular
   age-related macular degeneration; indocyanine green angiography; visual
   outcomes
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INDOCYANINE-GREEN ANGIOGRAPHY;
   TISSUE-PLASMINOGEN ACTIVATOR; MACULAR DEGENERATION; SUBRETINAL
   HEMORRHAGE; PHOTODYNAMIC THERAPY; NATURAL-HISTORY; PNEUMATIC
   DISPLACEMENT; VITREOUS HEMORRHAGE; RETINAL HEMORRHAGE
AB Purpose: To describe causes, visual outcomes, and prognostic factors in patients with submacular hemorrhage (SMH).
   Design: Retrospective case review.
   Methods: We performed a retrospective review of SMH with a size of at least 1 disc diameter. SMH causes were classified into 3 groups: 1) neovascular age-related macular degeneration (nAMD), 2) polypoidal choroidal vasculopathy (PCV), and 3) other miscellaneous causes.
   Results: Ninety-eight eyes of 98 patients were included. Based on clinical presentation and indocyanine green angiography (ICGA), the diagnoses of PCV (59%), nAMD (31%), and miscellaneous other causes (10%) were made. PCV patients were younger (P = 0.005) and had larger SMH size than nAMD patients (P = 0.008). Poor visual outcome [>1.0 logarithm of the minimum angle of resolution (logMAR)] at 6 months was associated with low initial visual acuity (VA; >1.0 logMAR; P = 0.002) and with the diagnosis of nAMD (P = 0.02). In addition, limited visual outcomes were noted for patients older than 65 years and those with persistent SMH for at least 2 months.
   Conclusions: PCV was the most common cause of SMH in Thailand. ICGA represented a valuable tool for the diagnosis. Visual outcomes were limited for patients with nAMD and for patients who presented with poor initial VA.
C1 [Kunavisarut, Paradee; Thithuan, Tipparut; Patikulsila, Direk; Choovuthayakorn, Janejit; Watanachai, Nawat; Chaikitmongkol, Voraporn; Pathanapitoon, Kessara] Chiang Mai Univ, Fac Med, Dept Ophthalmol, 110 Intawaroros Rd, Chiang Mai 50200, Thailand.
   [Rothova, Aniki] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
C3 Chiang Mai University; Erasmus University Rotterdam; Erasmus MC
RP Kunavisarut, P (通讯作者)，Chiang Mai Univ, Fac Med, Dept Ophthalmol, 110 Intawaroros Rd, Chiang Mai 50200, Thailand.
EM pkunavisarut@hotmail.com
RI Watanachai, Nawat/AAR-9240-2020; pathanapitoon, kessara/M-9711-2018
OI pathanapitoon, kessara/0000-0003-4447-1704; Chaikitmongkol,
   Voraporn/0000-0003-0426-7602; kunavisarut, paradee/0000-0003-4997-6285;
   watanachai, nawat/0000-0003-3097-8694; Choovuthayakorn,
   Janejit/0000-0001-5972-0270
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRINTON GS, 1982, AM J OPHTHALMOL, V93, P271, DOI 10.1016/0002-9394(82)90524-4
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Cohen SY, 2011, RETINA-J RET VIT DIS, V31, P209, DOI 10.1097/IAE.0b013e31820a69db
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   DUGAN JD, 1993, AM J OPHTHALMOL, V115, P677, DOI 10.1016/S0002-9394(14)71475-8
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   HAYASAKA S, 1990, GRAEF ARCH CLIN EXP, V228, P277, DOI 10.1007/BF00920048
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   HOTCHKISS ML, 1981, AM J OPHTHALMOL, V91, P177, DOI 10.1016/0002-9394(81)90170-7
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kim H, 2015, OPHTHALMOLOGICA, V233, P146, DOI 10.1159/000380830
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   Lin TC, 2016, J CHIN MED ASSOC, V79, P159, DOI 10.1016/j.jcma.2015.11.004
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Oh IK, 2009, OPHTHALMOLOGICA, V223, P78, DOI 10.1159/000173715
   Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x
   Panzardi G, 1992, Eur J Ophthalmol, V2, P83
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   RABB MF, 1988, SURV OPHTHALMOL, V33, P73, DOI 10.1016/0039-6257(88)90160-9
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   Rishi E, 2012, INDIAN J OPHTHALMOL, V60, P521, DOI 10.4103/0301-4738.103779
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   Woo J. John, 2004, International Ophthalmology Clinics, V44, P43, DOI 10.1097/00004397-200404410-00006
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 48
TC 7
Z9 7
U1 0
U2 0
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAR-APR
PY 2018
VL 7
IS 2
BP 109
EP 113
DI 10.22608/APO.2017389
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VF
UT WOS:000453996800009
PM 29063740
OA gold
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Hunyor, AP
   Arnold, JJ
   Guymer, RH
   Wolf, S
   Ng, P
   Pecheur, FL
   McAllister, IL
AF Gillies, Mark C.
   Hunyor, Alex P.
   Arnold, Jennifer J.
   Guymer, Robyn H.
   Wolf, Sebastian
   Ng, Paul
   Pecheur, Francois L.
   McAllister, Ian L.
TI Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in
   Treat-and-Extend for Neovascular Age-Related Macular Degeneration A
   Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL THERAPY; GEOGRAPHIC ATROPHY; 2-YEAR OUTCOMES; BEVACIZUMAB;
   REGIMEN
AB IMPORTANCE To our knowledge, this is the first randomized clinical trial to compare visual outcomes and injection loads between ranibizumab and aflibercept using an identical treat-and-extend (TE) regimen for neovascular age-related macular degeneration (nAMD).
   OBJECTIVE To report the results of the preplanned 12-month interim analysis of 2 predefined secondary efficacy end points of a randomized clinical trial.
   DESIGN, SETTING, AND PARTICIPANTS The Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL) trial was conducted in 24 sites in Australia and included 281 treatment-naive eyes from 281 participants with active choroidal neovascularization secondary to nAMD and a visual acuity letter score of 23 or greater who were recruited between April 11, 2014, and October 31, 2015. A preplanned interim analysis was performed at month 12. Best-corrected visual acuity (BCVA) assessors and the central reading center, which determined treatment intervals, were masked to treatment assignments.
   INTERVENTIONS Participants were randomized (1: 1) to receive intravitreal injections of 0.5mg of ranibizumab or 2.0mg of aflibercept. After receiving 3 initial monthly injections, participants entered the TE phase.
   MAIN OUTCOMES AND MEASURES Mean change in BCVA and the number of injections from baseline to month 12.
   RESULTS Of 281 participants, 148 (52.7%) were women and the mean (SD) age was 77.7 (8.1) years. The baseline mean BCVA letter score (approximate Snellen equivalent) was 65.3 (20/50) in the ranibizumab arm and 65.1 (20/50) in the aflibercept arm. One hundred twenty-seven ranibizumab participants (90.1%) and 121 aflibercept participants (88.3%) completed month 12 with a mean (SD [Snellen equivalent]) BCVA letter score of 72.9 (15.5 [20/32]) and 70.5 (14.6 [20/40]), respectively. The mean change in BCVA letter scores from baseline to month 12 was 7.2 (95% CI, 5.5-8.9) for ranibizumab and 4.9 (95% CI, 3.1-6.6) for aflibercept (letter score difference, 2.3; 95% CI, -0.1 to 4.7; P=.06). The mean number of injections from baseline to month 12 was 9.7 in both the ranibizumab (SD, 2.8) and aflibercept (SD, 2.6) arms with a rate ratio of 1.00 (95% CI, 1.0-1.1; P=.86).
   CONCLUSIONS AND RELEVANCE Our findings suggest that neither aflibercept nor ranibizumab for nAMD are superior to the other regarding the average visual acuity gains and number of injections during 1 year in a TE regimen. Further follow-up to 2 years may determine if advantages of one over the other can be identified.
C1 [Gillies, Mark C.; Hunyor, Alex P.] Univ Sydney, Save Sight Inst, Sydney Eye Hosp, Macular Res Grp, Sydney, NSW, Australia.
   [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp & Ophthalmol, Dept Surg, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Wolf, Sebastian] Univ Bern, Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Ng, Paul] Outlook Eye Specialists, Southport, Qld, Australia.
   [Pecheur, Francois L.] Healthcare Profess Grp Pty Ltd, Sydney, NSW, Australia.
   [McAllister, Ian L.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
C3 University of Sydney; Centre for Eye Research Australia; University of
   Melbourne; University of Bern; University Hospital of Bern; Lions Eye
   Institute; University of Western Australia
RP Gillies, MC (通讯作者)，Sydney Hosp, South Block,8 Macquarie St, Sydney, NSW 2001, Australia.
EM mark.gillies@sydney.edu.au
RI Wolf, Sebastian/B-8782-2008; Hunyor, Alex/AAT-8205-2021
OI Wolf, Sebastian/0000-0002-7467-7028; Hunyor, Alex/0000-0002-8182-6167
FU Novartis Pharmaceuticals Australia Pty Ltd.
FX This study was funded and sponsored by Novartis Pharmaceuticals
   Australia Pty Ltd.
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heraghty J, 2012, AM J PUBLIC HEALTH, V102, P1655, DOI 10.2105/AJPH.2012.300657
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   US Food and Drug Administration. Food and Drug Administration, HIGHL PRESCR INF LUC
   US Food and Drug Administration. S. Food and Drug Administration, HIGHL PRESCR INF EYL
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 22
TC 73
Z9 73
U1 1
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2019
VL 137
IS 4
BP 372
EP 379
DI 10.1001/jamaophthalmol.2018.6776
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HS9FO
UT WOS:000464173400012
PM 30676617
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hsu, MY
   Hung, YC
   Hwang, DK
   Lin, SC
   Lin, KH
   Wang, CY
   Choi, HY
   Wang, YP
   Cheng, CM
AF Hsu, Min-Yen
   Hung, Yu-Chien
   Hwang, De-Kuang
   Lin, Shang-Chi
   Lin, Keng-Hung
   Wang, Chun-Yuan
   Choi, Hin-Yeung
   Wang, Yu-Ping
   Cheng, Chao-Min
TI Detection of aqueous VEGF concentrations before and after intravitreal
   injection of anti-VEGF antibody using low-volume sampling paper-based
   ELISA
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   IMMUNOASSAY ANALYSIS; HUMOR LEVELS; RANIBIZUMAB; BEVACIZUMAB; THERAPY;
   AFLIBERCEPT; PHARMACOKINETICS
AB Intraocular vascular endothelial growth factor (VEGF) levels play an important role in the pathogenesis of blindness-related diseases, such as age-related macular degeneration (AMD). Here, we aimed to develop a paper-based enzyme-linked immunosorbent assay (P-ELISA) to analyze the suppression of aqueous VEGF concentrations following intravitreal injection (IVI) of anti-VEGF antibody (bevacizumab or ranibizumab). A total of 25 eyes with wet AMD, one with myopic neovascularization, and one with polypoidal choroidal vasculopathy were enrolled in this study. The limit of detection using P-ELISA was 0.03 pg/mL. Forty-six consecutive samples of aqueous humor were acquired. From all samples, 66.67% (10/15) achieved complete VEGF suppression (below the detection limit) within 5 weeks of receiving IVI of anti-VEGF antibody. Only 13.33% of samples (2/15) achieved complete VEGF suppression 5 weeks after receiving treatment. In some patients, elevated VEGF was still detected 5 weeks after receipt of anti-VEGF antibody, and all samples (10/10) were found to have elevated VEGF levels 49 days after treatment. Thus, we suggest that monthly IVI of anti-VEGF antibody may be required to ensure durable VEGF inhibition. Ultrasensitive P-ELISA can detect elevated VEGF at an earlier time point and may facilitate decision-making regarding appropriate treatment strategies.
C1 [Hsu, Min-Yen; Hung, Yu-Chien; Hwang, De-Kuang; Lin, Keng-Hung; Wang, Chun-Yuan] Taichung Vet Gen Hosp, Dept Ophthalmol, Taichung 407, Taiwan.
   [Hsu, Min-Yen; Lin, Shang-Chi] Natl Tsing Hua Univ, Inst Nanoengn & Microsyst, Hsinchu 300, Taiwan.
   [Hsu, Min-Yen] Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan.
   [Hsu, Min-Yen] Taichung Vet Gen Hosp, Dept Med Res, Ctr Translat Med, Taichung 407, Taiwan.
   [Hwang, De-Kuang] Natl Yang Ming Univ, Sch Med, Dept Ophthalmol, Taipei, Taiwan.
   [Choi, Hin-Yeung] Taichung Tzu Chi Hosp, Dept Ophthalmol, Taichung 40, Taiwan.
   [Wang, Yu-Ping] Taichung Vet Gen Hosp, Dept Radiol, Taichung 407, Taiwan.
   [Cheng, Chao-Min] Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu 300, Taiwan.
C3 Taichung Veterans General Hospital; National Tsing Hua University;
   National Chung Hsing University; Taichung Veterans General Hospital;
   National Yang Ming Chiao Tung University; Buddhist Tzu Chi General
   Hospital; Taichung Tzu Chi Hospital; Taichung Veterans General Hospital;
   National Tsing Hua University
RP Cheng, CM (通讯作者)，Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu 300, Taiwan.
EM chaomin@mx.nthu.edu.tw
RI Hwang, DK De-Kuang/J-3931-2016; Hsu, MinYen/AAT-2200-2021
OI Hwang, DK De-Kuang/0000-0001-6346-8485; 
FU Taiwan's National Science Council [MOST 104-2628-E-007-001-MY3];
   Taichung Veterans General Hospital (TCVGH) [1056904C]
FX We would like to thank Taiwan's National Science Council (MOST
   104-2628-E-007-001-MY3, to C.-M. Cheng) and Taichung Veterans General
   Hospital (TCVGH -1056904C, to M.-Y. Hsu) for financially supporting this
   research.
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Campochiaro PA, 2009, OPHTHALMOLOGY, V116, P2158, DOI 10.1016/j.ophtha.2009.04.038
   Cheng CM, 2010, ANGEW CHEM INT EDIT, V49, P4771, DOI 10.1002/anie.201001005
   Curnow SJ, 2005, INVEST OPHTH VIS SCI, V46, P4251, DOI 10.1167/iovs.05-0444
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hou X, 2010, P NATL ACAD SCI USA, V107, P12216, DOI 10.1073/pnas.1004143107
   Hsu CK, 2014, ANAL CHEM, V86, P4605, DOI 10.1021/ac500835k
   Hsu MY, 2015, LAB CHIP, V15, P2357, DOI 10.1039/c4lc01052c
   Hsu MY, 2014, BIOMATERIALS, V35, P3729, DOI 10.1016/j.biomaterials.2014.01.030
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Rajappa M, 2010, ADV CLIN CHEM, V50, P103, DOI 10.1016/S0065-2423(10)50006-4
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Sharma RK, 2009, MOL VIS, V15, P60
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Wang HK, 2014, ADV HEALTHC MATER, V3, P187, DOI 10.1002/adhm.201300150
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Yamada K, 2014, ANALYST, V139, P1637, DOI 10.1039/c3an01926h
NR 34
TC 27
Z9 29
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 11
PY 2016
VL 6
AR 34631
DI 10.1038/srep34631
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DY6MK
UT WOS:000385241200001
PM 27725716
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Oshima, Y
   Ohji, M
   Tano, Y
AF Oshima, Y.
   Ohji, M.
   Tano, Y.
TI Pars plana vitrectomy with peripheral retinotomy after injection of
   preoperative intravitreal tissue plasminogen activator: a modified
   procedure to drain massive subretinal haemorrhage
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; SUBMACULAR HEMORRHAGE; MACULAR
   DEGENERATION; PNEUMATIC DISPLACEMENT; SURGICAL REMOVAL; MANAGEMENT; GAS
AB Aims: To report outcome of a modified procedure for draining massive subretinal haemorrhages (SRHs).
   Methods: The charts of eight consecutive eyes from eight patients with massive SRHs extending to the periphery and involving two or more quadrants with haemorrhagic and bullous retinal detachment were reviewed. Tissue plasminogen activator (tPA) was injected intravitreally 12-24 h preoperatively; vitrectomy was carried out with peripheral retinotomy, drainage of the SRH from the retinotomy using perfluorocarbon liquid and gas tamponade with prone positioning postoperatively.
   Results: The preoperative visual acuities ranged from light perception to 20/200. Most of the subretinal haematomas moved postoperatively to the vitreous cavity through the peripheral retinotomy using perfluorocarbon liquid. Residual SRHs were drained from the anterior chamber at the bedside after prone positioning overnight. SRH recurred in one eye 14 months postoperatively and was successfully retreated. No other serious complications developed. The final visual acuity improved in seven eyes (range 20/1000-20/60). Polypoidal lesions in choroidal vasculatures were present in three of seven patients.
   Conclusions: The technique seems safe and effective for treating massive SRH. However, visual recovery is limited by the underlying macular pathology. Polypoidal choroidal vasculopathy, other than age-related macular degeneration, may be another cause of massive SRHs.
C1 Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Oshima, Y (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, 2-2 Yamadaoka,Rm E7, Suita, Osaka 5650871, Japan.
EM oshima@ophthal.med.osaka-u.ac.jp
CR AVERY RL, 1996, RETINA, V163, P183
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Boone DE, 1996, RETINA-J RET VIT DIS, V16, P518, DOI 10.1097/00006982-199616060-00009
   COLL GE, 1995, RETINA-J RET VIT DIS, V15, P319, DOI 10.1097/00006982-199515040-00009
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heriot W, 1996, AM AC OPHTH ANN VITR
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hesse L, 2000, RETINA-J RET VIT DIS, V20, P500, DOI 10.1097/00006982-200009000-00011
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   KIMURA AE, 1994, RETINA-J RET VIT DIS, V14, P83, DOI 10.1097/00006982-199401000-00018
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Lincoff H, 2003, ARCH OPHTHALMOL-CHIC, V121, P91
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Matsuo T, 2001, ACTA OPHTHALMOL SCAN, V79, P533, DOI 10.1034/j.1600-0420.2001.790522.x
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Schmidt JC, 2004, OPHTHALMOLOGE, V101, P584, DOI 10.1007/s00347-003-0912-1
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 25
Z9 30
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2007
VL 91
IS 2
BP 193
EP 198
DI 10.1136/bjo.2006.101444
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 128UL
UT WOS:000243684200021
PM 16916872
OA Green Published
DA 2022-11-30
ER

PT J
AU Muakkassa, NW
   Chin, AT
   De Carlo, T
   Klein, KA
   Baumal, CR
   Witkin, AJ
   Duker, JS
   Waheed, NK
AF Muakkassa, Nora W.
   Chin, Adam T.
   De Carlo, Talisa
   Klein, Kendra A.
   Baumal, Caroline R.
   Witkin, Andre J.
   Duker, Jay S.
   Waheed, Nadia K.
TI CHARACTERIZING THE EFFECT OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
   THERAPY ON TREATMENT-NAIVE CHOROIDAL NEOVASCULARIZATION USING OPTICAL
   COHERENCE TOMOGRAPHY ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; AMD; anti-vascular endothelial growth
   factor; anti-VEGF; choroidal neovascularization; optical coherence
   tomography angiography; OCTA
ID MACULAR DEGENERATION; SUBGROUP ANALYSIS; OCT ANGIOGRAPHY; RANIBIZUMAB
AB Purpose: To use optical coherence tomography angiography (OCTA) to characterize the effects of anti-VEGF injections on treatment-naive choroidal neovascularization (CNV).
   Methods: From August 2014 to May 2015, treatment-naive eyes with CNV were scanned using a prototype OCTA system on a commercially available SD-OCT device (Optovue Inc, Fremont, CA). Optical coherence tomography angiography scans were obtained before anti-VEGF injection and at follow-up visits. The CNV area and greatest linear dimension (GLD) were measured along with the maximum retinal pigment epithelial detachment (RPED) height. Changes in subretinal and/or intraretinal fluid were also assessed.
   Results: Six eyes of six patients with treatment-naive CNV were included. Diagnoses included neovascular age-related macular degeneration, idiopathic polypoidal choroidal vasculopathy, CNV secondary to central serous chorioretinopathy and multifocal choroiditis, and macular telangiectasia Type 2 with subretinal neovascularization. After treatment, all patients with fluid on OCT initially showed a decrease in the amount of fluid. Five of six patients demonstrated decreases in CNV GLD and area with an average reduction of 23.6% and 29.8% respectively.
   Conclusion: Both CNV greatest linear dimension and area measured using OCTA decreased after anti-VEGF treatment in most patients. Optical coherence tomography angiography may be a useful tool for monitoring and quantifying the response of CNV to treatment.
C1 [Muakkassa, Nora W.; Chin, Adam T.; De Carlo, Talisa; Klein, Kendra A.; Baumal, Caroline R.; Witkin, Andre J.; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, New England Eye Ctr, Boston, MA 02111 USA.
   [Muakkassa, Nora W.; Chin, Adam T.; De Carlo, Talisa; Klein, Kendra A.; Baumal, Caroline R.; Witkin, Andre J.; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, Tufts Med Ctr, Boston, MA 02111 USA.
   [De Carlo, Talisa] MIT, Dept Elect Engn & Comp Sci, Elect Res Lab, Cambridge, MA 02139 USA.
C3 Tufts University; Tufts Medical Center; Tufts University; Massachusetts
   Institute of Technology (MIT)
RP Waheed, NK (通讯作者)，Tufts Med Ctr, New England Eye Ctr, 260 Tremont St,Biewend Bldg,9-11th Floor, Boston, MA 02111 USA.
EM nadiakwaheed@gmail.com
OI Chin, Adam/0000-0002-8539-754X
FU Massachusetts Lions Club; Macula Vision Research Foundation
FX Supported in part by the Massachusetts Lions Club and the Macula Vision
   Research Foundation.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chan WM, 2003, AM J OPHTHALMOL, V136, P836, DOI 10.1016/S0002-9394(03)00462-8
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Coscas F, 2012, INVEST OPHTH VIS SCI, V53, P4147, DOI 10.1167/iovs.12-9878
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Diaz RI, 2015, SURV OPHTHALMOL, V60, P279, DOI 10.1016/j.survophthal.2015.02.005
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Gliem M, 2013, RETINA-J RET VIT DIS, V33, P1300, DOI 10.1097/IAE.0b013e3182914d2b
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Rouvas A, 2011, RETINA-J RET VIT DIS, V31, P871, DOI 10.1097/IAE.0b013e3182003ca8
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Wong TY, 2015, BRIT J OPHTHALMOL, V99, P289, DOI 10.1136/bjophthalmol-2014-305131
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 22
TC 79
Z9 83
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2015
VL 35
IS 11
BP 2252
EP 2259
DI 10.1097/IAE.0000000000000836
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV5LD
UT WOS:000364311100012
PM 26457400
DA 2022-11-30
ER

PT J
AU Hua, R
   Liu, LM
   Hu, YD
   Chen, L
AF Hua, Rui
   Liu, Limin
   Hu, Yuedong
   Chen, Lei
TI The occurrence and progression of outer retinal tubulation in Chinese
   patients after intravitreal injections of ranibizumab
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY
AB To investigate the occurrence and progression of outer retinal tubulation (ORT) in Chinese patients after intravitreal ranibizumab injections, using spectral domain optical coherence tomography (SD-OCT) with eye tracking function. 15 age related macular degeneration (AMD) and 6 polypoidal choroidal vasculopathy (PCV) eyes of 21 patients were enrolled and assessed by SD-OCT. One patient received photodynamic therapy (PDT) previously, and all patients received intravitreal injections of ranibizumab. At baseline, only one AMD eye (4.8%) showed ORT, which appeared as round or ovoid hyporeflective spaces with hyperreflective borders. During the follow ups, ORT was identified in nine of 15 AMD eyes (60.0%) and one of six PCV eyes (16.7%). These new ORTs in 10 eyes were originated from the intraretinal fluid. Inner nuclear layer (INL), outer plexiform layer (OPL) and outer nuclear layer (ONL) were pulled down to form "cynapsis'', separating each ORT. However, ORT in 3 eyes disappeared after intravitreal ranibizumab injections. This is the first observation on the occurrence and progression of ORT in Chinese AMD and PCV patients, in a point to point manner. The ORT could become stable or disappear after ranibizumab injections, and outer retina involved in the process of ORT formation.
C1 [Hua, Rui; Liu, Limin; Hu, Yuedong; Chen, Lei] China Med Univ, Dept Ophthalmol, Hosp 1, Shenyang, Peoples R China.
C3 China Medical University
RP Hua, R (通讯作者)，China Med Univ, Dept Ophthalmol, Hosp 1, Shenyang, Peoples R China.
EM woodshua@126.com
FU Liaoning Science and Technology Project [2011225014]
FX This study was supported by the Liaoning Science and Technology Project
   (Project #: 2011225014). The funders had no role in study design, data
   collection and analysis, decision to publish, and preparation of the
   manuscript.
CR Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   EWolff B., 2012, J OPHTHALMOL, V2012
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Tulvatana W, 1999, ARCH OPHTHALMOL-CHIC, V117, P399, DOI 10.1001/archopht.117.3.399
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 8
TC 6
Z9 9
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 7
PY 2015
VL 5
AR 7661
DI 10.1038/srep07661
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AY8IH
UT WOS:000347796900012
PM 25564457
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Akaza, E
   Yuzawa, M
   Matsumoto, Y
   Kashiwakura, S
   Fujita, K
   Mori, R
AF Akaza, Eriko
   Yuzawa, Mitsuko
   Matsumoto, Yoko
   Kashiwakura, Shiho
   Fujita, Kyoko
   Mori, Ryusaburo
TI Role of photodynamic therapy in polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE photodynamic therapy; polypoidal choroidal vasculopathy; recurrence of
   polypoidal lesion; remaining branching vascular networks; verteporfin
ID VERTEPORFIN
AB Purpose: To determine the efficacy of photodynamic therapy (PDT) with verteporfin for polypoidal choroidal vasculopathy (PCV).
   Methods: PDT was performed in 35 patients (35 eyes) with PCV. We evaluated the number of treatments and compared visual acuity (VA), ophthalmological findings, and changes in polypoidal lesions and branching vascular networks by measuring lesion diameters using Heidelberg retina angiography before PDT, and then every 3 months for 1 year after PDT.
   Results: The mean annual number of treatment sessions was 2.2. VA was improved or maintained in 80% of the patients. Retinal pigment epithelium detachment, retinal detachment, hemorrhage, and/or exudates disappeared in 69%, and leakage resolved in 74% of the patients. Polypoidal lesions disappeared completely on indocyanine green angiography in 83% of the patients. All branching vascular networks persisted. Polypoidal lesions had recurred at the termini of the remaining branching vascular networks at 9 months after the first PDT in two eyes and at 12 months in one eye.
   Conclusions: PDT with verteporfin for PCV appears to improve or maintain VA for the first posttreatment year. Approximately 70% of PCV cases showed improved ophthalmoscopic findings. However, as polypoidal lesions recur after PDT in some cases, further study is needed to confirm the long-term efficacy of PDT for PCV.
C1 Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, Tokyo 1018309, Japan.
C3 Nihon University
RP Akaza, E (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, 1-8-13 Surugadai,Kanda, Tokyo 1018309, Japan.
EM merryeriko@hotmail.com
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Rosenblatt BJ, 2005, RETINA-J RET VIT DIS, V25, P33, DOI 10.1097/00006982-200501000-00004
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 12
TC 76
Z9 88
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2007
VL 51
IS 4
BP 270
EP 277
DI 10.1007/s10384-007-0452-3
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 197UI
UT WOS:000248581600004
PM 17660987
DA 2022-11-30
ER

PT J
AU Wong, LJ
   Desai, RU
   Jain, A
   Feliciano, D
   Moshfeghi, DM
   Sanislo, SR
   Blumenkranz, MS
AF Wong, Lisa J.
   Desai, Rajen U.
   Jain, Atul
   Feliciano, David
   Moshfeghi, Darius M.
   Sanislo, Steven R.
   Blumenkranz, Mark S.
TI Surveillance for potential adverse events associated with the use of
   intravitreal bevacizumab for retinal and choroidal vascular disease
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE adverse events; Avastin; bevacizumab; choroidal neovascularization;
   diabetic macular edema; macular degeneration; neovascular glaucoma;
   retinal pigment epithelial detachment; retinal pigment epithelial tear;
   retinal vascular occlusion
ID AGERELATED MACULAR DEGENERATION; PATHOLOGICAL MYOPIA; PIGMENT
   EPITHELIUM; UNITED-STATES; AVASTIN; SAFETY; INJECTION; TEARS;
   RANIBIZUMAB; IMPAIRMENT
AB Purpose: To systematically study potential adverse events associated with the use of intraocular bevacizumab at a single medical center.
   Methods: Retrospective study of all consecutive patients receiving intraocular bevacizumab injections at the Stanford University Department of Ophthalmology between November 15, 2005 and July 14, 2006. Bevacizumab was given for exudative age-related macular degeneration, retinal vascular occlusion, diabetic macular edema, neovascular glaucoma, and five other indications.
   Results: We analyzed medical records of 186 subjects (203 eyes) who received a total of 578 injections of 1.25 mg of bevacizumab. The average follow-up was approximately 6 months. Five eyes with exudative age-related macular degeneration developed retinal pigment epithelial (RPE) tears, all with preexisting RPE detachments. These five eyes represented 2.9% of all age-related macular degeneration eyes treated and 7% of the age-related macular degeneration eyes with preexisting RPE detachments at initiation of treatment. Other adverse events were rare and included retinal ischemia, subretinal hemorrhage, vitreous hemorrhage, ocular irritation or pain, worsened hypertension, and headache. No death or thromboembolic events were observed.
   Conclusion: Intraocular bevacizumab appears to be well tolerated for the treatment of a variety of retinal and choroidal vascular diseases. RPE tears may occur when treating choroidal neovascularization, particularly in patients with preexisting RPE detachment.
C1 [Wong, Lisa J.; Desai, Rajen U.; Jain, Atul; Feliciano, David; Moshfeghi, Darius M.; Sanislo, Steven R.; Blumenkranz, Mark S.] Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA.
   [Wong, Lisa J.] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA.
C3 Stanford University; University of Colorado System; University of
   Colorado Denver
RP Sanislo, SR (通讯作者)，1225 Crane St, Menlo Pk, CA 94025 USA.
EM ssanislo@stanford.edu
OI Moshfeghi, Darius Mohammad/0000-0003-2254-292X
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Grover S, 1999, OPHTHALMOLOGY, V106, P1780, DOI 10.1016/S0161-6420(99)90342-1
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   Iliev ME, 2006, AM J OPHTHALMOL, V142, P1054, DOI 10.1016/j.ajo.2006.06.066
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Mitka M, 2007, JAMA-J AM MED ASSOC, V297, P1538, DOI 10.1001/jama.297.14.1538
   Quiroz-Mercado Hugo, 2007, Semin Ophthalmol, V22, P109, DOI 10.1080/08820530701420082
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   SCHULTZBONSEL K, 2006, INVEST OPHTH VIS SCI, V106, P1236
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
NR 21
TC 50
Z9 52
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2008
VL 28
IS 8
BP 1151
EP 1158
DI 10.1097/IAE.0b013e31817e100f
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 350CC
UT WOS:000259329100018
PM 18685542
DA 2022-11-30
ER

PT J
AU Chu, J
   Zhou, CC
   Lu, N
   Zhang, X
   Dong, FT
AF Chu Jie
   Zhou Cheng-chao
   Lu Ning
   Zhang Xue
   Dong Fang-tian
TI Genetic variants in three genes and smoking show strong associations
   with susceptibility to exudative age-related macular degeneration in a
   Chinese population
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE exudative age-related macular degeneration; complement factor H;
   complement factor B; HtrA serine peptidase I; smoking; gene-environment
   interaction
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; GEOGRAPHIC ATROPHY;
   GENOMEWIDE-SCAN; NO ASSOCIATION; MACULOPATHY; RISK; Y402H; CFH; JAPANESE
AB Background The present study was undertaken to replicate the associations of representative polymorphisms in three genes (complement factor H (CFH), complement factor B (BF) and HtrA serine peptidase 1 (HTRA1)) with exudative age-related macular degeneration (AMD) in a Han Chinese population, and to test if the modifiable environmental factors affect AMD susceptibility associated with different type of genotype in these genes.
   Methods An age, gender and ethnicity matched case-control study was conducted to genotype the representative single neucleotide polymorphisms (SNPs) loci including rs1061170 and rs1410996 in CFH, rs641153 and rs4151667 in BF and rs11200638 in HTRA1 gene in 144 exudative AMD patients and 126 normal controls using PCR-RFLP and direct resequencing. The demographic characteristics and behavioral risk factors were also recorded. Allelic and genotypic associations for individual SNP and joint associations with two loci were performed. The gene-gene and gene-environment interactions were analyzed using multivariate non-conditional Logistic regression analysis.
   Results The C risk allele frequencies for CFH Y402H (rs1061170) in cases and controls were 12.5% and 5.4% respectively, which were much lower than those in Caucasians (P<0.001). Compared with TT homozygous genotype, the CT heterozygous genotype was positively associated with AMD with odds ratio (OR) of 3.23 (1.36-5.07). However, the population attributable risk (PAR) of C allele was only 3.3% (1.4%-4.3%). rs-1410996 was also associated with AMD independent of Y402H. The ORs of exudative AMD for individuals carrying one copy risk allele and two copy risk alleles were 2.57 (1.21-5.45) and 4.76 (2.15-10.55) respectively, with correspondent PARs of 28.3% (2.0%-40.5%) and 38.2% (21.80/6-45.4%). rs11200638 in HTRA1 was another susceptible locus for AMD and the risk homozygotes were significantly susceptible for exudutive AMD (OR=3.98, 1.88-8.43) with PAR of 38.9% (24.3%-45.8%). Education status and cigarette smoking were also related to exudative AMD. After controlling for environmental risk factors, CFH and HTRA1 SNPs were independently associated with exudative AMD, with OR of 3.50 (1.45-8.45) for CT genotype in Y402H, 3.34 (1.33-8.36) for GG genotype in rs1410996 and 3.85 (1.58-9.42) for AA genotype in rs11200638 respectively. The interaction analysis between gene and environmental factors showed that smoking synergistically increased susceptibility of AMD for heterozygotes of rs1410996, with ORinteraction of 7.33 (P-interaction 0.029).
   Conclusions In a Han Chinese population, CFH and HTRA1 polymorphisms appear to be independently and possibly additively hereditary contributors to exudative AMD. Y402H polymorphism conferred a significant but relatively lower contribution in chinese than in Caucasians with a low frequency of risk allele. The gene-environment interaction may be a best way to encourage those with a high genetic risk to prevent AMD by avoiding modifiable factors until there effective treatment for AMD.
C1 [Zhang Xue] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Med Genet, Beijing 100730, Peoples R China.
   [Lu Ning] Beijing Tongren Hosp, Ctr Eye, Beijing 100005, Peoples R China.
   [Zhou Cheng-chao] Shandong Univ, Sch Publ Hlth, Jinan 250012, Shandong, Peoples R China.
   [Chu Jie] Shandong Ctr Dis Control & Prevent, Inst Noncommunicable Dis, Jinan 250014, Shandong, Peoples R China.
   [Chu Jie; Dong Fang-tian] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Chu Jie; Dong Fang-tian] Peking Union Med Coll, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Institute of Basic Medical Sciences - CAMS; Capital Medical University;
   Shandong University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Peking Union Medical College Hospital; Chinese Academy
   of Medical Sciences - Peking Union Medical College; Peking Union Medical
   College
RP Zhang, X (通讯作者)，Chinese Acad Med Sci, Inst Basic Med Sci, Dept Med Genet, Beijing 100730, Peoples R China.
EM zhangxue@pumc.edu.cn
FU Centre for Physical Examination of PUMCH
FX The authors are grateful to the Centre for Physical Examination of PUMCH
   for the support to this study.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Chen LJ, 2006, MOL VIS, V12, P1536
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li WY, 1996, CHINESE MED J-PEKING, V109, P65
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Okamoto H, 2006, MOL VIS, V12, P156
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   SCHIMICH S, 2006, AM J HUM GENET, V78, P852
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shiwaku K, 2004, LANCET, V363, P1077, DOI 10.1016/S0140-6736(04)15856-X
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Souied EH, 2005, MOL VIS, V11, P1135
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3
NR 51
TC 36
Z9 40
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366-6999
EI 2542-5641
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD DEC 20
PY 2008
VL 121
IS 24
BP 2525
EP 2533
DI 10.1097/00029330-200812020-00011
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 391EO
UT WOS:000262216800011
PM 19187590
OA gold
DA 2022-11-30
ER

PT J
AU Stem, MS
   Moinuddin, O
   Kline, N
   Thanos, A
   Rao, P
   Williams, GA
   Hassan, TS
AF Stem, Maxwell S.
   Moinuddin, Omar
   Kline, Noah
   Thanos, Aristomenis
   Rao, Prethy
   Williams, George A.
   Hassan, Tarek S.
TI Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for
   Choroidal Neovascularization in FellowEyes of Previously Treated
   Patients With Neovascular Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID EYE; RANIBIZUMAB
AB IMPORTANCE Neovascular age-related macular degeneration (nvAMD) is a leading cause of vision loss. The optimal screening protocol to detect choroidal neovascularization (CNV) in fellow eyes of patients undergoing treatment for unilateral CNV has not been determined.
   OBJECTIVE To compare the visual outcomes of eyes with established, active nvAMD in index eyes with outcomes of fellow eyes that subsequently developed CNV during the management protocol.
   DESIGN, SETTING, AND PARTICIPANTS In this retrospective single-center case series conducted at a private vitreoretinal practice, data were collected for all patients treated for bilateral nvAMD between October 1, 2015, and October 1, 2016, for whom we could determine the date of index eye and fellow eye conversion to nvAMD (n = 1600). Per institutional protocol, patients were screened for new CNV in the fellow eye at every office visit. Patients were excluded if they had a condition that could result in marked asymmetric vision loss.
   EXPOSURES Development of nvAMD.
   MAIN OUTCOMES AND MEASURES Visual acuity (VA) at the time of diagnosis of nvAMD and at equivalent time points following conversion to nvAMD for both index eyes and fellow eyes.
   RESULTS A total of 264 patients met the inclusion criteria; 197 (74.6%) were women and 253 (95.8%) were white, and the mean (SD) age was 79.1 (8.2) years at time of index eye conversion to nvAMD and 80.6 (8.2) years at time of fellow eye conversion to nvAMD. Fellow eyes presented with better VA (mean VA, 20/50 [0.40 logMAR]) compared with index eyes (mean VA, 20/90 [0.67 logMAR]) at the time of conversion (difference, 14 letters [0.27 logMAR]; 95% CI, 10-17 [0.20-0.34]; P < .001). Index eyes did not achieve the same level of VA as fellow eyes after an equivalent postconversion follow-up of approximately 20 months (mean VA: index eye; 20/70 [0.56 logMAR]; fellow eye, 20/50 [0.40 logMAR]; difference, 8 letters [0.15 logMAR]; 95% CI, 4-11 [0.08-0.22]; P < .001). No difference was detected between the mean number of anti-vascular endothelial growth factor injections received by fellow eyes and index eyes (9.7 vs 10.0 injections, respectively).
   CONCLUSIONS AND RELEVANCE This retrospective study suggests that fellow eyes of previously treated patients with nvAMD may achieve better VA than their index eye counterparts after an equivalent amount of follow-up. This may be because the CNV was detected and treated earlier and at a better level of VA, although it is unknown whether the frequent office visits, VA measurements, or optical coherence tomography testing was responsible for the detection at a better level of VA.
C1 [Stem, Maxwell S.; Thanos, Aristomenis; Rao, Prethy; Williams, George A.; Hassan, Tarek S.] William Beaumont Hosp, 3555 W Thirteen Mile Rd,Ste LL-20, Royal Oak, MI 48073 USA.
   [Moinuddin, Omar; Kline, Noah] Oakland Univ, William Beaumont Sch Med, Rochester, MI 48063 USA.
   [Thanos, Aristomenis] Legacy Hlth, Devers Eye Inst, Portland, OR USA.
C3 Beaumont Health; Oakland University; Devers Eye Institute; Legacy Health
RP Hassan, TS (通讯作者)，William Beaumont Hosp, 3555 W Thirteen Mile Rd,Ste LL-20, Royal Oak, MI 48073 USA.
EM tsahassan@arcpc.net
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
NR 9
TC 8
Z9 8
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2018
VL 136
IS 7
BP 820
EP +
DI 10.1001/jamaophthalmol.2018.1534
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM9GK
UT WOS:000438554300022
PM 29800991
OA Green Published
DA 2022-11-30
ER

PT J
AU Heimes, B
   Farecki, ML
   Bartels, S
   Barrelmann, A
   Gutfleisch, M
   Spital, G
   Lommatzsch, A
   Pauleikhoff, D
AF Heimes, Britta
   Farecki, Marie-Louise, Jr.
   Bartels, Sina
   Barrelmann, Anna
   Gutfleisch, Matthias
   Spital, Georg
   Lommatzsch, Albrecht
   Pauleikhoff, Daniel
TI RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION Clinical
   Course and Long-Term Prognosis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; RPE tears; anti-VEGF therapy; long-term prognosis
ID OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF THERAPY; PHOTODYNAMIC THERAPY;
   CHOROIDAL NEOVASCULARIZATION; ANGIOMATOUS PROLIFERATION; INTRAVITREAL
   BEVACIZUMAB; FUNDUS AUTOFLUORESCENCE; DETACHMENT; INJECTION; AMD
AB Background: To document the long-term outcome in cases of retinal pigment epithelial (RPE) tears after treatment of vascularized pigment epithelial detachments with anti-vascular endothelial growth factor therapy.
   Methods: A retrospective analysis of the long-term outcome of a consecutive series of eyes with RPE tear developed during anti-vascular endothelial growth factor therapy for pigment epithelial detachment associated with choroidal neovascularization or retinal angiomatous proliferation (vascularized pigment epithelial detachment) was performed. Best-corrected visual acuity (BCVA), spectral domain optical coherence tomography, and autofluorescence images and also fluorescein angiograms were analyzed to determine the functional and morphologic development over time.
   Results: The long-term outcome of 22 eyes (21 patients, 13 women and 8 men; 65-85 years; mean: 76 years) with RPE tear was performed with minimal follow-up of 3 years (range: 3-5 years, mean: 44 months) and re-treatment with different therapeutic strategies. The eyes were differentiated in 2 groups according to the course of BCVA after the first 2 years of follow-up: Group 1 (11 eyes) demonstrated a stabilized or improved BCVA after 2 years and Group 2 (11 eyes) demonstrated a decrease in BCVA after 2 years. The initial BCVA between both groups was comparable. Also the mean initial size of the RPE tear was the same between the 2 groups, the area of the RPE tear decreased continuously during follow-up in Group 1, whereas this was the case in Group 2 only at the beginning of treatment with a further increase of the size of the RPE tear with longer follow-up. This corresponded with a different morphologic development between the two groups. In Group 1, increasing recovery of autofluorescence at the RPE-free area was visible beginning from the outer border, whereas in Group 2, further growth of the neovascular complex in the area of the RPE tear was observed resulting in larger fibrovascular scars. In addition, in both groups, the development of hyperreflective tissue was seen on spectral domain optical coherence tomography in the RPE-free area. The major therapeutic difference between the 2 groups was a significantly larger number of injections especially during the first year in Group 1.
   Conclusion: The development of RPE tear after anti-vascular endothelial growth factor therapy for vascularized pigment epithelial detachment in exudative age-related macular degeneration does not necessarily result in large disciform scars and functional loss, but multiple injections seem to be beneficial especially in the first year. With this strategy, RPE tears seem to be covered by autofluorescent and hyperreflective tissue and a re-growth of the neovascular complex can be prohibited. As a result, photoreceptor cells regain their metabolic support with functional recovery.
C1 [Heimes, Britta; Farecki, Marie-Louise, Jr.; Bartels, Sina; Barrelmann, Anna; Gutfleisch, Matthias; Spital, Georg; Lommatzsch, Albrecht; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
C3 St. Franziskus-Hospital
RP Pauleikhoff, D (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
EM dapauleikhoff@muenster.de
OI Heimes-Bussmann, Britta/0000-0003-3898-1679
CR Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Bartels S, 2014, OPHTHALMOLOGE, V111, P460, DOI 10.1007/s00347-013-2883-1
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Ghazi NG, 2002, RETINA-J RET VIT DIS, V22, P509, DOI 10.1097/00006982-200208000-00023
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   HO PC, 1984, ANN OPHTHALMOL, V16, P213
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Lommatzsch A, 2011, OPHTHALMOLOGE, V108, P244, DOI 10.1007/s00347-010-2221-9
   Mendis R, 2014, GRAEF ARCH CLIN EXP, V252, P1059, DOI 10.1007/s00417-013-2549-3
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   PAULEIKHOFF D, 1988, KLIN MONATSBL AUGENH, V193, P152, DOI 10.1055/s-2008-1050237
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Sorensen NB, 2013, GRAEF ARCH CLIN EXP, V251, P2319, DOI 10.1007/s00417-013-2331-6
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zacks DN, 2004, ARCH OPHTHALMOL-CHIC, V122, P932, DOI 10.1001/archopht.122.6.932
NR 38
TC 19
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2016
VL 36
IS 5
BP 868
EP 874
DI 10.1097/IAE.0000000000000823
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL2RG
UT WOS:000375482100010
PM 26655607
DA 2022-11-30
ER

PT J
AU Obeid, A
   Gao, XX
   Ali, FS
   Aderman, CM
   Shahlaee, A
   Adam, MK
   Kasi, SK
   Hyman, L
   Ho, AC
   Hsu, J
AF Obeid, Anthony
   Gao, Xinxiao
   Ali, Ferhina S.
   Aderman, Christopher M.
   Shahlaee, Abtin
   Adam, Murtaza K.
   Kasi, Sundeep K.
   Hyman, Leslie
   Ho, Allen C.
   Hsu, Jason
TI Loss to Follow-up Among Patients With Neovascular Age-Related Macular
   Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth
   Factor Injections
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF AGENTS; EYE EXAMINATIONS; RANIBIZUMAB; CARE; BEVACIZUMAB;
   ADHERENCE; THERAPY
AB IMPORTANCE Loss to follow-up (LTFU) after anti-vascular endothelial growth factor (anti-VEGF) injections increases the risk of vision loss among patients with neovascular age-related macular degeneration (nAMD).
   OBJECTIVE To report rates of LTFU among patients with nAMD after anti-VEGF injections and to identify risk factors associated with LTFU in this population.
   DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study of data from 9007 patients who received anti-VEGF injections for treatment of nAMD was performed at an urban, private retina practice with multiple locations from April 1, 2012, to January 12, 2016.
   MAIN OUTCOMES AND MEASURES Rates of LTFU after anti-VEGF injections. Loss to follow-up was defined as receipt of 1 or more injections with no subsequent follow-up visit within 12 months.
   RESULTS Among the 9007 patients (mean [SD] age, 81.2 [8.8] years; 5917 [65.7%] female; 7905 [87.8%] white), 2003 (22.2%) were LTFU. Odds of LTFU were greater among patients 81 to 85 years of age (odds ratio [OR], 1.58; 95% CI, 1.38-1.82; P < .001), 86 to 90 years of age (OR, 2.29; 95% CI, 2.00-2.62; P < .001), and more than 90 years of age (OR, 3.31; 95% CI, 2.83-3.86; P < .001) compared with patients 80 years of age and younger. Odds of LTFU among African American patients (OR, 1.47; 95% CI, 1.00-2.16; P = .05), Asian patients (OR, 2.63; 95% CI, 1.71-4.03; P < .001), patients of other race (OR, 3.07; 95% CI, 1.38-6.82; P = .006), and patients of unreported race (OR, 2.29; 95% CI, 1.96-2.68; P < .001) were greater than odds of LTFU among white patients. Odds of LTFU were greater among patients with regional adjusted gross income of $50 000 or less (OR, 1.52; 95% CI, 1.30-1.79; P < .001), $51 000 to $75 000 (OR, 1.35; 95% CI, 1.17-1.56; P < .001), and $76 000 to $100 000 (OR, 1.28; 95% CI, 1.08-1.50; P = .004) compared with patients with incomes greater than $100 000. Odds of LTFU for patients living 21 to 30 miles (OR, 1.33; 95% CI, 1.05-1.69; P = .02) and more than 30 miles (OR, 1.55; 95% CI, 1.28-1.88; P < .001) from clinic were greater compared with patients who lived 10 miles or less from the clinic. Odds of LTFU were greater among patients who received unilateral injections (OR, 1.44; 95% CI, 1.28-1.61; P < .001) than among patients who received bilateral injections.
   CONCLUSIONS AND RELEVANCE We found a high rate of LTFU after anti-VEGF injections among patients with nAMD and identified multiple risk factors associated with LTFU among this population. Although our results may not be generalizable, data on LTFU in a clinical practice setting are needed to understand the scope of the problem so that interventions may be designed to improve outcomes.
C1 [Obeid, Anthony; Gao, Xinxiao; Ali, Ferhina S.; Aderman, Christopher M.; Shahlaee, Abtin; Adam, Murtaza K.; Kasi, Sundeep K.; Ho, Allen C.; Hsu, Jason] Wills Eye Hosp & Res Inst, Retina Serv, 840 Walnut St,Ste 1020, Philadelphia, PA 19107 USA.
   [Gao, Xinxiao] Capital Med Univ, Beijing Anzhen Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Hyman, Leslie] Wills Eye Hosp & Res Inst, Vis Res Ctr, Philadelphia, PA USA.
C3 Jefferson University; Capital Medical University; Jefferson University
RP Hsu, J (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, 840 Walnut St,Ste 1020, Philadelphia, PA 19107 USA.
EM jhsu@midatlanticretina.com
OI Ho, Allen/0000-0003-3921-608X
FU Roche/Genentech; Santen; Ophthotech; Allergan; Alcon; Iconic; Genentech
FX All authors have completed and submitted the ICMJE Form for Disclosure
   of Potential Conflicts of Interest. Dr Hsu reported receiving grants
   from Roche/Genentech and Santen and receiving both grants and personal
   fees from Ophthotech. Dr Ho reported being a consultant for Allergan,
   Alcon, and Genentech and receiving grants from Allergan, Alcon,
   Genentech, and Iconic. No other disclosures are reported.
CR BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002
   Bosma H, 2001, AM J EPIDEMIOL, V153, P363, DOI 10.1093/aje/153.4.363
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Coburn BJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0019
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Ellish NJ, 2007, INVEST OPHTH VIS SCI, V48, P1989, DOI 10.1167/iovs.06-0934
   Grimsrud AT, 2013, J CLIN EPIDEMIOL, V66, P1006, DOI 10.1016/j.jclinepi.2013.03.013
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Internal Revenue Service, SOI TAX STATS IND IN
   Jiang XJ, 2017, AM J OPHTHALMOL, V176, P183, DOI 10.1016/j.ajo.2017.01.018
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Lau M, 2017, JAMA OPHTHALMOL, V135, P791, DOI 10.1001/jamaophthalmol.2017.1595
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Paz SH, 2006, OPHTHALMOLOGY, V113, P1372, DOI 10.1016/j.ophtha.2006.04.018
   PDEP (Pennsylvania Department of Environmental Protection), 2008, BUR AB MIN RECL OFF
   Robusto CC., 1957, AM MATH MON, V64, P38, DOI DOI 10.2307/2309088
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saadine JB, 2008, RETINA-J RET VIT DIS, V28, P195, DOI 10.1097/IAE.0b013e318115169a
   Salive ME, 2013, EPIDEMIOL REV, V35, P75, DOI 10.1093/epirev/mxs009
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sloan FA, 2004, HEALTH SERV RES, V39, P1429, DOI 10.1111/j.1475-6773.2004.00297.x
   Sloan FA, 2014, OPHTHALMOLOGY, V121, P2452, DOI 10.1016/j.ophtha.2014.07.020
   Wang XX, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0635-7
NR 30
TC 46
Z9 47
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2018
VL 136
IS 11
BP 1251
EP 1259
DI 10.1001/jamaophthalmol.2018.3578
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ6OF
UT WOS:000449557200013
PM 30352121
OA Green Published
DA 2022-11-30
ER

PT J
AU Milton, RC
   Clemons, TE
   Kurinij, N
   Sperduto, RD
AF Milton, RC
   Clemons, TE
   Kurinij, N
   Sperduto, RD
CA Age Related Eye Dis Study Res Grp
TI Risk factors for the incidence of advanced age-related macular
   degeneration in the age-elated eye disease study (AREDS) - AREDS report
   no.19
SO OPHTHALMOLOGY
LA English
DT Article
ID BODY-MASS INDEX; CIGARETTE-SMOKING; POOLED FINDINGS; DIETARY-FAT; BEAVER
   DAM; 10-YEAR INCIDENCE; CATARACT-SURGERY; MACULOPATHY; ASSOCIATION;
   PROGRESSION
AB Purpose: To describe the association of demographic, behavioral, medical, and nonretinal ocular factors with the incidence of neovascular age-related macular degeneration (AMD) and central geographic atrophy (CGA) in the Age-Related Eye Disease Study (AREDS), a randomized trial of antioxidants and zinc supplementation prophylaxis for development of advanced AMD.
   Design: Clinic-based prospective cohort study.
   Participants: Of individuals with early or intermediate AMD at baseline with a median follow-up of 6.3 years, 788 were at risk of developing advanced AMD in one eye (the fellow eye had advanced AMD), and 2506 were at risk in both eyes.
   Methods: The incidence of neovascular AMD and CGA was assessed from stereoscopic color fundus photographs taken at baseline and at annual visits beginning at year 2.
   Main Outcome Measures: Neovascular AMD was defined as photocoagulation for choroidal neovascularization, or photographic documentation at the reading center of any of the following: nondrusenoid retinal pigment epithelial detachment, serous or hemorrhagic retinal detachment, hemorrhage under the retina or the retinal pigment epithelium, and subretinal fibrosis. Central geographic atrophy was defined as geographic atrophy involving the center of the macula.
   Results: In multivariable models, in persons at risk of advanced AMD in both eyes, while controlling for age, gender, and AREDS treatment group, the following variables were statistically significantly associated with the incidence of neovascular AMD: race (odds ratio [OR], white vs. black, 6.77; 95% confidence interval [CI], 1.24-36.9) and larger amount smoked (OR, > 10 vs. <= 10 pack-years [a pack-year is an average of 1 pack of cigarette smoked per day for a year], 1.55; 95% CI, 1.15-2.09). The following were statistically significantly associated with the incidence of CGA: less education (OR, high school graduate or less vs. college graduate, 1.75; 95% CI, 1.10-2.78), greater body mass index (BMI) (OR, obese vs. nonobese, 1.93; 95% CI, 1.25-2.65), larger amount smoked (OR, > 10 pack-years vs. <= 10 pack-years, 1.82; 95% CI, 1.25-2.65), and antacid use (OR, 0.29; 95% CI, 0.09-0.91). In persons at risk of developing advanced AMD in one eye, the incidence of neovascular AMD was associated with diabetes (OR, 1.88; 95% CI, 1.07-3.31), and the incidence of CGA was associated with use of anti inflammatory medications (OR, 0.22; 95% Cl, 0.08-0.59).
   Conclusions: Results suggest that, among persons with early or intermediate AMD, smoking and BMI are modifiable factors associated with progression to advanced AMD, and suggest other associations (e.g., use of antacids and anti inflammatory medications) that warrant further study. Ophthalmology 2005;112:533-539 (c) 2005 by the American Academy of Ophthalmology.
C1 EMMES Corp, AREDS Coordinating Ctr, Rockville, MD 20850 USA.
   Univ Wisconsin, Madison, WI USA.
   Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   NEI, Bethesda, MD 20892 USA.
C3 Emmes Corporation; University of Wisconsin System; University of
   Wisconsin Madison; Harvard University; Massachusetts Eye & Ear
   Infirmary; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Milton, RC (通讯作者)，EMMES Corp, AREDS Coordinating Ctr, 701 N Washington St,Suite 700, Rockville, MD 20850 USA.
EM rmilton@emmes.com
RI SanGiovanni, John Paul/AAU-3895-2020
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   *AREDS, 2000, MAN OP
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Diggle P., 2002, ANAL LONGITUDINAL DA
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   Pi-Sunyer FX, 1998, OBES RES, V6, p51S
   PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009
   *SAS I INC, 1999, PROC GENMOD COMP PRO
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SEDDON J, 2001, EPIDEMIOLOGY AGE REL, V2, P1039
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   *US DEPT HEW PUBL, 2004, HLTH CONS SMOK REP S
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 52
TC 424
Z9 431
U1 3
U2 40
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2005
VL 112
IS 4
BP 533
EP 539
DI 10.1016/j.ophtha.2004.10.047
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 910WF
UT WOS:000227962200002
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Inan, UU
   Baysal, Z
   Inan, S
AF Inan, Umit Ubeyt
   Baysal, Zeki
   Inan, Sibel
TI Long-term changes in retinal layers in patients undergoing intravitreal
   ranibizumab for neovascular age-related macular degeneration: Retinal
   layers after anti-VEGF therapy
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Macular edema; Retinal
   layers; Retinal segmentation
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL ATROPHY; GANGLION-CELL
   COMPLEX; SAFETY EVALUATION; FULL-LENGTH; THICKNESS; SEGMENTATION;
   BEVACIZUMAB; INJECTIONS; EYES
AB PurposeTo analyze long-term changes in individual retinal layers (RLs) after intravitreal injections of ranibizumab (IVRs) in patients with neovascular age-related macular degeneration (n-AMD).MethodsThe patients were treated with 0.5-mg IVRs based on an as-needed protocol after the first three monthly doses over a 12-month follow-up period. Patients underwent optical coherence tomography and best-corrected visual acuity (BCVA) evaluation at each visit. The ETDRS grid with central subfield (R1) (r 0.5 mm) and the inner ring (R2) (r 0.5-1.5 mm) was used for calculation of the mean thickness of each RL. Changes in the thickness of segmented RLs within the R1 and R2 of ETDRS circles at months-3, -6, and -12 were compared to baseline.ResultsThe mean age was 727.4 years. The mean number of injections was 9.08 (range 6-11). Mean BCVA improved from 49.7 +/- 22.1 to 60.1 +/- 19.8 letters. Central macular thickness decreased from 390.25 +/- 149.6 to 312.74 +/- 118.4 mu m. Thicknesses of GCL (from 23.93 +/- 13.73 to 19.50 +/- 9.50 mu m in R1; p 0.001, and from 44.5 +/- 12.6 to 39.6 +/- 10.6 mu m in R2; p 0.005), IPL (from 28.90 +/- 14.36 to 22.35 +/- 6.23 mu m in R1; p 0.001, and from 39.34 +/- 8.53 to 35.58 +/- 7.93 mu m in R2; p 0.004), and total inner RL (ILM to ELM) (from 222.93 +/- 93.09 to 180 +/- 53 mu m in R1; p 0.001, and from 255.06 +/- 42.74 to 240.25 +/- 40.37 mu m in R2; p 0.003) in the central and parafoveal rings decreased statistically at month-12. Decrease in INL was limited to month-6 (from 34.80 +/- 15.33 to 27.60 +/- 12.59 mu m in R1; p 0.001), while decreases in total outer RLs (ELM to RPE) (from 128.32 +/- 26.92 to 115.54 +/- 43.98 mu m in R1; p 0.001, and 103.81 +/- 16.73 to 96.38 +/- 16.22 mu m in R2; p 0.014) and RPE (from 39.12 +/- 22.33 to 29.70 +/- 22.05 mu m in R1; p 0.001, and from 31.27 +/- 13.11 to 24.40 +/- 9.99 mu m in R2; p 0.001) were limited to month-3.Conclusionsp id=ParSignificant changes were observed in the thickness of the inner RLs after 1-year treatment with IVRs for n-AMD. A significant decrease in RPE thickness confined to the first months disappeared at month-12.
C1 [Inan, Umit Ubeyt] ParkHayat Hosp, Dept Ophthalmol, Afyon, Turkey.
   [Baysal, Zeki] Batman State Hosp, Dept Ophthalmol, Batman, Turkey.
   [Inan, Sibel] Hlth Sci Univ, Sch Med, Dept Ophthalmol, TR-03200 Afyon, Turkey.
   [Inan, Umit Ubeyt; Baysal, Zeki; Inan, Sibel] Afyon Kocatepe Univ, Sch Med, Dept Ophthalmol, Afyon, Turkey.
C3 Batman Regional State Hospital; Afyon Kocatepe University
RP Inan, S (通讯作者)，Hlth Sci Univ, Sch Med, Dept Ophthalmol, TR-03200 Afyon, Turkey.
EM drinan33@gmail.com
RI Inan, sibel/AAB-7691-2021
FU Afyon Kocatepe University Scientific Research Projects Committee [14]
FX This study was supported in part by a Grant from Afyon Kocatepe
   University Scientific Research Projects Committee with Project No.
   14.TUS.12.
CR Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Brar VS, 2010, MOL VIS, V16, P1848
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Ebneter A, 2016, RETINA-J RET VIT DIS, V36, P1314, DOI 10.1097/IAE.0000000000000923
   Entezari Morteza, 2014, J Ophthalmic Vis Res, V9, P449, DOI 10.4103/2008-322X.150815
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holfort SK, 2010, INVEST OPHTH VIS SCI, V51, P2790, DOI 10.1167/iovs.09-4891
   Hollo G, 2015, J GLAUCOMA, V24, P245, DOI 10.1097/IJG.0000000000000092
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hondur G, 2018, CLIN OPHTHALMOL, V12, P401, DOI 10.2147/OPTH.S157429
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Huo YJ, 2018, CLIN EXP OPHTHALMOL, V46, P400, DOI 10.1111/ceo.13067
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Kashiwagi K, 2004, INVEST OPHTH VIS SCI, V45, P3778, DOI 10.1167/iovs.04-0277
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Loduca AL, 2010, AM J OPHTHALMOL, V150, P849, DOI 10.1016/j.ajo.2010.06.034
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Oberwahrenbrock T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137316
   Park HYL, 2014, AM J PATHOL, V184, P1752, DOI 10.1016/j.ajpath.2014.02.016
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Perdicchi A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/268796
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Shin HJ, 2016, INVEST OPHTH VIS SCI, V57, P1798, DOI 10.1167/iovs.15-18404
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Villegas-Perez MP, 1998, J COMP NEUROL, V392, P58, DOI 10.1002/(SICI)1096-9861(19980302)392:1<58::AID-CNE5>3.0.CO;2-O
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 39
TC 4
Z9 4
U1 1
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD DEC
PY 2019
VL 39
IS 12
BP 2721
EP 2730
DI 10.1007/s10792-019-01116-6
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JY0IH
UT WOS:000504108000004
PM 31069616
DA 2022-11-30
ER

PT J
AU Fu, ZJ
   Gong, Y
   Liegl, R
   Wang, ZX
   Liu, CH
   Meng, SS
   Burnim, SB
   Saba, NJ
   Fredrick, TW
   Morss, PC
   Hellstrom, A
   Talukdar, S
   Smith, LEH
AF Fu, Zhongjie
   Gong, Yan
   Liegl, Raffael
   Wang, Zhongxiao
   Liu, Chi-Hsiu
   Meng, Steven S.
   Burnim, Samuel B.
   Saba, Nicholas J.
   Fredrick, Thomas W.
   Morss, Peyton C.
   Hellstrom, Ann
   Talukdar, Saswata
   Smith, Lois E. H.
TI FGF21 Administration Suppresses Retinal and Choroidal Neovascularization
   in Mice
SO CELL REPORTS
LA English
DT Article
ID OXYGEN-INDUCED RETINOPATHY; ENDOTHELIAL GROWTH-FACTOR; BROWN
   ADIPOSE-TISSUE; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; BETA-KLOTHO;
   TNF-ALPHA; ADIPONECTIN; GLUCOSE; ANGIOGENESIS
AB Pathological neovascularization, a leading cause of blindness, is seen in retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. Using a mouse model of hypoxia-driven retinal neovascularization, wefind that fibroblast growth factor 21 (FGF21) administration suppresses, and FGF21 deficiency worsens, retinal neovessel growth. The protective effect of FGF21 against neovessel growth was abolished in adiponectin (APN)-deficient mice. FGF21 administration also decreased neovascular lesions in two models of neovascular age-related macular degeneration: very-low-density lipoprotein-receptor-deficient mice with retinal angiomatous proliferation and laser-induced choroidal neovascularization. FGF21 inhibited tumor necrosis alpha (TNF-alpha) expression but did not alter Vegfa expression in neovascular eyes. These data suggest that FGF21 may be a therapeutic target for pathologic vessel growth in patients with neovascular eye diseases, including retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration.
C1 [Fu, Zhongjie; Gong, Yan; Liegl, Raffael; Wang, Zhongxiao; Liu, Chi-Hsiu; Meng, Steven S.; Burnim, Samuel B.; Saba, Nicholas J.; Fredrick, Thomas W.; Morss, Peyton C.; Smith, Lois E. H.] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
   [Hellstrom, Ann] Univ Gothenburg, Sahlgrenska Acad, Dept Ophthalmol, S-41390 Gothenburg, Sweden.
   [Talukdar, Saswata] Merck Res Labs, Cardiometab Dis, 33 Ave Louis Pasteur, Boston, MA 02115 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   University of Gothenburg; Merck & Company
RP Smith, LEH (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.; Talukdar, S (通讯作者)，Merck Res Labs, Cardiometab Dis, 33 Ave Louis Pasteur, Boston, MA 02115 USA.
EM mumpi462@yahoo.com; lois.smith@childrens.harvard.edu
OI Morss-Walton, Peyton/0000-0002-9200-9939; Gong, Yan/0000-0002-4805-0459;
   FU, ZHONGJIE/0000-0002-8182-2983
FU NIH [EY024864, EY017017, EY022275, P01 HD18655]; Lowy Medical Research
   Institute [84134]; European Commission (FP7) [305485]; Knights Templar
   Eye Foundation [76293]; Bernadotte Foundation; German Research
   Foundation (DFG) [Li2650/1-1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE
   OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD090255, P30HD018655] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY024864, R01EY017017,
   R01EY022275] Funding Source: NIH RePORTER
FX We thank Drs. Steven Kliewer and David Mangelsdorf from the University
   of Texas Southwestern for providing Fgf21<SUP>+/+</SUP> and
   Fgf21<SUP>-/-</SUP> mice. We thank Pfizer CVMED for providing native
   FGF21 and PF-05231023. L.E.H.S. is supported by the NIH (grants
   EY024864, EY017017, EY022275, and P01 HD18655), the Lowy Medical
   Research Institute (grant 84134), and the European Commission (FP7
   project 305485 PREVENT-ROP). Z.F. is supported by the Knights Templar
   Eye Foundation (grant 76293) and the Bernadotte Foundation. R.L. is
   supported by the German Research Foundation (DFG) (grant Li2650/1-1).
   S.T. is a current employee of Merck and was at the time the study was
   conducted. Merck had no role in any aspects of this work.
CR Abcouwer SF, 2014, ANN NY ACAD SCI, V1311, P174, DOI 10.1111/nyas.12412
   Arevalo J Fernando, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P20
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Bernardo B, 2015, SCI REP-UK, V5, DOI 10.1038/srep11382
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Cheung N, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2970
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   Ding XS, 2012, CELL METAB, V16, P387, DOI 10.1016/j.cmet.2012.08.002
   Engelbert M., 2012, EUR J OPHTHALMOL
   Esteghamati A, 2016, ANN ENDOCRINOL-PARIS, V77, P586, DOI 10.1016/j.ando.2016.01.005
   Foltz IN, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004690
   Fu ZF, 2016, BBA-MOL BASIS DIS, V1862, P1392, DOI 10.1016/j.bbadis.2016.05.002
   Fu ZJ, 2015, AM J CLIN NUTR, V101, P879, DOI 10.3945/ajcn.114.099291
   Gaich G, 2013, CELL METAB, V18, P333, DOI 10.1016/j.cmet.2013.08.005
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Hangai M, 2006, J NEUROIMMUNOL, V171, P45, DOI 10.1016/j.jneuroim.2005.09.018
   Heeren TFC, 2014, RETINA-J RET VIT DIS, V34, P916, DOI 10.1097/IAE.0000000000000082
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Higuchi A, 2010, ARTERIOSCL THROM VAS, V30, P46, DOI 10.1161/ATVBAHA.109.198465
   Higuchi A, 2009, CIRC RES, V104, P1058, DOI 10.1161/CIRCRESAHA.109.194506
   Holland WL, 2013, CELL METAB, V17, P790, DOI 10.1016/j.cmet.2013.03.019
   Huang J, 2013, J PHARMACOL EXP THER, V346, P270, DOI 10.1124/jpet.113.204420
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   Kim JH, 2015, DIABETES OBES METAB, V17, P161, DOI 10.1111/dom.12408
   Kociok N, 2006, INVEST OPHTH VIS SCI, V47, P5057, DOI 10.1167/iovs.06-0407
   Lai AKW, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/106594
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lin Y, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/929756
   Lin ZF, 2013, CELL METAB, V17, P779, DOI 10.1016/j.cmet.2013.04.005
   Lyzogubov VV, 2012, BBA-MOL CELL RES, V1823, P1264, DOI 10.1016/j.bbamcr.2012.05.017
   Mao DN, 2012, CURR EYE RES, V37, P803, DOI 10.3109/02713683.2012.676700
   Omae T, 2015, INVEST OPHTH VIS SCI, V56, P4143, DOI 10.1167/iovs.15-16447
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Park PH, 2008, J BIOL CHEM, V283, P26850, DOI 10.1074/jbc.M802787200
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Sainson RCA, 2008, BLOOD, V111, P4997, DOI 10.1182/blood-2007-08-108597
   Sato T, 2012, AM J OPHTHALMOL, V153, P327, DOI 10.1016/j.ajo.2011.07.005
   Schlein C, 2016, CELL METAB, V23, P441, DOI 10.1016/j.cmet.2016.01.006
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shin Eui Seok, 2014, J Ophthalmic Vis Res, V9, P362, DOI 10.4103/2008-322X.143378
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Suzuki M, 2008, MOL ENDOCRINOL, V22, P1006, DOI 10.1210/me.2007-0313
   Talukdar S, 2016, CELL METAB, V23, P427, DOI 10.1016/j.cmet.2016.02.001
   Wulster-Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130
   Xiao Y, 2012, J CLIN ENDOCR METAB, V97, pE54, DOI 10.1210/jc.2011-1930
   Yaqoob U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098130
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zhang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082275
   Zibar K, 2015, ENDOCRINE, V48, P848, DOI 10.1007/s12020-014-0413-9
NR 54
TC 33
Z9 34
U1 3
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD FEB 14
PY 2017
VL 18
IS 7
BP 1606
EP 1613
DI 10.1016/j.celrep.2017.01.014
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EP4BG
UT WOS:000397324900003
PM 28199833
OA gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, JY
   Kwon, OW
   Oh, HS
   Kim, SH
   You, YS
AF Kim, Ju Young
   Kwon, Oh Woong
   Oh, Hyun Sub
   Kim, Soon Hyun
   You, Yong Sung
TI Optical coherence tomography angiography in patients with polypoidal
   choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Optical coherence tomography angiography; Polypoidal choroidal
   vasculopathy
ID MACULAR DEGENERATION; INDOCYANINE GREEN; OCT ANGIOGRAPHY;
   NEOVASCULARIZATION
AB To report the characteristics of polypoidal choroidal vasculopathy (PCV) based on optical coherence tomography angiography (OCTA) results.
   A retrospective, cross-sectional case series was conducted. Patients treated for PCV were evaluated with the OCTA system. The OCTA images of these patients were compared with those from indocyanine green angiography (ICGA). All eyes of consecutive patients with PCV were included.
   The mean age of the patients (five men and two women) was 67.86 +/- 14.02 years. The mean number of anti-vascular endothelial growth factor injections was 10.43 +/- 10.01. OCTA demonstrated branched vascular networks, which were detected by ICGA; however, polyps were not revealed consistently by OCTA. A total of 24 polyps were detected in seven eyes from seven patients by hyper-fluorescence on ICGA. However, only 12 polyps (50 %) were hyper-reflective on OCTA.
   PCV polyps were not detected as consistently by OCTA as by ICGA. This suggests that the polyps were detected differently by OCTA depending on blood flow in the polyp.
C1 [Kim, Ju Young; Kwon, Oh Woong; Oh, Hyun Sub; Kim, Soon Hyun; You, Yong Sung] Nune Eye Hosp, Retina Ctr, Noon Bldg 404 Seonreung Ro, Seoul 135280, South Korea.
RP You, YS (通讯作者)，Nune Eye Hosp, Retina Ctr, Noon Bldg 404 Seonreung Ro, Seoul 135280, South Korea.
EM yongsung.you@gmail.com
CR Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Li X, 2013, RETINA, P1285
   Maftouhi MQ-E, 2015, CLIN OCT ANGIOGRAPHY, P62
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 17
TC 40
Z9 51
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2016
VL 254
IS 8
BP 1505
EP 1510
DI 10.1007/s00417-015-3228-3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS3IB
UT WOS:000380675200008
PM 26617178
DA 2022-11-30
ER

PT J
AU Rudolf, M
   Clark, ME
   Chimento, MF
   Li, CM
   Medeiros, NE
   Curcio, CA
AF Rudolf, Martin
   Clark, Mark E.
   Chimento, Melissa F.
   Li, Chuan-Ming
   Medeiros, Nancy E.
   Curcio, Christine A.
TI Prevalence and morphology of druse types in the macula and periphery of
   eyes with age-related maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BRUCHS MEMBRANE; CLINICOPATHOLOGICAL CORRELATION; UNESTERIFIED
   CHOLESTEROL; GEOGRAPHIC ATROPHY; 10-YEAR INCIDENCE; BASAL DEPOSITS;
   SEVERITY SCALE; GRADING SYSTEM; DEGENERATION; ATHEROSCLEROSIS
AB PURPOSE. Macular drusen are hallmarks of age-related maculopathy (ARM), but these focal extracellular lesions also appear with age in the peripheral retina. The present study was conducted to determine regional differences in morphology that contribute to the higher vulnerability of the macula to advanced disease.
   METHODS. Drusen from the macula (n=133) and periphery (n = 282) were isolated and concentrated from nine ARM-affected eyes. A semiquantitative light microscopic evaluation of 1-mu m-thick sections included 12 parameters.
   RESULTS. Significant differences were found between the macula and periphery in ease of isolation, distribution of druse type, composition qualities, and substructures. On harvesting, macular drusen were friable, with liquefied or crystallized contents. Peripheral drusen were resilient and never crystallized. On examination, soft drusen appeared in the macula only, had homogeneous content without significant substructures, and had abundant basal laminar deposits (BlamD). Several substructures, previously postulated as signatures of druse biogenesis, were found primarily in hard drusen. Specific to hard drusen, which appeared everywhere, were central subregions and reduced RPE coverage. Macular hard drusen with a rich substructure profile differed from primarily homogeneous peripheral hard drusen. Compound drusen, found in the periphery only, exhibited a composition profile that was not intermediate between hard and soft.
   CONCLUSIONS. The data confirm regional differences in druse morphology, composition, and physical properties, most likely based on different formative mechanisms that may contribute to macular susceptibility for ARM progression. Two other reasons that only the macula is at high risk despite having relatively few drusen are the exclusive presence of soft drusen and the abundant BlamD in this region.
C1 [Rudolf, Martin; Clark, Mark E.; Chimento, Melissa F.; Li, Chuan-Ming; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Rudolf, M (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, H020 Callahan Eye Fdn Hosp,700 S 18th St, Birmingham, AL 35294 USA.
EM mirudolf@aol.com
RI Mitchell, Paul/P-1498-2014
FU NATIONAL EYE INSTITUTE [R01EY006109] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY006109-20, EY06109, R01 EY006109] Funding Source: Medline
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dentchev T, 2003, MOL VIS, V9, P184
   ELBABA F, 1986, AM J OPHTHALMOL, V101, P576
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FRIEDMAN E, 1962, ARCH OPHTHALMOL-CHIC, V69, P114
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   LEWIS H, 1985, OPHTHALMOLOGY, V92, P1485
   LEWIS H, 1986, AM J OPHTHALMOL, V102, P801, DOI 10.1016/0002-9394(86)90417-4
   LEWIS H, 1986, OPHTHALMOLOGY, V93, P1098
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 53
TC 111
Z9 112
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2008
VL 49
IS 3
BP 1200
EP 1209
DI 10.1167/iovs.07-1466
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 271TZ
UT WOS:000253812900052
PM 18326750
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Patel, JI
AF Patel, Jignesh I.
TI Is cataract surgery a risk factor for progression of macular
   degeneration?
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; cataract surgery; circadian rhythm;
   scotopic sensitivity; short wavelength light
ID AGE-RELATED MACULOPATHY; BLUE-LIGHT; MELATONIN SUPPRESSION;
   INTRAOCULAR-LENS; BEAVER DAM; EXPOSURE; PIGMENT; EYE
AB Purpose of review
   There is a suggestion of increased risk or progression of age-related macular degeneration after cataract surgery; which is related to the increased exposure of the retina to short-wavelength light.
   Recent findings
   Cell culture and animal work has described retinal and retinal pigment epithelium phototoxicity on acute light exposure. Clinical studies suggest that the use of short-wavelength-blocking intraocular lenses can help but may also affect visual function and circadian rhythm.
   Summary
   Evidence to date fails to prove conclusively that light alone or cataract surgery can induce or cause the progression of age-related macular degeneration. A randomized clinical study of the use of short-wavelength (blue)-blocking lenses to prove or disprove the ability of these intraocular lenses to help in preventing progression of age-related macular degeneration is needed.
C1 Royal Perth Hosp, Dept Ophthalmol, Perth, WA 6008, Australia.
C3 Royal Perth Hospital; University of Western Australia
RP Patel, JI (通讯作者)，Royal Perth Hosp, Dept Ophthalmol, Wellington St, Perth, WA 6008, Australia.
EM jigs37@hotmail.com
CR AARNISALO EA, 1988, AM J OPHTHALMOL, V105, P408, DOI 10.1016/0002-9394(88)90307-8
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Charman WN, 2003, OPHTHAL PHYSL OPT, V23, P181, DOI 10.1046/j.1475-1313.2003.00105.x
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   GUTTMAN C, 2003, OPHTHALMOLOGY T 0301, V28
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   Herljevic M, 2005, EXP GERONTOL, V40, P237, DOI 10.1016/j.exger.2004.12.001
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   MARTIN D, 2002, ARVO E, P1907
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MCMURDO MET, 1991, GERONTOLOGY, V37, P221
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Van Gelder RN, 2004, BRIT J OPHTHALMOL, V88, P1353, DOI 10.1136/bjo.2004.042861/045120
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 28
TC 12
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD FEB
PY 2007
VL 18
IS 1
BP 9
EP 12
DI 10.1097/ICU.0b013e3280112a0f
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 124NG
UT WOS:000243373900003
PM 17159440
DA 2022-11-30
ER

PT J
AU Spaide, RF
   Donsoff, I
   Lam, DL
   Yannuzzi, LA
   Jampol, LM
   Slakter, J
   Sorenson, J
   Freund, KB
AF Spaide, RF
   Donsoff, I
   Lam, DL
   Yannuzzi, LA
   Jampol, LM
   Slakter, J
   Sorenson, J
   Freund, KB
TI Treatment of polypoidal choroidal vasculopathy with photodynamic therapy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; NEOVASCULARIZATION
AB Purpose: To study the effects of photodynamic therapy using verteporfin in the treatment of patients with subfoveal polypoidal choroidal vasculopathy (PCV).
   Methods: A retrospective chart review of 16 consecutive patients with subfoveal PCV treated with photodynamic therapy using verteporfin was performed.
   Results: The mean age of the patients involved was 70.5 years. The mean follow-up time was 12 months. The visual acuity improved in 9 (56.3%), remained the same in 5 (31.3%), and decreased in 2 (12.5%). The mean change in visual acuity was an improvement of 2.38 lines, a difference that was highly significant (P = 0.004). The change in visual acuity was negatively correlated with increasing age. The final visual acuity was positively correlated with initial acuity and negatively correlated with age. These results were confirmed by multiple linear regression. No patient had any lasting complication from the treatment.
   Conclusions: Subfoveal PCV has no proven method of treatment. Although the follow-up time and the number of patients in this pilot study were limited, the encouraging results and lack of complications suggest that further study is indicated.
C1 Vitreous Retina Macula Consultants New York, New York, NY 10021 USA.
   Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 519 E 72nd St,Suite 203, New York, NY 10021 USA.
EM VRMNY@aol.com
RI Spaide, Richard/ABD-7368-2020; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CAPONE A, 1994, ARCH OPHTHALMOL-CHIC, V112, P1091, DOI 10.1001/archopht.1994.01090200097029
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2001, JPN J OPHTHALMOL, V45, P192, DOI 10.1016/S0021-5155(00)00378-6
NR 24
TC 144
Z9 152
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2002
VL 22
IS 5
BP 529
EP 535
DI 10.1097/00006982-200210000-00001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 604LC
UT WOS:000178621400001
PM 12441716
DA 2022-11-30
ER

PT J
AU Owens, SL
   Bunce, C
   Brannon, AJ
   Xing, W
   Chisholm, IH
   Gross, M
   Guymer, RH
   Holz, FG
   Bird, AC
AF Owens, SL
   Bunce, C
   Brannon, AJ
   Xing, W
   Chisholm, IH
   Gross, M
   Guymer, RH
   Holz, FG
   Bird, AC
CA Drusen Laser Study Group
TI Prophylactic laser treatment hastens choroidal neovascularization in
   unilateral age-related maculopathy: Final results of the Drusen Laser
   Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SENILE MACULAR DEGENERATION; CLINICAL-TRIAL; 2ND EYE; PHOTOCOAGULATION;
   ABNORMALITIES; COMPLICATIONS; PROGNOSIS
AB PURPOSE: The Drusen Laser Study evaluated macular laser to prevent choroidal neovascularization (CNV) and vision loss in high,risk age-related maculopathy (ARM).
   DESIGN: Prospective, interventional, randomized, con, trolled clinical trial in five hospital centers.
   METHODS: Patients in the unilateral group had neovascular ARM and drusen in the study eye. Study eyes were randomized to laser,treated or no-laser groups. For patients in the bilateral drusen group, eyes were randomized to right eye, laser or no laser; and left eye, alternative. Laser treatment comprised 12 argon spots. Outcome was best-corrected visual acuity and CNV signs, which were monitored for 3 years.
   RESULTS: In the unilateral group, vision loss occurred in 21 (28.8%) of 73 patients in laser vs 13 (19.7%) of 66 no-laser patients (P = .214). Incidence of CNV was 27 (29.7%) of 91 in laser vs 15 (17.65%) of 85 no,laser patients (P = .061). CNV onset was approximately 6 months earlier in laser,treated compared with no-laser patients (P = .05). In the bilateral group, vision loss occurred in six (8.3%) of 72 laser-treated vs 10 (13.9%) of 72 fellow eyes (P =.3877). CNV incidence was 12 (11.6%) of 103 in laser-treated vs seven (6.8%) of 103 fellow eyes (P =.225). There was no difference in onset of CNV.
   CONCLUSIONS: Results do not support prophylactic laser of the fellow eye of patients with neovascular ARM. Its role in patients with bilateral drusen remains unclear.
C1 Moorfields Eye Hosp, Professorial Unit, London EC1V 2PD, England.
   Southampton Eye Unit, Southampton, Hants, England.
   Univ Klinikum Benjamin Franklin, Berlin, Germany.
   Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   Univ Heidelberg, Heidelberg, Germany.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Centre for Eye Research
   Australia; University of Melbourne; Ruprecht Karls University Heidelberg
RP Owens, SL (通讯作者)，Moorfields Eye Hosp, Professorial Unit, City Rd, London EC1V 2PD, England.
EM Sarah.Owens@moorfields.nhs.uk
OI Bunce, Catey/0000-0002-0935-3713; Guymer, Robyn/0000-0002-9441-4356
CR BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   Frennesson CI, 2003, ACTA OPHTHALMOL SCAN, V81, P449, DOI 10.1034/j.1600-0420.2003.00143.x
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Guymer RH, 2001, BRIT J OPHTHALMOL, V85, P40, DOI 10.1136/bjo.85.1.40
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Wetzig P C, 1988, Trans Am Ophthalmol Soc, V86, P276
NR 20
TC 37
Z9 40
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2006
VL 141
IS 2
BP 276
EP 281
DI 10.1016/j.ajo.2005.08.019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 013LF
UT WOS:000235410100006
PM 16458680
DA 2022-11-30
ER

PT J
AU De Salvo, G
   Vaz-Pereira, S
   Sehmi, KS
   Andrews, RM
   Sagoo, MS
AF De Salvo, Gabriella
   Vaz-Pereira, Sara
   Sehmi, Kulwant S.
   Andrews, Richard M.
   Sagoo, Mandeep S.
TI Spectral-Domain Optical Coherence Tomography of Polypoidal Choroidal
   Vasculopathy Associated With Benign Choroidal Nevus
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB Two cases of polypoidal choroidal vasculopathy (PCV) complicating benign choroidal nevus and their tomographic features at spectral-domain optical coherence tomography (SD-OCT) are reported. Two eyes with choroidal nevus and associated subretinal fluid underwent complete ophthalmological examination, SD-OCT, fundus fluorescein angiography, and indocyanine green angiography (ICGA). SD-OCT and ICGA confirmed the diagnosis of PCV in both cases. Ophthalmologists should be aware of this rare combination between choroidal nevus and PCV. If a choroidal nevus presents with subretinal fluid, this does not always herald malignant transformation, and PCV should be ruled out so that the correct treatment can be planned.
C1 [De Salvo, Gabriella; Sehmi, Kulwant S.; Andrews, Richard M.] Moorfields Eye Hosp NHS Fdn Trust, Med Retina Serv, London, England.
   [De Salvo, Gabriella] Univ Hosp Southampton NHS Fdn Trust, Dept Ophthalmol, Southampton, Hants, England.
   [Vaz-Pereira, Sara] Hosp Santa Maria, Dept Ophthalmol, Lisbon, Portugal.
   [Sagoo, Mandeep S.] St Barnabas Hosp, Ocular Oncol Serv, London, England.
   [Sagoo, Mandeep S.] UCL, Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Southampton; University Hospital
   Southampton NHS Foundation Trust; Universidade de Lisboa; Hospital Santa
   Maria; University of London; Queen Mary University London; University of
   London; University College London
RP De Salvo, G (通讯作者)，Moorfields Eye Hosp Fdn Trust, Med Retina Dept, 162 City Rd, London EC1V 2PD, England.
EM gabrydsl@tiscali.it
RI Vaz-Pereira, Sara/P-5777-2019; De Salvo, Gabriella/AAY-5016-2020
OI Vaz-Pereira, Sara/0000-0001-6125-5486; Sagoo,
   Mandeep/0000-0003-1530-3824; DE SALVO, Gabriella/0000-0002-1185-6942
CR Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Ishida T, 2013, INT OPHTHALMOL, V33, P305, DOI 10.1007/s10792-012-9657-7
   Katsimpris JM, 2003, J FR OPHTALMOL, V26, P489
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee CS, 2014, OPHTHALMOLOGY, V121, P1029, DOI 10.1016/j.ophtha.2013.11.043
   Papastefanou VP, 2013, BRIT J OPHTHALMOL, V97, P1014, DOI 10.1136/bjophthalmol-2013-303234
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   Rundle P, 2007, EYE, V21, P1531, DOI 10.1038/sj.eye.6702623
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 12
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV-DEC
PY 2015
VL 46
IS 10
BP 1062
EP 1064
DI 10.3928/23258160-20151027-15
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9UH
UT WOS:000378842400016
PM 26599253
DA 2022-11-30
ER

PT J
AU Holz, FG
   Sadda, SR
   Busbee, B
   Chew, EY
   Mitchell, P
   Tufail, A
   Brittain, C
   Ferrara, D
   Gray, S
   Honigberg, L
   Martin, J
   Tong, B
   Ehrlich, JS
   Bressler, NM
AF Holz, Frank G.
   Sadda, Srinivas R.
   Busbee, Brandon
   Chew, Emily Y.
   Mitchell, Paul
   Tufail, Adnan
   Brittain, Christopher
   Ferrara, Daniela
   Gray, Sarah
   Honigberg, Lee
   Martin, Jillian
   Tong, Barbara
   Ehrlich, Jason S.
   Bressler, Neil M.
CA Chroma Spectri Study Investigators
TI Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to
   Age-Related Macular Degeneration Chroma and Spectri Phase 3 Randomized
   Clinical Trials
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-I; RANIBIZUMAB; PROGRESSION; SECONDARY; INHIBITION;
   IMMUNOLOGY; PATHWAY; GROWTH; EYES; FORM
AB IMPORTANCE: Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of visual disability in older individuals. A phase 2 trial suggested that lampalizumab, a selective complement factor D inhibitor, reduced the rate of GA enlargement, warranting phase 3 trials.
   OBJECTIVE: To assess the safety and efficacy of lampalizumab vs sham procedure on enlargement of GA.
   DESIGN, SETTING, AND PARTICIPANTS: Two identically designed phase 3 double-masked, randomized, sham-controlled clinical trials, Chroma and Spectri, enrolled participants from August 28, 2014, to October 6, 2016, at 275 sites in 23 countries. Participants were aged 50 years or older, with bilateral GA and no prior or active choroidal neovascularization in either eye and GA lesions in the study eye measuring 2.54 to 17.78 mm(2) with diffuse or banded fundus autofluorescence patterns.
   INTERVENTIONS: Participants were randomized 2:1:2:1 to receive 10 mg of intravitreous lampalizumab every 4 weeks, sham procedure every 4 weeks, 10 mg of lampalizumab every 6 weeks, or sham procedure every 6 weeks, through 96 weeks.
   MAIN OUTCOMES AND MEASURES: Safety and efficacy assessed as mean change from baseline in GA lesion area at week 48 from centrally read fundus autofluorescence images of the lampalizumab arms vs pooled sham arms, in the intent-to-treat population and by complement factor I-profile genetic biomarker.
   RESULTS: A total of 906 participants (553 women and 353 men; mean [SD] age, 78.1 [8.1] years) were enrolled in Chroma and 975 participants (578 women and 397 men; mean [SD] age, 77.9 [8.1] years) were enrolled in Spectri; 1733 of the 1881 participants (92.1%) completed the studies through 48 weeks. The adjusted mean increases in GA lesion area from baseline at week 48 were 1.93 to 2.09 mm(2) across all groups in both studies. Differences in adjusted mean change in GA lesion area (lampalizumab minus sham) were -0.02 mm(2) (95% CI, -0.21 to 0.16 mm(2); P = .80) for lampalizumab every 4 weeks in Chroma, 0.16 mm(2) (95% CI, 0.00-0.31 mm(2); P = .048) for lampalizumab every 4 weeks in Spectri, 0.05 mm2 (95% CI, -0.13 to 0.24 mm(2); P = .59) for lampalizumab every 6 weeks in Chroma, and 0.09 mm(2) (95% CI, -0.07 to 0.24 mm(2); P = .27) for lampalizumab every 6 weeks in Spectri. No benefit of lampalizumab was observed across prespecified subgroups, including by complement factor I-profile biomarker. Endophthalmitis occurred after 5 of 12 447 injections (0.04%) or in 5 of 1252 treated participants (0.4%) through week 48.
   CONCLUSIONS AND RELEVANCE: In Chroma and Spectri, the largest studies of GA conducted to date, lampalizumab did not reduce GA enlargement vs sham during 48 weeks of treatment. Results highlight the substantial and consistent enlargement of GA, at a mean of approximately 2 mm(2) per year.
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Sadda, Srinivas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA.
   [Busbee, Brandon] Tennessee Retina, Nashville, TN USA.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Tufail, Adnan] Moorfields Eye Hosp, London, England.
   [Brittain, Christopher; Ferrara, Daniela; Gray, Sarah; Honigberg, Lee; Martin, Jillian; Tong, Barbara; Ehrlich, Jason S.] Genentech Inc, Roche Grp, San Francisco, CA 94080 USA.
   [Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
C3 University of Bonn; Doheny Eye Institute; University of California
   System; University of California Los Angeles; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); University of
   Sydney; University of Sydney; Westmead Institute for Medical Research;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Roche Holding; Genentech; Johns Hopkins University
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Maumenee 752,600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
RI ; Virgili, Gianni/P-6607-2014
OI Adrean, Sean/0000-0001-6004-0643; Mones, Jordi/0000-0003-3685-2160;
   Kiss, Szilard/0000-0003-3433-8432; Tufail, Adnan/0000-0001-6131-7640;
   Guner, Mehmet Eren/0000-0002-5335-4051; Schlottmann,
   Patricio/0000-0003-0196-0452; Virgili, Gianni/0000-0002-9960-2989;
   Figueira, Joao P/0000-0002-3511-1515
FU F. Hoffmann-La Roche Ltd
FX Funding was provided by F. Hoffmann-La Roche Ltd for third-party writing
   assistance, which was provided by Kathryn H. Condon, PhD, CMPP, Envision
   Pharma Group.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown JC, 2014, OPHTHALMOLOGY, V121, P1655, DOI 10.1016/j.ophtha.2014.02.030
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   ClinicalTrials.gov, CLG561 PROOF OF CONC
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Ophthotech, OPHTH PROV UPD ZIM C
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness Janet S, 2008, Retin Cases Brief Rep, V2, P83, DOI 10.1097/IAE.0b013e31802fa25d
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   VOLANAKIS JE, 1985, NEW ENGL J MED, V312, P395, DOI 10.1056/NEJM198502143120702
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Medical Association, WMA DECL HELS ETH PR
   Wurzelmann JI, 2015, INVEST OPHTH VIS SCI, V56
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2015, OSLI RETINA, V46, P772, DOI 10.3928/23258160-20150730-15
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zamiri P, 2016, ANG FEBR 6 MIAM FL
NR 42
TC 173
Z9 175
U1 2
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2018
VL 136
IS 6
BP 666
EP 677
DI 10.1001/jamaophthalmol.2018.1544
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GJ4NZ
UT WOS:000435359100018
PM 29801123
OA Green Published, Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Skorin, L
   Genereux, L
AF Skorin, Leonid, Jr.
   Genereux, Lucas
TI Intravitreal Aflibercept after Bilateral Bevacizumab-Induced Iritis
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE wet age-related macular degeneration (ARMD); anti-vascular endothelial
   growth factor (anti-VEGF); intravitreal injection; bevacizumab;
   ranibizumab; aflibercept; iritis
ID INTRAOCULAR PHARMACOKINETICS; MACULAR DEGENERATION; INJECTION;
   RANIBIZUMAB; SAFETY; HUMANS
AB Purpose. To present a case of neovascular age-related macular degeneration treated with aflibercept intravitreal injections after bilateral bevacizumab injections, administered on separate dates, resulted in bilateral iritis.
   Case Report. A 73-year-old woman with a previous history of two episodes of nongranulomatous iritis in her right eye that was believed to be associated with her systemic diagnosis of rheumatoid arthritis was treated with intravitreal bevacizumab injections for bilaterally occurring neovascular age-related macular degeneration. Initial bevacizumab injections in each eye administered sequentially over a week's timeresulted in immediate-onset nongranulomatous iritis in each eye. Subsequent intravitreal injections of aflibercept were administered, and therapeutic benefit was achieved without occurrence of iritis.
   Conclusions. In cases where intravitreal bevacizumab results in anterior uveitis, aflibercept may be a safe alternative therapeutic choice for the treatment of neovascular age-related macular degeneration.
C1 [Skorin, Leonid, Jr.] Mayo Clin Hlth Syst, Dept Ophthalmol, Albert Lea, MN 56007 USA.
   [Genereux, Lucas] Univ Pacific, Coll Optometry, Forest Grove, OR USA.
C3 University of the Pacific
RP Skorin, L (通讯作者)，Mayo Clin Hlth Syst, 404 W Fountain St, Albert Lea, MN 56007 USA.
EM skorin.leonid@mayo.edu
CR Abu-Yaghi NE, 2011, OCULAR THERAPEUTICS, P483
   Antonopoulos C, 2011, CLIN OPHTHALMOL, V5, P1659, DOI 10.2147/OPTH.S26880
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chong DY, 2010, RETINA-J RET VIT DIS, V30, P1432, DOI 10.1097/IAE.0b013e3181dc04da
   Damasceno N, 2012, CLIN OPHTHALMOL, V6, P1201, DOI 10.2147/OPTH.S31239
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Goldberg RA, 2014, AM J OPHTHALMOL, V158, P733, DOI 10.1016/j.ajo.2014.06.019
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Ophthalmologic Drugs Advisory Committee, 2011, VEGF TRAP EYE AFL OP, V61, P76
   Rosenfeld PJ, 2009, OPHTHALMOLOGY, P658
   Rosenfeld PJ, 2012, RETINA TODAY, P50
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
NR 17
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAY
PY 2015
VL 92
IS 5
BP E97
EP E105
DI 10.1097/OPX.0000000000000568
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG6OM
UT WOS:000353421500002
PM 25871873
DA 2022-11-30
ER

PT J
AU Read, S
   Lawrenson, JG
   Harper, RA
   Hanley, T
   Balaskas, K
   Waterman, H
AF Read, Simon
   Lawrenson, John G.
   Harper, Robert A.
   Hanley, Thomas
   Balaskas, Konstantinos
   Waterman, Heather
TI Evaluation of training, patient and practitioner perspectives on
   community-based monitoring of patients with stable age-related macular
   degeneration compared to hospital-based care: The FENETRE study report
   no. 1
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE accreditation; clinical competence; optometry; primary health care;
   secondary care; wet macular degeneration
AB Purpose Describe the development, delivery, acceptability and evaluation of a modular training programme for community-based, non-medical practitioners monitoring patients with quiescent neovascular age related macular degeneration (QnAMD). Also, report on a qualitative process evaluation conducted during the pilot phase of a randomised control trial (the FENETRE Study) exploring patient and practitioner acceptability of community-based QnAMD care relative to hospital-based care.
   Methods Learning outcomes from The College of Optometrists' Medical Retina higher qualifications and the Royal College of Ophthalmologists' Common Clinical Competency Framework were used to develop a competency framework for QnAMD care. Training was delivered online, comprising six asynchronous lectures followed by two synchronous case-based discussion webinars, with an accredited assessment of 24 case vignettes. An anonymous evaluation survey was conducted with the first two FENETRE cohorts (n = 38). Separately, we undertook a qualitative process evaluation, sampling purposively in four hospitals and five community-based practices, interviewing nine patients and eight practitioners.
   Results Survey responses (n = 26) showed community optometrists were very satisfied (n = 12; 46%) or satisfied (n = 14; 54%) with the training; feedback reflected by qualitative process evaluation data. Overall, optometrists also felt either confident (n = 15; 58%) or very confident (n = 8; 31%) in conducting AMD monitoring appointments following training, a finding also corroborated by interview data from optometrists participating in the initial pilot phase roll-out. Optometrists identified patient convenience and alleviating pressures in hospital care as the primary reasons for acceptability of community pathways. Data from patients entering community practices suggested they largely found this at least as safe and convenient as hospital care, although some patients randomised to hospital care perceived that as safer.
   Conclusion This pilot study has shown the development and implementation of a collaborative community monitoring model is feasible, with satisfaction from community optometrists for training and accreditation, and broad acceptance for the pathway by both patients and practitioners.
C1 [Read, Simon] Cardiff Univ, Sch Healthcare Sci, Cardiff, Wales.
   [Lawrenson, John G.; Hanley, Thomas] City Univ London, Sch Hlth Sci, London, England.
   [Harper, Robert A.] Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Harper, Robert A.] Univ Manchester, Sch Hlth Sci, Manchester, Lancs, England.
   [Balaskas, Konstantinos] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Waterman, Heather] Cardiff Univ, Sch Healthcare Sci, Cardiff, Wales.
C3 Cardiff University; City University London; Manchester Royal Eye
   Hospital; University of Manchester; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; Cardiff
   University
RP Read, S (通讯作者)，Cardiff Univ, Sch Healthcare Sci, Cardiff, Wales.
EM readsm@cardiff.ac.uk
RI Balaskas, Konstantinos/ABD-5979-2020; Waterman, Heather/I-6049-2014
OI Balaskas, Konstantinos/0000-0002-7690-6277; Waterman,
   Heather/0000-0001-7052-2734; Lawrenson, John/0000-0002-2031-6390; Read,
   Simon/0000-0003-2445-283X; Harper, Robert/0000-0001-5437-2553
FU National Institute for Health Research [17/85/05]
FX This work was supported by the National Institute for Health Research,
   Award ID: 17/85/05.
CR Baker H, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011934
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Learoyd AE, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-049411
   National Institute for Care Excellence (UK), 2018, AGE RELATED MACULAR
   QSR International, 2020, NVIVO ONL
   Qualtrics, 2020, ONL SURV SOFTW
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Reeves BC, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20800
   Ritchie J., 2002, ANAL QUALITATIVE DAT, V1, P187, DOI DOI 10.4135/9781412986274.N12
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   The College of Optometrists, 2020, HIGH QUAL MED RET
   The Royal College of Ophthalmologists, 2020, OPHTH COMM CLIN COMP
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 15
TC 0
Z9 0
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JUL
PY 2021
VL 41
IS 4
BP 864
EP 873
DI 10.1111/opo.12836
EA MAY 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SS9CB
UT WOS:000654036300001
PM 34036613
OA hybrid, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Valverde-Megias, A
   Veganzones-de-Castro, S
   Donate-Lopez, J
   Maestro-de-las-Casas, M
   Megias-Fresno, A
   Garcia-Feijoo, J
AF Valverde-Megias, Alicia
   Veganzones-de-Castro, Silvia
   Donate-Lopez, Juan
   Luisa Maestro-de-las-Casas, Maria
   Megias-Fresno, Alicia
   Garcia-Feijoo, Julian
TI ARMS2 A69S polymorphism is associated with the number of ranibizumab
   injections needed for exudative age-related macular degeneration in a
   pro re nata regimen during 4 years of follow-up
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE CNV recurrence; Exudative AMD; ARMS2; Pharmacogenetics; Ranibizumab
ID GROWTH-FACTOR TREATMENT; COMPLEMENT FACTOR-H; GEOGRAPHIC ATROPHY;
   TREATMENTS TRIALS; INTRAVITREAL BEVACIZUMAB; RISK; OUTCOMES;
   METAANALYSIS; LOC387715; THERAPY
AB To investigate whether single-nucleotide polymorphisms (SNPs) known to be strongly associated with the development of age-related macular degeneration (AMD) have an influence on recurrence rate of choroidal neovascularization (CNV) activity during 4-year ranibizumab treatment for exudative AMD.
   This prospective study included 103 treatment-na < ve patients (103 eyes) that received initially a loading dose of 3 monthly ranibizumab injections and thereafter, were treated according to an as-needed regimen for a 4-year follow-up period. Baseline values, visual outcome, and recurrence rate were examined. CFH Y402H and ARMS2 A69S polymorphisms were determined and their association with lesion recurrence and visual outcome was analyzed using a one-way analysis of variance (ANOVA) with post hoc comparison tested by Fisher's LSD method. Multivariate linear regression analysis was then used to identify factors associated with recurrence rate.
   The cumulative total mean number of ranibizumab injections at the end of each year of the follow-up was 5.3 +/- 1.8, 9.2 +/- 2.9, 12.6 +/- 4.6, and 15.7 +/- 6.1. There was great inter-patient variability. Nineteen eyes (18.5%) did not experience recurrence during the first year, and five (4.8%) still displayed inactive CNV after 4 years of follow-up. No significant association was found between the number of injections and mean best corrected visual acuity (BCVA) change or final BCVA at the end of the study period. Genotypes had no influence on baseline characteristics or visual outcome but a significant association was found between the A69S polymorphism and the number of injections needed by the patients. Homozygous for the T risk allele required more retreatments over the 48-month follow-up.
   The ARMS2 A69S polymorphism was associated with CNV recurrence rate in our patient cohort. Prediction of a greater risk of recurrence could help to design more appropriate follow-up treatment strategies for patients with neovascular AMD.
C1 [Valverde-Megias, Alicia; Donate-Lopez, Juan; Garcia-Feijoo, Julian] San Carlos Clin Hosp IdISSC, Sanitary Res Inst, Dept Ophthalmol, San Carlos Clin Hosp,Retina Serv, C Prof Martin Lagos S-N, Madrid 28040, Spain.
   [Veganzones-de-Castro, Silvia; Luisa Maestro-de-las-Casas, Maria] San Carlos Clin Hosp, Dept Clin Anal, Madrid, Spain.
   [Megias-Fresno, Alicia] Univ Complutense Madrid, Dept Biochem & Mol Biol 1, Fac Biol, Madrid, Spain.
C3 Complutense University of Madrid
RP Valverde-Megias, A (通讯作者)，San Carlos Clin Hosp IdISSC, Sanitary Res Inst, Dept Ophthalmol, San Carlos Clin Hosp,Retina Serv, C Prof Martin Lagos S-N, Madrid 28040, Spain.
EM alicia.valgreen@gmail.com
RI GARCIA FEIJOO, JULIAN/G-9762-2017
OI GARCIA FEIJOO, JULIAN/0000-0002-7772-5718; Veganzones,
   Silvia/0000-0003-3719-2168; Valverde-Megias, Alicia/0000-0002-6166-114X;
   DONATE, JUAN/0000-0002-9944-6736
CR Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown D.M., 2009, OPHTHALMOLOGY, V116, pe5
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Ichiyama Y, 2017, RETINA-J RET VIT DIS, V37, P724, DOI 10.1097/IAE.0000000000001576
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park UC, 2014, MOL VIS, V20, P1680
   Pulido JS, 2007, MAYO CLIN PROC, V82, P301, DOI 10.4065/82.3.301
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tong Y, 2010, MOL VIS, V16, P1958
NR 32
TC 10
Z9 10
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2017
VL 255
IS 11
BP 2091
EP 2098
DI 10.1007/s00417-017-3748-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ8HR
UT WOS:000413006000002
PM 28744656
DA 2022-11-30
ER

PT J
AU Gomi, F
   Sawa, M
   Sakaguchi, H
   Tsujikawa, M
   Oshima, Y
   Kamei, M
   Tano, Y
AF Gomi, F.
   Sawa, M.
   Sakaguchi, H.
   Tsujikawa, M.
   Oshima, Y.
   Kamei, M.
   Tano, Y.
TI Efficacy of intravitreal bevacizumab for polypoidal choroidal
   vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; CLINICOPATHOLOGICAL CORRELATION;
   NEOVASCULARIZATION; INJECTION; AVASTIN; TRIAMCINOLONE; VERTEPORFIN
AB Aims: The aim of the study was to assess the short-term efficacy of intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV).
   Methods: Intravitreal bevacizumab (1 mg) was injected into 11 eyes of 11 patients with PCV in this retrospective, interventional case series. The main outcome measure was the change in the polypoidal vessels on indocyanine green angiography (IA) 3 months after injection. The foveal height determined by optical coherence tomography and the best-corrected visual acuity (BCVA) also were evaluated before and after treatment.
   Results: At baseline, subretinal fluid was observed in five eyes and a pigment epithelial detachment in eight eyes. The foveal height 1 month after injection decreased significantly (p = 0.023), but at 3 months, no significant decrease was observed, although an additional injection was administrated in five of 11 eyes. The IA at 3 months showed resolution of polyps in one eye but residual or enlarged lesions in the other ten eyes. The BCVA did not improve significantly, although the subjects had relatively good BCVA at baseline (mean 0.45).
   Conclusion: Intravitreal injection of bevacizumab may reduce the fluid from PCV but seems to be ineffective for diminishing its choroidal vascular changes.
C1 [Gomi, F.; Sawa, M.; Sakaguchi, H.; Tsujikawa, M.; Oshima, Y.; Kamei, M.; Tano, Y.] Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   GOMI F, IN PRESS OPHTHALMOLO
   Gomi F, 2007, AM J OPHTHALMOL, V143, P507, DOI 10.1016/j.ajo.2006.10.050
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 31
TC 201
Z9 214
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2008
VL 92
IS 1
BP 70
EP 73
DI 10.1136/bjo.2007.122283
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 247CM
UT WOS:000252054700016
PM 17567661
DA 2022-11-30
ER

PT J
AU Teo, KYC
   Yanagi, Y
   Lee, SY
   Yeo, IYS
   Tan, GSW
   Mathur, R
   Chan, CM
   Wong, TY
   Cheung, CMG
AF Teo, Kelvin Yi Chong
   Yanagi, Yasuo
   Lee, Shu Yen
   Yeo, Ian Yew San
   Tan, Gavin Siew Wei
   Mathur, Ranjana
   Chan, Choi Mun
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI COMPARISON OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHIC CHANGES AFTER
   ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY ALONE OR IN COMBINATION
   WITH PHOTODYNAMIC THERAPY IN POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF; AMD; choriocapillaris; Haller layer; OCTA; photodynamic
   therapy; polypoidal choroidal vasculopathy; PCV
ID RANIBIZUMAB; AFLIBERCEPT; THICKNESS; EFFICACY
AB Purpose: To compare changes in optical coherence tomography angiography in eyes with polypoidal choroidal vasculopathy after treatment with anti-vascular endothelial growth factor monotherapy or combined with photodynamic therapy.
   Methods: This is a longitudinal case-controlled study. The authors performed optical coherence tomography angiography at baseline and Month 3 in patients with treatment-naive polypoidal choroidal vasculopathy undergoing monotherapy (n = 10) or combination therapy (n = 13). We analyzed flow signal within the outer retina and choriocapillaris using automated segmentation. The authors analyzed the presence of pachyvessels using a 10.4-mu m segment through Haller layer. The changes in each layer were compared between treatments.
   Results: At Month 3, both groups showed similar improvement in best-corrected visual acuity and central retinal thickness. However, flow signal within the polypoidal choroidal vasculopathy complex was decreased in more eyes after combination therapy than after monotherapy (84.6% vs. 40.0%, P = 0.04). Patchy reduction in flow signal within the choriocapillaris layer was noted in 15.4% and 10.0% after combination therapy and monotherapy, respectively (P = 0.61). Significant reduction in pachyvessel caliber was seen only after combination therapy but not after monotherapy (75.0% vs. 0.0%, P = 0.01).
   Conclusion: Longitudinal optical coherence tomography angiography demonstrates more significant reduction in lesion flow and pachyvessels in the short term after combination therapy than after monotherapy, although visual and structural OCT showed similar improvement.
C1 [Teo, Kelvin Yi Chong; Yanagi, Yasuo; Lee, Shu Yen; Yeo, Ian Yew San; Tan, Gavin Siew Wei; Mathur, Ranjana; Chan, Choi Mun; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Retina Dept, Singapore, Singapore.
   [Teo, Kelvin Yi Chong; Yanagi, Yasuo; Lee, Shu Yen; Yeo, Ian Yew San; Tan, Gavin Siew Wei; Mathur, Ranjana; Chan, Choi Mun; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Lee, Shu Yen; Yeo, Ian Yew San; Tan, Gavin Siew Wei; Mathur, Ranjana; Chan, Choi Mun; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Yeo, Ian Yew San; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Duke NUS Grad Med Sch, Ophthalmol Acad Clin Program, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Yanagi, Yasuo/AAF-2670-2020; Yanagi,
   Yasuo/AAA-5441-2022
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Teo, Kelvin/0000-0002-7458-7081; Yanagi,
   Yasuo/0000-0002-0362-7285
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Recchia FM, 2006, RETINA-J RET VIT DIS, V26, P1042, DOI 10.1097/01.iae.0000254894.94013.d8
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 17
Z9 18
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2018
VL 38
IS 9
BP 1675
EP 1687
DI 10.1097/IAE.0000000000001776
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VL
UT WOS:000454003500006
PM 28767554
DA 2022-11-30
ER

PT J
AU Finger, RP
   Daien, V
   Eldem, BM
   Talks, JS
   Korobelnik, JF
   Mitchell, P
   Sakamoto, T
   Wong, TY
   Pantiri, K
   Carrasco, J
AF Finger, Robert P.
   Daien, Vincent
   Eldem, Bora M.
   Talks, James S.
   Korobelnik, Jean-Francois
   Mitchell, Paul
   Sakamoto, Taiji
   Wong, Tien Yin
   Pantiri, Krystallia
   Carrasco, Joao
TI Anti-vascular endothelial growth factor in neovascular age-related
   macular degeneration - a systematic review of the impact of anti-VEGF on
   patient outcomes and healthcare systems
SO BMC OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; Neovascular; Anti-VEGF; Impact;
   Systematic review; Visual impairment; Vision-related QoL; Legal
   blindness; Cost
ID QUALITY-OF-LIFE; VISION IMPAIRMENT QUESTIONNAIRE; VISUAL IMPAIRMENT;
   RANIBIZUMAB TREATMENT; TREATMENT PATTERNS; LEGAL BLINDNESS; MEDICARE
   COSTS; DEPRESSION; EYE; INJECTION
AB Background: Systematically review the evidence describing the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on neovascular age-related macular degeneration (nAMD) patient outcomes and healthcare resource utilization.
   Methods: A systematic literature review was completed using Medline and EMBASE for publications prior to July 2018, and proceedings from major ophthalmology conferences (January 2016 to July 2018). The search strategy combined terms for nAMD with terms for anti-VEGF and study design. The review focused on publications describing the impact of anti-VEGF on blindness, visual impairment, vision-related quality of life (VRQoL), mortality, and costs. The search targeted data collected in epidemiological or observational studies to reflect real-world outcomes but also considered modeling-based approaches.
   Results: The use of anti-VEGF in clinical practice was associated with significant reduction in the incidence of blindness by nAMD. Population-based analyses reported reduction in incidence among the general population of 47% (9.1 cases/100,000 in 2006 to 4.8 cases/100,000 in 2011). Among patients aged >= 50 years, a reduction of 50% was observed (52.2 cases/100,000 in 2000 to 25.7 cases/100,000 in 2010). In some cases, the odds of decreased vision (defined as decline from normal to moderate, moderate to severe, or severe to blindness) fell by 41% following introduction of anti-VEGF. Patients' VRQoL improved with treatment, with patients reporting a positive impact shortly after treatment was initiated. Change on National Eye Institute 25-Item Visual Function Questionnaire score from baseline to month 12 ranged from 0.7 to 4.4. Although nAMD patients report signs of depression and anxiety, the evidence suggests that there is no association between the use of anti-VEGF and the prevalence or diagnosis of depression. The introduction of anti-VEGF led to increased overall treatment costs due to replacement of existing less frequently administered treatments (e.g. photodynamic therapy) and increased number of patients treated (prior to anti-VEGF, only similar to 20% of patients were eligible for treatment).
   Conclusions: The introduction of anti-VEGF agents has been associated with a positive impact on patient-relevant outcomes, including a significant reduction in incidence of blindness and visual impairment by nAMD. Anti-VEGF agents replaced less-effective treatments, improving patient outcomes and broadening the patient population eligible for treatment.
C1 [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Daien, Vincent] Gui de Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Eldem, Bora M.] Hacettepe Univ Hosp, Fac Med, Ophthalmol Dept, Ankara, Turkey.
   [Talks, James S.] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne, Tyne & Wear, England.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois] INSERM, Bordeaux Populat Hlth Res Ctr, Bordeaux, France.
   [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Sakamoto, Taiji] Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima, Japan.
   [Sakamoto, Taiji] Japan Clin Retina Study Grp J CREST Grp, Kagoshima, Japan.
   [Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Yin] Duke NUS Med Sch, Singapore, Singapore.
   [Pantiri, Krystallia] Pharmerit Int, Rotterdam, Netherlands.
   [Carrasco, Joao] Bayer Consumer Care AG, Peter Merian Str 84, CH-4052 Basel, Switzerland.
C3 University of Bonn; Universite de Montpellier; CHU de Montpellier;
   University of Sydney; Hacettepe University; Newcastle University - UK;
   CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); University of Sydney; Westmead Institute for Medical Research;
   Kagoshima University; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; Bayer AG
RP Carrasco, J (通讯作者)，Bayer Consumer Care AG, Peter Merian Str 84, CH-4052 Basel, Switzerland.
EM joao.carrasco@bayer.com
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Talks, James/0000-0001-6126-6476
FU Bayer
FX This work was funded by Bayer. Pharmerit International was commissioned
   by Bayer to carry out the systematic review (the design, data
   collection, analysis, and interpretation) and draft the manuscript.
   Editorial support was provided by ApotheCom, UK, and funded by Bayer.
CR Access Economics Pty Limited, 2010, GLOB EC COST VIS IMP
   Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   [Anonymous], 2006, SYSTEMATIC REV CRDS
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Cooley SSL, 2016, INVEST OPHTH VIS SCI, V57
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Fabiano G, 2018, INT J TECHNOL ASSESS, P33
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Inoue M, 2014, CLIN OPHTHALMOL, V8, P1711, DOI 10.2147/OPTH.S68293
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Kiss S, 2016, INVEST OPHTH VIS SCI, V57
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Kume A, 2016, OPHTHALMOLOGY, V123, P1263, DOI 10.1016/j.ophtha.2016.01.042
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Lee WJ, 2013, ASIA-PAC J OPHTHALMO, V2, P23, DOI 10.1097/APO.0b013e31827be8b1
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Qualls LG, 2013, RETINA-J RET VIT DIS, V33, P854, DOI 10.1097/IAE.0b013e31826f065e
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, AM J OPHTHALMOL, V191, P135, DOI 10.1016/j.ajo.2018.04.008
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Segal O, 2016, ACTA OPHTHALMOL, V94, P203, DOI 10.1111/aos.12802
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Shalaby AK, 2016, EYE, V30, P1404, DOI 10.1038/eye.2016.154
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Weiss Daniel S., 1997, P399
   Windsor MA, 2018, AM J OPHTHALMOL, V185, P115, DOI 10.1016/j.ajo.2017.09.027
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
   Zhu MD, 2017, GRAEF ARCH CLIN EXP, V255, P475, DOI 10.1007/s00417-016-3477-9
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 54
TC 25
Z9 25
U1 1
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 17
PY 2020
VL 20
IS 1
AR 294
DI 10.1186/s12886-020-01554-2
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MP7OM
UT WOS:000552390700002
PM 32680477
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Khan, S
   Engelbert, M
   Imamura, Y
   Freund, KB
AF Khan, Samira
   Engelbert, Michael
   Imamura, Yutaka
   Freund, K. Bailey
TI POLYPOIDAL CHOROIDAL VASCULOPATHY Simultaneous Indocyanine Green
   Angiography and Eye-Tracked Spectral Domain Optical Coherence Tomography
   Findings
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; Type 1 neovascularization;
   spectral-domain optical coherence tomography; indocyanine green
   angiography; choroidal neovascularization; age-related macular
   degeneration
ID PIGMENT EPITHELIAL DETACHMENTS; MACULAR DEGENERATION;
   CLINICOPATHOLOGICAL CORRELATION; PATIENT; NEOVASCULARIZATION;
   ASSOCIATION; HEMORRHAGE; FEATURES; GENE; CFH
AB Purpose: To describe simultaneous scanning laser ophthalmoscope indocyanine green angiographic and eye-tracked spectral-domain optical coherence tomography findings in eyes with polypoidal choroidal vasculopathy (PCV).
   Methods: Eighteen eyes of 18 patients with PCV because of a variety of different diagnoses were imaged with simultaneous scanning laser ophthalmoscope indocyanine green angiography and eye-tracked spectral-domain optical coherence tomography to localize the polyps and their associated vascular structures with respect to the retinal layers.
   Results: Regardless of the underlying diagnosis, simultaneous scanning laser ophthalmoscope indocyanine green angiography and eye-tracked spectral-domain optical coherence tomography imaging localized the polypoidal structures of PCV to within larger Type 1 neovascular complexes occurring within or above Bruch membrane. In 8 eyes, PCV appeared to adhere to the undersurface of an elevated retinal pigment epithelial detachment. In 1 eye, a PCV lesion was detected within the neurosensory retina having apparently eroded through the overlying retinal pigment epithelium.
   Conclusion: Simultaneous scanning laser ophthalmoscope indocyanine green angiography and eye-tracked spectral-domain optical coherence tomography demonstrate that a majority of PCV represents a variant of the Type 1 neovascular growth pattern, which can occur in a variety of different neovascularized maculopathies. Polypoidal choroidal vasculopathy lesions appear to originate from long-standing choroidal neovascularization, rather than from the choroidal vasculature itself. Given these observations, PCV would be more accurately described as a neovasculopathy rather than as a choroidal vasculopathy. RETINA 32: 1057-1068, 2012
C1 [Engelbert, Michael; Imamura, Yutaka; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Khan, Samira; Engelbert, Michael; Freund, K. Bailey] NYU, Med Ctr, Dept Ophthalmol, New York, NY 10016 USA.
   [Engelbert, Michael; Imamura, Yutaka; Freund, K. Bailey] Manhattan Eye Ear & Throat Inst, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Imamura, Yutaka] Teikyo Univ, Sch Med, Mizonokuchi Hosp, Dept Ophthalmol, Kawasaki, Kanagawa, Japan.
C3 Vitreous Retina Macula Consultants of New York; New York University;
   Teikyo University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc.; Koureisha Ganshikkan Kenkyu Zaidan; Mishima
   Saiichi-kinen Gankakenkyu Kokusaikouryu Kikin; Takeda Kagaku Shinku
   Zaidan
FX Supported in part by the Macula Foundation, Inc.; Dr Y. Imamura was
   funded by grants from Koureisha Ganshikkan Kenkyu Zaidan, Mishima
   Saiichi-kinen Gankakenkyu Kokusaikouryu Kikin and the Takeda Kagaku
   Shinku Zaidan.
CR Abe Sachi, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-76
   Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Baillif-Gostoli S, 2010, GRAEF ARCH CLIN EXP, V248, P1845, DOI 10.1007/s00417-010-1328-7
   Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fine Howard F, 2008, Retin Cases Brief Rep, V2, P15, DOI 10.1097/ICB.0b013e318159e7e9
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li HT, 2004, RETINA-J RET VIT DIS, V24, P629, DOI 10.1097/00006982-200408000-00026
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2011, EYE, V25, P481, DOI 10.1038/eye.2010.232
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 43
TC 86
Z9 94
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2012
VL 32
IS 6
BP 1057
EP 1068
DI 10.1097/IAE.0b013e31823beb14
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 948VY
UT WOS:000304532100003
PM 22127224
DA 2022-11-30
ER

PT J
AU Nilsson, SEG
AF Nilsson, Sven Erik G.
TI From basic to clinical research: a journey with the retina, the retinal
   pigment epithelium, the cornea, age-related macular degeneration and
   hereditary degenerations, as seen in the rear view mirror
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Review
DE photoreceptors; retinal pigment epithelium (RPE); age-related macular
   degeneration (AMD); hereditary diseases of the retina and RPE; animal
   models; electrophysiology; ultrastructure; photodynamic therapy;
   rehabilitation
ID DC-RECORDED ELECTRORETINOGRAM; PROPHYLACTIC LASER TREATMENT; ERG C-WAVE;
   INTRACELLULAR RESPONSES; PHOTODYNAMIC THERAPY; LIPOFUSCIN-FORMATION;
   ABYSSINIAN CAT; CANINE MODEL; BRIARD DOGS; LIGHT PEAK
AB Purpose: This Acta Ophthalmologica Award and Gold Medal Honorary Lecture (the Lundsgaard Gold Medal Honorary Lecture) reviews some of the work I have carried out with my mentors and many of my wonderful collaborators and research students over more than 40 years, also including related work by other groups. It concentrates on the basic electrophysiology and ultrastructure of the retina and the retinal pigment epithelium (RPE), as well as covering basic and clinical aspects of the cornea, contact lenses, age-related macular degeneration (AMD) and hereditary diseases.
   Methods: The review describes research performed using light and electron microscopy, basic and clinical electrophysiology, genetics and biochemistry in animal experiments and in research on patients. It also outlines clinically used techniques, such as laser and photodynamic treatment and scanning laser ophthalmoscopy.
   Results: The paper reports on the following subjects: the mechanisms behind some of the electrical potentials originating in the retina and the RPE and the use of these potentials in hereditary diseases; corneal receptors for lectins and presumably for bacteria; the turnover of the photoreceptor outer segment and the formation of tipofuscin, including the relation of these processes to AMD; certain treatments for AMD, and hereditary degenerations in animal models, such as the RPE65 gene mutation in Briard dogs, which makes them a model of Leber's congenital amaurosis. The dogs are now treated successfully with gene therapy in the USA, and a clinical trial is in preparation.
   Conclusions: During the last 40 years we have had the good fortune to experience a dramatic growth in knowledge and understanding within ophthalmic science of basic mechanisms. Huge progress has been made in diagnostics and clinical ophthalmological treatments, much to the benefit of our patients. Even a small contribution made by my group to these developments has been well worth the effort, particularly as scientific work is not just deeply satisfying: it is also fun!
C1 Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
C3 Linkoping University
RP Nilsson, SEG (通讯作者)，Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
EM nilsson.s.e@telia.com
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Aguirre G D, 1998, Mol Vis, V4, P23
   ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   ARDEN GB, 1962, J PHYSIOL-LONDON, V161, P189, DOI 10.1113/jphysiol.1962.sp006881
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bragadottir R, 1995, CURR EYE RES, V14, P1073, DOI 10.3109/02713689508995812
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BROWN KT, 1961, J PHYSIOL-LONDON, V158, P229, DOI 10.1113/jphysiol.1961.sp006767
   BROWN KT, 1961, J PHYSIOL-LONDON, V158, P257, DOI 10.1113/jphysiol.1961.sp006768
   BROWN KT, 1962, NATURE, V193, P958, DOI 10.1038/193958a0
   CRESCITELLI F, 1966, SCIENCE, V151, P1545, DOI 10.1126/science.151.3717.1545
   CUMMINGS RW, 1992, INVEST OPHTH VIS SCI, V33, P1418
   Fine SL, 1999, INVEST OPHTH VIS SCI, V40, pS318
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P645, DOI 10.1111/j.1600-0420.2004.00368.x
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P651, DOI 10.1111/j.1600-0420.2004.00382.x
   Frennesson CI, 2003, ACTA OPHTHALMOL SCAN, V81, P449, DOI 10.1034/j.1600-0420.2003.00143.x
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   FRIBERG TR, 2002, INVEST OPHTH VIS SCI, V43, P2004
   FRISHMAN LJ, 1989, J NEUROPHYSIOL, V61, P1233, DOI 10.1152/jn.1989.61.6.1233
   GALLEMORE RP, 1993, J NEUROPHYSIOL, V70, P1669, DOI 10.1152/jn.1993.70.4.1669
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Granit R, 1933, J PHYSIOL-LONDON, V77, P207, DOI 10.1113/jphysiol.1933.sp002964
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAMEL CP, 1993, J BIOL CHEM, V268, P15751
   HUSON HL, 2005, INVEST OPHTH VIS SCI, V46, P1375
   JARKMAN S, 1985, DOC OPHTHALMOL, V60, P383, DOI 10.1007/BF00158928
   JARKMAN S, 1987, DOC OPHTHALMOL, V67, P305, DOI 10.1007/BF00143948
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   KARWOSKI CJ, 1977, J NEUROPHYSIOL, V40, P244, DOI 10.1152/jn.1977.40.2.244
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KLINE RP, 1978, P NATL ACAD SCI USA, V75, P5727, DOI 10.1073/pnas.75.11.5727
   KNAVE B, 1973, ACTA OPHTHALMOL, V51, P716
   KNAVE B, 1974, ACTA PHYSIOL SCAND, V91, P180, DOI 10.1111/j.1748-1716.1974.tb05674.x
   KOLDER H, 1966, ARCH OPHTHALMOL-CHIC, V75, P232
   LACOUR M, 1986, J PHYSIOL-LONDON, V375, P461, DOI 10.1113/jphysiol.1986.sp016128
   LATKOVIC S, 1995, OPTOMETRY VISION SCI, V72, P643, DOI 10.1097/00006324-199509000-00007
   Latkovic Stefan, 1997, CLAO Journal, V23, P185
   LINSENMEIER RA, 1984, J GEN PHYSIOL, V83, P213, DOI 10.1085/jgp.83.2.213
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER SS, 1977, J MEMBRANE BIOL, V36, P337, DOI 10.1007/BF01868158
   NARFSTROM K, 1983, J HERED, V74, P273, DOI 10.1093/oxfordjournals.jhered.a109782
   Narfstrom K, 2005, DOC OPHTHALMOL, V111, P39, DOI [10.1007/s10633-005-3159-0, 10.1007/S10633-005-3159-0]
   NARFSTROM K, 1986, INVEST OPHTH VIS SCI, V27, P1569
   NARFSTROM K, 1994, VET COMP OPHTHALMOL, V4, P86
   NARFSTROM KL, 1985, BRIT J OPHTHALMOL, V69, P618, DOI 10.1136/bjo.69.8.618
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   NILSSON SEG, 1970, J ULTRA MOL STRUCT R, V30, P87, DOI 10.1016/S0022-5320(70)90066-3
   NILSSON SEG, 1980, ACTA OPHTHALMOL, V58, P659
   NILSSON SEG, 1983, INVEST OPHTH VIS SCI, V24, P77
   NILSSON SEG, 1988, DOC OPHTHALMOL, V68, P313, DOI 10.1007/BF00156437
   NILSSON SEG, 1975, ACTA OPHTHALMOL, V53, P721
   NILSSON SEG, 1992, EXP EYE RES, V54, P291, DOI 10.1016/S0014-4835(05)80218-0
   NILSSON SEG, 1964, J ULTRA MOL STRUCT R, V11, P581, DOI 10.1016/S0022-5320(64)80084-8
   NILSSON SEG, 1994, CONTACT LENS PRACTIC, P917
   NILSSON SEG, 1977, DOCUM OPHTHAL P SER, V13, P99
   Nilsson Sven Erik G., 2001, CLAO Journal, V27, P125
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   OAKLEY B, 1976, J NEUROPHYSIOL, V39, P1117, DOI 10.1152/jn.1976.39.5.1117
   OAKLEY B, 1977, INVEST OPHTH VIS SCI, V16, P771
   Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461
   QUINN RH, 1992, INVEST OPHTH VIS SCI, V33, P3513
   Ren David H., 1999, CLAO Journal, V25, P80
   Schein OD, 2005, OPHTHALMOLOGY, V112, P2172, DOI 10.1016/j.ophtha.2005.09.014
   SCHMIDT R, 1971, J PHYSIOL-LONDON, V217, P71, DOI 10.1113/jphysiol.1971.sp009560
   SKOOG KO, 1977, VISION RES, V17, P409, DOI 10.1016/0042-6989(77)90032-3
   SKOOG KO, 1974, ACTA OPHTHALMOL, V52, P904
   SKOOG KO, 1981, ACTA OPHTHALMOL, V59, P71
   SKOOG KO, 1975, ACTA OPHTHALMOL, V53, P120
   SKOOG KO, 1975, ACTA OPHTHALMOL, V53, P710
   STAPLETON F, 2005, INVEST OPHTHALMOL, V46, P5025
   STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922
   STEINBERG RH, 1970, NATURE, V227, P728, DOI 10.1038/227728a0
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   TEXTORIUS O, 1989, DOC OPHTHALMOL, V73, P149, DOI 10.1007/BF00155033
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   VESKE A, 1998, AM J HUM GENET, V63, P391
   WELINDER E, 1982, INVEST OPHTH VIS SCI, V23, P240
   Wihlmark U, 1996, APMIS, V104, P265, DOI 10.1111/j.1699-0463.1996.tb00716.x
   WRIGSTAD A, 1994, DOC OPHTHALMOL, V87, P337, DOI 10.1007/BF01203343
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 92
TC 2
Z9 3
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD AUG
PY 2006
VL 84
IS 4
BP 452
EP 465
DI 10.1111/j.1600-0420.2006.00751.x
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 073SE
UT WOS:000239762100003
PM 16879565
DA 2022-11-30
ER

PT J
AU Zhou, PX
   Zheng, SQ
   Wang, ET
   Men, P
   Zhai, SD
AF Zhou, Pengxiang
   Zheng, Siqian
   Wang, Ente
   Men, Peng
   Zhai, Suodi
TI Conbercept for Treatment of Neovascular Age-Related Macular Degeneration
   and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia
   Choroidal Neovascularization: A Systematic Review and Meta-Analysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE conbercept; neovascular age-related macular degeneration; diabetic
   macular edema; pathologic myopia choroidal neovascularization; anti-VEGF
ID GROWTH-FACTOR USE; COST-EFFECTIVENESS; RANIBIZUMAB; COMPLICATIONS;
   EXPERIENCES; INJECTIONS; EFFICACY; QUALITY; SAFETY; RISK
AB Background: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug. Here, we systematically conducted the efficacy, safety, compliance, and pharmacoeconomic evaluation of intravitreal conbercept (IVC) compared with other treatments in patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or pathologic myopia choroidal neovascularization (pmCNV).
   Methods: Databases of PubMed, Embase, Cochrane Library, , SinoMed, China National Knowledge Infrastructure, and WanFang Data were systematically searched from the inception to July 27, 2021. Randomized clinical trials and pharmacoeconomic studies comparing IVC with control groups in adults with nAMD, DME, or pmCNV were reviewed and selected. Meta-analyses were performed using the fixed-effects model when pooled data were homogeneous. Heterogeneous data were analyzed using the random-effects model. Primary outcomes included visual improvement rate, mean change in visual acuity or best corrected visual acuity, and pharmacoeconomic outcomes. Additional outcomes were the mean change in fundus examination values, adverse events (AEs), quality-of-life measures, and number of injections.
   Results: Among 3,591 screened articles, 22 original studies with 1,910 eyes of patients were finally included. For nAMD and DME, IVC was significantly associated with better visual acuity or best corrected visual acuity improvement and fundus quantitative measures than placebo, laser photocoagulation (LP), or intravitreal triamcinolone acetonide (IVT). However, IVC showed non-inferior efficacy to intravitreal ranibizumab (IVR) according to low quality of evidence, and there was lack of trials comparing the priority of IVC to other anti-VEGF regimens. No definitive increased risk of ocular or non-ocular AEs were observed in the study groups. All patients with AEs recovered after symptomatic treatments, and no severe AEs occurred. Patients treated with IVC might have higher quality-of-life scores than those in IVR in nAMD or LP in DME. Additionally, IVC showed cost-utility advantages in nAMD and cost-effectiveness advantages than IVR in pmCNV in China.
   Conclusion: IVC is well-tolerated and effective for improving vision acuity and quantitative measures in fundus condition in patients with nAMD and DME compared with LP, IVT, and placebo, but gains comparable efficacy to IVR. However, well-designed, large-sample, and long-term evaluation of IVC shall be conducted in additional studies worldwide.
C1 [Zhou, Pengxiang; Zheng, Siqian; Men, Peng; Zhai, Suodi] Peking Univ Third Hosp, Dept Pharm, Beijing, Peoples R China.
   [Zhou, Pengxiang; Zheng, Siqian; Zhai, Suodi] Peking Univ Hlth Sci Ctr, Inst Drug Evaluat, Beijing, Peoples R China.
   [Wang, Ente] Capital Med Univ, Beijing Tongren Hosp, Dept Pharm, Beijing, Peoples R China.
C3 Peking University; Capital Medical University
RP Zhai, SD (通讯作者)，Peking Univ Third Hosp, Dept Pharm, Beijing, Peoples R China.; Zhai, SD (通讯作者)，Peking Univ Hlth Sci Ctr, Inst Drug Evaluat, Beijing, Peoples R China.
EM zhaisuodi@163.com
RI Zhou, Pengxiang/AHD-6595-2022
OI Zhou, Pengxiang/0000-0003-1208-8217
FU Institute for Drug Evaluation, Peking University Health Science Center.
FX Funding This study was funded by the Institute for Drug Evaluation,
   Peking University Health Science Center.
CR Bai F, 2020, CHIN J GERONTOL, V40, P826
   Bandello F, 2017, DEV OPHTHALMOL, V58, P102, DOI 10.1159/000455277
   Boyle Jessica, 2018, Psychol Health Med, V23, P127, DOI 10.1080/13548506.2016.1274040
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen D, 2019, SHAANXI MED J, V48, P1063, DOI [10.3969/j.issn.1000-7377.2019.08.029, DOI 10.3969/J.ISSN.1000-7377.2019.08.029]
   Chen R, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-1334
   Cheng, 2016, INT EYE SCI, V16, P1310, DOI [10.3980/j.issn.1672-5123.2016.7.26, DOI 10.3980/J.ISSN.1672-5123.2016.7.26]
   Chhablani J, 2018, SURV OPHTHALMOL, V63, P307, DOI 10.1016/j.survophthal.2017.09.008
   Cui CM, 2018, CLIN INTERV AGING, V13, P51, DOI 10.2147/CIA.S151225
   Du Bo., 2016, PROG MOD BIOMED, V16, P6148, DOI [10.13241/j.cnki.pmb.2016.31.039, DOI 10.13241/J.CNKI.PMB.2016.31.039]
   Ehlken C, 2020, GRAEF ARCH CLIN EXP, V258, P2077, DOI 10.1007/s00417-020-04798-2
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   He, 2015, INT J OPHTHALMOL, V15, P1603, DOI [10.3980/j.issn.1672-5123.2015.9.30, DOI 10.3980/J.ISSN.1672-5123.2015.9.30]
   Higgins JPT., 2020, COCHRANE HDB SYSTEMA
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hodgson N, 2016, MOL PHARMACEUT, V13, P2877, DOI 10.1021/acs.molpharmaceut.5b00775
   Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010
   Kim EJ, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1188-4
   Lazzara F, 2019, BIOCHEM PHARMACOL, V168, P341, DOI 10.1016/j.bcp.2019.07.021
   Li, 2016, CHIN J CLIN PHARM, V25, P367, DOI [10.19577/j.cnki.issn10074406.2016.06.009, DOI 10.19577/J.CNKI.ISSN10074406.2016.06.009]
   Li Hong, 2018, Value Health Reg Issues, V15, P133, DOI 10.1016/j.vhri.2018.01.009
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2022, BRIT J OPHTHALMOL, V106, P1436, DOI 10.1136/bjophthalmol-2020-318690
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Liu Q, 2016, HEBEI MED, V22, P2021, DOI 10.969/j.ssn.006-6233.2016.12.034
   [刘瑞 Liu Rui], 2015, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V35, P104
   Liu WS, 2019, INT J OPHTHALMOL-CHI, V12, P1479, DOI 10.18240/ijo.2019.09.17
   Lock JHJ, 2011, CLIN EXP OPTOM, V94, P43, DOI 10.1111/j.1444-0938.2010.00529.x
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Mason JO, 2010, RETINA-J RET VIT DIS, V30, P1386, DOI 10.1097/IAE.0b013e3181e09739
   Meng WZ, 2019, PAK J MED SCI, V35, P1493, DOI 10.12669/pjms.35.6.512
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nct, 2013, RANDOMIZED DOUBLE BL
   Ohno-Matsui K, 2018, PROG RETIN EYE RES, V63, P92, DOI 10.1016/j.preteyeres.2017.10.005
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP66, DOI 10.1016/j.ophtha.2019.09.025
   Parikh R, 2019, OPHTHALMOL RETINA, V3, P16, DOI 10.1016/j.oret.2018.08.002
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Qiao G, 2017, INT J OPHTHALMOL-CHI, V10, P1113, DOI 10.18240/ijo.2017.07.15
   Qin B., 2017, INT EYE SCI, V17, P1108
   Qu D, 2019, CHIN J GERONTOL, V39, P3719, DOI [10.3969/j.issn.1005-9202.2019.15.038, DOI 10.3969/J.ISSN.1005-9202.2019.15.038]
   Scott IU, 2007, RETINA-J RET VIT DIS, V27, P10, DOI 10.1097/IAE.0b013e3180307271
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Sui Y, 2018, J AEROSPACE MED, V29, P522
   Sun XL, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/5809081
   Thulliez M, 2018, JAMA OPHTHALMOL, V136, P557, DOI 10.1001/jamaophthalmol.2018.0002
   VEGF, 2015, JAMA-J AM MED ASSOC, V314, P2184, DOI [10.1016/j.preteyeres.2017.10.005, DOI 10.1016/J.PRETEYERES.2017.10.005]
   Veritti D, 2012, EXPERT OPIN DRUG SAF, V11, P331, DOI 10.1517/14740338.2012.635141
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub6
   Wang HP, 2020, DIABETES THER, V11, P1103, DOI 10.1007/s13300-020-00806-0
   Wang J, 2017, INT EYE SCI, V17, P104, DOI [10.3980/j.issn.1672-5123.2017.1.27, DOI 10.3980/J.ISSN.1672-5123.2017.1.27]
   Wang LP, 2018, DRUG DES DEV THER, V12, P3625, DOI 10.2147/DDDT.S176021
   Wang X., 2018, DRUG EVAL RES, V41, P1703, DOI [10.7501/j.issn.1674-6376.2018.09.028, DOI 10.7501/J.ISSN.1674-6376.2018.09.028]
   Wei YL., 2018, PROG MOD BIOMED, V18, P1515
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   [张皇 Zhang Huang], 2019, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V24, P218
   Zhang J, 2018, CHINA J PHARM EC, V13, P27, DOI [10.12010/j.issn.1673-5846.2018.09.005, DOI 10.12010/J.ISSN.1673-5846.2018.09.005]
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhang L, 2019, VALUE HEALTH, V22, pS886
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhang YJ., 2018, CHIN J HOSP PHARM, V38, P412, DOI DOI 10.13286/j.cnki.chinhosppharmacyj.2018.04.14
   Zhao Y, 2019, PROG MOD BIOMED, V19, P3699, DOI [10.13241/j.cnki.pmb.2019.19.023, DOI 10.13241/J.CNKI.PMB.2019.19.023]
   Zhou LW, 2018, ATHEROSCLEROSIS SUPP, V32, P144, DOI 10.1016/j.atherosclerosissup.2018.04.442
NR 73
TC 2
Z9 2
U1 22
U2 26
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 12
PY 2021
VL 12
AR 696201
DI 10.3389/fphar.2021.696201
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA WQ2AA
UT WOS:000713621600001
PM 34712132
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kubicka-Trzaska, A
   Zuber-Laskawiec, K
   Dziedzina, S
   Sanak, M
   Romanowska-Dixon, B
   Karska-Basta, I
AF Kubicka-Trzaska, Agnieszka
   Zuber-Laskawiec, Katarzyna
   Dziedzina, Sylwia
   Sanak, Marek
   Romanowska-Dixon, Bozena
   Karska-Basta, Izabella
TI Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G
   (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal
   Anti-VEGF Treatment in Patients with Exudative Age-Related Macular
   Degeneration
SO MEDICINA-LITHUANIA
LA English
DT Article
DE complement system; single nucleotide polymorphism; age-related macular
   degeneration; anti-VEGF therapy; switching therapy
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR-B; RANIBIZUMAB TREATMENT; LOC387715
   GENOTYPES; ASSOCIATION; POLYMORPHISMS; THERAPY; CFH; SYSTEM; RARE
AB Background and Objectives: To assess the association between the single nucleotide polymorphisms (SNPs) in the genes encoding complement factors CFH, C2, and C3 (Y402H rs1061170, R102G rs2230199, and E318D rs9332739, respectively) and response to intravitreal anti-vascular endothelial growth factor (VEGF) therapy in patients with exudative age-related macular degeneration (AMD). Materials and Methods: The study included 111 patients with exudative AMD treated with intravitreal bevacizumab or ranibizumab injections. Response to therapy was assessed on the basis of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) measured every 4 weeks for 12 months. The control group included 58 individuals without AMD. The SNPs were genotyped by a real-time polymerase chain reaction in genomic DNA isolated from peripheral blood samples. Results: The CC genotype in SNP rs1061170 of the CFH gene was more frequent in patients with AMD than in controls (p = 0.0058). It was also more common among the 28 patients (25.2%) with poor response to therapy compared with good responders (p = 0.0002). Poor responders, especially those without this genotype, benefited from switching to another anti-VEGF drug. At the last follow-up assessment, carriers of this genotype had significantly worse BCVA (p = 0.0350) and greater CRT (p = 0.0168) than noncarriers. TT genotype carriers showed improved BCVA (p = 0.0467) and reduced CRT compared with CC and CT genotype carriers (p = 0.0194). No associations with AMD or anti-VEGF therapy outcomes for SNP rs9332739 in the C2 gene and SNP rs2230199 in the C3 gene were found. Conclusions: The CC genotype for SNP rs1061170 in the CFH gene was associated with AMD in our population. Additionally, it promoted a poor response to anti-VEGF therapy. On the other hand, TT genotype carriers showed better functional and anatomical response to anti-VEGF therapy at 12 months than carriers of the other genotypes for this SNP.
C1 [Kubicka-Trzaska, Agnieszka; Zuber-Laskawiec, Katarzyna; Romanowska-Dixon, Bozena; Karska-Basta, Izabella] Jagiellonian Univ, Fac Med, Dept Ophtalmol, Clin Ophtalmol & Ocular Oncol,Med Coll, PL-31501 Krakow, Poland.
   [Dziedzina, Sylwia; Sanak, Marek] Jagiellonian Univ, Fac Med, Dept Internal Med, Mol Biol & Clin Genet Unit,Med Coll, PL-31501 Krakow, Poland.
C3 Jagiellonian University; Collegium Medicum Jagiellonian University;
   Jagiellonian University; Collegium Medicum Jagiellonian University
RP Kubicka-Trzaska, A (通讯作者)，Jagiellonian Univ, Fac Med, Dept Ophtalmol, Clin Ophtalmol & Ocular Oncol,Med Coll, PL-31501 Krakow, Poland.
EM agnieszka.kubicka-trzaska@uj.edu.pl;
   katarzyna.zuber-laskawiec@uj.edu.pl; sylwia.dziedzina@uj.edu.pl;
   marek.sanak@uj.edu.pl; bozena.romanowska-dixon@uj.edu.pl;
   izabella.karska-basta@uj.edu.pl
OI Kubicka-Trzaska, Agnieszka/0000-0003-2859-4149
FU Jagiellonian University Medical College grant [N41/DBS/000310]
FX This research was funded by Jagiellonian University Medical College
   grant (no. N41/DBS/000310 to A.K.-T.).
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arjamaa O, 2012, BRIT J OPHTHALMOL, V96, P1153, DOI 10.1136/bjophthalmol-2012-301823
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Baatz H, 2009, KLIN MONATSBL AUGENH, V226, P654, DOI 10.1055/s-0028-1109318
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Deng YH, 2022, GENES DIS, V9, P62, DOI 10.1016/j.gendis.2021.02.009
   Veloso CED, 2014, OPHTHALMIC RES, V51, P1, DOI 10.1159/000354328
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hara C, 2019, GRAEF ARCH CLIN EXP, V257, P2559, DOI 10.1007/s00417-019-04456-2
   Havvas O, 2014, EUR J OPHTHALMOL, V24, P751, DOI 10.5301/ejo.5000427
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Jensen EG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249752
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kubicka-Trzaska A, 2021, J PHYSIOL PHARMACOL, V72, DOI 10.26402/jpp.2021.1.09
   Kubicka-Trzska A, 2020, POSTEP HIG MED DOSW, V74, P213, DOI 10.5604/01.3001.0014.2495
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110
   Marioli DI, 2009, GRAEF ARCH CLIN EXP, V247, P1547, DOI 10.1007/s00417-009-1129-z
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Pociej-Marciak W, 2015, CASE REP OPHTHALM, V6, P394, DOI 10.1159/000442182
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Su Y, 2020, EUR J OPHTHALMOL, V30, P743, DOI 10.1177/1120672119840245
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Wang ZL, 2022, ACTA OPHTHALMOL, V100, pE669, DOI 10.1111/aos.14970
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yildiz BK, 2016, OPHTHALMIC RES, V56, P132, DOI 10.1159/000446186
   Zuber-Laskawiec K, 2019, J PHYSIOL PHARMACOL, V70, P779, DOI 10.26402/jpp.2019.5.13
NR 82
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD MAY
PY 2022
VL 58
IS 5
AR 658
DI 10.3390/medicina58050658
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1O6FX
UT WOS:000801426700001
PM 35630075
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Acton, JH
   Ogino, K
   Akagi, Y
   Wild, JM
   Yoshimura, N
AF Acton, Jennifer H.
   Ogino, Ken
   Akagi, Yumiko
   Wild, John M.
   Yoshimura, Nagahisa
TI Microperimetry and multimodal imaging in polypoidal choroidal
   vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-FIELD LOSS; MACULAR DEGENERATION;
   PHOTODYNAMIC THERAPY; RETINAL SENSITIVITY; RANIBIZUMAB; EYES;
   ANGIOGRAPHY; INJECTION; THICKNESS
AB Polypoidal choroidal vasculopathy (PCV) is a degenerative macular disease. The study determined the topographical concordance in the areal extent of PCV, defined by indocyanine green angiography (ICGA), and the corresponding outcomes from spectral-domain optical coherence tomography (SD-OCT) and microperimetry, in 25 individuals (25 eyes) who had undergone 3 months of anti-vascular endothelial growth factor treatment. The differential light sensitivity within 10 degrees eccentricity was evaluated by Pattern Deviation probability analysis. The concordances and proportional areal extents of the abnormality for ICGA, SD-OCT and microperimetry were compared. The concordance in the areal extent between all three modalities was 59%. The median concordance between ICGA and microperimetry was 60%; between ICGA and SD-OCT, 70%; and between SD-OCT and microperimetry, 72%. SD-OCT and microperimetry each identified a greater areal extent (> 20%) compared to ICGA in 13 and 19 eyes, respectively. A greater areal extent (> 20%) was present in 9 eyes for microperimetry compared to SD-OCT and in 5 eyes for SD-OCT compared to microperimetry. SD-OCT and microperimetry each identified a greater area of abnormality than ICGA which supports the clinical utility of SD-OCT. Strong concordance was present between SD-OCT and microperimetry; however, microperimetry identified additional areas of functional abnormality.
C1 [Acton, Jennifer H.; Wild, John M.] Cardiff Univ, Coll Biomed & Life Sci, Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.
   [Ogino, Ken; Akagi, Yumiko; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Cardiff University; Kyoto University
RP Acton, JH (通讯作者)，Cardiff Univ, Coll Biomed & Life Sci, Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.
EM actonj@cardiff.ac.uk
RI Acton, Jennifer/AAU-3307-2021
OI Acton, Jennifer/0000-0002-0347-7651
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
FX Jennifer Acton was funded by the Japan Society for the Promotion of
   Science (JSPS), Tokyo, Japan.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Hudson C, 1998, DIABETOLOGIA, V41, P918, DOI 10.1007/s001250051008
   Imasawa M, 2009, JPN J OPHTHALMOL, V53, P588, DOI 10.1007/s10384-009-0732-1
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Johnson CA, 2002, AM J OPHTHALMOL, V134, P177, DOI 10.1016/S0002-9394(02)01577-5
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kimura S, 2017, JPN J OPHTHALMOL, V61, P472, DOI 10.1007/s10384-017-0530-0
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Machida S, 2012, DOC OPHTHALMOL, V124, P91, DOI 10.1007/s10633-011-9307-9
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   Ogino K, 2011, INVEST OPHTH VIS SCI, V52, P8047, DOI 10.1167/iovs.11-8143
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Takayama K, 2017, GRAEF ARCH CLIN EXP, V255, P449, DOI 10.1007/s00417-016-3468-x
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yodoi Y, 2007, AM J OPHTHALMOL, V143, P984, DOI 10.1016/j.ajo.2007.01.026
NR 31
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 25
PY 2018
VL 8
AR 15769
DI 10.1038/s41598-018-33781-5
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GY1FI
UT WOS:000448270100019
PM 30361520
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, VM
   Rosen, RB
   Meyerle, CB
   Kurup, SK
   Ardeljan, D
   Agron, E
   Tai, K
   Pomykala, M
   Chew, EY
   Chan, CC
   Tuo, J
AF Wang, Vinson M.
   Rosen, Richard B.
   Meyerle, Catherine B.
   Kurup, Shree K.
   Ardeljan, Daniel
   Agron, Elvira
   Tai, Katy
   Pomykala, Matthew
   Chew, Emily Y.
   Chan, Chi-Chao
   Tuo, Jingsheng
TI Suggestive association between PLA2G12A single nucleotide polymorphism
   rs2285714 and response to anti-vascular endothelial growth factor
   therapy in patients with exudative age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID FACTOR-H Y402H; PHOSPHOLIPASE A(2); INTRAVITREAL BEVACIZUMAB; EYE
   DISEASE; RANIBIZUMAB; ANGIOGENESIS; ROLES; LOCI; GENE
AB Purpose: The use of anti-vascular endothelial growth factor (anti-VEGF) therapy, with drugs such as ranibizumab and bevacizumab, to treat neovascular age-related macular degeneration (nAMD) produces an effective but widely variable response. Identifying markers that predict differentiated response could serve as a valuable assay in developing more personalized medicine. This study aimed to identify single nucleotide polymorphisms (SNPs) that influence the outcome of treatment with anti-VEGF therapy for AMD.
   Methods: One hundred six patients with nAMD were treated with either ranibizumab or bevacizumab as needed over a period of 12 months. Visual acuity and the presence of macular fluid were measured with optical coherence tomography at baseline, six months, and 12 months. Patients were then classified as good or poor responders based on change in visual acuity and macular fluid on follow-up visits. DNA extracted from blood was genotyped with a TaqMan-based allelic discrimination SNP assay for 21 SNPs in six candidate genes (PLAG12A, IL23R, STAT3, VEGFA, KDR, and HIF1A). The SNPs were primarily selected based on previously reported associations with AMD and functional involvement in angiogenesis pathways. SNPs shown to be promising for association with anti-VEGF therapy were then assessed in an independent AMD case-control cohort.
   Results: Of the 106 patients with nAMD, 77 were classified as good responders and 29 as poor responders. For rs2285714 (PLA2G12A), the frequency of minor allele T was 40.1% for good responders compared to 51.7% for poor responders (odds ratio: 1.60, 95% confidence interval of odds ratio: 0.87-2.94, p=0.13). Genetic model analysis of rs2285714 (PLA2G12A) demonstrated an association between rs2285714 (PLA2G12A) and therapy response in a dominant genotypic model. Patients carrying at least one T allele of rs2285714 were 2.79 times (95% confidence interval=1.02-7.69, p < 0.05) more likely to be poor responders (79.3% of poor responders) than good responders (57.3% of good responders). However, after adjusting for multiple testing by the false discovery rate or Bonferroni correction, the initially observed association was no longer statistically significant. No association was identified between the remaining SNPs and response status. The SNP rs2285714 of PLA2G12A was not significantly associated with AMD in an independent AMD case-control cohort.
   Conclusions: Data suggest a possible weak association between rs2285714 (PLA2G12A) and response to anti-VEGF therapy, but the association must be confirmed in additional cohorts with larger patient samples. Identifying factors that predict the differentiated response could provide a valuable assay for developing approaches in personalized medicine.
C1 [Wang, Vinson M.; Ardeljan, Daniel; Chan, Chi-Chao; Tuo, Jingsheng] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Wang, Vinson M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Rosen, Richard B.; Tai, Katy; Pomykala, Matthew] New York Eye & Ear Infirm, Dept Ophthalmol, New York, NY 10003 USA.
   [Meyerle, Catherine B.; Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Kurup, Shree K.] Wake Forest Univ, Dept Ophthalmol, Winston Salem, NC 27109 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Johns Hopkins University; New York Eye & Ear Infirmary of Mount
   Sinai; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Wake Forest University
RP Tuo, J (通讯作者)，NEI, Immunol Lab, NIH, 10-10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM tuoj@nei.nih.gov
OI Ardeljan, Daniel/0000-0002-5593-421X; Tuo, Jingsheng/0000-0002-1372-7810
FU Intramural Research Program of National Eye Institute; NATIONAL EYE
   INSTITUTE [ZIAEY000497, ZIAEY000523, ZIAEY000526, ZIAEY000524,
   ZIAEY000527, ZIAEY000418, ZIAEY000222] Funding Source: NIH RePORTER
FX The project was supported by Intramural Research Program of National Eye
   Institute. The authors thank the study participants and their families
   for enrolling in this study, and Ms. Kathy Chu (NEI) for English
   editing.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Barnett JM, 2010, INVEST OPHTH VIS SCI, V51, P1136, DOI 10.1167/iovs.09-3691
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dudbridge F, 2004, AM J HUM GENET, V75, P424, DOI 10.1086/423738
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Green W R, 1999, Mol Vis, V5, P27
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kolaczkowska E, 2006, J LEUKOCYTE BIOL, V80, P125, DOI 10.1189/jlb.0106013
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lambeau G, 2008, ANNU REV BIOCHEM, V77, P495, DOI 10.1146/annurev.biochem.76.062405.154007
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee HS, 2005, CELL CALCIUM, V38, P581, DOI 10.1016/j.ceca.2005.08.002
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Murakami M, 2011, J BIOCHEM, V150, P233, DOI 10.1093/jb/mvr088
   Murakami M, 2011, PROG LIPID RES, V50, P152, DOI 10.1016/j.plipres.2010.12.001
   Murakami M, 2010, BIOCHIMIE, V92, P561, DOI 10.1016/j.biochi.2010.03.015
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Wang Y, 2007, J AM COLL CARDIOL, V50, P760, DOI 10.1016/j.jacc.2007.04.074
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286
   Zou LH, 2011, THERANOSTICS, V1, P395, DOI 10.7150/thno/v01p0395
NR 40
TC 19
Z9 22
U1 1
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 20
PY 2012
VL 18
IS 267-70
BP 2578
EP 2585
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 052VH
UT WOS:000312226100001
PM 23112570
DA 2022-11-30
ER

PT J
AU Joachim, NDL
   Mitchell, P
   Kifley, A
   Wang, JJ
AF Joachim, Nichole D. L.
   Mitchell, Paul
   Kifley, Annette
   Wang, Jie Jin
TI Incidence, Progression, and Associated Risk Factors of Medium Drusen in
   Age-Related Macular Degeneration Findings From the 15-Year Follow-up of
   an Australian Cohort
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BLUE-MOUNTAINS EYE; LONG-TERM INCIDENCE; BLOOD-CELL COUNT; 5-YEAR
   INCIDENCE; INFLAMMATORY MARKERS; 10-YEAR INCIDENCE; GRADING SYSTEM;
   REYKJAVIK EYE; MACULOPATHY; CLASSIFICATION
AB IMPORTANCE The natural course and prognosis of medium drusen and risk factors associated with the incidence and progression of this lesion type in age-related macular degeneration (AMD) are not well understood.
   OBJECTIVE To assess the 15-year incidence and progression of medium drusen and associated risk factors.
   DESIGN, SETTING, AND PARTICIPANTS Population-based cohort in the Blue Mountains region, west of Sydney, Australia. Included in the study were 3654 participants 49 years or older who attended baseline examinations of the Blue Mountains Eye Study (1992-1994), and 75.8%, 76.7%, and 56.1% of survivors who attended the 5-year, 10-year, and 15-year follow-up examinations, respectively.
   MAIN OUTCOMES AND MEASURES Color retinal fundus photographs were obtained at each examination. The incidence and progression of medium drusen (maximum diameter, 63 to <125 mu m) were assessed using Kaplan-Meier product-limit survival methods, controlling for competing risk of death. Factors associated with a 15-year incidence of medium drusen were assessed using discrete logistic regression models after adjusting for age, sex, smoking status, serum lipid levels, systemic and dietary factors, and CFH rs1061170 and ARMS2 rs10490924 polymorphisms. Associations between lesion characteristics and the progression to late AMD were assessed using generalized estimating equation models and eye-specific data.
   RESULTS Among 1317 participants at risk, the 15-year cumulative incidence of medium drusen was 13.9% (n = 281). Increasing age (per decade older) (odds ratio [OR], 1.4; 95% CI, 1.2-1.8) and the presence of at least 3 risk alleles of the CFH rs1061170 or ARMS2 rs10490924 genes (OR, 2.1; 95% CI, 1.1-4.1) were associated with a higher incidence. There was no association between past smoking (OR, 0.8; 95% CI, 0.6-1.1) or current smoking (OR, 0.6; 95% CI, 0.4-1.1) and the development of medium drusen. The progression rate to late AMD in eyes with both medium drusen and retinal pigmentary abnormalities was 4-fold higher than that in eyes with medium drusen alone. Larger total area and central location of medium drusen were associated with a greater likelihood of the progression to worse stages of AMD.
   CONCLUSIONS AND RELEVANCE Older age and the presence of CFH and ARMS2 risk alleles are 2 main risk factors associated with the development of medium drusen. The copresence of medium drusen plus retinal pigment epithelium abnormalities signals a greater risk of the progression to late AMD than the presence of medium drusen alone.
C1 [Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW 2145, Australia.
   Westmead Hosp, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research
RP Wang, JJ (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, C24, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; wang, jie/GRS-0942-2022; Wang, Jie
   Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
FU National Health and Medical Research Council of Australia [974159,
   211069, 457349]
FX This work was supported by grants 974159, 211069, and 457349 from the
   National Health and Medical Research Council of Australia.
CR [Anonymous], 2004, SAS STAT 9 1 US GUID
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9
   Department of Community Services and Health, 1990, NUTTAB 90 NUTR DAT T
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Food Standards Australia New Zealand, 2010, NUTTAB 2010
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P204, DOI 10.3109/09286586.2014.909248
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   National Health and Medical Research Council, 2009, AUSTR GUID RED HLTH
   Shankar A, 2007, ATHEROSCLEROSIS, V192, P177, DOI 10.1016/j.atherosclerosis.2006.04.029
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
NR 35
TC 23
Z9 24
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2015
VL 133
IS 6
BP 698
EP 705
DI 10.1001/jamaophthalmol.2015.0498
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK2MI
UT WOS:000356044400021
PM 25838066
OA Bronze
DA 2022-11-30
ER

PT J
AU Musashi, K
   Tsujikawa, A
   Hirami, Y
   Otani, A
   Yodoi, Y
   Tamura, H
   Yoshimura, N
AF Musashi, Kunihiro
   Tsujikawa, Akitaka
   Hirami, Yasuhiko
   Otani, Atsushi
   Yodoi, Yuko
   Tamura, Hiroshi
   Yoshimura, Nagahisa
TI Microrips of the retinal pigment epithelium in polypoidal choroidal
   vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DETACHMENT
AB PURPOSE: To study the clinical characteristics of microrips of the retinal pigment epithelium (RPE) in polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective case series.
   METHODS: For this study, we retrospectively reviewed 156, consecutive eyes of 136 patients with PCV. The lesions were examined with fluorescein angiography and indocyanine green angiography.
   RESULTS: Of 156 eyes with PCV, 11 (7.1%) had microrips of the RPE at the margin of the pigment epithelial detachment. In the early phase of fluorescein angiography, the microrips showed pinpoint leakage from the RPE, which increased and pooled within the subretinal space in the late phase. Of the 11 eyes with microrips, the rip disappeared in 10 eyes (90.9%), and no eyes developed RPE tears during follow-up. The mean duration from the first detection of a microrip to resolution was 3.0 +/- 1.6 months.
   CONCLUSIONS: In eyes with PCV, microrips of the RPE are not uncommon, but have minimal clinical relevance.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   LE D, 1992, ARCH OPHTHALMOL-CHIC, V110, P1443
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Virgili G, 1998, OPHTHALMOLOGICA, V212, P284, DOI 10.1159/000027309
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YUZAWA M, 1995, OPHTHALMOLOGY, V102, P622, DOI 10.1016/S0161-6420(95)30990-6
NR 7
TC 17
Z9 23
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2007
VL 143
IS 5
BP 883
EP 886
DI 10.1016/j.ajo.2006.12.024
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 165FF
UT WOS:000246288800030
PM 17452180
DA 2022-11-30
ER

PT J
AU Nemcansky, J
   Stepanov, A
   Koubek, M
   Veith, M
   Klimesova, YM
   Studnicka, J
AF Nemcansky, Jan
   Stepanov, Alexandr
   Koubek, Michal
   Veith, Miroslav
   Klimesova, Yun Min
   Studnicka, Jan
TI Response to Aflibercept Therapy in Three Types of Choroidal Neovascular
   Membrane in Neovascular Age-Related Macular Degeneration: Real-Life
   Evidence in the Czech Republic
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VEGF TRAP; RANIBIZUMAB; TACHYPHYLAXIS; PEGAPTANIB; OUTCOMES; EYES
AB Purpose. To present a cohort of treatment-naive patients with the neovascular form of age-related macular degeneration (nAMD) treated with aflibercept in a fixed regimen and evaluate the treatment response of three types of choroidal neovascular membrane (CNV)-occult (Type 1), classic (Type 2), and minimally classic (Type 4). Methods. This was a multicentre, prospective, observational consecutive case series study. Patients diagnosed with three types of CNV of nAMD were treated in a fixed regimen (3 injections every 4weeks, and then injections at 8week intervals). The follow-up period was 48weeks. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and spectral-domain optical coherence tomography (OCT). The measurements were taken at the baseline and then at 16, 32, and 48weeks. Results. The treatment-naive group was composed of 135 eyes of 135 patients in the study. 61 eyes had Type 1 lesions of CNV, 50 eyes had Type 2 lesions, and 24 eyes had Type 4 lesions. Mean baseline BCVA +/- SD for Type 1 lesions was 56.1 +/- 10.8 ETDRS letters, and then 62.2 +/- 12.9 letters, 61.2 +/- 13.7 letters, and 62.8 +/- 15.1 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD for Type 1 lesions was 442.4 +/- 194.9 mu m, and then 302.5 +/- 144.4 mu m, 299.7 +/- 128.5 mu m, and 277.7 +/- 106.5 mu m at 16, 32, and 48weeks, respectively. Mean baseline BCVA +/- SD for Type 2 lesions was 55.6 +/- 9.9 ETDRS letters, and then 62.5 +/- 11.1 letters, 60.7 +/- 13.0 letters, and 62.5 +/- 14.2 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD. For Type 4 lesions mean baseline BCVA +/- SD was 56.7 +/- 9.0 ETDRS letters, and then 59.1 +/- 10.6 letters, 59.5 +/- 11.4 letters, and 59.2 +/- 12.6 letters at 16, 32, and 48 weeks respectively. Mean baseline CRT +/- SD for Type 4 lesions was 492.1 +/- 187.0 mu m, and then 333.3 +/- 137.5 mu m, 354.4 +/- 175.0 mu m, and 326.7 +/- 122.4 mu m at 16, 32, and 48 weeks respectively. All these changes were statistically significant (p<0.005). Conclusions. The primary outcome of our study is that the treatment with aflibercept in nAMD patients led to statistically significant improvement in BCVA and to a decrease in CRT throughout the follow-up period in both occult and classic types of CNV. The minimally classic type of CNV demonstrated a poorer functional and anatomical response to treatment.
C1 [Nemcansky, Jan; Koubek, Michal] Univ Ostrava, Fac Med, Dept Ophthalmol, Ostrava, Czech Republic.
   [Nemcansky, Jan; Koubek, Michal] Univ Hosp Ostrava, Ostrava, Czech Republic.
   [Stepanov, Alexandr; Studnicka, Jan] Charles Univ Prague, Dept Ophthalmol, Fac Med Hradec Kralove, Hradec Kralove, Czech Republic.
   [Stepanov, Alexandr; Studnicka, Jan] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic.
   [Veith, Miroslav; Klimesova, Yun Min] Charles Univ Prague, Fac Med 3, Dept Ophthalmol, Prague, Czech Republic.
   [Veith, Miroslav; Klimesova, Yun Min] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic.
C3 University of Ostrava; University Hospital Ostrava; Charles University
   Prague; Charles University Prague; University Hospital Vinohrady
RP Stepanov, A (通讯作者)，Charles Univ Prague, Dept Ophthalmol, Fac Med Hradec Kralove, Hradec Kralove, Czech Republic.; Stepanov, A (通讯作者)，Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic.
EM stepanov.doctor@gmail.com
RI Studnička, Jan/AAC-4127-2022; Koubek, Michal/O-4889-2019; Stepanov,
   Alexandr/N-9961-2017; Nemcansky, Jan/AAC-6619-2019
OI Koubek, Michal/0000-0003-0259-5776; Stepanov,
   Alexandr/0000-0002-8462-8756; Nemcansky, Jan/0000-0003-1979-6419
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Doguizi S, 2015, INT J OPHTHALMOL-CHI, V8, P846, DOI 10.3980/j.issn.2222-3959.2015.04.37
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Epstein D, 2016, RETINA-J RET VIT DIS, V36, P1773, DOI 10.1097/IAE.0000000000000978
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Framme CEN, 2017, OPHTHALMOL RETINA, V2, P539, DOI [10.1016/j.oret.2017.09.017, DOI 10.1016/J.ORET.2017.09.017]
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Krebs I, 2011, INVEST OPHTH VIS SCI, V52, P6925, DOI 10.1167/iovs.10-6612
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shiragami C, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000116
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Taylor HR, 2001, BRIT J OPHTHALMOL, V85, P261, DOI 10.1136/bjo.85.3.261
NR 20
TC 2
Z9 3
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2019
VL 2019
AR 2635689
DI 10.1155/2019/2635689
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IH5KL
UT WOS:000474532800001
PM 31316822
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Burns, SA
   Elsner, AE
   Mellem-Kairala, MB
   Simmons, RB
AF Burns, SA
   Elsner, AE
   Mellem-Kairala, MB
   Simmons, RB
TI Improved contrast of subretinal structures using polarization analysis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID NERVE-FIBER LAYER; SCANNING LASER POLARIMETRY; AGE-RELATED MACULOPATHY;
   LIVING HUMAN-EYE; RETINAL-PIGMENT EPITHELIUM; HUMAN OCULAR FUNDUS;
   MACULAR DEGENERATION; BRUCHS MEMBRANE; CORNEAL POLARIZATION; GEOGRAPHIC
   ATROPHY
AB Purpose. To improve the ability to detect and quantify the early retinal changes associated with aging, age-related maculopathy, and age-related macular degeneration.
   Methods. A computational approach was implemented for analyzing images using a readily available polarimeter that is used for glaucoma diagnosis. This device, the GDx Nerve Fiber Analyzer (Laser Diagnostic Technologies, Inc., San Diego, CA), takes a series of images as a function of the polarization angle of the illuminating light. For each of 20 input polarizations, pairs of retinal images are digitized. One image is made of the light returning from the eye that is polarized parallel to the input light, and the other image is made of the that is rotated by 90degrees from the input polarization. Using the raw data from these 40 images, and a simplified model of the polarization properties of the eye, we calculated the amount of light that returns in a parallel polarized state, and the amount of light that is depolarized by multiple scattering. Measurements were made in seven subjects with small drusen.
   Results. The depolarized light image produced a 34 times higher contrast of drusen and subretinal changes than the parallel polarized light images.
   Conclusion. Polarization-sensitive imaging combined with a simple computational approach allows the measurement of the retinal distribution of multiply scattered light. With this technique, retinal imaging of age-related changes in retinal and subretinal tissue can be improved.
C1 Schepens Eye Res Inst, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   Ophthalm Consultants Boston, Boston, MA USA.
C3 Harvard University; Schepens Eye Research Institute; Harvard University;
   Harvard Medical School; Ophthalmic Consultants of Boston
RP Burns, SA (通讯作者)，Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM sburns@vision.eri.harvard.edu
RI Burns, Stephen A/D-9259-2011; Burns, Stephen/AAN-3044-2021
OI Burns, Stephen A/0000-0001-5348-035X; 
FU NATIONAL EYE INSTITUTE [R29EY007624, R01EY004395, R01EY007624] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY004395-23, EY07624, R01
   EY007624, EY04395, R01 EY004395] Funding Source: Medline
CR AREND O, 1995, INVEST OPHTH VIS SCI, V36, P608
   Bille JF, 1997, PHYS MEDICA, V13, P308
   Blokland G. V., 1986, VISION RES, V26, P485
   BOUR LJ, 1981, VISION RES, V21, P1413, DOI 10.1016/0042-6989(81)90248-0
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRINK HBK, 1988, J OPT SOC AM A, V5, P49, DOI 10.1364/JOSAA.5.000049
   Brown B, 1987, CLIN EXP OPTOM, V70, P112
   Bueno JM, 2002, J OPT A-PURE APPL OP, V4, P553, DOI 10.1088/1464-4258/4/5/311
   Bueno JM, 2002, OPT LETT, V27, P830, DOI 10.1364/OL.27.000830
   Bueno JM, 2001, OPHTHAL PHYSL OPT, V21, P384, DOI 10.1046/j.1475-1313.2001.00601.x
   Bueno JM, 2000, VISION RES, V40, P3791, DOI 10.1016/S0042-6989(00)00220-0
   CHIPMAN RA, 1994, HDB OPTICS, P1
   COPE WT, 1978, J OPT SOC AM, V68, P1139, DOI 10.1364/JOSA.68.001139
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   Demos SG, 1997, APPL OPTICS, V36, P150, DOI 10.1364/AO.36.000150
   DREHER AW, 1992, CLIN VISION SCI, V7, P481
   DREHER AW, 1992, APPL OPTICS, V31, P3730, DOI 10.1364/AO.31.003730
   Ducros MG, 2001, J OPT SOC AM A, V18, P2945, DOI 10.1364/JOSAA.18.002945
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Elsner A. E., 2001, International Ophthalmology, V23, P245, DOI 10.1023/A:1014405320509
   Elsner A. E., 1998, LASERS LIGHT OPHTHAL, V8, P193
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   Elsner AE, 2000, OPT EXPRESS, V6, P243, DOI 10.1364/OE.6.000243
   ELSNER AE, 1992, APPL OPTICS, V31, P3697, DOI 10.1364/AO.31.003697
   Elsner AE, 2000, OPT EXPRESS, V7, P95, DOI 10.1364/OE.7.000095
   Elsner AE, 2003, ST HEAL T, V94, P59
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   ELSNER AE, 1998, OPT PHOTONICS NEWS, V8, P72
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Greenfield DS, 2000, AM J OPHTHALMOL, V129, P715, DOI 10.1016/S0002-9394(00)00353-6
   Greenfield DS, 2002, AM J OPHTHALMOL, V134, P27, DOI 10.1016/S0002-9394(02)01512-X
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   Jarry G, 1998, APPL OPTICS, V37, P7357, DOI 10.1364/AO.37.007357
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KELLEY LM, 1997, J OPHTHALMIC PHOTOGR, V3, P89
   Knighton RW, 2002, OPT EXPRESS, V10, P1179, DOI 10.1364/OE.10.001179
   Knighton RW, 2002, INVEST OPHTH VIS SCI, V43, P82
   Knighton RW, 2002, INVEST OPHTH VIS SCI, V43, P383
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LEWIS H, 1986, AM J OPHTHALMOL, V102, P801, DOI 10.1016/0002-9394(86)90417-4
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   Morgan JE, 1998, BRIT J OPHTHALMOL, V82, P684, DOI 10.1136/bjo.82.6.684
   Morgan JE, 2000, AM J OPHTHALMOL, V129, P76, DOI 10.1016/S0002-9394(99)00267-6
   Pierscionek BK, 1998, APPL OPTICS, V37, P6845, DOI 10.1364/AO.37.006845
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Remky A, 1995, Ger J Ophthalmol, V4, P203
   Remky A, 1999, GRAEF ARCH CLIN EXP, V237, P897, DOI 10.1007/s004170050383
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   ROWE MP, 1995, OPT LETT, V20, P608, DOI 10.1364/OL.20.000608
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SOMMER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P864
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tyo JS, 1996, APPL OPTICS, V35, P1855, DOI 10.1364/AO.35.001855
   VANBLOKLAND GJ, 1987, J OPT SOC AM A, V4, P82, DOI 10.1364/JOSAA.4.000082
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Weinreb RN, 2002, J GLAUCOMA, V11, P378, DOI 10.1097/00061198-200210000-00002
   WEINREB RN, 1990, ARCH OPHTHALMOL-CHIC, V108, P557, DOI 10.1001/archopht.1990.01070060105058
   Zhou QY, 2002, INVEST OPHTH VIS SCI, V43, P2221
NR 74
TC 47
Z9 47
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2003
VL 44
IS 9
BP 4061
EP 4068
DI 10.1167/iovs.03-0124
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 715WC
UT WOS:000184994900047
PM 12939329
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ho, AC
   Busbee, BG
   Regillo, CD
   Wieland, MR
   Van Everen, SA
   Li, ZR
   Rubio, RG
   Lai, P
AF Ho, Allen C.
   Busbee, Brandon G.
   Regillo, Carl D.
   Wieland, Mark R.
   Van Everen, Sherri A.
   Li, Zhengrong
   Rubio, Roman G.
   Lai, Phillip
CA HARBOR Study Grp
TI Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in
   Patients with Subfoveal Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL RANIBIZUMAB; THERAPY;
   VERTEPORFIN; LUCENTIS; TRIAL
AB Objective: To evaluate the 24-month efficacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg administered monthly or as needed (pro re nata [PRN]) in patients with neovascular age-related macular degeneration (wet AMD).
   Design: Twenty-four-month, multicenter, randomized, double-masked, active treatment-controlled phase 3 trial.
   Participants: Patients (n = 1098) >= 50 years of age with treatment-naive subfoveal wet AMD.
   Methods: Patients were randomized to receive intravitreal injections of ranibizumab 0.5 mg or 2.0 mg monthly or PRN after 3 monthly loading doses.
   Main Outcome Measures: The primary efficacy end point was the mean change in best-corrected visual acuity (BCVA) from baseline at month 12. Key secondary end points included mean change in BCVA from baseline at month 24, proportion of patients who gained >= 15 letters in BCVA, mean number of ranibizumab injections, and mean change in central foveal thickness from baseline over time by spectral-domain optical coherence tomography. Ocular and systemic safety events also were evaluated through month 24.
   Results: At month 24, the mean change from baseline in BCVA was (letters) +9.1 (0.5 mg monthly), +7.9 (0.5 mg PRN), +8.0 (2.0 mg monthly), and +7.6 (2.0 mg PRN). The change in mean BCVA from month 12 to 24 was (letters) -1.0, -0.3, -1.2, and -1.0, respectively. The proportion of patients who gained >= 15 letters from baseline in BCVA at month 24 was 34.5%, 33.1%, 37.6%, and 34.8%, respectively. The mean number of ranibizumab injections through month 24 was 21.4, 13.3, 21.6, and 11.2, respectively; 5.6 and 4.3 mean injections were required in year 2 in the 0.5 mg and 2.0 mg PRN groups, respectively. The average treatment interval in the 0.5 mg PRN group was 9.9 weeks after 3 monthly loading doses, and 93% of these patients did not require monthly dosing. Ocular and systemic safety profiles over 2 years were similar among all 4 treatment groups and were consistent with previous ranibizumab trials in AMD.
   Conclusions: At month 24, mean BCVA improvements were clinically meaningful and similar among all 4 ranibizumab treatment groups. The 0.5 mg PRN group achieved a mean gain of 7.9 letters at month 24 with an average of 13.3 injections (5.6 injections in year 2). No new safety events were identified over 24 months. (C) 2014 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
C1 [Ho, Allen C.] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
   [Busbee, Brandon G.] Tennessee Retina, Nashville, TN USA.
   [Wieland, Mark R.] Northern Calif Retina Vitreous Associates, Mountain View, CA USA.
   [Van Everen, Sherri A.; Li, Zhengrong; Rubio, Roman G.; Lai, Phillip] Genentech Inc, San Francisco, CA USA.
C3 Jefferson University; Roche Holding; Genentech
RP Ho, AC (通讯作者)，Wills Eye Hosp & Res Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM acho@att.net
OI Ho, Allen/0000-0003-3921-608X
FU Alcon; Allergan; Genentech; Janssen; Ophthotech; Regeneron;
   GlaxoSmithKline; QLT; Genentech, Inc., South San Francisco, California
FX The author(s) have made the following disclosure(s):; Allen C. Ho:
   Consultant - Alcon, Allergan, Janssen, Genentech, Merck, Ophthotech,
   Regeneron; Financial support - Alcon, Allergan, Genentech, Janssen,
   Ophthotech, Regeneron; Speakers bureau - Alcon, Genentech, Regeneron;
   Carl D. Regillo: Consultant and Financial support - Genentech,
   GlaxoSmithKline, QLT, Regeneron; Speakers bureau - Genentech; Supported
   by Genentech, Inc., South San Francisco, California, provided support
   for the study and participated in the study design; conducting the
   study; and data collection, management, and interpretation.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   [Anonymous], 2014, LUC RAN INJ PACK INS
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 26
TC 223
Z9 229
U1 3
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2014
VL 121
IS 11
BP 2181
EP 2192
DI 10.1016/j.ophtha.2014.05.009
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS8DM
UT WOS:000344480400023
PM 25015215
OA hybrid
DA 2022-11-30
ER

PT J
AU Dedania, VS
   Bakri, SJ
AF Dedania, Vaidehi S.
   Bakri, Sophie J.
TI SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF
   AGENTS What Is the Evidence?
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; bevacizumab; eye; intraocular
   pressure; intravitreal injection adverse events; ranibizumab; retina;
   sustained elevation; vascular endothelial growth factor
ID ANTERIOR-CHAMBER PARACENTESIS; TRABECULAR MESHWORK CELLS; DIABETIC
   MACULAR EDEMA; GROWTH-FACTOR THERAPY; OCULAR HYPERTENSION; BEVACIZUMAB
   AVASTIN; TRIAMCINOLONE ACETONIDE; CLINICAL-TRIALS; DEGENERATION;
   RANIBIZUMAB
AB Purpose: To summarize the literature addressing sustained and delayed elevation of intraocular pressure (IOP) in patients with neovascular age-related macular degeneration being treated with intravitreal vascular endothelial growth factor (VEGF) inhibitors and to present possible mechanisms of effect.
   Methods: Analysis of current literature evaluating sustained and delayed elevation of IOP in patients receiving intravitreal anti-VEGF therapy for neovascular age-related macular degeneration.
   Results: Studies have demonstrated that patients undergoing treatment with intravitreal anti-VEGF agents may experience sustained and delayed elevation of IOP. The incidence of sustained elevation of IOP in patients with neovascular age-related macular degeneration varied from 3.45% to 11.6%, and few patients required surgical management to control IOP. Possible risk factors associated with sustained and delayed elevation of IOP include, but are not limited to, history of glaucoma, phakia, history of glucocorticoid use, and/or extended treatment duration. There are multiple theories explaining the pathogenesis of sustained elevation of IOP, including microparticle obstruction of the trabecular meshwork, intraocular inflammation, and transient elevation of IOP.
   Conclusion: Sustained and delayed elevation of IOP in patients undergoing treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF agents is likely a multifactorial process. Further studies to prospectively investigate sustained elevation of IOP in large, randomized, controlled trials might lead to a better understanding of the long-term adverse events associated with intravitreal anti-VEGF therapy.
C1 [Dedania, Vaidehi S.] Albany Med Ctr, Lions Eye Inst, Dept Ophthalmol, Albany, NY USA.
   [Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Albany Medical College; Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
FU Research to Prevent Blindness, New York, NY
FX S. J. Bakri has, in the past, served as a consultant on advisory boards
   to Genentech, Regeneron, Allergan, SanBio, and Neumedics, but this work
   is not related to those consulting agreements. S. J. Bakri was supported
   by Research to Prevent Blindness, New York, NY. The remaining author has
   no conflicting interests to disclose.
CR Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Arnavielle S, 2007, GRAEF ARCH CLIN EXP, V245, P345, DOI 10.1007/s00417-006-0465-5
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Benz MS, 2006, OPHTHALMOLOGY, V113, P1174, DOI 10.1016/j.ophtha.2005.10.061
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang W, 2007, EUR J OPHTHALMOL, V17, P776, DOI 10.1177/112067210701700514
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   DRANCE SM, 1960, ARCH OPHTHALMOL-CHIC, V64, P494
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hohn F, 2010, GRAEF ARCH CLIN EXP, V248, P1371, DOI 10.1007/s00417-010-1382-1
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Jalil A, 2007, EYE, V21, P1541, DOI 10.1038/sj.eye.6703018
   Kahook MY, 2010, J GLAUCOMA, V19, P437, DOI 10.1097/IJG.0b013e3181ca74de
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kernt M, 2007, OPHTHALMOLOGE, V104, P965, DOI 10.1007/s00347-007-1569-y
   Kim D, 2014, J GLAUCOMA, V23, P446, DOI 10.1097/IJG.0b013e3182946505
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kubota T, 2006, J GLAUCOMA, V15, P117, DOI 10.1097/00061198-200604000-00007
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Leung YF, 2003, MOL VIS, V9, P425
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Menke MN, 2013, OPHTHALMOLOGICA, V229, P168, DOI 10.1159/000346397
   Pershing S, 2013, OPHTHAL SURG LAS IM, V44, P460, DOI 10.3928/23258160-20130909-07
   Pong JCF, 2008, GRAEF ARCH CLIN EXP, V246, P463, DOI 10.1007/s00417-007-0675-5
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rozsa FW, 2006, MOL VIS, V12, P125
   Segal O, 2013, IMAJ, V15, P420
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Shinzato M, 2007, OPHTHAL RES, V39, P330, DOI 10.1159/000109989
   Shukla D, 2007, AM J OPHTHALMOL, V144, P453, DOI 10.1016/j.ajo.2007.04.021
   Theoulakis PE, 2010, KLIN MONATSBL AUGENH, V227, P280, DOI 10.1055/s-0029-1245201
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
NR 54
TC 57
Z9 58
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2015
VL 35
IS 5
BP 841
EP 858
DI 10.1097/IAE.0000000000000520
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG6KI
UT WOS:000353408900003
PM 25905784
DA 2022-11-30
ER

PT J
AU Ehrenberg, M
   Benny, O
AF Ehrenberg, Moshe
   Benny, Ofra
TI Evolving multidimensional pharmacological approaches to CNV therapy in
   AMD
SO CURRENT EYE RESEARCH
LA English
DT Review
DE Macular degeneration; VEGF; review; therapy; pathogenesis
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; EXPERIMENTAL
   CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; INTRAVITREAL
   INJECTION; INTRAOCULAR-PRESSURE; KINASE INHIBITOR; EPITHELIAL-CELLS;
   TYROSINE KINASE; AQUEOUS-HUMOR
AB Purpose: The leading cause of severe visual loss world-wide is age-related macular degeneration. Although anti-Vascular Endothelial Growth Factor agents have significantly led to the initial pharmacologic reversal of vision loss in many cases of exudative macular degeneration, there still has been recurrence of choroidal neovascularization, and/or the onset of chorioretinal atrophy with fibrosis.
   Materials and Methods: In this review we discuss the status of anti-Vascular Endothelial Growth Factor in age-related macular degeneration and describe different studies focused on new potential therapeutic targets beyond anti-Vascular Endothelial Growth Factor.
   Results: Further investigations have elicited that Vascular Endothelial Growth Factor is only one of many angiogenic, and pro-inflammatory factors that bring about the growth and leakage of active choroidal neovascularization. Various new multifaceted strategies, including inhibitors to down-stream targets of endothelial cell division, such as TNP-470, may lead to a more permanent inactivation of choroidal neovascularization.
   Conclusions: Based on the accumulated results in the treatment of age-related macular degeneration, it is hoped that the appropriate combination of anti-Vascular Endothelial Growth Factor agents with longer-acting and multidimensional pharmaceuticals, such as Methionine Aminopeptidase-2 inhibitors, will more effectively control choroidal neovascularization, prevent atrophy and fibrosis, and reduce the burden of frequent intraocular injections in age-related macular degeneration.
C1 [Ehrenberg, Moshe; Benny, Ofra] Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Fac Med, Hadassah Ein Kerem Med Campus, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem
RP Benny, O (通讯作者)，Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Fac Med, Hadassah Ein Kerem Med Campus, IL-91120 Jerusalem, Israel.
EM OfraB@ekmd.huji.ac.il
RI Benny, Ofra/AAB-3294-2021
FU Adolf and Klara Brettler Center for Research in Molecular Pharmacology
   and Therapeutics at The Hebrew University of Jerusalem, Jerusalem,
   Israel
FX Ofra Benny acknowledges support of The Adolf and Klara Brettler Center
   for Research in Molecular Pharmacology and Therapeutics at The Hebrew
   University of Jerusalem, Jerusalem, Israel.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 2017, REGENERON ANNOUNCES
   [Anonymous], 2017, OPTH REP POS PHAS 1
   [Anonymous], 2017, SQUAL
   [Anonymous], 2017, OPHTH ANN RES PIV PH
   [Anonymous], 2016, PANOPTICA REP POS RE
   [Anonymous], 2017, AB MULTIVEGF PDGF DA
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Benny O, 2008, NAT BIOTECHNOL, V26, P799, DOI 10.1038/nbt1415
   Benny O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012515
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2007, DRUG TODAY, V43, P529, DOI 10.1358/dot.2007.43.8.1120868
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Chaplin DJ, 2006, CURR OPIN INVEST DR, V7, P522
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Dong AL, 2011, P NATL ACAD SCI USA, V108, P14614, DOI 10.1073/pnas.1012859108
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gong Y, 2016, EBIOMEDICINE, V13, P201, DOI 10.1016/j.ebiom.2016.09.025
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirasawa M, 2016, J BIOL CHEM, V291, P7373, DOI 10.1074/jbc.M115.710186
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ibrahim MA, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-7
   Jackson TL, 2017, JAMA OPHTHALMOL, V135, P761, DOI 10.1001/jamaophthalmol.2017.1571
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuwada SK, 2007, CURR OPIN MOL THER, V9, P92
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Michaelson IC., 1948, T OPHTHALMOL SOC, V68, P137
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nagaiah G, 2010, FUTURE ONCOL, V6, P1219, DOI [10.2217/fon.10.90, 10.2217/FON.10.90]
   Narayanan R, 2006, NAT REV DRUG DISCOV, V5, P815, DOI 10.1038/nrd2157
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Patel S, 2009, RETINA-J RET VIT DIS, V29, pS45, DOI 10.1097/IAE.0b013e3181ad22d5
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Popp N, 2013, J CLIN EXP OPHTHALMO, V4
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rezar-Dreindl S, 2017, RETINA-J RET VIT DIS, V37, P962, DOI 10.1097/IAE.0000000000001264
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Smithwick Elizabeth, 2017, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V16, P33, DOI 10.2174/1871523016666170502115816
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   Strittmatter K, 2016, AM J PATHOL, V186, P1890, DOI 10.1016/j.ajpath.2016.02.018
   Sulaiman RS, 2014, EXP EYE RES, V129, P161, DOI 10.1016/j.exer.2014.10.002
   Sun JN, 2015, STEM CELLS, V33, P1543, DOI 10.1002/stem.1960
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Taketani Y, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.1
   Takeyama M, 2015, BIOL RES, V48, DOI [10.1186/s40659-015-0034-7, 10.1186/S40659-015-0034-7]
   Vakalis N, 2015, SCI REP-UK, V5, DOI 10.1038/srep08627
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
NR 88
TC 6
Z9 6
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2018
VL 43
IS 2
BP 147
EP 154
DI 10.1080/02713683.2017.1385088
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ1GH
UT WOS:000427324400001
PM 29111834
DA 2022-11-30
ER

PT J
AU Risseeuw, S
   Ossewaarde-Van Norel, J
   Klaver, CCW
   Colijn, JM
   Imhof, SM
   Van Leeuwen, R
AF Risseeuw, Sara
   Ossewaarde-Van Norel, Jeannette
   Klaver, Caroline C. W.
   Colijn, Johanna M.
   Imhof, Saskia M.
   Van Leeuwen, Redmer
TI VISUAL ACUITY IN PSEUDOXANTHOMA ELASTICUM
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE angioid streaks; atrophy; Bruch membrane; choroidal neovascularization;
   pseudoxanthoma elasticum; visual impairment
ID CHOROIDAL NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC
   ATROPHY; ANGIOID STREAKS; MUTATIONS; RANIBIZUMAB; BEVACIZUMAB;
   IMPAIRMENT; ROTTERDAM; AVASTIN
AB Purpose: To assess the age-specific proportion of visual impairment in patients with pseudoxanthoma elasticum (PXE) and to compare this with foveal abnormality and similar data of late age-related macular degeneration patients.
   Methods: Cross-sectional data of 195 patients with PXE were reviewed, including best-corrected visual acuity and imaging. The World Health Organisation criteria were used to categorize bilateral visual impairment. These results were compared with similar data of 131 patients with late age-related macular degeneration from the Rotterdam study.
   Results: Overall, 50 PXE patients (26.0%) were visually impaired, including 21 (11%) with legal blindness. Visual functioning declined with increasing age. In patients older than 50 years, 37% was visually impaired and 15% legally blind. Foveal choroidal neovascularization was found in 84% of eyes with a best-corrected visual acuity lower than 20/70 (0.30) and macular atrophy in the fovea in 16%. In late age-related macular degeneration patients, 40% were visually impaired and 13% legally blind. Visual impairment started approximately 20 years later as compared with PXE patients.
   Conclusion: Visual impairment and blindness are frequent in PXE, particularly in patients older than 50 years. Although choroidal neovascularization is associated with the majority of vision loss, macular atrophy is also common. The proportion of visual impairment in PXE is comparable with late age-related macular degeneration but manifests earlier in life.
C1 [Risseeuw, Sara; Ossewaarde-Van Norel, Jeannette; Imhof, Saskia M.; Van Leeuwen, Redmer] Univ Med Ctr Utrecht Utrecht, Dept Ophthalmol, Utrecht, Netherlands.
   [Klaver, Caroline C. W.; Colijn, Johanna M.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Klaver, Caroline C. W.; Colijn, Johanna M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Radboud Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Radboud University Nijmegen
RP Risseeuw, S (通讯作者)，Univ Utrecht, Univ Med Ctr Utrecht, Dept Ophthalmol, POB 85500,E 03-136, NL-3508 GA Utrecht, Netherlands.
EM S.Risseeuw@umcutrecht.nl
FU Dr. F.P. Fischer Foundation, Amersfoort, the Netherlands
FX Supported by the Dr. F.P. Fischer Foundation, Amersfoort, the
   Netherlands (unrestricted funding). The Fischer Foundation had no role
   in designing or performing this research.
CR Audo I, 2007, INVEST OPHTH VIS SCI, V48, P4250, DOI 10.1167/iovs.05-1604
   Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Ebran JM, 2014, BRIT J OPHTHALMOL, V98, P142, DOI 10.1136/bjophthalmol-2013-303235
   ETDRS Research Group, 1985, EARL TREATM DIAB RET, P1
   Finger RP, 2008, BRIT J OPHTHALMOL, V92, P483, DOI 10.1136/bjo.2007.129916
   Finger RP, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-113
   Finger RP, 2011, AM J OPHTHALMOL, V152, P695, DOI 10.1016/j.ajo.2011.03.022
   Finger RP, 2011, RETINA-J RET VIT DIS, V31, P1268, DOI 10.1097/IAE.0b013e318207d1dc
   Finger RP, 2009, RETINA-J RET VIT DIS, V29, P1496, DOI 10.1097/IAE.0b013e3181aade47
   Finger RP, 2009, SURV OPHTHALMOL, V54, P272, DOI 10.1016/j.survophthal.2008.12.006
   Georgalas Ilias, 2009, Ther Clin Risk Manag, V5, P81
   Gliem M, 2016, INVEST OPHTH VIS SCI, V57, P3323, DOI 10.1167/iovs.16-19388
   Gliem M, 2013, RETINA-J RET VIT DIS, V33, P1300, DOI 10.1097/IAE.0b013e3182914d2b
   Gliem Martin, 2013, Frontiers in Genetics, V4, P14, DOI 10.3389/fgene.2013.00014
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hocaoglu M, 2016, EUR J OPHTHALMOL, V26, P449, DOI 10.5301/ejo.5000766
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4
   Jansen RS, 2014, ARTERIOSCL THROM VAS, V34, P1985, DOI 10.1161/ATVBAHA.114.304017
   Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102
   Myung JS, 2010, RETINA-J RET VIT DIS, V30, P748, DOI 10.1097/IAE.0b013e3181c596b1
   Nakagawa S, 2013, RETINA-J RET VIT DIS, V33, P825, DOI 10.1097/IAE.0b013e31826b0bbe
   Orssaud C, 2015, OPHTHALMIC GENET, V36, P327, DOI 10.3109/13816810.2014.886268
   Plomp AS, 2010, AM J MED GENET A, V152A, P1049, DOI 10.1002/ajmg.a.33329
   Querques G, 2010, MIDDLE EAST AFR J OP, V17, P387, DOI 10.4103/0974-9233.71586
   Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawa M, 2006, OPHTHALMOLOGY, V113, P814, DOI 10.1016/j.ophtha.2006.01.037
   Schoenberger SD, 2013, AM J OPHTHALMOL, V156, P715, DOI 10.1016/j.ajo.2013.05.034
   Teixeira A, 2006, ACTA OPHTHALMOL SCAN, V84, P835, DOI 10.1111/j.1600-0420.2006.00762.x
   Tsui I, 2008, DOC OPHTHALMOL, V117, P65, DOI 10.1007/s10633-007-9100-y
   Uitto J, 2013, J INVEST DERMATOL, V133, P1444, DOI 10.1038/jid.2013.20
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   World Health Organization, 2016, ICD 10 DEF
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 37
TC 15
Z9 15
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2019
VL 39
IS 8
BP 1580
EP 1587
DI 10.1097/IAE.0000000000002173
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ5AL
UT WOS:000480763200022
PM 29652691
DA 2022-11-30
ER

PT J
AU Kelly, SJ
   Halasz, K
   Smalling, R
   Sutariya, V
AF Kelly, Shannon J.
   Halasz, Kathleen
   Smalling, Rudy
   Sutariya, Vijaykumar
TI Nanodelivery of doxorubicin for age-related macular degeneration
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Age-related macular degeneration; hypoxia-induced factors; doxorubicin;
   nanoparticles; vascular endothelial growth factor
ID GROWTH-FACTOR-B; NANOPARTICLES; BEVACIZUMAB; DELIVERY; VEGF
AB Objective: Polymeric nanoparticles (NPs) containing doxorubicin (DOX) were prepared for the inhibition of hypoxia-induced factor 1 alpha (HIF-1 alpha). Methods: DOX NPs were prepared using both polylactic coglycolic acid (PLGA) and chitosan. PLGA NPs were prepared via nanoprecipitation (NPC) and single and double emulsion diffusion (SE; DE). Chitosan NPs were formulated using ionic gelation (IG), and complex coacervation (CC). Size, polydispersity index (PDI), and zeta potential (ZP) were determined via dynamic light scattering (DLS) (n = 3). The encapsulation efficiency (EE), drug loading capacity (DLC) (n = 3) and in vitro drug release profiles (IVR) at 37 degrees C (n = 4) were analyzed via spectroscopy at 480 nm (lambda(max)). The cytotoxicity of each formulation as well as free DOX solution in ARPE-19 cells was determined via MTT assay after 24 h (n = 3). HIF-1 alpha and VEGF inhibition in ARPE-19 cells were measured via ELISA (n = 3). Results: The results were consistent with the hypothesis; the NP formulations decreased HIF-1 alpha and VEGF-A expression in ARPE-19 cells with reduced cytotoxicity. SE, DE, and CC demonstrated low ZP as well as the most rapid drug release of the tested formulations. FTIR confirmed the presence of DOX on the SE NP surface, indicating instability. Conclusions: SE, DE, and CC destabilized. NPC was the most efficient formulation for the nanodelivery of DOX for AMD.
C1 [Kelly, Shannon J.; Halasz, Kathleen; Smalling, Rudy; Sutariya, Vijaykumar] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC 30, Tampa, FL 33612 USA.
C3 State University System of Florida; University of South Florida
RP Sutariya, V (通讯作者)，Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC 30, Tampa, FL 33612 USA.
EM vsutariy@health.usf.edu
CR Berthold A, 1996, J CONTROL RELEASE, V39, P17, DOI 10.1016/0168-3659(95)00129-8
   Breznan D, 2017, NANOTOXICOLOGY, V11, P223, DOI 10.1080/17435390.2017.1287313
   Cunningham MA, 2008, SURV OPHTHALMOL, V53, P139, DOI 10.1016/j.survophthal.2007.12.005
   D'Souza Susan S, 2005, AAPS PharmSciTech, V6, pE323, DOI 10.1208/pt060242
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Gatoo MA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/498420
   Geldenhuys W, 2015, PHARM DEV TECHNOL, V20, P497, DOI 10.3109/10837450.2014.892130
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868
   Hughes JM, 2015, J APPL POLYM SCI, V132, DOI 10.1002/app.42061
   Iwase T, 2013, J CONTROL RELEASE, V172, P625, DOI 10.1016/j.jconrel.2013.10.008
   Kelly SJ, 2017, INT J NANOMED NANOSU
   KHEMANI M, 2012, ANN BIOL RES, V3, P4414
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Madan JR, 2014, INT J PHARM INVESTIG, V4, P60, DOI 10.4103/2230-973X.133047
   nanoComposix, 2012, ZET POT AN NAN, P1
   Rabuffetti FA, 2010, J PHYS CHEM C, V114, P11056, DOI 10.1021/jp101727c
   Reichle Michelle L, 2005, Optometry, V76, P450, DOI 10.1016/j.optm.2005.06.013
   Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stetefeld Jorg, 2016, Biophys Rev, V8, P409, DOI 10.1007/s12551-016-0218-6
   Subhani S, 2016, ANGIOGENESIS, V19, P257, DOI 10.1007/s10456-016-9510-0
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoshida D, 2006, J NEURO-ONCOL, V76, P13, DOI 10.1007/s11060-005-3279-0
   Ziello Jennifer E, 2007, Yale J Biol Med, V80, P51
NR 30
TC 7
Z9 7
U1 1
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD MAY 4
PY 2019
VL 45
IS 5
BP 715
EP 723
DI 10.1080/03639045.2019.1569024
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HR1VS
UT WOS:000462924700003
PM 30704311
DA 2022-11-30
ER

PT J
AU Nguyen, V
   Daien, V
   Guymer, RH
   McAllister, IL
   Morlet, N
   Barthelmes, D
   Gillies, MC
AF Vuong Nguyen
   Daien, Vincent
   Guymer, Robyn H.
   McAllister, Ian L.
   Morlet, Nigel
   Barthelmes, Daniel
   Gillies, Mark C.
TI Clinical and social characteristics associated with reduced visual
   acuity at presentation in Australian patients with neovascular
   age-related macular degeneration: a prospective study from a long-term
   observational data set. The Fight Retinal Blindness! Project
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE neovascular age-related macular degeneration; socio-economic factors;
   visual acuity
ID GROWTH-FACTOR TREATMENT; SOCIOECONOMIC-STATUS; 12-MONTH OUTCOMES;
   SUBGROUP ANALYSIS; RANIBIZUMAB; DEPRIVATION; EPIDEMIOLOGY; VISION;
   ANCHOR; MARINA
AB ImportanceIdentifying variables that influence presenting visual acuity (VA) in patients with neovascular age-related macular degeneration (nAMD) is important because it is a strong predictor of long-term outcomes.
   BackgroundTo assess the clinical and social characteristics associated with low presenting VA in nAMD patients.
   DesignThe present study is a cross-sectional analysis from a prospective, observational database.
   ParticipantsWe identified 3242 treatment-naive patients from 54 Australian practices in the Fight Retinal Blindness! registry.
   MethodsAge, gender, ethnicity and VA were recorded at the baseline visit. Socio-economic status was determined using the Australian Bureau of Statistics socio-economic indexes for areas.
   Main Outcome MeasuresAssociation between clinical and socio-economic characteristics with presenting VA was identified.
   ResultsPoor VA (35 letters) in the presenting eye was associated with older age (adjusted odds ratio [AOR]: 1.33 for patients aged 80years vs. <80years [95% confidence interval, CI: 1.04, 1.71]), treatment at a public practice (AOR: 1.91 for public vs. private practices [95% CI: 1.46, 2.50]) and intermediate (36-69 letters) VA in the fellow eye (AOR: 0.67 [95% CI: 0.47, 0.95] and 0.64 [95% CI: 0.48, 0.85] for poor [35 letters] and good [70 letters] VA vs. intermediate VA in the fellow eye). Gender, ethnicity and socio-economic status were not independently associated with VA at presentation.
   Conclusions and RelevancePoor presenting vision is detrimental to the long-term outcomes of nAMD. Poor presentation of nAMD in Australia may not be related to socio-economic circumstances, but due to systems of care. Further research is warranted to determine why patients at public practices present with worse vision compared with private practices in Australia.
C1 [Vuong Nguyen; Daien, Vincent; Gillies, Mark C.] Univ Sydney, Save Sight Inst, Sydney Med Sch, 8 Macquarie St, Sydney, NSW 2000, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [McAllister, Ian L.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Vis Sci, Perth, WA, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA, Australia.
   [Daien, Vincent] Gui De Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] INSERM, Montpellier, France.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne; Lions Eye Institute;
   University of Western Australia; University of Western Australia;
   Universite de Montpellier; CHU de Montpellier; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite de Montpellier;
   University of Zurich; University Zurich Hospital
RP Nguyen, V (通讯作者)，Univ Sydney, Save Sight Inst, Sydney Med Sch, 8 Macquarie St, Sydney, NSW 2000, Australia.
EM phuc.nguyen@sydney.edu.au
RI DAIEN, Vincent/Z-5516-2019
OI DAIEN, Vincent/0000-0001-5675-0861; Nguyen, Vuong/0000-0001-9070-9803;
   Guymer, Robyn/0000-0002-9441-4356
FU Royal Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia (NHMRC); Macular Disease
   Foundation, Australia; Novartis; Bayer
FX This study was supported by a grant from the Royal Australian NZ College
   of Ophthalmologists Eye Foundation (2007-2009), a grant from the
   National Health and Medical Research Council, Australia (NHMRC
   2010-2012) and a grant from the Macular Disease Foundation, Australia.
   Funding was also provided by Novartis and Bayer. The supporting
   organizations had no role in the design or conduct of the research.
CR Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   Archer E., 2013, RFPERMUTE ESTIMATE P
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Australian Bureau of Statistics, 2011, SOC EC IND AR GETT H
   Australian Bureau of Statistics, 2011, AUSTR STAT GEOGR STA
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chua PY, 2013, EUR J OPHTHALMOL, V23, P831, DOI 10.5301/ejo.5000302
   Daien V, 2014, ACTA OPHTHALMOL, V92, pe500, DOI 10.1111/aos.12335
   Finger RP, 2017, CLIN EXP OPHTHALMOL, V45, P143, DOI 10.1111/ceo.12804
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Foot B, 2017, EYE, V31, P771, DOI 10.1038/eye.2017.1
   Gillies MC, 2017, OPHTHALMOLOGY, V124, pE31, DOI 10.1016/j.ophtha.2016.05.054
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Heraghty J, 2012, AM J PUBLIC HEALTH, V102, P1655, DOI 10.2105/AJPH.2012.300657
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mitry D, 2010, INVEST OPHTH VIS SCI, V51, P4963, DOI 10.1167/iovs.10-5400
   Ng WS, 2010, BRIT J OPHTHALMOL, V94, P85, DOI 10.1136/bjo.2008.153312
   Pink B, 2013, SOC IND AR SEIFA
   Razavi H, 2017, OPHTHALMOLOGY, V124, P270, DOI 10.1016/j.ophtha.2016.08.013
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma HE, 2014, BRIT J OPHTHALMOL, V98, P1625, DOI 10.1136/bjophthalmol-2014-304959
   TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012
   World Health Organization, 2015, INT CLASS DIS REL HL
   Yip JLY, 2014, J EPIDEMIOL COMMUN H, V68, P204, DOI 10.1136/jech-2013-203265
   Zuur AF, 2010, METHODS ECOL EVOL, V1, P3, DOI 10.1111/j.2041-210X.2009.00001.x
NR 34
TC 3
Z9 3
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2018
VL 46
IS 3
BP 266
EP 274
DI 10.1111/ceo.13038
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GD0DU
UT WOS:000430170600008
PM 28842956
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Gomathy, N
   Sumantran, VN
   Shabna, A
   Sulochana, KN
AF Gomathy, Narayanan
   Sumantran, Venil N.
   Shabna, A.
   Sulochana, K. N.
TI Tolerance of ARPE 19 cells to organophosphorus pesticide chlorpyrifos is
   limited to concentration and time of exposure
SO PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY
LA English
DT Article
DE AMD; Oxidative stress; Chlorpyrifos; HPLC
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; OXIDATIVE STRESS;
   INSECTICIDE CHLORPYRIFOS; IN-VITRO; AGE; PROLIFERATION; GLUTATHIONE;
   TOXICITY; DAMAGE
AB Age related macular degeneration is a blinding disease common in elder adults. The prevalence of age related macular degeneration has been found to be 1.8% in the Indian population. Organophosphates are widely used insecticides with well documented neurological effects, and the persistent nature of these compounds in the body results in long term health effects. Farmers exposed to organophosphorus pesticides in USA had an earlier onset of age related macular degeneration when compared to unexposed controls. A recent study found significant levels of an organophosphate, termed chlorpyrifos, in the blood samples of Indian farmers. Therefore, in understanding the link between age related macular degeneration and chlorpyrifos, the need-for investigation is important. Our data show that ARPE-19 (retinal pigment epithelial cells) exhibit a cytoprotective response to chlorpyrifos as measured by viability, mitochondrial membrane potential, superoxide dismutase activity, and increased levels of glutathione peroxidase and reduced glutathione, after 24 h exposure to chlorpyrifos. However, this cytoprotective response was absent in ARPE-19 cells exposed to the same range of concentrations of chlorpyrifos for 48 h. These results have physiological significance, since HPLC analysis showed that effects of chlorpyrifos were mediated through its entry into ARPE-19 cells. HPLC analysis also showed that chlorpyrifos remained stable, as we recovered up to 80% of the chlorpyrifos added to 6 different ocular tissues. (C) 2014 Published by Elsevier Inc.
C1 [Gomathy, Narayanan; Sumantran, Venil N.; Shabna, A.; Sulochana, K. N.] RS Mehta Jain Dept Biochem & Cell Biol, Madras 600041, Tamil Nadu, India.
RP Sulochana, KN (通讯作者)，RS Mehta Jain Dept Biochem & Cell Biol, 18 Coll Rd, Madras 600008, Tamil Nadu, India.
EM drkns@snmail.org
FU Vision Research Foundation [84-2007-P]
FX We thank Vision Research Foundation for funding this project
   (84-2007-P).
CR ATKINSON JE, 1994, J APPL TOXICOL, V14, P145, DOI 10.1002/jat.2550140217
   Bebe FN, 2003, J ENVIRON SCI HEAL B, V38, P349, DOI 10.1081/PFC-120019901
   BECQUET F, 1994, EXP CELL RES, V212, P374, DOI 10.1006/excr.1994.1157
   BEUTLER E, 1963, J LAB CLIN MED, V61, P882
   Boyes WK, 1999, J APPL TOXICOL, V19, P473, DOI 10.1002/(SICI)1099-1263(199911/12)19:6<473::AID-JAT602>3.3.CO;2-1
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Ehrlich D., 1991, BIOESSAYS, V14, P355
   Geller AM, 2005, DOC OPHTHALMOL, V110, P79, DOI 10.1007/s10633-005-7347-8
   Giordano G, 2007, TOXICOL APPL PHARM, V219, P181, DOI 10.1016/j.taap.2006.09.016
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Goel A, 2005, CHEM-BIOL INTERACT, V156, P131, DOI 10.1016/j.cbi.2005.08.004
   Hreljac I, 2008, ENVIRON MOL MUTAGEN, V49, P360, DOI 10.1002/em.20392
   Kernt M, 2009, TOXICOLOGY, V258, P84, DOI 10.1016/j.tox.2009.01.008
   Kulkarni SR, 2013, INDIAN J OPHTHALMOL, V61, P196, DOI 10.4103/0301-4738.99870
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Mathur H. B., 2005, ANAL PESTICIDE RESID, P21
   MISRA HP, 1974, J BIOL CHEM, V249, P2151
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   Rao RN, 2002, ANAL SCI, V18, P1391, DOI 10.2116/analsci.18.1391
   ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588
   Ukpebor J, 2011, ENVIRON TOXICOL CHEM, V30, P632, DOI 10.1002/etc.417
   Venza I, 2012, AGING CLIN EXP RES, V24, P530, DOI 10.3275/8477
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Yu F, 2008, EXP TOXICOL PATHOL, V59, P415, DOI 10.1016/j.etp.2007.11.007
NR 26
TC 2
Z9 2
U1 1
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0048-3575
EI 1095-9939
J9 PESTIC BIOCHEM PHYS
JI Pest. Biochem. Physiol.
PD JAN
PY 2015
VL 117
BP 24
EP 30
DI 10.1016/j.pestbp.2014.10.004
PG 7
WC Biochemistry & Molecular Biology; Entomology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Entomology; Physiology
GA CB4CR
UT WOS:000349576300004
PM 25619908
DA 2022-11-30
ER

PT J
AU Frennesson, CI
AF Frennesson, CI
TI Prophylactic laser treatment in early age-related maculopathy: an 8-year
   follow-up in a randomized pilot study shows a reduced incidence of
   exudative complications
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related maculopathy; exudative complications; prophylactic laser
   treatment; soft drusen
ID MACULAR DEGENERATION; SOFT DRUSEN; PHOTOCOAGULATION; RISK; PREVALENCE;
   PROGNOSIS; ABNORMALITIES
AB Purpose: To study the effect of mild laser treatment on the incidence of exudative complications in patients with soft drusen maculopathy in a longterm perspective.
   Methods: In a prospective study, 38 patients with early age-related maculopathy and good visual acuity ( VA) were randomized either to laser treatment using an argon green laser or to observation. At 8 years, 29 patients remained in the study, 16 in the control group and 13 in the treatment group.
   Results: During follow-up, mean VA decreased significantly in both groups, to 0.53 in the treatment group ( p < 0.05) and to 0.25 in the control group ( p < 0.001). At 8 years, 9/16 in the control group showed exudative complications, whereas only 2/13 in the treatment group developed such changes ( p < 0.03).
   Conclusion: In this randomized pilot study, mild laser treatment of soft drusen maculopathy significantly reduced the rate of exudative complications in a longterm perspective. As the study is small, the results should be viewed with caution.
C1 Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
C3 Linkoping University
RP Frennesson, CI (通讯作者)，Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
EM Christina.Frennesson@lio.se
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   AHIR A, 2002, INVEST OPHTHALMOL VI, V43
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1998, Ophthalmology, V105, P11
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   DELLA NG, 1997, INVEST OPHTH VIS SCI, V38, P18
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Fine SL, 1999, INVEST OPHTH VIS SCI, V40, pS318
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   FRIBERG TR, 2002, INVEST OPHTHALMOL VI, V43
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Marshall J, 1981, Dev Ophthalmol, V2, P308
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WALLOW IH, 1984, ARCH OPHTHALMOL-CHIC, V102, P126
   Wetzig P C, 1994, Trans Am Ophthalmol Soc, V92, P299
NR 36
TC 14
Z9 17
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD OCT
PY 2003
VL 81
IS 5
BP 449
EP 454
DI 10.1034/j.1600-0420.2003.00143.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 726JQ
UT WOS:000185596300005
PM 14510790
DA 2022-11-30
ER

PT J
AU Ryu, E
   Fridley, BL
   Tosakulwong, N
   Bailey, KR
   Edwards, AO
AF Ryu, Euijung
   Fridley, Brooke L.
   Tosakulwong, Nirubol
   Bailey, Kent R.
   Edwards, Albert O.
TI Genome-wide association analyses of genetic, phenotypic, and
   environmental risks in the age-related eye disease study
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; BODY-MASS INDEX; MACULAR DEGENERATION; LOC387715
   POLYMORPHISM; POPULATION-STRUCTURE; CIGARETTE-SMOKING; SERPING1 GENE;
   CFH GENE; MACULOPATHY; SUSCEPTIBILITY
AB Purpose: To present genome-wide association analyses of genotypic and environmental risks on age-related macular degeneration (AMD) using 593 subjects from the age-related eye disease study (AREDS), after adjusting for population stratification and including questionable controls.
   Methods: Single nucleotide polymorphism (SNP) associations with AMD for the non-Hispanic white population were investigated using a log-additive model after adjusting for population stratification. Replication of possible SNP-disease association was performed by genotyping an independent group of 444 AMD case and 300 control subjects. Logistic regression models were used to assess interaction effects between smoking and SNPs associated with AMD. Independent genetic risk effects among the disease-associated SNPs were also investigated using multiple logistic regression models.
   Results: Population stratification was observed among the individuals having a self-reported race of non-Hispanic white. Risk allele frequencies at established AMD loci demonstrated that questionable control subjects were similar to control subjects in the AREDS, suggesting that they could be used as true controls in the analyses. Genetic loci (complement factor H [CFH], complement factor B [CFB], the age-related maculopathy susceptibility 2 locus containing the hypothetical gene [LOC387715]/the high-temperature requirement A-1 [HTRA1], and complement component 3 [C3]) that were already known to be associated with AMD were identified. An additional 26 novel SNPs potentially associated with AMD were identified, but none were definitely replicated in a second independent group of subjects. Smoking did not interact with known AMD loci, but was associated with late AMD. Statistically independent genetic signals were observed within the Pleckstrin homology domain-containing family A member 1 (PLEKHA1) region near LOC387715/HTRA1 and within a haplotype spanning exon 19 of the C3 gene.
   Conclusions: Population stratification among Caucasian subjects from the multicentered AREDS was observed, suggesting that it should be adjusted for in future studies. The AREDS questionable control subjects can be used as control subjects in the AREDS genome-wide association study (GWAS). Smoking was an independent risk factor for advanced AMD in the AREDS subjects. There continues to be evidence that the 10q26 (age-related maculopathy susceptibility 2 gene [ARMS2]) locus spanning PLEKHA1-LOC387715-HTRA1 and the C3 gene may contain multiple independent genetic risks contributing to AMD.
C1 [Ryu, Euijung; Fridley, Brooke L.; Tosakulwong, Nirubol; Bailey, Kent R.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
   [Edwards, Albert O.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
C3 Mayo Clinic; University of Oregon
RP Edwards, AO (通讯作者)，1229 Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
EM edwardsa@uoregon.edu
RI Fridley, Brooke L/D-8315-2015
OI Fridley, Brooke L/0000-0001-7739-7956
FU National Eye Institute, Bethesda, MD [R01EY014467]; American Health
   Assistance Foundation, Clarksburg, MD; Foundation Fighting Blindness,
   Owing Mills, MD; NATIONAL EYE INSTITUTE [R01EY014467] Funding Source:
   NIH RePORTER
FX We thank the AREDS participants and the AREDS Research Group for their
   valuable contribution to this research. This work was supported by the
   National Eye Institute (R01EY014467), Bethesda, MD; the Foundation
   Fighting Blindness, Owing Mills, MD, and the American Health Assistance
   Foundation, Clarksburg, MD.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Ambati J, 2009, NEW ENGL J MED, V360, P2255
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2008, ADV EXP MED BIOL, V613, P211, DOI 10.1007/978-0-387-74904-4_24
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2009, NEW ENGL J MED, V360, P2254
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Park KH, 2009, MOL VIS, V15, P200
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Pritchard JK, 2000, GENETICS, V155, P945
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schaid DJ, 1999, AM J EPIDEMIOL, V149, P706
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Teo YY, 2008, CURR OPIN LIPIDOL, V19, P133, DOI 10.1097/MOL.0b013e3282f5dd77
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   1992, ARCH OPHTHALMOL, V110, P1701
   2001, ARCH OPHTHALMOL, V119, P1417
NR 52
TC 37
Z9 39
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 17
PY 2010
VL 16
IS 301-02
BP 2811
EP 2821
PG 11
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 697IW
UT WOS:000285508200001
PM 21197116
DA 2022-11-30
ER

PT J
AU Eris, E
   Perente, I
   Vural, E
   Yasa, D
   Ozkaya, A
AF Eris, Erdem
   Perente, Irfan
   Vural, Esra
   Yasa, Dilek
   Ozkaya, Abdullah
TI Assessment of focal laser photocoagulations' early effect on polypoidal
   choroidal vasculopathy with optical coherence tomography angiography
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE OCT angiography; Polypoidal choroidal vasculopathy; Focal laser
   photocoagulation; PCV; ICGA
AB Polypoidal choroidal vasculopathy (PCV) is seen with polypoidal lesions and branching vascular networks (BVNs) (Spaide et al. in Retina 15(2):100-110, 1995; Yannuzzi et al. in Retina 10(1):1-8, 1990). There are reports about laser photocoagulation for PCV (Yuzawa et al. in Japan J Ophthalmol 47(4):379-384, 2003; Lee et al. in Eye 23(1):145-148, 2009); however, all these reports are about final vision and frequent relapses. Therefore, this treatment merits rigorous scrutiny using optical coherence tomography angiography (OCTA).
C1 [Eris, Erdem; Perente, Irfan; Yasa, Dilek; Ozkaya, Abdullah] Beyoglu Eye Training & Res Hosp, Istanbul, Turkey.
   [Vural, Esra] Mardin Govt Hosp, Mardin, Turkey.
C3 Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research
   Hospital; Mardin State Hospital
RP Eris, E (通讯作者)，Beyoglu Eye Training & Res Hosp, Istanbul, Turkey.
EM perente@gmail.com; vural_esra@yahoo.com; dilekyasa2@gmail.com;
   abdozkaya@gmail.com
RI Yaşa, Dilek/U-9345-2018
OI Yaşa, Dilek/0000-0002-2445-8484
CR Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 8
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-8921
EI 1435-604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD NOV
PY 2018
VL 33
IS 8
BP 1833
EP 1835
DI 10.1007/s10103-018-2463-3
PG 3
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Surgery
GA GX2BZ
UT WOS:000447524700027
PM 29497888
DA 2022-11-30
ER

PT J
AU Olsen, TW
   Al-Rajhi, A
   Ambrus, A
   Daly, M
   Lum, FC
AF Olsen, Timothy W.
   Al-Rajhi, Ali
   Ambrus, Andre
   Daly, Meghan
   Lum, Flora C.
TI Age-Related Macular Degeneration Preferred Practice Pattern (R)
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; COMPLEMENT FACTOR-H; OPTICAL
   COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; SUBRETINAL DRUSENOID
   DEPOSITS; VERTEPORFIN PLUS RANIBIZUMAB; HIGH-DOSE SUPPLEMENTATION;
   GENOME-WIDE ASSOCIATION; LONG-TERM INCIDENCE; C-REACTIVE PROTEIN
RP Al-Rajhi, A (通讯作者)，Amer Acad Ophthalmol, POB 7424, San Francisco, CA 94120 USA.
EM aalrajhi@aao.org
RI fawzi, amani/AAA-9199-2021
OI fawzi, amani/0000-0002-9568-3558; Bailey, Steven/0000-0003-4949-1464
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Albanes D, 2007, JAMA-J AM MED ASSOC, V298, P400, DOI 10.1001/jama.298.4.400-a
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, NEW ENGL J MED, V330, P1029, DOI DOI 10.1056/NEJM199404143301501
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amer Acad Ophthalmology, 1998, OPHTHALMOLOGY, V105, P1564
   American Academy of Ophthalmology, 2014, VER SOURC COMP BEV I
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bjelakovic G, 2007, JAMA-J AM MED ASSOC, V297, P842, DOI 10.1001/jama.297.8.842
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bourne RRA, 2003, BRIT J OPHTHALMOL, V87, P1069, DOI 10.1136/bjo.87.9.1069
   Bourne RRA, 2001, ACTA OPHTHALMOL SCAN, V79, P462, DOI 10.1034/j.1600-0420.2001.790506.x
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2011, OPHTHALMOLOGY, V118, P1834, DOI 10.1016/j.ophtha.2011.02.012
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2002, INVEST OPHTH VIS SCI, V43
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christ SL, 2014, JAMA OPHTHALMOL, V132, P1400, DOI 10.1001/jamaophthalmol.2014.2847
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2014, JAMA OPHTHALMOL, V132, P9, DOI 10.1001/jamaophthalmol.2013.5193
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Delcourt C., 2010, AMD AGE RELATED MACU, P13
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehlken C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1226, DOI 10.1001/archophthalmol.2012.112
   Evans B, 2012, J APPL REMOTE SENS, V6, DOI 10.1117/1.JRS.6.063605
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Fong DS, 1999, AM J OPHTHALMOL, V127, P137, DOI 10.1016/S0002-9394(98)00309-2
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2003, ARCH OPHTHALMOL-CHIC, V121, P633, DOI 10.1001/archopht.121.5.633
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Giansanti F, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006931.pub2
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goldberg RA, 2014, AM J OPHTHALMOL, V158, P733, DOI 10.1016/j.ajo.2014.06.019
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta A, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011140.pub2
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hemila H, 2007, JAMA-J AM MED ASSOC, V298, P401, DOI 10.1001/jama.298.4.401-a
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P1722, DOI 10.1167/iovs.12-10578
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P18, DOI 10.1186/1478-7547-6-18
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liu L, 2017, PHOTODIAGN PHOTODYN, V20, P215, DOI 10.1016/j.pdpdt.2017.09.008
   Lum F, 2016, OPHTHALMOLOGY, V123, P928, DOI [10.1016/j.ophtha.2016.01.024, 10.1016/j.ophtha.2015.10.047]
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARSH MJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P56
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McClintic SM, 2018, OPHTHALMOL RETINA, V2, P931, DOI 10.1016/j.oret.2018.01.014
   McDonald HR, 2007, OPHTHALMOLOGY, V114, P1221, DOI 10.1016/j.ophtha.2007.03.035
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Modjtahedi BS, 2018, AM J OPHTHALMOL, V188, P111, DOI 10.1016/j.ajo.2018.01.012
   Moja L, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0105-0
   Moriarty-Craige SE, 2005, AM J OPHTHALMOL, V140, P1020, DOI 10.1016/j.ajo.2005.06.043
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Nwanze CC, 2012, CLIN MED INSIGHTS-TH, V4, P29, DOI 10.4137/CMT.S7439
   Ogura Y., 2019, OPHTHALMOLOGY
   Olea JL, 2012, EUR J OPHTHALMOL, V22, P404, DOI 10.5301/ejo.5000023
   Olsen TW, 2018, OPHTHALMOLOGY, V125, pP228, DOI 10.1016/j.ophtha.2017.09.030
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Paques M, 2018, PROG RETIN EYE RES, V66, P1, DOI 10.1016/j.preteyeres.2018.07.001
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Pielen A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078538
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Pilotto A, 2018, PRAC ISS GERIATRICS, P1, DOI 10.1007/978-3-319-62503-4
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rim TH, 2019, OPHTHALMOLOGY, V126, P274, DOI 10.1016/j.ophtha.2018.09.014
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Ryan S. J., 2005, RETINA
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schmidt-Erfurth U, 2006, ARCH OPHTHALMOL-CHIC, V124, P561, DOI 10.1001/archopht.124.4.561
   Schneider EW, 2018, CURR OPIN OPHTHALMOL, V29, P217, DOI 10.1097/ICU.0000000000000469
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000165.pub3
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stein JD, 2012, ARCH OPHTHALMOL-CHIC, V130, P1579, DOI 10.1001/archophthalmol.2012.1325
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Su YX, 2018, PHOTODIAGN PHOTODYN, V22, P263, DOI 10.1016/j.pdpdt.2018.05.002
   Su ZA, 2012, J OCUL PHARMACOL TH, V28, P410, DOI 10.1089/jop.2011.0221
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tarantola RM, 2010, RETINA-J RET VIT DIS, V30, P1405, DOI 10.1097/IAE.0b013e3181f57d58
   Taylor PR, 2007, JAMA-J AM MED ASSOC, V298, P401, DOI 10.1001/jama.298.4.401-b
   Thomas R, 2003, ACTA OPHTHALMOL SCAN, V81, P480, DOI 10.1034/j.1600-0420.2003.00135.x
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   TIEDEMAN JS, 1991, AM J OPHTHALMOL, V111, P338, DOI 10.1016/S0002-9394(14)72319-0
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   US Food and Drug Administration Center for Drug Evaluation and Research, 25156 US FDA BLA
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Vincent GK, 2010, NEXT 4 DECADES OLDER, P25
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Virgili G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub3
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang R, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1163-5
   Web JA., 2008, OPHTHALMOL TIME 0115
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
   Wei Y, 2018, MEDICINE, V97, DOI DOI 10.1097/MD.0000000000010422
   Windsor MA, 2018, AM J OPHTHALMOL, V185, P115, DOI 10.1016/j.ajo.2017.09.027
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zarbin M, 2006, ARCH OPHTHALMOL-CHIC, V124, P563, DOI 10.1001/archopht.124.4.563
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 290
TC 62
Z9 68
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2020
VL 127
IS 1
BP P1
EP P65
DI 10.1016/j.ophtha.2019.09.024
PG 65
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JW7JM
UT WOS:000503224300009
PM 31757502
DA 2022-11-30
ER

PT J
AU Bressler, NM
AF Bressler, NM
CA Verteporfin Roundtable
TI Guidelines for using verteporfin (visudyne) in photodynamic therapy for
   choroidal neovascularization due to age related macular degeneration and
   other causes: Update
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; REPORT NO. 3; VISUAL-ACUITY; PATHOLOGICAL
   MYOPIA; TAP; OUTCOMES; LESIONS
AB Guidelines originally were published in 2002 based on best available scientific data as well as consensus of expert opinion in the absence of controlled clinical trial data to assist ophthalmologists with selection of patients for whom photodynamic therapy with verteporfin (Visudyne, Novartis AG, Basel, Switzerland), termed "verteporfin therapy," should be considered, and to offer suggestions regarding initial treatment, follow-up, and additional courses of treatment at follow-up. Consensus was based on results of clinical trials and expert opinion. Additional input and advice were received from representatives on behalf of the American Society of Retina Specialists, the Macula Society, and the Retina Society, as well as principal investigators of randomized clinical trials evaluating verteporfin therapy. Since 2002, additional information relevant to clinical care was published in the peer-reviewed literature; therefore, revisions to the originally published guidelines judged warranted are provided here. Patient selection criteria include the following: (1) in cases due to age-related macular degeneration (AMD), lesion composition of (a) predominantly classic choroidal neovascularization (CNV), (b) occult with no classic CNV with presumed recent disease progression, or (c) relatively small minimally classic lesions; (2) CNV location subfoveal or so close to the foveal center that conventional laser photocoagulation treatment almost certainly would extend under the center; (3) etiology of CNV from AMD, pathologic myopia, or other causes in which the outcome without treatment is likely to be worse than with treatment; and (4) vision at a level where further loss would be recognized as detrimental to the quality of life of the patient. Criteria include lesion size for AMD patients with either a minimally classic lesion composition (where treatment usually should be considered only for relatively smaller lesions) or occult with no classic lesions (where treatment usually should be considered for relatively smaller lesions or those >4 Macular Photocoagulation Study disc areas with a relatively lower or poorer best-corrected visual acuity) but not patient age, history of systemic arterial hypertension, or prior laser photocoagulation. Therapy should be initiated ideally within 1 week of the initial fluorescein angiogram on which the clinical decision to treat is based. Patients should return for follow-up at least as often as every 3 months (+/-2 weeks) after any initial or subsequent treatment to determine if there is fluorescein leakage from CNV. Additional courses of treatment should be considered as often as every 3 months (+/-2 weeks) if fluorescein leakage from CNV is noted at that time. Additional courses of treatment could be deferred if the biomicroscopic and fluorescein angiographic appearances of the lesion are unchanged and show minimal fluorescein leakage, especially when there is no subretinal fluid or fluorescein leakage from CNV underlying the center of the foveal avascular zone. Patients should avoid exposure of skin or eyes to direct sunlight or bright indoor light for 48 hours after treatment or until resolution of any swelling or discoloration from extravasation. Follow-up of relatively larger minimally classic lesions and occult with no classic lesions that initially do not undergo therapy appears indicated so therapy can be considered if a predominantly classic lesion develops or, in the case of occult with no classic lesions, if visual acuity declines slightly to a lower (poorer) level without a marked increase in lesion size.
   Additional revisions of these guidelines may be required as new data become available.
RP Bressler, NM (通讯作者)，Suite 115,550 N Broadway, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
CR *AM AC OPHTH, 2003, PREF PRACT PATT AG R
   Anand R, 2003, ARCH OPHTHALMOL-CHIC, V121, P415
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   *CMS US DHHS, OC PHOT THER VERT MA
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   Ladd BS, 2001, AM J OPHTHALMOL, V132, P659, DOI 10.1016/S0002-9394(01)01198-9
   Packo KH, 2001, INVEST OPHTH VIS SCI, V42, pS449
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Rosenfeld PJ, 2001, INVEST OPHTH VIS SCI, V42, pS512
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Snyers B, 2004, AM J OPHTHALMOL, V137, P812, DOI 10.1016/j.ajo.2003.11.076
   TAP and VIP Study Group, 2002, RETINA, V22, P6
   *TAP VIP STUD GROU, 2004, RETINA, V24, P1
   TUNIS SR, MEDICARE COVERAGE PO
   *VIM STUD GROUP, 2005, IN PRESS
   *VIP STUD GROUP, 2005, IN PRESS ARCH OPHTHA
NR 27
TC 107
Z9 115
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB-MAR
PY 2005
VL 25
IS 2
BP 119
EP 134
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 895RJ
UT WOS:000226880400002
PM 15689800
DA 2022-11-30
ER

PT J
AU Oliver, VF
   Jaffe, AE
   Song, J
   Wang, GH
   Zhang, PW
   Branham, KE
   Swaroop, A
   Eberhart, CG
   Zack, DJ
   Qian, J
   Merbs, SL
AF Oliver, Verity F.
   Jaffe, Andrew E.
   Song, Jin
   Wang, Guohua
   Zhang, Pingwu
   Branham, Kari E.
   Swaroop, Anand
   Eberhart, Charles G.
   Zack, Donald J.
   Qian, Jiang
   Merbs, Shannath L.
TI Differential DNA methylation identified in the blood and retina of AMD
   patients
SO EPIGENETICS
LA English
DT Article
DE age-related macular degeneration; DNA methylation; genome-wide
   methylation; methyl-QTL; peripheral blood leukocytes; retina
ID EPIGENOME-WIDE ASSOCIATION; MACULAR DEGENERATION; GENE-EXPRESSION;
   IL17RC PROMOTER; SMOKING; DISEASE; GENOME; TSP50; CELLS; RISK
AB Age-related macular degeneration (AMD) is a major cause of blindness in the western world. While genetic studies have linked both common and rare variants in genes involved in regulation of the complement system to increased risk of development of AMD, environmental factors, such as smoking and nutrition, can also significantly affect the risk of developing the disease and the rate of disease progression. Since epigenetics has been implicated in mediating, in part, the disease risk associated with some environmental factors, we investigated a possible epigenetic contribution to AMD. We performed genome-wide DNA methylation profiling of blood from AMD patients and controls. No differential methylation site reached genome-wide significance; however, when epigenetic changes in and around known GWAS-defined AMD risk loci were explored, we found small but significant DNA methylation differences in the blood of neovascular AMD patients near age-related maculopathy susceptibility 2 (ARMS2), a top-ranked GWAS locus preferentially associated with neovascular AMD. The methylation level of one of the CpG sites significantly correlated with the genotype of the risk SNP rs10490924, suggesting a possible epigenetic mechanism of risk. Integrating genome-wide DNA methylation analysis of retina samples with and without AMD together with blood samples, we further identified a consistent, replicable change in DNA methylation in the promoter region of protease serine 50 (PRSS50). These methylation changes may identify sites in novel genes that are susceptible to non-genetic factors known to contribute to AMD development and progression.
C1 [Oliver, Verity F.; Song, Jin; Wang, Guohua; Zhang, Pingwu; Eberhart, Charles G.; Zack, Donald J.; Qian, Jiang; Merbs, Shannath L.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Jaffe, Andrew E.] Lieber Inst Brain Dev, Baltimore, MD USA.
   [Jaffe, Andrew E.] Johns Hopkins Univ, Johns Hopkins Computat Biol Ctr, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA.
   [Jaffe, Andrew E.] Johns Hopkins Univ, Johns Hopkins Computat Biol Ctr, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA.
   [Branham, Kari E.] Univ Michigan, Dept Ophthalmol & Visual Sci, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA.
   [Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Eberhart, Charles G.; Merbs, Shannath L.] Johns Hopkins Univ, Sch Med, Oncol, Baltimore, MD USA.
   [Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Pathol, Baltimore, MD USA.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Mol Biol & Genet, Baltimore, MD USA.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Neurosci, Baltimore, MD USA.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD USA.
   [Zack, Donald J.] Inst Vis, Paris, France.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   Bloomberg School of Public Health; Johns Hopkins University; Johns
   Hopkins Bloomberg School of Public Health; University of Michigan
   System; University of Michigan; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); Johns Hopkins University; Johns
   Hopkins University; Johns Hopkins University; Johns Hopkins University;
   Johns Hopkins University; UDICE-French Research Universities; Sorbonne
   Universite
RP Qian, J (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
EM jiang.qian@jhmi.edu; smerbs@jhmi.edu
RI Jaffe, Andrew/GPF-5693-2022; Wang, Guohua/GLR-7939-2022; Jaffe,
   Andrew/L-3089-2016; Branham, Kari/AAA-8336-2022; Todd,
   Verity/K-7336-2012
OI Jaffe, Andrew/0000-0001-6886-1454; Jaffe, Andrew/0000-0001-6886-1454;
   Todd, Verity/0000-0003-4786-8272; Branham, Kari/0000-0002-2492-254X;
   Swaroop, Anand/0000-0002-1975-1141
FU National Institutes of Health [R01EY020406, R01EY023188, R01EY024580];
   National Eye Institute [P30EY001765, EY016862]; Foundation Fighting
   Blindness; generosity of Agnes Nixon; Center for Inherited Disease
   Research (CIDR) through the NEI grant [X01HG006605]; NATIONAL EYE
   INSTITUTE [R01EY024580, R01EY023188, R01EY020406, R01EY016862,
   P30EY001765, ZIAEY000546] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health
   [R01EY020406 to SLM, R01EY023188 to SLM and JQ, R01EY024580 to JQ]; the
   National Eye Institute Core Grant [P30EY001765]; the Intramural Research
   Program of the National Eye Institute (to AS); Foundation Fighting
   Blindness (to KEB); the generosity of Agnes Nixon (SLM). The collection
   of the Michigan AMD-MMAP cohort was funded by the National Eye Institute
   [EY016862 to AS]. Illumina Human Methylation 450K profiling was
   performed by the Center for Inherited Disease Research (CIDR) through
   the NEI grant X01HG006605.
CR Acevedo N, 2015, HUM MOL GENET, V24, P875, DOI 10.1093/hmg/ddu479
   Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dayeh T, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004160
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Dempster EL, 2011, HUM MOL GENET, V20, P4786, DOI 10.1093/hmg/ddr416
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Drong AW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055923
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gavin DP, 2010, NEUROSCI BIOBEHAV R, V34, P882, DOI 10.1016/j.neubiorev.2009.10.010
   Gervin K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002454
   Grafodatskaya D, 2010, J AM ACAD CHILD PSY, V49, P794, DOI 10.1016/j.jaac.2010.05.005
   Huang Y, 2008, BIOCHEM BIOPH RES CO, V374, P658, DOI 10.1016/j.bbrc.2008.07.087
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Huynh JL, 2014, NAT NEUROSCI, V17, P121, DOI 10.1038/nn.3588
   Liu X, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-271
   Liu Y, 2013, NAT BIOTECHNOL, V31, P142, DOI 10.1038/nbt.2487
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meleth AD, 2011, CURR OPIN OPHTHALMOL, V22, P190, DOI 10.1097/ICU.0b013e32834594b0
   Michels KB, 2013, NAT METHODS, V10, P949, DOI 10.1038/nmeth.2632
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nimmo ER, 2012, INFLAMM BOWEL DIS, V18, P889, DOI 10.1002/ibd.21912
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163
   Shan JD, 2002, CANCER RES, V62, P290
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111
   Wang XL, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-87
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Zhou LA, 2010, IUBMB LIFE, V62, P825, DOI 10.1002/iub.390
NR 41
TC 49
Z9 52
U1 0
U2 18
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD AUG 3
PY 2015
VL 10
IS 8
BP 698
EP 707
DI 10.1080/15592294.2015.1060388
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CP1AH
UT WOS:000359607700004
PM 26067391
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Keenan, TD
   Wiley, HE
   Agron, E
   Aronow, ME
   Christen, WG
   Clemons, TE
   Chew, EY
AF Keenan, Tiarnan D.
   Wiley, Henry E.
   Agron, Elvira
   Aronow, Mary E.
   Christen, William G.
   Clemons, Traci E.
   Chew, Emily Y.
CA Age-Related Eye Dis Study Grp
   Age-Related Eye Dis Study 2 Res Gr
TI The Association of Aspirin Use with Age-Related Macular Degeneration
   Progression in the Age-Related Eye Disease Studies Age-Related Eye
   Disease Study 2 Report No. 20
SO OPHTHALMOLOGY
LA English
DT Article
ID LOW-DOSE ASPIRIN; SECONDARY PREVENTION; CARDIOVASCULAR-DISEASE;
   RISK-FACTORS; STATIN USE; DESIGN; PREVALENCE; ADULTS; SUBDISTRIBUTION;
   RECOMMENDATION
AB Purpose: To analyze the potential association between aspirin use and progression of age-related macular degeneration (AMD).
   Design: Two prospective cohort studies within 2 controlled clinical trials of oral supplementation for age-related eye disease.
   Participants: Age-Related Eye Disease Study (AREDS) participants 55 to 80 years of age and AREDS2 participants 50 to 85 years of age.
   Methods: Propensity scores for aspirin use were calculated for AREDS and AREDS2 participants separately by logistic regression. Of the participants without late AMD (geographic atrophy [GA] or neovascular AMD) in either eye at study baseline, aspirin users were matched 1:1 with nonusers by propensity score (separately for AREDS and AREDS2). Proportional hazards regression was performed, adjusting for age, on the matched participants to evaluate associations between aspirin propensity score and progression to late AMD (and its subtypes).
   Main Outcome Measures: Progression to late AMD on color fundus photographs, graded centrally.
   Results: Of the 3734 eligible AREDS participants, 1049 (28.1%) were taking aspirin, and of the 2403 eligible AREDS2 participants, 1198 (49.9%) were taking aspirin. After matching by propensity score, the characteristics of the users and nonusers were similar in both studies. Of the 1950 matched AREDS participants and 1694 matched AREDS2 participants, over a median follow-up of 10.1 years and 5.0 years, respectively, the numbers who progressed to late AMD, GA, or neovascular AMD were 454 (23.3%), 345 (17.7%), and 278 (14.3%), respectively, in AREDS and 643 (38.0%), 402 (24.6%), and 341 (20.1 %) in AREDS2. The hazard ratios of progression in quintile 5 (highest propensity for aspirin use) versus 1 (reference) were 1.17 (P = 0.35), 1.24 (0.25), and 0.95 (0.81), respectively, in AREDS and 1.26 (0.09), 1.46 (0.03), and 1.12 (0.58) in AREDS2. No significant association with progression to late AMD was observed for quintiles 2 through 5 for any of the 3 outcomes in either study.
   Conclusions: Aspirin use was not associated significantly with progression to late AMD or its subtypes in either the AREDS or AREDS2. Patients with AMD need not avoid aspirin for this reason when its use is medically indicated. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Keenan, Tiarnan D.; Wiley, Henry E.; Agron, Elvira; Aronow, Mary E.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Christen, William G.] Harvard Med Sch, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
   [Clemons, Traci E.] Emmes Corp, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Harvard University; Brigham & Women's Hospital; Harvard Medical
   School; Emmes Corporation
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, CRC, Bldg 10,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [EY000546]; National Eye Institute, National Institutes of
   Health, Bethesda, Maryland (Age-Related Eye Disease Study [AREDS] 2)
   [HHS-N-260-2005-00007-C, HHS-N-264-2013-00005-C]; National Eye
   Institute, National Institutes of Health, Bethesda, Maryland
   (Administrative Data Base) [N01-EY-5-0007]; National Eye Institute,
   National Institutes of Health, Bethesda, Maryland (AREDS)
   [NOI-EY-0-2127]; Office of Dietary Supplements, National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; National Institute of
   Neurological Disorders and Stroke; AREDS; AREDS2
FX Supported by the Intramural Research Program of the National Eye
   Institute, National Institutes of Health, Bethesda, Maryland (grant no.:
   EY000546; Age-Related Eye Disease Study [AREDS] 2 contract no.:
   HHS-N-260-2005-00007-C; HHS-N-264-2013-00005-C; Administrative Data Base
   contract no.: N01-EY-5-0007; and AREDS contract no.: NOI-EY-0-2127). The
   following National Institutes of Health institutes contributed funds to
   the AREDS2 contracts: Office of Dietary Supplements, National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; and National Institute of
   Neurological Disorders and Stroke. The AREDS and AREDS2 sponsor and
   funding organization participated in the design and conduct of the
   study; data collection, management, analysis, and interpretation; and
   preparation, review, and approval of the manuscript.
CR Al-Holou SN, 2016, OPHTHALMOLOGY, V123, P916, DOI 10.1016/j.ophtha.2015.10.040
   Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Berg AO, 2002, ANN INTERN MED, V136, P157, DOI 10.7326/0003-4819-136-2-200201150-00015
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Calonge N, 2009, ANN INTERN MED, V150, P396
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung N, 2013, BRIT J OPHTHALMOL, V97, P785, DOI 10.1136/bjophthalmol-2012-302253
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chong EW, 2014, EXPERT OPIN DRUG SAF, V13, P691, DOI 10.1517/14740338.2014.914169
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2014, EXPERT OPIN DRUG SAF, V13, P421, DOI 10.1517/14740338.2014.889680
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Fanaroff AC, 2017, INT J CARDIOL, V241, P87, DOI 10.1016/j.ijcard.2017.03.046
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Kahawita SK, 2014, CAN J OPHTHALMOL, V49, P35, DOI 10.1016/j.jcjo.2013.07.016
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kim C, 2004, AM J PREV MED, V27, P1, DOI 10.1016/j.amepre.2004.03.008
   KINGHAM JD, 1988, NEW ENGL J MED, V318, P1126
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Kohl M, 2015, COMPUT METH PROG BIO, V118, P218, DOI 10.1016/j.cmpb.2014.11.009
   Kwok CS, 2015, STROKE, V46, P1014, DOI 10.1161/STROKEAHA.114.008422
   Li L, 2015, J CLIN PHARM THER, V40, P144, DOI 10.1111/jcpt.12241
   Lievre M, 2010, FUND CLIN PHARMACOL, V24, P385, DOI 10.1111/j.1472-8206.2009.00769.x
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   McNeil JJ, 2018, NEW ENGL J MED, V379, P1519, DOI 10.1056/NEJMoa1803955
   McNeil JJ, 2018, NEW ENGL J MED, V379, P1499, DOI 10.1056/NEJMoa1800722
   McNeil JJ, 2018, NEW ENGL J MED, V379, P1509, DOI 10.1056/NEJMoa1805819
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Nowak JZ, 2014, EXPERT OPIN DRUG SAF, V13, P687, DOI 10.1517/14740338.2014.915939
   Ornelas A, 2017, CANCER METAST REV, V36, P289, DOI 10.1007/s10555-017-9675-z
   Parsons LS, REDUCING BIAS PROPEN
   Pignone M, 2007, AM J PREV MED, V32, P403, DOI 10.1016/j.amepre.2007.01.010
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Rim TH, 2019, OPHTHALMOLOGY, V126, P274, DOI 10.1016/j.ophtha.2018.09.014
   Robman L, 2017, CONT CLIN TRIAL COMM, V6, P105, DOI 10.1016/j.conctc.2017.03.005
   Rudnicka AR, 2010, EYE, V24, P1199, DOI 10.1038/eye.2010.8
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Small KW, 2017, RETINA-J RET VIT DIS, V37, P1630, DOI 10.1097/IAE.0000000000001475
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sobrin L, 2013, AM J OPHTHALMOL, V156, P213, DOI 10.1016/j.ajo.2013.04.023
   Williams CD, 2015, AM J PREV MED, V48, P501, DOI 10.1016/j.amepre.2014.11.005
   Williamson EJ, 2014, RESPIROLOGY, V19, P625, DOI 10.1111/resp.12312
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ye J, 2014, INVEST OPHTH VIS SCI, V55, P2687, DOI 10.1167/iovs.13-13206
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Zanutto EL, 2006, J DATA SCI, P67, DOI DOI 10.6339/JDS.2006.04(1).233
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 58
TC 8
Z9 8
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2019
VL 126
IS 12
BP 1647
EP 1656
DI 10.1016/j.ophtha.2019.06.023
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JP0KL
UT WOS:000497960600017
PM 31358390
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Moreira-Neto, CA
   Moult, EM
   Fujimoto, JG
   Waheed, NK
   Ferrara, D
AF Moreira-Neto, Carlos A.
   Moult, Eric M.
   Fujimoto, James G.
   Waheed, Nadia K.
   Ferrara, Daniela
TI Choriocapillaris Loss in Advanced Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; MEMBRANE ATTACK COMPLEX; BRUCHS
   MEMBRANE; PIGMENT EPITHELIUM; ULTRAHIGH-SPEED; VASCULATURE; KIDNEY;
   EYES; RPE
AB The purpose of this review is to summarize the current knowledge on choriocapillaris loss in advanced age macular degeneration (AMD). Several histopathological studies in animal models and human eyes had showed that the choriocapillaris density decreases with age. However, the role of choriocapillaris loss is still unclear in AMD and its advanced forms, either choroidal neovascularization (CNV) or geographic atrophy (GA). Some authors have hypothesized that choriocapillaris loss might precede overt retinal pigment epithelium atrophy. Others have hypothesized that deposition of complement complexes on and around the choriocapillaris could be related to the tissue loss observed in early AMD. The development of imaging modalities, such as optical coherence tomography angiography (OCTA), have led to a better understanding of underlying physiopathological mechanisms in AMD. OCTA showed atrophy of choriocapillaris underneath and beyond the region of photoreceptors and RPE loss, in agreement with previous histopathologic studies. The evolution of OCTA technology suggests that CNV seems to originate from regions of severe choriocapillaris alteration. Significant progress has been made in the understanding of development and progression of GA and CNV. In vivo investigation of the choriocapillaris using OCTA may lead to new insights related to underlying disease mechanisms in AMD.
C1 [Moreira-Neto, Carlos A.; Waheed, Nadia K.; Ferrara, Daniela] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Moreira-Neto, Carlos A.] Hosp Olhos Parana, Curitiba, Parana, Brazil.
   [Moult, Eric M.; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Moult, Eric M.; Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
C3 Tufts University; Massachusetts Institute of Technology (MIT);
   Massachusetts Institute of Technology (MIT)
RP Ferrara, D (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
EM daniela@ferrara.md
FU Carl Zeiss Meditec; Topcon; Nidek; NATIONAL CANCER INSTITUTE
   [R01CA075289] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY011289] Funding Source: NIH RePORTER
FX Nadia K. Waheed received research support from Carl Zeiss Meditec,
   Topcon, and Nidek.
CR Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Dryja TP, 2016, JAMA OPHTHALMOL, V134, P1281, DOI 10.1001/jamaophthalmol.2016.3031
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Ida H, 2004, INVEST OPHTH VIS SCI, V45, P2348, DOI 10.1167/iovs.03-1337
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   OLSEN S, 1989, MEDICINE, V68, P173, DOI 10.1097/00005792-198905000-00005
   OLSEN TS, 1986, ULTRASTRUCT PATHOL, V10, P1
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
NR 30
TC 36
Z9 36
U1 1
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2018
VL 2018
AR 8125267
DI 10.1155/2018/8125267
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FV8EB
UT WOS:000424816600001
PM 29651346
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Eckardt, C
   Eckardt, U
AF Eckardt, C
   Eckardt, U
TI Macular translocation in nonexudative age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID FOVEAL TRANSLOCATION; GEOGRAPHIC ATROPHY; RETINOTOMY; SURGERY
C1 Augenklin Stadit Kliniken Frankfurt AM Hochst, D-65929 Frankfurt, Germany.
RP Eckardt, C (通讯作者)，Augenklin Stadit Kliniken Frankfurt AM Hochst, Gotenstr 6-8, D-65929 Frankfurt, Germany.
CR Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt U, 1998, KLIN MONATSBL AUGENH, V212, P212, DOI 10.1055/s-2008-1034867
   Faude F, 1999, RETINA-J RET VIT DIS, V19, P173, DOI 10.1097/00006982-199902000-00018
   Fujii GY, 2001, RETINA-J RET VIT DIS, V21, P380, DOI 10.1097/00006982-200108000-00017
   Fujikado T, 2001, INVEST OPHTH VIS SCI, V42, pS686
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Ohji M, 2000, ARCH OPHTHALMOL-CHIC, V118, P1422
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Sunness JS, 2001, INVEST OPHTH VIS SCI, V42, pS687
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 14
TC 28
Z9 28
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2002
VL 22
IS 6
BP 786
EP 794
DI 10.1097/00006982-200212000-00017
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 627UQ
UT WOS:000179954900017
PM 12476108
DA 2022-11-30
ER

PT J
AU Garrity, ST
   Sarraf, D
   Freund, KB
   Sadda, SR
AF Garrity, Sean T.
   Sarraf, David
   Freund, K. Bailey
   Sadda, Srinivas R.
TI Multimodal Imaging of Nonneovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE multimodal imaging; nonneovascular age-related macular degeneration; dry
   age-related macular degeneration; geographic atrophy; optical coherence
   tomography
ID OPTICAL-COHERENCE-TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; OUTER
   RETINAL TUBULATION; QUANTITATIVE FUNDUS AUTOFLUORESCENCE; PIGMENT
   EPITHELIAL DETACHMENT; GEOGRAPHIC ATROPHY PROGRESSION; CHOROIDAL
   BLOOD-FLOW; NATURAL-HISTORY; RETICULAR PSEUDODRUSEN; TYPE-3
   NEOVASCULARIZATION
AB Nonneovascular (dry) AMD is a retinal disease with potential for significant central visual impairment. The hallmarks of this disease are macular drusen, RPE alterations, and geographic atrophy (GA). Classification schemes for nonneovascular AMD have evolved over the years as major advances in retinal imaging have enabled a greater understanding of disease pathophysiology. The original classifications of nonneovascular AMD were based on color fundus photography (CFP), while more modern schemes rely on a multimodal imaging approach. Effective diagnosis and management of nonneovascular AMD requires a thorough understanding of its multimodal imaging features as detailed in this review. Future imaging modalities and imaging biomarkers that may aid in diagnosis and management are also discussed.
C1 [Garrity, Sean T.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Greater Los Angeles Healthcare System; Vitreous
   Retina Macula Consultants of New York; New York University; Doheny Eye
   Institute; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Dept Ophthalmol, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Research To Prevent Blindness, Inc., New York, New York, United States;
   Macula Foundation, Inc., New York, New York, United States
FX Supported by Research To Prevent Blindness, Inc., New York, New York,
   United States (DS) and Macula Foundation, Inc., New York, New York,
   United States (KBF, DS).
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allingham MJ, 2016, INVEST OPHTH VIS SCI, V57, P2283, DOI 10.1167/iovs.15-19008
   [Anonymous], 1984, AM J OPHTHALMOL, V98, P376
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Bastos RR, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/6037537
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borelli E, 2017, BR J OPHTHALMOL, DOI [10.1136/bjophthalmol-2017-310881, DOI 10.1136/BJOPHTHALMOL-2017-310881.]
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Christenbury JG, 2017, RETINA, DOI [10.1097/IAE.0000000000001766, DOI 10.1097/IAE.0000000000001766.]
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Csutak A, 2010, EYE, V24, P1568, DOI 10.1038/eye.2010.85
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P7274, DOI 10.1167/iovs.15-17371
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P1471, DOI 10.1167/iovs.13-13834
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Freund KB, 2017, THE RETINAL ATLAS
   Friberg TR, 2007, OPHTHAL SURG LAS IM, V38, P126, DOI 10.3928/15428877-20070301-07
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Gass JD, 1970, STEREOSCOPIC ATLAS M
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Giocanti-Auregan A, 2015, INVEST OPHTH VIS SCI, V56, P8325, DOI 10.1167/iovs.14-15480
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Goerdt L, 2017, INVEST OPHTH VIS SCI, V58
   Gorczynska I, 2009, BRIT J OPHTHALMOL, V93, P603, DOI 10.1136/bjo.2007.136101
   Govetto A, 2017, AM J OPHTHALMOL, V184, P167, DOI 10.1016/j.ajo.2017.10.011
   Govetto A, 2017, BRIT J OPHTHALMOL, V101, P764, DOI 10.1136/bjophthalmol-2016-309281
   Gramatikov BI, 2014, BIOMED ENG ONLINE, V13, DOI 10.1186/1475-925X-13-52
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Keilhauer CN, 2010, MED RETINA ESSENTIAL
   Khan Nadia, 2006, Semin Ophthalmol, V21, P135, DOI 10.1080/08820530500350662
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   KIMIZUKA Y, 1993, RETINA-J RET VIT DIS, V13, P129, DOI 10.1097/00006982-199313020-00007
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Litts KM, 2017, RETINA-J RET VIT DIS, V37, P978, DOI 10.1097/IAE.0000000000001265
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Lois N, 2004, AM J OPHTHALMOL, V138, P55, DOI 10.1016/j.ajo.2004.02.056
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P407, DOI 10.1097/IAE.0000000000000368
   Pang CE, 2014, AM J OPHTHALMOL, V158, P171, DOI 10.1016/j.ajo.2014.03.003
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58
   Pilotto E, 2015, INVEST OPHTH VIS SCI, V56, P8120, DOI 10.1167/iovs.15-17366
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Preti RC, 2017, RETINA, DOI [10.1097/IAE.0000000000001810, DOI 10.1097/IAE.0000000000001810.]
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P2433, DOI 10.1097/IAE.0000000000000761
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   Rahimy E, 2013, SURV OPHTHALMOL, V58, P430, DOI 10.1016/j.survophthal.2012.09.001
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rodriguez-Padilla JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P775, DOI 10.1001/archopht.125.6.775
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sacconi R, 2017, RETINA, DOI [10.1097/IAE.0000000000001873, DOI 10.1097/IAE.0000000000001873.]
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Schaal KB, 2017, AM J OPHTHALMOL, V174, P145, DOI 10.1016/j.ajo.2016.11.002
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2006, OPHTHALMOLOGY, V113, P1392, DOI 10.1016/j.ophtha.2006.03.023
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Weger M, 2007, MOL VIS, V13, P1274
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   Wintergerst MWM, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.10
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   YANNUZZI LA, 1987, RETINA-J RET VIT DIS, V7, P111, DOI 10.1097/00006982-198700720-00009
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 161
TC 32
Z9 32
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
BP AMD48
EP AMD64
DI 10.1167/iovs.18-24158
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GN7JZ
UT WOS:000439314600001
PM 30025107
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Fukuyama, H
   Komuku, Y
   Araki, T
   Gomi, F
AF Fukuyama, Hisashi
   Komuku, Yuki
   Araki, Takashi
   Gomi, Fumi
TI ASSOCIATION OF FLOW SIGNALS WITHIN POLYPS ON OPTICAL COHERENCE
   TOMOGRAPHY ANGIOGRAPHY WITH TREATMENT RESPONSES AFTER COMBINATION
   THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE photodynamic therapy; en face; optical coherence tomography; polypoidal
   choroidal vasculopathy; combination therapy
ID VERTEPORFIN PHOTODYNAMIC THERAPY; NEOVASCULARIZATION; RANIBIZUMAB;
   EFFICACY; SAFETY
AB Purpose: To evaluate the changes of blood circulation within the polypoidal lesions by OCT angiography in eyes with polypoidal choroidal vasculopathy after combination therapy with aflibercept and photodynamic therapy. Methods: A total of 46 eyes from 46 patients who underwent the combination therapy for polypoidal choroidal vasculopathy were followed for more than 6 months. OCT angiography, covering an area 6 mm(2) x 6 mm(2) including the macula, were performed at baseline, 2 weeks, and 3 months and 6 months post-treatment. Results: The subretinal fluid resolved within 3 months after treatment in 44 eyes (95.7%), and 27 eyes (58.7%) showed no recurrence, with no additional treatment. Seventeen eyes (37.0%) showed recurrence, and two eyes (4.3%) showed poor response. On OCT angiography at 2 weeks after treatment, flow signals were detected in 3 of 27 eyes (11.1%) without recurrence and in 8 of 19 eyes (42.1%) with recurrence or poor responses. A detectable flow signal at 2 weeks was significantly associated with recurrence or poor response (P = 0.032). Conclusion: Persistent flow signals within polyps on OCT angiography at 2 weeks after combination therapy suggest less effectiveness of the initial treatment.
C1 [Fukuyama, Hisashi; Komuku, Yuki; Araki, Takashi; Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.
C3 Hyogo College of Medicine
RP Fukuyama, H (通讯作者)，Hyogo Coll Med, Dept Ophthalmol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.
EM fukuyama1985@gmail.com; yuki.kom0923@gmail.com; t-a0820@hyo-med.ac.jp;
   gomi.fumi@gmail.com
FU Novartis Pharma (Tokyo, Japan)
FX Supported in part by a grant from Novartis Pharma (Tokyo, Japan). The
   company had no role in the design or conduct of this research.
CR Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chang CJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241230
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Choi S, 2021, GRAEF ARCH CLIN EXP, V259, P837, DOI 10.1007/s00417-020-04924-0
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Fujita A, 2020, RETINA-J RET VIT DIS, V40, P2296, DOI 10.1097/IAE.0000000000002760
   Fukuyama H, 2018, OPHTHALMOL RETINA, V2, P803, DOI 10.1016/j.oret.2017.11.016
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kim K, 2020, AM J OPHTHALMOL, V217, P240, DOI 10.1016/j.ajo.2020.05.017
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Komuku Y, 2020, JPN J OPHTHALMOL, V64, P265, DOI 10.1007/s10384-020-00734-3
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2022
VL 42
IS 5
BP 942
EP 948
DI 10.1097/IAE.0000000000003395
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0U0LT
UT WOS:000787351800017
PM 34954774
DA 2022-11-30
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Nutritional Supplements for Age-Related Macular Degeneration Revisited
SO MEDICAL LETTER ON DRUGS AND THERAPEUTICS
LA English
DT Article
ID CLINICAL-TRIAL; BETA-CAROTENE; EYE DISEASE
CR Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
NR 4
TC 0
Z9 0
U1 0
U2 3
PU MED LETTER INC
PI NEW ROCHELLE
PA 145 HUGUENOT ST, SUITE 312, NEW ROCHELLE, NY 10801-7537 USA
SN 0025-732X
J9 MED LETT DRUGS THER
JI Med. Lett. Drugs Ther.
PD JUN 24
PY 2013
VL 55
IS 1419
BP 50
EP 51
PG 2
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 172CR
UT WOS:000320978100002
PM 23797797
DA 2022-11-30
ER

PT J
AU Patel, SN
   Wu, C
   Obeid, A
   Sivalingam, M
   Gervasio, K
   Wibbelsman, TD
   Levin, H
   Xu, D
   Regillo, CD
   Hsu, J
   Ho, AC
AF Patel, Samir N.
   Wu, Connie
   Obeid, Anthony
   Sivalingam, Meera
   Gervasio, Kalla
   Wibbelsman, Turner D.
   Levin, Hannah
   Xu, David
   Regillo, Carl D.
   Hsu, Jason
   Ho, Allen C.
TI Sociodemographic Factors in Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SOCIOECONOMIC-STATUS
C1 [Patel, Samir N.; Wu, Connie; Obeid, Anthony; Sivalingam, Meera; Gervasio, Kalla; Wibbelsman, Turner D.; Levin, Hannah; Xu, David; Regillo, Carl D.; Hsu, Jason; Ho, Allen C.] Mid Atlantic Retina, Wills Eye Hosp, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Ho, AC (通讯作者)，Mid Atlantic Retina, Wills Eye Hosp, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM acho@midatlanticretina.com
RI Gervasio, Kalla/AAM-3471-2020
OI Gervasio, Kalla/0000-0003-4277-7347; Xu, David/0000-0003-3649-4746; Ho,
   Allen/0000-0003-3921-608X
CR Bosma H, 2001, AM J EPIDEMIOL, V153, P363, DOI 10.1093/aje/153.4.363
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Hiscock R, 2012, ANN NY ACAD SCI, V1248, P107, DOI 10.1111/j.1749-6632.2011.06202.x
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
NR 7
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2020
VL 127
IS 2
BP 280
EP 282
DI 10.1016/j.ophtha.2019.09.038
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KE0BS
UT WOS:000508226400029
PM 31785890
DA 2022-11-30
ER

PT J
AU Folk, JC
   Stone, EM
AF Folk, James C.
   Stone, Edwin M.
TI Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; PHOTODYNAMIC THERAPY;
   MACULOPATHY; MEMBRANES; RISK; VERTEPORFIN; BEVACIZUMAB; LESIONS;
   PHOTOCOAGULATION
AB This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors' clinical recommendations.
C1 [Folk, James C.; Stone, Edwin M.] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Stone, Edwin M.] Univ Iowa, Carver Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Iowa; Howard Hughes Medical Institute; University of Iowa
RP Stone, EM (通讯作者)，Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, 375 Newton Rd,4111 MERF, Iowa City, IA 52242 USA.
EM edwin-stone@uiowa.edu
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768; Stone, Edwin
   M./0000-0003-3343-4414; Folk, James/0000-0002-6271-2906
FU Robert C. Watzke Research Fund; Research to Prevent Blindness;
   Foundation Fighting Blindness [EY016822]; National Eye Institute; Howard
   Hughes Medical Institute; NATIONAL EYE INSTITUTE [R01EY016822] Funding
   Source: NIH RePORTER
FX Supported by the Robert C. Watzke Research Fund, Research to Prevent
   Blindness, the Foundation Fighting Blindness, a grant (EY016822) from
   the National Eye Institute, and the Howard Hughes Medical Institute.
CR American Academy of Ophthalmology Retina Panel, 2008, PREF PRACT PATT GUID
   [Anonymous], 1991, ARCH OPHTHALMOL, V109, P1242
   [Anonymous], 1991, ARCH OPHTHALMOL, V109, P1220
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   [Anonymous], 2000, ARCH OPHTHALMOL, V118, P488
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   BOK D, 1993, J CELL SCI, P189
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehlers JP, 2010, OPHTHAL SURG LAS IM, V41, P182, DOI 10.3928/15428877-20100303-05
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HAYREH SS, 1972, BRIT J OPHTHALMOL, V56, P736, DOI 10.1136/bjo.56.10.736
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P571
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2010, NEW ENGL J MED, V363, P105, DOI 10.1056/NEJMp1001201
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tufail A, 2010, BMJ-BRIT MED J, V340, pc2459
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 49
TC 68
Z9 71
U1 0
U2 9
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 21
PY 2010
VL 363
IS 17
BP 1648
EP 1655
DI 10.1056/NEJMct1000495
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 668BD
UT WOS:000283242700009
PM 20961248
DA 2022-11-30
ER

PT J
AU Gill, CR
   Hewitt, CE
   Lightfoot, T
   Gale, RP
AF Gill, Claire R.
   Hewitt, Catherine E.
   Lightfoot, Tracy
   Gale, Richard P.
TI Demographic and Clinical Factors that Influence the Visual Response to
   Anti-Vascular Endothelial Growth Factor Therapy in Patients with
   Neovascular Age-Related Macular Degeneration: A Systematic Review
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Anti-vascular endothelial growth factor; Anti-VEGF; Effectiveness; nAMD;
   Neovascular age-related macular degeneration; Systematic review
ID INTRAVITREAL RANIBIZUMAB; ACUITY OUTCOMES; BEVACIZUMAB; PREDICTORS;
   INJECTION; BURDEN
AB Background Neovascular age-related macular degeneration (nAMD) is a leading cause of blind registrations in the developed world. Standard therapy includes the use of anti-vascular endothelial growth factor (anti-VEGF) drugs, and whilst the clinical efficacy is well established, there is variability in the clinical effect of visual outcome. The purpose of this systematic review is to identify whether there is evidence for the influence of demographic and clinical factors on the effectiveness of anti-VEGF therapy in patients with nAMD, in settings comparable to the National Health Service (NHS). Methods This systematic review followed the PRISMA guidelines for systematic reviews. Electronic databases Medline, EMBASE, Web of Science, CINAHL and the Cochrane Library were searched for studies dated from 2005 onwards. Studies were appraised using the Newcastle-Ottawa Score, and a narrative synthesis was used. Eligibility Criteria Population: Patients with nAMD being treated with anti-VEGF therapy. Comparator: Presence or absence of potential predictive demographic and clinical factors. Settings: Comparable settings to NHS hospitals. Outcomes: Predicting demographic and clinical factors. Study designs: Randomised controlled trials, prospective cohort studies, retrospective cohort studies and case series dated from 2005. Results Thirty papers were identified in this review. The evidence suggests that the number of anti-VEGF injections that patients receive, age and lesion size at baseline are factors that influence how effective anti-VEGF therapy is in the short and long term. There was also evidence that suggested that baseline visual acuity influenced the effectiveness of anti-VEGF therapy at longer time points of more than 2 years. Due to a lack of standardised statistical reporting among the included studies, it was not possible to undertake a meaningful statistical synthesis or meta-analysis. Conclusions This review has demonstrated that there is some evidence of clinical and demographic factors that affect the effectiveness of anti-VEGF therapy and hence variation in visual acuity (VA) outcome. However, this review was unable to identify as wide a range of factors as was hoped. The findings of this review are important because some of the factors, such as VA and lesion size at diagnosis and the number of injections, are potentially modifiable through improvements in early diagnosis and service provision. Future work also needs to focus on the importance of this variation, such as the effect on patients' quality of life, and how variation can be minimised. Systematic Review Registration This review has been registered with PROSPERO (Registration number CRD42018094191).
C1 [Gill, Claire R.] Univ York, Res Ctr Social Sci, York, N Yorkshire, England.
   [Hewitt, Catherine E.; Lightfoot, Tracy] Univ York, Dept Hlth Sci, York, N Yorkshire, England.
   [Gale, Richard P.] York Teaching Hosp, Dept Ophthalmol, York, N Yorkshire, England.
C3 University of York - UK; University of York - UK
RP Gill, CR (通讯作者)，Univ York, Res Ctr Social Sci, York, N Yorkshire, England.
EM crm552@york.ac.uk
OI Hewitt, Catherine Elizabeth/0000-0002-0415-3536
FU Bayer UK [UKBAY09160131]
FX This study and Rapid Service Fee were funded as part of a PhD
   studentship by Bayer UK (Grant no. UKBAY09160131).
CR Airody A, 2015, ACTA OPHTHALMOL, V93, pE511, DOI 10.1111/aos.12618
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo P, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/820605
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Chrapek O, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/867479
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   El-Mollayess GM, 2013, RETINA-J RET VIT DIS, V33, P1828, DOI 10.1097/IAE.0b013e3182877a0d
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Gale R, 2016, OPHTHALMOLOGICA, V236, P193, DOI 10.1159/000451065
   Guber J, 2014, OPEN OPHTHALMOL J, V8, P3, DOI 10.2174/1874364101408010003
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Jonas JB, 2011, J OCUL PHARMACOL TH, V27, P401, DOI 10.1089/jop.2011.0080
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   National Institute for Health and Care Excellence (NICE), 2018, AGE RELATED MACULAR
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Ozkaya A, 2014, J FR OPHTALMOL, V37, P280, DOI 10.1016/j.jfo.2013.08.006
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Razi F, 2016, CLIN OPHTHALMOL, V10, P313, DOI 10.2147/OPTH.S97775
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Subhi Y, 2017, CASE REP OPHTHALMOL, V2017, DOI 10.1155/2017/9650287
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 35
TC 4
Z9 4
U1 0
U2 4
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD DEC
PY 2020
VL 9
IS 4
BP 725
EP 737
DI 10.1007/s40123-020-00288-0
EA AUG 2020
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PA9GG
UT WOS:000557305800001
PM 32770474
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Singh, A
AF Singh, Amardeep
TI Systemic Changes in Neovascular Age-Related Macular Degeneration
SO DANISH MEDICAL JOURNAL
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; FACTOR-H
   POLYMORPHISM; VITAMIN-D STATUS; PLASMINOGEN-ACTIVATOR INHIBITOR-1;
   RETINAL PIGMENTED EPITHELIUM; 3RD NATIONAL-HEALTH; COMPLEMENT
   ACTIVATION; CIGARETTE-SMOKING; ALTERNATIVE PATHWAY
C1 Copenhagen Univ Hosp, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
C3 University of Copenhagen
RP Singh, A (通讯作者)，Copenhagen Univ Hosp, Dept Ophthalmol, Kogevej 7-13, DK-4000 Roskilde, Denmark.
EM asingh@dadlnet.dk
RI Singh, Amardeep/ABI-4544-2020
CR Agborsangaya C, 2010, NUTR CANCER, V62, P51, DOI 10.1080/01635580903191460
   Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901
   Ahmad FK, 2009, OPHTHAL SURG LAS IM, V40, P366, DOI 10.3928/15428877-20096030-03
   Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Alliot F, 1999, DEV BRAIN RES, V117, P145, DOI 10.1016/S0165-3806(99)00113-3
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   AMD Alliance International, 2010, GLOB EC COST VIS IMP
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Arjamaa O, 2012, BRIT J OPHTHALMOL, V96, P1153, DOI 10.1136/bjophthalmol-2012-301823
   Artaza JN, 2009, J ENDOCRINOL, V200, P207, DOI 10.1677/JOE-08-0241
   Aschenbrenner JK, 2001, J SURG RES, V100, P171, DOI 10.1006/jsre.2001.6221
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Benhar I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00296
   BERNSTEIN M. H., 1965, INVEST OPHTHAL MOL, V4, P1016
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Brown DR, 2009, THESCIENTIFICWORLDJO, V9, P1061, DOI 10.1100/tsw.2009.111
   Burgisser P, 2007, CYTOM PART A, V71A, P632, DOI 10.1002/cyto.a.20414
   Caserta S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035466
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chan-Ling T, 2007, MICROCIRCULATION, V14, P63, DOI 10.1080/10739680601073451
   Chang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012925
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chew EY, 2013, JAMA OPHTHALMOL, P1
   Chitnis T, 2007, AM J PATHOL, V170, P1695, DOI 10.2353/ajpath.2007.060677
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Couturier A, 2013, INVEST OPHTHALMOL VI, V54
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crane IJ, 2008, SEMIN IMMUNOPATHOL, V30, P165, DOI 10.1007/s00281-008-0106-7
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Dick AD, 2001, INVEST OPHTH VIS SCI, V42, P170
   Do DV, 2013, RETINA, V34, P313
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fogo AB, 2003, J CLIN INVEST, V112, P326, DOI 10.1172/JCI200319375
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gonzalez-Sancho JM, 1998, FEBS LETT, V426, P225, DOI 10.1016/S0014-5793(98)00348-2
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114
   Guillot X, 2010, JOINT BONE SPINE, V77, P552, DOI 10.1016/j.jbspin.2010.09.018
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halder SK, 2013, HUM REPROD, V28, P2407, DOI 10.1093/humrep/det265
   Halder SK, 2011, J CLIN ENDOCR METAB, V96, pE754, DOI 10.1210/jc.2010-2131
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Harman D, 2003, ANTIOXID REDOX SIGN, V5, P557, DOI 10.1089/152308603770310202
   HAWKINS BS, 1984, CONTROL CLIN TRIALS, V5, P203
   Hayes CE, 2003, CELL MOL BIOL, V49, P277
   Heaney RP, 2006, J NUTR, V136, P1123, DOI 10.1093/jn/136.4.1123
   Hegyi Z, 2012, J INVEST DERMATOL, V132, P1416, DOI 10.1038/jid.2011.486
   Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Holick MF, 2008, AM J CLIN NUTR, V87, p1080S
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick Michael F, 2006, Curr Osteoporos Rep, V4, P96, DOI 10.1007/s11914-996-0028-z
   Hollis BW, 2008, AM J CLIN NUTR, V88, p507S, DOI 10.1093/ajcn/88.2.507S
   Hollis BW, 2008, CURR OPIN ENDOCRINOL, V15, P489, DOI 10.1097/MED.0b013e328317ca6c
   Horie S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03072
   Hutchinson J., 1874, R LOND OPHTHALMIC HO, V8, P231
   Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5&lt;730::AID-IJC11&gt;3.0.CO;2-Q
   Isik S, 2012, EUR J INTERN MED, V23, P93, DOI 10.1016/j.ejim.2011.09.017
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Jeong WI, 2008, J GASTROEN HEPATOL, V23, pS112, DOI 10.1111/j.1440-1746.2007.05274.x
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Joshi S, 2011, MOL CELL BIOL, V31, P3653, DOI 10.1128/MCB.05020-11
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kanski J.J., 2011, CLIN OPHTHALMOLOGY S, V7th
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Kierdorf K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00044
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, AM J OPHTHALMOL, V152, P153, DOI 10.1016/j.ajo.2011.02.016
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Koch N, 2009, J LEUKOCYTE BIOL, V86, P155, DOI [10.1189/JLB.0708443, 10.1189/jlb.0708443]
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lachmann P, 2006, MOL IMMUNOL, V43, P496, DOI 10.1016/j.molimm.2005.04.005
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luo XG, 2010, NEUROCHEM RES, V35, P540, DOI 10.1007/s11064-009-0094-6
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Manson JE, 2012, CONTEMP CLIN TRIALS, V33, P159, DOI 10.1016/j.cct.2011.09.009
   Mansouritorghabe H, 2013, ENDOCR METAB IMMUNE
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Michigan A, 2011, MOL DIAGN THER, V15, P265, DOI 10.2165/11593400-000000000-00000
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mollnes TE, 1998, VOX SANG, V74, P303, DOI 10.1111/j.1423-0410.1998.tb05435.x
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagaharu K, 2011, AM J PATHOL, V178, P754, DOI 10.1016/j.ajpath.2010.10.015
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PALESTINE AG, 1985, OPHTHALMOLOGY, V92, P838
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Petta S, 2010, HEPATOLOGY, V51, P1158, DOI 10.1002/hep.23489
   Prietl B, 2013, NUTRIENTS, V5, P2502, DOI 10.3390/nu5072502
   Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x
   Ramirez AM, 2010, J STEROID BIOCHEM, V118, P142, DOI 10.1016/j.jsbmb.2009.11.004
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   ROBBINS RA, 1991, AM J PHYSIOL, V260, pL254, DOI 10.1152/ajplung.1991.260.4.L254
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SCHECHTMAN KB, 1991, AM J PUBLIC HEALTH, V81, P771, DOI 10.2105/AJPH.81.6.771
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seamans KM, 2009, AM J CLIN NUTR, V89, p1997S, DOI 10.3945/ajcn.2009.27230D
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Senoo T, 2010, THORAX, V65, P334, DOI 10.1136/thx.2009.119974
   Shechter R, 2013, NAT REV IMMUNOL, V13, P206, DOI 10.1038/nri3391
   Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113
   Shen CL, 2012, J MED FOOD, V15, P269, DOI 10.1089/jmf.2011.0163
   SHOKRAVI MT, 1995, INVEST OPHTH VIS SCI, V36, P83
   Silva AS, 2012, MOL VIS, V18, P2288
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sweigard JH, 2011, GENE THER, V18, P613, DOI 10.1038/gt.2011.6
   Takahashi Y, 2013, ANTICANCER RES, V33, P1927
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Walker DG, 2009, EXP NEUROL, V215, P5, DOI 10.1016/j.expneurol.2008.09.003
   Wasse H, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-24
   Wick G, 2013, ANNU REV IMMUNOL, V31, P107, DOI 10.1146/annurev-immunol-032712-095937
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034
   Wu-Wong JR, 2007, J VASC RES, V44, P11, DOI 10.1159/000097812
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P2162, DOI 10.1167/iovs.06-0783
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yanoff M., 2009, OPHTHALMOLOGY
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-154
NR 205
TC 3
Z9 3
U1 0
U2 3
PU DANISH MEDICAL ASSOC
PI COPENHAGEN
PA TRONDHJEMSGADE 9, DK-2100 COPENHAGEN, DENMARK
SN 2245-1919
J9 DAN MED J
JI Dan. Med. J.
PD JUN
PY 2014
VL 61
IS 6
AR B4872
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AP4JD
UT WOS:000342042100018
PM 24947635
DA 2022-11-30
ER

PT J
AU Cho, JH
   Park, SE
   Han, JR
   Kim, H
   Nam, WH
AF Cho, Joon Hee
   Park, Soo Eun
   Han, Jae Ryong
   Kim, Ha Kyoung
   Nam, Woo Ho
TI Macular hole after intravitreal ranibizumab injection for polypoidal
   choroidal vasculopathy
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE anti-vascular endothelial growth factor; intravitreal injection;
   Lucentis; macular hole; polypoidal choroidal vasculopathy; ranibizumab
   injection
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; TEARS
AB A 67-year-old man visited the clinic presenting with the complaint of decreased vision in his left eye. Visual acuity of the left eye was 6/6. On fundus examination, an orange polypoidal lesion and retinal pigment epithelial (RPE) detachment were seen. Fluorescein angiography and indocyanine green angiography were performed. There was hyperfluorescence of a clustered polyp-like lesion. The patient was diagnosed with polypoidal choroidal vasculopathy and we recommended that he be seen again in three months. At this visit, visual acuity of the left eye had decreased to 6/9 and the RPE detachment was aggravated. Intravitreal injection of ranibizumab was performed. One month after the injection, visual acuity of his left eye was 6/96. A macular hole was seen in his left eye and vitrectomy of the left eye was performed. Optical coherence tomography was checked and it showed that the macular hole was closed. Two more intravitreal ranibizumab injections were done on the left eye. Visual acuity of his left eye subsequently improved to 6/18.8.
C1 [Cho, Joon Hee; Park, Soo Eun; Kim, Ha Kyoung; Nam, Woo Ho] Hallym Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Ophthalmol, 948-1 Daerim Dong, Seoul 150950, South Korea.
   [Han, Jae Ryong] Hallym Univ, Coll Med, Hangang Sacred Heart Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Hallym University; Hallym University
RP Nam, WH (通讯作者)，Hallym Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Ophthalmol, 948-1 Daerim Dong, Seoul 150950, South Korea.
EM eyedrnam@naver.com
OI jae ryong, Han/0000-0003-1663-1440
CR Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lima LH, 2009, RETINA-J RET VIT DIS, V29, P1213, DOI 10.1097/IAE.0b013e3181b32d27
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Querques G, 2009, ACTA OPHTHALMOL, V87, P235, DOI 10.1111/j.1755-3768.2008.01226.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 10
TC 9
Z9 9
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD NOV 1
PY 2011
VL 94
IS 6
BP 586
EP 588
DI 10.1111/j.1444-0938.2011.00614.x
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA VJ8QV
UT WOS:000640406200013
PM 21517972
DA 2022-11-30
ER

PT J
AU Jenchitr, W
   Ruamviboonsuk, P
   Sanmee, A
   Pokawattana, N
AF Jenchitr, Watanee
   Ruamviboonsuk, Paisan
   Sanmee, Achareeya
   Pokawattana, Nattapol
TI Prevalence of Age-Related Macular Degeneration in Thailand
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
ID ADULT-POPULATION; RISK-FACTORS; BEIJING EYE; MACULOPATHY; CHINA
AB Methods: In this population-based study, data of participants in the Thailand National Survey of Visual Impairment in 2006--2007 were analyzed. Participants selected for this study were more than 50 years old, and were recruited from 42 districts of 21 provinces. They were interviewed, tested for visual acuity, examined for eye screening, and measured for intraocular pressure. They had digital fundus photographs taken using a nonmydriatic fundus camera through dilated pupils. The diagnosis of AMD, according to the standard international grading system, was made from the interpretation of the digital images by at least 2 retinal specialists. The observed data were used for predicting estimates of the prevalence of AMD in Thailand.
   Results: Data from 10,788 participants were analyzed. There were 321/10,788 (3%, 95% CI: 2.7--3.3%) participants diagnosed as having AMD. The mean age was 62.1 (range 50--98, SD 8.8) years old. There were 294 (2.7%) and 27 (0.3%) participants with early AMD (38.4% male) and late AMD (74.1% male) respectively. Of the late AMD, 20 (74.1%) were wet AMD and 7 (25.9%) were geographic atrophy. Based on the population census of Thailand, this could be translated into 351,000 and 39,000 patients with early and late AMD respectively.
   Conclusions: Based on these data, it is projected that Thailand will have a large number of late AMD sufferers. This makes it imperative to develop new strategies for the national public health system, aiming to incorporate already available late AMD treatment.
C1 [Ruamviboonsuk, Paisan; Sanmee, Achareeya; Pokawattana, Nattapol] Rajavithi Hosp, Dept Ophthalmol, Bangkok 10400, Thailand.
   [Jenchitr, Watanee] Rangsit Univ, Rangsit Univ Eye Ctr, Bangkok, Thailand.
   [Jenchitr, Watanee] Rangsit Univ, Fac Optometry, Bangkok, Thailand.
C3 Rajavithi Hospital; Rangsit University; Rangsit University
RP Sanmee, A (通讯作者)，Rajavithi Hosp, Dept Ophthalmol, Bangkok 10400, Thailand.
EM achareeya141@yahoo.com
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   National Statistical Office, POP HOUS CENS
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   ROH MI, YONSEI MED J, V49, P931
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   United Nations Population Division, WORLD POP PROSP 2008
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 20
TC 15
Z9 15
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD FEB
PY 2011
VL 18
IS 1
BP 48
EP 52
DI 10.3109/09286586.2010.545502
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 715XM
UT WOS:000286928600006
PM 21275595
DA 2022-11-30
ER

PT J
AU Wu, L
   Arevalo, JF
   Maia, M
   Berrocal, M
   Sanchez, J
   Evans, T
AF Wu, Lihteh
   Fernando Arevalo, J.
   Maia, Mauricio
   Berrocal, Maria H.
   Sanchez, Juan
   Evans, Teodoro
CA Pan-Amer Collaborat Retina Study
TI Comparing outcomes in patients with subfoveal choroidal
   neovascularization secondary to age-related macular degeneration treated
   with two different doses of primary intravitreal bevacizumab: results of
   the pan-american collaborative retina study group (PACORES) at the
   12-month follow-up
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; AVASTIN TREATMENT; EYE DISEASE; SHORT-TERM;
   MEMBRANES; THERAPY; RANIBIZUMAB; VERTEPORFIN; ANTIBODY; CANCER
AB To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months.
   This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg).
   The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained a parts per thousand yen3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost a parts per thousand yen3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by a parts per thousand yen3 lines, and four (16%) lost a parts per thousand yen3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 +/- 201 mu m at baseline to 268 +/- 96 mu m, compared with a decrease from 388 +/- 162 to 296 +/- 114 mu m in the 2.5-mg group (P = 0.7896).
   There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.
C1 [Wu, Lihteh; Evans, Teodoro] Inst Cirugia Ocular, San Jose, Costa Rica.
   [Fernando Arevalo, J.; Sanchez, Juan] Clin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas, Venezuela.
   [Maia, Mauricio] Univ Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil.
   [Berrocal, Maria H.] Univ Puerto Rico, San Juan, PR 00936 USA.
C3 Universidade Federal de Sao Paulo (UNIFESP); University of Puerto Rico
RP Wu, L (通讯作者)，Apdo 144-1225 Plaza Mayor, San Jose 1225, Costa Rica.
EM LW65@CORNELL.EDU
RI Maia, Mauricio/Z-1042-2019; Maia, Mauricio/I-5892-2015; Fromow-Guerra,
   J. Jans/A-3346-2015
OI Maia, Mauricio/0000-0002-7034-8091; Maia, Mauricio/0000-0002-7034-8091;
   Fromow-Guerra, J. Jans/0000-0001-5335-1275; Arevalo Suarez, Fernando
   Antonio/0000-0002-4114-5949
FU Arevalo-Coutinho Foundation, Caracas, Venezuela
FX This work was supported in part by the Arevalo-Coutinho Foundation for
   Research in Ophthalmology, Caracas, Venezuela.
CR Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schachat AP, 2003, OPHTHALMOLOGY, V110, P2073, DOI 10.1016/S0161-6420(03)01004-2
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 37
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2009
VL 53
IS 2
BP 125
EP 130
DI 10.1007/s10384-008-0622-y
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 427YJ
UT WOS:000264814700007
PM 19333696
DA 2022-11-30
ER

PT J
AU Thompson, CL
   Jun, G
   Klein, BEK
   Klein, R
   Capriotti, J
   Lee, KE
   Iyengar, SK
AF Thompson, Cheryl L.
   Jun, Gyungah
   Klein, Barbara E. K.
   Klein, Ronald
   Capriotti, Jennifer
   Lee, Kristine E.
   Iyengar, Sudha K.
TI Genetics of pigment changes and geographic atrophy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; COMPLEMENT FACTOR-H; BEAVER DAM EYE; MACULAR
   DEGENERATION; SUSCEPTIBILITY LOCI; EXTENDED FAMILIES; GENOMEWIDE-SCAN;
   LINKAGE; VARIANT; POLYMORPHISM
AB PURPOSE. Studies of age-related macular degeneration (AMD) often involve persons with both choroidal neovascularization and geographic atrophy (GA), but few genome-wide scans (GWSs) have discriminated between these two outcomes.
   METHODS. To comprehend the role of pigmentary abnormalities (PA) and GA in AMD, the authors analyzed the data from a previous GWS on AMD (FARMS [Family Age-Related Maculopathy Study] sample of 34 extended families) looking only at PA. Presented are new GWS data from the full Beaver Dam Eye Study (BDES) family cohort, including longitudinal data at baseline and 5- and 10-year follow-up. A linkage analysis for PA/GA was performed on both samples for 338 markers covering all autosomes. Another linkage analysis using the rate of change along the PA/GA scale was performed with the BDES sample.
   RESULTS. Analysis of the FARMS sample provided evidence for linkage with P < 0.01 in the 1q25, 5p13, 6q21- 23, and 11q14 regions. The most significant peak was found on chromosome 1, near complement factor H (CFH), with P = 6.20 x 10(-4). Analysis using the rate of change in BDES replicated the peaks in 5p13 and 6q21- 23, suggesting that these loci may contribute to the rate of progression of PA/GA. Association analysis of CFH polymorphisms suggest that CFH may play a role in the development of pigmentary abnormalities and may modify the progression along the PA/GA scale.
   CONCLUSIONS. These findings suggest a complex, heterogeneous model for PA/GA.
C1 Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Case Western Reserve University; Case Western Reserve University;
   University of Wisconsin System; University of Wisconsin Madison
RP Iyengar, SK (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Wolstein Res Bldg 1315,10900 Euclid Ave, Cleveland, OH 44106 USA.
EM ski@case.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Jun, Gyungah/0000-0002-3230-8697
FU NCRR NIH HHS [RR03655] Funding Source: Medline; NEI NIH HHS [EY015810,
   EY13438, EY10605, U10-EY06594, EY015286] Funding Source: Medline; NHGRI
   NIH HHS [N01-HG-65403] Funding Source: Medline; NHLBI NIH HHS [HL07567]
   Funding Source: Medline; NIGMS NIH HHS [GM28356] Funding Source:
   Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R03EY013438, R01EY015286,
   U10EY006594, R01EY015810, R01EY010605] Funding Source: NIH RePORTER;
   NATIONAL HUMAN GENOME RESEARCH INSTITUTE [N01HG065403] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [R01GM028356, R37GM028356] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keverline MR, 1998, OPHTHALMIC GENET, V19, P19, DOI 10.1076/opge.19.1.19.2176
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, WISCONSIN AGE RELATE
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008
   *NEI, AG REL EY DIS STUD A
   Schick James H., 2001, International Journal of Human Genetics, V1, P11
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Shete S, 2003, HUM HERED, V55, P79, DOI 10.1159/000072312
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yoshida A, 2000, JPN J OPHTHALMOL, V44, P290, DOI 10.1016/S0021-5155(99)00227-0
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 33
TC 12
Z9 12
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2007
VL 48
IS 7
BP 3005
EP 3013
DI 10.1167/iovs.06-1325
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 187NT
UT WOS:000247855600008
PM 17591865
DA 2022-11-30
ER

PT J
AU Owsley, C
   McGwin, G
   Scilley, K
   Kallies, K
AF Owsley, C
   McGwin, G
   Scilley, K
   Kallies, K
TI Development of a questionnaire to assess vision problems under low
   luminance in age-related maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID QUALITY-OF-LIFE; DRIVING CESSATION; DARK-ADAPTATION; DESIGN
AB PURPOSE. To develop a questionnaire for assessing self-reported visual problems under low luminance and at night for use in studies on age-related maculopathy ( ARM).
   METHODS. The questionnaire was developed in three steps: ( 1) Content for questionnaire items was identified through focus groups of older adults with ARM and those exhibiting normal retinal aging. The topic for discussion was "vision at night and under low lighting." Discussion was audiotaped, transcribed, and subjected to content analysis to identify problem categories expressed by patients. ( 2) This content was used to develop a preliminary questionnaire administered by telephone to persons with ARM or normal retinal aging. Principal-components analysis identified groups of items that formed the questionnaire's subscales that were evaluated for internal consistency, and an item-reduction strategy was implemented to generate a briefer questionnaire. ( 3) Psychometric properties of the shortened Low-Luminance Questionnaire (LLQ) were determined, including construct validity, criterion validity, and test-retest reliability.
   RESULTS. The 32-item LLQ has six subscales ( driving, extreme lighting, mobility, emotional distress, general dim lighting, and peripheral vision), all with good internal consistency (Cronbach alpha >= 0.82). Scores on LLQ subscales correlated moderately with nearly all National Eye Institute Visual Function Questionnaire (NEI VFQ)-25 subscales and decreased in value ( indicating more disability) for patients with increasing ARM disease severity. Whereas rod-mediated parameters of dark adaptation were significantly associated with LLQ subscale scores (r = 0.19 - 0.43, all P < 0.03), cone-mediated parameters were not. Test-retest reliability ranged from 0.74 to 0.88 for all subscales ( P < 0.0001), except for peripheral vision (0.46; P = 0.0003), which also exhibited a ceiling effect in almost half of the respondents.
   CONCLUSIONS. The 32-item LLQ, derived from the content of focus group comments by persons with ARM, has good construct validity, subscale scores related to rod-mediated visual function, and good test-retest reliability for five of six subscales. The LLQ may ultimately be useful in patient-centered evaluation of the outcome of interventions to prevent ARM or to arrest progression of early disease.
C1 Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Surg, Sch Med, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
FU NATIONAL EYE INSTITUTE [R21EY014071] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R01AG004212] Funding Source: NIH RePORTER;
   NEI NIH HHS [R21-EY14071] Funding Source: Medline; NIA NIH HHS
   [R01-AG04212] Funding Source: Medline
CR [Anonymous], 2000, FOCUS GROUPS PRACTIC
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Berry S, 2003, OPHTHALMOLOGY, V110, P2285, DOI 10.1016/j.ophtha.2003.08.021
   CAMPBELL MK, 1993, J GERONTOL, V48, pS230, DOI 10.1093/geronj/48.4.S230
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Elliot TR, 2004, HDB GROUP COUNSELING, P338
   ELLWEIN LB, 1994, INT OPHTHALMOL, V18, P263
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Frost N A, 1998, Ophthalmic Epidemiol, V5, P185, DOI 10.1076/opep.5.4.185.4191
   Holsti O.R., 1969, CONTENT ANAL SOCIAL
   HOROWITZ A, 1991, VISION AGING ISSUES, P37
   HU PS, 1999, FHWAPL00006 US DEP T
   Jackson GR, 2005, MACULAR DEGENERATION, P45, DOI 10.1007/3-540-26977-0_3
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MANGIONE CM, 1996, QUALITY LIFE PHARMAC, P1045
   MAROTTOLI RA, 1993, J GERONTOL, V48, pS255, DOI 10.1093/geronj/48.5.S255
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   OSWLEY C, IN PRESS REHAB PSYCH
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018
   Scilley K, 2002, QUAL LIFE RES, V11, P449, DOI 10.1023/A:1015677501386
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
NR 32
TC 93
Z9 98
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2006
VL 47
IS 2
BP 528
EP 535
DI 10.1167/iovs.05-1222
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 006UF
UT WOS:000234922100010
PM 16431946
DA 2022-11-30
ER

PT J
AU Bryhn, M
AF Bryhn, Morten
TI Can omega-3 fatty acids prevent blindness?
SO AGRO FOOD INDUSTRY HI-TECH
LA English
DT Article
ID DIETARY-FAT
AB Age-related macular degeneration is a disease of the eye in the elderly population usually leading to blindness. Besides age smoking, elevated blood lipids, hypertension and diabetes are risk factors for the development of the disease. Epidemiological studies have demonstrated that a frequent intake of seafood and antioxidants seems to prevent development of this disease. Studies are ongoing where omega-3 concentrates alone or in combination with lutein are tested in patients with early stage of age-related macular degeneration.
C1 Silentia AS, Svelvik, Norway.
RP Bryhn, M (通讯作者)，Silentia AS, Svelvik, Norway.
CR Cho E, 2001, AM J CLIN NUTR, V73, P209
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Neuringer M, 2000, AM J CLIN NUTR, V71, p256S, DOI 10.1093/ajcn/71.1.256S
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
NR 5
TC 1
Z9 1
U1 0
U2 0
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1722-6996
EI 2035-4606
J9 AGRO FOOD IND HI TEC
JI Agro Food Ind. Hi-Tech
PD SEP-OCT
PY 2007
VL 18
IS 5
BP 6
EP 7
PG 2
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 294OJ
UT WOS:000255415100002
DA 2022-11-30
ER

PT J
AU Ebell, MH
AF Ebell, Mark H.
TI Antioxidants and minerals for age-related macular degeneration
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID VITAMIN-E; SUPPLEMENTATION
CR ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD SEP 1
PY 2006
VL 74
IS 5
BP 750
EP 750
PG 1
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 081NJ
UT WOS:000240324000007
DA 2022-11-30
ER

PT J
AU Singh, RP
   Srivastava, S
   Ehlers, JP
   Bedi, R
   Schachat, AP
   Kaiser, PK
AF Singh, Rishi P.
   Srivastava, Sunil
   Ehlers, Justis P.
   Bedi, Rumneek
   Schachat, Andrew P.
   Kaiser, Peter K.
TI A single-arm, investigator-initiated study of the efficacy, safety and
   tolerability of intravitreal aflibercept injection in subjects with
   exudative age-related macular degeneration, previously treated with
   ranibizumab or bevacizumab: 6-month interim analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION;
   DIABETIC-RETINOPATHY; VEGF TRAP; TACHYPHYLAXIS; THERAPY; EYE; MG
AB Aim To evaluate efficacy and safety of intravitreal aflibercept injection (IAI) in subjects who were previously treated with ranibizumab and/or bevacizumab for active exudative age-related macular degeneration (AMD).
   Methods Patients (n=26) were enrolled in a 12-month prospective, interventional, single arm, investigator-initiated study with planned 6-month interim analysis. Patients with active exudative AMD, previously treated with ranibizumab and/or bevacizumab, were treated with 2 mg IAI every month for the first 3 months, followed by a fixed dosing schedule of 2 mg IAI every 2 months. The primary study endpoint was the mean absolute change from baseline central subfield thickness (CST) at month 12 as measured by SDOCT. Secondary outcomes included mean change from baseline best-corrected visual acuity (BCVA) score, percentage of subjects who gained or lost greater than or equal to 15 letters of vision, percentage of subjects who are 20/40 or better, percentage of subjects who are 20/200 or worse, and the incidence of adverse events (AE) and serious AEs.
   Results Planned 6-month interim analysis demonstrated a mean decrease in CST of 38.6 mm (p<0.001) and a mean increase in ETDRS BCVA of +5.9 letters (p<0.001). Fifteen percent of subjects experienced a greater than 15-letter improvement in visual acuity, 84.6% of patients gained visual acuity, and no patient lost 3 lines of vision from baseline. Forty-two percent of subjects were 20/40 or better, and 11.5% of subjects were 20/200 or worse at month 6. No serious ocular or systemic AEs were encountered.
   Conclusions IAI-treated eyes demonstrated improved short-term functional and anatomic endpoints in subjects with active exudative AMD switching from previous anti-VEGF treatment when given in a fixed dosing scheme for 6 months.
C1 [Singh, Rishi P.; Srivastava, Sunil; Ehlers, Justis P.; Bedi, Rumneek; Schachat, Andrew P.; Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation
RP Singh, RP (通讯作者)，Cole Eye Inst, Cole Eye Ctr, Dept Ophthalmol, 9500 Euclid Ave,i32, Cleveland, OH 44195 USA.
EM drrishisingh@gmail.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Regeneron Inc.
FX Support provided by a research trial grant from Regeneron Inc.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 2011, EYL PACK INS
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rofagha S, 2013, OPHTHALMOLOGY, P1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sivaprasad S, 2013, BRIT MED B, P1
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
NR 24
TC 46
Z9 47
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2014
VL 98
SU 1
BP 22
EP 27
DI 10.1136/bjophthalmol-2013-304798
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI4MX
UT WOS:000336840600006
PM 24836866
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Park, DH
   Kim, IT
AF Park, Dong Ho
   Kim, In Taek
TI Asymptomatic extramacular abnormal choroidal lesions in eyes with
   macular polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE extramacular lesion; indocyanine green angiography; polypoidal choroidal
   vasculopathy
ID CLINICOPATHOLOGICAL CORRELATION; DEGENERATION
AB To classify polypoidal choroidal vasculopathy (PCV) presenting with both extramacular and macular lesions according to location and clinical manifestations.
   We performed a retrospective analysis of 29 eyes presenting with both extramacular and macular PCV lesions by indocyanine green angiography. The patients were classified according to the location of the extramacular lesions and clinical manifestations.
   PCV locations were identified as peripapillary (32.1%), superior (10.7%) or inferior (17.9%) to the optic disc, superior (14.3%) or inferior (7.1%) temporal arcade, temporal to the macula (10.7%), and nasal to the optic disc (7.1%). Clinical manifestations were identified as polyp (10.7%), branching vascular networks (42.9%), pigment epithelial detachment (PED) (17.9%), polyp and branching vascular networks (7.1%), polyp and PED (14.3%), and all three (7.1%).
   PCV showed extramacular lesions with various clinical manifestations discontinuous from the macular lesions.
C1 [Park, Dong Ho; Kim, In Taek] Kyungpook Natl Univ, Dept Ophthalmol, Sch Med, Taegu 700721, South Korea.
C3 Kyungpook National University
RP Kim, IT (通讯作者)，Kyungpook Natl Univ, Dept Ophthalmol, Sch Med, 50 Samduk Dong 2 Ga, Taegu 700721, South Korea.
EM itkim@knu.ac.kr
CR Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 14
TC 2
Z9 3
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2010
VL 54
IS 1
BP 48
EP 54
DI 10.1007/s10384-009-0765-5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 554TH
UT WOS:000274456800009
PM 20151276
DA 2022-11-30
ER

PT J
AU Smiddy, WE
AF Smiddy, William E.
TI The cost of vision for vitreoretinal interventions
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE cost-effectiveness; cost utility; vitreoretinal surgery
ID QUALITY-OF-LIFE; INTRAVITREAL BEVACIZUMAB AVASTIN; CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
   TRIAMCINOLONE ACETONIDE; VERTEPORFIN; RANIBIZUMAB; CARE; UTILITY
AB Purpose of review
   This article reviews the current status of treatments for age-related macular degeneration from a cost-effectiveness perspective.
   Recent findings
   Treatments are now available to a broad range of patients with age-related macular degeneration, but they are pharmaceutical based and require repeated evaluation and treatment. The resulting unprecedented levels of cost make cost-effectiveness considerations more prescient. Newer methods to evaluate cost-effectiveness and treatment outcomes have included utility and value-based analyses. These have attempted to utilize accurate, objective parameters, but are calibrated by subjective patient assessments and are limited by certain methodological assumptions. Treatment methods to improve outcomes are increasingly being considered within the context of cost-effectiveness.
   Summary
   Although improved understanding of basic, cellular processes has led to markedly improved treatment options for age-related macular degeneration within the past decade, the high costs and wide applicability threaten the balance and viability of the payor system. Accurate means of assessing cost-effectiveness are critical to defining clinical applications.
C1 Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Smiddy, WE (通讯作者)，Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM wsmiddy@med.miami.edu
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2007, CURR OPIN OPHTHALMOL, V18, P206, DOI 10.1097/ICU.0b013e328129089e
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P27
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   COSTA RA, 2007, GRAFES ARCH CLIN EXP
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Heudebert GR, 2000, J GEN INTERN MED, V15, P175, DOI 10.1046/j.1525-1497.2000.02639.x
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   JAVIFT JC, 1983, OPHTHALMOLOGY, V97, P483
   JAVITT JC, 1990, OPHTHALMOLOGY, V97, P483, DOI 10.1016/S0161-6420(90)32573-3
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   JOHNSON A, 2007, WALL ST J NEW Y 0406, pB1
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KE KIM, 2007, BR J OPHTHALMOL
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lee PP, 2007, ARCH OPHTHALMOL-CHIC, V125, P406, DOI 10.1001/archopht.125.3.406
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   PREECE D, 2007, EYENET           JUN, P75
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Salm M, 2006, AM J OPHTHALMOL, V142, P976, DOI 10.1016/j.ajo.2006.07.057
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   US Social Security Administration, 2007, PER LIF TABL
   WILLIAMS GA, 2006, OPHTHALMOLOGY, V113, P156
NR 55
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2008
VL 19
IS 3
BP 195
EP 201
DI 10.1097/ICU.0b013e3282fc239f
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 296MG
UT WOS:000255548100005
PM 18408493
DA 2022-11-30
ER

PT J
AU Arnold, JJ
   Markey, CM
   Kurstjens, NP
   Guymer, RH
AF Arnold, Jennifer J.
   Markey, Caroline M.
   Kurstjens, Nicol P.
   Guymer, Robyn H.
TI The role of sub-retinal fluid in determining treatment outcomes in
   patients with neovascular age-related macular degeneration - a phase IV
   randomised clinical trial with ranibizumab: the FLUID study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Neovascular AMD; Ranibizumab; Treat and extend regimen; Intra-retinal
   fluid; Sub-retinal fluid
ID REGIMEN; EFFICACY; THERAPY; SAFETY
AB Background: With increasing experience using anti-VEGF therapy for the treatment of neovascular age-related macular degeneration (nAMD), ophthalmologists have shifted away from a "one size fits all" to an "individualised" approach based on disease activity with the aim of achieving a fluid-free retina. The FLUID study investigates the non-inferiority of a Treat and Extend (T&E) protocol of 0.5 mg ranibizumab, which allows treatment extension in the presence of incomplete resolution of sub-retinal fluid (SRF) <= 200 mu m at the foveal centre relative to a T&E protocol that requires complete resolution of all retinal fluid (i.e., both SRF and intra-retinal fluid [IRF]) in patients with nAMD.
   Methods/Design: This 24 month, randomised, phase IV trial has completed recruitment of treatment-naive patients randomised 1: 1 to ranibizumab "intensive" treatment (complete resolution of IRF and SRF) or ranibizumab "relaxed" treatment (resolution of IRF or >200 mu m SRF only at foveal centre). Patients in both arms follow a T&E regimen where extension decisions are based upon assessment of lesion activity: loss of >= 5 letters of visual acuity, new haemorrhage, presence of IRF and SRF on an optical coherence tomography (OCT) scan. The determination of SRF is conducted at a reading centre while the assessment of IRF is physician-determined. The primary endpoint is the mean change in best-corrected visual acuity (BCVA) from baseline to 24 months. Secondary endpoints include the mean change in central retinal thickness (CRT) from baseline to 12 and 24 months, the number of ranibizumab injections administered at 12 and 24 months, and the pharmacogenomic assessment of AMD Gene Consortium-identified single-nucleotide polymorphisms (SNPs) and their association with treatment response. Three hundred and forty seven (347) patients have been recruited by 16 Australian sites within approximately 16 months. A protocol to adjudicate on SRF has been established by the central reading centre and is demonstrating good concordance with investigator assessment.
   Discussion: This study will provide important insights into retreatment criteria for managing nAMD using a T&E regimen. The current paper describes the clinical rationale for using a less intensive treatment approach using ranibizumab and details of the treatment protocol.
C1 [Arnold, Jennifer J.] Marsden Eye Specialists, 152 Marsden St, Parramatta, NSW 2150, Australia.
   [Markey, Caroline M.] Markey Med Consulting Pty Ltd, POB 136, Frenchs Forest, NSW 1640, Australia.
   [Kurstjens, Nicol P.] Novartis Pharmaceut Australia Pty Ltd, 54 Waterloo Rd, Macquarie Pk, NSW 2113, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Arnold, JJ (通讯作者)，Marsden Eye Specialists, 152 Marsden St, Parramatta, NSW 2150, Australia.
EM jennifer.arnold@marsdeneye.com
OI Guymer, Robyn/0000-0002-9441-4356
FU Novartis Pharmaceuticals Australia Pty Ltd.
FX The study is fully supported by funding from Novartis Pharmaceuticals
   Australia Pty Ltd.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Deloitte Access Economics, 2011, EYES FUT CLEAR OUTL
   ELDEM MB, 2009, INVEST OPHTH VIS SCI, V50, P2374
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Novartis Pharmaceuticals Australia, 2011, LUC AUSTR PRESCR INF
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
NR 25
TC 59
Z9 63
U1 1
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAR 24
PY 2016
VL 16
AR 31
DI 10.1186/s12886-016-0207-3
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH4UQ
UT WOS:000372781300001
PM 27009515
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Colquitt, JL
   Jones, J
   Tan, SC
   Takeda, A
   Clegg, AJ
   Price, A
AF Colquitt, J. L.
   Jones, J.
   Tan, S. C.
   Takeda, A.
   Clegg, A. J.
   Price, A.
TI Ranibizumab and pegaptanib for the treatment of age-related macular
   degeneration: a systematic review and economic evaluation
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Review
ID QUALITY-OF-LIFE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VISUAL FUNCTION
   QUESTIONNAIRE; COST-EFFECTIVENESS MODEL; BODY-MASS INDEX; PHOTODYNAMIC
   THERAPY; HIP FRACTURE; VERTEPORFIN THERAPY; RANDOMIZED-TRIAL; ELDERLY
   PATIENTS
AB Objectives: To assess the clinical effectiveness and cost-effectiveness of ranibizumab and pegaptanib for subfoveal choroidal neovascularisation (CNV) associated with wet age-related macular degeneration (AMD).
   Data sources: Electronic databases were searched from inception to September 2006. Experts in the field were consulted and manufacturers' submissions were examined.
   Review methods: The quality of included studies was assessed using standard methods and the clinical effectiveness data were synthesised through a narrative review with full tabulation of results. A model was developed to estimate the cost-effectiveness of ranibizumab and of pegaptanib (separately), compared with current practice or best supportive care, from the perspective of the NHS and Personal Social Services. Two time horizons were adopted for each model. The first adopted time horizons determined by the available trial data. The second analysis extrapolated effects of treatment beyond the clinical trials, adopting a time horizon of 10 years.
   Results: The combined analysis of two randomised controlled trials (RCTs) of pegaptanib [0.3 mg (licensed dose), 1.0 mg and 3.0 mg] versus sham injection in patients with all lesion types was reported by three publications (the VISION study). Three published RCTs of ranibizumab were identified (MARINA, ANCHOR, FOCUS), and an additional unpublished RCT was provided by the manufacturer (PIER). Significantly more patients lost less than 15 letters of visual acuity at 12 months when taking pegaptanib (0.3 mg: 70% of patients; 1.0 mg: 71% of patients; 3.0 mg: 65% of patients) or ranibizumab (0.3 mg: 94.3-94.5%; 0.5 mg: 94.6-96.4%) than sham injection patients (55% versus pegaptanib and 62.2% versus ranibizumab) or, in the case of ranibizumab, photodynamic therapy (PDT) (64.3%). The proportion of patients gaining 15 letters or more (a clinically important outcome having a significant impact on quality of life) was statistically significantly greater in the pegaptanib group for doses of 0.3 and 1.0 mg but not for 3.0 mg, and for all ranibizumab groups compared to the sham injection groups or PDT. This was also statistically significant for patients receiving 0.5 mg ranibizumab plus PDT compared with PDT plus sham injection. Pegaptanib patients lost statistically significantly fewer letters after 12 months of treatment than the sham group [mean letters lost: 7.5 (0.3 mg), 6.5 (1.0 mg) or 10 (3.0 mg) vs 14.5 (sham)]. In the MARINA and ANCHOR trials, ranibizumab patients gained letters of visual acuity at 12 months whereas patients with sham injection or PDT lost about 10 letters (p < 0.001) and in the PIER study, ranibizumab patients lost significantly fewer than the sham injection group. Significantly fewer patients receiving pegaptanib or ranibizumab deteriorated to legal blindness compared with the control groups. Adverse events were common for both pegaptanib and ranibizumab but most were mild to moderate. Drug costs for 1 year of treatment were estimated as 4626 pound for pegaptanib and 9134 pound for ranibizumab. Nondrug costs accounted for an additional 2614 pound for pegaptanib and 3120 pound for ranibizumab. Further costs are associated with the management of injection-related adverse events, from 1200 pound to 2100 pound. For pegaptanib compared with usual care, the incremental cost-effectiveness ratio (ICER) ranged from 163,603 pound for the 2-year model to 30,986 pound for the 10-year model. Similarly, the ICERs for ranibizumab for patients with minimally classic and occult no classic lesions, compared with usual care, ranged from 152,464 pound for the 2-year model to 25,098 pound for the 10-year model.
   Conclusions: Patients with AMD of any lesion type benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. Patients who continued treatment with either drug appeared to maintain benefits after 2 years of follow-up. When comparing pegaptanib and ranibizumab, the evidence was less clear due to the lack of direct comparison through head-to-head trials and the lack of opportunity for indirect statistical comparison due to heterogeneity. The cost-effectiveness analysis showed that the two drugs offered additional benefit over the comparators of usual care and PDT but at increased cost. Future research should encompass trials to compare pegaptanib with ranibizumab and bevacizumab, and to investigate the role of verteporfin PDT in combination with these drugs. Studies are also needed to assess adverse events outside the proposed RCTs, to consider the optimal dosing regimes of these drugs and the benefits of re-treatment after initial treatment, and to review costing in more detail. Health state utilities and their relationship with visual acuity and contrast sensitivity, the relationship between duration of vision loss and the quality of life and functional impact of vision loss, behavioural studies of those genetically at risk are other topics requiring further research.
C1 [Colquitt, J. L.; Jones, J.; Tan, S. C.; Takeda, A.; Clegg, A. J.; Price, A.] Univ Southampton, SHTAC, WIHRD, Southampton SO9 5NH, Hants, England.
C3 University of Southampton
RP Colquitt, JL (通讯作者)，Univ Southampton, SHTAC, WIHRD, Southampton SO9 5NH, Hants, England.
OI Colquitt, Jillian Leigh/0000-0001-5962-2689
CR *AM AC OPHTH, 2000, AG REL MAC DEG PREF
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   ARNOLD J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Barry SJ, 2006, VALUE HEALTH, V9, pA141, DOI 10.1016/S1098-3015(10)64743-2
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   BRAZIER JE, 2006, GEN POPULATION SURVE
   Brennan J, 2003, OSTEOPOROSIS INT, V14, P515, DOI 10.1007/s00198-003-1404-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER S B, 1989, Investigative Ophthalmology and Visual Science, V30, P154
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown M., 2005, CLIN REFRACT OPTOM, V16, P240
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy Usha, 2005, Curr Opin Ophthalmol, V16, P179, DOI 10.1097/01.icu.0000163035.37957.c2
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   *CTR MED MED SERV, STAND AN FIL LTD DAT
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Curtis L, 2005, UNIT COSTS HLTH SOCI
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   *DEP HLTH, 2005, CERT VIS IMP EXPL NO
   *DEP HLTH, 2005, NHS REF COSTS
   Drummond MF., 2015, METHODS EC EVALUATIO, V4
   Earnshaw SR, 2005, VALUE HEALTH, V8, pA179, DOI 10.1016/S1098-3015(10)67696-6
   Earnshaw SR, 2005, VALUE HEALTH, V8, pA177, DOI 10.1016/S1098-3015(10)67690-5
   Earnshaw SR, 2005, VALUE HEALTH, V8, pA176, DOI 10.1016/S1098-3015(10)67688-7
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   EVANS J, 1998, EPIDEMIOLOGY EYE DIS, P356
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JR, 1994, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253
   Evers S, 2005, INT J TECHNOL ASSESS, V21, P240, DOI 10.1017/S0266462305050324
   *EYE TECH PHARM, 2004, DERM OPHTH DRUGS ADV
   *FDA CTR DRUG EV R, 2004, NDA21756 FDA CTR DRU
   FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   *GENENTECH, FULL PRESCR INF LUC
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   HAWKES N, THOUSANDS DENIED EYE
   Hawkins BS, 2005, ARCH OPHTHALMOL-CHIC, V123, P78, DOI 10.1001/archopht.123.1.78
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   JACK CIA, 1995, GERONTOLOGY, V41, P280
   *JOINT FORM COMM, 2006, 52 JOINT FORM COMM
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KNAPP M, 1995, BRIT J PSYCHIAT, V166, P10, DOI 10.1192/S0007125000293343
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   Legood R, 2002, INJ PREV, V8, P155, DOI 10.1136/ip.8.2.155
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MCLAUGHLAN B, LEFT PAY OWN PEOPLE
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   MEADS C, 2001, 24 U BIRM DEP PUBL H
   MEADS C, 2001, HLTH TECHNOL ASSES, V7
   MEADS C, 2003, HLTH TECHNOL ASSESS, V7
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   MILLER DK, 1994, MED DECIS MAKING, V14, P52, DOI 10.1177/0272989X9401400107
   Mills E, 2007, J CLIN EPIDEMIOL, V60, P456, DOI 10.1016/j.jclinepi.2006.09.001
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P1513
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moore LW, 2000, WESTERN J NURS RES, V22, P571, DOI 10.1177/01939450022044601
   Morse AR, 1999, ARCH OPHTHALMOL-CHIC, V117, P943
   *NAT I CLIN EXC, 2004, GUID METH TECHN APP
   *NAT I CLIN EXC, 2003, GUID US PHOT THER AG, P68
   NHS Centre for Reviews and Dissemination, 2001, 4 CRD NHS CTR REV DI
   *NOV PHARM UK, 2006, LUC RAN THER TREATM
   *OFF NAT STAT, MID 2005 POP EST ENG
   *OFF NAT STAT, 2000, ENGL WAL MB, V6
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   *PFIZER, SUMM PROD CHAR MAC 0
   *PFIZER, 2006, MACUGEN PEGATANIB SO
   Philips Z., 2004, HLTH TECHNOL ASSESS, V8, piii
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   *ROY COLL OPHTH, 2002, AG REL MAC DEG GUID
   *ROY COLL OPHTH, US BEV AV
   *ROY COLL OPHTH, 2000, AG REL MAC DEG GUID
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   *SCOTT MED CONS, 29006 SCOTT MED CONS
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Shah VA, 2004, OPHTHAL EPIDEMIOL, V11, P43, DOI 10.1076/opep.11.1.43.26436
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2002, VALUE HEALTH, V5, P553, DOI 10.1016/S1098-3015(10)61459-3
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   SHMUELYDULITZKI Y, 1995, AM J GERIAT PSYCHIAT, V3, P325, DOI 10.1097/00019442-199503040-00007
   SHRAHLMAN E, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Spaide R, 2006, OPHTHALMOLOGY, V113, P160, DOI 10.1016/j.ophtha.2005.10.023
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   THOMPSON D, 2005, OPTOMETRY TODAY OPTI, P22
   Thomson D., 2005, OPTOMETRY TODAY OPTI, P55
   Tromp AM, 2001, J CLIN EPIDEMIOL, V54, P837, DOI 10.1016/S0895-4356(01)00349-3
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   Vinding T, 1995, ACTA OPHTHALMOL SCAN, V73, P3
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WAKKER P, 1995, MED DECIS MAKING, V15, P180, DOI 10.1177/0272989X9501500212
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   WONG D, AVASTIN COMING
   ZHOU S, 2006, INVEST OPHTH VIS SCI, V47, P2213
   ZHOU SWD, 2004, EC BURDEN PROGR VISI
   ZLATEVA G, 2006, INVEST OPHTHALMOL VI, V47
   2006, MONTHLY INDEX MED SP
   ENCY CONTRAST SENSIT
NR 163
TC 81
Z9 82
U1 0
U2 5
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD MAY
PY 2008
VL 12
IS 16
BP 1
EP +
PG 187
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA 301HG
UT WOS:000255886400001
DA 2022-11-30
ER

PT J
AU Saenz-de-Viteri, M
   Recalde, S
   Fernandez-Robredo, P
   Galvez, MIL
   Barquet, LA
   Figueroa, MS
   Garcia-Arumi, J
   Garcia-Layana, A
AF Saenz-de-Viteri, Manuel
   Recalde, Sergio
   Fernandez-Robredo, Patricia
   Lopez Galvez, Maria Isabel
   Arias Barquet, Lluis
   Figueroa, Marta S.
   Garcia-Arumi, Jose
   Garcia-Layana, Alfredo
CA In-Eye Study Grp
TI Role of intraretinal and subretinal fluid on clinical and anatomical
   outcomes in patients with neovascular age-related macular degeneration
   treated with bimonthly, treat-and-extend and as-needed ranibizumab in
   the In-Eye study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age&#8208; related macular degeneration; fixed bimonthly; intraretinal
   fluid; intravitreal anti&#8208; VEGF; neovascular age&#8208; related
   macular degeneration; pro re nata; ranibizumab; subretinal fluid;
   treat&#8208; and&#8208; extend
AB Purpose To assess the effect of fluid status at baseline (BL) and at the end of the loading phase (LP) of three different ranibizumab regimens: treat-and-extend (T&E), fixed bimonthly (FBM) injections and pro re nata (PRN), in patients with neovascular age-related macular degeneration (nAMD).
   Design Post hoc analysis of the In-Eye study (phase IV clinical trial).
   Methods Patients were randomized 1:1:1 to the three study arms and were treated accordingly. The presence and type of fluid, intraretinal fluid (IRF) or subretinal fluid (SRF) and the anatomical and visual outcomes were analysed.
   Main outcome measures Best-corrected visual acuity (BCVA), the mean change from baseline BCVA (BL BCVA), and the proportion of eyes gaining more than 15 letters or losing more than five letters were analysed. Morphological characteristics including the subtype of choroidal neovascular membrane and the development of atrophy and fibrosis were also evaluated.
   Results Patients with SRF at LP had better visual outcomes than patients with IRF. The persistence of SRF did not affect the mean change from BL BCVA among the three treatment regimens. However, in patients with IRF mean change from BL BCVA was significantly lower in the FBM group. The presence of IRF at BL and at the end of the loading phase was associated with the development of fibrosis at the end of the study; this result was contrary to that observed for patients with SRF.
   Conclusions While SRF is compatible with good visual and anatomical outcomes, IRF leads to worse results in patients with nAMD; our results suggest that patients with IRF have better outcomes when individualized treatment regimens are used (PRN or T&E) in contrast with a FBM regimen.
C1 [Saenz-de-Viteri, Manuel; Garcia-Layana, Alfredo] Clin Univ Navarra, Dept Ophthalmol, Pamplona, Spain.
   [Saenz-de-Viteri, Manuel; Recalde, Sergio; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Univ Navarra, Expt Ophthalmol Lab, Pamplona, Spain.
   [Saenz-de-Viteri, Manuel; Recalde, Sergio; Fernandez-Robredo, Patricia; Arias Barquet, Lluis; Garcia-Layana, Alfredo] Inst Salud Carlos III, Minist Ciencia Innovac & Univ, Red Temat Invest Cooperat Salud Prevent Early Det, Madrid, Spain.
   [Recalde, Sergio; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain.
   [Lopez Galvez, Maria Isabel] Hosp Clin Univ Valladolid, Dept Ophthalmol, Valladolid, Spain.
   [Arias Barquet, Lluis] Hosp Univ Bellvitge, Dept Ophthalmol, Barcelona, Spain.
   [Figueroa, Marta S.] Hosp Univ Ramon y Cajal, Dept Ophthalmol, Madrid, Spain.
   [Garcia-Arumi, Jose] Hosp Univ Vall dHebron, Dept Ophthalmol, Barcelona, Spain.
C3 University of Navarra; University of Navarra; Instituto de Salud Carlos
   III; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona; Hospital Universitario
   Ramon y Cajal; Hospital Universitari Vall d'Hebron
RP Recalde, S (通讯作者)，Lab Oftalmol Expt Irunlarrea 1, Edificio Castanos Pamplona, Navarra 31008, Spain.
EM srecalde@unav.es; pfrobredo@unav.es
OI Garcia-Arumi, Jose/0000-0001-8827-1160; LLORENTE GONZALEZ,
   SARA/0000-0001-8815-4757; Saenz-de-Viteri, Manuel/0000-0002-9375-4535;
   Lopez, Maria Isabel/0000-0002-7878-287X
FU Spanish Ministry of Health, Institutode SaludCarlos III, Red Tematicade
   Investigacion Cooperativa en Salud: 'Prevencion, deteccion precoz, y
   tratamiento de la patologia ocular prevalente, degenerativa y cronica'
   [RD16/0008/0021]; Novartis Farmaceutica, S.A
FX This study has been supported in part by a grant of the Spanish Ministry
   of Health, Institutode SaludCarlos III, Red Tematicade Investigacion
   Cooperativa en Salud: 'Prevencion, deteccion precoz, y tratamiento de la
   patologia ocular prevalente, degenerativa y cronica' (RD16/0008/0021).
   The study was promoted by the Spanish Vitreoretinal Society (SERV) and
   supported by Novartis Farmaceutica, S.A. The funding organization had no
   role in the design or conduct of this research.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Feltgen N, 2017, GRAEF ARCH CLIN EXP, V255, P923, DOI 10.1007/s00417-017-3589-x
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Galvez MIL, 2020, ACTA OPHTHALMOL, V98, pE820, DOI 10.1111/aos.14399
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Saenz-de-Viteri M, 2016, BIOCHEM PHARMACOL, V103, P129, DOI 10.1016/j.bcp.2015.12.017
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 46
TC 6
Z9 6
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2021
VL 99
IS 8
BP 861
EP 870
DI 10.1111/aos.14786
EA MAR 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW9GS
UT WOS:000628845500001
PM 33720541
DA 2022-11-30
ER

PT J
AU Dietzel, M
   Zeimer, M
   Heimes, B
   Pauleikhoff, D
   Hense, HW
AF Dietzel, Martha
   Zeimer, Meike
   Heimes, Britta
   Pauleikhoff, Daniel
   Hense, Hans-Werner
TI The Ringlike Structure of Macular Pigment in Age-Related Maculopathy:
   Results from the Muenster Aging and Retina Study (MARS)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HETEROCHROMATIC FLICKER PHOTOMETRY; OPTICAL-DENSITY;
   SPATIAL-DISTRIBUTION; AUTOFLUORESCENCE; CAROTENOIDS; POPULATION;
   PROFILE; AMD
AB PURPOSE. The role of macular pigment (MP) in age-related maculopathy (ARM) is still not clearly understood. Recent studies have reported on variations in the spatial distribution of MP optical density (MPOD) including a secondary peak ("ring") in the slope of the MPOD profile. The authors investigated in a cross-sectional manner the presence of ringlike structures, their determinants, and their relationship with ARM.
   METHODS. In all, 369 participants of the Muenster Aging and Retina Study were examined using dual-wavelength analysis of autofluorescence images. ARM was graded using digital fundus photographs according to the International Classification System.
   RESULTS. A ringlike structure was observed in 73 (19.8%) study participants. The MP maximum of the ring was located on average at 0.85 degrees and the minimum at 0.48 degrees from the center of the fovea. Their concordance between pairs of eyes was highly significant. MPOD measured at eccentricities of 0 degrees, 0.25 degrees, and 0.5 degrees from the fovea was significantly lower in eyes with ringlike structure, whereas it was significantly higher at 1.0 degrees and 2.0 degrees than that in eyes without the ring. Ringlike structures were significantly more common in females and never smokers and were found significantly less often in eyes with ARM than in healthy eyes, even after adjustment for influential factors (adjusted odds ratio, 0.347; 95% confidence interval, 0.196-0.617).
   CONCLUSIONS. Ringlike structures in the MP spatial profile are fairly common, show a high degree of bilaterality, and appeared inversely related with ARM. (Invest Ophthalmol Vis Sci. 2011;52:8016-8024) DOI:10.1167/iovs.11-7610
C1 [Dietzel, Martha; Hense, Hans-Werner] Univ Hosp Muenster, Inst Epidemiol & Social Med, D-48129 Munster, Germany.
   [Dietzel, Martha; Zeimer, Meike; Heimes, Britta; Pauleikhoff, Daniel] St Franziskus Hosp Muenster, Dept Ophthalmol, Munster, Germany.
C3 University of Munster; St. Franziskus-Hospital
RP Dietzel, M (通讯作者)，Univ Hosp Muenster, Inst Epidemiol & Social Med, Domagkstr 3, D-48129 Munster, Germany.
EM martha.dietzel@uni-muenster.de
OI Heimes-Bussmann, Britta/0000-0003-3898-1679
FU Deutsche Forschungsgemeinschaft [HE 2293/5-1, 5-2, 5-3, PA 357/7-1];
   University of Muenster; Pro Retina Foundation; Jackstaedt Foundation
FX Supported in part by Deutsche Forschungsgemeinschaft Grants HE 2293/5-1,
   5-2, 5-3, and PA 357/7-1; the Intramural International Monetary Fund of
   the University of Muenster; the Pro Retina Foundation; and the
   Jackstaedt Foundation.
CR Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Canovas R, 2010, INVEST OPHTH VIS SCI, V51, P3152, DOI 10.1167/iovs.09-3608
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P1338
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Gallaher KT, 2007, VISION RES, V47, P1253, DOI 10.1016/j.visres.2007.01.013
   Iannaccone A, 2007, INVEST OPHTH VIS SCI, V48, P1458, DOI 10.1167/iovs.06-0438
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Kanis MJ, 2008, INVEST OPHTH VIS SCI, V49, P2077, DOI 10.1167/iovs.07-1181
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Lima VC, 2010, INVEST OPHTH VIS SCI, V51, P5840, DOI 10.1167/iovs.09-4695
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wagner-Schuman M, 2011, INVEST OPHTH VIS SCI, V52, P625, DOI 10.1167/iovs.10-5886
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
NR 30
TC 32
Z9 33
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2011
VL 52
IS 11
BP 8016
EP 8024
DI 10.1167/iovs.11-7610
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 834MY
UT WOS:000295966600031
PM 21896850
DA 2022-11-30
ER

EF